Secondary	16214598	0	9	O
prevention	16214598	10	20	O
of	16214598	21	23	O
macrovascular	16214598	24	37	O
events	16214598	38	44	O
in	16214598	45	47	O
patients	16214598	48	56	O
with	16214598	57	61	O
type	16214598	62	66	O
2	16214598	67	68	O
diabetes	16214598	69	77	O
in	16214598	78	80	O
the	16214598	81	84	O
PROactive	16214598	85	94	O
Study	16214598	95	100	O
(	16214598	101	102	O
PROspective	16214598	102	113	O
pioglitAzone	16214598	114	126	O
Clinical	16214598	127	135	O
Trial	16214598	136	141	O
In	16214598	142	144	O
macroVascular	16214598	145	158	O
Events	16214598	159	165	O
):	16214598	165	167	O
a	16214598	168	169	O
randomised	16214598	170	180	O
controlled	16214598	181	191	O
trial	16214598	192	197	O
.	16214598	197	198	O

BACKGROUND	16214598	200	210	O
:	16214598	211	212	O
Patients	16214598	213	221	O
with	16214598	222	226	O
type	16214598	227	231	O
2	16214598	232	233	O
diabetes	16214598	234	242	O
are	16214598	243	246	O
at	16214598	247	249	O
high	16214598	250	254	O
risk	16214598	255	259	O
of	16214598	260	262	O
fatal	16214598	263	268	O
and	16214598	269	272	O
non-fatal	16214598	273	282	O
myocardial	16214598	283	293	O
infarction	16214598	294	304	O
and	16214598	305	308	O
stroke	16214598	309	315	O
.	16214598	315	316	O

There	16214598	317	322	O
is	16214598	323	325	O
indirect	16214598	326	334	O
evidence	16214598	335	343	O
that	16214598	344	348	O
agonists	16214598	349	357	O
of	16214598	358	360	O
peroxisome	16214598	361	371	O
proliferator-activated	16214598	372	394	O
receptor	16214598	395	403	O
gamma	16214598	404	409	O
(	16214598	410	411	O
PPAR	16214598	411	415	O
gamma	16214598	416	421	O
)	16214598	421	422	O
could	16214598	423	428	O
reduce	16214598	429	435	O
macrovascular	16214598	436	449	O
complications	16214598	450	463	O
.	16214598	463	464	O

Our	16214598	465	468	O
aim	16214598	469	472	O
,	16214598	472	473	O
therefore	16214598	474	483	O
,	16214598	483	484	O
was	16214598	485	488	O
to	16214598	489	491	O
ascertain	16214598	492	501	O
whether	16214598	502	509	O
pioglitazone	16214598	510	522	O
reduces	16214598	523	530	O
macrovascular	16214598	531	544	O
morbidity	16214598	545	554	O
and	16214598	555	558	O
mortality	16214598	559	568	O
in	16214598	569	571	O
high-risk	16214598	572	581	O
patients	16214598	582	590	O
with	16214598	591	595	O
type	16214598	596	600	O
2	16214598	601	602	O
diabetes	16214598	603	611	O
.	16214598	611	612	O

METHODS	16214598	614	621	O
:	16214598	622	623	O
We	16214598	624	626	O
did	16214598	627	630	O
a	16214598	631	632	O
prospective	16214598	633	644	O
,	16214598	644	645	O
randomised	16214598	646	656	O
controlled	16214598	657	667	O
trial	16214598	668	673	O
in	16214598	674	676	O
5238	16214598	677	681	O
patients	16214598	682	690	O
with	16214598	691	695	O
type	16214598	696	700	O
2	16214598	701	702	O
diabetes	16214598	703	711	O
who	16214598	712	715	O
had	16214598	716	719	O
evidence	16214598	720	728	O
of	16214598	729	731	O
macrovascular	16214598	732	745	O
disease	16214598	746	753	O
.	16214598	753	754	O

We	16214598	755	757	O
recruited	16214598	758	767	O
patients	16214598	768	776	O
from	16214598	777	781	O
primary-care	16214598	782	794	O
practices	16214598	795	804	O
and	16214598	805	808	O
hospitals	16214598	809	818	O
.	16214598	818	819	O

We	16214598	820	822	O
assigned	16214598	823	831	O
patients	16214598	832	840	O
to	16214598	841	843	O
oral	16214598	844	848	O
pioglitazone	16214598	849	861	O
titrated	16214598	862	870	O
from	16214598	871	875	O
15	16214598	876	878	O
mg	16214598	879	881	O
to	16214598	882	884	O
45	16214598	885	887	O
mg	16214598	888	890	O
(	16214598	891	892	O
n=2605	16214598	892	898	O
)	16214598	898	899	O
or	16214598	900	902	O
matching	16214598	903	911	O
placebo	16214598	912	919	O
(	16214598	920	921	O
n=2633	16214598	921	927	O
)	16214598	927	928	O
,	16214598	928	929	O
to	16214598	930	932	O
be	16214598	933	935	O
taken	16214598	936	941	O
in	16214598	942	944	O
addition	16214598	945	953	O
to	16214598	954	956	O
their	16214598	957	962	O
glucose-lowering	16214598	963	979	O
drugs	16214598	980	985	O
and	16214598	986	989	O
other	16214598	990	995	O
medications	16214598	996	1007	O
.	16214598	1007	1008	O

Our	16214598	1009	1012	O
primary	16214598	1013	1020	O
endpoint	16214598	1021	1029	O
was	16214598	1030	1033	O
the	16214598	1034	1037	O
composite	16214598	1038	1047	O
of	16214598	1048	1050	O
all-cause	16214598	1051	1060	O
mortality	16214598	1061	1070	O
,	16214598	1070	1071	O
non	16214598	1072	1075	O
fatal	16214598	1076	1081	O
myocardial	16214598	1082	1092	O
infarction	16214598	1093	1103	O
(	16214598	1104	1105	O
including	16214598	1105	1114	O
silent	16214598	1115	1121	O
myocardial	16214598	1122	1132	O
infarction	16214598	1133	1143	O
)	16214598	1143	1144	O
,	16214598	1144	1145	O
stroke	16214598	1146	1152	O
,	16214598	1152	1153	O
acute	16214598	1154	1159	O
coronary	16214598	1160	1168	O
syndrome	16214598	1169	1177	O
,	16214598	1177	1178	O
endovascular	16214598	1179	1191	O
or	16214598	1192	1194	O
surgical	16214598	1195	1203	O
intervention	16214598	1204	1216	O
in	16214598	1217	1219	O
the	16214598	1220	1223	O
coronary	16214598	1224	1232	O
or	16214598	1233	1235	O
leg	16214598	1236	1239	O
arteries	16214598	1240	1248	O
,	16214598	1248	1249	O
and	16214598	1250	1253	O
amputation	16214598	1254	1264	O
above	16214598	1265	1270	O
the	16214598	1271	1274	O
ankle	16214598	1275	1280	O
.	16214598	1280	1281	O

Analysis	16214598	1282	1290	O
was	16214598	1291	1294	O
by	16214598	1295	1297	O
intention	16214598	1298	1307	O
to	16214598	1308	1310	O
treat	16214598	1311	1316	O
.	16214598	1316	1317	O

This	16214598	1318	1322	O
study	16214598	1323	1328	O
is	16214598	1329	1331	O
registered	16214598	1332	1342	O
as	16214598	1343	1345	O
an	16214598	1346	1348	O
International	16214598	1349	1362	O
Standard	16214598	1363	1371	O
Randomised	16214598	1372	1382	O
Controlled	16214598	1383	1393	O
Trial	16214598	1394	1399	O
,	16214598	1399	1400	O
number	16214598	1401	1407	O
ISRCTN	16214598	1408	1414	O
NCT00174993	16214598	1415	1426	O
.	16214598	1426	1427	O

FINDINGS	16214598	1429	1437	O
:	16214598	1438	1439	O
Two	16214598	1440	1443	O
patients	16214598	1444	1452	O
were	16214598	1453	1457	O
lost	16214598	1458	1462	O
to	16214598	1463	1465	O
follow-up	16214598	1466	1475	O
,	16214598	1475	1476	O
but	16214598	1477	1480	O
were	16214598	1481	1485	O
included	16214598	1486	1494	O
in	16214598	1495	1497	O
analyses	16214598	1498	1506	O
.	16214598	1506	1507	O

The	16214598	1508	1511	O
average	16214598	1512	1519	O
time	16214598	1520	1524	O
of	16214598	1525	1527	O
observation	16214598	1528	1539	O
was	16214598	1540	1543	O
34.5	16214598	1544	1548	O
months	16214598	1549	1555	O
.	16214598	1555	1556	O

514	16214598	1557	1560	O
of	16214598	1561	1563	O
2605	16214598	1564	1568	O
patients	16214598	1569	1577	O
in	16214598	1578	1580	O
the	16214598	1581	1584	O
pioglitazone	16214598	1585	1597	O
group	16214598	1598	1603	O
and	16214598	1604	1607	O
572	16214598	1608	1611	O
of	16214598	1612	1614	O
2633	16214598	1615	1619	O
patients	16214598	1620	1628	O
in	16214598	1629	1631	O
the	16214598	1632	1635	O
placebo	16214598	1636	1643	O
group	16214598	1644	1649	O
had	16214598	1650	1653	O
at	16214598	1654	1656	O
least	16214598	1657	1662	O
one	16214598	1663	1666	O
event	16214598	1667	1672	O
in	16214598	1673	1675	O
the	16214598	1676	1679	O
primary	16214598	1680	1687	O
composite	16214598	1688	1697	O
endpoint	16214598	1698	1706	O
(	16214598	1707	1708	O
HR	16214598	1708	1710	O
0.90	16214598	1711	1715	O
,	16214598	1715	1716	O
95	16214598	1717	1719	O
%	16214598	1719	1720	O
CI	16214598	1721	1723	O
0.80	16214598	1724	1728	O
-	16214598	1728	1729	O
1.02	16214598	1729	1733	O
,	16214598	1733	1734	O
p=0.095	16214598	1735	1742	O
)	16214598	1742	1743	O
.	16214598	1743	1744	O

The	16214598	1745	1748	O
main	16214598	1749	1753	O
secondary	16214598	1754	1763	O
endpoint	16214598	1764	1772	O
was	16214598	1773	1776	O
the	16214598	1777	1780	O
composite	16214598	1781	1790	O
of	16214598	1791	1793	O
all-cause	16214598	1794	1803	B-Outcome
mortality	16214598	1804	1813	I-Outcome
,	16214598	1813	1814	O
non-fatal	16214598	1815	1824	B-Outcome
myocardial	16214598	1825	1835	I-Outcome
infarction	16214598	1836	1846	I-Outcome
,	16214598	1846	1847	O
and	16214598	1848	1851	O
stroke	16214598	1852	1858	B-Outcome
.	16214598	1858	1859	O

301	16214598	1860	1863	O
patients	16214598	1864	1872	O
in	16214598	1873	1875	O
the	16214598	1876	1879	O
pioglitazone	16214598	1880	1892	O
group	16214598	1893	1898	O
and	16214598	1899	1902	O
358	16214598	1903	1906	O
in	16214598	1907	1909	O
the	16214598	1910	1913	O
placebo	16214598	1914	1921	O
group	16214598	1922	1927	O
reached	16214598	1928	1935	O
this	16214598	1936	1940	O
endpoint	16214598	1941	1949	O
(	16214598	1950	1951	O
0.84	16214598	1951	1955	O
,	16214598	1955	1956	O
0.72	16214598	1957	1961	O
-	16214598	1961	1962	O
0.98	16214598	1962	1966	O
,	16214598	1966	1967	O
p=0.027	16214598	1968	1975	O
)	16214598	1975	1976	O
.	16214598	1976	1977	O

Overall	16214598	1978	1985	O
safety	16214598	1986	1992	B-Outcome
and	16214598	1993	1996	O
tolerability	16214598	1997	2009	B-Outcome
was	16214598	2010	2013	O
good	16214598	2014	2018	O
with	16214598	2019	2023	O
no	16214598	2024	2026	O
change	16214598	2027	2033	O
in	16214598	2034	2036	O
the	16214598	2037	2040	O
safety	16214598	2041	2047	B-Outcome
profile	16214598	2048	2055	O
of	16214598	2056	2058	O
pioglitazone	16214598	2059	2071	O
identified	16214598	2072	2082	O
.	16214598	2082	2083	O

6	16214598	2084	2085	O
%	16214598	2085	2086	O
(	16214598	2087	2088	O
149	16214598	2088	2091	O
of	16214598	2092	2094	O
2065	16214598	2095	2099	O
)	16214598	2099	2100	O
and	16214598	2101	2104	O
4	16214598	2105	2106	O
%	16214598	2106	2107	O
(	16214598	2108	2109	O
108	16214598	2109	2112	O
of	16214598	2113	2115	O
2633	16214598	2116	2120	O
)	16214598	2120	2121	O
of	16214598	2122	2124	O
those	16214598	2125	2130	O
in	16214598	2131	2133	O
the	16214598	2134	2137	O
pioglitazone	16214598	2138	2150	O
and	16214598	2151	2154	O
placebo	16214598	2155	2162	O
groups	16214598	2163	2169	O
,	16214598	2169	2170	O
respectively	16214598	2171	2183	O
,	16214598	2183	2184	O
were	16214598	2185	2189	O
admitted	16214598	2190	2198	O
to	16214598	2199	2201	O
hospital	16214598	2202	2210	O
with	16214598	2211	2215	O
heart	16214598	2216	2221	B-Outcome
failure	16214598	2222	2229	I-Outcome
;	16214598	2229	2230	O
mortality	16214598	2231	2240	B-Outcome
rates	16214598	2241	2246	I-Outcome
from	16214598	2247	2251	I-Outcome
heart	16214598	2252	2257	I-Outcome
failure	16214598	2258	2265	I-Outcome
did	16214598	2266	2269	O
not	16214598	2270	2273	O
differ	16214598	2274	2280	O
between	16214598	2281	2288	O
groups	16214598	2289	2295	O
.	16214598	2295	2296	O

INTERPRETATION	16214598	2298	2312	O
:	16214598	2313	2314	O
Pioglitazone	16214598	2315	2327	O
reduces	16214598	2328	2335	O
the	16214598	2336	2339	O
composite	16214598	2340	2349	O
of	16214598	2350	2352	O
all-cause	16214598	2353	2362	B-Outcome
mortality	16214598	2363	2372	I-Outcome
,	16214598	2372	2373	O
non-fatal	16214598	2374	2383	B-Outcome
myocardial	16214598	2384	2394	I-Outcome
infarction	16214598	2395	2405	I-Outcome
,	16214598	2405	2406	O
and	16214598	2407	2410	O
stroke	16214598	2411	2417	B-Outcome
in	16214598	2418	2420	O
patients	16214598	2421	2429	O
with	16214598	2430	2434	O
type	16214598	2435	2439	O
2	16214598	2440	2441	O
diabetes	16214598	2442	2450	O
who	16214598	2451	2454	O
have	16214598	2455	2459	O
a	16214598	2460	2461	O
high	16214598	2462	2466	O
risk	16214598	2467	2471	O
of	16214598	2472	2474	O
macrovascular	16214598	2475	2488	O
events	16214598	2489	2495	O
.	16214598	2495	2496	O


Supplemental	16249417	0	12	O
perioperative	16249417	13	26	O
oxygen	16249417	27	33	O
and	16249417	34	37	O
the	16249417	38	41	O
risk	16249417	42	46	O
of	16249417	47	49	O
surgical	16249417	50	58	O
wound	16249417	59	64	O
infection	16249417	65	74	O
:	16249417	74	75	O
a	16249417	76	77	O
randomized	16249417	78	88	O
controlled	16249417	89	99	O
trial	16249417	100	105	O
.	16249417	105	106	O

BACKGROUND	16249417	108	118	O
:	16249417	119	120	O
Supplemental	16249417	121	133	O
perioperative	16249417	134	147	O
oxygen	16249417	148	154	O
has	16249417	155	158	O
been	16249417	159	163	O
variously	16249417	164	173	O
reported	16249417	174	182	O
to	16249417	183	185	O
halve	16249417	186	191	O
or	16249417	192	194	O
double	16249417	195	201	O
the	16249417	202	205	O
risk	16249417	206	210	O
of	16249417	211	213	O
surgical	16249417	214	222	O
wound	16249417	223	228	O
infection	16249417	229	238	O
.	16249417	238	239	O

OBJECTIVE	16249417	241	250	O
:	16249417	251	252	O
To	16249417	253	255	O
test	16249417	256	260	O
the	16249417	261	264	O
hypothesis	16249417	265	275	O
that	16249417	276	280	O
supplemental	16249417	281	293	O
oxygen	16249417	294	300	O
reduces	16249417	301	308	O
infection	16249417	309	318	O
risk	16249417	319	323	O
in	16249417	324	326	O
patients	16249417	327	335	O
following	16249417	336	345	O
colorectal	16249417	346	356	O
surgery	16249417	357	364	O
.	16249417	364	365	O

METHODS	16249417	367	374	O
:	16249417	375	376	O
A	16249417	377	378	O
double-blind	16249417	379	391	O
,	16249417	391	392	O
randomized	16249417	393	403	O
controlled	16249417	404	414	O
trial	16249417	415	420	O
of	16249417	421	423	O
300	16249417	424	427	O
patients	16249417	428	436	O
aged	16249417	437	441	O
18	16249417	442	444	O
to	16249417	445	447	O
80	16249417	448	450	O
years	16249417	451	456	O
who	16249417	457	460	O
underwent	16249417	461	470	O
elective	16249417	471	479	O
colorectal	16249417	480	490	O
surgery	16249417	491	498	O
in	16249417	499	501	O
14	16249417	502	504	O
Spanish	16249417	505	512	O
hospitals	16249417	513	522	O
from	16249417	523	527	O
March	16249417	528	533	O
1	16249417	534	535	O
,	16249417	535	536	O
2003	16249417	537	541	O
,	16249417	541	542	O
to	16249417	543	545	O
October	16249417	546	553	O
31	16249417	554	556	O
,	16249417	556	557	O
2004	16249417	558	562	O
.	16249417	562	563	O

Wound	16249417	564	569	O
infections	16249417	570	580	O
were	16249417	581	585	O
diagnosed	16249417	586	595	O
by	16249417	596	598	O
blinded	16249417	599	606	O
investigators	16249417	607	620	O
using	16249417	621	626	O
Centers	16249417	627	634	O
for	16249417	635	638	O
Disease	16249417	639	646	O
Control	16249417	647	654	O
and	16249417	655	658	O
Prevention	16249417	659	669	O
criteria	16249417	670	678	O
.	16249417	678	679	O

Baseline	16249417	680	688	O
patient	16249417	689	696	O
characteristics	16249417	697	712	O
,	16249417	712	713	O
anesthetic	16249417	714	724	O
treatment	16249417	725	734	O
,	16249417	734	735	O
and	16249417	736	739	O
potential	16249417	740	749	O
confounding	16249417	750	761	O
factors	16249417	762	769	O
were	16249417	770	774	O
recorded	16249417	775	783	O
.	16249417	783	784	O

METHODS	16249417	786	793	O
:	16249417	794	795	O
Patients	16249417	796	804	O
were	16249417	805	809	O
randomly	16249417	810	818	O
assigned	16249417	819	827	O
to	16249417	828	830	O
either	16249417	831	837	O
30	16249417	838	840	O
%	16249417	840	841	O
or	16249417	842	844	O
80	16249417	845	847	O
%	16249417	847	848	O
fraction	16249417	849	857	O
of	16249417	858	860	O
inspired	16249417	861	869	O
oxygen	16249417	870	876	O
(	16249417	877	878	O
FIO2	16249417	878	882	O
)	16249417	882	883	O
intraoperatively	16249417	884	900	O
and	16249417	901	904	O
for	16249417	905	908	O
6	16249417	909	910	O
hours	16249417	911	916	O
after	16249417	917	922	O
surgery	16249417	923	930	O
.	16249417	930	931	O

Anesthetic	16249417	932	942	O
treatment	16249417	943	952	O
and	16249417	953	956	O
antibiotic	16249417	957	967	O
administration	16249417	968	982	O
were	16249417	983	987	O
standardized	16249417	988	1000	O
.	16249417	1000	1001	O

METHODS	16249417	1003	1010	O
:	16249417	1011	1012	O
Any	16249417	1013	1016	O
surgical	16249417	1017	1025	O
site	16249417	1026	1030	O
infection	16249417	1031	1040	O
(	16249417	1041	1042	O
SSI	16249417	1042	1045	O
)	16249417	1045	1046	O
;	16249417	1046	1047	O
secondary	16249417	1048	1057	O
outcomes	16249417	1058	1066	O
included	16249417	1067	1075	O
return	16249417	1076	1082	O
of	16249417	1083	1085	O
bowel	16249417	1086	1091	O
function	16249417	1092	1100	O
and	16249417	1101	1104	O
ability	16249417	1105	1112	O
to	16249417	1113	1115	O
tolerate	16249417	1116	1124	O
solid	16249417	1125	1130	O
food	16249417	1131	1135	O
,	16249417	1135	1136	O
ambulation	16249417	1137	1147	O
,	16249417	1147	1148	O
suture	16249417	1149	1155	O
removal	16249417	1156	1163	O
,	16249417	1163	1164	O
and	16249417	1165	1168	O
duration	16249417	1169	1177	O
of	16249417	1178	1180	O
hospitalization	16249417	1181	1196	O
.	16249417	1196	1197	O

RESULTS	16249417	1199	1206	O
:	16249417	1207	1208	O
A	16249417	1209	1210	O
total	16249417	1211	1216	O
of	16249417	1217	1219	O
143	16249417	1220	1223	O
patients	16249417	1224	1232	O
received	16249417	1233	1241	O
30	16249417	1242	1244	O
%	16249417	1244	1245	O
perioperative	16249417	1246	1259	O
oxygen	16249417	1260	1266	O
and	16249417	1267	1270	O
148	16249417	1271	1274	O
received	16249417	1275	1283	O
80	16249417	1284	1286	O
%	16249417	1286	1287	O
perioperative	16249417	1288	1301	O
oxygen	16249417	1302	1308	O
.	16249417	1308	1309	O

Surgical	16249417	1310	1318	B-Outcome
site	16249417	1319	1323	I-Outcome
infection	16249417	1324	1333	I-Outcome
occurred	16249417	1334	1342	O
in	16249417	1343	1345	O
35	16249417	1346	1348	O
patients	16249417	1349	1357	O
(	16249417	1358	1359	O
24.4	16249417	1359	1363	O
%	16249417	1363	1364	O
)	16249417	1364	1365	O
administered	16249417	1366	1378	O
30	16249417	1379	1381	O
%	16249417	1381	1382	O
FIO2	16249417	1383	1387	O
and	16249417	1388	1391	O
in	16249417	1392	1394	O
22	16249417	1395	1397	O
patients	16249417	1398	1406	O
(	16249417	1407	1408	O
14.9	16249417	1408	1412	O
%	16249417	1412	1413	O
)	16249417	1413	1414	O
administered	16249417	1415	1427	O
80	16249417	1428	1430	O
%	16249417	1430	1431	O
FIO2	16249417	1432	1436	O
(	16249417	1437	1438	O
P=.04	16249417	1438	1443	O
)	16249417	1443	1444	O
.	16249417	1444	1445	O

The	16249417	1446	1449	O
risk	16249417	1450	1454	O
of	16249417	1455	1457	O
SSI	16249417	1458	1461	B-Outcome
was	16249417	1462	1465	O
39	16249417	1466	1468	O
%	16249417	1468	1469	O
lower	16249417	1470	1475	O
in	16249417	1476	1478	O
the	16249417	1479	1482	O
80	16249417	1483	1485	O
%	16249417	1485	1486	O
FIO2	16249417	1487	1491	O
group	16249417	1492	1497	O
(	16249417	1498	1499	O
relative	16249417	1499	1507	O
risk	16249417	1508	1512	O
[	16249417	1513	1514	O
RR	16249417	1514	1516	O
]	16249417	1516	1517	O
,	16249417	1517	1518	O
0.61	16249417	1519	1523	O
;	16249417	1523	1524	O
95	16249417	1525	1527	O
%	16249417	1527	1528	O
confidence	16249417	1529	1539	O
interval	16249417	1540	1548	O
[	16249417	1549	1550	O
CI	16249417	1550	1552	O
]	16249417	1552	1553	O
,	16249417	1553	1554	O
0.38	16249417	1555	1559	O
-	16249417	1559	1560	O
0.98	16249417	1560	1564	O
)	16249417	1564	1565	O
vs	16249417	1566	1568	O
the	16249417	1569	1572	O
30	16249417	1573	1575	O
%	16249417	1575	1576	O
FIO2	16249417	1577	1581	O
group	16249417	1582	1587	O
.	16249417	1587	1588	O

After	16249417	1589	1594	O
adjustment	16249417	1595	1605	O
for	16249417	1606	1609	O
important	16249417	1610	1619	O
covariates	16249417	1620	1630	O
,	16249417	1630	1631	O
the	16249417	1632	1635	O
RR	16249417	1636	1638	B-Outcome
of	16249417	1639	1641	I-Outcome
infection	16249417	1642	1651	I-Outcome
in	16249417	1652	1654	O
patients	16249417	1655	1663	O
administered	16249417	1664	1676	O
supplemental	16249417	1677	1689	O
oxygen	16249417	1690	1696	O
was	16249417	1697	1700	O
0.46	16249417	1701	1705	O
(	16249417	1706	1707	O
95	16249417	1707	1709	O
%	16249417	1709	1710	O
CI	16249417	1711	1713	O
,	16249417	1713	1714	O
0.22	16249417	1715	1719	O
-	16249417	1719	1720	O
0.95	16249417	1720	1724	O
;	16249417	1724	1725	O
P	16249417	1726	1727	O
=	16249417	1728	1729	O
.04	16249417	1730	1733	O
)	16249417	1733	1734	O
.	16249417	1734	1735	O

None	16249417	1736	1740	O
of	16249417	1741	1743	O
the	16249417	1744	1747	O
secondary	16249417	1748	1757	O
outcomes	16249417	1758	1766	O
varied	16249417	1767	1773	O
significantly	16249417	1774	1787	O
between	16249417	1788	1795	O
the	16249417	1796	1799	O
2	16249417	1800	1801	O
treatment	16249417	1802	1811	O
groups	16249417	1812	1818	O
.	16249417	1818	1819	O

CONCLUSIONS	16249417	1821	1832	O
:	16249417	1833	1834	O
Patients	16249417	1835	1843	O
receiving	16249417	1844	1853	O
supplemental	16249417	1854	1866	O
inspired	16249417	1867	1875	O
oxygen	16249417	1876	1882	O
had	16249417	1883	1886	O
a	16249417	1887	1888	O
significant	16249417	1889	1900	O
reduction	16249417	1901	1910	O
in	16249417	1911	1913	O
the	16249417	1914	1917	O
risk	16249417	1918	1922	O
of	16249417	1923	1925	O
wound	16249417	1926	1931	B-Outcome
infection	16249417	1932	1941	I-Outcome
.	16249417	1941	1942	O

Supplemental	16249417	1943	1955	O
oxygen	16249417	1956	1962	O
appears	16249417	1963	1970	O
to	16249417	1971	1973	O
be	16249417	1974	1976	O
an	16249417	1977	1979	O
effective	16249417	1980	1989	O
intervention	16249417	1990	2002	O
to	16249417	2003	2005	O
reduce	16249417	2006	2012	O
SSI	16249417	2013	2016	B-Outcome
in	16249417	2017	2019	O
patients	16249417	2020	2028	O
undergoing	16249417	2029	2039	O
colon	16249417	2040	2045	O
or	16249417	2046	2048	O
rectal	16249417	2049	2055	O
surgery	16249417	2056	2063	O
.	16249417	2063	2064	O

Trial	16249417	2065	2070	O
Registration	16249417	2071	2083	O
ClinicalTrials.gov	16249417	2084	2102	O
Identifier	16249417	2103	2113	O
:	16249417	2113	2114	O
NCT00235456	16249417	2115	2126	O
.	16249417	2126	2127	O


Left	16887481	0	4	O
thoracoabdominal	16887481	5	21	O
approach	16887481	22	30	O
versus	16887481	31	37	O
abdominal-transhiatal	16887481	38	59	O
approach	16887481	60	68	O
for	16887481	69	72	O
gastric	16887481	73	80	O
cancer	16887481	81	87	O
of	16887481	88	90	O
the	16887481	91	94	O
cardia	16887481	95	101	O
or	16887481	102	104	O
subcardia	16887481	105	114	O
:	16887481	114	115	O
a	16887481	116	117	O
randomised	16887481	118	128	O
controlled	16887481	129	139	O
trial	16887481	140	145	O
.	16887481	145	146	O

BACKGROUND	16887481	148	158	O
:	16887481	159	160	O
Because	16887481	161	168	O
of	16887481	169	171	O
the	16887481	172	175	O
inaccessibility	16887481	176	191	O
of	16887481	192	194	O
mediastinal	16887481	195	206	O
nodal	16887481	207	212	O
metastases	16887481	213	223	O
,	16887481	223	224	O
the	16887481	225	228	O
left	16887481	229	233	O
thoracoabdominal	16887481	234	250	O
approach	16887481	251	259	O
(	16887481	260	261	O
LTA	16887481	261	264	O
)	16887481	264	265	O
has	16887481	266	269	O
often	16887481	270	275	O
been	16887481	276	280	O
used	16887481	281	285	O
to	16887481	286	288	O
treat	16887481	289	294	O
gastric	16887481	295	302	O
cancer	16887481	303	309	O
of	16887481	310	312	O
the	16887481	313	316	O
cardia	16887481	317	323	O
or	16887481	324	326	O
subcardia	16887481	327	336	O
.	16887481	336	337	O

In	16887481	338	340	O
a	16887481	341	342	O
randomised	16887481	343	353	O
phase	16887481	354	359	O
III	16887481	360	363	O
study	16887481	364	369	O
,	16887481	369	370	O
we	16887481	371	373	O
aimed	16887481	374	379	O
to	16887481	380	382	O
compare	16887481	383	390	O
LTA	16887481	391	394	O
with	16887481	395	399	O
the	16887481	400	403	O
abdominal-transhiatal	16887481	404	425	O
approach	16887481	426	434	O
(	16887481	435	436	O
TH	16887481	436	438	O
)	16887481	438	439	O
in	16887481	440	442	O
the	16887481	443	446	O
treatment	16887481	447	456	O
of	16887481	457	459	O
these	16887481	460	465	O
tumours	16887481	466	473	O
.	16887481	473	474	O

METHODS	16887481	476	483	O
:	16887481	484	485	O
Between	16887481	486	493	O
July	16887481	494	498	O
,	16887481	498	499	O
1995	16887481	500	504	O
,	16887481	504	505	O
and	16887481	506	509	O
December	16887481	510	518	O
,	16887481	518	519	O
2003	16887481	520	524	O
,	16887481	524	525	O
167	16887481	526	529	O
patients	16887481	530	538	O
were	16887481	539	543	O
enrolled	16887481	544	552	O
from	16887481	553	557	O
27	16887481	558	560	O
Japanese	16887481	561	569	O
hospitals	16887481	570	579	O
and	16887481	580	583	O
randomly	16887481	584	592	O
assigned	16887481	593	601	O
to	16887481	602	604	O
TH	16887481	605	607	O
(	16887481	608	609	O
n=82	16887481	609	613	O
)	16887481	613	614	O
or	16887481	615	617	O
LTA	16887481	618	621	O
(	16887481	622	623	O
n=85	16887481	623	627	O
)	16887481	627	628	O
.	16887481	628	629	O

The	16887481	630	633	O
primary	16887481	634	641	O
endpoint	16887481	642	650	O
was	16887481	651	654	O
overall	16887481	655	662	O
survival	16887481	663	671	O
,	16887481	671	672	O
and	16887481	673	676	O
secondary	16887481	677	686	O
endpoints	16887481	687	696	O
were	16887481	697	701	O
disease-free	16887481	702	714	O
survival	16887481	715	723	O
,	16887481	723	724	O
postoperative	16887481	725	738	O
morbidity	16887481	739	748	O
and	16887481	749	752	O
hospital	16887481	753	761	O
mortality	16887481	762	771	O
,	16887481	771	772	O
and	16887481	773	776	O
postoperative	16887481	777	790	O
symptoms	16887481	791	799	O
and	16887481	800	803	O
change	16887481	804	810	O
of	16887481	811	813	O
respiratory	16887481	814	825	O
function	16887481	826	834	O
.	16887481	834	835	O

The	16887481	836	839	O
projected	16887481	840	849	O
sample	16887481	850	856	O
size	16887481	857	861	O
was	16887481	862	865	O
302	16887481	866	869	O
.	16887481	869	870	O
After	16887481	871	876	O
the	16887481	877	880	O
first	16887481	881	886	O
interim	16887481	887	894	O
analysis	16887481	895	903	O
,	16887481	903	904	O
the	16887481	905	908	O
predicted	16887481	909	918	O
probability	16887481	919	930	O
of	16887481	931	933	O
LTA	16887481	934	937	O
having	16887481	938	944	O
a	16887481	945	946	O
significantly	16887481	947	960	O
better	16887481	961	967	O
overall	16887481	968	975	O
survival	16887481	976	984	O
than	16887481	985	989	O
TH	16887481	990	992	O
at	16887481	993	995	O
the	16887481	996	999	O
final	16887481	1000	1005	O
analysis	16887481	1006	1014	O
was	16887481	1015	1018	O
only	16887481	1019	1023	O
3.65	16887481	1024	1028	O
%	16887481	1028	1029	O
,	16887481	1029	1030	O
and	16887481	1031	1034	O
the	16887481	1035	1038	O
trial	16887481	1039	1044	O
was	16887481	1045	1048	O
closed	16887481	1049	1055	O
immediately	16887481	1056	1067	O
.	16887481	1067	1068	O

Analysis	16887481	1069	1077	O
was	16887481	1078	1081	O
by	16887481	1082	1084	O
intention	16887481	1085	1094	O
to	16887481	1095	1097	O
treat	16887481	1098	1103	O
.	16887481	1103	1104	O

This	16887481	1105	1109	O
study	16887481	1110	1115	O
is	16887481	1116	1118	O
registered	16887481	1119	1129	O
with	16887481	1130	1134	O
,	16887481	1135	1136	O
number	16887481	1137	1143	O
NCT00149266	16887481	1144	1155	O
.	16887481	1155	1156	O

FINDINGS	16887481	1158	1166	O
:	16887481	1167	1168	O
5-year	16887481	1169	1175	B-Outcome
overall	16887481	1176	1183	I-Outcome
survival	16887481	1184	1192	I-Outcome
was	16887481	1193	1196	O
52.3	16887481	1197	1201	O
%	16887481	1201	1202	O
(	16887481	1203	1204	O
95	16887481	1204	1206	O
%	16887481	1206	1207	O
CI	16887481	1208	1210	O
40.4	16887481	1211	1215	O
-	16887481	1215	1216	O
64.1	16887481	1216	1220	O
)	16887481	1220	1221	O
in	16887481	1222	1224	O
the	16887481	1225	1228	O
TH	16887481	1229	1231	O
group	16887481	1232	1237	O
and	16887481	1238	1241	O
37.9	16887481	1242	1246	O
%	16887481	1246	1247	O
(	16887481	1248	1249	O
26.1	16887481	1249	1253	O
-	16887481	1253	1254	O
49.6	16887481	1254	1258	O
)	16887481	1258	1259	O
in	16887481	1260	1262	O
the	16887481	1263	1266	O
LTA	16887481	1267	1270	O
group	16887481	1271	1276	O
.	16887481	1276	1277	O

The	16887481	1278	1281	O
hazard	16887481	1282	1288	B-Outcome
ratio	16887481	1289	1294	I-Outcome
of	16887481	1295	1297	I-Outcome
death	16887481	1298	1303	I-Outcome
for	16887481	1304	1307	O
LTA	16887481	1308	1311	O
compared	16887481	1312	1320	O
with	16887481	1321	1325	O
TH	16887481	1326	1328	O
was	16887481	1329	1332	O
1.36	16887481	1333	1337	O
(	16887481	1338	1339	O
0.89	16887481	1339	1343	O
-	16887481	1343	1344	O
2.08	16887481	1344	1348	O
,	16887481	1348	1349	O
p=0.92	16887481	1350	1356	O
)	16887481	1356	1357	O
.	16887481	1357	1358	O

Three	16887481	1359	1364	O
patients	16887481	1365	1373	O
died	16887481	1374	1378	B-Outcome
in	16887481	1379	1381	I-Outcome
hospital	16887481	1382	1390	I-Outcome
after	16887481	1391	1396	O
LTA	16887481	1397	1400	O
but	16887481	1401	1404	O
none	16887481	1405	1409	O
after	16887481	1410	1415	O
TH	16887481	1416	1418	O
.	16887481	1418	1419	O

Morbidity	16887481	1420	1429	B-Outcome
was	16887481	1430	1433	O
worse	16887481	1434	1439	O
after	16887481	1440	1445	O
LTA	16887481	1446	1449	O
than	16887481	1450	1454	O
after	16887481	1455	1460	O
TH	16887481	1461	1463	O
.	16887481	1463	1464	O

INTERPRETATION	16887481	1466	1480	O
:	16887481	1481	1482	O
Because	16887481	1483	1490	O
LTA	16887481	1491	1494	O
does	16887481	1495	1499	O
not	16887481	1500	1503	O
improve	16887481	1504	1511	O
survival	16887481	1512	1520	B-Outcome
after	16887481	1521	1526	O
TH	16887481	1527	1529	O
and	16887481	1530	1533	O
leads	16887481	1534	1539	O
to	16887481	1540	1542	O
increased	16887481	1543	1552	O
morbidity	16887481	1553	1562	B-Outcome
in	16887481	1563	1565	O
patients	16887481	1566	1574	O
with	16887481	1575	1579	O
cancer	16887481	1580	1586	O
of	16887481	1587	1589	O
the	16887481	1590	1593	O
cardia	16887481	1594	1600	O
or	16887481	1601	1603	O
subcardia	16887481	1604	1613	O
,	16887481	1613	1614	O
LTA	16887481	1615	1618	O
can	16887481	1619	1622	O
not	16887481	1622	1625	O
be	16887481	1626	1628	O
justified	16887481	1629	1638	O
to	16887481	1639	1641	O
treat	16887481	1642	1647	O
these	16887481	1648	1653	O
tumours	16887481	1654	1661	O
.	16887481	1661	1662	O


A	17174704	0	1	O
comparison	17174704	2	12	O
of	17174704	13	15	O
three	17174704	16	21	O
highly	17174704	22	28	O
active	17174704	29	35	O
antiretroviral	17174704	36	50	O
treatment	17174704	51	60	O
strategies	17174704	61	71	O
consisting	17174704	72	82	O
of	17174704	83	85	O
non-nucleoside	17174704	86	100	O
reverse	17174704	101	108	O
transcriptase	17174704	109	122	O
inhibitors	17174704	123	133	O
,	17174704	133	134	O
protease	17174704	135	143	O
inhibitors	17174704	144	154	O
,	17174704	154	155	O
or	17174704	156	158	O
both	17174704	159	163	O
in	17174704	164	166	O
the	17174704	167	170	O
presence	17174704	171	179	O
of	17174704	180	182	O
nucleoside	17174704	183	193	O
reverse	17174704	194	201	O
transcriptase	17174704	202	215	O
inhibitors	17174704	216	226	O
as	17174704	227	229	O
initial	17174704	230	237	O
therapy	17174704	238	245	O
(	17174704	246	247	O
CPCRA	17174704	247	252	O
058	17174704	253	256	O
FIRST	17174704	257	262	O
Study	17174704	263	268	O
):	17174704	268	270	O
a	17174704	271	272	O
long-term	17174704	273	282	O
randomised	17174704	283	293	O
trial	17174704	294	299	O
.	17174704	299	300	O

BACKGROUND	17174704	302	312	O
:	17174704	313	314	O
Long-term	17174704	315	324	O
data	17174704	325	329	O
from	17174704	330	334	O
randomised	17174704	335	345	O
trials	17174704	346	352	O
on	17174704	353	355	O
the	17174704	356	359	O
consequences	17174704	360	372	O
of	17174704	373	375	O
treatment	17174704	376	385	O
with	17174704	386	390	O
a	17174704	391	392	O
protease	17174704	393	401	O
inhibitor	17174704	402	411	O
(	17174704	412	413	O
PI	17174704	413	415	O
)	17174704	415	416	O
,	17174704	416	417	O
non-nucleoside	17174704	418	432	O
reverse	17174704	433	440	O
transcriptase	17174704	441	454	O
inhibitor	17174704	455	464	O
(	17174704	465	466	O
NNRTI	17174704	466	471	O
)	17174704	471	472	O
,	17174704	472	473	O
or	17174704	474	476	O
both	17174704	477	481	O
are	17174704	482	485	O
lacking	17174704	486	493	O
.	17174704	493	494	O

Here	17174704	495	499	O
,	17174704	499	500	O
we	17174704	501	503	O
report	17174704	504	510	O
results	17174704	511	518	O
from	17174704	519	523	O
the	17174704	524	527	O
FIRST	17174704	528	533	O
trial	17174704	534	539	O
,	17174704	539	540	O
which	17174704	541	546	O
compared	17174704	547	555	O
initial	17174704	556	563	O
treatment	17174704	564	573	O
strategies	17174704	574	584	O
for	17174704	585	588	O
clinical	17174704	589	597	O
,	17174704	597	598	O
immunological	17174704	599	612	O
,	17174704	612	613	O
and	17174704	614	617	O
virological	17174704	618	629	O
outcomes	17174704	630	638	O
.	17174704	638	639	O

METHODS	17174704	641	648	O
:	17174704	649	650	O
Between	17174704	651	658	O
1999	17174704	659	663	O
and	17174704	664	667	O
2002	17174704	668	672	O
,	17174704	672	673	O
1397	17174704	674	678	O
antiretroviral-treatment-naive	17174704	679	709	O
patients	17174704	710	718	O
,	17174704	718	719	O
presenting	17174704	720	730	O
at	17174704	731	733	O
18	17174704	734	736	O
clinical	17174704	737	745	O
trial	17174704	746	751	O
units	17174704	752	757	O
with	17174704	758	762	O
80	17174704	763	765	O
research	17174704	766	774	O
sites	17174704	775	780	O
in	17174704	781	783	O
the	17174704	784	787	O
USA	17174704	788	791	O
,	17174704	791	792	O
were	17174704	793	797	O
randomly	17174704	798	806	O
assigned	17174704	807	815	O
in	17174704	816	818	O
a	17174704	819	820	O
ratio	17174704	821	826	O
of	17174704	827	829	O
1:1:1	17174704	830	835	O
to	17174704	836	838	O
a	17174704	839	840	O
protease	17174704	841	849	O
inhibitor	17174704	850	859	O
(	17174704	860	861	O
PI	17174704	861	863	O
)	17174704	863	864	O
strategy	17174704	865	873	O
(	17174704	874	875	O
PI	17174704	875	877	O
plus	17174704	878	882	O
nucleoside	17174704	883	893	O
reverse	17174704	894	901	O
transcriptase	17174704	902	915	O
inhibitor	17174704	916	925	O
[	17174704	926	927	O
NRTI	17174704	927	931	O
]	17174704	931	932	O
;	17174704	932	933	O
n=470	17174704	934	939	O
)	17174704	939	940	O
,	17174704	940	941	O
a	17174704	942	943	O
non-nucleoside	17174704	944	958	O
reverse	17174704	959	966	O
transcriptase	17174704	967	980	O
inhibitor	17174704	981	990	O
(	17174704	991	992	O
NNRTI	17174704	992	997	O
)	17174704	997	998	O
strategy	17174704	999	1007	O
(	17174704	1008	1009	O
NNRTI	17174704	1009	1014	O
plus	17174704	1015	1019	O
NRTI	17174704	1020	1024	O
;	17174704	1024	1025	O
n=463	17174704	1026	1031	O
)	17174704	1031	1032	O
,	17174704	1032	1033	O
or	17174704	1034	1036	O
a	17174704	1037	1038	O
three-class	17174704	1039	1050	O
strategy	17174704	1051	1059	O
(	17174704	1060	1061	O
PI	17174704	1061	1063	O
plus	17174704	1064	1068	O
NNRTI	17174704	1069	1074	O
plus	17174704	1075	1079	O
NRTI	17174704	1080	1084	O
;	17174704	1084	1085	O
n=464	17174704	1086	1091	O
)	17174704	1091	1092	O
.	17174704	1092	1093	O

Primary	17174704	1094	1101	O
endpoints	17174704	1102	1111	O
were	17174704	1112	1116	O
a	17174704	1117	1118	O
composite	17174704	1119	1128	O
of	17174704	1129	1131	O
an	17174704	1132	1134	O
AIDS-defining	17174704	1135	1148	O
event	17174704	1149	1154	O
,	17174704	1154	1155	O
death	17174704	1156	1161	O
,	17174704	1161	1162	O
or	17174704	1163	1165	O
CD4	17174704	1166	1169	O
cell	17174704	1170	1174	O
count	17174704	1175	1180	O
decline	17174704	1181	1188	O
to	17174704	1189	1191	O
less	17174704	1192	1196	O
than	17174704	1197	1201	O
200	17174704	1202	1205	O
cells	17174704	1206	1211	O
per	17174704	1212	1215	O
mm3	17174704	1216	1219	O
for	17174704	1220	1223	O
the	17174704	1224	1227	O
PI	17174704	1228	1230	O
versus	17174704	1231	1237	O
NNRTI	17174704	1238	1243	O
comparison	17174704	1244	1254	O
,	17174704	1254	1255	O
and	17174704	1256	1259	O
average	17174704	1260	1267	O
change	17174704	1268	1274	O
in	17174704	1275	1277	O
CD4	17174704	1278	1281	O
cell	17174704	1282	1286	O
count	17174704	1287	1292	O
at	17174704	1293	1295	O
or	17174704	1296	1298	O
after	17174704	1299	1304	O
32	17174704	1305	1307	O
months	17174704	1308	1314	O
for	17174704	1315	1318	O
the	17174704	1319	1322	O
three-class	17174704	1323	1334	O
versus	17174704	1335	1341	O
combined	17174704	1342	1350	O
two-class	17174704	1351	1360	O
comparison	17174704	1361	1371	O
.	17174704	1371	1372	O

Analyses	17174704	1373	1381	O
were	17174704	1382	1386	O
by	17174704	1387	1389	O
intention-to-treat	17174704	1390	1408	O
.	17174704	1408	1409	O

This	17174704	1410	1414	O
study	17174704	1415	1420	O
is	17174704	1421	1423	O
registered	17174704	1424	1434	O
ClinicalTrials.gov	17174704	1435	1453	O
,	17174704	1453	1454	O
number	17174704	1455	1461	O
NCT00000922	17174704	1462	1473	O
.	17174704	1473	1474	O

FINDINGS	17174704	1476	1484	O
:	17174704	1485	1486	O
1397	17174704	1487	1491	O
patients	17174704	1492	1500	O
were	17174704	1501	1505	O
assessed	17174704	1506	1514	O
for	17174704	1515	1518	O
the	17174704	1519	1522	O
composite	17174704	1523	1532	O
endpoint	17174704	1533	1541	O
.	17174704	1541	1542	O

A	17174704	1543	1544	O
total	17174704	1545	1550	O
of	17174704	1551	1553	O
388	17174704	1554	1557	O
participants	17174704	1558	1570	O
developed	17174704	1571	1580	O
the	17174704	1581	1584	O
composite	17174704	1585	1594	O
endpoint	17174704	1595	1603	O
,	17174704	1603	1604	O
302	17174704	1605	1608	O
developed	17174704	1609	1618	O
AIDS	17174704	1619	1623	B-Outcome
or	17174704	1624	1626	O
died	17174704	1627	1631	B-Outcome
,	17174704	1631	1632	O
and	17174704	1633	1636	O
188	17174704	1637	1640	O
died	17174704	1641	1645	B-Outcome
.	17174704	1645	1646	O

NNRTI	17174704	1647	1652	O
versus	17174704	1653	1659	O
PI	17174704	1660	1662	O
hazard	17174704	1663	1669	O
ratios	17174704	1670	1676	O
(	17174704	1677	1678	O
HRs	17174704	1678	1681	O
)	17174704	1681	1682	O
for	17174704	1683	1686	O
the	17174704	1687	1690	O
composite	17174704	1691	1700	O
endpoint	17174704	1701	1709	O
,	17174704	1709	1710	O
for	17174704	1711	1714	O
AIDS	17174704	1715	1719	B-Outcome
or	17174704	1720	1722	O
death	17174704	1723	1728	B-Outcome
,	17174704	1728	1729	O
for	17174704	1730	1733	O
death	17174704	1734	1739	B-Outcome
,	17174704	1739	1740	O
and	17174704	1741	1744	O
for	17174704	1745	1748	O
virological	17174704	1749	1760	B-Outcome
failure	17174704	1761	1768	I-Outcome
were	17174704	1769	1773	O
1.02	17174704	1774	1778	O
(	17174704	1779	1780	O
95	17174704	1780	1782	O
%	17174704	1782	1783	O
CI	17174704	1784	1786	O
0.79	17174704	1787	1791	O
-	17174704	1791	1792	O
1.31	17174704	1792	1796	O
)	17174704	1796	1797	O
,	17174704	1797	1798	O
1.07	17174704	1799	1803	O
(	17174704	1804	1805	O
0.80	17174704	1805	1809	O
-	17174704	1809	1810	O
1.41	17174704	1810	1814	O
)	17174704	1814	1815	O
,	17174704	1815	1816	O
0.95	17174704	1817	1821	O
(	17174704	1822	1823	O
0.66	17174704	1823	1827	O
-	17174704	1827	1828	O
1.37	17174704	1828	1832	O
)	17174704	1832	1833	O
,	17174704	1833	1834	O
and	17174704	1835	1838	O
0.66	17174704	1839	1843	O
(	17174704	1844	1845	O
0.56	17174704	1845	1849	O
-	17174704	1849	1850	O
0.78	17174704	1850	1854	O
)	17174704	1854	1855	O
,	17174704	1855	1856	O
respectively	17174704	1857	1869	O
.	17174704	1869	1870	O

1196	17174704	1871	1875	O
patients	17174704	1876	1884	O
were	17174704	1885	1889	O
assessed	17174704	1890	1898	O
for	17174704	1899	1902	O
the	17174704	1903	1906	O
three-class	17174704	1907	1918	O
versus	17174704	1919	1925	O
combined	17174704	1926	1934	O
two-class	17174704	1935	1944	O
primary	17174704	1945	1952	O
endpoint	17174704	1953	1961	O
.	17174704	1961	1962	O

Mean	17174704	1963	1967	B-Outcome
change	17174704	1968	1974	I-Outcome
in	17174704	1975	1977	I-Outcome
CD4	17174704	1978	1981	I-Outcome
cell	17174704	1982	1986	I-Outcome
count	17174704	1987	1992	I-Outcome
at	17174704	1993	1995	I-Outcome
or	17174704	1996	1998	I-Outcome
after	17174704	1999	2004	I-Outcome
32	17174704	2005	2007	I-Outcome
months	17174704	2008	2014	I-Outcome
was	17174704	2015	2018	O
+	17174704	2019	2020	O
234	17174704	2020	2023	O
cells	17174704	2024	2029	O
per	17174704	2030	2033	O
mm3	17174704	2034	2037	O
and	17174704	2038	2041	O
+	17174704	2042	2043	O
227	17174704	2043	2046	O
cells	17174704	2047	2052	O
per	17174704	2053	2056	O
mm3	17174704	2057	2060	O
for	17174704	2061	2064	O
the	17174704	2065	2068	O
three-class	17174704	2069	2080	O
and	17174704	2081	2084	O
the	17174704	2085	2088	O
combined	17174704	2089	2097	O
two-class	17174704	2098	2107	O
strategies	17174704	2108	2118	O
(	17174704	2119	2120	O
p=0.62	17174704	2120	2126	O
)	17174704	2126	2127	O
,	17174704	2127	2128	O
respectively	17174704	2129	2141	O
.	17174704	2141	2142	O

HRs	17174704	2143	2146	B-Outcome
(	17174704	2147	2148	I-Outcome
three-class	17174704	2148	2159	I-Outcome
vs	17174704	2160	2162	I-Outcome
combined	17174704	2163	2171	I-Outcome
two-class	17174704	2172	2181	I-Outcome
)	17174704	2181	2182	I-Outcome
for	17174704	2183	2186	I-Outcome
AIDS	17174704	2187	2191	I-Outcome
or	17174704	2192	2194	O
death	17174704	2195	2200	B-Outcome
and	17174704	2201	2204	O
virological	17174704	2205	2216	B-Outcome
failure	17174704	2217	2224	I-Outcome
were	17174704	2225	2229	O
1.15	17174704	2230	2234	O
(	17174704	2235	2236	O
0.91	17174704	2236	2240	O
-	17174704	2240	2241	O
1.45	17174704	2241	2245	O
)	17174704	2245	2246	O
and	17174704	2247	2250	O
0.87	17174704	2251	2255	O
(	17174704	2256	2257	O
0.75	17174704	2257	2261	O
-	17174704	2261	2262	O
1.00	17174704	2262	2266	O
)	17174704	2266	2267	O
,	17174704	2267	2268	O
respectively	17174704	2269	2281	O
.	17174704	2281	2282	O

HRs	17174704	2283	2286	B-Outcome
(	17174704	2287	2288	I-Outcome
three-class	17174704	2288	2299	I-Outcome
vs	17174704	2300	2302	I-Outcome
combined	17174704	2303	2311	I-Outcome
two-class	17174704	2312	2321	I-Outcome
)	17174704	2321	2322	I-Outcome
for	17174704	2323	2326	I-Outcome
AIDS	17174704	2327	2331	I-Outcome
or	17174704	2332	2334	O
death	17174704	2335	2340	B-Outcome
were	17174704	2341	2345	O
similar	17174704	2346	2353	O
for	17174704	2354	2357	O
participants	17174704	2358	2370	O
with	17174704	2371	2375	O
baseline	17174704	2376	2384	O
CD4	17174704	2385	2388	O
cell	17174704	2389	2393	O
counts	17174704	2394	2400	O
of	17174704	2401	2403	O
200	17174704	2404	2407	O
cells	17174704	2408	2413	O
per	17174704	2414	2417	O
mm3	17174704	2418	2421	O
or	17174704	2422	2424	O
less	17174704	2425	2429	O
and	17174704	2430	2433	O
of	17174704	2434	2436	O
more	17174704	2437	2441	O
than	17174704	2442	2446	O
200	17174704	2447	2450	O
cells	17174704	2451	2456	O
per	17174704	2457	2460	O
mm3	17174704	2461	2464	O
(	17174704	2465	2466	O
p=0.38	17174704	2466	2472	O
for	17174704	2473	2476	O
interaction	17174704	2477	2488	O
)	17174704	2488	2489	O
,	17174704	2489	2490	O
and	17174704	2491	2494	O
for	17174704	2495	2498	O
participants	17174704	2499	2511	O
with	17174704	2512	2516	O
baseline	17174704	2517	2525	O
HIV	17174704	2526	2529	O
RNA	17174704	2530	2533	O
concentrations	17174704	2534	2548	O
less	17174704	2549	2553	O
than	17174704	2554	2558	O
100	17174704	2559	2562	O
000	17174704	2563	2566	O
copies	17174704	2567	2573	O
per	17174704	2574	2577	O
mL	17174704	2578	2580	O
and	17174704	2581	2584	O
100,000	17174704	2585	2592	O
copies	17174704	2593	2599	O
per	17174704	2600	2603	O
mL	17174704	2604	2606	O
or	17174704	2607	2609	O
more	17174704	2610	2614	O
(	17174704	2615	2616	O
p=0.26	17174704	2616	2622	O
for	17174704	2623	2626	O
interaction	17174704	2627	2638	O
)	17174704	2638	2639	O
.	17174704	2639	2640	O

Participants	17174704	2641	2653	O
assigned	17174704	2654	2662	O
the	17174704	2663	2666	O
three-class	17174704	2667	2678	O
strategy	17174704	2679	2687	O
were	17174704	2688	2692	O
significantly	17174704	2693	2706	O
more	17174704	2707	2711	O
likely	17174704	2712	2718	O
to	17174704	2719	2721	O
discontinue	17174704	2722	2733	O
treatment	17174704	2734	2743	O
because	17174704	2744	2751	O
of	17174704	2752	2754	O
toxic	17174704	2755	2760	B-Outcome
effects	17174704	2761	2768	I-Outcome
than	17174704	2769	2773	O
were	17174704	2774	2778	O
those	17174704	2779	2784	O
assigned	17174704	2785	2793	O
to	17174704	2794	2796	O
the	17174704	2797	2800	O
two-class	17174704	2801	2810	O
strategies	17174704	2811	2821	O
(	17174704	2822	2823	O
HR	17174704	2823	2825	O
1.58	17174704	2826	2830	O
;	17174704	2830	2831	O
p<0.0001	17174704	2832	2840	O
)	17174704	2840	2841	O
.	17174704	2841	2842	O

INTERPRETATION	17174704	2844	2858	O
:	17174704	2859	2860	O
Initial	17174704	2861	2868	O
treatment	17174704	2869	2878	O
with	17174704	2879	2883	O
either	17174704	2884	2890	O
an	17174704	2891	2893	O
NNRTI-based	17174704	2894	2905	O
regimen	17174704	2906	2913	O
or	17174704	2914	2916	O
a	17174704	2917	2918	O
PI-based	17174704	2919	2927	O
regimen	17174704	2928	2935	O
,	17174704	2935	2936	O
but	17174704	2937	2940	O
not	17174704	2941	2944	O
both	17174704	2945	2949	O
together	17174704	2950	2958	O
,	17174704	2958	2959	O
is	17174704	2960	2962	O
a	17174704	2963	2964	O
good	17174704	2965	2969	O
strategy	17174704	2970	2978	O
for	17174704	2979	2982	O
long-term	17174704	2983	2992	O
antiretroviral	17174704	2993	3007	O
management	17174704	3008	3018	O
in	17174704	3019	3021	O
treatment-naive	17174704	3022	3037	O
patients	17174704	3038	3046	O
with	17174704	3047	3051	O
HIV	17174704	3052	3055	O
.	17174704	3055	3056	O


Continuous	17174705	0	10	O
pralidoxime	17174705	11	22	O
infusion	17174705	23	31	O
versus	17174705	32	38	O
repeated	17174705	39	47	O
bolus	17174705	48	53	O
injection	17174705	54	63	O
to	17174705	64	66	O
treat	17174705	67	72	O
organophosphorus	17174705	73	89	O
pesticide	17174705	90	99	O
poisoning	17174705	100	109	O
:	17174705	109	110	O
a	17174705	111	112	O
randomised	17174705	113	123	O
controlled	17174705	124	134	O
trial	17174705	135	140	O
.	17174705	140	141	O

BACKGROUND	17174705	143	153	O
:	17174705	154	155	O
The	17174705	156	159	O
role	17174705	160	164	O
of	17174705	165	167	O
oximes	17174705	168	174	O
for	17174705	175	178	O
the	17174705	179	182	O
treatment	17174705	183	192	O
of	17174705	193	195	O
organophosphorus	17174705	196	212	O
pesticide	17174705	213	222	O
poisoning	17174705	223	232	O
has	17174705	233	236	O
not	17174705	237	240	O
been	17174705	241	245	O
conclusively	17174705	246	258	O
established	17174705	259	270	O
.	17174705	270	271	O

We	17174705	272	274	O
aimed	17174705	275	280	O
to	17174705	281	283	O
assess	17174705	284	290	O
the	17174705	291	294	O
effectiveness	17174705	295	308	O
of	17174705	309	311	O
a	17174705	312	313	O
constant	17174705	314	322	O
pralidoxime	17174705	323	334	O
infusion	17174705	335	343	O
compared	17174705	344	352	O
with	17174705	353	357	O
repeated	17174705	358	366	O
bolus	17174705	367	372	O
doses	17174705	373	378	O
to	17174705	379	381	O
treat	17174705	382	387	O
patients	17174705	388	396	O
with	17174705	397	401	O
moderately	17174705	402	412	O
severe	17174705	413	419	O
poisoning	17174705	420	429	O
from	17174705	430	434	O
organophosphorus	17174705	435	451	O
pesticides	17174705	452	462	O
.	17174705	462	463	O

METHODS	17174705	465	472	O
:	17174705	473	474	O
200	17174705	475	478	O
patients	17174705	479	487	O
were	17174705	488	492	O
recruited	17174705	493	502	O
to	17174705	503	505	O
our	17174705	506	509	O
single-centre	17174705	510	523	O
,	17174705	523	524	O
open	17174705	525	529	O
randomised	17174705	530	540	O
controlled	17174705	541	551	O
trial	17174705	552	557	O
after	17174705	558	563	O
moderately	17174705	564	574	O
severe	17174705	575	581	O
poisoning	17174705	582	591	O
by	17174705	592	594	O
anticholinesterase	17174705	595	613	O
pesticide	17174705	614	623	O
.	17174705	623	624	O

All	17174705	625	628	O
were	17174705	629	633	O
given	17174705	634	639	O
a	17174705	640	641	O
2	17174705	642	643	O
g	17174705	644	645	O
loading	17174705	646	653	O
dose	17174705	654	658	O
of	17174705	659	661	O
pralidoxime	17174705	662	673	O
over	17174705	674	678	O
30	17174705	679	681	O
min	17174705	682	685	O
.	17174705	685	686	O

Patients	17174705	687	695	O
were	17174705	696	700	O
then	17174705	701	705	O
randomly	17174705	706	714	O
assigned	17174705	715	723	O
to	17174705	724	726	O
control	17174705	727	734	O
and	17174705	735	738	O
study	17174705	739	744	O
groups	17174705	745	751	O
.	17174705	751	752	O

Controls	17174705	753	761	O
were	17174705	762	766	O
given	17174705	767	772	O
a	17174705	773	774	O
bolus	17174705	775	780	O
dose	17174705	781	785	O
of	17174705	786	788	O
1	17174705	789	790	O
g	17174705	791	792	O
pralidoxime	17174705	793	804	O
over	17174705	805	809	O
1	17174705	810	811	O
h	17174705	812	813	O
every	17174705	814	819	O
4	17174705	820	821	O
h	17174705	822	823	O
for	17174705	824	827	O
48	17174705	828	830	O
h.	17174705	831	833	O
The	17174705	834	837	O
study	17174705	838	843	O
group	17174705	844	849	O
had	17174705	850	853	O
a	17174705	854	855	O
constant	17174705	856	864	O
infusion	17174705	865	873	O
of	17174705	874	876	O
1	17174705	877	878	O
g	17174705	879	880	O
over	17174705	881	885	O
an	17174705	886	888	O
hour	17174705	889	893	O
every	17174705	894	899	O
hour	17174705	900	904	O
for	17174705	905	908	O
48	17174705	909	911	O
h.	17174705	912	914	O
Thereafter	17174705	915	925	O
,	17174705	925	926	O
all	17174705	927	930	O
patients	17174705	931	939	O
were	17174705	940	944	O
given	17174705	945	950	O
1	17174705	951	952	O
g	17174705	953	954	O
every	17174705	955	960	O
4	17174705	961	962	O
h	17174705	963	964	O
until	17174705	965	970	O
they	17174705	971	975	O
could	17174705	976	981	O
be	17174705	982	984	O
weaned	17174705	985	991	O
from	17174705	992	996	O
ventilators	17174705	997	1008	O
.	17174705	1008	1009	O

Analysis	17174705	1010	1018	O
was	17174705	1019	1022	O
by	17174705	1023	1025	O
intention	17174705	1026	1035	O
to	17174705	1036	1038	O
treat	17174705	1039	1044	O
.	17174705	1044	1045	O

Primary	17174705	1046	1053	O
outcome	17174705	1054	1061	O
measures	17174705	1062	1070	O
were	17174705	1071	1075	O
median	17174705	1076	1082	O
atropine	17174705	1083	1091	O
dose	17174705	1092	1096	O
needed	17174705	1097	1103	O
within	17174705	1104	1110	O
24	17174705	1111	1113	O
h	17174705	1114	1115	O
,	17174705	1115	1116	O
proportion	17174705	1117	1127	O
of	17174705	1128	1130	O
patients	17174705	1131	1139	O
who	17174705	1140	1143	O
needed	17174705	1144	1150	O
intubation	17174705	1151	1161	O
,	17174705	1161	1162	O
and	17174705	1163	1166	O
number	17174705	1167	1173	O
of	17174705	1174	1176	O
days	17174705	1177	1181	O
on	17174705	1182	1184	O
ventilation	17174705	1185	1196	O
.	17174705	1196	1197	O

The	17174705	1198	1201	O
study	17174705	1202	1207	O
is	17174705	1208	1210	O
registered	17174705	1211	1221	O
at	17174705	1222	1224	O
http://www.clinicaltrials.gov	17174705	1225	1254	O
with	17174705	1255	1259	O
the	17174705	1260	1263	O
identifier	17174705	1264	1274	O
NCT00333944	17174705	1275	1286	O
.	17174705	1286	1287	O

FINDINGS	17174705	1289	1297	O
:	17174705	1298	1299	O
100	17174705	1300	1303	O
patients	17174705	1304	1312	O
were	17174705	1313	1317	O
assigned	17174705	1318	1326	O
the	17174705	1327	1330	O
high-dose	17174705	1331	1340	O
regimen	17174705	1341	1348	O
,	17174705	1348	1349	O
and	17174705	1350	1353	O
100	17174705	1354	1357	O
the	17174705	1358	1361	O
control	17174705	1362	1369	O
regimen	17174705	1370	1377	O
.	17174705	1377	1378	O

There	17174705	1379	1384	O
were	17174705	1385	1389	O
no	17174705	1390	1392	O
drop-outs	17174705	1393	1402	O
.	17174705	1402	1403	O

Patients	17174705	1404	1412	O
receiving	17174705	1413	1422	O
the	17174705	1423	1426	O
high-dose	17174705	1427	1436	O
pralidoxime	17174705	1437	1448	O
regimen	17174705	1449	1456	O
required	17174705	1457	1465	O
less	17174705	1466	1470	O
atropine	17174705	1471	1479	B-Outcome
during	17174705	1480	1486	I-Outcome
the	17174705	1487	1490	I-Outcome
first	17174705	1491	1496	I-Outcome
24	17174705	1497	1499	I-Outcome
h	17174705	1500	1501	I-Outcome
than	17174705	1502	1506	O
controls	17174705	1507	1515	O
(	17174705	1516	1517	O
median	17174705	1517	1523	O
6	17174705	1524	1525	O
mg	17174705	1526	1528	O
vs	17174705	1529	1531	O
30	17174705	1532	1534	O
mg	17174705	1535	1537	O
;	17174705	1537	1538	O
difference	17174705	1539	1549	O
24	17174705	1550	1552	O
mg	17174705	1553	1555	O
[	17174705	1556	1557	O
95	17174705	1557	1559	O
%	17174705	1559	1560	O
CI	17174705	1561	1563	O
24	17174705	1564	1566	O
-	17174705	1566	1567	O
26	17174705	1567	1569	O
,	17174705	1569	1570	O
p<0.0001	17174705	1571	1579	O
]	17174705	1579	1580	O
)	17174705	1580	1581	O
.	17174705	1581	1582	O

88	17174705	1583	1585	O
(	17174705	1586	1587	O
88	17174705	1587	1589	O
%	17174705	1589	1590	O
)	17174705	1590	1591	O
and	17174705	1592	1595	O
64	17174705	1596	1598	O
(	17174705	1599	1600	O
64	17174705	1600	1602	O
%	17174705	1602	1603	O
)	17174705	1603	1604	O
of	17174705	1605	1607	O
controls	17174705	1608	1616	O
and	17174705	1617	1620	O
high-dose	17174705	1621	1630	O
patients	17174705	1631	1639	O
,	17174705	1639	1640	O
respectively	17174705	1641	1653	O
,	17174705	1653	1654	O
needed	17174705	1655	1661	O
intubation	17174705	1662	1672	B-Outcome
during	17174705	1673	1679	I-Outcome
admission	17174705	1680	1689	I-Outcome
to	17174705	1690	1692	I-Outcome
hospital	17174705	1693	1701	I-Outcome
(	17174705	1702	1703	O
relative	17174705	1703	1711	O
risk=0.72	17174705	1712	1721	O
,	17174705	1721	1722	O
0.62	17174705	1723	1727	O
-	17174705	1727	1728	O
0.86	17174705	1728	1732	O
,	17174705	1732	1733	O
p=0.0001	17174705	1734	1742	O
)	17174705	1742	1743	O
.	17174705	1743	1744	O

Control	17174705	1745	1752	O
patients	17174705	1753	1761	O
required	17174705	1762	1770	O
ventilatory	17174705	1771	1782	B-Outcome
support	17174705	1783	1790	I-Outcome
for	17174705	1791	1794	O
longer	17174705	1795	1801	O
(	17174705	1802	1803	O
median	17174705	1803	1809	O
10	17174705	1810	1812	O
days	17174705	1813	1817	O
vs	17174705	1818	1820	O
5	17174705	1821	1822	O
days	17174705	1823	1827	O
;	17174705	1827	1828	O
difference	17174705	1829	1839	O
5	17174705	1840	1841	O
days	17174705	1842	1846	O
[	17174705	1847	1848	O
5	17174705	1848	1849	O
-	17174705	1849	1850	O
6	17174705	1850	1851	O
,	17174705	1851	1852	O
p<0.0001	17174705	1853	1861	O
]	17174705	1861	1862	O
)	17174705	1862	1863	O
.	17174705	1863	1864	O

INTERPRETATION	17174705	1866	1880	O
:	17174705	1881	1882	O
A	17174705	1883	1884	O
high-dose	17174705	1885	1894	O
regimen	17174705	1895	1902	O
of	17174705	1903	1905	O
pralidoxime	17174705	1906	1917	O
,	17174705	1917	1918	O
consisting	17174705	1919	1929	O
of	17174705	1930	1932	O
a	17174705	1933	1934	O
constant	17174705	1935	1943	O
infusion	17174705	1944	1952	O
of	17174705	1953	1955	O
1	17174705	1956	1957	O
g/h	17174705	1958	1961	O
for	17174705	1962	1965	O
48	17174705	1966	1968	O
h	17174705	1969	1970	O
after	17174705	1971	1976	O
a	17174705	1977	1978	O
2	17174705	1979	1980	O
g	17174705	1981	1982	O
loading	17174705	1983	1990	O
dose	17174705	1991	1995	O
,	17174705	1995	1996	O
reduces	17174705	1997	2004	O
morbidity	17174705	2005	2014	B-Outcome
and	17174705	2015	2018	O
mortality	17174705	2019	2028	B-Outcome
in	17174705	2029	2031	O
moderately	17174705	2032	2042	O
severe	17174705	2043	2049	O
cases	17174705	2050	2055	O
of	17174705	2056	2058	O
acute	17174705	2059	2064	O
organophosphorus-pesticide	17174705	2065	2091	O
poisoning	17174705	2092	2101	O
.	17174705	2101	2102	O


A	17438178	0	1	O
randomized	17438178	2	12	O
,	17438178	12	13	O
double-blind	17438178	14	26	O
,	17438178	26	27	O
placebo-controlled	17438178	28	46	O
trial	17438178	47	52	O
of	17438178	53	55	O
pentoxifylline	17438178	56	70	O
for	17438178	71	74	O
the	17438178	75	78	O
treatment	17438178	79	88	O
of	17438178	89	91	O
recurrent	17438178	92	101	O
aphthous	17438178	102	110	O
stomatitis	17438178	111	121	O
.	17438178	121	122	O

OBJECTIVE	17438178	124	133	O
:	17438178	134	135	O
To	17438178	136	138	O
evaluate	17438178	139	147	O
pentoxifylline	17438178	148	162	O
for	17438178	163	166	O
the	17438178	167	170	O
treatment	17438178	171	180	O
of	17438178	181	183	O
recurrent	17438178	184	193	O
aphthous	17438178	194	202	O
stomatitis	17438178	203	213	O
.	17438178	213	214	O

DESIGN	17438178	216	222	O
:	17438178	223	224	O
A	17438178	225	226	O
60-day	17438178	227	233	O
,	17438178	233	234	O
randomized	17438178	235	245	O
,	17438178	245	246	O
double-blind	17438178	247	259	O
,	17438178	259	260	O
placebo-controlled	17438178	261	279	O
trial	17438178	280	285	O
with	17438178	286	290	O
a	17438178	291	292	O
60-day	17438178	293	299	O
no	17438178	300	302	O
treatment	17438178	303	312	O
follow-up	17438178	313	322	O
.	17438178	322	323	O

SETTING	17438178	325	332	O
:	17438178	333	334	O
An	17438178	335	337	O
oral	17438178	338	342	O
medicine	17438178	343	351	O
specialist	17438178	352	362	O
referral	17438178	363	371	O
center	17438178	372	378	O
in	17438178	379	381	O
Manchester	17438178	382	392	O
.	17438178	392	393	O

PARTICIPANTS	17438178	395	407	O
:	17438178	408	409	O
Forty-nine	17438178	410	420	O
volunteers	17438178	421	431	O
who	17438178	432	435	O
passed	17438178	436	442	O
the	17438178	443	446	O
initial	17438178	447	454	O
assessment	17438178	455	465	O
for	17438178	466	469	O
recurrent	17438178	470	479	O
aphthous	17438178	480	488	O
stomatitis	17438178	489	499	O
entered	17438178	500	507	O
a	17438178	508	509	O
pretrial	17438178	510	518	O
phase	17438178	519	524	O
in	17438178	525	527	O
which	17438178	528	533	O
their	17438178	534	539	O
eligibility	17438178	540	551	O
for	17438178	552	555	O
the	17438178	556	559	O
trial	17438178	560	565	O
phase	17438178	566	571	O
of	17438178	572	574	O
the	17438178	575	578	O
study	17438178	579	584	O
was	17438178	585	588	O
assessed	17438178	589	597	O
.	17438178	597	598	O

Sixteen	17438178	599	606	O
subjects	17438178	607	615	O
were	17438178	616	620	O
deemed	17438178	621	627	O
ineligible	17438178	628	638	O
,	17438178	638	639	O
and	17438178	640	643	O
7	17438178	644	645	O
failed	17438178	646	652	O
to	17438178	653	655	O
attend	17438178	656	662	O
or	17438178	663	665	O
withdrew	17438178	666	674	O
.	17438178	674	675	O

The	17438178	676	679	O
remaining	17438178	680	689	O
26	17438178	690	692	O
subjects	17438178	693	701	O
were	17438178	702	706	O
randomized	17438178	707	717	O
to	17438178	718	720	O
placebo	17438178	721	728	O
or	17438178	729	731	O
treatment	17438178	732	741	O
.	17438178	741	742	O

Six	17438178	743	746	O
subjects	17438178	747	755	O
withdrew	17438178	756	764	O
because	17438178	765	772	O
of	17438178	773	775	O
adverse	17438178	776	783	O
effects	17438178	784	791	O
,	17438178	791	792	O
and	17438178	793	796	O
1	17438178	797	798	O
was	17438178	799	802	O
unavailable	17438178	803	814	O
for	17438178	815	818	O
follow-up	17438178	819	828	O
.	17438178	828	829	O

INTERVENTION	17438178	831	843	O
:	17438178	844	845	O
Pentoxifylline	17438178	846	860	O
(	17438178	861	862	O
also	17438178	862	866	O
called	17438178	867	873	O
oxpentifylline	17438178	874	888	O
)	17438178	888	889	O
,	17438178	889	890	O
400	17438178	891	894	O
mg	17438178	895	897	O
3	17438178	898	899	O
times	17438178	900	905	O
daily	17438178	906	911	O
,	17438178	911	912	O
or	17438178	913	915	O
matching	17438178	916	924	O
placebo	17438178	925	932	O
.	17438178	932	933	O

MAIN	17438178	935	939	O
OUTCOME	17438178	940	947	O
MEASURE	17438178	948	955	O
:	17438178	956	957	O
A	17438178	958	959	O
reduction	17438178	960	969	O
in	17438178	970	972	O
the	17438178	973	976	O
median	17438178	977	983	O
pain	17438178	984	988	O
score	17438178	989	994	O
,	17438178	994	995	O
ulcer	17438178	996	1001	O
size	17438178	1002	1006	O
,	17438178	1006	1007	O
number	17438178	1008	1014	O
of	17438178	1015	1017	O
ulcers	17438178	1018	1024	O
,	17438178	1024	1025	O
or	17438178	1026	1028	O
total	17438178	1029	1034	O
number	17438178	1035	1041	O
of	17438178	1042	1044	O
ulcer	17438178	1045	1050	O
episodes	17438178	1051	1059	O
.	17438178	1059	1060	O

RESULTS	17438178	1062	1069	O
:	17438178	1070	1071	O
Patients	17438178	1072	1080	O
taking	17438178	1081	1087	O
pentoxifylline	17438178	1088	1102	O
had	17438178	1103	1106	O
less	17438178	1107	1111	O
pain	17438178	1112	1116	B-Outcome
and	17438178	1117	1120	O
reported	17438178	1121	1129	O
smaller	17438178	1130	1137	O
and	17438178	1138	1141	O
fewer	17438178	1142	1147	O
ulcers	17438178	1148	1154	B-Outcome
compared	17438178	1155	1163	O
with	17438178	1164	1168	O
baseline	17438178	1169	1177	O
.	17438178	1177	1178	O

Patients	17438178	1179	1187	O
taking	17438178	1188	1194	O
placebo	17438178	1195	1202	O
reported	17438178	1203	1211	O
no	17438178	1212	1214	O
improvement	17438178	1215	1226	O
in	17438178	1227	1229	O
these	17438178	1230	1235	O
variables	17438178	1236	1245	O
.	17438178	1245	1246	O

Patients	17438178	1247	1255	O
taking	17438178	1256	1262	O
pentoxifylline	17438178	1263	1277	O
also	17438178	1278	1282	O
reported	17438178	1283	1291	O
more	17438178	1292	1296	O
ulcer-free	17438178	1297	1307	B-Outcome
days	17438178	1308	1312	I-Outcome
than	17438178	1313	1317	O
those	17438178	1318	1323	O
taking	17438178	1324	1330	O
placebo	17438178	1331	1338	O
.	17438178	1338	1339	O

However	17438178	1340	1347	O
,	17438178	1347	1348	O
the	17438178	1349	1352	O
differences	17438178	1353	1364	O
were	17438178	1365	1369	O
small	17438178	1370	1375	O
and	17438178	1376	1379	O
,	17438178	1379	1380	O
with	17438178	1381	1385	O
the	17438178	1386	1389	O
exception	17438178	1390	1399	O
of	17438178	1400	1402	O
median	17438178	1403	1409	B-Outcome
ulcer	17438178	1410	1415	I-Outcome
size	17438178	1416	1420	I-Outcome
(	17438178	1421	1422	O
P	17438178	1422	1423	O
=	17438178	1424	1425	O
.05	17438178	1426	1429	O
)	17438178	1429	1430	O
,	17438178	1430	1431	O
did	17438178	1432	1435	O
not	17438178	1436	1439	O
reach	17438178	1440	1445	O
statistical	17438178	1446	1457	O
significance	17438178	1458	1470	O
.	17438178	1470	1471	O

Adverse	17438178	1472	1479	B-Outcome
effects	17438178	1480	1487	I-Outcome
were	17438178	1488	1492	O
common	17438178	1493	1499	O
with	17438178	1500	1504	O
pentoxifylline	17438178	1505	1519	O
,	17438178	1519	1520	O
but	17438178	1521	1524	O
not	17438178	1525	1528	O
significantly	17438178	1529	1542	O
different	17438178	1543	1552	O
from	17438178	1553	1557	O
those	17438178	1558	1563	O
experienced	17438178	1564	1575	O
by	17438178	1576	1578	O
patients	17438178	1579	1587	O
taking	17438178	1588	1594	O
placebo	17438178	1595	1602	O
.	17438178	1602	1603	O

CONCLUSIONS	17438178	1605	1616	O
:	17438178	1617	1618	O
Although	17438178	1619	1627	O
pentoxifylline	17438178	1628	1642	O
may	17438178	1643	1646	O
have	17438178	1647	1651	O
some	17438178	1652	1656	O
benefit	17438178	1657	1664	O
in	17438178	1665	1667	O
the	17438178	1668	1671	O
treatment	17438178	1672	1681	O
of	17438178	1682	1684	O
recurrent	17438178	1685	1694	O
aphthous	17438178	1695	1703	O
stomatitis	17438178	1704	1714	O
,	17438178	1714	1715	O
the	17438178	1716	1719	O
benefit	17438178	1720	1727	O
is	17438178	1728	1730	O
limited	17438178	1731	1738	O
.	17438178	1738	1739	O

It	17438178	1740	1742	O
may	17438178	1743	1746	O
have	17438178	1747	1751	O
a	17438178	1752	1753	O
role	17438178	1754	1758	O
in	17438178	1759	1761	O
the	17438178	1762	1765	O
treatment	17438178	1766	1775	O
of	17438178	1776	1778	O
patients	17438178	1779	1787	O
unresponsive	17438178	1788	1800	O
to	17438178	1801	1803	O
other	17438178	1804	1809	O
treatments	17438178	1810	1820	O
,	17438178	1820	1821	O
but	17438178	1822	1825	O
can	17438178	1826	1829	O
not	17438178	1829	1832	O
yet	17438178	1833	1836	O
be	17438178	1837	1839	O
recommended	17438178	1840	1851	O
as	17438178	1852	1854	O
a	17438178	1855	1856	O
first-line	17438178	1857	1867	O
treatment	17438178	1868	1877	O
.	17438178	1877	1878	O


Efficacy	17472838	0	8	O
and	17472838	9	12	O
safety	17472838	13	19	O
of	17472838	20	22	O
a	17472838	23	24	O
very-low-protein	17472838	25	41	O
diet	17472838	42	46	O
when	17472838	47	51	O
postponing	17472838	52	62	O
dialysis	17472838	63	71	O
in	17472838	72	74	O
the	17472838	75	78	O
elderly	17472838	79	86	O
:	17472838	86	87	O
a	17472838	88	89	O
prospective	17472838	90	101	O
randomized	17472838	102	112	O
multicenter	17472838	113	124	O
controlled	17472838	125	135	O
study	17472838	136	141	O
.	17472838	141	142	O

BACKGROUND	17472838	144	154	O
:	17472838	155	156	O
A	17472838	157	158	O
supplemented	17472838	159	171	O
very-low-protein	17472838	172	188	O
diet	17472838	189	193	O
(	17472838	194	195	O
sVLPD	17472838	195	200	O
)	17472838	200	201	O
seems	17472838	202	207	O
to	17472838	208	210	O
be	17472838	211	213	O
safe	17472838	214	218	O
when	17472838	219	223	O
postponing	17472838	224	234	O
dialysis	17472838	235	243	O
therapy	17472838	244	251	O
.	17472838	251	252	O

STUDY	17472838	254	259	O
DESIGN	17472838	260	266	O
:	17472838	267	268	O
Prospective	17472838	269	280	O
multicenter	17472838	281	292	O
randomized	17472838	293	303	O
controlled	17472838	304	314	O
study	17472838	315	320	O
designed	17472838	321	329	O
to	17472838	330	332	O
assess	17472838	333	339	O
the	17472838	340	343	O
noninferiority	17472838	344	358	O
of	17472838	359	361	O
diet	17472838	362	366	O
versus	17472838	367	373	O
dialysis	17472838	374	382	O
in	17472838	383	385	O
1-year	17472838	386	392	O
mortality	17472838	393	402	O
assessed	17472838	403	411	O
by	17472838	412	414	O
using	17472838	415	420	O
intention-to-treat	17472838	421	439	O
and	17472838	440	443	O
per-protocol	17472838	444	456	O
analysis	17472838	457	465	O
.	17472838	465	466	O

SETTING	17472838	468	475	O
&	17472838	476	477	O
PARTICIPANTS	17472838	478	490	O
:	17472838	491	492	O
Italian	17472838	493	500	O
uremic	17472838	501	507	O
patients	17472838	508	516	O
without	17472838	517	524	O
diabetes	17472838	525	533	O
older	17472838	534	539	O
than	17472838	540	544	O
70	17472838	545	547	O
years	17472838	548	553	O
with	17472838	554	558	O
glomerular	17472838	559	569	O
filtration	17472838	570	580	O
rate	17472838	581	585	O
of	17472838	586	588	O
5	17472838	589	590	O
to	17472838	591	593	O
7	17472838	594	595	O
mL/min	17472838	596	602	O
(	17472838	603	604	O
0.08	17472838	604	608	O
to	17472838	609	611	O
0.12	17472838	612	616	O
mL/s	17472838	617	621	O
)	17472838	621	622	O
.	17472838	622	623	O

INTERVENTION	17472838	625	637	O
:	17472838	638	639	O
Randomization	17472838	640	653	O
to	17472838	654	656	O
an	17472838	657	659	O
sVLPD	17472838	660	665	O
(	17472838	666	667	O
diet	17472838	667	671	O
group	17472838	672	677	O
)	17472838	677	678	O
or	17472838	679	681	O
dialysis	17472838	682	690	O
.	17472838	690	691	O

The	17472838	692	695	O
sVLPD	17472838	696	701	O
is	17472838	702	704	O
a	17472838	705	706	O
vegan	17472838	707	712	O
diet	17472838	713	717	O
(	17472838	718	719	O
35	17472838	719	721	O
kcal	17472838	722	726	O
;	17472838	726	727	O
proteins	17472838	728	736	O
,	17472838	736	737	O
0.3	17472838	738	741	O
g/kg	17472838	742	746	O
body	17472838	747	751	O
weight	17472838	752	758	O
daily	17472838	759	764	O
)	17472838	764	765	O
supplemented	17472838	766	778	O
with	17472838	779	783	O
keto-analogues	17472838	784	798	O
,	17472838	798	799	O
amino	17472838	800	805	O
acids	17472838	806	811	O
,	17472838	811	812	O
and	17472838	813	816	O
vitamins	17472838	817	825	O
.	17472838	825	826	O

Patients	17472838	827	835	O
following	17472838	836	845	O
an	17472838	846	848	O
sVLPD	17472838	849	854	O
started	17472838	855	862	O
dialysis	17472838	863	871	O
therapy	17472838	872	879	O
in	17472838	880	882	O
the	17472838	883	886	O
case	17472838	887	891	O
of	17472838	892	894	O
malnutrition	17472838	895	907	O
,	17472838	907	908	O
intractable	17472838	909	920	O
fluid	17472838	921	926	O
overload	17472838	927	935	O
,	17472838	935	936	O
hyperkalemia	17472838	937	949	O
,	17472838	949	950	O
or	17472838	951	953	O
appearance	17472838	954	964	O
of	17472838	965	967	O
uremic	17472838	968	974	O
symptoms	17472838	975	983	O
.	17472838	983	984	O

OUTCOMES	17472838	986	994	O
&	17472838	995	996	O
MEASUREMENTS	17472838	997	1009	O
:	17472838	1010	1011	O
Mortality	17472838	1012	1021	O
,	17472838	1021	1022	O
hospitalization	17472838	1023	1038	O
,	17472838	1038	1039	O
and	17472838	1040	1043	O
metabolic	17472838	1044	1053	O
markers	17472838	1054	1061	O
.	17472838	1061	1062	O

RESULTS	17472838	1064	1071	O
:	17472838	1072	1073	O
56	17472838	1074	1076	O
patients	17472838	1077	1085	O
were	17472838	1086	1090	O
randomly	17472838	1091	1099	O
assigned	17472838	1100	1108	O
to	17472838	1109	1111	O
each	17472838	1112	1116	O
group	17472838	1117	1122	O
,	17472838	1122	1123	O
median	17472838	1124	1130	O
follow-up	17472838	1131	1140	O
was	17472838	1141	1144	O
26.5	17472838	1145	1149	O
months	17472838	1150	1156	O
(	17472838	1157	1158	O
interquartile	17472838	1158	1171	O
range	17472838	1172	1177	O
,	17472838	1177	1178	O
40	17472838	1179	1181	O
)	17472838	1181	1182	O
,	17472838	1182	1183	O
and	17472838	1184	1187	O
patients	17472838	1188	1196	O
in	17472838	1197	1199	O
the	17472838	1200	1203	O
diet	17472838	1204	1208	O
group	17472838	1209	1214	O
spent	17472838	1215	1220	O
a	17472838	1221	1222	O
median	17472838	1223	1229	O
of	17472838	1230	1232	O
10.7	17472838	1233	1237	O
months	17472838	1238	1244	O
(	17472838	1245	1246	O
interquartile	17472838	1246	1259	O
range	17472838	1260	1265	O
,	17472838	1265	1266	O
11	17472838	1267	1269	O
)	17472838	1269	1270	O
following	17472838	1271	1280	O
an	17472838	1281	1283	O
sVLPD	17472838	1284	1289	O
.	17472838	1289	1290	O

Forty	17472838	1291	1296	O
patients	17472838	1297	1305	O
in	17472838	1306	1308	O
the	17472838	1309	1312	O
diet	17472838	1313	1317	O
group	17472838	1318	1323	O
started	17472838	1324	1331	O
dialysis	17472838	1332	1340	O
treatment	17472838	1341	1350	O
because	17472838	1351	1358	O
of	17472838	1359	1361	O
either	17472838	1362	1368	O
fluid	17472838	1369	1374	O
overload	17472838	1375	1383	O
or	17472838	1384	1386	O
hyperkalemia	17472838	1387	1399	O
.	17472838	1399	1400	O

There	17472838	1401	1406	O
were	17472838	1407	1411	O
31	17472838	1412	1414	O
deaths	17472838	1415	1421	B-Outcome
(	17472838	1422	1423	O
55	17472838	1423	1425	O
%	17472838	1425	1426	O
)	17472838	1426	1427	O
in	17472838	1428	1430	O
the	17472838	1431	1434	O
dialysis	17472838	1435	1443	O
group	17472838	1444	1449	O
and	17472838	1450	1453	O
28	17472838	1454	1456	O
deaths	17472838	1457	1463	B-Outcome
(	17472838	1464	1465	O
50	17472838	1465	1467	O
%	17472838	1467	1468	O
)	17472838	1468	1469	O
in	17472838	1470	1472	O
the	17472838	1473	1476	O
diet	17472838	1477	1481	O
group	17472838	1482	1487	O
.	17472838	1487	1488	O

One-year	17472838	1489	1497	B-Outcome
observed	17472838	1498	1506	I-Outcome
survival	17472838	1507	1515	I-Outcome
rates	17472838	1516	1521	I-Outcome
at	17472838	1522	1524	O
intention	17472838	1525	1534	O
to	17472838	1535	1537	O
treat	17472838	1538	1543	O
were	17472838	1544	1548	O
83.7	17472838	1549	1553	O
%	17472838	1553	1554	O
(	17472838	1555	1556	O
95	17472838	1556	1558	O
%	17472838	1558	1559	O
confidence	17472838	1560	1570	O
interval	17472838	1571	1579	O
[	17472838	1580	1581	O
CI	17472838	1581	1583	O
]	17472838	1583	1584	O
,	17472838	1584	1585	O
74.5	17472838	1586	1590	O
to	17472838	1591	1593	O
94.0	17472838	1594	1598	O
)	17472838	1598	1599	O
in	17472838	1600	1602	O
the	17472838	1603	1606	O
dialysis	17472838	1607	1615	O
group	17472838	1616	1621	O
versus	17472838	1622	1628	O
87.3	17472838	1629	1633	O
%	17472838	1633	1634	O
(	17472838	1635	1636	O
95	17472838	1636	1638	O
%	17472838	1638	1639	O
CI	17472838	1640	1642	O
,	17472838	1642	1643	O
78.9	17472838	1644	1648	O
to	17472838	1649	1651	O
96.5	17472838	1652	1656	O
)	17472838	1656	1657	O
in	17472838	1658	1660	O
the	17472838	1661	1664	O
diet	17472838	1665	1669	O
group	17472838	1670	1675	O
(	17472838	1676	1677	O
log-rank	17472838	1677	1685	O
test	17472838	1686	1690	O
for	17472838	1691	1694	O
noninferiority	17472838	1695	1709	O
,	17472838	1709	1710	O
P	17472838	1711	1712	O
<	17472838	1713	1714	O
0.001	17472838	1715	1720	O
;	17472838	1720	1721	O
for	17472838	1722	1725	O
superiority	17472838	1726	1737	O
,	17472838	1737	1738	O
P	17472838	1739	1740	O
=	17472838	1741	1742	O
0.6	17472838	1743	1746	O
):	17472838	1746	1748	O
the	17472838	1749	1752	O
difference	17472838	1753	1763	O
in	17472838	1764	1766	O
survival	17472838	1767	1775	B-Outcome
was	17472838	1776	1779	O
-3.6	17472838	1780	1784	O
%	17472838	1784	1785	O
(	17472838	1786	1787	O
95	17472838	1787	1789	O
%	17472838	1789	1790	O
CI	17472838	1791	1793	O
,	17472838	1793	1794	O
-17	17472838	1795	1798	O
to	17472838	1799	1801	O
+	17472838	1802	1803	O
10	17472838	1803	1805	O
;	17472838	1805	1806	O
P	17472838	1807	1808	O
=	17472838	1809	1810	O
0.002	17472838	1811	1816	O
)	17472838	1816	1817	O
.	17472838	1817	1818	O

The	17472838	1819	1822	O
hazard	17472838	1823	1829	B-Outcome
ratio	17472838	1830	1835	I-Outcome
for	17472838	1836	1839	I-Outcome
hospitalization	17472838	1840	1855	I-Outcome
was	17472838	1856	1859	O
1.50	17472838	1860	1864	O
for	17472838	1865	1868	O
the	17472838	1869	1872	O
dialysis	17472838	1873	1881	O
group	17472838	1882	1887	O
(	17472838	1888	1889	O
95	17472838	1889	1891	O
%	17472838	1891	1892	O
CI	17472838	1893	1895	O
,	17472838	1895	1896	O
1.11	17472838	1897	1901	O
to	17472838	1902	1904	O
2.01	17472838	1905	1909	O
;	17472838	1909	1910	O
P	17472838	1911	1912	O
<	17472838	1913	1914	O
0.01	17472838	1915	1919	O
)	17472838	1919	1920	O
.	17472838	1920	1921	O

LIMITATIONS	17472838	1923	1934	O
:	17472838	1935	1936	O
The	17472838	1937	1940	O
unblinded	17472838	1941	1950	O
nature	17472838	1951	1957	O
of	17472838	1958	1960	O
the	17472838	1961	1964	O
study	17472838	1965	1970	O
,	17472838	1970	1971	O
exclusion	17472838	1972	1981	O
of	17472838	1982	1984	O
patients	17472838	1985	1993	O
with	17472838	1994	1998	O
diabetes	17472838	1999	2007	O
,	17472838	2007	2008	O
and	17472838	2009	2012	O
incomplete	17472838	2013	2023	O
enrollment	17472838	2024	2034	O
.	17472838	2034	2035	O

CONCLUSION	17472838	2037	2047	O
:	17472838	2048	2049	O
An	17472838	2050	2052	O
sVLPD	17472838	2053	2058	O
was	17472838	2059	2062	O
effective	17472838	2063	2072	O
and	17472838	2073	2076	O
safe	17472838	2077	2081	B-Outcome
when	17472838	2082	2086	O
postponing	17472838	2087	2097	O
dialysis	17472838	2098	2106	O
treatment	17472838	2107	2116	O
in	17472838	2117	2119	O
elderly	17472838	2120	2127	O
patients	17472838	2128	2136	O
without	17472838	2137	2144	O
diabetes	17472838	2145	2153	O
.	17472838	2153	2154	O


A	17631392	0	1	O
randomized	17631392	2	12	O
placebo-controlled	17631392	13	31	O
trial	17631392	32	37	O
comparing	17631392	38	47	O
the	17631392	48	51	O
efficacy	17631392	52	60	O
of	17631392	61	63	O
etoricoxib	17631392	64	74	O
30	17631392	75	77	O
mg	17631392	78	80	O
and	17631392	81	84	O
ibuprofen	17631392	85	94	O
2400	17631392	95	99	O
mg	17631392	100	102	O
for	17631392	103	106	O
the	17631392	107	110	O
treatment	17631392	111	120	O
of	17631392	121	123	O
patients	17631392	124	132	O
with	17631392	133	137	O
osteoarthritis	17631392	138	152	O
.	17631392	152	153	O

OBJECTIVE	17631392	155	164	O
:	17631392	165	166	O
We	17631392	167	169	O
compared	17631392	170	178	O
the	17631392	179	182	O
efficacy	17631392	183	191	O
of	17631392	192	194	O
etoricoxib	17631392	195	205	O
30	17631392	206	208	O
mg	17631392	209	211	O
to	17631392	212	214	O
placebo	17631392	215	222	O
and	17631392	223	226	O
ibuprofen	17631392	227	236	O
2400	17631392	237	241	O
mg	17631392	242	244	O
for	17631392	245	248	O
the	17631392	249	252	O
treatment	17631392	253	262	O
of	17631392	263	265	O
osteoarthritis	17631392	266	280	O
(	17631392	281	282	O
OA	17631392	282	284	O
)	17631392	284	285	O
of	17631392	286	288	O
the	17631392	289	292	O
hip	17631392	293	296	O
and	17631392	297	300	O
knee	17631392	301	305	O
.	17631392	305	306	O

DESIGN	17631392	308	314	O
:	17631392	315	316	O
In	17631392	317	319	O
this	17631392	320	324	O
12-week	17631392	325	332	O
,	17631392	332	333	O
randomized	17631392	334	344	O
,	17631392	344	345	O
double-blind	17631392	346	358	O
,	17631392	358	359	O
placebo-	17631392	360	368	O
and	17631392	369	372	O
active-comparator-controlled	17631392	373	401	O
trial	17631392	402	407	O
,	17631392	407	408	O
548	17631392	409	412	O
patients	17631392	413	421	O
(	17631392	422	423	O
median	17631392	423	429	O
age	17631392	430	433	O
63	17631392	434	436	O
years	17631392	437	442	O
)	17631392	442	443	O
with	17631392	444	448	O
OA	17631392	449	451	O
of	17631392	452	454	O
the	17631392	455	458	O
hip	17631392	459	462	O
or	17631392	463	465	O
knee	17631392	466	470	O
were	17631392	471	475	O
randomized	17631392	476	486	O
to	17631392	487	489	O
receive	17631392	490	497	O
placebo	17631392	498	505	O
,	17631392	505	506	O
etoricoxib	17631392	507	517	O
30	17631392	518	520	O
mg	17631392	521	523	O
q.d	17631392	524	527	O
.	17631392	527	528	O
,	17631392	528	529	O
or	17631392	530	532	O
ibuprofen	17631392	533	542	O
800	17631392	543	546	O
mg	17631392	547	549	O
t.i.d	17631392	550	555	O
.	17631392	555	556	O

Demonstration	17631392	557	570	O
of	17631392	571	573	O
etoricoxib	17631392	574	584	O
's	17631392	584	586	O
efficacy	17631392	587	595	O
vs	17631392	596	598	O
placebo	17631392	599	606	O
and	17631392	607	610	O
comparison	17631392	611	621	O
of	17631392	622	624	O
its	17631392	625	628	O
efficacy	17631392	629	637	O
to	17631392	638	640	O
ibuprofen	17631392	641	650	O
were	17631392	651	655	O
assessed	17631392	656	664	O
using	17631392	665	670	O
three	17631392	671	676	O
co-primary	17631392	677	687	O
endpoints	17631392	688	697	O
:	17631392	697	698	O
Western	17631392	699	706	O
Ontario	17631392	707	714	O
and	17631392	715	718	O
McMaster	17631392	719	727	O
's	17631392	727	729	O
University	17631392	730	740	O
Osteoarthritis	17631392	741	755	O
Index	17631392	756	761	O
(	17631392	762	763	O
WOMAC	17631392	763	768	O
)	17631392	768	769	O
Pain	17631392	770	774	O
Subscale	17631392	775	783	O
(	17631392	784	785	O
WOMAC-PS	17631392	785	793	O
)	17631392	793	794	O
;	17631392	794	795	O
WOMAC	17631392	796	801	O
Physical	17631392	802	810	O
Function	17631392	811	819	O
Subscale	17631392	820	828	O
(	17631392	829	830	O
WOMAC-PFS	17631392	830	839	O
)	17631392	839	840	O
;	17631392	840	841	O
and	17631392	842	845	O
Patient	17631392	846	853	O
Global	17631392	854	860	O
Assessment	17631392	861	871	O
of	17631392	872	874	O
Disease	17631392	875	882	O
Status	17631392	883	889	O
(	17631392	890	891	O
PGADS	17631392	891	896	O
)	17631392	896	897	O
.	17631392	897	898	O

Each	17631392	899	903	O
primary	17631392	904	911	O
endpoint	17631392	912	920	O
utilizes	17631392	921	929	O
a	17631392	930	931	O
0	17631392	932	933	O
-	17631392	933	934	O
100	17631392	934	937	O
mm	17631392	938	940	O
visual	17631392	941	947	O
analog	17631392	948	954	O
scale	17631392	955	960	O
.	17631392	960	961	O

To	17631392	962	964	O
demonstrate	17631392	965	976	O
comparable	17631392	977	987	O
efficacy	17631392	988	996	O
of	17631392	997	999	O
etoricoxib	17631392	1000	1010	O
vs	17631392	1011	1013	O
ibuprofen	17631392	1014	1023	O
,	17631392	1023	1024	O
the	17631392	1025	1028	O
95	17631392	1029	1031	O
%	17631392	1031	1032	O
confidence	17631392	1033	1043	O
intervals	17631392	1044	1053	O
(	17631392	1054	1055	O
CIs	17631392	1055	1058	O
)	17631392	1058	1059	O
for	17631392	1060	1063	O
the	17631392	1064	1067	O
difference	17631392	1068	1078	O
in	17631392	1079	1081	O
the	17631392	1082	1085	O
least	17631392	1086	1091	O
squares	17631392	1092	1099	O
(	17631392	1100	1101	O
LS	17631392	1101	1103	O
)	17631392	1103	1104	O
mean	17631392	1105	1109	O
change	17631392	1110	1116	O
over	17631392	1117	1121	O
12	17631392	1122	1124	O
weeks	17631392	1125	1130	O
for	17631392	1131	1134	O
all	17631392	1135	1138	O
three	17631392	1139	1144	O
co-primary	17631392	1145	1155	O
endpoints	17631392	1156	1165	O
had	17631392	1166	1169	O
to	17631392	1170	1172	O
fall	17631392	1173	1177	O
within	17631392	1178	1184	O
+	17631392	1185	1186	O
/-10	17631392	1186	1190	O
mm	17631392	1191	1193	O
.	17631392	1193	1194	O

Safety	17631392	1195	1201	O
and	17631392	1202	1205	O
tolerability	17631392	1206	1218	O
data	17631392	1219	1223	O
were	17631392	1224	1228	O
collected	17631392	1229	1238	O
throughout	17631392	1239	1249	O
the	17631392	1250	1253	O
study	17631392	1254	1259	O
.	17631392	1259	1260	O

RESULTS	17631392	1262	1269	O
:	17631392	1270	1271	O
Mean	17631392	1272	1276	O
baseline	17631392	1277	1285	O
values	17631392	1286	1292	O
for	17631392	1293	1296	O
the	17631392	1297	1300	O
three	17631392	1301	1306	O
co-primary	17631392	1307	1317	O
endpoints	17631392	1318	1327	O
ranged	17631392	1328	1334	O
from	17631392	1335	1339	O
62.52	17631392	1340	1345	O
to	17631392	1346	1348	O
70.14	17631392	1349	1354	O
mm	17631392	1355	1357	O
.	17631392	1357	1358	O

Both	17631392	1359	1363	O
etoricoxib	17631392	1364	1374	O
and	17631392	1375	1378	O
ibuprofen	17631392	1379	1388	O
demonstrated	17631392	1389	1401	O
superior	17631392	1402	1410	O
(	17631392	1411	1412	O
P	17631392	1412	1413	O
<	17631392	1413	1414	O
or	17631392	1415	1417	O
=	17631392	1418	1419	O
0.002	17631392	1419	1424	O
)	17631392	1424	1425	O
efficacy	17631392	1426	1434	B-Outcome
for	17631392	1435	1438	O
all	17631392	1439	1442	O
primary	17631392	1443	1450	O
endpoints	17631392	1451	1460	O
.	17631392	1460	1461	O

The	17631392	1462	1465	O
LS	17631392	1466	1468	O
mean	17631392	1469	1473	O
(	17631392	1474	1475	O
mm	17631392	1475	1477	O
)	17631392	1477	1478	O
changes	17631392	1479	1486	O
(	17631392	1487	1488	O
95	17631392	1488	1490	O
%	17631392	1490	1491	O
CI	17631392	1492	1494	O
)	17631392	1494	1495	O
over	17631392	1496	1500	O
12	17631392	1501	1503	O
weeks	17631392	1504	1509	O
for	17631392	1510	1513	O
etoricoxib	17631392	1514	1524	O
and	17631392	1525	1528	O
ibuprofen	17631392	1529	1538	O
,	17631392	1538	1539	O
respectively	17631392	1540	1552	O
,	17631392	1552	1553	O
compared	17631392	1554	1562	O
to	17631392	1563	1565	O
placebo	17631392	1566	1573	O
were	17631392	1574	1578	O
given	17631392	1579	1584	O
as	17631392	1585	1587	O
follows	17631392	1588	1595	O
:	17631392	1595	1596	O
WOMAC-PS	17631392	1597	1605	B-Outcome
:	17631392	1605	1606	O
-11.66	17631392	1607	1613	O
(	17631392	1614	1615	O
-16.31	17631392	1615	1621	O
,	17631392	1621	1622	O
-7.01	17631392	1623	1628	O
)	17631392	1628	1629	O
and	17631392	1630	1633	O
-7.62	17631392	1634	1639	O
(	17631392	1640	1641	O
-12.30	17631392	1641	1647	O
,	17631392	1647	1648	O
-2.94	17631392	1649	1654	O
)	17631392	1654	1655	O
;	17631392	1655	1656	O
WOMAC-PFS	17631392	1657	1666	B-Outcome
:	17631392	1666	1667	O
-10.15	17631392	1668	1674	O
(	17631392	1675	1676	O
-14.74	17631392	1676	1682	O
,	17631392	1682	1683	O
-5.57	17631392	1684	1689	O
)	17631392	1689	1690	O
and	17631392	1691	1694	O
-7.23	17631392	1695	1700	O
(	17631392	1701	1702	O
-11.85	17631392	1702	1708	O
,	17631392	1708	1709	O
-2.61	17631392	1710	1715	O
)	17631392	1715	1716	O
;	17631392	1716	1717	O
PGADS	17631392	1718	1723	B-Outcome
:	17631392	1723	1724	O
-11.65	17631392	1725	1731	O
(	17631392	1732	1733	O
-16.81	17631392	1733	1739	O
,	17631392	1739	1740	O
-6.50	17631392	1741	1746	O
)	17631392	1746	1747	O
and	17631392	1748	1751	O
-8.11	17631392	1752	1757	O
(	17631392	1758	1759	O
-13.30	17631392	1759	1765	O
,	17631392	1765	1766	O
-2.92	17631392	1767	1772	O
)	17631392	1772	1773	O
.	17631392	1773	1774	O

The	17631392	1775	1778	O
efficacy	17631392	1779	1787	B-Outcome
of	17631392	1788	1790	O
etoricoxib	17631392	1791	1801	O
30	17631392	1802	1804	O
mg	17631392	1805	1807	O
was	17631392	1808	1811	O
comparable	17631392	1812	1822	O
to	17631392	1823	1825	O
ibuprofen	17631392	1826	1835	O
2400	17631392	1836	1840	O
mg	17631392	1841	1843	O
.	17631392	1843	1844	O

All	17631392	1845	1848	O
treatments	17631392	1849	1859	O
were	17631392	1860	1864	O
similarly	17631392	1865	1874	O
well	17631392	1875	1879	O
tolerated	17631392	1880	1889	B-Outcome
.	17631392	1889	1890	O

CONCLUSION	17631392	1892	1902	O
:	17631392	1903	1904	O
Treatment	17631392	1905	1914	O
with	17631392	1915	1919	O
etoricoxib	17631392	1920	1930	O
30	17631392	1931	1933	O
mg	17631392	1934	1936	O
q.d	17631392	1937	1940	O
.	17631392	1940	1941	O
provides	17631392	1942	1950	O
superior	17631392	1951	1959	O
efficacy	17631392	1960	1968	B-Outcome
vs	17631392	1969	1971	O
placebo	17631392	1972	1979	O
and	17631392	1980	1983	O
comparable	17631392	1984	1994	O
clinical	17631392	1995	2003	O
efficacy	17631392	2004	2012	B-Outcome
vs	17631392	2013	2015	O
ibuprofen	17631392	2016	2025	O
2400	17631392	2026	2030	O
mg	17631392	2031	2033	O
(	17631392	2034	2035	O
800	17631392	2035	2038	O
mg	17631392	2039	2041	O
t.i.d	17631392	2042	2047	O
.	17631392	2047	2048	O
)	17631392	2048	2049	O
for	17631392	2050	2053	O
the	17631392	2054	2057	O
treatment	17631392	2058	2067	O
of	17631392	2068	2070	O
OA	17631392	2071	2073	O
of	17631392	2074	2076	O
the	17631392	2077	2080	O
hip	17631392	2081	2084	O
and	17631392	2085	2088	O
knee	17631392	2089	2093	O
.	17631392	2093	2094	O


Effect	17694216	0	6	O
of	17694216	7	9	O
liquid-polish	17694216	10	23	O
coating	17694216	24	31	O
on	17694216	32	34	O
in	17694216	35	37	O
vivo	17694216	38	42	O
biofilm	17694216	43	50	O
accumulation	17694216	51	63	O
on	17694216	64	66	O
provisional	17694216	67	78	O
restorations	17694216	79	91	O
:	17694216	91	92	O
part	17694216	93	97	O
1	17694216	98	99	O
.	17694216	99	100	O

OBJECTIVE	17694216	102	111	O
:	17694216	112	113	O
Biofilm	17694216	114	121	O
accumulation	17694216	122	134	O
on	17694216	135	137	O
provisional	17694216	138	149	O
restorations	17694216	150	162	O
may	17694216	163	166	O
affect	17694216	167	173	O
the	17694216	174	177	O
surrounding	17694216	178	189	O
tissues	17694216	190	197	O
'	17694216	197	198	O
integrity	17694216	199	208	O
.	17694216	208	209	O

The	17694216	210	213	O
purpose	17694216	214	221	O
of	17694216	222	224	O
this	17694216	225	229	O
study	17694216	230	235	O
was	17694216	236	239	O
to	17694216	240	242	O
test	17694216	243	247	O
in	17694216	248	250	O
vivo	17694216	251	255	O
biofilm	17694216	256	263	O
formation	17694216	264	273	O
on	17694216	274	276	O
polymethyl	17694216	277	287	O
methacrylate	17694216	288	300	O
(	17694216	301	302	O
PMMA	17694216	302	306	O
)	17694216	306	307	O
self-cured	17694216	308	318	O
acrylic	17694216	319	326	O
resin	17694216	327	332	O
provisional	17694216	333	344	O
crowns	17694216	345	351	O
.	17694216	351	352	O

METHOD	17694216	354	360	O
AND	17694216	361	364	O
MATERIALS	17694216	365	374	O
:	17694216	375	376	O
Three	17694216	377	382	O
types	17694216	383	388	O
of	17694216	389	391	O
PMMA	17694216	392	396	O
surfaces	17694216	397	405	O
were	17694216	406	410	O
tested	17694216	411	417	O
:	17694216	417	418	O
(	17694216	419	420	O
1	17694216	420	421	O
)	17694216	421	422	O
polished	17694216	423	431	O
,	17694216	431	432	O
(	17694216	433	434	O
2	17694216	434	435	O
)	17694216	435	436	O
polished	17694216	437	445	O
and	17694216	446	449	O
coated	17694216	450	456	O
with	17694216	457	461	O
bonding	17694216	462	469	O
agent	17694216	470	475	O
,	17694216	475	476	O
and	17694216	477	480	O
(	17694216	481	482	O
3	17694216	482	483	O
)	17694216	483	484	O
polished	17694216	485	493	O
and	17694216	494	497	O
coated	17694216	498	504	O
with	17694216	505	509	O
light-cured	17694216	510	521	O
liquid	17694216	522	528	O
polish	17694216	529	535	O
.	17694216	535	536	O

After	17694216	537	542	O
12	17694216	543	545	O
hours	17694216	546	551	O
in	17694216	552	554	O
the	17694216	555	558	O
oral	17694216	559	563	O
cavity	17694216	564	570	O
,	17694216	570	571	O
the	17694216	572	575	O
crown	17694216	576	581	O
was	17694216	582	585	O
removed	17694216	586	593	O
and	17694216	594	597	O
examined	17694216	598	606	O
by	17694216	607	609	O
confocal	17694216	610	618	O
laser	17694216	619	624	O
scanning	17694216	625	633	O
microscope	17694216	634	644	O
(	17694216	645	646	O
CLSM	17694216	646	650	O
)	17694216	650	651	O
and	17694216	652	655	O
scanning	17694216	656	664	O
electron	17694216	665	673	O
microscope	17694216	674	684	O
(	17694216	685	686	O
SEM	17694216	686	689	O
)	17694216	689	690	O
.	17694216	690	691	O

RESULTS	17694216	693	700	O
:	17694216	701	702	O
Biofilm	17694216	703	710	B-Outcome
,	17694216	710	711	O
250	17694216	712	715	O
Mum	17694216	716	719	O
thick	17694216	720	725	O
,	17694216	725	726	O
was	17694216	727	730	O
observed	17694216	731	739	O
with	17694216	740	744	O
CLSM	17694216	745	749	O
on	17694216	750	752	O
the	17694216	753	756	O
polished	17694216	757	765	O
acrylic	17694216	766	773	O
surface	17694216	774	781	O
.	17694216	781	782	O

Significantly	17694216	783	796	O
less	17694216	797	801	O
bacterial	17694216	802	811	B-Outcome
accumulation	17694216	812	824	I-Outcome
was	17694216	825	828	O
observed	17694216	829	837	O
on	17694216	838	840	O
the	17694216	841	844	O
crowns	17694216	845	851	O
coated	17694216	852	858	O
with	17694216	859	863	O
bonding	17694216	864	871	O
agent	17694216	872	877	O
,	17694216	877	878	O
whereas	17694216	879	886	O
no	17694216	887	889	O
biofilm	17694216	890	897	B-Outcome
was	17694216	898	901	O
observed	17694216	902	910	O
on	17694216	911	913	O
the	17694216	914	917	O
crowns	17694216	918	924	O
coated	17694216	925	931	O
with	17694216	932	936	O
liquid	17694216	937	943	O
polish	17694216	944	950	O
(	17694216	951	952	O
P	17694216	952	953	O
<	17694216	954	955	O
.001	17694216	955	959	O
)	17694216	959	960	O
.	17694216	960	961	O

SEM	17694216	962	965	O
examination	17694216	966	977	O
confirmed	17694216	978	987	O
these	17694216	988	993	O
findings	17694216	994	1002	O
.	17694216	1002	1003	O

CONCLUSIONS	17694216	1005	1016	O
:	17694216	1017	1018	O
Bonding	17694216	1019	1026	O
resin	17694216	1027	1032	O
or	17694216	1033	1035	O
liquid	17694216	1036	1042	O
polish	17694216	1043	1049	O
coatings	17694216	1050	1058	O
significantly	17694216	1059	1072	O
reduce	17694216	1073	1079	O
early	17694216	1080	1085	B-Outcome
biofilm	17694216	1086	1093	I-Outcome
formation	17694216	1094	1103	I-Outcome
,	17694216	1103	1104	O
which	17694216	1105	1110	O
in	17694216	1111	1113	O
turn	17694216	1114	1118	O
might	17694216	1119	1124	O
affect	17694216	1125	1131	O
the	17694216	1132	1135	O
overall	17694216	1136	1143	O
plaque	17694216	1144	1150	O
accumulation	17694216	1151	1163	O
on	17694216	1164	1166	O
provisional	17694216	1167	1178	O
restorations	17694216	1179	1191	O
.	17694216	1191	1192	O


Severe	17853393	0	6	O
enteropathy	17853393	7	18	O
among	17853393	19	24	O
patients	17853393	25	33	O
with	17853393	34	38	O
stage	17853393	39	44	O
II/III	17853393	45	51	O
colon	17853393	52	57	O
cancer	17853393	58	64	O
treated	17853393	65	72	O
on	17853393	73	75	O
a	17853393	76	77	O
randomized	17853393	78	88	O
trial	17853393	89	94	O
of	17853393	95	97	O
bolus	17853393	98	103	O
5-fluorouracil/leucovorin	17853393	104	129	O
plus	17853393	130	134	O
or	17853393	135	137	O
minus	17853393	138	143	O
oxaliplatin	17853393	144	155	O
:	17853393	155	156	O
a	17853393	157	158	O
prospective	17853393	159	170	O
analysis	17853393	171	179	O
.	17853393	179	180	O

BACKGROUND	17853393	182	192	O
:	17853393	193	194	O
Cases	17853393	195	200	O
of	17853393	201	203	O
severe	17853393	204	210	O
gastrointestinal	17853393	211	227	O
toxicity	17853393	228	236	O
were	17853393	237	241	O
monitored	17853393	242	251	O
prospectively	17853393	252	265	O
during	17853393	266	272	O
NSABP	17853393	273	278	O
C-07	17853393	279	283	O
,	17853393	283	284	O
a	17853393	285	286	O
randomized	17853393	287	297	O
clinical	17853393	298	306	O
trial	17853393	307	312	O
of	17853393	313	315	O
adjuvant	17853393	316	324	O
therapy	17853393	325	332	O
for	17853393	333	336	O
patients	17853393	337	345	O
with	17853393	346	350	O
stage	17853393	351	356	O
II/III	17853393	357	363	O
colon	17853393	364	369	O
cancer	17853393	370	376	O
.	17853393	376	377	O

METHODS	17853393	379	386	O
:	17853393	387	388	O
Patients	17853393	389	397	O
were	17853393	398	402	O
treated	17853393	403	410	O
with	17853393	411	415	O
weekly	17853393	416	422	O
bolus	17853393	423	428	O
5-fluorouracil	17853393	429	443	O
(	17853393	444	445	O
5-FU	17853393	445	449	O
)	17853393	449	450	O
and	17853393	451	454	O
leucovorin	17853393	455	465	O
(	17853393	466	467	O
FL	17853393	467	469	O
;	17853393	469	470	O
"	17853393	471	472	O
Roswell	17853393	472	479	O
Park	17853393	480	484	O
Regimen	17853393	485	492	O
"	17853393	492	493	O
)	17853393	493	494	O
or	17853393	495	497	O
the	17853393	498	501	O
same	17853393	502	506	O
regimen	17853393	507	514	O
plus	17853393	515	519	O
oxaliplatin	17853393	520	531	O
(	17853393	532	533	O
FLOX	17853393	533	537	O
)	17853393	537	538	O
.	17853393	538	539	O

RESULTS	17853393	541	548	O
:	17853393	549	550	O
Of	17853393	551	553	O
1857	17853393	554	558	O
patients	17853393	559	567	O
,	17853393	567	568	O
79	17853393	569	571	O
(	17853393	572	573	O
4.3	17853393	573	576	O
%	17853393	576	577	O
)	17853393	577	578	O
developed	17853393	579	588	O
a	17853393	589	590	O
syndrome	17853393	591	599	O
of	17853393	600	602	O
bowel	17853393	603	608	B-Outcome
wall	17853393	609	613	I-Outcome
injury	17853393	614	620	I-Outcome
(	17853393	621	622	O
BWI	17853393	622	625	B-Outcome
,	17853393	625	626	O
small	17853393	627	632	O
or	17853393	633	635	O
large	17853393	636	641	O
)	17853393	641	642	O
characterized	17853393	643	656	O
by	17853393	657	659	O
hospitalization	17853393	660	675	O
for	17853393	676	679	O
the	17853393	680	683	O
management	17853393	684	694	O
of	17853393	695	697	O
severe	17853393	698	704	O
diarrhea	17853393	705	713	O
or	17853393	714	716	O
dehydration	17853393	717	728	O
and	17853393	729	732	O
radiographic	17853393	733	745	O
or	17853393	746	748	O
endoscopic	17853393	749	759	O
evidence	17853393	760	768	O
of	17853393	769	771	O
bowel	17853393	772	777	O
wall	17853393	778	782	O
thickening	17853393	783	793	O
or	17853393	794	796	O
ulceration	17853393	797	807	O
.	17853393	807	808	O

Fifty-one	17853393	809	818	O
(	17853393	819	820	O
64.6	17853393	820	824	O
%	17853393	824	825	O
)	17853393	825	826	O
of	17853393	827	829	O
these	17853393	830	835	O
adverse	17853393	836	843	B-Outcome
events	17853393	844	850	I-Outcome
occurred	17853393	851	859	O
in	17853393	860	862	O
patients	17853393	863	871	O
treated	17853393	872	879	O
with	17853393	880	884	O
FLOX	17853393	885	889	O
and	17853393	890	893	O
28	17853393	894	896	O
(	17853393	897	898	O
35.4	17853393	898	902	O
%	17853393	902	903	O
)	17853393	903	904	O
in	17853393	905	907	O
those	17853393	908	913	O
treated	17853393	914	921	O
with	17853393	922	926	O
FL	17853393	927	929	O
(	17853393	930	931	O
P	17853393	931	932	O
<	17853393	933	934	O
.01	17853393	935	938	O
)	17853393	938	939	O
.	17853393	939	940	O

Enteric	17853393	941	948	B-Outcome
sepsis	17853393	949	955	I-Outcome
(	17853393	956	957	O
ES	17853393	957	959	B-Outcome
)	17853393	959	960	O
,	17853393	960	961	O
characterized	17853393	962	975	O
by	17853393	976	978	O
grade	17853393	979	984	O
3	17853393	985	986	O
or	17853393	987	989	O
greater	17853393	990	997	O
diarrhea	17853393	998	1006	O
and	17853393	1007	1010	O
grade	17853393	1011	1016	O
4	17853393	1017	1018	O
neutropenia	17853393	1019	1030	O
with	17853393	1031	1035	O
or	17853393	1036	1038	O
without	17853393	1039	1046	O
proven	17853393	1047	1053	O
bacteremia	17853393	1054	1064	O
occurred	17853393	1065	1073	O
in	17853393	1074	1076	O
22	17853393	1077	1079	O
patients	17853393	1080	1088	O
treated	17853393	1089	1096	O
with	17853393	1097	1101	O
FLOX	17853393	1102	1106	O
,	17853393	1106	1107	O
versus	17853393	1108	1114	O
8	17853393	1115	1116	O
in	17853393	1117	1119	O
those	17853393	1120	1125	O
treated	17853393	1126	1133	O
with	17853393	1134	1138	O
FL	17853393	1139	1141	O
(	17853393	1142	1143	O
P	17853393	1143	1144	O
=	17853393	1145	1146	O
.01	17853393	1147	1150	O
)	17853393	1150	1151	O
.	17853393	1151	1152	O

Patients	17853393	1153	1161	O
>	17853393	1162	1163	O
60	17853393	1163	1165	O
years	17853393	1166	1171	O
were	17853393	1172	1176	O
at	17853393	1177	1179	O
higher	17853393	1180	1186	O
risk	17853393	1187	1191	O
for	17853393	1192	1195	O
BWI	17853393	1196	1199	B-Outcome
after	17853393	1200	1205	O
treatment	17853393	1206	1215	O
with	17853393	1216	1220	O
FLOX	17853393	1221	1225	O
(	17853393	1226	1227	O
6.7	17853393	1227	1230	O
%	17853393	1230	1231	O
)	17853393	1231	1232	O
versus	17853393	1233	1239	O
treatment	17853393	1240	1249	O
with	17853393	1250	1254	O
FL	17853393	1255	1257	O
(	17853393	1258	1259	O
2.9	17853393	1259	1262	O
%	17853393	1262	1263	O
,	17853393	1263	1264	O
P	17853393	1265	1266	O
<	17853393	1267	1268	O
.01	17853393	1269	1272	O
)	17853393	1272	1273	O
.	17853393	1273	1274	O

Female	17853393	1275	1281	O
patients	17853393	1282	1290	O
had	17853393	1291	1294	O
a	17853393	1295	1296	O
higher	17853393	1297	1303	O
incidence	17853393	1304	1313	O
of	17853393	1314	1316	O
BWI	17853393	1317	1320	B-Outcome
with	17853393	1321	1325	O
FLOX	17853393	1326	1330	O
(	17853393	1331	1332	O
9.1	17853393	1332	1335	O
%	17853393	1335	1336	O
)	17853393	1336	1337	O
than	17853393	1338	1342	O
with	17853393	1343	1347	O
FL	17853393	1348	1350	O
(	17853393	1351	1352	O
3.9	17853393	1352	1355	O
%	17853393	1355	1356	O
,	17853393	1356	1357	O
P	17853393	1358	1359	O
<	17853393	1360	1361	O
.01	17853393	1362	1365	O
)	17853393	1365	1366	O
.	17853393	1366	1367	O

Severe	17853393	1368	1374	B-Outcome
gastrointestinal	17853393	1375	1391	I-Outcome
toxicity	17853393	1392	1400	I-Outcome
usually	17853393	1401	1408	O
occurred	17853393	1409	1417	O
during	17853393	1418	1424	O
the	17853393	1425	1428	O
third	17853393	1429	1434	O
or	17853393	1435	1437	O
fourth	17853393	1438	1444	O
week	17853393	1445	1449	O
on	17853393	1450	1452	O
the	17853393	1453	1456	O
first	17853393	1457	1462	O
cycle	17853393	1463	1468	O
of	17853393	1469	1471	O
therapy	17853393	1472	1479	O
,	17853393	1479	1480	O
required	17853393	1481	1489	O
hospitalization	17853393	1490	1505	O
,	17853393	1505	1506	O
and	17853393	1507	1510	O
was	17853393	1511	1514	O
managed	17853393	1515	1522	O
with	17853393	1523	1527	O
fluids	17853393	1528	1534	O
,	17853393	1534	1535	O
antidiarrheals	17853393	1536	1550	O
,	17853393	1550	1551	O
and	17853393	1552	1555	O
antibiotics	17853393	1556	1567	O
.	17853393	1567	1568	O

There	17853393	1569	1574	O
were	17853393	1575	1579	O
5	17853393	1580	1581	O
deaths	17853393	1582	1588	O
(	17853393	1589	1590	O
0.3	17853393	1590	1593	O
%	17853393	1593	1594	O
)	17853393	1594	1595	O
due	17853393	1596	1599	O
to	17853393	1600	1602	O
enteropathy	17853393	1603	1614	O
,	17853393	1614	1615	O
2	17853393	1616	1617	O
related	17853393	1618	1625	O
to	17853393	1626	1628	O
ES	17853393	1629	1631	B-Outcome
and	17853393	1632	1635	O
3	17853393	1636	1637	O
related	17853393	1638	1645	O
to	17853393	1646	1648	O
both	17853393	1649	1653	O
BWI	17853393	1654	1657	B-Outcome
and	17853393	1658	1661	O
ES	17853393	1662	1664	B-Outcome
.	17853393	1664	1665	O

Seventy-one	17853393	1666	1677	O
percent	17853393	1678	1685	O
of	17853393	1686	1688	O
patients	17853393	1689	1697	O
resumed	17853393	1698	1705	O
treatment	17853393	1706	1715	O
with	17853393	1716	1720	O
FL	17853393	1721	1723	O
after	17853393	1724	1729	O
recovery	17853393	1730	1738	O
.	17853393	1738	1739	O

CONCLUSIONS	17853393	1741	1752	O
:	17853393	1753	1754	O
Patients	17853393	1755	1763	O
treated	17853393	1764	1771	O
with	17853393	1772	1776	O
adjuvant	17853393	1777	1785	O
FL	17853393	1786	1788	O
should	17853393	1789	1795	O
be	17853393	1796	1798	O
closely	17853393	1799	1806	O
monitored	17853393	1807	1816	O
for	17853393	1817	1820	O
diarrhea	17853393	1821	1829	O
and	17853393	1830	1833	O
aggressively	17853393	1834	1846	O
managed	17853393	1847	1854	O
,	17853393	1854	1855	O
especially	17853393	1856	1866	O
if	17853393	1867	1869	O
oxaliplatin	17853393	1870	1881	O
has	17853393	1882	1885	O
been	17853393	1886	1890	O
added	17853393	1891	1896	O
to	17853393	1897	1899	O
the	17853393	1900	1903	O
regimen	17853393	1904	1911	O
.	17853393	1911	1912	O

Society	17853393	1913	1920	O
.	17853393	1920	1921	O


Chlorhexidine-based	17954800	0	19	O
antiseptic	17954800	20	30	O
solution	17954800	31	39	O
vs	17954800	40	42	O
alcohol-based	17954800	43	56	O
povidone-iodine	17954800	57	72	O
for	17954800	73	76	O
central	17954800	77	84	O
venous	17954800	85	91	O
catheter	17954800	92	100	O
care	17954800	101	105	O
.	17954800	105	106	O

BACKGROUND	17954800	108	118	O
:	17954800	119	120	O
Although	17954800	121	129	O
chlorhexidine-based	17954800	130	149	O
solutions	17954800	150	159	O
and	17954800	160	163	O
alcohol-based	17954800	164	177	O
povidone-iodine	17954800	178	193	O
have	17954800	194	198	O
been	17954800	199	203	O
shown	17954800	204	209	O
to	17954800	210	212	O
be	17954800	213	215	O
more	17954800	216	220	O
efficient	17954800	221	230	O
than	17954800	231	235	O
aqueous	17954800	236	243	O
povidone-iodine	17954800	244	259	O
for	17954800	260	263	O
skin	17954800	264	268	O
disinfection	17954800	269	281	O
at	17954800	282	284	O
catheter	17954800	285	293	O
insertion	17954800	294	303	O
sites	17954800	304	309	O
,	17954800	309	310	O
their	17954800	311	316	O
abilities	17954800	317	326	O
to	17954800	327	329	O
reduce	17954800	330	336	O
catheter-related	17954800	337	353	O
infection	17954800	354	363	O
have	17954800	364	368	O
never	17954800	369	374	O
been	17954800	375	379	O
compared	17954800	380	388	O
.	17954800	388	389	O

METHODS	17954800	391	398	O
:	17954800	399	400	O
Consecutively	17954800	401	414	O
scheduled	17954800	415	424	O
central	17954800	425	432	O
venous	17954800	433	439	O
catheters	17954800	440	449	O
inserted	17954800	450	458	O
into	17954800	459	463	O
jugular	17954800	464	471	O
or	17954800	472	474	O
subclavian	17954800	475	485	O
veins	17954800	486	491	O
were	17954800	492	496	O
randomly	17954800	497	505	O
assigned	17954800	506	514	O
to	17954800	515	517	O
be	17954800	518	520	O
disinfected	17954800	521	532	O
with	17954800	533	537	O
5	17954800	538	539	O
%	17954800	539	540	O
povidone-iodine	17954800	541	556	O
in	17954800	557	559	O
70	17954800	560	562	O
%	17954800	562	563	O
ethanol	17954800	564	571	O
or	17954800	572	574	O
with	17954800	575	579	O
a	17954800	580	581	O
combination	17954800	582	593	O
of	17954800	594	596	O
0.25	17954800	597	601	O
%	17954800	601	602	O
chlorhexidine	17954800	603	616	O
gluconate	17954800	617	626	O
,	17954800	626	627	O
0.025	17954800	628	633	O
%	17954800	633	634	O
benzalkonium	17954800	635	647	O
chloride	17954800	648	656	O
,	17954800	656	657	O
and	17954800	658	661	O
4	17954800	662	663	O
%	17954800	663	664	O
benzylic	17954800	665	673	O
alcohol	17954800	674	681	O
.	17954800	681	682	O

Solutions	17954800	683	692	O
were	17954800	693	697	O
used	17954800	698	702	O
for	17954800	703	706	O
skin	17954800	707	711	O
disinfection	17954800	712	724	O
before	17954800	725	731	O
catheter	17954800	732	740	O
insertion	17954800	741	750	O
(	17954800	751	752	O
2	17954800	752	753	O
consecutive	17954800	754	765	O
30-second	17954800	766	775	O
applications	17954800	776	788	O
separated	17954800	789	798	O
by	17954800	799	801	O
a	17954800	802	803	O
period	17954800	804	810	O
sufficiently	17954800	811	823	O
long	17954800	824	828	O
to	17954800	829	831	O
allow	17954800	832	837	O
for	17954800	838	841	O
dryness	17954800	842	849	O
)	17954800	849	850	O
and	17954800	851	854	O
then	17954800	855	859	O
as	17954800	860	862	O
single	17954800	863	869	O
applications	17954800	870	882	O
during	17954800	883	889	O
subsequent	17954800	890	900	O
dressing	17954800	901	909	O
changes	17954800	910	917	O
(	17954800	918	919	O
every	17954800	919	924	O
72	17954800	925	927	O
hours	17954800	928	933	O
,	17954800	933	934	O
or	17954800	935	937	O
earlier	17954800	938	945	O
if	17954800	946	948	O
soiled	17954800	949	955	O
or	17954800	956	958	O
wet	17954800	959	962	O
)	17954800	962	963	O
.	17954800	963	964	O

RESULTS	17954800	966	973	O
:	17954800	974	975	O
Of	17954800	976	978	O
538	17954800	979	982	O
catheters	17954800	983	992	O
randomized	17954800	993	1003	O
,	17954800	1003	1004	O
481	17954800	1005	1008	O
(	17954800	1009	1010	O
89.4	17954800	1010	1014	O
%	17954800	1014	1015	O
)	17954800	1015	1016	O
produced	17954800	1017	1025	O
evaluable	17954800	1026	1035	O
culture	17954800	1036	1043	O
results	17954800	1044	1051	O
.	17954800	1051	1052	O

Compared	17954800	1053	1061	O
with	17954800	1062	1066	O
povidone-iodine	17954800	1067	1082	O
,	17954800	1082	1083	O
the	17954800	1084	1087	O
chlorhexidine-based	17954800	1088	1107	O
solution	17954800	1108	1116	O
was	17954800	1117	1120	O
associated	17954800	1121	1131	O
with	17954800	1132	1136	O
a	17954800	1137	1138	O
50	17954800	1139	1141	O
%	17954800	1141	1142	O
decrease	17954800	1143	1151	O
in	17954800	1152	1154	O
the	17954800	1155	1158	O
incidence	17954800	1159	1168	O
of	17954800	1169	1171	O
catheter	17954800	1172	1180	B-Outcome
colonization	17954800	1181	1193	I-Outcome
(	17954800	1194	1195	O
11.6	17954800	1195	1199	O
%	17954800	1199	1200	O
vs	17954800	1201	1203	O
22.2	17954800	1204	1208	O
%	17954800	1208	1209	O
[	17954800	1210	1211	O
P	17954800	1211	1212	O
=	17954800	1213	1214	O
.002	17954800	1215	1219	O
]	17954800	1219	1220	O
;	17954800	1220	1221	O
incidence	17954800	1222	1231	O
density	17954800	1232	1239	O
,	17954800	1239	1240	O
9.7	17954800	1241	1244	O
vs	17954800	1245	1247	O
18.3	17954800	1248	1252	O
per	17954800	1253	1256	O
1000	17954800	1257	1261	O
catheter-days	17954800	1262	1275	O
)	17954800	1275	1276	O
and	17954800	1277	1280	O
with	17954800	1281	1285	O
a	17954800	1286	1287	O
trend	17954800	1288	1293	O
toward	17954800	1294	1300	O
lower	17954800	1301	1306	O
rates	17954800	1307	1312	B-Outcome
of	17954800	1313	1315	I-Outcome
catheter-related	17954800	1316	1332	I-Outcome
bloodstream	17954800	1333	1344	I-Outcome
infection	17954800	1345	1354	I-Outcome
(	17954800	1355	1356	O
1.7	17954800	1356	1359	O
%	17954800	1359	1360	O
vs	17954800	1361	1363	O
4.2	17954800	1364	1367	O
%	17954800	1367	1368	O
[	17954800	1369	1370	O
P	17954800	1370	1371	O
=	17954800	1372	1373	O
.09	17954800	1374	1377	O
]	17954800	1377	1378	O
;	17954800	1378	1379	O
incidence	17954800	1380	1389	O
density	17954800	1390	1397	O
,	17954800	1397	1398	O
1.4	17954800	1399	1402	O
vs	17954800	1403	1405	O
3.4	17954800	1406	1409	O
per	17954800	1410	1413	O
1000	17954800	1414	1418	O
catheter-days	17954800	1419	1432	O
)	17954800	1432	1433	O
.	17954800	1433	1434	O

Independent	17954800	1435	1446	O
risk	17954800	1447	1451	B-Outcome
factors	17954800	1452	1459	I-Outcome
for	17954800	1460	1463	I-Outcome
catheter	17954800	1464	1472	I-Outcome
colonization	17954800	1473	1485	I-Outcome
were	17954800	1486	1490	O
catheter	17954800	1491	1499	O
insertion	17954800	1500	1509	O
into	17954800	1510	1514	O
the	17954800	1515	1518	O
jugular	17954800	1519	1526	O
vein	17954800	1527	1531	O
(	17954800	1532	1533	O
adjusted	17954800	1533	1541	O
relative	17954800	1542	1550	O
risk	17954800	1551	1555	O
,	17954800	1555	1556	O
2.01	17954800	1557	1561	O
;	17954800	1561	1562	O
95	17954800	1563	1565	O
%	17954800	1565	1566	O
confidence	17954800	1567	1577	O
interval	17954800	1578	1586	O
,	17954800	1586	1587	O
1.24	17954800	1588	1592	O
-	17954800	1592	1593	O
3.24	17954800	1593	1597	O
)	17954800	1597	1598	O
and	17954800	1599	1602	O
use	17954800	1603	1606	O
of	17954800	1607	1609	O
povidone-iodine	17954800	1610	1625	O
(	17954800	1626	1627	O
adjusted	17954800	1627	1635	O
relative	17954800	1636	1644	O
risk	17954800	1645	1649	O
,	17954800	1649	1650	O
1.87	17954800	1651	1655	O
;	17954800	1655	1656	O
95	17954800	1657	1659	O
%	17954800	1659	1660	O
confidence	17954800	1661	1671	O
interval	17954800	1672	1680	O
,	17954800	1680	1681	O
1.18	17954800	1682	1686	O
-	17954800	1686	1687	O
2.96	17954800	1687	1691	O
)	17954800	1691	1692	O
.	17954800	1692	1693	O

CONCLUSION	17954800	1695	1705	O
:	17954800	1706	1707	O
Chlorhexidine-based	17954800	1708	1727	O
solutions	17954800	1728	1737	O
should	17954800	1738	1744	O
be	17954800	1745	1747	O
considered	17954800	1748	1758	O
as	17954800	1759	1761	O
a	17954800	1762	1763	O
replacement	17954800	1764	1775	O
for	17954800	1776	1779	O
povidone-iodine	17954800	1780	1795	O
(	17954800	1796	1797	O
including	17954800	1797	1806	O
alcohol-based	17954800	1807	1820	O
)	17954800	1820	1821	O
formulations	17954800	1822	1834	O
in	17954800	1835	1837	O
efforts	17954800	1838	1845	O
to	17954800	1846	1848	O
prevent	17954800	1849	1856	O
catheter-related	17954800	1857	1873	B-Outcome
infection	17954800	1874	1883	I-Outcome
.	17954800	1883	1884	O


Short-course	17998493	0	12	O
nitrofurantoin	17998493	13	27	O
for	17998493	28	31	O
the	17998493	32	35	O
treatment	17998493	36	45	O
of	17998493	46	48	O
acute	17998493	49	54	O
uncomplicated	17998493	55	68	O
cystitis	17998493	69	77	O
in	17998493	78	80	O
women	17998493	81	86	O
.	17998493	86	87	O

BACKGROUND	17998493	89	99	O
:	17998493	100	101	O
There	17998493	102	107	O
is	17998493	108	110	O
a	17998493	111	112	O
paucity	17998493	113	120	O
of	17998493	121	123	O
data	17998493	124	128	O
on	17998493	129	131	O
the	17998493	132	135	O
efficacy	17998493	136	144	O
of	17998493	145	147	O
nitrofurantoin	17998493	148	162	O
for	17998493	163	166	O
the	17998493	167	170	O
treatment	17998493	171	180	O
of	17998493	181	183	O
acute	17998493	184	189	O
uncomplicated	17998493	190	203	O
cystitis	17998493	204	212	O
in	17998493	213	215	O
regimens	17998493	216	224	O
shorter	17998493	225	232	O
than	17998493	233	237	O
7	17998493	238	239	O
days	17998493	240	244	O
.	17998493	244	245	O

Evidence-based	17998493	246	260	O
use	17998493	261	264	O
of	17998493	265	267	O
this	17998493	268	272	O
drug	17998493	273	277	O
is	17998493	278	280	O
increasingly	17998493	281	293	O
important	17998493	294	303	O
as	17998493	304	306	O
trimethoprim-sulfamethoxazole	17998493	307	336	O
resistance	17998493	337	347	O
among	17998493	348	353	O
uropathogens	17998493	354	366	O
increases	17998493	367	376	O
.	17998493	376	377	O

METHODS	17998493	379	386	O
:	17998493	387	388	O
To	17998493	389	391	O
assess	17998493	392	398	O
the	17998493	399	402	O
efficacy	17998493	403	411	O
of	17998493	412	414	O
nitrofurantoin	17998493	415	429	O
vs	17998493	430	432	O
trimethoprim-sulfamethoxazole	17998493	433	462	O
,	17998493	462	463	O
338	17998493	464	467	O
women	17998493	468	473	O
aged	17998493	474	478	O
18	17998493	479	481	O
to	17998493	482	484	O
45	17998493	485	487	O
years	17998493	488	493	O
with	17998493	494	498	O
acute	17998493	499	504	O
uncomplicated	17998493	505	518	O
cystitis	17998493	519	527	O
were	17998493	528	532	O
randomized	17998493	533	543	O
to	17998493	544	546	O
open-label	17998493	547	557	O
treatment	17998493	558	567	O
with	17998493	568	572	O
either	17998493	573	579	O
trimethoprim-sulfamethoxazole	17998493	580	609	O
,	17998493	609	610	O
1	17998493	611	612	O
double-strength	17998493	613	628	O
tablet	17998493	629	635	O
twice	17998493	636	641	O
daily	17998493	642	647	O
for	17998493	648	651	O
3	17998493	652	653	O
days	17998493	654	658	O
,	17998493	658	659	O
or	17998493	660	662	O
nitrofurantoin	17998493	663	677	O
,	17998493	677	678	O
100	17998493	679	682	O
mg	17998493	683	685	O
twice	17998493	686	691	O
daily	17998493	692	697	O
for	17998493	698	701	O
5	17998493	702	703	O
days	17998493	704	708	O
.	17998493	708	709	O

Clinical	17998493	710	718	O
cure	17998493	719	723	O
30	17998493	724	726	O
days	17998493	727	731	O
after	17998493	732	737	O
therapy	17998493	738	745	O
was	17998493	746	749	O
the	17998493	750	753	O
main	17998493	754	758	O
outcome	17998493	759	766	O
measure	17998493	767	774	O
.	17998493	774	775	O

Secondary	17998493	776	785	O
outcomes	17998493	786	794	O
included	17998493	795	803	O
clinical	17998493	804	812	O
and	17998493	813	816	O
microbiological	17998493	817	832	O
cure	17998493	833	837	O
rates	17998493	838	843	O
5	17998493	844	845	O
to	17998493	846	848	O
9	17998493	849	850	O
days	17998493	851	855	O
after	17998493	856	861	O
therapy	17998493	862	869	O
and	17998493	870	873	O
,	17998493	873	874	O
for	17998493	875	878	O
trimethoprim-sulfamethoxazole-treated	17998493	879	916	O
women	17998493	917	922	O
,	17998493	922	923	O
clinical	17998493	924	932	O
cure	17998493	933	937	O
stratified	17998493	938	948	O
by	17998493	949	951	O
the	17998493	952	955	O
trimethoprim-sulfamethoxazole	17998493	956	985	O
susceptibility	17998493	986	1000	O
of	17998493	1001	1003	O
the	17998493	1004	1007	O
uropathogen	17998493	1008	1019	O
.	17998493	1019	1020	O

RESULTS	17998493	1022	1029	O
:	17998493	1030	1031	O
Clinical	17998493	1032	1040	B-Outcome
cure	17998493	1041	1045	I-Outcome
was	17998493	1046	1049	O
achieved	17998493	1050	1058	O
in	17998493	1059	1061	O
79	17998493	1062	1064	O
%	17998493	1064	1065	O
of	17998493	1066	1068	O
the	17998493	1069	1072	O
trimethoprim-sulfamethoxazole	17998493	1073	1102	O
group	17998493	1103	1108	O
and	17998493	1109	1112	O
in	17998493	1113	1115	O
84	17998493	1116	1118	O
%	17998493	1118	1119	O
of	17998493	1120	1122	O
the	17998493	1123	1126	O
nitrofurantoin	17998493	1127	1141	O
group	17998493	1142	1147	O
,	17998493	1147	1148	O
for	17998493	1149	1152	O
a	17998493	1153	1154	O
difference	17998493	1155	1165	O
of	17998493	1166	1168	O
-5	17998493	1169	1171	O
%	17998493	1171	1172	O
(	17998493	1173	1174	O
95	17998493	1174	1176	O
%	17998493	1176	1177	O
confidence	17998493	1178	1188	O
interval	17998493	1189	1197	O
,	17998493	1197	1198	O
-13	17998493	1199	1202	O
%	17998493	1202	1203	O
to	17998493	1204	1206	O
4	17998493	1207	1208	O
%	17998493	1208	1209	O
)	17998493	1209	1210	O
.	17998493	1210	1211	O

Clinical	17998493	1212	1220	B-Outcome
and	17998493	1221	1224	O
microbiological	17998493	1225	1240	B-Outcome
cure	17998493	1241	1245	I-Outcome
rates	17998493	1246	1251	I-Outcome
at	17998493	1252	1254	O
the	17998493	1255	1258	O
first	17998493	1259	1264	O
follow-up	17998493	1265	1274	O
visit	17998493	1275	1280	O
were	17998493	1281	1285	O
also	17998493	1286	1290	O
equivalent	17998493	1291	1301	O
between	17998493	1302	1309	O
the	17998493	1310	1313	O
2	17998493	1314	1315	O
groups	17998493	1316	1322	O
.	17998493	1322	1323	O

In	17998493	1324	1326	O
the	17998493	1327	1330	O
trimethoprim-sulfamethoxazole	17998493	1331	1360	O
arm	17998493	1361	1364	O
,	17998493	1364	1365	O
7	17998493	1366	1367	O
of	17998493	1368	1370	O
17	17998493	1371	1373	O
women	17998493	1374	1379	O
(	17998493	1380	1381	O
41	17998493	1381	1383	O
%	17998493	1383	1384	O
)	17998493	1384	1385	O
with	17998493	1386	1390	O
a	17998493	1391	1392	O
trimethoprim-sulfamethoxazole-nonsusceptible	17998493	1393	1437	O
isolate	17998493	1438	1445	O
had	17998493	1446	1449	O
a	17998493	1450	1451	O
clinical	17998493	1452	1460	B-Outcome
cure	17998493	1461	1465	I-Outcome
compared	17998493	1466	1474	O
with	17998493	1475	1479	O
84	17998493	1480	1482	O
%	17998493	1482	1483	O
of	17998493	1484	1486	O
women	17998493	1487	1492	O
with	17998493	1493	1497	O
a	17998493	1498	1499	O
trimethoprim-sulfamethoxazole-susceptible	17998493	1500	1541	O
isolate	17998493	1542	1549	O
(	17998493	1550	1551	O
P	17998493	1551	1552	O
<	17998493	1553	1554	O
.001	17998493	1555	1559	O
)	17998493	1559	1560	O
.	17998493	1560	1561	O

CONCLUSION	17998493	1563	1573	O
:	17998493	1574	1575	O
A	17998493	1576	1577	O
5-day	17998493	1578	1583	O
course	17998493	1584	1590	O
of	17998493	1591	1593	O
nitrofurantoin	17998493	1594	1608	O
is	17998493	1609	1611	O
equivalent	17998493	1612	1622	O
clinically	17998493	1623	1633	O
and	17998493	1634	1637	O
microbiologically	17998493	1638	1655	O
to	17998493	1656	1658	O
a	17998493	1659	1660	O
3-day	17998493	1661	1666	O
course	17998493	1667	1673	O
of	17998493	1674	1676	O
trimethoprim-sulfamethoxazole	17998493	1677	1706	O
and	17998493	1707	1710	O
should	17998493	1711	1717	O
be	17998493	1718	1720	O
considered	17998493	1721	1731	O
an	17998493	1732	1734	O
effective	17998493	1735	1744	O
fluoroquinolone-sparing	17998493	1745	1768	O
alternative	17998493	1769	1780	O
for	17998493	1781	1784	O
the	17998493	1785	1788	O
treatment	17998493	1789	1798	O
of	17998493	1799	1801	O
acute	17998493	1802	1807	O
cystitis	17998493	1808	1816	O
in	17998493	1817	1819	O
women	17998493	1820	1825	O
.	17998493	1825	1826	O


Safety	18299305	0	6	O
and	18299305	7	10	O
tolerability	18299305	11	23	O
of	18299305	24	26	O
cold-adapted	18299305	27	39	O
influenza	18299305	40	49	O
vaccine	18299305	50	57	O
,	18299305	57	58	O
trivalent	18299305	59	68	O
,	18299305	68	69	O
in	18299305	70	72	O
infants	18299305	73	80	O
younger	18299305	81	88	O
than	18299305	89	93	O
6	18299305	94	95	O
months	18299305	96	102	O
of	18299305	103	105	O
age	18299305	106	109	O
.	18299305	109	110	O

OBJECTIVE	18299305	112	121	O
:	18299305	122	123	O
Young	18299305	124	129	O
children	18299305	130	138	O
are	18299305	139	142	O
at	18299305	143	145	O
high	18299305	146	150	O
risk	18299305	151	155	O
for	18299305	156	159	O
influenza-related	18299305	160	177	O
complications	18299305	178	191	O
.	18299305	191	192	O

Vaccination	18299305	193	204	O
of	18299305	205	207	O
close	18299305	208	213	O
household	18299305	214	223	O
contacts	18299305	224	232	O
is	18299305	233	235	O
recommended	18299305	236	247	O
to	18299305	248	250	O
provide	18299305	251	258	O
indirect	18299305	259	267	O
protection	18299305	268	278	O
to	18299305	279	281	O
children	18299305	282	290	O
<	18299305	291	292	O
6	18299305	292	293	O
months	18299305	294	300	O
of	18299305	301	303	O
age	18299305	304	307	O
.	18299305	307	308	O

Studies	18299305	309	316	O
have	18299305	317	321	O
shown	18299305	322	327	O
that	18299305	328	332	O
live	18299305	333	337	O
,	18299305	337	338	O
cold-adapted	18299305	339	351	O
influenza	18299305	352	361	O
vaccine	18299305	362	369	O
,	18299305	369	370	O
trivalent	18299305	371	380	O
,	18299305	380	381	O
is	18299305	382	384	O
efficacious	18299305	385	396	O
in	18299305	397	399	O
children	18299305	400	408	O
.	18299305	408	409	O

To	18299305	410	412	O
assess	18299305	413	419	O
the	18299305	420	423	O
risks	18299305	424	429	O
associated	18299305	430	440	O
with	18299305	441	445	O
inadvertent	18299305	446	457	O
exposure	18299305	458	466	O
of	18299305	467	469	O
infants	18299305	470	477	O
to	18299305	478	480	O
vaccine	18299305	481	488	O
viruses	18299305	489	496	O
from	18299305	497	501	O
vaccinated	18299305	502	512	O
contacts	18299305	513	521	O
,	18299305	521	522	O
this	18299305	523	527	O
study	18299305	528	533	O
was	18299305	534	537	O
designed	18299305	538	546	O
to	18299305	547	549	O
evaluate	18299305	550	558	O
the	18299305	559	562	O
safety	18299305	563	569	O
and	18299305	570	573	O
tolerability	18299305	574	586	O
of	18299305	587	589	O
cold-adapted	18299305	590	602	O
influenza	18299305	603	612	O
vaccine	18299305	613	620	O
,	18299305	620	621	O
trivalent	18299305	622	631	O
,	18299305	631	632	O
administered	18299305	633	645	O
intranasally	18299305	646	658	O
to	18299305	659	661	O
healthy	18299305	662	669	O
children	18299305	670	678	O
6	18299305	679	680	O
to	18299305	681	683	O
<	18299305	684	685	O
24	18299305	685	687	O
weeks	18299305	688	693	O
of	18299305	694	696	O
age	18299305	697	700	O
.	18299305	700	701	O

METHODS	18299305	703	710	O
:	18299305	711	712	O
Healthy	18299305	713	720	O
infants	18299305	721	728	O
aged	18299305	729	733	O
6	18299305	734	735	O
to	18299305	736	738	O
<	18299305	739	740	O
16	18299305	740	742	O
weeks	18299305	743	748	O
and	18299305	749	752	O
16	18299305	753	755	O
to	18299305	756	758	O
<	18299305	759	760	O
24	18299305	760	762	O
weeks	18299305	763	768	O
,	18299305	768	769	O
respectively	18299305	770	782	O
,	18299305	782	783	O
were	18299305	784	788	O
randomly	18299305	789	797	O
assigned	18299305	798	806	O
to	18299305	807	809	O
receive	18299305	810	817	O
2	18299305	818	819	O
doses	18299305	820	825	O
of	18299305	826	828	O
influenza	18299305	829	838	O
vaccine	18299305	839	846	O
,	18299305	846	847	O
or	18299305	848	850	O
placebo	18299305	851	858	O
intranasally	18299305	859	871	O
35	18299305	872	874	O
+	18299305	875	876	O
/-	18299305	876	878	O
7	18299305	879	880	O
days	18299305	881	885	O
apart	18299305	886	891	O
.	18299305	891	892	O

Reactogenicity	18299305	893	907	O
events	18299305	908	914	O
were	18299305	915	919	O
monitored	18299305	920	929	O
for	18299305	930	933	O
11	18299305	934	936	O
days	18299305	937	941	O
after	18299305	942	947	O
each	18299305	948	952	O
dose	18299305	953	957	O
.	18299305	957	958	O

Other	18299305	959	964	O
adverse	18299305	965	972	O
events	18299305	973	979	O
were	18299305	980	984	O
monitored	18299305	985	994	O
through	18299305	995	1002	O
28	18299305	1003	1005	O
to	18299305	1006	1008	O
35	18299305	1009	1011	O
days	18299305	1012	1016	O
after	18299305	1017	1022	O
dose	18299305	1023	1027	O
2	18299305	1028	1029	O
.	18299305	1029	1030	O

RESULTS	18299305	1032	1039	O
:	18299305	1040	1041	O
Of	18299305	1042	1044	O
the	18299305	1045	1048	O
infants	18299305	1049	1056	O
aged	18299305	1057	1061	O
6	18299305	1062	1063	O
to	18299305	1064	1066	O
<	18299305	1067	1068	O
16	18299305	1068	1070	O
weeks	18299305	1071	1076	O
,	18299305	1076	1077	O
31	18299305	1078	1080	O
received	18299305	1081	1089	O
influenza	18299305	1090	1099	O
vaccine	18299305	1100	1107	O
and	18299305	1108	1111	O
28	18299305	1112	1114	O
received	18299305	1115	1123	O
placebo	18299305	1124	1131	O
,	18299305	1131	1132	O
and	18299305	1133	1136	O
of	18299305	1137	1139	O
those	18299305	1140	1145	O
aged	18299305	1146	1150	O
16	18299305	1151	1153	O
to	18299305	1154	1156	O
<	18299305	1157	1158	O
24	18299305	1158	1160	O
weeks	18299305	1161	1166	O
,	18299305	1166	1167	O
30	18299305	1168	1170	O
received	18299305	1171	1179	O
influenza	18299305	1180	1189	O
vaccine	18299305	1190	1197	O
and	18299305	1198	1201	O
31	18299305	1202	1204	O
received	18299305	1205	1213	O
placebo	18299305	1214	1221	O
.	18299305	1221	1222	O

In	18299305	1223	1225	O
the	18299305	1226	1229	O
6-	18299305	1230	1232	O
to	18299305	1233	1235	O
<	18299305	1236	1237	O
16-week	18299305	1237	1244	O
cohort	18299305	1245	1251	O
,	18299305	1251	1252	O
more	18299305	1253	1257	O
influenza	18299305	1258	1267	O
vaccine	18299305	1268	1275	O
,	18299305	1275	1276	O
recipients	18299305	1277	1287	O
experienced	18299305	1288	1299	O
irritability	18299305	1300	1312	B-Outcome
(	18299305	1313	1314	O
66.7	18299305	1314	1318	O
%	18299305	1318	1319	O
vs	18299305	1320	1322	O
35.7	18299305	1323	1327	O
%	18299305	1327	1328	O
)	18299305	1328	1329	O
and	18299305	1330	1333	O
runny	18299305	1334	1339	B-Outcome
nose	18299305	1340	1344	I-Outcome
or	18299305	1345	1347	O
nasal	18299305	1348	1353	B-Outcome
congestion	18299305	1354	1364	I-Outcome
(	18299305	1365	1366	O
63.3	18299305	1366	1370	O
%	18299305	1370	1371	O
vs	18299305	1372	1374	O
33.3	18299305	1375	1379	O
%	18299305	1379	1380	O
)	18299305	1380	1381	O
after	18299305	1382	1387	O
dose	18299305	1388	1392	O
1	18299305	1393	1394	O
but	18299305	1395	1398	O
not	18299305	1399	1402	O
dose	18299305	1403	1407	O
2	18299305	1408	1409	O
.	18299305	1409	1410	O

There	18299305	1411	1416	O
were	18299305	1417	1421	O
no	18299305	1422	1424	O
significant	18299305	1425	1436	O
increases	18299305	1437	1446	O
in	18299305	1447	1449	O
any	18299305	1450	1453	O
other	18299305	1454	1459	O
reactogenicity	18299305	1460	1474	B-Outcome
events	18299305	1475	1481	I-Outcome
or	18299305	1482	1484	O
adverse	18299305	1485	1492	B-Outcome
events	18299305	1493	1499	I-Outcome
in	18299305	1500	1502	O
the	18299305	1503	1506	O
vaccine	18299305	1507	1514	O
recipients	18299305	1515	1525	O
compared	18299305	1526	1534	O
with	18299305	1535	1539	O
the	18299305	1540	1543	O
placebo	18299305	1544	1551	O
group	18299305	1552	1557	O
.	18299305	1557	1558	O

CONCLUSIONS	18299305	1560	1571	O
:	18299305	1572	1573	O
Although	18299305	1574	1582	O
there	18299305	1583	1588	O
was	18299305	1589	1592	O
an	18299305	1593	1595	O
increase	18299305	1596	1604	O
in	18299305	1605	1607	O
mild	18299305	1608	1612	B-Outcome
reactogenicity	18299305	1613	1627	I-Outcome
events	18299305	1628	1634	I-Outcome
in	18299305	1635	1637	O
children	18299305	1638	1646	O
6	18299305	1647	1648	O
to	18299305	1649	1651	O
<	18299305	1652	1653	O
16	18299305	1653	1655	O
weeks	18299305	1656	1661	O
of	18299305	1662	1664	O
age	18299305	1665	1668	O
,	18299305	1668	1669	O
cold-adapted	18299305	1670	1682	O
influenza	18299305	1683	1692	O
vaccine	18299305	1693	1700	O
,	18299305	1700	1701	O
trivalent	18299305	1702	1711	O
,	18299305	1711	1712	O
was	18299305	1713	1716	O
generally	18299305	1717	1726	O
well	18299305	1727	1731	O
tolerated	18299305	1732	1741	B-Outcome
in	18299305	1742	1744	O
infants	18299305	1745	1752	O
6	18299305	1753	1754	O
to	18299305	1755	1757	O
<	18299305	1758	1759	O
24	18299305	1759	1761	O
weeks	18299305	1762	1767	O
of	18299305	1768	1770	O
age	18299305	1771	1774	O
.	18299305	1774	1775	O

These	18299305	1776	1781	O
findings	18299305	1782	1790	O
support	18299305	1791	1798	O
further	18299305	1799	1806	O
evaluation	18299305	1807	1817	O
of	18299305	1818	1820	O
cold-adapted	18299305	1821	1833	O
influenza	18299305	1834	1843	O
vaccine	18299305	1844	1851	O
,	18299305	1851	1852	O
trivalent	18299305	1853	1862	O
,	18299305	1862	1863	O
in	18299305	1864	1866	O
infants	18299305	1867	1874	O
<	18299305	1875	1876	O
6	18299305	1876	1877	O
months	18299305	1878	1884	O
of	18299305	1885	1887	O
age	18299305	1888	1891	O
.	18299305	1891	1892	O


Long-term	18328090	0	9	O
retention	18328090	10	19	O
on	18328090	20	22	O
treatment	18328090	23	32	O
with	18328090	33	37	O
lumiracoxib	18328090	38	49	O
100	18328090	50	53	O
mg	18328090	54	56	O
once	18328090	57	61	O
or	18328090	62	64	O
twice	18328090	65	70	O
daily	18328090	71	76	O
compared	18328090	77	85	O
with	18328090	86	90	O
celecoxib	18328090	91	100	O
200	18328090	101	104	O
mg	18328090	105	107	O
once	18328090	108	112	O
daily	18328090	113	118	O
:	18328090	118	119	O
a	18328090	120	121	O
randomised	18328090	122	132	O
controlled	18328090	133	143	O
trial	18328090	144	149	O
in	18328090	150	152	O
patients	18328090	153	161	O
with	18328090	162	166	O
osteoarthritis	18328090	167	181	O
.	18328090	181	182	O

BACKGROUND	18328090	184	194	O
:	18328090	195	196	O
The	18328090	197	200	O
efficacy	18328090	201	209	O
,	18328090	209	210	O
safety	18328090	211	217	O
and	18328090	218	221	O
tolerability	18328090	222	234	O
of	18328090	235	237	O
lumiracoxib	18328090	238	249	O
,	18328090	249	250	O
a	18328090	251	252	O
novel	18328090	253	258	O
selective	18328090	259	268	O
cyclooxygenase-2	18328090	269	285	O
(	18328090	286	287	O
COX-2	18328090	287	292	O
)	18328090	292	293	O
inhibitor	18328090	294	303	O
,	18328090	303	304	O
has	18328090	305	308	O
been	18328090	309	313	O
demonstrated	18328090	314	326	O
in	18328090	327	329	O
previous	18328090	330	338	O
studies	18328090	339	346	O
of	18328090	347	349	O
patients	18328090	350	358	O
with	18328090	359	363	O
osteoarthritis	18328090	364	378	O
(	18328090	379	380	O
OA	18328090	380	382	O
)	18328090	382	383	O
.	18328090	383	384	O

As	18328090	385	387	O
it	18328090	388	390	O
is	18328090	391	393	O
important	18328090	394	403	O
to	18328090	404	406	O
establish	18328090	407	416	O
the	18328090	417	420	O
long-term	18328090	421	430	O
safety	18328090	431	437	O
and	18328090	438	441	O
efficacy	18328090	442	450	O
of	18328090	451	453	O
treatments	18328090	454	464	O
for	18328090	465	468	O
a	18328090	469	470	O
chronic	18328090	471	478	O
disease	18328090	479	486	O
such	18328090	487	491	O
as	18328090	492	494	O
OA	18328090	495	497	O
,	18328090	497	498	O
the	18328090	499	502	O
present	18328090	503	510	O
study	18328090	511	516	O
compared	18328090	517	525	O
the	18328090	526	529	O
effects	18328090	530	537	O
of	18328090	538	540	O
lumiracoxib	18328090	541	552	O
at	18328090	553	555	O
doses	18328090	556	561	O
of	18328090	562	564	O
100	18328090	565	568	O
mg	18328090	569	571	O
once	18328090	572	576	O
daily	18328090	577	582	O
(	18328090	583	584	O
o.d	18328090	584	587	O
.	18328090	587	588	O
)	18328090	588	589	O
and	18328090	590	593	O
100	18328090	594	597	O
mg	18328090	598	600	O
twice	18328090	601	606	O
daily	18328090	607	612	O
(	18328090	613	614	O
b.i.d	18328090	614	619	O
.	18328090	619	620	O
)	18328090	620	621	O
with	18328090	622	626	O
those	18328090	627	632	O
of	18328090	633	635	O
celecoxib	18328090	636	645	O
200	18328090	646	649	O
mg	18328090	650	652	O
o.d	18328090	653	656	O
.	18328090	656	657	O

on	18328090	658	660	O
retention	18328090	661	670	O
on	18328090	671	673	O
treatment	18328090	674	683	O
over	18328090	684	688	O
1	18328090	689	690	O
year	18328090	691	695	O
.	18328090	695	696	O

METHODS	18328090	698	705	O
:	18328090	706	707	O
In	18328090	708	710	O
this	18328090	711	715	O
52-week	18328090	716	723	O
,	18328090	723	724	O
multicentre	18328090	725	736	O
,	18328090	736	737	O
randomised	18328090	738	748	O
,	18328090	748	749	O
double-blind	18328090	750	762	O
,	18328090	762	763	O
parallel-group	18328090	764	778	O
study	18328090	779	784	O
,	18328090	784	785	O
male	18328090	786	790	O
and	18328090	791	794	O
female	18328090	795	801	O
patients	18328090	802	810	O
(	18328090	811	812	O
aged	18328090	812	816	O
at	18328090	817	819	O
least	18328090	820	825	O
40	18328090	826	828	O
years	18328090	829	834	O
)	18328090	834	835	O
with	18328090	836	840	O
symptomatic	18328090	841	852	O
primary	18328090	853	860	O
OA	18328090	861	863	O
of	18328090	864	866	O
the	18328090	867	870	O
hip	18328090	871	874	O
,	18328090	874	875	O
knee	18328090	876	880	O
,	18328090	880	881	O
hand	18328090	882	886	O
or	18328090	887	889	O
spine	18328090	890	895	O
were	18328090	896	900	O
randomised	18328090	901	911	O
(	18328090	912	913	O
1:2:1	18328090	913	918	O
)	18328090	918	919	O
to	18328090	920	922	O
lumiracoxib	18328090	923	934	O
100	18328090	935	938	O
mg	18328090	939	941	O
o.d	18328090	942	945	O
.	18328090	945	946	O
(	18328090	947	948	O
n	18328090	948	949	O
=	18328090	950	951	O
755	18328090	952	955	O
)	18328090	955	956	O
,	18328090	956	957	O
lumiracoxib	18328090	958	969	O
100	18328090	970	973	O
mg	18328090	974	976	O
b.i.d	18328090	977	982	O
.	18328090	982	983	O
(	18328090	984	985	O
n	18328090	985	986	O
=	18328090	987	988	O
1,519	18328090	989	994	O
)	18328090	994	995	O
or	18328090	996	998	O
celecoxib	18328090	999	1008	O
200	18328090	1009	1012	O
mg	18328090	1013	1015	O
o.d	18328090	1016	1019	O
.	18328090	1019	1020	O
(	18328090	1021	1022	O
n	18328090	1022	1023	O
=	18328090	1024	1025	O
758	18328090	1026	1029	O
)	18328090	1029	1030	O
.	18328090	1030	1031	O

The	18328090	1032	1035	O
primary	18328090	1036	1043	O
objective	18328090	1044	1053	O
of	18328090	1054	1056	O
the	18328090	1057	1060	O
study	18328090	1061	1066	O
was	18328090	1067	1070	O
to	18328090	1071	1073	O
demonstrate	18328090	1074	1085	O
non-inferiority	18328090	1086	1101	O
of	18328090	1102	1104	O
lumiracoxib	18328090	1105	1116	O
at	18328090	1117	1119	O
either	18328090	1120	1126	O
dose	18328090	1127	1131	O
compared	18328090	1132	1140	O
with	18328090	1141	1145	O
celecoxib	18328090	1146	1155	O
200	18328090	1156	1159	O
mg	18328090	1160	1162	O
o.d	18328090	1163	1166	O
.	18328090	1166	1167	O

with	18328090	1168	1172	O
respect	18328090	1173	1180	O
to	18328090	1181	1183	O
the	18328090	1184	1187	O
1-year	18328090	1188	1194	O
retention	18328090	1195	1204	O
on	18328090	1205	1207	O
treatment	18328090	1208	1217	O
rate	18328090	1218	1222	O
.	18328090	1222	1223	O

Secondary	18328090	1224	1233	O
outcome	18328090	1234	1241	O
variables	18328090	1242	1251	O
included	18328090	1252	1260	O
OA	18328090	1261	1263	O
pain	18328090	1264	1268	O
in	18328090	1269	1271	O
the	18328090	1272	1275	O
target	18328090	1276	1282	O
joint	18328090	1283	1288	O
,	18328090	1288	1289	O
patient	18328090	1290	1297	O
's	18328090	1297	1299	O
and	18328090	1300	1303	O
physician	18328090	1304	1313	O
's	18328090	1313	1315	O
global	18328090	1316	1322	O
assessments	18328090	1323	1334	O
of	18328090	1335	1337	O
disease	18328090	1338	1345	O
activity	18328090	1346	1354	O
,	18328090	1354	1355	O
Short	18328090	1356	1361	O
Arthritis	18328090	1362	1371	O
assessment	18328090	1372	1382	O
Scale	18328090	1383	1388	O
(	18328090	1389	1390	O
SAS	18328090	1390	1393	O
)	18328090	1393	1394	O
total	18328090	1395	1400	O
score	18328090	1401	1406	O
,	18328090	1406	1407	O
rescue	18328090	1408	1414	O
medication	18328090	1415	1425	O
use	18328090	1426	1429	O
,	18328090	1429	1430	O
and	18328090	1431	1434	O
safety	18328090	1435	1441	O
and	18328090	1442	1445	O
tolerability	18328090	1446	1458	O
.	18328090	1458	1459	O

RESULTS	18328090	1461	1468	O
:	18328090	1469	1470	O
Retention	18328090	1471	1480	B-Outcome
rates	18328090	1481	1486	I-Outcome
at	18328090	1487	1489	I-Outcome
1	18328090	1490	1491	I-Outcome
year	18328090	1492	1496	I-Outcome
were	18328090	1497	1501	O
similar	18328090	1502	1509	O
for	18328090	1510	1513	O
the	18328090	1514	1517	O
lumiracoxib	18328090	1518	1529	O
100	18328090	1530	1533	O
mg	18328090	1534	1536	O
o.d	18328090	1537	1540	O
.	18328090	1540	1541	O
,	18328090	1541	1542	O
lumiracoxib	18328090	1543	1554	O
100	18328090	1555	1558	O
mg	18328090	1559	1561	O
b.i.d	18328090	1562	1567	O
.	18328090	1567	1568	O

and	18328090	1569	1572	O
celecoxib	18328090	1573	1582	O
200	18328090	1583	1586	O
mg	18328090	1587	1589	O
o.d	18328090	1590	1593	O
.	18328090	1593	1594	O

groups	18328090	1595	1601	O
(	18328090	1602	1603	O
46.9	18328090	1603	1607	O
%	18328090	1607	1608	O
vs	18328090	1609	1611	O
47.5	18328090	1612	1616	O
%	18328090	1616	1617	O
vs	18328090	1618	1620	O
45.3	18328090	1621	1625	O
%	18328090	1625	1626	O
,	18328090	1626	1627	O
respectively	18328090	1628	1640	O
)	18328090	1640	1641	O
.	18328090	1641	1642	O

It	18328090	1643	1645	O
was	18328090	1646	1649	O
demonstrated	18328090	1650	1662	O
that	18328090	1663	1667	O
retention	18328090	1668	1677	B-Outcome
on	18328090	1678	1680	O
treatment	18328090	1681	1690	O
with	18328090	1691	1695	O
lumiracoxib	18328090	1696	1707	O
at	18328090	1708	1710	O
either	18328090	1711	1717	O
dose	18328090	1718	1722	O
was	18328090	1723	1726	O
non-inferior	18328090	1727	1739	O
to	18328090	1740	1742	O
celecoxib	18328090	1743	1752	O
200	18328090	1753	1756	O
mg	18328090	1757	1759	O
o.d	18328090	1760	1763	O
.	18328090	1763	1764	O

Similarly	18328090	1765	1774	O
,	18328090	1774	1775	O
Kaplan-Meier	18328090	1776	1788	O
curves	18328090	1789	1795	O
for	18328090	1796	1799	O
the	18328090	1800	1803	O
probability	18328090	1804	1815	O
of	18328090	1816	1818	O
premature	18328090	1819	1828	B-Outcome
discontinuation	18328090	1829	1844	I-Outcome
from	18328090	1845	1849	O
the	18328090	1850	1853	O
study	18328090	1854	1859	O
for	18328090	1860	1863	O
any	18328090	1864	1867	O
reason	18328090	1868	1874	O
were	18328090	1875	1879	O
similar	18328090	1880	1887	O
across	18328090	1888	1894	O
the	18328090	1895	1898	O
treatment	18328090	1899	1908	O
groups	18328090	1909	1915	O
.	18328090	1915	1916	O

All	18328090	1917	1920	O
three	18328090	1921	1926	O
treatments	18328090	1927	1937	O
generally	18328090	1938	1947	O
yielded	18328090	1948	1955	O
comparable	18328090	1956	1966	O
results	18328090	1967	1974	O
for	18328090	1975	1978	O
the	18328090	1979	1982	O
secondary	18328090	1983	1992	O
efficacy	18328090	1993	2001	B-Outcome
variables	18328090	2002	2011	O
and	18328090	2012	2015	O
all	18328090	2016	2019	O
treatments	18328090	2020	2030	O
were	18328090	2031	2035	O
well	18328090	2036	2040	O
tolerated	18328090	2041	2050	B-Outcome
.	18328090	2050	2051	O

CONCLUSION	18328090	2053	2063	O
:	18328090	2064	2065	O
Long-term	18328090	2066	2075	O
treatment	18328090	2076	2085	O
with	18328090	2086	2090	O
lumiracoxib	18328090	2091	2102	O
100	18328090	2103	2106	O
mg	18328090	2107	2109	O
o.d	18328090	2110	2113	O
.	18328090	2113	2114	O
,	18328090	2114	2115	O
the	18328090	2116	2119	O
recommended	18328090	2120	2131	O
dose	18328090	2132	2136	O
for	18328090	2137	2140	O
OA	18328090	2141	2143	O
,	18328090	2143	2144	O
was	18328090	2145	2148	O
as	18328090	2149	2151	O
effective	18328090	2152	2161	O
and	18328090	2162	2165	O
well	18328090	2166	2170	O
tolerated	18328090	2171	2180	B-Outcome
as	18328090	2181	2183	O
celecoxib	18328090	2184	2193	O
200	18328090	2194	2197	O
mg	18328090	2198	2200	O
o.d	18328090	2201	2204	O
.	18328090	2204	2205	O

in	18328090	2206	2208	O
patients	18328090	2209	2217	O
with	18328090	2218	2222	O
OA	18328090	2223	2225	O
.	18328090	2225	2226	O

TRIAL	18328090	2228	2233	O
REGISTRATION	18328090	2234	2246	O
:	18328090	2247	2248	O
clinicaltrials.gov	18328090	2249	2267	O
NCT00145301	18328090	2268	2279	O
.	18328090	2279	2280	O


New	18374024	0	3	O
introducer	18374024	4	14	O
PEG	18374024	15	18	O
gastropexy	18374024	19	29	O
does	18374024	30	34	O
not	18374024	35	38	O
require	18374024	39	46	O
prophylactic	18374024	47	59	O
antibiotics	18374024	60	71	O
:	18374024	71	72	O
multicenter	18374024	73	84	O
prospective	18374024	85	96	O
randomized	18374024	97	107	O
double-blind	18374024	108	120	O
placebo-controlled	18374024	121	139	O
study	18374024	140	145	O
.	18374024	145	146	O

BACKGROUND	18374024	148	158	O
:	18374024	159	160	O
Peristomal	18374024	161	171	O
infections	18374024	172	182	O
are	18374024	183	186	O
the	18374024	187	190	O
most	18374024	191	195	O
common	18374024	196	202	O
complications	18374024	203	216	O
of	18374024	217	219	O
PEG	18374024	220	223	O
,	18374024	223	224	O
despite	18374024	225	232	O
prophylactic	18374024	233	245	O
antibiotics	18374024	246	257	O
.	18374024	257	258	O

The	18374024	259	262	O
"	18374024	263	264	O
introducer	18374024	264	274	O
"	18374024	274	275	O
PEG-placement	18374024	276	289	O
technique	18374024	290	299	O
avoids	18374024	300	306	O
the	18374024	307	310	O
sojourn	18374024	311	318	O
of	18374024	319	321	O
a	18374024	322	323	O
PEG	18374024	324	327	O
catheter	18374024	328	336	O
through	18374024	337	344	O
the	18374024	345	348	O
oropharynx	18374024	349	359	O
,	18374024	359	360	O
and	18374024	361	364	O
hence	18374024	365	370	O
minimizes	18374024	371	380	O
the	18374024	381	384	O
chances	18374024	385	392	O
of	18374024	393	395	O
infectious	18374024	396	406	O
complications	18374024	407	420	O
.	18374024	420	421	O

Despite	18374024	422	429	O
the	18374024	430	433	O
obvious	18374024	434	441	O
potential	18374024	442	451	O
advantage	18374024	452	461	O
,	18374024	461	462	O
this	18374024	463	467	O
technique	18374024	468	477	O
failed	18374024	478	484	O
to	18374024	485	487	O
gain	18374024	488	492	O
popularity	18374024	493	503	O
,	18374024	503	504	O
mainly	18374024	505	511	O
as	18374024	512	514	O
a	18374024	515	516	O
result	18374024	517	523	O
of	18374024	524	526	O
other	18374024	527	532	O
associated	18374024	533	543	O
risks	18374024	544	549	O
and	18374024	550	553	O
complications	18374024	554	567	O
.	18374024	567	568	O

Recently	18374024	569	577	O
,	18374024	577	578	O
a	18374024	579	580	O
modified	18374024	581	589	O
introducer	18374024	590	600	O
endoscopic	18374024	601	611	O
PEG-gastropexy	18374024	612	626	O
technique	18374024	627	636	O
was	18374024	637	640	O
shown	18374024	641	646	O
to	18374024	647	649	O
be	18374024	650	652	O
quite	18374024	653	658	O
safe	18374024	659	663	O
.	18374024	663	664	O

The	18374024	665	668	O
present	18374024	669	676	O
study	18374024	677	682	O
is	18374024	683	685	O
the	18374024	686	689	O
first	18374024	690	695	O
study	18374024	696	701	O
that	18374024	702	706	O
evaluated	18374024	707	716	O
the	18374024	717	720	O
need	18374024	721	725	O
of	18374024	726	728	O
prophylactic	18374024	729	741	O
antibiotics	18374024	742	753	O
for	18374024	754	757	O
"	18374024	758	759	O
introducer	18374024	759	769	O
"	18374024	769	770	O
PEG	18374024	771	774	O
.	18374024	774	775	O

OBJECTIVE	18374024	777	786	O
:	18374024	787	788	O
To	18374024	789	791	O
determine	18374024	792	801	O
the	18374024	802	805	O
incidence	18374024	806	815	O
of	18374024	816	818	O
peristomal	18374024	819	829	O
wound	18374024	830	835	O
infections	18374024	836	846	O
during	18374024	847	853	O
the	18374024	854	857	O
immediate	18374024	858	867	O
7-day	18374024	868	873	O
postprocedure	18374024	874	887	O
follow-up	18374024	888	897	O
.	18374024	897	898	O

DESIGN	18374024	900	906	O
:	18374024	907	908	O
Prospective	18374024	909	920	O
,	18374024	920	921	O
randomized	18374024	922	932	O
,	18374024	932	933	O
double-blind	18374024	934	946	O
,	18374024	946	947	O
placebo-controlled	18374024	948	966	O
trial	18374024	967	972	O
.	18374024	972	973	O

SETTINGS	18374024	975	983	O
:	18374024	984	985	O
Multicenter	18374024	986	997	O
;	18374024	997	998	O
a	18374024	999	1000	O
university	18374024	1001	1011	O
tertiary-care	18374024	1012	1025	O
hospital	18374024	1026	1034	O
and	18374024	1035	1038	O
a	18374024	1039	1040	O
private	18374024	1041	1048	O
practice	18374024	1049	1057	O
endoscopy	18374024	1058	1067	O
clinic	18374024	1068	1074	O
.	18374024	1074	1075	O

PATIENTS	18374024	1077	1085	O
:	18374024	1086	1087	O
A	18374024	1088	1089	O
total	18374024	1090	1095	O
of	18374024	1096	1098	O
633	18374024	1099	1102	O
patients	18374024	1103	1111	O
undergoing	18374024	1112	1122	O
PEG	18374024	1123	1126	O
were	18374024	1127	1131	O
assessed	18374024	1132	1140	O
for	18374024	1141	1144	O
inclusion	18374024	1145	1154	O
.	18374024	1154	1155	O

Ninety-seven	18374024	1156	1168	O
patients	18374024	1169	1177	O
who	18374024	1178	1181	O
had	18374024	1182	1185	O
malignant	18374024	1186	1195	O
stenotic	18374024	1196	1204	O
oropharyngeal	18374024	1205	1218	O
stricture	18374024	1219	1228	O
were	18374024	1229	1233	O
randomized	18374024	1234	1244	O
:	18374024	1244	1245	O
group	18374024	1246	1251	O
I	18374024	1252	1253	O
(	18374024	1254	1255	O
49	18374024	1255	1257	O
patients	18374024	1258	1266	O
)	18374024	1266	1267	O
received	18374024	1268	1276	O
prophylactic	18374024	1277	1289	O
ceftriaxone	18374024	1290	1301	O
,	18374024	1301	1302	O
and	18374024	1303	1306	O
group	18374024	1307	1312	O
II	18374024	1313	1315	O
(	18374024	1316	1317	O
48	18374024	1317	1319	O
patients	18374024	1320	1328	O
)	18374024	1328	1329	O
received	18374024	1330	1338	O
a	18374024	1339	1340	O
placebo	18374024	1341	1348	O
.	18374024	1348	1349	O

Both	18374024	1350	1354	O
groups	18374024	1355	1361	O
were	18374024	1362	1366	O
similar	18374024	1367	1374	O
in	18374024	1375	1377	O
patient	18374024	1378	1385	O
characteristics	18374024	1386	1401	O
.	18374024	1401	1402	O

INTERVENTIONS	18374024	1404	1417	O
:	18374024	1418	1419	O
Introducer	18374024	1420	1430	O
PEG	18374024	1431	1434	O
was	18374024	1435	1438	O
performed	18374024	1439	1448	O
by	18374024	1449	1451	O
using	18374024	1452	1457	O
the	18374024	1458	1461	O
Freka	18374024	1462	1467	O
Pexact-15	18374024	1468	1477	O
CH/FR	18374024	1478	1483	O
,	18374024	1483	1484	O
with	18374024	1485	1489	O
the	18374024	1490	1493	O
gastric	18374024	1494	1501	O
wall	18374024	1502	1506	O
nonsurgically	18374024	1507	1520	O
sutured	18374024	1521	1528	O
to	18374024	1529	1531	O
the	18374024	1532	1535	O
anterior	18374024	1536	1544	O
abdominal	18374024	1545	1554	O
wall	18374024	1555	1559	O
by	18374024	1560	1562	O
use	18374024	1563	1566	O
of	18374024	1567	1569	O
an	18374024	1570	1572	O
endoscope	18374024	1573	1582	O
.	18374024	1582	1583	O

MAIN	18374024	1585	1589	O
OUTCOME	18374024	1590	1597	O
MEASUREMENTS	18374024	1598	1610	O
:	18374024	1611	1612	O
The	18374024	1613	1616	O
peristomal	18374024	1617	1627	O
area	18374024	1628	1632	O
was	18374024	1633	1636	O
assessed	18374024	1637	1645	O
daily	18374024	1646	1651	O
for	18374024	1652	1655	O
7	18374024	1656	1657	O
days	18374024	1658	1662	O
by	18374024	1663	1665	O
using	18374024	1666	1671	O
2	18374024	1672	1673	O
different	18374024	1674	1683	O
types	18374024	1684	1689	O
of	18374024	1690	1692	O
infection	18374024	1693	1702	O
scores	18374024	1703	1709	O
.	18374024	1709	1710	O

RESULTS	18374024	1712	1719	O
:	18374024	1720	1721	O
Clinically	18374024	1722	1732	B-Outcome
significant	18374024	1733	1744	I-Outcome
wound	18374024	1745	1750	I-Outcome
reaction	18374024	1751	1759	I-Outcome
was	18374024	1760	1763	O
observed	18374024	1764	1772	O
in	18374024	1773	1775	O
1	18374024	1776	1777	O
patient	18374024	1778	1785	O
in	18374024	1786	1788	O
each	18374024	1789	1793	O
group	18374024	1794	1799	O
.	18374024	1799	1800	O

Wound	18374024	1801	1806	B-Outcome
infection	18374024	1807	1816	I-Outcome
scores	18374024	1817	1823	I-Outcome
were	18374024	1824	1828	O
marginally	18374024	1829	1839	O
higher	18374024	1840	1846	O
in	18374024	1847	1849	O
the	18374024	1850	1853	O
placebo	18374024	1854	1861	O
group	18374024	1862	1867	O
,	18374024	1867	1868	O
but	18374024	1869	1872	O
the	18374024	1873	1876	O
differences	18374024	1877	1888	O
in	18374024	1889	1891	O
the	18374024	1892	1895	O
values	18374024	1896	1902	O
of	18374024	1903	1905	O
infection	18374024	1906	1915	B-Outcome
scores	18374024	1916	1922	I-Outcome
between	18374024	1923	1930	O
both	18374024	1931	1935	O
the	18374024	1936	1939	O
groups	18374024	1940	1946	O
were	18374024	1947	1951	O
not	18374024	1952	1955	O
statistically	18374024	1956	1969	O
significant	18374024	1970	1981	O
during	18374024	1982	1988	O
the	18374024	1989	1992	O
7-day	18374024	1993	1998	O
post-PEG	18374024	1999	2007	O
follow-up	18374024	2008	2017	O
.	18374024	2017	2018	O

LIMITATIONS	18374024	2020	2031	O
:	18374024	2032	2033	O
The	18374024	2034	2037	O
introducer	18374024	2038	2048	O
gastropexy	18374024	2049	2059	O
kit	18374024	2060	2063	O
is	18374024	2064	2066	O
5	18374024	2067	2068	O
times	18374024	2069	2074	O
more	18374024	2075	2079	O
expensive	18374024	2080	2089	O
than	18374024	2090	2094	O
the	18374024	2095	2098	O
"	18374024	2099	2100	O
pull	18374024	2100	2104	O
"	18374024	2104	2105	O
PEG	18374024	2106	2109	O
.	18374024	2109	2110	O

CONCLUSIONS	18374024	2112	2123	O
:	18374024	2124	2125	O
The	18374024	2126	2129	O
new	18374024	2130	2133	O
introducer	18374024	2134	2144	O
PEG-gastropexy	18374024	2145	2159	O
technique	18374024	2160	2169	O
can	18374024	2170	2173	O
be	18374024	2174	2176	O
performed	18374024	2177	2186	O
safely	18374024	2187	2193	B-Outcome
,	18374024	2193	2194	O
without	18374024	2195	2202	O
prophylactic	18374024	2203	2215	O
antibiotics	18374024	2216	2227	O
in	18374024	2228	2230	O
patients	18374024	2231	2239	O
potentially	18374024	2240	2251	O
at	18374024	2252	2254	O
high	18374024	2255	2259	O
risk	18374024	2260	2264	O
of	18374024	2265	2267	O
peristomal	18374024	2268	2278	O
infectious	18374024	2279	2289	O
complications	18374024	2290	2303	O
(	18374024	2304	2305	O
those	18374024	2305	2310	O
with	18374024	2311	2315	O
advanced	18374024	2316	2324	O
oropharyngeal	18374024	2325	2338	O
malignancy	18374024	2339	2349	O
)	18374024	2349	2350	O
(	18374024	2351	2352	O
ClinicalTrials.gov	18374024	2352	2370	O
identifier	18374024	2371	2381	O
NCT00375414	18374024	2382	2393	O
)	18374024	2393	2394	O
.	18374024	2394	2395	O


Benzodiazepine	18394874	0	14	O
and	18394874	15	18	O
opioid	18394874	19	25	O
sedation	18394874	26	34	O
attenuate	18394874	35	44	O
the	18394874	45	48	O
sympathetic	18394874	49	60	O
response	18394874	61	69	O
to	18394874	70	72	O
fiberoptic	18394874	73	83	O
bronchoscopy	18394874	84	96	O
.	18394874	96	97	O

Prophylactic	18394874	98	110	O
labetalol	18394874	111	120	O
gave	18394874	121	125	O
no	18394874	126	128	O
additional	18394874	129	139	O
benefit	18394874	140	147	O
.	18394874	147	148	O

Results	18394874	149	156	O
of	18394874	157	159	O
a	18394874	160	161	O
randomized	18394874	162	172	O
double-blind	18394874	173	185	O
placebo-controlled	18394874	186	204	O
study	18394874	205	210	O
.	18394874	210	211	O

BACKGROUND	18394874	213	223	O
:	18394874	224	225	O
Hypertension	18394874	226	238	O
and	18394874	239	242	O
tachycardia	18394874	243	254	O
are	18394874	255	258	O
common	18394874	259	265	O
during	18394874	266	272	O
fiber-optic	18394874	273	284	O
bronchoscopy	18394874	285	297	O
(	18394874	298	299	O
FOB	18394874	299	302	O
)	18394874	302	303	O
,	18394874	303	304	O
and	18394874	305	308	O
this	18394874	309	313	O
may	18394874	314	317	O
lead	18394874	318	322	O
to	18394874	323	325	O
cardiac	18394874	326	333	O
ischemia	18394874	334	342	O
.	18394874	342	343	O

The	18394874	344	347	O
prophylactic	18394874	348	360	O
addition	18394874	361	369	O
of	18394874	370	372	O
a	18394874	373	374	O
beta-adrenergic	18394874	375	390	O
anatagonist	18394874	391	402	O
might	18394874	403	408	O
mask	18394874	409	413	O
this	18394874	414	418	O
response	18394874	419	427	O
and	18394874	428	431	O
prevent	18394874	432	439	O
the	18394874	440	443	O
deleterious	18394874	444	455	O
cardiovascular	18394874	456	470	O
effects	18394874	471	478	O
of	18394874	479	481	O
FOB	18394874	482	485	O
.	18394874	485	486	O

METHODS	18394874	488	495	O
:	18394874	496	497	O
We	18394874	498	500	O
performed	18394874	501	510	O
a	18394874	511	512	O
randomized	18394874	513	523	O
double-blind	18394874	524	536	O
placebo-controlled	18394874	537	555	O
trial	18394874	556	561	O
of	18394874	562	564	O
labetalol	18394874	565	574	O
10	18394874	575	577	O
mg	18394874	577	579	O
iv	18394874	580	582	O
given	18394874	583	588	O
with	18394874	589	593	O
midazolam-alfentanil	18394874	594	614	O
sedation	18394874	615	623	O
.	18394874	623	624	O

We	18394874	625	627	O
monitored	18394874	628	637	O
heart	18394874	638	643	O
rate	18394874	644	648	O
(	18394874	649	650	O
HR	18394874	650	652	O
)	18394874	652	653	O
and	18394874	654	657	O
systolic/diastolic	18394874	658	676	O
blood	18394874	677	682	O
pressure	18394874	683	691	O
(	18394874	692	693	O
SBP/DBP	18394874	693	700	O
)	18394874	700	701	O
throughout	18394874	702	712	O
the	18394874	713	716	O
bronchoscopy	18394874	717	729	O
and	18394874	730	733	O
calculated	18394874	734	744	O
the	18394874	745	748	O
rate-pressure	18394874	749	762	O
product	18394874	763	770	O
(	18394874	771	772	O
RPP=(HRxSBP)/100	18394874	772	788	O
)	18394874	788	789	O
.	18394874	789	790	O

One-hundred	18394874	791	802	O
twenty	18394874	803	809	O
patients	18394874	810	818	O
were	18394874	819	823	O
enrolled	18394874	824	832	O
.	18394874	832	833	O

RESULTS	18394874	835	842	O
:	18394874	843	844	O
In	18394874	845	847	O
the	18394874	848	851	O
placebo	18394874	852	859	O
group	18394874	860	865	O
,	18394874	865	866	O
there	18394874	867	872	O
was	18394874	873	876	O
no	18394874	877	879	O
rise	18394874	880	884	O
in	18394874	885	887	O
HR	18394874	888	890	B-Outcome
,	18394874	890	891	O
SBP	18394874	892	895	B-Outcome
,	18394874	895	896	O
DBP	18394874	897	900	B-Outcome
or	18394874	901	903	O
RPP	18394874	904	907	B-Outcome
,	18394874	907	908	O
and	18394874	909	912	O
there	18394874	913	918	O
was	18394874	919	922	O
no	18394874	923	925	O
difference	18394874	926	936	O
between	18394874	937	944	O
the	18394874	945	948	O
placebo	18394874	949	956	O
and	18394874	957	960	O
labetalol	18394874	961	970	O
groups	18394874	971	977	O
.	18394874	977	978	O

Adverse	18394874	979	986	B-Outcome
events	18394874	987	993	I-Outcome
during	18394874	994	1000	O
bronchoscopy	18394874	1001	1013	O
were	18394874	1014	1018	O
similar	18394874	1019	1026	O
in	18394874	1027	1029	O
both	18394874	1030	1034	O
groups	18394874	1035	1041	O
.	18394874	1041	1042	O

In	18394874	1043	1045	O
a	18394874	1046	1047	O
subgroup	18394874	1048	1056	O
of	18394874	1057	1059	O
patients	18394874	1060	1068	O
undergoing	18394874	1069	1079	O
interventional	18394874	1080	1094	O
bronchoscopy	18394874	1095	1107	O
,	18394874	1107	1108	O
there	18394874	1109	1114	O
was	18394874	1115	1118	O
a	18394874	1119	1120	O
trend	18394874	1121	1126	O
towards	18394874	1127	1134	O
lower	18394874	1135	1140	O
SBP	18394874	1141	1144	B-Outcome
(	18394874	1145	1146	O
p=0.06	18394874	1146	1152	O
)	18394874	1152	1153	O
.	18394874	1153	1154	O

CONCLUSIONS	18394874	1156	1167	O
:	18394874	1168	1169	O
Patients	18394874	1170	1178	O
undergoing	18394874	1179	1189	O
FOB	18394874	1190	1193	O
under	18394874	1194	1199	O
adequate	18394874	1200	1208	O
midazolam-alfentanil	18394874	1209	1229	O
sedation	18394874	1230	1238	O
do	18394874	1239	1241	O
not	18394874	1242	1245	O
develop	18394874	1246	1253	O
excessive	18394874	1254	1263	O
sympathetic	18394874	1264	1275	O
drive	18394874	1276	1281	O
that	18394874	1282	1286	O
may	18394874	1287	1290	O
lead	18394874	1291	1295	O
to	18394874	1296	1298	O
cardiac	18394874	1299	1306	O
stress	18394874	1307	1313	O
.	18394874	1313	1314	O

The	18394874	1315	1318	O
addition	18394874	1319	1327	O
of	18394874	1328	1330	O
labetalol	18394874	1331	1340	O
did	18394874	1341	1344	O
not	18394874	1345	1348	O
confer	18394874	1349	1355	O
additional	18394874	1356	1366	O
benefit	18394874	1367	1374	O
or	18394874	1375	1377	O
risk	18394874	1378	1382	O
to	18394874	1383	1385	O
the	18394874	1386	1389	O
patients	18394874	1390	1398	O
.	18394874	1398	1399	O

(	18394874	1400	1401	O
ClinicalTrials.gov	18394874	1401	1419	O
number	18394874	1420	1426	O
,	18394874	1426	1427	O
NCT00394537	18394874	1428	1439	O
)	18394874	1439	1440	O
.	18394874	1440	1441	O


Does	18431478	0	4	O
3-day	18431478	5	10	O
course	18431478	11	17	O
of	18431478	18	20	O
oral	18431478	21	25	O
amoxycillin	18431478	26	37	O
benefit	18431478	38	45	O
children	18431478	46	54	O
of	18431478	55	57	O
non-severe	18431478	58	68	O
pneumonia	18431478	69	78	O
with	18431478	79	83	O
wheeze	18431478	84	90	O
:	18431478	90	91	O
a	18431478	92	93	O
multicentric	18431478	94	106	O
randomised	18431478	107	117	O
controlled	18431478	118	128	O
trial	18431478	129	134	O
.	18431478	134	135	O

BACKGROUND	18431478	137	147	O
:	18431478	148	149	O
WHO-defined	18431478	150	161	O
pneumonias	18431478	162	172	O
,	18431478	172	173	O
treated	18431478	174	181	O
with	18431478	182	186	O
antibiotics	18431478	187	198	O
,	18431478	198	199	O
are	18431478	200	203	O
responsible	18431478	204	215	O
for	18431478	216	219	O
a	18431478	220	221	O
significant	18431478	222	233	O
proportion	18431478	234	244	O
of	18431478	245	247	O
childhood	18431478	248	257	O
morbidity	18431478	258	267	O
and	18431478	268	271	O
mortality	18431478	272	281	O
in	18431478	282	284	O
the	18431478	285	288	O
developing	18431478	289	299	O
countries	18431478	300	309	O
.	18431478	309	310	O

Since	18431478	311	316	O
substantial	18431478	317	328	O
proportion	18431478	329	339	O
pneumonias	18431478	340	350	O
have	18431478	351	355	O
a	18431478	356	357	O
viral	18431478	358	363	O
etiology	18431478	364	372	O
,	18431478	372	373	O
where	18431478	374	379	O
children	18431478	380	388	O
are	18431478	389	392	O
more	18431478	393	397	O
likely	18431478	398	404	O
to	18431478	405	407	O
present	18431478	408	415	O
with	18431478	416	420	O
wheeze	18431478	421	427	O
,	18431478	427	428	O
there	18431478	429	434	O
is	18431478	435	437	O
a	18431478	438	439	O
concern	18431478	440	447	O
that	18431478	448	452	O
currently	18431478	453	462	O
antibiotics	18431478	463	474	O
are	18431478	475	478	O
being	18431478	479	484	O
over-prescribed	18431478	485	500	O
for	18431478	501	504	O
it	18431478	505	507	O
.	18431478	507	508	O

Hence	18431478	509	514	O
the	18431478	515	518	O
current	18431478	519	526	O
trial	18431478	527	532	O
was	18431478	533	536	O
conducted	18431478	537	546	O
with	18431478	547	551	O
the	18431478	552	555	O
objective	18431478	556	565	O
to	18431478	566	568	O
show	18431478	569	573	O
the	18431478	574	577	O
therapeutic	18431478	578	589	O
equivalence	18431478	590	601	O
of	18431478	602	604	O
two	18431478	605	608	O
treatments	18431478	609	619	O
(	18431478	620	621	O
placebo	18431478	621	628	O
and	18431478	629	632	O
amoxycillin	18431478	633	644	O
)	18431478	644	645	O
for	18431478	646	649	O
children	18431478	650	658	O
presenting	18431478	659	669	O
with	18431478	670	674	O
non-severe	18431478	675	685	O
pneumonia	18431478	686	695	O
with	18431478	696	700	O
wheeze	18431478	701	707	O
,	18431478	707	708	O
who	18431478	709	712	O
have	18431478	713	717	O
persistent	18431478	718	728	O
fast	18431478	729	733	O
breathing	18431478	734	743	O
after	18431478	744	749	O
nebulisation	18431478	750	762	O
with	18431478	763	767	O
salbutamol	18431478	768	778	O
,	18431478	778	779	O
and	18431478	780	783	O
have	18431478	784	788	O
normal	18431478	789	795	O
chest	18431478	796	801	O
radiograph	18431478	802	812	O
.	18431478	812	813	O

METHODOLOGY	18431478	815	826	O
:	18431478	827	828	O
This	18431478	829	833	O
multi-centric	18431478	834	847	O
,	18431478	847	848	O
randomised	18431478	849	859	O
placebo	18431478	860	867	O
controlled	18431478	868	878	O
double	18431478	879	885	O
blind	18431478	886	891	O
clinical	18431478	892	900	O
trial	18431478	901	906	O
intended	18431478	907	915	O
to	18431478	916	918	O
investigate	18431478	919	930	O
equivalent	18431478	931	941	O
efficacy	18431478	942	950	O
of	18431478	951	953	O
placebo	18431478	954	961	O
and	18431478	962	965	O
amoxicillin	18431478	966	977	O
and	18431478	978	981	O
was	18431478	982	985	O
conducted	18431478	986	995	O
in	18431478	996	998	O
ambulatory	18431478	999	1009	O
care	18431478	1010	1014	O
settings	18431478	1015	1023	O
in	18431478	1024	1026	O
eight	18431478	1027	1032	O
government	18431478	1033	1043	O
hospitals	18431478	1044	1053	O
in	18431478	1054	1056	O
India	18431478	1057	1062	O
.	18431478	1062	1063	O

Participants	18431478	1064	1076	O
were	18431478	1077	1081	O
children	18431478	1082	1090	O
aged	18431478	1091	1095	O
2	18431478	1096	1097	O
-	18431478	1097	1098	O
59	18431478	1098	1100	O
months	18431478	1101	1107	O
of	18431478	1108	1110	O
age	18431478	1111	1114	O
,	18431478	1114	1115	O
who	18431478	1116	1119	O
received	18431478	1120	1128	O
either	18431478	1129	1135	O
oral	18431478	1136	1140	O
amoxycillin	18431478	1141	1152	O
(	18431478	1153	1154	O
31	18431478	1154	1156	O
-	18431478	1156	1157	O
54	18431478	1157	1159	O
mg/Kg/day	18431478	1160	1169	O
,	18431478	1169	1170	O
in	18431478	1171	1173	O
three	18431478	1174	1179	O
divided	18431478	1180	1187	O
doses	18431478	1188	1193	O
for	18431478	1194	1197	O
three	18431478	1198	1203	O
days	18431478	1204	1208	O
)	18431478	1208	1209	O
or	18431478	1210	1212	O
placebo	18431478	1213	1220	O
,	18431478	1220	1221	O
and	18431478	1222	1225	O
standard	18431478	1226	1234	O
bronchodilator	18431478	1235	1249	O
therapy	18431478	1250	1257	O
.	18431478	1257	1258	O

Primary	18431478	1259	1266	O
outcome	18431478	1267	1274	O
was	18431478	1275	1278	O
clinical	18431478	1279	1287	O
failure	18431478	1288	1295	O
on	18431478	1296	1298	O
or	18431478	1299	1301	O
before	18431478	1302	1308	O
day-	18431478	1309	1313	O
4	18431478	1314	1315	O
.	18431478	1315	1316	O

PRINCIPAL	18431478	1318	1327	O
FINDINGS	18431478	1328	1336	O
:	18431478	1337	1338	O
We	18431478	1339	1341	O
randomized	18431478	1342	1352	O
836	18431478	1353	1356	O
cases	18431478	1357	1362	O
in	18431478	1363	1365	O
placebo	18431478	1366	1373	O
and	18431478	1374	1377	O
835	18431478	1378	1381	O
in	18431478	1382	1384	O
amoxycillin	18431478	1385	1396	O
group	18431478	1397	1402	O
.	18431478	1402	1403	O

Clinical	18431478	1404	1412	B-Outcome
failures	18431478	1413	1421	I-Outcome
occurred	18431478	1422	1430	O
in	18431478	1431	1433	O
201	18431478	1434	1437	O
(	18431478	1438	1439	O
24.0	18431478	1439	1443	O
%	18431478	1443	1444	O
)	18431478	1444	1445	O
on	18431478	1446	1448	O
placebo	18431478	1449	1456	O
and	18431478	1457	1460	O
166	18431478	1461	1464	O
(	18431478	1465	1466	O
19.9	18431478	1466	1470	O
%	18431478	1470	1471	O
)	18431478	1471	1472	O
on	18431478	1473	1475	O
amoxycillin	18431478	1476	1487	O
(	18431478	1488	1489	O
risk	18431478	1489	1493	O
difference	18431478	1494	1504	O
4.2	18431478	1505	1508	O
%	18431478	1508	1509	O
in	18431478	1510	1512	O
favour	18431478	1513	1519	O
of	18431478	1520	1522	O
antibiotic	18431478	1523	1533	O
,	18431478	1533	1534	O
95	18431478	1535	1537	O
%	18431478	1537	1538	O
CI	18431478	1539	1541	O
:	18431478	1541	1542	O
0.2	18431478	1543	1546	O
to	18431478	1547	1549	O
8.1	18431478	1550	1553	O
)	18431478	1553	1554	O
.	18431478	1554	1555	O

Adherence	18431478	1556	1565	O
for	18431478	1566	1569	O
both	18431478	1570	1574	O
placebo	18431478	1575	1582	O
and	18431478	1583	1586	O
amoxycillin	18431478	1587	1598	O
was	18431478	1599	1602	O
>	18431478	1603	1604	O
96	18431478	1604	1606	O
%	18431478	1606	1607	O
and	18431478	1608	1611	O
98.9	18431478	1612	1616	O
%	18431478	1616	1617	O
subjects	18431478	1618	1626	O
were	18431478	1627	1631	O
followed	18431478	1632	1640	O
up	18431478	1641	1643	O
on	18431478	1644	1646	O
day-	18431478	1647	1651	O
4	18431478	1652	1653	O
.	18431478	1653	1654	O

Clinical	18431478	1655	1663	B-Outcome
failure	18431478	1664	1671	I-Outcome
was	18431478	1672	1675	O
associated	18431478	1676	1686	O
with	18431478	1687	1691	O
(	18431478	1692	1693	O
i	18431478	1693	1694	O
)	18431478	1694	1695	O
placebo	18431478	1696	1703	O
treatment	18431478	1704	1713	O
(	18431478	1714	1715	O
adjusted	18431478	1715	1723	O
OR	18431478	1724	1726	O
=	18431478	1727	1728	O
1.28	18431478	1729	1733	O
,	18431478	1733	1734	O
95	18431478	1735	1737	O
%	18431478	1737	1738	O
CI	18431478	1739	1741	O
:	18431478	1741	1742	O
1.01	18431478	1743	1747	O
to1.62	18431478	1748	1754	O
)	18431478	1754	1755	O
,	18431478	1755	1756	O
(	18431478	1757	1758	O
ii	18431478	1758	1760	O
)	18431478	1760	1761	O
excess	18431478	1762	1768	O
respiratory	18431478	1769	1780	B-Outcome
rate	18431478	1781	1785	I-Outcome
of	18431478	1786	1788	O
>	18431478	1789	1790	O
10	18431478	1790	1792	O
breaths	18431478	1793	1800	O
per	18431478	1801	1804	O
minute	18431478	1805	1811	O
(	18431478	1812	1813	O
adjusted	18431478	1813	1821	O
OR	18431478	1822	1824	O
=	18431478	1825	1826	O
1.51	18431478	1827	1831	O
,	18431478	1831	1832	O
95	18431478	1833	1835	O
%	18431478	1835	1836	O
CI	18431478	1837	1839	O
:	18431478	1839	1840	O
1.19	18431478	1841	1845	O
,	18431478	1845	1846	O
1.92	18431478	1847	1851	O
)	18431478	1851	1852	O
,	18431478	1852	1853	O
(	18431478	1854	1855	O
iii	18431478	1855	1858	O
)	18431478	1858	1859	O
vomiting	18431478	1860	1868	O
at	18431478	1869	1871	O
enrolment	18431478	1872	1881	O
(	18431478	1882	1883	O
adjusted	18431478	1883	1891	O
OR	18431478	1892	1894	O
=	18431478	1895	1896	O
1.49	18431478	1897	1901	O
,	18431478	1901	1902	O
95	18431478	1903	1905	O
%	18431478	1905	1906	O
CI	18431478	1907	1909	O
:	18431478	1909	1910	O
1.13	18431478	1911	1915	O
,	18431478	1915	1916	O
1.96	18431478	1917	1921	O
)	18431478	1921	1922	O
,	18431478	1922	1923	O
(	18431478	1924	1925	O
iv	18431478	1925	1927	O
)	18431478	1927	1928	O
history	18431478	1929	1936	O
of	18431478	1937	1939	O
use	18431478	1940	1943	O
of	18431478	1944	1946	O
broncho-dilators	18431478	1947	1963	O
(	18431478	1964	1965	O
adjusted	18431478	1965	1973	O
OR	18431478	1974	1976	O
=	18431478	1977	1978	O
1.71	18431478	1979	1983	O
,	18431478	1983	1984	O
95	18431478	1985	1987	O
%	18431478	1987	1988	O
CI	18431478	1989	1991	O
:	18431478	1991	1992	O
1.30	18431478	1993	1997	O
,	18431478	1997	1998	O
2.24	18431478	1999	2003	O
)	18431478	2003	2004	O
and	18431478	2005	2008	O
(	18431478	2009	2010	O
v	18431478	2010	2011	O
)	18431478	2011	2012	O
non-adherence	18431478	2013	2026	O
(	18431478	2027	2028	O
adjusted	18431478	2028	2036	O
OR	18431478	2037	2039	O
=	18431478	2040	2041	O
8.06	18431478	2042	2046	O
,	18431478	2046	2047	O
95	18431478	2048	2050	O
%	18431478	2050	2051	O
CI	18431478	2052	2054	O
:	18431478	2054	2055	O
4.36	18431478	2056	2060	O
,	18431478	2060	2061	O
14.92	18431478	2062	2067	O
)	18431478	2067	2068	O
.	18431478	2068	2069	O

CONCLUSIONS	18431478	2071	2082	O
:	18431478	2083	2084	O
Treating	18431478	2085	2093	O
children	18431478	2094	2102	O
with	18431478	2103	2107	O
non-severe	18431478	2108	2118	O
pneumonia	18431478	2119	2128	O
and	18431478	2129	2132	O
wheeze	18431478	2133	2139	O
with	18431478	2140	2144	O
a	18431478	2145	2146	O
placebo	18431478	2147	2154	O
is	18431478	2155	2157	O
not	18431478	2158	2161	O
equivalent	18431478	2162	2172	O
to	18431478	2173	2175	O
treatment	18431478	2176	2185	O
with	18431478	2186	2190	O
oral	18431478	2191	2195	O
amoxycillin	18431478	2196	2207	O
.	18431478	2207	2208	O

TRIAL	18431478	2210	2215	O
REGISTRATION	18431478	2216	2228	O
:	18431478	2229	2230	O
ClinicalTrials.gov	18431478	2231	2249	O
NCT00407394	18431478	2250	2261	O
.	18431478	2261	2262	O


Heart	18523583	0	5	O
rate	18523583	6	10	O
variability	18523583	11	22	O
characteristics	18523583	23	38	O
in	18523583	39	41	O
sedentary	18523583	42	51	O
postmenopausal	18523583	52	66	O
women	18523583	67	72	O
following	18523583	73	82	O
six	18523583	83	86	O
months	18523583	87	93	O
of	18523583	94	96	O
exercise	18523583	97	105	O
training	18523583	106	114	O
:	18523583	114	115	O
the	18523583	116	119	O
DREW	18523583	120	124	O
study	18523583	125	130	O
.	18523583	130	131	O

BACKGROUND	18523583	133	143	O
:	18523583	144	145	O
Decreased	18523583	146	155	O
heart	18523583	156	161	O
rate	18523583	162	166	O
variability	18523583	167	178	O
(	18523583	179	180	O
HRV	18523583	180	183	O
)	18523583	183	184	O
is	18523583	185	187	O
associated	18523583	188	198	O
with	18523583	199	203	O
a	18523583	204	205	O
higher	18523583	206	212	O
risk	18523583	213	217	O
of	18523583	218	220	O
mortality	18523583	221	230	O
.	18523583	230	231	O

Overall	18523583	232	239	O
,	18523583	239	240	O
postmenopausal	18523583	241	255	O
women	18523583	256	261	O
have	18523583	262	266	O
lower	18523583	267	272	O
levels	18523583	273	279	O
of	18523583	280	282	O
HRV	18523583	283	286	O
than	18523583	287	291	O
premenopausal	18523583	292	305	O
women	18523583	306	311	O
,	18523583	311	312	O
which	18523583	313	318	O
may	18523583	319	322	O
be	18523583	323	325	O
additionally	18523583	326	338	O
complicated	18523583	339	350	O
by	18523583	351	353	O
lifestyle	18523583	354	363	O
related	18523583	364	371	O
behaviors	18523583	372	381	O
such	18523583	382	386	O
as	18523583	387	389	O
physical	18523583	390	398	O
inactivity	18523583	399	409	O
and	18523583	410	413	O
obesity	18523583	414	421	O
.	18523583	421	422	O

Though	18523583	423	429	O
cardiorespiratory	18523583	430	447	O
exercise	18523583	448	456	O
training	18523583	457	465	O
increases	18523583	466	475	O
HRV	18523583	476	479	O
,	18523583	479	480	O
little	18523583	481	487	O
is	18523583	488	490	O
known	18523583	491	496	O
regarding	18523583	497	506	O
the	18523583	507	510	O
exercise	18523583	511	519	O
dose	18523583	520	524	O
necessary	18523583	525	534	O
to	18523583	535	537	O
promote	18523583	538	545	O
this	18523583	546	550	O
improvement	18523583	551	562	O
.	18523583	562	563	O

METHODOLOGY/PRINCIPAL	18523583	565	586	O
FINDINGS	18523583	587	595	O
:	18523583	596	597	O
Our	18523583	598	601	O
primary	18523583	602	609	O
aim	18523583	610	613	O
was	18523583	614	617	O
to	18523583	618	620	O
measure	18523583	621	628	O
HRV	18523583	629	632	O
in	18523583	633	635	O
post-menopausal	18523583	636	651	O
women	18523583	652	657	O
following	18523583	658	667	O
6-months	18523583	668	676	O
of	18523583	677	679	O
exercise	18523583	680	688	O
training	18523583	689	697	O
.	18523583	697	698	O

We	18523583	699	701	O
examined	18523583	702	710	O
supine	18523583	711	717	O
resting	18523583	718	725	O
HRV	18523583	726	729	O
in	18523583	730	732	O
373	18523583	733	736	O
post-menopausal	18523583	737	752	O
women	18523583	753	758	O
(	18523583	759	760	O
45	18523583	760	762	O
-	18523583	762	763	O
75	18523583	763	765	O
y	18523583	766	767	O
)	18523583	767	768	O
after	18523583	769	774	O
6-months	18523583	775	783	O
of	18523583	784	786	O
randomly	18523583	787	795	O
assigned	18523583	796	804	O
and	18523583	805	808	O
double-blinded	18523583	809	823	O
administered	18523583	824	836	O
exercise	18523583	837	845	O
training	18523583	846	854	O
exercise	18523583	855	863	O
training	18523583	864	872	O
at	18523583	873	875	O
50	18523583	876	878	O
%	18523583	878	879	O
,	18523583	879	880	O
100	18523583	881	884	O
%	18523583	884	885	O
and	18523583	886	889	O
150	18523583	890	893	O
%	18523583	893	894	O
of	18523583	895	897	O
the	18523583	898	901	O
NIH	18523583	902	905	O
Consensus	18523583	906	915	O
Development	18523583	916	927	O
Panel	18523583	928	933	O
's	18523583	933	935	O
recommended	18523583	936	947	O
minimal	18523583	948	955	O
physical	18523583	956	964	O
activity	18523583	965	973	O
level	18523583	974	979	O
.	18523583	979	980	O

This	18523583	981	985	O
corresponded	18523583	986	998	O
to	18523583	999	1001	O
4	18523583	1002	1003	O
,	18523583	1003	1004	O
8	18523583	1005	1006	O
,	18523583	1006	1007	O
or	18523583	1008	1010	O
12	18523583	1011	1013	O
kcal/kg	18523583	1014	1021	O
per	18523583	1022	1025	O
week	18523583	1026	1030	O
(	18523583	1031	1032	O
KKW	18523583	1032	1035	O
)	18523583	1035	1036	O
of	18523583	1037	1039	O
energy	18523583	1040	1046	O
expenditure	18523583	1047	1058	O
.	18523583	1058	1059	O

At	18523583	1060	1062	O
baseline	18523583	1063	1071	O
,	18523583	1071	1072	O
we	18523583	1073	1075	O
observed	18523583	1076	1084	O
no	18523583	1085	1087	O
significant	18523583	1088	1099	O
differences	18523583	1100	1111	O
in	18523583	1112	1114	O
HRV	18523583	1115	1118	B-Outcome
or	18523583	1119	1121	O
hormone	18523583	1122	1129	B-Outcome
replacement	18523583	1130	1141	I-Outcome
use	18523583	1142	1145	I-Outcome
between	18523583	1146	1153	O
treatment	18523583	1154	1163	O
groups	18523583	1164	1170	O
.	18523583	1170	1171	O

However	18523583	1172	1179	O
,	18523583	1179	1180	O
we	18523583	1181	1183	O
did	18523583	1184	1187	O
observe	18523583	1188	1195	O
that	18523583	1196	1200	O
Caucasian	18523583	1201	1210	O
women	18523583	1211	1216	O
and	18523583	1217	1220	O
those	18523583	1221	1226	O
taking	18523583	1227	1233	O
antidepressant	18523583	1234	1248	O
medications	18523583	1249	1260	O
had	18523583	1261	1264	O
lower	18523583	1265	1270	O
levels	18523583	1271	1277	B-Outcome
of	18523583	1278	1280	I-Outcome
baseline	18523583	1281	1289	I-Outcome
HRV	18523583	1290	1293	I-Outcome
.	18523583	1293	1294	O

After	18523583	1295	1300	O
6-months	18523583	1301	1309	O
of	18523583	1310	1312	O
exercise	18523583	1313	1321	O
intervention	18523583	1322	1334	O
,	18523583	1334	1335	O
we	18523583	1336	1338	O
observed	18523583	1339	1347	O
a	18523583	1348	1349	O
dose	18523583	1350	1354	O
dependent	18523583	1355	1364	O
increase	18523583	1365	1373	O
in	18523583	1374	1376	O
all	18523583	1377	1380	O
parasympathetically	18523583	1381	1400	O
derived	18523583	1401	1408	O
time	18523583	1409	1413	O
and	18523583	1414	1417	O
frequency	18523583	1418	1427	O
domain	18523583	1428	1434	O
measurements	18523583	1435	1447	O
across	18523583	1448	1454	O
exercise	18523583	1455	1463	O
groups	18523583	1464	1470	O
after	18523583	1471	1476	O
adjustment	18523583	1477	1487	O
for	18523583	1488	1491	O
age	18523583	1492	1495	O
,	18523583	1495	1496	O
ethnicity	18523583	1497	1506	O
,	18523583	1506	1507	O
antidepressants	18523583	1508	1523	O
,	18523583	1523	1524	O
and	18523583	1525	1528	O
baseline	18523583	1529	1537	O
rMSSD	18523583	1538	1543	O
(	18523583	1544	1545	O
all	18523583	1545	1548	O
,	18523583	1548	1549	O
P<0.001	18523583	1550	1557	O
)	18523583	1557	1558	O
.	18523583	1558	1559	O

For	18523583	1560	1563	O
example	18523583	1564	1571	O
,	18523583	1571	1572	O
the	18523583	1573	1576	O
parasympathetic	18523583	1577	1592	B-Outcome
index	18523583	1593	1598	I-Outcome
rMSSD	18523583	1599	1604	I-Outcome
was	18523583	1605	1608	O
greater	18523583	1609	1616	O
than	18523583	1617	1621	O
control	18523583	1622	1629	O
(	18523583	1630	1631	O
23.19+/-1.0	18523583	1631	1642	O
)	18523583	1642	1643	O
for	18523583	1644	1647	O
the	18523583	1648	1651	O
4-KKW	18523583	1652	1657	O
(	18523583	1658	1659	O
25.98+/-0.8	18523583	1659	1670	O
;	18523583	1670	1671	O
P	18523583	1672	1673	O
=	18523583	1674	1675	O
0.14	18523583	1676	1680	O
)	18523583	1680	1681	O
,	18523583	1681	1682	O
8-KKW	18523583	1683	1688	O
(	18523583	1689	1690	O
27.66+/-1.0	18523583	1690	1701	O
;	18523583	1701	1702	O
P<0.05	18523583	1703	1709	O
)	18523583	1709	1710	O
,	18523583	1710	1711	O
and	18523583	1712	1715	O
12-KKW	18523583	1716	1722	O
(	18523583	1723	1724	O
27.40+/-0.0	18523583	1724	1735	O
;	18523583	1735	1736	O
P<0.05	18523583	1737	1743	O
)	18523583	1743	1744	O
groups	18523583	1745	1751	O
at	18523583	1752	1754	O
follow-up	18523583	1755	1764	O
.	18523583	1764	1765	O

CONCLUSIONS/SIGNIFICANCE	18523583	1767	1791	O
:	18523583	1792	1793	O
Moderate	18523583	1794	1802	O
intensity	18523583	1803	1812	O
exercise	18523583	1813	1821	O
training	18523583	1822	1830	O
exercise	18523583	1831	1839	O
is	18523583	1840	1842	O
sufficient	18523583	1843	1853	O
to	18523583	1854	1856	O
improve	18523583	1857	1864	O
HRV	18523583	1865	1868	B-Outcome
in	18523583	1869	1871	O
previously	18523583	1872	1882	O
sedentary	18523583	1883	1892	O
postmenopausal	18523583	1893	1907	O
women	18523583	1908	1913	O
in	18523583	1914	1916	O
a	18523583	1917	1918	O
dose-dependent	18523583	1919	1933	O
manner	18523583	1934	1940	O
,	18523583	1940	1941	O
as	18523583	1942	1944	O
4-KKW	18523583	1945	1950	O
is	18523583	1951	1953	O
insufficient	18523583	1954	1966	O
to	18523583	1967	1969	O
improve	18523583	1970	1977	O
parasympathetic	18523583	1978	1993	O
indices	18523583	1994	2001	O
of	18523583	2002	2004	O
HRV	18523583	2005	2008	B-Outcome
,	18523583	2008	2009	O
while	18523583	2010	2015	O
12-KKW	18523583	2016	2022	O
conferred	18523583	2023	2032	O
no	18523583	2033	2035	O
greater	18523583	2036	2043	O
improvement	18523583	2044	2055	O
than	18523583	2056	2060	O
8-KKW	18523583	2061	2066	O
.	18523583	2066	2067	O

TRIAL	18523583	2069	2074	O
REGISTRATION	18523583	2075	2087	O
:	18523583	2088	2089	O
Clinicaltrials.gov	18523583	2090	2108	O
NCT	18523583	2109	2112	O
00011193	18523583	2113	2121	O
.	18523583	2121	2122	O


Effects	18535816	0	7	O
of	18535816	8	10	O
20	18535816	11	13	O
mg	18535816	14	16	O
rosuvastatin	18535816	17	29	O
on	18535816	30	32	O
VLDL1-	18535816	33	39	O
,	18535816	39	40	O
VLDL2-	18535816	41	47	O
,	18535816	47	48	O
IDL-	18535816	49	53	O
and	18535816	54	57	O
LDL-ApoB	18535816	58	66	O
kinetics	18535816	67	75	O
in	18535816	76	78	O
type	18535816	79	83	O
2	18535816	84	85	O
diabetes	18535816	86	94	O
.	18535816	94	95	O

AIMS/HYPOTHESIS	18535816	97	112	O
:	18535816	113	114	O
In	18535816	115	117	O
addition	18535816	118	126	O
to	18535816	127	129	O
its	18535816	130	133	O
efficacy	18535816	134	142	O
in	18535816	143	145	O
reducing	18535816	146	154	O
LDL-cholesterol	18535816	155	170	O
,	18535816	170	171	O
rosuvastatin	18535816	172	184	O
has	18535816	185	188	O
been	18535816	189	193	O
shown	18535816	194	199	O
to	18535816	200	202	O
significantly	18535816	203	216	O
decrease	18535816	217	225	O
plasma	18535816	226	232	O
triacylglycerol	18535816	233	248	O
.	18535816	248	249	O

The	18535816	250	253	O
use	18535816	254	257	O
of	18535816	258	260	O
rosuvastatin	18535816	261	273	O
may	18535816	274	277	O
be	18535816	278	280	O
beneficial	18535816	281	291	O
in	18535816	292	294	O
patients	18535816	295	303	O
with	18535816	304	308	O
type	18535816	309	313	O
2	18535816	314	315	O
diabetes	18535816	316	324	O
,	18535816	324	325	O
who	18535816	326	329	O
usually	18535816	330	337	O
have	18535816	338	342	O
increased	18535816	343	352	O
triacylglycerol	18535816	353	368	O
levels	18535816	369	375	O
.	18535816	375	376	O

However	18535816	377	384	O
,	18535816	384	385	O
its	18535816	386	389	O
effects	18535816	390	397	O
on	18535816	398	400	O
the	18535816	401	404	O
metabolism	18535816	405	415	O
of	18535816	416	418	O
triacylglycerol-rich	18535816	419	439	O
lipoproteins	18535816	440	452	O
in	18535816	453	455	O
type	18535816	456	460	O
2	18535816	461	462	O
diabetic	18535816	463	471	O
patients	18535816	472	480	O
remains	18535816	481	488	O
unknown	18535816	489	496	O
.	18535816	496	497	O

METHODS	18535816	499	506	O
:	18535816	507	508	O
We	18535816	509	511	O
performed	18535816	512	521	O
a	18535816	522	523	O
randomised	18535816	524	534	O
double-blind	18535816	535	547	O
crossover	18535816	548	557	O
trial	18535816	558	563	O
of	18535816	564	566	O
6-week	18535816	567	573	O
treatment	18535816	574	583	O
with	18535816	584	588	O
placebo	18535816	589	596	O
or	18535816	597	599	O
rosuvastatin	18535816	600	612	O
20	18535816	613	615	O
mg	18535816	616	618	O
in	18535816	619	621	O
eight	18535816	622	627	O
patients	18535816	628	636	O
with	18535816	637	641	O
type	18535816	642	646	O
2	18535816	647	648	O
diabetes	18535816	649	657	O
who	18535816	658	661	O
were	18535816	662	666	O
being	18535816	667	672	O
treated	18535816	673	680	O
with	18535816	681	685	O
oral	18535816	686	690	O
glucose-lowering	18535816	691	707	O
agents	18535816	708	714	O
.	18535816	714	715	O

In	18535816	716	718	O
each	18535816	719	723	O
patient	18535816	724	731	O
,	18535816	731	732	O
an	18535816	733	735	O
in	18535816	736	738	O
vivo	18535816	739	743	O
kinetic	18535816	744	751	O
study	18535816	752	757	O
of	18535816	758	760	O
apolipoprotein	18535816	761	775	O
B	18535816	776	777	O
(ApoB)-containing	18535816	778	795	O
lipoproteins	18535816	796	808	O
with	18535816	809	813	O
[13C]leucine	18535816	814	826	O
was	18535816	827	830	O
performed	18535816	831	840	O
at	18535816	841	843	O
the	18535816	844	847	O
end	18535816	848	851	O
of	18535816	852	854	O
each	18535816	855	859	O
treatment	18535816	860	869	O
period	18535816	870	876	O
.	18535816	876	877	O

A	18535816	878	879	O
central	18535816	880	887	O
randomisation	18535816	888	901	O
centre	18535816	902	908	O
used	18535816	909	913	O
computer-generated	18535816	914	932	O
tables	18535816	933	939	O
to	18535816	940	942	O
allocate	18535816	943	951	O
treatments	18535816	952	962	O
.	18535816	962	963	O

Participants	18535816	964	976	O
,	18535816	976	977	O
caregivers	18535816	978	988	O
and	18535816	989	992	O
those	18535816	993	998	O
assessing	18535816	999	1008	O
the	18535816	1009	1012	O
outcomes	18535816	1013	1021	O
were	18535816	1022	1026	O
blinded	18535816	1027	1034	O
to	18535816	1035	1037	O
group	18535816	1038	1043	O
assignment	18535816	1044	1054	O
.	18535816	1054	1055	O

RESULTS	18535816	1057	1064	O
:	18535816	1065	1066	O
Rosuvastatin	18535816	1067	1079	O
20	18535816	1080	1082	O
mg	18535816	1083	1085	O
significantly	18535816	1086	1099	O
reduced	18535816	1100	1107	O
plasma	18535816	1108	1114	B-Outcome
LDL-cholesterol	18535816	1115	1130	I-Outcome
,	18535816	1130	1131	O
triacylglycerol	18535816	1132	1147	B-Outcome
and	18535816	1148	1151	O
total	18535816	1152	1157	B-Outcome
ApoB.	18535816	1158	1163	I-Outcome
It	18535816	1164	1166	O
also	18535816	1167	1171	O
significantly	18535816	1172	1185	O
reduced	18535816	1186	1193	O
ApoB	18535816	1194	1198	B-Outcome
pool	18535816	1199	1203	I-Outcome
sizes	18535816	1204	1209	I-Outcome
of	18535816	1210	1212	I-Outcome
larger	18535816	1213	1219	I-Outcome
triacylglycerol-rich	18535816	1220	1240	I-Outcome
VLDL	18535816	1241	1245	I-Outcome
particles	18535816	1246	1255	I-Outcome
(	18535816	1256	1257	I-Outcome
VLDL1	18535816	1257	1262	I-Outcome
;	18535816	1262	1263	O
p	18535816	1264	1265	O
=	18535816	1266	1267	O
0.011	18535816	1268	1273	O
)	18535816	1273	1274	O
,	18535816	1274	1275	O
smaller	18535816	1276	1283	B-Outcome
VLDL	18535816	1284	1288	I-Outcome
particles	18535816	1289	1298	I-Outcome
(	18535816	1299	1300	I-Outcome
VLDL2	18535816	1300	1305	I-Outcome
;	18535816	1305	1306	O
p	18535816	1307	1308	O
=	18535816	1309	1310	O
0.011	18535816	1311	1316	O
)	18535816	1316	1317	O
,	18535816	1317	1318	O
intermediate	18535816	1319	1331	B-Outcome
density	18535816	1332	1339	I-Outcome
lipoprotein	18535816	1340	1351	I-Outcome
(	18535816	1352	1353	I-Outcome
IDL	18535816	1353	1356	I-Outcome
;	18535816	1356	1357	O
p	18535816	1358	1359	O
=	18535816	1360	1361	O
0.011	18535816	1362	1367	O
)	18535816	1367	1368	O
and	18535816	1369	1372	O
LDL	18535816	1373	1376	B-Outcome
(	18535816	1377	1378	O
p	18535816	1378	1379	O
=	18535816	1380	1381	O
0.011	18535816	1382	1387	O
)	18535816	1387	1388	O
.	18535816	1388	1389	O

This	18535816	1390	1394	O
reduction	18535816	1395	1404	O
was	18535816	1405	1408	O
associated	18535816	1409	1419	O
with	18535816	1420	1424	O
a	18535816	1425	1426	O
significant	18535816	1427	1438	O
increase	18535816	1439	1447	O
in	18535816	1448	1450	O
the	18535816	1451	1454	O
total	18535816	1455	1460	B-Outcome
fractional	18535816	1461	1471	I-Outcome
catabolic	18535816	1472	1481	I-Outcome
rate	18535816	1482	1486	I-Outcome
of	18535816	1487	1489	I-Outcome
VLDL1-ApoB	18535816	1490	1500	I-Outcome
(	18535816	1501	1502	O
6.70	18535816	1502	1506	O
+	18535816	1507	1508	O
/-	18535816	1508	1510	O
3.24	18535816	1511	1515	O
vs	18535816	1516	1518	O
4.52	18535816	1519	1523	O
+	18535816	1524	1525	O
/-	18535816	1525	1527	O
2.34	18535816	1528	1532	O
pool/day	18535816	1533	1541	O
,	18535816	1541	1542	O
p	18535816	1543	1544	O
=	18535816	1545	1546	O
0.049	18535816	1547	1552	O
)	18535816	1552	1553	O
,	18535816	1553	1554	O
VLDL2-ApoB	18535816	1555	1565	B-Outcome
(	18535816	1566	1567	O
8.72	18535816	1567	1571	O
+	18535816	1572	1573	O
/-	18535816	1573	1575	O
3.37	18535816	1576	1580	O
vs	18535816	1581	1583	O
5.36	18535816	1584	1588	O
+	18535816	1589	1590	O
/-	18535816	1590	1592	O
2.64	18535816	1593	1597	O
,	18535816	1597	1598	O
p	18535816	1599	1600	O
=	18535816	1601	1602	O
0.011	18535816	1603	1608	O
)	18535816	1608	1609	O
,	18535816	1609	1610	O
IDL-ApoB	18535816	1611	1619	B-Outcome
(	18535816	1620	1621	O
7.06	18535816	1621	1625	O
+	18535816	1626	1627	O
/-	18535816	1627	1629	O
1.68	18535816	1630	1634	O
vs	18535816	1635	1637	O
4.21	18535816	1638	1642	O
+	18535816	1643	1644	O
/-	18535816	1644	1646	O
1.51	18535816	1647	1651	O
,	18535816	1651	1652	O
p	18535816	1653	1654	O
=	18535816	1655	1656	O
0.011	18535816	1657	1662	O
)	18535816	1662	1663	O
and	18535816	1664	1667	O
LDL-ApoB	18535816	1668	1676	B-Outcome
(	18535816	1677	1678	O
1.02	18535816	1678	1682	O
+	18535816	1683	1684	O
/-	18535816	1684	1686	O
0.27	18535816	1687	1691	O
vs	18535816	1692	1694	O
0.59	18535816	1695	1699	O
+	18535816	1700	1701	O
/-	18535816	1701	1703	O
0.13	18535816	1704	1708	O
,	18535816	1708	1709	O
p	18535816	1710	1711	O
=	18535816	1712	1713	O
0.011	18535816	1714	1719	O
)	18535816	1719	1720	O
.	18535816	1720	1721	O

Rosuvastatin	18535816	1722	1734	O
did	18535816	1735	1738	O
not	18535816	1739	1742	O
change	18535816	1743	1749	O
the	18535816	1750	1753	O
production	18535816	1754	1764	B-Outcome
rates	18535816	1765	1770	I-Outcome
of	18535816	1771	1773	I-Outcome
VLDL2-	18535816	1774	1780	I-Outcome
,	18535816	1780	1781	O
IDL-	18535816	1782	1786	B-Outcome
or	18535816	1787	1789	O
LDL-	18535816	1790	1794	B-Outcome
,	18535816	1794	1795	O
but	18535816	1796	1799	O
did	18535816	1800	1803	O
reduce	18535816	1804	1810	O
VLDL1-ApoB	18535816	1811	1821	B-Outcome
production	18535816	1822	1832	I-Outcome
rate	18535816	1833	1837	I-Outcome
(	18535816	1838	1839	O
12.4	18535816	1839	1843	O
+	18535816	1844	1845	O
/-	18535816	1845	1847	O
4.5	18535816	1848	1851	O
vs	18535816	1852	1854	O
19.5	18535816	1855	1859	O
+	18535816	1860	1861	O
/-	18535816	1861	1863	O
8.4	18535816	1864	1867	O
mg	18535816	1868	1870	O
kg(-1	18535816	1871	1876	O
)	18535816	1876	1877	O
day(-1	18535816	1878	1884	O
)	18535816	1884	1885	O
,	18535816	1885	1886	O
p	18535816	1887	1888	O
=	18535816	1889	1890	O
0.035	18535816	1891	1896	O
)	18535816	1896	1897	O
.	18535816	1897	1898	O

No	18535816	1899	1901	O
side	18535816	1902	1906	B-Outcome
effects	18535816	1907	1914	I-Outcome
of	18535816	1915	1917	O
rosuvastatin	18535816	1918	1930	O
were	18535816	1931	1935	O
observed	18535816	1936	1944	O
during	18535816	1945	1951	O
the	18535816	1952	1955	O
study	18535816	1956	1961	O
.	18535816	1961	1962	O

CONCLUSIONS/INTERPRETATION	18535816	1964	1990	O
:	18535816	1991	1992	O
In	18535816	1993	1995	O
type	18535816	1996	2000	O
2	18535816	2001	2002	O
diabetic	18535816	2003	2011	O
patients	18535816	2012	2020	O
rosuvastatin	18535816	2021	2033	O
20	18535816	2034	2036	O
mg	18535816	2037	2039	O
not	18535816	2040	2043	O
only	18535816	2044	2048	O
induces	18535816	2049	2056	O
a	18535816	2057	2058	O
significant	18535816	2059	2070	O
increase	18535816	2071	2079	O
of	18535816	2080	2082	O
LDL-ApoB	18535816	2083	2091	B-Outcome
catabolism	18535816	2092	2102	I-Outcome
(	18535816	2103	2104	O
73	18535816	2104	2106	O
%	18535816	2106	2107	O
)	18535816	2107	2108	O
,	18535816	2108	2109	O
but	18535816	2110	2113	O
also	18535816	2114	2118	O
has	18535816	2119	2122	O
favourable	18535816	2123	2133	O
effects	18535816	2134	2141	O
on	18535816	2142	2144	O
the	18535816	2145	2148	O
catabolism	18535816	2149	2159	B-Outcome
of	18535816	2160	2162	I-Outcome
triacylglycerol-rich	18535816	2163	2183	I-Outcome
lipoproteins	18535816	2184	2196	I-Outcome
,	18535816	2196	2197	O
e.g.	18535816	2198	2202	O
a	18535816	2203	2204	O
significant	18535816	2205	2216	O
increase	18535816	2217	2225	O
in	18535816	2226	2228	O
the	18535816	2229	2232	O
catabolism	18535816	2233	2243	B-Outcome
of	18535816	2244	2246	I-Outcome
VLDL1-ApoB	18535816	2247	2257	I-Outcome
(	18535816	2258	2259	O
48	18535816	2259	2261	O
%	18535816	2261	2262	O
)	18535816	2262	2263	O
,	18535816	2263	2264	O
VLDL2-ApoB	18535816	2265	2275	B-Outcome
(	18535816	2276	2277	O
63	18535816	2277	2279	O
%	18535816	2279	2280	O
)	18535816	2280	2281	O
and	18535816	2282	2285	O
IDL-ApoB	18535816	2286	2294	B-Outcome
(	18535816	2295	2296	O
68	18535816	2296	2298	O
%	18535816	2298	2299	O
)	18535816	2299	2300	O
,	18535816	2300	2301	O
and	18535816	2302	2305	O
a	18535816	2306	2307	O
reduction	18535816	2308	2317	O
in	18535816	2318	2320	O
the	18535816	2321	2324	O
production	18535816	2325	2335	B-Outcome
rate	18535816	2336	2340	I-Outcome
of	18535816	2341	2343	I-Outcome
VLDL1-ApoB	18535816	2344	2354	I-Outcome
(	18535816	2355	2356	O
-36	18535816	2356	2359	O
%	18535816	2359	2360	O
)	18535816	2360	2361	O
.	18535816	2361	2362	O

The	18535816	2363	2366	O
effects	18535816	2367	2374	O
of	18535816	2375	2377	O
rosuvastatin	18535816	2378	2390	O
on	18535816	2391	2393	O
the	18535816	2394	2397	O
metabolism	18535816	2398	2408	B-Outcome
of	18535816	2409	2411	I-Outcome
triacylglycerol-rich	18535816	2412	2432	I-Outcome
lipoproteins	18535816	2433	2445	I-Outcome
may	18535816	2446	2449	O
be	18535816	2450	2452	O
beneficial	18535816	2453	2463	O
for	18535816	2464	2467	O
prevention	18535816	2468	2478	O
of	18535816	2479	2481	O
atherosclerosis	18535816	2482	2497	O
in	18535816	2498	2500	O
type	18535816	2501	2505	O
2	18535816	2506	2507	O
diabetic	18535816	2508	2516	O
patients	18535816	2517	2525	O
.	18535816	2525	2526	O


Effect	18572078	0	6	O
of	18572078	7	9	O
laquinimod	18572078	10	20	O
on	18572078	21	23	O
MRI-monitored	18572078	24	37	O
disease	18572078	38	45	O
activity	18572078	46	54	O
in	18572078	55	57	O
patients	18572078	58	66	O
with	18572078	67	71	O
relapsing-remitting	18572078	72	91	O
multiple	18572078	92	100	O
sclerosis	18572078	101	110	O
:	18572078	110	111	O
a	18572078	112	113	O
multicentre	18572078	114	125	O
,	18572078	125	126	O
randomised	18572078	127	137	O
,	18572078	137	138	O
double-blind	18572078	139	151	O
,	18572078	151	152	O
placebo-controlled	18572078	153	171	O
phase	18572078	172	177	O
IIb	18572078	178	181	O
study	18572078	182	187	O
.	18572078	187	188	O

BACKGROUND	18572078	190	200	O
:	18572078	201	202	O
A	18572078	203	204	O
24-week	18572078	205	212	O
phase	18572078	213	218	O
II	18572078	219	221	O
trial	18572078	222	227	O
has	18572078	228	231	O
shown	18572078	232	237	O
that	18572078	238	242	O
0.3	18572078	243	246	O
mg	18572078	247	249	O
of	18572078	250	252	O
laquinimod	18572078	253	263	O
given	18572078	264	269	O
daily	18572078	270	275	O
to	18572078	276	278	O
patients	18572078	279	287	O
with	18572078	288	292	O
relapsing-remitting	18572078	293	312	O
multiple	18572078	313	321	O
sclerosis	18572078	322	331	O
was	18572078	332	335	O
well	18572078	336	340	O
tolerated	18572078	341	350	O
and	18572078	351	354	O
reduced	18572078	355	362	O
the	18572078	363	366	O
formation	18572078	367	376	O
of	18572078	377	379	O
active	18572078	380	386	O
lesions	18572078	387	394	O
.	18572078	394	395	O

We	18572078	396	398	O
assessed	18572078	399	407	O
the	18572078	408	411	O
effect	18572078	412	418	O
of	18572078	419	421	O
oral	18572078	422	426	O
daily	18572078	427	432	O
0.3	18572078	433	436	O
and	18572078	437	440	O
0.6	18572078	441	444	O
mg	18572078	445	447	O
laquinimod	18572078	448	458	O
on	18572078	459	461	O
MRI-monitored	18572078	462	475	O
disease	18572078	476	483	O
activity	18572078	484	492	O
in	18572078	493	495	O
a	18572078	496	497	O
36-week	18572078	498	505	O
double-blind	18572078	506	518	O
,	18572078	518	519	O
placebo-controlled	18572078	520	538	O
phase	18572078	539	544	O
IIb	18572078	545	548	O
study	18572078	549	554	O
.	18572078	554	555	O

METHODS	18572078	557	564	O
:	18572078	565	566	O
The	18572078	567	570	O
study	18572078	571	576	O
was	18572078	577	580	O
done	18572078	581	585	O
in	18572078	586	588	O
51	18572078	589	591	O
centres	18572078	592	599	O
in	18572078	600	602	O
nine	18572078	603	607	O
countries	18572078	608	617	O
.	18572078	617	618	O

Inclusion	18572078	619	628	O
criteria	18572078	629	637	O
were	18572078	638	642	O
one	18572078	643	646	O
or	18572078	647	649	O
more	18572078	650	654	O
relapses	18572078	655	663	O
in	18572078	664	666	O
the	18572078	667	670	O
year	18572078	671	675	O
before	18572078	676	682	O
entry	18572078	683	688	O
and	18572078	689	692	O
at	18572078	693	695	O
least	18572078	696	701	O
one	18572078	702	705	O
gadolinium	18572078	706	716	O
enhancing	18572078	717	726	O
(	18572078	727	728	O
GdE	18572078	728	731	O
)	18572078	731	732	O
lesion	18572078	733	739	O
on	18572078	740	742	O
screening	18572078	743	752	O
MRI	18572078	753	756	O
.	18572078	756	757	O

Of	18572078	758	760	O
720	18572078	761	764	O
patients	18572078	765	773	O
screened	18572078	774	782	O
,	18572078	782	783	O
306	18572078	784	787	O
eligible	18572078	788	796	O
patients	18572078	797	805	O
were	18572078	806	810	O
enrolled	18572078	811	819	O
.	18572078	819	820	O

Patients	18572078	821	829	O
,	18572078	829	830	O
aged	18572078	831	835	O
18	18572078	836	838	O
-	18572078	838	839	O
50	18572078	839	841	O
years	18572078	842	847	O
,	18572078	847	848	O
were	18572078	849	853	O
randomly	18572078	854	862	O
assigned	18572078	863	871	O
to	18572078	872	874	O
placebo	18572078	875	882	O
(	18572078	883	884	O
n=102	18572078	884	889	O
)	18572078	889	890	O
,	18572078	890	891	O
laquinimod	18572078	892	902	O
0.3	18572078	903	906	O
mg	18572078	907	909	O
a	18572078	910	911	O
day	18572078	912	915	O
(	18572078	916	917	O
n=98	18572078	917	921	O
)	18572078	921	922	O
,	18572078	922	923	O
or	18572078	924	926	O
0.6	18572078	927	930	O
mg	18572078	931	933	O
a	18572078	934	935	O
day	18572078	936	939	O
(	18572078	940	941	O
n=106	18572078	941	946	O
)	18572078	946	947	O
.	18572078	947	948	O

Brain	18572078	949	954	O
MRI	18572078	955	958	O
scans	18572078	959	964	O
and	18572078	965	968	O
clinical	18572078	969	977	O
assessments	18572078	978	989	O
were	18572078	990	994	O
done	18572078	995	999	O
at	18572078	1000	1002	O
week	18572078	1003	1007	O
-4	18572078	1008	1010	O
,	18572078	1010	1011	O
baseline	18572078	1012	1020	O
,	18572078	1020	1021	O
and	18572078	1022	1025	O
monthly	18572078	1026	1033	O
from	18572078	1034	1038	O
week	18572078	1039	1043	O
12	18572078	1044	1046	O
to	18572078	1047	1049	O
week	18572078	1050	1054	O
36	18572078	1055	1057	O
.	18572078	1057	1058	O

The	18572078	1059	1062	O
primary	18572078	1063	1070	O
outcome	18572078	1071	1078	O
was	18572078	1079	1082	O
the	18572078	1083	1086	O
cumulative	18572078	1087	1097	O
number	18572078	1098	1104	O
of	18572078	1105	1107	O
GdE	18572078	1108	1111	O
lesions	18572078	1112	1119	O
at	18572078	1120	1122	O
weeks	18572078	1123	1128	O
24	18572078	1129	1131	O
,	18572078	1131	1132	O
28	18572078	1133	1135	O
,	18572078	1135	1136	O
32	18572078	1137	1139	O
,	18572078	1139	1140	O
and	18572078	1141	1144	O
36	18572078	1145	1147	O
.	18572078	1147	1148	O

The	18572078	1149	1152	O
principal	18572078	1153	1162	O
analysis	18572078	1163	1171	O
of	18572078	1172	1174	O
the	18572078	1175	1178	O
primary	18572078	1179	1186	O
endpoint	18572078	1187	1195	O
was	18572078	1196	1199	O
done	18572078	1200	1204	O
on	18572078	1205	1207	O
the	18572078	1208	1211	O
intention-to-treat	18572078	1212	1230	O
cohort	18572078	1231	1237	O
.	18572078	1237	1238	O

This	18572078	1239	1243	O
study	18572078	1244	1249	O
is	18572078	1250	1252	O
registered	18572078	1253	1263	O
with	18572078	1264	1268	O
ClinicalTrials.gov	18572078	1269	1287	O
,	18572078	1287	1288	O
number	18572078	1289	1295	O
NCT00349193	18572078	1296	1307	O
.	18572078	1307	1308	O

FINDINGS	18572078	1310	1318	O
:	18572078	1319	1320	O
Compared	18572078	1321	1329	O
with	18572078	1330	1334	O
placebo	18572078	1335	1342	O
,	18572078	1342	1343	O
treatment	18572078	1344	1353	O
with	18572078	1354	1358	O
laquinimod	18572078	1359	1369	O
0.6	18572078	1370	1373	O
mg	18572078	1374	1376	O
per	18572078	1377	1380	O
day	18572078	1381	1384	O
showed	18572078	1385	1391	O
a	18572078	1392	1393	O
40.4	18572078	1394	1398	O
%	18572078	1398	1399	O
reduction	18572078	1400	1409	O
of	18572078	1410	1412	O
the	18572078	1413	1416	O
baseline	18572078	1417	1425	B-Outcome
adjusted	18572078	1426	1434	I-Outcome
mean	18572078	1435	1439	I-Outcome
cumulative	18572078	1440	1450	I-Outcome
number	18572078	1451	1457	I-Outcome
of	18572078	1458	1460	I-Outcome
GdE	18572078	1461	1464	I-Outcome
lesions	18572078	1465	1472	I-Outcome
per	18572078	1473	1476	O
scan	18572078	1477	1481	O
on	18572078	1482	1484	O
the	18572078	1485	1488	O
last	18572078	1489	1493	O
four	18572078	1494	1498	O
scans	18572078	1499	1504	O
(	18572078	1505	1506	O
simple	18572078	1506	1512	O
means	18572078	1513	1518	O
4.2	18572078	1519	1522	O
[	18572078	1523	1524	O
SD	18572078	1524	1526	O
9.2	18572078	1527	1530	O
]	18572078	1530	1531	O
vs	18572078	1532	1534	O
2.6	18572078	1535	1538	O
[	18572078	1539	1540	O
5.3	18572078	1540	1543	O
]	18572078	1543	1544	O
,	18572078	1544	1545	O
p=0.0048	18572078	1546	1554	O
)	18572078	1554	1555	O
;	18572078	1555	1556	O
treatment	18572078	1557	1566	O
with	18572078	1567	1571	O
0.3	18572078	1572	1575	O
mg	18572078	1576	1578	O
per	18572078	1579	1582	O
day	18572078	1583	1586	O
showed	18572078	1587	1593	O
no	18572078	1594	1596	O
significant	18572078	1597	1608	O
effects	18572078	1609	1616	O
(	18572078	1617	1618	O
3.9	18572078	1618	1621	O
[	18572078	1622	1623	O
5.5	18572078	1623	1626	O
]	18572078	1626	1627	O
vs	18572078	1628	1630	O
placebo	18572078	1631	1638	O
,	18572078	1638	1639	O
p=0.6740	18572078	1640	1648	O
)	18572078	1648	1649	O
.	18572078	1649	1650	O

Both	18572078	1651	1655	O
doses	18572078	1656	1661	O
of	18572078	1662	1664	O
laquinimod	18572078	1665	1675	O
were	18572078	1676	1680	O
well	18572078	1681	1685	O
tolerated	18572078	1686	1695	B-Outcome
,	18572078	1695	1696	O
with	18572078	1697	1701	O
some	18572078	1702	1706	O
transient	18572078	1707	1716	O
and	18572078	1717	1720	O
dose-dependent	18572078	1721	1735	O
increases	18572078	1736	1745	O
in	18572078	1746	1748	O
liver	18572078	1749	1754	B-Outcome
enzymes	18572078	1755	1762	I-Outcome
.	18572078	1762	1763	O

A	18572078	1764	1765	O
case	18572078	1766	1770	O
of	18572078	1771	1773	O
Budd-Chiari	18572078	1774	1785	O
syndrome-ie	18572078	1786	1797	O
,	18572078	1797	1798	O
a	18572078	1799	1800	O
thrombotic	18572078	1801	1811	O
venous	18572078	1812	1818	O
outflow	18572078	1819	1826	O
obstruction	18572078	1827	1838	O
of	18572078	1839	1841	O
the	18572078	1842	1845	O
liver-occurred	18572078	1846	1860	O
after	18572078	1861	1866	O
1	18572078	1867	1868	O
month	18572078	1869	1874	O
of	18572078	1875	1877	O
exposure	18572078	1878	1886	O
in	18572078	1887	1889	O
a	18572078	1890	1891	O
patient	18572078	1892	1899	O
with	18572078	1900	1904	O
underlying	18572078	1905	1915	O
hypercoagulability	18572078	1916	1934	O
who	18572078	1935	1938	O
received	18572078	1939	1947	O
0.6	18572078	1948	1951	O
mg	18572078	1952	1954	O
laquinimod	18572078	1955	1965	O
.	18572078	1965	1966	O

Anticoagulant	18572078	1967	1980	O
treatment	18572078	1981	1990	O
resulted	18572078	1991	1999	O
in	18572078	2000	2002	O
a	18572078	2003	2004	O
decline	18572078	2005	2012	O
of	18572078	2013	2015	O
liver	18572078	2016	2021	B-Outcome
enzymes	18572078	2022	2029	I-Outcome
to	18572078	2030	2032	O
normal	18572078	2033	2039	O
without	18572078	2040	2047	O
any	18572078	2048	2051	O
clinical	18572078	2052	2060	B-Outcome
signs	18572078	2061	2066	I-Outcome
of	18572078	2067	2069	I-Outcome
hepatic	18572078	2070	2077	I-Outcome
decompensation	18572078	2078	2092	I-Outcome
.	18572078	2092	2093	O

INTERPRETATION	18572078	2095	2109	O
:	18572078	2110	2111	O
In	18572078	2112	2114	O
patients	18572078	2115	2123	O
with	18572078	2124	2128	O
relapsing-remitting	18572078	2129	2148	O
multiple	18572078	2149	2157	O
sclerosis	18572078	2158	2167	O
,	18572078	2167	2168	O
0.6	18572078	2169	2172	O
mg	18572078	2173	2175	O
per	18572078	2176	2179	O
day	18572078	2180	2183	O
laquinimod	18572078	2184	2194	O
significantly	18572078	2195	2208	O
reduced	18572078	2209	2216	O
MRI-measured	18572078	2217	2229	B-Outcome
disease	18572078	2230	2237	I-Outcome
activity	18572078	2238	2246	I-Outcome
and	18572078	2247	2250	O
was	18572078	2251	2254	O
well	18572078	2255	2259	O
tolerated	18572078	2260	2269	B-Outcome
.	18572078	2269	2270	O


Complementary	18606932	0	13	O
feeding	18606932	14	21	O
with	18606932	22	26	O
fortified	18606932	27	36	O
spread	18606932	37	43	O
and	18606932	44	47	O
incidence	18606932	48	57	O
of	18606932	58	60	O
severe	18606932	61	67	O
stunting	18606932	68	76	O
in	18606932	77	79	O
6-	18606932	80	82	O
to	18606932	83	85	O
18-month-old	18606932	86	98	O
rural	18606932	99	104	O
Malawians	18606932	105	114	O
.	18606932	114	115	O

OBJECTIVE	18606932	116	125	O
:	18606932	126	127	O
To	18606932	128	130	O
compare	18606932	131	138	O
growth	18606932	139	145	O
and	18606932	146	149	O
incidence	18606932	150	159	O
of	18606932	160	162	O
malnutrition	18606932	163	175	O
in	18606932	176	178	O
infants	18606932	179	186	O
receiving	18606932	187	196	O
long-term	18606932	197	206	O
dietary	18606932	207	214	O
supplementation	18606932	215	230	O
with	18606932	231	235	O
ready-to-use	18606932	236	248	O
fortified	18606932	249	258	O
spread	18606932	259	265	O
(	18606932	266	267	O
FS	18606932	267	269	O
)	18606932	269	270	O
or	18606932	271	273	O
micronutrient-fortified	18606932	274	297	O
maize-soy	18606932	298	307	O
flour	18606932	308	313	O
(	18606932	314	315	O
likuni	18606932	315	321	O
phala	18606932	322	327	O
[	18606932	328	329	O
LP	18606932	329	331	O
]	18606932	331	332	O
)	18606932	332	333	O
.	18606932	333	334	O

DESIGN	18606932	336	342	O
:	18606932	343	344	O
Randomized	18606932	345	355	O
,	18606932	355	356	O
controlled	18606932	357	367	O
,	18606932	367	368	O
single-blind	18606932	369	381	O
trial	18606932	382	387	O
.	18606932	387	388	O

SETTING	18606932	390	397	O
:	18606932	398	399	O
Rural	18606932	400	405	O
Malawi	18606932	406	412	O
.	18606932	412	413	O
PARTICIPANTS	18606932	414	426	O
:	18606932	427	428	O
A	18606932	429	430	O
total	18606932	431	436	O
of	18606932	437	439	O
182	18606932	440	443	O
six-month-old	18606932	444	457	O
infants	18606932	458	465	O
.	18606932	465	466	O

INTERVENTION	18606932	468	480	O
:	18606932	481	482	O
Participants	18606932	483	495	O
were	18606932	496	500	O
randomized	18606932	501	511	O
to	18606932	512	514	O
receive	18606932	515	522	O
1	18606932	523	524	O
year	18606932	525	529	O
of	18606932	530	532	O
daily	18606932	533	538	O
supplementation	18606932	539	554	O
with	18606932	555	559	O
71	18606932	560	562	O
g	18606932	563	564	O
of	18606932	565	567	O
LP	18606932	568	570	O
(	18606932	571	572	O
282	18606932	572	575	O
kcal	18606932	576	580	O
)	18606932	580	581	O
,	18606932	581	582	O
50	18606932	583	585	O
g	18606932	586	587	O
of	18606932	588	590	O
FS	18606932	591	593	O
(	18606932	594	595	O
FS50	18606932	595	599	O
)	18606932	599	600	O
(	18606932	601	602	O
256	18606932	602	605	O
kcal	18606932	606	610	O
)	18606932	610	611	O
,	18606932	611	612	O
or	18606932	613	615	O
25	18606932	616	618	O
g	18606932	619	620	O
of	18606932	621	623	O
FS	18606932	624	626	O
(	18606932	627	628	O
FS25	18606932	628	632	O
)	18606932	632	633	O
(	18606932	634	635	O
130	18606932	635	638	O
[	18606932	639	640	O
corrected	18606932	640	649	O
]	18606932	649	650	O
kcal	18606932	651	655	O
)	18606932	655	656	O
.	18606932	656	657	O

OUTCOME	18606932	659	666	O
MEASURES	18606932	667	675	O
:	18606932	676	677	O
Weight	18606932	678	684	O
and	18606932	685	688	O
length	18606932	689	695	O
gains	18606932	696	701	O
and	18606932	702	705	O
the	18606932	706	709	O
incidences	18606932	710	720	O
of	18606932	721	723	O
severe	18606932	724	730	O
stunting	18606932	731	739	O
,	18606932	739	740	O
underweight	18606932	741	752	O
,	18606932	752	753	O
and	18606932	754	757	O
wasting	18606932	758	765	O
.	18606932	765	766	O

RESULTS	18606932	768	775	O
:	18606932	776	777	O

Mean	18606932	778	782	B-Outcome
weight	18606932	783	789	I-Outcome
and	18606932	790	793	O
length	18606932	794	800	B-Outcome
gains	18606932	801	806	I-Outcome
in	18606932	807	809	O
the	18606932	810	813	O
LP	18606932	814	816	O
,	18606932	816	817	O
FS50	18606932	818	822	O
,	18606932	822	823	O
and	18606932	824	827	O
FS25	18606932	828	832	O
groups	18606932	833	839	O
were	18606932	840	844	O
2.37	18606932	845	849	O
,	18606932	849	850	O
2.47	18606932	851	855	O
,	18606932	855	856	O
and	18606932	857	860	O
2.37	18606932	861	865	O
kg	18606932	866	868	O
(	18606932	869	870	O
P	18606932	870	871	O
=	18606932	872	873	O
.66	18606932	874	877	O
)	18606932	877	878	O
and	18606932	879	882	O
12.7	18606932	883	887	O
,	18606932	887	888	O
13.5	18606932	889	893	O
,	18606932	893	894	O
and	18606932	895	898	O
13.2	18606932	899	903	O
cm	18606932	904	906	O
(	18606932	907	908	O
P	18606932	908	909	O
=	18606932	910	911	O
.23	18606932	912	915	O
)	18606932	915	916	O
,	18606932	916	917	O
respectively	18606932	918	930	O
.	18606932	930	931	O

In	18606932	932	934	O
the	18606932	935	938	O
same	18606932	939	943	O
groups	18606932	944	950	O
,	18606932	950	951	O
the	18606932	952	955	O
cumulative	18606932	956	966	O
12-month	18606932	967	975	O
incidence	18606932	976	985	O
of	18606932	986	988	O
severe	18606932	989	995	B-Outcome
stunting	18606932	996	1004	I-Outcome
was	18606932	1005	1008	O
13.3	18606932	1009	1013	O
%	18606932	1013	1014	O
,	18606932	1014	1015	O
0.0	18606932	1016	1019	O
%	18606932	1019	1020	O
,	18606932	1020	1021	O
and	18606932	1022	1025	O
3.5	18606932	1026	1029	O
%	18606932	1029	1030	O
(	18606932	1031	1032	O
P	18606932	1032	1033	O
=	18606932	1034	1035	O
.01	18606932	1036	1039	O
)	18606932	1039	1040	O
,	18606932	1040	1041	O
of	18606932	1042	1044	O
severe	18606932	1045	1051	B-Outcome
underweight	18606932	1052	1063	I-Outcome
was	18606932	1064	1067	O
15.0	18606932	1068	1072	O
%	18606932	1072	1073	O
,	18606932	1073	1074	O
22.5	18606932	1075	1079	O
%	18606932	1079	1080	O
,	18606932	1080	1081	O
and	18606932	1082	1085	O
16.9	18606932	1086	1090	O
%	18606932	1090	1091	O
(	18606932	1092	1093	O
P	18606932	1093	1094	O
=	18606932	1095	1096	O
.71	18606932	1097	1100	O
)	18606932	1100	1101	O
,	18606932	1101	1102	O
and	18606932	1103	1106	O
of	18606932	1107	1109	O
severe	18606932	1110	1116	B-Outcome
wasting	18606932	1117	1124	I-Outcome
was	18606932	1125	1128	O
1.8	18606932	1129	1132	O
%	18606932	1132	1133	O
,	18606932	1133	1134	O
1.9	18606932	1135	1138	O
%	18606932	1138	1139	O
,	18606932	1139	1140	O
and	18606932	1141	1144	O
1.8	18606932	1145	1148	O
%	18606932	1148	1149	O
(	18606932	1150	1151	O
P	18606932	1151	1152	O
>	18606932	1153	1154	O
.99	18606932	1155	1158	O
)	18606932	1158	1159	O
.	18606932	1159	1160	O

Compared	18606932	1161	1169	O
with	18606932	1170	1174	O
LP-supplemented	18606932	1175	1190	O
infants	18606932	1191	1198	O
,	18606932	1198	1199	O
those	18606932	1200	1205	O
given	18606932	1206	1211	O
FS50	18606932	1212	1216	O
gained	18606932	1217	1223	O
a	18606932	1224	1225	O
mean	18606932	1226	1230	O
of	18606932	1231	1233	O
100	18606932	1234	1237	O
g	18606932	1238	1239	O
more	18606932	1240	1244	O
weight	18606932	1245	1251	B-Outcome
and	18606932	1252	1255	O
0.8	18606932	1256	1259	O
cm	18606932	1260	1262	O
more	18606932	1263	1267	O
length	18606932	1268	1274	B-Outcome
.	18606932	1274	1275	O

There	18606932	1276	1281	O
was	18606932	1282	1285	O
a	18606932	1286	1287	O
significant	18606932	1288	1299	O
interaction	18606932	1300	1311	O
between	18606932	1312	1319	O
baseline	18606932	1320	1328	B-Outcome
length	18606932	1329	1335	I-Outcome
and	18606932	1336	1339	O
intervention	18606932	1340	1352	O
(	18606932	1353	1354	O
P	18606932	1354	1355	O
=	18606932	1356	1357	O
.04	18606932	1358	1361	O
)	18606932	1361	1362	O
;	18606932	1362	1363	O
in	18606932	1364	1366	O
children	18606932	1367	1375	O
with	18606932	1376	1380	O
below-median	18606932	1381	1393	O
length	18606932	1394	1400	O
at	18606932	1401	1403	O
enrollment	18606932	1404	1414	O
,	18606932	1414	1415	O
those	18606932	1416	1421	O
given	18606932	1422	1427	O
FS50	18606932	1428	1432	O
gained	18606932	1433	1439	O
a	18606932	1440	1441	O
mean	18606932	1442	1446	O
of	18606932	1447	1449	O
1.9	18606932	1450	1453	O
cm	18606932	1454	1456	O
more	18606932	1457	1461	O
than	18606932	1462	1466	O
individuals	18606932	1467	1478	O
receiving	18606932	1479	1488	O
LP	18606932	1489	1491	O
.	18606932	1491	1492	O

CONCLUSION	18606932	1494	1504	O
:	18606932	1505	1506	O
One-year-long	18606932	1507	1520	O
complementary	18606932	1521	1534	O
feeding	18606932	1535	1542	O
with	18606932	1543	1547	O
FS	18606932	1548	1550	O
does	18606932	1551	1555	O
not	18606932	1556	1559	O
have	18606932	1560	1564	O
a	18606932	1565	1566	O
significantly	18606932	1567	1580	O
larger	18606932	1581	1587	O
effect	18606932	1588	1594	O
than	18606932	1595	1599	O
LP	18606932	1600	1602	O
on	18606932	1603	1605	O
mean	18606932	1606	1610	B-Outcome
weight	18606932	1611	1617	I-Outcome
gain	18606932	1618	1622	I-Outcome
in	18606932	1623	1625	O
all	18606932	1626	1629	O
infants	18606932	1630	1637	O
,	18606932	1637	1638	O
but	18606932	1639	1642	O
it	18606932	1643	1645	O
is	18606932	1646	1648	O
likely	18606932	1649	1655	O
to	18606932	1656	1658	O
boost	18606932	1659	1664	O
linear	18606932	1665	1671	O
growth	18606932	1672	1678	O
in	18606932	1679	1681	O
the	18606932	1682	1685	O
most	18606932	1686	1690	O
disadvantaged	18606932	1691	1704	O
individuals	18606932	1705	1716	O
and	18606932	1717	1720	O
,	18606932	1720	1721	O
hence	18606932	1722	1727	O
,	18606932	1727	1728	O
decrease	18606932	1729	1737	O
the	18606932	1738	1741	O
incidence	18606932	1742	1751	O
of	18606932	1752	1754	O
severe	18606932	1755	1761	B-Outcome
stunting	18606932	1762	1770	I-Outcome
.	18606932	1770	1771	O


Treatment	18779477	0	9	O
of	18779477	10	12	O
posterior	18779477	13	22	O
uveitis	18779477	23	30	O
with	18779477	31	35	O
a	18779477	36	37	O
fluocinolone	18779477	38	50	O
acetonide	18779477	51	60	O
implant	18779477	61	68	O
:	18779477	68	69	O
three-year	18779477	70	80	O
clinical	18779477	81	89	O
trial	18779477	90	95	O
results	18779477	96	103	O
.	18779477	103	104	O

OBJECTIVES	18779477	106	116	O
:	18779477	117	118	O
To	18779477	119	121	O
evaluate	18779477	122	130	O
the	18779477	131	134	O
safety	18779477	135	141	O
and	18779477	142	145	O
efficacy	18779477	146	154	O
of	18779477	155	157	O
0.59-mg	18779477	158	165	O
and	18779477	166	169	O
2.1-mg	18779477	170	176	O
fluocinolone	18779477	177	189	O
acetonide	18779477	190	199	O
(	18779477	200	201	O
FA	18779477	201	203	O
)	18779477	203	204	O
intravitreous	18779477	205	218	O
implants	18779477	219	227	O
in	18779477	228	230	O
noninfectious	18779477	231	244	O
posterior	18779477	245	254	O
uveitis	18779477	255	262	O
.	18779477	262	263	O

DESIGN	18779477	265	271	O
:	18779477	272	273	O
A	18779477	274	275	O
3-year	18779477	276	282	O
,	18779477	282	283	O
multicenter	18779477	284	295	O
,	18779477	295	296	O
randomized	18779477	297	307	O
,	18779477	307	308	O
historically	18779477	309	321	O
controlled	18779477	322	332	O
trial	18779477	333	338	O
of	18779477	339	341	O
the	18779477	342	345	O
0.59-mg	18779477	346	353	O
FA	18779477	354	356	O
intravitreous	18779477	357	370	O
implant	18779477	371	378	O
in	18779477	379	381	O
110	18779477	382	385	O
patients	18779477	386	394	O
and	18779477	395	398	O
the	18779477	399	402	O
2.1-mg	18779477	403	409	O
FA	18779477	410	412	O
intravitreous	18779477	413	426	O
implant	18779477	427	434	O
in	18779477	435	437	O
168	18779477	438	441	O
patients	18779477	442	450	O
.	18779477	450	451	O

MAIN	18779477	453	457	O
OUTCOME	18779477	458	465	O
MEASURES	18779477	466	474	O
:	18779477	475	476	O
Recurrence	18779477	477	487	O
rate	18779477	488	492	O
,	18779477	492	493	O
vision	18779477	494	500	O
,	18779477	500	501	O
and	18779477	502	505	O
complications	18779477	506	519	O
.	18779477	519	520	O

RESULTS	18779477	522	529	O
:	18779477	530	531	O
Uveitis	18779477	532	539	B-Outcome
recurrence	18779477	540	550	I-Outcome
was	18779477	551	554	O
reduced	18779477	555	562	O
in	18779477	563	565	O
implanted	18779477	566	575	O
eyes	18779477	576	580	O
from	18779477	581	585	O
62	18779477	586	588	O
%	18779477	588	589	O
(	18779477	590	591	O
during	18779477	591	597	O
the	18779477	598	601	O
1-year	18779477	602	608	O
preimplantation	18779477	609	624	O
period	18779477	625	631	O
)	18779477	631	632	O
to	18779477	633	635	O
4	18779477	636	637	O
%	18779477	637	638	O
,	18779477	638	639	O
10	18779477	640	642	O
%	18779477	642	643	O
,	18779477	643	644	O
and	18779477	645	648	O
20	18779477	649	651	O
%	18779477	651	652	O
during	18779477	653	659	O
the	18779477	660	663	O
1-	18779477	664	666	O
,	18779477	666	667	O
2-	18779477	668	670	O
,	18779477	670	671	O
and	18779477	672	675	O
3-year	18779477	676	682	O
postimplantation	18779477	683	699	O
periods	18779477	700	707	O
,	18779477	707	708	O
respectively	18779477	709	721	O
,	18779477	721	722	O
for	18779477	723	726	O
the	18779477	727	730	O
0.59-mg	18779477	731	738	O
dose	18779477	739	743	O
group	18779477	744	749	O
(	18779477	750	751	O
P	18779477	751	752	O
<	18779477	753	754	O
.01	18779477	755	758	O
)	18779477	758	759	O
and	18779477	760	763	O
from	18779477	764	768	O
58	18779477	769	771	O
%	18779477	771	772	O
to	18779477	773	775	O
7	18779477	776	777	O
%	18779477	777	778	O
,	18779477	778	779	O
17	18779477	780	782	O
%	18779477	782	783	O
,	18779477	783	784	O
and	18779477	785	788	O
41	18779477	789	791	O
%	18779477	791	792	O
,	18779477	792	793	O
respectively	18779477	794	806	O
,	18779477	806	807	O
for	18779477	808	811	O
the	18779477	812	815	O
2.1-mg	18779477	816	822	O
dose	18779477	823	827	O
group	18779477	828	833	O
(	18779477	834	835	O
P	18779477	835	836	O
<	18779477	837	838	O
.01	18779477	839	842	O
)	18779477	842	843	O
.	18779477	843	844	O

More	18779477	845	849	O
implanted	18779477	850	859	O
eyes	18779477	860	864	O
than	18779477	865	869	O
nonimplanted	18779477	870	882	O
eyes	18779477	883	887	O
had	18779477	888	891	O
improved	18779477	892	900	O
visual	18779477	901	907	B-Outcome
acuity	18779477	908	914	I-Outcome
(	18779477	915	916	O
P	18779477	916	917	O
<	18779477	918	919	O
.01	18779477	920	923	O
)	18779477	923	924	O
.	18779477	924	925	O

Implanted	18779477	926	935	O
eyes	18779477	936	940	O
had	18779477	941	944	O
higher	18779477	945	951	O
incidences	18779477	952	962	O
of	18779477	963	965	O
intraocular	18779477	966	977	B-Outcome
pressure	18779477	978	986	I-Outcome
elevation	18779477	987	996	I-Outcome
(	18779477	997	998	O
>	18779477	998	999	O
or	18779477	1000	1002	O
=	18779477	1003	1004	O
10	18779477	1005	1007	O
mm	18779477	1008	1010	O
Hg	18779477	1011	1013	O
)	18779477	1013	1014	O
than	18779477	1015	1019	O
nonimplanted	18779477	1020	1032	O
eyes	18779477	1033	1037	O
(	18779477	1038	1039	O
P	18779477	1039	1040	O
<	18779477	1041	1042	O
.01	18779477	1043	1046	O
)	18779477	1046	1047	O
,	18779477	1047	1048	O
and	18779477	1049	1052	O
glaucoma	18779477	1053	1061	B-Outcome
surgery	18779477	1062	1069	I-Outcome
was	18779477	1070	1073	O
required	18779477	1074	1082	O
in	18779477	1083	1085	O
40	18779477	1086	1088	O
%	18779477	1088	1089	O
of	18779477	1090	1092	O
implanted	18779477	1093	1102	O
eyes	18779477	1103	1107	O
vs	18779477	1108	1110	O
2	18779477	1111	1112	O
%	18779477	1112	1113	O
of	18779477	1114	1116	O
nonimplanted	18779477	1117	1129	O
eyes	18779477	1130	1134	O
(	18779477	1135	1136	O
P	18779477	1136	1137	O
<	18779477	1138	1139	O
.01	18779477	1140	1143	O
)	18779477	1143	1144	O
.	18779477	1144	1145	O

Cataracts	18779477	1146	1155	B-Outcome
were	18779477	1156	1160	O
extracted	18779477	1161	1170	O
in	18779477	1171	1173	O
93	18779477	1174	1176	O
%	18779477	1176	1177	O
of	18779477	1178	1180	O
phakic	18779477	1181	1187	O
implanted	18779477	1188	1197	O
eyes	18779477	1198	1202	O
vs	18779477	1203	1205	O
20	18779477	1206	1208	O
%	18779477	1208	1209	O
of	18779477	1210	1212	O
phakic	18779477	1213	1219	O
nonimplanted	18779477	1220	1232	O
eyes	18779477	1233	1237	O
(	18779477	1238	1239	O
P	18779477	1239	1240	O
<	18779477	1241	1242	O
.01	18779477	1243	1246	O
)	18779477	1246	1247	O
.	18779477	1247	1248	O

CONCLUSIONS	18779477	1250	1261	O
:	18779477	1262	1263	O
The	18779477	1264	1267	O
FA	18779477	1268	1270	O
implant	18779477	1271	1278	O
significantly	18779477	1279	1292	O
reduced	18779477	1293	1300	O
uveitis	18779477	1301	1308	B-Outcome
recurrence	18779477	1309	1319	I-Outcome
and	18779477	1320	1323	O
improved	18779477	1324	1332	O
or	18779477	1333	1335	O
stabilized	18779477	1336	1346	O
visual	18779477	1347	1353	B-Outcome
acuity	18779477	1354	1360	I-Outcome
in	18779477	1361	1363	O
subjects	18779477	1364	1372	O
with	18779477	1373	1377	O
noninfectious	18779477	1378	1391	O
posterior	18779477	1392	1401	O
uveitis	18779477	1402	1409	O
.	18779477	1409	1410	O

Most	18779477	1411	1415	O
subjects	18779477	1416	1424	O
required	18779477	1425	1433	O
cataract	18779477	1434	1442	B-Outcome
extraction	18779477	1443	1453	I-Outcome
,	18779477	1453	1454	O
and	18779477	1455	1458	O
a	18779477	1459	1460	O
significant	18779477	1461	1472	O
proportion	18779477	1473	1483	O
required	18779477	1484	1492	O
intraocular	18779477	1493	1504	B-Outcome
pressure-lowering	18779477	1505	1522	I-Outcome
surgery	18779477	1523	1530	I-Outcome
.	18779477	1530	1531	O

APPLICATION	18779477	1533	1544	O
TO	18779477	1545	1547	O
CLINICAL	18779477	1548	1556	O
PRACTICE	18779477	1557	1565	O
:	18779477	1566	1567	O
The	18779477	1568	1571	O
FA	18779477	1572	1574	O
implant	18779477	1575	1582	O
provides	18779477	1583	1591	O
an	18779477	1592	1594	O
alternative	18779477	1595	1606	O
therapy	18779477	1607	1614	O
for	18779477	1615	1618	O
prolonged	18779477	1619	1628	O
control	18779477	1629	1636	O
of	18779477	1637	1639	O
inflammation	18779477	1640	1652	O
in	18779477	1653	1655	O
noninfectious	18779477	1656	1669	O
posterior	18779477	1670	1679	O
uveitis	18779477	1680	1687	O
.	18779477	1687	1688	O

TRIAL	18779477	1690	1695	O
REGISTRATION	18779477	1696	1708	O
:	18779477	1709	1710	O
clinicaltrials.gov	18779477	1711	1729	O
Identifier	18779477	1730	1740	O
:	18779477	1740	1741	O
NCT00407082	18779477	1742	1753	O
.	18779477	1753	1754	O


Endobronchial	18812446	0	13	O
ultrasonography-guided	18812446	14	36	O
transbronchial	18812446	37	51	O
needle	18812446	52	58	O
aspiration	18812446	59	69	O
increases	18812446	70	79	O
the	18812446	80	83	O
diagnostic	18812446	84	94	O
yield	18812446	95	100	O
of	18812446	101	103	O
peripheral	18812446	104	114	O
pulmonary	18812446	115	124	O
lesions	18812446	125	132	O
:	18812446	132	133	O
a	18812446	134	135	O
randomized	18812446	136	146	O
trial	18812446	147	152	O
.	18812446	152	153	O

BACKGROUND	18812446	155	165	O
:	18812446	166	167	O
The	18812446	168	171	O
diagnostic	18812446	172	182	O
yield	18812446	183	188	O
of	18812446	189	191	O
endobronchial	18812446	192	205	O
ultrasonography	18812446	206	221	O
(EBUS)-guided	18812446	222	235	O
transbronchial	18812446	236	250	O
needle	18812446	251	257	O
aspiration	18812446	258	268	O
(	18812446	269	270	O
TBNA	18812446	270	274	O
)	18812446	274	275	O
for	18812446	276	279	O
peripheral	18812446	280	290	O
pulmonary	18812446	291	300	O
lesions	18812446	301	308	O
(	18812446	309	310	O
PPLs	18812446	310	314	O
)	18812446	314	315	O
has	18812446	316	319	O
not	18812446	320	323	O
been	18812446	324	328	O
evaluated	18812446	329	338	O
.	18812446	338	339	O

The	18812446	340	343	O
diagnostic	18812446	344	354	O
impact	18812446	355	361	O
of	18812446	362	364	O
TBNA	18812446	365	369	O
when	18812446	370	374	O
the	18812446	375	378	O
EBUS	18812446	379	383	O
probe	18812446	384	389	O
is	18812446	390	392	O
adjacent	18812446	393	401	O
to	18812446	402	404	O
lesions	18812446	405	412	O
remains	18812446	413	420	O
to	18812446	421	423	O
be	18812446	424	426	O
determined	18812446	427	437	O
.	18812446	437	438	O

DESIGN	18812446	440	446	O
:	18812446	447	448	O
A	18812446	449	450	O
prospective	18812446	451	462	O
,	18812446	462	463	O
randomized	18812446	464	474	O
trial	18812446	475	480	O
.	18812446	480	481	O

METHODS	18812446	483	490	O
:	18812446	491	492	O
Two	18812446	493	496	O
hundred	18812446	497	504	O
two	18812446	505	508	O
patients	18812446	509	517	O
with	18812446	518	522	O
PPLs	18812446	523	527	O
and	18812446	528	531	O
positive	18812446	532	540	O
EBUS	18812446	541	545	O
findings	18812446	546	554	O
were	18812446	555	559	O
enrolled	18812446	560	568	O
.	18812446	568	569	O

They	18812446	570	574	O
were	18812446	575	579	O
randomly	18812446	580	588	O
classified	18812446	589	599	O
into	18812446	600	604	O
two	18812446	605	608	O
groups	18812446	609	615	O
.	18812446	615	616	O

In	18812446	617	619	O
the	18812446	620	623	O
EBUS	18812446	624	628	O
conventional	18812446	629	641	O
diagnostic	18812446	642	652	O
procedures	18812446	653	663	O
(	18812446	664	665	O
CDPs	18812446	665	669	O
)	18812446	669	670	O
group	18812446	671	676	O
(	18812446	677	678	O
103	18812446	678	681	O
patients	18812446	682	690	O
)	18812446	690	691	O
,	18812446	691	692	O
both	18812446	693	697	O
transbronchial	18812446	698	712	O
biopsy	18812446	713	719	O
(	18812446	720	721	O
TBB	18812446	721	724	O
)	18812446	724	725	O
and	18812446	726	729	O
bronchial	18812446	730	739	O
washing	18812446	740	747	O
(	18812446	748	749	O
BW	18812446	749	751	O
)	18812446	751	752	O
were	18812446	753	757	O
performed	18812446	758	767	O
.	18812446	767	768	O

In	18812446	769	771	O
the	18812446	772	775	O
EBUS-TBNA	18812446	776	785	O
plus	18812446	786	790	O
CDPs	18812446	791	795	O
group	18812446	796	801	O
(	18812446	802	803	O
99	18812446	803	805	O
patients	18812446	806	814	O
)	18812446	814	815	O
,	18812446	815	816	O
TBNA	18812446	817	821	O
,	18812446	821	822	O
TBB	18812446	823	826	O
,	18812446	826	827	O
and	18812446	828	831	O
BW	18812446	832	834	O
were	18812446	835	839	O
performed	18812446	840	849	O
.	18812446	849	850	O

The	18812446	851	854	O
diagnostic	18812446	855	865	O
yield	18812446	866	871	O
in	18812446	872	874	O
each	18812446	875	879	O
group	18812446	880	885	O
was	18812446	886	889	O
compared	18812446	890	898	O
.	18812446	898	899	O

RESULTS	18812446	901	908	O
:	18812446	909	910	O
A	18812446	911	912	O
total	18812446	913	918	O
of	18812446	919	921	O
182	18812446	922	925	O
patients	18812446	926	934	O
(	18812446	935	936	O
94	18812446	936	938	O
in	18812446	939	941	O
the	18812446	942	945	O
EBUS	18812446	946	950	O
CDPs	18812446	951	955	O
group	18812446	956	961	O
and	18812446	962	965	O
88	18812446	966	968	O
in	18812446	969	971	O
the	18812446	972	975	O
EBUS-TBNA	18812446	976	985	O
plus	18812446	986	990	O
CDPs	18812446	991	995	O
group	18812446	996	1001	O
)	18812446	1001	1002	O
were	18812446	1003	1007	O
analyzed	18812446	1008	1016	O
.	18812446	1016	1017	O

The	18812446	1018	1021	O
yield	18812446	1022	1027	O
in	18812446	1028	1030	O
the	18812446	1031	1034	O
EBUS-TBNA	18812446	1035	1044	O
plus	18812446	1045	1049	O
CDPs	18812446	1050	1054	O
group	18812446	1055	1060	O
(	18812446	1061	1062	O
78.4	18812446	1062	1066	O
%	18812446	1066	1067	O
)	18812446	1067	1068	O
was	18812446	1069	1072	O
significantly	18812446	1073	1086	O
higher	18812446	1087	1093	O
than	18812446	1094	1098	O
the	18812446	1099	1102	O
EBUS	18812446	1103	1107	O
CDPs	18812446	1108	1112	O
group	18812446	1113	1118	O
(	18812446	1119	1120	O
60.6	18812446	1120	1124	O
%	18812446	1124	1125	O
,	18812446	1125	1126	O
p	18812446	1127	1128	O
=	18812446	1129	1130	O
0.015	18812446	1131	1136	O
)	18812446	1136	1137	O
.	18812446	1137	1138	O

Cases	18812446	1139	1144	O
in	18812446	1145	1147	O
which	18812446	1148	1153	O
the	18812446	1154	1157	O
EBUS	18812446	1158	1162	O
probe	18812446	1163	1168	O
was	18812446	1169	1172	O
located	18812446	1173	1180	O
within	18812446	1181	1187	O
the	18812446	1188	1191	O
lesions	18812446	1192	1199	O
had	18812446	1200	1203	O
a	18812446	1204	1205	O
significantly	18812446	1206	1219	O
higher	18812446	1220	1226	O
diagnostic	18812446	1227	1237	B-Outcome
yield	18812446	1238	1243	I-Outcome
(	18812446	1244	1245	O
78.3	18812446	1245	1249	O
%	18812446	1249	1250	O
)	18812446	1250	1251	O
than	18812446	1252	1256	O
when	18812446	1257	1261	O
the	18812446	1262	1265	O
EBUS	18812446	1266	1270	O
probe	18812446	1271	1276	O
was	18812446	1277	1280	O
adjacent	18812446	1281	1289	O
to	18812446	1290	1292	O
them	18812446	1293	1297	O
(	18812446	1298	1299	O
47.2	18812446	1299	1303	O
%	18812446	1303	1304	O
,	18812446	1304	1305	O
p	18812446	1306	1307	O
<	18812446	1308	1309	O
0.001	18812446	1310	1315	O
)	18812446	1315	1316	O
.	18812446	1316	1317	O

Concerning	18812446	1318	1328	O
the	18812446	1329	1332	O
three	18812446	1333	1338	O
different	18812446	1339	1348	O
techniques	18812446	1349	1359	O
,	18812446	1359	1360	O
TBNA	18812446	1361	1365	O
showed	18812446	1366	1372	O
the	18812446	1373	1376	O
highest	18812446	1377	1384	O
diagnostic	18812446	1385	1395	B-Outcome
yield	18812446	1396	1401	I-Outcome
(	18812446	1402	1403	O
62.5	18812446	1403	1407	O
%	18812446	1407	1408	O
)	18812446	1408	1409	O
in	18812446	1410	1412	O
comparison	18812446	1413	1423	O
to	18812446	1424	1426	O
TBB	18812446	1427	1430	O
(	18812446	1431	1432	O
48.9	18812446	1432	1436	O
%	18812446	1436	1437	O
)	18812446	1437	1438	O
and	18812446	1439	1442	O
to	18812446	1443	1445	O
BW	18812446	1446	1448	O
(	18812446	1449	1450	O
19.8	18812446	1450	1454	O
%	18812446	1454	1455	O
)	18812446	1455	1456	O
.	18812446	1456	1457	O

The	18812446	1458	1461	O
diagnostic	18812446	1462	1472	B-Outcome
yield	18812446	1473	1478	I-Outcome
of	18812446	1479	1481	O
TBNA	18812446	1482	1486	O
remained	18812446	1487	1495	O
unchanged	18812446	1496	1505	O
even	18812446	1506	1510	O
when	18812446	1511	1515	O
the	18812446	1516	1519	O
EBUS	18812446	1520	1524	O
probe	18812446	1525	1530	O
was	18812446	1531	1534	O
adjacent	18812446	1535	1543	O
to	18812446	1544	1546	O
the	18812446	1547	1550	O
lesions	18812446	1551	1558	O
(	18812446	1559	1560	O
p	18812446	1560	1561	O
=	18812446	1562	1563	O
0.89	18812446	1564	1568	O
)	18812446	1568	1569	O
.	18812446	1569	1570	O

No	18812446	1571	1573	O
additional	18812446	1574	1584	O
adverse	18812446	1585	1592	B-Outcome
effects	18812446	1593	1600	I-Outcome
were	18812446	1601	1605	O
observed	18812446	1606	1614	O
in	18812446	1615	1617	O
the	18812446	1618	1621	O
EBUS-TBNA	18812446	1622	1631	O
plus	18812446	1632	1636	O
CDPs	18812446	1637	1641	O
group	18812446	1642	1647	O
.	18812446	1647	1648	O

CONCLUSIONS	18812446	1650	1661	O
:	18812446	1662	1663	O
Applying	18812446	1664	1672	O
TBNA	18812446	1673	1677	O
to	18812446	1678	1680	O
EBUS-guided	18812446	1681	1692	O
CDPs	18812446	1693	1697	O
further	18812446	1698	1705	O
increased	18812446	1706	1715	O
the	18812446	1716	1719	O
diagnostic	18812446	1720	1730	B-Outcome
yield	18812446	1731	1736	I-Outcome
of	18812446	1737	1739	I-Outcome
PPLs	18812446	1740	1744	I-Outcome
without	18812446	1745	1752	O
additional	18812446	1753	1763	O
risk	18812446	1764	1768	O
.	18812446	1768	1769	O

The	18812446	1770	1773	O
diagnostic	18812446	1774	1784	O
advantage	18812446	1785	1794	O
of	18812446	1795	1797	O
TBNA	18812446	1798	1802	O
became	18812446	1803	1809	O
more	18812446	1810	1814	O
obvious	18812446	1815	1822	O
if	18812446	1823	1825	O
the	18812446	1826	1829	O
EBUS	18812446	1830	1834	O
probe	18812446	1835	1840	O
was	18812446	1841	1844	O
adjacent	18812446	1845	1853	O
to	18812446	1854	1856	O
the	18812446	1857	1860	O
lesions	18812446	1861	1868	O
.	18812446	1868	1869	O

TRIAL	18812446	1871	1876	O
REGISTRATION	18812446	1877	1889	O
:	18812446	1890	1891	O
Clinicaltrials.gov	18812446	1892	1910	O
Identifier	18812446	1911	1921	O
:	18812446	1921	1922	O
NCT00626587	18812446	1923	1934	O
.	18812446	1934	1935	O


Medium	18845704	0	6	O
chain	18845704	7	12	O
triglyceride	18845704	13	25	O
oil	18845704	26	29	O
consumption	18845704	30	41	O
as	18845704	42	44	O
part	18845704	45	49	O
of	18845704	50	52	O
a	18845704	53	54	O
weight	18845704	55	61	O
loss	18845704	62	66	O
diet	18845704	67	71	O
does	18845704	72	76	O
not	18845704	77	80	O
lead	18845704	81	85	O
to	18845704	86	88	O
an	18845704	89	91	O
adverse	18845704	92	99	O
metabolic	18845704	100	109	O
profile	18845704	110	117	O
when	18845704	118	122	O
compared	18845704	123	131	O
to	18845704	132	134	O
olive	18845704	135	140	O
oil	18845704	141	144	O
.	18845704	144	145	O

OBJECTIVE	18845704	147	156	O
:	18845704	157	158	O
Medium	18845704	159	165	O
chain	18845704	166	171	O
triglyceride	18845704	172	184	O
(	18845704	185	186	O
MCT	18845704	186	189	O
)	18845704	189	190	O
consumption	18845704	191	202	O
may	18845704	203	206	O
have	18845704	207	211	O
a	18845704	212	213	O
beneficial	18845704	214	224	O
impact	18845704	225	231	O
on	18845704	232	234	O
weight	18845704	235	241	O
management	18845704	242	252	O
,	18845704	252	253	O
however	18845704	254	261	O
,	18845704	261	262	O
some	18845704	263	267	O
studies	18845704	268	275	O
point	18845704	276	281	O
to	18845704	282	284	O
a	18845704	285	286	O
negative	18845704	287	295	O
impact	18845704	296	302	O
of	18845704	303	305	O
MCT	18845704	306	309	O
oil	18845704	310	313	O
consumption	18845704	314	325	O
on	18845704	326	328	O
cardiovascular	18845704	329	343	O
disease	18845704	344	351	O
risk	18845704	352	356	O
.	18845704	356	357	O

This	18845704	358	362	O
study	18845704	363	368	O
examined	18845704	369	377	O
the	18845704	378	381	O
effects	18845704	382	389	O
of	18845704	390	392	O
MCT	18845704	393	396	O
oil	18845704	397	400	O
consumption	18845704	401	412	O
,	18845704	412	413	O
as	18845704	414	416	O
part	18845704	417	421	O
of	18845704	422	424	O
a	18845704	425	426	O
weight	18845704	427	433	O
loss	18845704	434	438	O
diet	18845704	439	443	O
,	18845704	443	444	O
on	18845704	445	447	O
metabolic	18845704	448	457	O
risk	18845704	458	462	O
profile	18845704	463	470	O
compared	18845704	471	479	O
to	18845704	480	482	O
olive	18845704	483	488	O
oil	18845704	489	492	O
.	18845704	492	493	O

DESIGN	18845704	495	501	O
:	18845704	502	503	O
Thirty-one	18845704	504	514	O
men	18845704	515	518	O
and	18845704	519	522	O
women	18845704	523	528	O
,	18845704	528	529	O
age	18845704	530	533	O
19	18845704	534	536	O
-	18845704	536	537	O
50	18845704	537	539	O
y	18845704	540	541	O
and	18845704	542	545	O
body	18845704	546	550	O
mass	18845704	551	555	O
index	18845704	556	561	O
27	18845704	562	564	O
-	18845704	564	565	O
33	18845704	565	567	O
kg/m(2	18845704	568	574	O
)	18845704	574	575	O
,	18845704	575	576	O
completed	18845704	577	586	O
this	18845704	587	591	O
randomized	18845704	592	602	O
,	18845704	602	603	O
controlled	18845704	604	614	O
,	18845704	614	615	O
16-week	18845704	616	623	O
weight	18845704	624	630	O
loss	18845704	631	635	O
program	18845704	636	643	O
.	18845704	643	644	O

Oils	18845704	645	649	O
were	18845704	650	654	O
consumed	18845704	655	663	O
at	18845704	664	666	O
a	18845704	667	668	O
level	18845704	669	674	O
of	18845704	675	677	O
approximately	18845704	678	691	O
12	18845704	692	694	O
%	18845704	694	695	O
of	18845704	696	698	O
the	18845704	699	702	O
subjects	18845704	703	711	O
'	18845704	711	712	O
prescribed	18845704	713	723	O
energy	18845704	724	730	O
intakes	18845704	731	738	O
in	18845704	739	741	O
the	18845704	742	745	O
form	18845704	746	750	O
of	18845704	751	753	O
muffins	18845704	754	761	O
and	18845704	762	765	O
liquid	18845704	766	772	O
oil	18845704	773	776	O
.	18845704	776	777	O

RESULTS	18845704	779	786	O
:	18845704	787	788	O
After	18845704	789	794	O
controlling	18845704	795	806	O
for	18845704	807	810	O
body	18845704	811	815	B-Outcome
weight	18845704	816	822	I-Outcome
,	18845704	822	823	O
there	18845704	824	829	O
was	18845704	830	833	O
a	18845704	834	835	O
significant	18845704	836	847	O
effect	18845704	848	854	O
of	18845704	855	857	O
time	18845704	858	862	B-Outcome
on	18845704	863	865	I-Outcome
fasting	18845704	866	873	I-Outcome
serum	18845704	874	879	I-Outcome
glucose	18845704	880	887	I-Outcome
(	18845704	888	889	O
P	18845704	889	890	O
=	18845704	891	892	O
0.0177	18845704	893	899	O
)	18845704	899	900	O
and	18845704	901	904	O
total	18845704	905	910	B-Outcome
cholesterol	18845704	911	922	I-Outcome
(	18845704	923	924	O
P	18845704	924	925	O
=	18845704	926	927	O
0.0386	18845704	928	934	O
)	18845704	934	935	O
concentrations	18845704	936	950	O
,	18845704	950	951	O
and	18845704	952	955	O
on	18845704	956	958	O
diastolic	18845704	959	968	B-Outcome
blood	18845704	969	974	I-Outcome
pressure	18845704	975	983	I-Outcome
(	18845704	984	985	O
P	18845704	985	986	O
=	18845704	987	988	O
0.0413	18845704	989	995	O
)	18845704	995	996	O
,	18845704	996	997	O
with	18845704	998	1002	O
reductions	18845704	1003	1013	O
in	18845704	1014	1016	O
these	18845704	1017	1022	O
variables	18845704	1023	1032	O
occurring	18845704	1033	1042	O
over	18845704	1043	1047	O
time	18845704	1048	1052	O
;	18845704	1052	1053	O
there	18845704	1054	1059	O
was	18845704	1060	1063	O
no	18845704	1064	1066	O
time-by-diet	18845704	1067	1079	O
interaction	18845704	1080	1091	O
for	18845704	1092	1095	O
any	18845704	1096	1099	O
of	18845704	1100	1102	O
the	18845704	1103	1106	O
parameters	18845704	1107	1117	O
studied	18845704	1118	1125	O
.	18845704	1125	1126	O

Two	18845704	1127	1130	O
of	18845704	1131	1133	O
the	18845704	1134	1137	O
3	18845704	1138	1139	O
subjects	18845704	1140	1148	O
in	18845704	1149	1151	O
the	18845704	1152	1155	O
MCT	18845704	1156	1159	O
oil	18845704	1160	1163	O
group	18845704	1164	1169	O
with	18845704	1170	1174	O
evidence	18845704	1175	1183	O
of	18845704	1184	1186	O
the	18845704	1187	1190	O
metabolic	18845704	1191	1200	B-Outcome
syndrome	18845704	1201	1209	I-Outcome
at	18845704	1210	1212	I-Outcome
baseline	18845704	1213	1221	I-Outcome
did	18845704	1222	1225	O
not	18845704	1226	1229	O
have	18845704	1230	1234	O
metabolic	18845704	1235	1244	B-Outcome
syndrome	18845704	1245	1253	I-Outcome
at	18845704	1254	1256	O
endpoint	18845704	1257	1265	O
.	18845704	1265	1266	O

In	18845704	1267	1269	O
the	18845704	1270	1273	O
olive	18845704	1274	1279	O
oil	18845704	1280	1283	O
group	18845704	1284	1289	O
,	18845704	1289	1290	O
6	18845704	1291	1292	O
subjects	18845704	1293	1301	O
had	18845704	1302	1305	O
the	18845704	1306	1309	O
metabolic	18845704	1310	1319	B-Outcome
syndrome	18845704	1320	1328	I-Outcome
at	18845704	1329	1331	I-Outcome
baseline	18845704	1332	1340	I-Outcome
;	18845704	1340	1341	O
2	18845704	1342	1343	O
subjects	18845704	1344	1352	O
no	18845704	1353	1355	O
longer	18845704	1356	1362	O
had	18845704	1363	1366	O
metabolic	18845704	1367	1376	B-Outcome
syndrome	18845704	1377	1385	I-Outcome
at	18845704	1386	1388	O
endpoint	18845704	1389	1397	O
,	18845704	1397	1398	O
1	18845704	1399	1400	O
person	18845704	1401	1407	O
developed	18845704	1408	1417	O
metabolic	18845704	1418	1427	B-Outcome
syndrome	18845704	1428	1436	I-Outcome
,	18845704	1436	1437	O
and	18845704	1438	1441	O
4	18845704	1442	1443	O
subjects	18845704	1444	1452	O
did	18845704	1453	1456	O
not	18845704	1457	1460	O
have	18845704	1461	1465	O
any	18845704	1466	1469	O
change	18845704	1470	1476	O
in	18845704	1477	1479	O
their	18845704	1480	1485	O
metabolic	18845704	1486	1495	B-Outcome
syndrome	18845704	1496	1504	I-Outcome
status	18845704	1505	1511	I-Outcome
.	18845704	1511	1512	O

CONCLUSIONS	18845704	1514	1525	O
:	18845704	1526	1527	O
Our	18845704	1528	1531	O
results	18845704	1532	1539	O
suggest	18845704	1540	1547	O
that	18845704	1548	1552	O
MCT	18845704	1553	1556	O
oil	18845704	1557	1560	O
can	18845704	1561	1564	O
be	18845704	1565	1567	O
incorporated	18845704	1568	1580	O
into	18845704	1581	1585	O
a	18845704	1586	1587	O
weight	18845704	1588	1594	O
loss	18845704	1595	1599	O
program	18845704	1600	1607	O
without	18845704	1608	1615	O
fear	18845704	1616	1620	O
of	18845704	1621	1623	O
adversely	18845704	1624	1633	O
affecting	18845704	1634	1643	O
metabolic	18845704	1644	1653	B-Outcome
risk	18845704	1654	1658	I-Outcome
factors	18845704	1659	1666	I-Outcome
.	18845704	1666	1667	O

Distinction	18845704	1668	1679	O
should	18845704	1680	1686	O
be	18845704	1687	1689	O
made	18845704	1690	1694	O
regarding	18845704	1695	1704	O
chain	18845704	1705	1710	O
length	18845704	1711	1717	O
when	18845704	1718	1722	O
it	18845704	1723	1725	O
comes	18845704	1726	1731	O
to	18845704	1732	1734	O
discussing	18845704	1735	1745	O
the	18845704	1746	1749	O
effects	18845704	1750	1757	O
of	18845704	1758	1760	O
saturated	18845704	1761	1770	O
fats	18845704	1771	1775	O
on	18845704	1776	1778	O
metabolic	18845704	1779	1788	O
risk	18845704	1789	1793	O
factors	18845704	1794	1801	O
.	18845704	1801	1802	O


Treatment	18957505	0	9	O
with	18957505	10	14	O
the	18957505	15	18	O
dipeptidyl	18957505	19	29	O
peptidase-4	18957505	30	41	O
inhibitor	18957505	42	51	O
vildagliptin	18957505	52	64	O
improves	18957505	65	73	O
fasting	18957505	74	81	O
islet-cell	18957505	82	92	O
function	18957505	93	101	O
in	18957505	102	104	O
subjects	18957505	105	113	O
with	18957505	114	118	O
type	18957505	119	123	O
2	18957505	124	125	O
diabetes	18957505	126	134	O
.	18957505	134	135	O

CONTEXT	18957505	137	144	O
:	18957505	145	146	O
Dipeptidyl	18957505	147	157	O
peptidase	18957505	158	167	O
4	18957505	168	169	O
(	18957505	170	171	O
DPP-4	18957505	171	176	O
)	18957505	176	177	O
inhibitors	18957505	178	188	O
are	18957505	189	192	O
proposed	18957505	193	201	O
to	18957505	202	204	O
lower	18957505	205	210	O
blood	18957505	211	216	O
glucose	18957505	217	224	O
in	18957505	225	227	O
type	18957505	228	232	O
2	18957505	233	234	O
diabetes	18957505	235	243	O
mellitus	18957505	244	252	O
(	18957505	253	254	O
T2DM	18957505	254	258	O
)	18957505	258	259	O
by	18957505	260	262	O
prolonging	18957505	263	273	O
the	18957505	274	277	O
activity	18957505	278	286	O
of	18957505	287	289	O
the	18957505	290	293	O
circulating	18957505	294	305	O
incretins	18957505	306	315	O
,	18957505	315	316	O
glucose-dependent	18957505	317	334	O
insulinotropic	18957505	335	349	O
polypeptide	18957505	350	361	O
(	18957505	362	363	O
GIP	18957505	363	366	O
)	18957505	366	367	O
and	18957505	368	371	O
glucagon-like	18957505	372	385	O
peptide	18957505	386	393	O
1	18957505	394	395	O
(	18957505	396	397	O
GLP-1	18957505	397	402	O
)	18957505	402	403	O
.	18957505	403	404	O

Consistent	18957505	405	415	O
with	18957505	416	420	O
this	18957505	421	425	O
mechanism	18957505	426	435	O
of	18957505	436	438	O
action	18957505	439	445	O
,	18957505	445	446	O
DPP-4	18957505	447	452	O
inhibitors	18957505	453	463	O
improve	18957505	464	471	O
glucose	18957505	472	479	O
tolerance	18957505	480	489	O
after	18957505	490	495	O
meals	18957505	496	501	O
by	18957505	502	504	O
increasing	18957505	505	515	O
insulin	18957505	516	523	O
and	18957505	524	527	O
reducing	18957505	528	536	O
glucagon	18957505	537	545	O
levels	18957505	546	552	O
in	18957505	553	555	O
the	18957505	556	559	O
plasma	18957505	560	566	O
.	18957505	566	567	O

However	18957505	568	575	O
,	18957505	575	576	O
DPP-4	18957505	577	582	O
inhibitors	18957505	583	593	O
also	18957505	594	598	O
reduce	18957505	599	605	O
fasting	18957505	606	613	O
blood	18957505	614	619	O
glucose	18957505	620	627	O
,	18957505	627	628	O
an	18957505	629	631	O
unexpected	18957505	632	642	O
effect	18957505	643	649	O
because	18957505	650	657	O
circulating	18957505	658	669	O
levels	18957505	670	676	O
of	18957505	677	679	O
active	18957505	680	686	O
GIP	18957505	687	690	O
and	18957505	691	694	O
GLP-1	18957505	695	700	O
are	18957505	701	704	O
low	18957505	705	708	O
in	18957505	709	711	O
the	18957505	712	715	O
postabsorptive	18957505	716	730	O
state	18957505	731	736	O
.	18957505	736	737	O

OBJECTIVE	18957505	739	748	O
:	18957505	749	750	O
The	18957505	751	754	O
objective	18957505	755	764	O
of	18957505	765	767	O
the	18957505	768	771	O
study	18957505	772	777	O
was	18957505	778	781	O
to	18957505	782	784	O
examine	18957505	785	792	O
the	18957505	793	796	O
effects	18957505	797	804	O
of	18957505	805	807	O
DPP-4	18957505	808	813	O
inhibition	18957505	814	824	O
on	18957505	825	827	O
fasting	18957505	828	835	O
islet	18957505	836	841	O
function	18957505	842	850	O
.	18957505	850	851	O

DESIGN	18957505	853	859	O
:	18957505	860	861	O
We	18957505	862	864	O
conducted	18957505	865	874	O
a	18957505	875	876	O
randomized	18957505	877	887	O
,	18957505	887	888	O
double-blind	18957505	889	901	O
,	18957505	901	902	O
placebo-controlled	18957505	903	921	O
trial	18957505	922	927	O
.	18957505	927	928	O

SETTING	18957505	930	937	O
:	18957505	938	939	O
The	18957505	940	943	O
study	18957505	944	949	O
was	18957505	950	953	O
performed	18957505	954	963	O
in	18957505	964	966	O
General	18957505	967	974	O
Clinical	18957505	975	983	O
Research	18957505	984	992	O
Centers	18957505	993	1000	O
at	18957505	1001	1003	O
two	18957505	1004	1007	O
University	18957505	1008	1018	O
Hospitals	18957505	1019	1028	O
.	18957505	1028	1029	O

SUBJECTS	18957505	1031	1039	O
:	18957505	1040	1041	O
Forty-one	18957505	1042	1051	O
subjects	18957505	1052	1060	O
with	18957505	1061	1065	O
T2DM	18957505	1066	1070	O
were	18957505	1071	1075	O
treated	18957505	1076	1083	O
with	18957505	1084	1088	O
metformin	18957505	1089	1098	O
or	18957505	1099	1101	O
diet	18957505	1102	1106	O
,	18957505	1106	1107	O
having	18957505	1108	1114	O
good	18957505	1115	1119	O
glycemic	18957505	1120	1128	O
control	18957505	1129	1136	O
with	18957505	1137	1141	O
glycosylated	18957505	1142	1154	O
hemoglobin	18957505	1155	1165	O
values	18957505	1166	1172	O
of	18957505	1173	1175	O
6.2	18957505	1176	1179	O
-	18957505	1179	1180	O
7.5	18957505	1180	1183	O
%	18957505	1183	1184	O
.	18957505	1184	1185	O

INTERVENTION	18957505	1187	1199	O
:	18957505	1200	1201	O
Subjects	18957505	1202	1210	O
were	18957505	1211	1215	O
treated	18957505	1216	1223	O
with	18957505	1224	1228	O
vildagliptin	18957505	1229	1241	O
(	18957505	1242	1243	O
50	18957505	1243	1245	O
mg	18957505	1246	1248	O
twice	18957505	1249	1254	O
daily	18957505	1255	1260	O
)	18957505	1260	1261	O
or	18957505	1262	1264	O
placebo	18957505	1265	1272	O
for	18957505	1273	1276	O
3	18957505	1277	1278	O
months	18957505	1279	1285	O
,	18957505	1285	1286	O
followed	18957505	1287	1295	O
by	18957505	1296	1298	O
a	18957505	1299	1300	O
2-wk	18957505	1301	1305	O
washout	18957505	1306	1313	O
.	18957505	1313	1314	O

Major	18957505	1315	1320	O
Outcome	18957505	1321	1328	O
Measure	18957505	1329	1336	O
:	18957505	1336	1337	O
We	18957505	1338	1340	O
measured	18957505	1341	1349	O
insulin	18957505	1350	1357	O
secretion	18957505	1358	1367	O
in	18957505	1368	1370	O
response	18957505	1371	1379	O
to	18957505	1380	1382	O
iv	18957505	1383	1385	O
glucose	18957505	1386	1393	O
and	18957505	1394	1397	O
arginine	18957505	1398	1406	O
before	18957505	1407	1413	O
and	18957505	1414	1417	O
after	18957505	1418	1423	O
treatment	18957505	1424	1433	O
and	18957505	1434	1437	O
after	18957505	1438	1443	O
drug	18957505	1444	1448	O
washout	18957505	1449	1456	O
.	18957505	1456	1457	O

RESULTS	18957505	1459	1466	O
:	18957505	1467	1468	O
There	18957505	1469	1474	O
were	18957505	1475	1479	O
small	18957505	1480	1485	O
and	18957505	1486	1489	O
comparable	18957505	1490	1500	O
reductions	18957505	1501	1511	O
in	18957505	1512	1514	O
glycosylated	18957505	1515	1527	B-Outcome
hemoglobin	18957505	1528	1538	I-Outcome
in	18957505	1539	1541	O
both	18957505	1542	1546	O
groups	18957505	1547	1553	O
over	18957505	1554	1558	O
3	18957505	1559	1560	O
months	18957505	1561	1567	O
.	18957505	1567	1568	O

Vildagliptin	18957505	1569	1581	O
increased	18957505	1582	1591	O
fasting	18957505	1592	1599	B-Outcome
GLP-1	18957505	1600	1605	I-Outcome
levels	18957505	1606	1612	I-Outcome
in	18957505	1613	1615	O
subjects	18957505	1616	1624	O
taking	18957505	1625	1631	O
metformin	18957505	1632	1641	O
,	18957505	1641	1642	O
but	18957505	1643	1646	O
not	18957505	1647	1650	O
those	18957505	1651	1656	O
managed	18957505	1657	1664	O
with	18957505	1665	1669	O
diet	18957505	1670	1674	O
,	18957505	1674	1675	O
and	18957505	1676	1679	O
raised	18957505	1680	1686	O
active	18957505	1687	1693	B-Outcome
GIP	18957505	1694	1697	I-Outcome
levels	18957505	1698	1704	I-Outcome
slightly	18957505	1705	1713	O
.	18957505	1713	1714	O

DPP-4	18957505	1715	1720	O
inhibitor	18957505	1721	1730	O
treatment	18957505	1731	1740	O
improved	18957505	1741	1749	O
the	18957505	1750	1753	O
acute	18957505	1754	1759	B-Outcome
insulin	18957505	1760	1767	I-Outcome
and	18957505	1768	1771	O
C-peptide	18957505	1772	1781	B-Outcome
responses	18957505	1782	1791	I-Outcome
to	18957505	1792	1794	I-Outcome
glucose	18957505	1795	1802	I-Outcome
(	18957505	1803	1804	O
50	18957505	1804	1806	O
and	18957505	1807	1810	O
100	18957505	1811	1814	O
%	18957505	1814	1815	O
respectively	18957505	1816	1828	O
;	18957505	1828	1829	O
P	18957505	1830	1831	O
<	18957505	1832	1833	O
0.05	18957505	1834	1838	O
)	18957505	1838	1839	O
and	18957505	1840	1843	O
increased	18957505	1844	1853	O
the	18957505	1854	1857	O
slope	18957505	1858	1863	B-Outcome
of	18957505	1864	1866	I-Outcome
the	18957505	1867	1870	I-Outcome
C-peptide	18957505	1871	1880	I-Outcome
response	18957505	1881	1889	I-Outcome
to	18957505	1890	1892	I-Outcome
glucose	18957505	1893	1900	I-Outcome
(	18957505	1901	1902	O
33	18957505	1902	1904	O
%	18957505	1904	1905	O
;	18957505	1905	1906	O
P	18957505	1907	1908	O
=	18957505	1909	1910	O
0.023	18957505	1911	1916	O
)	18957505	1916	1917	O
.	18957505	1917	1918	O

CONCLUSION	18957505	1920	1930	O
:	18957505	1931	1932	O
Vildagliptin	18957505	1933	1945	O
improves	18957505	1946	1954	O
islet	18957505	1955	1960	B-Outcome
function	18957505	1961	1969	I-Outcome
in	18957505	1970	1972	O
T2DM	18957505	1973	1977	O
under	18957505	1978	1983	O
fasting	18957505	1984	1991	O
conditions	18957505	1992	2002	O
.	18957505	2002	2003	O

This	18957505	2004	2008	O
suggests	18957505	2009	2017	O
that	18957505	2018	2022	O
DPP-4	18957505	2023	2028	O
inhibition	18957505	2029	2039	O
has	18957505	2040	2043	O
metabolic	18957505	2044	2053	O
benefits	18957505	2054	2062	O
in	18957505	2063	2065	O
addition	18957505	2066	2074	O
to	18957505	2075	2077	O
enhancing	18957505	2078	2087	O
meal-induced	18957505	2088	2100	O
GLP-1	18957505	2101	2106	O
and	18957505	2107	2110	O
GIP	18957505	2111	2114	O
activity	18957505	2115	2123	O
.	18957505	2123	2124	O


Comparison	18989547	0	10	O
between	18989547	11	18	O
intermittent	18989547	19	31	O
mandatory	18989547	32	41	O
ventilation	18989547	42	53	O
and	18989547	54	57	O
synchronized	18989547	58	70	O
intermittent	18989547	71	83	O
mandatory	18989547	84	93	O
ventilation	18989547	94	105	O
with	18989547	106	110	O
pressure	18989547	111	119	O
support	18989547	120	127	O
in	18989547	128	130	O
children	18989547	131	139	O
.	18989547	139	140	O

OBJECTIVE	18989547	142	151	O
:	18989547	152	153	O
To	18989547	154	156	O
compare	18989547	157	164	O
intermittent	18989547	165	177	O
mandatory	18989547	178	187	O
ventilation	18989547	188	199	O
(	18989547	200	201	O
IMV	18989547	201	204	O
)	18989547	204	205	O
with	18989547	206	210	O
synchronized	18989547	211	223	O
intermittent	18989547	224	236	O
mandatory	18989547	237	246	O
ventilation	18989547	247	258	O
plus	18989547	259	263	O
pressure	18989547	264	272	O
support	18989547	273	280	O
(	18989547	281	282	O
SIMV+PS	18989547	282	289	O
)	18989547	289	290	O
in	18989547	291	293	O
terms	18989547	294	299	O
of	18989547	300	302	O
time	18989547	303	307	O
on	18989547	308	310	O
mechanical	18989547	311	321	O
ventilation	18989547	322	333	O
,	18989547	333	334	O
duration	18989547	335	343	O
of	18989547	344	346	O
weaning	18989547	347	354	O
and	18989547	355	358	O
length	18989547	359	365	O
of	18989547	366	368	O
stay	18989547	369	373	O
in	18989547	374	376	O
a	18989547	377	378	O
pediatric	18989547	379	388	O
intensive	18989547	389	398	O
care	18989547	399	403	O
unit	18989547	404	408	O
(	18989547	409	410	O
PICU	18989547	410	414	O
)	18989547	414	415	O
.	18989547	415	416	O

METHODS	18989547	418	425	O
:	18989547	426	427	O
This	18989547	428	432	O
was	18989547	433	436	O
a	18989547	437	438	O
randomized	18989547	439	449	O
clinical	18989547	450	458	O
trial	18989547	459	464	O
that	18989547	465	469	O
enrolled	18989547	470	478	O
children	18989547	479	487	O
aged	18989547	488	492	O
28	18989547	493	495	O
days	18989547	496	500	O
to	18989547	501	503	O
4	18989547	504	505	O
years	18989547	506	511	O
who	18989547	512	515	O
were	18989547	516	520	O
admitted	18989547	521	529	O
to	18989547	530	532	O
a	18989547	533	534	O
PICU	18989547	535	539	O
between	18989547	540	547	O
October	18989547	548	555	O
of	18989547	556	558	O
2005	18989547	559	563	O
and	18989547	564	567	O
June	18989547	568	572	O
of	18989547	573	575	O
2007	18989547	576	580	O
and	18989547	581	584	O
put	18989547	585	588	O
on	18989547	589	591	O
mechanical	18989547	592	602	O
ventilation	18989547	603	614	O
(	18989547	615	616	O
MV	18989547	616	618	O
)	18989547	618	619	O
for	18989547	620	623	O
more	18989547	624	628	O
than	18989547	629	633	O
48	18989547	634	636	O
hours	18989547	637	642	O
.	18989547	642	643	O

These	18989547	644	649	O
patients	18989547	650	658	O
were	18989547	659	663	O
allocated	18989547	664	673	O
to	18989547	674	676	O
one	18989547	677	680	O
of	18989547	681	683	O
two	18989547	684	687	O
groups	18989547	688	694	O
by	18989547	695	697	O
drawing	18989547	698	705	O
lots	18989547	706	710	O
:	18989547	710	711	O
IMV	18989547	712	715	O
group	18989547	716	721	O
(	18989547	722	723	O
IMVG	18989547	723	727	O
;	18989547	727	728	O
n	18989547	729	730	O
=	18989547	731	732	O
35	18989547	733	735	O
)	18989547	735	736	O
and	18989547	737	740	O
SIMV+PS	18989547	741	748	O
group	18989547	749	754	O
(	18989547	755	756	O
SIMVG	18989547	756	761	O
;	18989547	761	762	O
n	18989547	763	764	O
=	18989547	765	766	O
35	18989547	767	769	O
)	18989547	769	770	O
.	18989547	770	771	O

Children	18989547	772	780	O
were	18989547	781	785	O
excluded	18989547	786	794	O
if	18989547	795	797	O
they	18989547	798	802	O
had	18989547	803	806	O
undergone	18989547	807	816	O
tracheotomy	18989547	817	828	O
or	18989547	829	831	O
had	18989547	832	835	O
chronic	18989547	836	843	O
respiratory	18989547	844	855	O
diseases	18989547	856	864	O
.	18989547	864	865	O

Data	18989547	866	870	O
on	18989547	871	873	O
oxygenation	18989547	874	885	O
and	18989547	886	889	O
ventilation	18989547	890	901	O
were	18989547	902	906	O
recorded	18989547	907	915	O
at	18989547	916	918	O
admission	18989547	919	928	O
and	18989547	929	932	O
at	18989547	933	935	O
the	18989547	936	939	O
start	18989547	940	945	O
of	18989547	946	948	O
weaning	18989547	949	956	O
.	18989547	956	957	O

RESULTS	18989547	959	966	O
:	18989547	967	968	O
There	18989547	969	974	O
were	18989547	975	979	O
no	18989547	980	982	O
statistical	18989547	983	994	O
differences	18989547	995	1006	O
between	18989547	1007	1014	O
the	18989547	1015	1018	O
groups	18989547	1019	1025	O
in	18989547	1026	1028	O
terms	18989547	1029	1034	O
of	18989547	1035	1037	O
age	18989547	1038	1041	O
,	18989547	1041	1042	O
sex	18989547	1043	1046	O
,	18989547	1046	1047	O
indication	18989547	1048	1058	O
for	18989547	1059	1062	O
MV	18989547	1063	1065	O
,	18989547	1065	1066	O
PRISM	18989547	1067	1072	O
score	18989547	1073	1078	O
,	18989547	1078	1079	O
Comfort	18989547	1080	1087	O
scale	18989547	1088	1093	O
,	18989547	1093	1094	O
use	18989547	1095	1098	O
of	18989547	1099	1101	O
sedatives	18989547	1102	1111	O
or	18989547	1112	1114	O
ventilation	18989547	1115	1126	O
and	18989547	1127	1130	O
oxygenation	18989547	1131	1142	O
parameters	18989547	1143	1153	O
.	18989547	1153	1154	O

The	18989547	1155	1158	O
median	18989547	1159	1165	B-Outcome
time	18989547	1166	1170	I-Outcome
on	18989547	1171	1173	I-Outcome
MV	18989547	1174	1176	I-Outcome
was	18989547	1177	1180	O
5	18989547	1181	1182	O
days	18989547	1183	1187	O
for	18989547	1188	1191	O
both	18989547	1192	1196	O
groups	18989547	1197	1203	O
(	18989547	1204	1205	O
p	18989547	1205	1206	O
=	18989547	1207	1208	O
0.120	18989547	1209	1214	O
)	18989547	1214	1215	O
.	18989547	1215	1216	O

There	18989547	1217	1222	O
were	18989547	1223	1227	O
also	18989547	1228	1232	O
no	18989547	1233	1235	O
statistical	18989547	1236	1247	O
differences	18989547	1248	1259	O
between	18989547	1260	1267	O
the	18989547	1268	1271	O
two	18989547	1272	1275	O
groups	18989547	1276	1282	O
for	18989547	1283	1286	O
duration	18989547	1287	1295	B-Outcome
of	18989547	1296	1298	I-Outcome
weaning	18989547	1299	1306	I-Outcome
[	18989547	1307	1308	O
IMVG	18989547	1308	1312	O
:	18989547	1312	1313	O
1	18989547	1314	1315	O
day	18989547	1316	1319	O
(	18989547	1320	1321	O
1	18989547	1321	1322	O
-	18989547	1322	1323	O
6	18989547	1323	1324	O
)	18989547	1324	1325	O
vs.	18989547	1326	1329	O
SIMVG	18989547	1330	1335	O
:	18989547	1335	1336	O
1	18989547	1337	1338	O
day	18989547	1339	1342	O
(	18989547	1343	1344	O
1	18989547	1344	1345	O
-	18989547	1345	1346	O
6	18989547	1346	1347	O
)	18989547	1347	1348	O
;	18989547	1348	1349	O
p	18989547	1350	1351	O
=	18989547	1352	1353	O
0.262	18989547	1354	1359	O
]	18989547	1359	1360	O
or	18989547	1361	1363	O
length	18989547	1364	1370	B-Outcome
of	18989547	1371	1373	I-Outcome
hospital	18989547	1374	1382	I-Outcome
stay	18989547	1383	1387	I-Outcome
[	18989547	1388	1389	O
IMVG	18989547	1389	1393	O
:	18989547	1393	1394	O
8	18989547	1395	1396	O
days	18989547	1397	1401	O
(	18989547	1402	1403	O
2	18989547	1403	1404	O
-	18989547	1404	1405	O
22	18989547	1405	1407	O
)	18989547	1407	1408	O
vs.	18989547	1409	1412	O
SIMVG	18989547	1413	1418	O
:	18989547	1418	1419	O
6	18989547	1420	1421	O
days	18989547	1422	1426	O
(	18989547	1427	1428	O
3	18989547	1428	1429	O
-	18989547	1429	1430	O
20	18989547	1430	1432	O
)	18989547	1432	1433	O
;	18989547	1433	1434	O
p	18989547	1435	1436	O
=	18989547	1437	1438	O
0.113	18989547	1439	1444	O
]	18989547	1444	1445	O
.	18989547	1445	1446	O

CONCLUSION	18989547	1448	1458	O
:	18989547	1459	1460	O
Among	18989547	1461	1466	O
the	18989547	1467	1470	O
children	18989547	1471	1479	O
studied	18989547	1480	1487	O
here	18989547	1488	1492	O
,	18989547	1492	1493	O
there	18989547	1494	1499	O
was	18989547	1500	1503	O
no	18989547	1504	1506	O
statistically	18989547	1507	1520	O
significant	18989547	1521	1532	O
difference	18989547	1533	1543	O
between	18989547	1544	1551	O
IMV	18989547	1552	1555	O
and	18989547	1556	1559	O
SIMV+PS	18989547	1560	1567	O
in	18989547	1568	1570	O
terms	18989547	1571	1576	O
of	18989547	1577	1579	O
time	18989547	1580	1584	B-Outcome
on	18989547	1585	1587	I-Outcome
MV	18989547	1588	1590	I-Outcome
,	18989547	1590	1591	O
duration	18989547	1592	1600	B-Outcome
of	18989547	1601	1603	I-Outcome
weaning	18989547	1604	1611	I-Outcome
or	18989547	1612	1614	O
time	18989547	1615	1619	B-Outcome
spent	18989547	1620	1625	I-Outcome
in	18989547	1626	1628	I-Outcome
the	18989547	1629	1632	I-Outcome
PICU	18989547	1633	1637	I-Outcome
.	18989547	1637	1638	O

ClinicalTrials.govID	18989547	1639	1659	O
:	18989547	1659	1660	O
NCT00549809	18989547	1661	1672	O
.	18989547	1672	1673	O


Three-year	19081412	0	10	O
clinical	19081412	11	19	O
outcome	19081412	20	27	O
after	19081412	28	33	O
primary	19081412	34	41	O
stenting	19081412	42	50	O
of	19081412	51	53	O
totally	19081412	54	61	O
occluded	19081412	62	70	O
native	19081412	71	77	O
coronary	19081412	78	86	O
arteries	19081412	87	95	O
:	19081412	95	96	O
a	19081412	97	98	O
randomized	19081412	99	109	O
comparison	19081412	110	120	O
of	19081412	121	123	O
bare-metal	19081412	124	134	O
stent	19081412	135	140	O
implantation	19081412	141	153	O
with	19081412	154	158	O
sirolimus-eluting	19081412	159	176	O
stent	19081412	177	182	O
implantation	19081412	183	195	O
for	19081412	196	199	O
the	19081412	200	203	O
treatment	19081412	204	213	O
of	19081412	214	216	O
total	19081412	217	222	O
coronary	19081412	223	231	O
occlusions	19081412	232	242	O
(	19081412	243	244	O
Primary	19081412	244	251	O
Stenting	19081412	252	260	O
of	19081412	261	263	O
Totally	19081412	264	271	O
Occluded	19081412	272	280	O
Native	19081412	281	287	O
Coronary	19081412	288	296	O
Arteries	19081412	297	305	O
[	19081412	306	307	O
PRISON	19081412	307	313	O
]	19081412	313	314	O
II	19081412	315	317	O
study	19081412	318	323	O
)	19081412	323	324	O
.	19081412	324	325	O

BACKGROUND	19081412	327	337	O
:	19081412	338	339	O
The	19081412	340	343	O
purpose	19081412	344	351	O
of	19081412	352	354	O
this	19081412	355	359	O
study	19081412	360	365	O
was	19081412	366	369	O
to	19081412	370	372	O
examine	19081412	373	380	O
the	19081412	381	384	O
3-year	19081412	385	391	O
clinical	19081412	392	400	O
outcome	19081412	401	408	O
in	19081412	409	411	O
patients	19081412	412	420	O
enrolled	19081412	421	429	O
in	19081412	430	432	O
the	19081412	433	436	O
Primary	19081412	437	444	O
Stenting	19081412	445	453	O
of	19081412	454	456	O
Totally	19081412	457	464	O
Occluded	19081412	465	473	O
Native	19081412	474	480	O
Coronary	19081412	481	489	O
Arteries	19081412	490	498	O
II	19081412	499	501	O
study	19081412	502	507	O
.	19081412	507	508	O

METHODS	19081412	510	517	O
:	19081412	518	519	O
Patients	19081412	520	528	O
with	19081412	529	533	O
totally	19081412	534	541	O
occluded	19081412	542	550	O
coronary	19081412	551	559	O
arteries	19081412	560	568	O
randomized	19081412	569	579	O
to	19081412	580	582	O
either	19081412	583	589	O
sirolimus-eluting	19081412	590	607	O
Cypher	19081412	608	614	O
stents	19081412	615	621	O
(	19081412	622	623	O
SESs	19081412	623	627	O
)	19081412	627	628	O
(	19081412	629	630	O
Cordis	19081412	630	636	O
,	19081412	636	637	O
a	19081412	638	639	O
Johnson	19081412	640	647	O
&	19081412	648	649	O
Joshson	19081412	650	657	O
Company	19081412	658	665	O
,	19081412	665	666	O
Miami	19081412	667	672	O
Lakes	19081412	673	678	O
,	19081412	678	679	O
FL	19081412	680	682	O
)	19081412	682	683	O
(	19081412	684	685	O
100	19081412	685	688	O
patients	19081412	689	697	O
)	19081412	697	698	O
or	19081412	699	701	O
bare-metal	19081412	702	712	O
BxVelocity	19081412	713	723	O
stents	19081412	724	730	O
(	19081412	731	732	O
BMSs	19081412	732	736	O
)	19081412	736	737	O
(	19081412	738	739	O
Cordis	19081412	739	745	O
)	19081412	745	746	O
(	19081412	747	748	O
100	19081412	748	751	O
patients	19081412	752	760	O
)	19081412	760	761	O
were	19081412	762	766	O
followed	19081412	767	775	O
clinically	19081412	776	786	O
for	19081412	787	790	O
3	19081412	791	792	O
years	19081412	793	798	O
.	19081412	798	799	O

RESULTS	19081412	801	808	O
:	19081412	809	810	O
Between	19081412	811	818	O
1	19081412	819	820	O
and	19081412	821	824	O
3	19081412	825	826	O
years	19081412	827	832	O
,	19081412	832	833	O
there	19081412	834	839	O
were	19081412	840	844	O
infrequent	19081412	845	855	O
additional	19081412	856	866	O
clinical	19081412	867	875	O
events	19081412	876	882	O
that	19081412	883	887	O
were	19081412	888	892	O
equally	19081412	893	900	O
distributed	19081412	901	912	O
between	19081412	913	920	O
the	19081412	921	924	O
SES	19081412	925	928	O
and	19081412	929	932	O
the	19081412	933	936	O
BMS	19081412	937	940	O
group	19081412	941	946	O
.	19081412	946	947	O

After	19081412	948	953	O
3	19081412	954	955	O
years	19081412	956	961	O
,	19081412	961	962	O
target	19081412	963	969	B-Outcome
lesion	19081412	970	976	I-Outcome
revascularization	19081412	977	994	I-Outcome
was	19081412	995	998	O
7	19081412	999	1000	O
%	19081412	1000	1001	O
in	19081412	1002	1004	O
the	19081412	1005	1008	O
SES	19081412	1009	1012	O
group	19081412	1013	1018	O
versus	19081412	1019	1025	O
27	19081412	1026	1028	O
%	19081412	1028	1029	O
in	19081412	1030	1032	O
the	19081412	1033	1036	O
BMS	19081412	1037	1040	O
group	19081412	1041	1046	O
(	19081412	1047	1048	O
P	19081412	1048	1049	O
<	19081412	1050	1051	O
.001	19081412	1052	1056	O
)	19081412	1056	1057	O
;	19081412	1057	1058	O
and	19081412	1059	1062	O
target	19081412	1063	1069	B-Outcome
vessel	19081412	1070	1076	I-Outcome
revascularization	19081412	1077	1094	I-Outcome
was	19081412	1095	1098	O
seen	19081412	1099	1103	O
in	19081412	1104	1106	O
11	19081412	1107	1109	O
%	19081412	1109	1110	O
in	19081412	1111	1113	O
the	19081412	1114	1117	O
SES	19081412	1118	1121	O
group	19081412	1122	1127	O
versus	19081412	1128	1134	O
30	19081412	1135	1137	O
%	19081412	1137	1138	O
in	19081412	1139	1141	O
the	19081412	1142	1145	O
BMS	19081412	1146	1149	O
group	19081412	1150	1155	O
(	19081412	1156	1157	O
P	19081412	1157	1158	O
=	19081412	1159	1160	O
.002	19081412	1161	1165	O
)	19081412	1165	1166	O
.	19081412	1166	1167	O

Major	19081412	1168	1173	B-Outcome
adverse	19081412	1174	1181	I-Outcome
cardiac	19081412	1182	1189	I-Outcome
events	19081412	1190	1196	I-Outcome
were	19081412	1197	1201	O
noted	19081412	1202	1207	O
in	19081412	1208	1210	O
10	19081412	1211	1213	O
%	19081412	1213	1214	O
of	19081412	1215	1217	O
the	19081412	1218	1221	O
SES	19081412	1222	1225	O
group	19081412	1226	1231	O
versus	19081412	1232	1238	O
34	19081412	1239	1241	O
%	19081412	1241	1242	O
in	19081412	1243	1245	O
the	19081412	1246	1249	O
BMS	19081412	1250	1253	O
group	19081412	1254	1259	O
(	19081412	1260	1261	O
P	19081412	1261	1262	O
<	19081412	1263	1264	O
.001	19081412	1265	1269	O
)	19081412	1269	1270	O
.	19081412	1270	1271	O

There	19081412	1272	1277	O
were	19081412	1278	1282	O
no	19081412	1283	1285	O
statistically	19081412	1286	1299	O
significant	19081412	1300	1311	O
differences	19081412	1312	1323	O
in	19081412	1324	1326	O
death	19081412	1327	1332	B-Outcome
,	19081412	1332	1333	O
myocardial	19081412	1334	1344	B-Outcome
infarction	19081412	1345	1355	I-Outcome
,	19081412	1355	1356	O
and	19081412	1357	1360	O
stent	19081412	1361	1366	B-Outcome
thrombosis	19081412	1367	1377	I-Outcome
according	19081412	1378	1387	O
to	19081412	1388	1390	O
the	19081412	1391	1394	O
Academic	19081412	1395	1403	B-Outcome
Research	19081412	1404	1412	I-Outcome
Consortium	19081412	1413	1423	I-Outcome
criteria	19081412	1424	1432	I-Outcome
between	19081412	1433	1440	O
the	19081412	1441	1444	O
2	19081412	1445	1446	O
groups	19081412	1447	1453	O
.	19081412	1453	1454	O

CONCLUSIONS	19081412	1456	1467	O
:	19081412	1468	1469	O
Clinical	19081412	1470	1478	O
outcome	19081412	1479	1486	O
up	19081412	1487	1489	O
to	19081412	1490	1492	O
3	19081412	1493	1494	O
years	19081412	1495	1500	O
after	19081412	1501	1506	O
implantation	19081412	1507	1519	O
of	19081412	1520	1522	O
SESs	19081412	1523	1527	O
for	19081412	1528	1531	O
total	19081412	1532	1537	O
coronary	19081412	1538	1546	O
occlusions	19081412	1547	1557	O
continues	19081412	1558	1567	O
to	19081412	1568	1570	O
demonstrate	19081412	1571	1582	O
a	19081412	1583	1584	O
significant	19081412	1585	1596	O
reduction	19081412	1597	1606	O
in	19081412	1607	1609	O
adverse	19081412	1610	1617	B-Outcome
clinical	19081412	1618	1626	I-Outcome
events	19081412	1627	1633	I-Outcome
compared	19081412	1634	1642	O
with	19081412	1643	1647	O
BMSs	19081412	1648	1652	O
without	19081412	1653	1660	O
the	19081412	1661	1664	O
evidence	19081412	1665	1673	O
for	19081412	1674	1677	O
either	19081412	1678	1684	O
disproportionate	19081412	1685	1701	O
late	19081412	1702	1706	O
restenosis	19081412	1707	1717	B-Outcome
or	19081412	1718	1720	O
late	19081412	1721	1725	O
stent	19081412	1726	1731	B-Outcome
thrombosis	19081412	1732	1742	I-Outcome
.	19081412	1742	1743	O


Financial	19111789	0	9	O
and	19111789	10	13	O
quality-of-life	19111789	14	29	O
burden	19111789	30	36	O
of	19111789	37	39	O
dysfunctional	19111789	40	53	O
uterine	19111789	54	61	O
bleeding	19111789	62	70	O
among	19111789	71	76	O
women	19111789	77	82	O
agreeing	19111789	83	91	O
to	19111789	92	94	O
obtain	19111789	95	101	O
surgical	19111789	102	110	O
treatment	19111789	111	120	O
.	19111789	120	121	O

PURPOSE	19111789	123	130	O
:	19111789	131	132	O
In	19111789	133	135	O
this	19111789	136	140	O
study	19111789	141	146	O
,	19111789	146	147	O
we	19111789	148	150	O
sought	19111789	151	157	O
to	19111789	158	160	O
1	19111789	161	162	O
)	19111789	162	163	O
describe	19111789	164	172	O
elements	19111789	173	181	O
of	19111789	182	184	O
the	19111789	185	188	O
financial	19111789	189	198	O
and	19111789	199	202	O
quality-of-life	19111789	203	218	O
burden	19111789	219	225	O
of	19111789	226	228	O
dysfunctional	19111789	229	242	O
uterine	19111789	243	250	O
bleeding	19111789	251	259	O
(	19111789	260	261	O
DUB	19111789	261	264	O
)	19111789	264	265	O
from	19111789	266	270	O
the	19111789	271	274	O
perspective	19111789	275	286	O
of	19111789	287	289	O
women	19111789	290	295	O
who	19111789	296	299	O
agreed	19111789	300	306	O
to	19111789	307	309	O
obtain	19111789	310	316	O
surgical	19111789	317	325	O
treatment	19111789	326	335	O
;	19111789	335	336	O
2	19111789	337	338	O
)	19111789	338	339	O
explore	19111789	340	347	O
associations	19111789	348	360	O
between	19111789	361	368	O
DUB	19111789	369	372	O
symptom	19111789	373	380	O
characteristics	19111789	381	396	O
and	19111789	397	400	O
the	19111789	401	404	O
financial	19111789	405	414	O
and	19111789	415	418	O
quality-of-life	19111789	419	434	O
burden	19111789	435	441	O
;	19111789	441	442	O
3	19111789	443	444	O
)	19111789	444	445	O
estimate	19111789	446	454	O
the	19111789	455	458	O
annual	19111789	459	465	O
dollar	19111789	466	472	O
value	19111789	473	478	O
of	19111789	479	481	O
the	19111789	482	485	O
financial	19111789	486	495	O
burden	19111789	496	502	O
;	19111789	502	503	O
and	19111789	504	507	O
4	19111789	508	509	O
)	19111789	509	510	O
estimate	19111789	511	519	O
the	19111789	520	523	O
most	19111789	524	528	O
that	19111789	529	533	O
could	19111789	534	539	O
be	19111789	540	542	O
spent	19111789	543	548	O
on	19111789	549	551	O
surgery	19111789	552	559	O
to	19111789	560	562	O
eliminate	19111789	563	572	O
DUB	19111789	573	576	O
symptoms	19111789	577	585	O
for	19111789	586	589	O
which	19111789	590	595	O
medical	19111789	596	603	O
treatment	19111789	604	613	O
has	19111789	614	617	O
been	19111789	618	622	O
unsuccessful	19111789	623	635	O
that	19111789	636	640	O
would	19111789	641	646	O
result	19111789	647	653	O
in	19111789	654	656	O
a	19111789	657	658	O
$	19111789	659	660	O
50,000/quality-adjusted	19111789	660	683	O
life-year	19111789	684	693	O
incremental	19111789	694	705	O
cost-effectiveness	19111789	706	724	O
ratio	19111789	725	730	O
.	19111789	730	731	O

METHODS	19111789	733	740	O
:	19111789	741	742	O
We	19111789	743	745	O
collected	19111789	746	755	O
baseline	19111789	756	764	O
data	19111789	765	769	O
on	19111789	770	772	O
DUB	19111789	773	776	O
symptoms	19111789	777	785	O
and	19111789	786	789	O
aspects	19111789	790	797	O
of	19111789	798	800	O
the	19111789	801	804	O
financial	19111789	805	814	O
and	19111789	815	818	O
quality-of-life	19111789	819	834	O
burden	19111789	835	841	O
for	19111789	842	845	O
237	19111789	846	849	O
women	19111789	850	855	O
agreeing	19111789	856	864	O
to	19111789	865	867	O
surgery	19111789	868	875	O
for	19111789	876	879	O
DUB	19111789	880	883	O
in	19111789	884	886	O
a	19111789	887	888	O
randomized	19111789	889	899	O
trial	19111789	900	905	O
comparing	19111789	906	915	O
hysterectomy	19111789	916	928	O
with	19111789	929	933	O
endometrial	19111789	934	945	O
ablation	19111789	946	954	O
.	19111789	954	955	O

Measures	19111789	956	964	O
included	19111789	965	973	O
out-of-pocket	19111789	974	987	O
pharmaceutical	19111789	988	1002	O
expenditures	19111789	1003	1015	O
,	19111789	1015	1016	O
excess	19111789	1017	1023	O
expenditures	19111789	1024	1036	O
on	19111789	1037	1039	O
pads	19111789	1040	1044	O
or	19111789	1045	1047	O
tampons	19111789	1048	1055	O
,	19111789	1055	1056	O
the	19111789	1057	1060	O
value	19111789	1061	1066	O
of	19111789	1067	1069	O
time	19111789	1070	1074	O
missed	19111789	1075	1081	O
from	19111789	1082	1086	O
paid	19111789	1087	1091	O
work	19111789	1092	1096	O
and	19111789	1097	1100	O
home	19111789	1101	1105	O
management	19111789	1106	1116	O
activities	19111789	1117	1127	O
,	19111789	1127	1128	O
and	19111789	1129	1132	O
health	19111789	1133	1139	O
utility	19111789	1140	1147	O
.	19111789	1147	1148	O

We	19111789	1149	1151	O
used	19111789	1152	1156	O
chi2	19111789	1157	1161	O
and	19111789	1162	1165	O
t	19111789	1166	1167	O
tests	19111789	1168	1173	O
to	19111789	1174	1176	O
assess	19111789	1177	1183	O
the	19111789	1184	1187	O
statistical	19111789	1188	1199	O
significance	19111789	1200	1212	O
of	19111789	1213	1215	O
associations	19111789	1216	1228	O
between	19111789	1229	1236	O
DUB	19111789	1237	1240	O
characteristics	19111789	1241	1256	O
and	19111789	1257	1260	O
the	19111789	1261	1264	O
financial	19111789	1265	1274	O
and	19111789	1275	1278	O
quality-of-life	19111789	1279	1294	O
burden	19111789	1295	1301	O
.	19111789	1301	1302	O

The	19111789	1303	1306	O
annual	19111789	1307	1313	O
financial	19111789	1314	1323	O
burden	19111789	1324	1330	O
was	19111789	1331	1334	O
estimated	19111789	1335	1344	O
.	19111789	1344	1345	O

RESULTS	19111789	1347	1354	O
:	19111789	1355	1356	O
Pelvic	19111789	1357	1363	O
pain	19111789	1364	1368	O
and	19111789	1369	1372	O
cramps	19111789	1373	1379	O
were	19111789	1380	1384	O
associated	19111789	1385	1395	O
with	19111789	1396	1400	O
activity	19111789	1401	1409	B-Outcome
limitations	19111789	1410	1421	I-Outcome
and	19111789	1422	1425	O
tiredness	19111789	1426	1435	B-Outcome
was	19111789	1436	1439	O
associated	19111789	1440	1450	O
with	19111789	1451	1455	O
a	19111789	1456	1457	O
lower	19111789	1458	1463	O
health	19111789	1464	1470	B-Outcome
utility	19111789	1471	1478	I-Outcome
.	19111789	1478	1479	O

Excess	19111789	1480	1486	B-Outcome
pharmaceutical	19111789	1487	1501	I-Outcome
and	19111789	1502	1505	O
pad	19111789	1506	1509	B-Outcome
and	19111789	1510	1513	O
tampon	19111789	1514	1520	B-Outcome
costs	19111789	1521	1526	I-Outcome
were	19111789	1527	1531	O
$	19111789	1532	1533	O
333	19111789	1533	1536	O
per	19111789	1537	1540	O
patient	19111789	1541	1548	O
per	19111789	1549	1552	O
year	19111789	1553	1557	O
(	19111789	1558	1559	O
95	19111789	1559	1561	O
%	19111789	1561	1562	O
confidence	19111789	1563	1573	O
interval	19111789	1574	1582	O
[	19111789	1583	1584	O
CI	19111789	1584	1586	O
]	19111789	1586	1587	O
,	19111789	1587	1588	O
$	19111789	1589	1590	O
263-$403	19111789	1590	1598	O
)	19111789	1598	1599	O
.	19111789	1599	1600	O

Excess	19111789	1601	1607	B-Outcome
paid	19111789	1608	1612	I-Outcome
work	19111789	1613	1617	I-Outcome
and	19111789	1618	1621	O
home	19111789	1622	1626	B-Outcome
management	19111789	1627	1637	I-Outcome
loss	19111789	1638	1642	I-Outcome
costs	19111789	1643	1648	I-Outcome
were	19111789	1649	1653	O
$	19111789	1654	1655	O
2,291	19111789	1655	1660	O
per	19111789	1661	1664	O
patient	19111789	1665	1672	O
per	19111789	1673	1676	O
year	19111789	1677	1681	O
(	19111789	1682	1683	O
95	19111789	1683	1685	O
%	19111789	1685	1686	O
CI	19111789	1687	1689	O
,	19111789	1689	1690	O
$	19111789	1691	1692	O
1847-$2752	19111789	1692	1702	O
)	19111789	1702	1703	O
.	19111789	1703	1704	O

Effective	19111789	1705	1714	O
surgical	19111789	1715	1723	O
treatment	19111789	1724	1733	O
costing	19111789	1734	1741	O
$	19111789	1742	1743	O
40,000	19111789	1743	1749	O
would	19111789	1750	1755	O
be	19111789	1756	1758	O
cost-effective	19111789	1759	1773	B-Outcome
compared	19111789	1774	1782	O
with	19111789	1783	1787	O
unsuccessful	19111789	1788	1800	O
medical	19111789	1801	1808	O
treatment	19111789	1809	1818	O
.	19111789	1818	1819	O

CONCLUSION	19111789	1821	1831	O
:	19111789	1832	1833	O
The	19111789	1834	1837	O
financial	19111789	1838	1847	B-Outcome
and	19111789	1848	1851	O
quality-of-life	19111789	1852	1867	B-Outcome
effects	19111789	1868	1875	I-Outcome
of	19111789	1876	1878	I-Outcome
DUB	19111789	1879	1882	I-Outcome
represent	19111789	1883	1892	O
a	19111789	1893	1894	O
substantial	19111789	1895	1906	O
burden	19111789	1907	1913	O
.	19111789	1913	1914	O


Effect	19144729	0	6	O
of	19144729	7	9	O
testosterone	19144729	10	22	O
and	19144729	23	26	O
a	19144729	27	28	O
nutritional	19144729	29	40	O
supplement	19144729	41	51	O
,	19144729	51	52	O
alone	19144729	53	58	O
and	19144729	59	62	O
in	19144729	63	65	O
combination	19144729	66	77	O
,	19144729	77	78	O
on	19144729	79	81	O
hospital	19144729	82	90	O
admissions	19144729	91	101	O
in	19144729	102	104	O
undernourished	19144729	105	119	O
older	19144729	120	125	O
men	19144729	126	129	O
and	19144729	130	133	O
women	19144729	134	139	O
.	19144729	139	140	O

BACKGROUND	19144729	142	152	O
:	19144729	153	154	O
In	19144729	155	157	O
older	19144729	158	163	O
people	19144729	164	170	O
,	19144729	170	171	O
undernutrition	19144729	172	186	O
is	19144729	187	189	O
associated	19144729	190	200	O
with	19144729	201	205	O
increased	19144729	206	215	O
hospitalization	19144729	216	231	O
rates	19144729	232	237	O
and	19144729	238	241	O
mortality	19144729	242	251	O
.	19144729	251	252	O

Because	19144729	253	260	O
weight	19144729	261	267	O
loss	19144729	268	272	O
in	19144729	273	275	O
older	19144729	276	281	O
people	19144729	282	288	O
often	19144729	289	294	O
reflects	19144729	295	303	O
a	19144729	304	305	O
disproportionate	19144729	306	322	O
reduction	19144729	323	332	O
of	19144729	333	335	O
skeletal	19144729	336	344	O
muscle	19144729	345	351	O
,	19144729	351	352	O
anabolic	19144729	353	361	O
treatments	19144729	362	372	O
may	19144729	373	376	O
be	19144729	377	379	O
beneficial	19144729	380	390	O
.	19144729	390	391	O

OBJECTIVE	19144729	393	402	O
:	19144729	403	404	O
Our	19144729	405	408	O
aim	19144729	409	412	O
was	19144729	413	416	O
to	19144729	417	419	O
evaluate	19144729	420	428	O
the	19144729	429	432	O
hypothesis	19144729	433	443	O
that	19144729	444	448	O
testosterone	19144729	449	461	O
treatment	19144729	462	471	O
and	19144729	472	475	O
a	19144729	476	477	O
nutritional	19144729	478	489	O
supplement	19144729	490	500	O
have	19144729	501	505	O
additive	19144729	506	514	O
benefits	19144729	515	523	O
.	19144729	523	524	O

DESIGN	19144729	526	532	O
:	19144729	533	534	O
Oral	19144729	535	539	O
testosterone	19144729	540	552	O
undecanoate	19144729	553	564	O
(	19144729	565	566	O
40	19144729	566	568	O
mg	19144729	569	571	O
daily	19144729	572	577	O
for	19144729	578	581	O
women	19144729	582	587	O
,	19144729	587	588	O
80	19144729	589	591	O
mg	19144729	592	594	O
twice	19144729	595	600	O
daily	19144729	601	606	O
for	19144729	607	610	O
men	19144729	611	614	O
)	19144729	614	615	O
and	19144729	616	619	O
an	19144729	620	622	O
oral	19144729	623	627	O
nutritional	19144729	628	639	O
supplement	19144729	640	650	O
(	19144729	651	652	O
475	19144729	652	655	O
kcal/d	19144729	656	662	O
)	19144729	662	663	O
were	19144729	664	668	O
administered	19144729	669	681	O
,	19144729	681	682	O
alone	19144729	683	688	O
or	19144729	689	691	O
combined	19144729	692	700	O
,	19144729	700	701	O
for	19144729	702	705	O
1	19144729	706	707	O
y	19144729	708	709	O
to	19144729	710	712	O
49	19144729	713	715	O
community-dwelling	19144729	716	734	O
,	19144729	734	735	O
undernourished	19144729	736	750	O
people	19144729	751	757	O
[	19144729	758	759	O
Mini	19144729	759	763	O
Nutritional	19144729	764	775	O
Assessment	19144729	776	786	O
score	19144729	787	792	O
<	19144729	793	794	O
24	19144729	794	796	O
and	19144729	797	800	O
low	19144729	801	804	O
body	19144729	805	809	O
weight	19144729	810	816	O
(	19144729	817	818	O
body	19144729	818	822	O
mass	19144729	823	827	O
index	19144729	828	833	O
,	19144729	833	834	O
in	19144729	835	837	O
kg/m(2	19144729	838	844	O
):	19144729	844	846	O
<	19144729	847	848	O
22	19144729	848	850	O
)	19144729	850	851	O
or	19144729	852	854	O
recent	19144729	855	861	O
weight	19144729	862	868	O
loss	19144729	869	873	O
(	19144729	874	875	O
>	19144729	875	876	O
7.5	19144729	876	879	O
%	19144729	879	880	O
over	19144729	881	885	O
3	19144729	886	887	O
mo	19144729	888	890	O
)	19144729	890	891	O
]	19144729	891	892	O
aged	19144729	893	897	O
>	19144729	898	899	O
65	19144729	899	901	O
y	19144729	902	903	O
(	19144729	904	905	O
mean	19144729	905	909	O
age	19144729	910	913	O
:	19144729	913	914	O
77	19144729	915	917	O
y	19144729	918	919	O
;	19144729	919	920	O
26	19144729	921	923	O
women	19144729	924	929	O
and	19144729	930	933	O
23	19144729	934	936	O
men	19144729	937	940	O
)	19144729	940	941	O
.	19144729	941	942	O

Hospital	19144729	943	951	O
admissions	19144729	952	962	O
and	19144729	963	966	O
other	19144729	967	972	O
variables	19144729	973	982	O
were	19144729	983	987	O
assessed	19144729	988	996	O
.	19144729	996	997	O

RESULTS	19144729	999	1006	O
:	19144729	1007	1008	O
In	19144729	1009	1011	O
subjects	19144729	1012	1020	O
receiving	19144729	1021	1030	O
combined	19144729	1031	1039	O
testosterone	19144729	1040	1052	O
and	19144729	1053	1056	O
nutritional	19144729	1057	1068	O
supplements	19144729	1069	1080	O
(	19144729	1081	1082	O
n	19144729	1082	1083	O
=	19144729	1084	1085	O
11	19144729	1086	1088	O
)	19144729	1088	1089	O
,	19144729	1089	1090	O
there	19144729	1091	1096	O
were	19144729	1097	1101	O
no	19144729	1102	1104	O
hospital	19144729	1105	1113	B-Outcome
admissions	19144729	1114	1124	I-Outcome
,	19144729	1124	1125	O
whereas	19144729	1126	1133	O
there	19144729	1134	1139	O
were	19144729	1140	1144	O
9	19144729	1145	1146	O
admissions	19144729	1147	1157	O
(	19144729	1158	1159	O
2	19144729	1159	1160	O
elective	19144729	1161	1169	O
)	19144729	1169	1170	O
in	19144729	1171	1173	O
13	19144729	1174	1176	O
subjects	19144729	1177	1185	O
in	19144729	1186	1188	O
the	19144729	1189	1192	O
no-treatment	19144729	1193	1205	O
group	19144729	1206	1211	O
,	19144729	1211	1212	O
4	19144729	1213	1214	O
in	19144729	1215	1217	O
the	19144729	1218	1221	O
testosterone-treated	19144729	1222	1242	O
group	19144729	1243	1248	O
(	19144729	1249	1250	O
n	19144729	1250	1251	O
=	19144729	1252	1253	O
12	19144729	1254	1256	O
)	19144729	1256	1257	O
,	19144729	1257	1258	O
and	19144729	1259	1262	O
5	19144729	1263	1264	O
in	19144729	1265	1267	O
the	19144729	1268	1271	O
supplement-treated	19144729	1272	1290	O
group	19144729	1291	1296	O
(	19144729	1297	1298	O
n	19144729	1298	1299	O
=	19144729	1300	1301	O
13	19144729	1302	1304	O
)	19144729	1304	1305	O
;	19144729	1305	1306	O
P	19144729	1307	1308	O
=	19144729	1309	1310	O
0.06	19144729	1311	1315	O
with	19144729	1316	1320	O
no-treatment	19144729	1321	1333	O
compared	19144729	1334	1342	O
with	19144729	1343	1347	O
combined	19144729	1348	1356	O
treatment	19144729	1357	1366	O
.	19144729	1366	1367	O

When	19144729	1368	1372	O
compared	19144729	1373	1381	O
with	19144729	1382	1386	O
the	19144729	1387	1390	O
no-treatment	19144729	1391	1403	O
group	19144729	1404	1409	O
,	19144729	1409	1410	O
the	19144729	1411	1414	O
combined-treatment	19144729	1415	1433	O
group	19144729	1434	1439	O
had	19144729	1440	1443	O
significantly	19144729	1444	1457	O
fewer	19144729	1458	1463	O
subjects	19144729	1464	1472	B-Outcome
admitted	19144729	1473	1481	I-Outcome
to	19144729	1482	1484	I-Outcome
hospital	19144729	1485	1493	I-Outcome
(	19144729	1494	1495	O
0	19144729	1495	1496	O
compared	19144729	1497	1505	O
with	19144729	1506	1510	O
5	19144729	1511	1512	O
,	19144729	1512	1513	O
P	19144729	1514	1515	O
=	19144729	1516	1517	O
0.03	19144729	1518	1522	O
)	19144729	1522	1523	O
,	19144729	1523	1524	O
fewer	19144729	1525	1530	O
days	19144729	1531	1535	B-Outcome
in	19144729	1536	1538	I-Outcome
hospital	19144729	1539	1547	I-Outcome
(	19144729	1548	1549	O
0	19144729	1549	1550	O
compared	19144729	1551	1559	O
with	19144729	1560	1564	O
74	19144729	1565	1567	O
,	19144729	1567	1568	O
P	19144729	1569	1570	O
=	19144729	1571	1572	O
0.041	19144729	1573	1578	O
)	19144729	1578	1579	O
,	19144729	1579	1580	O
and	19144729	1581	1584	O
a	19144729	1585	1586	O
longer	19144729	1587	1593	O
time	19144729	1594	1598	B-Outcome
to	19144729	1599	1601	I-Outcome
hospital	19144729	1602	1610	I-Outcome
admission	19144729	1611	1620	I-Outcome
(	19144729	1621	1622	O
P	19144729	1622	1623	O
=	19144729	1624	1625	O
0.017	19144729	1626	1631	O
)	19144729	1631	1632	O
.	19144729	1632	1633	O

CONCLUSIONS	19144729	1635	1646	O
:	19144729	1647	1648	O
In	19144729	1649	1651	O
undernourished	19144729	1652	1666	O
older	19144729	1667	1672	O
people	19144729	1673	1679	O
,	19144729	1679	1680	O
combined	19144729	1681	1689	O
treatment	19144729	1690	1699	O
with	19144729	1700	1704	O
testosterone	19144729	1705	1717	O
and	19144729	1718	1721	O
nutritional	19144729	1722	1733	O
supplementation	19144729	1734	1749	O
reduced	19144729	1750	1757	O
the	19144729	1758	1761	O
number	19144729	1762	1768	B-Outcome
of	19144729	1769	1771	I-Outcome
people	19144729	1772	1778	I-Outcome
hospitalized	19144729	1779	1791	I-Outcome
and	19144729	1792	1795	O
the	19144729	1796	1799	O
duration	19144729	1800	1808	B-Outcome
of	19144729	1809	1811	I-Outcome
hospital	19144729	1812	1820	I-Outcome
admissions	19144729	1821	1831	I-Outcome
,	19144729	1831	1832	O
which	19144729	1833	1838	O
are	19144729	1839	1842	O
important	19144729	1843	1852	O
endpoints	19144729	1853	1862	O
in	19144729	1863	1865	O
this	19144729	1866	1870	O
group	19144729	1871	1876	O
.	19144729	1876	1877	O

Larger	19144729	1878	1884	O
,	19144729	1884	1885	O
confirmatory	19144729	1886	1898	O
studies	19144729	1899	1906	O
are	19144729	1907	1910	O
now	19144729	1911	1914	O
needed	19144729	1915	1921	O
.	19144729	1921	1922	O

This	19144729	1923	1927	O
trial	19144729	1928	1933	O
was	19144729	1934	1937	O
registered	19144729	1938	1948	O
before	19144729	1949	1955	O
commencement	19144729	1956	1968	O
at	19144729	1969	1971	O
clinical	19144729	1972	1980	O
trials.gov	19144729	1981	1991	O
as	19144729	1992	1994	O
NCT00117000	19144729	1995	2006	O
.	19144729	2006	2007	O


Hyperbaric	19284641	0	10	O
treatment	19284641	11	20	O
for	19284641	21	24	O
children	19284641	25	33	O
with	19284641	34	38	O
autism	19284641	39	45	O
:	19284641	45	46	O
a	19284641	47	48	O
multicenter	19284641	49	60	O
,	19284641	60	61	O
randomized	19284641	62	72	O
,	19284641	72	73	O
double-blind	19284641	74	86	O
,	19284641	86	87	O
controlled	19284641	88	98	O
trial	19284641	99	104	O
.	19284641	104	105	O

BACKGROUND	19284641	107	117	O
:	19284641	118	119	O
Several	19284641	120	127	O
uncontrolled	19284641	128	140	O
studies	19284641	141	148	O
of	19284641	149	151	O
hyperbaric	19284641	152	162	O
treatment	19284641	163	172	O
in	19284641	173	175	O
children	19284641	176	184	O
with	19284641	185	189	O
autism	19284641	190	196	O
have	19284641	197	201	O
reported	19284641	202	210	O
clinical	19284641	211	219	O
improvements	19284641	220	232	O
;	19284641	232	233	O
however	19284641	234	241	O
,	19284641	241	242	O
this	19284641	243	247	O
treatment	19284641	248	257	O
has	19284641	258	261	O
not	19284641	262	265	O
been	19284641	266	270	O
evaluated	19284641	271	280	O
to	19284641	281	283	O
date	19284641	284	288	O
with	19284641	289	293	O
a	19284641	294	295	O
controlled	19284641	296	306	O
study	19284641	307	312	O
.	19284641	312	313	O

We	19284641	314	316	O
performed	19284641	317	326	O
a	19284641	327	328	O
multicenter	19284641	329	340	O
,	19284641	340	341	O
randomized	19284641	342	352	O
,	19284641	352	353	O
double-blind	19284641	354	366	O
,	19284641	366	367	O
controlled	19284641	368	378	O
trial	19284641	379	384	O
to	19284641	385	387	O
assess	19284641	388	394	O
the	19284641	395	398	O
efficacy	19284641	399	407	O
of	19284641	408	410	O
hyperbaric	19284641	411	421	O
treatment	19284641	422	431	O
in	19284641	432	434	O
children	19284641	435	443	O
with	19284641	444	448	O
autism	19284641	449	455	O
.	19284641	455	456	O

METHODS	19284641	458	465	O
:	19284641	466	467	O
62	19284641	468	470	O
children	19284641	471	479	O
with	19284641	480	484	O
autism	19284641	485	491	O
recruited	19284641	492	501	O
from	19284641	502	506	O
6	19284641	507	508	O
centers	19284641	509	516	O
,	19284641	516	517	O
ages	19284641	518	522	O
2	19284641	523	524	O
-	19284641	524	525	O
7	19284641	525	526	O
years	19284641	527	532	O
(	19284641	533	534	O
mean	19284641	534	538	O
4.92	19284641	539	543	O
+	19284641	544	545	O
/-	19284641	545	547	O
1.21	19284641	548	552	O
)	19284641	552	553	O
,	19284641	553	554	O
were	19284641	555	559	O
randomly	19284641	560	568	O
assigned	19284641	569	577	O
to	19284641	578	580	O
40	19284641	581	583	O
hourly	19284641	584	590	O
treatments	19284641	591	601	O
of	19284641	602	604	O
either	19284641	605	611	O
hyperbaric	19284641	612	622	O
treatment	19284641	623	632	O
at	19284641	633	635	O
1.3	19284641	636	639	O
atmosphere	19284641	640	650	O
(	19284641	651	652	O
atm	19284641	652	655	O
)	19284641	655	656	O
and	19284641	657	660	O
24	19284641	661	663	O
%	19284641	663	664	O
oxygen	19284641	665	671	O
(	19284641	672	673	O
"	19284641	673	674	O
treatment	19284641	674	683	O
group	19284641	684	689	O
"	19284641	689	690	O
,	19284641	690	691	O
n	19284641	692	693	O
=	19284641	694	695	O
33	19284641	696	698	O
)	19284641	698	699	O
or	19284641	700	702	O
slightly	19284641	703	711	O
pressurized	19284641	712	723	O
room	19284641	724	728	O
air	19284641	729	732	O
at	19284641	733	735	O
1.03	19284641	736	740	O
atm	19284641	741	744	O
and	19284641	745	748	O
21	19284641	749	751	O
%	19284641	751	752	O
oxygen	19284641	753	759	O
(	19284641	760	761	O
"	19284641	761	762	O
control	19284641	762	769	O
group	19284641	770	775	O
"	19284641	775	776	O
,	19284641	776	777	O
n	19284641	778	779	O
=	19284641	780	781	O
29	19284641	782	784	O
)	19284641	784	785	O
.	19284641	785	786	O

Outcome	19284641	787	794	O
measures	19284641	795	803	O
included	19284641	804	812	O
Clinical	19284641	813	821	O
Global	19284641	822	828	O
Impression	19284641	829	839	O
(	19284641	840	841	O
CGI	19284641	841	844	O
)	19284641	844	845	O
scale	19284641	846	851	O
,	19284641	851	852	O
Aberrant	19284641	853	861	O
Behavior	19284641	862	870	O
Checklist	19284641	871	880	O
(	19284641	881	882	O
ABC	19284641	882	885	O
)	19284641	885	886	O
,	19284641	886	887	O
and	19284641	888	891	O
Autism	19284641	892	898	O
Treatment	19284641	899	908	O
Evaluation	19284641	909	919	O
Checklist	19284641	920	929	O
(	19284641	930	931	O
ATEC	19284641	931	935	O
)	19284641	935	936	O
.	19284641	936	937	O

RESULTS	19284641	939	946	O
:	19284641	947	948	O
After	19284641	949	954	O
40	19284641	955	957	O
sessions	19284641	958	966	O
,	19284641	966	967	O
mean	19284641	968	972	B-Outcome
physician	19284641	973	982	I-Outcome
CGI	19284641	983	986	I-Outcome
scores	19284641	987	993	I-Outcome
significantly	19284641	994	1007	O
improved	19284641	1008	1016	O
in	19284641	1017	1019	O
the	19284641	1020	1023	O
treatment	19284641	1024	1033	O
group	19284641	1034	1039	O
compared	19284641	1040	1048	O
to	19284641	1049	1051	O
controls	19284641	1052	1060	O
in	19284641	1061	1063	O
overall	19284641	1064	1071	B-Outcome
functioning	19284641	1072	1083	I-Outcome
(	19284641	1084	1085	O
p	19284641	1085	1086	O
=	19284641	1087	1088	O
0.0008	19284641	1089	1095	O
)	19284641	1095	1096	O
,	19284641	1096	1097	O
receptive	19284641	1098	1107	B-Outcome
language	19284641	1108	1116	I-Outcome
(	19284641	1117	1118	O
p	19284641	1118	1119	O
<	19284641	1120	1121	O
0.0001	19284641	1122	1128	O
)	19284641	1128	1129	O
,	19284641	1129	1130	O
social	19284641	1131	1137	B-Outcome
interaction	19284641	1138	1149	I-Outcome
(	19284641	1150	1151	O
p	19284641	1151	1152	O
=	19284641	1153	1154	O
0.0473	19284641	1155	1161	O
)	19284641	1161	1162	O
,	19284641	1162	1163	O
and	19284641	1164	1167	O
eye	19284641	1168	1171	B-Outcome
contact	19284641	1172	1179	I-Outcome
(	19284641	1180	1181	O
p	19284641	1181	1182	O
=	19284641	1183	1184	O
0.0102	19284641	1185	1191	O
)	19284641	1191	1192	O
;	19284641	1192	1193	O
9/30	19284641	1194	1198	O
children	19284641	1199	1207	O
(	19284641	1208	1209	O
30	19284641	1209	1211	O
%	19284641	1211	1212	O
)	19284641	1212	1213	O
in	19284641	1214	1216	O
the	19284641	1217	1220	O
treatment	19284641	1221	1230	O
group	19284641	1231	1236	O
were	19284641	1237	1241	O
rated	19284641	1242	1247	O
as	19284641	1248	1250	O
"	19284641	1251	1252	O
very	19284641	1252	1256	O
much	19284641	1257	1261	O
improved	19284641	1262	1270	O
"	19284641	1270	1271	O
or	19284641	1272	1274	O
"	19284641	1275	1276	O
much	19284641	1276	1280	O
improved	19284641	1281	1289	O
"	19284641	1289	1290	O
compared	19284641	1291	1299	O
to	19284641	1300	1302	O
2/26	19284641	1303	1307	O
(	19284641	1308	1309	O
8	19284641	1309	1310	O
%	19284641	1310	1311	O
)	19284641	1311	1312	O
of	19284641	1313	1315	O
controls	19284641	1316	1324	O
(	19284641	1325	1326	O
p	19284641	1326	1327	O
=	19284641	1328	1329	O
0.0471	19284641	1330	1336	O
)	19284641	1336	1337	O
;	19284641	1337	1338	O
24/30	19284641	1339	1344	O
(	19284641	1345	1346	O
80	19284641	1346	1348	O
%	19284641	1348	1349	O
)	19284641	1349	1350	O
in	19284641	1351	1353	O
the	19284641	1354	1357	O
treatment	19284641	1358	1367	O
group	19284641	1368	1373	O
improved	19284641	1374	1382	O
compared	19284641	1383	1391	O
to	19284641	1392	1394	O
10/26	19284641	1395	1400	O
(	19284641	1401	1402	O
38	19284641	1402	1404	O
%	19284641	1404	1405	O
)	19284641	1405	1406	O
of	19284641	1407	1409	O
controls	19284641	1410	1418	O
(	19284641	1419	1420	O
p	19284641	1420	1421	O
=	19284641	1422	1423	O
0.0024	19284641	1424	1430	O
)	19284641	1430	1431	O
.	19284641	1431	1432	O

Mean	19284641	1433	1437	B-Outcome
parental	19284641	1438	1446	I-Outcome
CGI	19284641	1447	1450	I-Outcome
scores	19284641	1451	1457	I-Outcome
significantly	19284641	1458	1471	O
improved	19284641	1472	1480	O
in	19284641	1481	1483	O
the	19284641	1484	1487	O
treatment	19284641	1488	1497	O
group	19284641	1498	1503	O
compared	19284641	1504	1512	O
to	19284641	1513	1515	O
controls	19284641	1516	1524	O
in	19284641	1525	1527	O
overall	19284641	1528	1535	B-Outcome
functioning	19284641	1536	1547	I-Outcome
(	19284641	1548	1549	O
p	19284641	1549	1550	O
=	19284641	1551	1552	O
0.0336	19284641	1553	1559	O
)	19284641	1559	1560	O
,	19284641	1560	1561	O
receptive	19284641	1562	1571	B-Outcome
language	19284641	1572	1580	I-Outcome
(	19284641	1581	1582	O
p	19284641	1582	1583	O
=	19284641	1584	1585	O
0.0168	19284641	1586	1592	O
)	19284641	1592	1593	O
,	19284641	1593	1594	O
and	19284641	1595	1598	O
eye	19284641	1599	1602	B-Outcome
contact	19284641	1603	1610	I-Outcome
(	19284641	1611	1612	O
p	19284641	1612	1613	O
=	19284641	1614	1615	O
0.0322	19284641	1616	1622	O
)	19284641	1622	1623	O
.	19284641	1623	1624	O

On	19284641	1625	1627	O
the	19284641	1628	1631	O
ABC	19284641	1632	1635	B-Outcome
,	19284641	1635	1636	O
significant	19284641	1637	1648	O
improvements	19284641	1649	1661	O
were	19284641	1662	1666	O
observed	19284641	1667	1675	O
in	19284641	1676	1678	O
the	19284641	1679	1682	O
treatment	19284641	1683	1692	O
group	19284641	1693	1698	O
in	19284641	1699	1701	O
total	19284641	1702	1707	O
score	19284641	1708	1713	O
,	19284641	1713	1714	O
irritability	19284641	1715	1727	B-Outcome
,	19284641	1727	1728	O
stereotypy	19284641	1729	1739	B-Outcome
,	19284641	1739	1740	O
hyperactivity	19284641	1741	1754	B-Outcome
,	19284641	1754	1755	O
and	19284641	1756	1759	O
speech	19284641	1760	1766	B-Outcome
(	19284641	1767	1768	O
p	19284641	1768	1769	O
<	19284641	1770	1771	O
0.03	19284641	1772	1776	O
for	19284641	1777	1780	O
each	19284641	1781	1785	O
)	19284641	1785	1786	O
,	19284641	1786	1787	O
but	19284641	1788	1791	O
not	19284641	1792	1795	O
in	19284641	1796	1798	O
the	19284641	1799	1802	O
control	19284641	1803	1810	O
group	19284641	1811	1816	O
.	19284641	1816	1817	O

In	19284641	1818	1820	O
the	19284641	1821	1824	O
treatment	19284641	1825	1834	O
group	19284641	1835	1840	O
compared	19284641	1841	1849	O
to	19284641	1850	1852	O
the	19284641	1853	1856	O
control	19284641	1857	1864	O
group	19284641	1865	1870	O
,	19284641	1870	1871	O
mean	19284641	1872	1876	O
changes	19284641	1877	1884	O
on	19284641	1885	1887	O
the	19284641	1888	1891	O
ABC	19284641	1892	1895	B-Outcome
total	19284641	1896	1901	I-Outcome
score	19284641	1902	1907	I-Outcome
and	19284641	1908	1911	O
subscales	19284641	1912	1921	B-Outcome
were	19284641	1922	1926	O
similar	19284641	1927	1934	O
except	19284641	1935	1941	O
a	19284641	1942	1943	O
greater	19284641	1944	1951	O
number	19284641	1952	1958	O
of	19284641	1959	1961	O
children	19284641	1962	1970	O
improved	19284641	1971	1979	O
in	19284641	1980	1982	O
irritability	19284641	1983	1995	B-Outcome
(	19284641	1996	1997	O
p	19284641	1997	1998	O
=	19284641	1999	2000	O
0.0311	19284641	2001	2007	O
)	19284641	2007	2008	O
.	19284641	2008	2009	O

On	19284641	2010	2012	O
the	19284641	2013	2016	O
ATEC	19284641	2017	2021	B-Outcome
,	19284641	2021	2022	O
sensory/cognitive	19284641	2023	2040	B-Outcome
awareness	19284641	2041	2050	I-Outcome
significantly	19284641	2051	2064	O
improved	19284641	2065	2073	O
(	19284641	2074	2075	O
p	19284641	2075	2076	O
=	19284641	2077	2078	O
0.0367	19284641	2079	2085	O
)	19284641	2085	2086	O
in	19284641	2087	2089	O
the	19284641	2090	2093	O
treatment	19284641	2094	2103	O
group	19284641	2104	2109	O
compared	19284641	2110	2118	O
to	19284641	2119	2121	O
the	19284641	2122	2125	O
control	19284641	2126	2133	O
group	19284641	2134	2139	O
.	19284641	2139	2140	O

Post-hoc	19284641	2141	2149	O
analysis	19284641	2150	2158	O
indicated	19284641	2159	2168	O
that	19284641	2169	2173	O
children	19284641	2174	2182	O
over	19284641	2183	2187	O
age	19284641	2188	2191	O
5	19284641	2192	2193	O
and	19284641	2194	2197	O
children	19284641	2198	2206	O
with	19284641	2207	2211	O
lower	19284641	2212	2217	O
initial	19284641	2218	2225	O
autism	19284641	2226	2232	O
severity	19284641	2233	2241	O
had	19284641	2242	2245	O
the	19284641	2246	2249	O
most	19284641	2250	2254	O
robust	19284641	2255	2261	O
improvements	19284641	2262	2274	O
.	19284641	2274	2275	O

Hyperbaric	19284641	2276	2286	O
treatment	19284641	2287	2296	O
was	19284641	2297	2300	O
safe	19284641	2301	2305	B-Outcome
and	19284641	2306	2309	O
well-tolerated	19284641	2310	2324	B-Outcome
.	19284641	2324	2325	O

CONCLUSION	19284641	2327	2337	O
:	19284641	2338	2339	O
Children	19284641	2340	2348	O
with	19284641	2349	2353	O
autism	19284641	2354	2360	O
who	19284641	2361	2364	O
received	19284641	2365	2373	O
hyperbaric	19284641	2374	2384	O
treatment	19284641	2385	2394	O
at	19284641	2395	2397	O
1.3	19284641	2398	2401	O
atm	19284641	2402	2405	O
and	19284641	2406	2409	O
24	19284641	2410	2412	O
%	19284641	2412	2413	O
oxygen	19284641	2414	2420	O
for	19284641	2421	2424	O
40	19284641	2425	2427	O
hourly	19284641	2428	2434	O
sessions	19284641	2435	2443	O
had	19284641	2444	2447	O
significant	19284641	2448	2459	O
improvements	19284641	2460	2472	O
in	19284641	2473	2475	O
overall	19284641	2476	2483	B-Outcome
functioning	19284641	2484	2495	I-Outcome
,	19284641	2495	2496	O
receptive	19284641	2497	2506	B-Outcome
language	19284641	2507	2515	I-Outcome
,	19284641	2515	2516	O
social	19284641	2517	2523	B-Outcome
interaction	19284641	2524	2535	I-Outcome
,	19284641	2535	2536	O
eye	19284641	2537	2540	B-Outcome
contact	19284641	2541	2548	I-Outcome
,	19284641	2548	2549	O
and	19284641	2550	2553	O
sensory/cognitive	19284641	2554	2571	B-Outcome
awareness	19284641	2572	2581	I-Outcome
compared	19284641	2582	2590	O
to	19284641	2591	2593	O
children	19284641	2594	2602	O
who	19284641	2603	2606	O
received	19284641	2607	2615	O
slightly	19284641	2616	2624	O
pressurized	19284641	2625	2636	O
room	19284641	2637	2641	O
air	19284641	2642	2645	O
.	19284641	2645	2646	O

TRIAL	19284641	2648	2653	O
REGISTRATION	19284641	2654	2666	O
:	19284641	2667	2668	O
clinicaltrials.gov	19284641	2669	2687	O
NCT00335790	19284641	2688	2699	O
.	19284641	2699	2700	O


Cognitive	19309326	0	9	O
behavioral	19309326	10	20	O
therapy	19309326	21	28	O
for	19309326	29	32	O
anxiety	19309326	33	40	O
in	19309326	41	43	O
children	19309326	44	52	O
with	19309326	53	57	O
autism	19309326	58	64	O
spectrum	19309326	65	73	O
disorders	19309326	74	83	O
:	19309326	83	84	O
a	19309326	85	86	O
randomized	19309326	87	97	O
,	19309326	97	98	O
controlled	19309326	99	109	O
trial	19309326	110	115	O
.	19309326	115	116	O

BACKGROUND	19309326	118	128	O
:	19309326	129	130	O
Children	19309326	131	139	O
with	19309326	140	144	O
autism	19309326	145	151	O
spectrum	19309326	152	160	O
disorders	19309326	161	170	O
often	19309326	171	176	O
present	19309326	177	184	O
with	19309326	185	189	O
comorbid	19309326	190	198	O
anxiety	19309326	199	206	O
disorders	19309326	207	216	O
that	19309326	217	221	O
cause	19309326	222	227	O
significant	19309326	228	239	O
functional	19309326	240	250	O
impairment	19309326	251	261	O
.	19309326	261	262	O

This	19309326	263	267	O
study	19309326	268	273	O
tested	19309326	274	280	O
a	19309326	281	282	O
modular	19309326	283	290	O
cognitive	19309326	291	300	O
behavioral	19309326	301	311	O
therapy	19309326	312	319	O
(	19309326	320	321	O
CBT	19309326	321	324	O
)	19309326	324	325	O
program	19309326	326	333	O
for	19309326	334	337	O
children	19309326	338	346	O
with	19309326	347	351	O
this	19309326	352	356	O
profile	19309326	357	364	O
.	19309326	364	365	O

A	19309326	366	367	O
standard	19309326	368	376	O
CBT	19309326	377	380	O
program	19309326	381	388	O
was	19309326	389	392	O
augmented	19309326	393	402	O
with	19309326	403	407	O
multiple	19309326	408	416	O
treatment	19309326	417	426	O
components	19309326	427	437	O
designed	19309326	438	446	O
to	19309326	447	449	O
accommodate	19309326	450	461	O
or	19309326	462	464	O
remediate	19309326	465	474	O
the	19309326	475	478	O
social	19309326	479	485	O
and	19309326	486	489	O
adaptive	19309326	490	498	O
skill	19309326	499	504	O
deficits	19309326	505	513	O
of	19309326	514	516	O
children	19309326	517	525	O
with	19309326	526	530	O
ASD	19309326	531	534	O
that	19309326	535	539	O
could	19309326	540	545	O
pose	19309326	546	550	O
barriers	19309326	551	559	O
to	19309326	560	562	O
anxiety	19309326	563	570	O
reduction	19309326	571	580	O
.	19309326	580	581	O

METHOD	19309326	583	589	O
:	19309326	590	591	O
Forty	19309326	592	597	O
children	19309326	598	606	O
(	19309326	607	608	O
7	19309326	608	609	O
-	19309326	609	610	O
11	19309326	610	612	O
years	19309326	613	618	O
old	19309326	619	622	O
)	19309326	622	623	O
were	19309326	624	628	O
randomly	19309326	629	637	O
assigned	19309326	638	646	O
to	19309326	647	649	O
16	19309326	650	652	O
sessions	19309326	653	661	O
of	19309326	662	664	O
CBT	19309326	665	668	O
or	19309326	669	671	O
a	19309326	672	673	O
3-month	19309326	674	681	O
waitlist	19309326	682	690	O
(	19309326	691	692	O
36	19309326	692	694	O
completed	19309326	695	704	O
treatment	19309326	705	714	O
or	19309326	715	717	O
waitlist	19309326	718	726	O
)	19309326	726	727	O
.	19309326	727	728	O

Therapists	19309326	729	739	O
worked	19309326	740	746	O
with	19309326	747	751	O
individual	19309326	752	762	O
families	19309326	763	771	O
.	19309326	771	772	O

The	19309326	773	776	O
CBT	19309326	777	780	O
model	19309326	781	786	O
emphasized	19309326	787	797	O
behavioral	19309326	798	808	O
experimentation	19309326	809	824	O
,	19309326	824	825	O
parent-training	19309326	826	841	O
,	19309326	841	842	O
and	19309326	843	846	O
school	19309326	847	853	O
consultation	19309326	854	866	O
.	19309326	866	867	O

Independent	19309326	868	879	O
evaluators	19309326	880	890	O
blind	19309326	891	896	O
to	19309326	897	899	O
treatment	19309326	900	909	O
condition	19309326	910	919	O
conducted	19309326	920	929	O
structured	19309326	930	940	O
diagnostic	19309326	941	951	O
interviews	19309326	952	962	O
and	19309326	963	966	O
parents	19309326	967	974	O
and	19309326	975	978	O
children	19309326	979	987	O
completed	19309326	988	997	O
anxiety	19309326	998	1005	O
symptom	19309326	1006	1013	O
checklists	19309326	1014	1024	O
at	19309326	1025	1027	O
baseline	19309326	1028	1036	O
and	19309326	1037	1040	O
posttreatment/postwaitlist	19309326	1041	1067	O
.	19309326	1067	1068	O

RESULTS	19309326	1070	1077	O
:	19309326	1078	1079	O
In	19309326	1080	1082	O
intent-to-treat	19309326	1083	1098	O
analyses	19309326	1099	1107	O
,	19309326	1107	1108	O
78.5	19309326	1109	1113	O
%	19309326	1113	1114	O
of	19309326	1115	1117	O
the	19309326	1118	1121	O
CBT	19309326	1122	1125	O
group	19309326	1126	1131	O
met	19309326	1132	1135	O
Clinical	19309326	1136	1144	B-Outcome
Global	19309326	1145	1151	I-Outcome
Impressions-Improvement	19309326	1152	1175	I-Outcome
scale	19309326	1176	1181	I-Outcome
criteria	19309326	1182	1190	O
for	19309326	1191	1194	O
positive	19309326	1195	1203	O
treatment	19309326	1204	1213	O
response	19309326	1214	1222	O
at	19309326	1223	1225	O
posttreatment	19309326	1226	1239	O
,	19309326	1239	1240	O
as	19309326	1241	1243	O
compared	19309326	1244	1252	O
to	19309326	1253	1255	O
only	19309326	1256	1260	O
8.7	19309326	1261	1264	O
%	19309326	1264	1265	O
of	19309326	1266	1268	O
the	19309326	1269	1272	O
waitlist	19309326	1273	1281	O
group	19309326	1282	1287	O
.	19309326	1287	1288	O

CBT	19309326	1289	1292	O
also	19309326	1293	1297	O
outperformed	19309326	1298	1310	O
the	19309326	1311	1314	O
waitlist	19309326	1315	1323	O
on	19309326	1324	1326	O
diagnostic	19309326	1327	1337	B-Outcome
outcomes	19309326	1338	1346	I-Outcome
and	19309326	1347	1350	O
parent	19309326	1351	1357	B-Outcome
reports	19309326	1358	1365	I-Outcome
of	19309326	1366	1368	I-Outcome
child	19309326	1369	1374	I-Outcome
anxiety	19309326	1375	1382	I-Outcome
,	19309326	1382	1383	O
but	19309326	1384	1387	O
not	19309326	1388	1391	O
children	19309326	1392	1400	B-Outcome
's	19309326	1400	1402	I-Outcome
self-reports	19309326	1403	1415	I-Outcome
.	19309326	1415	1416	O

Treatment	19309326	1417	1426	O
gains	19309326	1427	1432	O
were	19309326	1433	1437	O
maintained	19309326	1438	1448	O
at	19309326	1449	1451	O
3-month	19309326	1452	1459	O
follow-up	19309326	1460	1469	O
.	19309326	1469	1470	O

CONCLUSIONS	19309326	1472	1483	O
:	19309326	1484	1485	O
The	19309326	1486	1489	O
CBT	19309326	1490	1493	O
manual	19309326	1494	1500	O
employed	19309326	1501	1509	O
in	19309326	1510	1512	O
this	19309326	1513	1517	O
study	19309326	1518	1523	O
is	19309326	1524	1526	O
one	19309326	1527	1530	O
of	19309326	1531	1533	O
the	19309326	1534	1537	O
first	19309326	1538	1543	O
adaptations	19309326	1544	1555	O
of	19309326	1556	1558	O
an	19309326	1559	1561	O
evidence-based	19309326	1562	1576	O
treatment	19309326	1577	1586	O
for	19309326	1587	1590	O
children	19309326	1591	1599	O
with	19309326	1600	1604	O
autism	19309326	1605	1611	O
spectrum	19309326	1612	1620	O
disorders	19309326	1621	1630	O
.	19309326	1630	1631	O

Remission	19309326	1632	1641	O
of	19309326	1642	1644	O
anxiety	19309326	1645	1652	O
disorders	19309326	1653	1662	O
appears	19309326	1663	1670	O
to	19309326	1671	1673	O
be	19309326	1674	1676	O
an	19309326	1677	1679	O
achievable	19309326	1680	1690	O
goal	19309326	1691	1695	O
among	19309326	1696	1701	O
high-functioning	19309326	1702	1718	O
children	19309326	1719	1727	O
with	19309326	1728	1732	O
autism	19309326	1733	1739	O
.	19309326	1739	1740	O


Diverting	19333040	0	9	O
stoma	19333040	10	15	O
after	19333040	16	21	O
low	19333040	22	25	O
anterior	19333040	26	34	O
resection	19333040	35	44	O
:	19333040	44	45	O
more	19333040	46	50	O
arguments	19333040	51	60	O
in	19333040	61	63	O
favor	19333040	64	69	O
.	19333040	69	70	O

PURPOSE	19333040	72	79	O
:	19333040	80	81	O
The	19333040	82	85	O
necessity	19333040	86	95	O
of	19333040	96	98	O
a	19333040	99	100	O
protective	19333040	101	111	O
stoma	19333040	112	117	O
in	19333040	118	120	O
patients	19333040	121	129	O
undergoing	19333040	130	140	O
low	19333040	141	144	O
anterior	19333040	145	153	O
resection	19333040	154	163	O
with	19333040	164	168	O
total	19333040	169	174	O
mesorectal	19333040	175	185	O
excision	19333040	186	194	O
for	19333040	195	198	O
primary	19333040	199	206	O
rectal	19333040	207	213	O
cancer	19333040	214	220	O
is	19333040	221	223	O
discussed	19333040	224	233	O
controversially	19333040	234	249	O
.	19333040	249	250	O

We	19333040	251	253	O
conducted	19333040	254	263	O
a	19333040	264	265	O
randomized	19333040	266	276	O
,	19333040	276	277	O
controlled	19333040	278	288	O
,	19333040	288	289	O
pilot-study	19333040	290	301	O
to	19333040	302	304	O
evaluate	19333040	305	313	O
the	19333040	314	317	O
need	19333040	318	322	O
for	19333040	323	326	O
diverting	19333040	327	336	O
ileostomy	19333040	337	346	O
in	19333040	347	349	O
patients	19333040	350	358	O
undergoing	19333040	359	369	O
low	19333040	370	373	O
anterior	19333040	374	382	O
resection	19333040	383	392	O
[	19333040	393	394	O
NCT00457327	19333040	394	405	O
]	19333040	405	406	O
.	19333040	406	407	O

METHODS	19333040	409	416	O
:	19333040	417	418	O
Forty	19333040	419	424	O
patients	19333040	425	433	O
after	19333040	434	439	O
elective	19333040	440	448	O
sphincter-saving	19333040	449	465	O
low	19333040	466	469	O
anterior	19333040	470	478	O
resection	19333040	479	488	O
were	19333040	489	493	O
eligible	19333040	494	502	O
for	19333040	503	506	O
intraoperative	19333040	507	521	O
randomization	19333040	522	535	O
.	19333040	535	536	O

The	19333040	537	540	O
primary	19333040	541	548	O
objective	19333040	549	558	O
of	19333040	559	561	O
this	19333040	562	566	O
trial	19333040	567	572	O
was	19333040	573	576	O
to	19333040	577	579	O
demonstrate	19333040	580	591	O
similar	19333040	592	599	O
risks	19333040	600	605	O
after	19333040	606	611	O
the	19333040	612	615	O
resection	19333040	616	625	O
with	19333040	626	630	O
both	19333040	631	635	O
techniques	19333040	636	646	O
.	19333040	646	647	O

A	19333040	648	649	O
priori	19333040	650	656	O
stopping	19333040	657	665	O
rules	19333040	666	671	O
were	19333040	672	676	O
defined	19333040	677	684	O
for	19333040	685	688	O
early	19333040	689	694	O
termination	19333040	695	706	O
of	19333040	707	709	O
the	19333040	710	713	O
trial	19333040	714	719	O
.	19333040	719	720	O

RESULTS	19333040	722	729	O
:	19333040	730	731	O
Between	19333040	732	739	O
July	19333040	740	744	O
4	19333040	745	746	O
,	19333040	746	747	O
2006	19333040	748	752	O
and	19333040	753	756	O
March	19333040	757	762	O
12	19333040	763	765	O
,	19333040	765	766	O
2007	19333040	767	771	O
,	19333040	771	772	O
a	19333040	773	774	O
total	19333040	775	780	O
of	19333040	781	783	O
41	19333040	784	786	O
patients	19333040	787	795	O
were	19333040	796	800	O
screened	19333040	801	809	O
and	19333040	810	813	O
34	19333040	814	816	O
patients	19333040	817	825	O
were	19333040	826	830	O
randomized	19333040	831	841	O
.	19333040	841	842	O

Eighteen	19333040	843	851	O
patients	19333040	852	860	O
were	19333040	861	865	O
randomized	19333040	866	876	O
to	19333040	877	879	O
the	19333040	880	883	O
stoma	19333040	884	889	O
group	19333040	890	895	O
and	19333040	896	899	O
16	19333040	900	902	O
patients	19333040	903	911	O
to	19333040	912	914	O
the	19333040	915	918	O
nonstoma	19333040	919	927	O
group	19333040	928	933	O
The	19333040	934	937	O
symptomatic	19333040	938	949	B-Outcome
anastomotic	19333040	950	961	I-Outcome
leakage	19333040	962	969	I-Outcome
rate	19333040	970	974	I-Outcome
was	19333040	975	978	O
significantly	19333040	979	992	O
higher	19333040	993	999	O
in	19333040	1000	1002	O
the	19333040	1003	1006	O
nonstoma	19333040	1007	1015	O
group	19333040	1016	1021	O
(	19333040	1022	1023	O
37.5	19333040	1023	1027	O
percent	19333040	1028	1035	O
)	19333040	1035	1036	O
than	19333040	1037	1041	O
in	19333040	1042	1044	O
the	19333040	1045	1048	O
stoma	19333040	1049	1054	O
group	19333040	1055	1060	O
(	19333040	1061	1062	O
5.5	19333040	1062	1065	O
percent	19333040	1066	1073	O
,	19333040	1073	1074	O
P	19333040	1075	1076	O
=	19333040	1077	1078	O
0.02	19333040	1079	1083	O
)	19333040	1083	1084	O
.	19333040	1084	1085	O

In	19333040	1086	1088	O
all	19333040	1089	1092	O
six	19333040	1093	1096	O
cases	19333040	1097	1102	O
in	19333040	1103	1105	O
the	19333040	1106	1109	O
nonstoma	19333040	1110	1118	O
group	19333040	1119	1124	O
,	19333040	1124	1125	O
reoperations	19333040	1126	1138	O
were	19333040	1139	1143	O
necessary	19333040	1144	1153	O
.	19333040	1153	1154	O

The	19333040	1155	1158	O
study	19333040	1159	1164	O
was	19333040	1165	1168	O
stopped	19333040	1169	1176	O
after	19333040	1177	1182	O
34	19333040	1183	1185	O
patients	19333040	1186	1194	O
were	19333040	1195	1199	O
included	19333040	1200	1208	O
.	19333040	1208	1209	O

A	19333040	1210	1211	O
meta-analysis	19333040	1212	1225	O
of	19333040	1226	1228	O
the	19333040	1229	1232	O
available	19333040	1233	1242	O
data	19333040	1243	1247	O
confirmed	19333040	1248	1257	O
the	19333040	1258	1261	O
value	19333040	1262	1267	O
of	19333040	1268	1270	O
a	19333040	1271	1272	O
protective	19333040	1273	1283	O
ostomy	19333040	1284	1290	O
for	19333040	1291	1294	O
patients	19333040	1295	1303	O
undergoing	19333040	1304	1314	O
low	19333040	1315	1318	O
anterior	19333040	1319	1327	O
resection	19333040	1328	1337	O
.	19333040	1337	1338	O

CONCLUSIONS	19333040	1340	1351	O
:	19333040	1352	1353	O
The	19333040	1354	1357	O
data	19333040	1358	1362	O
demonstrate	19333040	1363	1374	O
a	19333040	1375	1376	O
high	19333040	1377	1381	O
risk	19333040	1382	1386	O
for	19333040	1387	1390	O
patients	19333040	1391	1399	O
undergoing	19333040	1400	1410	O
low	19333040	1411	1414	O
anterior	19333040	1415	1423	O
resection	19333040	1424	1433	O
without	19333040	1434	1441	O
diverting	19333040	1442	1451	O
ileostomy	19333040	1452	1461	O
.	19333040	1461	1462	O


Rapid	19371887	0	5	O
efficacy	19371887	6	14	O
of	19371887	15	17	O
the	19371887	18	21	O
highly	19371887	22	28	O
selective	19371887	29	38	O
alpha1A-adrenoceptor	19371887	39	59	O
antagonist	19371887	60	70	O
silodosin	19371887	71	80	O
in	19371887	81	83	O
men	19371887	84	87	O
with	19371887	88	92	O
signs	19371887	93	98	O
and	19371887	99	102	O
symptoms	19371887	103	111	O
of	19371887	112	114	O
benign	19371887	115	121	O
prostatic	19371887	122	131	O
hyperplasia	19371887	132	143	O
:	19371887	143	144	O
pooled	19371887	145	151	O
results	19371887	152	159	O
of	19371887	160	162	O
2	19371887	163	164	O
phase	19371887	165	170	O
3	19371887	171	172	O
studies	19371887	173	180	O
.	19371887	180	181	O

PURPOSE	19371887	183	190	O
:	19371887	191	192	O
We	19371887	193	195	O
evaluated	19371887	196	205	O
the	19371887	206	209	O
efficacy	19371887	210	218	O
and	19371887	219	222	O
safety	19371887	223	229	O
of	19371887	230	232	O
silodosin	19371887	233	242	O
for	19371887	243	246	O
treatment	19371887	247	256	O
of	19371887	257	259	O
benign	19371887	260	266	O
prostatic	19371887	267	276	O
hyperplasia	19371887	277	288	O
symptoms	19371887	289	297	O
in	19371887	298	300	O
2	19371887	301	302	O
randomized	19371887	303	313	O
,	19371887	313	314	O
placebo	19371887	315	322	O
controlled	19371887	323	333	O
,	19371887	333	334	O
phase	19371887	335	340	O
3	19371887	341	342	O
studies	19371887	343	350	O
.	19371887	350	351	O

MATERIALS	19371887	353	362	O
AND	19371887	363	366	O
METHODS	19371887	367	374	O
:	19371887	375	376	O
Men	19371887	377	380	O
50	19371887	381	383	O
years	19371887	384	389	O
or	19371887	390	392	O
older	19371887	393	398	O
with	19371887	399	403	O
an	19371887	404	406	O
International	19371887	407	420	O
Prostate	19371887	421	429	O
Symptom	19371887	430	437	O
Score	19371887	438	443	O
of	19371887	444	446	O
13	19371887	447	449	O
or	19371887	450	452	O
greater	19371887	453	460	O
and	19371887	461	464	O
peak	19371887	465	469	O
urinary	19371887	470	477	O
flow	19371887	478	482	O
rate	19371887	483	487	O
of	19371887	488	490	O
4	19371887	491	492	O
to	19371887	493	495	O
15	19371887	496	498	O
ml	19371887	499	501	O
per	19371887	502	505	O
second	19371887	506	512	O
received	19371887	513	521	O
placebo	19371887	522	529	O
or	19371887	530	532	O
8	19371887	533	534	O
mg	19371887	535	537	O
silodosin	19371887	538	547	O
daily	19371887	548	553	O
with	19371887	554	558	O
breakfast	19371887	559	568	O
for	19371887	569	572	O
12	19371887	573	575	O
weeks	19371887	576	581	O
.	19371887	581	582	O

The	19371887	583	586	O
primary	19371887	587	594	O
end	19371887	595	598	O
point	19371887	599	604	O
was	19371887	605	608	O
International	19371887	609	622	O
Prostate	19371887	623	631	O
Symptom	19371887	632	639	O
Score	19371887	640	645	O
change	19371887	646	652	O
from	19371887	653	657	O
baseline	19371887	658	666	O
to	19371887	667	669	O
last	19371887	670	674	O
observation	19371887	675	686	O
.	19371887	686	687	O

Change	19371887	688	694	O
in	19371887	695	697	O
peak	19371887	698	702	O
urinary	19371887	703	710	O
flow	19371887	711	715	O
rate	19371887	716	720	O
was	19371887	721	724	O
a	19371887	725	726	O
secondary	19371887	727	736	O
end	19371887	737	740	O
point	19371887	741	746	O
.	19371887	746	747	O

Differences	19371887	748	759	O
in	19371887	760	762	O
treatment	19371887	763	772	O
efficacy	19371887	773	781	O
were	19371887	782	786	O
assessed	19371887	787	795	O
by	19371887	796	798	O
ANCOVA	19371887	799	805	O
.	19371887	805	806	O

RESULTS	19371887	808	815	O
:	19371887	816	817	O
Of	19371887	818	820	O
923	19371887	821	824	O
patients	19371887	825	833	O
(	19371887	834	835	O
mean	19371887	835	839	O
age	19371887	840	843	O
65	19371887	844	846	O
years	19371887	847	852	O
)	19371887	852	853	O
466	19371887	854	857	O
received	19371887	858	866	O
silodosin	19371887	867	876	O
and	19371887	877	880	O
457	19371887	881	884	O
placebo	19371887	885	892	O
.	19371887	892	893	O

After	19371887	894	899	O
0.5	19371887	900	903	O
week	19371887	904	908	O
(	19371887	909	910	O
range	19371887	910	915	O
3	19371887	916	917	O
to	19371887	918	920	O
4	19371887	921	922	O
days	19371887	923	927	O
)	19371887	927	928	O
of	19371887	929	931	O
treatment	19371887	932	941	O
patients	19371887	942	950	O
receiving	19371887	951	960	O
silodosin	19371887	961	970	O
vs	19371887	971	973	O
placebo	19371887	974	981	O
achieved	19371887	982	990	O
significant	19371887	991	1002	O
improvement	19371887	1003	1014	O
in	19371887	1015	1017	O
total	19371887	1018	1023	B-Outcome
International	19371887	1024	1037	I-Outcome
Prostate	19371887	1038	1046	I-Outcome
Symptom	19371887	1047	1054	I-Outcome
Score	19371887	1055	1060	I-Outcome
(	19371887	1061	1062	O
difference	19371887	1062	1072	O
-1.9	19371887	1073	1077	O
,	19371887	1077	1078	O
p	19371887	1079	1080	O
<	19371887	1081	1082	O
0.0001	19371887	1082	1088	O
)	19371887	1088	1089	O
and	19371887	1090	1093	O
irritative	19371887	1094	1104	B-Outcome
(	19371887	1105	1106	O
-0.5	19371887	1106	1110	O
,	19371887	1110	1111	O
p	19371887	1112	1113	O
=	19371887	1114	1115	O
0.0002	19371887	1116	1122	O
)	19371887	1122	1123	O
and	19371887	1124	1127	O
obstructive	19371887	1128	1139	B-Outcome
(	19371887	1140	1141	O
-1.4	19371887	1141	1145	O
,	19371887	1145	1146	O
p	19371887	1147	1148	O
<	19371887	1149	1150	O
0.0001	19371887	1150	1156	O
)	19371887	1156	1157	O
subscores	19371887	1158	1167	B-Outcome
.	19371887	1167	1168	O

The	19371887	1169	1172	O
mean	19371887	1173	1177	B-Outcome
+	19371887	1178	1179	I-Outcome
/-	19371887	1179	1181	I-Outcome
SD	19371887	1182	1184	I-Outcome
change	19371887	1185	1191	I-Outcome
from	19371887	1192	1196	I-Outcome
baseline	19371887	1197	1205	I-Outcome
in	19371887	1206	1208	I-Outcome
total	19371887	1209	1214	I-Outcome
International	19371887	1215	1228	I-Outcome
Prostate	19371887	1229	1237	I-Outcome
Symptom	19371887	1238	1245	I-Outcome
Score	19371887	1246	1251	I-Outcome
was	19371887	1252	1255	O
-4.2	19371887	1256	1260	O
+	19371887	1261	1262	O
/-	19371887	1262	1264	O
5.3	19371887	1265	1268	O
for	19371887	1269	1272	O
silodosin	19371887	1273	1282	O
vs	19371887	1283	1285	O
-2.3	19371887	1286	1290	O
+	19371887	1291	1292	O
/-	19371887	1292	1294	O
4.4	19371887	1295	1298	O
for	19371887	1299	1302	O
placebo	19371887	1303	1310	O
.	19371887	1310	1311	O

Differences	19371887	1312	1323	O
(	19371887	1324	1325	O
silodosin	19371887	1325	1334	O
vs	19371887	1335	1337	O
placebo	19371887	1338	1345	O
)	19371887	1345	1346	O
in	19371887	1347	1349	O
International	19371887	1350	1363	B-Outcome
Prostate	19371887	1364	1372	I-Outcome
Symptom	19371887	1373	1380	I-Outcome
Score	19371887	1381	1386	I-Outcome
and	19371887	1387	1390	O
subscores	19371887	1391	1400	B-Outcome
increased	19371887	1401	1410	O
by	19371887	1411	1413	O
week	19371887	1414	1418	O
12	19371887	1419	1421	O
(	19371887	1422	1423	O
p	19371887	1423	1424	O
<	19371887	1425	1426	O
0.0001	19371887	1426	1432	O
)	19371887	1432	1433	O
.	19371887	1433	1434	O

Mean	19371887	1435	1439	B-Outcome
change	19371887	1440	1446	I-Outcome
from	19371887	1447	1451	I-Outcome
baseline	19371887	1452	1460	I-Outcome
in	19371887	1461	1463	I-Outcome
peak	19371887	1464	1468	I-Outcome
urinary	19371887	1469	1476	I-Outcome
flow	19371887	1477	1481	I-Outcome
rate	19371887	1482	1486	I-Outcome
(	19371887	1487	1488	I-Outcome
ml	19371887	1488	1490	I-Outcome
per	19371887	1491	1494	I-Outcome
second	19371887	1495	1501	I-Outcome
)	19371887	1501	1502	I-Outcome
2	19371887	1503	1504	O
to	19371887	1505	1507	O
6	19371887	1508	1509	O
hours	19371887	1510	1515	O
after	19371887	1516	1521	O
initial	19371887	1522	1529	O
dose	19371887	1530	1534	O
was	19371887	1535	1538	O
greater	19371887	1539	1546	O
(	19371887	1547	1548	O
p	19371887	1548	1549	O
<	19371887	1550	1551	O
0.0001	19371887	1551	1557	O
)	19371887	1557	1558	O
with	19371887	1559	1563	O
silodosin	19371887	1564	1573	O
(	19371887	1574	1575	O
2.8	19371887	1575	1578	O
+	19371887	1579	1580	O
/-	19371887	1580	1582	O
3.4	19371887	1583	1586	O
)	19371887	1586	1587	O
than	19371887	1588	1592	O
placebo	19371887	1593	1600	O
(	19371887	1601	1602	O
1.5	19371887	1602	1605	O
+	19371887	1606	1607	O
/-	19371887	1607	1609	O
3.8	19371887	1610	1613	O
)	19371887	1613	1614	O
.	19371887	1614	1615	O

Differences	19371887	1616	1627	O
remained	19371887	1628	1636	O
significant	19371887	1637	1648	O
(	19371887	1649	1650	O
p	19371887	1650	1651	O
<	19371887	1652	1653	O
0.001	19371887	1653	1658	O
)	19371887	1658	1659	O
through	19371887	1660	1667	O
week	19371887	1668	1672	O
12	19371887	1673	1675	O
.	19371887	1675	1676	O

The	19371887	1677	1680	O
most	19371887	1681	1685	O
common	19371887	1686	1692	O
treatment	19371887	1693	1702	B-Outcome
emergent	19371887	1703	1711	I-Outcome
adverse	19371887	1712	1719	I-Outcome
event	19371887	1720	1725	I-Outcome
was	19371887	1726	1729	O
(	19371887	1730	1731	O
mostly	19371887	1731	1737	O
mild	19371887	1738	1742	O
)	19371887	1742	1743	O
retrograde	19371887	1744	1754	O
ejaculation	19371887	1755	1766	O
(	19371887	1767	1768	O
silodosin	19371887	1768	1777	O
28.1	19371887	1778	1782	O
%	19371887	1782	1783	O
of	19371887	1784	1786	O
patients	19371887	1787	1795	O
,	19371887	1795	1796	O
placebo	19371887	1797	1804	O
0.9	19371887	1805	1808	O
%	19371887	1808	1809	O
)	19371887	1809	1810	O
.	19371887	1810	1811	O

Few	19371887	1812	1815	O
patients	19371887	1816	1824	O
receiving	19371887	1825	1834	O
silodosin	19371887	1835	1844	O
(	19371887	1845	1846	O
2.8	19371887	1846	1849	O
%	19371887	1849	1850	O
)	19371887	1850	1851	O
discontinued	19371887	1852	1864	O
because	19371887	1865	1872	O
of	19371887	1873	1875	O
retrograde	19371887	1876	1886	O
ejaculation	19371887	1887	1898	O
.	19371887	1898	1899	O

Proportions	19371887	1900	1911	O
of	19371887	1912	1914	O
patients	19371887	1915	1923	O
with	19371887	1924	1928	O
treatment	19371887	1929	1938	O
emergent	19371887	1939	1947	O
orthostatic	19371887	1948	1959	O
hypotension	19371887	1960	1971	O
were	19371887	1972	1976	O
similar	19371887	1977	1984	O
for	19371887	1985	1988	O
silodosin	19371887	1989	1998	O
(	19371887	1999	2000	O
2.6	19371887	2000	2003	O
%	19371887	2003	2004	O
)	19371887	2004	2005	O
and	19371887	2006	2009	O
placebo	19371887	2010	2017	O
(	19371887	2018	2019	O
1.5	19371887	2019	2022	O
%	19371887	2022	2023	O
)	19371887	2023	2024	O
.	19371887	2024	2025	O

CONCLUSIONS	19371887	2027	2038	O
:	19371887	2039	2040	O
Treatment	19371887	2041	2050	O
with	19371887	2051	2055	O
silodosin	19371887	2056	2065	O
produced	19371887	2066	2074	O
rapid	19371887	2075	2080	O
improvement	19371887	2081	2092	O
in	19371887	2093	2095	O
urinary	19371887	2096	2103	B-Outcome
symptoms	19371887	2104	2112	I-Outcome
that	19371887	2113	2117	O
was	19371887	2118	2121	O
sustained	19371887	2122	2131	O
for	19371887	2132	2135	O
12	19371887	2136	2138	O
weeks	19371887	2139	2144	O
.	19371887	2144	2145	O

Silodosin	19371887	2146	2155	O
was	19371887	2156	2159	O
well	19371887	2160	2164	O
tolerated	19371887	2165	2174	B-Outcome
with	19371887	2175	2179	O
a	19371887	2180	2181	O
low	19371887	2182	2185	O
incidence	19371887	2186	2195	O
of	19371887	2196	2198	O
orthostatic	19371887	2199	2210	O
hypotension	19371887	2211	2222	O
.	19371887	2222	2223	O


Pulse	19397502	0	5	O
oximeter	19397502	6	14	O
perfusion	19397502	15	24	O
index	19397502	25	30	O
as	19397502	31	33	O
an	19397502	34	36	O
early	19397502	37	42	O
indicator	19397502	43	52	O
of	19397502	53	55	O
sympathectomy	19397502	56	69	O
after	19397502	70	75	O
epidural	19397502	76	84	O
anesthesia	19397502	85	95	O
.	19397502	95	96	O

BACKGROUND	19397502	98	108	O
:	19397502	109	110	O
The	19397502	111	114	O
pulse	19397502	115	120	O
oximeter	19397502	121	129	O
perfusion	19397502	130	139	O
index	19397502	140	145	O
(	19397502	146	147	O
PI	19397502	147	149	O
)	19397502	149	150	O
has	19397502	151	154	O
been	19397502	155	159	O
used	19397502	160	164	O
to	19397502	165	167	O
indicate	19397502	168	176	O
sympathectomy-induced	19397502	177	198	O
vasodilatation	19397502	199	213	O
.	19397502	213	214	O

We	19397502	215	217	O
hypothesized	19397502	218	230	O
that	19397502	231	235	O
pulse	19397502	236	241	O
oximeter	19397502	242	250	O
PI	19397502	251	253	O
provides	19397502	254	262	O
an	19397502	263	265	O
earlier	19397502	266	273	O
and	19397502	274	277	O
clearer	19397502	278	285	O
indication	19397502	286	296	O
of	19397502	297	299	O
sympathectomy	19397502	300	313	O
following	19397502	314	323	O
epidural	19397502	324	332	O
anesthesia	19397502	333	343	O
than	19397502	344	348	O
skin	19397502	349	353	O
temperature	19397502	354	365	O
and	19397502	366	369	O
arterial	19397502	370	378	O
pressure	19397502	379	387	O
.	19397502	387	388	O

METHODS	19397502	390	397	O
:	19397502	398	399	O
Forty	19397502	400	405	O
patients	19397502	406	414	O
received	19397502	415	423	O
lumbar	19397502	424	430	O
epidural	19397502	431	439	O
catheters	19397502	440	449	O
.	19397502	449	450	O

Patients	19397502	451	459	O
were	19397502	460	464	O
randomized	19397502	465	475	O
to	19397502	476	478	O
receive	19397502	479	486	O
either	19397502	487	493	O
10	19397502	494	496	O
ml	19397502	497	499	O
0.5	19397502	500	503	O
%	19397502	503	504	O
bupivacaine	19397502	505	516	O
or	19397502	517	519	O
10	19397502	520	522	O
ml	19397502	523	525	O
0.25	19397502	526	530	O
%	19397502	530	531	O
bupivacaine	19397502	532	543	O
.	19397502	543	544	O

PI	19397502	545	547	O
in	19397502	548	550	O
the	19397502	551	554	O
toe	19397502	555	558	O
,	19397502	558	559	O
mean	19397502	560	564	O
arterial	19397502	565	573	O
pressure	19397502	574	582	O
(	19397502	583	584	O
MAP	19397502	584	587	O
)	19397502	587	588	O
and	19397502	589	592	O
toe	19397502	593	596	O
temperature	19397502	597	608	O
were	19397502	609	613	O
all	19397502	614	617	O
assessed	19397502	618	626	O
at	19397502	627	629	O
baseline	19397502	630	638	O
and	19397502	639	642	O
at	19397502	643	645	O
5	19397502	646	647	O
,	19397502	647	648	O
10	19397502	649	651	O
and	19397502	652	655	O
20	19397502	656	658	O
min	19397502	659	662	O
following	19397502	663	672	O
epidural	19397502	673	681	O
anesthesia	19397502	682	692	O
.	19397502	692	693	O

The	19397502	694	697	O
effect	19397502	698	704	O
of	19397502	705	707	O
epidural	19397502	708	716	O
anesthesia	19397502	717	727	O
over	19397502	728	732	O
time	19397502	733	737	O
was	19397502	738	741	O
assessed	19397502	742	750	O
by	19397502	751	753	O
repeated	19397502	754	762	O
measures	19397502	763	771	O
analysis	19397502	772	780	O
of	19397502	781	783	O
variance	19397502	784	792	O
.	19397502	792	793	O

Additionally	19397502	794	806	O
,	19397502	806	807	O
we	19397502	808	810	O
defined	19397502	811	818	O
clinically	19397502	819	829	O
evident	19397502	830	837	O
sympathectomy	19397502	838	851	O
criteria	19397502	852	860	O
(	19397502	861	862	O
a	19397502	862	863	O
100	19397502	864	867	O
%	19397502	867	868	O
increase	19397502	869	877	O
in	19397502	878	880	O
the	19397502	881	884	O
PI	19397502	885	887	O
,	19397502	887	888	O
a	19397502	889	890	O
15	19397502	891	893	O
%	19397502	893	894	O
decrease	19397502	895	903	O
in	19397502	904	906	O
MAP	19397502	907	910	O
and	19397502	911	914	O
a	19397502	915	916	O
1	19397502	917	918	O
degrees	19397502	919	926	O
C	19397502	927	928	O
increase	19397502	929	937	O
in	19397502	938	940	O
toe	19397502	941	944	O
temperature	19397502	945	956	O
)	19397502	956	957	O
.	19397502	957	958	O

The	19397502	959	962	O
numbers	19397502	963	970	O
of	19397502	971	973	O
patients	19397502	974	982	O
demonstrating	19397502	983	996	O
these	19397502	997	1002	O
changes	19397502	1003	1010	O
for	19397502	1011	1014	O
each	19397502	1015	1019	O
test	19397502	1020	1024	O
were	19397502	1025	1029	O
compared	19397502	1030	1038	O
using	19397502	1039	1044	O
the	19397502	1045	1048	O
McNemar	19397502	1049	1056	O
test	19397502	1057	1061	O
for	19397502	1062	1065	O
each	19397502	1066	1070	O
time	19397502	1071	1075	O
point	19397502	1076	1081	O
.	19397502	1081	1082	O

RESULTS	19397502	1084	1091	O
:	19397502	1092	1093	O
Twenty-nine	19397502	1094	1105	O
subjects	19397502	1106	1114	O
had	19397502	1115	1118	O
photoplethysmography	19397502	1119	1139	O
signals	19397502	1140	1147	O
that	19397502	1148	1152	O
met	19397502	1153	1156	O
a	19397502	1157	1158	O
priori	19397502	1159	1165	O
signal	19397502	1166	1172	O
quality	19397502	1173	1180	O
criteria	19397502	1181	1189	O
for	19397502	1190	1193	O
analysis	19397502	1194	1202	O
.	19397502	1202	1203	O

By	19397502	1204	1206	O
20	19397502	1207	1209	O
min	19397502	1210	1213	O
,	19397502	1213	1214	O
PI	19397502	1215	1217	B-Outcome
increased	19397502	1218	1227	O
by	19397502	1228	1230	O
326	19397502	1231	1234	O
%	19397502	1234	1235	O
,	19397502	1235	1236	O
compared	19397502	1237	1245	O
with	19397502	1246	1250	O
a	19397502	1251	1252	O
10	19397502	1253	1255	O
%	19397502	1255	1256	O
decrease	19397502	1257	1265	O
and	19397502	1266	1269	O
a	19397502	1270	1271	O
3	19397502	1272	1273	O
%	19397502	1273	1274	O
increase	19397502	1275	1283	O
in	19397502	1284	1286	O
MAP	19397502	1287	1290	B-Outcome
and	19397502	1291	1294	O
toe	19397502	1295	1298	B-Outcome
temperature	19397502	1299	1310	I-Outcome
,	19397502	1310	1311	O
respectively	19397502	1312	1324	O
.	19397502	1324	1325	O

For	19397502	1326	1329	O
PI	19397502	1330	1332	B-Outcome
15/29	19397502	1333	1338	O
,	19397502	1338	1339	O
26/29	19397502	1340	1345	O
and	19397502	1346	1349	O
29/29	19397502	1350	1355	O
of	19397502	1356	1358	O
the	19397502	1359	1362	O
subjects	19397502	1363	1371	O
met	19397502	1372	1375	O
the	19397502	1376	1379	O
sympathectomy	19397502	1380	1393	O
criteria	19397502	1394	1402	O
at	19397502	1403	1405	O
5	19397502	1406	1407	O
,	19397502	1407	1408	O
10	19397502	1409	1411	O
and	19397502	1412	1415	O
20	19397502	1416	1418	O
min	19397502	1419	1422	O
,	19397502	1422	1423	O
respectively	19397502	1424	1436	O
,	19397502	1436	1437	O
compared	19397502	1438	1446	O
with	19397502	1447	1451	O
4/29	19397502	1452	1456	O
,	19397502	1456	1457	O
6/29	19397502	1458	1462	O
and	19397502	1463	1466	O
18/29	19397502	1467	1472	O
for	19397502	1473	1476	O
MAP	19397502	1477	1480	B-Outcome
changes	19397502	1481	1488	I-Outcome
and	19397502	1489	1492	O
3/29	19397502	1493	1497	O
,	19397502	1497	1498	O
8/29	19397502	1499	1503	O
and	19397502	1504	1507	O
14/29	19397502	1508	1513	O
for	19397502	1514	1517	O
toe	19397502	1518	1521	B-Outcome
temperature	19397502	1522	1533	I-Outcome
changes	19397502	1534	1541	I-Outcome
.	19397502	1541	1542	O

CONCLUSIONS	19397502	1544	1555	O
:	19397502	1556	1557	O
PI	19397502	1558	1560	B-Outcome
was	19397502	1561	1564	O
an	19397502	1565	1567	O
earlier	19397502	1568	1575	O
,	19397502	1575	1576	O
clearer	19397502	1577	1584	O
and	19397502	1585	1588	O
more	19397502	1589	1593	O
sensitive	19397502	1594	1603	O
indicator	19397502	1604	1613	O
of	19397502	1614	1616	O
the	19397502	1617	1620	O
development	19397502	1621	1632	O
of	19397502	1633	1635	O
epidural-induced	19397502	1636	1652	O
sympathectomy	19397502	1653	1666	O
than	19397502	1667	1671	O
either	19397502	1672	1678	O
skin	19397502	1679	1683	B-Outcome
temperature	19397502	1684	1695	I-Outcome
or	19397502	1696	1698	O
MAP	19397502	1699	1702	B-Outcome
.	19397502	1702	1703	O


Ambulatory	19407805	0	10	O
blood	19407805	11	16	O
pressure	19407805	17	25	O
control	19407805	26	33	O
with	19407805	34	38	O
bedtime	19407805	39	46	O
aspirin	19407805	47	54	O
administration	19407805	55	69	O
in	19407805	70	72	O
subjects	19407805	73	81	O
with	19407805	82	86	O
prehypertension	19407805	87	102	O
.	19407805	102	103	O

BACKGROUND	19407805	105	115	O
:	19407805	116	117	O
Aspirin	19407805	118	125	O
has	19407805	126	129	O
been	19407805	130	134	O
found	19407805	135	140	O
to	19407805	141	143	O
prevent	19407805	144	151	O
angiotensin	19407805	152	163	O
II-induced	19407805	164	174	O
hypertension	19407805	175	187	O
and	19407805	188	191	O
to	19407805	192	194	O
induce	19407805	195	201	O
nitric	19407805	202	208	O
oxide	19407805	209	214	O
(	19407805	215	216	O
NO	19407805	216	218	O
)	19407805	218	219	O
release	19407805	220	227	O
from	19407805	228	232	O
vascular	19407805	233	241	O
endothelium	19407805	242	253	O
.	19407805	253	254	O

Low-dose	19407805	255	263	O
aspirin	19407805	264	271	O
has	19407805	272	275	O
also	19407805	276	280	O
been	19407805	281	285	O
shown	19407805	286	291	O
to	19407805	292	294	O
reduce	19407805	295	301	O
blood	19407805	302	307	O
pressure	19407805	308	316	O
(	19407805	317	318	O
BP	19407805	318	320	O
)	19407805	320	321	O
when	19407805	322	326	O
administered	19407805	327	339	O
at	19407805	340	342	O
bedtime	19407805	343	350	O
,	19407805	350	351	O
as	19407805	352	354	O
opposed	19407805	355	362	O
to	19407805	363	365	O
upon	19407805	366	370	O
awakening	19407805	371	380	O
,	19407805	380	381	O
in	19407805	382	384	O
untreated	19407805	385	394	O
hypertensive	19407805	395	407	O
patients	19407805	408	416	O
and	19407805	417	420	O
high-risk	19407805	421	430	O
pregnant	19407805	431	439	O
women	19407805	440	445	O
.	19407805	445	446	O

Accordingly	19407805	447	458	O
,	19407805	458	459	O
we	19407805	460	462	O
investigated	19407805	463	475	O
the	19407805	476	479	O
effects	19407805	480	487	O
on	19407805	488	490	O
ambulatory	19407805	491	501	O
BP	19407805	502	504	O
of	19407805	505	507	O
aspirin	19407805	508	515	O
administered	19407805	516	528	O
at	19407805	529	531	O
different	19407805	532	541	O
times	19407805	542	547	O
of	19407805	548	550	O
the	19407805	551	554	O
day	19407805	555	558	O
in	19407805	559	561	O
prehypertension	19407805	562	577	O
.	19407805	577	578	O

METHODS	19407805	580	587	O
:	19407805	588	589	O
We	19407805	590	592	O
studied	19407805	593	600	O
244	19407805	601	604	O
subjects	19407805	605	613	O
with	19407805	614	618	O
prehypertension	19407805	619	634	O
,	19407805	634	635	O
43.0	19407805	636	640	O
+	19407805	641	642	O
/-	19407805	642	644	O
13.0	19407805	645	649	O
years	19407805	650	655	O
of	19407805	656	658	O
age	19407805	659	662	O
,	19407805	662	663	O
randomly	19407805	664	672	O
divided	19407805	673	680	O
in	19407805	681	683	O
three	19407805	684	689	O
groups	19407805	690	696	O
:	19407805	696	697	O
nonpharmacological	19407805	698	716	O
hygienic-dietary	19407805	717	733	O
recommendations	19407805	734	749	O
;	19407805	749	750	O
the	19407805	751	754	O
same	19407805	755	759	O
recommendations	19407805	760	775	O
and	19407805	776	779	O
aspirin	19407805	780	787	O
(	19407805	788	789	O
100	19407805	789	792	O
mg/day	19407805	793	799	O
)	19407805	799	800	O
on	19407805	801	803	O
awakening	19407805	804	813	O
;	19407805	813	814	O
or	19407805	815	817	O
the	19407805	818	821	O
same	19407805	822	826	O
recommendations	19407805	827	842	O
and	19407805	843	846	O
aspirin	19407805	847	854	O
at	19407805	855	857	O
bedtime	19407805	858	865	O
.	19407805	865	866	O

BP	19407805	867	869	O
was	19407805	870	873	O
measured	19407805	874	882	O
for	19407805	883	886	O
48	19407805	887	889	O
consecutive	19407805	890	901	O
hours	19407805	902	907	O
before	19407805	908	914	O
and	19407805	915	918	O
after	19407805	919	924	O
3	19407805	925	926	O
months	19407805	927	933	O
of	19407805	934	936	O
intervention	19407805	937	949	O
.	19407805	949	950	O

RESULTS	19407805	952	959	O
:	19407805	960	961	O
Ambulatory	19407805	962	972	B-Outcome
BP	19407805	973	975	I-Outcome
was	19407805	976	979	O
unchanged	19407805	980	989	O
in	19407805	990	992	O
subjects	19407805	993	1001	O
randomized	19407805	1002	1012	O
to	19407805	1013	1015	O
either	19407805	1016	1022	O
nonpharmacological	19407805	1023	1041	O
intervention	19407805	1042	1054	O
or	19407805	1055	1057	O
aspirin	19407805	1058	1065	O
on	19407805	1066	1068	O
awakening	19407805	1069	1078	O
.	19407805	1078	1079	O

A	19407805	1080	1081	O
significant	19407805	1082	1093	O
ambulatory	19407805	1094	1104	B-Outcome
BP	19407805	1105	1107	I-Outcome
reduction	19407805	1108	1117	O
was	19407805	1118	1121	O
,	19407805	1121	1122	O
however	19407805	1123	1130	O
,	19407805	1130	1131	O
observed	19407805	1132	1140	O
in	19407805	1141	1143	O
the	19407805	1144	1147	O
subjects	19407805	1148	1156	O
who	19407805	1157	1160	O
received	19407805	1161	1169	O
aspirin	19407805	1170	1177	O
at	19407805	1178	1180	O
bedtime	19407805	1181	1188	O
(	19407805	1189	1190	O
decrease	19407805	1190	1198	O
of	19407805	1199	1201	O
6/3	19407805	1202	1205	O
mm	19407805	1206	1208	O
Hg	19407805	1209	1211	O
in	19407805	1212	1214	O
the	19407805	1215	1218	O
24-h	19407805	1219	1223	B-Outcome
mean	19407805	1224	1228	I-Outcome
of	19407805	1229	1231	I-Outcome
systolic	19407805	1232	1240	I-Outcome
(SBP)/diastolic	19407805	1241	1256	I-Outcome
BP	19407805	1257	1259	I-Outcome
(	19407805	1260	1261	I-Outcome
DBP	19407805	1261	1264	I-Outcome
)	19407805	1264	1265	I-Outcome
,	19407805	1265	1266	O
respectively	19407805	1267	1279	O
;	19407805	1279	1280	O
P	19407805	1281	1282	O
<	19407805	1283	1284	O
0.001	19407805	1285	1290	O
)	19407805	1290	1291	O
,	19407805	1291	1292	O
without	19407805	1293	1300	O
changes	19407805	1301	1308	O
in	19407805	1309	1311	O
heart	19407805	1312	1317	B-Outcome
rate	19407805	1318	1322	I-Outcome
(	19407805	1323	1324	O
HR	19407805	1324	1326	B-Outcome
)	19407805	1326	1327	O
from	19407805	1328	1332	O
baseline	19407805	1333	1341	O
.	19407805	1341	1342	O

BP	19407805	1343	1345	B-Outcome
was	19407805	1346	1349	O
homogeneously	19407805	1350	1363	O
controlled	19407805	1364	1374	O
along	19407805	1375	1380	O
the	19407805	1381	1384	O
24	19407805	1385	1387	O
h	19407805	1388	1389	O
after	19407805	1390	1395	O
bedtime	19407805	1396	1403	O
aspirin	19407805	1404	1411	O
administration	19407805	1412	1426	O
(	19407805	1427	1428	O
6/4	19407805	1428	1431	O
mm	19407805	1432	1434	O
Hg	19407805	1435	1437	O
reduction	19407805	1438	1447	O
in	19407805	1448	1450	O
activity	19407805	1451	1459	O
mean	19407805	1460	1464	O
of	19407805	1465	1467	O
SBP/DBP	19407805	1468	1475	B-Outcome
;	19407805	1475	1476	O
6/3	19407805	1477	1480	O
mm	19407805	1481	1483	O
Hg	19407805	1484	1486	O
reduction	19407805	1487	1496	O
in	19407805	1497	1499	O
sleep-time	19407805	1500	1510	O
mean	19407805	1511	1515	O
,	19407805	1515	1516	O
respectively	19407805	1517	1529	O
)	19407805	1529	1530	O
.	19407805	1530	1531	O

CONCLUSIONS	19407805	1533	1544	O
:	19407805	1545	1546	O
This	19407805	1547	1551	O
prospective	19407805	1552	1563	O
trial	19407805	1564	1569	O
documents	19407805	1570	1579	O
a	19407805	1580	1581	O
significant	19407805	1582	1593	O
effect	19407805	1594	1600	O
on	19407805	1601	1603	O
BP	19407805	1604	1606	B-Outcome
of	19407805	1607	1609	O
low	19407805	1610	1613	O
dose	19407805	1614	1618	O
aspirin	19407805	1619	1626	O
only	19407805	1627	1631	O
when	19407805	1632	1636	O
ingested	19407805	1637	1645	O
at	19407805	1646	1648	O
bedtime	19407805	1649	1656	O
by	19407805	1657	1659	O
prehypertensive	19407805	1660	1675	O
subjects	19407805	1676	1684	O
.	19407805	1684	1685	O

The	19407805	1686	1689	O
timed	19407805	1690	1695	O
administration	19407805	1696	1710	O
of	19407805	1711	1713	O
low-dose	19407805	1714	1722	O
aspirin	19407805	1723	1730	O
could	19407805	1731	1736	O
thus	19407805	1737	1741	O
provide	19407805	1742	1749	O
a	19407805	1750	1751	O
valuable	19407805	1752	1760	O
and	19407805	1761	1764	O
cost-effective	19407805	1765	1779	O
approach	19407805	1780	1788	O
for	19407805	1789	1792	O
BP	19407805	1793	1795	B-Outcome
control	19407805	1796	1803	O
in	19407805	1804	1806	O
subjects	19407805	1807	1815	O
at	19407805	1816	1818	O
elevated	19407805	1819	1827	O
risk	19407805	1828	1832	O
of	19407805	1833	1835	O
developing	19407805	1836	1846	O
hypertension	19407805	1847	1859	O
.	19407805	1859	1860	O


Loss	19512937	0	4	O
of	19512937	5	7	O
bone	19512937	8	12	O
mineral	19512937	13	20	O
density	19512937	21	28	O
after	19512937	29	34	O
antiretroviral	19512937	35	49	O
therapy	19512937	50	57	O
initiation	19512937	58	68	O
,	19512937	68	69	O
independent	19512937	70	81	O
of	19512937	82	84	O
antiretroviral	19512937	85	99	O
regimen	19512937	100	107	O
.	19512937	107	108	O

BACKGROUND	19512937	110	120	O
:	19512937	121	122	O
Decreased	19512937	123	132	O
bone	19512937	133	137	O
mineral	19512937	138	145	O
density	19512937	146	153	O
(	19512937	154	155	O
BMD	19512937	155	158	O
)	19512937	158	159	O
has	19512937	160	163	O
been	19512937	164	168	O
described	19512937	169	178	O
in	19512937	179	181	O
HIV-infected	19512937	182	194	O
patients	19512937	195	203	O
initiating	19512937	204	214	O
antiretroviral	19512937	215	229	O
therapy	19512937	230	237	O
(	19512937	238	239	O
ART	19512937	239	242	O
)	19512937	242	243	O
,	19512937	243	244	O
but	19512937	245	248	O
the	19512937	249	252	O
contributions	19512937	253	266	O
of	19512937	267	269	O
ART	19512937	270	273	O
and	19512937	274	277	O
immunologic	19512937	278	289	O
and/or	19512937	290	296	O
virologic	19512937	297	306	O
factors	19512937	307	314	O
remain	19512937	315	321	O
unclear	19512937	322	329	O
.	19512937	329	330	O

METHODS	19512937	332	339	O
:	19512937	340	341	O
We	19512937	342	344	O
compared	19512937	345	353	O
total	19512937	354	359	O
BMD	19512937	360	363	O
changes	19512937	364	371	O
over	19512937	372	376	O
96	19512937	377	379	O
weeks	19512937	380	385	O
in	19512937	386	388	O
106	19512937	389	392	O
ART-naive	19512937	393	402	O
HIV-infected	19512937	403	415	O
subjects	19512937	416	424	O
who	19512937	425	428	O
were	19512937	429	433	O
randomized	19512937	434	444	O
to	19512937	445	447	O
receive	19512937	448	455	O
efavirenz	19512937	456	465	O
(	19512937	466	467	O
EFV	19512937	467	470	O
)	19512937	470	471	O
+	19512937	472	473	O
zidovudine/lamivudine	19512937	474	495	O
(	19512937	496	497	O
n	19512937	497	498	O
=	19512937	499	500	O
32	19512937	501	503	O
)	19512937	503	504	O
or	19512937	505	507	O
lopinavir/ritonavir	19512937	508	527	O
(	19512937	528	529	O
LPV/r	19512937	529	534	O
)	19512937	534	535	O
+	19512937	536	537	O
zidovudine/lamivudine	19512937	538	559	O
induction	19512937	560	569	O
(	19512937	570	571	O
n	19512937	571	572	O
=	19512937	573	574	O
74	19512937	575	577	O
)	19512937	577	578	O
for	19512937	579	582	O
24	19512937	583	585	O
-	19512937	585	586	O
48	19512937	586	588	O
weeks	19512937	589	594	O
followed	19512937	595	603	O
by	19512937	604	606	O
LPV/r	19512937	607	612	O
monotherapy	19512937	613	624	O
.	19512937	624	625	O

We	19512937	626	628	O
also	19512937	629	633	O
sought	19512937	634	640	O
to	19512937	641	643	O
identify	19512937	644	652	O
factors	19512937	653	660	O
associated	19512937	661	671	O
with	19512937	672	676	O
BMD	19512937	677	680	O
loss	19512937	681	685	O
,	19512937	685	686	O
including	19512937	687	696	O
markers	19512937	697	704	O
of	19512937	705	707	O
systemic	19512937	708	716	O
inflammation	19512937	717	729	O
[	19512937	730	731	O
soluble	19512937	731	738	O
tumor	19512937	739	744	O
necrosis	19512937	745	753	O
factor-alpha	19512937	754	766	O
receptors	19512937	767	776	O
(	19512937	777	778	O
sTNFR	19512937	778	783	O
I	19512937	784	785	O
and	19512937	786	789	O
II	19512937	790	792	O
)	19512937	792	793	O
]	19512937	793	794	O
.	19512937	794	795	O

RESULTS	19512937	797	804	O
:	19512937	805	806	O
After	19512937	807	812	O
96	19512937	813	815	O
weeks	19512937	816	821	O
,	19512937	821	822	O
the	19512937	823	826	O
mean	19512937	827	831	B-Outcome
percent	19512937	832	839	I-Outcome
change	19512937	840	846	I-Outcome
from	19512937	847	851	I-Outcome
baseline	19512937	852	860	I-Outcome
in	19512937	861	863	I-Outcome
total	19512937	864	869	I-Outcome
BMD	19512937	870	873	I-Outcome
was	19512937	874	877	O
-2.5	19512937	878	882	O
%	19512937	882	883	O
(	19512937	884	885	O
LPV/r	19512937	885	890	O
)	19512937	890	891	O
and	19512937	892	895	O
-2.3	19512937	896	900	O
%	19512937	900	901	O
(	19512937	902	903	O
EFV	19512937	903	906	O
)	19512937	906	907	O
(	19512937	908	909	O
P	19512937	909	910	O
<	19512937	911	912	O
0.01	19512937	913	917	O
for	19512937	918	921	O
within-group	19512937	922	934	O
changes	19512937	935	942	O
in	19512937	943	945	O
either	19512937	946	952	O
arm	19512937	953	956	O
;	19512937	956	957	O
P	19512937	958	959	O
=	19512937	960	961	O
0.86	19512937	962	966	O
for	19512937	967	970	O
between-group	19512937	971	984	O
differences	19512937	985	996	O
)	19512937	996	997	O
.	19512937	997	998	O

No	19512937	999	1001	O
alteration	19512937	1002	1012	O
in	19512937	1013	1015	O
the	19512937	1016	1019	O
rate	19512937	1020	1024	B-Outcome
of	19512937	1025	1027	I-Outcome
BMD	19512937	1028	1031	I-Outcome
change	19512937	1032	1038	I-Outcome
was	19512937	1039	1042	O
observed	19512937	1043	1051	O
upon	19512937	1052	1056	O
simplification	19512937	1057	1071	O
to	19512937	1072	1074	O
LPV/r	19512937	1075	1080	O
monotherapy	19512937	1081	1092	O
.	19512937	1092	1093	O

Although	19512937	1094	1102	O
soluble	19512937	1103	1110	B-Outcome
tumor	19512937	1111	1116	I-Outcome
necrosis	19512937	1117	1125	I-Outcome
factor-alpha	19512937	1126	1138	I-Outcome
receptor	19512937	1139	1147	I-Outcome
II	19512937	1148	1150	I-Outcome
concentrations	19512937	1151	1165	I-Outcome
at	19512937	1166	1168	O
baseline	19512937	1169	1177	O
and	19512937	1178	1181	O
24	19512937	1182	1184	O
weeks	19512937	1185	1190	O
were	19512937	1191	1195	O
at	19512937	1196	1198	O
least	19512937	1199	1204	O
marginally	19512937	1205	1215	O
associated	19512937	1216	1226	O
with	19512937	1227	1231	O
subsequent	19512937	1232	1242	O
changes	19512937	1243	1250	B-Outcome
in	19512937	1251	1253	I-Outcome
BMD	19512937	1254	1257	I-Outcome
(	19512937	1258	1259	O
P	19512937	1259	1260	O
=	19512937	1261	1262	O
0.06	19512937	1263	1267	O
and	19512937	1268	1271	O
P	19512937	1272	1273	O
=	19512937	1274	1275	O
0.028	19512937	1276	1281	O
,	19512937	1281	1282	O
respectively	19512937	1283	1295	O
)	19512937	1295	1296	O
,	19512937	1296	1297	O
these	19512937	1298	1303	O
associations	19512937	1304	1316	O
were	19512937	1317	1321	O
no	19512937	1322	1324	O
longer	19512937	1325	1331	O
significant	19512937	1332	1343	O
after	19512937	1344	1349	O
adjustment	19512937	1350	1360	O
for	19512937	1361	1364	O
CD4	19512937	1365	1368	O
T	19512937	1369	1370	O
cell	19512937	1371	1375	O
count	19512937	1376	1381	O
.	19512937	1381	1382	O

Subjects	19512937	1383	1391	O
with	19512937	1392	1396	O
lower	19512937	1397	1402	O
baseline	19512937	1403	1411	O
CD4	19512937	1412	1415	O
T	19512937	1416	1417	O
cell	19512937	1418	1422	O
count	19512937	1423	1428	O
,	19512937	1428	1429	O
non-black	19512937	1430	1439	O
race	19512937	1440	1444	O
,	19512937	1444	1445	O
and	19512937	1446	1449	O
higher	19512937	1450	1456	O
baseline	19512937	1457	1465	O
glucose	19512937	1466	1473	O
demonstrated	19512937	1474	1486	O
a	19512937	1487	1488	O
higher	19512937	1489	1495	O
risk	19512937	1496	1500	O
for	19512937	1501	1504	O
>	19512937	1505	1506	O
5	19512937	1506	1507	O
%	19512937	1507	1508	O
decrease	19512937	1509	1517	O
in	19512937	1518	1520	O
BMD	19512937	1521	1524	B-Outcome
.	19512937	1524	1525	O

CONCLUSIONS	19512937	1527	1538	O
:	19512937	1539	1540	O
Similar	19512937	1541	1548	O
decreases	19512937	1549	1558	O
in	19512937	1559	1561	O
BMD	19512937	1562	1565	B-Outcome
over	19512937	1566	1570	I-Outcome
96	19512937	1571	1573	I-Outcome
weeks	19512937	1574	1579	I-Outcome
occurred	19512937	1580	1588	O
in	19512937	1589	1591	O
ART-naive	19512937	1592	1601	O
subjects	19512937	1602	1610	O
receiving	19512937	1611	1620	O
either	19512937	1621	1627	O
EFV-based	19512937	1628	1637	O
regimen	19512937	1638	1645	O
or	19512937	1646	1648	O
LPV/r-based	19512937	1649	1660	O
regimen	19512937	1661	1668	O
,	19512937	1668	1669	O
which	19512937	1670	1675	O
was	19512937	1676	1679	O
not	19512937	1680	1683	O
altered	19512937	1684	1691	O
by	19512937	1692	1694	O
simplification	19512937	1695	1709	O
to	19512937	1710	1712	O
LPV/r	19512937	1713	1718	O
monotherapy	19512937	1719	1730	O
and	19512937	1731	1734	O
was	19512937	1735	1738	O
unrelated	19512937	1739	1748	O
to	19512937	1749	1751	O
markers	19512937	1752	1759	O
of	19512937	1760	1762	O
tumor	19512937	1763	1768	O
necrosis	19512937	1769	1777	O
factor-alpha	19512937	1778	1790	O
activity	19512937	1791	1799	O
.	19512937	1799	1800	O


Effects	19570717	0	7	O
of	19570717	8	10	O
tonabersat	19570717	11	21	O
on	19570717	22	24	O
migraine	19570717	25	33	O
with	19570717	34	38	O
aura	19570717	39	43	O
:	19570717	43	44	O
a	19570717	45	46	O
randomised	19570717	47	57	O
,	19570717	57	58	O
double-blind	19570717	59	71	O
,	19570717	71	72	O
placebo-controlled	19570717	73	91	O
crossover	19570717	92	101	O
study	19570717	102	107	O
.	19570717	107	108	O

BACKGROUND	19570717	110	120	O
:	19570717	121	122	O
Migraine	19570717	123	131	O
with	19570717	132	136	O
aura	19570717	137	141	O
is	19570717	142	144	O
thought	19570717	145	152	O
likely	19570717	153	159	O
to	19570717	160	162	O
be	19570717	163	165	O
caused	19570717	166	172	O
by	19570717	173	175	O
cortical	19570717	176	184	O
spreading	19570717	185	194	O
depression	19570717	195	205	O
(	19570717	206	207	O
CSD	19570717	207	210	O
)	19570717	210	211	O
.	19570717	211	212	O

Tonabersat	19570717	213	223	O
inhibits	19570717	224	232	O
CSD	19570717	233	236	O
,	19570717	236	237	O
and	19570717	238	241	O
we	19570717	242	244	O
therefore	19570717	245	254	O
investigated	19570717	255	267	O
whether	19570717	268	275	O
tonabersat	19570717	276	286	O
has	19570717	287	290	O
a	19570717	291	292	O
preventive	19570717	293	303	O
effect	19570717	304	310	O
in	19570717	311	313	O
migraine	19570717	314	322	O
with	19570717	323	327	O
aura	19570717	328	332	O
.	19570717	332	333	O

METHODS	19570717	335	342	O
:	19570717	343	344	O
In	19570717	345	347	O
this	19570717	348	352	O
randomised	19570717	353	363	O
,	19570717	363	364	O
double-blind	19570717	365	377	O
,	19570717	377	378	O
placebo-controlled	19570717	379	397	O
crossover	19570717	398	407	O
trial	19570717	408	413	O
,	19570717	413	414	O
40	19570717	415	417	O
mg	19570717	418	420	O
tonabersat	19570717	421	431	O
once	19570717	432	436	O
daily	19570717	437	442	O
was	19570717	443	446	O
compared	19570717	447	455	O
with	19570717	456	460	O
matched	19570717	461	468	O
placebo	19570717	469	476	O
in	19570717	477	479	O
patients	19570717	480	488	O
who	19570717	489	492	O
had	19570717	493	496	O
at	19570717	497	499	O
least	19570717	500	505	O
one	19570717	506	509	O
aura	19570717	510	514	O
attack	19570717	515	521	O
per	19570717	522	525	O
month	19570717	526	531	O
during	19570717	532	538	O
the	19570717	539	542	O
past	19570717	543	547	O
3	19570717	548	549	O
months	19570717	550	556	O
.	19570717	556	557	O

Randomisation	19570717	558	571	O
was	19570717	572	575	O
by	19570717	576	578	O
computer-generated	19570717	579	597	O
list	19570717	598	602	O
.	19570717	602	603	O

Patients	19570717	604	612	O
kept	19570717	613	617	O
a	19570717	618	619	O
detailed	19570717	620	628	O
diary	19570717	629	634	O
to	19570717	635	637	O
enable	19570717	638	644	O
objective	19570717	645	654	O
diagnosis	19570717	655	664	O
of	19570717	665	667	O
each	19570717	668	672	O
attack	19570717	673	679	O
as	19570717	680	682	O
migraine	19570717	683	691	O
with	19570717	692	696	O
aura	19570717	697	701	O
,	19570717	701	702	O
migraine	19570717	703	711	O
without	19570717	712	719	O
aura	19570717	720	724	O
,	19570717	724	725	O
or	19570717	726	728	O
other	19570717	729	734	O
type	19570717	735	739	O
of	19570717	740	742	O
headache	19570717	743	751	O
.	19570717	751	752	O

Primary	19570717	753	760	O
endpoints	19570717	761	770	O
were	19570717	771	775	O
a	19570717	776	777	O
reduction	19570717	778	787	O
in	19570717	788	790	O
aura	19570717	791	795	O
attacks	19570717	796	803	O
with	19570717	804	808	O
or	19570717	809	811	O
without	19570717	812	819	O
headache	19570717	820	828	O
and	19570717	829	832	O
a	19570717	833	834	O
reduction	19570717	835	844	O
in	19570717	845	847	O
migraine	19570717	848	856	O
headache	19570717	857	865	O
days	19570717	866	870	O
with	19570717	871	875	O
or	19570717	876	878	O
without	19570717	879	886	O
an	19570717	887	889	O
aura	19570717	890	894	O
.	19570717	894	895	O

Analysis	19570717	896	904	O
was	19570717	905	908	O
per	19570717	909	912	O
protocol	19570717	913	921	O
.	19570717	921	922	O

This	19570717	923	927	O
trial	19570717	928	933	O
is	19570717	934	936	O
registered	19570717	937	947	O
,	19570717	947	948	O
number	19570717	949	955	O
NCT00332007	19570717	956	967	O
.	19570717	967	968	O

FINDINGS	19570717	970	978	O
:	19570717	979	980	O
39	19570717	981	983	O
patients	19570717	984	992	O
were	19570717	993	997	O
included	19570717	998	1006	O
in	19570717	1007	1009	O
the	19570717	1010	1013	O
study	19570717	1014	1019	O
,	19570717	1019	1020	O
of	19570717	1021	1023	O
whom	19570717	1024	1028	O
31	19570717	1029	1031	O
were	19570717	1032	1036	O
included	19570717	1037	1045	O
in	19570717	1046	1048	O
the	19570717	1049	1052	O
statistical	19570717	1053	1064	O
analysis	19570717	1065	1073	O
of	19570717	1074	1076	O
efficacy	19570717	1077	1085	O
.	19570717	1085	1086	O

Median	19570717	1087	1093	B-Outcome
(	19570717	1094	1095	I-Outcome
IQR	19570717	1095	1098	I-Outcome
)	19570717	1098	1099	I-Outcome
attacks	19570717	1100	1107	I-Outcome
of	19570717	1108	1110	I-Outcome
aura	19570717	1111	1115	I-Outcome
were	19570717	1116	1120	O
reduced	19570717	1121	1128	O
from	19570717	1129	1133	O
3.2	19570717	1134	1137	O
(	19570717	1138	1139	O
1.0	19570717	1139	1142	O
-	19570717	1142	1143	O
5.0	19570717	1143	1146	O
)	19570717	1146	1147	O
per	19570717	1148	1151	O
12	19570717	1152	1154	O
weeks	19570717	1155	1160	O
on	19570717	1161	1163	O
placebo	19570717	1164	1171	O
to	19570717	1172	1174	O
1.0	19570717	1175	1178	O
(	19570717	1179	1180	O
0	19570717	1180	1181	O
-	19570717	1181	1182	O
3.0	19570717	1182	1185	O
)	19570717	1185	1186	O
on	19570717	1187	1189	O
tonabersat	19570717	1190	1200	O
(	19570717	1201	1202	O
p=0.01	19570717	1202	1208	O
)	19570717	1208	1209	O
,	19570717	1209	1210	O
whereas	19570717	1211	1218	O
the	19570717	1219	1222	O
other	19570717	1223	1228	O
primary	19570717	1229	1236	O
outcome	19570717	1237	1244	O
measure	19570717	1245	1252	O
,	19570717	1252	1253	O
median	19570717	1254	1260	B-Outcome
migraine	19570717	1261	1269	I-Outcome
headache	19570717	1270	1278	I-Outcome
days	19570717	1279	1283	I-Outcome
with	19570717	1284	1288	I-Outcome
or	19570717	1289	1291	O
without	19570717	1292	1299	B-Outcome
aura	19570717	1300	1304	I-Outcome
,	19570717	1304	1305	O
was	19570717	1306	1309	O
not	19570717	1310	1313	O
significantly	19570717	1314	1327	O
different	19570717	1328	1337	O
between	19570717	1338	1345	O
placebo	19570717	1346	1353	O
and	19570717	1354	1357	O
tonabersat	19570717	1358	1368	O
groups	19570717	1369	1375	O
(	19570717	1376	1377	O
3.0	19570717	1377	1380	O
days	19570717	1381	1385	O
in	19570717	1386	1388	O
each	19570717	1389	1393	O
group	19570717	1394	1399	O
;	19570717	1399	1400	O
p=0.09	19570717	1401	1407	O
)	19570717	1407	1408	O
.	19570717	1408	1409	O

Tonabersat	19570717	1410	1420	O
was	19570717	1421	1424	O
well	19570717	1425	1429	O
tolerated	19570717	1430	1439	B-Outcome
but	19570717	1440	1443	O
overall	19570717	1444	1451	O
had	19570717	1452	1455	O
more	19570717	1456	1460	O
side-effects	19570717	1461	1473	B-Outcome
than	19570717	1474	1478	O
placebo	19570717	1479	1486	O
.	19570717	1486	1487	O

INTERPRETATION	19570717	1489	1503	O
:	19570717	1504	1505	O
Tonabersat	19570717	1506	1516	O
showed	19570717	1517	1523	O
a	19570717	1524	1525	O
preventive	19570717	1526	1536	O
effect	19570717	1537	1543	O
on	19570717	1544	1546	O
attacks	19570717	1547	1554	B-Outcome
of	19570717	1555	1557	I-Outcome
migraine	19570717	1558	1566	I-Outcome
aura	19570717	1567	1571	I-Outcome
but	19570717	1572	1575	O
no	19570717	1576	1578	O
efficacy	19570717	1579	1587	B-Outcome
on	19570717	1588	1590	O
non-aura	19570717	1591	1599	B-Outcome
attacks	19570717	1600	1607	I-Outcome
,	19570717	1607	1608	O
in	19570717	1609	1611	O
keeping	19570717	1612	1619	O
with	19570717	1620	1624	O
its	19570717	1625	1628	O
known	19570717	1629	1634	O
inhibitory	19570717	1635	1645	O
effect	19570717	1646	1652	O
on	19570717	1653	1655	O
CSD	19570717	1656	1659	O
.	19570717	1659	1660	O

The	19570717	1661	1664	O
results	19570717	1665	1672	O
support	19570717	1673	1680	O
the	19570717	1681	1684	O
theory	19570717	1685	1691	O
that	19570717	1692	1696	O
auras	19570717	1697	1702	O
are	19570717	1703	1706	O
caused	19570717	1707	1713	O
by	19570717	1714	1716	O
CSD	19570717	1717	1720	O
and	19570717	1721	1724	O
that	19570717	1725	1729	O
this	19570717	1730	1734	O
phenomenon	19570717	1735	1745	O
is	19570717	1746	1748	O
not	19570717	1749	1752	O
involved	19570717	1753	1761	O
in	19570717	1762	1764	O
attacks	19570717	1765	1772	O
without	19570717	1773	1780	O
aura	19570717	1781	1785	O
.	19570717	1785	1786	O

FUNDING	19570717	1788	1795	O
:	19570717	1796	1797	O
Minster	19570717	1798	1805	O
Pharmaceuticals	19570717	1806	1821	O
;	19570717	1821	1822	O
Lundbeck	19570717	1823	1831	O
Foundation	19570717	1832	1842	O
.	19570717	1842	1843	O


Verapamil	19594501	0	9	O
augmentation	19594501	10	22	O
of	19594501	23	25	O
lithium	19594501	26	33	O
treatment	19594501	34	43	O
improves	19594501	44	52	O
outcome	19594501	53	60	O
in	19594501	61	63	O
mania	19594501	64	69	O
unresponsive	19594501	70	82	O
to	19594501	83	85	O
lithium	19594501	86	93	O
alone	19594501	94	99	O
:	19594501	99	100	O
preliminary	19594501	101	112	O
findings	19594501	113	121	O
and	19594501	122	125	O
a	19594501	126	127	O
discussion	19594501	128	138	O
of	19594501	139	141	O
therapeutic	19594501	142	153	O
mechanisms	19594501	154	164	O
.	19594501	164	165	O

OBJECTIVES	19594501	167	177	O
:	19594501	178	179	O
Attenuation	19594501	180	191	O
of	19594501	192	194	O
protein	19594501	195	202	O
kinase	19594501	203	209	O
C	19594501	210	211	O
(	19594501	212	213	O
PKC	19594501	213	216	O
)	19594501	216	217	O
is	19594501	218	220	O
a	19594501	221	222	O
mechanism	19594501	223	232	O
common	19594501	233	239	O
to	19594501	240	242	O
both	19594501	243	247	O
established	19594501	248	259	O
(	19594501	260	261	O
lithium	19594501	261	268	O
,	19594501	268	269	O
valproate	19594501	270	279	O
)	19594501	279	280	O
and	19594501	281	284	O
some	19594501	285	289	O
novel	19594501	290	295	O
(	19594501	296	297	O
tamoxifen	19594501	297	306	O
)	19594501	306	307	O
antimanic	19594501	308	317	O
agents	19594501	318	324	O
.	19594501	324	325	O

Verapamil	19594501	326	335	O
,	19594501	335	336	O
although	19594501	337	345	O
primarily	19594501	346	355	O
known	19594501	356	361	O
as	19594501	362	364	O
a	19594501	365	366	O
calcium	19594501	367	374	O
channel	19594501	375	382	O
blocker	19594501	383	390	O
,	19594501	390	391	O
also	19594501	392	396	O
has	19594501	397	400	O
PKC	19594501	401	404	O
inhibitory	19594501	405	415	O
activity	19594501	416	424	O
.	19594501	424	425	O

Verapamil	19594501	426	435	O
has	19594501	436	439	O
shown	19594501	440	445	O
antimanic	19594501	446	455	O
activity	19594501	456	464	O
in	19594501	465	467	O
some	19594501	468	472	O
but	19594501	473	476	O
not	19594501	477	480	O
all	19594501	481	484	O
studies	19594501	485	492	O
.	19594501	492	493	O

Therefore	19594501	494	503	O
,	19594501	503	504	O
we	19594501	505	507	O
investigated	19594501	508	520	O
verapamil	19594501	521	530	O
,	19594501	530	531	O
used	19594501	532	536	O
alone	19594501	537	542	O
or	19594501	543	545	O
as	19594501	546	548	O
an	19594501	549	551	O
adjunctive	19594501	552	562	O
treatment	19594501	563	572	O
,	19594501	572	573	O
in	19594501	574	576	O
manic	19594501	577	582	O
patients	19594501	583	591	O
who	19594501	592	595	O
did	19594501	596	599	O
not	19594501	600	603	O
respond	19594501	604	611	O
to	19594501	612	614	O
an	19594501	615	617	O
initial	19594501	618	625	O
adequate	19594501	626	634	O
trial	19594501	635	640	O
of	19594501	641	643	O
lithium	19594501	644	651	O
.	19594501	651	652	O

METHODS	19594501	654	661	O
:	19594501	662	663	O
Each	19594501	664	668	O
study	19594501	669	674	O
phase	19594501	675	680	O
lasted	19594501	681	687	O
three	19594501	688	693	O
weeks	19594501	694	699	O
.	19594501	699	700	O

Subjects	19594501	701	709	O
were	19594501	710	714	O
treated	19594501	715	722	O
openly	19594501	723	729	O
with	19594501	730	734	O
lithium	19594501	735	742	O
in	19594501	743	745	O
Phase	19594501	746	751	O
1	19594501	752	753	O
(	19594501	754	755	O
n	19594501	755	756	O
=	19594501	757	758	O
45	19594501	759	761	O
)	19594501	761	762	O
.	19594501	762	763	O

Those	19594501	764	769	O
who	19594501	770	773	O
failed	19594501	774	780	O
to	19594501	781	783	O
respond	19594501	784	791	O
were	19594501	792	796	O
randomly	19594501	797	805	O
assigned	19594501	806	814	O
to	19594501	815	817	O
double-blind	19594501	818	830	O
treatment	19594501	831	840	O
in	19594501	841	843	O
Phase	19594501	844	849	O
2	19594501	850	851	O
with	19594501	852	856	O
either	19594501	857	863	O
verapamil	19594501	864	873	O
(	19594501	874	875	O
n	19594501	875	876	O
=	19594501	877	878	O
10	19594501	879	881	O
)	19594501	881	882	O
or	19594501	883	885	O
continued-lithium	19594501	886	903	O
(	19594501	904	905	O
n	19594501	905	906	O
=	19594501	907	908	O
8)	19594501	909	911	O
.	19594501	911	912	O

Phase	19594501	913	918	O
2	19594501	919	920	O
nonresponders	19594501	921	934	O
(	19594501	935	936	O
n	19594501	936	937	O
=	19594501	938	939	O
10	19594501	940	942	O
)	19594501	942	943	O
were	19594501	944	948	O
assigned	19594501	949	957	O
to	19594501	958	960	O
combined	19594501	961	969	O
verapamil/lithium	19594501	970	987	O
in	19594501	988	990	O
Phase	19594501	991	996	O
3	19594501	997	998	O
.	19594501	998	999	O

RESULTS	19594501	1001	1008	O
:	19594501	1009	1010	O
Response	19594501	1011	1019	O
in	19594501	1020	1022	O
Phase	19594501	1023	1028	O
2	19594501	1029	1030	O
did	19594501	1031	1034	O
not	19594501	1035	1038	O
differ	19594501	1039	1045	O
significantly	19594501	1046	1059	O
between	19594501	1060	1067	O
verapamil	19594501	1068	1077	O
and	19594501	1078	1081	O
continued-lithium	19594501	1082	1099	O
.	19594501	1099	1100	O

During	19594501	1101	1107	O
Phase	19594501	1108	1113	O
3	19594501	1114	1115	O
,	19594501	1115	1116	O
response	19594501	1117	1125	O
to	19594501	1126	1128	O
combined	19594501	1129	1137	O
treatment	19594501	1138	1147	O
was	19594501	1148	1151	O
significantly	19594501	1152	1165	O
better	19594501	1166	1172	O
than	19594501	1173	1177	O
overall	19594501	1178	1185	B-Outcome
response	19594501	1186	1194	I-Outcome
to	19594501	1195	1197	O
monotherapy	19594501	1198	1209	O
in	19594501	1210	1212	O
Phase	19594501	1213	1218	O
2	19594501	1219	1220	O
(	19594501	1221	1222	O
Fisher	19594501	1222	1228	O
's	19594501	1228	1230	O
Exact	19594501	1231	1236	O
test	19594501	1237	1241	O
,	19594501	1241	1242	O
p	19594501	1243	1244	O
=	19594501	1245	1246	O
0.043	19594501	1247	1252	O
)	19594501	1252	1253	O
.	19594501	1253	1254	O

Mania	19594501	1255	1260	B-Outcome
ratings	19594501	1261	1268	I-Outcome
improved	19594501	1269	1277	O
during	19594501	1278	1284	O
combined	19594501	1285	1293	O
treatment	19594501	1294	1303	O
in	19594501	1304	1306	O
Phase	19594501	1307	1312	O
3	19594501	1313	1314	O
by	19594501	1315	1317	O
88.2	19594501	1318	1322	O
%	19594501	1322	1323	O
(	19594501	1324	1325	O
linear	19594501	1325	1331	O
mixed	19594501	1332	1337	O
model	19594501	1338	1343	O
analysis	19594501	1344	1352	O
,	19594501	1352	1353	O
F	19594501	1354	1355	O
=	19594501	1356	1357	O
4.34	19594501	1358	1362	O
,	19594501	1362	1363	O
p	19594501	1364	1365	O
=	19594501	1366	1367	O
0.013	19594501	1368	1373	O
)	19594501	1373	1374	O
,	19594501	1374	1375	O
compared	19594501	1376	1384	O
with	19594501	1385	1389	O
10.5	19594501	1390	1394	O
%	19594501	1394	1395	O
improvement	19594501	1396	1407	O
during	19594501	1408	1414	O
Phase	19594501	1415	1420	O
2	19594501	1421	1422	O
.	19594501	1422	1423	O

CONCLUSIONS	19594501	1425	1436	O
:	19594501	1437	1438	O
In	19594501	1439	1441	O
this	19594501	1442	1446	O
preliminary	19594501	1447	1458	O
investigation	19594501	1459	1472	O
,	19594501	1472	1473	O
verapamil	19594501	1474	1483	O
monotherapy	19594501	1484	1495	O
did	19594501	1496	1499	O
not	19594501	1500	1503	O
demonstrate	19594501	1504	1515	O
antimanic	19594501	1516	1525	O
efficacy	19594501	1526	1534	B-Outcome
.	19594501	1534	1535	O

By	19594501	1536	1538	O
contrast	19594501	1539	1547	O
,	19594501	1547	1548	O
the	19594501	1549	1552	O
combination	19594501	1553	1564	O
of	19594501	1565	1567	O
verapamil	19594501	1568	1577	O
plus	19594501	1578	1582	O
lithium	19594501	1583	1590	O
was	19594501	1591	1594	O
highly	19594501	1595	1601	O
efficacious	19594501	1602	1613	B-Outcome
.	19594501	1613	1614	O

Our	19594501	1615	1618	O
findings	19594501	1619	1627	O
thus	19594501	1628	1632	O
suggest	19594501	1633	1640	O
that	19594501	1641	1645	O
verapamil	19594501	1646	1655	O
may	19594501	1656	1659	O
have	19594501	1660	1664	O
potential	19594501	1665	1674	O
utility	19594501	1675	1682	O
as	19594501	1683	1685	O
an	19594501	1686	1688	O
adjunct	19594501	1689	1696	O
to	19594501	1697	1699	O
lithium	19594501	1700	1707	O
.	19594501	1707	1708	O

This	19594501	1709	1713	O
effect	19594501	1714	1720	O
may	19594501	1721	1724	O
be	19594501	1725	1727	O
mediated	19594501	1728	1736	O
by	19594501	1737	1739	O
additive	19594501	1740	1748	O
actions	19594501	1749	1756	O
on	19594501	1757	1759	O
PKC	19594501	1760	1763	O
inhibition	19594501	1764	1774	O
,	19594501	1774	1775	O
which	19594501	1776	1781	O
may	19594501	1782	1785	O
be	19594501	1786	1788	O
an	19594501	1789	1791	O
important	19594501	1792	1801	O
mechanism	19594501	1802	1811	O
for	19594501	1812	1815	O
antimanic	19594501	1816	1825	O
agents	19594501	1826	1832	O
in	19594501	1833	1835	O
general	19594501	1836	1843	O
.	19594501	1843	1844	O


Sustained	19675193	0	9	O
benefit	19675193	10	17	O
of	19675193	18	20	O
continuous	19675193	21	31	O
glucose	19675193	32	39	O
monitoring	19675193	40	50	O
on	19675193	51	53	O
A1C	19675193	54	57	O
,	19675193	57	58	O
glucose	19675193	59	66	O
profiles	19675193	67	75	O
,	19675193	75	76	O
and	19675193	77	80	O
hypoglycemia	19675193	81	93	O
in	19675193	94	96	O
adults	19675193	97	103	O
with	19675193	104	108	O
type	19675193	109	113	O
1	19675193	114	115	O
diabetes	19675193	116	124	O
.	19675193	124	125	O

OBJECTIVE	19675193	127	136	O
:	19675193	137	138	O
To	19675193	139	141	O
evaluate	19675193	142	150	O
long-term	19675193	151	160	O
effects	19675193	161	168	O
of	19675193	169	171	O
continuous	19675193	172	182	O
glucose	19675193	183	190	O
monitoring	19675193	191	201	O
(	19675193	202	203	O
CGM	19675193	203	206	O
)	19675193	206	207	O
in	19675193	208	210	O
intensively	19675193	211	222	O
treated	19675193	223	230	O
adults	19675193	231	237	O
with	19675193	238	242	O
type	19675193	243	247	O
1	19675193	248	249	O
diabetes	19675193	250	258	O
.	19675193	258	259	O

RESEARCH	19675193	261	269	O
DESIGN	19675193	270	276	O
AND	19675193	277	280	O
METHODS	19675193	281	288	O
:	19675193	289	290	O
We	19675193	291	293	O
studied	19675193	294	301	O
83	19675193	302	304	O
of	19675193	305	307	O
86	19675193	308	310	O
individuals	19675193	311	322	O
>	19675193	323	324	O
or=25	19675193	324	329	O
years	19675193	330	335	O
of	19675193	336	338	O
age	19675193	339	342	O
with	19675193	343	347	O
type	19675193	348	352	O
1	19675193	353	354	O
diabetes	19675193	355	363	O
who	19675193	364	367	O
used	19675193	368	372	O
CGM	19675193	373	376	O
as	19675193	377	379	O
part	19675193	380	384	O
of	19675193	385	387	O
a	19675193	388	389	O
6-month	19675193	390	397	O
randomized	19675193	398	408	O
clinical	19675193	409	417	O
trial	19675193	418	423	O
in	19675193	424	426	O
a	19675193	427	428	O
subsequent	19675193	429	439	O
6-month	19675193	440	447	O
extension	19675193	448	457	O
study	19675193	458	463	O
.	19675193	463	464	O

RESULTS	19675193	465	472	O
After	19675193	473	478	O
12	19675193	479	481	O
months	19675193	482	488	O
,	19675193	488	489	O
median	19675193	490	496	O
CGM	19675193	497	500	O
use	19675193	501	504	O
was	19675193	505	508	O
6.8	19675193	509	512	O
days	19675193	513	517	O
per	19675193	518	521	O
week	19675193	522	526	O
.	19675193	526	527	O

Mean	19675193	528	532	B-Outcome
change	19675193	533	539	I-Outcome
in	19675193	540	542	I-Outcome
A1C	19675193	543	546	I-Outcome
level	19675193	547	552	I-Outcome
from	19675193	553	557	I-Outcome
baseline	19675193	558	566	I-Outcome
to	19675193	567	569	O
12	19675193	570	572	O
months	19675193	573	579	O
was	19675193	580	583	O
-0.4	19675193	584	588	O
+	19675193	589	590	O
/-	19675193	590	592	O
0.6	19675193	593	596	O
%	19675193	596	597	O
(	19675193	598	599	O
P	19675193	599	600	O
<	19675193	601	602	O
0.001	19675193	603	608	O
)	19675193	608	609	O
in	19675193	610	612	O
subjects	19675193	613	621	O
with	19675193	622	626	O
baseline	19675193	627	635	O
A1C	19675193	636	639	O
>	19675193	640	641	O
or=7.0	19675193	641	647	O
%	19675193	647	648	O
.	19675193	648	649	O

A1C	19675193	650	653	B-Outcome
remained	19675193	654	662	O
stable	19675193	663	669	O
at	19675193	670	672	O
6.4	19675193	673	676	O
%	19675193	676	677	O
in	19675193	678	680	O
those	19675193	681	686	O
with	19675193	687	691	O
baseline	19675193	692	700	O
A1C	19675193	701	704	O
<	19675193	705	706	O
7.0	19675193	706	709	O
%	19675193	709	710	O
.	19675193	710	711	O

The	19675193	712	715	O
incidence	19675193	716	725	O
rate	19675193	726	730	B-Outcome
of	19675193	731	733	I-Outcome
severe	19675193	734	740	I-Outcome
hypoglycemia	19675193	741	753	I-Outcome
was	19675193	754	757	O
21.8	19675193	758	762	O
and	19675193	763	766	O
7.1	19675193	767	770	O
events	19675193	771	777	O
per	19675193	778	781	O
100	19675193	782	785	O
person-years	19675193	786	798	O
in	19675193	799	801	O
the	19675193	802	805	O
first	19675193	806	811	O
and	19675193	812	815	O
last	19675193	816	820	O
6	19675193	821	822	O
months	19675193	823	829	O
,	19675193	829	830	O
respectively	19675193	831	843	O
.	19675193	843	844	O

Time	19675193	845	849	B-Outcome
per	19675193	850	853	I-Outcome
day	19675193	854	857	I-Outcome
with	19675193	858	862	I-Outcome
glucose	19675193	863	870	I-Outcome
levels	19675193	871	877	I-Outcome
in	19675193	878	880	I-Outcome
the	19675193	881	884	I-Outcome
range	19675193	885	890	I-Outcome
of	19675193	891	893	I-Outcome
71	19675193	894	896	I-Outcome
-	19675193	896	897	I-Outcome
180	19675193	897	900	I-Outcome
mg/dl	19675193	901	906	I-Outcome
increased	19675193	907	916	O
significantly	19675193	917	930	O
(	19675193	931	932	O
P	19675193	932	933	O
=	19675193	934	935	O
0.02	19675193	936	940	O
)	19675193	940	941	O
from	19675193	942	946	O
baseline	19675193	947	955	O
to	19675193	956	958	O
12	19675193	959	961	O
months	19675193	962	968	O
.	19675193	968	969	O

CONCLUSIONS	19675193	971	982	O
:	19675193	983	984	O
In	19675193	985	987	O
intensively	19675193	988	999	O
treated	19675193	1000	1007	O
adults	19675193	1008	1014	O
with	19675193	1015	1019	O
type	19675193	1020	1024	O
1	19675193	1025	1026	O
diabetes	19675193	1027	1035	O
,	19675193	1035	1036	O
CGM	19675193	1037	1040	O
use	19675193	1041	1044	O
and	19675193	1045	1048	O
benefit	19675193	1049	1056	O
can	19675193	1057	1060	O
be	19675193	1061	1063	O
sustained	19675193	1064	1073	O
for	19675193	1074	1077	O
12	19675193	1078	1080	O
months	19675193	1081	1087	O
.	19675193	1087	1088	O


Long-term	19682100	0	9	O
(	19682100	10	11	O
96-week	19682100	11	18	O
)	19682100	18	19	O
follow-up	19682100	20	29	O
of	19682100	30	32	O
antiretroviral-naïve	19682100	33	53	O
HIV-infected	19682100	54	66	O
patients	19682100	67	75	O
treated	19682100	76	83	O
with	19682100	84	88	O
first-line	19682100	89	99	O
lopinavir/ritonavir	19682100	100	119	O
monotherapy	19682100	120	131	O
in	19682100	132	134	O
the	19682100	135	138	O
MONARK	19682100	139	145	O
trial	19682100	146	151	O
.	19682100	151	152	O

BACKGROUND	19682100	154	164	O
:	19682100	165	166	O
The	19682100	167	170	O
toxicities	19682100	171	181	O
,	19682100	181	182	O
cost	19682100	183	187	O
and	19682100	188	191	O
complexity	19682100	192	202	O
of	19682100	203	205	O
triple	19682100	206	212	O
combinations	19682100	213	225	O
warrant	19682100	226	233	O
the	19682100	234	237	O
search	19682100	238	244	O
for	19682100	245	248	O
other	19682100	249	254	O
treatment	19682100	255	264	O
options	19682100	265	272	O
,	19682100	272	273	O
such	19682100	274	278	O
as	19682100	279	281	O
boosted	19682100	282	289	O
protease	19682100	290	298	O
inhibitor	19682100	299	308	O
(	19682100	309	310	O
PI	19682100	310	312	O
)	19682100	312	313	O
monotherapy	19682100	314	325	O
.	19682100	325	326	O

MONotherapy	19682100	327	338	O
AntiRetroviral	19682100	339	353	O
Kaletra	19682100	354	361	O
(	19682100	362	363	O
MONARK	19682100	363	369	O
)	19682100	369	370	O
is	19682100	371	373	O
the	19682100	374	377	O
first	19682100	378	383	O
randomized	19682100	384	394	O
trial	19682100	395	400	O
comparing	19682100	401	410	O
lopinavir/ritonavir	19682100	411	430	O
monotherapy	19682100	431	442	O
to	19682100	443	445	O
triple	19682100	446	452	O
combination	19682100	453	464	O
therapy	19682100	465	472	O
with	19682100	473	477	O
zidovudine/lamivudine	19682100	478	499	O
and	19682100	500	503	O
lopinavir/ritonavir	19682100	504	523	O
in	19682100	524	526	O
antiretroviral-naïve	19682100	527	547	O
patients	19682100	548	556	O
.	19682100	556	557	O

METHODS	19682100	559	566	O
:	19682100	567	568	O
A	19682100	569	570	O
total	19682100	571	576	O
of	19682100	577	579	O
136	19682100	580	583	O
antiretroviral-naïve	19682100	584	604	O
patients	19682100	605	613	O
,	19682100	613	614	O
with	19682100	615	619	O
a	19682100	620	621	O
CD4	19682100	622	625	O
cell	19682100	626	630	O
count	19682100	631	636	O
above	19682100	637	642	O
100	19682100	643	646	O
cells/microL	19682100	647	659	O
and	19682100	660	663	O
a	19682100	664	665	O
plasma	19682100	666	672	O
HIV	19682100	673	676	O
RNA	19682100	677	680	O
below	19682100	681	686	O
100,000	19682100	687	694	O
HIV-1	19682100	695	700	O
RNA	19682100	701	704	O
copies/mL	19682100	705	714	O
,	19682100	714	715	O
were	19682100	716	720	O
randomized	19682100	721	731	O
and	19682100	732	735	O
dosed	19682100	736	741	O
with	19682100	742	746	O
either	19682100	747	753	O
lopinavir/ritonavir	19682100	754	773	O
monotherapy	19682100	774	785	O
(	19682100	786	787	O
n	19682100	787	788	O
=	19682100	789	790	O
83	19682100	791	793	O
)	19682100	793	794	O
or	19682100	795	797	O
lopinavir/ritonavir	19682100	798	817	O
+	19682100	818	819	O
zidovudine/lamivudine	19682100	820	841	O
(	19682100	842	843	O
n	19682100	843	844	O
=	19682100	845	846	O
53	19682100	847	849	O
)	19682100	849	850	O
.	19682100	850	851	O

We	19682100	852	854	O
focus	19682100	855	860	O
here	19682100	861	865	O
on	19682100	866	868	O
patients	19682100	869	877	O
in	19682100	878	880	O
the	19682100	881	884	O
lopinavir/ritonavir	19682100	885	904	O
monotherapy	19682100	905	916	O
arm	19682100	917	920	O
followed	19682100	921	929	O
to	19682100	930	932	O
week	19682100	933	937	O
96	19682100	938	940	O
.	19682100	940	941	O

The	19682100	942	945	O
intent-to-treat	19682100	946	961	O
(	19682100	962	963	O
ITT	19682100	963	966	O
)	19682100	966	967	O
analysis	19682100	968	976	O
initially	19682100	977	986	O
involved	19682100	987	995	O
all	19682100	996	999	O
patients	19682100	1000	1008	O
randomized	19682100	1009	1019	O
to	19682100	1020	1022	O
lopinavir/ritonavir	19682100	1023	1042	O
monotherapy	19682100	1043	1054	O
(	19682100	1055	1056	O
n	19682100	1056	1057	O
=	19682100	1058	1059	O
83	19682100	1060	1062	O
)	19682100	1062	1063	O
,	19682100	1063	1064	O
and	19682100	1065	1068	O
then	19682100	1069	1073	O
focused	19682100	1074	1081	O
on	19682100	1082	1084	O
patients	19682100	1085	1093	O
who	19682100	1094	1097	O
had	19682100	1098	1101	O
an	19682100	1102	1104	O
HIV	19682100	1105	1108	O
RNA	19682100	1109	1112	O
<	19682100	1113	1114	O
50	19682100	1115	1117	O
copies/mL	19682100	1118	1127	O
at	19682100	1128	1130	O
week	19682100	1131	1135	O
48	19682100	1136	1138	O
(	19682100	1139	1140	O
n	19682100	1140	1141	O
=	19682100	1142	1143	O
56	19682100	1144	1146	O
)	19682100	1146	1147	O
.	19682100	1147	1148	O

RESULTS	19682100	1150	1157	O
:	19682100	1158	1159	O
At	19682100	1160	1162	O
week	19682100	1163	1167	O
96	19682100	1168	1170	O
,	19682100	1170	1171	O
39	19682100	1172	1174	O
of	19682100	1175	1177	O
83	19682100	1178	1180	O
patients	19682100	1181	1189	O
(	19682100	1190	1191	O
47	19682100	1191	1193	O
%	19682100	1193	1194	O
)	19682100	1194	1195	O
had	19682100	1196	1199	O
HIV	19682100	1200	1203	B-Outcome
RNA	19682100	1204	1207	I-Outcome
<	19682100	1208	1209	O
50	19682100	1210	1212	O
copies/mL	19682100	1213	1222	O
,	19682100	1222	1223	O
five	19682100	1224	1228	O
of	19682100	1229	1231	O
83	19682100	1232	1234	O
had	19682100	1235	1238	O
HIV	19682100	1239	1242	B-Outcome
RNA	19682100	1243	1246	I-Outcome
between	19682100	1247	1254	O
50	19682100	1255	1257	O
and	19682100	1258	1261	O
400	19682100	1262	1265	O
copies/mL	19682100	1266	1275	O
,	19682100	1275	1276	O
and	19682100	1277	1280	O
three	19682100	1281	1286	O
of	19682100	1287	1289	O
83	19682100	1290	1292	O
had	19682100	1293	1296	O
HIV	19682100	1297	1300	B-Outcome
RNA	19682100	1301	1304	I-Outcome
>	19682100	1305	1306	O
400	19682100	1307	1310	O
copies/mL.	19682100	1311	1321	O
Focusing	19682100	1322	1330	O
on	19682100	1331	1333	O
the	19682100	1334	1337	O
56	19682100	1338	1340	O
patients	19682100	1341	1349	O
with	19682100	1350	1354	O
an	19682100	1355	1357	O
HIV	19682100	1358	1361	O
RNA	19682100	1362	1365	O
<	19682100	1366	1367	O
50	19682100	1368	1370	O
copies/mL	19682100	1371	1380	O
at	19682100	1381	1383	O
week	19682100	1384	1388	O
48	19682100	1389	1391	O
,	19682100	1391	1392	O
38	19682100	1393	1395	O
of	19682100	1396	1398	O
56	19682100	1399	1401	O
patients	19682100	1402	1410	O
(	19682100	1411	1412	O
68	19682100	1412	1414	O
%	19682100	1414	1415	O
)	19682100	1415	1416	O
had	19682100	1417	1420	O
a	19682100	1421	1422	O
sustained	19682100	1423	1432	O
HIV	19682100	1433	1436	B-Outcome
RNA	19682100	1437	1440	I-Outcome
<	19682100	1441	1442	O
50	19682100	1443	1445	O
copies/mL	19682100	1446	1455	O
to	19682100	1456	1458	O
week	19682100	1459	1463	O
96	19682100	1464	1466	O
.	19682100	1466	1467	O

To	19682100	1468	1470	O
week	19682100	1471	1475	O
96	19682100	1476	1478	O
,	19682100	1478	1479	O
a	19682100	1480	1481	O
total	19682100	1482	1487	O
of	19682100	1488	1490	O
28	19682100	1491	1493	O
patients	19682100	1494	1502	O
(	19682100	1503	1504	O
34	19682100	1504	1506	O
%	19682100	1506	1507	O
)	19682100	1507	1508	O
had	19682100	1509	1512	O
discontinued	19682100	1513	1525	O
the	19682100	1526	1529	O
study	19682100	1530	1535	O
treatment	19682100	1536	1545	O
.	19682100	1545	1546	O

In	19682100	1547	1549	O
addition	19682100	1550	1558	O
,	19682100	1558	1559	O
the	19682100	1560	1563	O
allocated	19682100	1564	1573	O
treatment	19682100	1574	1583	O
was	19682100	1584	1587	O
changed	19682100	1588	1595	O
for	19682100	1596	1599	O
seven	19682100	1600	1605	O
patients	19682100	1606	1614	O
.	19682100	1614	1615	O

PI-associated	19682100	1616	1629	B-Outcome
resistance	19682100	1630	1640	I-Outcome
mutations	19682100	1641	1650	I-Outcome
were	19682100	1651	1655	O
evident	19682100	1656	1663	O
in	19682100	1664	1666	O
five	19682100	1667	1671	O
of	19682100	1672	1674	O
83	19682100	1675	1677	O
patients	19682100	1678	1686	O
in	19682100	1687	1689	O
the	19682100	1690	1693	O
monotherapy	19682100	1694	1705	O
arm	19682100	1706	1709	O
from	19682100	1710	1714	O
baseline	19682100	1715	1723	O
to	19682100	1724	1726	O
week	19682100	1727	1731	O
96	19682100	1732	1734	O
.	19682100	1734	1735	O

CONCLUSION	19682100	1737	1747	O
:	19682100	1748	1749	O
By	19682100	1750	1752	O
ITT	19682100	1753	1756	O
analysis	19682100	1757	1765	O
,	19682100	1765	1766	O
39	19682100	1767	1769	O
of	19682100	1770	1772	O
the	19682100	1773	1776	O
83	19682100	1777	1779	O
patients	19682100	1780	1788	O
initially	19682100	1789	1798	O
randomized	19682100	1799	1809	O
to	19682100	1810	1812	O
lopinavir/ritonavir	19682100	1813	1832	O
monotherapy	19682100	1833	1844	O
had	19682100	1845	1848	O
HIV	19682100	1849	1852	B-Outcome
RNA	19682100	1853	1856	I-Outcome
<	19682100	1857	1858	O
50	19682100	1859	1861	O
copies/mL	19682100	1862	1871	O
at	19682100	1872	1874	O
week	19682100	1875	1879	O
96	19682100	1880	1882	O
.	19682100	1882	1883	O

The	19682100	1884	1887	O
occurrence	19682100	1888	1898	O
in	19682100	1899	1901	O
some	19682100	1902	1906	O
patients	19682100	1907	1915	O
of	19682100	1916	1918	O
low-level	19682100	1919	1928	O
viraemia	19682100	1929	1937	O
(	19682100	1938	1939	O
50	19682100	1939	1941	O
-	19682100	1941	1942	O
500	19682100	1942	1945	O
copies/mL	19682100	1946	1955	O
)	19682100	1955	1956	O
may	19682100	1957	1960	O
increase	19682100	1961	1969	O
the	19682100	1970	1973	O
risk	19682100	1974	1978	O
of	19682100	1979	1981	O
drug	19682100	1982	1986	O
resistance	19682100	1987	1997	O
.	19682100	1997	1998	O

First-line	19682100	1999	2009	O
lopinavir/ritonavir	19682100	2010	2029	O
monotherapy	19682100	2030	2041	O
can	19682100	2042	2045	O
not	19682100	2045	2048	O
be	19682100	2049	2051	O
systematically	19682100	2052	2066	O
recommended	19682100	2067	2078	O
.	19682100	2078	2079	O


Large-dose	19682342	0	10	O
intravenous	19682342	11	22	O
ferric	19682342	23	29	O
carboxymaltose	19682342	30	44	O
injection	19682342	45	54	O
for	19682342	55	58	O
iron	19682342	59	63	O
deficiency	19682342	64	74	O
anemia	19682342	75	81	O
in	19682342	82	84	O
heavy	19682342	85	90	O
uterine	19682342	91	98	O
bleeding	19682342	99	107	O
:	19682342	107	108	O
a	19682342	109	110	O
randomized	19682342	111	121	O
,	19682342	121	122	O
controlled	19682342	123	133	O
trial	19682342	134	139	O
.	19682342	139	140	O

BACKGROUND	19682342	142	152	O
:	19682342	153	154	O
The	19682342	155	158	O
objective	19682342	159	168	O
was	19682342	169	172	O
to	19682342	173	175	O
evaluate	19682342	176	184	O
efficacy	19682342	185	193	O
and	19682342	194	197	O
safety	19682342	198	204	O
of	19682342	205	207	O
rapid	19682342	208	213	O
,	19682342	213	214	O
large-dose	19682342	215	225	O
intravenous	19682342	226	237	O
(	19682342	238	239	O
IV	19682342	239	241	O
)	19682342	241	242	O
administration	19682342	243	257	O
of	19682342	258	260	O
ferric	19682342	261	267	O
carboxymaltose	19682342	268	282	O
compared	19682342	283	291	O
to	19682342	292	294	O
oral	19682342	295	299	O
iron	19682342	300	304	O
in	19682342	305	307	O
correcting	19682342	308	318	O
iron	19682342	319	323	O
deficiency	19682342	324	334	O
anemia	19682342	335	341	O
due	19682342	342	345	O
to	19682342	346	348	O
heavy	19682342	349	354	O
uterine	19682342	355	362	O
bleeding	19682342	363	371	O
.	19682342	371	372	O

STUDY	19682342	374	379	O
DESIGN	19682342	380	386	O
AND	19682342	387	390	O
METHODS	19682342	391	398	O
:	19682342	399	400	O
In	19682342	401	403	O
a	19682342	404	405	O
randomized	19682342	406	416	O
,	19682342	416	417	O
controlled	19682342	418	428	O
trial	19682342	429	434	O
,	19682342	434	435	O
477	19682342	436	439	O
women	19682342	440	445	O
with	19682342	446	450	O
anemia	19682342	451	457	O
,	19682342	457	458	O
iron	19682342	459	463	O
deficiency	19682342	464	474	O
,	19682342	474	475	O
and	19682342	476	479	O
heavy	19682342	480	485	O
uterine	19682342	486	493	O
bleeding	19682342	494	502	O
were	19682342	503	507	O
assigned	19682342	508	516	O
to	19682342	517	519	O
receive	19682342	520	527	O
either	19682342	528	534	O
IV	19682342	535	537	O
ferric	19682342	538	544	O
carboxymaltose	19682342	545	559	O
(	19682342	560	561	O
<	19682342	561	562	O
or=1000	19682342	562	569	O
mg	19682342	570	572	O
over	19682342	573	577	O
15	19682342	578	580	O
min	19682342	581	584	O
,	19682342	584	585	O
repeated	19682342	586	594	O
weekly	19682342	595	601	O
to	19682342	602	604	O
achieve	19682342	605	612	O
a	19682342	613	614	O
total	19682342	615	620	O
calculated	19682342	621	631	O
replacement	19682342	632	643	O
dose	19682342	644	648	O
)	19682342	648	649	O
or	19682342	650	652	O
325	19682342	653	656	O
mg	19682342	657	659	O
of	19682342	660	662	O
ferrous	19682342	663	670	O
sulfate	19682342	671	678	O
(	19682342	679	680	O
65	19682342	680	682	O
mg	19682342	683	685	O
elemental	19682342	686	695	O
iron	19682342	696	700	O
)	19682342	700	701	O
prescribed	19682342	702	712	O
orally	19682342	713	719	O
thrice	19682342	720	726	O
daily	19682342	727	732	O
for	19682342	733	736	O
6	19682342	737	738	O
weeks	19682342	739	744	O
.	19682342	744	745	O

RESULTS	19682342	747	754	O
:	19682342	755	756	O
Compared	19682342	757	765	O
to	19682342	766	768	O
those	19682342	769	774	O
assigned	19682342	775	783	O
to	19682342	784	786	O
ferrous	19682342	787	794	O
sulfate	19682342	795	802	O
,	19682342	802	803	O
more	19682342	804	808	O
patients	19682342	809	817	O
assigned	19682342	818	826	O
to	19682342	827	829	O
ferric	19682342	830	836	O
carboxymaltose	19682342	837	851	O
responded	19682342	852	861	O
with	19682342	862	866	O
a	19682342	867	868	O
hemoglobin	19682342	869	879	B-Outcome
(	19682342	880	881	I-Outcome
Hb	19682342	881	883	I-Outcome
)	19682342	883	884	I-Outcome
increase	19682342	885	893	I-Outcome
of	19682342	894	896	I-Outcome
2.0	19682342	897	900	I-Outcome
g/dL	19682342	901	905	I-Outcome
or	19682342	906	908	I-Outcome
more	19682342	909	913	I-Outcome
(	19682342	914	915	O
82	19682342	915	917	O
%	19682342	917	918	O
vs.	19682342	919	922	O
62	19682342	923	925	O
%	19682342	925	926	O
,	19682342	926	927	O
95	19682342	928	930	O
%	19682342	930	931	O
confidence	19682342	932	942	O
interval	19682342	943	951	O
for	19682342	952	955	O
treatment	19682342	956	965	O
difference	19682342	966	976	O
12.2	19682342	977	981	O
-	19682342	981	982	O
28.3	19682342	982	986	O
,	19682342	986	987	O
p	19682342	988	989	O
<	19682342	990	991	O
0.001	19682342	992	997	O
)	19682342	997	998	O
,	19682342	998	999	O
more	19682342	1000	1004	O
achieved	19682342	1005	1013	O
a	19682342	1014	1015	O
3.0	19682342	1016	1019	O
g/dL	19682342	1020	1024	O
or	19682342	1025	1027	O
more	19682342	1028	1032	O
increase	19682342	1033	1041	O
(	19682342	1042	1043	O
53	19682342	1043	1045	O
%	19682342	1045	1046	O
vs.	19682342	1047	1050	O
36	19682342	1051	1053	O
%	19682342	1053	1054	O
,	19682342	1054	1055	O
p	19682342	1056	1057	O
<	19682342	1058	1059	O
0.001	19682342	1060	1065	O
)	19682342	1065	1066	O
,	19682342	1066	1067	O
and	19682342	1068	1071	O
more	19682342	1072	1076	O
achieved	19682342	1077	1085	O
correction	19682342	1086	1096	B-Outcome
(	19682342	1097	1098	I-Outcome
Hb	19682342	1098	1100	I-Outcome
>	19682342	1101	1102	I-Outcome
or=	19682342	1102	1105	I-Outcome
12	19682342	1106	1108	I-Outcome
g/dL	19682342	1109	1113	I-Outcome
)	19682342	1113	1114	I-Outcome
of	19682342	1115	1117	I-Outcome
anemia	19682342	1118	1124	I-Outcome
(	19682342	1125	1126	O
73	19682342	1126	1128	O
%	19682342	1128	1129	O
vs.	19682342	1130	1133	O
50	19682342	1134	1136	O
%	19682342	1136	1137	O
,	19682342	1137	1138	O
p	19682342	1139	1140	O
<	19682342	1141	1142	O
0.001	19682342	1143	1148	O
)	19682342	1148	1149	O
.	19682342	1149	1150	O

Patients	19682342	1151	1159	O
treated	19682342	1160	1167	O
with	19682342	1168	1172	O
ferric	19682342	1173	1179	O
carboxymaltose	19682342	1180	1194	O
compared	19682342	1195	1203	O
to	19682342	1204	1206	O
those	19682342	1207	1212	O
prescribed	19682342	1213	1223	O
ferrous	19682342	1224	1231	O
sulfate	19682342	1232	1239	O
reported	19682342	1240	1248	O
greater	19682342	1249	1256	O
gains	19682342	1257	1262	O
in	19682342	1263	1265	O
vitality	19682342	1266	1274	B-Outcome
and	19682342	1275	1278	O
physical	19682342	1279	1287	B-Outcome
function	19682342	1288	1296	I-Outcome
and	19682342	1297	1300	O
experienced	19682342	1301	1312	O
greater	19682342	1313	1320	O
improvement	19682342	1321	1332	O
in	19682342	1333	1335	O
symptoms	19682342	1336	1344	B-Outcome
of	19682342	1345	1347	I-Outcome
fatigue	19682342	1348	1355	I-Outcome
(	19682342	1356	1357	O
p	19682342	1357	1358	O
<	19682342	1359	1360	O
0.05	19682342	1361	1365	O
)	19682342	1365	1366	O
.	19682342	1366	1367	O

There	19682342	1368	1373	O
were	19682342	1374	1378	O
no	19682342	1379	1381	O
serious	19682342	1382	1389	B-Outcome
adverse	19682342	1390	1397	I-Outcome
drug	19682342	1398	1402	I-Outcome
events	19682342	1403	1409	I-Outcome
.	19682342	1409	1410	O

CONCLUSIONS	19682342	1412	1423	O
:	19682342	1424	1425	O
In	19682342	1426	1428	O
patients	19682342	1429	1437	O
with	19682342	1438	1442	O
iron	19682342	1443	1447	O
deficiency	19682342	1448	1458	O
anemia	19682342	1459	1465	O
due	19682342	1466	1469	O
to	19682342	1470	1472	O
heavy	19682342	1473	1478	O
uterine	19682342	1479	1486	O
bleeding	19682342	1487	1495	O
,	19682342	1495	1496	O
rapid	19682342	1497	1502	O
IV	19682342	1503	1505	O
administration	19682342	1506	1520	O
of	19682342	1521	1523	O
large	19682342	1524	1529	O
doses	19682342	1530	1535	O
of	19682342	1536	1538	O
a	19682342	1539	1540	O
new	19682342	1541	1544	O
iron	19682342	1545	1549	O
agent	19682342	1550	1555	O
,	19682342	1555	1556	O
ferric	19682342	1557	1563	O
carboxymaltose	19682342	1564	1578	O
,	19682342	1578	1579	O
is	19682342	1580	1582	O
more	19682342	1583	1587	O
effective	19682342	1588	1597	O
than	19682342	1598	1602	O
oral	19682342	1603	1607	O
iron	19682342	1608	1612	O
therapy	19682342	1613	1620	O
in	19682342	1621	1623	O
correcting	19682342	1624	1634	O
anemia	19682342	1635	1641	B-Outcome
,	19682342	1641	1642	O
replenishing	19682342	1643	1655	O
iron	19682342	1656	1660	B-Outcome
stores	19682342	1661	1667	I-Outcome
,	19682342	1667	1668	O
and	19682342	1669	1672	O
improving	19682342	1673	1682	O
quality	19682342	1683	1690	B-Outcome
of	19682342	1691	1693	I-Outcome
life	19682342	1694	1698	I-Outcome
.	19682342	1698	1699	O


Assessment	19686304	0	10	O
of	19686304	11	13	O
elementary	19686304	14	24	O
school	19686304	25	31	O
students	19686304	32	40	O
'	19686304	40	41	O
sun	19686304	42	45	O
protection	19686304	46	56	O
behaviors	19686304	57	66	O
.	19686304	66	67	O

BACKGROUND/OBJECTIVES	19686304	69	90	O
:	19686304	91	92	O
Studies	19686304	93	100	O
suggest	19686304	101	108	O
that	19686304	109	113	O
excessive	19686304	114	123	O
sun	19686304	124	127	O
exposure	19686304	128	136	O
in	19686304	137	139	O
childhood	19686304	140	149	O
contributes	19686304	150	161	O
to	19686304	162	164	O
the	19686304	165	168	O
development	19686304	169	180	O
of	19686304	181	183	O
skin	19686304	184	188	O
cancer	19686304	189	195	O
later	19686304	196	201	O
in	19686304	202	204	O
life	19686304	205	209	O
.	19686304	209	210	O

METHODS	19686304	212	219	O
:	19686304	220	221	O
This	19686304	222	226	O
study	19686304	227	232	O
explores	19686304	233	241	O
4th	19686304	242	245	O
grade	19686304	246	251	O
student	19686304	252	259	O
assessment	19686304	260	270	O
of	19686304	271	273	O
their	19686304	274	279	O
sun	19686304	280	283	O
protection	19686304	284	294	O
behaviors	19686304	295	304	O
.	19686304	304	305	O

This	19686304	306	310	O
study	19686304	311	316	O
used	19686304	317	321	O
baseline	19686304	322	330	O
data	19686304	331	335	O
collected	19686304	336	345	O
in	19686304	346	348	O
the	19686304	349	352	O
Fall	19686304	353	357	O
of	19686304	358	360	O
2006	19686304	361	365	O
for	19686304	366	369	O
the	19686304	370	373	O
Sun	19686304	374	377	O
Protection	19686304	378	388	O
for	19686304	389	392	O
Florida	19686304	393	400	O
's	19686304	400	402	O
Children	19686304	403	411	O
(	19686304	412	413	O
SPF	19686304	413	416	O
)	19686304	416	417	O
project	19686304	418	425	O
.	19686304	425	426	O

In	19686304	427	429	O
brief	19686304	430	435	O
,	19686304	435	436	O
the	19686304	437	440	O
SPF	19686304	441	444	O
project	19686304	445	452	O
is	19686304	453	455	O
a	19686304	456	457	O
group	19686304	458	463	O
randomized	19686304	464	474	O
trial	19686304	475	480	O
to	19686304	481	483	O
test	19686304	484	488	O
the	19686304	489	492	O
effectiveness	19686304	493	506	O
of	19686304	507	509	O
a	19686304	510	511	O
school	19686304	512	518	O
based	19686304	519	524	O
intervention	19686304	525	537	O
promoting	19686304	538	547	O
sun	19686304	548	551	O
protection	19686304	552	562	O
in	19686304	563	565	O
general	19686304	566	573	O
,	19686304	573	574	O
and	19686304	575	578	O
hat	19686304	579	582	O
use	19686304	583	586	O
in	19686304	587	589	O
particular	19686304	590	600	O
,	19686304	600	601	O
in	19686304	602	604	O
Hillsborough	19686304	605	617	O
County	19686304	618	624	O
Schools	19686304	625	632	O
,	19686304	632	633	O
Florida	19686304	634	641	O
.	19686304	641	642	O

The	19686304	643	646	O
data	19686304	647	651	O
reported	19686304	652	660	O
in	19686304	661	663	O
this	19686304	664	668	O
study	19686304	669	674	O
were	19686304	675	679	O
collected	19686304	680	689	O
at	19686304	690	692	O
baseline	19686304	693	701	O
before	19686304	702	708	O
any	19686304	709	712	O
intervention	19686304	713	725	O
activities	19686304	726	736	O
was	19686304	737	740	O
initiated	19686304	741	750	O
.	19686304	750	751	O

RESULTS	19686304	753	760	O
:	19686304	761	762	O
The	19686304	763	766	O
self-reported	19686304	767	780	B-Outcome
use	19686304	781	784	I-Outcome
of	19686304	785	787	I-Outcome
various	19686304	788	795	I-Outcome
methods	19686304	796	803	I-Outcome
of	19686304	804	806	I-Outcome
sun	19686304	807	810	I-Outcome
protection	19686304	811	821	I-Outcome
was	19686304	822	825	O
low	19686304	826	829	O
.	19686304	829	830	O

Only	19686304	831	835	O
a	19686304	836	837	O
small	19686304	838	843	O
percentage	19686304	844	854	B-Outcome
of	19686304	855	857	I-Outcome
students	19686304	858	866	I-Outcome
wore	19686304	867	871	I-Outcome
long	19686304	872	876	I-Outcome
sleeves	19686304	877	884	I-Outcome
or	19686304	885	887	O
a	19686304	888	889	B-Outcome
hat	19686304	890	893	I-Outcome
with	19686304	894	898	I-Outcome
a	19686304	899	900	I-Outcome
brim	19686304	901	905	I-Outcome
before	19686304	906	912	I-Outcome
leaving	19686304	913	920	I-Outcome
for	19686304	921	924	I-Outcome
school	19686304	925	931	I-Outcome
.	19686304	931	932	O

In	19686304	933	935	O
addition	19686304	936	944	O
,	19686304	944	945	O
few	19686304	946	949	O
students	19686304	950	958	B-Outcome
wore	19686304	959	963	I-Outcome
a	19686304	964	965	I-Outcome
hat	19686304	966	969	I-Outcome
with	19686304	970	974	I-Outcome
a	19686304	975	976	I-Outcome
wide	19686304	977	981	I-Outcome
brim	19686304	982	986	I-Outcome
when	19686304	987	991	I-Outcome
outside	19686304	992	999	I-Outcome
but	19686304	1000	1003	I-Outcome
not	19686304	1004	1007	I-Outcome
at	19686304	1008	1010	I-Outcome
school	19686304	1011	1017	I-Outcome
.	19686304	1017	1018	O

Students	19686304	1019	1027	O
spent	19686304	1028	1033	O
an	19686304	1034	1036	O
average	19686304	1037	1044	O
of	19686304	1045	1047	O
59.1	19686304	1048	1052	O
minutes	19686304	1053	1060	B-Outcome
per	19686304	1061	1064	I-Outcome
week	19686304	1065	1069	I-Outcome
outdoors	19686304	1070	1078	I-Outcome
while	19686304	1079	1084	I-Outcome
attending	19686304	1085	1094	I-Outcome
school	19686304	1095	1101	I-Outcome
and	19686304	1102	1105	O
35.5	19686304	1106	1110	O
minutes	19686304	1111	1118	B-Outcome
during	19686304	1119	1125	I-Outcome
peak	19686304	1126	1130	I-Outcome
sun	19686304	1131	1134	I-Outcome
exposure	19686304	1135	1143	I-Outcome
.	19686304	1143	1144	O

CONCLUSION	19686304	1146	1156	O
:	19686304	1157	1158	O
Sun	19686304	1159	1162	B-Outcome
exposure	19686304	1163	1171	I-Outcome
at	19686304	1172	1174	I-Outcome
school	19686304	1175	1181	I-Outcome
poses	19686304	1182	1187	O
a	19686304	1188	1189	O
significant	19686304	1190	1201	O
risk	19686304	1202	1206	O
to	19686304	1207	1209	O
student	19686304	1210	1217	O
health	19686304	1218	1224	O
and	19686304	1225	1228	O
more	19686304	1229	1233	O
needs	19686304	1234	1239	O
to	19686304	1240	1242	O
be	19686304	1243	1245	O
carried	19686304	1246	1253	O
out	19686304	1254	1257	O
to	19686304	1258	1260	O
promote	19686304	1261	1268	O
the	19686304	1269	1272	O
use	19686304	1273	1276	B-Outcome
of	19686304	1277	1279	I-Outcome
a	19686304	1280	1281	I-Outcome
wide-brimmed	19686304	1282	1294	I-Outcome
hat	19686304	1295	1298	I-Outcome
and	19686304	1299	1302	O
limiting	19686304	1303	1311	O
student	19686304	1312	1319	B-Outcome
sun	19686304	1320	1323	I-Outcome
exposure	19686304	1324	1332	I-Outcome
.	19686304	1332	1333	O


Randomized	19805710	0	10	O
clinical	19805710	11	19	O
trial	19805710	20	25	O
of	19805710	26	28	O
behavioral	19805710	29	39	O
intervention	19805710	40	52	O
and	19805710	53	56	O
nutrition	19805710	57	66	O
education	19805710	67	76	O
to	19805710	77	79	O
improve	19805710	80	87	O
caloric	19805710	88	95	O
intake	19805710	96	102	O
and	19805710	103	106	O
weight	19805710	107	113	O
in	19805710	114	116	O
children	19805710	117	125	O
with	19805710	126	130	O
cystic	19805710	131	137	O
fibrosis	19805710	138	146	O
.	19805710	146	147	O

OBJECTIVE	19805710	149	158	O
:	19805710	159	160	O
To	19805710	161	163	O
evaluate	19805710	164	172	O
the	19805710	173	176	O
efficacy	19805710	177	185	O
of	19805710	186	188	O
a	19805710	189	190	O
behavioral	19805710	191	201	O
plus	19805710	202	206	O
nutrition	19805710	207	216	O
education	19805710	217	226	O
intervention	19805710	227	239	O
,	19805710	239	240	O
Be	19805710	241	243	O
In	19805710	244	246	O
CHARGE	19805710	247	253	O
!	19805710	253	254	O
,	19805710	254	255	O
compared	19805710	256	264	O
with	19805710	265	269	O
that	19805710	270	274	O
of	19805710	275	277	O
a	19805710	278	279	O
nutrition	19805710	280	289	O
education	19805710	290	299	O
intervention	19805710	300	312	O
alone	19805710	313	318	O
on	19805710	319	321	O
caloric	19805710	322	329	O
intake	19805710	330	336	O
and	19805710	337	340	O
weight	19805710	341	347	O
gain	19805710	348	352	O
in	19805710	353	355	O
children	19805710	356	364	O
with	19805710	365	369	O
cystic	19805710	370	376	O
fibrosis	19805710	377	385	O
and	19805710	386	389	O
pancreatic	19805710	390	400	O
insufficiency	19805710	401	414	O
.	19805710	414	415	O

DESIGN	19805710	417	423	O
:	19805710	424	425	O
Randomized	19805710	426	436	O
controlled	19805710	437	447	O
trial	19805710	448	453	O
.	19805710	453	454	O

SETTING	19805710	456	463	O
:	19805710	464	465	O
Cystic	19805710	466	472	O
fibrosis	19805710	473	481	O
centers	19805710	482	489	O
in	19805710	490	492	O
the	19805710	493	496	O
eastern	19805710	497	504	O
,	19805710	504	505	O
midwestern	19805710	506	516	O
,	19805710	516	517	O
and	19805710	518	521	O
southern	19805710	522	530	O
United	19805710	531	537	O
States	19805710	538	544	O
.	19805710	544	545	O

PARTICIPANTS	19805710	547	559	O
:	19805710	560	561	O
Seventy-nine	19805710	562	574	O
children	19805710	575	583	O
aged	19805710	584	588	O
4	19805710	589	590	O
to	19805710	591	593	O
12	19805710	594	596	O
years	19805710	597	602	O
below	19805710	603	608	O
the	19805710	609	612	O
40th	19805710	613	617	O
percentile	19805710	618	628	O
for	19805710	629	632	O
weight	19805710	633	639	O
for	19805710	640	643	O
age	19805710	644	647	O
were	19805710	648	652	O
recruited	19805710	653	662	O
.	19805710	662	663	O

Sixty-seven	19805710	664	675	O
completed	19805710	676	685	O
the	19805710	686	689	O
intervention	19805710	690	702	O
and	19805710	703	706	O
59	19805710	707	709	O
completed	19805710	710	719	O
a	19805710	720	721	O
24-month	19805710	722	730	O
follow-up	19805710	731	740	O
assessment	19805710	741	751	O
.	19805710	751	752	O

INTERVENTION	19805710	754	766	O
:	19805710	767	768	O
Comparison	19805710	769	779	O
of	19805710	780	782	O
a	19805710	783	784	O
behavioral	19805710	785	795	O
plus	19805710	796	800	O
nutrition	19805710	801	810	O
education	19805710	811	820	O
intervention	19805710	821	833	O
with	19805710	834	838	O
a	19805710	839	840	O
nutrition	19805710	841	850	O
education	19805710	851	860	O
intervention	19805710	861	873	O
alone	19805710	874	879	O
.	19805710	879	880	O

MAIN	19805710	882	886	O
OUTCOME	19805710	887	894	O
MEASURES	19805710	895	903	O
:	19805710	904	905	O
Primary	19805710	906	913	O
outcomes	19805710	914	922	O
were	19805710	923	927	O
changes	19805710	928	935	O
from	19805710	936	940	O
pretreatment	19805710	941	953	O
to	19805710	954	956	O
posttreatment	19805710	957	970	O
in	19805710	971	973	O
caloric	19805710	974	981	O
intake	19805710	982	988	O
and	19805710	989	992	O
weight	19805710	993	999	O
gain	19805710	1000	1004	O
.	19805710	1004	1005	O

Secondary	19805710	1006	1015	O
outcomes	19805710	1016	1024	O
were	19805710	1025	1029	O
changes	19805710	1030	1037	O
from	19805710	1038	1042	O
pretreatment	19805710	1043	1055	O
to	19805710	1056	1058	O
posttreatment	19805710	1059	1072	O
in	19805710	1073	1075	O
percentage	19805710	1076	1086	O
of	19805710	1087	1089	O
the	19805710	1090	1093	O
estimated	19805710	1094	1103	O
energy	19805710	1104	1110	O
requirement	19805710	1111	1122	O
and	19805710	1123	1126	O
body	19805710	1127	1131	O
mass	19805710	1132	1136	O
index	19805710	1137	1142	O
z	19805710	1143	1144	O
score	19805710	1145	1150	O
.	19805710	1150	1151	O

These	19805710	1152	1157	O
outcomes	19805710	1158	1166	O
were	19805710	1167	1171	O
also	19805710	1172	1176	O
examined	19805710	1177	1185	O
24	19805710	1186	1188	O
months	19805710	1189	1195	O
posttreatment	19805710	1196	1209	O
.	19805710	1209	1210	O

RESULTS	19805710	1212	1219	O
:	19805710	1220	1221	O
After	19805710	1222	1227	O
treatment	19805710	1228	1237	O
,	19805710	1237	1238	O
the	19805710	1239	1242	O
behavioral	19805710	1243	1253	O
plus	19805710	1254	1258	O
nutrition	19805710	1259	1268	O
education	19805710	1269	1278	O
intervention	19805710	1279	1291	O
as	19805710	1292	1294	O
compared	19805710	1295	1303	O
with	19805710	1304	1308	O
the	19805710	1309	1312	O
nutrition	19805710	1313	1322	O
education	19805710	1323	1332	O
intervention	19805710	1333	1345	O
alone	19805710	1346	1351	O
had	19805710	1352	1355	O
a	19805710	1356	1357	O
statistically	19805710	1358	1371	O
greater	19805710	1372	1379	O
average	19805710	1380	1387	O
increase	19805710	1388	1396	O
on	19805710	1397	1399	O
the	19805710	1400	1403	O
primary	19805710	1404	1411	O
and	19805710	1412	1415	O
secondary	19805710	1416	1425	O
outcomes	19805710	1426	1434	O
of	19805710	1435	1437	O
caloric	19805710	1438	1445	B-Outcome
intake	19805710	1446	1452	I-Outcome
(	19805710	1453	1454	O
mean	19805710	1454	1458	O
,	19805710	1458	1459	O
872	19805710	1460	1463	O
vs	19805710	1464	1466	O
489	19805710	1467	1470	O
cal/d	19805710	1471	1476	O
,	19805710	1476	1477	O
respectively	19805710	1478	1490	O
)	19805710	1490	1491	O
,	19805710	1491	1492	O
percentage	19805710	1493	1503	B-Outcome
of	19805710	1504	1506	I-Outcome
the	19805710	1507	1510	I-Outcome
estimated	19805710	1511	1520	I-Outcome
energy	19805710	1521	1527	I-Outcome
requirement	19805710	1528	1539	I-Outcome
(	19805710	1540	1541	O
mean	19805710	1541	1545	O
,	19805710	1545	1546	O
148	19805710	1547	1550	O
%	19805710	1550	1551	O
vs	19805710	1552	1554	O
127	19805710	1555	1558	O
%	19805710	1558	1559	O
,	19805710	1559	1560	O
respectively	19805710	1561	1573	O
)	19805710	1573	1574	O
,	19805710	1574	1575	O
weight	19805710	1576	1582	B-Outcome
gain	19805710	1583	1587	I-Outcome
(	19805710	1588	1589	O
mean	19805710	1589	1593	O
,	19805710	1593	1594	O
1.47	19805710	1595	1599	O
vs	19805710	1600	1602	O
0.92	19805710	1603	1607	O
kg	19805710	1608	1610	O
,	19805710	1610	1611	O
respectively	19805710	1612	1624	O
)	19805710	1624	1625	O
,	19805710	1625	1626	O
and	19805710	1627	1630	O
body	19805710	1631	1635	B-Outcome
mass	19805710	1636	1640	I-Outcome
index	19805710	1641	1646	I-Outcome
z	19805710	1647	1648	I-Outcome
score	19805710	1649	1654	I-Outcome
(	19805710	1655	1656	O
0.38	19805710	1656	1660	O
vs	19805710	1661	1663	O
0.18	19805710	1664	1668	O
,	19805710	1668	1669	O
respectively	19805710	1670	1682	O
)	19805710	1682	1683	O
.	19805710	1683	1684	O

At	19805710	1685	1687	O
the	19805710	1688	1691	O
24-month	19805710	1692	1700	O
follow-up	19805710	1701	1710	O
,	19805710	1710	1711	O
children	19805710	1712	1720	O
in	19805710	1721	1723	O
both	19805710	1724	1728	O
conditions	19805710	1729	1739	O
maintained	19805710	1740	1750	O
an	19805710	1751	1753	O
estimated	19805710	1754	1763	B-Outcome
energy	19805710	1764	1770	I-Outcome
requirement	19805710	1771	1782	I-Outcome
of	19805710	1783	1785	O
around	19805710	1786	1792	O
120	19805710	1793	1796	O
%	19805710	1796	1797	O
and	19805710	1798	1801	O
did	19805710	1802	1805	O
not	19805710	1806	1809	O
significantly	19805710	1810	1823	O
differ	19805710	1824	1830	O
on	19805710	1831	1833	O
any	19805710	1834	1837	O
outcomes	19805710	1838	1846	O
.	19805710	1846	1847	O

CONCLUSIONS	19805710	1849	1860	O
:	19805710	1861	1862	O
A	19805710	1863	1864	O
behavioral	19805710	1865	1875	O
plus	19805710	1876	1880	O
nutrition	19805710	1881	1890	O
education	19805710	1891	1900	O
intervention	19805710	1901	1913	O
was	19805710	1914	1917	O
more	19805710	1918	1922	O
effective	19805710	1923	1932	O
than	19805710	1933	1937	O
a	19805710	1938	1939	O
nutrition	19805710	1940	1949	O
education	19805710	1950	1959	O
intervention	19805710	1960	1972	O
alone	19805710	1973	1978	O
at	19805710	1979	1981	O
increasing	19805710	1982	1992	O
dietary	19805710	1993	2000	B-Outcome
intake	19805710	2001	2007	I-Outcome
and	19805710	2008	2011	O
weight	19805710	2012	2018	B-Outcome
over	19805710	2019	2023	O
a	19805710	2024	2025	O
9-week	19805710	2026	2032	O
period	19805710	2033	2039	O
.	19805710	2039	2040	O

However	19805710	2041	2048	O
,	19805710	2048	2049	O
across	19805710	2050	2056	O
the	19805710	2057	2060	O
24-month	19805710	2061	2069	O
follow-up	19805710	2070	2079	O
,	19805710	2079	2080	O
both	19805710	2081	2085	O
treatments	19805710	2086	2096	O
achieved	19805710	2097	2105	O
similar	19805710	2106	2113	O
outcomes	19805710	2114	2122	O
.	19805710	2122	2123	O

Trial	19805710	2124	2129	O
Registration	19805710	2130	2142	O
clinicaltrials.gov	19805710	2143	2161	O
Identifier	19805710	2162	2172	O
:	19805710	2172	2173	O
NCT00006169	19805710	2174	2185	O
.	19805710	2185	2186	O


Efficacy	19814586	0	8	O
and	19814586	9	12	O
long-term	19814586	13	22	O
tolerability	19814586	23	35	O
of	19814586	36	38	O
sublingual	19814586	39	49	O
fentanyl	19814586	50	58	O
orally	19814586	59	65	O
disintegrating	19814586	66	80	O
tablet	19814586	81	87	O
in	19814586	88	90	O
the	19814586	91	94	O
treatment	19814586	95	104	O
of	19814586	105	107	O
breakthrough	19814586	108	120	O
cancer	19814586	121	127	O
pain	19814586	128	132	O
.	19814586	132	133	O

BACKGROUND	19814586	135	145	O
AND	19814586	146	149	O
OBJECTIVES	19814586	150	160	O
:	19814586	161	162	O
Breakthrough	19814586	163	175	O
cancer	19814586	176	182	O
pain	19814586	183	187	O
(	19814586	188	189	O
BTcP	19814586	189	193	O
)	19814586	193	194	O
represents	19814586	195	205	O
an	19814586	206	208	O
important	19814586	209	218	O
clinical	19814586	219	227	O
challenge	19814586	228	237	O
in	19814586	238	240	O
the	19814586	241	244	O
care	19814586	245	249	O
of	19814586	250	252	O
patients	19814586	253	261	O
with	19814586	262	266	O
cancer	19814586	267	273	O
.	19814586	273	274	O

This	19814586	275	279	O
trial	19814586	280	285	O
evaluated	19814586	286	295	O
the	19814586	296	299	O
efficacy	19814586	300	308	O
and	19814586	309	312	O
long-term	19814586	313	322	O
tolerability	19814586	323	335	O
of	19814586	336	338	O
a	19814586	339	340	O
sublingual	19814586	341	351	O
formulation	19814586	352	363	O
of	19814586	364	366	O
the	19814586	367	370	O
fast-acting	19814586	371	382	O
opioid	19814586	383	389	O
fentanyl	19814586	390	398	O
,	19814586	398	399	O
for	19814586	400	403	O
the	19814586	404	407	O
treatment	19814586	408	417	O
of	19814586	418	420	O
BTcP	19814586	421	425	O
in	19814586	426	428	O
opioid-tolerant	19814586	429	444	O
patients	19814586	445	453	O
with	19814586	454	458	O
cancer	19814586	459	465	O
.	19814586	465	466	O

RESEARCH	19814586	468	476	O
DESIGN	19814586	477	483	O
AND	19814586	484	487	O
METHODS	19814586	488	495	O
:	19814586	496	497	O
This	19814586	498	502	O
was	19814586	503	506	O
a	19814586	507	508	O
randomized	19814586	509	519	O
,	19814586	519	520	O
placebo-controlled	19814586	521	539	O
,	19814586	539	540	O
multi-center	19814586	541	553	O
,	19814586	553	554	O
phase	19814586	555	560	O
III	19814586	561	564	O
trial	19814586	565	570	O
,	19814586	570	571	O
conducted	19814586	572	581	O
in	19814586	582	584	O
opioid-tolerant	19814586	585	600	O
male	19814586	601	605	O
and	19814586	606	609	O
female	19814586	610	616	O
patients	19814586	617	625	O
(	19814586	626	627	O
aged	19814586	627	631	O
>	19814586	632	633	O
or	19814586	634	636	O
=	19814586	637	638	O
17	19814586	638	640	O
years	19814586	641	646	O
)	19814586	646	647	O
with	19814586	648	652	O
BTcP.	19814586	653	658	O
The	19814586	659	662	O
study	19814586	663	668	O
was	19814586	669	672	O
conducted	19814586	673	682	O
at	19814586	683	685	O
36	19814586	686	688	O
centers	19814586	689	696	O
across	19814586	697	703	O
the	19814586	704	707	O
USA	19814586	708	711	O
.	19814586	711	712	O

The	19814586	713	716	O
study	19814586	717	722	O
comprised	19814586	723	732	O
a	19814586	733	734	O
2-week	19814586	735	741	O
open-label	19814586	742	752	O
titration	19814586	753	762	O
phase	19814586	763	768	O
,	19814586	768	769	O
followed	19814586	770	778	O
by	19814586	779	781	O
a	19814586	782	783	O
double-blind	19814586	784	796	O
efficacy	19814586	797	805	O
phase	19814586	806	811	O
,	19814586	811	812	O
during	19814586	813	819	O
which	19814586	820	825	O
patients	19814586	826	834	O
received	19814586	835	843	O
sublingual	19814586	844	854	O
fentanyl	19814586	855	863	O
citrate	19814586	864	871	O
orally	19814586	872	878	O
disintegrating	19814586	879	893	O
tablet	19814586	894	900	O
(	19814586	901	902	O
sublingual	19814586	902	912	O
fentanyl	19814586	913	921	O
ODT	19814586	922	925	O
)	19814586	925	926	O
or	19814586	927	929	O
placebo	19814586	930	937	O
,	19814586	937	938	O
in	19814586	939	941	O
a	19814586	942	943	O
random	19814586	944	950	O
order	19814586	951	956	O
.	19814586	956	957	O

The	19814586	958	961	O
primary	19814586	962	969	O
efficacy	19814586	970	978	O
endpoint	19814586	979	987	O
was	19814586	988	991	O
the	19814586	992	995	O
sum	19814586	996	999	O
of	19814586	1000	1002	O
pain	19814586	1003	1007	O
intensity	19814586	1008	1017	O
difference	19814586	1018	1028	O
(	19814586	1029	1030	O
SPID	19814586	1030	1034	O
)	19814586	1034	1035	O
over	19814586	1036	1040	O
30	19814586	1041	1043	O
min	19814586	1044	1047	O
post-administration	19814586	1048	1067	O
.	19814586	1067	1068	O

Secondary	19814586	1069	1078	O
efficacy	19814586	1079	1087	O
endpoints	19814586	1088	1097	O
included	19814586	1098	1106	O
pain	19814586	1107	1111	O
intensity	19814586	1112	1121	O
difference	19814586	1122	1132	O
(	19814586	1133	1134	O
PID	19814586	1134	1137	O
)	19814586	1137	1138	O
and	19814586	1139	1142	O
pain	19814586	1143	1147	O
relief	19814586	1148	1154	O
(	19814586	1155	1156	O
PR	19814586	1156	1158	O
)	19814586	1158	1159	O
throughout	19814586	1160	1170	O
the	19814586	1171	1174	O
60-min	19814586	1175	1181	O
post-dose	19814586	1182	1191	O
assessment	19814586	1192	1202	O
period	19814586	1203	1209	O
.	19814586	1209	1210	O

Following	19814586	1211	1220	O
efficacy	19814586	1221	1229	O
evaluation	19814586	1230	1240	O
,	19814586	1240	1241	O
patients	19814586	1242	1250	O
entered	19814586	1251	1258	O
a	19814586	1259	1260	O
long-term	19814586	1261	1270	O
safety	19814586	1271	1277	O
phase	19814586	1278	1283	O
of	19814586	1284	1286	O
up	19814586	1287	1289	O
to	19814586	1290	1292	O
12	19814586	1293	1295	O
months	19814586	1296	1302	O
.	19814586	1302	1303	O

Adverse	19814586	1304	1311	O
events	19814586	1312	1318	O
were	19814586	1319	1323	O
recorded	19814586	1324	1332	O
throughout	19814586	1333	1343	O
the	19814586	1344	1347	O
study	19814586	1348	1353	O
.	19814586	1353	1354	O

[	19814586	1355	1356	O
CLINICAL	19814586	1357	1365	O
TRIAL	19814586	1366	1371	O
REGISTRATION	19814586	1372	1384	O
:	19814586	1385	1386	O
NCT00262678	19814586	1387	1398	O
]	19814586	1398	1399	O
RESULTS	19814586	1400	1407	O
:	19814586	1408	1409	O
A	19814586	1410	1411	O
total	19814586	1412	1417	O
of	19814586	1418	1420	O
131	19814586	1421	1424	O
patients	19814586	1425	1433	O
entered	19814586	1434	1441	O
the	19814586	1442	1445	O
titration	19814586	1446	1455	O
phase	19814586	1456	1461	O
,	19814586	1461	1462	O
of	19814586	1463	1465	O
whom	19814586	1466	1470	O
61	19814586	1471	1473	O
were	19814586	1474	1478	O
included	19814586	1479	1487	O
in	19814586	1488	1490	O
the	19814586	1491	1494	O
primary	19814586	1495	1502	O
efficacy	19814586	1503	1511	O
analysis	19814586	1512	1520	O
.	19814586	1520	1521	O

Sublingual	19814586	1522	1532	O
fentanyl	19814586	1533	1541	O
ODT	19814586	1542	1545	O
provided	19814586	1546	1554	O
significant	19814586	1555	1566	O
improvements	19814586	1567	1579	O
in	19814586	1580	1582	O
SPID	19814586	1583	1587	B-Outcome
relative	19814586	1588	1596	O
to	19814586	1597	1599	O
placebo	19814586	1600	1607	O
at	19814586	1608	1610	O
30	19814586	1611	1613	O
min	19814586	1614	1617	O
(	19814586	1618	1619	O
49.5	19814586	1619	1623	O
vs.	19814586	1624	1627	O
36.6	19814586	1628	1632	O
,	19814586	1632	1633	O
p	19814586	1634	1635	O
=	19814586	1636	1637	O
0.0004	19814586	1638	1644	O
)	19814586	1644	1645	O
and	19814586	1646	1649	O
60	19814586	1650	1652	O
min	19814586	1653	1656	O
post-administration	19814586	1657	1676	O
(	19814586	1677	1678	O
143.0	19814586	1678	1683	O
vs.	19814586	1684	1687	O
104.5	19814586	1688	1693	O
,	19814586	1693	1694	O
p	19814586	1695	1696	O
=	19814586	1697	1698	O
0.0002	19814586	1699	1705	O
)	19814586	1705	1706	O
.	19814586	1706	1707	O

Furthermore	19814586	1708	1719	O
,	19814586	1719	1720	O
sublingual	19814586	1721	1731	O
fentanyl	19814586	1732	1740	O
ODT	19814586	1741	1744	O
provided	19814586	1745	1753	O
significant	19814586	1754	1765	O
improvements	19814586	1766	1778	O
in	19814586	1779	1781	O
PID	19814586	1782	1785	B-Outcome
and	19814586	1786	1789	O
PR	19814586	1790	1792	B-Outcome
compared	19814586	1793	1801	O
to	19814586	1802	1804	O
placebo	19814586	1805	1812	O
,	19814586	1812	1813	O
from	19814586	1814	1818	O
10	19814586	1819	1821	O
min	19814586	1822	1825	O
post-dose	19814586	1826	1835	O
(	19814586	1836	1837	O
p	19814586	1837	1838	O
=	19814586	1839	1840	O
0.0055	19814586	1841	1847	O
and	19814586	1848	1851	O
p	19814586	1852	1853	O
=	19814586	1854	1855	O
0.049	19814586	1856	1861	O
for	19814586	1862	1865	O
PID	19814586	1866	1869	B-Outcome
and	19814586	1870	1873	O
PR	19814586	1874	1876	B-Outcome
,	19814586	1876	1877	O
respectively	19814586	1878	1890	O
)	19814586	1890	1891	O
.	19814586	1891	1892	O

Patient	19814586	1893	1900	O
recruitment	19814586	1901	1912	O
was	19814586	1913	1916	O
stopped	19814586	1917	1924	O
early	19814586	1925	1930	O
,	19814586	1930	1931	O
due	19814586	1932	1935	O
to	19814586	1936	1938	O
positive	19814586	1939	1947	O
interim	19814586	1948	1955	O
analysis	19814586	1956	1964	O
results	19814586	1965	1972	O
(	19814586	1973	1974	O
significant	19814586	1974	1985	O
at	19814586	1986	1988	O
prespecified	19814586	1989	2001	O
level	19814586	2002	2007	O
,	19814586	2007	2008	O
p	19814586	2009	2010	O
<	19814586	2011	2012	O
or	19814586	2013	2015	O
=	19814586	2016	2017	O
0.0414	19814586	2018	2024	O
)	19814586	2024	2025	O
.	19814586	2025	2026	O

Overall	19814586	2027	2034	O
,	19814586	2034	2035	O
sublingual	19814586	2036	2046	O
fentanyl	19814586	2047	2055	O
ODT	19814586	2056	2059	O
was	19814586	2060	2063	O
well-tolerated	19814586	2064	2078	B-Outcome
both	19814586	2079	2083	O
systemically	19814586	2084	2096	O
and	19814586	2097	2100	O
sublingually	19814586	2101	2113	O
,	19814586	2113	2114	O
with	19814586	2115	2119	O
41	19814586	2120	2122	O
patients	19814586	2123	2131	O
experiencing	19814586	2132	2144	O
>	19814586	2145	2146	O
or	19814586	2147	2149	O
=	19814586	2150	2151	O
1	19814586	2151	2152	O
study	19814586	2153	2158	O
drug-related	19814586	2159	2171	B-Outcome
adverse	19814586	2172	2179	I-Outcome
event	19814586	2180	2185	I-Outcome
(	19814586	2186	2187	O
AE	19814586	2187	2189	B-Outcome
)	19814586	2189	2190	O
.	19814586	2190	2191	O

The	19814586	2192	2195	O
most	19814586	2196	2200	O
common	19814586	2201	2207	O
AEs	19814586	2208	2211	B-Outcome
included	19814586	2212	2220	O
nausea	19814586	2221	2227	O
(	19814586	2228	2229	O
12.2	19814586	2229	2233	O
%	19814586	2233	2234	O
)	19814586	2234	2235	O
,	19814586	2235	2236	O
vomiting	19814586	2237	2245	O
(	19814586	2246	2247	O
5.3	19814586	2247	2250	O
%	19814586	2250	2251	O
)	19814586	2251	2252	O
and	19814586	2253	2256	O
somnolence	19814586	2257	2267	O
(	19814586	2268	2269	O
4.6	19814586	2269	2272	O
%	19814586	2272	2273	O
)	19814586	2273	2274	O
.	19814586	2274	2275	O

One	19814586	2276	2279	O
serious	19814586	2280	2287	B-Outcome
AE	19814586	2288	2290	I-Outcome
(	19814586	2291	2292	O
mild	19814586	2292	2296	O
affect	19814586	2297	2303	O
lability	19814586	2304	2312	O
)	19814586	2312	2313	O
was	19814586	2314	2317	O
considered	19814586	2318	2328	O
possibly	19814586	2329	2337	O
related	19814586	2338	2345	O
to	19814586	2346	2348	O
study	19814586	2349	2354	O
medication	19814586	2355	2365	O
.	19814586	2365	2366	O

The	19814586	2367	2370	O
observed	19814586	2371	2379	O
pattern	19814586	2380	2387	O
of	19814586	2388	2390	O
AEs	19814586	2391	2394	B-Outcome
was	19814586	2395	2398	O
consistent	19814586	2399	2409	O
with	19814586	2410	2414	O
that	19814586	2415	2419	O
previously	19814586	2420	2430	O
observed	19814586	2431	2439	O
with	19814586	2440	2444	O
fentanyl	19814586	2445	2453	O
.	19814586	2453	2454	O

CONCLUSIONS	19814586	2456	2467	O
:	19814586	2468	2469	O
Sublingual	19814586	2470	2480	O
fentanyl	19814586	2481	2489	O
ODT	19814586	2490	2493	O
was	19814586	2494	2497	O
efficacious	19814586	2498	2509	B-Outcome
and	19814586	2510	2513	O
well-tolerated	19814586	2514	2528	B-Outcome
for	19814586	2529	2532	O
the	19814586	2533	2536	O
treatment	19814586	2537	2546	O
of	19814586	2547	2549	O
BTcP	19814586	2550	2554	O
in	19814586	2555	2557	O
opioid-tolerant	19814586	2558	2573	O
patients	19814586	2574	2582	O
with	19814586	2583	2587	O
cancer	19814586	2588	2594	O
.	19814586	2594	2595	O

Sublingual	19814586	2596	2606	O
fentanyl	19814586	2607	2615	O
ODT	19814586	2616	2619	O
provided	19814586	2620	2628	O
significant	19814586	2629	2640	O
improvements	19814586	2641	2653	O
in	19814586	2654	2656	O
pain	19814586	2657	2661	B-Outcome
intensity	19814586	2662	2671	I-Outcome
compared	19814586	2672	2680	O
to	19814586	2681	2683	O
placebo	19814586	2684	2691	O
,	19814586	2691	2692	O
from	19814586	2693	2697	O
10	19814586	2698	2700	O
min	19814586	2701	2704	O
post-administration	19814586	2705	2724	O
and	19814586	2725	2728	O
throughout	19814586	2729	2739	O
the	19814586	2740	2743	O
60-min	19814586	2744	2750	O
post-dose	19814586	2751	2760	O
assessment	19814586	2761	2771	O
period	19814586	2772	2778	O
.	19814586	2778	2779	O

Sublingual	19814586	2780	2790	O
fentanyl	19814586	2791	2799	O
ODT	19814586	2800	2803	O
was	19814586	2804	2807	O
well	19814586	2808	2812	O
tolerated	19814586	2813	2822	B-Outcome
over	19814586	2823	2827	O
12	19814586	2828	2830	O
months	19814586	2831	2837	O
of	19814586	2838	2840	O
treatment	19814586	2841	2850	O
.	19814586	2850	2851	O


Effect	19919399	0	6	O
of	19919399	7	9	O
device-guided	19919399	10	23	O
breathing	19919399	24	33	O
exercises	19919399	34	43	O
on	19919399	44	46	O
blood	19919399	47	52	O
pressure	19919399	53	61	O
in	19919399	62	64	O
patients	19919399	65	73	O
with	19919399	74	78	O
hypertension	19919399	79	91	O
:	19919399	91	92	O
a	19919399	93	94	O
randomized	19919399	95	105	O
controlled	19919399	106	116	O
trial	19919399	117	122	O
.	19919399	122	123	O

OBJECTIVE	19919399	125	134	O
:	19919399	135	136	O
Hypertension	19919399	137	149	O
is	19919399	150	152	O
a	19919399	153	154	O
chronic	19919399	155	162	O
disorder	19919399	163	171	O
with	19919399	172	176	O
a	19919399	177	178	O
high	19919399	179	183	O
prevalence	19919399	184	194	O
worldwide	19919399	195	204	O
.	19919399	204	205	O

Despite	19919399	206	213	O
considerable	19919399	214	226	O
efforts	19919399	227	234	O
,	19919399	234	235	O
it	19919399	236	238	O
is	19919399	239	241	O
sometimes	19919399	242	251	O
hard	19919399	252	256	O
to	19919399	257	259	O
reach	19919399	260	265	O
treatment	19919399	266	275	O
goals	19919399	276	281	O
for	19919399	282	285	O
blood	19919399	286	291	O
pressure	19919399	292	300	O
(	19919399	301	302	O
BP	19919399	302	304	O
)	19919399	304	305	O
with	19919399	306	310	O
classical	19919399	311	320	O
treatment	19919399	321	330	O
options	19919399	331	338	O
.	19919399	338	339	O

Reducing	19919399	340	348	O
breathing	19919399	349	358	O
frequency	19919399	359	368	O
has	19919399	369	372	O
been	19919399	373	377	O
advocated	19919399	378	387	O
as	19919399	388	390	O
a	19919399	391	392	O
method	19919399	393	399	O
to	19919399	400	402	O
reduce	19919399	403	409	O
BP	19919399	410	412	O
.	19919399	412	413	O

METHODS	19919399	415	422	O
:	19919399	423	424	O
A	19919399	425	426	O
randomized	19919399	427	437	O
,	19919399	437	438	O
single-blind	19919399	439	451	O
,	19919399	451	452	O
controlled	19919399	453	463	O
trial	19919399	464	469	O
was	19919399	470	473	O
conducted	19919399	474	483	O
in	19919399	484	486	O
30	19919399	487	489	O
non-diabetic	19919399	490	502	O
patients	19919399	503	511	O
with	19919399	512	516	O
hypertension	19919399	517	529	O
over	19919399	530	534	O
a	19919399	535	536	O
period	19919399	537	543	O
of	19919399	544	546	O
9	19919399	547	548	O
weeks	19919399	549	554	O
to	19919399	555	557	O
evaluate	19919399	558	566	O
the	19919399	567	570	O
effect	19919399	571	577	O
of	19919399	578	580	O
a	19919399	581	582	O
device	19919399	583	589	O
that	19919399	590	594	O
helps	19919399	595	600	O
to	19919399	601	603	O
slow	19919399	604	608	O
breathing	19919399	609	618	O
(	19919399	619	620	O
Resperate	19919399	620	629	O
)	19919399	629	630	O
on	19919399	631	633	O
BP	19919399	634	636	O
and	19919399	637	640	O
quality	19919399	641	648	O
of	19919399	649	651	O
life	19919399	652	656	O
(	19919399	657	658	O
QoL	19919399	658	661	O
)	19919399	661	662	O
.	19919399	662	663	O

The	19919399	664	667	O
control	19919399	668	675	O
group	19919399	676	681	O
listened	19919399	682	690	O
to	19919399	691	693	O
music	19919399	694	699	O
and	19919399	700	703	O
used	19919399	704	708	O
no	19919399	709	711	O
other	19919399	712	717	O
therapeutic	19919399	718	729	O
device	19919399	730	736	O
.	19919399	736	737	O

RESULTS	19919399	739	746	O
:	19919399	747	748	O
There	19919399	749	754	O
was	19919399	755	758	O
no	19919399	759	761	O
significant	19919399	762	773	O
difference	19919399	774	784	O
in	19919399	785	787	O
change	19919399	788	794	O
in	19919399	795	797	O
BP	19919399	798	800	B-Outcome
between	19919399	801	808	O
intervention	19919399	809	821	O
and	19919399	822	825	O
control	19919399	826	833	O
;	19919399	833	834	O
BP	19919399	835	837	B-Outcome
-4.2	19919399	838	842	O
mmHg	19919399	843	847	O
(	19919399	848	849	O
95	19919399	849	851	O
%	19919399	851	852	O
CI	19919399	853	855	O
-12.4	19919399	856	861	O
to	19919399	862	864	O
3.9)/-2.6	19919399	865	874	O
mmHg	19919399	875	879	O
(	19919399	880	881	O
95	19919399	881	883	O
%	19919399	883	884	O
CI	19919399	885	887	O
-8.4	19919399	888	892	O
to	19919399	893	895	O
3.3	19919399	896	899	O
)	19919399	899	900	O
.	19919399	900	901	O

This	19919399	902	906	O
result	19919399	907	913	O
did	19919399	914	917	O
not	19919399	918	921	O
alter	19919399	922	927	O
in	19919399	928	930	O
post	19919399	931	935	O
hoc	19919399	936	939	O
analyses	19919399	940	948	O
,	19919399	948	949	O
when	19919399	950	954	O
patients	19919399	955	963	O
not	19919399	964	967	O
achieving	19919399	968	977	O
target	19919399	978	984	O
breathing	19919399	985	994	O
frequency	19919399	995	1004	O
(	19919399	1005	1006	O
<	19919399	1006	1007	O
10	19919399	1007	1009	O
breaths/min	19919399	1010	1021	O
)	19919399	1021	1022	O
or	19919399	1023	1025	O
non-compliant	19919399	1026	1039	O
patients	19919399	1040	1048	O
were	19919399	1049	1053	O
excluded	19919399	1054	1062	O
.	19919399	1062	1063	O

QoL	19919399	1064	1067	B-Outcome
did	19919399	1068	1071	O
not	19919399	1072	1075	O
change	19919399	1076	1082	O
over	19919399	1083	1087	O
time	19919399	1088	1092	O
.	19919399	1092	1093	O

CONCLUSIONS	19919399	1095	1106	O
:	19919399	1107	1108	O
We	19919399	1109	1111	O
found	19919399	1112	1117	O
no	19919399	1118	1120	O
effect	19919399	1121	1127	O
of	19919399	1128	1130	O
the	19919399	1131	1134	O
Resperate	19919399	1135	1144	O
on	19919399	1145	1147	O
BP	19919399	1148	1150	B-Outcome
or	19919399	1151	1153	O
QoL	19919399	1154	1157	B-Outcome
compared	19919399	1158	1166	O
with	19919399	1167	1171	O
the	19919399	1172	1175	O
control	19919399	1176	1183	O
group	19919399	1184	1189	O
.	19919399	1189	1190	O

We	19919399	1191	1193	O
conclude	19919399	1194	1202	O
that	19919399	1203	1207	O
,	19919399	1207	1208	O
at	19919399	1209	1211	O
this	19919399	1212	1216	O
moment	19919399	1217	1223	O
,	19919399	1223	1224	O
this	19919399	1225	1229	O
device	19919399	1230	1236	O
has	19919399	1237	1240	O
no	19919399	1241	1243	O
added	19919399	1244	1249	O
value	19919399	1250	1255	O
in	19919399	1256	1258	O
the	19919399	1259	1262	O
treatment	19919399	1263	1272	O
of	19919399	1273	1275	O
hypertension	19919399	1276	1288	O
.	19919399	1288	1289	O


Randomized	19948568	0	10	O
,	19948568	10	11	O
controlled	19948568	12	22	O
trial	19948568	23	28	O
of	19948568	29	31	O
an	19948568	32	34	O
intervention	19948568	35	47	O
for	19948568	48	51	O
toddlers	19948568	52	60	O
with	19948568	61	65	O
autism	19948568	66	72	O
:	19948568	72	73	O
the	19948568	74	77	O
Early	19948568	78	83	O
Start	19948568	84	89	O
Denver	19948568	90	96	O
Model	19948568	97	102	O
.	19948568	102	103	O

OBJECTIVE	19948568	105	114	O
:	19948568	115	116	O
To	19948568	117	119	O
conduct	19948568	120	127	O
a	19948568	128	129	O
randomized	19948568	130	140	O
,	19948568	140	141	O
controlled	19948568	142	152	O
trial	19948568	153	158	O
to	19948568	159	161	O
evaluate	19948568	162	170	O
the	19948568	171	174	O
efficacy	19948568	175	183	O
of	19948568	184	186	O
the	19948568	187	190	O
Early	19948568	191	196	O
Start	19948568	197	202	O
Denver	19948568	203	209	O
Model	19948568	210	215	O
(	19948568	216	217	O
ESDM	19948568	217	221	O
)	19948568	221	222	O
,	19948568	222	223	O
a	19948568	224	225	O
comprehensive	19948568	226	239	O
developmental	19948568	240	253	O
behavioral	19948568	254	264	O
intervention	19948568	265	277	O
,	19948568	277	278	O
for	19948568	279	282	O
improving	19948568	283	292	O
outcomes	19948568	293	301	O
of	19948568	302	304	O
toddlers	19948568	305	313	O
diagnosed	19948568	314	323	O
with	19948568	324	328	O
autism	19948568	329	335	O
spectrum	19948568	336	344	O
disorder	19948568	345	353	O
(	19948568	354	355	O
ASD	19948568	355	358	O
)	19948568	358	359	O
.	19948568	359	360	O

METHODS	19948568	362	369	O
:	19948568	370	371	O
Forty-eight	19948568	372	383	O
children	19948568	384	392	O
diagnosed	19948568	393	402	O
with	19948568	403	407	O
ASD	19948568	408	411	O
between	19948568	412	419	O
18	19948568	420	422	O
and	19948568	423	426	O
30	19948568	427	429	O
months	19948568	430	436	O
of	19948568	437	439	O
age	19948568	440	443	O
were	19948568	444	448	O
randomly	19948568	449	457	O
assigned	19948568	458	466	O
to	19948568	467	469	O
1	19948568	470	471	O
of	19948568	472	474	O
2	19948568	475	476	O
groups	19948568	477	483	O
:	19948568	483	484	O
(	19948568	485	486	O
1	19948568	486	487	O
)	19948568	487	488	O
ESDM	19948568	489	493	O
intervention	19948568	494	506	O
,	19948568	506	507	O
which	19948568	508	513	O
is	19948568	514	516	O
based	19948568	517	522	O
on	19948568	523	525	O
developmental	19948568	526	539	O
and	19948568	540	543	O
applied	19948568	544	551	O
behavioral	19948568	552	562	O
analytic	19948568	563	571	O
principles	19948568	572	582	O
and	19948568	583	586	O
delivered	19948568	587	596	O
by	19948568	597	599	O
trained	19948568	600	607	O
therapists	19948568	608	618	O
and	19948568	619	622	O
parents	19948568	623	630	O
for	19948568	631	634	O
2	19948568	635	636	O
years	19948568	637	642	O
;	19948568	642	643	O
or	19948568	644	646	O
(	19948568	647	648	O
2	19948568	648	649	O
)	19948568	649	650	O
referral	19948568	651	659	O
to	19948568	660	662	O
community	19948568	663	672	O
providers	19948568	673	682	O
for	19948568	683	686	O
intervention	19948568	687	699	O
commonly	19948568	700	708	O
available	19948568	709	718	O
in	19948568	719	721	O
the	19948568	722	725	O
community	19948568	726	735	O
.	19948568	735	736	O

RESULTS	19948568	738	745	O
:	19948568	746	747	O
Compared	19948568	748	756	O
with	19948568	757	761	O
children	19948568	762	770	O
who	19948568	771	774	O
received	19948568	775	783	O
community-intervention	19948568	784	806	O
,	19948568	806	807	O
children	19948568	808	816	O
who	19948568	817	820	O
received	19948568	821	829	O
ESDM	19948568	830	834	O
showed	19948568	835	841	O
significant	19948568	842	853	O
improvements	19948568	854	866	O
in	19948568	867	869	O
IQ	19948568	870	872	B-Outcome
,	19948568	872	873	O
adaptive	19948568	874	882	B-Outcome
behavior	19948568	883	891	I-Outcome
,	19948568	891	892	O
and	19948568	893	896	O
autism	19948568	897	903	B-Outcome
diagnosis	19948568	904	913	I-Outcome
.	19948568	913	914	O

Two	19948568	915	918	O
years	19948568	919	924	O
after	19948568	925	930	O
entering	19948568	931	939	O
intervention	19948568	940	952	O
,	19948568	952	953	O
the	19948568	954	957	O
ESDM	19948568	958	962	O
group	19948568	963	968	O
on	19948568	969	971	O
average	19948568	972	979	O
improved	19948568	980	988	O
17.6	19948568	989	993	O
standard	19948568	994	1002	O
score	19948568	1003	1008	O
points	19948568	1009	1015	O
(	19948568	1016	1017	O
1	19948568	1017	1018	O
SD	19948568	1019	1021	O
:	19948568	1021	1022	O
15	19948568	1023	1025	O
points	19948568	1026	1032	O
)	19948568	1032	1033	O
compared	19948568	1034	1042	O
with	19948568	1043	1047	O
7.0	19948568	1048	1051	O
points	19948568	1052	1058	O
in	19948568	1059	1061	O
the	19948568	1062	1065	O
comparison	19948568	1066	1076	O
group	19948568	1077	1082	O
relative	19948568	1083	1091	O
to	19948568	1092	1094	O
baseline	19948568	1095	1103	O
scores	19948568	1104	1110	O
.	19948568	1110	1111	O

The	19948568	1112	1115	O
ESDM	19948568	1116	1120	O
group	19948568	1121	1126	O
maintained	19948568	1127	1137	O
its	19948568	1138	1141	O
rate	19948568	1142	1146	O
of	19948568	1147	1149	O
growth	19948568	1150	1156	O
in	19948568	1157	1159	O
adaptive	19948568	1160	1168	B-Outcome
behavior	19948568	1169	1177	I-Outcome
compared	19948568	1178	1186	O
with	19948568	1187	1191	O
a	19948568	1192	1193	O
normative	19948568	1194	1203	O
sample	19948568	1204	1210	O
of	19948568	1211	1213	O
typically	19948568	1214	1223	O
developing	19948568	1224	1234	O
children	19948568	1235	1243	O
.	19948568	1243	1244	O

In	19948568	1245	1247	O
contrast	19948568	1248	1256	O
,	19948568	1256	1257	O
over	19948568	1258	1262	O
the	19948568	1263	1266	O
2-year	19948568	1267	1273	O
span	19948568	1274	1278	O
,	19948568	1278	1279	O
the	19948568	1280	1283	O
comparison	19948568	1284	1294	O
group	19948568	1295	1300	O
showed	19948568	1301	1307	O
greater	19948568	1308	1315	O
delays	19948568	1316	1322	O
in	19948568	1323	1325	O
adaptive	19948568	1326	1334	B-Outcome
behavior	19948568	1335	1343	I-Outcome
.	19948568	1343	1344	O

Children	19948568	1345	1353	O
who	19948568	1354	1357	O
received	19948568	1358	1366	O
ESDM	19948568	1367	1371	O
also	19948568	1372	1376	O
were	19948568	1377	1381	O
more	19948568	1382	1386	O
likely	19948568	1387	1393	O
to	19948568	1394	1396	O
experience	19948568	1397	1407	O
a	19948568	1408	1409	O
change	19948568	1410	1416	O
in	19948568	1417	1419	O
diagnosis	19948568	1420	1429	O
from	19948568	1430	1434	O
autism	19948568	1435	1441	O
to	19948568	1442	1444	O
pervasive	19948568	1445	1454	O
developmental	19948568	1455	1468	O
disorder	19948568	1469	1477	O
,	19948568	1477	1478	O
not	19948568	1479	1482	O
otherwise	19948568	1483	1492	O
specified	19948568	1493	1502	O
,	19948568	1502	1503	O
than	19948568	1504	1508	O
the	19948568	1509	1512	O
comparison	19948568	1513	1523	O
group	19948568	1524	1529	O
.	19948568	1529	1530	O

CONCLUSIONS	19948568	1532	1543	O
:	19948568	1544	1545	O
This	19948568	1546	1550	O
is	19948568	1551	1553	O
the	19948568	1554	1557	O
first	19948568	1558	1563	O
randomized	19948568	1564	1574	O
,	19948568	1574	1575	O
controlled	19948568	1576	1586	O
trial	19948568	1587	1592	O
to	19948568	1593	1595	O
demonstrate	19948568	1596	1607	O
the	19948568	1608	1611	O
efficacy	19948568	1612	1620	B-Outcome
of	19948568	1621	1623	O
a	19948568	1624	1625	O
comprehensive	19948568	1626	1639	O
developmental	19948568	1640	1653	O
behavioral	19948568	1654	1664	O
intervention	19948568	1665	1677	O
for	19948568	1678	1681	O
toddlers	19948568	1682	1690	O
with	19948568	1691	1695	O
ASD	19948568	1696	1699	O
for	19948568	1700	1703	O
improving	19948568	1704	1713	O
cognitive	19948568	1714	1723	B-Outcome
and	19948568	1724	1727	O
adaptive	19948568	1728	1736	B-Outcome
behavior	19948568	1737	1745	I-Outcome
and	19948568	1746	1749	O
reducing	19948568	1750	1758	O
severity	19948568	1759	1767	B-Outcome
of	19948568	1768	1770	I-Outcome
ASD	19948568	1771	1774	I-Outcome
diagnosis	19948568	1775	1784	I-Outcome
.	19948568	1784	1785	O

Results	19948568	1786	1793	O
of	19948568	1794	1796	O
this	19948568	1797	1801	O
study	19948568	1802	1807	O
underscore	19948568	1808	1818	O
the	19948568	1819	1822	O
importance	19948568	1823	1833	O
of	19948568	1834	1836	O
early	19948568	1837	1842	O
detection	19948568	1843	1852	O
of	19948568	1853	1855	O
and	19948568	1856	1859	O
intervention	19948568	1860	1872	O
in	19948568	1873	1875	O
autism	19948568	1876	1882	O
.	19948568	1882	1883	O


Aripiprazole	19948625	0	12	O
in	19948625	13	15	O
the	19948625	16	19	O
treatment	19948625	20	29	O
of	19948625	30	32	O
irritability	19948625	33	45	O
in	19948625	46	48	O
children	19948625	49	57	O
and	19948625	58	61	O
adolescents	19948625	62	73	O
with	19948625	74	78	O
autistic	19948625	79	87	O
disorder	19948625	88	96	O
.	19948625	96	97	O

OBJECTIVE	19948625	99	108	O
:	19948625	109	110	O
The	19948625	111	114	O
objective	19948625	115	124	O
of	19948625	125	127	O
this	19948625	128	132	O
study	19948625	133	138	O
was	19948625	139	142	O
to	19948625	143	145	O
evaluate	19948625	146	154	O
short-term	19948625	155	165	O
efficacy	19948625	166	174	O
and	19948625	175	178	O
safety	19948625	179	185	O
of	19948625	186	188	O
aripiprazole	19948625	189	201	O
in	19948625	202	204	O
the	19948625	205	208	O
treatment	19948625	209	218	O
of	19948625	219	221	O
irritability	19948625	222	234	O
in	19948625	235	237	O
children	19948625	238	246	O
and	19948625	247	250	O
adolescents	19948625	251	262	O
with	19948625	263	267	O
autistic	19948625	268	276	O
disorder	19948625	277	285	O
who	19948625	286	289	O
were	19948625	290	294	O
manifesting	19948625	295	306	O
behaviors	19948625	307	316	O
such	19948625	317	321	O
as	19948625	322	324	O
tantrums	19948625	325	333	O
,	19948625	333	334	O
aggression	19948625	335	345	O
,	19948625	345	346	O
self-injurious	19948625	347	361	O
behavior	19948625	362	370	O
,	19948625	370	371	O
or	19948625	372	374	O
a	19948625	375	376	O
combination	19948625	377	388	O
of	19948625	389	391	O
these	19948625	392	397	O
.	19948625	397	398	O

METHODS	19948625	400	407	O
:	19948625	408	409	O
This	19948625	410	414	O
8-week	19948625	415	421	O
,	19948625	421	422	O
double-blind	19948625	423	435	O
,	19948625	435	436	O
randomized	19948625	437	447	O
,	19948625	447	448	O
placebo-controlled	19948625	449	467	O
,	19948625	467	468	O
parallel-group	19948625	469	483	O
study	19948625	484	489	O
was	19948625	490	493	O
conducted	19948625	494	503	O
of	19948625	504	506	O
children	19948625	507	515	O
and	19948625	516	519	O
adolescents	19948625	520	531	O
(	19948625	532	533	O
aged	19948625	533	537	O
6	19948625	538	539	O
-	19948625	539	540	O
17	19948625	540	542	O
years	19948625	543	548	O
)	19948625	548	549	O
with	19948625	550	554	O
autistic	19948625	555	563	O
disorder	19948625	564	572	O
.	19948625	572	573	O

Patients	19948625	574	582	O
were	19948625	583	587	O
randomly	19948625	588	596	O
assigned	19948625	597	605	O
(	19948625	606	607	O
1:1	19948625	607	610	O
)	19948625	610	611	O
to	19948625	612	614	O
flexibly	19948625	615	623	O
dosed	19948625	624	629	O
aripiprazole	19948625	630	642	O
(	19948625	643	644	O
target	19948625	644	650	O
dosage	19948625	651	657	O
:	19948625	657	658	O
5	19948625	659	660	O
,	19948625	660	661	O
10	19948625	662	664	O
,	19948625	664	665	O
or	19948625	666	668	O
15	19948625	669	671	O
mg/day	19948625	672	678	O
)	19948625	678	679	O
or	19948625	680	682	O
placebo	19948625	683	690	O
.	19948625	690	691	O

Efficacy	19948625	692	700	O
outcome	19948625	701	708	O
measures	19948625	709	717	O
included	19948625	718	726	O
the	19948625	727	730	O
Aberrant	19948625	731	739	O
Behavior	19948625	740	748	O
Checklist	19948625	749	758	O
irritability	19948625	759	771	O
subscale	19948625	772	780	O
and	19948625	781	784	O
the	19948625	785	788	O
Clinical	19948625	789	797	O
Global	19948625	798	804	O
Impression-Improvement	19948625	805	827	O
score	19948625	828	833	O
(	19948625	834	835	O
CGI-I	19948625	835	840	O
)	19948625	840	841	O
.	19948625	841	842	O

Safety	19948625	843	849	O
and	19948625	850	853	O
tolerability	19948625	854	866	O
were	19948625	867	871	O
also	19948625	872	876	O
assessed	19948625	877	885	O
.	19948625	885	886	O

RESULTS	19948625	888	895	O
:	19948625	896	897	O
Ninety-eight	19948625	898	910	O
patients	19948625	911	919	O
were	19948625	920	924	O
randomly	19948625	925	933	O
assigned	19948625	934	942	O
to	19948625	943	945	O
receive	19948625	946	953	O
placebo	19948625	954	961	O
(	19948625	962	963	O
n	19948625	963	964	O
=	19948625	965	966	O
51	19948625	967	969	O
)	19948625	969	970	O
or	19948625	971	973	O
aripiprazole	19948625	974	986	O
(	19948625	987	988	O
n	19948625	988	989	O
=	19948625	990	991	O
47	19948625	992	994	O
)	19948625	994	995	O
.	19948625	995	996	O

Mean	19948625	997	1001	O
improvement	19948625	1002	1013	O
in	19948625	1014	1016	O
Aberrant	19948625	1017	1025	B-Outcome
Behavior	19948625	1026	1034	I-Outcome
Checklist	19948625	1035	1044	I-Outcome
irritability	19948625	1045	1057	I-Outcome
subscale	19948625	1058	1066	I-Outcome
score	19948625	1067	1072	I-Outcome
was	19948625	1073	1076	O
significantly	19948625	1077	1090	O
greater	19948625	1091	1098	O
with	19948625	1099	1103	O
aripiprazole	19948625	1104	1116	O
than	19948625	1117	1121	O
with	19948625	1122	1126	O
placebo	19948625	1127	1134	O
from	19948625	1135	1139	O
week	19948625	1140	1144	O
1	19948625	1145	1146	O
through	19948625	1147	1154	O
week	19948625	1155	1159	O
8	19948625	1160	1161	O
.	19948625	1161	1162	O

Aripiprazole	19948625	1163	1175	O
demonstrated	19948625	1176	1188	O
significantly	19948625	1189	1202	O
greater	19948625	1203	1210	O
global	19948625	1211	1217	O
improvements	19948625	1218	1230	O
than	19948625	1231	1235	O
placebo	19948625	1236	1243	O
,	19948625	1243	1244	O
as	19948625	1245	1247	O
assessed	19948625	1248	1256	O
by	19948625	1257	1259	O
the	19948625	1260	1263	O
mean	19948625	1264	1268	B-Outcome
CGI-I	19948625	1269	1274	I-Outcome
score	19948625	1275	1280	I-Outcome
from	19948625	1281	1285	I-Outcome
week	19948625	1286	1290	I-Outcome
1	19948625	1291	1292	I-Outcome
through	19948625	1293	1300	I-Outcome
week	19948625	1301	1305	I-Outcome
8	19948625	1306	1307	I-Outcome
;	19948625	1307	1308	O
however	19948625	1309	1316	O
,	19948625	1316	1317	O
clinically	19948625	1318	1328	O
significant	19948625	1329	1340	O
residual	19948625	1341	1349	O
symptoms	19948625	1350	1358	O
may	19948625	1359	1362	O
still	19948625	1363	1368	O
persist	19948625	1369	1376	O
for	19948625	1377	1380	O
some	19948625	1381	1385	O
patients	19948625	1386	1394	O
.	19948625	1394	1395	O

Discontinuation	19948625	1396	1411	O
rates	19948625	1412	1417	O
as	19948625	1418	1420	O
a	19948625	1421	1422	O
result	19948625	1423	1429	O
of	19948625	1430	1432	O
adverse	19948625	1433	1440	B-Outcome
events	19948625	1441	1447	I-Outcome
(	19948625	1448	1449	O
AEs	19948625	1449	1452	B-Outcome
)	19948625	1452	1453	O
were	19948625	1454	1458	O
10.6	19948625	1459	1463	O
%	19948625	1463	1464	O
for	19948625	1465	1468	O
aripiprazole	19948625	1469	1481	O
and	19948625	1482	1485	O
5.9	19948625	1486	1489	O
%	19948625	1489	1490	O
for	19948625	1491	1494	O
placebo	19948625	1495	1502	O
.	19948625	1502	1503	O

Extrapyramidal	19948625	1504	1518	B-Outcome
symptom-related	19948625	1519	1534	I-Outcome
AE	19948625	1535	1537	I-Outcome
rates	19948625	1538	1543	O
were	19948625	1544	1548	O
14.9	19948625	1549	1553	O
%	19948625	1553	1554	O
for	19948625	1555	1558	O
aripiprazole	19948625	1559	1571	O
and	19948625	1572	1575	O
8.0	19948625	1576	1579	O
%	19948625	1579	1580	O
for	19948625	1581	1584	O
placebo	19948625	1585	1592	O
.	19948625	1592	1593	O

No	19948625	1594	1596	O
serious	19948625	1597	1604	B-Outcome
AEs	19948625	1605	1608	I-Outcome
were	19948625	1609	1613	O
reported	19948625	1614	1622	O
.	19948625	1622	1623	O

Mean	19948625	1624	1628	B-Outcome
weight	19948625	1629	1635	I-Outcome
gain	19948625	1636	1640	O
was	19948625	1641	1644	O
2.0	19948625	1645	1648	O
kg	19948625	1649	1651	O
on	19948625	1652	1654	O
aripiprazole	19948625	1655	1667	O
and	19948625	1668	1671	O
0.8	19948625	1672	1675	O
kg	19948625	1676	1678	O
on	19948625	1679	1681	O
placebo	19948625	1682	1689	O
at	19948625	1690	1692	O
week	19948625	1693	1697	O
8	19948625	1698	1699	O
.	19948625	1699	1700	O

CONCLUSIONS	19948625	1702	1713	O
:	19948625	1714	1715	O
Aripiprazole	19948625	1716	1728	O
was	19948625	1729	1732	O
efficacious	19948625	1733	1744	B-Outcome
in	19948625	1745	1747	O
children	19948625	1748	1756	O
and	19948625	1757	1760	O
adolescents	19948625	1761	1772	O
with	19948625	1773	1777	O
irritability	19948625	1778	1790	O
associated	19948625	1791	1801	O
with	19948625	1802	1806	O
autistic	19948625	1807	1815	O
disorder	19948625	1816	1824	O
and	19948625	1825	1828	O
was	19948625	1829	1832	O
generally	19948625	1833	1842	O
safe	19948625	1843	1847	B-Outcome
and	19948625	1848	1851	O
well	19948625	1852	1856	O
tolerated	19948625	1857	1866	B-Outcome
.	19948625	1866	1867	O


Evaluation	20048611	0	10	O
of	20048611	11	13	O
a	20048611	14	15	O
new	20048611	16	19	O
wound	20048611	20	25	O
closure	20048611	26	33	O
device	20048611	34	40	O
for	20048611	41	44	O
linear	20048611	45	51	O
surgical	20048611	52	60	O
incisions	20048611	61	70	O
:	20048611	70	71	O
3	20048611	72	73	O
M	20048611	73	74	O
Steri-Strip	20048611	75	86	O
S	20048611	87	88	O
Surgical	20048611	89	97	O
Skin	20048611	98	102	O
Closure	20048611	103	110	O
versus	20048611	111	117	O
subcuticular	20048611	118	130	O
closure	20048611	131	138	O
.	20048611	138	139	O

BACKGROUND	20048611	141	151	O
:	20048611	152	153	O
Technological	20048611	154	167	O
innovations	20048611	168	179	O
are	20048611	180	183	O
often	20048611	184	189	O
adopted	20048611	190	197	O
before	20048611	198	204	O
scientific	20048611	205	215	O
comparison	20048611	216	226	O
to	20048611	227	229	O
an	20048611	230	232	O
accepted	20048611	233	241	O
standard	20048611	242	250	O
.	20048611	250	251	O

The	20048611	252	255	O
authors	20048611	256	263	O
'	20048611	263	264	O
study	20048611	265	270	O
compared	20048611	271	279	O
suture	20048611	280	286	O
with	20048611	287	291	O
a	20048611	292	293	O
new	20048611	294	297	O
coaptive	20048611	298	306	O
film	20048611	307	311	O
device	20048611	312	318	O
,	20048611	318	319	O
3	20048611	320	321	O
M	20048611	321	322	O
Steri-Strip	20048611	323	334	O
S	20048611	335	336	O
Surgical	20048611	337	345	O
Skin	20048611	346	350	O
Closure	20048611	351	358	O
,	20048611	358	359	O
on	20048611	360	362	O
linear	20048611	363	369	O
incisions	20048611	370	379	O
.	20048611	379	380	O

METHODS	20048611	382	389	O
:	20048611	390	391	O
Patients	20048611	392	400	O
undergoing	20048611	401	411	O
Wise-pattern	20048611	412	424	O
breast	20048611	425	431	O
reduction	20048611	432	441	O
or	20048611	442	444	O
abdominal	20048611	445	454	O
procedures	20048611	455	465	O
had	20048611	466	469	O
paired	20048611	470	476	O
incisions	20048611	477	486	O
randomly	20048611	487	495	O
assigned	20048611	496	504	O
to	20048611	505	507	O
Steri-Strip	20048611	508	519	O
S	20048611	520	521	O
or	20048611	522	524	O
suture	20048611	525	531	O
closure	20048611	532	539	O
.	20048611	539	540	O

Key	20048611	541	544	O
outcome	20048611	545	552	O
measures	20048611	553	561	O
were	20048611	562	566	O
closure	20048611	567	574	O
time	20048611	575	579	O
,	20048611	579	580	O
patient	20048611	581	588	O
comfort	20048611	589	596	O
,	20048611	596	597	O
and	20048611	598	601	O
scar	20048611	602	606	O
quality	20048611	607	614	O
at	20048611	615	617	O
6	20048611	618	619	O
months	20048611	620	626	O
by	20048611	627	629	O
patients	20048611	630	638	O
and	20048611	639	642	O
surgeons	20048611	643	651	O
using	20048611	652	657	O
a	20048611	658	659	O
new	20048611	660	663	O
scar	20048611	664	668	O
evaluation	20048611	669	679	O
tool	20048611	680	684	O
,	20048611	684	685	O
visual	20048611	686	692	O
assessment	20048611	693	703	O
of	20048611	704	706	O
linear	20048611	707	713	O
scars	20048611	714	719	O
.	20048611	719	720	O

Statistical	20048611	721	732	O
differences	20048611	733	744	O
between	20048611	745	752	O
the	20048611	753	756	O
two	20048611	757	760	O
closure	20048611	761	768	O
techniques	20048611	769	779	O
were	20048611	780	784	O
assessed	20048611	785	793	O
by	20048611	794	796	O
Wilcoxon	20048611	797	805	O
signed	20048611	806	812	O
rank	20048611	813	817	O
test	20048611	818	822	O
.	20048611	822	823	O

RESULTS	20048611	825	832	O
:	20048611	833	834	O
Of	20048611	835	837	O
59	20048611	838	840	O
patients	20048611	841	849	O
,	20048611	849	850	O
eight	20048611	851	856	O
were	20048611	857	861	O
excluded	20048611	862	870	O
from	20048611	871	875	O
randomization	20048611	876	889	O
(	20048611	890	891	O
a	20048611	891	892	O
surgeon	20048611	893	900	O
judged	20048611	901	907	O
Steri-Strip	20048611	908	919	O
S	20048611	920	921	O
to	20048611	922	924	O
be	20048611	925	927	O
a	20048611	928	929	O
nonviable	20048611	930	939	O
closure	20048611	940	947	O
technique	20048611	948	957	O
for	20048611	958	961	O
mismatched	20048611	962	972	O
wound	20048611	973	978	O
edges	20048611	979	984	O
)	20048611	984	985	O
.	20048611	985	986	O

Fifty-one	20048611	987	996	O
patients	20048611	997	1005	O
(	20048611	1006	1007	O
breast	20048611	1007	1013	O
,	20048611	1013	1014	O
n	20048611	1015	1016	O
=	20048611	1017	1018	O
24	20048611	1019	1021	O
;	20048611	1021	1022	O
abdomen	20048611	1023	1030	O
,	20048611	1030	1031	O
n	20048611	1032	1033	O
=	20048611	1034	1035	O
27	20048611	1036	1038	O
)	20048611	1038	1039	O
were	20048611	1040	1044	O
randomized	20048611	1045	1055	O
.	20048611	1055	1056	O

Operative	20048611	1057	1066	B-Outcome
time	20048611	1067	1071	I-Outcome
with	20048611	1072	1076	O
Steri-Strip	20048611	1077	1088	O
S	20048611	1089	1090	O
for	20048611	1091	1094	O
breast	20048611	1095	1101	O
was	20048611	1102	1105	O
2.0	20048611	1106	1109	O
minutes	20048611	1110	1117	O
(	20048611	1118	1119	O
SD	20048611	1119	1121	O
=	20048611	1122	1123	O
1.1	20048611	1124	1127	O
)	20048611	1127	1128	O
versus	20048611	1129	1135	O
suture	20048611	1136	1142	O
closure	20048611	1143	1150	O
at	20048611	1151	1153	O
4.6	20048611	1154	1157	O
minutes	20048611	1158	1165	O
(	20048611	1166	1167	O
SD	20048611	1167	1169	O
=	20048611	1170	1171	O
1.5	20048611	1172	1175	O
;	20048611	1175	1176	O
p	20048611	1177	1178	O
<	20048611	1179	1180	O
0.001	20048611	1181	1186	O
)	20048611	1186	1187	O
.	20048611	1187	1188	O

Similarly	20048611	1189	1198	O
,	20048611	1198	1199	O
Steri-Strip	20048611	1200	1211	O
S	20048611	1212	1213	O
versus	20048611	1214	1220	O
suture	20048611	1221	1227	O
for	20048611	1228	1231	O
the	20048611	1232	1235	O
abdomen	20048611	1236	1243	O
was	20048611	1244	1247	O
faster	20048611	1248	1254	O
(	20048611	1255	1256	O
p	20048611	1256	1257	O
<	20048611	1258	1259	O
0.001	20048611	1260	1265	O
;	20048611	1265	1266	O
4.9	20048611	1267	1270	O
minutes	20048611	1271	1278	O
,	20048611	1278	1279	O
SD	20048611	1280	1282	O
=	20048611	1283	1284	O
2.3	20048611	1285	1288	O
versus	20048611	1289	1295	O
10.1	20048611	1296	1300	O
minutes	20048611	1301	1308	O
,	20048611	1308	1309	O
SD	20048611	1310	1312	O
=	20048611	1313	1314	O
3.4	20048611	1315	1318	O
)	20048611	1318	1319	O
.	20048611	1319	1320	O

Comfort	20048611	1321	1328	B-Outcome
scores	20048611	1329	1335	I-Outcome
did	20048611	1336	1339	O
not	20048611	1340	1343	O
differ	20048611	1344	1350	O
between	20048611	1351	1358	O
closures	20048611	1359	1367	O
[	20048611	1368	1369	O
5.8	20048611	1369	1372	O
(	20048611	1373	1374	O
SD	20048611	1374	1376	O
=	20048611	1377	1378	O
2.7	20048611	1379	1382	O
)	20048611	1382	1383	O
versus	20048611	1384	1390	O
6.9	20048611	1391	1394	O
(	20048611	1395	1396	O
SD	20048611	1396	1398	O
=	20048611	1399	1400	O
2.0	20048611	1401	1404	O
)	20048611	1404	1405	O
,	20048611	1405	1406	O
respectively	20048611	1407	1419	O
,	20048611	1419	1420	O
on	20048611	1421	1423	O
breast	20048611	1424	1430	O
(	20048611	1431	1432	O
p	20048611	1432	1433	O
=	20048611	1434	1435	O
0.142	20048611	1436	1441	O
)	20048611	1441	1442	O
and	20048611	1443	1446	O
7.7	20048611	1447	1450	O
(	20048611	1451	1452	O
SD	20048611	1452	1454	O
=	20048611	1455	1456	O
1.8	20048611	1457	1460	O
)	20048611	1460	1461	O
versus	20048611	1462	1468	O
7.7	20048611	1469	1472	O
(	20048611	1473	1474	O
SD	20048611	1474	1476	O
=	20048611	1477	1478	O
2.3	20048611	1479	1482	O
)	20048611	1482	1483	O
on	20048611	1484	1486	O
abdomen	20048611	1487	1494	O
(	20048611	1495	1496	O
p	20048611	1496	1497	O
=	20048611	1498	1499	O
0.903	20048611	1500	1505	O
)	20048611	1505	1506	O
]	20048611	1506	1507	O
.	20048611	1507	1508	O

Complication	20048611	1509	1521	B-Outcome
rates	20048611	1522	1527	I-Outcome
did	20048611	1528	1531	O
not	20048611	1532	1535	O
differ	20048611	1536	1542	O
between	20048611	1543	1550	O
closure	20048611	1551	1558	O
types	20048611	1559	1564	O
.	20048611	1564	1565	O

Patients	20048611	1566	1574	B-Outcome
'	20048611	1574	1575	I-Outcome
visual	20048611	1576	1582	I-Outcome
assessment	20048611	1583	1593	I-Outcome
of	20048611	1594	1596	I-Outcome
linear	20048611	1597	1603	I-Outcome
scars	20048611	1604	1609	I-Outcome
rating	20048611	1610	1616	I-Outcome
of	20048611	1617	1619	I-Outcome
breasts	20048611	1620	1627	I-Outcome
was	20048611	1628	1631	O
3.8	20048611	1632	1635	O
(	20048611	1636	1637	O
SD	20048611	1637	1639	O
=	20048611	1640	1641	O
2.9	20048611	1642	1645	O
)	20048611	1645	1646	O
for	20048611	1647	1650	O
Steri-Strip	20048611	1651	1662	O
S	20048611	1663	1664	O
and	20048611	1665	1668	O
better	20048611	1669	1675	O
at	20048611	1676	1678	O
2.6	20048611	1679	1682	O
(	20048611	1683	1684	O
SD	20048611	1684	1686	O
=	20048611	1687	1688	O
2.9	20048611	1689	1692	O
)	20048611	1692	1693	O
for	20048611	1694	1697	O
suture	20048611	1698	1704	O
(	20048611	1705	1706	O
p	20048611	1706	1707	O
=	20048611	1708	1709	O
0.008	20048611	1710	1715	O
)	20048611	1715	1716	O
.	20048611	1716	1717	O

One	20048611	1718	1721	O
surgeon	20048611	1722	1729	O
rated	20048611	1730	1735	O
breast	20048611	1736	1742	O
Steri-Strip	20048611	1743	1754	O
S	20048611	1755	1756	O
scars	20048611	1757	1762	B-Outcome
worse	20048611	1763	1768	O
than	20048611	1769	1773	O
suture	20048611	1774	1780	O
scars	20048611	1781	1786	B-Outcome
(	20048611	1787	1788	O
4.3	20048611	1788	1791	O
versus	20048611	1792	1798	O
3.7	20048611	1799	1802	O
;	20048611	1802	1803	O
p	20048611	1804	1805	O
=	20048611	1806	1807	O
0.014	20048611	1808	1813	O
)	20048611	1813	1814	O
.	20048611	1814	1815	O

For	20048611	1816	1819	O
abdominal	20048611	1820	1829	B-Outcome
scars	20048611	1830	1835	I-Outcome
,	20048611	1835	1836	O
there	20048611	1837	1842	O
was	20048611	1843	1846	O
no	20048611	1847	1849	O
difference	20048611	1850	1860	O
in	20048611	1861	1863	O
the	20048611	1864	1867	O
patient	20048611	1868	1875	O
or	20048611	1876	1878	O
surgeon	20048611	1879	1886	O
ratings	20048611	1887	1894	O
.	20048611	1894	1895	O

CONCLUSIONS	20048611	1897	1908	O
:	20048611	1909	1910	O
Steri-Strip	20048611	1911	1922	O
S	20048611	1923	1924	O
permits	20048611	1925	1932	O
faster	20048611	1933	1939	O
wound	20048611	1940	1945	B-Outcome
closure	20048611	1946	1953	I-Outcome
than	20048611	1954	1958	O
suture	20048611	1959	1965	O
.	20048611	1965	1966	O

On	20048611	1967	1969	O
the	20048611	1970	1973	O
basis	20048611	1974	1979	O
of	20048611	1980	1982	O
patient	20048611	1983	1990	B-Outcome
reports	20048611	1991	1998	I-Outcome
of	20048611	1999	2001	I-Outcome
comfort	20048611	2002	2009	I-Outcome
and	20048611	2010	2013	O
scar	20048611	2014	2018	B-Outcome
quality	20048611	2019	2026	I-Outcome
,	20048611	2026	2027	O
surgeons	20048611	2028	2036	O
increase	20048611	2037	2045	O
efficiency	20048611	2046	2056	O
and	20048611	2057	2060	O
maintain	20048611	2061	2069	O
quality	20048611	2070	2077	O
with	20048611	2078	2082	O
the	20048611	2083	2086	O
use	20048611	2087	2090	O
of	20048611	2091	2093	O
Steri-Strip	20048611	2094	2105	O
S	20048611	2106	2107	O
on	20048611	2108	2110	O
abdominal	20048611	2111	2120	O
wounds	20048611	2121	2127	O
but	20048611	2128	2131	O
not	20048611	2132	2135	O
on	20048611	2136	2138	O
breast	20048611	2139	2145	O
wounds	20048611	2146	2152	O
.	20048611	2152	2153	O


Preoperative	20061334	0	12	O
lanreotide	20061334	13	23	O
treatment	20061334	24	33	O
in	20061334	34	36	O
acromegalic	20061334	37	48	O
patients	20061334	49	57	O
with	20061334	58	62	O
macroadenomas	20061334	63	76	O
increases	20061334	77	86	O
short-term	20061334	87	97	O
postoperative	20061334	98	111	O
cure	20061334	112	116	O
rates	20061334	117	122	O
:	20061334	122	123	O
a	20061334	124	125	O
prospective	20061334	126	137	O
,	20061334	137	138	O
randomised	20061334	139	149	O
trial	20061334	150	155	O
.	20061334	155	156	O

OBJECTIVE	20061334	158	167	O
:	20061334	168	169	O
To	20061334	170	172	O
investigate	20061334	173	184	O
whether	20061334	185	192	O
4-month	20061334	193	200	O
preoperative	20061334	201	213	O
lanreotide	20061334	214	224	O
treatment	20061334	225	234	O
would	20061334	235	240	O
improve	20061334	241	248	O
the	20061334	249	252	O
surgical	20061334	253	261	O
cure	20061334	262	266	O
rate	20061334	267	271	O
of	20061334	272	274	O
newly	20061334	275	280	O
diagnosed	20061334	281	290	O
acromegalic	20061334	291	302	O
patients	20061334	303	311	O
with	20061334	312	316	O
macroadenomas	20061334	317	330	O
.	20061334	330	331	O

DESIGN	20061334	333	339	O
:	20061334	340	341	O
A	20061334	342	343	O
prospective	20061334	344	355	O
,	20061334	355	356	O
randomised	20061334	357	367	O
study	20061334	368	373	O
.	20061334	373	374	O

METHODS	20061334	376	383	O
:	20061334	384	385	O
After	20061334	386	391	O
a	20061334	392	393	O
baseline	20061334	394	402	O
evaluation	20061334	403	413	O
,	20061334	413	414	O
patients	20061334	415	423	O
were	20061334	424	428	O
randomly	20061334	429	437	O
assigned	20061334	438	446	O
to	20061334	447	449	O
4-month	20061334	450	457	O
preoperative	20061334	458	470	O
treatment	20061334	471	480	O
with	20061334	481	485	O
lanreotide	20061334	486	496	O
(	20061334	497	498	O
starting	20061334	498	506	O
with	20061334	507	511	O
30	20061334	512	514	O
mg/2	20061334	515	519	O
weeks	20061334	520	525	O
i.m	20061334	526	529	O
.	20061334	529	530	O
and	20061334	531	534	O
increasing	20061334	535	545	O
to	20061334	546	548	O
30	20061334	549	551	O
mg/week	20061334	552	559	O
i.m	20061334	560	563	O
.	20061334	563	564	O

at	20061334	565	567	O
week	20061334	568	572	O
8	20061334	573	574	O
if	20061334	575	577	O
mean	20061334	578	582	O
GH	20061334	583	585	O
>	20061334	586	587	O
2.5	20061334	587	590	O
microg/l	20061334	591	599	O
on	20061334	600	602	O
GH	20061334	603	605	O
day	20061334	606	609	O
curves	20061334	610	616	O
;	20061334	616	617	O
pretreatment	20061334	618	630	O
group	20061334	631	636	O
,	20061334	636	637	O
Group	20061334	638	643	O
1	20061334	644	645	O
)	20061334	645	646	O
or	20061334	647	649	O
to	20061334	650	652	O
transsphenoidal	20061334	653	668	O
surgery	20061334	669	676	O
(	20061334	677	678	O
direct	20061334	678	684	O
surgery	20061334	685	692	O
group	20061334	693	698	O
,	20061334	698	699	O
Group	20061334	700	705	O
2	20061334	706	707	O
)	20061334	707	708	O
.	20061334	708	709	O

Cure	20061334	710	714	O
was	20061334	715	718	O
evaluated	20061334	719	728	O
4	20061334	729	730	O
months	20061334	731	737	O
postoperatively	20061334	738	753	O
primarily	20061334	754	763	O
by	20061334	764	766	O
fasting	20061334	767	774	O
IGF1	20061334	775	779	O
less	20061334	780	784	O
than	20061334	785	789	O
or	20061334	790	792	O
equal	20061334	793	798	O
to	20061334	799	801	O
age-adjusted	20061334	802	814	O
upper	20061334	815	820	O
limit	20061334	821	826	O
of	20061334	827	829	O
normal	20061334	830	836	O
.	20061334	836	837	O

RESULTS	20061334	839	846	O
:	20061334	847	848	O
A	20061334	849	850	O
pool	20061334	851	855	O
of	20061334	856	858	O
108	20061334	859	862	O
patients	20061334	863	871	O
was	20061334	872	875	O
randomly	20061334	876	884	O
divided	20061334	885	892	O
into	20061334	893	897	O
two	20061334	898	901	O
groups	20061334	902	908	O
.	20061334	908	909	O

Five	20061334	910	914	O
patients	20061334	915	923	O
in	20061334	924	926	O
each	20061334	927	931	O
group	20061334	932	937	O
were	20061334	938	942	O
lost	20061334	943	947	O
to	20061334	948	950	O
follow-up	20061334	951	960	O
during	20061334	961	967	O
the	20061334	968	971	O
study	20061334	972	977	O
period	20061334	978	984	O
,	20061334	984	985	O
so	20061334	986	988	O
49	20061334	989	991	O
patients	20061334	992	1000	O
in	20061334	1001	1003	O
each	20061334	1004	1008	O
group	20061334	1009	1014	O
were	20061334	1015	1019	O
analysed	20061334	1020	1028	O
.	20061334	1028	1029	O

At	20061334	1030	1032	O
baseline	20061334	1033	1041	O
,	20061334	1041	1042	O
no	20061334	1043	1045	O
difference	20061334	1046	1056	O
was	20061334	1057	1060	O
observed	20061334	1061	1069	O
between	20061334	1070	1077	O
the	20061334	1078	1081	O
two	20061334	1082	1085	O
groups	20061334	1086	1092	O
.	20061334	1092	1093	O

Cure	20061334	1094	1098	B-Outcome
was	20061334	1099	1102	O
established	20061334	1103	1114	O
in	20061334	1115	1117	O
24	20061334	1118	1120	O
of	20061334	1121	1123	O
49	20061334	1124	1126	O
(	20061334	1127	1128	O
49.0	20061334	1128	1132	O
%	20061334	1132	1133	O
,	20061334	1133	1134	O
95	20061334	1135	1137	O
%	20061334	1137	1138	O
confidence	20061334	1139	1149	O
interval	20061334	1150	1158	O
(	20061334	1159	1160	O
CI	20061334	1160	1162	O
)	20061334	1162	1163	O
,	20061334	1163	1164	O
35.0	20061334	1165	1169	O
-	20061334	1169	1170	O
63.0	20061334	1170	1174	O
%	20061334	1174	1175	O
)	20061334	1175	1176	O
pretreated	20061334	1177	1187	O
patients	20061334	1188	1196	O
(	20061334	1197	1198	O
Group	20061334	1198	1203	O
1	20061334	1204	1205	O
)	20061334	1205	1206	O
versus	20061334	1207	1213	O
9	20061334	1214	1215	O
of	20061334	1216	1218	O
49	20061334	1219	1221	O
(	20061334	1222	1223	O
18.4	20061334	1223	1227	O
%	20061334	1227	1228	O
,	20061334	1228	1229	O
95	20061334	1230	1232	O
%	20061334	1232	1233	O
CI	20061334	1234	1236	O
,	20061334	1236	1237	O
7.6	20061334	1238	1241	O
-	20061334	1241	1242	O
29.2	20061334	1242	1246	O
%	20061334	1246	1247	O
)	20061334	1247	1248	O
direct	20061334	1249	1255	O
surgery	20061334	1256	1263	O
patients	20061334	1264	1272	O
(	20061334	1273	1274	O
Group	20061334	1274	1279	O
2	20061334	1280	1281	O
;	20061334	1281	1282	O
P=0.001	20061334	1283	1290	O
)	20061334	1290	1291	O
.	20061334	1291	1292	O

Surgical	20061334	1293	1301	B-Outcome
morbidity	20061334	1302	1311	I-Outcome
was	20061334	1312	1315	O
recorded	20061334	1316	1324	O
in	20061334	1325	1327	O
12	20061334	1328	1330	O
patients	20061334	1331	1339	O
(	20061334	1340	1341	O
12.2	20061334	1341	1345	O
%	20061334	1345	1346	O
)	20061334	1346	1347	O
and	20061334	1348	1351	O
was	20061334	1352	1355	O
similar	20061334	1356	1363	O
in	20061334	1364	1366	O
Group	20061334	1367	1372	O
1	20061334	1373	1374	O
and	20061334	1375	1378	O
2	20061334	1379	1380	O
patients	20061334	1381	1389	O
(	20061334	1390	1391	O
14.3	20061334	1391	1395	O
and	20061334	1396	1399	O
10.2	20061334	1400	1404	O
%	20061334	1404	1405	O
respectively	20061334	1406	1418	O
;	20061334	1418	1419	O
P=0.538	20061334	1420	1427	O
)	20061334	1427	1428	O
.	20061334	1428	1429	O

The	20061334	1430	1433	O
postoperative	20061334	1434	1447	B-Outcome
hospital	20061334	1448	1456	I-Outcome
stay	20061334	1457	1461	I-Outcome
was	20061334	1462	1465	O
similar	20061334	1466	1473	O
between	20061334	1474	1481	O
groups	20061334	1482	1488	O
:	20061334	1488	1489	O
being	20061334	1490	1495	O
4.5+/-1.6	20061334	1496	1505	O
days	20061334	1506	1510	O
in	20061334	1511	1513	O
Group	20061334	1514	1519	O
1	20061334	1520	1521	O
vs	20061334	1522	1524	O
4.8+/-1.9	20061334	1525	1534	O
days	20061334	1535	1539	O
in	20061334	1540	1542	O
Group	20061334	1543	1548	O
2	20061334	1549	1550	O
(	20061334	1551	1552	O
P=0.328	20061334	1552	1559	O
)	20061334	1559	1560	O
.	20061334	1560	1561	O

CONCLUSIONS	20061334	1563	1574	O
:	20061334	1575	1576	O
Pretreatment	20061334	1577	1589	O
with	20061334	1590	1594	O
lanreotide	20061334	1595	1605	O
before	20061334	1606	1612	O
transsphenoidal	20061334	1613	1628	O
surgery	20061334	1629	1636	O
improves	20061334	1637	1645	O
surgical	20061334	1646	1654	B-Outcome
cure	20061334	1655	1659	I-Outcome
rates	20061334	1660	1665	I-Outcome
in	20061334	1666	1668	O
patients	20061334	1669	1677	O
with	20061334	1678	1682	O
GH-secreting	20061334	1683	1695	O
pituitary	20061334	1696	1705	O
macroadenomas	20061334	1706	1719	O
.	20061334	1719	1720	O

Pretreatment	20061334	1721	1733	O
does	20061334	1734	1738	O
not	20061334	1739	1742	O
affect	20061334	1743	1749	O
surgical	20061334	1750	1758	B-Outcome
complications	20061334	1759	1772	I-Outcome
or	20061334	1773	1775	O
duration	20061334	1776	1784	B-Outcome
of	20061334	1785	1787	I-Outcome
hospital	20061334	1788	1796	I-Outcome
stay	20061334	1797	1801	I-Outcome
(	20061334	1802	1803	O
ClinicalTrials.gov	20061334	1803	1821	O
number	20061334	1822	1828	O
,	20061334	1828	1829	O
NCT00993356	20061334	1830	1841	O
)	20061334	1841	1842	O
.	20061334	1842	1843	O


Changes	20070284	0	7	O
in	20070284	8	10	O
quality	20070284	11	18	O
of	20070284	19	21	O
life	20070284	22	26	O
and	20070284	27	30	O
sexual	20070284	31	37	O
health	20070284	38	44	O
are	20070284	45	48	O
associated	20070284	49	59	O
with	20070284	60	64	O
low-dose	20070284	65	73	O
peginterferon	20070284	74	87	O
therapy	20070284	88	95	O
and	20070284	96	99	O
disease	20070284	100	107	O
progression	20070284	108	119	O
in	20070284	120	122	O
patients	20070284	123	131	O
with	20070284	132	136	O
chronic	20070284	137	144	O
hepatitis	20070284	145	154	O
C.	20070284	155	157	O
BACKGROUND	20070284	158	168	O
:	20070284	169	170	O
Primary	20070284	171	178	O
analysis	20070284	179	187	O
of	20070284	188	190	O
the	20070284	191	194	O
Hepatitis	20070284	195	204	O
C	20070284	205	206	O
Antiviral	20070284	207	216	O
Long-Term	20070284	217	226	O
Treatment	20070284	227	236	O
against	20070284	237	244	O
Cirrhosis	20070284	245	254	O
(	20070284	255	256	O
HALT-C	20070284	256	262	O
)	20070284	262	263	O
Trial	20070284	264	269	O
showed	20070284	270	276	O
long-term	20070284	277	286	O
peginterferon	20070284	287	300	O
therapy	20070284	301	308	O
did	20070284	309	312	O
not	20070284	313	316	O
reduce	20070284	317	323	O
complications	20070284	324	337	O
in	20070284	338	340	O
patients	20070284	341	349	O
with	20070284	350	354	O
chronic	20070284	355	362	O
hepatitis	20070284	363	372	O
C	20070284	373	374	O
and	20070284	375	378	O
advanced	20070284	379	387	O
fibrosis	20070284	388	396	O
or	20070284	397	399	O
cirrhosis	20070284	400	409	O
.	20070284	409	410	O

AIM	20070284	412	415	O
:	20070284	416	417	O
To	20070284	418	420	O
assess	20070284	421	427	O
the	20070284	428	431	O
effects	20070284	432	439	O
of	20070284	440	442	O
long-term	20070284	443	452	O
peginterferon	20070284	453	466	O
therapy	20070284	467	474	O
and	20070284	475	478	O
disease	20070284	479	486	O
progression	20070284	487	498	O
on	20070284	499	501	O
health-related	20070284	502	516	O
quality	20070284	517	524	O
of	20070284	525	527	O
life	20070284	528	532	O
(	20070284	533	534	O
HRQOL	20070284	534	539	O
)	20070284	539	540	O
,	20070284	540	541	O
symptoms	20070284	542	550	O
and	20070284	551	554	O
sexual	20070284	555	561	O
health	20070284	562	568	O
in	20070284	569	571	O
HALT-C	20070284	572	578	O
patients	20070284	579	587	O
.	20070284	587	588	O

METHODS	20070284	590	597	O
:	20070284	598	599	O
A	20070284	600	601	O
total	20070284	602	607	O
of	20070284	608	610	O
517	20070284	611	614	O
HALT-C	20070284	615	621	O
patients	20070284	622	630	O
received	20070284	631	639	O
peginterferon	20070284	640	653	O
alfa-2a	20070284	654	661	O
(	20070284	662	663	O
90	20070284	663	665	O
microg/week	20070284	666	677	O
)	20070284	677	678	O
;	20070284	678	679	O
532	20070284	680	683	O
received	20070284	684	692	O
no	20070284	693	695	O
additional	20070284	696	706	O
treatment	20070284	707	716	O
for	20070284	717	720	O
3.5	20070284	721	724	O
years	20070284	725	730	O
.	20070284	730	731	O

Patients	20070284	732	740	O
were	20070284	741	745	O
followed	20070284	746	754	O
up	20070284	755	757	O
for	20070284	758	761	O
outcomes	20070284	762	770	O
of	20070284	771	773	O
death	20070284	774	779	O
,	20070284	779	780	O
hepatocellular	20070284	781	795	O
carcinoma	20070284	796	805	O
and	20070284	806	809	O
hepatic	20070284	810	817	O
decompensation	20070284	818	832	O
.	20070284	832	833	O

Sexual	20070284	834	840	O
health	20070284	841	847	O
,	20070284	847	848	O
SF-36	20070284	849	854	O
scores	20070284	855	861	O
and	20070284	862	865	O
symptoms	20070284	866	874	O
were	20070284	875	879	O
serially	20070284	880	888	O
assessed	20070284	889	897	O
by	20070284	898	900	O
repeated-measures	20070284	901	918	O
analyses	20070284	919	927	O
of	20070284	928	930	O
covariance	20070284	931	941	O
.	20070284	941	942	O

RESULTS	20070284	944	951	O
:	20070284	952	953	O
Patients	20070284	954	962	O
with	20070284	963	967	O
cirrhosis	20070284	968	977	O
(	20070284	978	979	O
n	20070284	979	980	O
=	20070284	981	982	O
427	20070284	983	986	O
)	20070284	986	987	O
reported	20070284	988	996	O
lower	20070284	997	1002	O
general	20070284	1003	1010	B-Outcome
well-being	20070284	1011	1021	I-Outcome
and	20070284	1022	1025	O
more	20070284	1026	1030	O
fatigue	20070284	1031	1038	B-Outcome
(	20070284	1039	1040	O
P	20070284	1040	1041	O
<	20070284	1042	1043	O
0.001	20070284	1044	1049	O
)	20070284	1049	1050	O
than	20070284	1051	1055	O
patients	20070284	1056	1064	O
with	20070284	1065	1069	O
fibrosis	20070284	1070	1078	O
(	20070284	1079	1080	O
n	20070284	1080	1081	O
=	20070284	1082	1083	O
622	20070284	1084	1087	O
)	20070284	1087	1088	O
.	20070284	1088	1089	O

Physical	20070284	1090	1098	B-Outcome
scores	20070284	1099	1105	I-Outcome
declined	20070284	1106	1114	O
significantly	20070284	1115	1128	O
over	20070284	1129	1133	O
time	20070284	1134	1138	O
,	20070284	1138	1139	O
independent	20070284	1140	1151	O
of	20070284	1152	1154	O
treatment	20070284	1155	1164	O
,	20070284	1164	1165	O
and	20070284	1166	1169	O
patients	20070284	1170	1178	O
with	20070284	1179	1183	O
cirrhosis	20070284	1184	1193	O
reported	20070284	1194	1202	O
lower	20070284	1203	1208	O
scores	20070284	1209	1215	O
.	20070284	1215	1216	O

Vitality	20070284	1217	1225	B-Outcome
scores	20070284	1226	1232	I-Outcome
were	20070284	1233	1237	O
lower	20070284	1238	1243	O
in	20070284	1244	1246	O
those	20070284	1247	1252	O
with	20070284	1253	1257	O
cirrhosis	20070284	1258	1267	O
,	20070284	1267	1268	O
and	20070284	1269	1272	O
treated	20070284	1273	1280	O
patients	20070284	1281	1289	O
experienced	20070284	1290	1301	O
a	20070284	1302	1303	O
greater	20070284	1304	1311	O
decline	20070284	1312	1319	O
over	20070284	1320	1324	O
time	20070284	1325	1329	O
than	20070284	1330	1334	O
untreated	20070284	1335	1344	O
patients	20070284	1345	1353	O
;	20070284	1353	1354	O
HRQOL	20070284	1355	1360	B-Outcome
rebounded	20070284	1361	1370	O
after	20070284	1371	1376	O
treatment	20070284	1377	1386	O
ended	20070284	1387	1392	O
.	20070284	1392	1393	O

Patients	20070284	1394	1402	O
with	20070284	1403	1407	O
a	20070284	1408	1409	O
clinical	20070284	1410	1418	O
outcome	20070284	1419	1426	O
had	20070284	1427	1430	O
significantly	20070284	1431	1444	O
greater	20070284	1445	1452	O
declines	20070284	1453	1461	O
in	20070284	1462	1464	O
all	20070284	1465	1468	O
SF-36	20070284	1469	1474	B-Outcome
and	20070284	1475	1478	O
symptom	20070284	1479	1486	B-Outcome
scores	20070284	1487	1493	I-Outcome
.	20070284	1493	1494	O

Among	20070284	1495	1500	O
men	20070284	1501	1504	O
,	20070284	1504	1505	O
Sexual	20070284	1506	1512	B-Outcome
Health	20070284	1513	1519	I-Outcome
scores	20070284	1520	1526	I-Outcome
were	20070284	1527	1531	O
significantly	20070284	1532	1545	O
worse	20070284	1546	1551	O
in	20070284	1552	1554	O
treated	20070284	1555	1562	O
patients	20070284	1563	1571	O
and	20070284	1572	1575	O
in	20070284	1576	1578	O
those	20070284	1579	1584	O
with	20070284	1585	1589	O
a	20070284	1590	1591	O
clinical	20070284	1592	1600	O
outcome	20070284	1601	1608	O
.	20070284	1608	1609	O

CONCLUSION	20070284	1611	1621	O
:	20070284	1622	1623	O
Clinical	20070284	1624	1632	O
progression	20070284	1633	1644	O
of	20070284	1645	1647	O
chronic	20070284	1648	1655	O
hepatitis	20070284	1656	1665	O
C	20070284	1666	1667	O
and	20070284	1668	1671	O
maintenance	20070284	1672	1683	O
peginterferon	20070284	1684	1697	O
therapy	20070284	1698	1705	O
led	20070284	1706	1709	O
to	20070284	1710	1712	O
worsening	20070284	1713	1722	O
of	20070284	1723	1725	O
symptoms	20070284	1726	1734	B-Outcome
,	20070284	1734	1735	O
HRQOL	20070284	1736	1741	B-Outcome
and	20070284	1742	1745	O
,	20070284	1745	1746	O
in	20070284	1747	1749	O
men	20070284	1750	1753	O
,	20070284	1753	1754	O
sexual	20070284	1755	1761	B-Outcome
health	20070284	1762	1768	I-Outcome
in	20070284	1769	1771	O
a	20070284	1772	1773	O
large	20070284	1774	1779	O
patient	20070284	1780	1787	O
cohort	20070284	1788	1794	O
followed	20070284	1795	1803	O
up	20070284	1804	1806	O
over	20070284	1807	1811	O
4	20070284	1812	1813	O
years	20070284	1814	1819	O
(	20070284	1820	1821	O
NCT00006164	20070284	1821	1832	O
)	20070284	1832	1833	O
.	20070284	1833	1834	O


Enhancing	20122038	0	9	O
caregiver	20122038	10	19	O
health	20122038	20	26	O
:	20122038	26	27	O
findings	20122038	28	36	O
from	20122038	37	41	O
the	20122038	42	45	O
resources	20122038	46	55	O
for	20122038	56	59	O
enhancing	20122038	60	69	O
Alzheimer	20122038	70	79	O
's	20122038	79	81	O
caregiver	20122038	82	91	O
health	20122038	92	98	O
II	20122038	99	101	O
intervention	20122038	102	114	O
.	20122038	114	115	O

OBJECTIVES	20122038	117	127	O
:	20122038	128	129	O
To	20122038	130	132	O
examine	20122038	133	140	O
the	20122038	141	144	O
relationships	20122038	145	158	O
between	20122038	159	166	O
changes	20122038	167	174	O
from	20122038	175	179	O
baseline	20122038	180	188	O
to	20122038	189	191	O
post-Resources	20122038	192	206	O
for	20122038	207	210	O
Enhancing	20122038	211	220	O
Alzheimer	20122038	221	230	O
's	20122038	230	232	O
Caregiver	20122038	233	242	O
Health	20122038	243	249	O
(	20122038	250	251	O
REACH	20122038	251	256	O
)	20122038	256	257	O
intervention	20122038	258	270	O
in	20122038	271	273	O
caregiver	20122038	274	283	O
(	20122038	284	285	O
CG	20122038	285	287	O
)	20122038	287	288	O
self-reported	20122038	289	302	O
health	20122038	303	309	O
,	20122038	309	310	O
burden	20122038	311	317	O
,	20122038	317	318	O
and	20122038	319	322	O
bother	20122038	323	329	O
.	20122038	329	330	O

DESIGN	20122038	332	338	O
:	20122038	339	340	O
Randomized	20122038	341	351	O
,	20122038	351	352	O
multisite	20122038	353	362	O
clinical	20122038	363	371	O
trial	20122038	372	377	O
.	20122038	377	378	O

SETTING	20122038	380	387	O
:	20122038	388	389	O
CG	20122038	390	392	O
and	20122038	393	396	O
care	20122038	397	401	O
recipient	20122038	402	411	O
(	20122038	412	413	O
CR	20122038	413	415	O
)	20122038	415	416	O
homes	20122038	417	422	O
in	20122038	423	425	O
five	20122038	426	430	O
U.S.	20122038	431	435	O
cities	20122038	436	442	O
.	20122038	442	443	O

PARTICIPANTS	20122038	445	457	O
:	20122038	458	459	O
Four	20122038	460	464	O
hundred	20122038	465	472	O
ninety-five	20122038	473	484	O
dementia	20122038	485	493	O
CG	20122038	494	496	O
and	20122038	497	500	O
CR	20122038	501	503	O
dyads	20122038	504	509	O
(	20122038	510	511	O
169	20122038	511	514	O
Hispanic	20122038	515	523	O
,	20122038	523	524	O
160	20122038	525	528	O
white	20122038	529	534	O
,	20122038	534	535	O
and	20122038	536	539	O
166	20122038	540	543	O
African	20122038	544	551	O
American	20122038	552	560	O
)	20122038	560	561	O
receiving	20122038	562	571	O
intervention	20122038	572	584	O
and	20122038	585	588	O
their	20122038	589	594	O
controls	20122038	595	603	O
.	20122038	603	604	O

INTERVENTION	20122038	606	618	O
:	20122038	619	620	O
CGs	20122038	621	624	O
were	20122038	625	629	O
assigned	20122038	630	638	O
to	20122038	639	641	O
the	20122038	642	645	O
REACH	20122038	646	651	O
intervention	20122038	652	664	O
or	20122038	665	667	O
a	20122038	668	669	O
no-treatment	20122038	670	682	O
control	20122038	683	690	O
group	20122038	691	696	O
.	20122038	696	697	O

Intervention	20122038	698	710	O
subjects	20122038	711	719	O
received	20122038	720	728	O
individual	20122038	729	739	O
risk	20122038	740	744	O
profiles	20122038	745	753	O
and	20122038	754	757	O
the	20122038	758	761	O
REACH	20122038	762	767	O
intervention	20122038	768	780	O
through	20122038	781	788	O
nine	20122038	789	793	O
in-home	20122038	794	801	O
and	20122038	802	805	O
three	20122038	806	811	O
telephone	20122038	812	821	O
sessions	20122038	822	830	O
over	20122038	831	835	O
6	20122038	836	837	O
months	20122038	838	844	O
.	20122038	844	845	O

Control	20122038	846	853	O
subjects	20122038	854	862	O
received	20122038	863	871	O
two	20122038	872	875	O
brief	20122038	876	881	O
"	20122038	882	883	O
check-in	20122038	883	891	O
"	20122038	891	892	O
telephone	20122038	893	902	O
calls	20122038	903	908	O
during	20122038	909	915	O
this	20122038	916	920	O
6-month	20122038	921	928	O
period	20122038	929	935	O
.	20122038	935	936	O

MEASUREMENTS	20122038	938	950	O
:	20122038	951	952	O
The	20122038	953	956	O
primary	20122038	957	964	O
outcome	20122038	965	972	O
was	20122038	973	976	O
change	20122038	977	983	O
in	20122038	984	986	O
CG	20122038	987	989	O
health	20122038	990	996	O
status	20122038	997	1003	O
from	20122038	1004	1008	O
baseline	20122038	1009	1017	O
to	20122038	1018	1020	O
after	20122038	1021	1026	O
the	20122038	1027	1030	O
intervention	20122038	1031	1043	O
.	20122038	1043	1044	O

Secondary	20122038	1045	1054	O
outcomes	20122038	1055	1063	O
were	20122038	1064	1068	O
CG	20122038	1069	1071	O
burden	20122038	1072	1078	O
and	20122038	1079	1082	O
bother	20122038	1083	1089	O
after	20122038	1090	1095	O
the	20122038	1096	1099	O
intervention	20122038	1100	1112	O
.	20122038	1112	1113	O

RESULTS	20122038	1115	1122	O
:	20122038	1123	1124	O
After	20122038	1125	1130	O
the	20122038	1131	1134	O
intervention	20122038	1135	1147	O
,	20122038	1147	1148	O
CGs	20122038	1149	1152	O
reported	20122038	1153	1161	O
better	20122038	1162	1168	O
self-rated	20122038	1169	1179	B-Outcome
health	20122038	1180	1186	I-Outcome
,	20122038	1186	1187	O
sleep	20122038	1188	1193	B-Outcome
quality	20122038	1194	1201	I-Outcome
,	20122038	1201	1202	O
physical	20122038	1203	1211	B-Outcome
health	20122038	1212	1218	I-Outcome
,	20122038	1218	1219	O
and	20122038	1220	1223	O
emotional	20122038	1224	1233	B-Outcome
health	20122038	1234	1240	I-Outcome
,	20122038	1240	1241	O
which	20122038	1242	1247	O
was	20122038	1248	1251	O
related	20122038	1252	1259	O
to	20122038	1260	1262	O
less	20122038	1263	1267	O
burden	20122038	1268	1274	O
and	20122038	1275	1278	O
bother	20122038	1279	1285	O
with	20122038	1286	1290	O
their	20122038	1291	1296	O
caregiving	20122038	1297	1307	O
role	20122038	1308	1312	O
than	20122038	1313	1317	O
for	20122038	1318	1321	O
CGs	20122038	1322	1325	O
not	20122038	1326	1329	O
receiving	20122038	1330	1339	O
the	20122038	1340	1343	O
intervention	20122038	1344	1356	O
.	20122038	1356	1357	O

Changes	20122038	1358	1365	O
in	20122038	1366	1368	O
depression	20122038	1369	1379	B-Outcome
appeared	20122038	1380	1388	O
to	20122038	1389	1391	O
mediate	20122038	1392	1399	O
these	20122038	1400	1405	O
relationships	20122038	1406	1419	O
.	20122038	1419	1420	O

Several	20122038	1421	1428	O
racial	20122038	1429	1435	O
and	20122038	1436	1439	O
ethnic	20122038	1440	1446	O
group	20122038	1447	1452	O
differences	20122038	1453	1464	O
existed	20122038	1465	1472	O
in	20122038	1473	1475	O
physical	20122038	1476	1484	B-Outcome
and	20122038	1485	1488	O
emotional	20122038	1489	1498	B-Outcome
health	20122038	1499	1505	I-Outcome
,	20122038	1505	1506	O
as	20122038	1507	1509	O
well	20122038	1510	1514	O
as	20122038	1515	1517	O
in	20122038	1518	1520	O
total	20122038	1521	1526	B-Outcome
frustration	20122038	1527	1538	I-Outcome
with	20122038	1539	1543	I-Outcome
caregiving	20122038	1544	1554	I-Outcome
,	20122038	1554	1555	O
emotional	20122038	1556	1565	B-Outcome
burden	20122038	1566	1572	I-Outcome
,	20122038	1572	1573	O
and	20122038	1574	1577	O
CG-rated	20122038	1578	1586	B-Outcome
bother	20122038	1587	1593	I-Outcome
with	20122038	1594	1598	I-Outcome
CR	20122038	1599	1601	I-Outcome
's	20122038	1601	1603	I-Outcome
activities	20122038	1604	1614	I-Outcome
of	20122038	1615	1617	I-Outcome
daily	20122038	1618	1623	I-Outcome
living	20122038	1624	1630	I-Outcome
and	20122038	1631	1634	O
instrumental	20122038	1635	1647	B-Outcome
activities	20122038	1648	1658	I-Outcome
of	20122038	1659	1661	I-Outcome
daily	20122038	1662	1667	I-Outcome
living	20122038	1668	1674	I-Outcome
at	20122038	1675	1677	O
baseline	20122038	1678	1686	O
and	20122038	1687	1690	O
at	20122038	1691	1693	O
follow-up	20122038	1694	1703	O
,	20122038	1703	1704	O
although	20122038	1705	1713	O
differences	20122038	1714	1725	O
between	20122038	1726	1733	O
baseline	20122038	1734	1742	O
and	20122038	1743	1746	O
posttest	20122038	1747	1755	O
did	20122038	1756	1759	O
not	20122038	1760	1763	O
vary	20122038	1764	1768	O
according	20122038	1769	1778	O
to	20122038	1779	1781	O
race	20122038	1782	1786	O
.	20122038	1786	1787	O

CONCLUSION	20122038	1789	1799	O
:	20122038	1800	1801	O
A	20122038	1802	1803	O
structured	20122038	1804	1814	O
,	20122038	1814	1815	O
multicomponent	20122038	1816	1830	O
skills	20122038	1831	1837	O
training	20122038	1838	1846	O
intervention	20122038	1847	1859	O
that	20122038	1860	1864	O
targeted	20122038	1865	1873	O
CG	20122038	1874	1876	B-Outcome
self-care	20122038	1877	1886	I-Outcome
behaviors	20122038	1887	1896	I-Outcome
as	20122038	1897	1899	O
one	20122038	1900	1903	O
of	20122038	1904	1906	O
five	20122038	1907	1911	O
target	20122038	1912	1918	O
areas	20122038	1919	1924	O
,	20122038	1924	1925	O
improved	20122038	1926	1934	O
self-reported	20122038	1935	1948	B-Outcome
health	20122038	1949	1955	I-Outcome
status	20122038	1956	1962	I-Outcome
,	20122038	1962	1963	O
and	20122038	1964	1967	O
decreased	20122038	1968	1977	O
burden	20122038	1978	1984	O
and	20122038	1985	1988	O
bother	20122038	1989	1995	O
in	20122038	1996	1998	O
racially	20122038	1999	2007	O
and	20122038	2008	2011	O
ethnically	20122038	2012	2022	O
diverse	20122038	2023	2030	O
CGs	20122038	2031	2034	O
of	20122038	2035	2037	O
people	20122038	2038	2044	O
with	20122038	2045	2049	O
dementia	20122038	2050	2058	O
.	20122038	2058	2059	O


The	20199680	0	3	O
development	20199680	4	15	O
of	20199680	16	18	O
a	20199680	19	20	O
web-	20199680	21	25	O
and	20199680	26	29	O
a	20199680	30	31	O
print-based	20199680	32	43	O
decision	20199680	44	52	O
aid	20199680	53	56	O
for	20199680	57	60	O
prostate	20199680	61	69	O
cancer	20199680	70	76	O
screening	20199680	77	86	O
.	20199680	86	87	O

BACKGROUND	20199680	89	99	O
:	20199680	100	101	O
Whether	20199680	102	109	O
early	20199680	110	115	O
detection	20199680	116	125	O
and	20199680	126	129	O
treatment	20199680	130	139	O
of	20199680	140	142	O
prostate	20199680	143	151	O
cancer	20199680	152	158	O
(	20199680	159	160	O
PCa	20199680	160	163	O
)	20199680	163	164	O
will	20199680	165	169	O
reduce	20199680	170	176	O
disease-related	20199680	177	192	O
mortality	20199680	193	202	O
remains	20199680	203	210	O
uncertain	20199680	211	220	O
.	20199680	220	221	O

As	20199680	222	224	O
a	20199680	225	226	O
result	20199680	227	233	O
,	20199680	233	234	O
tools	20199680	235	240	O
are	20199680	241	244	O
needed	20199680	245	251	O
to	20199680	252	254	O
facilitate	20199680	255	265	O
informed	20199680	266	274	O
decision	20199680	275	283	O
making	20199680	284	290	O
.	20199680	290	291	O

While	20199680	292	297	O
there	20199680	298	303	O
have	20199680	304	308	O
been	20199680	309	313	O
several	20199680	314	321	O
decision	20199680	322	330	O
aids	20199680	331	335	O
(	20199680	336	337	O
DAs	20199680	337	340	O
)	20199680	340	341	O
developed	20199680	342	351	O
and	20199680	352	355	O
tested	20199680	356	362	O
,	20199680	362	363	O
very	20199680	364	368	O
few	20199680	369	372	O
have	20199680	373	377	O
included	20199680	378	386	O
an	20199680	387	389	O
exercise	20199680	390	398	O
to	20199680	399	401	O
help	20199680	402	406	O
men	20199680	407	410	O
clarify	20199680	411	418	O
their	20199680	419	424	O
values	20199680	425	431	O
and	20199680	432	435	O
preferences	20199680	436	447	O
about	20199680	448	453	O
PCa	20199680	454	457	O
screening	20199680	458	467	O
.	20199680	467	468	O

Further	20199680	469	476	O
,	20199680	476	477	O
only	20199680	478	482	O
one	20199680	483	486	O
DA	20199680	487	489	O
has	20199680	490	493	O
utilized	20199680	494	502	O
an	20199680	503	505	O
interactive	20199680	506	517	O
web-based	20199680	518	527	O
format	20199680	528	534	O
,	20199680	534	535	O
which	20199680	536	541	O
allows	20199680	542	548	O
for	20199680	549	552	O
an	20199680	553	555	O
expansion	20199680	556	565	O
and	20199680	566	569	O
customization	20199680	570	583	O
of	20199680	584	586	O
the	20199680	587	590	O
material	20199680	591	599	O
.	20199680	599	600	O

We	20199680	601	603	O
describe	20199680	604	612	O
the	20199680	613	616	O
development	20199680	617	628	O
of	20199680	629	631	O
two	20199680	632	635	O
DAs	20199680	636	639	O
,	20199680	639	640	O
a	20199680	641	642	O
booklet	20199680	643	650	O
and	20199680	651	654	O
an	20199680	655	657	O
interactive	20199680	658	669	O
website	20199680	670	677	O
,	20199680	677	678	O
each	20199680	679	683	O
with	20199680	684	688	O
a	20199680	689	690	O
values	20199680	691	697	O
clarification	20199680	698	711	O
component	20199680	712	721	O
and	20199680	722	725	O
designed	20199680	726	734	O
for	20199680	735	738	O
use	20199680	739	742	O
in	20199680	743	745	O
diverse	20199680	746	753	O
settings	20199680	754	762	O
.	20199680	762	763	O

METHODS	20199680	765	772	O
:	20199680	773	774	O
We	20199680	775	777	O
conducted	20199680	778	787	O
two	20199680	788	791	O
feasibility	20199680	792	803	O
studies	20199680	804	811	O
to	20199680	812	814	O
assess	20199680	815	821	O
men	20199680	822	825	O
's	20199680	825	827	O
(	20199680	828	829	O
45	20199680	829	831	O
-	20199680	831	832	O
70	20199680	832	834	O
years	20199680	835	840	O
)	20199680	840	841	O
Internet	20199680	842	850	O
access	20199680	851	857	O
and	20199680	858	861	O
their	20199680	862	867	O
willingness	20199680	868	879	O
to	20199680	880	882	O
use	20199680	883	886	O
a	20199680	887	888	O
web-	20199680	889	893	O
vs.	20199680	894	897	O
a	20199680	898	899	O
print-based	20199680	900	911	O
tool	20199680	912	916	O
.	20199680	916	917	O

The	20199680	918	921	O
booklet	20199680	922	929	O
was	20199680	930	933	O
adapted	20199680	934	941	O
from	20199680	942	946	O
two	20199680	947	950	O
previous	20199680	951	959	O
versions	20199680	960	968	O
evaluated	20199680	969	978	O
in	20199680	979	981	O
randomized	20199680	982	992	O
controlled	20199680	993	1003	O
trials	20199680	1004	1010	O
(	20199680	1011	1012	O
RCTs	20199680	1012	1016	O
)	20199680	1016	1017	O
and	20199680	1018	1021	O
the	20199680	1022	1025	O
website	20199680	1026	1033	O
was	20199680	1034	1037	O
created	20199680	1038	1045	O
to	20199680	1046	1048	O
closely	20199680	1049	1056	O
match	20199680	1057	1062	O
the	20199680	1063	1066	O
content	20199680	1067	1074	O
of	20199680	1075	1077	O
the	20199680	1078	1081	O
revised	20199680	1082	1089	O
booklet	20199680	1090	1097	O
.	20199680	1097	1098	O

Usability	20199680	1099	1108	O
testing	20199680	1109	1116	O
was	20199680	1117	1120	O
conducted	20199680	1121	1130	O
to	20199680	1131	1133	O
obtain	20199680	1134	1140	O
feedback	20199680	1141	1149	O
regarding	20199680	1150	1159	O
draft	20199680	1160	1165	O
versions	20199680	1166	1174	O
of	20199680	1175	1177	O
the	20199680	1178	1181	O
materials	20199680	1182	1191	O
.	20199680	1191	1192	O

The	20199680	1193	1196	O
tools	20199680	1197	1202	O
were	20199680	1203	1207	O
also	20199680	1208	1212	O
reviewed	20199680	1213	1221	O
by	20199680	1222	1224	O
a	20199680	1225	1226	O
plain	20199680	1227	1232	O
language	20199680	1233	1241	O
expert	20199680	1242	1248	O
and	20199680	1249	1252	O
the	20199680	1253	1256	O
interdisciplinary	20199680	1257	1274	O
research	20199680	1275	1283	O
team	20199680	1284	1288	O
.	20199680	1288	1289	O

Feedback	20199680	1290	1298	O
on	20199680	1299	1301	O
the	20199680	1302	1305	O
content	20199680	1306	1313	O
and	20199680	1314	1317	O
presentation	20199680	1318	1330	O
led	20199680	1331	1334	O
to	20199680	1335	1337	O
iterative	20199680	1338	1347	O
modifications	20199680	1348	1361	O
of	20199680	1362	1364	O
the	20199680	1365	1368	O
tools	20199680	1369	1374	O
.	20199680	1374	1375	O

RESULTS	20199680	1377	1384	O
:	20199680	1385	1386	O
The	20199680	1387	1390	O
feasibility	20199680	1391	1402	O
studies	20199680	1403	1410	O
confirmed	20199680	1411	1420	O
that	20199680	1421	1425	O
the	20199680	1426	1429	O
Internet	20199680	1430	1438	O
was	20199680	1439	1442	O
a	20199680	1443	1444	O
viable	20199680	1445	1451	O
medium	20199680	1452	1458	O
,	20199680	1458	1459	O
as	20199680	1460	1462	O
the	20199680	1463	1466	O
majority	20199680	1467	1475	O
of	20199680	1476	1478	O
men	20199680	1479	1482	O
used	20199680	1483	1487	O
a	20199680	1488	1489	O
computer	20199680	1490	1498	O
,	20199680	1498	1499	O
had	20199680	1500	1503	O
access	20199680	1504	1510	O
to	20199680	1511	1513	O
the	20199680	1514	1517	O
Internet	20199680	1518	1526	O
,	20199680	1526	1527	O
and	20199680	1528	1531	O
Internet	20199680	1532	1540	O
use	20199680	1541	1544	O
increased	20199680	1545	1554	O
over	20199680	1555	1559	O
time	20199680	1560	1564	O
.	20199680	1564	1565	O

Feedback	20199680	1566	1574	O
from	20199680	1575	1579	O
the	20199680	1580	1583	O
usability	20199680	1584	1593	O
testing	20199680	1594	1601	O
on	20199680	1602	1604	O
the	20199680	1605	1608	O
length	20199680	1609	1615	O
,	20199680	1615	1616	O
presentation	20199680	1617	1629	O
,	20199680	1629	1630	O
and	20199680	1631	1634	O
content	20199680	1635	1642	O
of	20199680	1643	1645	O
the	20199680	1646	1649	O
materials	20199680	1650	1659	O
was	20199680	1660	1663	O
incorporated	20199680	1664	1676	O
into	20199680	1677	1681	O
the	20199680	1682	1685	O
final	20199680	1686	1691	O
versions	20199680	1692	1700	O
of	20199680	1701	1703	O
the	20199680	1704	1707	O
booklet	20199680	1708	1715	O
and	20199680	1716	1719	O
website	20199680	1720	1727	O
.	20199680	1727	1728	O

Both	20199680	1729	1733	O
the	20199680	1734	1737	O
feasibility	20199680	1738	1749	O
studies	20199680	1750	1757	O
and	20199680	1758	1761	O
the	20199680	1762	1765	O
usability	20199680	1766	1775	O
testing	20199680	1776	1783	O
highlighted	20199680	1784	1795	O
the	20199680	1796	1799	O
need	20199680	1800	1804	O
to	20199680	1805	1807	O
address	20199680	1808	1815	O
men	20199680	1816	1819	O
's	20199680	1819	1821	O
informed	20199680	1822	1830	B-Outcome
decision	20199680	1831	1839	I-Outcome
making	20199680	1840	1846	I-Outcome
regarding	20199680	1847	1856	I-Outcome
screening	20199680	1857	1866	I-Outcome
.	20199680	1866	1867	O

CONCLUSIONS	20199680	1869	1880	O
:	20199680	1881	1882	O
Informed	20199680	1883	1891	B-Outcome
decision	20199680	1892	1900	I-Outcome
making	20199680	1901	1907	I-Outcome
for	20199680	1908	1911	I-Outcome
PCa	20199680	1912	1915	I-Outcome
screening	20199680	1916	1925	I-Outcome
is	20199680	1926	1928	O
crucial	20199680	1929	1936	O
at	20199680	1937	1939	O
present	20199680	1940	1947	O
and	20199680	1948	1951	O
may	20199680	1952	1955	O
be	20199680	1956	1958	O
important	20199680	1959	1968	O
for	20199680	1969	1972	O
some	20199680	1973	1977	O
time	20199680	1978	1982	O
,	20199680	1982	1983	O
particularly	20199680	1984	1996	O
if	20199680	1997	1999	O
a	20199680	2000	2001	O
definitive	20199680	2002	2012	O
recommendation	20199680	2013	2027	O
either	20199680	2028	2034	O
for	20199680	2035	2038	O
or	20199680	2039	2041	O
against	20199680	2042	2049	O
screening	20199680	2050	2059	O
does	20199680	2060	2064	O
not	20199680	2065	2068	O
emerge	20199680	2069	2075	O
from	20199680	2076	2080	O
ongoing	20199680	2081	2088	O
prostate	20199680	2089	2097	O
cancer	20199680	2098	2104	O
screening	20199680	2105	2114	O
trials	20199680	2115	2121	O
.	20199680	2121	2122	O

We	20199680	2123	2125	O
have	20199680	2126	2130	O
detailed	20199680	2131	2139	O
our	20199680	2140	2143	O
efforts	20199680	2144	2151	O
at	20199680	2152	2154	O
developing	20199680	2155	2165	O
print-	20199680	2166	2172	O
and	20199680	2173	2176	O
web-based	20199680	2177	2186	O
DAs	20199680	2187	2190	O
to	20199680	2191	2193	O
assist	20199680	2194	2200	O
men	20199680	2201	2204	O
in	20199680	2205	2207	O
determining	20199680	2208	2219	O
how	20199680	2220	2223	O
to	20199680	2224	2226	O
best	20199680	2227	2231	O
meet	20199680	2232	2236	O
their	20199680	2237	2242	O
PCa	20199680	2243	2246	B-Outcome
screening	20199680	2247	2256	I-Outcome
preferences	20199680	2257	2268	I-Outcome
.	20199680	2268	2269	O

Following	20199680	2270	2279	O
completion	20199680	2280	2290	O
of	20199680	2291	2293	O
our	20199680	2294	2297	O
ongoing	20199680	2298	2305	O
RCT	20199680	2306	2309	O
designed	20199680	2310	2318	O
to	20199680	2319	2321	O
test	20199680	2322	2326	O
these	20199680	2327	2332	O
materials	20199680	2333	2342	O
,	20199680	2342	2343	O
our	20199680	2344	2347	O
goal	20199680	2348	2352	O
will	20199680	2353	2357	O
be	20199680	2358	2360	O
to	20199680	2361	2363	O
develop	20199680	2364	2371	O
a	20199680	2372	2373	O
dissemination	20199680	2374	2387	O
project	20199680	2388	2395	O
for	20199680	2396	2399	O
the	20199680	2400	2403	O
more	20199680	2404	2408	O
effective	20199680	2409	2418	O
tool	20199680	2419	2423	O
.	20199680	2423	2424	O

TRIAL	20199680	2426	2431	O
REGISTRATION	20199680	2432	2444	O
:	20199680	2445	2446	O
NCT00623090	20199680	2447	2458	O
.	20199680	2458	2459	O


The	20332358	0	3	O
role	20332358	4	8	O
of	20332358	9	11	O
adjunctive	20332358	12	22	O
exenatide	20332358	23	32	O
therapy	20332358	33	40	O
in	20332358	41	43	O
pediatric	20332358	44	53	O
type	20332358	54	58	O
1	20332358	59	60	O
diabetes	20332358	61	69	O
.	20332358	69	70	O

OBJECTIVE	20332358	72	81	O
:	20332358	82	83	O
Exenatide	20332358	84	93	O
improves	20332358	94	102	O
postprandial	20332358	103	115	O
glycemic	20332358	116	124	O
excursions	20332358	125	135	O
in	20332358	136	138	O
type	20332358	139	143	O
2	20332358	144	145	O
diabetes	20332358	146	154	O
.	20332358	154	155	O

Exenatide	20332358	156	165	O
could	20332358	166	171	O
benefit	20332358	172	179	O
type	20332358	180	184	O
1	20332358	185	186	O
diabetes	20332358	187	195	O
as	20332358	196	198	O
well	20332358	199	203	O
.	20332358	203	204	O

We	20332358	205	207	O
aimed	20332358	208	213	O
to	20332358	214	216	O
determine	20332358	217	226	O
an	20332358	227	229	O
effective	20332358	230	239	O
and	20332358	240	243	O
safe	20332358	244	248	O
glucose-lowering	20332358	249	265	O
adjuvant	20332358	266	274	O
exenatide	20332358	275	284	O
dose	20332358	285	289	O
in	20332358	290	292	O
adolescents	20332358	293	304	O
with	20332358	305	309	O
type	20332358	310	314	O
1	20332358	315	316	O
diabetes	20332358	317	325	O
.	20332358	325	326	O

RESEARCH	20332358	328	336	O
DESIGN	20332358	337	343	O
AND	20332358	344	347	O
METHODS	20332358	348	355	O
:	20332358	356	357	O
Eight	20332358	358	363	O
subjects	20332358	364	372	O
completed	20332358	373	382	O
a	20332358	383	384	O
three-part	20332358	385	395	O
double-blinded	20332358	396	410	O
randomized	20332358	411	421	O
controlled	20332358	422	432	O
study	20332358	433	438	O
of	20332358	439	441	O
premeal	20332358	442	449	O
exenatide	20332358	450	459	O
.	20332358	459	460	O

Two	20332358	461	464	O
doses	20332358	465	470	O
of	20332358	471	473	O
exenatide	20332358	474	483	O
(	20332358	484	485	O
1.25	20332358	485	489	O
and	20332358	490	493	O
2.5	20332358	494	497	O
microg	20332358	498	504	O
)	20332358	504	505	O
were	20332358	506	510	O
compared	20332358	511	519	O
with	20332358	520	524	O
insulin	20332358	525	532	O
monotherapy	20332358	533	544	O
.	20332358	544	545	O

Prandial	20332358	546	554	O
insulin	20332358	555	562	O
dose	20332358	563	567	O
was	20332358	568	571	O
reduced	20332358	572	579	O
by	20332358	580	582	O
20	20332358	583	585	O
%	20332358	585	586	O
.	20332358	586	587	O

Gastric	20332358	588	595	O
emptying	20332358	596	604	O
and	20332358	605	608	O
hormones	20332358	609	617	O
were	20332358	618	622	O
analyzed	20332358	623	631	O
for	20332358	632	635	O
300	20332358	636	639	O
min	20332358	640	643	O
postmeal	20332358	644	652	O
.	20332358	652	653	O

RESULTS	20332358	655	662	O
:	20332358	663	664	O
Treatment	20332358	665	674	O
with	20332358	675	679	O
both	20332358	680	684	O
doses	20332358	685	690	O
of	20332358	691	693	O
exenatide	20332358	694	703	O
versus	20332358	704	710	O
insulin	20332358	711	718	O
monotherapy	20332358	719	730	O
significantly	20332358	731	744	O
reduced	20332358	745	752	O
glucose	20332358	753	760	B-Outcome
excursions	20332358	761	771	I-Outcome
over	20332358	772	776	O
300	20332358	777	780	O
min	20332358	781	784	O
(	20332358	785	786	O
P	20332358	786	787	O
<	20332358	788	789	O
0.0001	20332358	790	796	O
)	20332358	796	797	O
.	20332358	797	798	O

Exenatide	20332358	799	808	O
administration	20332358	809	823	O
failed	20332358	824	830	O
to	20332358	831	833	O
suppress	20332358	834	842	O
glucagon	20332358	843	851	B-Outcome
but	20332358	852	855	O
delayed	20332358	856	863	O
gastric	20332358	864	871	B-Outcome
emptying	20332358	872	880	I-Outcome
(	20332358	881	882	O
P	20332358	882	883	O
<	20332358	884	885	O
0.004	20332358	886	891	O
)	20332358	891	892	O
.	20332358	892	893	O

CONCLUSIONS	20332358	895	906	O
:	20332358	907	908	O
Adjunctive	20332358	909	919	O
exenatide	20332358	920	929	O
therapy	20332358	930	937	O
reduces	20332358	938	945	O
postprandial	20332358	946	958	B-Outcome
hyperglycemia	20332358	959	972	I-Outcome
in	20332358	973	975	O
adolescents	20332358	976	987	O
with	20332358	988	992	O
type	20332358	993	997	O
1	20332358	998	999	O
diabetes	20332358	1000	1008	O
.	20332358	1008	1009	O

This	20332358	1010	1014	O
reduction	20332358	1015	1024	O
in	20332358	1025	1027	O
glucose	20332358	1028	1035	B-Outcome
excursion	20332358	1036	1045	I-Outcome
occurs	20332358	1046	1052	O
despite	20332358	1053	1060	O
reduction	20332358	1061	1070	O
in	20332358	1071	1073	O
insulin	20332358	1074	1081	O
dose	20332358	1082	1086	O
.	20332358	1086	1087	O

We	20332358	1088	1090	O
suggest	20332358	1091	1098	O
that	20332358	1099	1103	O
exenatide	20332358	1104	1113	O
has	20332358	1114	1117	O
therapeutic	20332358	1118	1129	O
potential	20332358	1130	1139	O
as	20332358	1140	1142	O
adjunctive	20332358	1143	1153	O
therapy	20332358	1154	1161	O
in	20332358	1162	1164	O
type	20332358	1165	1169	O
1	20332358	1170	1171	O
diabetes	20332358	1172	1180	O
.	20332358	1180	1181	O


Effect	20357382	0	6	O
of	20357382	7	9	O
ranolazine	20357382	10	20	O
on	20357382	21	23	O
A1C	20357382	24	27	O
and	20357382	28	31	O
glucose	20357382	32	39	O
levels	20357382	40	46	O
in	20357382	47	49	O
hyperglycemic	20357382	50	63	O
patients	20357382	64	72	O
with	20357382	73	77	O
non-ST	20357382	78	84	O
elevation	20357382	85	94	O
acute	20357382	95	100	O
coronary	20357382	101	109	O
syndrome	20357382	110	118	O
.	20357382	118	119	O

OBJECTIVE	20357382	121	130	O
:	20357382	131	132	O
We	20357382	133	135	O
determined	20357382	136	146	O
the	20357382	147	150	O
relationships	20357382	151	164	O
between	20357382	165	172	O
glycemia	20357382	173	181	O
at	20357382	182	184	O
randomization	20357382	185	198	O
,	20357382	198	199	O
concurrent	20357382	200	210	O
antidiabetic	20357382	211	223	O
therapy	20357382	224	231	O
,	20357382	231	232	O
and	20357382	233	236	O
change	20357382	237	243	O
in	20357382	244	246	O
A1C	20357382	247	250	O
and	20357382	251	254	O
fasting	20357382	255	262	O
plasma	20357382	263	269	O
glucose	20357382	270	277	O
(	20357382	278	279	O
FPG	20357382	279	282	O
)	20357382	282	283	O
in	20357382	284	286	O
patients	20357382	287	295	O
with	20357382	296	300	O
diabetes	20357382	301	309	O
receiving	20357382	310	319	O
standard	20357382	320	328	O
treatment	20357382	329	338	O
for	20357382	339	342	O
diabetes	20357382	343	351	O
and	20357382	352	355	O
randomized	20357382	356	366	O
to	20357382	367	369	O
ranolazine	20357382	370	380	O
or	20357382	381	383	O
placebo	20357382	384	391	O
within	20357382	392	398	O
the	20357382	399	402	O
MERLIN-TIMI-36	20357382	403	417	O
(	20357382	418	419	O
MERLIN	20357382	419	425	O
)	20357382	425	426	O
study	20357382	427	432	O
.	20357382	432	433	O

Ranolazine	20357382	434	444	O
is	20357382	445	447	O
a	20357382	448	449	O
novel	20357382	450	455	O
first-in-class	20357382	456	470	O
drug	20357382	471	475	O
approved	20357382	476	484	O
for	20357382	485	488	O
treating	20357382	489	497	O
angina	20357382	498	504	O
pectoris	20357382	505	513	O
.	20357382	513	514	O

RESEARCH	20357382	516	524	O
DESIGN	20357382	525	531	O
AND	20357382	532	535	O
METHODS	20357382	536	543	O
:	20357382	544	545	O
Randomization	20357382	546	559	O
and	20357382	560	563	O
4-month	20357382	564	571	O
glycemic	20357382	572	580	O
and	20357382	581	584	O
antidiabetes	20357382	585	597	O
drug	20357382	598	602	O
usage	20357382	603	608	O
data	20357382	609	613	O
from	20357382	614	618	O
MERLIN	20357382	619	625	O
were	20357382	626	630	O
analyzed	20357382	631	639	O
using	20357382	640	645	O
Spotfire	20357382	646	654	O
and	20357382	655	658	O
SAS	20357382	659	662	O
version	20357382	663	670	O
9.1	20357382	671	674	O
software	20357382	675	683	O
.	20357382	683	684	O

RESULTS	20357382	686	693	O
:	20357382	694	695	O
In	20357382	696	698	O
patients	20357382	699	707	O
with	20357382	708	712	O
diabetes	20357382	713	721	O
and	20357382	722	725	O
A1C	20357382	726	729	O
of	20357382	730	732	O
>	20357382	733	734	O
or=8	20357382	734	738	O
-	20357382	738	739	O
10	20357382	739	741	O
%	20357382	741	742	O
at	20357382	743	745	O
randomization	20357382	746	759	O
(	20357382	760	761	O
n	20357382	761	762	O
=	20357382	763	764	O
171	20357382	765	768	O
)	20357382	768	769	O
,	20357382	769	770	O
there	20357382	771	776	O
was	20357382	777	780	O
an	20357382	781	783	O
absolute	20357382	784	792	O
A1C	20357382	793	796	B-Outcome
reduction	20357382	797	806	O
in	20357382	807	809	O
the	20357382	810	813	O
ranolazine	20357382	814	824	O
group	20357382	825	830	O
of	20357382	831	833	O
1.2	20357382	834	837	O
%	20357382	837	838	O
(	20357382	839	840	O
95	20357382	840	842	O
%	20357382	842	843	O
CI	20357382	844	846	O
-1.4	20357382	847	851	O
to	20357382	852	854	O
-1.0	20357382	855	859	O
)	20357382	859	860	O
,	20357382	860	861	O
and	20357382	862	865	O
the	20357382	866	869	O
placebo-adjusted	20357382	870	886	O
(	20357382	887	888	O
n	20357382	888	889	O
=	20357382	890	891	O
182	20357382	892	895	O
)	20357382	895	896	O
decrease	20357382	897	905	O
in	20357382	906	908	O
A1C	20357382	909	912	B-Outcome
by	20357382	913	915	O
ranolazine	20357382	916	926	O
was	20357382	927	930	O
0.59	20357382	931	935	O
%	20357382	935	936	O
(	20357382	937	938	O
95	20357382	938	940	O
%	20357382	940	941	O
CI	20357382	942	944	O
-0.99	20357382	945	950	O
to	20357382	951	953	O
-0.20	20357382	954	959	O
,	20357382	959	960	O
P	20357382	961	962	O
<	20357382	963	964	O
0.001	20357382	965	970	O
)	20357382	970	971	O
.	20357382	971	972	O

In	20357382	973	975	O
patients	20357382	976	984	O
with	20357382	985	989	O
FPG	20357382	990	993	O
of	20357382	994	996	O
150	20357382	997	1000	O
-	20357382	1000	1001	O
400	20357382	1001	1004	O
mg/dl	20357382	1005	1010	O
at	20357382	1011	1013	O
randomization	20357382	1014	1027	O
,	20357382	1027	1028	O
ranolazine	20357382	1029	1039	O
(	20357382	1040	1041	O
n	20357382	1041	1042	O
=	20357382	1043	1044	O
131	20357382	1045	1048	O
)	20357382	1048	1049	O
compared	20357382	1050	1058	O
with	20357382	1059	1063	O
placebo	20357382	1064	1071	O
(	20357382	1072	1073	O
n	20357382	1073	1074	O
=	20357382	1075	1076	O
147	20357382	1077	1080	O
)	20357382	1080	1081	O
reduced	20357382	1082	1089	O
FPG	20357382	1090	1093	B-Outcome
by	20357382	1094	1096	O
25.7	20357382	1097	1101	O
mg/dl	20357382	1102	1107	O
(	20357382	1108	1109	O
95	20357382	1109	1111	O
%	20357382	1111	1112	O
CI	20357382	1113	1115	O
-43.3	20357382	1116	1121	O
to	20357382	1122	1124	O
-8.1	20357382	1125	1129	O
,	20357382	1129	1130	O
P	20357382	1131	1132	O
=	20357382	1133	1134	O
0.001	20357382	1135	1140	O
)	20357382	1140	1141	O
.	20357382	1141	1142	O

When	20357382	1143	1147	O
changes	20357382	1148	1155	O
in	20357382	1156	1158	O
either	20357382	1159	1165	O
A1C	20357382	1166	1169	B-Outcome
or	20357382	1170	1172	O
FPG	20357382	1173	1176	B-Outcome
were	20357382	1177	1181	O
correlated	20357382	1182	1192	O
to	20357382	1193	1195	O
A1C	20357382	1196	1199	B-Outcome
or	20357382	1200	1202	O
FPG	20357382	1203	1206	B-Outcome
at	20357382	1207	1209	O
randomization	20357382	1210	1223	O
,	20357382	1223	1224	O
the	20357382	1225	1228	O
slopes	20357382	1229	1235	O
were	20357382	1236	1240	O
significantly	20357382	1241	1254	O
steeper	20357382	1255	1262	O
for	20357382	1263	1266	O
ranolazine	20357382	1267	1277	O
than	20357382	1278	1282	O
placebo	20357382	1283	1290	O
(	20357382	1291	1292	O
A1C	20357382	1292	1295	B-Outcome
,	20357382	1295	1296	O
P	20357382	1297	1298	O
=	20357382	1299	1300	O
0.046	20357382	1301	1306	O
;	20357382	1306	1307	O
FPG	20357382	1308	1311	B-Outcome
,	20357382	1311	1312	O
P	20357382	1313	1314	O
<	20357382	1315	1316	O
0.001	20357382	1317	1322	O
)	20357382	1322	1323	O
,	20357382	1323	1324	O
indicating	20357382	1325	1335	O
that	20357382	1336	1340	O
lowering	20357382	1341	1349	O
of	20357382	1350	1352	O
A1C	20357382	1353	1356	B-Outcome
and	20357382	1357	1360	O
FPG	20357382	1361	1364	B-Outcome
by	20357382	1365	1367	O
ranolazine	20357382	1368	1378	O
is	20357382	1379	1381	O
related	20357382	1382	1389	O
to	20357382	1390	1392	O
hyperglycemia	20357382	1393	1406	B-Outcome
at	20357382	1407	1409	O
randomization	20357382	1410	1423	O
.	20357382	1423	1424	O

Ranolazine	20357382	1425	1435	O
,	20357382	1435	1436	O
compared	20357382	1437	1445	O
with	20357382	1446	1450	O
placebo	20357382	1451	1458	O
,	20357382	1458	1459	O
was	20357382	1460	1463	O
not	20357382	1464	1467	O
associated	20357382	1468	1478	O
with	20357382	1479	1483	O
serious	20357382	1484	1491	B-Outcome
hypoglycemic	20357382	1492	1504	I-Outcome
events	20357382	1505	1511	I-Outcome
,	20357382	1511	1512	O
associated	20357382	1513	1523	O
with	20357382	1524	1528	O
significant	20357382	1529	1540	O
changes	20357382	1541	1548	O
in	20357382	1549	1551	O
concurrent	20357382	1552	1562	O
antidiabetic	20357382	1563	1575	O
therapy	20357382	1576	1583	O
,	20357382	1583	1584	O
or	20357382	1585	1587	O
dependent	20357382	1588	1597	O
on	20357382	1598	1600	O
a	20357382	1601	1602	O
history	20357382	1603	1610	O
of	20357382	1611	1613	O
angina	20357382	1614	1620	O
.	20357382	1620	1621	O

CONCLUSIONS	20357382	1623	1634	O
:	20357382	1635	1636	O
Ranolazine	20357382	1637	1647	O
,	20357382	1647	1648	O
when	20357382	1649	1653	O
added	20357382	1654	1659	O
to	20357382	1660	1662	O
concurrent	20357382	1663	1673	O
antidiabetes	20357382	1674	1686	O
treatment	20357382	1687	1696	O
,	20357382	1696	1697	O
lowers	20357382	1698	1704	O
FPG	20357382	1705	1708	B-Outcome
and	20357382	1709	1712	O
A1C	20357382	1713	1716	B-Outcome
in	20357382	1717	1719	O
patients	20357382	1720	1728	O
with	20357382	1729	1733	O
cardiovascular	20357382	1734	1748	O
disease	20357382	1749	1756	O
and	20357382	1757	1760	O
poorly	20357382	1761	1767	O
controlled	20357382	1768	1778	O
diabetes	20357382	1779	1787	O
.	20357382	1787	1788	O


The	20413513	0	3	O
11-beta-hydroxysteroid	20413513	4	26	O
dehydrogenase	20413513	27	40	O
type	20413513	41	45	O
1	20413513	46	47	O
inhibitor	20413513	48	57	O
INCB13739	20413513	58	67	O
improves	20413513	68	76	O
hyperglycemia	20413513	77	90	O
in	20413513	91	93	O
patients	20413513	94	102	O
with	20413513	103	107	O
type	20413513	108	112	O
2	20413513	113	114	O
diabetes	20413513	115	123	O
inadequately	20413513	124	136	O
controlled	20413513	137	147	O
by	20413513	148	150	O
metformin	20413513	151	160	O
monotherapy	20413513	161	172	O
.	20413513	172	173	O

OBJECTIVE	20413513	175	184	O
:	20413513	185	186	O
11-Beta-hydroxysteroid	20413513	187	209	O
dehydrogenase	20413513	210	223	O
type	20413513	224	228	O
1	20413513	229	230	O
(	20413513	231	232	O
11betaHSD1	20413513	232	242	O
)	20413513	242	243	O
converts	20413513	244	252	O
inactive	20413513	253	261	O
cortisone	20413513	262	271	O
into	20413513	272	276	O
active	20413513	277	283	O
cortisol	20413513	284	292	O
,	20413513	292	293	O
thereby	20413513	294	301	O
amplifying	20413513	302	312	O
intracellular	20413513	313	326	O
glucocorticoid	20413513	327	341	O
action	20413513	342	348	O
.	20413513	348	349	O

The	20413513	350	353	O
efficacy	20413513	354	362	O
and	20413513	363	366	O
safety	20413513	367	373	O
of	20413513	374	376	O
the	20413513	377	380	O
11betaHSD1	20413513	381	391	O
inhibitor	20413513	392	401	O
INCB13739	20413513	402	411	O
were	20413513	412	416	O
assessed	20413513	417	425	O
when	20413513	426	430	O
added	20413513	431	436	O
to	20413513	437	439	O
ongoing	20413513	440	447	O
metformin	20413513	448	457	O
monotherapy	20413513	458	469	O
in	20413513	470	472	O
patients	20413513	473	481	O
with	20413513	482	486	O
type	20413513	487	491	O
2	20413513	492	493	O
diabetes	20413513	494	502	O
exhibiting	20413513	503	513	O
inadequate	20413513	514	524	O
glycemic	20413513	525	533	O
control	20413513	534	541	O
(	20413513	542	543	O
A1C	20413513	543	546	O
7	20413513	547	548	O
-	20413513	548	549	O
11	20413513	549	551	O
%	20413513	551	552	O
)	20413513	552	553	O
.	20413513	553	554	O

RESEARCH	20413513	556	564	O
DESIGN	20413513	565	571	O
AND	20413513	572	575	O
METHODS	20413513	576	583	O
:	20413513	584	585	O
This	20413513	586	590	O
double-blind	20413513	591	603	O
placebo-controlled	20413513	604	622	O
paralleled	20413513	623	633	O
study	20413513	634	639	O
randomized	20413513	640	650	O
302	20413513	651	654	O
patients	20413513	655	663	O
with	20413513	664	668	O
type	20413513	669	673	O
2	20413513	674	675	O
diabetes	20413513	676	684	O
(	20413513	685	686	O
mean	20413513	686	690	O
A1C	20413513	691	694	O
8.3	20413513	695	698	O
%	20413513	698	699	O
)	20413513	699	700	O
on	20413513	701	703	O
metformin	20413513	704	713	O
monotherapy	20413513	714	725	O
(	20413513	726	727	O
mean	20413513	727	731	O
1.5	20413513	732	735	O
g/day	20413513	736	741	O
)	20413513	741	742	O
to	20413513	743	745	O
receive	20413513	746	753	O
one	20413513	754	757	O
of	20413513	758	760	O
five	20413513	761	765	O
INCB13739	20413513	766	775	O
doses	20413513	776	781	O
or	20413513	782	784	O
placebo	20413513	785	792	O
once	20413513	793	797	O
daily	20413513	798	803	O
for	20413513	804	807	O
12	20413513	808	810	O
weeks	20413513	811	816	O
.	20413513	816	817	O

The	20413513	818	821	O
primary	20413513	822	829	O
end	20413513	830	833	O
point	20413513	834	839	O
was	20413513	840	843	O
the	20413513	844	847	O
change	20413513	848	854	O
in	20413513	855	857	O
A1C	20413513	858	861	O
at	20413513	862	864	O
study	20413513	865	870	O
end	20413513	871	874	O
.	20413513	874	875	O

Other	20413513	876	881	O
end	20413513	882	885	O
points	20413513	886	892	O
included	20413513	893	901	O
changes	20413513	902	909	O
in	20413513	910	912	O
fasting	20413513	913	920	O
glucose	20413513	921	928	O
,	20413513	928	929	O
lipids	20413513	930	936	O
,	20413513	936	937	O
weight	20413513	938	944	O
,	20413513	944	945	O
adverse	20413513	946	953	O
events	20413513	954	960	O
,	20413513	960	961	O
and	20413513	962	965	O
safety	20413513	966	972	O
.	20413513	972	973	O

RESULTS	20413513	975	982	O
:	20413513	983	984	O
After	20413513	985	990	O
12	20413513	991	993	O
weeks	20413513	994	999	O
,	20413513	999	1000	O
200	20413513	1001	1004	O
mg	20413513	1005	1007	O
of	20413513	1008	1010	O
INCB13739	20413513	1011	1020	O
resulted	20413513	1021	1029	O
in	20413513	1030	1032	O
significant	20413513	1033	1044	O
reductions	20413513	1045	1055	O
in	20413513	1056	1058	O
A1C	20413513	1059	1062	B-Outcome
(	20413513	1063	1064	O
-0.6	20413513	1064	1068	O
%	20413513	1068	1069	O
)	20413513	1069	1070	O
,	20413513	1070	1071	O
fasting	20413513	1072	1079	B-Outcome
plasma	20413513	1080	1086	I-Outcome
glucose	20413513	1087	1094	I-Outcome
(	20413513	1095	1096	O
-24	20413513	1096	1099	O
mg/dl	20413513	1100	1105	O
)	20413513	1105	1106	O
,	20413513	1106	1107	O
and	20413513	1108	1111	O
homeostasis	20413513	1112	1123	B-Outcome
model	20413513	1124	1129	I-Outcome
assessment-insulin	20413513	1130	1148	I-Outcome
resistance	20413513	1149	1159	I-Outcome
(	20413513	1160	1161	O
HOMA-IR	20413513	1161	1168	B-Outcome
)	20413513	1168	1169	O
(	20413513	1170	1171	O
-24	20413513	1171	1174	O
%	20413513	1174	1175	O
)	20413513	1175	1176	O
compared	20413513	1177	1185	O
with	20413513	1186	1190	O
placebo	20413513	1191	1198	O
.	20413513	1198	1199	O

Total	20413513	1200	1205	B-Outcome
cholesterol	20413513	1206	1217	I-Outcome
,	20413513	1217	1218	O
LDL	20413513	1219	1222	B-Outcome
cholesterol	20413513	1223	1234	I-Outcome
,	20413513	1234	1235	O
and	20413513	1236	1239	O
triglycerides	20413513	1240	1253	B-Outcome
were	20413513	1254	1258	O
all	20413513	1259	1262	O
significantly	20413513	1263	1276	O
decreased	20413513	1277	1286	O
in	20413513	1287	1289	O
hyperlipidemic	20413513	1290	1304	O
patients	20413513	1305	1313	O
.	20413513	1313	1314	O

Body	20413513	1315	1319	B-Outcome
weight	20413513	1320	1326	I-Outcome
decreased	20413513	1327	1336	O
relative	20413513	1337	1345	O
to	20413513	1346	1348	O
placebo	20413513	1349	1356	O
after	20413513	1357	1362	O
INCB13739	20413513	1363	1372	O
therapy	20413513	1373	1380	O
.	20413513	1380	1381	O

A	20413513	1382	1383	O
reversible	20413513	1384	1394	O
dose-dependent	20413513	1395	1409	O
elevation	20413513	1410	1419	O
in	20413513	1420	1422	O
adrenocorticotrophic	20413513	1423	1443	B-Outcome
hormone	20413513	1444	1451	I-Outcome
,	20413513	1451	1452	O
generally	20413513	1453	1462	O
within	20413513	1463	1469	O
the	20413513	1470	1473	O
normal	20413513	1474	1480	O
reference	20413513	1481	1490	O
range	20413513	1491	1496	O
,	20413513	1496	1497	O
was	20413513	1498	1501	O
observed	20413513	1502	1510	O
.	20413513	1510	1511	O

Basal	20413513	1512	1517	B-Outcome
cortisol	20413513	1518	1526	I-Outcome
homeostasis	20413513	1527	1538	I-Outcome
,	20413513	1538	1539	O
testosterone	20413513	1540	1552	B-Outcome
in	20413513	1553	1555	O
men	20413513	1556	1559	O
,	20413513	1559	1560	O
and	20413513	1561	1564	O
free	20413513	1565	1569	B-Outcome
androgen	20413513	1570	1578	I-Outcome
index	20413513	1579	1584	I-Outcome
in	20413513	1585	1587	O
women	20413513	1588	1593	O
were	20413513	1594	1598	O
unchanged	20413513	1599	1608	O
by	20413513	1609	1611	O
INCB13739	20413513	1612	1621	O
.	20413513	1621	1622	O

Adverse	20413513	1623	1630	B-Outcome
events	20413513	1631	1637	I-Outcome
were	20413513	1638	1642	O
similar	20413513	1643	1650	O
across	20413513	1651	1657	O
all	20413513	1658	1661	O
treatment	20413513	1662	1671	O
groups	20413513	1672	1678	O
.	20413513	1678	1679	O

CONCLUSIONS	20413513	1681	1692	O
:	20413513	1693	1694	O
INCB13739	20413513	1695	1704	O
added	20413513	1705	1710	O
to	20413513	1711	1713	O
ongoing	20413513	1714	1721	O
metformin	20413513	1722	1731	O
therapy	20413513	1732	1739	O
was	20413513	1740	1743	O
efficacious	20413513	1744	1755	B-Outcome
and	20413513	1756	1759	O
well	20413513	1760	1764	O
tolerated	20413513	1765	1774	B-Outcome
in	20413513	1775	1777	O
patients	20413513	1778	1786	O
with	20413513	1787	1791	O
type	20413513	1792	1796	O
2	20413513	1797	1798	O
diabetes	20413513	1799	1807	O
who	20413513	1808	1811	O
had	20413513	1812	1815	O
inadequate	20413513	1816	1826	O
glycemic	20413513	1827	1835	O
control	20413513	1836	1843	O
with	20413513	1844	1848	O
metformin	20413513	1849	1858	O
alone	20413513	1859	1864	O
.	20413513	1864	1865	O

11BetaHSD1	20413513	1866	1876	O
inhibition	20413513	1877	1887	O
offers	20413513	1888	1894	O
a	20413513	1895	1896	O
new	20413513	1897	1900	O
potential	20413513	1901	1910	O
approach	20413513	1911	1919	O
to	20413513	1920	1922	O
control	20413513	1923	1930	O
glucose	20413513	1931	1938	B-Outcome
and	20413513	1939	1942	O
cardiovascular	20413513	1943	1957	B-Outcome
risk	20413513	1958	1962	I-Outcome
factors	20413513	1963	1970	I-Outcome
in	20413513	1971	1973	O
type	20413513	1974	1978	O
2	20413513	1979	1980	O
diabetes	20413513	1981	1989	O
.	20413513	1989	1990	O


Efficacy	20486273	0	8	O
and	20486273	9	12	O
safety	20486273	13	19	O
of	20486273	20	22	O
routine	20486273	23	30	O
blood	20486273	31	36	O
pressure	20486273	37	45	O
lowering	20486273	46	54	O
in	20486273	55	57	O
older	20486273	58	63	O
patients	20486273	64	72	O
with	20486273	73	77	O
diabetes	20486273	78	86	O
:	20486273	86	87	O
results	20486273	88	95	O
from	20486273	96	100	O
the	20486273	101	104	O
ADVANCE	20486273	105	112	O
trial	20486273	113	118	O
.	20486273	118	119	O

OBJECTIVE	20486273	121	130	O
:	20486273	131	132	O
The	20486273	133	136	O
efficacy	20486273	137	145	O
and	20486273	146	149	O
safety	20486273	150	156	O
of	20486273	157	159	O
blood	20486273	160	165	O
pressure	20486273	166	174	O
lowering	20486273	175	183	O
in	20486273	184	186	O
elderly	20486273	187	194	O
patients	20486273	195	203	O
have	20486273	204	208	O
not	20486273	209	212	O
been	20486273	213	217	O
sufficiently	20486273	218	230	O
investigated	20486273	231	243	O
in	20486273	244	246	O
patients	20486273	247	255	O
with	20486273	256	260	O
diabetes	20486273	261	269	O
.	20486273	269	270	O

Using	20486273	271	276	O
data	20486273	277	281	O
from	20486273	282	286	O
the	20486273	287	290	O
Action	20486273	291	297	O
in	20486273	298	300	O
Diabetes	20486273	301	309	O
and	20486273	310	313	O
Vascular	20486273	314	322	O
disease	20486273	323	330	O
:	20486273	330	331	O
preterAx	20486273	332	340	O
and	20486273	341	344	O
diamicroN-MR	20486273	345	357	O
Controlled	20486273	358	368	O
Evaluation	20486273	369	379	O
study	20486273	380	385	O
,	20486273	385	386	O
we	20486273	387	389	O
assessed	20486273	390	398	O
the	20486273	399	402	O
efficacy	20486273	403	411	O
and	20486273	412	415	O
safety	20486273	416	422	O
of	20486273	423	425	O
routine	20486273	426	433	O
blood	20486273	434	439	O
pressure	20486273	440	448	O
lowering	20486273	449	457	O
to	20486273	458	460	O
prevent	20486273	461	468	O
major	20486273	469	474	O
clinical	20486273	475	483	O
outcomes	20486273	484	492	O
in	20486273	493	495	O
elderly	20486273	496	503	O
patients	20486273	504	512	O
with	20486273	513	517	O
type	20486273	518	522	O
2	20486273	523	524	O
diabetes	20486273	525	533	O
.	20486273	533	534	O

METHODS	20486273	536	543	O
:	20486273	544	545	O
Eleven	20486273	546	552	O
thousand	20486273	553	561	O
one	20486273	562	565	O
hundred	20486273	566	573	O
and	20486273	574	577	O
forty	20486273	578	583	O
patients	20486273	584	592	O
aged	20486273	593	597	O
at	20486273	598	600	O
least	20486273	601	606	O
55	20486273	607	609	O
years	20486273	610	615	O
with	20486273	616	620	O
type	20486273	621	625	O
2	20486273	626	627	O
diabetes	20486273	628	636	O
(	20486273	637	638	O
mean	20486273	638	642	O
66+/-6	20486273	643	649	O
years	20486273	650	655	O
)	20486273	655	656	O
were	20486273	657	661	O
randomly	20486273	662	670	O
assigned	20486273	671	679	O
to	20486273	680	682	O
perindopril-indapamide	20486273	683	705	O
or	20486273	706	708	O
placebo	20486273	709	716	O
.	20486273	716	717	O

The	20486273	718	721	O
primary	20486273	722	729	O
endpoint	20486273	730	738	O
was	20486273	739	742	O
a	20486273	743	744	O
composite	20486273	745	754	O
of	20486273	755	757	O
major	20486273	758	763	O
macrovascular	20486273	764	777	O
and	20486273	778	781	O
microvascular	20486273	782	795	O
disease	20486273	796	803	O
.	20486273	803	804	O

The	20486273	805	808	O
effects	20486273	809	816	O
of	20486273	817	819	O
active	20486273	820	826	O
treatment	20486273	827	836	O
on	20486273	837	839	O
outcomes	20486273	840	848	O
were	20486273	849	853	O
estimated	20486273	854	863	O
in	20486273	864	866	O
subgroups	20486273	867	876	O
according	20486273	877	886	O
to	20486273	887	889	O
age	20486273	890	893	O
:	20486273	893	894	O
below	20486273	895	900	O
65	20486273	901	903	O
,	20486273	903	904	O
65	20486273	905	907	O
-	20486273	907	908	O
74	20486273	908	910	O
and	20486273	911	914	O
at	20486273	915	917	O
least	20486273	918	923	O
75	20486273	924	926	O
years	20486273	927	932	O
.	20486273	932	933	O

RESULTS	20486273	935	942	O
:	20486273	943	944	O
During	20486273	945	951	O
a	20486273	952	953	O
mean	20486273	954	958	O
4.3-year	20486273	959	967	O
follow-up	20486273	968	977	O
,	20486273	977	978	O
1799	20486273	979	983	O
(	20486273	984	985	O
16.1	20486273	985	989	O
%	20486273	989	990	O
)	20486273	990	991	O
patients	20486273	992	1000	O
experienced	20486273	1001	1012	O
a	20486273	1013	1014	O
major	20486273	1015	1020	O
event	20486273	1021	1026	O
.	20486273	1026	1027	O

Active	20486273	1028	1034	O
treatment	20486273	1035	1044	O
produced	20486273	1045	1053	O
similar	20486273	1054	1061	O
relative	20486273	1062	1070	O
risk	20486273	1071	1075	O
reductions	20486273	1076	1086	O
for	20486273	1087	1090	O
the	20486273	1091	1094	O
primary	20486273	1095	1102	O
outcome	20486273	1103	1110	O
,	20486273	1110	1111	O
major	20486273	1112	1117	B-Outcome
macrovascular	20486273	1118	1131	I-Outcome
disease	20486273	1132	1139	I-Outcome
,	20486273	1139	1140	O
death	20486273	1141	1146	B-Outcome
and	20486273	1147	1150	O
renal	20486273	1151	1156	B-Outcome
events	20486273	1157	1163	I-Outcome
across	20486273	1164	1170	O
age	20486273	1171	1174	O
groups	20486273	1175	1181	O
(	20486273	1182	1183	O
all	20486273	1183	1186	O
P	20486273	1187	1188	O
heterogeneity	20486273	1189	1202	O
>	20486273	1203	1204	O
0.3	20486273	1204	1207	O
)	20486273	1207	1208	O
.	20486273	1208	1209	O

Over	20486273	1210	1214	O
5	20486273	1215	1216	O
years	20486273	1217	1222	O
,	20486273	1222	1223	O
active	20486273	1224	1230	O
treatment	20486273	1231	1240	O
was	20486273	1241	1244	O
estimated	20486273	1245	1254	O
to	20486273	1255	1257	O
prevent	20486273	1258	1265	O
one	20486273	1266	1269	O
primary	20486273	1270	1277	O
outcome	20486273	1278	1285	O
in	20486273	1286	1288	O
every	20486273	1289	1294	O
21	20486273	1295	1297	O
,	20486273	1297	1298	O
71	20486273	1299	1301	O
and	20486273	1302	1305	O
118	20486273	1306	1309	O
patients	20486273	1310	1318	O
of	20486273	1319	1321	O
at	20486273	1322	1324	O
least	20486273	1325	1330	O
75	20486273	1331	1333	O
,	20486273	1333	1334	O
65	20486273	1335	1337	O
-	20486273	1337	1338	O
74	20486273	1338	1340	O
and	20486273	1341	1344	O
below	20486273	1345	1350	O
65	20486273	1351	1353	O
years	20486273	1354	1359	O
,	20486273	1359	1360	O
respectively	20486273	1361	1373	O
.	20486273	1373	1374	O

Similar	20486273	1375	1382	O
patterns	20486273	1383	1391	O
of	20486273	1392	1394	O
benefits	20486273	1395	1403	O
were	20486273	1404	1408	O
observed	20486273	1409	1417	O
for	20486273	1418	1421	O
secondary	20486273	1422	1431	O
outcomes	20486273	1432	1440	O
.	20486273	1440	1441	O

There	20486273	1442	1447	O
were	20486273	1448	1452	O
no	20486273	1453	1455	O
differences	20486273	1456	1467	O
in	20486273	1468	1470	O
the	20486273	1471	1474	O
tolerability	20486273	1475	1487	B-Outcome
between	20486273	1488	1495	O
randomized	20486273	1496	1506	O
allocations	20486273	1507	1518	O
across	20486273	1519	1525	O
age	20486273	1526	1529	O
groups	20486273	1530	1536	O
(	20486273	1537	1538	O
all	20486273	1538	1541	O
P	20486273	1542	1543	O
heterogeneity	20486273	1544	1557	O
>	20486273	1558	1559	O
0.6	20486273	1559	1562	O
)	20486273	1562	1563	O
CONCLUSION	20486273	1564	1574	O
:	20486273	1575	1576	O
Routine	20486273	1577	1584	O
administration	20486273	1585	1599	O
of	20486273	1600	1602	O
perindopril-indapamide	20486273	1603	1625	O
lowers	20486273	1626	1632	O
blood	20486273	1633	1638	B-Outcome
pressure	20486273	1639	1647	I-Outcome
safely	20486273	1648	1654	O
and	20486273	1655	1658	O
reduces	20486273	1659	1666	O
the	20486273	1667	1670	O
risk	20486273	1671	1675	O
of	20486273	1676	1678	O
major	20486273	1679	1684	B-Outcome
clinical	20486273	1685	1693	I-Outcome
outcomes	20486273	1694	1702	I-Outcome
in	20486273	1703	1705	O
patients	20486273	1706	1714	O
of	20486273	1715	1717	O
at	20486273	1718	1720	O
least	20486273	1721	1726	O
75	20486273	1727	1729	O
years	20486273	1730	1735	O
with	20486273	1736	1740	O
type	20486273	1741	1745	O
2	20486273	1746	1747	O
diabetes	20486273	1748	1756	O
.	20486273	1756	1757	O

The	20486273	1758	1761	O
greater	20486273	1762	1769	O
absolute	20486273	1770	1778	O
benefits	20486273	1779	1787	O
in	20486273	1788	1790	O
older	20486273	1791	1796	O
patients	20486273	1797	1805	O
in	20486273	1806	1808	O
this	20486273	1809	1813	O
age	20486273	1814	1817	O
group	20486273	1818	1823	O
were	20486273	1824	1828	O
not	20486273	1829	1832	O
offset	20486273	1833	1839	O
by	20486273	1840	1842	O
an	20486273	1843	1845	O
increased	20486273	1846	1855	O
risk	20486273	1856	1860	O
of	20486273	1861	1863	O
side	20486273	1864	1868	B-Outcome
effects	20486273	1869	1876	I-Outcome
.	20486273	1876	1877	O


Improving	20504165	0	9	O
the	20504165	10	13	O
immunogenicity	20504165	14	28	O
of	20504165	29	31	O
pneumococcal	20504165	32	44	O
conjugate	20504165	45	54	O
vaccine	20504165	55	62	O
in	20504165	63	65	O
HIV-infected	20504165	66	78	O
adults	20504165	79	85	O
with	20504165	86	90	O
a	20504165	91	92	O
toll-like	20504165	93	102	O
receptor	20504165	103	111	O
9	20504165	112	113	O
agonist	20504165	114	121	O
adjuvant	20504165	122	130	O
:	20504165	130	131	O
a	20504165	132	133	O
randomized	20504165	134	144	O
,	20504165	144	145	O
controlled	20504165	146	156	O
trial	20504165	157	162	O
.	20504165	162	163	O

BACKGROUND	20504165	165	175	O
:	20504165	176	177	O
Persons	20504165	178	185	O
infected	20504165	186	194	O
with	20504165	195	199	O
human	20504165	200	205	O
immunodeficiency	20504165	206	222	O
virus	20504165	223	228	O
(	20504165	229	230	O
HIV	20504165	230	233	O
)	20504165	233	234	O
are	20504165	235	238	O
often	20504165	239	244	O
hyporesponsive	20504165	245	259	O
to	20504165	260	262	O
immunization	20504165	263	275	O
,	20504165	275	276	O
including	20504165	277	286	O
pneumococcal	20504165	287	299	O
vaccines	20504165	300	308	O
.	20504165	308	309	O

We	20504165	310	312	O
hypothesized	20504165	313	325	O
that	20504165	326	330	O
adding	20504165	331	337	O
CPG	20504165	338	341	O
7909	20504165	342	346	O
,	20504165	346	347	O
a	20504165	348	349	O
toll-like	20504165	350	359	O
receptor	20504165	360	368	O
9	20504165	369	370	O
(	20504165	371	372	O
TLR9	20504165	372	376	O
)	20504165	376	377	O
agonist	20504165	378	385	O
and	20504165	386	389	O
vaccine	20504165	390	397	O
adjuvant	20504165	398	406	O
,	20504165	406	407	O
to	20504165	408	410	O
7-valent	20504165	411	419	O
pneumococcal	20504165	420	432	O
conjugate	20504165	433	442	O
vaccine	20504165	443	450	O
(	20504165	451	452	O
7vPnC	20504165	452	457	O
)	20504165	457	458	O
would	20504165	459	464	O
increase	20504165	465	473	O
its	20504165	474	477	O
immunogenicity	20504165	478	492	O
in	20504165	493	495	O
HIV-infected	20504165	496	508	O
adults	20504165	509	515	O
.	20504165	515	516	O

METHODS	20504165	518	525	O
:	20504165	526	527	O
We	20504165	528	530	O
performed	20504165	531	540	O
a	20504165	541	542	O
double-blind	20504165	543	555	O
,	20504165	555	556	O
placebo-controlled	20504165	557	575	O
,	20504165	575	576	O
phase	20504165	577	582	O
1b/2a	20504165	583	588	O
trial	20504165	589	594	O
randomizing	20504165	595	606	O
HIV-positive	20504165	607	619	O
patients	20504165	620	628	O
to	20504165	629	631	O
receive	20504165	632	639	O
double	20504165	640	646	O
doses	20504165	647	652	O
of	20504165	653	655	O
7vPnC	20504165	656	661	O
(	20504165	662	663	O
Prevnar	20504165	663	670	O
)	20504165	670	671	O
at	20504165	672	674	O
0	20504165	675	676	O
and	20504165	677	680	O
3	20504165	681	682	O
months	20504165	683	689	O
and	20504165	690	693	O
1	20504165	694	695	O
dose	20504165	696	700	O
of	20504165	701	703	O
23-valent	20504165	704	713	O
pneumococcal	20504165	714	726	O
polysaccharide	20504165	727	741	O
vaccine	20504165	742	749	O
(	20504165	750	751	O
PPV-23	20504165	751	757	O
;	20504165	757	758	O
Pneumo	20504165	759	765	O
Novum	20504165	766	771	O
)	20504165	771	772	O
at	20504165	773	775	O
9	20504165	776	777	O
months	20504165	778	784	O
,	20504165	784	785	O
with	20504165	786	790	O
experimental	20504165	791	803	O
patients	20504165	804	812	O
receiving	20504165	813	822	O
1	20504165	823	824	O
mg	20504165	825	827	O
of	20504165	828	830	O
CPG	20504165	831	834	O
7909	20504165	835	839	O
added	20504165	840	845	O
to	20504165	846	848	O
each	20504165	849	853	O
of	20504165	854	856	O
their	20504165	857	862	O
3	20504165	863	864	O
vaccine	20504165	865	872	O
doses	20504165	873	878	O
;	20504165	878	879	O
control	20504165	880	887	O
patients	20504165	888	896	O
had	20504165	897	900	O
phosphate-buffered	20504165	901	919	O
saline	20504165	920	926	O
added	20504165	927	932	O
instead	20504165	933	940	O
.	20504165	940	941	O

Immunogenicity	20504165	942	956	O
and	20504165	957	960	O
safety	20504165	961	967	O
were	20504165	968	972	O
evaluated	20504165	973	982	O
for	20504165	983	986	O
up	20504165	987	989	O
to	20504165	990	992	O
10	20504165	993	995	O
months	20504165	996	1002	O
.	20504165	1002	1003	O

The	20504165	1004	1007	O
primary	20504165	1008	1015	O
end	20504165	1016	1019	O
point	20504165	1020	1025	O
was	20504165	1026	1029	O
the	20504165	1030	1033	O
proportion	20504165	1034	1044	O
of	20504165	1045	1047	O
vaccine	20504165	1048	1055	O
high	20504165	1056	1060	O
responders	20504165	1061	1071	O
at	20504165	1072	1074	O
9	20504165	1075	1076	O
months	20504165	1077	1083	O
,	20504165	1083	1084	O
defined	20504165	1085	1092	O
as	20504165	1093	1095	O
a	20504165	1096	1097	O
2-fold	20504165	1098	1104	O
increase	20504165	1105	1113	O
in	20504165	1114	1116	O
IgG	20504165	1117	1120	O
levels	20504165	1121	1127	O
to	20504165	1128	1130	O
>	20504165	1131	1132	O
or	20504165	1133	1135	O
=	20504165	1136	1137	O
1	20504165	1138	1139	O
microg/mL	20504165	1140	1149	O
for	20504165	1150	1153	O
at	20504165	1154	1156	O
least	20504165	1157	1162	O
5	20504165	1163	1164	O
of	20504165	1165	1167	O
7	20504165	1168	1169	O
of	20504165	1170	1172	O
the	20504165	1173	1176	O
7vPnC	20504165	1177	1182	O
serotypes	20504165	1183	1192	O
.	20504165	1192	1193	O

RESULTS	20504165	1195	1202	O
:	20504165	1203	1204	O
Ninety-seven	20504165	1205	1217	O
participants	20504165	1218	1230	O
were	20504165	1231	1235	O
included	20504165	1236	1244	O
in	20504165	1245	1247	O
the	20504165	1248	1251	O
study	20504165	1252	1257	O
.	20504165	1257	1258	O

The	20504165	1259	1262	O
proportion	20504165	1263	1273	B-Outcome
of	20504165	1274	1276	I-Outcome
vaccine	20504165	1277	1284	I-Outcome
high	20504165	1285	1289	I-Outcome
responders	20504165	1290	1300	I-Outcome
was	20504165	1301	1304	O
higher	20504165	1305	1311	O
in	20504165	1312	1314	O
the	20504165	1315	1318	O
experimental	20504165	1319	1331	O
group	20504165	1332	1337	O
(	20504165	1338	1339	O
n	20504165	1339	1340	O
=	20504165	1341	1342	O
48	20504165	1343	1345	O
)	20504165	1345	1346	O
than	20504165	1347	1351	O
among	20504165	1352	1357	O
controls	20504165	1358	1366	O
(	20504165	1367	1368	O
n	20504165	1368	1369	O
=	20504165	1370	1371	O
49	20504165	1372	1374	O
;	20504165	1374	1375	O
48.8	20504165	1376	1380	O
%	20504165	1380	1381	O
vs	20504165	1382	1384	O
25.0	20504165	1385	1389	O
%	20504165	1389	1390	O
;	20504165	1390	1391	O
P	20504165	1392	1393	O
=	20504165	1394	1395	O
.02	20504165	1396	1399	O
)	20504165	1399	1400	O
at	20504165	1401	1403	O
9	20504165	1404	1405	O
months	20504165	1406	1412	O
.	20504165	1412	1413	O

Greater	20504165	1414	1421	O
proportions	20504165	1422	1433	B-Outcome
of	20504165	1434	1436	I-Outcome
high	20504165	1437	1441	I-Outcome
responders	20504165	1442	1452	I-Outcome
were	20504165	1453	1457	O
also	20504165	1458	1462	O
observed	20504165	1463	1471	O
at	20504165	1472	1474	O
3	20504165	1475	1476	O
(	20504165	1477	1478	O
51.1	20504165	1478	1482	O
%	20504165	1482	1483	O
vs	20504165	1484	1486	O
39.6	20504165	1487	1491	O
%	20504165	1491	1492	O
;	20504165	1492	1493	O
P	20504165	1494	1495	O
=	20504165	1496	1497	O
.26	20504165	1498	1501	O
)	20504165	1501	1502	O
,	20504165	1502	1503	O
4	20504165	1504	1505	O
(	20504165	1506	1507	O
77.3	20504165	1507	1511	O
%	20504165	1511	1512	O
vs	20504165	1513	1515	O
56.3	20504165	1516	1520	O
%	20504165	1520	1521	O
;	20504165	1521	1522	O
P	20504165	1523	1524	O
=	20504165	1525	1526	O
.03	20504165	1527	1530	O
)	20504165	1530	1531	O
,	20504165	1531	1532	O
and	20504165	1533	1536	O
10	20504165	1537	1539	O
months	20504165	1540	1546	O
(	20504165	1547	1548	O
87.8	20504165	1548	1552	O
%	20504165	1552	1553	O
vs	20504165	1554	1556	O
51.1	20504165	1557	1561	O
%	20504165	1561	1562	O
;	20504165	1562	1563	O
P	20504165	1564	1565	O
<	20504165	1566	1567	O
.001	20504165	1568	1572	O
)	20504165	1572	1573	O
.	20504165	1573	1574	O

Mild	20504165	1575	1579	B-Outcome
systemic	20504165	1580	1588	I-Outcome
and	20504165	1589	1592	O
injection	20504165	1593	1602	B-Outcome
site	20504165	1603	1607	I-Outcome
reactions	20504165	1608	1617	I-Outcome
to	20504165	1618	1620	O
7vPnC	20504165	1621	1626	O
were	20504165	1627	1631	O
more	20504165	1632	1636	O
common	20504165	1637	1643	O
in	20504165	1644	1646	O
the	20504165	1647	1650	O
experimental	20504165	1651	1663	O
group	20504165	1664	1669	O
than	20504165	1670	1674	O
the	20504165	1675	1678	O
control	20504165	1679	1686	O
group	20504165	1687	1692	O
(	20504165	1693	1694	O
100	20504165	1694	1697	O
%	20504165	1697	1698	O
vs	20504165	1699	1701	O
81.3	20504165	1702	1706	O
%	20504165	1706	1707	O
;	20504165	1707	1708	O
P	20504165	1709	1710	O
=	20504165	1711	1712	O
.002	20504165	1713	1717	O
)	20504165	1717	1718	O
.	20504165	1718	1719	O

CPG	20504165	1720	1723	O
7909	20504165	1724	1728	O
did	20504165	1729	1732	O
not	20504165	1733	1736	O
increase	20504165	1737	1745	O
non-7vPnC	20504165	1746	1755	B-Outcome
IgG	20504165	1756	1759	I-Outcome
levels	20504165	1760	1766	I-Outcome
after	20504165	1767	1772	O
PPV-23	20504165	1773	1779	O
immunization	20504165	1780	1792	O
.	20504165	1792	1793	O

No	20504165	1794	1796	O
adverse	20504165	1797	1804	B-Outcome
effects	20504165	1805	1812	I-Outcome
on	20504165	1813	1815	O
CD4(+	20504165	1816	1821	O
)	20504165	1821	1822	O
cell	20504165	1823	1827	O
count	20504165	1828	1833	O
or	20504165	1834	1836	O
organ	20504165	1837	1842	O
functions	20504165	1843	1852	O
occurred	20504165	1853	1861	O
in	20504165	1862	1864	O
either	20504165	1865	1871	O
group	20504165	1872	1877	O
.	20504165	1877	1878	O

CONCLUSIONS	20504165	1880	1891	O
:	20504165	1892	1893	O
The	20504165	1894	1897	O
addition	20504165	1898	1906	O
of	20504165	1907	1909	O
a	20504165	1910	1911	O
TLR9	20504165	1912	1916	O
agonist	20504165	1917	1924	O
to	20504165	1925	1927	O
7vPnC	20504165	1928	1933	O
significantly	20504165	1934	1947	O
enhanced	20504165	1948	1956	O
the	20504165	1957	1960	O
proportion	20504165	1961	1971	B-Outcome
of	20504165	1972	1974	I-Outcome
vaccine	20504165	1975	1982	I-Outcome
high	20504165	1983	1987	I-Outcome
responders	20504165	1988	1998	I-Outcome
.	20504165	1998	1999	O

TRIAL	20504165	2001	2006	O
REGISTRATION	20504165	2007	2019	O
:	20504165	2020	2021	O
ClinicalTrials.gov	20504165	2022	2040	O
identifier	20504165	2041	2051	O
:	20504165	2051	2052	O
NCT00562939	20504165	2053	2064	O
.	20504165	2065	2066	O


Recombinant	20519346	0	11	O
human	20519346	12	17	O
thyrotropin-stimulated	20519346	18	40	O
radioiodine	20519346	41	52	O
therapy	20519346	53	60	O
of	20519346	61	63	O
nodular	20519346	64	71	O
goiter	20519346	72	78	O
allows	20519346	79	85	O
major	20519346	86	91	O
reduction	20519346	92	101	O
of	20519346	102	104	O
the	20519346	105	108	O
radiation	20519346	109	118	O
burden	20519346	119	125	O
with	20519346	126	130	O
retained	20519346	131	139	O
efficacy	20519346	140	148	O
.	20519346	148	149	O

CONTEXT	20519346	151	158	O
AND	20519346	159	162	O
OBJECTIVE	20519346	163	172	O
:	20519346	173	174	O
Stimulation	20519346	175	186	O
with	20519346	187	191	O
recombinant	20519346	192	203	O
human	20519346	204	209	O
TSH	20519346	210	213	O
(	20519346	214	215	O
rhTSH	20519346	215	220	O
)	20519346	220	221	O
before	20519346	222	228	O
radioiodine	20519346	229	240	O
(	20519346	241	242	O
131I	20519346	242	246	O
)	20519346	246	247	O
therapy	20519346	248	255	O
augments	20519346	256	264	O
goiter	20519346	265	271	O
volume	20519346	272	278	O
reduction	20519346	279	288	O
(	20519346	289	290	O
GVR	20519346	290	293	O
)	20519346	293	294	O
.	20519346	294	295	O

Observations	20519346	296	308	O
indicate	20519346	309	317	O
that	20519346	318	322	O
rhTSH	20519346	323	328	O
has	20519346	329	332	O
a	20519346	333	334	O
preconditioning	20519346	335	350	O
effect	20519346	351	357	O
beyond	20519346	358	364	O
increasing	20519346	365	375	O
thyroid	20519346	376	383	O
(131)I	20519346	384	390	O
uptake	20519346	391	397	O
.	20519346	397	398	O

We	20519346	399	401	O
test	20519346	402	406	O
the	20519346	407	410	O
hypothesis	20519346	411	421	O
that	20519346	422	426	O
an	20519346	427	429	O
equivalent	20519346	430	440	O
GVR	20519346	441	444	O
might	20519346	445	450	O
be	20519346	451	453	O
obtained	20519346	454	462	O
by	20519346	463	465	O
an	20519346	466	468	O
absorbed	20519346	469	477	O
thyroid	20519346	478	485	O
dose	20519346	486	490	O
well	20519346	491	495	O
below	20519346	496	501	O
what	20519346	502	506	O
has	20519346	507	510	O
been	20519346	511	515	O
used	20519346	516	520	O
previously	20519346	521	531	O
.	20519346	531	532	O

PATIENTS	20519346	534	542	O
AND	20519346	543	546	O
DESIGN	20519346	547	553	O
:	20519346	554	555	O
In	20519346	556	558	O
a	20519346	559	560	O
double-blinded	20519346	561	575	O
setup	20519346	576	581	O
,	20519346	581	582	O
90	20519346	583	585	O
patients	20519346	586	594	O
(	20519346	595	596	O
78	20519346	596	598	O
women	20519346	599	604	O
;	20519346	604	605	O
median	20519346	606	612	O
age	20519346	613	616	O
,	20519346	616	617	O
52	20519346	618	620	O
yr	20519346	621	623	O
;	20519346	623	624	O
range	20519346	625	630	O
,	20519346	630	631	O
22	20519346	632	634	O
-	20519346	634	635	O
83	20519346	635	637	O
)	20519346	637	638	O
with	20519346	639	643	O
a	20519346	644	645	O
nontoxic	20519346	646	654	O
nodular	20519346	655	662	O
goiter	20519346	663	669	O
(	20519346	670	671	O
median	20519346	671	677	O
size	20519346	678	682	O
,	20519346	682	683	O
63	20519346	684	686	O
ml	20519346	687	689	O
;	20519346	689	690	O
range	20519346	691	696	O
,	20519346	696	697	O
25	20519346	698	700	O
-	20519346	700	701	O
379	20519346	701	704	O
ml	20519346	705	707	O
)	20519346	707	708	O
were	20519346	709	713	O
randomized	20519346	714	724	O
to	20519346	725	727	O
either	20519346	728	734	O
0.1	20519346	735	738	O
mg	20519346	739	741	O
rhTSH	20519346	742	747	O
(	20519346	748	749	O
n=60	20519346	749	753	O
)	20519346	753	754	O
followed	20519346	755	763	O
by	20519346	764	766	O
a	20519346	767	768	O
thyroid	20519346	769	776	O
dose	20519346	777	781	O
of	20519346	782	784	O
50	20519346	785	787	O
Gy	20519346	788	790	O
or	20519346	791	793	O
placebo	20519346	794	801	O
followed	20519346	802	810	O
by	20519346	811	813	O
100	20519346	814	817	O
Gy	20519346	818	820	O
(	20519346	821	822	O
n=30	20519346	822	826	O
)	20519346	826	827	O
.	20519346	827	828	O

RESULTS	20519346	830	837	O
:	20519346	838	839	O
At	20519346	840	842	O
12	20519346	843	845	O
months	20519346	846	852	O
,	20519346	852	853	O
the	20519346	854	857	O
mean	20519346	858	862	B-Outcome
relative	20519346	863	871	I-Outcome
GVR	20519346	872	875	I-Outcome
in	20519346	876	878	O
the	20519346	879	882	O
placebo	20519346	883	890	O
and	20519346	891	894	O
the	20519346	895	898	O
rhTSH	20519346	899	904	O
group	20519346	905	910	O
was	20519346	911	914	O
identical	20519346	915	924	O
(	20519346	925	926	O
35+/-3	20519346	926	932	O
%	20519346	932	933	O
;	20519346	933	934	O
P=0.81	20519346	935	941	O
)	20519346	941	942	O
.	20519346	942	943	O

The	20519346	944	947	O
median	20519346	948	954	B-Outcome
administered	20519346	955	967	I-Outcome
131I-activity	20519346	968	981	I-Outcome
was	20519346	982	985	O
170	20519346	986	989	O
MBq	20519346	990	993	O
(	20519346	994	995	O
45	20519346	995	997	O
-	20519346	997	998	O
1269	20519346	998	1002	O
)	20519346	1002	1003	O
in	20519346	1004	1006	O
the	20519346	1007	1010	O
rhTSH	20519346	1011	1016	O
group	20519346	1017	1022	O
and	20519346	1023	1026	O
559	20519346	1027	1030	O
MBq	20519346	1031	1034	O
(	20519346	1035	1036	O
245	20519346	1036	1039	O
-	20519346	1039	1040	O
3530	20519346	1040	1044	O
)	20519346	1044	1045	O
in	20519346	1046	1048	O
the	20519346	1049	1052	O
placebo	20519346	1053	1060	O
group	20519346	1061	1066	O
(	20519346	1067	1068	O
70	20519346	1068	1070	O
%	20519346	1070	1071	O
reduction	20519346	1072	1081	O
,	20519346	1081	1082	O
P<0.0001	20519346	1083	1091	O
)	20519346	1091	1092	O
.	20519346	1092	1093	O

According	20519346	1094	1103	O
to	20519346	1104	1106	O
the	20519346	1107	1110	O
official	20519346	1111	1119	O
radiation	20519346	1120	1129	O
regulation	20519346	1130	1140	O
,	20519346	1140	1141	O
hospitalization	20519346	1142	1157	O
was	20519346	1158	1161	O
required	20519346	1162	1170	O
in	20519346	1171	1173	O
14	20519346	1174	1176	O
patients	20519346	1177	1185	O
in	20519346	1186	1188	O
the	20519346	1189	1192	O
placebo	20519346	1193	1200	O
group	20519346	1201	1206	O
vs.	20519346	1207	1210	O
one	20519346	1211	1214	O
patient	20519346	1215	1222	O
in	20519346	1223	1225	O
the	20519346	1226	1229	O
rhTSH	20519346	1230	1235	O
group	20519346	1236	1241	O
(	20519346	1242	1243	O
P<0.0001	20519346	1243	1251	O
)	20519346	1251	1252	O
.	20519346	1252	1253	O

In	20519346	1254	1256	O
both	20519346	1257	1261	O
groups	20519346	1262	1268	O
,	20519346	1268	1269	O
goiter-related	20519346	1270	1284	B-Outcome
symptoms	20519346	1285	1293	I-Outcome
were	20519346	1294	1298	O
effectively	20519346	1299	1310	O
relieved	20519346	1311	1319	O
in	20519346	1320	1322	O
the	20519346	1323	1326	O
majority	20519346	1327	1335	O
of	20519346	1336	1338	O
patients	20519346	1339	1347	O
.	20519346	1347	1348	O

The	20519346	1349	1352	O
prevalence	20519346	1353	1363	O
of	20519346	1364	1366	O
myxedema	20519346	1367	1375	B-Outcome
(	20519346	1376	1377	O
10	20519346	1377	1379	O
%	20519346	1379	1380	O
)	20519346	1380	1381	O
did	20519346	1382	1385	O
not	20519346	1386	1389	O
differ	20519346	1390	1396	O
among	20519346	1397	1402	O
groups	20519346	1403	1409	O
.	20519346	1409	1410	O

CONCLUSIONS	20519346	1412	1423	O
:	20519346	1424	1425	O
This	20519346	1426	1430	O
is	20519346	1431	1433	O
the	20519346	1434	1437	O
first	20519346	1438	1443	O
study	20519346	1444	1449	O
to	20519346	1450	1452	O
demonstrate	20519346	1453	1464	O
that	20519346	1465	1469	O
rhTSH	20519346	1470	1475	O
not	20519346	1476	1479	O
only	20519346	1480	1484	O
increases	20519346	1485	1494	O
the	20519346	1495	1498	O
thyroid	20519346	1499	1506	B-Outcome
131I	20519346	1507	1511	I-Outcome
uptake	20519346	1512	1518	I-Outcome
,	20519346	1518	1519	O
but	20519346	1520	1523	O
per	20519346	1524	1527	O
se	20519346	1528	1530	O
potentiates	20519346	1531	1542	O
the	20519346	1543	1546	O
effect	20519346	1547	1553	O
of	20519346	1554	1556	O
131I-therapy	20519346	1557	1569	O
,	20519346	1569	1570	O
allowing	20519346	1571	1579	O
a	20519346	1580	1581	O
major	20519346	1582	1587	O
reduction	20519346	1588	1597	O
of	20519346	1598	1600	O
the	20519346	1601	1604	O
131I-activity	20519346	1605	1618	B-Outcome
without	20519346	1619	1626	O
compromising	20519346	1627	1639	O
efficacy	20519346	1640	1648	B-Outcome
.	20519346	1648	1649	O

This	20519346	1650	1654	O
approach	20519346	1655	1663	O
is	20519346	1664	1666	O
attractive	20519346	1667	1677	O
in	20519346	1678	1680	O
terms	20519346	1681	1686	O
of	20519346	1687	1689	O
minimizing	20519346	1690	1700	O
posttherapeutic	20519346	1701	1716	O
restrictions	20519346	1717	1729	O
and	20519346	1730	1733	O
in	20519346	1734	1736	O
reducing	20519346	1737	1745	O
the	20519346	1746	1749	O
potential	20519346	1750	1759	O
risk	20519346	1760	1764	O
of	20519346	1765	1767	O
radiation-induced	20519346	1768	1785	O
malignancy	20519346	1786	1796	O
.	20519346	1796	1797	O


Effect	20522464	0	6	O
of	20522464	7	9	O
addition	20522464	10	18	O
of	20522464	19	21	O
single	20522464	22	28	O
dose	20522464	29	33	O
of	20522464	34	36	O
oral	20522464	37	41	O
montelukast	20522464	42	53	O
to	20522464	54	56	O
standard	20522464	57	65	O
treatment	20522464	66	75	O
in	20522464	76	78	O
acute	20522464	79	84	O
moderate	20522464	85	93	O
to	20522464	94	96	O
severe	20522464	97	103	O
asthma	20522464	104	110	O
in	20522464	111	113	O
children	20522464	114	122	O
between	20522464	123	130	O
5	20522464	131	132	O
and	20522464	133	136	O
15	20522464	137	139	O
years	20522464	140	145	O
of	20522464	146	148	O
age	20522464	149	152	O
:	20522464	152	153	O
a	20522464	154	155	O
randomised	20522464	156	166	O
,	20522464	166	167	O
double-blind	20522464	168	180	O
,	20522464	180	181	O
placebo	20522464	182	189	O
controlled	20522464	190	200	O
trial	20522464	201	206	O
.	20522464	206	207	O

OBJECTIVE	20522464	209	218	O
:	20522464	219	220	O
To	20522464	221	223	O
study	20522464	224	229	O
the	20522464	230	233	O
effect	20522464	234	240	O
of	20522464	241	243	O
the	20522464	244	247	O
addition	20522464	248	256	O
of	20522464	257	259	O
a	20522464	260	261	O
single	20522464	262	268	O
dose	20522464	269	273	O
of	20522464	274	276	O
oral	20522464	277	281	O
montelukast	20522464	282	293	O
to	20522464	294	296	O
standard	20522464	297	305	O
therapy	20522464	306	313	O
in	20522464	314	316	O
acute	20522464	317	322	O
moderate	20522464	323	331	O
to	20522464	332	334	O
severe	20522464	335	341	O
asthma	20522464	342	348	O
.	20522464	348	349	O

DESIGN	20522464	351	357	O
:	20522464	358	359	O
Double-blind	20522464	360	372	O
randomised	20522464	373	383	O
controlled	20522464	384	394	O
trial	20522464	395	400	O
.	20522464	400	401	O

Setting	20522464	402	409	O
Emergency	20522464	410	419	O
room/outpatient	20522464	420	435	O
paediatric	20522464	436	446	O
services	20522464	447	455	O
of	20522464	456	458	O
a	20522464	459	460	O
tertiary	20522464	461	469	O
care	20522464	470	474	O
hospital	20522464	475	483	O
.	20522464	483	484	O

PATIENTS	20522464	486	494	O
:	20522464	495	496	O
Children	20522464	497	505	O
aged	20522464	506	510	O
5	20522464	511	512	O
-	20522464	512	513	O
15	20522464	513	515	O
years	20522464	516	521	O
(	20522464	522	523	O
without	20522464	523	530	O
prior	20522464	531	536	O
use	20522464	537	540	O
of	20522464	541	543	O
montelukast	20522464	544	555	O
)	20522464	555	556	O
with	20522464	557	561	O
acute	20522464	562	567	O
moderate	20522464	568	576	O
to	20522464	577	579	O
severe	20522464	580	586	O
asthma	20522464	587	593	O
exacerbation	20522464	594	606	O
,	20522464	606	607	O
as	20522464	608	610	O
defined	20522464	611	618	O
using	20522464	619	624	O
Modified	20522464	625	633	O
Pulmonary	20522464	634	643	O
Index	20522464	644	649	O
Score	20522464	650	655	O
(	20522464	656	657	O
MPIS	20522464	657	661	O
)	20522464	661	662	O
>	20522464	663	664	O
or	20522464	665	667	O
=	20522464	668	669	O
9	20522464	669	670	O
,	20522464	670	671	O
were	20522464	672	676	O
enrolled	20522464	677	685	O
.	20522464	685	686	O

INTERVENTION	20522464	688	700	O
:	20522464	701	702	O
Children	20522464	703	711	O
received	20522464	712	720	O
montelukast	20522464	721	732	O
(	20522464	733	734	O
5	20522464	734	735	O
-	20522464	735	736	O
12	20522464	736	738	O
years	20522464	739	744	O
:	20522464	744	745	O
5	20522464	746	747	O
mg	20522464	748	750	O
and	20522464	751	754	O
>	20522464	755	756	O
12	20522464	756	758	O
years	20522464	759	764	O
:	20522464	764	765	O
10	20522464	766	768	O
mg	20522464	769	771	O
)	20522464	771	772	O
or	20522464	773	775	O
placebo	20522464	776	783	O
orally	20522464	784	790	O
in	20522464	791	793	O
addition	20522464	794	802	O
to	20522464	803	805	O
the	20522464	806	809	O
standard	20522464	810	818	O
therapy	20522464	819	826	O
.	20522464	826	827	O

MPIS	20522464	828	832	O
and	20522464	833	836	O
forced	20522464	837	843	O
expiratory	20522464	844	854	O
volume	20522464	855	861	O
in	20522464	862	864	O
1	20522464	865	866	O
second	20522464	867	873	O
(	20522464	874	875	O
FEV(1	20522464	875	880	O
)	20522464	880	881	O
)	20522464	881	882	O
were	20522464	883	887	O
recorded	20522464	888	896	O
before	20522464	897	903	O
administering	20522464	904	917	O
study	20522464	918	923	O
medication	20522464	924	934	O
and	20522464	935	938	O
thereafter	20522464	939	949	O
,	20522464	949	950	O
hourly	20522464	951	957	O
for	20522464	958	961	O
4	20522464	962	963	O
hours	20522464	964	969	O
.	20522464	969	970	O

MAIN	20522464	972	976	O
OUTCOME	20522464	977	984	O
MEASURES	20522464	985	993	O
:	20522464	994	995	O
The	20522464	996	999	O
primary	20522464	1000	1007	O
outcome	20522464	1008	1015	O
was	20522464	1016	1019	O
decrease	20522464	1020	1028	O
in	20522464	1029	1031	O
MPIS	20522464	1032	1036	O
to	20522464	1037	1039	O
less	20522464	1040	1044	O
than	20522464	1045	1049	O
9	20522464	1050	1051	O
at	20522464	1052	1054	O
the	20522464	1055	1058	O
end	20522464	1059	1062	O
of	20522464	1063	1065	O
4	20522464	1066	1067	O
hours	20522464	1068	1073	O
.	20522464	1073	1074	O

RESULTS	20522464	1076	1083	O
:	20522464	1084	1085	O
117	20522464	1086	1089	O
children	20522464	1090	1098	O
(	20522464	1099	1100	O
60	20522464	1100	1102	O
in	20522464	1103	1105	O
montelukast	20522464	1106	1117	O
group	20522464	1118	1123	O
and	20522464	1124	1127	O
57	20522464	1128	1130	O
in	20522464	1131	1133	O
placebo	20522464	1134	1141	O
group	20522464	1142	1147	O
)	20522464	1147	1148	O
were	20522464	1149	1153	O
enrolled	20522464	1154	1162	O
in	20522464	1163	1165	O
the	20522464	1166	1169	O
study	20522464	1170	1175	O
.	20522464	1175	1176	O

The	20522464	1177	1180	O
number	20522464	1181	1187	O
of	20522464	1188	1190	O
children	20522464	1191	1199	O
with	20522464	1200	1204	O
decrease	20522464	1205	1213	B-Outcome
in	20522464	1214	1216	I-Outcome
MPIS	20522464	1217	1221	I-Outcome
to	20522464	1222	1224	I-Outcome
less	20522464	1225	1229	I-Outcome
than	20522464	1230	1234	I-Outcome
9	20522464	1235	1236	I-Outcome
at	20522464	1237	1239	I-Outcome
4	20522464	1240	1241	I-Outcome
hours	20522464	1242	1247	I-Outcome
was	20522464	1248	1251	O
33	20522464	1252	1254	O
(	20522464	1255	1256	O
55	20522464	1256	1258	O
%	20522464	1258	1259	O
)	20522464	1259	1260	O
in	20522464	1261	1263	O
the	20522464	1264	1267	O
montelukast	20522464	1268	1279	O
group	20522464	1280	1285	O
and	20522464	1286	1289	O
36	20522464	1290	1292	O
(	20522464	1293	1294	O
63.2	20522464	1294	1298	O
%	20522464	1298	1299	O
)	20522464	1299	1300	O
in	20522464	1301	1303	O
the	20522464	1304	1307	O
placebo	20522464	1308	1315	O
group	20522464	1316	1321	O
(	20522464	1322	1323	O
p=0.37	20522464	1323	1329	O
)	20522464	1329	1330	O
.	20522464	1330	1331	O

There	20522464	1332	1337	O
was	20522464	1338	1341	O
significant	20522464	1342	1353	O
improvement	20522464	1354	1365	O
in	20522464	1366	1368	O
MPIS	20522464	1369	1373	B-Outcome
and	20522464	1374	1377	O
FEV(1	20522464	1378	1383	B-Outcome
)	20522464	1383	1384	I-Outcome
within	20522464	1385	1391	O
both	20522464	1392	1396	O
the	20522464	1397	1400	O
groups	20522464	1401	1407	O
from	20522464	1408	1412	O
baseline	20522464	1413	1421	O
to	20522464	1422	1424	O
the	20522464	1425	1428	O
end	20522464	1429	1432	O
of	20522464	1433	1435	O
4	20522464	1436	1437	O
hours	20522464	1438	1443	O
.	20522464	1443	1444	O

No	20522464	1445	1447	O
differences	20522464	1448	1459	O
in	20522464	1460	1462	O
side	20522464	1463	1467	B-Outcome
effects	20522464	1468	1475	I-Outcome
and	20522464	1476	1479	O
hospitalisation	20522464	1480	1495	B-Outcome
rates	20522464	1496	1501	I-Outcome
were	20522464	1502	1506	O
noticed	20522464	1507	1514	O
between	20522464	1515	1522	O
the	20522464	1523	1526	O
two	20522464	1527	1530	O
groups	20522464	1531	1537	O
.	20522464	1537	1538	O

CONCLUSION	20522464	1540	1550	O
:	20522464	1551	1552	O
Single	20522464	1553	1559	O
dose	20522464	1560	1564	O
oral	20522464	1565	1569	O
montelukast	20522464	1570	1581	O
added	20522464	1582	1587	O
to	20522464	1588	1590	O
standard	20522464	1591	1599	O
therapy	20522464	1600	1607	O
of	20522464	1608	1610	O
inhaled	20522464	1611	1618	O
bronchodilators	20522464	1619	1634	O
and	20522464	1635	1638	O
systemic	20522464	1639	1647	O
glucocorticoids	20522464	1648	1663	O
did	20522464	1664	1667	O
not	20522464	1668	1671	O
provide	20522464	1672	1679	O
additional	20522464	1680	1690	O
clinical	20522464	1691	1699	B-Outcome
benefit	20522464	1700	1707	I-Outcome
in	20522464	1708	1710	O
children	20522464	1711	1719	O
with	20522464	1720	1724	O
acute	20522464	1725	1730	O
moderate	20522464	1731	1739	O
to	20522464	1740	1742	O
severe	20522464	1743	1749	O
asthma	20522464	1750	1756	O
.	20522464	1756	1757	O

Trial	20522464	1758	1763	O
registration	20522464	1764	1776	O
number	20522464	1777	1783	O
The	20522464	1784	1787	O
trial	20522464	1788	1793	O
was	20522464	1794	1797	O
registered	20522464	1798	1808	O
at	20522464	1809	1811	O
the	20522464	1812	1815	O
http://clinicaltrials.gov	20522464	1816	1841	O
site	20522464	1842	1846	O
(	20522464	1847	1848	O
trial	20522464	1848	1853	O
ID	20522464	1854	1856	O
:	20522464	1856	1857	O
NCT00565955	20522464	1858	1869	O
)	20522464	1869	1870	O
.	20522464	1870	1871	O


Alvimopan	20526599	0	9	O
for	20526599	10	13	O
the	20526599	14	17	O
management	20526599	18	28	O
of	20526599	29	31	O
postoperative	20526599	32	45	O
ileus	20526599	46	51	O
after	20526599	52	57	O
bowel	20526599	58	63	O
resection	20526599	64	73	O
:	20526599	73	74	O
characterization	20526599	75	91	O
of	20526599	92	94	O
clinical	20526599	95	103	O
benefit	20526599	104	111	O
by	20526599	112	114	O
pooled	20526599	115	121	O
responder	20526599	122	131	O
analysis	20526599	132	140	O
.	20526599	140	141	O

BACKGROUND	20526599	143	153	O
:	20526599	154	155	O
A	20526599	156	157	O
pooled	20526599	158	164	O
post	20526599	165	169	O
hoc	20526599	170	173	O
responder	20526599	174	183	O
analysis	20526599	184	192	O
was	20526599	193	196	O
performed	20526599	197	206	O
to	20526599	207	209	O
assess	20526599	210	216	O
the	20526599	217	220	O
clinical	20526599	221	229	O
benefit	20526599	230	237	O
of	20526599	238	240	O
alvimopan	20526599	241	250	O
,	20526599	250	251	O
a	20526599	252	253	O
peripherally	20526599	254	266	O
acting	20526599	267	273	O
mu-opioid	20526599	274	283	O
receptor	20526599	284	292	O
(	20526599	293	294	O
PAM-OR	20526599	294	300	O
)	20526599	300	301	O
antagonist	20526599	302	312	O
,	20526599	312	313	O
for	20526599	314	317	O
the	20526599	318	321	O
management	20526599	322	332	O
of	20526599	333	335	O
postoperative	20526599	336	349	O
ileus	20526599	350	355	O
after	20526599	356	361	O
bowel	20526599	362	367	O
resection	20526599	368	377	O
.	20526599	377	378	O

METHODS	20526599	380	387	O
:	20526599	388	389	O
Adult	20526599	390	395	O
patients	20526599	396	404	O
who	20526599	405	408	O
underwent	20526599	409	418	O
laparotomy	20526599	419	429	O
for	20526599	430	433	O
bowel	20526599	434	439	O
resection	20526599	440	449	O
scheduled	20526599	450	459	O
for	20526599	460	463	O
opioid-based	20526599	464	476	O
intravenous	20526599	477	488	O
patient-controlled	20526599	489	507	O
analgesia	20526599	508	517	O
received	20526599	518	526	O
oral	20526599	527	531	O
alvimopan	20526599	532	541	O
or	20526599	542	544	O
placebo	20526599	545	552	O
preoperatively	20526599	553	567	O
and	20526599	568	571	O
twice	20526599	572	577	O
daily	20526599	578	583	O
postoperatively	20526599	584	599	O
until	20526599	600	605	O
hospital	20526599	606	614	O
discharge	20526599	615	624	O
or	20526599	625	627	O
for	20526599	628	631	O
7	20526599	632	633	O
postoperative	20526599	634	647	O
days	20526599	648	652	O
.	20526599	652	653	O

The	20526599	654	657	O
proportion	20526599	658	668	O
of	20526599	669	671	O
responders	20526599	672	682	O
and	20526599	683	686	O
numbers	20526599	687	694	O
needed	20526599	695	701	O
to	20526599	702	704	O
treat	20526599	705	710	O
(	20526599	711	712	O
NNT	20526599	712	715	O
)	20526599	715	716	O
were	20526599	717	721	O
examined	20526599	722	730	O
on	20526599	731	733	O
postoperative	20526599	734	747	O
days	20526599	748	752	O
(	20526599	753	754	O
POD	20526599	754	757	O
)	20526599	757	758	O
3	20526599	759	760	O
-	20526599	760	761	O
8	20526599	761	762	O
for	20526599	763	766	O
GI-2	20526599	767	771	O
recovery	20526599	772	780	O
(	20526599	781	782	O
first	20526599	782	787	O
bowel	20526599	788	793	O
movement	20526599	794	802	O
,	20526599	802	803	O
toleration	20526599	804	814	O
of	20526599	815	817	O
solid	20526599	818	823	O
food	20526599	824	828	O
)	20526599	828	829	O
and	20526599	830	833	O
hospital	20526599	834	842	O
discharge	20526599	843	852	O
order	20526599	853	858	O
(	20526599	859	860	O
DCO	20526599	860	863	O
)	20526599	863	864	O
written	20526599	865	872	O
.	20526599	872	873	O

RESULTS	20526599	875	882	O
:	20526599	883	884	O
Alvimopan	20526599	885	894	O
significantly	20526599	895	908	O
increased	20526599	909	918	O
the	20526599	919	922	O
proportion	20526599	923	933	B-Outcome
of	20526599	934	936	I-Outcome
patients	20526599	937	945	I-Outcome
with	20526599	946	950	I-Outcome
GI-2	20526599	951	955	I-Outcome
recovery	20526599	956	964	I-Outcome
and	20526599	965	968	O
DCO	20526599	969	972	B-Outcome
written	20526599	973	980	I-Outcome
by	20526599	981	983	O
each	20526599	984	988	O
POD	20526599	989	992	O
(	20526599	993	994	O
P	20526599	994	995	O
<	20526599	996	997	O
0.001	20526599	998	1003	O
for	20526599	1004	1007	O
all	20526599	1008	1011	O
)	20526599	1011	1012	O
.	20526599	1012	1013	O

More	20526599	1014	1018	O
patients	20526599	1019	1027	O
who	20526599	1028	1031	O
received	20526599	1032	1040	O
alvimopan	20526599	1041	1050	O
achieved	20526599	1051	1059	O
GI-2	20526599	1060	1064	B-Outcome
recovery	20526599	1065	1073	I-Outcome
on	20526599	1074	1076	O
or	20526599	1077	1079	O
before	20526599	1080	1086	O
POD	20526599	1087	1090	O
5	20526599	1091	1092	O
(	20526599	1093	1094	O
alvimopan	20526599	1094	1103	O
,	20526599	1103	1104	O
80	20526599	1105	1107	O
%	20526599	1107	1108	O
;	20526599	1108	1109	O
placebo	20526599	1110	1117	O
,	20526599	1117	1118	O
66	20526599	1119	1121	O
%	20526599	1121	1122	O
)	20526599	1122	1123	O
and	20526599	1124	1127	O
DCO	20526599	1128	1131	B-Outcome
written	20526599	1132	1139	I-Outcome
before	20526599	1140	1146	O
POD	20526599	1147	1150	O
7	20526599	1151	1152	O
(	20526599	1153	1154	O
alvimopan	20526599	1154	1163	O
,	20526599	1163	1164	O
87	20526599	1165	1167	O
%	20526599	1167	1168	O
;	20526599	1168	1169	O
placebo	20526599	1170	1177	O
,	20526599	1177	1178	O
72	20526599	1179	1181	O
%	20526599	1181	1182	O
)	20526599	1182	1183	O
,	20526599	1183	1184	O
with	20526599	1185	1189	O
corresponding	20526599	1190	1203	O
NNTs	20526599	1204	1208	B-Outcome
equal	20526599	1209	1214	O
to	20526599	1215	1217	O
7	20526599	1218	1219	O
.	20526599	1219	1220	O

CONCLUSIONS	20526599	1222	1233	O
:	20526599	1234	1235	O
On	20526599	1236	1238	O
each	20526599	1239	1243	O
POD	20526599	1244	1247	O
analyzed	20526599	1248	1256	O
,	20526599	1256	1257	O
alvimopan	20526599	1258	1267	O
significantly	20526599	1268	1281	O
increased	20526599	1282	1291	O
the	20526599	1292	1295	O
proportion	20526599	1296	1306	B-Outcome
of	20526599	1307	1309	I-Outcome
patients	20526599	1310	1318	I-Outcome
who	20526599	1319	1322	I-Outcome
achieved	20526599	1323	1331	I-Outcome
GI-2	20526599	1332	1336	I-Outcome
recovery	20526599	1337	1345	I-Outcome
and	20526599	1346	1349	O
DCO	20526599	1350	1353	B-Outcome
written	20526599	1354	1361	I-Outcome
versus	20526599	1362	1368	O
placebo	20526599	1369	1376	O
and	20526599	1377	1380	O
was	20526599	1381	1384	O
associated	20526599	1385	1395	O
with	20526599	1396	1400	O
relatively	20526599	1401	1411	O
low	20526599	1412	1415	O
NNTs	20526599	1416	1420	B-Outcome
.	20526599	1420	1421	O

The	20526599	1422	1425	O
results	20526599	1426	1433	O
of	20526599	1434	1436	O
these	20526599	1437	1442	O
analyses	20526599	1443	1451	O
provide	20526599	1452	1459	O
additional	20526599	1460	1470	O
characterization	20526599	1471	1487	O
and	20526599	1488	1491	O
support	20526599	1492	1499	O
for	20526599	1500	1503	O
the	20526599	1504	1507	O
overall	20526599	1508	1515	B-Outcome
clinical	20526599	1516	1524	I-Outcome
benefit	20526599	1525	1532	I-Outcome
of	20526599	1533	1535	O
alvimopan	20526599	1536	1545	O
in	20526599	1546	1548	O
patients	20526599	1549	1557	O
undergoing	20526599	1558	1568	O
bowel	20526599	1569	1574	O
resection	20526599	1575	1584	O
.	20526599	1584	1585	O


Predictors	20646286	0	10	O
of	20646286	11	13	O
stable	20646286	14	20	O
return-to-work	20646286	21	35	O
in	20646286	36	38	O
non-acute	20646286	39	48	O
,	20646286	48	49	O
non-specific	20646286	50	62	O
spinal	20646286	63	69	O
pain	20646286	70	74	O
:	20646286	74	75	O
low	20646286	76	79	O
total	20646286	80	85	O
prior	20646286	86	91	O
sick-listing	20646286	92	104	O
,	20646286	104	105	O
high	20646286	106	110	O
self	20646286	111	115	O
prediction	20646286	116	126	O
and	20646286	127	130	O
young	20646286	131	136	O
age	20646286	137	140	O
.	20646286	140	141	O

A	20646286	142	143	O
two-year	20646286	144	152	O
prospective	20646286	153	164	O
cohort	20646286	165	171	O
study	20646286	172	177	O
.	20646286	177	178	O

BACKGROUND	20646286	180	190	O
:	20646286	191	192	O
Non-specific	20646286	193	205	O
spinal	20646286	206	212	O
pain	20646286	213	217	O
(	20646286	218	219	O
NSP	20646286	219	222	O
)	20646286	222	223	O
,	20646286	223	224	O
comprising	20646286	225	235	O
back	20646286	236	240	O
and/or	20646286	241	247	O
neck	20646286	248	252	O
pain	20646286	253	257	O
,	20646286	257	258	O
is	20646286	259	261	O
one	20646286	262	265	O
of	20646286	266	268	O
the	20646286	269	272	O
leading	20646286	273	280	O
disorders	20646286	281	290	O
in	20646286	291	293	O
long-term	20646286	294	303	O
sick-listing	20646286	304	316	O
.	20646286	316	317	O

During	20646286	318	324	O
2000	20646286	325	329	O
-	20646286	329	330	O
2004	20646286	330	334	O
,	20646286	334	335	O
125	20646286	336	339	O
Swedish	20646286	340	347	O
primary-care	20646286	348	360	O
patients	20646286	361	369	O
with	20646286	370	374	O
non-acute	20646286	375	384	O
NSP	20646286	385	388	O
,	20646286	388	389	O
full-time	20646286	390	399	O
sick-listed	20646286	400	411	O
6	20646286	412	413	O
weeks-2	20646286	414	421	O
years	20646286	422	427	O
,	20646286	427	428	O
were	20646286	429	433	O
included	20646286	434	442	O
in	20646286	443	445	O
a	20646286	446	447	O
randomized	20646286	448	458	O
controlled	20646286	459	469	O
trial	20646286	470	475	O
to	20646286	476	478	O
compare	20646286	479	486	O
a	20646286	487	488	O
cognitive-behavioural	20646286	489	510	O
programme	20646286	511	520	O
with	20646286	521	525	O
traditional	20646286	526	537	O
primary	20646286	538	545	O
care	20646286	546	550	O
.	20646286	550	551	O

This	20646286	552	556	O
prospective	20646286	557	568	O
cohort	20646286	569	575	O
study	20646286	576	581	O
is	20646286	582	584	O
a	20646286	585	586	O
re-assessment	20646286	587	600	O
of	20646286	601	603	O
the	20646286	604	607	O
data	20646286	608	612	O
from	20646286	613	617	O
the	20646286	618	621	O
randomized	20646286	622	632	O
trial	20646286	633	638	O
with	20646286	639	643	O
the	20646286	644	647	O
2	20646286	648	649	O
treatment	20646286	650	659	O
groups	20646286	660	666	O
considered	20646286	667	677	O
as	20646286	678	680	O
a	20646286	681	682	O
single	20646286	683	689	O
cohort	20646286	690	696	O
.	20646286	696	697	O

The	20646286	698	701	O
aim	20646286	702	705	O
was	20646286	706	709	O
to	20646286	710	712	O
investigate	20646286	713	724	O
which	20646286	725	730	O
baseline	20646286	731	739	O
variables	20646286	740	749	O
predict	20646286	750	757	O
a	20646286	758	759	O
stable	20646286	760	766	O
return-to-work	20646286	767	781	O
during	20646286	782	788	O
a	20646286	789	790	O
2-year	20646286	791	797	O
period	20646286	798	804	O
after	20646286	805	810	O
baseline	20646286	811	819	O
:	20646286	819	820	O
objective	20646286	821	830	O
variables	20646286	831	840	O
from	20646286	841	845	O
function	20646286	846	854	O
tests	20646286	855	860	O
,	20646286	860	861	O
socioeconomic	20646286	862	875	O
,	20646286	875	876	O
subjective	20646286	877	887	O
and/or	20646286	888	894	O
treatment	20646286	895	904	O
variables	20646286	905	914	O
.	20646286	914	915	O

Stable	20646286	916	922	O
return-to-work	20646286	923	937	O
was	20646286	938	941	O
a	20646286	942	943	O
return-to-work	20646286	944	958	O
lasting	20646286	959	966	O
for	20646286	967	970	O
at	20646286	971	973	O
least	20646286	974	979	O
1	20646286	980	981	O
month	20646286	982	987	O
from	20646286	988	992	O
the	20646286	993	996	O
start	20646286	997	1002	O
of	20646286	1003	1005	O
follow-up	20646286	1006	1015	O
.	20646286	1015	1016	O

METHODS	20646286	1018	1025	O
:	20646286	1026	1027	O
Stable	20646286	1028	1034	O
return-to-work	20646286	1035	1049	O
was	20646286	1050	1053	O
the	20646286	1054	1057	O
outcome	20646286	1058	1065	O
variable	20646286	1066	1074	O
,	20646286	1074	1075	O
the	20646286	1076	1079	O
above-mentioned	20646286	1080	1095	O
factors	20646286	1096	1103	O
were	20646286	1104	1108	O
the	20646286	1109	1112	O
predictive	20646286	1113	1123	O
variables	20646286	1124	1133	O
in	20646286	1134	1136	O
multiple-logistic	20646286	1137	1154	O
regression	20646286	1155	1165	O
models	20646286	1166	1172	O
,	20646286	1172	1173	O
one	20646286	1174	1177	O
per	20646286	1178	1181	O
follow-up	20646286	1182	1191	O
at	20646286	1192	1194	O
6	20646286	1195	1196	O
,	20646286	1196	1197	O
12	20646286	1198	1200	O
,	20646286	1200	1201	O
18	20646286	1202	1204	O
and	20646286	1205	1208	O
24	20646286	1209	1211	O
months	20646286	1212	1218	O
after	20646286	1219	1224	O
baseline	20646286	1225	1233	O
.	20646286	1233	1234	O

The	20646286	1235	1238	O
factors	20646286	1239	1246	O
from	20646286	1247	1251	O
univariate	20646286	1252	1262	O
analyzes	20646286	1263	1271	O
with	20646286	1272	1276	O
a	20646286	1277	1278	O
p-value	20646286	1279	1286	O
of	20646286	1287	1289	O
at	20646286	1290	1292	O
most	20646286	1293	1297	O
.10	20646286	1298	1301	O
were	20646286	1302	1306	O
included	20646286	1307	1315	O
.	20646286	1315	1316	O

The	20646286	1317	1320	O
non-significant	20646286	1321	1336	O
variables	20646286	1337	1346	O
were	20646286	1347	1351	O
excluded	20646286	1352	1360	O
stepwise	20646286	1361	1369	O
to	20646286	1370	1372	O
yield	20646286	1373	1378	O
models	20646286	1379	1385	O
comprising	20646286	1386	1396	O
only	20646286	1397	1401	O
significant	20646286	1402	1413	O
factors	20646286	1414	1421	O
(	20646286	1422	1423	O
p	20646286	1423	1424	O
<	20646286	1425	1426	O
.05	20646286	1427	1430	O
)	20646286	1430	1431	O
.	20646286	1431	1432	O

As	20646286	1433	1435	O
the	20646286	1436	1439	O
comparatively	20646286	1440	1453	O
few	20646286	1454	1457	O
cases	20646286	1458	1463	O
made	20646286	1464	1468	O
it	20646286	1469	1471	O
risky	20646286	1472	1477	O
to	20646286	1478	1480	O
associate	20646286	1481	1490	O
certain	20646286	1491	1498	O
predictors	20646286	1499	1509	O
with	20646286	1510	1514	O
certain	20646286	1515	1522	O
time-points	20646286	1523	1534	O
,	20646286	1534	1535	O
we	20646286	1536	1538	O
finally	20646286	1539	1546	O
considered	20646286	1547	1557	O
the	20646286	1558	1561	O
predictors	20646286	1562	1572	O
which	20646286	1573	1578	O
were	20646286	1579	1583	O
represented	20646286	1584	1595	O
in	20646286	1596	1598	O
at	20646286	1599	1601	O
least	20646286	1602	1607	O
3	20646286	1608	1609	O
follow-ups	20646286	1610	1620	O
.	20646286	1620	1621	O

They	20646286	1622	1626	O
are	20646286	1627	1630	O
presented	20646286	1631	1640	O
with	20646286	1641	1645	O
odds	20646286	1646	1650	O
ratios	20646286	1651	1657	O
(	20646286	1658	1659	O
OR	20646286	1659	1661	O
)	20646286	1661	1662	O
and	20646286	1663	1666	O
95	20646286	1667	1669	O
%	20646286	1669	1670	O
confidence	20646286	1671	1681	O
intervals	20646286	1682	1691	O
.	20646286	1691	1692	O

RESULTS	20646286	1694	1701	O
:	20646286	1702	1703	O
Three	20646286	1704	1709	O
variables	20646286	1710	1719	O
qualified	20646286	1720	1729	O
,	20646286	1729	1730	O
all	20646286	1731	1734	O
of	20646286	1735	1737	O
them	20646286	1738	1742	O
represented	20646286	1743	1754	O
in	20646286	1755	1757	O
3	20646286	1758	1759	O
follow-ups	20646286	1760	1770	O
:	20646286	1770	1771	O
Low	20646286	1772	1775	O
total	20646286	1776	1781	B-Outcome
prior	20646286	1782	1787	I-Outcome
sick-listing	20646286	1788	1800	I-Outcome
(	20646286	1801	1802	O
including	20646286	1802	1811	O
all	20646286	1812	1815	O
diagnoses	20646286	1816	1825	O
)	20646286	1825	1826	O
was	20646286	1827	1830	O
the	20646286	1831	1834	O
strongest	20646286	1835	1844	O
predictor	20646286	1845	1854	O
in	20646286	1855	1857	O
2	20646286	1858	1859	O
follow-ups	20646286	1860	1870	O
,	20646286	1870	1871	O
18	20646286	1872	1874	O
and	20646286	1875	1878	O
24	20646286	1879	1881	O
months	20646286	1882	1888	O
,	20646286	1888	1889	O
OR	20646286	1890	1892	O
4.8	20646286	1893	1896	O
[	20646286	1897	1898	O
1.9	20646286	1898	1901	O
-	20646286	1901	1902	O
12.3	20646286	1902	1906	O
]	20646286	1906	1907	O
and	20646286	1908	1911	O
3.8	20646286	1912	1915	O
[	20646286	1916	1917	O
1.6	20646286	1917	1920	O
-	20646286	1920	1921	O
8.7	20646286	1921	1924	O
]	20646286	1924	1925	O
respectively	20646286	1926	1938	O
,	20646286	1938	1939	O
High	20646286	1940	1944	O
self	20646286	1945	1949	B-Outcome
prediction	20646286	1950	1960	I-Outcome
(	20646286	1961	1962	I-Outcome
the	20646286	1962	1965	I-Outcome
patients	20646286	1966	1974	I-Outcome
'	20646286	1974	1975	I-Outcome
own	20646286	1976	1979	I-Outcome
belief	20646286	1980	1986	I-Outcome
in	20646286	1987	1989	I-Outcome
return-to-work	20646286	1990	2004	I-Outcome
)	20646286	2004	2005	I-Outcome
was	20646286	2006	2009	O
the	20646286	2010	2013	O
strongest	20646286	2014	2023	O
at	20646286	2024	2026	O
12	20646286	2027	2029	O
months	20646286	2030	2036	O
,	20646286	2036	2037	O
OR	20646286	2038	2040	O
5.2	20646286	2041	2044	O
[	20646286	2045	2046	O
1.5	20646286	2046	2049	O
-	20646286	2049	2050	O
17.5	20646286	2050	2054	O
]	20646286	2054	2055	O
and	20646286	2056	2059	O
Young	20646286	2060	2065	B-Outcome
age	20646286	2066	2069	I-Outcome
(	20646286	2070	2071	I-Outcome
max	20646286	2071	2074	I-Outcome
44	20646286	2075	2077	I-Outcome
years	20646286	2078	2083	I-Outcome
)	20646286	2083	2084	I-Outcome
the	20646286	2085	2088	O
second	20646286	2089	2095	O
strongest	20646286	2096	2105	O
at	20646286	2106	2108	O
18	20646286	2109	2111	O
months	20646286	2112	2118	O
,	20646286	2118	2119	O
OR	20646286	2120	2122	O
3.5	20646286	2123	2126	O
[	20646286	2127	2128	O
1.3	20646286	2128	2131	O
-	20646286	2131	2132	O
9.1	20646286	2132	2135	O
]	20646286	2135	2136	O
.	20646286	2136	2137	O

CONCLUSIONS	20646286	2139	2150	O
:	20646286	2151	2152	O
In	20646286	2153	2155	O
primary-care	20646286	2156	2168	O
patients	20646286	2169	2177	O
with	20646286	2178	2182	O
non-acute	20646286	2183	2192	O
NSP	20646286	2193	2196	O
,	20646286	2196	2197	O
the	20646286	2198	2201	O
strong	20646286	2202	2208	O
predictors	20646286	2209	2219	O
of	20646286	2220	2222	O
stable	20646286	2223	2229	O
return-to-work	20646286	2230	2244	O
were	20646286	2245	2249	O
2	20646286	2250	2251	O
socioeconomic	20646286	2252	2265	O
variables	20646286	2266	2275	O
,	20646286	2275	2276	O
Low	20646286	2277	2280	O
total	20646286	2281	2286	B-Outcome
prior	20646286	2287	2292	I-Outcome
sick-listing	20646286	2293	2305	I-Outcome
and	20646286	2306	2309	O
Young	20646286	2310	2315	B-Outcome
age	20646286	2316	2319	I-Outcome
,	20646286	2319	2320	O
and	20646286	2321	2324	O
1	20646286	2325	2326	O
subjective	20646286	2327	2337	O
variable	20646286	2338	2346	O
,	20646286	2346	2347	O
High	20646286	2348	2352	O
self-prediction	20646286	2353	2368	B-Outcome
.	20646286	2368	2369	O

Objective	20646286	2370	2379	O
variables	20646286	2380	2389	O
from	20646286	2390	2394	O
function	20646286	2395	2403	O
tests	20646286	2404	2409	O
and	20646286	2410	2413	O
treatment	20646286	2414	2423	O
variables	20646286	2424	2433	O
were	20646286	2434	2438	O
non-predictors	20646286	2439	2453	O
.	20646286	2453	2454	O

Except	20646286	2455	2461	O
for	20646286	2462	2465	O
Young	20646286	2466	2471	B-Outcome
age	20646286	2472	2475	I-Outcome
,	20646286	2475	2476	O
the	20646286	2477	2480	O
predictors	20646286	2481	2491	O
have	20646286	2492	2496	O
previously	20646286	2497	2507	O
been	20646286	2508	2512	O
insufficiently	20646286	2513	2527	O
studied	20646286	2528	2535	O
,	20646286	2535	2536	O
and	20646286	2537	2540	O
so	20646286	2541	2543	O
our	20646286	2544	2547	O
study	20646286	2548	2553	O
should	20646286	2554	2560	O
widen	20646286	2561	2566	O
knowledge	20646286	2567	2576	O
within	20646286	2577	2583	O
clinical	20646286	2584	2592	O
practice	20646286	2593	2601	O
.	20646286	2601	2602	O


Denosumab	21060033	0	9	O
compared	21060033	10	18	O
with	21060033	19	23	O
zoledronic	21060033	24	34	O
acid	21060033	35	39	O
for	21060033	40	43	O
the	21060033	44	47	O
treatment	21060033	48	57	O
of	21060033	58	60	O
bone	21060033	61	65	O
metastases	21060033	66	76	O
in	21060033	77	79	O
patients	21060033	80	88	O
with	21060033	89	93	O
advanced	21060033	94	102	O
breast	21060033	103	109	O
cancer	21060033	110	116	O
:	21060033	116	117	O
a	21060033	118	119	O
randomized	21060033	120	130	O
,	21060033	130	131	O
double-blind	21060033	132	144	O
study	21060033	145	150	O
.	21060033	150	151	O

PURPOSE	21060033	153	160	O
:	21060033	161	162	O
This	21060033	163	167	O
randomized	21060033	168	178	O
study	21060033	179	184	O
compared	21060033	185	193	O
denosumab	21060033	194	203	O
,	21060033	203	204	O
a	21060033	205	206	O
fully	21060033	207	212	O
human	21060033	213	218	O
monoclonal	21060033	219	229	O
antibody	21060033	230	238	O
against	21060033	239	246	O
receptor	21060033	247	255	O
activator	21060033	256	265	O
of	21060033	266	268	O
nuclear	21060033	269	276	O
factor	21060033	277	283	O
κ	21060033	284	285	O
B	21060033	286	287	O
(	21060033	288	289	O
RANK	21060033	289	293	O
)	21060033	293	294	O
ligand	21060033	295	301	O
,	21060033	301	302	O
with	21060033	303	307	O
zoledronic	21060033	308	318	O
acid	21060033	319	323	O
in	21060033	324	326	O
delaying	21060033	327	335	O
or	21060033	336	338	O
preventing	21060033	339	349	O
skeletal-related	21060033	350	366	O
events	21060033	367	373	O
(	21060033	374	375	O
SREs	21060033	375	379	O
)	21060033	379	380	O
in	21060033	381	383	O
patients	21060033	384	392	O
with	21060033	393	397	O
breast	21060033	398	404	O
cancer	21060033	405	411	O
with	21060033	412	416	O
bone	21060033	417	421	O
metastases	21060033	422	432	O
.	21060033	432	433	O

PATIENTS	21060033	435	443	O
AND	21060033	444	447	O
METHODS	21060033	448	455	O
:	21060033	456	457	O
Patients	21060033	458	466	O
were	21060033	467	471	O
randomly	21060033	472	480	O
assigned	21060033	481	489	O
to	21060033	490	492	O
receive	21060033	493	500	O
either	21060033	501	507	O
subcutaneous	21060033	508	520	O
denosumab	21060033	521	530	O
120	21060033	531	534	O
mg	21060033	535	537	O
and	21060033	538	541	O
intravenous	21060033	542	553	O
placebo	21060033	554	561	O
(	21060033	562	563	O
n	21060033	563	564	O
=	21060033	565	566	O
1,026	21060033	567	572	O
)	21060033	572	573	O
or	21060033	574	576	O
intravenous	21060033	577	588	O
zoledronic	21060033	589	599	O
acid	21060033	600	604	O
4	21060033	605	606	O
mg	21060033	607	609	O
adjusted	21060033	610	618	O
for	21060033	619	622	O
creatinine	21060033	623	633	O
clearance	21060033	634	643	O
and	21060033	644	647	O
subcutaneous	21060033	648	660	O
placebo	21060033	661	668	O
(	21060033	669	670	O
n	21060033	670	671	O
=	21060033	672	673	O
1,020	21060033	674	679	O
)	21060033	679	680	O
every	21060033	681	686	O
4	21060033	687	688	O
weeks	21060033	689	694	O
.	21060033	694	695	O

All	21060033	696	699	O
patients	21060033	700	708	O
were	21060033	709	713	O
strongly	21060033	714	722	O
recommended	21060033	723	734	O
to	21060033	735	737	O
take	21060033	738	742	O
daily	21060033	743	748	O
calcium	21060033	749	756	O
and	21060033	757	760	O
vitamin	21060033	761	768	O
D	21060033	769	770	O
supplements	21060033	771	782	O
.	21060033	782	783	O

The	21060033	784	787	O
primary	21060033	788	795	O
end	21060033	796	799	O
point	21060033	800	805	O
was	21060033	806	809	O
time	21060033	810	814	O
to	21060033	815	817	O
first	21060033	818	823	O
on-study	21060033	824	832	O
SRE	21060033	833	836	O
(	21060033	837	838	O
defined	21060033	838	845	O
as	21060033	846	848	O
pathologic	21060033	849	859	O
fracture	21060033	860	868	O
,	21060033	868	869	O
radiation	21060033	870	879	O
or	21060033	880	882	O
surgery	21060033	883	890	O
to	21060033	891	893	O
bone	21060033	894	898	O
,	21060033	898	899	O
or	21060033	900	902	O
spinal	21060033	903	909	O
cord	21060033	910	914	O
compression	21060033	915	926	O
)	21060033	926	927	O
.	21060033	927	928	O

RESULTS	21060033	930	937	O
:	21060033	938	939	O
Denosumab	21060033	940	949	O
was	21060033	950	953	O
superior	21060033	954	962	O
to	21060033	963	965	O
zoledronic	21060033	966	976	O
acid	21060033	977	981	O
in	21060033	982	984	O
delaying	21060033	985	993	O
time	21060033	994	998	B-Outcome
to	21060033	999	1001	I-Outcome
first	21060033	1002	1007	I-Outcome
on-study	21060033	1008	1016	I-Outcome
SRE	21060033	1017	1020	I-Outcome
(	21060033	1021	1022	O
hazard	21060033	1022	1028	O
ratio	21060033	1029	1034	O
,	21060033	1034	1035	O
0.82	21060033	1036	1040	O
;	21060033	1040	1041	O
95	21060033	1042	1044	O
%	21060033	1044	1045	O
CI	21060033	1046	1048	O
,	21060033	1048	1049	O
0.71	21060033	1050	1054	O
to	21060033	1055	1057	O
0.95	21060033	1058	1062	O
;	21060033	1062	1063	O
P	21060033	1064	1065	O
=	21060033	1066	1067	O
.01	21060033	1068	1071	O
superiority	21060033	1072	1083	O
)	21060033	1083	1084	O
and	21060033	1085	1088	O
time	21060033	1089	1093	B-Outcome
to	21060033	1094	1096	I-Outcome
first	21060033	1097	1102	I-Outcome
and	21060033	1103	1106	I-Outcome
subsequent	21060033	1107	1117	I-Outcome
(	21060033	1118	1119	I-Outcome
multiple	21060033	1119	1127	I-Outcome
)	21060033	1127	1128	I-Outcome
on-study	21060033	1129	1137	I-Outcome
SREs	21060033	1138	1142	I-Outcome
(	21060033	1143	1144	O
rate	21060033	1144	1148	O
ratio	21060033	1149	1154	O
,	21060033	1154	1155	O
0.77	21060033	1156	1160	O
;	21060033	1160	1161	O
95	21060033	1162	1164	O
%	21060033	1164	1165	O
CI	21060033	1166	1168	O
,	21060033	1168	1169	O
0.66	21060033	1170	1174	O
to	21060033	1175	1177	O
0.89	21060033	1178	1182	O
;	21060033	1182	1183	O
P	21060033	1184	1185	O
=	21060033	1186	1187	O
.001	21060033	1188	1192	O
)	21060033	1192	1193	O
.	21060033	1193	1194	O

Reduction	21060033	1195	1204	O
in	21060033	1205	1207	O
bone	21060033	1208	1212	B-Outcome
turnover	21060033	1213	1221	I-Outcome
markers	21060033	1222	1229	I-Outcome
was	21060033	1230	1233	O
greater	21060033	1234	1241	O
with	21060033	1242	1246	O
denosumab	21060033	1247	1256	O
.	21060033	1256	1257	O

Overall	21060033	1258	1265	B-Outcome
survival	21060033	1266	1274	I-Outcome
,	21060033	1274	1275	O
disease	21060033	1276	1283	B-Outcome
progression	21060033	1284	1295	I-Outcome
,	21060033	1295	1296	O
and	21060033	1297	1300	O
rates	21060033	1301	1306	O
of	21060033	1307	1309	O
adverse	21060033	1310	1317	B-Outcome
events	21060033	1318	1324	I-Outcome
(	21060033	1325	1326	O
AEs	21060033	1326	1329	B-Outcome
)	21060033	1329	1330	O
and	21060033	1331	1334	O
serious	21060033	1335	1342	B-Outcome
AEs	21060033	1343	1346	I-Outcome
were	21060033	1347	1351	O
similar	21060033	1352	1359	O
between	21060033	1360	1367	O
groups	21060033	1368	1374	O
.	21060033	1374	1375	O

An	21060033	1376	1378	O
excess	21060033	1379	1385	O
of	21060033	1386	1388	O
renal	21060033	1389	1394	B-Outcome
AEs	21060033	1395	1398	I-Outcome
and	21060033	1399	1402	O
acute-phase	21060033	1403	1414	B-Outcome
reactions	21060033	1415	1424	I-Outcome
occurred	21060033	1425	1433	O
with	21060033	1434	1438	O
zoledronic	21060033	1439	1449	O
acid	21060033	1450	1454	O
;	21060033	1454	1455	O
hypocalcemia	21060033	1456	1468	O
occurred	21060033	1469	1477	O
more	21060033	1478	1482	O
frequently	21060033	1483	1493	O
with	21060033	1494	1498	O
denosumab	21060033	1499	1508	O
.	21060033	1508	1509	O

Osteonecrosis	21060033	1510	1523	O
of	21060033	1524	1526	O
the	21060033	1527	1530	O
jaw	21060033	1531	1534	O
occurred	21060033	1535	1543	O
infrequently	21060033	1544	1556	O
(	21060033	1557	1558	O
2.0	21060033	1558	1561	O
%	21060033	1561	1562	O
,	21060033	1562	1563	O
denosumab	21060033	1564	1573	O
;	21060033	1573	1574	O
1.4	21060033	1575	1578	O
%	21060033	1578	1579	O
,	21060033	1579	1580	O
zoledronic	21060033	1581	1591	O
acid	21060033	1592	1596	O
;	21060033	1596	1597	O
P	21060033	1598	1599	O
=	21060033	1600	1601	O
.39	21060033	1602	1605	O
)	21060033	1605	1606	O
.	21060033	1606	1607	O

CONCLUSION	21060033	1609	1619	O
:	21060033	1620	1621	O
Denosumab	21060033	1622	1631	O
was	21060033	1632	1635	O
superior	21060033	1636	1644	O
to	21060033	1645	1647	O
zoledronic	21060033	1648	1658	O
acid	21060033	1659	1663	O
in	21060033	1664	1666	O
delaying	21060033	1667	1675	O
or	21060033	1676	1678	O
preventing	21060033	1679	1689	O
SREs	21060033	1690	1694	B-Outcome
in	21060033	1695	1697	O
patients	21060033	1698	1706	O
with	21060033	1707	1711	O
breast	21060033	1712	1718	O
cancer	21060033	1719	1725	O
metastatic	21060033	1726	1736	O
to	21060033	1737	1739	O
bone	21060033	1740	1744	O
and	21060033	1745	1748	O
was	21060033	1749	1752	O
generally	21060033	1753	1762	O
well	21060033	1763	1767	O
tolerated	21060033	1768	1777	B-Outcome
.	21060033	1777	1778	O

With	21060033	1779	1783	O
the	21060033	1784	1787	O
convenience	21060033	1788	1799	O
of	21060033	1800	1802	O
a	21060033	1803	1804	O
subcutaneous	21060033	1805	1817	O
injection	21060033	1818	1827	O
and	21060033	1828	1831	O
no	21060033	1832	1834	O
requirement	21060033	1835	1846	O
for	21060033	1847	1850	O
renal	21060033	1851	1856	O
monitoring	21060033	1857	1867	O
,	21060033	1867	1868	O
denosumab	21060033	1869	1878	O
represents	21060033	1879	1889	O
a	21060033	1890	1891	O
potential	21060033	1892	1901	O
treatment	21060033	1902	1911	O
option	21060033	1912	1918	O
for	21060033	1919	1922	O
patients	21060033	1923	1931	O
with	21060033	1932	1936	O
bone	21060033	1937	1941	O
metastases	21060033	1942	1952	O
.	21060033	1952	1953	O


Effect	21083385	0	6	O
of	21083385	7	9	O
VX-770	21083385	10	16	O
in	21083385	17	19	O
persons	21083385	20	27	O
with	21083385	28	32	O
cystic	21083385	33	39	O
fibrosis	21083385	40	48	O
and	21083385	49	52	O
the	21083385	53	56	O
G551D-CFTR	21083385	57	67	O
mutation	21083385	68	76	O
.	21083385	76	77	O

BACKGROUND	21083385	79	89	O
:	21083385	90	91	O
A	21083385	92	93	O
new	21083385	94	97	O
approach	21083385	98	106	O
in	21083385	107	109	O
the	21083385	110	113	O
treatment	21083385	114	123	O
of	21083385	124	126	O
cystic	21083385	127	133	O
fibrosis	21083385	134	142	O
involves	21083385	143	151	O
improving	21083385	152	161	O
the	21083385	162	165	O
function	21083385	166	174	O
of	21083385	175	177	O
mutant	21083385	178	184	O
cystic	21083385	185	191	O
fibrosis	21083385	192	200	O
transmembrane	21083385	201	214	O
conductance	21083385	215	226	O
regulator	21083385	227	236	O
(	21083385	237	238	O
CFTR	21083385	238	242	O
)	21083385	242	243	O
.	21083385	243	244	O

VX-770	21083385	245	251	O
,	21083385	251	252	O
a	21083385	253	254	O
CFTR	21083385	255	259	O
potentiator	21083385	260	271	O
,	21083385	271	272	O
has	21083385	273	276	O
been	21083385	277	281	O
shown	21083385	282	287	O
to	21083385	288	290	O
increase	21083385	291	299	O
the	21083385	300	303	O
activity	21083385	304	312	O
of	21083385	313	315	O
wild-type	21083385	316	325	O
and	21083385	326	329	O
defective	21083385	330	339	O
cell-surface	21083385	340	352	O
CFTR	21083385	353	357	O
in	21083385	358	360	O
vitro	21083385	361	366	O
.	21083385	366	367	O

METHODS	21083385	369	376	O
:	21083385	377	378	O
We	21083385	379	381	O
randomly	21083385	382	390	O
assigned	21083385	391	399	O
39	21083385	400	402	O
adults	21083385	403	409	O
with	21083385	410	414	O
cystic	21083385	415	421	O
fibrosis	21083385	422	430	O
and	21083385	431	434	O
at	21083385	435	437	O
least	21083385	438	443	O
one	21083385	444	447	O
G551D-CFTR	21083385	448	458	O
allele	21083385	459	465	O
to	21083385	466	468	O
receive	21083385	469	476	O
oral	21083385	477	481	O
VX-770	21083385	482	488	O
every	21083385	489	494	O
12	21083385	495	497	O
hours	21083385	498	503	O
at	21083385	504	506	O
a	21083385	507	508	O
dose	21083385	509	513	O
of	21083385	514	516	O
25	21083385	517	519	O
,	21083385	519	520	O
75	21083385	521	523	O
,	21083385	523	524	O
or	21083385	525	527	O
150	21083385	528	531	O
mg	21083385	532	534	O
or	21083385	535	537	O
placebo	21083385	538	545	O
for	21083385	546	549	O
14	21083385	550	552	O
days	21083385	553	557	O
(	21083385	558	559	O
in	21083385	559	561	O
part	21083385	562	566	O
1	21083385	567	568	O
of	21083385	569	571	O
the	21083385	572	575	O
study	21083385	576	581	O
)	21083385	581	582	O
or	21083385	583	585	O
VX-770	21083385	586	592	O
every	21083385	593	598	O
12	21083385	599	601	O
hours	21083385	602	607	O
at	21083385	608	610	O
a	21083385	611	612	O
dose	21083385	613	617	O
of	21083385	618	620	O
150	21083385	621	624	O
or	21083385	625	627	O
250	21083385	628	631	O
mg	21083385	632	634	O
or	21083385	635	637	O
placebo	21083385	638	645	O
for	21083385	646	649	O
28	21083385	650	652	O
days	21083385	653	657	O
(	21083385	658	659	O
in	21083385	659	661	O
part	21083385	662	666	O
2	21083385	667	668	O
of	21083385	669	671	O
the	21083385	672	675	O
study	21083385	676	681	O
)	21083385	681	682	O
.	21083385	682	683	O

RESULTS	21083385	685	692	O
:	21083385	693	694	O
At	21083385	695	697	O
day	21083385	698	701	O
28	21083385	702	704	O
,	21083385	704	705	O
in	21083385	706	708	O
the	21083385	709	712	O
group	21083385	713	718	O
of	21083385	719	721	O
subjects	21083385	722	730	O
who	21083385	731	734	O
received	21083385	735	743	O
150	21083385	744	747	O
mg	21083385	748	750	O
of	21083385	751	753	O
VX-770	21083385	754	760	O
,	21083385	760	761	O
the	21083385	762	765	O
median	21083385	766	772	B-Outcome
change	21083385	773	779	I-Outcome
in	21083385	780	782	I-Outcome
the	21083385	783	786	I-Outcome
nasal	21083385	787	792	I-Outcome
potential	21083385	793	802	I-Outcome
difference	21083385	803	813	I-Outcome
(	21083385	814	815	O
in	21083385	815	817	O
response	21083385	818	826	O
to	21083385	827	829	O
the	21083385	830	833	O
administration	21083385	834	848	O
of	21083385	849	851	O
a	21083385	852	853	O
chloride-free	21083385	854	867	O
isoproterenol	21083385	868	881	O
solution	21083385	882	890	O
)	21083385	890	891	O
from	21083385	892	896	O
baseline	21083385	897	905	O
was	21083385	906	909	O
-3.5	21083385	910	914	O
mV	21083385	915	917	O
(	21083385	918	919	O
range	21083385	919	924	O
,	21083385	924	925	O
-8.3	21083385	926	930	O
to	21083385	931	933	O
0.5	21083385	934	937	O
;	21083385	937	938	O
P=0.02	21083385	939	945	O
for	21083385	946	949	O
the	21083385	950	953	O
within-subject	21083385	954	968	O
comparison	21083385	969	979	O
,	21083385	979	980	O
P=0.13	21083385	981	987	O
vs.	21083385	988	991	O
placebo	21083385	992	999	O
)	21083385	999	1000	O
,	21083385	1000	1001	O
and	21083385	1002	1005	O
the	21083385	1006	1009	O
median	21083385	1010	1016	B-Outcome
change	21083385	1017	1023	I-Outcome
in	21083385	1024	1026	I-Outcome
the	21083385	1027	1030	I-Outcome
level	21083385	1031	1036	I-Outcome
of	21083385	1037	1039	I-Outcome
sweat	21083385	1040	1045	I-Outcome
chloride	21083385	1046	1054	I-Outcome
was	21083385	1055	1058	O
-59.5	21083385	1059	1064	O
mmol	21083385	1065	1069	O
per	21083385	1070	1073	O
liter	21083385	1074	1079	O
(	21083385	1080	1081	O
range	21083385	1081	1086	O
,	21083385	1086	1087	O
-66.0	21083385	1088	1093	O
to	21083385	1094	1096	O
-19.0	21083385	1097	1102	O
;	21083385	1102	1103	O
P=0.008	21083385	1104	1111	O
within-subject	21083385	1112	1126	O
,	21083385	1126	1127	O
P=0.02	21083385	1128	1134	O
vs.	21083385	1135	1138	O
placebo	21083385	1139	1146	O
)	21083385	1146	1147	O
.	21083385	1147	1148	O

The	21083385	1149	1152	O
median	21083385	1153	1159	B-Outcome
change	21083385	1160	1166	I-Outcome
from	21083385	1167	1171	I-Outcome
baseline	21083385	1172	1180	I-Outcome
in	21083385	1181	1183	I-Outcome
the	21083385	1184	1187	I-Outcome
percent	21083385	1188	1195	I-Outcome
of	21083385	1196	1198	I-Outcome
predicted	21083385	1199	1208	I-Outcome
forced	21083385	1209	1215	I-Outcome
expiratory	21083385	1216	1226	I-Outcome
volume	21083385	1227	1233	I-Outcome
in	21083385	1234	1236	I-Outcome
1	21083385	1237	1238	I-Outcome
second	21083385	1239	1245	I-Outcome
was	21083385	1246	1249	O
8.7	21083385	1250	1253	O
%	21083385	1253	1254	O
(	21083385	1255	1256	O
range	21083385	1256	1261	O
,	21083385	1261	1262	O
2.3	21083385	1263	1266	O
to	21083385	1267	1269	O
31.3	21083385	1270	1274	O
;	21083385	1274	1275	O
P=0.008	21083385	1276	1283	O
for	21083385	1284	1287	O
the	21083385	1288	1291	O
within-subject	21083385	1292	1306	O
comparison	21083385	1307	1317	O
,	21083385	1317	1318	O
P=0.56	21083385	1319	1325	O
vs.	21083385	1326	1329	O
placebo	21083385	1330	1337	O
)	21083385	1337	1338	O
.	21083385	1338	1339	O

None	21083385	1340	1344	O
of	21083385	1345	1347	O
the	21083385	1348	1351	O
subjects	21083385	1352	1360	O
withdrew	21083385	1361	1369	O
from	21083385	1370	1374	O
the	21083385	1375	1378	O
study	21083385	1379	1384	O
.	21083385	1384	1385	O

Six	21083385	1386	1389	O
severe	21083385	1390	1396	B-Outcome
adverse	21083385	1397	1404	I-Outcome
events	21083385	1405	1411	I-Outcome
occurred	21083385	1412	1420	O
in	21083385	1421	1423	O
two	21083385	1424	1427	O
subjects	21083385	1428	1436	O
(	21083385	1437	1438	O
diffuse	21083385	1438	1445	O
macular	21083385	1446	1453	O
rash	21083385	1454	1458	O
in	21083385	1459	1461	O
one	21083385	1462	1465	O
subject	21083385	1466	1473	O
and	21083385	1474	1477	O
five	21083385	1478	1482	O
incidents	21083385	1483	1492	O
of	21083385	1493	1495	O
elevated	21083385	1496	1504	O
blood	21083385	1505	1510	O
and	21083385	1511	1514	O
urine	21083385	1515	1520	O
glucose	21083385	1521	1528	O
levels	21083385	1529	1535	O
in	21083385	1536	1538	O
one	21083385	1539	1542	O
subject	21083385	1543	1550	O
with	21083385	1551	1555	O
diabetes	21083385	1556	1564	O
)	21083385	1564	1565	O
.	21083385	1565	1566	O

All	21083385	1567	1570	O
severe	21083385	1571	1577	B-Outcome
adverse	21083385	1578	1585	I-Outcome
events	21083385	1586	1592	I-Outcome
resolved	21083385	1593	1601	O
without	21083385	1602	1609	O
the	21083385	1610	1613	O
discontinuation	21083385	1614	1629	O
of	21083385	1630	1632	O
VX-770	21083385	1633	1639	O
.	21083385	1639	1640	O

CONCLUSIONS	21083385	1642	1653	O
:	21083385	1654	1655	O
This	21083385	1656	1660	O
study	21083385	1661	1666	O
to	21083385	1667	1669	O
evaluate	21083385	1670	1678	O
the	21083385	1679	1682	O
safety	21083385	1683	1689	B-Outcome
and	21083385	1690	1693	O
adverse-event	21083385	1694	1707	B-Outcome
profile	21083385	1708	1715	O
of	21083385	1716	1718	O
VX-770	21083385	1719	1725	O
showed	21083385	1726	1732	O
that	21083385	1733	1737	O
VX-770	21083385	1738	1744	O
was	21083385	1745	1748	O
associated	21083385	1749	1759	O
with	21083385	1760	1764	O
within-subject	21083385	1765	1779	O
improvements	21083385	1780	1792	O
in	21083385	1793	1795	O
CFTR	21083385	1796	1800	B-Outcome
and	21083385	1801	1804	O
lung	21083385	1805	1809	B-Outcome
function	21083385	1810	1818	I-Outcome
.	21083385	1818	1819	O

These	21083385	1820	1825	O
findings	21083385	1826	1834	O
provide	21083385	1835	1842	O
support	21083385	1843	1850	O
for	21083385	1851	1854	O
further	21083385	1855	1862	O
studies	21083385	1863	1870	O
of	21083385	1871	1873	O
pharmacologic	21083385	1874	1887	O
potentiation	21083385	1888	1900	O
of	21083385	1901	1903	O
CFTR	21083385	1904	1908	O
as	21083385	1909	1911	O
a	21083385	1912	1913	O
means	21083385	1914	1919	O
to	21083385	1920	1922	O
treat	21083385	1923	1928	O
cystic	21083385	1929	1935	O
fibrosis	21083385	1936	1944	O
.	21083385	1944	1945	O

(	21083385	1946	1947	O
Funded	21083385	1947	1953	O
by	21083385	1954	1956	O
Vertex	21083385	1957	1963	O
Pharmaceuticals	21083385	1964	1979	O
and	21083385	1980	1983	O
others	21083385	1984	1990	O
;	21083385	1990	1991	O
ClinicalTrials.gov	21083385	1992	2010	O
number	21083385	2011	2017	O
,	21083385	2017	2018	O
NCT00457821	21083385	2019	2030	O
.	21083385	2030	2031	O
)	21083385	2031	2032	O
.	21083385	2032	2033	O


Treatment	21226576	0	9	O
of	21226576	10	12	O
acute	21226576	13	18	O
otitis	21226576	19	25	O
media	21226576	26	31	O
in	21226576	32	34	O
children	21226576	35	43	O
under	21226576	44	49	O
2	21226576	50	51	O
years	21226576	52	57	O
of	21226576	58	60	O
age	21226576	61	64	O
.	21226576	64	65	O

BACKGROUND	21226576	67	77	O
:	21226576	78	79	O
Recommendations	21226576	80	95	O
vary	21226576	96	100	O
regarding	21226576	101	110	O
immediate	21226576	111	120	O
antimicrobial	21226576	121	134	O
treatment	21226576	135	144	O
versus	21226576	145	151	O
watchful	21226576	152	160	O
waiting	21226576	161	168	O
for	21226576	169	172	O
children	21226576	173	181	O
younger	21226576	182	189	O
than	21226576	190	194	O
2	21226576	195	196	O
years	21226576	197	202	O
of	21226576	203	205	O
age	21226576	206	209	O
with	21226576	210	214	O
acute	21226576	215	220	O
otitis	21226576	221	227	O
media	21226576	228	233	O
.	21226576	233	234	O

METHODS	21226576	236	243	O
:	21226576	244	245	O
We	21226576	246	248	O
randomly	21226576	249	257	O
assigned	21226576	258	266	O
291	21226576	267	270	O
children	21226576	271	279	O
6	21226576	280	281	O
to	21226576	282	284	O
23	21226576	285	287	O
months	21226576	288	294	O
of	21226576	295	297	O
age	21226576	298	301	O
,	21226576	301	302	O
with	21226576	303	307	O
acute	21226576	308	313	O
otitis	21226576	314	320	O
media	21226576	321	326	O
diagnosed	21226576	327	336	O
with	21226576	337	341	O
the	21226576	342	345	O
use	21226576	346	349	O
of	21226576	350	352	O
stringent	21226576	353	362	O
criteria	21226576	363	371	O
,	21226576	371	372	O
to	21226576	373	375	O
receive	21226576	376	383	O
amoxicillin-clavulanate	21226576	384	407	O
or	21226576	408	410	O
placebo	21226576	411	418	O
for	21226576	419	422	O
10	21226576	423	425	O
days	21226576	426	430	O
.	21226576	430	431	O

We	21226576	432	434	O
measured	21226576	435	443	O
symptomatic	21226576	444	455	O
response	21226576	456	464	O
and	21226576	465	468	O
rates	21226576	469	474	O
of	21226576	475	477	O
clinical	21226576	478	486	O
failure	21226576	487	494	O
.	21226576	494	495	O

RESULTS	21226576	497	504	O
:	21226576	505	506	O
Among	21226576	507	512	O
the	21226576	513	516	O
children	21226576	517	525	O
who	21226576	526	529	O
received	21226576	530	538	O
amoxicillin-clavulanate	21226576	539	562	O
,	21226576	562	563	O
35	21226576	564	566	O
%	21226576	566	567	O
had	21226576	568	571	O
initial	21226576	572	579	O
resolution	21226576	580	590	B-Outcome
of	21226576	591	593	I-Outcome
symptoms	21226576	594	602	I-Outcome
by	21226576	603	605	O
day	21226576	606	609	O
2	21226576	610	611	O
,	21226576	611	612	O
61	21226576	613	615	O
%	21226576	615	616	O
by	21226576	617	619	O
day	21226576	620	623	O
4	21226576	624	625	O
,	21226576	625	626	O
and	21226576	627	630	O
80	21226576	631	633	O
%	21226576	633	634	O
by	21226576	635	637	O
day	21226576	638	641	O
7	21226576	642	643	O
;	21226576	643	644	O
among	21226576	645	650	O
children	21226576	651	659	O
who	21226576	660	663	O
received	21226576	664	672	O
placebo	21226576	673	680	O
,	21226576	680	681	O
28	21226576	682	684	O
%	21226576	684	685	O
had	21226576	686	689	O
initial	21226576	690	697	O
resolution	21226576	698	708	B-Outcome
of	21226576	709	711	I-Outcome
symptoms	21226576	712	720	I-Outcome
by	21226576	721	723	O
day	21226576	724	727	O
2	21226576	728	729	O
,	21226576	729	730	O
54	21226576	731	733	O
%	21226576	733	734	O
by	21226576	735	737	O
day	21226576	738	741	O
4	21226576	742	743	O
,	21226576	743	744	O
and	21226576	745	748	O
74	21226576	749	751	O
%	21226576	751	752	O
by	21226576	753	755	O
day	21226576	756	759	O
7	21226576	760	761	O
(	21226576	762	763	O
P=0.14	21226576	763	769	O
for	21226576	770	773	O
the	21226576	774	777	O
overall	21226576	778	785	O
comparison	21226576	786	796	O
)	21226576	796	797	O
.	21226576	797	798	O

For	21226576	799	802	O
sustained	21226576	803	812	O
resolution	21226576	813	823	B-Outcome
of	21226576	824	826	I-Outcome
symptoms	21226576	827	835	I-Outcome
,	21226576	835	836	O
the	21226576	837	840	O
corresponding	21226576	841	854	O
values	21226576	855	861	O
were	21226576	862	866	O
20	21226576	867	869	O
%	21226576	869	870	O
,	21226576	870	871	O
41	21226576	872	874	O
%	21226576	874	875	O
,	21226576	875	876	O
and	21226576	877	880	O
67	21226576	881	883	O
%	21226576	883	884	O
with	21226576	885	889	O
amoxicillin-clavulanate	21226576	890	913	O
,	21226576	913	914	O
as	21226576	915	917	O
compared	21226576	918	926	O
with	21226576	927	931	O
14	21226576	932	934	O
%	21226576	934	935	O
,	21226576	935	936	O
36	21226576	937	939	O
%	21226576	939	940	O
,	21226576	940	941	O
and	21226576	942	945	O
53	21226576	946	948	O
%	21226576	948	949	O
with	21226576	950	954	O
placebo	21226576	955	962	O
(	21226576	963	964	O
P=0.04	21226576	964	970	O
for	21226576	971	974	O
the	21226576	975	978	O
overall	21226576	979	986	O
comparison	21226576	987	997	O
)	21226576	997	998	O
.	21226576	998	999	O

Mean	21226576	1000	1004	B-Outcome
symptom	21226576	1005	1012	I-Outcome
scores	21226576	1013	1019	I-Outcome
over	21226576	1020	1024	O
the	21226576	1025	1028	O
first	21226576	1029	1034	O
7	21226576	1035	1036	O
days	21226576	1037	1041	O
were	21226576	1042	1046	O
lower	21226576	1047	1052	O
for	21226576	1053	1056	O
the	21226576	1057	1060	O
children	21226576	1061	1069	O
treated	21226576	1070	1077	O
with	21226576	1078	1082	O
amoxicillin-clavulanate	21226576	1083	1106	O
than	21226576	1107	1111	O
for	21226576	1112	1115	O
those	21226576	1116	1121	O
who	21226576	1122	1125	O
received	21226576	1126	1134	O
placebo	21226576	1135	1142	O
(	21226576	1143	1144	O
P=0.02	21226576	1144	1150	O
)	21226576	1150	1151	O
.	21226576	1151	1152	O

The	21226576	1153	1156	O
rate	21226576	1157	1161	B-Outcome
of	21226576	1162	1164	I-Outcome
clinical	21226576	1165	1173	I-Outcome
failure	21226576	1174	1181	I-Outcome
--	21226576	1181	1183	O
defined	21226576	1183	1190	O
as	21226576	1191	1193	O
the	21226576	1194	1197	O
persistence	21226576	1198	1209	B-Outcome
of	21226576	1210	1212	I-Outcome
signs	21226576	1213	1218	I-Outcome
of	21226576	1219	1221	I-Outcome
acute	21226576	1222	1227	I-Outcome
infection	21226576	1228	1237	I-Outcome
on	21226576	1238	1240	I-Outcome
otoscopic	21226576	1241	1250	I-Outcome
examination	21226576	1251	1262	I-Outcome
--	21226576	1262	1264	O
was	21226576	1264	1267	O
also	21226576	1268	1272	O
lower	21226576	1273	1278	O
among	21226576	1279	1284	O
the	21226576	1285	1288	O
children	21226576	1289	1297	O
treated	21226576	1298	1305	O
with	21226576	1306	1310	O
amoxicillin-clavulanate	21226576	1311	1334	O
than	21226576	1335	1339	O
among	21226576	1340	1345	O
those	21226576	1346	1351	O
who	21226576	1352	1355	O
received	21226576	1356	1364	O
placebo	21226576	1365	1372	O
:	21226576	1372	1373	O
4	21226576	1374	1375	O
%	21226576	1375	1376	O
versus	21226576	1377	1383	O
23	21226576	1384	1386	O
%	21226576	1386	1387	O
at	21226576	1388	1390	O
or	21226576	1391	1393	O
before	21226576	1394	1400	O
the	21226576	1401	1404	O
visit	21226576	1405	1410	O
on	21226576	1411	1413	O
day	21226576	1414	1417	O
4	21226576	1418	1419	O
or	21226576	1420	1422	O
5	21226576	1423	1424	O
(	21226576	1425	1426	O
P<0.001	21226576	1426	1433	O
)	21226576	1433	1434	O
and	21226576	1435	1438	O
16	21226576	1439	1441	O
%	21226576	1441	1442	O
versus	21226576	1443	1449	O
51	21226576	1450	1452	O
%	21226576	1452	1453	O
at	21226576	1454	1456	O
or	21226576	1457	1459	O
before	21226576	1460	1466	O
the	21226576	1467	1470	O
visit	21226576	1471	1476	O
on	21226576	1477	1479	O
day	21226576	1480	1483	O
10	21226576	1484	1486	O
to	21226576	1487	1489	O
12	21226576	1490	1492	O
(	21226576	1493	1494	O
P<0.001	21226576	1494	1501	O
)	21226576	1501	1502	O
.	21226576	1502	1503	O

Mastoiditis	21226576	1504	1515	O
developed	21226576	1516	1525	O
in	21226576	1526	1528	O
one	21226576	1529	1532	O
child	21226576	1533	1538	O
who	21226576	1539	1542	O
received	21226576	1543	1551	O
placebo	21226576	1552	1559	O
.	21226576	1559	1560	O

Diarrhea	21226576	1561	1569	O
and	21226576	1570	1573	O
diaper-area	21226576	1574	1585	O
dermatitis	21226576	1586	1596	O
were	21226576	1597	1601	O
more	21226576	1602	1606	O
common	21226576	1607	1613	O
among	21226576	1614	1619	O
children	21226576	1620	1628	O
who	21226576	1629	1632	O
received	21226576	1633	1641	O
amoxicillin-clavulanate	21226576	1642	1665	O
.	21226576	1665	1666	O

There	21226576	1667	1672	O
were	21226576	1673	1677	O
no	21226576	1678	1680	O
significant	21226576	1681	1692	O
changes	21226576	1693	1700	O
in	21226576	1701	1703	O
either	21226576	1704	1710	O
group	21226576	1711	1716	O
in	21226576	1717	1719	O
the	21226576	1720	1723	O
rates	21226576	1724	1729	B-Outcome
of	21226576	1730	1732	I-Outcome
nasopharyngeal	21226576	1733	1747	I-Outcome
colonization	21226576	1748	1760	I-Outcome
with	21226576	1761	1765	O
nonsusceptible	21226576	1766	1780	O
Streptococcus	21226576	1781	1794	O
pneumoniae	21226576	1795	1805	O
.	21226576	1805	1806	O

CONCLUSIONS	21226576	1808	1819	O
:	21226576	1820	1821	O
Among	21226576	1822	1827	O
children	21226576	1828	1836	O
6	21226576	1837	1838	O
to	21226576	1839	1841	O
23	21226576	1842	1844	O
months	21226576	1845	1851	O
of	21226576	1852	1854	O
age	21226576	1855	1858	O
with	21226576	1859	1863	O
acute	21226576	1864	1869	O
otitis	21226576	1870	1876	O
media	21226576	1877	1882	O
,	21226576	1882	1883	O
treatment	21226576	1884	1893	O
with	21226576	1894	1898	O
amoxicillin-clavulanate	21226576	1899	1922	O
for	21226576	1923	1926	O
10	21226576	1927	1929	O
days	21226576	1930	1934	O
tended	21226576	1935	1941	O
to	21226576	1942	1944	O
reduce	21226576	1945	1951	O
the	21226576	1952	1955	O
time	21226576	1956	1960	B-Outcome
to	21226576	1961	1963	I-Outcome
resolution	21226576	1964	1974	I-Outcome
of	21226576	1975	1977	I-Outcome
symptoms	21226576	1978	1986	I-Outcome
and	21226576	1987	1990	O
reduced	21226576	1991	1998	O
the	21226576	1999	2002	O
overall	21226576	2003	2010	B-Outcome
symptom	21226576	2011	2018	I-Outcome
burden	21226576	2019	2025	I-Outcome
and	21226576	2026	2029	O
the	21226576	2030	2033	O
rate	21226576	2034	2038	B-Outcome
of	21226576	2039	2041	I-Outcome
persistent	21226576	2042	2052	I-Outcome
signs	21226576	2053	2058	I-Outcome
of	21226576	2059	2061	I-Outcome
acute	21226576	2062	2067	I-Outcome
infection	21226576	2068	2077	I-Outcome
on	21226576	2078	2080	I-Outcome
otoscopic	21226576	2081	2090	I-Outcome
examination	21226576	2091	2102	I-Outcome
.	21226576	2102	2103	O
(	21226576	2104	2105	O
Funded	21226576	2105	2111	O
by	21226576	2112	2114	O
the	21226576	2115	2118	O
National	21226576	2119	2127	O
Institute	21226576	2128	2137	O
of	21226576	2138	2140	O
Allergy	21226576	2141	2148	O
and	21226576	2149	2152	O
Infectious	21226576	2153	2163	O
Diseases	21226576	2164	2172	O
;	21226576	2172	2173	O
ClinicalTrials.gov	21226576	2174	2192	O
number	21226576	2193	2199	O
,	21226576	2199	2200	O
NCT00377260	21226576	2201	2212	O
.	21226576	2212	2213	O
)	21226576	2213	2214	O
.	21226576	2214	2215	O


Effects	21327867	0	7	O
of	21327867	8	10	O
weight	21327867	11	17	O
loss	21327867	18	22	O
and	21327867	23	26	O
exercise	21327867	27	35	O
on	21327867	36	38	O
insulin	21327867	39	46	O
resistance	21327867	47	57	O
,	21327867	57	58	O
and	21327867	59	62	O
intramyocellular	21327867	63	79	O
triacylglycerol	21327867	80	95	O
,	21327867	95	96	O
diacylglycerol	21327867	97	111	O
and	21327867	112	115	O
ceramide	21327867	116	124	O
.	21327867	124	125	O

AIMS/HYPOTHESIS	21327867	127	142	O
:	21327867	143	144	O
Intramyocellular	21327867	145	161	O
lipids	21327867	162	168	O
,	21327867	168	169	O
including	21327867	170	179	O
diacylglycerol	21327867	180	194	O
(	21327867	195	196	O
DAG	21327867	196	199	O
)	21327867	199	200	O
and	21327867	201	204	O
ceramides	21327867	205	214	O
,	21327867	214	215	O
have	21327867	216	220	O
been	21327867	221	225	O
linked	21327867	226	232	O
to	21327867	233	235	O
insulin	21327867	236	243	O
resistance	21327867	244	254	O
.	21327867	254	255	O

This	21327867	256	260	O
randomised	21327867	261	271	O
repeated-measures	21327867	272	289	O
study	21327867	290	295	O
examined	21327867	296	304	O
the	21327867	305	308	O
effects	21327867	309	316	O
of	21327867	317	319	O
diet-induced	21327867	320	332	O
weight	21327867	333	339	O
loss	21327867	340	344	O
(	21327867	345	346	O
DIWL	21327867	346	350	O
)	21327867	350	351	O
and	21327867	352	355	O
aerobic	21327867	356	363	O
exercise	21327867	364	372	O
(	21327867	373	374	O
EX	21327867	374	376	O
)	21327867	376	377	O
on	21327867	378	380	O
insulin	21327867	381	388	O
sensitivity	21327867	389	400	O
and	21327867	401	404	O
intramyocellular	21327867	405	421	O
triacylglycerol	21327867	422	437	O
(	21327867	438	439	O
IMTG	21327867	439	443	O
)	21327867	443	444	O
,	21327867	444	445	O
DAG	21327867	446	449	O
and	21327867	450	453	O
ceramide	21327867	454	462	O
.	21327867	462	463	O

METHODS	21327867	465	472	O
:	21327867	473	474	O
Sixteen	21327867	475	482	O
overweight	21327867	483	493	O
to	21327867	494	496	O
obese	21327867	497	502	O
adults	21327867	503	509	O
(	21327867	510	511	O
BMI	21327867	511	514	O
30.6	21327867	515	519	O
±	21327867	520	521	O
0.8	21327867	522	525	O
;	21327867	525	526	O
67.2	21327867	527	531	O
±	21327867	532	533	O
4.0	21327867	534	537	O
years	21327867	538	543	O
of	21327867	544	546	O
age	21327867	547	550	O
)	21327867	550	551	O
with	21327867	552	556	O
either	21327867	557	563	O
impaired	21327867	564	572	O
fasting	21327867	573	580	O
glucose	21327867	581	588	O
,	21327867	588	589	O
or	21327867	590	592	O
impaired	21327867	593	601	O
glucose	21327867	602	609	O
tolerance	21327867	610	619	O
completed	21327867	620	629	O
one	21327867	630	633	O
of	21327867	634	636	O
two	21327867	637	640	O
lifestyle	21327867	641	650	O
interventions	21327867	651	664	O
:	21327867	664	665	O
DIWL	21327867	666	670	O
(	21327867	671	672	O
n	21327867	672	673	O
=	21327867	674	675	O
8)	21327867	676	678	O
or	21327867	679	681	O
EX	21327867	682	684	O
(	21327867	685	686	O
n	21327867	686	687	O
=	21327867	688	689	O
8)	21327867	690	692	O
.	21327867	692	693	O

Insulin	21327867	694	701	O
sensitivity	21327867	702	713	O
was	21327867	714	717	O
determined	21327867	718	728	O
using	21327867	729	734	O
hyperinsulinaemic-euglycaemic	21327867	735	764	O
clamps	21327867	765	771	O
.	21327867	771	772	O

Intramyocellular	21327867	773	789	O
lipids	21327867	790	796	O
were	21327867	797	801	O
measured	21327867	802	810	O
in	21327867	811	813	O
muscle	21327867	814	820	O
biopsies	21327867	821	829	O
using	21327867	830	835	O
histochemistry	21327867	836	850	O
and	21327867	851	854	O
tandem	21327867	855	861	O
mass	21327867	862	866	O
spectrometry	21327867	867	879	O
.	21327867	879	880	O

RESULTS	21327867	882	889	O
:	21327867	890	891	O
Insulin	21327867	892	899	B-Outcome
sensitivity	21327867	900	911	I-Outcome
was	21327867	912	915	O
improved	21327867	916	924	O
with	21327867	925	929	O
DIWL	21327867	930	934	O
(	21327867	935	936	O
20.6	21327867	936	940	O
±	21327867	941	942	O
4.7	21327867	943	946	O
%	21327867	946	947	O
)	21327867	947	948	O
and	21327867	949	952	O

EX	21327867	953	955	O
(	21327867	956	957	O
19.2	21327867	957	961	O
±	21327867	962	963	O
12.9	21327867	964	968	O
%	21327867	968	969	O
)	21327867	969	970	O
.	21327867	970	971	O

Body	21327867	972	976	B-Outcome
weight	21327867	977	983	I-Outcome
and	21327867	984	987	O
body	21327867	988	992	B-Outcome
fat	21327867	993	996	I-Outcome
were	21327867	997	1001	O
decreased	21327867	1002	1011	O
by	21327867	1012	1014	O
both	21327867	1015	1019	O
interventions	21327867	1020	1033	O
,	21327867	1033	1034	O
with	21327867	1035	1039	O
greater	21327867	1040	1047	O
decreases	21327867	1048	1057	O
in	21327867	1058	1060	O
DIWL	21327867	1061	1065	O
compared	21327867	1066	1074	O
with	21327867	1075	1079	O
EX	21327867	1080	1082	O
.	21327867	1082	1083	O

Muscle	21327867	1084	1090	B-Outcome
glycogen	21327867	1091	1099	I-Outcome
,	21327867	1099	1100	O
IMTG	21327867	1101	1105	B-Outcome
content	21327867	1106	1113	I-Outcome
and	21327867	1114	1117	O
oxidative	21327867	1118	1127	B-Outcome
capacity	21327867	1128	1136	I-Outcome
were	21327867	1137	1141	O
all	21327867	1142	1145	O
significantly	21327867	1146	1159	O
(	21327867	1160	1161	O
p	21327867	1161	1162	O
<	21327867	1163	1164	O
0.05	21327867	1165	1169	O
)	21327867	1169	1170	O
decreased	21327867	1171	1180	O
with	21327867	1181	1185	O
DIWL	21327867	1186	1190	O
and	21327867	1191	1194	O
increased	21327867	1195	1204	O
with	21327867	1205	1209	O
EX	21327867	1210	1212	O
.	21327867	1212	1213	O

There	21327867	1214	1219	O
were	21327867	1220	1224	O
decreases	21327867	1225	1234	O
in	21327867	1235	1237	O
DAG	21327867	1238	1241	B-Outcome
with	21327867	1242	1246	O
DIWL	21327867	1247	1251	O
(	21327867	1252	1253	O
-12.4	21327867	1253	1258	O
±	21327867	1259	1260	O
14.6	21327867	1261	1265	O
%	21327867	1265	1266	O
)	21327867	1266	1267	O
and	21327867	1268	1271	O
EX	21327867	1272	1274	O
(	21327867	1275	1276	O
-40.9	21327867	1276	1281	O
±	21327867	1282	1283	O
12.0	21327867	1284	1288	O
%	21327867	1288	1289	O
)	21327867	1289	1290	O
.	21327867	1290	1291	O

Ceramide	21327867	1292	1300	B-Outcome
decreased	21327867	1301	1310	O
with	21327867	1311	1315	O
EX	21327867	1316	1318	O
(	21327867	1319	1320	O
-33.7	21327867	1320	1325	O
±	21327867	1326	1327	O
11.2	21327867	1328	1332	O
%	21327867	1332	1333	O
)	21327867	1333	1334	O
,	21327867	1334	1335	O
but	21327867	1336	1339	O
not	21327867	1340	1343	O
with	21327867	1344	1348	O
DIWL	21327867	1349	1353	O
.	21327867	1353	1354	O

Dihydroceramide	21327867	1355	1370	B-Outcome
was	21327867	1371	1374	O
decreased	21327867	1375	1384	O
with	21327867	1385	1389	O
both	21327867	1390	1394	O
interventions	21327867	1395	1408	O
.	21327867	1408	1409	O

Sphingosine	21327867	1410	1421	B-Outcome
was	21327867	1422	1425	O
decreased	21327867	1426	1435	O
only	21327867	1436	1440	O
with	21327867	1441	1445	O
EX	21327867	1446	1448	O
.	21327867	1448	1449	O

Changes	21327867	1450	1457	O
in	21327867	1458	1460	O
total	21327867	1461	1466	B-Outcome
DAG	21327867	1467	1470	I-Outcome
,	21327867	1470	1471	O
total	21327867	1472	1477	B-Outcome
ceramides	21327867	1478	1487	I-Outcome
and	21327867	1488	1491	O
other	21327867	1492	1497	O
sphingolipids	21327867	1498	1511	B-Outcome
did	21327867	1512	1515	O
not	21327867	1516	1519	O
correlate	21327867	1520	1529	O
with	21327867	1530	1534	O
changes	21327867	1535	1542	O
in	21327867	1543	1545	O
glucose	21327867	1546	1553	B-Outcome
disposal	21327867	1554	1562	I-Outcome
.	21327867	1562	1563	O

Stearoyl-coenzyme	21327867	1564	1581	B-Outcome
A	21327867	1582	1583	I-Outcome
desaturase	21327867	1584	1594	I-Outcome
1	21327867	1595	1596	I-Outcome
(	21327867	1597	1598	O
SCD1	21327867	1598	1602	B-Outcome
)	21327867	1602	1603	O
content	21327867	1604	1611	O
was	21327867	1612	1615	O
decreased	21327867	1616	1625	O
with	21327867	1626	1630	O
DIWL	21327867	1631	1635	O
(	21327867	1636	1637	O
-19.5	21327867	1637	1642	O
±	21327867	1643	1644	O
8.5	21327867	1645	1648	O
%	21327867	1648	1649	O
,	21327867	1649	1650	O
p	21327867	1651	1652	O
<	21327867	1653	1654	O
0.05	21327867	1655	1659	O
)	21327867	1659	1660	O
,	21327867	1660	1661	O
but	21327867	1662	1665	O
increased	21327867	1666	1675	O
with	21327867	1676	1680	O
EX	21327867	1681	1683	O
(	21327867	1684	1685	O
19.6	21327867	1685	1689	O
±	21327867	1690	1691	O
7.4	21327867	1692	1695	O
%	21327867	1695	1696	O
,	21327867	1696	1697	O
p	21327867	1698	1699	O
<	21327867	1700	1701	O
0.05	21327867	1702	1706	O
)	21327867	1706	1707	O
.	21327867	1707	1708	O

Diacylglycerol	21327867	1709	1723	B-Outcome
acyltransferase	21327867	1724	1739	I-Outcome
1	21327867	1740	1741	I-Outcome
(	21327867	1742	1743	O
DGAT1	21327867	1743	1748	B-Outcome
)	21327867	1748	1749	O
was	21327867	1750	1753	O
unchanged	21327867	1754	1763	O
with	21327867	1764	1768	O
the	21327867	1769	1772	O
interventions	21327867	1773	1786	O
.	21327867	1786	1787	O

CONCLUSIONS/INTERPRETATION	21327867	1789	1815	O
:	21327867	1816	1817	O
Diet-induced	21327867	1818	1830	O
weight	21327867	1831	1837	O
loss	21327867	1838	1842	O
and	21327867	1843	1846	O
exercise	21327867	1847	1855	O
training	21327867	1856	1864	O
both	21327867	1865	1869	O
improved	21327867	1870	1878	O
insulin	21327867	1879	1886	B-Outcome
resistance	21327867	1887	1897	I-Outcome
and	21327867	1898	1901	O
decreased	21327867	1902	1911	O
DAG	21327867	1912	1915	B-Outcome
,	21327867	1915	1916	O
while	21327867	1917	1922	O
only	21327867	1923	1927	O
exercise	21327867	1928	1936	O
decreased	21327867	1937	1946	O
ceramides	21327867	1947	1956	B-Outcome
,	21327867	1956	1957	O
despite	21327867	1958	1965	O
the	21327867	1966	1969	O
interventions	21327867	1970	1983	O
having	21327867	1984	1990	O
different	21327867	1991	2000	O
effects	21327867	2001	2008	O
on	21327867	2009	2011	O
IMTG	21327867	2012	2016	B-Outcome
.	21327867	2016	2017	O

These	21327867	2018	2023	O
alterations	21327867	2024	2035	O
may	21327867	2036	2039	O
be	21327867	2040	2042	O
mediated	21327867	2043	2051	O
through	21327867	2052	2059	O
differential	21327867	2060	2072	O
changes	21327867	2073	2080	O
in	21327867	2081	2083	O
skeletal	21327867	2084	2092	O
muscle	21327867	2093	2099	O
capacity	21327867	2100	2108	O
for	21327867	2109	2112	O
oxidation	21327867	2113	2122	O
and	21327867	2123	2126	O
triacylglycerol	21327867	2127	2142	O
synthesis	21327867	2143	2152	O
.	21327867	2152	2153	O

TRIAL	21327867	2155	2160	O
REGISTRATION	21327867	2161	2173	O
:	21327867	2174	2175	O
ClinicalTrials.gov	21327867	2176	2194	O
NCT00766298	21327867	2195	2206	O
.	21327867	2206	2207	O


Effects	21586714	0	7	O
of	21586714	8	10	O
vitamin	21586714	11	18	O
A	21586714	19	20	O
or	21586714	21	23	O
beta	21586714	24	28	O
carotene	21586714	29	37	O
supplementation	21586714	38	53	O
on	21586714	54	56	O
pregnancy-related	21586714	57	74	O
mortality	21586714	75	84	O
and	21586714	85	88	O
infant	21586714	89	95	O
mortality	21586714	96	105	O
in	21586714	106	108	O
rural	21586714	109	114	O
Bangladesh	21586714	115	125	O
:	21586714	125	126	O
a	21586714	127	128	O
cluster	21586714	129	136	O
randomized	21586714	137	147	O
trial	21586714	148	153	O
.	21586714	153	154	O

CONTEXT	21586714	156	163	O
:	21586714	164	165	O
Maternal	21586714	166	174	O
vitamin	21586714	175	182	O
A	21586714	183	184	O
deficiency	21586714	185	195	O
is	21586714	196	198	O
a	21586714	199	200	O
public	21586714	201	207	O
health	21586714	208	214	O
concern	21586714	215	222	O
in	21586714	223	225	O
the	21586714	226	229	O
developing	21586714	230	240	O
world	21586714	241	246	O
.	21586714	246	247	O

Its	21586714	248	251	O
prevention	21586714	252	262	O
may	21586714	263	266	O
improve	21586714	267	274	O
maternal	21586714	275	283	O
and	21586714	284	287	O
infant	21586714	288	294	O
survival	21586714	295	303	O
.	21586714	303	304	O

OBJECTIVE	21586714	306	315	O
:	21586714	316	317	O
To	21586714	318	320	O
assess	21586714	321	327	O
efficacy	21586714	328	336	O
of	21586714	337	339	O
maternal	21586714	340	348	O
vitamin	21586714	349	356	O
A	21586714	357	358	O
or	21586714	359	361	O
beta	21586714	362	366	O
carotene	21586714	367	375	O
supplementation	21586714	376	391	O
in	21586714	392	394	O
reducing	21586714	395	403	O
pregnancy-related	21586714	404	421	O
and	21586714	422	425	O
infant	21586714	426	432	O
mortality	21586714	433	442	O
.	21586714	442	443	O

DESIGN	21586714	445	451	O
,	21586714	451	452	O
SETTING	21586714	453	460	O
,	21586714	460	461	O
AND	21586714	462	465	O
PARTICIPANTS	21586714	466	478	O
:	21586714	479	480	O
Cluster	21586714	481	488	O
randomized	21586714	489	499	O
,	21586714	499	500	O
double-masked	21586714	501	514	O
,	21586714	514	515	O
placebo-controlled	21586714	516	534	O
trial	21586714	535	540	O
among	21586714	541	546	O
pregnant	21586714	547	555	O
women	21586714	556	561	O
13	21586714	562	564	O
to	21586714	565	567	O
45	21586714	568	570	O
years	21586714	571	576	O
of	21586714	577	579	O
age	21586714	580	583	O
and	21586714	584	587	O
their	21586714	588	593	O
live-born	21586714	594	603	O
infants	21586714	604	611	O
to	21586714	612	614	O
12	21586714	615	617	O
weeks	21586714	618	623	O
(	21586714	624	625	O
84	21586714	625	627	O
days	21586714	628	632	O
)	21586714	632	633	O
postpartum	21586714	634	644	O
in	21586714	645	647	O
rural	21586714	648	653	O
northern	21586714	654	662	O
Bangladesh	21586714	663	673	O
between	21586714	674	681	O
2001	21586714	682	686	O
and	21586714	687	690	O
2007	21586714	691	695	O
.	21586714	695	696	O

Interventions	21586714	697	710	O
Five	21586714	711	715	O
hundred	21586714	716	723	O
ninety-six	21586714	724	734	O
community	21586714	735	744	O
clusters	21586714	745	753	O
(	21586714	754	755	O
study	21586714	755	760	O
sectors	21586714	761	768	O
)	21586714	768	769	O
were	21586714	770	774	O
randomized	21586714	775	785	O
for	21586714	786	789	O
pregnant	21586714	790	798	O
women	21586714	799	804	O
to	21586714	805	807	O
receive	21586714	808	815	O
weekly	21586714	816	822	O
,	21586714	822	823	O
from	21586714	824	828	O
the	21586714	829	832	O
first	21586714	833	838	O
trimester	21586714	839	848	O
through	21586714	849	856	O
12	21586714	857	859	O
weeks	21586714	860	865	O
postpartum	21586714	866	876	O
,	21586714	876	877	O
7000	21586714	878	882	O
μg	21586714	883	885	O
of	21586714	886	888	O
retinol	21586714	889	896	O
equivalents	21586714	897	908	O
as	21586714	909	911	O
retinyl	21586714	912	919	O
palmitate	21586714	920	929	O
,	21586714	929	930	O
42	21586714	931	933	O
mg	21586714	934	936	O
of	21586714	937	939	O
all-trans	21586714	940	949	O
beta	21586714	950	954	O
carotene	21586714	955	963	O
,	21586714	963	964	O
or	21586714	965	967	O
placebo	21586714	968	975	O
.	21586714	975	976	O

Married	21586714	977	984	O
women	21586714	985	990	O
(	21586714	991	992	O
n	21586714	992	993	O
=	21586714	994	995	O
125,257	21586714	996	1003	O
)	21586714	1003	1004	O
underwent	21586714	1005	1014	O
5-week	21586714	1015	1021	O
surveillance	21586714	1022	1034	O
for	21586714	1035	1038	O
pregnancy	21586714	1039	1048	O
,	21586714	1048	1049	O
ascertained	21586714	1050	1061	O
by	21586714	1062	1064	O
a	21586714	1065	1066	O
history	21586714	1067	1074	O
of	21586714	1075	1077	O
amenorrhea	21586714	1078	1088	O
and	21586714	1089	1092	O
confirmed	21586714	1093	1102	O
by	21586714	1103	1105	O
urine	21586714	1106	1111	O
test	21586714	1112	1116	O
.	21586714	1116	1117	O

Blood	21586714	1118	1123	O
samples	21586714	1124	1131	O
were	21586714	1132	1136	O
obtained	21586714	1137	1145	O
from	21586714	1146	1150	O
participants	21586714	1151	1163	O
in	21586714	1164	1166	O
32	21586714	1167	1169	O
sectors	21586714	1170	1177	O
(	21586714	1178	1179	O
5	21586714	1179	1180	O
%	21586714	1180	1181	O
)	21586714	1181	1182	O
for	21586714	1183	1186	O
biochemical	21586714	1187	1198	O
studies	21586714	1199	1206	O
.	21586714	1206	1207	O

MAIN	21586714	1209	1213	O
OUTCOME	21586714	1214	1221	O
MEASURES	21586714	1222	1230	O
:	21586714	1231	1232	O
All-cause	21586714	1233	1242	O
mortality	21586714	1243	1252	O
of	21586714	1253	1255	O
women	21586714	1256	1261	O
related	21586714	1262	1269	O
to	21586714	1270	1272	O
pregnancy	21586714	1273	1282	O
,	21586714	1282	1283	O
stillbirth	21586714	1284	1294	O
,	21586714	1294	1295	O
and	21586714	1296	1299	O
infant	21586714	1300	1306	O
mortality	21586714	1307	1316	O
to	21586714	1317	1319	O
12	21586714	1320	1322	O
weeks	21586714	1323	1328	O
(	21586714	1329	1330	O
84	21586714	1330	1332	O
days	21586714	1333	1337	O
)	21586714	1337	1338	O
following	21586714	1339	1348	O
pregnancy	21586714	1349	1358	O
outcome	21586714	1359	1366	O
.	21586714	1366	1367	O

RESULTS	21586714	1369	1376	O
:	21586714	1377	1378	O
Groups	21586714	1379	1385	O
were	21586714	1386	1390	O
comparable	21586714	1391	1401	O
across	21586714	1402	1408	O
risk	21586714	1409	1413	O
factors	21586714	1414	1421	O
.	21586714	1421	1422	O

For	21586714	1423	1426	O
the	21586714	1427	1430	O
mortality	21586714	1431	1440	B-Outcome
outcomes	21586714	1441	1449	I-Outcome
,	21586714	1449	1450	O
neither	21586714	1451	1458	O
of	21586714	1459	1461	O
the	21586714	1462	1465	O
supplement	21586714	1466	1476	O
group	21586714	1477	1482	O
outcomes	21586714	1483	1491	O
was	21586714	1492	1495	O
significantly	21586714	1496	1509	O
different	21586714	1510	1519	O
from	21586714	1520	1524	O
the	21586714	1525	1528	O
placebo	21586714	1529	1536	O
group	21586714	1537	1542	O
outcomes	21586714	1543	1551	O
.	21586714	1551	1552	O

The	21586714	1553	1556	O
numbers	21586714	1557	1564	B-Outcome
of	21586714	1565	1567	I-Outcome
deaths	21586714	1568	1574	I-Outcome
and	21586714	1575	1578	O
all-cause	21586714	1579	1588	B-Outcome
,	21586714	1588	1589	I-Outcome
pregnancy-related	21586714	1590	1607	I-Outcome
mortality	21586714	1608	1617	I-Outcome
rates	21586714	1618	1623	I-Outcome
(	21586714	1624	1625	O
per	21586714	1625	1628	O
100,000	21586714	1629	1636	O
pregnancies	21586714	1637	1648	O
)	21586714	1648	1649	O
were	21586714	1650	1654	O
41	21586714	1655	1657	O
and	21586714	1658	1661	O
206	21586714	1662	1665	O
(	21586714	1666	1667	O
95	21586714	1667	1669	O
%	21586714	1669	1670	O
confidence	21586714	1671	1681	O
interval	21586714	1682	1690	O
[	21586714	1691	1692	O
CI	21586714	1692	1694	O
]	21586714	1694	1695	O
,	21586714	1695	1696	O
140	21586714	1697	1700	O
-	21586714	1700	1701	O
273	21586714	1701	1704	O
)	21586714	1704	1705	O
in	21586714	1706	1708	O
the	21586714	1709	1712	O
placebo	21586714	1713	1720	O
group	21586714	1721	1726	O
,	21586714	1726	1727	O
47	21586714	1728	1730	O
and	21586714	1731	1734	O
237	21586714	1735	1738	O
(	21586714	1739	1740	O
95	21586714	1740	1742	O
%	21586714	1742	1743	O
CI	21586714	1744	1746	O
,	21586714	1746	1747	O
166	21586714	1748	1751	O
-	21586714	1751	1752	O
309	21586714	1752	1755	O
)	21586714	1755	1756	O
in	21586714	1757	1759	O
the	21586714	1760	1763	O
vitamin	21586714	1764	1771	O
A	21586714	1772	1773	O
group	21586714	1774	1779	O
,	21586714	1779	1780	O
and	21586714	1781	1784	O
50	21586714	1785	1787	O
and	21586714	1788	1791	O
250	21586714	1792	1795	O
(	21586714	1796	1797	O
95	21586714	1797	1799	O
%	21586714	1799	1800	O
CI	21586714	1801	1803	O
,	21586714	1803	1804	O
177	21586714	1805	1808	O
-	21586714	1808	1809	O
323	21586714	1809	1812	O
)	21586714	1812	1813	O
in	21586714	1814	1816	O
the	21586714	1817	1820	O
beta	21586714	1821	1825	O
carotene	21586714	1826	1834	O
group	21586714	1835	1840	O
.	21586714	1840	1841	O

Relative	21586714	1842	1850	B-Outcome
risks	21586714	1851	1856	I-Outcome
for	21586714	1857	1860	I-Outcome
mortality	21586714	1861	1870	I-Outcome
in	21586714	1871	1873	O
the	21586714	1874	1877	O
vitamin	21586714	1878	1885	O
A	21586714	1886	1887	O
and	21586714	1888	1891	O
beta	21586714	1892	1896	O
carotene	21586714	1897	1905	O
groups	21586714	1906	1912	O
were	21586714	1913	1917	O
1.15	21586714	1918	1922	O
(	21586714	1923	1924	O
95	21586714	1924	1926	O
%	21586714	1926	1927	O
CI	21586714	1928	1930	O
,	21586714	1930	1931	O
0.75	21586714	1932	1936	O
-	21586714	1936	1937	O
1.76	21586714	1937	1941	O
)	21586714	1941	1942	O
and	21586714	1943	1946	O
1.21	21586714	1947	1951	O
(	21586714	1952	1953	O
95	21586714	1953	1955	O
%	21586714	1955	1956	O
CI	21586714	1957	1959	O
,	21586714	1959	1960	O
0.81	21586714	1961	1965	O
-	21586714	1965	1966	O
1.81	21586714	1966	1970	O
)	21586714	1970	1971	O
,	21586714	1971	1972	O
respectively	21586714	1973	1985	O
.	21586714	1985	1986	O

In	21586714	1987	1989	O
the	21586714	1990	1993	O
placebo	21586714	1994	2001	O
,	21586714	2001	2002	O
vitamin	21586714	2003	2010	O
A	21586714	2011	2012	O
,	21586714	2012	2013	O
and	21586714	2014	2017	O
beta	21586714	2018	2022	O
carotene	21586714	2023	2031	O
groups	21586714	2032	2038	O
the	21586714	2039	2042	O
rates	21586714	2043	2048	B-Outcome
of	21586714	2049	2051	I-Outcome
stillbirth	21586714	2052	2062	I-Outcome
and	21586714	2063	2066	O
infant	21586714	2067	2073	B-Outcome
mortality	21586714	2074	2083	I-Outcome
were	21586714	2084	2088	O
47.9	21586714	2089	2093	O
(	21586714	2094	2095	O
95	21586714	2095	2097	O
%	21586714	2097	2098	O
CI	21586714	2099	2101	O
,	21586714	2101	2102	O
44.3	21586714	2103	2107	O
-	21586714	2107	2108	O
51.5	21586714	2108	2112	O
)	21586714	2112	2113	O
,	21586714	2113	2114	O
45.6	21586714	2115	2119	O
(	21586714	2120	2121	O
95	21586714	2121	2123	O
%	21586714	2123	2124	O
CI	21586714	2125	2127	O
,	21586714	2127	2128	O
42.1	21586714	2129	2133	O
-	21586714	2133	2134	O
49.2	21586714	2134	2138	O
)	21586714	2138	2139	O
,	21586714	2139	2140	O
and	21586714	2141	2144	O
51.8	21586714	2145	2149	O
(	21586714	2150	2151	O
95	21586714	2151	2153	O
%	21586714	2153	2154	O
CI	21586714	2155	2157	O
,	21586714	2157	2158	O
48.0	21586714	2159	2163	O
-	21586714	2163	2164	O
55.6	21586714	2164	2168	O
)	21586714	2168	2169	O
per	21586714	2170	2173	O
1000	21586714	2174	2178	O
births	21586714	2179	2185	O
and	21586714	2186	2189	O
68.1	21586714	2190	2194	O
(	21586714	2195	2196	O
95	21586714	2196	2198	O
%	21586714	2198	2199	O
CI	21586714	2200	2202	O
,	21586714	2202	2203	O
63.7	21586714	2204	2208	O
-	21586714	2208	2209	O
72.5	21586714	2209	2213	O
)	21586714	2213	2214	O
,	21586714	2214	2215	O
65.0	21586714	2216	2220	O
(	21586714	2221	2222	O
95	21586714	2222	2224	O
%	21586714	2224	2225	O
CI	21586714	2226	2228	O
,	21586714	2228	2229	O
60.7	21586714	2230	2234	O
-	21586714	2234	2235	O
69.4	21586714	2235	2239	O
)	21586714	2239	2240	O
,	21586714	2240	2241	O
and	21586714	2242	2245	O
69.8	21586714	2246	2250	O
(	21586714	2251	2252	O
95	21586714	2252	2254	O
%	21586714	2254	2255	O
CI	21586714	2256	2258	O
,	21586714	2258	2259	O
65.4	21586714	2260	2264	O
-	21586714	2264	2265	O
72.3	21586714	2265	2269	O
)	21586714	2269	2270	O
per	21586714	2271	2274	O
1000	21586714	2275	2279	O
live	21586714	2280	2284	O
births	21586714	2285	2291	O
,	21586714	2291	2292	O
respectively	21586714	2293	2305	O
.	21586714	2305	2306	O

Vitamin	21586714	2307	2314	O
A	21586714	2315	2316	O
compared	21586714	2317	2325	O
with	21586714	2326	2330	O
either	21586714	2331	2337	O
placebo	21586714	2338	2345	O
or	21586714	2346	2348	O
beta	21586714	2349	2353	O
carotene	21586714	2354	2362	O
supplementation	21586714	2363	2378	O
increased	21586714	2379	2388	O
plasma	21586714	2389	2395	B-Outcome
retinol	21586714	2396	2403	I-Outcome
concentrations	21586714	2404	2418	I-Outcome
by	21586714	2419	2421	O
end	21586714	2422	2425	O
of	21586714	2426	2428	O
study	21586714	2429	2434	O
(	21586714	2435	2436	O
1.46	21586714	2436	2440	O
[	21586714	2441	2442	O
95	21586714	2442	2444	O
%	21586714	2444	2445	O
CI	21586714	2446	2448	O
,	21586714	2448	2449	O
1.42	21586714	2450	2454	O
-	21586714	2454	2455	O
1.50	21586714	2455	2459	O
]	21586714	2459	2460	O
μmol/L	21586714	2461	2467	O
vs	21586714	2468	2470	O
1.13	21586714	2471	2475	O
[	21586714	2476	2477	O
95	21586714	2477	2479	O
%	21586714	2479	2480	O
CI	21586714	2481	2483	O
,	21586714	2483	2484	O
1.09	21586714	2485	2489	O
-	21586714	2489	2490	O
1.17	21586714	2490	2494	O
]	21586714	2494	2495	O
μmol/L	21586714	2496	2502	O
and	21586714	2503	2506	O
1.18	21586714	2507	2511	O
[	21586714	2512	2513	O
95	21586714	2513	2515	O
%	21586714	2515	2516	O
CI	21586714	2517	2519	O
,	21586714	2519	2520	O
1.14	21586714	2521	2525	O
-	21586714	2525	2526	O
1.22	21586714	2526	2530	O
]	21586714	2530	2531	O
μmol/L	21586714	2532	2538	O
,	21586714	2538	2539	O
respectively	21586714	2540	2552	O
;	21586714	2552	2553	O
P	21586714	2554	2555	O
<	21586714	2556	2557	O
.001	21586714	2558	2562	O
)	21586714	2562	2563	O
and	21586714	2564	2567	O
reduced	21586714	2568	2575	O
,	21586714	2575	2576	O
but	21586714	2577	2580	O
did	21586714	2581	2584	O
not	21586714	2585	2588	O
eliminate	21586714	2589	2598	O
,	21586714	2598	2599	O
gestational	21586714	2600	2611	B-Outcome
night	21586714	2612	2617	I-Outcome
blindness	21586714	2618	2627	I-Outcome
(	21586714	2628	2629	O
7.1	21586714	2629	2632	O
%	21586714	2632	2633	O
for	21586714	2634	2637	O
vitamin	21586714	2638	2645	O
A	21586714	2646	2647	O
vs	21586714	2648	2650	O
9.2	21586714	2651	2654	O
%	21586714	2654	2655	O
for	21586714	2656	2659	O
placebo	21586714	2660	2667	O
and	21586714	2668	2671	O
8.9	21586714	2672	2675	O
%	21586714	2675	2676	O
for	21586714	2677	2680	O
beta	21586714	2681	2685	O
carotene	21586714	2686	2694	O
[	21586714	2695	2696	O
P	21586714	2696	2697	O
<	21586714	2698	2699	O
.001	21586714	2700	2704	O
for	21586714	2705	2708	O
both	21586714	2709	2713	O
]	21586714	2713	2714	O
)	21586714	2714	2715	O
.	21586714	2715	2716	O

CONCLUSION	21586714	2718	2728	O
:	21586714	2729	2730	O
Use	21586714	2731	2734	O
of	21586714	2735	2737	O
weekly	21586714	2738	2744	O
vitamin	21586714	2745	2752	O
A	21586714	2753	2754	O
or	21586714	2755	2757	O
beta	21586714	2758	2762	O
carotene	21586714	2763	2771	O
in	21586714	2772	2774	O
pregnant	21586714	2775	2783	O
women	21586714	2784	2789	O
in	21586714	2790	2792	O
Bangladesh	21586714	2793	2803	O
,	21586714	2803	2804	O
compared	21586714	2805	2813	O
with	21586714	2814	2818	O
placebo	21586714	2819	2826	O
,	21586714	2826	2827	O
did	21586714	2828	2831	O
not	21586714	2832	2835	O
reduce	21586714	2836	2842	O
all-cause	21586714	2843	2852	B-Outcome
maternal	21586714	2853	2861	I-Outcome
,	21586714	2861	2862	O
fetal	21586714	2863	2868	B-Outcome
,	21586714	2868	2869	O
or	21586714	2870	2872	O
infant	21586714	2873	2879	B-Outcome
mortality	21586714	2880	2889	I-Outcome
.	21586714	2889	2890	O

TRIAL	21586714	2892	2897	O
REGISTRATION	21586714	2898	2910	O
:	21586714	2911	2912	O
clinicaltrials.gov	21586714	2913	2931	O
Identifier	21586714	2932	2942	O
:	21586714	2942	2943	O
NCT00198822	21586714	2944	2955	O
.	21586714	2955	2956	O


Effect	21632816	0	6	O
of	21632816	7	9	O
intensive	21632816	10	19	O
insulin	21632816	20	27	O
therapy	21632816	28	35	O
on	21632816	36	38	O
the	21632816	39	42	O
somatotropic	21632816	43	55	O
axis	21632816	56	60	O
of	21632816	61	63	O
critically	21632816	64	74	O
ill	21632816	75	78	O
children	21632816	79	87	O
.	21632816	87	88	O

CONTEXT	21632816	90	97	O
:	21632816	98	99	O
Intensive	21632816	100	109	O
insulin	21632816	110	117	O
therapy	21632816	118	125	O
(	21632816	126	127	O
IIT	21632816	127	130	O
)	21632816	130	131	O
improved	21632816	132	140	O
outcome	21632816	141	148	O
in	21632816	149	151	O
the	21632816	152	155	O
adult	21632816	156	161	O
and	21632816	162	165	O
pediatric	21632816	166	175	O
intensive	21632816	176	185	O
care	21632816	186	190	O
unit	21632816	191	195	O
(	21632816	196	197	O
PICU	21632816	197	201	O
)	21632816	201	202	O
compared	21632816	203	211	O
with	21632816	212	216	O
conventional	21632816	217	229	O
insulin	21632816	230	237	O
therapy	21632816	238	245	O
(	21632816	246	247	O
CIT	21632816	247	250	O
)	21632816	250	251	O
.	21632816	251	252	O

IIT	21632816	253	256	O
did	21632816	257	260	O
not	21632816	261	264	O
increase	21632816	265	273	O
the	21632816	274	277	O
anabolic	21632816	278	286	O
hormone	21632816	287	294	O
IGF-I	21632816	295	300	O
in	21632816	301	303	O
critically	21632816	304	314	O
ill	21632816	315	318	O
adults	21632816	319	325	O
,	21632816	325	326	O
but	21632816	327	330	O
feeding	21632816	331	338	O
in	21632816	339	341	O
critically	21632816	342	352	O
ill	21632816	353	356	O
children	21632816	357	365	O
and	21632816	366	369	O
pediatric	21632816	370	379	O
hormonal	21632816	380	388	O
responses	21632816	389	398	O
may	21632816	399	402	O
differ	21632816	403	409	O
.	21632816	409	410	O

Twenty-five	21632816	411	422	O
percent	21632816	423	430	O
of	21632816	431	433	O
the	21632816	434	437	O
children	21632816	438	446	O
with	21632816	447	451	O
IIT	21632816	452	455	O
experienced	21632816	456	467	O
hypoglycemia	21632816	468	480	O
,	21632816	480	481	O
which	21632816	482	487	O
may	21632816	488	491	O
have	21632816	492	496	O
evoked	21632816	497	503	O
counterregulatory	21632816	504	521	O
responses	21632816	522	531	O
.	21632816	531	532	O

OBJECTIVE	21632816	534	543	O
:	21632816	544	545	O
We	21632816	546	548	O
hypothesized	21632816	549	561	O
that	21632816	562	566	O
IIT	21632816	567	570	O
reactivates	21632816	571	582	O
the	21632816	583	586	O
somatotropic	21632816	587	599	O
axis	21632816	600	604	O
and	21632816	605	608	O
anabolism	21632816	609	618	O
in	21632816	619	621	O
PICU	21632816	622	626	O
patients	21632816	627	635	O
.	21632816	635	636	O

DESIGN	21632816	638	644	O
:	21632816	645	646	O
This	21632816	647	651	O
was	21632816	652	655	O
a	21632816	656	657	O
preplanned	21632816	658	668	O
subanalysis	21632816	669	680	O
of	21632816	681	683	O
a	21632816	684	685	O
randomized	21632816	686	696	O
controlled	21632816	697	707	O
trial	21632816	708	713	O
on	21632816	714	716	O
IIT	21632816	717	720	O
.	21632816	720	721	O

PATIENTS	21632816	723	731	O
:	21632816	732	733	O
We	21632816	734	736	O
studied	21632816	737	744	O
369	21632816	745	748	O
patients	21632816	749	757	O
who	21632816	758	761	O
stayed	21632816	762	768	O
in	21632816	769	771	O
PICU	21632816	772	776	O
for	21632816	777	780	O
at	21632816	781	783	O
least	21632816	784	789	O
3	21632816	790	791	O
d	21632816	792	793	O
(	21632816	794	795	O
study	21632816	795	800	O
1	21632816	801	802	O
)	21632816	802	803	O
and	21632816	804	807	O
126	21632816	808	811	O
patients	21632816	812	820	O
in	21632816	821	823	O
a	21632816	824	825	O
nested	21632816	826	832	O
case-control	21632816	833	845	O
study	21632816	846	851	O
(	21632816	852	853	O
study	21632816	853	858	O
2	21632816	859	860	O
)	21632816	860	861	O
.	21632816	861	862	O

MAIN	21632816	864	868	O
OUTCOME	21632816	869	876	O
MEASURES	21632816	877	885	O
:	21632816	886	887	O
Circulating	21632816	888	899	O
insulin	21632816	900	907	O
,	21632816	907	908	O
C-peptide	21632816	909	918	O
,	21632816	918	919	O
GH	21632816	920	922	O
,	21632816	922	923	O
IGF-I	21632816	924	929	O
,	21632816	929	930	O
bioavailable	21632816	931	943	O
IGF-I	21632816	944	949	O
,	21632816	949	950	O
IGF-binding	21632816	951	962	O
protein	21632816	963	970	O
(IGFBP)-1	21632816	971	980	O
,	21632816	980	981	O
IGFBP-3	21632816	982	989	O
,	21632816	989	990	O
and	21632816	991	994	O
acid-labile	21632816	995	1006	O
subunit	21632816	1007	1014	O
were	21632816	1015	1019	O
analyzed	21632816	1020	1028	O
upon	21632816	1029	1033	O
admission	21632816	1034	1043	O
and	21632816	1044	1047	O
d	21632816	1048	1049	O
3	21632816	1050	1051	O
.	21632816	1051	1052	O

In	21632816	1053	1055	O
the	21632816	1056	1059	O
nested	21632816	1060	1066	O
case-control	21632816	1067	1079	O
study	21632816	1080	1085	O
,	21632816	1085	1086	O
the	21632816	1087	1090	O
somatotropic	21632816	1091	1103	O
axis	21632816	1104	1108	O
,	21632816	1108	1109	O
cortisol	21632816	1110	1118	O
,	21632816	1118	1119	O
and	21632816	1120	1123	O
glucagon	21632816	1124	1132	O
were	21632816	1133	1137	O
analyzed	21632816	1138	1146	O
before	21632816	1147	1153	O
and	21632816	1154	1157	O
after	21632816	1158	1163	O
hypoglycemia	21632816	1164	1176	O
.	21632816	1176	1177	O

RESULTS	21632816	1179	1186	O
:	21632816	1187	1188	O
On	21632816	1189	1191	O
d	21632816	1192	1193	O
3	21632816	1194	1195	O
,	21632816	1195	1196	O
C-peptide	21632816	1197	1206	B-Outcome
was	21632816	1207	1210	O
more	21632816	1211	1215	O
than	21632816	1216	1220	O
10-fold	21632816	1221	1228	O
lower	21632816	1229	1234	O
(	21632816	1235	1236	O
P	21632816	1236	1237	O
<	21632816	1238	1239	O
0.0001	21632816	1240	1246	O
)	21632816	1246	1247	O
in	21632816	1248	1250	O
the	21632816	1251	1254	O
IIT	21632816	1255	1258	O
group	21632816	1259	1264	O
than	21632816	1265	1269	O
in	21632816	1270	1272	O
the	21632816	1273	1276	O
CIT	21632816	1277	1280	O
group	21632816	1281	1286	O
.	21632816	1286	1287	O

IIT	21632816	1288	1291	O
increased	21632816	1292	1301	O
circulating	21632816	1302	1313	B-Outcome
GH	21632816	1314	1316	I-Outcome
(	21632816	1317	1318	O
P	21632816	1318	1319	O
=	21632816	1320	1321	O
0.04	21632816	1322	1326	O
)	21632816	1326	1327	O
and	21632816	1328	1331	O
lowered	21632816	1332	1339	O
bioavailable	21632816	1340	1352	B-Outcome
IGF-I	21632816	1353	1358	I-Outcome
(	21632816	1359	1360	O
P	21632816	1360	1361	O
=	21632816	1362	1363	O
0.002	21632816	1364	1369	O
)	21632816	1369	1370	O
.	21632816	1370	1371	O

IIT	21632816	1372	1375	O
also	21632816	1376	1380	O
decreased	21632816	1381	1390	O
IGFBP-3	21632816	1391	1398	B-Outcome
(	21632816	1399	1400	O
P	21632816	1400	1401	O
=	21632816	1402	1403	O
0.0005	21632816	1404	1410	O
)	21632816	1410	1411	O
and	21632816	1412	1415	O
acid-labile	21632816	1416	1427	B-Outcome
subunit	21632816	1428	1435	I-Outcome
(	21632816	1436	1437	O
P	21632816	1437	1438	O
=	21632816	1439	1440	O
0.007	21632816	1441	1446	O
)	21632816	1446	1447	O
,	21632816	1447	1448	O
while	21632816	1449	1454	O
increasing	21632816	1455	1465	O
IGFBP-1	21632816	1466	1473	B-Outcome
(	21632816	1474	1475	O
P	21632816	1475	1476	O
=	21632816	1477	1478	O
0.04	21632816	1479	1483	O
)	21632816	1483	1484	O
and	21632816	1485	1488	O
the	21632816	1489	1492	O
urea/creatinine	21632816	1493	1508	B-Outcome
ratio	21632816	1509	1514	I-Outcome
,	21632816	1514	1515	O
a	21632816	1516	1517	O
marker	21632816	1518	1524	O
of	21632816	1525	1527	O
catabolism	21632816	1528	1538	B-Outcome
(	21632816	1539	1540	O
P	21632816	1540	1541	O
=	21632816	1542	1543	O
0.03	21632816	1544	1548	O
)	21632816	1548	1549	O
.	21632816	1549	1550	O

In	21632816	1551	1553	O
the	21632816	1554	1557	O
nested	21632816	1558	1564	O
case-control	21632816	1565	1577	O
study	21632816	1578	1583	O
,	21632816	1583	1584	O
IGFBP-1	21632816	1585	1592	B-Outcome
was	21632816	1593	1596	O
increased	21632816	1597	1606	O
after	21632816	1607	1612	O
hypoglycemia	21632816	1613	1625	O
,	21632816	1625	1626	O
whereas	21632816	1627	1634	O
the	21632816	1635	1638	O
somatotropic	21632816	1639	1651	B-Outcome
axis	21632816	1652	1656	I-Outcome
and	21632816	1657	1660	O
the	21632816	1661	1664	O
counterregulatory	21632816	1665	1682	B-Outcome
hormones	21632816	1683	1691	I-Outcome
cortisol	21632816	1692	1700	B-Outcome
and	21632816	1701	1704	O
glucagon	21632816	1705	1713	B-Outcome
did	21632816	1714	1717	O
not	21632816	1718	1721	O
change	21632816	1722	1728	O
.	21632816	1728	1729	O

CONCLUSIONS	21632816	1731	1742	O
:	21632816	1743	1744	O
Despite	21632816	1745	1752	O
improved	21632816	1753	1761	O
PICU	21632816	1762	1766	B-Outcome
outcome	21632816	1767	1774	I-Outcome
,	21632816	1774	1775	O
IIT	21632816	1776	1779	O
did	21632816	1780	1783	O
not	21632816	1784	1787	O
counteract	21632816	1788	1798	O
the	21632816	1799	1802	O
catabolic	21632816	1803	1812	O
state	21632816	1813	1818	O
of	21632816	1819	1821	O
critical	21632816	1822	1830	O
illness	21632816	1831	1838	O
.	21632816	1838	1839	O

Suppression	21632816	1840	1851	O
of	21632816	1852	1854	O
portal	21632816	1855	1861	O
insulin	21632816	1862	1869	O
may	21632816	1870	1873	O
have	21632816	1874	1878	O
resulted	21632816	1879	1887	O
in	21632816	1888	1890	O
lower	21632816	1891	1896	O
bioavailable	21632816	1897	1909	B-Outcome
IGF-I.	21632816	1910	1916	I-Outcome

Exemestane	21639806	0	10	O
for	21639806	11	14	O
breast-cancer	21639806	15	28	O
prevention	21639806	29	39	O
in	21639806	40	42	O
postmenopausal	21639806	43	57	O
women	21639806	58	63	O
.	21639806	63	64	O

BACKGROUND	21639806	66	76	O
:	21639806	77	78	O
Tamoxifen	21639806	79	88	O
and	21639806	89	92	O
raloxifene	21639806	93	103	O
have	21639806	104	108	O
limited	21639806	109	116	O
patient	21639806	117	124	O
acceptance	21639806	125	135	O
for	21639806	136	139	O
primary	21639806	140	147	O
prevention	21639806	148	158	O
of	21639806	159	161	O
breast	21639806	162	168	O
cancer	21639806	169	175	O
.	21639806	175	176	O

Aromatase	21639806	177	186	O
inhibitors	21639806	187	197	O
prevent	21639806	198	205	O
more	21639806	206	210	O
contralateral	21639806	211	224	O
breast	21639806	225	231	O
cancers	21639806	232	239	O
and	21639806	240	243	O
cause	21639806	244	249	O
fewer	21639806	250	255	O
side	21639806	256	260	O
effects	21639806	261	268	O
than	21639806	269	273	O
tamoxifen	21639806	274	283	O
in	21639806	284	286	O
patients	21639806	287	295	O
with	21639806	296	300	O
early-stage	21639806	301	312	O
breast	21639806	313	319	O
cancer	21639806	320	326	O
.	21639806	326	327	O

METHODS	21639806	329	336	O
:	21639806	337	338	O
In	21639806	339	341	O
a	21639806	342	343	O
randomized	21639806	344	354	O
,	21639806	354	355	O
placebo-controlled	21639806	356	374	O
,	21639806	374	375	O
double-blind	21639806	376	388	O
trial	21639806	389	394	O
of	21639806	395	397	O
exemestane	21639806	398	408	O
designed	21639806	409	417	O
to	21639806	418	420	O
detect	21639806	421	427	O
a	21639806	428	429	O
65	21639806	430	432	O
%	21639806	432	433	O
relative	21639806	434	442	O
reduction	21639806	443	452	O
in	21639806	453	455	O
invasive	21639806	456	464	O
breast	21639806	465	471	O
cancer	21639806	472	478	O
,	21639806	478	479	O
eligible	21639806	480	488	O
postmenopausal	21639806	489	503	O
women	21639806	504	509	O
35	21639806	510	512	O
years	21639806	513	518	O
of	21639806	519	521	O
age	21639806	522	525	O
or	21639806	526	528	O
older	21639806	529	534	O
had	21639806	535	538	O
at	21639806	539	541	O
least	21639806	542	547	O
one	21639806	548	551	O
of	21639806	552	554	O
the	21639806	555	558	O
following	21639806	559	568	O
risk	21639806	569	573	O
factors	21639806	574	581	O
:	21639806	581	582	O
60	21639806	583	585	O
years	21639806	586	591	O
of	21639806	592	594	O
age	21639806	595	598	O
or	21639806	599	601	O
older	21639806	602	607	O
;	21639806	607	608	O
Gail	21639806	609	613	O
5-year	21639806	614	620	O
risk	21639806	621	625	O
score	21639806	626	631	O
greater	21639806	632	639	O
than	21639806	640	644	O
1.66	21639806	645	649	O
%	21639806	649	650	O
(	21639806	651	652	O
chances	21639806	652	659	O
in	21639806	660	662	O
100	21639806	663	666	O
of	21639806	667	669	O
invasive	21639806	670	678	O
breast	21639806	679	685	O
cancer	21639806	686	692	O
developing	21639806	693	703	O
within	21639806	704	710	O
5	21639806	711	712	O
years	21639806	713	718	O
)	21639806	718	719	O
;	21639806	719	720	O
prior	21639806	721	726	O
atypical	21639806	727	735	O
ductal	21639806	736	742	O
or	21639806	743	745	O
lobular	21639806	746	753	O
hyperplasia	21639806	754	765	O
or	21639806	766	768	O
lobular	21639806	769	776	O
carcinoma	21639806	777	786	O
in	21639806	787	789	O
situ	21639806	790	794	O
;	21639806	794	795	O
or	21639806	796	798	O
ductal	21639806	799	805	O
carcinoma	21639806	806	815	O
in	21639806	816	818	O
situ	21639806	819	823	O
with	21639806	824	828	O
mastectomy	21639806	829	839	O
.	21639806	839	840	O

Toxic	21639806	841	846	O
effects	21639806	847	854	O
and	21639806	855	858	O
health-related	21639806	859	873	O
and	21639806	874	877	O
menopause-specific	21639806	878	896	O
qualities	21639806	897	906	O
of	21639806	907	909	O
life	21639806	910	914	O
were	21639806	915	919	O
measured	21639806	920	928	O
.	21639806	928	929	O

RESULTS	21639806	931	938	O
:	21639806	939	940	O
A	21639806	941	942	O
total	21639806	943	948	O
of	21639806	949	951	O
4560	21639806	952	956	O
women	21639806	957	962	O
for	21639806	963	966	O
whom	21639806	967	971	O
the	21639806	972	975	O
median	21639806	976	982	O
age	21639806	983	986	O
was	21639806	987	990	O
62.5	21639806	991	995	O
years	21639806	996	1001	O
and	21639806	1002	1005	O
the	21639806	1006	1009	O
median	21639806	1010	1016	O
Gail	21639806	1017	1021	O
risk	21639806	1022	1026	O
score	21639806	1027	1032	O
was	21639806	1033	1036	O
2.3	21639806	1037	1040	O
%	21639806	1040	1041	O
were	21639806	1042	1046	O
randomly	21639806	1047	1055	O
assigned	21639806	1056	1064	O
to	21639806	1065	1067	O
either	21639806	1068	1074	O
exemestane	21639806	1075	1085	O
or	21639806	1086	1088	O
placebo	21639806	1089	1096	O
.	21639806	1096	1097	O

At	21639806	1098	1100	O
a	21639806	1101	1102	O
median	21639806	1103	1109	O
follow-up	21639806	1110	1119	O
of	21639806	1120	1122	O
35	21639806	1123	1125	O
months	21639806	1126	1132	O
,	21639806	1132	1133	O
11	21639806	1134	1136	O
invasive	21639806	1137	1145	B-Outcome
breast	21639806	1146	1152	I-Outcome
cancers	21639806	1153	1160	I-Outcome
were	21639806	1161	1165	O
detected	21639806	1166	1174	O
in	21639806	1175	1177	O
those	21639806	1178	1183	O
given	21639806	1184	1189	O
exemestane	21639806	1190	1200	O
and	21639806	1201	1204	O
in	21639806	1205	1207	O
32	21639806	1208	1210	O
of	21639806	1211	1213	O
those	21639806	1214	1219	O
given	21639806	1220	1225	O
placebo	21639806	1226	1233	O
,	21639806	1233	1234	O
with	21639806	1235	1239	O
a	21639806	1240	1241	O
65	21639806	1242	1244	O
%	21639806	1244	1245	O
relative	21639806	1246	1254	O
reduction	21639806	1255	1264	O
in	21639806	1265	1267	O
the	21639806	1268	1271	O
annual	21639806	1272	1278	B-Outcome
incidence	21639806	1279	1288	I-Outcome
of	21639806	1289	1291	I-Outcome
invasive	21639806	1292	1300	I-Outcome
breast	21639806	1301	1307	I-Outcome
cancer	21639806	1308	1314	I-Outcome
(	21639806	1315	1316	O
0.19	21639806	1316	1320	O
%	21639806	1320	1321	O
vs.	21639806	1322	1325	O
0.55	21639806	1326	1330	O
%	21639806	1330	1331	O
;	21639806	1331	1332	O
hazard	21639806	1333	1339	O
ratio	21639806	1340	1345	O
,	21639806	1345	1346	O
0.35	21639806	1347	1351	O
;	21639806	1351	1352	O
95	21639806	1353	1355	O
%	21639806	1355	1356	O
confidence	21639806	1357	1367	O
interval	21639806	1368	1376	O
[	21639806	1377	1378	O
CI	21639806	1378	1380	O
]	21639806	1380	1381	O
,	21639806	1381	1382	O
0.18	21639806	1383	1387	O
to	21639806	1388	1390	O
0.70	21639806	1391	1395	O
;	21639806	1395	1396	O
P=0.002	21639806	1397	1404	O
)	21639806	1404	1405	O
.	21639806	1405	1406	O

The	21639806	1407	1410	O
annual	21639806	1411	1417	B-Outcome
incidence	21639806	1418	1427	I-Outcome
of	21639806	1428	1430	I-Outcome
invasive	21639806	1431	1439	I-Outcome
plus	21639806	1440	1444	I-Outcome
noninvasive	21639806	1445	1456	I-Outcome
(	21639806	1457	1458	I-Outcome
ductal	21639806	1458	1464	I-Outcome
carcinoma	21639806	1465	1474	I-Outcome
in	21639806	1475	1477	I-Outcome
situ	21639806	1478	1482	I-Outcome
)	21639806	1482	1483	I-Outcome
breast	21639806	1484	1490	I-Outcome
cancers	21639806	1491	1498	I-Outcome
was	21639806	1499	1502	O
0.35	21639806	1503	1507	O
%	21639806	1507	1508	O
on	21639806	1509	1511	O
exemestane	21639806	1512	1522	O
and	21639806	1523	1526	O
0.77	21639806	1527	1531	O
%	21639806	1531	1532	O
on	21639806	1533	1535	O
placebo	21639806	1536	1543	O
(	21639806	1544	1545	O
hazard	21639806	1545	1551	O
ratio	21639806	1552	1557	O
,	21639806	1557	1558	O
0.47	21639806	1559	1563	O
;	21639806	1563	1564	O
95	21639806	1565	1567	O
%	21639806	1567	1568	O
CI	21639806	1569	1571	O
,	21639806	1571	1572	O
0.27	21639806	1573	1577	O
to	21639806	1578	1580	O
0.79	21639806	1581	1585	O
;	21639806	1585	1586	O
P=0.004	21639806	1587	1594	O
)	21639806	1594	1595	O
.	21639806	1595	1596	O

Adverse	21639806	1597	1604	B-Outcome
events	21639806	1605	1611	I-Outcome
occurred	21639806	1612	1620	O
in	21639806	1621	1623	O
88	21639806	1624	1626	O
%	21639806	1626	1627	O
of	21639806	1628	1630	O
the	21639806	1631	1634	O
exemestane	21639806	1635	1645	O
group	21639806	1646	1651	O
and	21639806	1652	1655	O
85	21639806	1656	1658	O
%	21639806	1658	1659	O
of	21639806	1660	1662	O
the	21639806	1663	1666	O
placebo	21639806	1667	1674	O
group	21639806	1675	1680	O
(	21639806	1681	1682	O
P=0.003	21639806	1682	1689	O
)	21639806	1689	1690	O
,	21639806	1690	1691	O
with	21639806	1692	1696	O
no	21639806	1697	1699	O
significant	21639806	1700	1711	O
differences	21639806	1712	1723	O
between	21639806	1724	1731	O
the	21639806	1732	1735	O
two	21639806	1736	1739	O
groups	21639806	1740	1746	O
in	21639806	1747	1749	O
terms	21639806	1750	1755	O
of	21639806	1756	1758	O
skeletal	21639806	1759	1767	O
fractures	21639806	1768	1777	O
,	21639806	1777	1778	O
cardiovascular	21639806	1779	1793	O
events	21639806	1794	1800	O
,	21639806	1800	1801	O
other	21639806	1802	1807	O
cancers	21639806	1808	1815	O
,	21639806	1815	1816	O
or	21639806	1817	1819	O
treatment-related	21639806	1820	1837	O
deaths	21639806	1838	1844	O
.	21639806	1844	1845	O

Minimal	21639806	1846	1853	O
quality-of-life	21639806	1854	1869	B-Outcome
differences	21639806	1870	1881	O
were	21639806	1882	1886	O
observed	21639806	1887	1895	O
.	21639806	1895	1896	O

CONCLUSIONS	21639806	1898	1909	O
:	21639806	1910	1911	O
Exemestane	21639806	1912	1922	O
significantly	21639806	1923	1936	O
reduced	21639806	1937	1944	O
invasive	21639806	1945	1953	B-Outcome
breast	21639806	1954	1960	I-Outcome
cancers	21639806	1961	1968	I-Outcome
in	21639806	1969	1971	O
postmenopausal	21639806	1972	1986	O
women	21639806	1987	1992	O
who	21639806	1993	1996	O
were	21639806	1997	2001	O
at	21639806	2002	2004	O
moderately	21639806	2005	2015	O
increased	21639806	2016	2025	O
risk	21639806	2026	2030	O
for	21639806	2031	2034	O
breast	21639806	2035	2041	O
cancer	21639806	2042	2048	O
.	21639806	2048	2049	O

During	21639806	2050	2056	O
a	21639806	2057	2058	O
median	21639806	2059	2065	O
follow-up	21639806	2066	2075	O
period	21639806	2076	2082	O
of	21639806	2083	2085	O
3	21639806	2086	2087	O
years	21639806	2088	2093	O
,	21639806	2093	2094	O
exemestane	21639806	2095	2105	O
was	21639806	2106	2109	O
associated	21639806	2110	2120	O
with	21639806	2121	2125	O
no	21639806	2126	2128	O
serious	21639806	2129	2136	B-Outcome
toxic	21639806	2137	2142	I-Outcome
effects	21639806	2143	2150	I-Outcome
and	21639806	2151	2154	O
only	21639806	2155	2159	O
minimal	21639806	2160	2167	O
changes	21639806	2168	2175	O
in	21639806	2176	2178	O
health-related	21639806	2179	2193	B-Outcome
quality	21639806	2194	2201	I-Outcome
of	21639806	2202	2204	I-Outcome
life	21639806	2205	2209	I-Outcome
.	21639806	2209	2210	O

(	21639806	2211	2212	O
Funded	21639806	2212	2218	O
by	21639806	2219	2221	O
Pfizer	21639806	2222	2228	O
and	21639806	2229	2232	O
others	21639806	2233	2239	O
;	21639806	2239	2240	O
NCIC	21639806	2241	2245	O
CTG	21639806	2246	2249	O
MAP.3	21639806	2250	2255	O
ClinicalTrials.gov	21639806	2256	2274	O
number	21639806	2275	2281	O
,	21639806	2281	2282	O
NCT00083174	21639806	2283	2294	O
.	21639806	2294	2295	O
)	21639806	2295	2296	O
.	21639806	2296	2297	O


Infliximab	21639907	0	10	O
in	21639907	11	13	O
ankylosing	21639907	14	24	O
spondylitis	21639907	25	36	O
:	21639907	36	37	O
alone	21639907	38	43	O
or	21639907	44	46	O
in	21639907	47	49	O
combination	21639907	50	61	O
with	21639907	62	66	O
methotrexate	21639907	67	79	O
?	21639907	79	80	O

A	21639907	81	82	O
pharmacokinetic	21639907	83	98	O
comparative	21639907	99	110	O
study	21639907	111	116	O
.	21639907	116	117	O

INTRODUCTION	21639907	119	131	O
:	21639907	132	133	O
Methotrexate	21639907	134	146	O
(	21639907	147	148	O
MTX	21639907	148	151	O
)	21639907	151	152	O
has	21639907	153	156	O
been	21639907	157	161	O
shown	21639907	162	167	O
to	21639907	168	170	O
modify	21639907	171	177	O
infliximab	21639907	178	188	O
pharmacokinetics	21639907	189	205	O
in	21639907	206	208	O
rheumatoid	21639907	209	219	O
arthritis	21639907	220	229	O
.	21639907	229	230	O

However	21639907	231	238	O
,	21639907	238	239	O
its	21639907	240	243	O
combination	21639907	244	255	O
with	21639907	256	260	O
infliximab	21639907	261	271	O
in	21639907	272	274	O
the	21639907	275	278	O
treatment	21639907	279	288	O
of	21639907	289	291	O
ankylosing	21639907	292	302	O
spondylitis	21639907	303	314	O
(	21639907	315	316	O
AS	21639907	316	318	O
)	21639907	318	319	O
is	21639907	320	322	O
not	21639907	323	326	O
recommended	21639907	327	338	O
.	21639907	338	339	O

The	21639907	340	343	O
objective	21639907	344	353	O
of	21639907	354	356	O
this	21639907	357	361	O
study	21639907	362	367	O
was	21639907	368	371	O
to	21639907	372	374	O
examine	21639907	375	382	O
the	21639907	383	386	O
influence	21639907	387	396	O
of	21639907	397	399	O
MTX	21639907	400	403	O
on	21639907	404	406	O
infliximab	21639907	407	417	O
exposure	21639907	418	426	O
in	21639907	427	429	O
patients	21639907	430	438	O
with	21639907	439	443	O
AS	21639907	444	446	O
.	21639907	446	447	O

METHODS	21639907	449	456	O
:	21639907	457	458	O
Patients	21639907	459	467	O
with	21639907	468	472	O
AS	21639907	473	475	O
patients	21639907	476	484	O
who	21639907	485	488	O
had	21639907	489	492	O
predominantly	21639907	493	506	O
axial	21639907	507	512	O
symptoms	21639907	513	521	O
were	21639907	522	526	O
randomised	21639907	527	537	O
to	21639907	538	540	O
receive	21639907	541	548	O
infliximab	21639907	549	559	O
alone	21639907	560	565	O
(	21639907	566	567	O
infusions	21639907	567	576	O
of	21639907	577	579	O
5	21639907	580	581	O
mg/kg	21639907	582	587	O
at	21639907	588	590	O
weeks	21639907	591	596	O
0	21639907	597	598	O
,	21639907	598	599	O
2	21639907	600	601	O
,	21639907	601	602	O
6	21639907	603	604	O
,	21639907	604	605	O
12	21639907	606	608	O
and	21639907	609	612	O
18	21639907	613	615	O
)	21639907	615	616	O
or	21639907	617	619	O
infliximab	21639907	620	630	O
combined	21639907	631	639	O
with	21639907	640	644	O
MTX	21639907	645	648	O
(	21639907	649	650	O
10	21639907	650	652	O
mg/week	21639907	653	660	O
)	21639907	660	661	O
.	21639907	661	662	O

Infliximab	21639907	663	673	O
concentrations	21639907	674	688	O
were	21639907	689	693	O
measured	21639907	694	702	O
before	21639907	703	709	O
and	21639907	710	713	O
2	21639907	714	715	O
hours	21639907	716	721	O
after	21639907	722	727	O
each	21639907	728	732	O
infusion	21639907	733	741	O
and	21639907	742	745	O
at	21639907	746	748	O
1	21639907	749	750	O
,	21639907	750	751	O
3	21639907	752	753	O
,	21639907	753	754	O
4	21639907	755	756	O
,	21639907	756	757	O
5	21639907	758	759	O
,	21639907	759	760	O
8	21639907	761	762	O
,	21639907	762	763	O
10	21639907	764	766	O
,	21639907	766	767	O
14	21639907	768	770	O
and	21639907	771	774	O
18	21639907	775	777	O
weeks	21639907	778	783	O
.	21639907	783	784	O

We	21639907	785	787	O
estimated	21639907	788	797	O
individual	21639907	798	808	O
cumulative	21639907	809	819	O
area	21639907	820	824	O
under	21639907	825	830	O
the	21639907	831	834	O
concentration	21639907	835	848	O
versus	21639907	849	855	O
time	21639907	856	860	O
curves	21639907	861	867	O
(	21639907	868	869	O
AUC	21639907	869	872	O
)	21639907	872	873	O
for	21639907	874	877	O
infliximab	21639907	878	888	O
concentration	21639907	889	902	O
between	21639907	903	910	O
baseline	21639907	911	919	O
and	21639907	920	923	O
week	21639907	924	928	O
18	21639907	929	931	O
(	21639907	932	933	O
AUC(0	21639907	933	938	O
-	21639907	938	939	O
18	21639907	939	941	O
)	21639907	941	942	O
)	21639907	942	943	O
.	21639907	943	944	O

Clinical	21639907	945	953	O
and	21639907	954	957	O
laboratory	21639907	958	968	O
evaluations	21639907	969	980	O
were	21639907	981	985	O
performed	21639907	986	995	O
at	21639907	996	998	O
each	21639907	999	1003	O
visit	21639907	1004	1009	O
.	21639907	1009	1010	O

The	21639907	1011	1014	O
Bath	21639907	1015	1019	O
Ankylosing	21639907	1020	1030	O
Spondylitis	21639907	1031	1042	O
Disease	21639907	1043	1050	O
Activity	21639907	1051	1059	O
Index	21639907	1060	1065	O
(	21639907	1066	1067	O
BASDAI	21639907	1067	1073	O
)	21639907	1073	1074	O
score	21639907	1075	1080	O
was	21639907	1081	1084	O
the	21639907	1085	1088	O
primary	21639907	1089	1096	O
end	21639907	1097	1100	O
point	21639907	1101	1106	O
for	21639907	1107	1110	O
clinical	21639907	1111	1119	O
response	21639907	1120	1128	O
.	21639907	1128	1129	O

RESULTS	21639907	1131	1138	O
:	21639907	1139	1140	O
Twenty-six	21639907	1141	1151	O
patients	21639907	1152	1160	O
were	21639907	1161	1165	O
included	21639907	1166	1174	O
(	21639907	1175	1176	O
infliximab	21639907	1176	1186	O
group	21639907	1187	1192	O
:	21639907	1192	1193	O
n	21639907	1194	1195	O
=	21639907	1196	1197	O
12	21639907	1198	1200	O
,	21639907	1200	1201	O
infliximab	21639907	1202	1212	O
+	21639907	1213	1214	O
MTX	21639907	1215	1218	O
group	21639907	1219	1224	O
:	21639907	1224	1225	O
n	21639907	1226	1227	O
=	21639907	1228	1229	O
14	21639907	1230	1232	O
)	21639907	1232	1233	O
,	21639907	1233	1234	O
and	21639907	1235	1238	O
507	21639907	1239	1242	O
serum	21639907	1243	1248	O
samples	21639907	1249	1256	O
were	21639907	1257	1261	O
available	21639907	1262	1271	O
for	21639907	1272	1275	O
measurement	21639907	1276	1287	O
of	21639907	1288	1290	O
infliximab	21639907	1291	1301	B-Outcome
concentration	21639907	1302	1315	I-Outcome
.	21639907	1315	1316	O

The	21639907	1317	1320	O
two	21639907	1321	1324	O
groups	21639907	1325	1331	O
did	21639907	1332	1335	O
not	21639907	1336	1339	O
differ	21639907	1340	1346	O
with	21639907	1347	1351	O
regard	21639907	1352	1358	O
to	21639907	1359	1361	O
AUC(0	21639907	1362	1367	B-Outcome
-	21639907	1367	1368	I-Outcome
18	21639907	1368	1370	I-Outcome
)	21639907	1370	1371	I-Outcome
or	21639907	1372	1374	O
evolution	21639907	1375	1384	O
of	21639907	1385	1387	O
BASDAI	21639907	1388	1394	B-Outcome
scores	21639907	1395	1401	I-Outcome
and	21639907	1402	1405	O
biomarkers	21639907	1406	1416	B-Outcome
of	21639907	1417	1419	I-Outcome
inflammation	21639907	1420	1432	I-Outcome
.	21639907	1432	1433	O

CONCLUSIONS	21639907	1435	1446	O
:	21639907	1447	1448	O
The	21639907	1449	1452	O
combination	21639907	1453	1464	O
of	21639907	1465	1467	O
MTX	21639907	1468	1471	O
and	21639907	1472	1475	O
infliximab	21639907	1476	1486	O
does	21639907	1487	1491	O
not	21639907	1492	1495	O
increase	21639907	1496	1504	O
the	21639907	1505	1508	O
exposure	21639907	1509	1517	B-Outcome
to	21639907	1518	1520	I-Outcome
infliximab	21639907	1521	1531	I-Outcome
over	21639907	1532	1536	O
infliximab	21639907	1537	1547	O
alone	21639907	1548	1553	O
in	21639907	1554	1556	O
patients	21639907	1557	1565	O
with	21639907	1566	1570	O
AS	21639907	1571	1573	O
.	21639907	1573	1574	O

TRIAL	21639907	1576	1581	O
REGISTRATION	21639907	1582	1594	O
:	21639907	1595	1596	O
ClinicalTrials.gov	21639907	1597	1615	O
:	21639907	1615	1616	O
NCT00507403	21639907	1617	1628	O
.	21639907	1628	1629	O


Rivaroxaban	21830957	0	11	O
versus	21830957	12	18	O
warfarin	21830957	19	27	O
in	21830957	28	30	O
nonvalvular	21830957	31	42	O
atrial	21830957	43	49	O
fibrillation	21830957	50	62	O
.	21830957	62	63	O

BACKGROUND	21830957	65	75	O
:	21830957	76	77	O
The	21830957	78	81	O
use	21830957	82	85	O
of	21830957	86	88	O
warfarin	21830957	89	97	O
reduces	21830957	98	105	O
the	21830957	106	109	O
rate	21830957	110	114	O
of	21830957	115	117	O
ischemic	21830957	118	126	O
stroke	21830957	127	133	O
in	21830957	134	136	O
patients	21830957	137	145	O
with	21830957	146	150	O
atrial	21830957	151	157	O
fibrillation	21830957	158	170	O
but	21830957	171	174	O
requires	21830957	175	183	O
frequent	21830957	184	192	O
monitoring	21830957	193	203	O
and	21830957	204	207	O
dose	21830957	208	212	O
adjustment	21830957	213	223	O
.	21830957	223	224	O

Rivaroxaban	21830957	225	236	O
,	21830957	236	237	O
an	21830957	238	240	O
oral	21830957	241	245	O
factor	21830957	246	252	O
Xa	21830957	253	255	O
inhibitor	21830957	256	265	O
,	21830957	265	266	O
may	21830957	267	270	O
provide	21830957	271	278	O
more	21830957	279	283	O
consistent	21830957	284	294	O
and	21830957	295	298	O
predictable	21830957	299	310	O
anticoagulation	21830957	311	326	O
than	21830957	327	331	O
warfarin	21830957	332	340	O
.	21830957	340	341	O

METHODS	21830957	343	350	O
:	21830957	351	352	O
In	21830957	353	355	O
a	21830957	356	357	O
double-blind	21830957	358	370	O
trial	21830957	371	376	O
,	21830957	376	377	O
we	21830957	378	380	O
randomly	21830957	381	389	O
assigned	21830957	390	398	O
14,264	21830957	399	405	O
patients	21830957	406	414	O
with	21830957	415	419	O
nonvalvular	21830957	420	431	O
atrial	21830957	432	438	O
fibrillation	21830957	439	451	O
who	21830957	452	455	O
were	21830957	456	460	O
at	21830957	461	463	O
increased	21830957	464	473	O
risk	21830957	474	478	O
for	21830957	479	482	O
stroke	21830957	483	489	O
to	21830957	490	492	O
receive	21830957	493	500	O
either	21830957	501	507	O
rivaroxaban	21830957	508	519	O
(	21830957	520	521	O
at	21830957	521	523	O
a	21830957	524	525	O
daily	21830957	526	531	O
dose	21830957	532	536	O
of	21830957	537	539	O
20	21830957	540	542	O
mg	21830957	543	545	O
)	21830957	545	546	O
or	21830957	547	549	O
dose-adjusted	21830957	550	563	O
warfarin	21830957	564	572	O
.	21830957	572	573	O

The	21830957	574	577	O
per-protocol	21830957	578	590	O
,	21830957	590	591	O
as-treated	21830957	592	602	O
primary	21830957	603	610	O
analysis	21830957	611	619	O
was	21830957	620	623	O
designed	21830957	624	632	O
to	21830957	633	635	O
determine	21830957	636	645	O
whether	21830957	646	653	O
rivaroxaban	21830957	654	665	O
was	21830957	666	669	O
noninferior	21830957	670	681	O
to	21830957	682	684	O
warfarin	21830957	685	693	O
for	21830957	694	697	O
the	21830957	698	701	O
primary	21830957	702	709	O
end	21830957	710	713	O
point	21830957	714	719	O
of	21830957	720	722	O
stroke	21830957	723	729	O
or	21830957	730	732	O
systemic	21830957	733	741	O
embolism	21830957	742	750	O
.	21830957	750	751	O

RESULTS	21830957	753	760	O
:	21830957	761	762	O
In	21830957	763	765	O
the	21830957	766	769	O
primary	21830957	770	777	O
analysis	21830957	778	786	O
,	21830957	786	787	O
the	21830957	788	791	O
primary	21830957	792	799	O
end	21830957	800	803	O
point	21830957	804	809	O
occurred	21830957	810	818	O
in	21830957	819	821	O
188	21830957	822	825	O
patients	21830957	826	834	O
in	21830957	835	837	O
the	21830957	838	841	O
rivaroxaban	21830957	842	853	O
group	21830957	854	859	O
(	21830957	860	861	O
1.7	21830957	861	864	O
%	21830957	864	865	O
per	21830957	866	869	O
year	21830957	870	874	O
)	21830957	874	875	O
and	21830957	876	879	O
in	21830957	880	882	O
241	21830957	883	886	O
in	21830957	887	889	O
the	21830957	890	893	O
warfarin	21830957	894	902	O
group	21830957	903	908	O
(	21830957	909	910	O
2.2	21830957	910	913	O
%	21830957	913	914	O
per	21830957	915	918	O
year	21830957	919	923	O
)	21830957	923	924	O
(	21830957	925	926	O
hazard	21830957	926	932	O
ratio	21830957	933	938	O
in	21830957	939	941	O
the	21830957	942	945	O
rivaroxaban	21830957	946	957	O
group	21830957	958	963	O
,	21830957	963	964	O
0.79	21830957	965	969	O
;	21830957	969	970	O
95	21830957	971	973	O
%	21830957	973	974	O
confidence	21830957	975	985	O
interval	21830957	986	994	O
[	21830957	995	996	O
CI	21830957	996	998	O
]	21830957	998	999	O
,	21830957	999	1000	O
0.66	21830957	1001	1005	O
to	21830957	1006	1008	O
0.96	21830957	1009	1013	O
;	21830957	1013	1014	O
P<0.001	21830957	1015	1022	O
for	21830957	1023	1026	O
noninferiority	21830957	1027	1041	O
)	21830957	1041	1042	O
.	21830957	1042	1043	O

In	21830957	1044	1046	O
the	21830957	1047	1050	O
intention-to-treat	21830957	1051	1069	O
analysis	21830957	1070	1078	O
,	21830957	1078	1079	O
the	21830957	1080	1083	O
primary	21830957	1084	1091	O
end	21830957	1092	1095	O
point	21830957	1096	1101	O
occurred	21830957	1102	1110	O
in	21830957	1111	1113	O
269	21830957	1114	1117	O
patients	21830957	1118	1126	O
in	21830957	1127	1129	O
the	21830957	1130	1133	O
rivaroxaban	21830957	1134	1145	O
group	21830957	1146	1151	O
(	21830957	1152	1153	O
2.1	21830957	1153	1156	O
%	21830957	1156	1157	O
per	21830957	1158	1161	O
year	21830957	1162	1166	O
)	21830957	1166	1167	O
and	21830957	1168	1171	O
in	21830957	1172	1174	O
306	21830957	1175	1178	O
patients	21830957	1179	1187	O
in	21830957	1188	1190	O
the	21830957	1191	1194	O
warfarin	21830957	1195	1203	O
group	21830957	1204	1209	O
(	21830957	1210	1211	O
2.4	21830957	1211	1214	O
%	21830957	1214	1215	O
per	21830957	1216	1219	O
year	21830957	1220	1224	O
)	21830957	1224	1225	O
(	21830957	1226	1227	O
hazard	21830957	1227	1233	O
ratio	21830957	1234	1239	O
,	21830957	1239	1240	O
0.88	21830957	1241	1245	O
;	21830957	1245	1246	O
95	21830957	1247	1249	O
%	21830957	1249	1250	O
CI	21830957	1251	1253	O
,	21830957	1253	1254	O
0.74	21830957	1255	1259	O
to	21830957	1260	1262	O
1.03	21830957	1263	1267	O
;	21830957	1267	1268	O
P<0.001	21830957	1269	1276	O
for	21830957	1277	1280	O
noninferiority	21830957	1281	1295	O
;	21830957	1295	1296	O
P=0.12	21830957	1297	1303	O
for	21830957	1304	1307	O
superiority	21830957	1308	1319	O
)	21830957	1319	1320	O
.	21830957	1320	1321	O

Major	21830957	1322	1327	B-Outcome
and	21830957	1328	1331	O
nonmajor	21830957	1332	1340	B-Outcome
clinically	21830957	1341	1351	I-Outcome
relevant	21830957	1352	1360	I-Outcome
bleeding	21830957	1361	1369	I-Outcome
occurred	21830957	1370	1378	O
in	21830957	1379	1381	O
1475	21830957	1382	1386	O
patients	21830957	1387	1395	O
in	21830957	1396	1398	O
the	21830957	1399	1402	O
rivaroxaban	21830957	1403	1414	O
group	21830957	1415	1420	O
(	21830957	1421	1422	O
14.9	21830957	1422	1426	O
%	21830957	1426	1427	O
per	21830957	1428	1431	O
year	21830957	1432	1436	O
)	21830957	1436	1437	O
and	21830957	1438	1441	O
in	21830957	1442	1444	O
1449	21830957	1445	1449	O
in	21830957	1450	1452	O
the	21830957	1453	1456	O
warfarin	21830957	1457	1465	O
group	21830957	1466	1471	O
(	21830957	1472	1473	O
14.5	21830957	1473	1477	O
%	21830957	1477	1478	O
per	21830957	1479	1482	O
year	21830957	1483	1487	O
)	21830957	1487	1488	O
(	21830957	1489	1490	O
hazard	21830957	1490	1496	O
ratio	21830957	1497	1502	O
,	21830957	1502	1503	O
1.03	21830957	1504	1508	O
;	21830957	1508	1509	O
95	21830957	1510	1512	O
%	21830957	1512	1513	O
CI	21830957	1514	1516	O
,	21830957	1516	1517	O
0.96	21830957	1518	1522	O
to	21830957	1523	1525	O
1.11	21830957	1526	1530	O
;	21830957	1530	1531	O
P=0.44	21830957	1532	1538	O
)	21830957	1538	1539	O
,	21830957	1539	1540	O
with	21830957	1541	1545	O
significant	21830957	1546	1557	O
reductions	21830957	1558	1568	O
in	21830957	1569	1571	O
intracranial	21830957	1572	1584	B-Outcome
hemorrhage	21830957	1585	1595	I-Outcome
(	21830957	1596	1597	O
0.5	21830957	1597	1600	O
%	21830957	1600	1601	O
vs.	21830957	1602	1605	O
0.7	21830957	1606	1609	O
%	21830957	1609	1610	O
,	21830957	1610	1611	O
P=0.02	21830957	1612	1618	O
)	21830957	1618	1619	O
and	21830957	1620	1623	O
fatal	21830957	1624	1629	B-Outcome
bleeding	21830957	1630	1638	I-Outcome
(	21830957	1639	1640	O
0.2	21830957	1640	1643	O
%	21830957	1643	1644	O
vs.	21830957	1645	1648	O
0.5	21830957	1649	1652	O
%	21830957	1652	1653	O
,	21830957	1653	1654	O
P=0.003	21830957	1655	1662	O
)	21830957	1662	1663	O
in	21830957	1664	1666	O
the	21830957	1667	1670	O
rivaroxaban	21830957	1671	1682	O
group	21830957	1683	1688	O
.	21830957	1688	1689	O

CONCLUSIONS	21830957	1691	1702	O
:	21830957	1703	1704	O
In	21830957	1705	1707	O
patients	21830957	1708	1716	O
with	21830957	1717	1721	O
atrial	21830957	1722	1728	O
fibrillation	21830957	1729	1741	O
,	21830957	1741	1742	O
rivaroxaban	21830957	1743	1754	O
was	21830957	1755	1758	O
noninferior	21830957	1759	1770	O
to	21830957	1771	1773	O
warfarin	21830957	1774	1782	O
for	21830957	1783	1786	O
the	21830957	1787	1790	O
prevention	21830957	1791	1801	O
of	21830957	1802	1804	O
stroke	21830957	1805	1811	B-Outcome
or	21830957	1812	1814	O
systemic	21830957	1815	1823	B-Outcome
embolism	21830957	1824	1832	I-Outcome
.	21830957	1832	1833	O

There	21830957	1834	1839	O
was	21830957	1840	1843	O
no	21830957	1844	1846	O
significant	21830957	1847	1858	O
between-group	21830957	1859	1872	O
difference	21830957	1873	1883	O
in	21830957	1884	1886	O
the	21830957	1887	1890	O
risk	21830957	1891	1895	O
of	21830957	1896	1898	O
major	21830957	1899	1904	B-Outcome
bleeding	21830957	1905	1913	I-Outcome
,	21830957	1913	1914	O
although	21830957	1915	1923	O
intracranial	21830957	1924	1936	B-Outcome
and	21830957	1937	1940	O
fatal	21830957	1941	1946	B-Outcome
bleeding	21830957	1947	1955	I-Outcome
occurred	21830957	1956	1964	O
less	21830957	1965	1969	O
frequently	21830957	1970	1980	O
in	21830957	1981	1983	O
the	21830957	1984	1987	O
rivaroxaban	21830957	1988	1999	O
group	21830957	2000	2005	O
.	21830957	2005	2006	O

(	21830957	2007	2008	O
Funded	21830957	2008	2014	O
by	21830957	2015	2017	O
Johnson	21830957	2018	2025	O
&	21830957	2026	2027	O
Johnson	21830957	2028	2035	O
and	21830957	2036	2039	O
Bayer	21830957	2040	2045	O
;	21830957	2045	2046	O
ROCKET	21830957	2047	2053	O
AF	21830957	2054	2056	O
ClinicalTrials.gov	21830957	2057	2075	O
number	21830957	2076	2082	O
,	21830957	2082	2083	O
NCT00403767	21830957	2084	2095	O
.	21830957	2095	2096	O
)	21830957	2096	2097	O
.	21830957	2097	2098	O


Randomised	21909698	0	10	O
multicentre	21909698	11	22	O
trial	21909698	23	28	O
of	21909698	29	31	O
circular	21909698	32	40	O
stapling	21909698	41	49	O
devices	21909698	50	57	O
.	21909698	57	58	O

PURPOSE	21909698	60	67	O
:	21909698	68	69	O
In	21909698	70	72	O
a	21909698	73	74	O
register	21909698	75	83	O
study	21909698	84	89	O
,	21909698	89	90	O
the	21909698	91	94	O
risk	21909698	95	99	O
of	21909698	100	102	O
anastomotic	21909698	103	114	O
leakage	21909698	115	122	O
correlated	21909698	123	133	O
to	21909698	134	136	O
the	21909698	137	140	O
choice	21909698	141	147	O
of	21909698	148	150	O
circular	21909698	151	159	O
stapling	21909698	160	168	O
device	21909698	169	175	O
with	21909698	176	180	O
a	21909698	181	182	O
4	21909698	183	184	O
%	21909698	184	185	O
difference	21909698	186	196	O
between	21909698	197	204	O
the	21909698	205	208	O
two	21909698	209	212	O
brands	21909698	213	219	O
used	21909698	220	224	O
.	21909698	224	225	O

Based	21909698	226	231	O
on	21909698	232	234	O
those	21909698	235	240	O
data	21909698	241	245	O
,	21909698	245	246	O
a	21909698	247	248	O
randomised	21909698	249	259	O
multicentre	21909698	260	271	O
study	21909698	272	277	O
was	21909698	278	281	O
started	21909698	282	289	O
to	21909698	290	292	O
explore	21909698	293	300	O
the	21909698	301	304	O
risk	21909698	305	309	O
of	21909698	310	312	O
an	21909698	313	315	O
anastomotic	21909698	316	327	O
leakage	21909698	328	335	O
based	21909698	336	341	O
upon	21909698	342	346	O
the	21909698	347	350	O
surgical	21909698	351	359	O
device	21909698	360	366	O
.	21909698	366	367	O

METHODS	21909698	369	376	O
:	21909698	377	378	O
Patients	21909698	379	387	O
above	21909698	388	393	O
18	21909698	394	396	O
years	21909698	397	402	O
with	21909698	403	407	O
a	21909698	408	409	O
rectal	21909698	410	416	O
cancer	21909698	417	423	O
,	21909698	423	424	O
able	21909698	425	429	O
to	21909698	430	432	O
give	21909698	433	437	O
informed	21909698	438	446	O
consent	21909698	447	454	O
,	21909698	454	455	O
and	21909698	456	459	O
scheduled	21909698	460	469	O
for	21909698	470	473	O
an	21909698	474	476	O
anterior	21909698	477	485	O
resection	21909698	486	495	O
were	21909698	496	500	O
eligible	21909698	501	509	O
for	21909698	510	513	O
the	21909698	514	517	O
study	21909698	518	523	O
.	21909698	523	524	O

Perioperative	21909698	525	538	O
randomisation	21909698	539	552	O
was	21909698	553	556	O
to	21909698	557	559	O
Ethicon	21909698	560	567	O
™	21909698	567	568	O
PROXIMATE	21909698	569	578	O
™	21909698	578	579	O
ILS	21909698	580	583	O
™	21909698	583	584	O
or	21909698	585	587	O
Autosuture	21909698	588	598	O
™	21909698	598	599	O
Premium	21909698	600	607	O
Plus	21909698	608	612	O
CEEA	21909698	613	617	O
™	21909698	617	618	O
.	21909698	618	619	O

Anastomotic	21909698	620	631	O
leakage	21909698	632	639	O
was	21909698	640	643	O
defined	21909698	644	651	O
as	21909698	652	654	O
a	21909698	655	656	O
clinically	21909698	657	667	O
manifest	21909698	668	676	O
leak	21909698	677	681	O
.	21909698	681	682	O

RESULTS	21909698	684	691	O
:	21909698	692	693	O
Five	21909698	694	698	O
hundred	21909698	699	706	O
twenty-nine	21909698	707	718	O
patients	21909698	719	727	O
were	21909698	728	732	O
randomised	21909698	733	743	O
(	21909698	744	745	O
58	21909698	745	747	O
%	21909698	747	748	O
male	21909698	749	753	O
)	21909698	753	754	O
.	21909698	754	755	O

A	21909698	756	757	O
leak	21909698	758	762	B-Outcome
occurred	21909698	763	771	O
in	21909698	772	774	O
8.3	21909698	775	778	O
%	21909698	778	779	O
.	21909698	779	780	O

The	21909698	781	784	O
anastomoses	21909698	785	796	O
created	21909698	797	804	O
by	21909698	805	807	O
PROXIMATE	21909698	808	817	O
™	21909698	817	818	O
ILS	21909698	819	822	O
™	21909698	822	823	O
leaked	21909698	824	830	B-Outcome
in	21909698	831	833	O
25/265	21909698	834	840	O
(	21909698	841	842	O
9.4	21909698	842	845	O
%	21909698	845	846	O
)	21909698	846	847	O
anastomoses	21909698	848	859	O
,	21909698	859	860	O
and	21909698	861	864	O
the	21909698	865	868	O
Premium	21909698	869	876	O
Plus	21909698	877	881	O
CEEA	21909698	882	886	O
™	21909698	886	887	O
leaked	21909698	888	894	B-Outcome
in	21909698	895	897	O
19/260	21909698	898	904	O
(	21909698	905	906	O
7.3	21909698	906	909	O
%	21909698	909	910	O
)	21909698	910	911	O
,	21909698	911	912	O
p	21909698	913	914	O
=	21909698	915	916	O
.419	21909698	917	921	O
.	21909698	921	922	O

CONCLUSION	21909698	924	934	O
:	21909698	935	936	O
No	21909698	937	939	O
difference	21909698	940	950	O
in	21909698	951	953	O
the	21909698	954	957	O
leak	21909698	958	962	B-Outcome
rate	21909698	963	967	I-Outcome
could	21909698	968	973	O
be	21909698	974	976	O
revealed	21909698	977	985	O
.	21909698	985	986	O

Several	21909698	987	994	O
centres	21909698	995	1002	O
replaced	21909698	1003	1011	O
one	21909698	1012	1015	O
of	21909698	1016	1018	O
the	21909698	1019	1022	O
staplers	21909698	1023	1031	O
by	21909698	1032	1034	O
a	21909698	1035	1036	O
new	21909698	1037	1040	O
product	21909698	1041	1048	O
,	21909698	1048	1049	O
and	21909698	1050	1053	O
the	21909698	1054	1057	O
study	21909698	1058	1063	O
was	21909698	1064	1067	O
ended	21909698	1068	1073	O
before	21909698	1074	1080	O
the	21909698	1081	1084	O
stipulated	21909698	1085	1095	O
number	21909698	1096	1102	O
of	21909698	1103	1105	O
patients	21909698	1106	1114	O
was	21909698	1115	1118	O
reached	21909698	1119	1126	O
.	21909698	1126	1127	O

In	21909698	1128	1130	O
the	21909698	1131	1134	O
future	21909698	1135	1141	O
,	21909698	1141	1142	O
surgical	21909698	1143	1151	O
devices	21909698	1152	1159	O
may	21909698	1160	1163	O
have	21909698	1164	1168	O
to	21909698	1169	1171	O
prove	21909698	1172	1177	O
superiority	21909698	1178	1189	O
in	21909698	1190	1192	O
randomised	21909698	1193	1203	O
trials	21909698	1204	1210	O
or	21909698	1211	1213	O
be	21909698	1214	1216	O
monitored	21909698	1217	1226	O
in	21909698	1227	1229	O
quality	21909698	1230	1237	O
registers	21909698	1238	1247	O
before	21909698	1248	1254	O
they	21909698	1255	1259	O
can	21909698	1260	1263	O
be	21909698	1264	1266	O
introduced	21909698	1267	1277	O
into	21909698	1278	1282	O
day	21909698	1283	1286	O
to	21909698	1287	1289	O
day	21909698	1290	1293	O
surgical	21909698	1294	1302	O
practice	21909698	1303	1311	O
.	21909698	1311	1312	O

The	21909698	1313	1316	O
study	21909698	1317	1322	O
was	21909698	1323	1326	O
registered	21909698	1327	1337	O
at	21909698	1338	1340	O
ClinicalTrials.gov	21909698	1341	1359	O
:	21909698	1359	1360	O
NCT00399009	21909698	1361	1372	O
.	21909698	1372	1373	O


Oral	21987240	0	4	O
bioavailability	21987240	5	20	O
of	21987240	21	23	O
moxifloxacin	21987240	24	36	O
after	21987240	37	42	O
Roux-en-Y	21987240	43	52	O
gastric	21987240	53	60	O
bypass	21987240	61	67	O
surgery	21987240	68	75	O
.	21987240	75	76	O

OBJECTIVES	21987240	78	88	O
:	21987240	89	90	O
Roux-en-Y	21987240	91	100	O
gastric	21987240	101	108	O
bypass	21987240	109	115	O
surgery	21987240	116	123	O
is	21987240	124	126	O
the	21987240	127	130	O
most	21987240	131	135	O
commonly	21987240	136	144	O
performed	21987240	145	154	O
procedure	21987240	155	164	O
for	21987240	165	168	O
the	21987240	169	172	O
treatment	21987240	173	182	O
of	21987240	183	185	O
morbid	21987240	186	192	O
obesity	21987240	193	200	O
.	21987240	200	201	O

This	21987240	202	206	O
anatomical	21987240	207	217	O
alteration	21987240	218	228	O
may	21987240	229	232	O
affect	21987240	233	239	O
the	21987240	240	243	O
absorption	21987240	244	254	O
and	21987240	255	258	O
consequently	21987240	259	271	O
the	21987240	272	275	O
bioavailability	21987240	276	291	O
of	21987240	292	294	O
oral	21987240	295	299	O
drugs	21987240	300	305	O
.	21987240	305	306	O

This	21987240	307	311	O
study	21987240	312	317	O
aims	21987240	318	322	O
to	21987240	323	325	O
investigate	21987240	326	337	O
the	21987240	338	341	O
oral	21987240	342	346	O
bioavailability	21987240	347	362	O
of	21987240	363	365	O
moxifloxacin	21987240	366	378	O
in	21987240	379	381	O
12	21987240	382	384	O
healthy	21987240	385	392	O
volunteers	21987240	393	403	O
who	21987240	404	407	O
underwent	21987240	408	417	O
gastric	21987240	418	425	O
bypass	21987240	426	432	O
surgery	21987240	433	440	O
.	21987240	440	441	O

PATIENTS	21987240	443	451	O
AND	21987240	452	455	O
METHODS	21987240	456	463	O
:	21987240	464	465	O
In	21987240	466	468	O
this	21987240	469	473	O
randomized	21987240	474	484	O
crossover	21987240	485	494	O
study	21987240	495	500	O
,	21987240	500	501	O
each	21987240	502	506	O
subject	21987240	507	514	O
received	21987240	515	523	O
two	21987240	524	527	O
single	21987240	528	534	O
standard	21987240	535	543	O
doses	21987240	544	549	O
of	21987240	550	552	O
400	21987240	553	556	O
mg	21987240	557	559	O
of	21987240	560	562	O
moxifloxacin	21987240	563	575	O
orally	21987240	576	582	O
or	21987240	583	585	O
intravenously	21987240	586	599	O
administered	21987240	600	612	O
on	21987240	613	615	O
two	21987240	616	619	O
occasions	21987240	620	629	O
separated	21987240	630	639	O
by	21987240	640	642	O
a	21987240	643	644	O
washout	21987240	645	652	O
period	21987240	653	659	O
of	21987240	660	662	O
1	21987240	663	664	O
week	21987240	665	669	O
.	21987240	669	670	O

Serial	21987240	671	677	O
venous	21987240	678	684	O
blood	21987240	685	690	O
samples	21987240	691	698	O
were	21987240	699	703	O
drawn	21987240	704	709	O
up	21987240	710	712	O
to	21987240	713	715	O
72	21987240	716	718	O
h	21987240	719	720	O
after	21987240	721	726	O
dosing	21987240	727	733	O
and	21987240	734	737	O
moxifloxacin	21987240	738	750	O
plasma	21987240	751	757	O
levels	21987240	758	764	O
were	21987240	765	769	O
measured	21987240	770	778	O
by	21987240	779	781	O
a	21987240	782	783	O
validated	21987240	784	793	O
HPLC	21987240	794	798	O
method	21987240	799	805	O
with	21987240	806	810	O
fluorescence	21987240	811	823	O
detection	21987240	824	833	O
.	21987240	833	834	O

[	21987240	835	836	O
clinicaltrials.gov	21987240	836	854	O
database	21987240	855	863	O
(	21987240	864	865	O
identifier	21987240	865	875	O
:	21987240	875	876	O
NCT01130922	21987240	877	888	O
)	21987240	888	889	O
.	21987240	889	890	O

]	21987240	891	892	O
RESULTS	21987240	893	900	O
:	21987240	901	902	O
After	21987240	903	908	O
oral	21987240	909	913	O
dosing	21987240	914	920	O
,	21987240	920	921	O
moxifloxacin	21987240	922	934	B-Outcome
plasma	21987240	935	941	I-Outcome
concentrations	21987240	942	956	I-Outcome
reached	21987240	957	964	O
a	21987240	965	966	O
maximum	21987240	967	974	O
(	21987240	975	976	O
C(max	21987240	976	981	O
)	21987240	981	982	O
)	21987240	982	983	O
of	21987240	984	986	O
3.38	21987240	987	991	O
±	21987240	992	993	O
1.41	21987240	994	998	O
mg/L	21987240	999	1003	O
after	21987240	1004	1009	O
1.75	21987240	1010	1014	O
h	21987240	1015	1016	O
(	21987240	1017	1018	O
0.75	21987240	1018	1022	O
-	21987240	1022	1023	O
4.00	21987240	1023	1027	O
)	21987240	1027	1028	O
.	21987240	1028	1029	O

After	21987240	1030	1035	O
intravenous	21987240	1036	1047	O
dosing	21987240	1048	1054	O
,	21987240	1054	1055	O
C(max	21987240	1056	1061	O
)	21987240	1061	1062	O
and	21987240	1063	1066	O
T(max	21987240	1067	1072	O
)	21987240	1072	1073	O
were	21987240	1074	1078	O
4.53	21987240	1079	1083	O
±	21987240	1084	1085	O
1.43	21987240	1086	1090	O
mg/L	21987240	1091	1095	O
and	21987240	1096	1099	O
1.03	21987240	1100	1104	O
h	21987240	1105	1106	O
(	21987240	1107	1108	O
0.75	21987240	1108	1112	O
-	21987240	1112	1113	O
2.50	21987240	1113	1117	O
)	21987240	1117	1118	O
,	21987240	1118	1119	O
respectively	21987240	1120	1132	O
.	21987240	1132	1133	O

The	21987240	1134	1137	O
mean	21987240	1138	1142	B-Outcome
areas	21987240	1143	1148	I-Outcome
under	21987240	1149	1154	I-Outcome
the	21987240	1155	1158	I-Outcome
plasma	21987240	1159	1165	I-Outcome
concentration	21987240	1166	1179	I-Outcome
time	21987240	1180	1184	I-Outcome
curve	21987240	1185	1190	I-Outcome
extrapolated	21987240	1191	1203	I-Outcome
to	21987240	1204	1206	I-Outcome
infinity	21987240	1207	1215	I-Outcome
(	21987240	1216	1217	O
AUC(∞	21987240	1217	1222	B-Outcome
)	21987240	1222	1223	I-Outcome
)	21987240	1223	1224	O
were	21987240	1225	1229	O
46.2	21987240	1230	1234	O
±	21987240	1235	1236	O
1.4	21987240	1237	1240	O
mg	21987240	1241	1243	O
·	21987240	1244	1245	O
h/L	21987240	1246	1249	O
after	21987240	1250	1255	O
oral	21987240	1256	1260	O
dosing	21987240	1261	1267	O
and	21987240	1268	1271	O
52.3	21987240	1272	1276	O
±	21987240	1277	1278	O
1.3	21987240	1279	1282	O
mg	21987240	1283	1285	O
·	21987240	1286	1287	O
h/L	21987240	1288	1291	O
after	21987240	1292	1297	O
intravenous	21987240	1298	1309	O
dosing	21987240	1310	1316	O
,	21987240	1316	1317	O
resulting	21987240	1318	1327	O
in	21987240	1328	1330	O
a	21987240	1331	1332	O
mean	21987240	1333	1337	B-Outcome
oral	21987240	1338	1342	I-Outcome
bioavailability	21987240	1343	1358	I-Outcome
of	21987240	1359	1361	O
88.32	21987240	1362	1367	O
%	21987240	1367	1368	O
[	21987240	1369	1370	O
90	21987240	1370	1372	O
%	21987240	1372	1373	O
confidence	21987240	1374	1384	O
interval	21987240	1385	1393	O
(	21987240	1394	1395	O
CI	21987240	1395	1397	O
)	21987240	1397	1398	O
85.64%-91.08	21987240	1399	1411	O
%	21987240	1411	1412	O
]	21987240	1412	1413	O
.	21987240	1413	1414	O

CONCLUSIONS	21987240	1416	1427	O
:	21987240	1428	1429	O
This	21987240	1430	1434	O
study	21987240	1435	1440	O
confirms	21987240	1441	1449	O
that	21987240	1450	1454	O
exposure	21987240	1455	1463	B-Outcome
to	21987240	1464	1466	I-Outcome
moxifloxacin	21987240	1467	1479	I-Outcome
is	21987240	1480	1482	O
equivalent	21987240	1483	1493	O
for	21987240	1494	1497	O
oral	21987240	1498	1502	O
and	21987240	1503	1506	O
intravenous	21987240	1507	1518	O
administration	21987240	1519	1533	O
of	21987240	1534	1536	O
400	21987240	1537	1540	O
mg	21987240	1541	1543	O
dosages	21987240	1544	1551	O
in	21987240	1552	1554	O
healthy	21987240	1555	1562	O
volunteers	21987240	1563	1573	O
who	21987240	1574	1577	O
underwent	21987240	1578	1587	O
gastric	21987240	1588	1595	O
bypass	21987240	1596	1602	O
surgery	21987240	1603	1610	O
.	21987240	1610	1611	O

But	21987240	1612	1615	O
these	21987240	1616	1621	O
exposures	21987240	1622	1631	O
were	21987240	1632	1636	O
more	21987240	1637	1641	O
than	21987240	1642	1646	O
50	21987240	1647	1649	O
%	21987240	1649	1650	O
higher	21987240	1651	1657	O
than	21987240	1658	1662	O
those	21987240	1663	1668	O
described	21987240	1669	1678	O
for	21987240	1679	1682	O
subjects	21987240	1683	1691	O
without	21987240	1692	1699	O
gastric	21987240	1700	1707	O
bypass	21987240	1708	1714	O
.	21987240	1714	1715	O

This	21987240	1716	1720	O
may	21987240	1721	1724	O
suggest	21987240	1725	1732	O
a	21987240	1733	1734	O
higher	21987240	1735	1741	O
enterohepatic	21987240	1742	1755	O
recirculation	21987240	1756	1769	O
of	21987240	1770	1772	O
moxifloxacin	21987240	1773	1785	O
after	21987240	1786	1791	O
gastric	21987240	1792	1799	O
bypass	21987240	1800	1806	O
.	21987240	1806	1807	O


Hemiarthroplasty	21997224	0	16	O
compared	21997224	17	25	O
to	21997224	26	28	O
internal	21997224	29	37	O
fixation	21997224	38	46	O
with	21997224	47	51	O
percutaneous	21997224	52	64	O
cannulated	21997224	65	75	O
screws	21997224	76	82	O
as	21997224	83	85	O
treatment	21997224	86	95	O
of	21997224	96	98	O
displaced	21997224	99	108	O
femoral	21997224	109	116	O
neck	21997224	117	121	O
fractures	21997224	122	131	O
in	21997224	132	134	O
the	21997224	135	138	O
elderly	21997224	139	146	O
:	21997224	146	147	O
cost-utility	21997224	148	160	O
analysis	21997224	161	169	O
performed	21997224	170	179	O
alongside	21997224	180	189	O
a	21997224	190	191	O
randomized	21997224	192	202	O
,	21997224	202	203	O
controlled	21997224	204	214	O
trial	21997224	215	220	O
.	21997224	220	221	O

UNLABELLED	21997224	223	233	O
:	21997224	234	235	O
We	21997224	236	238	O
estimated	21997224	239	248	O
the	21997224	249	252	O
cost-effectiveness	21997224	253	271	O
of	21997224	272	274	O
hemiarthroplasty	21997224	275	291	O
compared	21997224	292	300	O
to	21997224	301	303	O
internal	21997224	304	312	O
fixation	21997224	313	321	O
for	21997224	322	325	O
elderly	21997224	326	333	O
patients	21997224	334	342	O
with	21997224	343	347	O
displaced	21997224	348	357	O
femoral	21997224	358	365	O
neck	21997224	366	370	O
fractures	21997224	371	380	O
.	21997224	380	381	O

Over	21997224	382	386	O
2	21997224	387	388	O
years	21997224	389	394	O
,	21997224	394	395	O
patients	21997224	396	404	O
treated	21997224	405	412	O
with	21997224	413	417	O
hemiarthroplasty	21997224	418	434	O
gained	21997224	435	441	O
more	21997224	442	446	O
quality-adjusted	21997224	447	463	O
life	21997224	464	468	O
years	21997224	469	474	O
than	21997224	475	479	O
patients	21997224	480	488	O
treated	21997224	489	496	O
with	21997224	497	501	O
internal	21997224	502	510	O
fixation	21997224	511	519	O
.	21997224	519	520	O

In	21997224	521	523	O
addition	21997224	524	532	O
,	21997224	532	533	O
costs	21997224	534	539	O
for	21997224	540	543	O
hemiarthroplasty	21997224	544	560	O
were	21997224	561	565	O
lower	21997224	566	571	O
.	21997224	571	572	O

Hemiarthroplasty	21997224	573	589	O
was	21997224	590	593	O
thus	21997224	594	598	O
cost	21997224	599	603	O
effective	21997224	604	613	O
.	21997224	613	614	O

INTRODUCTION	21997224	616	628	O
:	21997224	629	630	O
Estimating	21997224	631	641	O
the	21997224	642	645	O
cost	21997224	646	650	O
utility	21997224	651	658	O
of	21997224	659	661	O
hemiarthroplasty	21997224	662	678	O
compared	21997224	679	687	O
to	21997224	688	690	O
internal	21997224	691	699	O
fixation	21997224	700	708	O
in	21997224	709	711	O
the	21997224	712	715	O
treatment	21997224	716	725	O
of	21997224	726	728	O
displaced	21997224	729	738	O
femoral	21997224	739	746	O
neck	21997224	747	751	O
fractures	21997224	752	761	O
in	21997224	762	764	O
the	21997224	765	768	O
elderly	21997224	769	776	O
.	21997224	776	777	O

METHODS	21997224	779	786	O
:	21997224	787	788	O
A	21997224	789	790	O
cost-utility	21997224	791	803	O
analysis	21997224	804	812	O
(	21997224	813	814	O
CUA	21997224	814	817	O
)	21997224	817	818	O
was	21997224	819	822	O
conducted	21997224	823	832	O
alongside	21997224	833	842	O
a	21997224	843	844	O
clinical	21997224	845	853	O
randomized	21997224	854	864	O
controlled	21997224	865	875	O
trial	21997224	876	881	O
at	21997224	882	884	O
a	21997224	885	886	O
university	21997224	887	897	O
hospital	21997224	898	906	O
in	21997224	907	909	O
Norway	21997224	910	916	O
;	21997224	916	917	O
166	21997224	918	921	O
patients	21997224	922	930	O
,	21997224	930	931	O
124	21997224	932	935	O
(	21997224	936	937	O
75	21997224	937	939	O
%	21997224	939	940	O
)	21997224	940	941	O
women	21997224	942	947	O
with	21997224	948	952	O
a	21997224	953	954	O
mean	21997224	955	959	O
age	21997224	960	963	O
of	21997224	964	966	O
82	21997224	967	969	O
years	21997224	970	975	O
were	21997224	976	980	O
randomized	21997224	981	991	O
to	21997224	992	994	O
either	21997224	995	1001	O
internal	21997224	1002	1010	O
fixation	21997224	1011	1019	O
(	21997224	1020	1021	O
n	21997224	1021	1022	O
=	21997224	1023	1024	O
86	21997224	1025	1027	O
)	21997224	1027	1028	O
or	21997224	1029	1031	O
hemiarthroplasty	21997224	1032	1048	O
(	21997224	1049	1050	O
n	21997224	1050	1051	O
=	21997224	1052	1053	O
80	21997224	1054	1056	O
)	21997224	1056	1057	O
.	21997224	1057	1058	O

Patients	21997224	1059	1067	O
were	21997224	1068	1072	O
followed	21997224	1073	1081	O
up	21997224	1082	1084	O
at	21997224	1085	1087	O
4	21997224	1088	1089	O
,	21997224	1089	1090	O
12	21997224	1091	1093	O
,	21997224	1093	1094	O
and	21997224	1095	1098	O
24	21997224	1099	1101	O
months	21997224	1102	1108	O
.	21997224	1108	1109	O

Health-related	21997224	1110	1124	O
quality	21997224	1125	1132	O
of	21997224	1133	1135	O
life	21997224	1136	1140	O
was	21997224	1141	1144	O
assessed	21997224	1145	1153	O
with	21997224	1154	1158	O
the	21997224	1159	1162	O
EQ-5D	21997224	1163	1168	O
,	21997224	1168	1169	O
and	21997224	1170	1173	O
in	21997224	1174	1176	O
combination	21997224	1177	1188	O
with	21997224	1189	1193	O
time	21997224	1194	1198	O
used	21997224	1199	1203	O
to	21997224	1204	1206	O
calculate	21997224	1207	1216	O
patients	21997224	1217	1225	O
'	21997224	1225	1226	O
quality-adjusted	21997224	1227	1243	O
life	21997224	1244	1248	O
years	21997224	1249	1254	O
(	21997224	1255	1256	O
QALYs	21997224	1256	1261	O
)	21997224	1261	1262	O
.	21997224	1262	1263	O

Resource	21997224	1264	1272	O
use	21997224	1273	1276	O
was	21997224	1277	1280	O
identified	21997224	1281	1291	O
,	21997224	1291	1292	O
quantified	21997224	1293	1303	O
,	21997224	1303	1304	O
and	21997224	1305	1308	O
valued	21997224	1309	1315	O
for	21997224	1316	1319	O
direct	21997224	1320	1326	O
and	21997224	1327	1330	O
indirect	21997224	1331	1339	O
hospital	21997224	1340	1348	O
costs	21997224	1349	1354	O
and	21997224	1355	1358	O
for	21997224	1359	1362	O
societal	21997224	1363	1371	O
costs	21997224	1372	1377	O
.	21997224	1377	1378	O

Results	21997224	1379	1386	O
were	21997224	1387	1391	O
expressed	21997224	1392	1401	O
in	21997224	1402	1404	O
incremental	21997224	1405	1416	O
cost-effectiveness	21997224	1417	1435	O
ratios	21997224	1436	1442	O
.	21997224	1442	1443	O

RESULTS	21997224	1445	1452	O
:	21997224	1453	1454	O
Over	21997224	1455	1459	O
the	21997224	1460	1463	O
2-year	21997224	1464	1470	O
period	21997224	1471	1477	O
,	21997224	1477	1478	O
patients	21997224	1479	1487	O
treated	21997224	1488	1495	O
with	21997224	1496	1500	O
hemiarthroplasty	21997224	1501	1517	O
gained	21997224	1518	1524	O
0.15	21997224	1525	1529	O
-	21997224	1529	1530	O
0.20	21997224	1530	1534	O
more	21997224	1535	1539	O
QALYs	21997224	1540	1545	B-Outcome
than	21997224	1546	1550	O
patients	21997224	1551	1559	O
treated	21997224	1560	1567	O
with	21997224	1568	1572	O
internal	21997224	1573	1581	O
fixation	21997224	1582	1590	O
.	21997224	1590	1591	O

For	21997224	1592	1595	O
the	21997224	1596	1599	O
hemiarthroplasty	21997224	1600	1616	O
group	21997224	1617	1622	O
,	21997224	1622	1623	O
the	21997224	1624	1627	O
direct	21997224	1628	1634	B-Outcome
hospital	21997224	1635	1643	I-Outcome
costs	21997224	1644	1649	I-Outcome
,	21997224	1649	1650	O
total	21997224	1651	1656	B-Outcome
hospital	21997224	1657	1665	I-Outcome
costs	21997224	1666	1671	I-Outcome
,	21997224	1671	1672	O
and	21997224	1673	1676	O
total	21997224	1677	1682	B-Outcome
costs	21997224	1683	1688	I-Outcome
were	21997224	1689	1693	O
non-significantly	21997224	1694	1711	O
less	21997224	1712	1716	O
costly	21997224	1717	1723	O
compared	21997224	1724	1732	O
with	21997224	1733	1737	O
the	21997224	1738	1741	O
internal	21997224	1742	1750	O
fixation	21997224	1751	1759	O
group	21997224	1760	1765	O
,	21997224	1765	1766	O
with	21997224	1767	1771	O
an	21997224	1772	1774	O
incremental	21997224	1775	1786	B-Outcome
cost	21997224	1787	1791	I-Outcome
of	21997224	1792	1794	O
€	21997224	1795	1796	O
2,731	21997224	1796	1801	O
(	21997224	1802	1803	O
p	21997224	1803	1804	O
=	21997224	1805	1806	O
0.81	21997224	1807	1811	O
)	21997224	1811	1812	O
,	21997224	1812	1813	O
€	21997224	1814	1815	O
2,474	21997224	1815	1820	O
(	21997224	1821	1822	O
p	21997224	1822	1823	O
=	21997224	1824	1825	O
0.80	21997224	1826	1830	O
)	21997224	1830	1831	O
,	21997224	1831	1832	O
and	21997224	1833	1836	O
€	21997224	1837	1838	O
14,160	21997224	1838	1844	O
(	21997224	1845	1846	O
p	21997224	1846	1847	O
=	21997224	1848	1849	O
0.07	21997224	1850	1854	O
)	21997224	1854	1855	O
,	21997224	1855	1856	O
respectively	21997224	1857	1869	O
.	21997224	1869	1870	O

Thus	21997224	1871	1875	O
,	21997224	1875	1876	O
hemiarthroplasty	21997224	1877	1893	O
was	21997224	1894	1897	O
the	21997224	1898	1901	O
dominant	21997224	1902	1910	O
treatment	21997224	1911	1920	O
.	21997224	1920	1921	O

Sensitivity	21997224	1922	1933	O
analyses	21997224	1934	1942	O
by	21997224	1943	1945	O
bootstrapping	21997224	1946	1959	O
supported	21997224	1960	1969	O
these	21997224	1970	1975	O
findings	21997224	1976	1984	O
.	21997224	1984	1985	O

CONCLUSION	21997224	1987	1997	O
:	21997224	1998	1999	O
Hemiarthroplasty	21997224	2000	2016	O
was	21997224	2017	2020	O
a	21997224	2021	2022	O
cost-effective	21997224	2023	2037	B-Outcome
treatment	21997224	2038	2047	O
.	21997224	2047	2048	O

Trial	21997224	2049	2054	O
registration	21997224	2055	2067	O
,	21997224	2067	2068	O
NCT00464230	21997224	2069	2080	O
.	21997224	2080	2081	O


Use	22007005	0	3	O
of	22007005	4	6	O
an	22007005	7	9	O
Internet	22007005	10	18	O
portal	22007005	19	25	O
to	22007005	26	28	O
improve	22007005	29	36	O
community-based	22007005	37	52	O
pediatric	22007005	53	62	O
ADHD	22007005	63	67	O
care	22007005	68	72	O
:	22007005	72	73	O
a	22007005	74	75	O
cluster	22007005	76	83	O
randomized	22007005	84	94	O
trial	22007005	95	100	O
.	22007005	100	101	O

OBJECTIVE	22007005	103	112	O
:	22007005	113	114	O
To	22007005	115	117	O
determine	22007005	118	127	O
the	22007005	128	131	O
effectiveness	22007005	132	145	O
of	22007005	146	148	O
a	22007005	149	150	O
quality	22007005	151	158	O
improvement	22007005	159	170	O
program	22007005	171	178	O
to	22007005	179	181	O
improve	22007005	182	189	O
pediatricians	22007005	190	203	O
'	22007005	203	204	O
adherence	22007005	205	214	O
to	22007005	215	217	O
existing	22007005	218	226	O
,	22007005	226	227	O
evidence-based	22007005	228	242	O
,	22007005	242	243	O
attention-deficit/hyperactivity	22007005	244	275	O
disorder	22007005	276	284	O
(	22007005	285	286	O
ADHD	22007005	286	290	O
)	22007005	290	291	O
practice	22007005	292	300	O
guidelines	22007005	301	311	O
.	22007005	311	312	O

METHODS	22007005	314	321	O
:	22007005	322	323	O
Forty-nine	22007005	324	334	O
community-based	22007005	335	350	O
pediatricians	22007005	351	364	O
at	22007005	365	367	O
8	22007005	368	369	O
practices	22007005	370	379	O
participated	22007005	380	392	O
in	22007005	393	395	O
a	22007005	396	397	O
cluster-randomized	22007005	398	416	O
trial	22007005	417	422	O
.	22007005	422	423	O

Practices	22007005	424	433	O
were	22007005	434	438	O
matched	22007005	439	446	O
according	22007005	447	456	O
to	22007005	457	459	O
the	22007005	460	463	O
numbers	22007005	464	471	O
of	22007005	472	474	O
pediatricians	22007005	475	488	O
and	22007005	489	492	O
the	22007005	493	496	O
proportions	22007005	497	508	O
of	22007005	509	511	O
patients	22007005	512	520	O
receiving	22007005	521	530	O
Medicaid	22007005	531	539	O
.	22007005	539	540	O

The	22007005	541	544	O
medical	22007005	545	552	O
charts	22007005	553	559	O
for	22007005	560	563	O
a	22007005	564	565	O
random	22007005	566	572	O
sample	22007005	573	579	O
of	22007005	580	582	O
patients	22007005	583	591	O
with	22007005	592	596	O
ADHD	22007005	597	601	O
for	22007005	602	605	O
each	22007005	606	610	O
of	22007005	611	613	O
the	22007005	614	617	O
participating	22007005	618	631	O
pediatricians	22007005	632	645	O
were	22007005	646	650	O
examined	22007005	651	659	O
at	22007005	660	662	O
baseline	22007005	663	671	O
and	22007005	672	675	O
6	22007005	676	677	O
months	22007005	678	684	O
.	22007005	684	685	O

All	22007005	686	689	O
practices	22007005	690	699	O
participated	22007005	700	712	O
in	22007005	713	715	O
4	22007005	716	717	O
sessions	22007005	718	726	O
of	22007005	727	729	O
training	22007005	730	738	O
,	22007005	738	739	O
including	22007005	740	749	O
didactic	22007005	750	758	O
lectures	22007005	759	767	O
and	22007005	768	771	O
office	22007005	772	778	O
flow	22007005	779	783	O
modification	22007005	784	796	O
workshops	22007005	797	806	O
.	22007005	806	807	O

Practices	22007005	808	817	O
were	22007005	818	822	O
then	22007005	823	827	O
given	22007005	828	833	O
access	22007005	834	840	O
to	22007005	841	843	O
an	22007005	844	846	O
ADHD	22007005	847	851	O
Internet	22007005	852	860	O
portal	22007005	861	867	O
that	22007005	868	872	O
allowed	22007005	873	880	O
parents	22007005	881	888	O
,	22007005	888	889	O
teachers	22007005	890	898	O
,	22007005	898	899	O
and	22007005	900	903	O
pediatricians	22007005	904	917	O
to	22007005	918	920	O
input	22007005	921	926	O
information	22007005	927	938	O
(	22007005	939	940	O
eg	22007005	940	942	O
,	22007005	942	943	O
rating	22007005	944	950	O
scales	22007005	951	957	O
)	22007005	957	958	O
about	22007005	959	964	O
patients	22007005	965	973	O
,	22007005	973	974	O
after	22007005	975	980	O
which	22007005	981	986	O
information	22007005	987	998	O
was	22007005	999	1002	O
scored	22007005	1003	1009	O
,	22007005	1009	1010	O
interpreted	22007005	1011	1022	O
,	22007005	1022	1023	O
and	22007005	1024	1027	O
formatted	22007005	1028	1037	O
in	22007005	1038	1040	O
a	22007005	1041	1042	O
report	22007005	1043	1049	O
style	22007005	1050	1055	O
that	22007005	1056	1060	O
was	22007005	1061	1064	O
helpful	22007005	1065	1072	O
for	22007005	1073	1076	O
assessment	22007005	1077	1087	O
and	22007005	1088	1091	O
treatment	22007005	1092	1101	O
of	22007005	1102	1104	O
patients	22007005	1105	1113	O
with	22007005	1114	1118	O
ADHD	22007005	1119	1123	O
.	22007005	1123	1124	O

Physicians	22007005	1125	1135	O
evaluated	22007005	1136	1145	O
their	22007005	1146	1151	O
practice	22007005	1152	1160	O
behaviors	22007005	1161	1170	O
quarterly	22007005	1171	1180	O
and	22007005	1181	1184	O
addressed	22007005	1185	1194	O
underperforming	22007005	1195	1210	O
areas	22007005	1211	1216	O
.	22007005	1216	1217	O

RESULTS	22007005	1219	1226	O
:	22007005	1227	1228	O
Pediatricians	22007005	1229	1242	O
in	22007005	1243	1245	O
the	22007005	1246	1249	O
intervention	22007005	1250	1262	O
group	22007005	1263	1268	O
,	22007005	1268	1269	O
compared	22007005	1270	1278	O
with	22007005	1279	1283	O
those	22007005	1284	1289	O
in	22007005	1290	1292	O
the	22007005	1293	1296	O
control	22007005	1297	1304	O
group	22007005	1305	1310	O
,	22007005	1310	1311	O
demonstrated	22007005	1312	1324	O
significantly	22007005	1325	1338	O
higher	22007005	1339	1345	O
rates	22007005	1346	1351	B-Outcome
of	22007005	1352	1354	I-Outcome
many	22007005	1355	1359	I-Outcome
American	22007005	1360	1368	I-Outcome
Academy	22007005	1369	1376	I-Outcome
of	22007005	1377	1379	I-Outcome
Pediatrics-recommended	22007005	1380	1402	I-Outcome
ADHD	22007005	1403	1407	I-Outcome
care	22007005	1408	1412	I-Outcome
practices	22007005	1413	1422	I-Outcome
,	22007005	1422	1423	O
including	22007005	1424	1433	O
collection	22007005	1434	1444	O
of	22007005	1445	1447	O
parent	22007005	1448	1454	O
(	22007005	1455	1456	O
Cohen	22007005	1456	1461	O
's	22007005	1461	1463	O
d	22007005	1464	1465	O
=	22007005	1466	1467	O
0.69	22007005	1468	1472	O
)	22007005	1472	1473	O
and	22007005	1474	1477	O
teacher	22007005	1478	1485	O
(	22007005	1486	1487	O
d	22007005	1487	1488	O
=	22007005	1489	1490	O
0.68	22007005	1491	1495	O
)	22007005	1495	1496	O
rating	22007005	1497	1503	B-Outcome
scales	22007005	1504	1510	I-Outcome
for	22007005	1511	1514	I-Outcome
assessment	22007005	1515	1525	I-Outcome
of	22007005	1526	1528	I-Outcome
children	22007005	1529	1537	I-Outcome
with	22007005	1538	1542	I-Outcome
ADHD	22007005	1543	1547	I-Outcome
,	22007005	1547	1548	O
use	22007005	1549	1552	B-Outcome
of	22007005	1553	1555	I-Outcome
Diagnostic	22007005	1556	1566	I-Outcome
and	22007005	1567	1570	I-Outcome
Statistical	22007005	1571	1582	I-Outcome
Manual	22007005	1583	1589	I-Outcome
of	22007005	1590	1592	I-Outcome
Mental	22007005	1593	1599	I-Outcome
Disorders	22007005	1600	1609	I-Outcome
,	22007005	1609	1610	I-Outcome
Fourth	22007005	1611	1617	I-Outcome
Edition	22007005	1618	1625	I-Outcome
,	22007005	1625	1626	I-Outcome
criteria	22007005	1627	1635	I-Outcome
(	22007005	1636	1637	O
d	22007005	1637	1638	O
=	22007005	1639	1640	O
0.85	22007005	1641	1645	O
)	22007005	1645	1646	O
,	22007005	1646	1647	O
and	22007005	1648	1651	O
use	22007005	1652	1655	B-Outcome
of	22007005	1656	1658	I-Outcome
teacher	22007005	1659	1666	I-Outcome
rating	22007005	1667	1673	I-Outcome
scales	22007005	1674	1680	I-Outcome
to	22007005	1681	1683	O
monitor	22007005	1684	1691	O
treatment	22007005	1692	1701	O
responses	22007005	1702	1711	O
(	22007005	1712	1713	O
d	22007005	1713	1714	O
=	22007005	1715	1716	O
1.01	22007005	1717	1721	O
)	22007005	1721	1722	O
.	22007005	1722	1723	O

CONCLUSION	22007005	1725	1735	O
:	22007005	1736	1737	O
A	22007005	1738	1739	O
quality	22007005	1740	1747	O
improvement	22007005	1748	1759	O
intervention	22007005	1760	1772	O
that	22007005	1773	1777	O
can	22007005	1778	1781	O
be	22007005	1782	1784	O
widely	22007005	1785	1791	O
disseminated	22007005	1792	1804	O
by	22007005	1805	1807	O
using	22007005	1808	1813	O
Internet-based	22007005	1814	1828	O
information	22007005	1829	1840	O
technology	22007005	1841	1851	O
significantly	22007005	1852	1865	O
improved	22007005	1866	1874	O
the	22007005	1875	1878	O
quality	22007005	1879	1886	B-Outcome
of	22007005	1887	1889	I-Outcome
ADHD	22007005	1890	1894	I-Outcome
care	22007005	1895	1899	I-Outcome
in	22007005	1900	1902	O
community-based	22007005	1903	1918	O
pediatric	22007005	1919	1928	O
settings	22007005	1929	1937	O
.	22007005	1937	1938	O


Atrial	22082673	0	6	O
fibrillation	22082673	7	19	O
catheter	22082673	20	28	O
ablation	22082673	29	37	O
versus	22082673	38	44	O
surgical	22082673	45	53	O
ablation	22082673	54	62	O
treatment	22082673	63	72	O
(	22082673	73	74	O
FAST	22082673	74	78	O
):	22082673	78	80	O
a	22082673	81	82	O
2-center	22082673	83	91	O
randomized	22082673	92	102	O
clinical	22082673	103	111	O
trial	22082673	112	117	O
.	22082673	117	118	O

BACKGROUND	22082673	120	130	O
:	22082673	131	132	O
Catheter	22082673	133	141	O
ablation	22082673	142	150	O
(	22082673	151	152	O
CA	22082673	152	154	O
)	22082673	154	155	O
and	22082673	156	159	O
minimally	22082673	160	169	O
invasive	22082673	170	178	O
surgical	22082673	179	187	O
ablation	22082673	188	196	O
(	22082673	197	198	O
SA	22082673	198	200	O
)	22082673	200	201	O
have	22082673	202	206	O
become	22082673	207	213	O
accepted	22082673	214	222	O
therapy	22082673	223	230	O
for	22082673	231	234	O
antiarrhythmic	22082673	235	249	O
drug-refractory	22082673	250	265	O
atrial	22082673	266	272	O
fibrillation	22082673	273	285	O
.	22082673	285	286	O

This	22082673	287	291	O
study	22082673	292	297	O
describes	22082673	298	307	O
the	22082673	308	311	O
first	22082673	312	317	O
randomized	22082673	318	328	O
clinical	22082673	329	337	O
trial	22082673	338	343	O
comparing	22082673	344	353	O
their	22082673	354	359	O
efficacy	22082673	360	368	O
and	22082673	369	372	O
safety	22082673	373	379	O
during	22082673	380	386	O
a	22082673	387	388	O
12-month	22082673	389	397	O
follow-up	22082673	398	407	O
.	22082673	407	408	O

RESULTS	22082673	410	417	O
:	22082673	418	419	O
One	22082673	420	423	O
hundred	22082673	424	431	O
twenty-four	22082673	432	443	O
patients	22082673	444	452	O
with	22082673	453	457	O
antiarrhythmic	22082673	458	472	O
drug-refractory	22082673	473	488	O
atrial	22082673	489	495	O
fibrillation	22082673	496	508	O
with	22082673	509	513	O
left	22082673	514	518	O
atrial	22082673	519	525	O
dilatation	22082673	526	536	O
and	22082673	537	540	O
hypertension	22082673	541	553	O
(	22082673	554	555	O
42	22082673	555	557	O
patients	22082673	558	566	O
,	22082673	566	567	O
33	22082673	568	570	O
%	22082673	570	571	O
)	22082673	571	572	O
or	22082673	573	575	O
failed	22082673	576	582	O
prior	22082673	583	588	O
CA	22082673	589	591	O
(	22082673	592	593	O
82	22082673	593	595	O
patients	22082673	596	604	O
,	22082673	604	605	O
67	22082673	606	608	O
%	22082673	608	609	O
)	22082673	609	610	O
were	22082673	611	615	O
randomized	22082673	616	626	O
to	22082673	627	629	O
CA	22082673	630	632	O
(	22082673	633	634	O
63	22082673	634	636	O
patients	22082673	637	645	O
)	22082673	645	646	O
or	22082673	647	649	O
SA	22082673	650	652	O
(	22082673	653	654	O
61	22082673	654	656	O
patients	22082673	657	665	O
)	22082673	665	666	O
.	22082673	666	667	O

CA	22082673	668	670	O
consisted	22082673	671	680	O
of	22082673	681	683	O
linear	22082673	684	690	O
antral	22082673	691	697	O
pulmonary	22082673	698	707	O
vein	22082673	708	712	O
isolation	22082673	713	722	O
and	22082673	723	726	O
optional	22082673	727	735	O
additional	22082673	736	746	O
lines	22082673	747	752	O
.	22082673	752	753	O

SA	22082673	754	756	O
consisted	22082673	757	766	O
of	22082673	767	769	O
bipolar	22082673	770	777	O
radiofrequency	22082673	778	792	O
isolation	22082673	793	802	O
of	22082673	803	805	O
the	22082673	806	809	O
bilateral	22082673	810	819	O
pulmonary	22082673	820	829	O
vein	22082673	830	834	O
,	22082673	834	835	O
ganglionated	22082673	836	848	O
plexi	22082673	849	854	O
ablation	22082673	855	863	O
,	22082673	863	864	O
and	22082673	865	868	O
left	22082673	869	873	O
atrial	22082673	874	880	O
appendage	22082673	881	890	O
excision	22082673	891	899	O
with	22082673	900	904	O
optional	22082673	905	913	O
additional	22082673	914	924	O
lines	22082673	925	930	O
.	22082673	930	931	O

Follow-up	22082673	932	941	O
at	22082673	942	944	O
6	22082673	945	946	O
and	22082673	947	950	O
12	22082673	951	953	O
months	22082673	954	960	O
was	22082673	961	964	O
performed	22082673	965	974	O
by	22082673	975	977	O
ECG	22082673	978	981	O
and	22082673	982	985	O
7-day	22082673	986	991	O
Holter	22082673	992	998	O
recording	22082673	999	1008	O
.	22082673	1008	1009	O

The	22082673	1010	1013	O
primary	22082673	1014	1021	O
end	22082673	1022	1025	O
point	22082673	1026	1031	O
,	22082673	1031	1032	O
freedom	22082673	1033	1040	B-Outcome
from	22082673	1041	1045	I-Outcome
left	22082673	1046	1050	I-Outcome
atrial	22082673	1051	1057	I-Outcome
arrhythmia	22082673	1058	1068	I-Outcome
>	22082673	1069	1070	I-Outcome
30	22082673	1070	1072	I-Outcome
seconds	22082673	1073	1080	I-Outcome
without	22082673	1081	1088	I-Outcome
antiarrhythmic	22082673	1089	1103	I-Outcome
drugs	22082673	1104	1109	I-Outcome
after	22082673	1110	1115	I-Outcome
12	22082673	1116	1118	I-Outcome
months	22082673	1119	1125	I-Outcome
,	22082673	1125	1126	O
was	22082673	1127	1130	O
36.5	22082673	1131	1135	O
%	22082673	1135	1136	O
for	22082673	1137	1140	O
CA	22082673	1141	1143	O
and	22082673	1144	1147	O
65.6	22082673	1148	1152	O
%	22082673	1152	1153	O
for	22082673	1154	1157	O
SA	22082673	1158	1160	O
(	22082673	1161	1162	O
P=0.0022	22082673	1162	1170	O
)	22082673	1170	1171	O
.	22082673	1171	1172	O

There	22082673	1173	1178	O
was	22082673	1179	1182	O
no	22082673	1183	1185	O
difference	22082673	1186	1196	O
in	22082673	1197	1199	O
effect	22082673	1200	1206	O
for	22082673	1207	1210	O
subgroups	22082673	1211	1220	O
,	22082673	1220	1221	O
which	22082673	1222	1227	O
was	22082673	1228	1231	O
consistent	22082673	1232	1242	O
at	22082673	1243	1245	O
both	22082673	1246	1250	O
sites	22082673	1251	1256	O
.	22082673	1256	1257	O

The	22082673	1258	1261	O
primary	22082673	1262	1269	O
safety	22082673	1270	1276	O
end	22082673	1277	1280	O
point	22082673	1281	1286	O
of	22082673	1287	1289	O
significant	22082673	1290	1301	O
adverse	22082673	1302	1309	B-Outcome
events	22082673	1310	1316	I-Outcome
during	22082673	1317	1323	O
the	22082673	1324	1327	O
12-month	22082673	1328	1336	O
follow-up	22082673	1337	1346	O
was	22082673	1347	1350	O
significantly	22082673	1351	1364	O
higher	22082673	1365	1371	O
for	22082673	1372	1375	O
SA	22082673	1376	1378	O
than	22082673	1379	1383	O
for	22082673	1384	1387	O
CA	22082673	1388	1390	O
(	22082673	1391	1392	O
n=21	22082673	1392	1396	O
[	22082673	1397	1398	O
34.4	22082673	1398	1402	O
%	22082673	1402	1403	O
]	22082673	1403	1404	O
versus	22082673	1405	1411	O
n=10	22082673	1412	1416	O
[	22082673	1417	1418	O
15.9	22082673	1418	1422	O
%	22082673	1422	1423	O
]	22082673	1423	1424	O
;	22082673	1424	1425	O
P=0.027	22082673	1426	1433	O
)	22082673	1433	1434	O
,	22082673	1434	1435	O
driven	22082673	1436	1442	O
mainly	22082673	1443	1449	O
by	22082673	1450	1452	O
procedural	22082673	1453	1463	O
complications	22082673	1464	1477	O
such	22082673	1478	1482	O
as	22082673	1483	1485	O
pneumothorax	22082673	1486	1498	O
,	22082673	1498	1499	O
major	22082673	1500	1505	O
bleeding	22082673	1506	1514	O
,	22082673	1514	1515	O
and	22082673	1516	1519	O
the	22082673	1520	1523	O
need	22082673	1524	1528	O
for	22082673	1529	1532	O
pacemaker	22082673	1533	1542	O
.	22082673	1542	1543	O

In	22082673	1544	1546	O
the	22082673	1547	1550	O
CA	22082673	1551	1553	O
group	22082673	1554	1559	O
,	22082673	1559	1560	O
1	22082673	1561	1562	O
patient	22082673	1563	1570	O
died	22082673	1571	1575	O
at	22082673	1576	1578	O
1	22082673	1579	1580	O
month	22082673	1581	1586	O
of	22082673	1587	1589	O
subarachnoid	22082673	1590	1602	O
hemorrhage	22082673	1603	1613	O
.	22082673	1613	1614	O

CONCLUSIONS	22082673	1616	1627	O
:	22082673	1628	1629	O
In	22082673	1630	1632	O
atrial	22082673	1633	1639	O
fibrillation	22082673	1640	1652	O
patients	22082673	1653	1661	O
with	22082673	1662	1666	O
dilated	22082673	1667	1674	O
left	22082673	1675	1679	O
atrium	22082673	1680	1686	O
and	22082673	1687	1690	O
hypertension	22082673	1691	1703	O
or	22082673	1704	1706	O
failed	22082673	1707	1713	O
prior	22082673	1714	1719	O
atrial	22082673	1720	1726	O
fibrillation	22082673	1727	1739	O
CA	22082673	1740	1742	O
,	22082673	1742	1743	O
SA	22082673	1744	1746	O
is	22082673	1747	1749	O
superior	22082673	1750	1758	O
to	22082673	1759	1761	O
CA	22082673	1762	1764	O
in	22082673	1765	1767	O
achieving	22082673	1768	1777	O
freedom	22082673	1778	1785	B-Outcome
from	22082673	1786	1790	I-Outcome
left	22082673	1791	1795	I-Outcome
atrial	22082673	1796	1802	I-Outcome
arrhythmias	22082673	1803	1814	I-Outcome
after	22082673	1815	1820	I-Outcome
12	22082673	1821	1823	I-Outcome
months	22082673	1824	1830	I-Outcome
of	22082673	1831	1833	I-Outcome
follow-up	22082673	1834	1843	I-Outcome
,	22082673	1843	1844	O
although	22082673	1845	1853	O
the	22082673	1854	1857	O
procedural	22082673	1858	1868	O
adverse	22082673	1869	1876	B-Outcome
event	22082673	1877	1882	I-Outcome
rate	22082673	1883	1887	O
is	22082673	1888	1890	O
significantly	22082673	1891	1904	O
higher	22082673	1905	1911	O
for	22082673	1912	1915	O
SA	22082673	1916	1918	O
than	22082673	1919	1923	O
for	22082673	1924	1927	O
CA	22082673	1928	1930	O
.	22082673	1930	1931	O

BACKGROUND	22082673	1933	1943	O
:	22082673	1944	1945	O
URL	22082673	1946	1949	O
:	22082673	1949	1950	O
http://clinicaltrials.gov	22082673	1951	1976	O
.	22082673	1976	1977	O

Unique	22082673	1978	1984	O
identifier	22082673	1985	1995	O
:	22082673	1995	1996	O
NCT00662701	22082673	1997	2008	O
.	22082673	2008	2009	O


Effect	22151477	0	6	O
of	22151477	7	9	O
a	22151477	10	11	O
vitamin/mineral	22151477	12	27	O
supplement	22151477	28	38	O
on	22151477	39	41	O
children	22151477	42	50	O
and	22151477	51	54	O
adults	22151477	55	61	O
with	22151477	62	66	O
autism	22151477	67	73	O
.	22151477	73	74	O

BACKGROUND	22151477	76	86	O
:	22151477	87	88	O
Vitamin/mineral	22151477	89	104	O
supplements	22151477	105	116	O
are	22151477	117	120	O
among	22151477	121	126	O
the	22151477	127	130	O
most	22151477	131	135	O
commonly	22151477	136	144	O
used	22151477	145	149	O
treatments	22151477	150	160	O
for	22151477	161	164	O
autism	22151477	165	171	O
,	22151477	171	172	O
but	22151477	173	176	O
the	22151477	177	180	O
research	22151477	181	189	O
on	22151477	190	192	O
their	22151477	193	198	O
use	22151477	199	202	O
for	22151477	203	206	O
treating	22151477	207	215	O
autism	22151477	216	222	O
has	22151477	223	226	O
been	22151477	227	231	O
limited	22151477	232	239	O
.	22151477	239	240	O

METHOD	22151477	242	248	O
:	22151477	249	250	O
This	22151477	251	255	O
study	22151477	256	261	O
is	22151477	262	264	O
a	22151477	265	266	O
randomized	22151477	267	277	O
,	22151477	277	278	O
double-blind	22151477	279	291	O
,	22151477	291	292	O
placebo-controlled	22151477	293	311	O
three	22151477	312	317	O
month	22151477	318	323	O
vitamin/mineral	22151477	324	339	O
treatment	22151477	340	349	O
study	22151477	350	355	O
.	22151477	355	356	O

The	22151477	357	360	O
study	22151477	361	366	O
involved	22151477	367	375	O
141	22151477	376	379	O
children	22151477	380	388	O
and	22151477	389	392	O
adults	22151477	393	399	O
with	22151477	400	404	O
autism	22151477	405	411	O
,	22151477	411	412	O
and	22151477	413	416	O
pre	22151477	417	420	O
and	22151477	421	424	O
post	22151477	425	429	O
symptoms	22151477	430	438	O
of	22151477	439	441	O
autism	22151477	442	448	O
were	22151477	449	453	O
assessed	22151477	454	462	O
.	22151477	462	463	O

None	22151477	464	468	O
of	22151477	469	471	O
the	22151477	472	475	O
participants	22151477	476	488	O
had	22151477	489	492	O
taken	22151477	493	498	O
a	22151477	499	500	O
vitamin/mineral	22151477	501	516	O
supplement	22151477	517	527	O
in	22151477	528	530	O
the	22151477	531	534	O
two	22151477	535	538	O
months	22151477	539	545	O
prior	22151477	546	551	O
to	22151477	552	554	O
the	22151477	555	558	O
start	22151477	559	564	O
of	22151477	565	567	O
the	22151477	568	571	O
study	22151477	572	577	O
.	22151477	577	578	O

For	22151477	579	582	O
a	22151477	583	584	O
subset	22151477	585	591	O
of	22151477	592	594	O
the	22151477	595	598	O
participants	22151477	599	611	O
(	22151477	612	613	O
53	22151477	613	615	O
children	22151477	616	624	O
ages	22151477	625	629	O
5	22151477	630	631	O
-	22151477	631	632	O
16	22151477	632	634	O
)	22151477	634	635	O
pre	22151477	636	639	O
and	22151477	640	643	O
post	22151477	644	648	O
measurements	22151477	649	661	O
of	22151477	662	664	O
nutritional	22151477	665	676	O
and	22151477	677	680	O
metabolic	22151477	681	690	O
status	22151477	691	697	O
were	22151477	698	702	O
also	22151477	703	707	O
conducted	22151477	708	717	O
.	22151477	717	718	O

RESULTS	22151477	720	727	O
:	22151477	728	729	O
The	22151477	730	733	O
vitamin/mineral	22151477	734	749	O
supplement	22151477	750	760	O
was	22151477	761	764	O
generally	22151477	765	774	O
well-tolerated	22151477	775	789	B-Outcome
,	22151477	789	790	O
and	22151477	791	794	O
individually	22151477	795	807	O
titrated	22151477	808	816	O
to	22151477	817	819	O
optimum	22151477	820	827	O
benefit	22151477	828	835	O
.	22151477	835	836	O

Levels	22151477	837	843	B-Outcome
of	22151477	844	846	I-Outcome
many	22151477	847	851	I-Outcome
vitamins	22151477	852	860	I-Outcome
,	22151477	860	861	O
minerals	22151477	862	870	B-Outcome
,	22151477	870	871	O
and	22151477	872	875	O
biomarkers	22151477	876	886	B-Outcome
improved/increased	22151477	887	905	O
showing	22151477	906	913	O
good	22151477	914	918	O
compliance	22151477	919	929	O
and	22151477	930	933	O
absorption	22151477	934	944	O
.	22151477	944	945	O

Statistically	22151477	946	959	O
significant	22151477	960	971	O
improvements	22151477	972	984	O
in	22151477	985	987	O
metabolic	22151477	988	997	B-Outcome
status	22151477	998	1004	I-Outcome
were	22151477	1005	1009	O
many	22151477	1010	1014	O
including	22151477	1015	1024	O
:	22151477	1024	1025	O
total	22151477	1026	1031	B-Outcome
sulfate	22151477	1032	1039	I-Outcome
(	22151477	1040	1041	O
+	22151477	1041	1042	O
17	22151477	1042	1044	O
%	22151477	1044	1045	O
,	22151477	1045	1046	O
p	22151477	1047	1048	O
=	22151477	1049	1050	O
0.001	22151477	1051	1056	O
)	22151477	1056	1057	O
,	22151477	1057	1058	O
S-adenosylmethionine	22151477	1059	1079	B-Outcome
(	22151477	1080	1081	O
SAM	22151477	1081	1084	B-Outcome
;	22151477	1084	1085	O
+	22151477	1086	1087	O
6	22151477	1087	1088	O
%	22151477	1088	1089	O
,	22151477	1089	1090	O
p	22151477	1091	1092	O
=	22151477	1093	1094	O
0.003	22151477	1095	1100	O
)	22151477	1100	1101	O
,	22151477	1101	1102	O
reduced	22151477	1103	1110	O
glutathione	22151477	1111	1122	B-Outcome
(	22151477	1123	1124	O
+	22151477	1124	1125	O
17	22151477	1125	1127	O
%	22151477	1127	1128	O
,	22151477	1128	1129	O
p	22151477	1130	1131	O
=	22151477	1132	1133	O
0.0008	22151477	1134	1140	O
)	22151477	1140	1141	O
,	22151477	1141	1142	O
ratio	22151477	1143	1148	B-Outcome
of	22151477	1149	1151	I-Outcome
oxidized	22151477	1152	1160	I-Outcome
glutathione	22151477	1161	1172	I-Outcome
to	22151477	1173	1175	I-Outcome
reduced	22151477	1176	1183	I-Outcome
glutathione	22151477	1184	1195	I-Outcome
(	22151477	1196	1197	O
GSSG	22151477	1197	1201	B-Outcome
:	22151477	1201	1202	I-Outcome
GSH	22151477	1202	1205	I-Outcome
;	22151477	1205	1206	O
-27	22151477	1207	1210	O
%	22151477	1210	1211	O
,	22151477	1211	1212	O
p	22151477	1213	1214	O
=	22151477	1215	1216	O
0.002	22151477	1217	1222	O
)	22151477	1222	1223	O
,	22151477	1223	1224	O
nitrotyrosine	22151477	1225	1238	B-Outcome
(	22151477	1239	1240	O
-29	22151477	1240	1243	O
%	22151477	1243	1244	O
,	22151477	1244	1245	O
p	22151477	1246	1247	O
=	22151477	1248	1249	O
0.004	22151477	1250	1255	O
)	22151477	1255	1256	O
,	22151477	1256	1257	O
ATP	22151477	1258	1261	B-Outcome
(	22151477	1262	1263	O
+	22151477	1263	1264	O
25	22151477	1264	1266	O
%	22151477	1266	1267	O
,	22151477	1267	1268	O
p	22151477	1269	1270	O
=	22151477	1271	1272	O
0.000001	22151477	1273	1281	O
)	22151477	1281	1282	O
,	22151477	1282	1283	O
NADH	22151477	1284	1288	B-Outcome
(	22151477	1289	1290	O
+	22151477	1290	1291	O
28	22151477	1291	1293	O
%	22151477	1293	1294	O
,	22151477	1294	1295	O
p	22151477	1296	1297	O
=	22151477	1298	1299	O
0.0002	22151477	1300	1306	O
)	22151477	1306	1307	O
,	22151477	1307	1308	O
and	22151477	1309	1312	O
NADPH	22151477	1313	1318	B-Outcome
(	22151477	1319	1320	O
+	22151477	1320	1321	O
30	22151477	1321	1323	O
%	22151477	1323	1324	O
,	22151477	1324	1325	O
p	22151477	1326	1327	O
=	22151477	1328	1329	O
0.001	22151477	1330	1335	O
)	22151477	1335	1336	O
.	22151477	1336	1337	O

Most	22151477	1338	1342	O
of	22151477	1343	1345	O
these	22151477	1346	1351	O
metabolic	22151477	1352	1361	B-Outcome
biomarkers	22151477	1362	1372	I-Outcome
improved	22151477	1373	1381	O
to	22151477	1382	1384	O
normal	22151477	1385	1391	O
or	22151477	1392	1394	O
near-normal	22151477	1395	1406	O
levels	22151477	1407	1413	O
.	22151477	1413	1414	O

The	22151477	1415	1418	O
supplement	22151477	1419	1429	O
group	22151477	1430	1435	O
had	22151477	1436	1439	O
significantly	22151477	1440	1453	O
greater	22151477	1454	1461	O
improvements	22151477	1462	1474	O
than	22151477	1475	1479	O
the	22151477	1480	1483	O
placebo	22151477	1484	1491	O
group	22151477	1492	1497	O
on	22151477	1498	1500	O
the	22151477	1501	1504	O
Parental	22151477	1505	1513	B-Outcome
Global	22151477	1514	1520	I-Outcome
Impressions-Revised	22151477	1521	1540	I-Outcome
(	22151477	1541	1542	O
PGI-R	22151477	1542	1547	B-Outcome
,	22151477	1547	1548	O
Average	22151477	1549	1556	O
Change	22151477	1557	1563	O
,	22151477	1563	1564	O
p	22151477	1565	1566	O
=	22151477	1567	1568	O
0.008	22151477	1569	1574	O
)	22151477	1574	1575	O
,	22151477	1575	1576	O
and	22151477	1577	1580	O
on	22151477	1581	1583	O
the	22151477	1584	1587	O
subscores	22151477	1588	1597	B-Outcome
for	22151477	1598	1601	I-Outcome
Hyperactivity	22151477	1602	1615	I-Outcome
(	22151477	1616	1617	O
p	22151477	1617	1618	O
=	22151477	1619	1620	O
0.003	22151477	1621	1626	O
)	22151477	1626	1627	O
,	22151477	1627	1628	O
Tantrumming	22151477	1629	1640	B-Outcome
(	22151477	1641	1642	O
p	22151477	1642	1643	O
=	22151477	1644	1645	O
0.009	22151477	1646	1651	O
)	22151477	1651	1652	O
,	22151477	1652	1653	O
Overall	22151477	1654	1661	B-Outcome
(	22151477	1662	1663	O
p	22151477	1663	1664	O
=	22151477	1665	1666	O
0.02	22151477	1667	1671	O
)	22151477	1671	1672	O
,	22151477	1672	1673	O
and	22151477	1674	1677	O
Receptive	22151477	1678	1687	B-Outcome
Language	22151477	1688	1696	I-Outcome
(	22151477	1697	1698	O
p	22151477	1698	1699	O
=	22151477	1700	1701	O
0.03	22151477	1702	1706	O
)	22151477	1706	1707	O
.	22151477	1707	1708	O

For	22151477	1709	1712	O
the	22151477	1713	1716	O
other	22151477	1717	1722	O
three	22151477	1723	1728	O
assessment	22151477	1729	1739	O
tools	22151477	1740	1745	O
the	22151477	1746	1749	O
difference	22151477	1750	1760	O
between	22151477	1761	1768	O
treatment	22151477	1769	1778	O
group	22151477	1779	1784	O
and	22151477	1785	1788	O
placebo	22151477	1789	1796	O
group	22151477	1797	1802	O
was	22151477	1803	1806	O
not	22151477	1807	1810	O
statistically	22151477	1811	1824	O
significant	22151477	1825	1836	O
.	22151477	1836	1837	O

Regression	22151477	1838	1848	O
analysis	22151477	1849	1857	O
revealed	22151477	1858	1866	O
that	22151477	1867	1871	O
the	22151477	1872	1875	O
degree	22151477	1876	1882	O
of	22151477	1883	1885	O
improvement	22151477	1886	1897	O
on	22151477	1898	1900	O
the	22151477	1901	1904	O
Average	22151477	1905	1912	B-Outcome
Change	22151477	1913	1919	I-Outcome
of	22151477	1920	1922	I-Outcome
the	22151477	1923	1926	I-Outcome
PGI-R	22151477	1927	1932	I-Outcome
was	22151477	1933	1936	O
strongly	22151477	1937	1945	O
associated	22151477	1946	1956	O
with	22151477	1957	1961	O
several	22151477	1962	1969	O
biomarkers	22151477	1970	1980	O
(	22151477	1981	1982	O
adj	22151477	1982	1985	O
.	22151477	1985	1986	O
R2	22151477	1987	1989	O
=	22151477	1990	1991	O
0.61	22151477	1992	1996	O
,	22151477	1996	1997	O
p	22151477	1998	1999	O
<	22151477	2000	2001	O
0.0005	22151477	2002	2008	O
)	22151477	2008	2009	O
with	22151477	2010	2014	O
the	22151477	2015	2018	O
initial	22151477	2019	2026	O
levels	22151477	2027	2033	B-Outcome
of	22151477	2034	2036	I-Outcome
biotin	22151477	2037	2043	I-Outcome
and	22151477	2044	2047	O
vitamin	22151477	2048	2055	B-Outcome
K	22151477	2056	2057	I-Outcome
being	22151477	2058	2063	O
the	22151477	2064	2067	O
most	22151477	2068	2072	O
significant	22151477	2073	2084	O
(	22151477	2085	2086	O
p	22151477	2086	2087	O
<	22151477	2088	2089	O
0.05	22151477	2090	2094	O
)	22151477	2094	2095	O
;	22151477	2095	2096	O
both	22151477	2097	2101	O
biotin	22151477	2102	2108	O
and	22151477	2109	2112	O
vitamin	22151477	2113	2120	O
K	22151477	2121	2122	O
are	22151477	2123	2126	O
made	22151477	2127	2131	O
by	22151477	2132	2134	O
beneficial	22151477	2135	2145	O
intestinal	22151477	2146	2156	O
flora	22151477	2157	2162	O
.	22151477	2162	2163	O

CONCLUSIONS	22151477	2165	2176	O
:	22151477	2177	2178	O
Oral	22151477	2179	2183	O
vitamin/mineral	22151477	2184	2199	O
supplementation	22151477	2200	2215	O
is	22151477	2216	2218	O
beneficial	22151477	2219	2229	O
in	22151477	2230	2232	O
improving	22151477	2233	2242	O
the	22151477	2243	2246	O
nutritional	22151477	2247	2258	B-Outcome
and	22151477	2259	2262	O
metabolic	22151477	2263	2272	B-Outcome
status	22151477	2273	2279	I-Outcome
of	22151477	2280	2282	O
children	22151477	2283	2291	O
with	22151477	2292	2296	O
autism	22151477	2297	2303	O
,	22151477	2303	2304	O
including	22151477	2305	2314	O
improvements	22151477	2315	2327	O
in	22151477	2328	2330	O
methylation	22151477	2331	2342	B-Outcome
,	22151477	2342	2343	O
glutathione	22151477	2344	2355	B-Outcome
,	22151477	2355	2356	O
oxidative	22151477	2357	2366	B-Outcome
stress	22151477	2367	2373	I-Outcome
,	22151477	2373	2374	O
sulfation	22151477	2375	2384	B-Outcome
,	22151477	2384	2385	O
ATP	22151477	2386	2389	B-Outcome
,	22151477	2389	2390	O
NADH	22151477	2391	2395	B-Outcome
,	22151477	2395	2396	O
and	22151477	2397	2400	O
NADPH	22151477	2401	2406	B-Outcome
.	22151477	2406	2407	O

The	22151477	2408	2411	O
supplement	22151477	2412	2422	O
group	22151477	2423	2428	O
had	22151477	2429	2432	O
significantly	22151477	2433	2446	O
greater	22151477	2447	2454	O
improvements	22151477	2455	2467	O
than	22151477	2468	2472	O
did	22151477	2473	2476	O
the	22151477	2477	2480	O
placebo	22151477	2481	2488	O
group	22151477	2489	2494	O
on	22151477	2495	2497	O
the	22151477	2498	2501	O
PGI-R	22151477	2502	2507	B-Outcome
Average	22151477	2508	2515	I-Outcome
Change	22151477	2516	2522	I-Outcome
.	22151477	2522	2523	O

This	22151477	2524	2528	O
suggests	22151477	2529	2537	O
that	22151477	2538	2542	O
a	22151477	2543	2544	O
vitamin/mineral	22151477	2545	2560	O
supplement	22151477	2561	2571	O
is	22151477	2572	2574	O
a	22151477	2575	2576	O
reasonable	22151477	2577	2587	O
adjunct	22151477	2588	2595	O
therapy	22151477	2596	2603	O
to	22151477	2604	2606	O
consider	22151477	2607	2615	O
for	22151477	2616	2619	O
most	22151477	2620	2624	O
children	22151477	2625	2633	O
and	22151477	2634	2637	O
adults	22151477	2638	2644	O
with	22151477	2645	2649	O
autism	22151477	2650	2656	O
.	22151477	2656	2657	O

CLINICAL	22151477	2659	2667	O
TRIAL	22151477	2668	2673	O
REGISTRATION	22151477	2674	2686	O
NUMBER	22151477	2687	2693	O
:	22151477	2694	2695	O
NCT01225198	22151477	2696	2707	O
.	22151477	2707	2708	O


Non-verbal	22185349	0	10	O
communication	22185349	11	24	O
of	22185349	25	27	O
compassion	22185349	28	38	O
:	22185349	38	39	O
measuring	22185349	40	49	O
psychophysiologic	22185349	50	67	O
effects	22185349	68	75	O
.	22185349	75	76	O

BACKGROUND	22185349	78	88	O
:	22185349	89	90	O
Calm	22185349	91	95	O
,	22185349	95	96	O
compassionate	22185349	97	110	O
clinicians	22185349	111	121	O
comfort	22185349	122	129	O
others	22185349	130	136	O
.	22185349	136	137	O

To	22185349	138	140	O
evaluate	22185349	141	149	O
the	22185349	150	153	O
direct	22185349	154	160	O
psychophysiologic	22185349	161	178	O
benefits	22185349	179	187	O
of	22185349	188	190	O
non-verbal	22185349	191	201	O
communication	22185349	202	215	O
of	22185349	216	218	O
compassion	22185349	219	229	O
(	22185349	230	231	O
NVCC	22185349	231	235	O
)	22185349	235	236	O
,	22185349	236	237	O
it	22185349	238	240	O
is	22185349	241	243	O
important	22185349	244	253	O
to	22185349	254	256	O
minimize	22185349	257	265	O
the	22185349	266	269	O
effect	22185349	270	276	O
of	22185349	277	279	O
subjects	22185349	280	288	O
'	22185349	288	289	O
expectation	22185349	290	301	O
.	22185349	301	302	O

This	22185349	303	307	O
preliminary	22185349	308	319	O
study	22185349	320	325	O
was	22185349	326	329	O
designed	22185349	330	338	O
to	22185349	339	341	O
a	22185349	342	343	O
)	22185349	343	344	O
test	22185349	345	349	O
the	22185349	350	353	O
feasibility	22185349	354	365	O
of	22185349	366	368	O
two	22185349	369	372	O
strategies	22185349	373	383	O
for	22185349	384	387	O
maintaining	22185349	388	399	O
subject	22185349	400	407	O
blinding	22185349	408	416	O
to	22185349	417	419	O
non-verbal	22185349	420	430	O
communication	22185349	431	444	O
of	22185349	445	447	O
compassion	22185349	448	458	O
(	22185349	459	460	O
NVCC	22185349	460	464	O
)	22185349	464	465	O
,	22185349	465	466	O
and	22185349	467	470	O
b	22185349	471	472	O
)	22185349	472	473	O
determine	22185349	474	483	O
whether	22185349	484	491	O
blinded	22185349	492	499	O
subjects	22185349	500	508	O
would	22185349	509	514	O
experience	22185349	515	525	O
psychophysiologic	22185349	526	543	O
effects	22185349	544	551	O
from	22185349	552	556	O
NVCC	22185349	557	561	O
.	22185349	561	562	O

METHODS	22185349	564	571	O
:	22185349	572	573	O
Subjects	22185349	574	582	O
were	22185349	583	587	O
healthy	22185349	588	595	O
volunteers	22185349	596	606	O
who	22185349	607	610	O
were	22185349	611	615	O
told	22185349	616	620	O
the	22185349	621	624	O
study	22185349	625	630	O
was	22185349	631	634	O
evaluating	22185349	635	645	O
the	22185349	646	649	O
effect	22185349	650	656	O
of	22185349	657	659	O
time	22185349	660	664	O
and	22185349	665	668	O
touch	22185349	669	674	O
on	22185349	675	677	O
the	22185349	678	681	O
autonomic	22185349	682	691	O
nervous	22185349	692	699	O
system	22185349	700	706	O
.	22185349	706	707	O

The	22185349	708	711	O
practitioner	22185349	712	724	O
had	22185349	725	728	O
more	22185349	729	733	O
than	22185349	734	738	O
10	22185349	739	741	O
years	22185349	742	747	O
'	22185349	747	748	O
experience	22185349	749	759	O
with	22185349	760	764	O
loving-kindness	22185349	765	780	O
meditation	22185349	781	791	O
(	22185349	792	793	O
LKM	22185349	793	796	O
)	22185349	796	797	O
,	22185349	797	798	O
a	22185349	799	800	O
form	22185349	801	805	O
of	22185349	806	808	O
NVCC	22185349	809	813	O
.	22185349	813	814	O

Subjects	22185349	815	823	O
completed	22185349	824	833	O
10-point	22185349	834	842	O
visual	22185349	843	849	O
analog	22185349	850	856	O
scales	22185349	857	863	O
(	22185349	864	865	O
VAS	22185349	865	868	O
)	22185349	868	869	O
for	22185349	870	873	O
stress	22185349	874	880	O
,	22185349	880	881	O
relaxation	22185349	882	892	O
,	22185349	892	893	O
and	22185349	894	897	O
peacefulness	22185349	898	910	O
before	22185349	911	917	O
and	22185349	918	921	O
after	22185349	922	927	O
LKM	22185349	928	931	O
.	22185349	931	932	O

To	22185349	933	935	O
assess	22185349	936	942	O
physiologic	22185349	943	954	O
effects	22185349	955	962	O
,	22185349	962	963	O
practitioners	22185349	964	977	O
and	22185349	978	981	O
subjects	22185349	982	990	O
wore	22185349	991	995	O
cardiorespiratory	22185349	996	1013	O
monitors	22185349	1014	1022	O
to	22185349	1023	1025	O
assess	22185349	1026	1032	O
respiratory	22185349	1033	1044	O
rate	22185349	1045	1049	O
(	22185349	1050	1051	O
RR	22185349	1051	1053	O
)	22185349	1053	1054	O
,	22185349	1054	1055	O
heart	22185349	1056	1061	O
rate	22185349	1062	1066	O
(	22185349	1067	1068	O
HR	22185349	1068	1070	O
)	22185349	1070	1071	O
and	22185349	1072	1075	O
heart	22185349	1076	1081	O
rate	22185349	1082	1086	O
variability	22185349	1087	1098	O
(	22185349	1099	1100	O
HRV	22185349	1100	1103	O
)	22185349	1103	1104	O
throughout	22185349	1105	1115	O
the	22185349	1116	1119	O
4	22185349	1120	1121	O
10-minute	22185349	1122	1131	O
study	22185349	1132	1137	O
periods	22185349	1138	1145	O
:	22185349	1145	1146	O
Baseline	22185349	1147	1155	O
(	22185349	1156	1157	O
both	22185349	1157	1161	O
practitioner	22185349	1162	1174	O
and	22185349	1175	1178	O
subjects	22185349	1179	1187	O
read	22185349	1188	1192	O
neutral	22185349	1193	1200	O
material	22185349	1201	1209	O
)	22185349	1209	1210	O
;	22185349	1210	1211	O
non-tactile-LKM	22185349	1212	1227	O
(	22185349	1228	1229	O
subjects	22185349	1229	1237	O
read	22185349	1238	1242	O
while	22185349	1243	1248	O
the	22185349	1249	1252	O
practitioner	22185349	1253	1265	O
practiced	22185349	1266	1275	O
LKM	22185349	1276	1279	O
while	22185349	1280	1285	O
pretending	22185349	1286	1296	O
to	22185349	1297	1299	O
read	22185349	1300	1304	O
)	22185349	1304	1305	O
;	22185349	1305	1306	O
tactile-LKM	22185349	1307	1318	O
(	22185349	1319	1320	O
subjects	22185349	1320	1328	O
rested	22185349	1329	1335	O
while	22185349	1336	1341	O
the	22185349	1342	1345	O
practitioner	22185349	1346	1358	O
practiced	22185349	1359	1368	O
LKM	22185349	1369	1372	O
while	22185349	1373	1378	O
lightly	22185349	1379	1386	O
touching	22185349	1387	1395	O
the	22185349	1396	1399	O
subject	22185349	1400	1407	O
on	22185349	1408	1410	O
arms	22185349	1411	1415	O
,	22185349	1415	1416	O
shoulders	22185349	1417	1426	O
,	22185349	1426	1427	O
hands	22185349	1428	1433	O
,	22185349	1433	1434	O
feet	22185349	1435	1439	O
,	22185349	1439	1440	O
and	22185349	1441	1444	O
legs	22185349	1445	1449	O
)	22185349	1449	1450	O
;	22185349	1450	1451	O
Post-Intervention	22185349	1452	1469	O
Rest	22185349	1470	1474	O
(	22185349	1475	1476	O
subjects	22185349	1476	1484	O
rested	22185349	1485	1491	O
;	22185349	1491	1492	O
the	22185349	1493	1496	O
practitioner	22185349	1497	1509	O
read	22185349	1510	1514	O
)	22185349	1514	1515	O
.	22185349	1515	1516	O

To	22185349	1517	1519	O
assess	22185349	1520	1526	O
blinding	22185349	1527	1535	O
,	22185349	1535	1536	O
subjects	22185349	1537	1545	O
were	22185349	1546	1550	O
asked	22185349	1551	1556	O
after	22185349	1557	1562	O
the	22185349	1563	1566	O
interventions	22185349	1567	1580	O
what	22185349	1581	1585	O
the	22185349	1586	1589	O
practitioner	22185349	1590	1602	O
was	22185349	1603	1606	O
doing	22185349	1607	1612	O
during	22185349	1613	1619	O
each	22185349	1620	1624	O
period	22185349	1625	1631	O
(	22185349	1632	1633	O
reading	22185349	1633	1640	O
,	22185349	1640	1641	O
touch	22185349	1642	1647	O
,	22185349	1647	1648	O
or	22185349	1649	1651	O
something	22185349	1652	1661	O
else	22185349	1662	1666	O
)	22185349	1666	1667	O
.	22185349	1667	1668	O

RESULTS	22185349	1670	1677	O
:	22185349	1678	1679	O
Subjects	22185349	1680	1688	O
'	22185349	1688	1689	O
mean	22185349	1690	1694	O
age	22185349	1695	1698	O
was	22185349	1699	1702	O
43.6	22185349	1703	1707	O
years	22185349	1708	1713	O
;	22185349	1713	1714	O
all	22185349	1715	1718	O
were	22185349	1719	1723	O
women	22185349	1724	1729	O
.	22185349	1729	1730	O

Blinding	22185349	1731	1739	O
was	22185349	1740	1743	O
maintained	22185349	1744	1754	O
and	22185349	1755	1758	O
the	22185349	1759	1762	O
practitioner	22185349	1763	1775	O
was	22185349	1776	1779	O
able	22185349	1780	1784	O
to	22185349	1785	1787	O
maintain	22185349	1788	1796	O
meditation	22185349	1797	1807	O
for	22185349	1808	1811	O
both	22185349	1812	1816	O
tactile	22185349	1817	1824	O
and	22185349	1825	1828	O
non-tactile	22185349	1829	1840	O
LKM	22185349	1841	1844	O
interventions	22185349	1845	1858	O
as	22185349	1859	1861	O
reflected	22185349	1862	1871	O
in	22185349	1872	1874	O
significantly	22185349	1875	1888	O
reduced	22185349	1889	1896	O
RR	22185349	1897	1899	B-Outcome
.	22185349	1899	1900	O

Despite	22185349	1901	1908	O
blinding	22185349	1909	1917	O
,	22185349	1917	1918	O
subjects	22185349	1919	1927	O
'	22185349	1927	1928	O
VAS	22185349	1929	1932	B-Outcome
scores	22185349	1933	1939	I-Outcome
improved	22185349	1940	1948	O
from	22185349	1949	1953	O
baseline	22185349	1954	1962	O
to	22185349	1963	1965	O
post-intervention	22185349	1966	1983	O
for	22185349	1984	1987	O
stress	22185349	1988	1994	B-Outcome
(	22185349	1995	1996	O
5.5	22185349	1996	1999	O
vs.	22185349	2000	2003	O
2.2	22185349	2004	2007	O
)	22185349	2007	2008	O
,	22185349	2008	2009	O
relaxation	22185349	2010	2020	B-Outcome
(	22185349	2021	2022	O
3.8	22185349	2022	2025	O
vs.	22185349	2026	2029	O
8.8	22185349	2030	2033	O
)	22185349	2033	2034	O
and	22185349	2035	2038	O
peacefulness	22185349	2039	2051	B-Outcome
(	22185349	2052	2053	O
3.8	22185349	2053	2056	O
vs.	22185349	2057	2060	O
9.0	22185349	2061	2064	O
,	22185349	2064	2065	O
P	22185349	2066	2067	O
<	22185349	2068	2069	O
0.05	22185349	2070	2074	O
for	22185349	2075	2078	O
all	22185349	2079	2082	O
comparisons	22185349	2083	2094	O
)	22185349	2094	2095	O
.	22185349	2095	2096	O

Subjects	22185349	2097	2105	O
also	22185349	2106	2110	O
had	22185349	2111	2114	O
significant	22185349	2115	2126	O
reductions	22185349	2127	2137	O
in	22185349	2138	2140	O
RR	22185349	2141	2143	B-Outcome
(	22185349	2144	2145	O
P	22185349	2145	2146	O
<	22185349	2147	2148	O
0.0001	22185349	2149	2155	O
)	22185349	2155	2156	O
and	22185349	2157	2160	O
improved	22185349	2161	2169	O
HRV	22185349	2170	2173	B-Outcome
(	22185349	2174	2175	O
P	22185349	2175	2176	O
<	22185349	2177	2178	O
0.05	22185349	2179	2183	O
)	22185349	2183	2184	O
with	22185349	2185	2189	O
both	22185349	2190	2194	O
tactile	22185349	2195	2202	O
and	22185349	2203	2206	O
non-tactile	22185349	2207	2218	O
LKM	22185349	2219	2222	O
.	22185349	2222	2223	O

CONCLUSION	22185349	2225	2235	O
:	22185349	2236	2237	O
It	22185349	2238	2240	O
is	22185349	2241	2243	O
possible	22185349	2244	2252	O
to	22185349	2253	2255	O
test	22185349	2256	2260	O
the	22185349	2261	2264	O
effects	22185349	2265	2272	O
of	22185349	2273	2275	O
LKM	22185349	2276	2279	O
with	22185349	2280	2284	O
tactile	22185349	2285	2292	O
and	22185349	2293	2296	O
non-tactile	22185349	2297	2308	O
blinding	22185349	2309	2317	O
strategies	22185349	2318	2328	O
;	22185349	2328	2329	O
even	22185349	2330	2334	O
with	22185349	2335	2339	O
blinding	22185349	2340	2348	O
in	22185349	2349	2351	O
this	22185349	2352	2356	O
small	22185349	2357	2362	O
preliminary	22185349	2363	2374	O
study	22185349	2375	2380	O
,	22185349	2380	2381	O
subjects	22185349	2382	2390	O
reported	22185349	2391	2399	O
significant	22185349	2400	2411	O
improvements	22185349	2412	2424	O
in	22185349	2425	2427	O
well-being	22185349	2428	2438	B-Outcome
which	22185349	2439	2444	O
were	22185349	2445	2449	O
reflected	22185349	2450	2459	O
in	22185349	2460	2462	O
objective	22185349	2463	2472	B-Outcome
physiologic	22185349	2473	2484	I-Outcome
measures	22185349	2485	2493	I-Outcome
of	22185349	2494	2496	I-Outcome
autonomic	22185349	2497	2506	I-Outcome
activity	22185349	2507	2515	I-Outcome
.	22185349	2515	2516	O

Extending	22185349	2517	2526	O
compassion	22185349	2527	2537	O
is	22185349	2538	2540	O
not	22185349	2541	2544	O
only	22185349	2545	2549	O
good	22185349	2550	2554	O
care	22185349	2555	2559	O
;	22185349	2559	2560	O
it	22185349	2561	2563	O
may	22185349	2564	2567	O
also	22185349	2568	2572	O
be	22185349	2573	2575	O
good	22185349	2576	2580	O
medicine	22185349	2581	2589	O
.	22185349	2589	2590	O

TRIAL	22185349	2592	2597	O
REGISTRATION	22185349	2598	2610	O
NUMBER	22185349	2611	2617	O
:	22185349	2618	2619	O
US	22185349	2620	2622	O
National	22185349	2623	2631	O
ClinicalTrials.gov	22185349	2632	2650	O
registration	22185349	2651	2663	O
number	22185349	2664	2670	O
,	22185349	2670	2671	O
NCT01428674	22185349	2672	2683	O
.	22185349	2683	2684	O


Effects	22265360	0	7	O
of	22265360	8	10	O
risperidone	22265360	11	22	O
and	22265360	23	26	O
parent	22265360	27	33	O
training	22265360	34	42	O
on	22265360	43	45	O
adaptive	22265360	46	54	O
functioning	22265360	55	66	O
in	22265360	67	69	O
children	22265360	70	78	O
with	22265360	79	83	O
pervasive	22265360	84	93	O
developmental	22265360	94	107	O
disorders	22265360	108	117	O
and	22265360	118	121	O
serious	22265360	122	129	O
behavioral	22265360	130	140	O
problems	22265360	141	149	O
.	22265360	149	150	O

OBJECTIVE	22265360	152	161	O
:	22265360	162	163	O
Children	22265360	164	172	O
with	22265360	173	177	O
Pervasive	22265360	178	187	O
Developmental	22265360	188	201	O
Disorders	22265360	202	211	O
(	22265360	212	213	O
PDDs	22265360	213	217	O
)	22265360	217	218	O
have	22265360	219	223	O
social	22265360	224	230	O
interaction	22265360	231	242	O
deficits	22265360	243	251	O
,	22265360	251	252	O
delayed	22265360	253	260	O
communication	22265360	261	274	O
,	22265360	274	275	O
and	22265360	276	279	O
repetitive	22265360	280	290	O
behaviors	22265360	291	300	O
as	22265360	301	303	O
well	22265360	304	308	O
as	22265360	309	311	O
impairments	22265360	312	323	O
in	22265360	324	326	O
adaptive	22265360	327	335	O
functioning	22265360	336	347	O
.	22265360	347	348	O

Many	22265360	349	353	O
children	22265360	354	362	O
actually	22265360	363	371	O
show	22265360	372	376	O
a	22265360	377	378	O
decline	22265360	379	386	O
in	22265360	387	389	O
adaptive	22265360	390	398	O
skills	22265360	399	405	O
compared	22265360	406	414	O
with	22265360	415	419	O
age	22265360	420	423	O
mates	22265360	424	429	O
over	22265360	430	434	O
time	22265360	435	439	O
.	22265360	439	440	O

METHOD	22265360	442	448	O
:	22265360	449	450	O
This	22265360	451	455	O
24-week	22265360	456	463	O
,	22265360	463	464	O
three-site	22265360	465	475	O
,	22265360	475	476	O
controlled	22265360	477	487	O
clinical	22265360	488	496	O
trial	22265360	497	502	O
randomized	22265360	503	513	O
124	22265360	514	517	O
children	22265360	518	526	O
(	22265360	527	528	O
4	22265360	528	529	O
through	22265360	530	537	O
13	22265360	538	540	O
years	22265360	541	546	O
of	22265360	547	549	O
age	22265360	550	553	O
)	22265360	553	554	O
with	22265360	555	559	O
PDDs	22265360	560	564	O
and	22265360	565	568	O
serious	22265360	569	576	O
behavioral	22265360	577	587	O
problems	22265360	588	596	O
to	22265360	597	599	O
medication	22265360	600	610	O
alone	22265360	611	616	O
(	22265360	617	618	O
MED	22265360	618	621	O
;	22265360	621	622	O
n	22265360	623	624	O
=	22265360	625	626	O
49	22265360	627	629	O
;	22265360	629	630	O
risperidone	22265360	631	642	O
0.5	22265360	643	646	O
to	22265360	647	649	O
3.5	22265360	650	653	O
mg/day	22265360	654	660	O
;	22265360	660	661	O
if	22265360	662	664	O
ineffective	22265360	665	676	O
,	22265360	676	677	O
switch	22265360	678	684	O
to	22265360	685	687	O
aripiprazole	22265360	688	700	O
was	22265360	701	704	O
permitted	22265360	705	714	O
)	22265360	714	715	O
or	22265360	716	718	O
a	22265360	719	720	O
combination	22265360	721	732	O
of	22265360	733	735	O
medication	22265360	736	746	O
plus	22265360	747	751	O
parent	22265360	752	758	O
training	22265360	759	767	O
(	22265360	768	769	O
PT	22265360	769	771	O
)	22265360	771	772	O
(	22265360	773	774	O
COMB	22265360	774	778	O
;	22265360	778	779	O
n	22265360	780	781	O
=	22265360	782	783	O
75	22265360	784	786	O
)	22265360	786	787	O
.	22265360	787	788	O

Parents	22265360	789	796	O
of	22265360	797	799	O
children	22265360	800	808	O
in	22265360	809	811	O
COMB	22265360	812	816	O
received	22265360	817	825	O
an	22265360	826	828	O
average	22265360	829	836	O
of	22265360	837	839	O
11.4	22265360	840	844	O
PT	22265360	845	847	O
sessions	22265360	848	856	O
.	22265360	856	857	O

Standard	22265360	858	866	O
scores	22265360	867	873	O
and	22265360	874	877	O
Age-Equivalent	22265360	878	892	O
scores	22265360	893	899	O
on	22265360	900	902	O
Vineland	22265360	903	911	O
Adaptive	22265360	912	920	O
Behavior	22265360	921	929	O
Scales	22265360	930	936	O
were	22265360	937	941	O
the	22265360	942	945	O
outcome	22265360	946	953	O
measures	22265360	954	962	O
of	22265360	963	965	O
primary	22265360	966	973	O
interest	22265360	974	982	O
.	22265360	982	983	O

RESULTS	22265360	985	992	O
:	22265360	993	994	O
Seventeen	22265360	995	1004	O
subjects	22265360	1005	1013	O
did	22265360	1014	1017	O
not	22265360	1018	1021	O
have	22265360	1022	1026	O
a	22265360	1027	1028	O
post-randomization	22265360	1029	1047	O
Vineland	22265360	1048	1056	B-Outcome
assessment	22265360	1057	1067	I-Outcome
.	22265360	1067	1068	O

Thus	22265360	1069	1073	O
,	22265360	1073	1074	O
we	22265360	1075	1077	O
used	22265360	1078	1082	O
a	22265360	1083	1084	O
mixed	22265360	1085	1090	O
model	22265360	1091	1096	O
with	22265360	1097	1101	O
outcome	22265360	1102	1109	O
conditioned	22265360	1110	1121	O
on	22265360	1122	1124	O
the	22265360	1125	1128	O
baseline	22265360	1129	1137	B-Outcome
Vineland	22265360	1138	1146	I-Outcome
scores	22265360	1147	1153	I-Outcome
.	22265360	1153	1154	O

Both	22265360	1155	1159	O
groups	22265360	1160	1166	O
showed	22265360	1167	1173	O
improvement	22265360	1174	1185	O
over	22265360	1186	1190	O
the	22265360	1191	1194	O
24-week	22265360	1195	1202	O
trial	22265360	1203	1208	O
on	22265360	1209	1211	O
all	22265360	1212	1215	O
Vineland	22265360	1216	1224	B-Outcome
domains	22265360	1225	1232	I-Outcome
.	22265360	1232	1233	O

Compared	22265360	1234	1242	O
with	22265360	1243	1247	O
MED	22265360	1248	1251	O
,	22265360	1251	1252	O
Vineland	22265360	1253	1261	B-Outcome
Socialization	22265360	1262	1275	I-Outcome
and	22265360	1276	1279	I-Outcome
Adaptive	22265360	1280	1288	I-Outcome
Composite	22265360	1289	1298	I-Outcome
Standard	22265360	1299	1307	I-Outcome
scores	22265360	1308	1314	I-Outcome
showed	22265360	1315	1321	O
greater	22265360	1322	1329	O
improvement	22265360	1330	1341	O
in	22265360	1342	1344	O
the	22265360	1345	1348	O
COMB	22265360	1349	1353	O
group	22265360	1354	1359	O
(	22265360	1360	1361	O
p	22265360	1361	1362	O
=	22265360	1363	1364	O
.01	22265360	1365	1368	O
and	22265360	1369	1372	O
.05	22265360	1373	1376	O
,	22265360	1376	1377	O
and	22265360	1378	1381	O
effect	22265360	1382	1388	O
sizes	22265360	1389	1394	O
=	22265360	1395	1396	O
0.35	22265360	1397	1401	O
and	22265360	1402	1405	O
0.22	22265360	1406	1410	O
,	22265360	1410	1411	O
respectively	22265360	1412	1424	O
)	22265360	1424	1425	O
.	22265360	1425	1426	O

On	22265360	1427	1429	O
Age	22265360	1430	1433	B-Outcome
Equivalent	22265360	1434	1444	I-Outcome
scores	22265360	1445	1451	I-Outcome
,	22265360	1451	1452	O
Socialization	22265360	1453	1466	B-Outcome
and	22265360	1467	1470	O
Communication	22265360	1471	1484	B-Outcome
domains	22265360	1485	1492	I-Outcome
showed	22265360	1493	1499	O
greater	22265360	1500	1507	O
improvement	22265360	1508	1519	O
in	22265360	1520	1522	O
COMB	22265360	1523	1527	O
versus	22265360	1528	1534	O
MED	22265360	1535	1538	O
(	22265360	1539	1540	O
p	22265360	1540	1541	O
=	22265360	1542	1543	O
.03	22265360	1544	1547	O
and	22265360	1548	1551	O
0.05	22265360	1552	1556	O
,	22265360	1556	1557	O
and	22265360	1558	1561	O
effect	22265360	1562	1568	O
sizes	22265360	1569	1574	O
=	22265360	1575	1576	O
0.33	22265360	1577	1581	O
and	22265360	1582	1585	O
0.14	22265360	1586	1590	O
,	22265360	1590	1591	O
respectively	22265360	1592	1604	O
)	22265360	1604	1605	O
.	22265360	1605	1606	O

Using	22265360	1607	1612	O
logistic	22265360	1613	1621	O
regression	22265360	1622	1632	O
,	22265360	1632	1633	O
children	22265360	1634	1642	O
in	22265360	1643	1645	O
the	22265360	1646	1649	O
COMB	22265360	1650	1654	O
group	22265360	1655	1660	O
were	22265360	1661	1665	O
twice	22265360	1666	1671	O
as	22265360	1672	1674	O
likely	22265360	1675	1681	O
to	22265360	1682	1684	O
make	22265360	1685	1689	O
at	22265360	1690	1692	O
least	22265360	1693	1698	O
6	22265360	1699	1700	O
months	22265360	1701	1707	O
'	22265360	1707	1708	O
gain	22265360	1709	1713	O
(	22265360	1714	1715	O
equal	22265360	1715	1720	O
to	22265360	1721	1723	O
the	22265360	1724	1727	O
passage	22265360	1728	1735	O
of	22265360	1736	1738	O
time	22265360	1739	1743	O
)	22265360	1743	1744	O
in	22265360	1745	1747	O
the	22265360	1748	1751	O
Vineland	22265360	1752	1760	B-Outcome
Communication	22265360	1761	1774	I-Outcome
Age	22265360	1775	1778	I-Outcome
Equivalent	22265360	1779	1789	I-Outcome
score	22265360	1790	1795	I-Outcome
compared	22265360	1796	1804	O
with	22265360	1805	1809	O
MED	22265360	1810	1813	O
(	22265360	1814	1815	O
p	22265360	1815	1816	O
=	22265360	1817	1818	O
.02	22265360	1819	1822	O
)	22265360	1822	1823	O
.	22265360	1823	1824	O

After	22265360	1825	1830	O
controlling	22265360	1831	1842	O
for	22265360	1843	1846	O
IQ	22265360	1847	1849	O
,	22265360	1849	1850	O
this	22265360	1851	1855	O
difference	22265360	1856	1866	O
was	22265360	1867	1870	O
no	22265360	1871	1873	O
longer	22265360	1874	1880	O
significant	22265360	1881	1892	O
.	22265360	1892	1893	O

CONCLUSION	22265360	1895	1905	O
:	22265360	1906	1907	O
Reduction	22265360	1908	1917	O
of	22265360	1918	1920	O
serious	22265360	1921	1928	O
maladaptive	22265360	1929	1940	O
behavior	22265360	1941	1949	O
promotes	22265360	1950	1958	O
improvement	22265360	1959	1970	O
in	22265360	1971	1973	O
adaptive	22265360	1974	1982	O
behavior	22265360	1983	1991	O
.	22265360	1991	1992	O

Medication	22265360	1993	2003	O
plus	22265360	2004	2008	O
PT	22265360	2009	2011	O
shows	22265360	2012	2017	O
modest	22265360	2018	2024	O
additional	22265360	2025	2035	O
benefit	22265360	2036	2043	O
over	22265360	2044	2048	O
medication	22265360	2049	2059	O
alone	22265360	2060	2065	O
.	22265360	2065	2066	O

Clinical	22265360	2067	2075	O
trial	22265360	2076	2081	O
registration	22265360	2082	2094	O
information-RUPP	22265360	2095	2111	O
PI	22265360	2112	2114	O
PDD	22265360	2115	2118	O
:	22265360	2118	2119	O
Drug	22265360	2120	2124	O
and	22265360	2125	2128	O
Behavioral	22265360	2129	2139	O
Therapy	22265360	2140	2147	O
for	22265360	2148	2151	O
Children	22265360	2152	2160	O
With	22265360	2161	2165	O
Pervasive	22265360	2166	2175	O
Developmental	22265360	2176	2189	O
Disorders	22265360	2190	2199	O
;	22265360	2199	2200	O
http://www.clinicaltrials.gov	22265360	2201	2230	O
;	22265360	2230	2231	O
NCT00080145	22265360	2232	2243	O
.	22265360	2243	2244	O


Efficacy	22344198	0	8	O
and	22344198	9	12	O
safety	22344198	13	19	O
of	22344198	20	22	O
leuprolide	22344198	23	33	O
acetate	22344198	34	41	O
3-month	22344198	42	49	O
depot	22344198	50	55	O
11.25	22344198	56	61	O
milligrams	22344198	62	72	O
or	22344198	73	75	O
30	22344198	76	78	O
milligrams	22344198	79	89	O
for	22344198	90	93	O
the	22344198	94	97	O
treatment	22344198	98	107	O
of	22344198	108	110	O
central	22344198	111	118	O
precocious	22344198	119	129	O
puberty	22344198	130	137	O
.	22344198	137	138	O

CONTEXT	22344198	140	147	O
:	22344198	148	149	O
GnRH	22344198	150	154	O
agonist	22344198	155	162	O
(	22344198	163	164	O
GnRHa	22344198	164	169	O
)	22344198	169	170	O
monthly	22344198	171	178	O
injections	22344198	179	189	O
are	22344198	190	193	O
frequently	22344198	194	204	O
used	22344198	205	209	O
in	22344198	210	212	O
the	22344198	213	216	O
treatment	22344198	217	226	O
of	22344198	227	229	O
central	22344198	230	237	O
precocious	22344198	238	248	O
puberty	22344198	249	256	O
(	22344198	257	258	O
CPP	22344198	258	261	O
)	22344198	261	262	O
.	22344198	262	263	O

The	22344198	264	267	O
3-month	22344198	268	275	O
leuprolide	22344198	276	286	O
depot	22344198	287	292	O
11.25-	22344198	293	299	O
and	22344198	300	303	O
30-mg	22344198	304	309	O
formulations	22344198	310	322	O
are	22344198	323	326	O
newly	22344198	327	332	O
approved	22344198	333	341	O
treatment	22344198	342	351	O
options	22344198	352	359	O
.	22344198	359	360	O

OBJECTIVE	22344198	362	371	O
:	22344198	372	373	O
The	22344198	374	377	O
aim	22344198	378	381	O
of	22344198	382	384	O
the	22344198	385	388	O
study	22344198	389	394	O
was	22344198	395	398	O
to	22344198	399	401	O
investigate	22344198	402	413	O
the	22344198	414	417	O
safety	22344198	418	424	O
and	22344198	425	428	O
efficacy	22344198	429	437	O
of	22344198	438	440	O
leuprolide	22344198	441	451	O
acetate	22344198	452	459	O
3-month	22344198	460	467	O
depot	22344198	468	473	O
formulations	22344198	474	486	O
for	22344198	487	490	O
the	22344198	491	494	O
treatment	22344198	495	504	O
of	22344198	505	507	O
CPP	22344198	508	511	O
in	22344198	512	514	O
children	22344198	515	523	O
.	22344198	523	524	O

DESIGN	22344198	526	532	O
:	22344198	533	534	O
This	22344198	535	539	O
was	22344198	540	543	O
a	22344198	544	545	O
phase	22344198	546	551	O
III	22344198	552	555	O
,	22344198	555	556	O
randomized	22344198	557	567	O
,	22344198	567	568	O
open-label	22344198	569	579	O
,	22344198	579	580	O
dose-ranging	22344198	581	593	O
6-month	22344198	594	601	O
study	22344198	602	607	O
.	22344198	607	608	O

SETTING	22344198	610	617	O
:	22344198	618	619	O
Twenty-two	22344198	620	630	O
U.S.	22344198	631	635	O
medical	22344198	636	643	O
centers	22344198	644	651	O
(	22344198	652	653	O
including	22344198	653	662	O
Puerto	22344198	663	669	O
Rico	22344198	670	674	O
)	22344198	674	675	O
participated	22344198	676	688	O
.	22344198	688	689	O

PATIENTS	22344198	691	699	O
:	22344198	700	701	O
Children	22344198	702	710	O
diagnosed	22344198	711	720	O
with	22344198	721	725	O
CPP	22344198	726	729	O
(	22344198	730	731	O
n	22344198	731	732	O
=	22344198	733	734	O
84	22344198	735	737	O
)	22344198	737	738	O
,	22344198	738	739	O
who	22344198	740	743	O
were	22344198	744	748	O
either	22344198	749	755	O
treatment	22344198	756	765	O
naive	22344198	766	771	O
or	22344198	772	774	O
previously	22344198	775	785	O
treated	22344198	786	793	O
with	22344198	794	798	O
GnRHa	22344198	799	804	O
,	22344198	804	805	O
were	22344198	806	810	O
recruited	22344198	811	820	O
.	22344198	820	821	O

Chronological	22344198	822	835	O
age	22344198	836	839	O
at	22344198	840	842	O
onset	22344198	843	848	O
of	22344198	849	851	O
pubertal	22344198	852	860	O
signs	22344198	861	866	O
was	22344198	867	870	O
less	22344198	871	875	O
than	22344198	876	880	O
8	22344198	881	882	O
yr	22344198	883	885	O
in	22344198	886	888	O
girls	22344198	889	894	O
and	22344198	895	898	O
less	22344198	899	903	O
than	22344198	904	908	O
9	22344198	909	910	O
yr	22344198	911	913	O
in	22344198	914	916	O
boys	22344198	917	921	O
,	22344198	921	922	O
and	22344198	923	926	O
bone	22344198	927	931	O
age	22344198	932	935	O
was	22344198	936	939	O
advanced	22344198	940	948	O
over	22344198	949	953	O
chronological	22344198	954	967	O
age	22344198	968	971	O
at	22344198	972	974	O
least	22344198	975	980	O
1	22344198	981	982	O
yr	22344198	983	985	O
.	22344198	985	986	O

INTERVENTION	22344198	988	1000	O
:	22344198	1001	1002	O
Leuprolide	22344198	1003	1013	O
acetate	22344198	1014	1021	O
depot	22344198	1022	1027	O
(	22344198	1028	1029	O
11.25	22344198	1029	1034	O
or	22344198	1035	1037	O
30	22344198	1038	1040	O
mg	22344198	1041	1043	O
)	22344198	1043	1044	O
was	22344198	1045	1048	O
administered	22344198	1049	1061	O
i	22344198	1062	1063	O
m	22344198	1063	1064	O
every	22344198	1065	1070	O
3	22344198	1071	1072	O
months	22344198	1073	1079	O
.	22344198	1079	1080	O

MAIN	22344198	1082	1086	O
OUTCOME	22344198	1087	1094	O
MEASURES	22344198	1095	1103	O
:	22344198	1104	1105	O
Biochemical	22344198	1106	1117	O
[	22344198	1118	1119	O
peak-stimulated	22344198	1119	1134	O
LH	22344198	1135	1137	O
,	22344198	1137	1138	O
estradiol	22344198	1139	1148	O
(	22344198	1149	1150	O
girls	22344198	1150	1155	O
)	22344198	1155	1156	O
,	22344198	1156	1157	O
and	22344198	1158	1161	O
testosterone	22344198	1162	1174	O
(	22344198	1175	1176	O
boys	22344198	1176	1180	O
)	22344198	1180	1181	O
]	22344198	1181	1182	O
and	22344198	1183	1186	O
anthropometric	22344198	1187	1201	O
(	22344198	1202	1203	O
growth	22344198	1203	1209	O
rate	22344198	1210	1214	O
,	22344198	1214	1215	O
bone	22344198	1216	1220	O
age	22344198	1221	1224	O
acceleration	22344198	1225	1237	O
,	22344198	1237	1238	O
pubertal	22344198	1239	1247	O
progression	22344198	1248	1259	O
)	22344198	1259	1260	O
parameters	22344198	1261	1271	O
and	22344198	1272	1275	O
safety	22344198	1276	1282	O
were	22344198	1283	1287	O
assessed	22344198	1288	1296	O
.	22344198	1296	1297	O

RESULTS	22344198	1299	1306	O
:	22344198	1307	1308	O
Peak-stimulated	22344198	1309	1324	B-Outcome
LH	22344198	1325	1327	I-Outcome
was	22344198	1328	1331	O
suppressed	22344198	1332	1342	O
in	22344198	1343	1345	O
the	22344198	1346	1349	O
11.25-	22344198	1350	1356	O
and	22344198	1357	1360	O
30-mg	22344198	1361	1366	O
dose	22344198	1367	1371	O
groups	22344198	1372	1378	O
in	22344198	1379	1381	O
78.4	22344198	1382	1386	O
and	22344198	1387	1390	O
95.2	22344198	1391	1395	O
%	22344198	1395	1396	O
,	22344198	1396	1397	O
respectively	22344198	1398	1410	O
,	22344198	1410	1411	O
of	22344198	1412	1414	O
children	22344198	1415	1423	O
from	22344198	1424	1428	O
months	22344198	1429	1435	O
2	22344198	1436	1437	O
through	22344198	1438	1445	O
6	22344198	1446	1447	O
.	22344198	1447	1448	O

There	22344198	1449	1454	O
were	22344198	1455	1459	O
nine	22344198	1460	1464	O
treatment	22344198	1465	1474	B-Outcome
failures	22344198	1475	1483	I-Outcome
(	22344198	1484	1485	I-Outcome
peak-stimulated	22344198	1485	1500	I-Outcome
LH	22344198	1501	1503	I-Outcome
>	22344198	1504	1505	I-Outcome
4	22344198	1505	1506	I-Outcome
IU/liter	22344198	1507	1515	I-Outcome
)	22344198	1515	1516	I-Outcome
in	22344198	1517	1519	O
the	22344198	1520	1523	O
11.25-mg	22344198	1524	1532	O
group	22344198	1533	1538	O
and	22344198	1539	1542	O
two	22344198	1543	1546	O
in	22344198	1547	1549	O
the	22344198	1550	1553	O
30-mg	22344198	1554	1559	O
group	22344198	1560	1565	O
.	22344198	1565	1566	O

Basal	22344198	1567	1572	B-Outcome
sex	22344198	1573	1576	I-Outcome
steroid	22344198	1577	1584	I-Outcome
suppression	22344198	1585	1596	I-Outcome
,	22344198	1596	1597	O
growth	22344198	1598	1604	B-Outcome
rates	22344198	1605	1610	I-Outcome
,	22344198	1610	1611	O
pubertal	22344198	1612	1620	B-Outcome
progression	22344198	1621	1632	I-Outcome
,	22344198	1632	1633	O
bone	22344198	1634	1638	B-Outcome
age	22344198	1639	1642	I-Outcome
advancement	22344198	1643	1654	I-Outcome
,	22344198	1654	1655	O
and	22344198	1656	1659	O
adverse	22344198	1660	1667	B-Outcome
events	22344198	1668	1674	I-Outcome
were	22344198	1675	1679	O
similar	22344198	1680	1687	O
with	22344198	1688	1692	O
either	22344198	1693	1699	O
dose	22344198	1700	1704	O
.	22344198	1704	1705	O

CONCLUSIONS	22344198	1707	1718	O
:	22344198	1719	1720	O
Treatment	22344198	1721	1730	O
with	22344198	1731	1735	O
leuprolide	22344198	1736	1746	O
acetate	22344198	1747	1754	O
3-month	22344198	1755	1762	O
depot	22344198	1763	1768	O
formulations	22344198	1769	1781	O
(	22344198	1782	1783	O
11.25	22344198	1783	1788	O
and	22344198	1789	1792	O
30	22344198	1793	1795	O
mg	22344198	1796	1798	O
)	22344198	1798	1799	O
effectively	22344198	1800	1811	O
suppressed	22344198	1812	1822	O
the	22344198	1823	1826	O
GnRH	22344198	1827	1831	B-Outcome
axis	22344198	1832	1836	I-Outcome
,	22344198	1836	1837	O
was	22344198	1838	1841	O
well	22344198	1842	1846	O
tolerated	22344198	1847	1856	B-Outcome
,	22344198	1856	1857	O
and	22344198	1858	1861	O
may	22344198	1862	1865	O
positively	22344198	1866	1876	O
impact	22344198	1877	1883	O
patient	22344198	1884	1891	O
convenience	22344198	1892	1903	O
and	22344198	1904	1907	O
compliance	22344198	1908	1918	O
.	22344198	1918	1919	O


Utility	22395144	0	7	O
of	22395144	8	10	O
the	22395144	11	14	O
bladder	22395144	15	22	O
flap	22395144	23	27	O
at	22395144	28	30	O
cesarean	22395144	31	39	O
delivery	22395144	40	48	O
:	22395144	48	49	O
a	22395144	50	51	O
randomized	22395144	52	62	O
controlled	22395144	63	73	O
trial	22395144	74	79	O
.	22395144	79	80	O

OBJECTIVE	22395144	82	91	O
:	22395144	92	93	O
To	22395144	94	96	O
test	22395144	97	101	O
the	22395144	102	105	O
hypothesis	22395144	106	116	O
that	22395144	117	121	O
omission	22395144	122	130	O
of	22395144	131	133	O
the	22395144	134	137	O
bladder	22395144	138	145	O
flap	22395144	146	150	O
in	22395144	151	153	O
primary	22395144	154	161	O
and	22395144	162	165	O
repeat	22395144	166	172	O
cesarean	22395144	173	181	O
deliveries	22395144	182	192	O
shortens	22395144	193	201	O
operating	22395144	202	211	O
time	22395144	212	216	O
without	22395144	217	224	O
increasing	22395144	225	235	O
intraoperative	22395144	236	250	O
and	22395144	251	254	O
postoperative	22395144	255	268	O
complications	22395144	269	282	O
.	22395144	282	283	O

METHODS	22395144	285	292	O
:	22395144	293	294	O
We	22395144	295	297	O
randomized	22395144	298	308	O
258	22395144	309	312	O
women	22395144	313	318	O
undergoing	22395144	319	329	O
primary	22395144	330	337	O
and	22395144	338	341	O
repeat	22395144	342	348	O
cesarean	22395144	349	357	O
deliveries	22395144	358	368	O
at	22395144	369	371	O
32	22395144	372	374	O
weeks	22395144	375	380	O
of	22395144	381	383	O
gestation	22395144	384	393	O
or	22395144	394	396	O
more	22395144	397	401	O
to	22395144	402	404	O
creation	22395144	405	413	O
(	22395144	414	415	O
n=131	22395144	415	420	O
)	22395144	420	421	O
or	22395144	422	424	O
omission	22395144	425	433	O
(	22395144	434	435	O
n=127	22395144	435	440	O
)	22395144	440	441	O
of	22395144	442	444	O
the	22395144	445	448	O
bladder	22395144	449	456	O
flap	22395144	457	461	O
.	22395144	461	462	O

Emergency	22395144	463	472	O
cesarean	22395144	473	481	O
deliveries	22395144	482	492	O
,	22395144	492	493	O
planned	22395144	494	501	O
vertical	22395144	502	510	O
uterine	22395144	511	518	O
incisions	22395144	519	528	O
,	22395144	528	529	O
and	22395144	530	533	O
previous	22395144	534	542	O
abdominal	22395144	543	552	O
surgeries	22395144	553	562	O
besides	22395144	563	570	O
cesarean	22395144	571	579	O
deliveries	22395144	580	590	O
were	22395144	591	595	O
excluded	22395144	596	604	O
.	22395144	604	605	O

The	22395144	606	609	O
primary	22395144	610	617	O
outcome	22395144	618	625	O
measure	22395144	626	633	O
was	22395144	634	637	O
total	22395144	638	643	O
operating	22395144	644	653	O
time	22395144	654	658	O
.	22395144	658	659	O

Secondary	22395144	660	669	O
outcomes	22395144	670	678	O
were	22395144	679	683	O
bladder	22395144	684	691	O
injury	22395144	692	698	O
,	22395144	698	699	O
incision-to-delivery	22395144	700	720	O
time	22395144	721	725	O
,	22395144	725	726	O
incision-to-fascial	22395144	727	746	O
closure	22395144	747	754	O
time	22395144	755	759	O
,	22395144	759	760	O
estimated	22395144	761	770	O
blood	22395144	771	776	O
loss	22395144	777	781	O
,	22395144	781	782	O
postoperative	22395144	783	796	O
microhematuria	22395144	797	811	O
,	22395144	811	812	O
postoperative	22395144	813	826	O
pain	22395144	827	831	O
,	22395144	831	832	O
hospital	22395144	833	841	O
days	22395144	842	846	O
,	22395144	846	847	O
endometritis	22395144	848	860	O
,	22395144	860	861	O
and	22395144	862	865	O
urinary	22395144	866	873	O
tract	22395144	874	879	O
infection	22395144	880	889	O
.	22395144	889	890	O

Analysis	22395144	891	899	O
followed	22395144	900	908	O
the	22395144	909	912	O
intention-to-treat	22395144	913	931	O
principle	22395144	932	941	O
.	22395144	941	942	O

RESULTS	22395144	944	951	O
:	22395144	952	953	O
The	22395144	954	957	O
median	22395144	958	964	B-Outcome
skin	22395144	965	969	I-Outcome
incision	22395144	970	978	I-Outcome
to	22395144	979	981	I-Outcome
delivery	22395144	982	990	I-Outcome
interval	22395144	991	999	I-Outcome
was	22395144	1000	1003	O
shorter	22395144	1004	1011	O
with	22395144	1012	1016	O
omission	22395144	1017	1025	O
of	22395144	1026	1028	O
the	22395144	1029	1032	O
bladder	22395144	1033	1040	O
flap	22395144	1041	1045	O
(	22395144	1046	1047	O
9	22395144	1047	1048	O
[	22395144	1049	1050	O
range	22395144	1050	1055	O
1	22395144	1056	1057	O
-	22395144	1057	1058	O
43	22395144	1058	1060	O
]	22395144	1060	1061	O
compared	22395144	1062	1070	O
with	22395144	1071	1075	O
10	22395144	1076	1078	O
[	22395144	1079	1080	O
range	22395144	1080	1085	O
2	22395144	1086	1087	O
-	22395144	1087	1088	O
70	22395144	1088	1090	O
]	22395144	1090	1091	O
minutes	22395144	1092	1099	O
;	22395144	1099	1100	O
P=.04	22395144	1101	1106	O
)	22395144	1106	1107	O
,	22395144	1107	1108	O
but	22395144	1109	1112	O
there	22395144	1113	1118	O
was	22395144	1119	1122	O
no	22395144	1123	1125	O
difference	22395144	1126	1136	O
in	22395144	1137	1139	O
total	22395144	1140	1145	B-Outcome
operating	22395144	1146	1155	I-Outcome
time	22395144	1156	1160	I-Outcome
(	22395144	1161	1162	O
51	22395144	1162	1164	O
[	22395144	1165	1166	O
range	22395144	1166	1171	O
18	22395144	1172	1174	O
-	22395144	1174	1175	O
124	22395144	1175	1178	O
]	22395144	1178	1179	O
minutes	22395144	1180	1187	O
compared	22395144	1188	1196	O
with	22395144	1197	1201	O
51	22395144	1202	1204	O
[	22395144	1205	1206	O
range	22395144	1206	1211	O
16	22395144	1212	1214	O
-	22395144	1214	1215	O
178	22395144	1215	1218	O
]	22395144	1218	1219	O
;	22395144	1219	1220	O
P=.10	22395144	1221	1226	O
)	22395144	1226	1227	O
.	22395144	1227	1228	O

No	22395144	1229	1231	O
bladder	22395144	1232	1239	B-Outcome
injuries	22395144	1240	1248	I-Outcome
occurred	22395144	1249	1257	O
in	22395144	1258	1260	O
either	22395144	1261	1267	O
group	22395144	1268	1273	O
and	22395144	1274	1277	O
there	22395144	1278	1283	O
were	22395144	1284	1288	O
no	22395144	1289	1291	O
significant	22395144	1292	1303	O
differences	22395144	1304	1315	O
in	22395144	1316	1318	O
estimated	22395144	1319	1328	B-Outcome
blood	22395144	1329	1334	I-Outcome
loss	22395144	1335	1339	I-Outcome
,	22395144	1339	1340	O
change	22395144	1341	1347	O
in	22395144	1348	1350	O
hemoglobin	22395144	1351	1361	B-Outcome
level	22395144	1362	1367	I-Outcome
,	22395144	1367	1368	O
postoperative	22395144	1369	1382	B-Outcome
microhematuria	22395144	1383	1397	I-Outcome
,	22395144	1397	1398	O
postoperative	22395144	1399	1412	B-Outcome
pain	22395144	1413	1417	I-Outcome
,	22395144	1417	1418	O
hospital	22395144	1419	1427	B-Outcome
days	22395144	1428	1432	I-Outcome
,	22395144	1432	1433	O
endometritis	22395144	1434	1446	B-Outcome
,	22395144	1446	1447	O
or	22395144	1448	1450	O
urinary	22395144	1451	1458	B-Outcome
tract	22395144	1459	1464	I-Outcome
infection	22395144	1465	1474	I-Outcome
.	22395144	1474	1475	O

CONCLUSION	22395144	1477	1487	O
:	22395144	1488	1489	O
Omission	22395144	1490	1498	O
of	22395144	1499	1501	O
the	22395144	1502	1505	O
bladder	22395144	1506	1513	O
flap	22395144	1514	1518	O
at	22395144	1519	1521	O
primary	22395144	1522	1529	O
and	22395144	1530	1533	O
repeat	22395144	1534	1540	O
cesarean	22395144	1541	1549	O
deliveries	22395144	1550	1560	O
does	22395144	1561	1565	O
not	22395144	1566	1569	O
increase	22395144	1570	1578	O
intraoperative	22395144	1579	1593	B-Outcome
or	22395144	1594	1596	O
postoperative	22395144	1597	1610	B-Outcome
complications	22395144	1611	1624	I-Outcome
.	22395144	1624	1625	O

Incision-to-delivery	22395144	1626	1646	B-Outcome
time	22395144	1647	1651	I-Outcome
is	22395144	1652	1654	O
shortened	22395144	1655	1664	O
but	22395144	1665	1668	O
total	22395144	1669	1674	B-Outcome
operating	22395144	1675	1684	I-Outcome
time	22395144	1685	1689	I-Outcome
appears	22395144	1690	1697	O
unchanged	22395144	1698	1707	O
.	22395144	1707	1708	O

CLINICAL	22395144	1710	1718	O
TRIAL	22395144	1719	1724	O
REGISTRATION	22395144	1725	1737	O
:	22395144	1738	1739	O
ClinicalTrials.gov	22395144	1740	1758	O
,	22395144	1758	1759	O
www	22395144	1759	1762	O
.	22395144	1762	1763	O
ClinicalTrials.gov	22395144	1764	1782	O
,	22395144	1782	1783	O
NCT00918996	22395144	1784	1795	O
.	22395144	1795	1796	O

LEVEL	22395144	1798	1803	O
OF	22395144	1804	1806	O
EVIDENCE	22395144	1807	1815	O
:	22395144	1816	1817	O
I.	22395144	1818	1820	O

Successful	22527308	0	10	O
treatment	22527308	11	20	O
of	22527308	21	23	O
blepharitis	22527308	24	35	O
with	22527308	36	40	O
bibrocathol	22527308	41	52	O
(	22527308	53	54	O
Posiformin	22527308	54	64	O
®	22527308	64	65	O
2	22527308	66	67	O
%	22527308	68	69	O
)	22527308	69	70	O
.	22527308	70	71	O

BACKGROUND	22527308	73	83	O
:	22527308	84	85	O
Bibrocathol	22527308	86	97	O
is	22527308	98	100	O
a	22527308	101	102	O
well-established	22527308	103	119	O
antiseptic	22527308	120	130	O
drug	22527308	131	135	O
for	22527308	136	139	O
the	22527308	140	143	O
treatment	22527308	144	153	O
of	22527308	154	156	O
acute	22527308	157	162	O
eyelid	22527308	163	169	O
diseases	22527308	170	178	O
like	22527308	179	183	O
blepharitis	22527308	184	195	O
.	22527308	195	196	O

Despite	22527308	197	204	O
its	22527308	205	208	O
frequent	22527308	209	217	O
use	22527308	218	221	O
in	22527308	222	224	O
clinical	22527308	225	233	O
practice	22527308	234	242	O
,	22527308	242	243	O
no	22527308	244	246	O
controlled	22527308	247	257	O
clinical	22527308	258	266	O
trial	22527308	267	272	O
on	22527308	273	275	O
the	22527308	276	279	O
efficacy	22527308	280	288	O
of	22527308	289	291	O
bibrocathol	22527308	292	303	O
2	22527308	304	305	O
%	22527308	305	306	O
eye	22527308	307	310	O
ointment	22527308	311	319	O
has	22527308	320	323	O
been	22527308	324	328	O
performed	22527308	329	338	O
until	22527308	339	344	O
now	22527308	345	348	O
.	22527308	348	349	O

The	22527308	350	353	O
aim	22527308	354	357	O
of	22527308	358	360	O
the	22527308	361	364	O
study	22527308	365	370	O
was	22527308	371	374	O
to	22527308	375	377	O
investigate	22527308	378	389	O
efficacy	22527308	390	398	O
,	22527308	398	399	O
safety	22527308	400	406	O
and	22527308	407	410	O
tolerability	22527308	411	423	O
of	22527308	424	426	O
bibrocathol	22527308	427	438	O
(	22527308	439	440	O
Posiformin	22527308	440	450	O
®	22527308	450	451	O
2	22527308	452	453	O
%	22527308	454	455	O
)	22527308	455	456	O
eye	22527308	457	460	O
ointment	22527308	461	469	O
in	22527308	470	472	O
patients	22527308	473	481	O
diagnosed	22527308	482	491	O
with	22527308	492	496	O
blepharitis	22527308	497	508	O
.	22527308	508	509	O

METHODS	22527308	511	518	O
:	22527308	519	520	O
In	22527308	521	523	O
this	22527308	524	528	O
multi-center	22527308	529	541	O
,	22527308	541	542	O
randomized	22527308	543	553	O
,	22527308	553	554	O
double-masked	22527308	555	568	O
,	22527308	568	569	O
placebo-controlled	22527308	570	588	O
parallel-group	22527308	589	603	O
comparison	22527308	604	614	O
,	22527308	614	615	O
the	22527308	616	619	O
change	22527308	620	626	O
of	22527308	627	629	O
signs	22527308	630	635	O
and	22527308	636	639	O
symptoms	22527308	640	648	O
(	22527308	649	650	O
sum	22527308	650	653	O
score	22527308	654	659	O
)	22527308	659	660	O
of	22527308	661	663	O
blepharitis	22527308	664	675	O
in	22527308	676	678	O
197	22527308	679	682	O
patients	22527308	683	691	O
(	22527308	692	693	O
ITT	22527308	693	696	O
(	22527308	697	698	O
intention-to-treat-group	22527308	698	722	O
)	22527308	722	723	O
;	22527308	723	724	O
mean	22527308	725	729	O
age	22527308	730	733	O
56	22527308	734	736	O
±	22527308	737	738	O
18	22527308	739	741	O
years	22527308	742	747	O
,	22527308	747	748	O
56	22527308	749	751	O
%	22527308	752	753	O
female	22527308	754	760	O
,	22527308	760	761	O
active	22527308	762	768	O
drug	22527308	769	773	O
:	22527308	773	774	O
vehicle	22527308	774	781	O
=	22527308	782	783	O
97:100	22527308	784	790	O
)	22527308	790	791	O
over	22527308	792	796	O
2	22527308	797	798	O
weeks	22527308	799	804	O
treatment	22527308	805	814	O
with	22527308	815	819	O
bibrocathol	22527308	820	831	O
2	22527308	832	833	O
%	22527308	834	835	O
eye	22527308	836	839	O
ointment	22527308	840	848	O
was	22527308	849	852	O
evaluated	22527308	853	862	O
.	22527308	862	863	O

RESULTS	22527308	865	872	O
:	22527308	873	874	O
Patients	22527308	875	883	O
receiving	22527308	884	893	O
bibrocathol	22527308	894	905	O
2	22527308	906	907	O
%	22527308	908	909	O
showed	22527308	910	916	O
greater	22527308	917	924	O
improvement	22527308	925	936	O
in	22527308	937	939	O
the	22527308	940	943	O
sum	22527308	944	947	O
score	22527308	948	953	O
than	22527308	954	958	O
the	22527308	959	962	O
placebo	22527308	963	970	O
patients	22527308	971	979	O
(	22527308	980	981	O
p	22527308	981	982	O
<	22527308	983	984	O
0.0001	22527308	985	991	O
,	22527308	991	992	O
Cohen	22527308	993	998	O
's	22527308	998	1000	O
effect	22527308	1001	1007	O
size	22527308	1008	1012	O
d	22527308	1013	1014	O
=	22527308	1015	1016	O
0.73	22527308	1017	1021	O
)	22527308	1021	1022	O
.	22527308	1022	1023	O

Also	22527308	1024	1028	O
,	22527308	1028	1029	O
the	22527308	1030	1033	O
results	22527308	1034	1041	O
from	22527308	1042	1046	O
further	22527308	1047	1054	O
efficacy	22527308	1055	1063	B-Outcome
assessments	22527308	1064	1075	O
improvement	22527308	1076	1087	O
of	22527308	1088	1090	O
single	22527308	1091	1097	B-Outcome
symptoms	22527308	1098	1106	I-Outcome
and	22527308	1107	1110	O
ocular	22527308	1111	1117	B-Outcome
discomfort	22527308	1118	1128	I-Outcome
measured	22527308	1129	1137	O
by	22527308	1138	1140	O
a	22527308	1141	1142	O
VAS	22527308	1143	1146	B-Outcome
(	22527308	1147	1148	O
visual	22527308	1148	1154	B-Outcome
analogue	22527308	1155	1163	I-Outcome
scale	22527308	1164	1169	I-Outcome
)	22527308	1169	1170	O
supported	22527308	1171	1180	O
treatment	22527308	1181	1190	O
with	22527308	1191	1195	O
bibrocathol	22527308	1196	1207	O
.	22527308	1207	1208	O

Patients	22527308	1209	1217	O
and	22527308	1218	1221	O
investigators	22527308	1222	1235	O
provided	22527308	1236	1244	O
favorable	22527308	1245	1254	O
tolerability	22527308	1255	1267	B-Outcome
ratings	22527308	1268	1275	O
preferring	22527308	1276	1286	O
bibrocathol	22527308	1287	1298	O
over	22527308	1299	1303	O
placebo	22527308	1304	1311	O
.	22527308	1311	1312	O

No	22527308	1313	1315	O
safety	22527308	1316	1322	B-Outcome
issues	22527308	1323	1329	O
were	22527308	1330	1334	O
observed	22527308	1335	1343	O
with	22527308	1344	1348	O
regard	22527308	1349	1355	O
to	22527308	1356	1358	O
intraocular	22527308	1359	1370	B-Outcome
pressure	22527308	1371	1379	I-Outcome
,	22527308	1379	1380	O
visual	22527308	1381	1387	B-Outcome
acuity	22527308	1388	1394	I-Outcome
,	22527308	1394	1395	O
or	22527308	1396	1398	O
occurrence	22527308	1399	1409	O
of	22527308	1410	1412	O
adverse	22527308	1413	1420	B-Outcome
events	22527308	1421	1427	I-Outcome
.	22527308	1427	1428	O

CONCLUSIONS	22527308	1430	1441	O
:	22527308	1442	1443	O
Blepharitis	22527308	1444	1455	O
therapy	22527308	1456	1463	O
with	22527308	1464	1468	O
the	22527308	1469	1472	O
antiseptic	22527308	1473	1483	O
bibrocathol	22527308	1484	1495	O
2	22527308	1496	1497	O
%	22527308	1498	1499	O
in	22527308	1500	1502	O
this	22527308	1503	1507	O
trial	22527308	1508	1513	O
was	22527308	1514	1517	O
highly	22527308	1518	1524	O
efficacious	22527308	1525	1536	B-Outcome
and	22527308	1537	1540	O
safe	22527308	1541	1545	B-Outcome
.	22527308	1545	1546	O


Evaluation	22631032	0	10	O
of	22631032	11	13	O
the	22631032	14	17	O
pharmacodynamics	22631032	18	34	O
of	22631032	35	37	O
acetylsalicylic	22631032	38	53	O
acid	22631032	54	58	O
81	22631032	59	61	O
mg	22631032	62	64	O
with	22631032	65	69	O
or	22631032	70	72	O
without	22631032	73	80	O
esomeprazole	22631032	81	93	O
20	22631032	94	96	O
mg	22631032	97	99	O
in	22631032	100	102	O
healthy	22631032	103	110	O
volunteers	22631032	111	121	O
.	22631032	121	122	O

BACKGROUND	22631032	124	134	O
:	22631032	135	136	O
The	22631032	137	140	O
absence	22631032	141	148	O
of	22631032	149	151	O
a	22631032	152	153	O
pharmacokinetic	22631032	154	169	O
interaction	22631032	170	181	O
between	22631032	182	189	O
the	22631032	190	193	O
proton	22631032	194	200	O
pump	22631032	201	205	O
inhibitor	22631032	206	215	O
esomeprazole	22631032	216	228	O
(	22631032	229	230	O
40	22631032	230	232	O
mg	22631032	233	235	O
)	22631032	235	236	O
and	22631032	237	240	O
acetylsalicylic	22631032	241	256	O
acid	22631032	257	261	O
(	22631032	262	263	O
aspirin	22631032	263	270	O
,	22631032	270	271	O
ASA	22631032	272	275	O
;	22631032	275	276	O
325	22631032	277	280	O
mg	22631032	281	283	O
)	22631032	283	284	O
has	22631032	285	288	O
previously	22631032	289	299	O
been	22631032	300	304	O
established	22631032	305	316	O
.	22631032	316	317	O

OBJECTIVE	22631032	319	328	O
:	22631032	329	330	O
This	22631032	331	335	O
study	22631032	336	341	O
set	22631032	342	345	O
out	22631032	346	349	O
to	22631032	350	352	O
investigate	22631032	353	364	O
the	22631032	365	368	O
potential	22631032	369	378	O
for	22631032	379	382	O
pharmacodynamic	22631032	383	398	O
interaction	22631032	399	410	O
between	22631032	411	418	O
low-dose	22631032	419	427	O
ASA	22631032	428	431	O
and	22631032	432	435	O
esomeprazole	22631032	436	448	O
in	22631032	449	451	O
healthy	22631032	452	459	O
volunteers	22631032	460	470	O
,	22631032	470	471	O
by	22631032	472	474	O
measuring	22631032	475	484	O
ASA	22631032	485	488	O
antiplatelet	22631032	489	501	O
activity	22631032	502	510	O
.	22631032	510	511	O

STUDY	22631032	513	518	O
DESIGN	22631032	519	525	O
:	22631032	526	527	O
This	22631032	528	532	O
was	22631032	533	536	O
a	22631032	537	538	O
single-center	22631032	539	552	O
,	22631032	552	553	O
open-label	22631032	554	564	O
,	22631032	564	565	O
two-period	22631032	566	576	O
,	22631032	576	577	O
randomized	22631032	578	588	O
crossover	22631032	589	598	O
study	22631032	599	604	O
.	22631032	604	605	O

PARTICIPANTS	22631032	607	619	O
:	22631032	620	621	O
Healthy	22631032	622	629	O
male	22631032	630	634	O
and	22631032	635	638	O
female	22631032	639	645	O
volunteers	22631032	646	656	O
aged	22631032	657	661	O
18	22631032	662	664	O
-	22631032	664	665	O
75	22631032	665	667	O
years	22631032	668	673	O
were	22631032	674	678	O
included	22631032	679	687	O
.	22631032	687	688	O

All	22631032	689	692	O
volunteers	22631032	693	703	O
received	22631032	704	712	O
ASA	22631032	713	716	O
81	22631032	717	719	O
mg	22631032	720	722	O
once	22631032	723	727	O
daily	22631032	728	733	O
for	22631032	734	737	O
5	22631032	738	739	O
days	22631032	740	744	O
prior	22631032	745	750	O
to	22631032	751	753	O
the	22631032	754	757	O
study	22631032	758	763	O
(	22631032	764	765	O
pre-screen	22631032	765	775	O
)	22631032	775	776	O
.	22631032	776	777	O

Subjects	22631032	778	786	O
were	22631032	787	791	O
eligible	22631032	792	800	O
for	22631032	801	804	O
inclusion	22631032	805	814	O
if	22631032	815	817	O
they	22631032	818	822	O
had	22631032	823	826	O
aspirin	22631032	827	834	O
reactivity	22631032	835	845	O
units	22631032	846	851	O
(	22631032	852	853	O
ARU	22631032	853	856	O
,	22631032	856	857	O
as	22631032	858	860	O
measured	22631032	861	869	O
by	22631032	870	872	O
the	22631032	873	876	O
VerifyNow	22631032	877	886	O
ASA	22631032	887	890	O
assay	22631032	891	896	O
)	22631032	896	897	O
of	22631032	898	900	O
<	22631032	901	902	O
550	22631032	902	905	O
on	22631032	906	908	O
Day	22631032	909	912	O
6	22631032	913	914	O
.	22631032	914	915	O

INTERVENTION	22631032	917	929	O
:	22631032	930	931	O
After	22631032	932	937	O
pre-screening	22631032	938	951	O
and	22631032	952	955	O
a	22631032	956	957	O
washout	22631032	958	965	O
period	22631032	966	972	O
of	22631032	973	975	O
at	22631032	976	978	O
least	22631032	979	984	O
14	22631032	985	987	O
days	22631032	988	992	O
,	22631032	992	993	O
eligible	22631032	994	1002	O
volunteers	22631032	1003	1013	O
received	22631032	1014	1022	O
ASA	22631032	1023	1026	O
81	22631032	1027	1029	O
mg	22631032	1030	1032	O
with	22631032	1033	1037	O
or	22631032	1038	1040	O
without	22631032	1041	1048	O
esomeprazole	22631032	1049	1061	O
20	22631032	1062	1064	O
mg	22631032	1065	1067	O
once	22631032	1068	1072	O
daily	22631032	1073	1078	O
for	22631032	1079	1082	O
5	22631032	1083	1084	O
days	22631032	1085	1089	O
in	22631032	1090	1092	O
randomized	22631032	1093	1103	O
order	22631032	1104	1109	O
,	22631032	1109	1110	O
with	22631032	1111	1115	O
a	22631032	1116	1117	O
14-day	22631032	1118	1124	O
washout	22631032	1125	1132	O
between	22631032	1133	1140	O
treatments	22631032	1141	1151	O
.	22631032	1151	1152	O

MAIN	22631032	1154	1158	O
OUTCOME	22631032	1159	1166	O
MEASURE	22631032	1167	1174	O
:	22631032	1175	1176	O
The	22631032	1177	1180	O
main	22631032	1181	1185	O
outcome	22631032	1186	1193	O
measure	22631032	1194	1201	O
was	22631032	1202	1205	O
the	22631032	1206	1209	O
antiplatelet	22631032	1210	1222	O
activity	22631032	1223	1231	O
of	22631032	1232	1234	O
ASA	22631032	1235	1238	O
,	22631032	1238	1239	O
as	22631032	1240	1242	O
assessed	22631032	1243	1251	O
by	22631032	1252	1254	O
ARU	22631032	1255	1258	O
ratio	22631032	1259	1264	O
relative	22631032	1265	1273	O
to	22631032	1274	1276	O
baseline	22631032	1277	1285	O
in	22631032	1286	1288	O
the	22631032	1289	1292	O
VerifyNow	22631032	1293	1302	O
ASA	22631032	1303	1306	O
assay	22631032	1307	1312	O
;	22631032	1312	1313	O
suppression	22631032	1314	1325	O
of	22631032	1326	1328	O
serum	22631032	1329	1334	O
thromboxane	22631032	1335	1346	O
B(2	22631032	1347	1350	O
)	22631032	1350	1351	O
(	22631032	1352	1353	O
TXB(2	22631032	1353	1358	O
)	22631032	1358	1359	O
)	22631032	1359	1360	O
was	22631032	1361	1364	O
a	22631032	1365	1366	O
secondary	22631032	1367	1376	O
endpoint	22631032	1377	1385	O
.	22631032	1385	1386	O

Statistical	22631032	1387	1398	O
comparisons	22631032	1399	1410	O
were	22631032	1411	1415	O
made	22631032	1416	1420	O
using	22631032	1421	1426	O
linear	22631032	1427	1433	O
mixed	22631032	1434	1439	O
models	22631032	1440	1446	O
.	22631032	1446	1447	O

RESULTS	22631032	1449	1456	O
:	22631032	1457	1458	O
A	22631032	1459	1460	O
total	22631032	1461	1466	O
of	22631032	1467	1469	O
29	22631032	1470	1472	O
volunteers	22631032	1473	1483	O
(	22631032	1484	1485	O
19	22631032	1485	1487	O
aged	22631032	1488	1492	O
≥50	22631032	1493	1496	O
years	22631032	1497	1502	O
;	22631032	1502	1503	O
8	22631032	1504	1505	O
women	22631032	1506	1511	O
;	22631032	1511	1512	O
21	22631032	1513	1515	O
men	22631032	1516	1519	O
)	22631032	1519	1520	O
were	22631032	1521	1525	O
evaluable	22631032	1526	1535	O
for	22631032	1536	1539	O
pharmacodynamic	22631032	1540	1555	O
analysis	22631032	1556	1564	O
(	22631032	1565	1566	O
per	22631032	1566	1569	O
protocol	22631032	1570	1578	O
)	22631032	1578	1579	O
.	22631032	1579	1580	O

All	22631032	1581	1584	O
volunteers	22631032	1585	1595	O
on	22631032	1596	1598	O
both	22631032	1599	1603	O
treatments	22631032	1604	1614	O
achieved	22631032	1615	1623	O
ARU	22631032	1624	1627	O
<	22631032	1628	1629	O
550	22631032	1629	1632	O
at	22631032	1633	1635	O
Day	22631032	1636	1639	O
6	22631032	1640	1641	O
.	22631032	1641	1642	O

The	22631032	1643	1646	O
geometric	22631032	1647	1656	B-Outcome
mean	22631032	1657	1661	I-Outcome
ratio	22631032	1662	1667	I-Outcome
of	22631032	1668	1670	I-Outcome
Day	22631032	1671	1674	I-Outcome
6	22631032	1675	1676	I-Outcome
to	22631032	1677	1679	I-Outcome
Day	22631032	1680	1683	I-Outcome
1	22631032	1684	1685	I-Outcome
(	22631032	1686	1687	I-Outcome
baseline	22631032	1687	1695	I-Outcome
)	22631032	1695	1696	I-Outcome
platelet	22631032	1697	1705	I-Outcome
aggregation	22631032	1706	1717	I-Outcome
was	22631032	1718	1721	O
0.70	22631032	1722	1726	O
(	22631032	1727	1728	O
95	22631032	1728	1730	O
%	22631032	1730	1731	O
confidence	22631032	1732	1742	O
interval	22631032	1743	1751	O
[	22631032	1752	1753	O
CI	22631032	1753	1755	O
]	22631032	1755	1756	O
0.68	22631032	1757	1761	O
,	22631032	1761	1762	O
0.72	22631032	1763	1767	O
)	22631032	1767	1768	O
with	22631032	1769	1773	O
ASA	22631032	1774	1777	O
alone	22631032	1778	1783	O
and	22631032	1784	1787	O
0.71	22631032	1788	1792	O
(	22631032	1793	1794	O
95	22631032	1794	1796	O
%	22631032	1796	1797	O
CI	22631032	1798	1800	O
0.69	22631032	1801	1805	O
,	22631032	1805	1806	O
0.74	22631032	1807	1811	O
)	22631032	1811	1812	O
with	22631032	1813	1817	O
ASA	22631032	1818	1821	O
+	22631032	1822	1823	O
esomeprazole	22631032	1824	1836	O
.	22631032	1836	1837	O

The	22631032	1838	1841	O
ratio	22631032	1842	1847	B-Outcome
of	22631032	1848	1850	I-Outcome
platelet	22631032	1851	1859	I-Outcome
aggregation	22631032	1860	1871	I-Outcome
(	22631032	1872	1873	O
ASA	22631032	1873	1876	O
+	22631032	1877	1878	O
esomeprazole/ASA	22631032	1879	1895	O
)	22631032	1895	1896	O
was	22631032	1897	1900	O
1.02	22631032	1901	1905	O
(	22631032	1906	1907	O
95	22631032	1907	1909	O
%	22631032	1909	1910	O
CI	22631032	1911	1913	O
0.99	22631032	1914	1918	O
,	22631032	1918	1919	O
1.05	22631032	1920	1924	O
)	22631032	1924	1925	O
.	22631032	1925	1926	O

ASA	22631032	1927	1930	O
administered	22631032	1931	1943	O
alone	22631032	1944	1949	O
or	22631032	1950	1952	O
with	22631032	1953	1957	O
esomeprazole	22631032	1958	1970	O
reduced	22631032	1971	1978	O
serum	22631032	1979	1984	B-Outcome
TXB(2	22631032	1985	1990	I-Outcome
)	22631032	1990	1991	I-Outcome
by	22631032	1992	1994	O
more	22631032	1995	1999	O
than	22631032	2000	2004	O
99.5	22631032	2005	2009	O
%	22631032	2009	2010	O
.	22631032	2010	2011	O

The	22631032	2012	2015	O
ratio	22631032	2016	2021	B-Outcome
of	22631032	2022	2024	I-Outcome
suppression	22631032	2025	2036	I-Outcome
of	22631032	2037	2039	I-Outcome
serum	22631032	2040	2045	I-Outcome
TXB(2	22631032	2046	2051	I-Outcome
)	22631032	2051	2052	I-Outcome
levels	22631032	2053	2059	I-Outcome
(	22631032	2060	2061	O
ASA	22631032	2061	2064	O
+	22631032	2065	2066	O
esomeprazole/ASA	22631032	2067	2083	O
)	22631032	2083	2084	O
was	22631032	2085	2088	O
1.06	22631032	2089	2093	O
(	22631032	2094	2095	O
95	22631032	2095	2097	O
%	22631032	2097	2098	O
CI	22631032	2099	2101	O
0.88	22631032	2102	2106	O
,	22631032	2106	2107	O
1.29	22631032	2108	2112	O
)	22631032	2112	2113	O
.	22631032	2113	2114	O

The	22631032	2115	2118	O
combination	22631032	2119	2130	O
of	22631032	2131	2133	O
ASA	22631032	2134	2137	O
and	22631032	2138	2141	O
esomeprazole	22631032	2142	2154	O
was	22631032	2155	2158	O
well	22631032	2159	2163	O
tolerated	22631032	2164	2173	B-Outcome
.	22631032	2173	2174	O

CONCLUSION	22631032	2176	2186	O
:	22631032	2187	2188	O
No	22631032	2189	2191	O
pharmacodynamic	22631032	2192	2207	O
interaction	22631032	2208	2219	O
between	22631032	2220	2227	O
low-dose	22631032	2228	2236	O
ASA	22631032	2237	2240	O
and	22631032	2241	2244	O
esomeprazole	22631032	2245	2257	O
was	22631032	2258	2261	O
found	22631032	2262	2267	O
with	22631032	2268	2272	O
regard	22631032	2273	2279	O
to	22631032	2280	2282	O
platelet	22631032	2283	2291	B-Outcome
function	22631032	2292	2300	I-Outcome
.	22631032	2300	2301	O

TRIAL	22631032	2303	2308	O
REGISTRATION	22631032	2309	2321	O
:	22631032	2322	2323	O
Registered	22631032	2324	2334	O
at	22631032	2335	2337	O
ClinicalTrials	22631032	2338	2352	O
.	22631032	2352	2353	O

gov	22631032	2354	2357	O
as	22631032	2358	2360	O
NCT01199328	22631032	2361	2372	O
.	22631032	2372	2373	O


Reaching	22768793	0	8	O
out	22768793	9	12	O
,	22768793	12	13	O
inviting	22768793	14	22	O
back	22768793	23	27	O
:	22768793	27	28	O
using	22768793	29	34	O
Interactive	22768793	35	46	O
voice	22768793	47	52	O
response	22768793	53	61	O
(	22768793	62	63	O
IVR	22768793	63	66	O
)	22768793	66	67	O
technology	22768793	68	78	O
to	22768793	79	81	O
recycle	22768793	82	89	O
relapsed	22768793	90	98	O
smokers	22768793	99	106	O
back	22768793	107	111	O
to	22768793	112	114	O
Quitline	22768793	115	123	O
treatment	22768793	124	133	O
--	22768793	133	135	O
a	22768793	135	136	O
randomized	22768793	137	147	O
controlled	22768793	148	158	O
trial	22768793	159	164	O
.	22768793	164	165	O

BACKGROUND	22768793	167	177	O
:	22768793	178	179	O
Tobacco	22768793	180	187	O
dependence	22768793	188	198	O
is	22768793	199	201	O
a	22768793	202	203	O
chronic	22768793	204	211	O
,	22768793	211	212	O
relapsing	22768793	213	222	O
condition	22768793	223	232	O
that	22768793	233	237	O
typically	22768793	238	247	O
requires	22768793	248	256	O
multiple	22768793	257	265	O
quit	22768793	266	270	O
attempts	22768793	271	279	O
and	22768793	280	283	O
extended	22768793	284	292	O
treatment	22768793	293	302	O
.	22768793	302	303	O

When	22768793	304	308	O
offered	22768793	309	316	O
the	22768793	317	320	O
opportunity	22768793	321	332	O
,	22768793	332	333	O
relapsed	22768793	334	342	O
smokers	22768793	343	350	O
are	22768793	351	354	O
interested	22768793	355	365	O
in	22768793	366	368	O
recycling	22768793	369	378	O
back	22768793	379	383	O
into	22768793	384	388	O
treatment	22768793	389	398	O
for	22768793	399	402	O
a	22768793	403	404	O
new	22768793	405	408	O
,	22768793	408	409	O
assisted	22768793	410	418	O
quit	22768793	419	423	O
attempt	22768793	424	431	O
.	22768793	431	432	O

This	22768793	433	437	O
manuscript	22768793	438	448	O
presents	22768793	449	457	O
the	22768793	458	461	O
results	22768793	462	469	O
of	22768793	470	472	O
a	22768793	473	474	O
randomized	22768793	475	485	O
controlled	22768793	486	496	O
trial	22768793	497	502	O
testing	22768793	503	510	O
the	22768793	511	514	O
efficacy	22768793	515	523	O
of	22768793	524	526	O
interactive	22768793	527	538	O
voice	22768793	539	544	O
response	22768793	545	553	O
(	22768793	554	555	O
IVR	22768793	555	558	O
)	22768793	558	559	O
in	22768793	560	562	O
recycling	22768793	563	572	O
low	22768793	573	576	O
income	22768793	577	583	O
smokers	22768793	584	591	O
who	22768793	592	595	O
had	22768793	596	599	O
previously	22768793	600	610	O
used	22768793	611	615	O
quitline	22768793	616	624	O
(	22768793	625	626	O
QL	22768793	626	628	O
)	22768793	628	629	O
support	22768793	630	637	O
back	22768793	638	642	O
to	22768793	643	645	O
QL	22768793	646	648	O
support	22768793	649	656	O
for	22768793	657	660	O
a	22768793	661	662	O
new	22768793	663	666	O
quit	22768793	667	671	O
attempt	22768793	672	679	O
.	22768793	679	680	O

METHODS	22768793	682	689	O
:	22768793	690	691	O
A	22768793	692	693	O
sample	22768793	694	700	O
of	22768793	701	703	O
2985	22768793	704	708	O
previous	22768793	709	717	O
QL	22768793	718	720	O
callers	22768793	721	728	O
were	22768793	729	733	O
randomized	22768793	734	744	O
to	22768793	745	747	O
either	22768793	748	754	O
receive	22768793	755	762	O
IVR	22768793	763	766	O
screening	22768793	767	776	O
for	22768793	777	780	O
current	22768793	781	788	O
smoking	22768793	789	796	O
(	22768793	797	798	O
control	22768793	798	805	O
group	22768793	806	811	O
)	22768793	811	812	O
or	22768793	813	815	O
IVR	22768793	816	819	O
screening	22768793	820	829	O
plus	22768793	830	834	O
an	22768793	835	837	O
IVR	22768793	838	841	O
intervention	22768793	842	854	O
.	22768793	854	855	O

The	22768793	856	859	O
IVR	22768793	860	863	O
intervention	22768793	864	876	O
consists	22768793	877	885	O
of	22768793	886	888	O
automated	22768793	889	898	O
questions	22768793	899	908	O
to	22768793	909	911	O
identify	22768793	912	920	O
and	22768793	921	924	O
address	22768793	925	932	O
barriers	22768793	933	941	O
to	22768793	942	944	O
re-cycling	22768793	945	955	O
in	22768793	956	958	O
QL	22768793	959	961	O
support	22768793	962	969	O
,	22768793	969	970	O
followed	22768793	971	979	O
by	22768793	980	982	O
an	22768793	983	985	O
offer	22768793	986	991	O
to	22768793	992	994	O
be	22768793	995	997	O
transferred	22768793	998	1009	O
to	22768793	1010	1012	O
the	22768793	1013	1016	O
QL	22768793	1017	1019	O
and	22768793	1020	1023	O
reinitiate	22768793	1024	1034	O
treatment	22768793	1035	1044	O
.	22768793	1044	1045	O

Re-enrollment	22768793	1046	1059	O
in	22768793	1060	1062	O
QL	22768793	1063	1065	O
services	22768793	1066	1074	O
for	22768793	1075	1078	O
both	22768793	1079	1083	O
groups	22768793	1084	1090	O
was	22768793	1091	1094	O
documented	22768793	1095	1105	O
.	22768793	1105	1106	O

RESULTS	22768793	1108	1115	O
:	22768793	1116	1117	O
The	22768793	1118	1121	O
IVR	22768793	1122	1125	O
system	22768793	1126	1132	O
successfully	22768793	1133	1145	O
reached	22768793	1146	1153	O
715	22768793	1154	1157	O
(	22768793	1158	1159	O
23.9	22768793	1159	1163	O
%	22768793	1163	1164	O
)	22768793	1164	1165	O
former	22768793	1166	1172	O
QL	22768793	1173	1175	O
participants	22768793	1176	1188	O
.	22768793	1188	1189	O

Of	22768793	1190	1192	O
those	22768793	1193	1198	O
,	22768793	1198	1199	O
27	22768793	1200	1202	O
%	22768793	1202	1203	O
(	22768793	1204	1205	O
194/715	22768793	1205	1212	O
)	22768793	1212	1213	O
reported	22768793	1214	1222	O
to	22768793	1223	1225	O
the	22768793	1226	1229	O
IVR	22768793	1230	1233	O
system	22768793	1234	1240	O
that	22768793	1241	1245	O
they	22768793	1246	1250	O
had	22768793	1251	1254	O
quit	22768793	1255	1259	O
smoking	22768793	1260	1267	O
and	22768793	1268	1271	O
were	22768793	1272	1276	O
therefore	22768793	1277	1286	O
excluded	22768793	1287	1295	O
from	22768793	1296	1300	O
the	22768793	1301	1304	O
study	22768793	1305	1310	O
and	22768793	1311	1314	O
analysis	22768793	1315	1323	O
.	22768793	1323	1324	O

The	22768793	1325	1328	O
trial	22768793	1329	1334	O
's	22768793	1334	1336	O
final	22768793	1337	1342	O
sample	22768793	1343	1349	O
was	22768793	1350	1353	O
composed	22768793	1354	1362	O
of	22768793	1363	1365	O
521	22768793	1366	1369	O
current	22768793	1370	1377	O
smokers	22768793	1378	1385	O
.	22768793	1385	1386	O

The	22768793	1387	1390	O
re-enrollment	22768793	1391	1404	B-Outcome
rate	22768793	1405	1409	I-Outcome
was	22768793	1410	1413	O
3.3	22768793	1414	1417	O
%	22768793	1417	1418	O
for	22768793	1419	1422	O
the	22768793	1423	1426	O
control	22768793	1427	1434	O
group	22768793	1435	1440	O
and	22768793	1441	1444	O
28.2	22768793	1445	1449	O
%	22768793	1449	1450	O
for	22768793	1451	1454	O
the	22768793	1455	1458	O
intervention	22768793	1459	1471	O
group	22768793	1472	1477	O
(	22768793	1478	1479	O
p	22768793	1479	1480	O
<	22768793	1481	1482	O
.001	22768793	1483	1487	O
)	22768793	1487	1488	O
.	22768793	1488	1489	O

Logistic	22768793	1490	1498	O
regression	22768793	1499	1509	O
results	22768793	1510	1517	O
indicated	22768793	1518	1527	O
an	22768793	1528	1530	O
11.2	22768793	1531	1535	O
times	22768793	1536	1541	O
higher	22768793	1542	1548	O
odds	22768793	1549	1553	B-Outcome
for	22768793	1554	1557	I-Outcome
re-enrollment	22768793	1558	1571	I-Outcome
of	22768793	1572	1574	O
the	22768793	1575	1578	O
intervention	22768793	1579	1591	O
group	22768793	1592	1597	O
than	22768793	1598	1602	O
the	22768793	1603	1606	O
control	22768793	1607	1614	O
group	22768793	1615	1620	O
(	22768793	1621	1622	O
p	22768793	1622	1623	O
<	22768793	1624	1625	O
.001	22768793	1626	1630	O
)	22768793	1630	1631	O
.	22768793	1631	1632	O

Results	22768793	1633	1640	O
did	22768793	1641	1644	O
not	22768793	1645	1648	O
vary	22768793	1649	1653	O
by	22768793	1654	1656	O
gender	22768793	1657	1663	O
,	22768793	1663	1664	O
race	22768793	1665	1669	O
,	22768793	1669	1670	O
ethnicity	22768793	1671	1680	O
,	22768793	1680	1681	O
or	22768793	1682	1684	O
level	22768793	1685	1690	O
of	22768793	1691	1693	O
education	22768793	1694	1703	O
,	22768793	1703	1704	O
however	22768793	1705	1712	O
recycled	22768793	1713	1721	O
smokers	22768793	1722	1729	O
were	22768793	1730	1734	O
older	22768793	1735	1740	O
(	22768793	1741	1742	O
Mean	22768793	1742	1746	O
=	22768793	1747	1748	O
45.2	22768793	1749	1753	O
;	22768793	1753	1754	O
SD	22768793	1755	1757	O
=	22768793	1758	1759	O
11.7	22768793	1760	1764	O
)	22768793	1764	1765	O
than	22768793	1766	1770	O
smokers	22768793	1771	1778	O
who	22768793	1779	1782	O
declined	22768793	1783	1791	O
a	22768793	1792	1793	O
new	22768793	1794	1797	O
treatment	22768793	1798	1807	O
cycle	22768793	1808	1813	O
(	22768793	1814	1815	O
Mean	22768793	1815	1819	O
=	22768793	1820	1821	O
41.8	22768793	1822	1826	O
;	22768793	1826	1827	O
SD	22768793	1828	1830	O
=	22768793	1831	1832	O
13.2	22768793	1833	1837	O
)	22768793	1837	1838	O
;	22768793	1838	1839	O
(	22768793	1840	1841	O
p	22768793	1841	1842	O
=	22768793	1843	1844	O
0.013	22768793	1845	1850	O
)	22768793	1850	1851	O
.	22768793	1851	1852	O

The	22768793	1853	1856	O
main	22768793	1857	1861	O
barriers	22768793	1862	1870	O
reported	22768793	1871	1879	O
for	22768793	1880	1883	O
not	22768793	1884	1887	O
engaging	22768793	1888	1896	O
in	22768793	1897	1899	O
a	22768793	1900	1901	O
new	22768793	1902	1905	O
treatment	22768793	1906	1915	O
cycle	22768793	1916	1921	O
were	22768793	1922	1926	O
low	22768793	1927	1930	O
self-efficacy	22768793	1931	1944	O
and	22768793	1945	1948	O
lack	22768793	1949	1953	O
of	22768793	1954	1956	O
interest	22768793	1957	1965	O
in	22768793	1966	1968	O
quitting	22768793	1969	1977	O
.	22768793	1977	1978	O

After	22768793	1979	1984	O
delivering	22768793	1985	1995	O
IVR	22768793	1996	1999	O
messages	22768793	2000	2008	O
targeting	22768793	2009	2018	O
these	22768793	2019	2024	O
reported	22768793	2025	2033	O
barriers	22768793	2034	2042	O
,	22768793	2042	2043	O
32	22768793	2044	2046	O
%	22768793	2046	2047	O
of	22768793	2048	2050	O
the	22768793	2051	2054	O
smokers	22768793	2055	2062	O
reporting	22768793	2063	2072	O
low	22768793	2073	2076	O
self-efficacy	22768793	2077	2090	O
and	22768793	2091	2094	O
4.8	22768793	2095	2098	O
%	22768793	2098	2099	O
of	22768793	2100	2102	O
those	22768793	2103	2108	O
reporting	22768793	2109	2118	O
lack	22768793	2119	2123	O
of	22768793	2124	2126	O
interest	22768793	2127	2135	O
in	22768793	2136	2138	O
quitting	22768793	2139	2147	O
re-engaged	22768793	2148	2158	B-Outcome
in	22768793	2159	2161	I-Outcome
a	22768793	2162	2163	I-Outcome
new	22768793	2164	2167	I-Outcome
QL	22768793	2168	2170	I-Outcome
treatment	22768793	2171	2180	I-Outcome
cycle	22768793	2181	2186	I-Outcome
.	22768793	2186	2187	O

CONCLUSION	22768793	2189	2199	O
:	22768793	2200	2201	O
Proactive	22768793	2202	2211	O
IVR	22768793	2212	2215	O
outreach	22768793	2216	2224	O
is	22768793	2225	2227	O
a	22768793	2228	2229	O
promising	22768793	2230	2239	O
tool	22768793	2240	2244	O
to	22768793	2245	2247	O
engage	22768793	2248	2254	O
low	22768793	2255	2258	O
income	22768793	2259	2265	O
,	22768793	2265	2266	O
relapsed	22768793	2267	2275	O
smokers	22768793	2276	2283	O
back	22768793	2284	2288	O
into	22768793	2289	2293	O
a	22768793	2294	2295	O
new	22768793	2296	2299	O
cycle	22768793	2300	2305	O
of	22768793	2306	2308	O
treatment	22768793	2309	2318	O
.	22768793	2318	2319	O

Integration	22768793	2320	2331	O
of	22768793	2332	2334	O
IVR	22768793	2335	2338	O
intervention	22768793	2339	2351	O
for	22768793	2352	2355	O
recycling	22768793	2356	2365	O
smokers	22768793	2366	2373	O
with	22768793	2374	2378	O
previous	22768793	2379	2387	O
QL	22768793	2388	2390	O
treatment	22768793	2391	2400	O
has	22768793	2401	2404	O
the	22768793	2405	2408	O
potential	22768793	2409	2418	O
to	22768793	2419	2421	O
decrease	22768793	2422	2430	O
tobacco-related	22768793	2431	2446	O
disparities	22768793	2447	2458	O
.	22768793	2458	2459	O

TRIAL	22768793	2461	2466	O
REGISTRATION	22768793	2467	2479	O
:	22768793	2480	2481	O
ClinicalTrials.gov	22768793	2482	2500	O
Identifier	22768793	2501	2511	O
:	22768793	2511	2512	O
NCT01260597	22768793	2513	2524	O
.	22768793	2524	2525	O


Promoting	22808053	0	9	O
physical	22808053	10	18	O
activity	22808053	19	27	O
in	22808053	28	30	O
patients	22808053	31	39	O
with	22808053	40	44	O
colon	22808053	45	50	O
adenomas	22808053	51	59	O
:	22808053	59	60	O
a	22808053	61	62	O
randomized	22808053	63	73	O
pilot	22808053	74	79	O
intervention	22808053	80	92	O
trial	22808053	93	98	O
.	22808053	98	99	O

BACKGROUND	22808053	101	111	O
:	22808053	112	113	O
Physical	22808053	114	122	O
activity	22808053	123	131	O
decreases	22808053	132	141	O
risk	22808053	142	146	O
of	22808053	147	149	O
colon	22808053	150	155	O
polyps	22808053	156	162	O
and	22808053	163	166	O
colon	22808053	167	172	O
cancer	22808053	173	179	O
and	22808053	180	183	O
might	22808053	184	189	O
reduce	22808053	190	196	O
risk	22808053	197	201	O
of	22808053	202	204	O
colon	22808053	205	210	O
cancer	22808053	211	217	O
recurrence	22808053	218	228	O
.	22808053	228	229	O

Focusing	22808053	230	238	O
on	22808053	239	241	O
recent	22808053	242	248	O
calls	22808053	249	254	O
for	22808053	255	258	O
translation	22808053	259	270	O
of	22808053	271	273	O
epidemiologic	22808053	274	287	O
evidence	22808053	288	296	O
into	22808053	297	301	O
clinical	22808053	302	310	O
care	22808053	311	315	O
,	22808053	315	316	O
our	22808053	317	320	O
pilot	22808053	321	326	O
study	22808053	327	332	O
delivered	22808053	333	342	O
an	22808053	343	345	O
evidence-based	22808053	346	360	O
physical	22808053	361	369	O
activity	22808053	370	378	O
intervention	22808053	379	391	O
in	22808053	392	394	O
adults	22808053	395	401	O
with	22808053	402	406	O
polyps	22808053	407	413	O
,	22808053	413	414	O
who	22808053	415	418	O
are	22808053	419	422	O
thus	22808053	423	427	O
at	22808053	428	430	O
elevated	22808053	431	439	O
risk	22808053	440	444	O
of	22808053	445	447	O
developing	22808053	448	458	O
colon	22808053	459	464	O
cancer	22808053	465	471	O
.	22808053	471	472	O

The	22808053	473	476	O
objective	22808053	477	486	O
was	22808053	487	490	O
to	22808053	491	493	O
evaluate	22808053	494	502	O
change	22808053	503	509	O
in	22808053	510	512	O
physical	22808053	513	521	O
activity	22808053	522	530	O
,	22808053	530	531	O
measured	22808053	532	540	O
by	22808053	541	543	O
steps	22808053	544	549	O
per	22808053	550	553	O
day	22808053	554	557	O
and	22808053	558	561	O
minutes	22808053	562	569	O
of	22808053	570	572	O
moderate/vigorous	22808053	573	590	O
physical	22808053	591	599	O
activity	22808053	600	608	O
.	22808053	608	609	O

METHODS	22808053	611	618	O
:	22808053	619	620	O
Sixteen	22808053	621	628	O
adults	22808053	629	635	O
with	22808053	636	640	O
adenomas	22808053	641	649	O
detected	22808053	650	658	O
and	22808053	659	662	O
removed	22808053	663	670	O
at	22808053	671	673	O
screening	22808053	674	683	O
colonoscopy	22808053	684	695	O
were	22808053	696	700	O
recruited	22808053	701	710	O
to	22808053	711	713	O
a	22808053	714	715	O
12-week	22808053	716	723	O
physical	22808053	724	732	O
activity	22808053	733	741	O
intervention	22808053	742	754	O
.	22808053	754	755	O

Participants	22808053	756	768	O
were	22808053	769	773	O
randomized	22808053	774	784	O
to	22808053	785	787	O
receive	22808053	788	795	O
a	22808053	796	797	O
standard	22808053	798	806	O
(	22808053	807	808	O
30	22808053	808	810	O
minutes/day	22808053	811	822	O
)	22808053	822	823	O
or	22808053	824	826	O
high	22808053	827	831	O
(	22808053	832	833	O
60	22808053	833	835	O
minutes/day	22808053	836	847	O
)	22808053	847	848	O
walking	22808053	849	856	O
program	22808053	857	864	O
.	22808053	864	865	O

Physical	22808053	866	874	O
activity	22808053	875	883	O
was	22808053	884	887	O
measured	22808053	888	896	O
via	22808053	897	900	O
blinded	22808053	901	908	O
pedometer	22808053	909	918	O
and	22808053	919	922	O
accelerometer	22808053	923	936	O
at	22808053	937	939	O
baseline	22808053	940	948	O
and	22808053	949	952	O
follow-up	22808053	953	962	O
.	22808053	962	963	O

Intervention	22808053	964	976	O
messages	22808053	977	985	O
focused	22808053	986	993	O
on	22808053	994	996	O
self-monitoring	22808053	997	1012	O
using	22808053	1013	1018	O
pedometers	22808053	1019	1029	O
and	22808053	1030	1033	O
overcoming	22808053	1034	1044	O
barriers	22808053	1045	1053	O
to	22808053	1054	1056	O
engaging	22808053	1057	1065	O
in	22808053	1066	1068	O
physical	22808053	1069	1077	O
activity	22808053	1078	1086	O
.	22808053	1086	1087	O

RESULTS	22808053	1089	1096	O
:	22808053	1097	1098	O
Participants	22808053	1099	1111	O
in	22808053	1112	1114	O
both	22808053	1115	1119	O
arms	22808053	1120	1124	O
significantly	22808053	1125	1138	O
increased	22808053	1139	1148	O
objectively	22808053	1149	1160	O
measured	22808053	1161	1169	O
minutes	22808053	1170	1177	B-Outcome
of	22808053	1178	1180	I-Outcome
moderate/vigorous	22808053	1181	1198	I-Outcome
physical	22808053	1199	1207	I-Outcome
activity	22808053	1208	1216	I-Outcome
over	22808053	1217	1221	O
the	22808053	1222	1225	O
course	22808053	1226	1232	O
of	22808053	1233	1235	O
the	22808053	1236	1239	O
intervention	22808053	1240	1252	O
.	22808053	1252	1253	O

Both	22808053	1254	1258	O
arms	22808053	1259	1263	O
exceeded	22808053	1264	1272	O
the	22808053	1273	1276	O
intervention	22808053	1277	1289	O
goal	22808053	1290	1294	O
,	22808053	1294	1295	O
but	22808053	1296	1299	O
there	22808053	1300	1305	O
was	22808053	1306	1309	O
not	22808053	1310	1313	O
a	22808053	1314	1315	O
significant	22808053	1316	1327	O
difference	22808053	1328	1338	O
between	22808053	1339	1346	O
arms	22808053	1347	1351	O
at	22808053	1352	1354	O
follow-up	22808053	1355	1364	O
.	22808053	1364	1365	O

Results	22808053	1366	1373	O
were	22808053	1374	1378	O
similar	22808053	1379	1386	O
for	22808053	1387	1390	O
pedometer	22808053	1391	1400	B-Outcome
measured	22808053	1401	1409	I-Outcome
physical	22808053	1410	1418	I-Outcome
activity	22808053	1419	1427	I-Outcome
,	22808053	1427	1428	O
with	22808053	1429	1433	O
a	22808053	1434	1435	O
significant	22808053	1436	1447	O
overall	22808053	1448	1455	O
increase	22808053	1456	1464	O
in	22808053	1465	1467	O
steps/day	22808053	1468	1477	B-Outcome
from	22808053	1478	1482	O
baseline	22808053	1483	1491	O
to	22808053	1492	1494	O
follow-up	22808053	1495	1504	O
,	22808053	1504	1505	O
but	22808053	1506	1509	O
no	22808053	1510	1512	O
between	22808053	1513	1520	O
arm	22808053	1521	1524	O
difference	22808053	1525	1535	O
in	22808053	1536	1538	O
change	22808053	1539	1545	O
.	22808053	1545	1546	O

CONCLUSION	22808053	1548	1558	O
:	22808053	1559	1560	O
Simple	22808053	1561	1567	O
interventions	22808053	1568	1581	O
of	22808053	1582	1584	O
minimal	22808053	1585	1592	O
contact	22808053	1593	1600	O
time	22808053	1601	1605	O
focusing	22808053	1606	1614	O
on	22808053	1615	1617	O
walking	22808053	1618	1625	O
can	22808053	1626	1629	O
significantly	22808053	1630	1643	O
increase	22808053	1644	1652	O
physical	22808053	1653	1661	B-Outcome
activity	22808053	1662	1670	I-Outcome
in	22808053	1671	1673	O
individuals	22808053	1674	1685	O
at	22808053	1686	1688	O
increased	22808053	1689	1698	O
risk	22808053	1699	1703	O
of	22808053	1704	1706	O
developing	22808053	1707	1717	O
colon	22808053	1718	1723	O
cancer	22808053	1724	1730	O
.	22808053	1730	1731	O

TRIAL	22808053	1733	1738	O
REGISTRATION	22808053	1739	1751	O
:	22808053	1752	1753	O
ClinicalTrials.gov	22808053	1754	1772	O
NCT01476631	22808053	1773	1784	O
.	22808053	1784	1785	O


Different	22821273	0	9	O
cardiac	22821273	10	17	O
biomarkers	22821273	18	28	O
to	22821273	29	31	O
detect	22821273	32	38	O
peri-procedural	22821273	39	54	O
myocardial	22821273	55	65	O
infarction	22821273	66	76	O
in	22821273	77	79	O
contemporary	22821273	80	92	O
coronary	22821273	93	101	O
stent	22821273	102	107	O
trials	22821273	108	114	O
:	22821273	114	115	O
impact	22821273	116	122	O
on	22821273	123	125	O
outcome	22821273	126	133	O
reporting	22821273	134	143	O
.	22821273	143	144	O

OBJECTIVE	22821273	146	155	O
:	22821273	156	157	O
To	22821273	158	160	O
assess	22821273	161	167	O
the	22821273	168	171	O
differential	22821273	172	184	O
implications	22821273	185	197	O
of	22821273	198	200	O
cardiac	22821273	201	208	O
biomarker	22821273	209	218	O
type	22821273	219	223	O
on	22821273	224	226	O
peri-procedural	22821273	227	242	O
myocardial	22821273	243	253	O
infarction	22821273	254	264	O
(	22821273	265	266	O
PMI	22821273	266	269	O
)	22821273	269	270	O
reporting	22821273	271	280	O
.	22821273	280	281	O

SETTING	22821273	283	290	O
:	22821273	291	292	O
The	22821273	293	296	O
Resolute	22821273	297	305	O
'	22821273	306	307	O
All-Comers	22821273	307	317	O
'	22821273	317	318	O
stent	22821273	319	324	O
trial	22821273	325	330	O
.	22821273	330	331	O

INTERVENTIONS	22821273	333	346	O
:	22821273	347	348	O
Blood	22821273	349	354	O
samples	22821273	355	362	O
for	22821273	363	366	O
creatine	22821273	367	375	O
kinase	22821273	376	382	O
(	22821273	383	384	O
CK	22821273	384	386	O
)	22821273	386	387	O
,	22821273	387	388	O
CK-myoband	22821273	389	399	O
(	22821273	400	401	O
CK-MB	22821273	401	406	O
)	22821273	406	407	O
mass	22821273	408	412	O
or	22821273	413	415	O
cardiac	22821273	416	423	O
troponin	22821273	424	432	O
(	22821273	433	434	O
cTn	22821273	434	437	O
)	22821273	437	438	O
(	22821273	439	440	O
optional	22821273	440	448	O
)	22821273	448	449	O
were	22821273	450	454	O
collected	22821273	455	464	O
before	22821273	465	471	O
and	22821273	472	475	O
at	22821273	476	478	O
6	22821273	479	480	O
,	22821273	480	481	O
12	22821273	482	484	O
and	22821273	485	488	O
18	22821273	489	491	O
h	22821273	492	493	O
after	22821273	494	499	O
the	22821273	500	503	O
assigned	22821273	504	512	O
percutaneous	22821273	513	525	O
coronary	22821273	526	534	O
intervention	22821273	535	547	O
or	22821273	548	550	O
at	22821273	551	553	O
discharge	22821273	554	563	O
.	22821273	563	564	O

PMIs	22821273	565	569	O
were	22821273	570	574	O
adjudicated	22821273	575	586	O
using	22821273	587	592	O
either	22821273	593	599	O
the	22821273	600	603	O
2007	22821273	604	608	O
universal	22821273	609	618	O
definition	22821273	619	629	O
of	22821273	630	632	O
MI	22821273	633	635	O
(	22821273	636	637	O
type-4a	22821273	637	644	O
)	22821273	644	645	O
or	22821273	646	648	O
the	22821273	649	652	O
extended	22821273	653	661	O
historical	22821273	662	672	O
definition	22821273	673	683	O
of	22821273	684	686	O
MI	22821273	687	689	O
.	22821273	689	690	O

PATIENTS	22821273	692	700	O
:	22821273	701	702	O
2121/2292	22821273	703	712	O
patients	22821273	713	721	O
(	22821273	722	723	O
92.5	22821273	723	727	O
%	22821273	727	728	O
)	22821273	728	729	O
had	22821273	730	733	O
an	22821273	734	736	O
analysable	22821273	737	747	O
dataset	22821273	748	755	O
for	22821273	756	759	O
either	22821273	760	766	O
biomarker	22821273	767	776	O
.	22821273	776	777	O

890/2121	22821273	778	786	O
patients	22821273	787	795	O
(	22821273	796	797	O
42	22821273	797	799	O
%	22821273	799	800	O
)	22821273	800	801	O
presented	22821273	802	811	O
with	22821273	812	816	O
an	22821273	817	819	O
acute	22821273	820	825	O
coronary	22821273	826	834	O
syndrome	22821273	835	843	O
(	22821273	844	845	O
ACS	22821273	845	848	O
)	22821273	848	849	O
.	22821273	849	850	O

267/890	22821273	851	858	O
patients	22821273	859	867	O
(	22821273	868	869	O
30	22821273	869	871	O
%	22821273	871	872	O
)	22821273	872	873	O
were	22821273	874	878	O
within	22821273	879	885	O
24	22821273	886	888	O
h	22821273	889	890	O
of	22821273	891	893	O
an	22821273	894	896	O
ST-segment	22821273	897	907	O
elevation	22821273	908	917	O
MI	22821273	918	920	O
.	22821273	920	921	O

MAIN	22821273	923	927	O
OUTCOME	22821273	928	935	O
MEASURES	22821273	936	944	O
:	22821273	945	946	O
Type-4a	22821273	947	954	B-Outcome
MI	22821273	955	957	I-Outcome
was	22821273	958	961	O
diagnosed	22821273	962	971	O
in	22821273	972	974	O
208/2121	22821273	975	983	O
patients	22821273	984	992	O
(	22821273	993	994	O
9.8	22821273	994	997	O
%	22821273	997	998	O
)	22821273	998	999	O
when	22821273	1000	1004	O
cTn	22821273	1005	1008	O
was	22821273	1009	1012	O
used	22821273	1013	1017	O
(	22821273	1018	1019	O
CK-MB	22821273	1019	1024	O
mass	22821273	1025	1029	O
if	22821273	1030	1032	O
cTn	22821273	1033	1036	O
not	22821273	1037	1040	O
available	22821273	1041	1050	O
)	22821273	1050	1051	O
,	22821273	1051	1052	O
and	22821273	1053	1056	O
in	22821273	1057	1059	O
93/2121	22821273	1060	1067	O
of	22821273	1068	1070	O
patients	22821273	1071	1079	O
(	22821273	1080	1081	O
4.4	22821273	1081	1084	O
%	22821273	1084	1085	O
)	22821273	1085	1086	O
when	22821273	1087	1091	O
CK-MB	22821273	1092	1097	O
mass	22821273	1098	1102	O
was	22821273	1103	1106	O
used	22821273	1107	1111	O
(	22821273	1112	1113	O
cTn	22821273	1113	1116	O
if	22821273	1117	1119	O
CK-MB	22821273	1120	1125	O
mass	22821273	1126	1130	O
not	22821273	1131	1134	O
available	22821273	1135	1144	O
)	22821273	1144	1145	O
.	22821273	1145	1146	O

With	22821273	1147	1151	O
the	22821273	1152	1155	O
extended	22821273	1156	1164	O
historical	22821273	1165	1175	O
CK-based	22821273	1176	1184	B-Outcome
definition	22821273	1185	1195	I-Outcome
of	22821273	1196	1198	I-Outcome
MI	22821273	1199	1201	I-Outcome
,	22821273	1201	1202	O
PMI	22821273	1203	1206	B-Outcome
was	22821273	1207	1210	O
diagnosed	22821273	1211	1220	O
in	22821273	1221	1223	O
65/2121	22821273	1224	1231	O
patients	22821273	1232	1240	O
(	22821273	1241	1242	O
3.1	22821273	1242	1245	O
%	22821273	1245	1246	O
)	22821273	1246	1247	O
.	22821273	1247	1248	O

Adjudication	22821273	1249	1261	B-Outcome
of	22821273	1262	1264	I-Outcome
type-4a	22821273	1265	1272	I-Outcome
MI	22821273	1273	1275	I-Outcome
in	22821273	1276	1278	O
patients	22821273	1279	1287	O
with	22821273	1288	1292	O
an	22821273	1293	1295	O
ACS	22821273	1296	1299	O
was	22821273	1300	1303	O
problematic	22821273	1304	1315	O
with	22821273	1316	1320	O
<	22821273	1321	1322	O
10	22821273	1322	1324	O
%	22821273	1324	1325	O
of	22821273	1326	1328	O
the	22821273	1329	1332	O
potential	22821273	1333	1342	O
type-4a	22821273	1343	1350	B-Outcome
MI	22821273	1351	1353	I-Outcome
being	22821273	1354	1359	I-Outcome
confirmed	22821273	1360	1369	I-Outcome
as	22821273	1370	1372	I-Outcome
an	22821273	1373	1375	I-Outcome
event	22821273	1376	1381	I-Outcome
,	22821273	1381	1382	O
as	22821273	1383	1385	O
compared	22821273	1386	1394	O
with	22821273	1395	1399	O
approximately	22821273	1400	1413	O
95	22821273	1414	1416	O
%	22821273	1416	1417	O
in	22821273	1418	1420	O
stable	22821273	1421	1427	O
patients	22821273	1428	1436	O
undergoing	22821273	1437	1447	O
elective	22821273	1448	1456	O
PCI	22821273	1457	1460	O
.	22821273	1460	1461	O

Type-4a	22821273	1462	1469	B-Outcome
MI	22821273	1470	1472	I-Outcome
was	22821273	1473	1476	O
not	22821273	1477	1480	O
associated	22821273	1481	1491	O
with	22821273	1492	1496	O
the	22821273	1497	1500	O
subsequent	22821273	1501	1511	O
hazard	22821273	1512	1518	O
for	22821273	1519	1522	O
cardiac	22821273	1523	1530	O
mortality	22821273	1531	1540	O
(	22821273	1541	1542	O
p=0.6	22821273	1542	1547	O
)	22821273	1547	1548	O
.	22821273	1548	1549	O

CONCLUSIONS	22821273	1551	1562	O
:	22821273	1563	1564	O
The	22821273	1565	1568	O
percentage	22821273	1569	1579	B-Outcome
of	22821273	1580	1582	I-Outcome
adjudicated	22821273	1583	1594	I-Outcome
PMI	22821273	1595	1598	I-Outcome
events	22821273	1599	1605	I-Outcome
is	22821273	1606	1608	O
driven	22821273	1609	1615	O
by	22821273	1616	1618	O
the	22821273	1619	1622	O
MI-definition	22821273	1623	1636	O
criteria	22821273	1637	1645	O
and	22821273	1646	1649	O
biomarker	22821273	1650	1659	O
type	22821273	1660	1664	O
.	22821273	1664	1665	O

Type-4a	22821273	1666	1673	B-Outcome
MI	22821273	1674	1676	I-Outcome
may	22821273	1677	1680	O
not	22821273	1681	1684	O
be	22821273	1685	1687	O
a	22821273	1688	1689	O
reliable	22821273	1690	1698	O
component	22821273	1699	1708	O
of	22821273	1709	1711	O
the	22821273	1712	1715	O
primary	22821273	1716	1723	O
composite	22821273	1724	1733	O
end	22821273	1734	1737	O
point	22821273	1738	1743	O
in	22821273	1744	1746	O
coronary	22821273	1747	1755	O
stent	22821273	1756	1761	O
investigations	22821273	1762	1776	O
which	22821273	1777	1782	O
recruit	22821273	1783	1790	O
patients	22821273	1791	1799	O
with	22821273	1800	1804	O
ACS	22821273	1805	1808	O
.	22821273	1808	1809	O

TRIAL	22821273	1811	1816	O
REGISTRATION	22821273	1817	1829	O
NUMBER	22821273	1830	1836	O
:	22821273	1837	1838	O
http://www	22821273	1839	1849	O
.	22821273	1849	1850	O

ClinicalTrials.gov	22821273	1851	1869	O
;	22821273	1869	1870	O
Unique	22821273	1871	1877	O
identifier	22821273	1878	1888	O
:	22821273	1888	1889	O
NCT00617084	22821273	1890	1901	O
.	22821273	1901	1902	O


Adjunctive	22843280	0	10	O
perampanel	22843280	11	21	O
for	22843280	22	25	O
refractory	22843280	26	36	O
partial-onset	22843280	37	50	O
seizures	22843280	51	59	O
:	22843280	59	60	O
randomized	22843280	61	71	O
phase	22843280	72	77	O
III	22843280	78	81	O
study	22843280	82	87	O
304	22843280	88	91	O
.	22843280	91	92	O

OBJECTIVE	22843280	94	103	O
:	22843280	104	105	O
To	22843280	106	108	O
assess	22843280	109	115	O
efficacy	22843280	116	124	O
and	22843280	125	128	O
safety	22843280	129	135	O
of	22843280	136	138	O
once-daily	22843280	139	149	O
8	22843280	150	151	O
or	22843280	152	154	O
12	22843280	155	157	O
mg	22843280	158	160	O
perampanel	22843280	161	171	O
,	22843280	171	172	O
a	22843280	173	174	O
noncompetitive	22843280	175	189	O
α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic	22843280	190	238	O
acid	22843280	239	243	O
(	22843280	244	245	O
AMPA	22843280	245	249	O
)	22843280	249	250	O
receptor	22843280	251	259	O
antagonist	22843280	260	270	O
,	22843280	270	271	O
when	22843280	272	276	O
added	22843280	277	282	O
to	22843280	283	285	O
concomitant	22843280	286	297	O
antiepileptic	22843280	298	311	O
drugs	22843280	312	317	O
(	22843280	318	319	O
AEDs	22843280	319	323	O
)	22843280	323	324	O
in	22843280	325	327	O
the	22843280	328	331	O
treatment	22843280	332	341	O
of	22843280	342	344	O
drug-resistant	22843280	345	359	O
partial-onset	22843280	360	373	O
seizures	22843280	374	382	O
.	22843280	382	383	O

METHODS	22843280	385	392	O
:	22843280	393	394	O
This	22843280	395	399	O
was	22843280	400	403	O
a	22843280	404	405	O
multicenter	22843280	406	417	O
,	22843280	417	418	O
double-blind	22843280	419	431	O
,	22843280	431	432	O
placebo-controlled	22843280	433	451	O
trial	22843280	452	457	O
(	22843280	458	459	O
ClinicalTrials.gov	22843280	459	477	O
identifier	22843280	478	488	O
:	22843280	488	489	O
NCT00699972	22843280	490	501	O
)	22843280	501	502	O
.	22843280	502	503	O

Patients	22843280	504	512	O
(	22843280	513	514	O
≥12	22843280	514	517	O
years	22843280	518	523	O
,	22843280	523	524	O
with	22843280	525	529	O
ongoing	22843280	530	537	O
seizures	22843280	538	546	O
despite	22843280	547	554	O
1	22843280	555	556	O
-	22843280	556	557	O
3	22843280	557	558	O
AEDs	22843280	559	563	O
)	22843280	563	564	O
were	22843280	565	569	O
randomized	22843280	570	580	O
(	22843280	581	582	O
1:1:1	22843280	582	587	O
)	22843280	587	588	O
to	22843280	589	591	O
once-daily	22843280	592	602	O
perampanel	22843280	603	613	O
8	22843280	614	615	O
mg	22843280	616	618	O
,	22843280	618	619	O
12	22843280	620	622	O
mg	22843280	623	625	O
,	22843280	625	626	O
or	22843280	627	629	O
placebo	22843280	630	637	O
.	22843280	637	638	O

Following	22843280	639	648	O
baseline	22843280	649	657	O
(	22843280	658	659	O
6	22843280	659	660	O
weeks	22843280	661	666	O
)	22843280	666	667	O
,	22843280	667	668	O
patients	22843280	669	677	O
entered	22843280	678	685	O
a	22843280	686	687	O
19-week	22843280	688	695	O
double-blind	22843280	696	708	O
phase	22843280	709	714	O
:	22843280	714	715	O
6-week	22843280	716	722	O
titration	22843280	723	732	O
(	22843280	733	734	O
2	22843280	734	735	O
mg/week	22843280	736	743	O
increments	22843280	744	754	O
to	22843280	755	757	O
target	22843280	758	764	O
dose	22843280	765	769	O
)	22843280	769	770	O
followed	22843280	771	779	O
by	22843280	780	782	O
a	22843280	783	784	O
13-week	22843280	785	792	O
maintenance	22843280	793	804	O
period	22843280	805	811	O
.	22843280	811	812	O

Percent	22843280	813	820	O
change	22843280	821	827	O
in	22843280	828	830	O
seizure	22843280	831	838	O
frequency	22843280	839	848	O
was	22843280	849	852	O
the	22843280	853	856	O
primary	22843280	857	864	O
endpoint	22843280	865	873	O
;	22843280	873	874	O
50	22843280	875	877	O
%	22843280	877	878	O
responder	22843280	879	888	O
rate	22843280	889	893	O
was	22843280	894	897	O
the	22843280	898	901	O
primary	22843280	902	909	O
endpoint	22843280	910	918	O
for	22843280	919	922	O
EU	22843280	923	925	O
registration	22843280	926	938	O
.	22843280	938	939	O

RESULTS	22843280	941	948	O
:	22843280	949	950	O
Of	22843280	951	953	O
388	22843280	954	957	O
patients	22843280	958	966	O
randomized	22843280	967	977	O
and	22843280	978	981	O
treated	22843280	982	989	O
,	22843280	989	990	O
387	22843280	991	994	O
provided	22843280	995	1003	O
seizure	22843280	1004	1011	O
frequency	22843280	1012	1021	O
data	22843280	1022	1026	O
.	22843280	1026	1027	O

Using	22843280	1028	1033	O
this	22843280	1034	1038	O
intent-to-treat	22843280	1039	1054	O
population	22843280	1055	1065	O
over	22843280	1066	1070	O
the	22843280	1071	1074	O
double-blind	22843280	1075	1087	O
phase	22843280	1088	1093	O
,	22843280	1093	1094	O
the	22843280	1095	1098	O
median	22843280	1099	1105	B-Outcome
percent	22843280	1106	1113	I-Outcome
change	22843280	1114	1120	I-Outcome
in	22843280	1121	1123	I-Outcome
seizure	22843280	1124	1131	I-Outcome
frequency	22843280	1132	1141	I-Outcome
was	22843280	1142	1145	O
-21.0	22843280	1146	1151	O
%	22843280	1151	1152	O
,	22843280	1152	1153	O
-26.3	22843280	1154	1159	O
%	22843280	1159	1160	O
,	22843280	1160	1161	O
and	22843280	1162	1165	O
-34.5	22843280	1166	1171	O
%	22843280	1171	1172	O
for	22843280	1173	1176	O
placebo	22843280	1177	1184	O
and	22843280	1185	1188	O
perampanel	22843280	1189	1199	O
8	22843280	1200	1201	O
and	22843280	1202	1205	O
12	22843280	1206	1208	O
mg	22843280	1209	1211	O
,	22843280	1211	1212	O
respectively	22843280	1213	1225	O
(	22843280	1226	1227	O
p	22843280	1227	1228	O
=	22843280	1229	1230	O
0.0261	22843280	1231	1237	O
and	22843280	1238	1241	O
p	22843280	1242	1243	O
=	22843280	1244	1245	O
0.0158	22843280	1246	1252	O
for	22843280	1253	1256	O
8	22843280	1257	1258	O
and	22843280	1259	1262	O
12	22843280	1263	1265	O
mg	22843280	1266	1268	O
vs	22843280	1269	1271	O
placebo	22843280	1272	1279	O
,	22843280	1279	1280	O
respectively	22843280	1281	1293	O
)	22843280	1293	1294	O
.	22843280	1294	1295	O

Fifty	22843280	1296	1301	B-Outcome
percent	22843280	1302	1309	I-Outcome
responder	22843280	1310	1319	I-Outcome
rates	22843280	1320	1325	I-Outcome
during	22843280	1326	1332	O
the	22843280	1333	1336	O
maintenance	22843280	1337	1348	O
period	22843280	1349	1355	O
were	22843280	1356	1360	O
26.4	22843280	1361	1365	O
%	22843280	1365	1366	O
,	22843280	1366	1367	O
37.6	22843280	1368	1372	O
%	22843280	1372	1373	O
,	22843280	1373	1374	O
and	22843280	1375	1378	O
36.1	22843280	1379	1383	O
%	22843280	1383	1384	O
,	22843280	1384	1385	O
respectively	22843280	1386	1398	O
,	22843280	1398	1399	O
for	22843280	1400	1403	O
placebo	22843280	1404	1411	O
,	22843280	1411	1412	O
perampanel	22843280	1413	1423	O
8	22843280	1424	1425	O
mg	22843280	1426	1428	O
,	22843280	1428	1429	O
and	22843280	1430	1433	O
perampanel	22843280	1434	1444	O
12	22843280	1445	1447	O
mg	22843280	1448	1450	O
;	22843280	1450	1451	O
these	22843280	1452	1457	O
differences	22843280	1458	1469	O
were	22843280	1470	1474	O
not	22843280	1475	1478	O
statistically	22843280	1479	1492	O
significant	22843280	1493	1504	O
for	22843280	1505	1508	O
8	22843280	1509	1510	O
mg	22843280	1511	1513	O
(	22843280	1514	1515	O
p	22843280	1515	1516	O
=	22843280	1517	1518	O
0.0760	22843280	1519	1525	O
)	22843280	1525	1526	O
or	22843280	1527	1529	O
12	22843280	1530	1532	O
mg	22843280	1533	1535	O
(	22843280	1536	1537	O
p	22843280	1537	1538	O
=	22843280	1539	1540	O
0.0914	22843280	1541	1547	O
)	22843280	1547	1548	O
.	22843280	1548	1549	O

Sixty-eight	22843280	1550	1561	O
(	22843280	1562	1563	O
17.5	22843280	1563	1567	O
%	22843280	1567	1568	O
)	22843280	1568	1569	O
patients	22843280	1570	1578	O
discontinued	22843280	1579	1591	O
,	22843280	1591	1592	O
including	22843280	1593	1602	O
40	22843280	1603	1605	O
(	22843280	1606	1607	O
10.3	22843280	1607	1611	O
%	22843280	1611	1612	O
)	22843280	1612	1613	O
for	22843280	1614	1617	O
adverse	22843280	1618	1625	B-Outcome
events	22843280	1626	1632	I-Outcome
.	22843280	1632	1633	O

Most	22843280	1634	1638	O
frequent	22843280	1639	1647	O
treatment-emergent	22843280	1648	1666	B-Outcome
adverse	22843280	1667	1674	I-Outcome
events	22843280	1675	1681	I-Outcome
were	22843280	1682	1686	O
dizziness	22843280	1687	1696	O
,	22843280	1696	1697	O
somnolence	22843280	1698	1708	O
,	22843280	1708	1709	O
irritability	22843280	1710	1722	O
,	22843280	1722	1723	O
headache	22843280	1724	1732	O
,	22843280	1732	1733	O
fall	22843280	1734	1738	O
,	22843280	1738	1739	O
and	22843280	1740	1743	O
ataxia	22843280	1744	1750	O
.	22843280	1750	1751	O

CONCLUSIONS	22843280	1753	1764	O
:	22843280	1765	1766	O
This	22843280	1767	1771	O
trial	22843280	1772	1777	O
demonstrated	22843280	1778	1790	O
that	22843280	1791	1795	O
once-daily	22843280	1796	1806	O
,	22843280	1806	1807	O
adjunctive	22843280	1808	1818	O
perampanel	22843280	1819	1829	O
at	22843280	1830	1832	O
doses	22843280	1833	1838	O
of	22843280	1839	1841	O
8	22843280	1842	1843	O
or	22843280	1844	1846	O
12	22843280	1847	1849	O
mg	22843280	1850	1852	O
improved	22843280	1853	1861	O
seizure	22843280	1862	1869	B-Outcome
control	22843280	1870	1877	I-Outcome
in	22843280	1878	1880	O
patients	22843280	1881	1889	O
with	22843280	1890	1894	O
uncontrolled	22843280	1895	1907	O
partial-onset	22843280	1908	1921	O
seizures	22843280	1922	1930	O
.	22843280	1930	1931	O

Doses	22843280	1932	1937	O
of	22843280	1938	1940	O
perampanel	22843280	1941	1951	O
8	22843280	1952	1953	O
and	22843280	1954	1957	O
12	22843280	1958	1960	O
mg	22843280	1961	1963	O
were	22843280	1964	1968	O
safe	22843280	1969	1973	B-Outcome
,	22843280	1973	1974	O
and	22843280	1975	1978	O
tolerability	22843280	1979	1991	B-Outcome
was	22843280	1992	1995	O
acceptable	22843280	1996	2006	O
.	22843280	2006	2007	O

CLASSIFICATION	22843280	2009	2023	O
OF	22843280	2024	2026	O
EVIDENCE	22843280	2027	2035	O
:	22843280	2036	2037	O
This	22843280	2038	2042	O
study	22843280	2043	2048	O
provides	22843280	2049	2057	O
Class	22843280	2058	2063	O
I	22843280	2064	2065	O
evidence	22843280	2066	2074	O
that	22843280	2075	2079	O
once-daily	22843280	2080	2090	O
8	22843280	2091	2092	O
and	22843280	2093	2096	O
12	22843280	2097	2099	O
mg	22843280	2100	2102	O
doses	22843280	2103	2108	O
of	22843280	2109	2111	O
adjunctive	22843280	2112	2122	O
perampanel	22843280	2123	2133	O
are	22843280	2134	2137	O
effective	22843280	2138	2147	O
in	22843280	2148	2150	O
patients	22843280	2151	2159	O
with	22843280	2160	2164	O
uncontrolled	22843280	2165	2177	O
partial-onset	22843280	2178	2191	O
seizures	22843280	2192	2200	O
.	22843280	2200	2201	O


RESPECT-PTSD	22865017	0	12	O
:	22865017	12	13	O
re-engineering	22865017	14	28	O
systems	22865017	29	36	O
for	22865017	37	40	O
the	22865017	41	44	O
primary	22865017	45	52	O
care	22865017	53	57	O
treatment	22865017	58	67	O
of	22865017	68	70	O
PTSD	22865017	71	75	O
,	22865017	75	76	O
a	22865017	77	78	O
randomized	22865017	79	89	O
controlled	22865017	90	100	O
trial	22865017	101	106	O
.	22865017	106	107	O

BACKGROUND	22865017	109	119	O
:	22865017	120	121	O
Although	22865017	122	130	O
collaborative	22865017	131	144	O
care	22865017	145	149	O
is	22865017	150	152	O
effective	22865017	153	162	O
for	22865017	163	166	O
treating	22865017	167	175	O
depression	22865017	176	186	O
and	22865017	187	190	O
other	22865017	191	196	O
mental	22865017	197	203	O
disorders	22865017	204	213	O
in	22865017	214	216	O
primary	22865017	217	224	O
care	22865017	225	229	O
,	22865017	229	230	O
there	22865017	231	236	O
have	22865017	237	241	O
been	22865017	242	246	O
no	22865017	247	249	O
randomized	22865017	250	260	O
trials	22865017	261	267	O
of	22865017	268	270	O
collaborative	22865017	271	284	O
care	22865017	285	289	O
specifically	22865017	290	302	O
for	22865017	303	306	O
patients	22865017	307	315	O
with	22865017	316	320	O
Posttraumatic	22865017	321	334	O
stress	22865017	335	341	O
disorder	22865017	342	350	O
(	22865017	351	352	O
PTSD	22865017	352	356	O
)	22865017	356	357	O
.	22865017	357	358	O

OBJECTIVE	22865017	360	369	O
:	22865017	370	371	O
To	22865017	372	374	O
compare	22865017	375	382	O
a	22865017	383	384	O
collaborative	22865017	385	398	O
approach	22865017	399	407	O
,	22865017	407	408	O
the	22865017	409	412	O
Three	22865017	413	418	O
Component	22865017	419	428	O
Model	22865017	429	434	O
(	22865017	435	436	O
3CM	22865017	436	439	O
)	22865017	439	440	O
,	22865017	440	441	O
with	22865017	442	446	O
usual	22865017	447	452	O
care	22865017	453	457	O
for	22865017	458	461	O
treating	22865017	462	470	O
PTSD	22865017	471	475	O
in	22865017	476	478	O
primary	22865017	479	486	O
care	22865017	487	491	O
.	22865017	491	492	O

DESIGN	22865017	494	500	O
:	22865017	501	502	O
The	22865017	503	506	O
study	22865017	507	512	O
was	22865017	513	516	O
a	22865017	517	518	O
two-arm	22865017	519	526	O
,	22865017	526	527	O
parallel	22865017	528	536	O
randomized	22865017	537	547	O
clinical	22865017	548	556	O
trial	22865017	557	562	O
.	22865017	562	563	O

PTSD	22865017	564	568	O
patients	22865017	569	577	O
were	22865017	578	582	O
recruited	22865017	583	592	O
from	22865017	593	597	O
five	22865017	598	602	O
primary	22865017	603	610	O
care	22865017	611	615	O
clinics	22865017	616	623	O
at	22865017	624	626	O
four	22865017	627	631	O
Veterans	22865017	632	640	O
Affairs	22865017	641	648	O
healthcare	22865017	649	659	O
facilities	22865017	660	670	O
and	22865017	671	674	O
randomized	22865017	675	685	O
to	22865017	686	688	O
receive	22865017	689	696	O
usual	22865017	697	702	O
care	22865017	703	707	O
or	22865017	708	710	O
usual	22865017	711	716	O
care	22865017	717	721	O
plus	22865017	722	726	O
3CM	22865017	727	730	O
.	22865017	730	731	O

Blinded	22865017	732	739	O
assessors	22865017	740	749	O
collected	22865017	750	759	O
data	22865017	760	764	O
at	22865017	765	767	O
baseline	22865017	768	776	O
and	22865017	777	780	O
3-month	22865017	781	788	O
and	22865017	789	792	O
6-month	22865017	793	800	O
follow-up	22865017	801	810	O
.	22865017	810	811	O

PARTICIPANTS	22865017	813	825	O
:	22865017	826	827	O
Participants	22865017	828	840	O
were	22865017	841	845	O
195	22865017	846	849	O
Veterans	22865017	850	858	O
.	22865017	858	859	O

Their	22865017	860	865	O
average	22865017	866	873	O
age	22865017	874	877	O
was	22865017	878	881	O
45	22865017	882	884	O
years	22865017	885	890	O
,	22865017	890	891	O
91	22865017	892	894	O
%	22865017	894	895	O
were	22865017	896	900	O
male	22865017	901	905	O
,	22865017	905	906	O
58	22865017	907	909	O
%	22865017	909	910	O
were	22865017	911	915	O
white	22865017	916	921	O
,	22865017	921	922	O
40	22865017	923	925	O
%	22865017	925	926	O
served	22865017	927	933	O
in	22865017	934	936	O
Iraq	22865017	937	941	O
or	22865017	942	944	O
Afghanistan	22865017	945	956	O
,	22865017	956	957	O
and	22865017	958	961	O
42	22865017	962	964	O
%	22865017	964	965	O
served	22865017	966	972	O
in	22865017	973	975	O
Vietnam	22865017	976	983	O
.	22865017	983	984	O

INTERVENTION	22865017	986	998	O
:	22865017	999	1000	O
All	22865017	1001	1004	O
participants	22865017	1005	1017	O
received	22865017	1018	1026	O
usual	22865017	1027	1032	O
care	22865017	1033	1037	O
.	22865017	1037	1038	O

Participants	22865017	1039	1051	O
assigned	22865017	1052	1060	O
to	22865017	1061	1063	O
3CM	22865017	1064	1067	O
also	22865017	1068	1072	O
received	22865017	1073	1081	O
telephone	22865017	1082	1091	O
care	22865017	1092	1096	O
management	22865017	1097	1107	O
.	22865017	1107	1108	O

Care	22865017	1109	1113	O
managers	22865017	1114	1122	O
received	22865017	1123	1131	O
supervision	22865017	1132	1143	O
from	22865017	1144	1148	O
a	22865017	1149	1150	O
psychiatrist	22865017	1151	1163	O
.	22865017	1163	1164	O

MAIN	22865017	1166	1170	O
MEASURES	22865017	1171	1179	O
:	22865017	1180	1181	O
PTSD	22865017	1182	1186	O
symptom	22865017	1187	1194	O
severity	22865017	1195	1203	O
was	22865017	1204	1207	O
the	22865017	1208	1211	O
primary	22865017	1212	1219	O
outcome	22865017	1220	1227	O
.	22865017	1227	1228	O

Depression	22865017	1229	1239	O
,	22865017	1239	1240	O
functioning	22865017	1241	1252	O
,	22865017	1252	1253	O
perceived	22865017	1254	1263	O
quality	22865017	1264	1271	O
of	22865017	1272	1274	O
care	22865017	1275	1279	O
,	22865017	1279	1280	O
utilization	22865017	1281	1292	O
,	22865017	1292	1293	O
and	22865017	1294	1297	O
costs	22865017	1298	1303	O
were	22865017	1304	1308	O
secondary	22865017	1309	1318	O
outcomes	22865017	1319	1327	O
.	22865017	1327	1328	O

KEY	22865017	1330	1333	O
RESULTS	22865017	1334	1341	O
:	22865017	1342	1343	O
There	22865017	1344	1349	O
were	22865017	1350	1354	O
no	22865017	1355	1357	O
differences	22865017	1358	1369	O
between	22865017	1370	1377	O
3CM	22865017	1378	1381	O
and	22865017	1382	1385	O
usual	22865017	1386	1391	O
care	22865017	1392	1396	O
in	22865017	1397	1399	O
symptoms	22865017	1400	1408	B-Outcome
or	22865017	1409	1411	O
functioning	22865017	1412	1423	O
.	22865017	1423	1424	O

Participants	22865017	1425	1437	O
assigned	22865017	1438	1446	O
to	22865017	1447	1449	O
3CM	22865017	1450	1453	O
were	22865017	1454	1458	O
more	22865017	1459	1463	O
likely	22865017	1464	1470	O
to	22865017	1471	1473	O
have	22865017	1474	1478	O
a	22865017	1479	1480	O
mental	22865017	1481	1487	B-Outcome
health	22865017	1488	1494	I-Outcome
visit	22865017	1495	1500	I-Outcome
,	22865017	1500	1501	O
fill	22865017	1502	1506	B-Outcome
an	22865017	1507	1509	I-Outcome
antidepressant	22865017	1510	1524	I-Outcome
prescription	22865017	1525	1537	I-Outcome
,	22865017	1537	1538	O
and	22865017	1539	1542	O
have	22865017	1543	1547	B-Outcome
adequate	22865017	1548	1556	I-Outcome
antidepressant	22865017	1557	1571	I-Outcome
refills	22865017	1572	1579	I-Outcome
.	22865017	1579	1580	O

3CM	22865017	1581	1584	O
participants	22865017	1585	1597	O
also	22865017	1598	1602	O
had	22865017	1603	1606	O
more	22865017	1607	1611	O
mental	22865017	1612	1618	B-Outcome
health	22865017	1619	1625	I-Outcome
visits	22865017	1626	1632	I-Outcome
and	22865017	1633	1636	O
higher	22865017	1637	1643	O
outpatient	22865017	1644	1654	B-Outcome
pharmacy	22865017	1655	1663	I-Outcome
costs	22865017	1664	1669	I-Outcome
.	22865017	1669	1670	O

CONCLUSIONS	22865017	1672	1683	O
:	22865017	1684	1685	O
Results	22865017	1686	1693	O
suggest	22865017	1694	1701	O
the	22865017	1702	1705	O
need	22865017	1706	1710	O
for	22865017	1711	1714	O
careful	22865017	1715	1722	O
examination	22865017	1723	1734	O
of	22865017	1735	1737	O
the	22865017	1738	1741	O
way	22865017	1742	1745	O
that	22865017	1746	1750	O
collaborative	22865017	1751	1764	O
care	22865017	1765	1769	O
models	22865017	1770	1776	O
are	22865017	1777	1780	O
implemented	22865017	1781	1792	O
for	22865017	1793	1796	O
treating	22865017	1797	1805	O
PTSD	22865017	1806	1810	O
,	22865017	1810	1811	O
and	22865017	1812	1815	O
for	22865017	1816	1819	O
additional	22865017	1820	1830	O
supports	22865017	1831	1839	O
to	22865017	1840	1842	O
encourage	22865017	1843	1852	O
primary	22865017	1853	1860	O
care	22865017	1861	1865	O
providers	22865017	1866	1875	O
to	22865017	1876	1878	O
manage	22865017	1879	1885	O
PTSD	22865017	1886	1890	O
.	22865017	1890	1891	O


Airway	22989372	0	6	O
responses	22989372	7	16	O
and	22989372	17	20	O
inflammation	22989372	21	33	O
in	22989372	34	36	O
subjects	22989372	37	45	O
with	22989372	46	50	O
asthma	22989372	51	57	O
after	22989372	58	63	O
four	22989372	64	68	O
days	22989372	69	73	O
of	22989372	74	76	O
repeated	22989372	77	85	O
high-single-dose	22989372	86	102	O
allergen	22989372	103	111	O
challenge	22989372	112	121	O
.	22989372	121	122	O

BACKGROUND	22989372	124	134	O
:	22989372	135	136	O
Both	22989372	137	141	O
standard	22989372	142	150	O
and	22989372	151	154	O
low-dose	22989372	155	163	O
allergen	22989372	164	172	O
provocations	22989372	173	185	O
are	22989372	186	189	O
an	22989372	190	192	O
established	22989372	193	204	O
tool	22989372	205	209	O
in	22989372	210	212	O
asthma	22989372	213	219	O
research	22989372	220	228	O
to	22989372	229	231	O
improve	22989372	232	239	O
our	22989372	240	243	O
understanding	22989372	244	257	O
of	22989372	258	260	O
the	22989372	261	264	O
pathophysiological	22989372	265	283	O
mechanism	22989372	284	293	O
of	22989372	294	296	O
allergic	22989372	297	305	O
asthma	22989372	306	312	O
.	22989372	312	313	O

However	22989372	314	321	O
,	22989372	321	322	O
clinical	22989372	323	331	O
symptoms	22989372	332	340	O
are	22989372	341	344	O
less	22989372	345	349	O
likely	22989372	350	356	O
to	22989372	357	359	O
be	22989372	360	362	O
induced	22989372	363	370	O
.	22989372	370	371	O

Therefore	22989372	372	381	O
,	22989372	381	382	O
we	22989372	383	385	O
designed	22989372	386	394	O
a	22989372	395	396	O
protocol	22989372	397	405	O
for	22989372	406	409	O
repetitive	22989372	410	420	O
high-dose	22989372	421	430	O
bronchial	22989372	431	440	O
allergen	22989372	441	449	O
challenges	22989372	450	460	O
to	22989372	461	463	O
generate	22989372	464	472	O
clinical	22989372	473	481	O
symptoms	22989372	482	490	O
and	22989372	491	494	O
airway	22989372	495	501	O
inflammation	22989372	502	514	O
.	22989372	514	515	O

METHODS	22989372	517	524	O
:	22989372	525	526	O
A	22989372	527	528	O
total	22989372	529	534	O
of	22989372	535	537	O
27	22989372	538	540	O
patients	22989372	541	549	O
aged	22989372	550	554	O
18	22989372	555	557	O
to	22989372	558	560	O
40	22989372	561	563	O
years	22989372	564	569	O
with	22989372	570	574	O
positive	22989372	575	583	O
skin-prick	22989372	584	594	O
tests	22989372	595	600	O
and	22989372	601	604	O
mild	22989372	605	609	O
asthma	22989372	610	616	O
underwent	22989372	617	626	O
repetitive	22989372	627	637	O
high-dose	22989372	638	647	O
allergen	22989372	648	656	O
challenges	22989372	657	667	O
with	22989372	668	672	O
household	22989372	673	682	O
dust	22989372	683	687	O
mites	22989372	688	693	O
for	22989372	694	697	O
four	22989372	698	702	O
consecutive	22989372	703	714	O
days	22989372	715	719	O
.	22989372	719	720	O

Pulmonary	22989372	721	730	O
function	22989372	731	739	O
and	22989372	740	743	O
exhaled	22989372	744	751	O
NO	22989372	752	754	O
were	22989372	755	759	O
measured	22989372	760	768	O
at	22989372	769	771	O
every	22989372	772	777	O
visit	22989372	778	783	O
.	22989372	783	784	O

Induced	22989372	785	792	O
sputum	22989372	793	799	O
was	22989372	800	803	O
analysed	22989372	804	812	O
before	22989372	813	819	O
and	22989372	820	823	O
after	22989372	824	829	O
the	22989372	830	833	O
allergen	22989372	834	842	O
challenges	22989372	843	853	O
for	22989372	854	857	O
cell	22989372	858	862	O
counts	22989372	863	869	O
,	22989372	869	870	O
ECP	22989372	871	874	O
,	22989372	874	875	O
IL-5	22989372	876	880	O
,	22989372	880	881	O
INF-γ	22989372	882	887	O
,	22989372	887	888	O
IL-8	22989372	889	893	O
,	22989372	893	894	O
and	22989372	895	898	O
the	22989372	899	902	O
transcription	22989372	903	916	O
factor	22989372	917	923	O
Foxp3	22989372	924	929	O
.	22989372	929	930	O

RESULTS	22989372	932	939	O
:	22989372	940	941	O
We	22989372	942	944	O
found	22989372	945	950	O
a	22989372	951	952	O
significant	22989372	953	964	O
decrease	22989372	965	973	O
in	22989372	974	976	O
pulmonary	22989372	977	986	B-Outcome
function	22989372	987	995	I-Outcome
,	22989372	995	996	O
an	22989372	997	999	O
increased	22989372	1000	1009	O
use	22989372	1010	1013	B-Outcome
of	22989372	1014	1016	I-Outcome
salbutamol	22989372	1017	1027	I-Outcome
and	22989372	1028	1031	O
the	22989372	1032	1035	O
development	22989372	1036	1047	O
of	22989372	1048	1050	O
a	22989372	1051	1052	O
late	22989372	1053	1057	B-Outcome
asthmatic	22989372	1058	1067	I-Outcome
response	22989372	1068	1076	I-Outcome
and	22989372	1077	1080	O
bronchial	22989372	1081	1090	B-Outcome
hyperresponsiveness	22989372	1091	1110	I-Outcome
,	22989372	1110	1111	O
as	22989372	1112	1114	O
well	22989372	1115	1119	O
as	22989372	1120	1122	O
a	22989372	1123	1124	O
significant	22989372	1125	1136	O
induction	22989372	1137	1146	O
of	22989372	1147	1149	O
eNO	22989372	1150	1153	B-Outcome
,	22989372	1153	1154	O
eosinophils	22989372	1155	1166	B-Outcome
,	22989372	1166	1167	O
and	22989372	1168	1171	O
Th-2	22989372	1172	1176	B-Outcome
cytokines	22989372	1177	1186	I-Outcome
.	22989372	1186	1187	O

Repeated	22989372	1188	1196	O
provocation	22989372	1197	1208	O
was	22989372	1209	1212	O
feasible	22989372	1213	1221	O
in	22989372	1222	1224	O
the	22989372	1225	1228	O
majority	22989372	1229	1237	O
of	22989372	1238	1240	O
patients	22989372	1241	1249	O
.	22989372	1249	1250	O

Two	22989372	1251	1254	O
subjects	22989372	1255	1263	O
had	22989372	1264	1267	O
severe	22989372	1268	1274	B-Outcome
adverse	22989372	1275	1282	I-Outcome
events	22989372	1283	1289	I-Outcome
requiring	22989372	1290	1299	O
prednisolone	22989372	1300	1312	O
to	22989372	1313	1315	O
cope	22989372	1316	1320	O
with	22989372	1321	1325	O
nocturnal	22989372	1326	1335	O
asthma	22989372	1336	1342	O
symptoms	22989372	1343	1351	O
.	22989372	1351	1352	O

CONCLUSIONS	22989372	1354	1365	O
:	22989372	1366	1367	O
Repeated	22989372	1368	1376	O
high-dose	22989372	1377	1386	O
bronchial	22989372	1387	1396	O
allergen	22989372	1397	1405	O
challenges	22989372	1406	1416	O
resulted	22989372	1417	1425	O
in	22989372	1426	1428	O
severe	22989372	1429	1435	B-Outcome
asthma	22989372	1436	1442	I-Outcome
symptoms	22989372	1443	1451	I-Outcome
and	22989372	1452	1455	O
marked	22989372	1456	1462	O
Th-2-mediated	22989372	1463	1476	B-Outcome
allergic	22989372	1477	1485	I-Outcome
airway	22989372	1486	1492	I-Outcome
inflammation	22989372	1493	1505	I-Outcome
.	22989372	1505	1506	O

The	22989372	1507	1510	O
high-dose	22989372	1511	1520	O
challenge	22989372	1521	1530	O
model	22989372	1531	1536	O
is	22989372	1537	1539	O
suitable	22989372	1540	1548	O
only	22989372	1549	1553	O
in	22989372	1554	1556	O
an	22989372	1557	1559	O
attenuated	22989372	1560	1570	O
form	22989372	1571	1575	O
in	22989372	1576	1578	O
diseased	22989372	1579	1587	O
volunteers	22989372	1588	1598	O
for	22989372	1599	1602	O
proof-of-concept	22989372	1603	1619	O
studies	22989372	1620	1627	O
and	22989372	1628	1631	O
in	22989372	1632	1634	O
clinical	22989372	1635	1643	O
settings	22989372	1644	1652	O
to	22989372	1653	1655	O
reduce	22989372	1656	1662	O
the	22989372	1663	1666	O
risk	22989372	1667	1671	O
of	22989372	1672	1674	O
severe	22989372	1675	1681	B-Outcome
asthma	22989372	1682	1688	I-Outcome
exacerbations	22989372	1689	1702	I-Outcome
.	22989372	1702	1703	O

TRIAL	22989372	1705	1710	O
REGISTRATION	22989372	1711	1723	O
:	22989372	1724	1725	O
ClinicalTrials.govNCT00677209	22989372	1726	1755	O
.	22989372	1755	1756	O


Effects	23020253	0	7	O
of	23020253	8	10	O
saxagliptin	23020253	11	22	O
added	23020253	23	28	O
to	23020253	29	31	O
sub-maximal	23020253	32	43	O
doses	23020253	44	49	O
of	23020253	50	52	O
metformin	23020253	53	62	O
compared	23020253	63	71	O
with	23020253	72	76	O
uptitration	23020253	77	88	O
of	23020253	89	91	O
metformin	23020253	92	101	O
in	23020253	102	104	O
type	23020253	105	109	O
2	23020253	110	111	O
diabetes	23020253	112	120	O
:	23020253	120	121	O
the	23020253	122	125	O
PROMPT	23020253	126	132	O
study	23020253	133	138	O
.	23020253	138	139	O

OBJECTIVE	23020253	141	150	O
:	23020253	151	152	O
The	23020253	153	156	O
PROMPT	23020253	157	163	O
study	23020253	164	169	O
compared	23020253	170	178	O
efficacy	23020253	179	187	O
and	23020253	188	191	O
tolerability	23020253	192	204	O
of	23020253	205	207	O
two	23020253	208	211	O
treatment	23020253	212	221	O
intensification	23020253	222	237	O
strategies	23020253	238	248	O
:	23020253	248	249	O
adding	23020253	250	256	O
saxagliptin	23020253	257	268	O
or	23020253	269	271	O
uptitrating	23020253	272	283	O
metformin	23020253	284	293	O
monotherapy	23020253	294	305	O
,	23020253	305	306	O
in	23020253	307	309	O
patients	23020253	310	318	O
with	23020253	319	323	O
type	23020253	324	328	O
2	23020253	329	330	O
diabetes	23020253	331	339	O
(	23020253	340	341	O
T2D	23020253	341	344	O
)	23020253	344	345	O
and	23020253	346	349	O
inadequate	23020253	350	360	O
glycaemic	23020253	361	370	O
control	23020253	371	378	O
on	23020253	379	381	O
a	23020253	382	383	O
sub-maximal	23020253	384	395	O
metformin	23020253	396	405	O
dose	23020253	406	410	O
.	23020253	410	411	O

RESEARCH	23020253	413	421	O
DESIGN	23020253	422	428	O
AND	23020253	429	432	O
METHODS	23020253	433	440	O
:	23020253	441	442	O
In	23020253	443	445	O
this	23020253	446	450	O
double-blind	23020253	451	463	O
,	23020253	463	464	O
24-week	23020253	465	472	O
study	23020253	473	478	O
,	23020253	478	479	O
metformin-tolerant	23020253	480	498	O
patients	23020253	499	507	O
with	23020253	508	512	O
T2D	23020253	513	516	O
on	23020253	517	519	O
metformin	23020253	520	529	O
monotherapy	23020253	530	541	O
were	23020253	542	546	O
randomised	23020253	547	557	O
to	23020253	558	560	O
receive	23020253	561	568	O
fixed-dose	23020253	569	579	O
metformin	23020253	580	589	O
1500	23020253	590	594	O
mg/day	23020253	595	601	O
,	23020253	601	602	O
plus	23020253	603	607	O
either	23020253	608	614	O
add-on	23020253	615	621	O
saxagliptin	23020253	622	633	O
5	23020253	634	635	O
mg/day	23020253	636	642	O
(	23020253	643	644	O
SAXA-MET	23020253	644	652	O
)	23020253	652	653	O
or	23020253	654	656	O
a	23020253	657	658	O
two-step	23020253	659	667	O
metformin	23020253	668	677	O
uptitration	23020253	678	689	O
(	23020253	690	691	O
MET-UP	23020253	691	697	O
)	23020253	697	698	O
to	23020253	699	701	O
a	23020253	702	703	O
maximum	23020253	704	711	O
dose	23020253	712	716	O
(	23020253	717	718	O
2500	23020253	718	722	O
mg/day	23020253	723	729	O
)	23020253	729	730	O
.	23020253	730	731	O

CLINICAL	23020253	733	741	O
TRIAL	23020253	742	747	O
REGISTRATION	23020253	748	760	O
:	23020253	761	762	O
NCT01006590	23020253	763	774	O
.	23020253	774	775	O

MAIN	23020253	777	781	O
OUTCOME	23020253	782	789	O
MEASURES	23020253	790	798	O
:	23020253	799	800	O
Primary	23020253	801	808	O
:	23020253	808	809	O
absolute	23020253	810	818	O
change	23020253	819	825	O
from	23020253	826	830	O
baseline	23020253	831	839	O
in	23020253	840	842	O
glycated	23020253	843	851	O
haemoglobin	23020253	852	863	O
A(1c	23020253	864	868	O
)	23020253	868	869	O
(	23020253	870	871	O
HbA(1c	23020253	871	877	O
)	23020253	877	878	O
)	23020253	878	879	O
(	23020253	880	881	O
Week	23020253	881	885	O
24	23020253	886	888	O
)	23020253	888	889	O
.	23020253	889	890	O

Secondary	23020253	891	900	O
:	23020253	900	901	O
proportion	23020253	902	912	O
of	23020253	913	915	O
patients	23020253	916	924	O
achieving	23020253	925	934	O
a	23020253	935	936	O
therapeutic	23020253	937	948	O
glycaemic	23020253	949	958	O
response	23020253	959	967	O
(	23020253	968	969	O
Week	23020253	969	973	O
24	23020253	974	976	O
)	23020253	976	977	O
;	23020253	977	978	O
change	23020253	979	985	O
from	23020253	986	990	O
baseline	23020253	991	999	O
in	23020253	1000	1002	O
fasting	23020253	1003	1010	O
plasma	23020253	1011	1017	O
glucose	23020253	1018	1025	O
(	23020253	1026	1027	O
Week	23020253	1027	1031	O
24	23020253	1032	1034	O
)	23020253	1034	1035	O
;	23020253	1035	1036	O
safety	23020253	1037	1043	O
and	23020253	1044	1047	O
tolerability	23020253	1048	1060	O
.	23020253	1060	1061	O

Exploratory	23020253	1062	1073	O
analyses	23020253	1074	1082	O
comprised	23020253	1083	1092	O
three	23020253	1093	1098	O
patient-related	23020253	1099	1114	O
questionnaires	23020253	1115	1129	O
,	23020253	1129	1130	O
including	23020253	1131	1140	O
the	23020253	1141	1144	O
validated	23020253	1145	1154	O
5-dimension	23020253	1155	1166	O
Digestive	23020253	1167	1176	O
Health	23020253	1177	1183	O
Status	23020253	1184	1190	O
Index	23020253	1191	1196	O
(	23020253	1197	1198	O
DHSI	23020253	1198	1202	O
)	23020253	1202	1203	O
.	23020253	1203	1204	O

RESULTS	23020253	1206	1213	O
:	23020253	1214	1215	O
A	23020253	1216	1217	O
total	23020253	1218	1223	O
of	23020253	1224	1226	O
286	23020253	1227	1230	O
patients	23020253	1231	1239	O
were	23020253	1240	1244	O
randomised	23020253	1245	1255	O
:	23020253	1255	1256	O
(	23020253	1257	1258	O
SAXA-MET	23020253	1258	1266	O
:	23020253	1266	1267	O
147	23020253	1268	1271	O
;	23020253	1271	1272	O
MET-UP	23020253	1273	1279	O
:	23020253	1279	1280	O
139	23020253	1281	1284	O
)	23020253	1284	1285	O
.	23020253	1285	1286	O

Baseline	23020253	1287	1295	B-Outcome
mean	23020253	1296	1300	I-Outcome
(	23020253	1301	1302	I-Outcome
SD	23020253	1302	1304	I-Outcome
)	23020253	1304	1305	I-Outcome
HbA(1c	23020253	1306	1312	I-Outcome
):	23020253	1312	1314	I-Outcome
7.71	23020253	1315	1319	O
(	23020253	1320	1321	O
0.85	23020253	1321	1325	O
;	23020253	1325	1326	O
SAXA-MET	23020253	1327	1335	O
)	23020253	1335	1336	O
;	23020253	1336	1337	O
7.80	23020253	1338	1342	O
(	23020253	1343	1344	O
0.82	23020253	1344	1348	O
;	23020253	1348	1349	O
MET-UP	23020253	1350	1356	O
)	23020253	1356	1357	O
.	23020253	1357	1358	O

Adjusted	23020253	1359	1367	O
mean	23020253	1368	1372	O
reductions	23020253	1373	1383	O
from	23020253	1384	1388	O
baseline	23020253	1389	1397	O
in	23020253	1398	1400	O
HbA(1c	23020253	1401	1407	B-Outcome
)	23020253	1407	1408	I-Outcome
(	23020253	1409	1410	I-Outcome
Week	23020253	1410	1414	I-Outcome
24	23020253	1415	1417	I-Outcome
):	23020253	1417	1419	I-Outcome
-0.47	23020253	1420	1425	O
%	23020253	1425	1426	O
(	23020253	1427	1428	O
SAXA-MET	23020253	1428	1436	O
)	23020253	1436	1437	O
;	23020253	1437	1438	O
-0.38	23020253	1439	1444	O
%	23020253	1444	1445	O
(	23020253	1446	1447	O
MET-UP	23020253	1447	1453	O
)	23020253	1453	1454	O
;	23020253	1454	1455	O
mean	23020253	1456	1460	O
(	23020253	1461	1462	O
95	23020253	1462	1464	O
%	23020253	1464	1465	O
CI	23020253	1466	1468	O
)	23020253	1468	1469	O
difference	23020253	1470	1480	O
in	23020253	1481	1483	O
treatment	23020253	1484	1493	O
effect	23020253	1494	1500	O
,	23020253	1500	1501	O
-0.10	23020253	1502	1507	O
%	23020253	1507	1508	O
(	23020253	1509	1510	O
-0.26	23020253	1510	1515	O
,	23020253	1515	1516	O
0.07	23020253	1517	1521	O
)	23020253	1521	1522	O
;	23020253	1522	1523	O
p	23020253	1524	1525	O
=	23020253	1526	1527	O
0.260	23020253	1528	1533	O
.	23020253	1533	1534	O

The	23020253	1535	1538	O
proportion	23020253	1539	1549	B-Outcome
of	23020253	1550	1552	I-Outcome
patients	23020253	1553	1561	I-Outcome
(	23020253	1562	1563	I-Outcome
95	23020253	1563	1565	I-Outcome
%	23020253	1565	1566	I-Outcome
CI	23020253	1567	1569	I-Outcome
)	23020253	1569	1570	I-Outcome
achieving	23020253	1571	1580	I-Outcome
a	23020253	1581	1582	I-Outcome
therapeutic	23020253	1583	1594	I-Outcome
glycaemic	23020253	1595	1604	I-Outcome
response	23020253	1605	1613	I-Outcome
(	23020253	1614	1615	I-Outcome
HbA(1c	23020253	1615	1621	I-Outcome
)	23020253	1621	1622	I-Outcome
<	23020253	1623	1624	I-Outcome
7	23020253	1625	1626	I-Outcome
%	23020253	1626	1627	I-Outcome
):	23020253	1627	1629	I-Outcome
43.8	23020253	1630	1634	O
%	23020253	1634	1635	O
(	23020253	1636	1637	O
34.8	23020253	1637	1641	O
,	23020253	1641	1642	O
49.6	23020253	1643	1647	O
)	23020253	1647	1648	O
(	23020253	1649	1650	O
SAXA-MET	23020253	1650	1658	O
)	23020253	1658	1659	O
vs.	23020253	1660	1663	O
35.0	23020253	1664	1668	O
%	23020253	1668	1669	O
(	23020253	1670	1671	O
29.0	23020253	1671	1675	O
,	23020253	1675	1676	O
43.8	23020253	1677	1681	O
)	23020253	1681	1682	O
(	23020253	1683	1684	O
MET-UP	23020253	1684	1690	O
)	23020253	1690	1691	O
.	23020253	1691	1692	O

Of	23020253	1693	1695	O
the	23020253	1696	1699	O
five	23020253	1700	1704	O
DHSI	23020253	1705	1709	B-Outcome
domains	23020253	1710	1717	I-Outcome
,	23020253	1717	1718	O
mean	23020253	1719	1723	O
(	23020253	1724	1725	O
95	23020253	1725	1727	O
%	23020253	1727	1728	O
CI	23020253	1729	1731	O
)	23020253	1731	1732	O
differences	23020253	1733	1744	O
were	23020253	1745	1749	O
observed	23020253	1750	1758	O
for	23020253	1759	1762	O
diarrhoea-predominant	23020253	1763	1784	B-Outcome
score	23020253	1785	1790	I-Outcome
(	23020253	1791	1792	O
+	23020253	1792	1793	O
0.8	23020253	1793	1796	O
[	23020253	1797	1798	O
-2.5	23020253	1798	1802	O
,	23020253	1802	1803	O
4.0	23020253	1804	1807	O
]	23020253	1807	1808	O
vs.	23020253	1809	1812	O
+	23020253	1813	1814	O
7.9	23020253	1814	1817	O
[	23020253	1818	1819	O
4.6	23020253	1819	1822	O
,	23020253	1822	1823	O
11.2	23020253	1824	1828	O
]	23020253	1828	1829	O
)	23020253	1829	1830	O
and	23020253	1831	1834	O
dysmotility	23020253	1835	1846	B-Outcome
score	23020253	1847	1852	I-Outcome
(	23020253	1853	1854	O
-0.5	23020253	1854	1858	O
[	23020253	1859	1860	O
-2.0	23020253	1860	1864	O
,	23020253	1864	1865	O
1.0	23020253	1866	1869	O
]	23020253	1869	1870	O
vs.	23020253	1871	1874	O
+	23020253	1875	1876	O
1.9	23020253	1876	1879	O
[	23020253	1880	1881	O
0.3	23020253	1881	1884	O
,	23020253	1884	1885	O
3.4	23020253	1886	1889	O
]	23020253	1889	1890	O
)	23020253	1890	1891	O
,	23020253	1891	1892	O
(	23020253	1893	1894	O
SAXA-MET	23020253	1894	1902	O
and	23020253	1903	1906	O
MET-UP	23020253	1907	1913	O
,	23020253	1913	1914	O
respectively	23020253	1915	1927	O
)	23020253	1927	1928	O
.	23020253	1928	1929	O

The	23020253	1930	1933	O
most	23020253	1934	1938	O
common	23020253	1939	1945	O
adverse	23020253	1946	1953	B-Outcome
event	23020253	1954	1959	I-Outcome
was	23020253	1960	1963	O
diarrhoea	23020253	1964	1973	O
:	23020253	1973	1974	O
6.1	23020253	1975	1978	O
%	23020253	1978	1979	O
(	23020253	1980	1981	O
SAXA-MET	23020253	1981	1989	O
)	23020253	1989	1990	O
vs.	23020253	1991	1994	O
12.2	23020253	1995	1999	O
%	23020253	1999	2000	O
(	23020253	2001	2002	O
MET-UP	23020253	2002	2008	O
)	23020253	2008	2009	O
.	23020253	2009	2010	O

CONCLUSIONS	23020253	2012	2023	O
:	23020253	2024	2025	O
In	23020253	2026	2028	O
metformin-tolerant	23020253	2029	2047	O
patients	23020253	2048	2056	O
with	23020253	2057	2061	O
T2D	23020253	2062	2065	O
(	23020253	2066	2067	O
inadequately	23020253	2067	2079	O
controlled	23020253	2080	2090	O
on	23020253	2091	2093	O
sub-maximal	23020253	2094	2105	O
metformin	23020253	2106	2115	O
monotherapy	23020253	2116	2127	O
)	23020253	2127	2128	O
,	23020253	2128	2129	O
saxagliptin	23020253	2130	2141	O
was	23020253	2142	2145	O
well	23020253	2146	2150	O
tolerated	23020253	2151	2160	B-Outcome
.	23020253	2160	2161	O

Although	23020253	2162	2170	O
HbA(1c	23020253	2171	2177	B-Outcome
)	23020253	2177	2178	I-Outcome
reduction	23020253	2179	2188	O
was	23020253	2189	2192	O
not	23020253	2193	2196	O
significantly	23020253	2197	2210	O
different	23020253	2211	2220	O
between	23020253	2221	2228	O
treatment	23020253	2229	2238	O
groups	23020253	2239	2245	O
,	23020253	2245	2246	O
the	23020253	2247	2250	O
lower	23020253	2251	2256	O
occurrence	23020253	2257	2267	O
of	23020253	2268	2270	O
gastrointestinal	23020253	2271	2287	B-Outcome
symptoms	23020253	2288	2296	I-Outcome
in	23020253	2297	2299	O
the	23020253	2300	2303	O
SAXA-MET	23020253	2304	2312	O
group	23020253	2313	2318	O
suggests	23020253	2319	2327	O
that	23020253	2328	2332	O
saxagliptin	23020253	2333	2344	O
add-on	23020253	2345	2351	O
treatment	23020253	2352	2361	O
may	23020253	2362	2365	O
be	23020253	2366	2368	O
a	23020253	2369	2370	O
suitable	23020253	2371	2379	O
alternative	23020253	2380	2391	O
treatment	23020253	2392	2401	O
strategy	23020253	2402	2410	O
to	23020253	2411	2413	O
metformin	23020253	2414	2423	O
uptitration	23020253	2424	2435	O
.	23020253	2435	2436	O


Efficacy	23095369	0	8	O
of	23095369	9	11	O
different	23095369	12	21	O
gonadotropin	23095369	22	34	O
combinations	23095369	35	47	O
to	23095369	48	50	O
support	23095369	51	58	O
ovulation	23095369	59	68	O
induction	23095369	69	78	O
in	23095369	79	81	O
WHO	23095369	82	85	O
type	23095369	86	90	O
I	23095369	91	92	O
anovulation	23095369	93	104	O
infertility	23095369	105	116	O
:	23095369	116	117	O
clinical	23095369	118	126	O
evidences	23095369	127	136	O
of	23095369	137	139	O
human	23095369	140	145	O
recombinant	23095369	146	157	O
FSH/human	23095369	158	167	O
recombinant	23095369	168	179	O
LH	23095369	180	182	O
in	23095369	183	185	O
a	23095369	186	187	O
2:1	23095369	188	191	O
ratio	23095369	192	197	O
and	23095369	198	201	O
highly	23095369	202	208	O
purified	23095369	209	217	O
human	23095369	218	223	O
menopausal	23095369	224	234	O
gonadotropin	23095369	235	247	O
stimulation	23095369	248	259	O
protocols	23095369	260	269	O
.	23095369	269	270	O

BACKGROUND	23095369	272	282	O
:	23095369	283	284	O
The	23095369	285	288	O
World	23095369	289	294	O
Helath	23095369	295	301	O
Organization	23095369	302	314	O
(	23095369	315	316	O
WHO	23095369	316	319	O
)	23095369	319	320	O
Group	23095369	321	326	O
I	23095369	327	328	O
anovulation	23095369	329	340	O
,	23095369	340	341	O
or	23095369	342	344	O
hypogonadotropic	23095369	345	361	O
hypogonadism	23095369	362	374	O
(	23095369	375	376	O
HH	23095369	376	378	O
)	23095369	378	379	O
,	23095369	379	380	O
is	23095369	381	383	O
characterized	23095369	384	397	O
by	23095369	398	400	O
reduced	23095369	401	408	O
hypothalamic/pituitary	23095369	409	431	O
activity	23095369	432	440	O
which	23095369	441	446	O
results	23095369	447	454	O
in	23095369	455	457	O
abnormally	23095369	458	468	O
low	23095369	469	472	O
serum	23095369	473	478	O
FSH	23095369	479	482	O
and	23095369	483	486	O
LH	23095369	487	489	O
levels	23095369	490	496	O
and	23095369	497	500	O
negligible	23095369	501	511	O
estrogen	23095369	512	520	O
activity	23095369	521	529	O
.	23095369	529	530	O

AIM	23095369	532	535	O
:	23095369	536	537	O
To	23095369	538	540	O
compare	23095369	541	548	O
the	23095369	549	552	O
efficacy	23095369	553	561	O
of	23095369	562	564	O
human	23095369	565	570	O
recombinant	23095369	571	582	O
FSH	23095369	583	586	O
(	23095369	587	588	O
r-hFSH	23095369	588	594	O
)	23095369	594	595	O
plus	23095369	596	600	O
human	23095369	601	606	O
recombinant	23095369	607	618	O
LH	23095369	619	621	O
(	23095369	622	623	O
r-hLH	23095369	623	628	O
)	23095369	628	629	O
in	23095369	630	632	O
a	23095369	633	634	O
2:1	23095369	635	638	O
ratio	23095369	639	644	O
with	23095369	645	649	O
highly	23095369	650	656	O
purified	23095369	657	665	O
human	23095369	666	671	O
menopausal	23095369	672	682	O
gonadotropin	23095369	683	695	O
(	23095369	696	697	O
hMG-HP	23095369	697	703	O
)	23095369	703	704	O
urinary	23095369	705	712	O
extract	23095369	713	720	O
,	23095369	720	721	O
containing	23095369	722	732	O
LH-like	23095369	733	740	O
activity	23095369	741	749	O
,	23095369	749	750	O
in	23095369	751	753	O
women	23095369	754	759	O
with	23095369	760	764	O
HH	23095369	765	767	O
.	23095369	767	768	O

SUBJECTS	23095369	770	778	O
AND	23095369	779	782	O
METHODS	23095369	783	790	O
:	23095369	791	792	O
This	23095369	793	797	O
two-arm	23095369	798	805	O
randomized	23095369	806	816	O
open-label	23095369	817	827	O
study	23095369	828	833	O
included	23095369	834	842	O
35	23095369	843	845	O
HH	23095369	846	848	O
women	23095369	849	854	O
(	23095369	855	856	O
aged	23095369	856	860	O
25	23095369	861	863	O
-	23095369	863	864	O
36	23095369	864	866	O
yr	23095369	867	869	O
)	23095369	869	870	O
attending	23095369	871	880	O
our	23095369	881	884	O
Center	23095369	885	891	O
.	23095369	891	892	O

Eighteen	23095369	893	901	O
patients	23095369	902	910	O
received	23095369	911	919	O
150	23095369	920	923	O
IU	23095369	924	926	O
hMG-HP	23095369	927	933	O
(	23095369	934	935	O
150	23095369	935	938	O
IU	23095369	939	941	O
FSH	23095369	942	945	O
+	23095369	946	947	O
150	23095369	948	951	O
IU	23095369	952	954	O
LH-like	23095369	955	962	O
activity	23095369	963	971	O
)	23095369	971	972	O
and	23095369	973	976	O
seventeen	23095369	977	986	O
received	23095369	987	995	O
150IU	23095369	996	1001	O
r-hFSH/75IU	23095369	1002	1013	O
rhLH	23095369	1014	1018	O
daily	23095369	1019	1024	O
for	23095369	1025	1028	O
a	23095369	1029	1030	O
maximum	23095369	1031	1038	O
of	23095369	1039	1041	O
16	23095369	1042	1044	O
days	23095369	1045	1049	O
.	23095369	1049	1050	O

Ovulation	23095369	1051	1060	O
was	23095369	1061	1064	O
induced	23095369	1065	1072	O
by	23095369	1073	1075	O
a	23095369	1076	1077	O
single	23095369	1078	1084	O
administration	23095369	1085	1099	O
of	23095369	1100	1102	O
hCG	23095369	1103	1106	O
on	23095369	1107	1109	O
the	23095369	1110	1113	O
day	23095369	1114	1117	O
after	23095369	1118	1123	O
the	23095369	1124	1127	O
last	23095369	1128	1132	O
hMG-HP	23095369	1133	1139	O
or	23095369	1140	1142	O
r-hFSH/r-hLH	23095369	1143	1155	O
.	23095369	1155	1156	O

RESULTS	23095369	1158	1165	O
:	23095369	1166	1167	O
The	23095369	1168	1171	O
primary	23095369	1172	1179	O
efficacy	23095369	1180	1188	B-Outcome
endpoint	23095369	1189	1197	O
was	23095369	1198	1201	O
ovulation	23095369	1202	1211	B-Outcome
induction	23095369	1212	1221	I-Outcome
as	23095369	1222	1224	O
measured	23095369	1225	1233	O
by	23095369	1234	1236	O
follicle	23095369	1237	1245	B-Outcome
≥17	23095369	1246	1249	I-Outcome
mm	23095369	1250	1252	I-Outcome
,	23095369	1252	1253	O
pre-ovulatory	23095369	1254	1267	B-Outcome
estradiol	23095369	1268	1277	I-Outcome
(	23095369	1278	1279	I-Outcome
E	23095369	1279	1280	I-Outcome
2	23095369	1281	1282	I-Outcome
)	23095369	1283	1284	I-Outcome
≥400	23095369	1285	1289	I-Outcome
pmol/l	23095369	1290	1296	I-Outcome
and	23095369	1297	1300	O
mid-luteal	23095369	1301	1311	B-Outcome
phase	23095369	1312	1317	I-Outcome
progesterone	23095369	1318	1330	I-Outcome
(	23095369	1331	1332	I-Outcome
P	23095369	1332	1333	I-Outcome
4	23095369	1334	1335	I-Outcome
)	23095369	1336	1337	I-Outcome
≥25	23095369	1338	1341	I-Outcome
nmol/l	23095369	1342	1348	I-Outcome
.	23095369	1348	1349	O

Secondary	23095369	1350	1359	O
efficacy	23095369	1360	1368	B-Outcome
endpoints	23095369	1369	1378	O
included	23095369	1379	1387	O
E	23095369	1388	1389	B-Outcome
2	23095369	1390	1391	I-Outcome
levels/follicle	23095369	1392	1407	I-Outcome
at	23095369	1408	1410	I-Outcome
mid-cycle	23095369	1411	1420	I-Outcome
,	23095369	1420	1421	O
number	23095369	1422	1428	B-Outcome
of	23095369	1429	1431	I-Outcome
follicles	23095369	1432	1441	I-Outcome
at	23095369	1442	1444	I-Outcome
mid-cycle	23095369	1445	1454	I-Outcome
and	23095369	1455	1458	O
pregnancy	23095369	1459	1468	B-Outcome
rate	23095369	1469	1473	I-Outcome
(	23095369	1474	1475	O
PR	23095369	1475	1477	B-Outcome
)	23095369	1477	1478	O
.	23095369	1478	1479	O

Following	23095369	1480	1489	O
a	23095369	1490	1491	O
total	23095369	1492	1497	O
of	23095369	1498	1500	O
70	23095369	1501	1503	O
cycles	23095369	1504	1510	O
,	23095369	1510	1511	O
70	23095369	1512	1514	O
%	23095369	1514	1515	O
of	23095369	1516	1518	O
r-hFSH/r-hLH	23095369	1519	1531	O
treated	23095369	1532	1539	O
patients	23095369	1540	1548	O
met	23095369	1549	1552	O
the	23095369	1553	1556	O
primary	23095369	1557	1564	O
endpoint	23095369	1565	1573	O
vs	23095369	1574	1576	O
88	23095369	1577	1579	O
%	23095369	1579	1580	O
in	23095369	1581	1583	O
hMG-HP	23095369	1584	1590	O
group	23095369	1591	1596	O
(	23095369	1597	1598	O
p=0.11	23095369	1598	1604	O
)	23095369	1604	1605	O
.	23095369	1605	1606	O

However	23095369	1607	1614	O
,	23095369	1614	1615	O
PR	23095369	1616	1618	B-Outcome
in	23095369	1619	1621	O
r-hFSH/r-hLH	23095369	1622	1634	O
group	23095369	1635	1640	O
was	23095369	1641	1644	O
55.6	23095369	1645	1649	O
%	23095369	1649	1650	O
compared	23095369	1651	1659	O
to	23095369	1660	1662	O
23.3	23095369	1663	1667	O
%	23095369	1667	1668	O
in	23095369	1669	1671	O
hMG-HP	23095369	1672	1678	O
group	23095369	1679	1684	O
(	23095369	1685	1686	O
p=0.01	23095369	1686	1692	O
)	23095369	1692	1693	O
.	23095369	1693	1694	O

CONCLUSIONS	23095369	1696	1707	O
:	23095369	1708	1709	O
The	23095369	1710	1713	O
primary	23095369	1714	1721	O
endpoint	23095369	1722	1730	O
achievement	23095369	1731	1742	O
did	23095369	1743	1746	O
not	23095369	1747	1750	O
correlate	23095369	1751	1760	O
with	23095369	1761	1765	O
PR	23095369	1766	1768	B-Outcome
.	23095369	1768	1769	O

This	23095369	1770	1774	O
study	23095369	1775	1780	O
has	23095369	1781	1784	O
shown	23095369	1785	1790	O
the	23095369	1791	1794	O
superiority	23095369	1795	1806	O
of	23095369	1807	1809	O
LH	23095369	1810	1812	O
compared	23095369	1813	1821	O
to	23095369	1822	1824	O
hCG	23095369	1825	1828	O
in	23095369	1829	1831	O
supporting	23095369	1832	1842	O
FSH-induced	23095369	1843	1854	B-Outcome
follicular	23095369	1855	1865	I-Outcome
development	23095369	1866	1877	I-Outcome
in	23095369	1878	1880	O
HH	23095369	1881	1883	O
women	23095369	1884	1889	O
.	23095369	1889	1890	O


The	23128568	0	3	O
effect	23128568	4	10	O
of	23128568	11	13	O
values	23128568	14	20	O
affirmation	23128568	21	32	O
on	23128568	33	35	O
race-discordant	23128568	36	51	O
patient-provider	23128568	52	68	O
communication	23128568	69	82	O
.	23128568	82	83	O

BACKGROUND	23128568	85	95	O
:	23128568	96	97	O
Communication	23128568	98	111	O
between	23128568	112	119	O
African	23128568	120	127	O
American	23128568	128	136	O
patients	23128568	137	145	O
and	23128568	146	149	O
white	23128568	150	155	O
health	23128568	156	162	O
care	23128568	163	167	O
providers	23128568	168	177	O
has	23128568	178	181	O
been	23128568	182	186	O
shown	23128568	187	192	O
to	23128568	193	195	O
be	23128568	196	198	O
of	23128568	199	201	O
poorer	23128568	202	208	O
quality	23128568	209	216	O
when	23128568	217	221	O
compared	23128568	222	230	O
with	23128568	231	235	O
race-concordant	23128568	236	251	O
patient-provider	23128568	252	268	O
communication	23128568	269	282	O
.	23128568	282	283	O

Fear	23128568	284	288	O
on	23128568	289	291	O
the	23128568	292	295	O
part	23128568	296	300	O
of	23128568	301	303	O
patients	23128568	304	312	O
that	23128568	313	317	O
providers	23128568	318	327	O
stereotype	23128568	328	338	O
them	23128568	339	343	O
negatively	23128568	344	354	O
might	23128568	355	360	O
be	23128568	361	363	O
one	23128568	364	367	O
cause	23128568	368	373	O
of	23128568	374	376	O
this	23128568	377	381	O
poorer	23128568	382	388	O
communication	23128568	389	402	O
.	23128568	402	403	O

This	23128568	404	408	O
stereotype	23128568	409	419	O
threat	23128568	420	426	O
may	23128568	427	430	O
be	23128568	431	433	O
lessened	23128568	434	442	O
by	23128568	443	445	O
a	23128568	446	447	O
values-affirmation	23128568	448	466	O
intervention	23128568	467	479	O
.	23128568	479	480	O

METHODS	23128568	482	489	O
:	23128568	490	491	O
In	23128568	492	494	O
a	23128568	495	496	O
blinded	23128568	497	504	O
experiment	23128568	505	515	O
,	23128568	515	516	O
we	23128568	517	519	O
randomized	23128568	520	530	O
99	23128568	531	533	O
African	23128568	534	541	O
American	23128568	542	550	O
patients	23128568	551	559	O
with	23128568	560	564	O
hypertension	23128568	565	577	O
to	23128568	578	580	O
perform	23128568	581	588	O
a	23128568	589	590	O
values-affirmation	23128568	591	609	O
exercise	23128568	610	618	O
or	23128568	619	621	O
a	23128568	622	623	O
control	23128568	624	631	O
exercise	23128568	632	640	O
before	23128568	641	647	O
a	23128568	648	649	O
visit	23128568	650	655	O
with	23128568	656	660	O
their	23128568	661	666	O
primary	23128568	667	674	O
care	23128568	675	679	O
provider	23128568	680	688	O
.	23128568	688	689	O

We	23128568	690	692	O
compared	23128568	693	701	O
patient-provider	23128568	702	718	O
communication	23128568	719	732	O
for	23128568	733	736	O
the	23128568	737	740	O
2	23128568	741	742	O
groups	23128568	743	749	O
using	23128568	750	755	O
audio	23128568	756	761	O
recordings	23128568	762	772	O
of	23128568	773	775	O
the	23128568	776	779	O
visit	23128568	780	785	O
analyzed	23128568	786	794	O
with	23128568	795	799	O
the	23128568	800	803	O
Roter	23128568	804	809	O
Interaction	23128568	810	821	O
Analysis	23128568	822	830	O
System	23128568	831	837	O
.	23128568	837	838	O

We	23128568	839	841	O
also	23128568	842	846	O
evaluated	23128568	847	856	O
visit	23128568	857	862	O
satisfaction	23128568	863	875	O
,	23128568	875	876	O
trust	23128568	877	882	O
,	23128568	882	883	O
stress	23128568	884	890	O
,	23128568	890	891	O
and	23128568	892	895	O
mood	23128568	896	900	O
after	23128568	901	906	O
the	23128568	907	910	O
visit	23128568	911	916	O
by	23128568	917	919	O
means	23128568	920	925	O
of	23128568	926	928	O
a	23128568	929	930	O
questionnaire	23128568	931	944	O
.	23128568	944	945	O

RESULTS	23128568	947	954	O
:	23128568	955	956	O
Patients	23128568	957	965	O
in	23128568	966	968	O
the	23128568	969	972	O
intervention	23128568	973	985	O
group	23128568	986	991	O
requested	23128568	992	1001	O
and	23128568	1002	1005	O
provided	23128568	1006	1014	O
more	23128568	1015	1019	O
information	23128568	1020	1031	B-Outcome
about	23128568	1032	1037	I-Outcome
their	23128568	1038	1043	I-Outcome
medical	23128568	1044	1051	I-Outcome
condition	23128568	1052	1061	I-Outcome
(	23128568	1062	1063	I-Outcome
mean	23128568	1063	1067	I-Outcome
[	23128568	1068	1069	I-Outcome
SE	23128568	1069	1071	I-Outcome
]	23128568	1071	1072	I-Outcome
number	23128568	1073	1079	I-Outcome
of	23128568	1080	1082	I-Outcome
utterances	23128568	1083	1093	I-Outcome
,	23128568	1093	1094	O
66.3	23128568	1095	1099	O
[	23128568	1100	1101	O
6.8	23128568	1101	1104	O
]	23128568	1104	1105	O
in	23128568	1106	1108	O
the	23128568	1109	1112	O
values-affirmation	23128568	1113	1131	O
group	23128568	1132	1137	O
vs	23128568	1138	1140	O
48.1	23128568	1141	1145	O
[	23128568	1146	1147	O
5.9	23128568	1147	1150	O
]	23128568	1150	1151	O
in	23128568	1152	1154	O
the	23128568	1155	1158	O
control	23128568	1159	1166	O
group	23128568	1167	1172	O
[	23128568	1173	1174	O
P	23128568	1174	1175	O
=	23128568	1176	1177	O
.03	23128568	1178	1181	O
]	23128568	1181	1182	O
)	23128568	1182	1183	O
.	23128568	1183	1184	O

Patient-provider	23128568	1185	1201	B-Outcome
communication	23128568	1202	1215	I-Outcome
in	23128568	1216	1218	O
the	23128568	1219	1222	O
intervention	23128568	1223	1235	O
group	23128568	1236	1241	O
was	23128568	1242	1245	O
characterized	23128568	1246	1259	O
as	23128568	1260	1262	O
being	23128568	1263	1268	O
more	23128568	1269	1273	O
interested	23128568	1274	1284	O
,	23128568	1284	1285	O
friendly	23128568	1286	1294	O
,	23128568	1294	1295	O
responsive	23128568	1296	1306	O
,	23128568	1306	1307	O
interactive	23128568	1308	1319	O
,	23128568	1319	1320	O
and	23128568	1321	1324	O
respectful	23128568	1325	1335	O
(	23128568	1336	1337	O
P	23128568	1337	1338	O
=	23128568	1339	1340	O
.02	23128568	1341	1344	O
)	23128568	1344	1345	O
and	23128568	1346	1349	O
less	23128568	1350	1354	O
depressed	23128568	1355	1364	O
and	23128568	1365	1368	O
distressed	23128568	1369	1379	O
(	23128568	1380	1381	O
P	23128568	1381	1382	O
=	23128568	1383	1384	O
.03	23128568	1385	1388	O
)	23128568	1388	1389	O
.	23128568	1389	1390	O

Patient	23128568	1391	1398	O
questionnaires	23128568	1399	1413	O
did	23128568	1414	1417	O
not	23128568	1418	1421	O
detect	23128568	1422	1428	O
differences	23128568	1429	1440	O
in	23128568	1441	1443	O
visit	23128568	1444	1449	B-Outcome
satisfaction	23128568	1450	1462	I-Outcome
,	23128568	1462	1463	O
trust	23128568	1464	1469	B-Outcome
,	23128568	1469	1470	O
stress	23128568	1471	1477	B-Outcome
,	23128568	1477	1478	O
or	23128568	1479	1481	O
mood	23128568	1482	1486	B-Outcome
.	23128568	1486	1487	O

Mean	23128568	1488	1492	B-Outcome
visit	23128568	1493	1498	I-Outcome
duration	23128568	1499	1507	I-Outcome
did	23128568	1508	1511	O
not	23128568	1512	1515	O
differ	23128568	1516	1522	O
significantly	23128568	1523	1536	O
between	23128568	1537	1544	O
the	23128568	1545	1548	O
groups	23128568	1549	1555	O
(	23128568	1556	1557	O
19.2	23128568	1557	1561	O
minutes	23128568	1562	1569	O
in	23128568	1570	1572	O
the	23128568	1573	1576	O
control	23128568	1577	1584	O
group	23128568	1585	1590	O
vs	23128568	1591	1593	O
20.5	23128568	1594	1598	O
minutes	23128568	1599	1606	O
in	23128568	1607	1609	O
the	23128568	1610	1613	O
intervention	23128568	1614	1626	O
group	23128568	1627	1632	O
[	23128568	1633	1634	O
P	23128568	1634	1635	O
=	23128568	1636	1637	O
.29	23128568	1638	1641	O
]	23128568	1641	1642	O
)	23128568	1642	1643	O
.	23128568	1643	1644	O

CONCLUSIONS	23128568	1646	1657	O
:	23128568	1658	1659	O
A	23128568	1660	1661	O
values-affirmation	23128568	1662	1680	O
exercise	23128568	1681	1689	O
improves	23128568	1690	1698	O
aspects	23128568	1699	1706	O
of	23128568	1707	1709	O
patient-provider	23128568	1710	1726	B-Outcome
communication	23128568	1727	1740	I-Outcome
in	23128568	1741	1743	O
race-discordant	23128568	1744	1759	O
primary	23128568	1760	1767	O
care	23128568	1768	1772	O
visits	23128568	1773	1779	O
.	23128568	1779	1780	O

The	23128568	1781	1784	O
clinical	23128568	1785	1793	O
impact	23128568	1794	1800	O
of	23128568	1801	1803	O
the	23128568	1804	1807	O
intervention	23128568	1808	1820	O
must	23128568	1821	1825	O
be	23128568	1826	1828	O
defined	23128568	1829	1836	O
before	23128568	1837	1843	O
widespread	23128568	1844	1854	O
implementation	23128568	1855	1869	O
can	23128568	1870	1873	O
be	23128568	1874	1876	O
recommended	23128568	1877	1888	O
.	23128568	1888	1889	O


Accuracy	23303244	0	8	O
of	23303244	9	11	O
noninvasive	23303244	12	23	O
haemoglobin	23303244	24	35	O
measurement	23303244	36	47	O
by	23303244	48	50	O
pulse	23303244	51	56	O
oximetry	23303244	57	65	O
depends	23303244	66	73	O
on	23303244	74	76	O
the	23303244	77	80	O
type	23303244	81	85	O
of	23303244	86	88	O
infusion	23303244	89	97	O
fluid	23303244	98	103	O
.	23303244	103	104	O

CONTEXT	23303244	106	113	O
:	23303244	114	115	O
Measurement	23303244	116	127	O
of	23303244	128	130	O
blood	23303244	131	136	O
haemoglobin	23303244	137	148	O
concentration	23303244	149	162	O
by	23303244	163	165	O
pulse	23303244	166	171	O
oximetry	23303244	172	180	O
could	23303244	181	186	O
be	23303244	187	189	O
of	23303244	190	192	O
value	23303244	193	198	O
in	23303244	199	201	O
determining	23303244	202	213	O
when	23303244	214	218	O
erythrocytes	23303244	219	231	O
should	23303244	232	238	O
be	23303244	239	241	O
transfused	23303244	242	252	O
during	23303244	253	259	O
surgery	23303244	260	267	O
,	23303244	267	268	O
but	23303244	269	272	O
the	23303244	273	276	O
effect	23303244	277	283	O
of	23303244	284	286	O
infusion	23303244	287	295	O
fluids	23303244	296	302	O
on	23303244	303	305	O
the	23303244	306	309	O
results	23303244	310	317	O
is	23303244	318	320	O
unclear	23303244	321	328	O
.	23303244	328	329	O

OBJECTIVE	23303244	331	340	O
:	23303244	341	342	O
To	23303244	343	345	O
study	23303244	346	351	O
the	23303244	352	355	O
effect	23303244	356	362	O
of	23303244	363	365	O
crystalloid	23303244	366	377	O
and	23303244	378	381	O
colloid	23303244	382	389	O
fluid	23303244	390	395	O
on	23303244	396	398	O
the	23303244	399	402	O
accuracy	23303244	403	411	O
(	23303244	412	413	O
bias	23303244	413	417	O
)	23303244	417	418	O
and	23303244	419	422	O
precision	23303244	423	432	O
of	23303244	433	435	O
pulse	23303244	436	441	O
oximetry	23303244	442	450	O
haemoglobin	23303244	451	462	O
estimation	23303244	463	473	O
to	23303244	474	476	O
indicate	23303244	477	485	O
the	23303244	486	489	O
venous	23303244	490	496	O
haemoglobin	23303244	497	508	O
concentration	23303244	509	522	O
in	23303244	523	525	O
volunteers	23303244	526	536	O
.	23303244	536	537	O

DESIGN	23303244	539	545	O
:	23303244	546	547	O
Open	23303244	548	552	O
interventional	23303244	553	567	O
crossover	23303244	568	577	O
study	23303244	578	583	O
.	23303244	583	584	O

SETTING	23303244	586	593	O
:	23303244	594	595	O
Single	23303244	596	602	O
university	23303244	603	613	O
hospital	23303244	614	622	O
.	23303244	622	623	O

PARTICIPANTS	23303244	625	637	O
:	23303244	638	639	O
Ten	23303244	640	643	O
male	23303244	644	648	O
volunteers	23303244	649	659	O
aged	23303244	660	664	O
18	23303244	665	667	O
-	23303244	667	668	O
28	23303244	668	670	O
(	23303244	671	672	O
mean	23303244	672	676	O
22	23303244	677	679	O
)	23303244	679	680	O
years	23303244	681	686	O
.	23303244	686	687	O

INTERVENTIONS	23303244	689	702	O
:	23303244	703	704	O
Each	23303244	705	709	O
volunteer	23303244	710	719	O
underwent	23303244	720	729	O
three	23303244	730	735	O
infusion	23303244	736	744	O
experiments	23303244	745	756	O
on	23303244	757	759	O
separate	23303244	760	768	O
days	23303244	769	773	O
and	23303244	774	777	O
in	23303244	778	780	O
random	23303244	781	787	O
order	23303244	788	793	O
.	23303244	793	794	O

The	23303244	795	798	O
infusions	23303244	799	808	O
were	23303244	809	813	O
Ringer	23303244	814	820	O
's	23303244	820	822	O
acetate	23303244	823	830	O
(	23303244	831	832	O
20	23303244	832	834	O
ml	23303244	835	837	O
kg	23303244	838	840	O
)	23303244	840	841	O
,	23303244	841	842	O
hydroxyethyl	23303244	843	855	O
starch	23303244	856	862	O
130/0.4	23303244	863	870	O
(	23303244	871	872	O
10	23303244	872	874	O
ml	23303244	875	877	O
kg	23303244	878	880	O
)	23303244	880	881	O
and	23303244	882	885	O
a	23303244	886	887	O
combination	23303244	888	899	O
of	23303244	900	902	O
both	23303244	903	907	O
.	23303244	907	908	O

RESULTS	23303244	910	917	O
:	23303244	918	919	O
At	23303244	920	922	O
the	23303244	923	926	O
end	23303244	927	930	O
of	23303244	931	933	O
the	23303244	934	937	O
infusions	23303244	938	947	O
of	23303244	948	950	O
Ringer	23303244	951	957	O
's	23303244	957	959	O
acetate	23303244	960	967	O
,	23303244	967	968	O
pulse	23303244	969	974	B-Outcome
oximetry	23303244	975	983	I-Outcome
haemoglobin	23303244	984	995	I-Outcome
concentration	23303244	996	1009	I-Outcome
had	23303244	1010	1013	O
decreased	23303244	1014	1023	O
more	23303244	1024	1028	O
than	23303244	1029	1033	O
the	23303244	1034	1037	O
true	23303244	1038	1042	O
haemoglobin	23303244	1043	1054	B-Outcome
concentration	23303244	1055	1068	I-Outcome
(	23303244	1069	1070	O
15	23303244	1070	1072	O
vs.	23303244	1073	1076	O
8	23303244	1077	1078	O
%	23303244	1078	1079	O
;	23303244	1079	1080	O
P	23303244	1081	1082	O
<	23303244	1083	1084	O
0.005	23303244	1085	1090	O
;	23303244	1090	1091	O
n	23303244	1092	1093	O
=	23303244	1094	1095	O
10	23303244	1096	1098	O
)	23303244	1098	1099	O
whereas	23303244	1100	1107	O
starch	23303244	1108	1114	O
solution	23303244	1115	1123	O
decreased	23303244	1124	1133	O
pulse	23303244	1134	1139	B-Outcome
oximetry	23303244	1140	1148	I-Outcome
haemoglobin	23303244	1149	1160	I-Outcome
concentration	23303244	1161	1174	I-Outcome
less	23303244	1175	1179	O
than	23303244	1180	1184	O
true	23303244	1185	1189	O
haemoglobin	23303244	1190	1201	B-Outcome
concentration	23303244	1202	1215	I-Outcome
(	23303244	1216	1217	O
7	23303244	1217	1218	O
vs.	23303244	1219	1222	O
11	23303244	1223	1225	O
%	23303244	1225	1226	O
;	23303244	1226	1227	O
P	23303244	1228	1229	O
<	23303244	1230	1231	O
0.02	23303244	1232	1236	O
;	23303244	1236	1237	O
n	23303244	1238	1239	O
=	23303244	1240	1241	O
20	23303244	1242	1244	O
)	23303244	1244	1245	O
.	23303244	1245	1246	O

The	23303244	1247	1250	O
same	23303244	1251	1255	O
differences	23303244	1256	1267	O
were	23303244	1268	1272	O
seen	23303244	1273	1277	O
when	23303244	1278	1282	O
the	23303244	1283	1286	O
fluids	23303244	1287	1293	O
were	23303244	1294	1298	O
infused	23303244	1299	1306	O
separately	23303244	1307	1317	O
and	23303244	1318	1321	O
when	23303244	1322	1326	O
they	23303244	1327	1331	O
were	23303244	1332	1336	O
combined	23303244	1337	1345	O
.	23303244	1345	1346	O

The	23303244	1347	1350	O
overall	23303244	1351	1358	O
difference	23303244	1359	1369	O
between	23303244	1370	1377	O
all	23303244	1378	1381	O
956	23303244	1382	1385	O
pairs	23303244	1386	1391	O
of	23303244	1392	1394	O
pulse	23303244	1395	1400	B-Outcome
oximetry	23303244	1401	1409	I-Outcome
haemoglobin	23303244	1410	1421	I-Outcome
concentration	23303244	1422	1435	I-Outcome
and	23303244	1436	1439	O
true	23303244	1440	1444	O
haemoglobin	23303244	1445	1456	B-Outcome
concentrations	23303244	1457	1471	I-Outcome
(	23303244	1472	1473	O
the	23303244	1473	1476	O
bias	23303244	1477	1481	O
)	23303244	1481	1482	O
averaged	23303244	1483	1491	O
only	23303244	1492	1496	O
-0.7	23303244	1497	1501	O
g	23303244	1502	1503	O
l	23303244	1504	1505	O
whereas	23303244	1506	1513	O
the	23303244	1514	1517	O
95	23303244	1518	1520	O
%	23303244	1520	1521	O
prediction	23303244	1522	1532	O
interval	23303244	1533	1541	O
was	23303244	1542	1545	O
wide	23303244	1546	1550	O
,	23303244	1550	1551	O
ranging	23303244	1552	1559	O
from	23303244	1560	1564	O
-24.9	23303244	1565	1570	O
to	23303244	1571	1573	O
23.7	23303244	1574	1578	O
g	23303244	1579	1580	O
l.	23303244	1581	1583	O
In	23303244	1584	1586	O
addition	23303244	1587	1595	O
to	23303244	1596	1598	O
the	23303244	1599	1602	O
choice	23303244	1603	1609	O
of	23303244	1610	1612	O
infusion	23303244	1613	1621	O
fluid	23303244	1622	1627	O
,	23303244	1627	1628	O
the	23303244	1629	1632	O
bias	23303244	1633	1637	O
was	23303244	1638	1641	O
strongly	23303244	1642	1650	O
dependent	23303244	1651	1660	O
on	23303244	1661	1663	O
the	23303244	1664	1667	O
volunteer	23303244	1668	1677	O
(	23303244	1678	1679	O
each	23303244	1679	1683	O
factor	23303244	1684	1690	O
,	23303244	1690	1691	O
P	23303244	1692	1693	O
<	23303244	1694	1695	O
0.001	23303244	1696	1701	O
)	23303244	1701	1702	O
.	23303244	1702	1703	O

CONCLUSION	23303244	1705	1715	O
:	23303244	1716	1717	O
The	23303244	1718	1721	O
bias	23303244	1722	1726	O
of	23303244	1727	1729	O
measuring	23303244	1730	1739	O
haemoglobin	23303244	1740	1751	B-Outcome
concentration	23303244	1752	1765	I-Outcome
by	23303244	1766	1768	I-Outcome
pulse	23303244	1769	1774	I-Outcome
oximetry	23303244	1775	1783	I-Outcome
is	23303244	1784	1786	O
dependent	23303244	1787	1796	O
on	23303244	1797	1799	O
whether	23303244	1800	1807	O
a	23303244	1808	1809	O
crystalloid	23303244	1810	1821	O
or	23303244	1822	1824	O
a	23303244	1825	1826	O
colloid	23303244	1827	1834	O
fluid	23303244	1835	1840	O
is	23303244	1841	1843	O
infused	23303244	1844	1851	O
.	23303244	1851	1852	O

TRIAL	23303244	1854	1859	O
REGISTRATION	23303244	1860	1872	O
:	23303244	1873	1874	O
ClinicalTrials	23303244	1875	1889	O
identifier	23303244	1890	1900	O
:	23303244	1900	1901	O
NCT01195025	23303244	1902	1913	O
.	23303244	1913	1914	O


Effects	23343686	0	7	O
of	23343686	8	10	O
coronary	23343686	11	19	O
sinus	23343686	20	25	O
occlusion	23343686	26	35	O
on	23343686	36	38	O
myocardial	23343686	39	49	O
ischaemia	23343686	50	59	O
in	23343686	60	62	O
humans	23343686	63	69	O
:	23343686	69	70	O
role	23343686	71	75	O
of	23343686	76	78	O
coronary	23343686	79	87	O
collateral	23343686	88	98	O
function	23343686	99	107	O
.	23343686	107	108	O

OBJECTIVE	23343686	110	119	O
:	23343686	120	121	O
This	23343686	122	126	O
study	23343686	127	132	O
tested	23343686	133	139	O
the	23343686	140	143	O
hypotheses	23343686	144	154	O
that	23343686	155	159	O
intermittent	23343686	160	172	O
coronary	23343686	173	181	O
sinus	23343686	182	187	O
occlusion	23343686	188	197	O
(	23343686	198	199	O
iCSO	23343686	199	203	O
)	23343686	203	204	O
reduces	23343686	205	212	O
myocardial	23343686	213	223	O
ischaemia	23343686	224	233	O
,	23343686	233	234	O
and	23343686	235	238	O
that	23343686	239	243	O
the	23343686	244	247	O
amount	23343686	248	254	O
of	23343686	255	257	O
ischaemia	23343686	258	267	O
reduction	23343686	268	277	O
is	23343686	278	280	O
related	23343686	281	288	O
to	23343686	289	291	O
coronary	23343686	292	300	O
collateral	23343686	301	311	O
function	23343686	312	320	O
.	23343686	320	321	O

DESIGN	23343686	323	329	O
:	23343686	330	331	O
Prospective	23343686	332	343	O
case-control	23343686	344	356	O
study	23343686	357	362	O
with	23343686	363	367	O
intraindividual	23343686	368	383	O
comparison	23343686	384	394	O
of	23343686	395	397	O
myocardial	23343686	398	408	O
ischaemia	23343686	409	418	O
during	23343686	419	425	O
two	23343686	426	429	O
2-min	23343686	430	435	O
coronary	23343686	436	444	O
artery	23343686	445	451	O
balloon	23343686	452	459	O
occlusions	23343686	460	470	O
with	23343686	471	475	O
and	23343686	476	479	O
without	23343686	480	487	O
simultaneous	23343686	488	500	O
iCSO	23343686	501	505	O
by	23343686	506	508	O
a	23343686	509	510	O
balloon-tipped	23343686	511	525	O
catheter	23343686	526	534	O
.	23343686	534	535	O

SETTING	23343686	537	544	O
:	23343686	545	546	O
University	23343686	547	557	O
Hospital	23343686	558	566	O
.	23343686	566	567	O

PATIENTS	23343686	569	577	O
:	23343686	578	579	O
35	23343686	580	582	O
patients	23343686	583	591	O
with	23343686	592	596	O
chronic	23343686	597	604	O
stable	23343686	605	611	O
coronary	23343686	612	620	O
artery	23343686	621	627	O
disease	23343686	628	635	O
.	23343686	635	636	O

INTERVENTION	23343686	638	650	O
:	23343686	651	652	O
2-min	23343686	653	658	O
iCSO	23343686	659	663	O
.	23343686	663	664	O

MAIN	23343686	666	670	O
OUTCOME	23343686	671	678	O
MEASURES	23343686	679	687	O
:	23343686	688	689	O
Myocardial	23343686	690	700	O
ischaemia	23343686	701	710	O
as	23343686	711	713	O
assessed	23343686	714	722	O
by	23343686	723	725	O
intracoronary	23343686	726	739	O
(	23343686	740	741	O
i.c	23343686	741	744	O
.	23343686	744	745	O
)	23343686	745	746	O
ECG	23343686	747	750	O
ST	23343686	751	753	O
shift	23343686	754	759	O
at	23343686	760	762	O
2	23343686	763	764	O
min	23343686	765	768	O
of	23343686	769	771	O
coronary	23343686	772	780	O
artery	23343686	781	787	O
balloon	23343686	788	795	O
occlusion	23343686	796	805	O
.	23343686	805	806	O

Collateral	23343686	807	817	O
flow	23343686	818	822	O
index	23343686	823	828	O
(	23343686	829	830	O
CFI	23343686	830	833	O
)	23343686	833	834	O
without	23343686	835	842	O
iCSO	23343686	843	847	O
,	23343686	847	848	O
that	23343686	849	853	O
is	23343686	854	856	O
,	23343686	856	857	O
the	23343686	858	861	O
ratio	23343686	862	867	O
between	23343686	868	875	O
mean	23343686	876	880	O
distal	23343686	881	887	O
coronary	23343686	888	896	O
occlusive	23343686	897	906	O
(	23343686	907	908	O
Poccl	23343686	908	913	O
)	23343686	913	914	O
and	23343686	915	918	O
mean	23343686	919	923	O
aortic	23343686	924	930	O
pressure	23343686	931	939	O
(	23343686	940	941	O
Pao	23343686	941	944	O
)	23343686	944	945	O
both	23343686	946	950	O
minus	23343686	951	956	O
central	23343686	957	964	O
venous	23343686	965	971	O
pressure	23343686	972	980	O
.	23343686	980	981	O

RESULTS	23343686	983	990	O
:	23343686	991	992	O
I.c	23343686	993	996	B-Outcome
.	23343686	996	997	I-Outcome

ECG	23343686	998	1001	B-Outcome
ST	23343686	1002	1004	I-Outcome
segment	23343686	1005	1012	I-Outcome
shift	23343686	1013	1018	I-Outcome
(	23343686	1019	1020	O
elevation	23343686	1020	1029	O
in	23343686	1030	1032	O
all	23343686	1033	1036	O
)	23343686	1036	1037	O
at	23343686	1038	1040	O
the	23343686	1041	1044	O
end	23343686	1045	1048	O
of	23343686	1049	1051	O
the	23343686	1052	1055	O
procedure	23343686	1056	1065	O
with	23343686	1066	1070	O
iCSO	23343686	1071	1075	O
versus	23343686	1076	1082	O
without	23343686	1083	1090	O
iCSO	23343686	1091	1095	O
was	23343686	1096	1099	O
1.33±1.25	23343686	1100	1109	O
mV	23343686	1110	1112	O
versus	23343686	1113	1119	O
1.85±1.45	23343686	1120	1129	O
mV	23343686	1130	1132	O
,	23343686	1132	1133	O
p<0.0001	23343686	1134	1142	O
.	23343686	1142	1143	O

Regression	23343686	1144	1154	O
analysis	23343686	1155	1163	O
showed	23343686	1164	1170	O
that	23343686	1171	1175	O
the	23343686	1176	1179	O
degree	23343686	1180	1186	O
of	23343686	1187	1189	O
i.c	23343686	1190	1193	O
.	23343686	1193	1194	O

ECG	23343686	1195	1198	B-Outcome
ST	23343686	1199	1201	I-Outcome
shift	23343686	1202	1207	I-Outcome
reduction	23343686	1208	1217	O
during	23343686	1218	1224	O
iCSO	23343686	1225	1229	O
was	23343686	1230	1233	O
related	23343686	1234	1241	O
to	23343686	1242	1244	O
CFI	23343686	1245	1248	B-Outcome
,	23343686	1248	1249	O
best	23343686	1250	1254	O
fitting	23343686	1255	1262	O
a	23343686	1263	1264	O
Lorentzian	23343686	1265	1275	O
function	23343686	1276	1284	O
(	23343686	1285	1286	O
r(2)=0.61	23343686	1286	1295	O
)	23343686	1295	1296	O
.	23343686	1296	1297	O

Ischaemia	23343686	1298	1307	B-Outcome
reduction	23343686	1308	1317	O
with	23343686	1318	1322	O
iCSO	23343686	1323	1327	O
was	23343686	1328	1331	O
greatest	23343686	1332	1340	O
at	23343686	1341	1343	O
a	23343686	1344	1345	O
CFI	23343686	1346	1349	B-Outcome
of	23343686	1350	1352	O
0.05	23343686	1353	1357	O
-	23343686	1357	1358	O
0.20	23343686	1358	1362	O
,	23343686	1362	1363	O
whereas	23343686	1364	1371	O
in	23343686	1372	1374	O
the	23343686	1375	1378	O
low	23343686	1379	1382	O
and	23343686	1383	1386	O
high	23343686	1387	1391	O
CFI	23343686	1392	1395	B-Outcome
range	23343686	1396	1401	O
the	23343686	1402	1405	O
effect	23343686	1406	1412	O
of	23343686	1413	1415	O
iCSO	23343686	1416	1420	O
was	23343686	1421	1424	O
absent	23343686	1425	1431	O
.	23343686	1431	1432	O

CONCLUSIONS	23343686	1434	1445	O
:	23343686	1446	1447	O
ICSO	23343686	1448	1452	O
reduces	23343686	1453	1460	O
myocardial	23343686	1461	1471	B-Outcome
ischaemia	23343686	1472	1481	I-Outcome
in	23343686	1482	1484	O
patients	23343686	1485	1493	O
with	23343686	1494	1498	O
chronic	23343686	1499	1506	O
coronary	23343686	1507	1515	O
artery	23343686	1516	1522	O
disease	23343686	1523	1530	O
.	23343686	1530	1531	O

Ischaemia	23343686	1532	1541	B-Outcome
reduction	23343686	1542	1551	O
by	23343686	1552	1554	O
iCSO	23343686	1555	1559	O
depends	23343686	1560	1567	O
on	23343686	1568	1570	O
coronary	23343686	1571	1579	O
collateral	23343686	1580	1590	O
function	23343686	1591	1599	O
.	23343686	1599	1600	O

A	23343686	1601	1602	O
minimal	23343686	1603	1610	O
degree	23343686	1611	1617	O
of	23343686	1618	1620	O
collateral	23343686	1621	1631	O
function	23343686	1632	1640	O
is	23343686	1641	1643	O
necessary	23343686	1644	1653	O
to	23343686	1654	1656	O
render	23343686	1657	1663	O
iCSO	23343686	1664	1668	O
effective	23343686	1669	1678	O
.	23343686	1678	1679	O

ICSO	23343686	1680	1684	O
can	23343686	1685	1688	O
not	23343686	1688	1691	O
manifest	23343686	1692	1700	O
an	23343686	1701	1703	O
effect	23343686	1704	1710	O
when	23343686	1711	1715	O
collateral	23343686	1716	1726	O
function	23343686	1727	1735	O
prevents	23343686	1736	1744	O
ischaemia	23343686	1745	1754	O
in	23343686	1755	1757	O
the	23343686	1758	1761	O
first	23343686	1762	1767	O
place	23343686	1768	1773	O
.	23343686	1773	1774	O


Family	23410851	0	6	O
economic	23410851	7	15	O
empowerment	23410851	16	27	O
and	23410851	28	31	O
mental	23410851	32	38	O
health	23410851	39	45	O
among	23410851	46	51	O
AIDS-affected	23410851	52	65	O
children	23410851	66	74	O
living	23410851	75	81	O
in	23410851	82	84	O
AIDS-impacted	23410851	85	98	O
communities	23410851	99	110	O
:	23410851	110	111	O
evidence	23410851	112	120	O
from	23410851	121	125	O
a	23410851	126	127	O
randomised	23410851	128	138	O
evaluation	23410851	139	149	O
in	23410851	150	152	O
southwestern	23410851	153	165	O
Uganda	23410851	166	172	O
.	23410851	172	173	O

OBJECTIVE	23410851	175	184	O
:	23410851	185	186	O
The	23410851	187	190	O
authors	23410851	191	198	O
examine	23410851	199	206	O
whether	23410851	207	214	O
an	23410851	215	217	O
innovative	23410851	218	228	O
family	23410851	229	235	O
economic	23410851	236	244	O
empowerment	23410851	245	256	O
intervention	23410851	257	269	O
addresses	23410851	270	279	O
mental	23410851	280	286	O
health	23410851	287	293	O
functioning	23410851	294	305	O
of	23410851	306	308	O
AIDS-affected	23410851	309	322	O
children	23410851	323	331	O
in	23410851	332	334	O
communities	23410851	335	346	O
heavily	23410851	347	354	O
impacted	23410851	355	363	O
by	23410851	364	366	O
HIV/AIDS	23410851	367	375	O
in	23410851	376	378	O
Uganda	23410851	379	385	O
.	23410851	385	386	O

METHODS	23410851	388	395	O
:	23410851	396	397	O
A	23410851	398	399	O
cluster	23410851	400	407	O
randomised	23410851	408	418	O
controlled	23410851	419	429	O
trial	23410851	430	435	O
consisting	23410851	436	446	O
of	23410851	447	449	O
two	23410851	450	453	O
study	23410851	454	459	O
arms	23410851	460	464	O
,	23410851	464	465	O
a	23410851	466	467	O
treatment	23410851	468	477	O
condition	23410851	478	487	O
(	23410851	488	489	O
n=179	23410851	489	494	O
)	23410851	494	495	O
and	23410851	496	499	O
a	23410851	500	501	O
control	23410851	502	509	O
condition	23410851	510	519	O
(	23410851	520	521	O
n=118	23410851	521	526	O
)	23410851	526	527	O
,	23410851	527	528	O
was	23410851	529	532	O
used	23410851	533	537	O
to	23410851	538	540	O
examine	23410851	541	548	O
the	23410851	549	552	O
impact	23410851	553	559	O
of	23410851	560	562	O
the	23410851	563	566	O
family	23410851	567	573	O
economic	23410851	574	582	O
empowerment	23410851	583	594	O
intervention	23410851	595	607	O
on	23410851	608	610	O
children	23410851	611	619	O
's	23410851	619	621	O
levels	23410851	622	628	O
of	23410851	629	631	O
hopelessness	23410851	632	644	O
and	23410851	645	648	O
depression	23410851	649	659	O
.	23410851	659	660	O

The	23410851	661	664	O
intervention	23410851	665	677	O
comprised	23410851	678	687	O
matched	23410851	688	695	O
children	23410851	696	704	O
savings	23410851	705	712	O
accounts	23410851	713	721	O
,	23410851	721	722	O
financial	23410851	723	732	O
management	23410851	733	743	O
workshops	23410851	744	753	O
and	23410851	754	757	O
mentorship	23410851	758	768	O
.	23410851	768	769	O

Data	23410851	770	774	O
were	23410851	775	779	O
collected	23410851	780	789	O
at	23410851	790	792	O
baseline	23410851	793	801	O
and	23410851	802	805	O
12	23410851	806	808	O
months	23410851	809	815	O
post-intervention	23410851	816	833	O
.	23410851	833	834	O

RESULTS	23410851	836	843	O
:	23410851	844	845	O
Using	23410851	846	851	O
multivariate	23410851	852	864	O
analysis	23410851	865	873	O
with	23410851	874	878	O
several	23410851	879	886	O
socioeconomic	23410851	887	900	O
controls	23410851	901	909	O
,	23410851	909	910	O
the	23410851	911	914	O
authors	23410851	915	922	O
find	23410851	923	927	O
that	23410851	928	932	O
children	23410851	933	941	O
in	23410851	942	944	O
the	23410851	945	948	O
treatment	23410851	949	958	O
condition	23410851	959	968	O
(	23410851	969	970	O
receiving	23410851	970	979	O
the	23410851	980	983	O
intervention	23410851	984	996	O
)	23410851	996	997	O
report	23410851	998	1004	O
significant	23410851	1005	1016	O
improvement	23410851	1017	1028	O
in	23410851	1029	1031	O
their	23410851	1032	1037	O
mental	23410851	1038	1044	B-Outcome
health	23410851	1045	1051	I-Outcome
functioning	23410851	1052	1063	I-Outcome
.	23410851	1063	1064	O

Specifically	23410851	1065	1077	O
,	23410851	1077	1078	O
the	23410851	1079	1082	O
intervention	23410851	1083	1095	O
reduces	23410851	1096	1103	O
hopelessness	23410851	1104	1116	B-Outcome
and	23410851	1117	1120	O
depression	23410851	1121	1131	B-Outcome
levels	23410851	1132	1138	I-Outcome
.	23410851	1138	1139	O

On	23410851	1140	1142	O
the	23410851	1143	1146	O
other	23410851	1147	1152	O
hand	23410851	1153	1157	O
,	23410851	1157	1158	O
children	23410851	1159	1167	O
in	23410851	1168	1170	O
the	23410851	1171	1174	O
control	23410851	1175	1182	O
condition	23410851	1183	1192	O
(	23410851	1193	1194	O
not	23410851	1194	1197	O
receiving	23410851	1198	1207	O
the	23410851	1208	1211	O
intervention	23410851	1212	1224	O
)	23410851	1224	1225	O
report	23410851	1226	1232	O
no	23410851	1233	1235	O
changes	23410851	1236	1243	O
on	23410851	1244	1246	O
both	23410851	1247	1251	O
measures	23410851	1252	1260	O
.	23410851	1260	1261	O

CONCLUSIONS	23410851	1263	1274	O
:	23410851	1275	1276	O
The	23410851	1277	1280	O
findings	23410851	1281	1289	O
indicate	23410851	1290	1298	O
that	23410851	1299	1303	O
children	23410851	1304	1312	O
with	23410851	1313	1317	O
poor	23410851	1318	1322	O
mental	23410851	1323	1329	O
health	23410851	1330	1336	O
functioning	23410851	1337	1348	O
living	23410851	1349	1355	O
in	23410851	1356	1358	O
communities	23410851	1359	1370	O
affected	23410851	1371	1379	O
by	23410851	1380	1382	O
HIV/AIDS	23410851	1383	1391	O
may	23410851	1392	1395	O
benefit	23410851	1396	1403	O
from	23410851	1404	1408	O
innovative	23410851	1409	1419	O
family	23410851	1420	1426	O
economic	23410851	1427	1435	O
empowerment	23410851	1436	1447	O
interventions	23410851	1448	1461	O
.	23410851	1461	1462	O

As	23410851	1463	1465	O
measures	23410851	1466	1474	O
of	23410851	1475	1477	O
mental	23410851	1478	1484	B-Outcome
health	23410851	1485	1491	I-Outcome
functioning	23410851	1492	1503	I-Outcome
,	23410851	1503	1504	O
both	23410851	1505	1509	O
hopelessness	23410851	1510	1522	B-Outcome
and	23410851	1523	1526	O
depression	23410851	1527	1537	B-Outcome
have	23410851	1538	1542	O
long-term	23410851	1543	1552	O
negative	23410851	1553	1561	O
psychosocial	23410851	1562	1574	O
and	23410851	1575	1578	O
developmental	23410851	1579	1592	O
impacts	23410851	1593	1600	O
on	23410851	1601	1603	O
children	23410851	1604	1612	O
.	23410851	1612	1613	O

These	23410851	1614	1619	O
findings	23410851	1620	1628	O
have	23410851	1629	1633	O
implications	23410851	1634	1646	O
for	23410851	1647	1650	O
public	23410851	1651	1657	O
health	23410851	1658	1664	O
programmes	23410851	1665	1675	O
intended	23410851	1676	1684	O
for	23410851	1685	1688	O
long-term	23410851	1689	1698	O
care	23410851	1699	1703	O
and	23410851	1704	1707	O
support	23410851	1708	1715	O
of	23410851	1716	1718	O
children	23410851	1719	1727	O
living	23410851	1728	1734	O
in	23410851	1735	1737	O
resource	23410851	1738	1746	O
poor	23410851	1747	1751	O
AIDS-impacted	23410851	1752	1765	O
communities	23410851	1766	1777	O
.	23410851	1777	1778	O


Effect	23549581	0	6	O
of	23549581	7	9	O
duloxetine	23549581	10	20	O
on	23549581	21	23	O
pain	23549581	24	28	O
,	23549581	28	29	O
function	23549581	30	38	O
,	23549581	38	39	O
and	23549581	40	43	O
quality	23549581	44	51	O
of	23549581	52	54	O
life	23549581	55	59	O
among	23549581	60	65	O
patients	23549581	66	74	O
with	23549581	75	79	O
chemotherapy-induced	23549581	80	100	O
painful	23549581	101	108	O
peripheral	23549581	109	119	O
neuropathy	23549581	120	130	O
:	23549581	130	131	O
a	23549581	132	133	O
randomized	23549581	134	144	O
clinical	23549581	145	153	O
trial	23549581	154	159	O
.	23549581	159	160	O

IMPORTANCE	23549581	162	172	O
:	23549581	173	174	O
There	23549581	175	180	O
are	23549581	181	184	O
no	23549581	185	187	O
known	23549581	188	193	O
effective	23549581	194	203	O
treatments	23549581	204	214	O
for	23549581	215	218	O
painful	23549581	219	226	O
chemotherapy-induced	23549581	227	247	O
peripheral	23549581	248	258	O
neuropathy	23549581	259	269	O
.	23549581	269	270	O

OBJECTIVE	23549581	272	281	O
:	23549581	282	283	O
To	23549581	284	286	O
determine	23549581	287	296	O
the	23549581	297	300	O
effect	23549581	301	307	O
of	23549581	308	310	O
duloxetine	23549581	311	321	O
,	23549581	321	322	O
60	23549581	323	325	O
mg	23549581	326	328	O
daily	23549581	329	334	O
,	23549581	334	335	O
on	23549581	336	338	O
average	23549581	339	346	O
pain	23549581	347	351	O
severity	23549581	352	360	O
.	23549581	360	361	O

DESIGN	23549581	363	369	O
,	23549581	369	370	O
SETTING	23549581	371	378	O
,	23549581	378	379	O
AND	23549581	380	383	O
PATIENTS	23549581	384	392	O
:	23549581	393	394	O
Randomized	23549581	395	405	O
,	23549581	405	406	O
double-blind	23549581	407	419	O
,	23549581	419	420	O
placebo-controlled	23549581	421	439	O
crossover	23549581	440	449	O
trial	23549581	450	455	O
at	23549581	456	458	O
8	23549581	459	460	O
National	23549581	461	469	O
Cancer	23549581	470	476	O
Institute	23549581	477	486	O
(NCI)-funded	23549581	487	499	O
cooperative	23549581	500	511	O
research	23549581	512	520	O
networks	23549581	521	529	O
that	23549581	530	534	O
enrolled	23549581	535	543	O
231	23549581	544	547	O
patients	23549581	548	556	O
who	23549581	557	560	O
were	23549581	561	565	O
25	23549581	566	568	O
years	23549581	569	574	O
or	23549581	575	577	O
older	23549581	578	583	O
being	23549581	584	589	O
treated	23549581	590	597	O
at	23549581	598	600	O
community	23549581	601	610	O
and	23549581	611	614	O
academic	23549581	615	623	O
settings	23549581	624	632	O
between	23549581	633	640	O
April	23549581	641	646	O
2008	23549581	647	651	O
and	23549581	652	655	O
March	23549581	656	661	O
2011	23549581	662	666	O
.	23549581	666	667	O

Study	23549581	668	673	O
follow-up	23549581	674	683	O
was	23549581	684	687	O
completed	23549581	688	697	O
July	23549581	698	702	O
2012	23549581	703	707	O
.	23549581	707	708	O

Stratified	23549581	709	719	O
by	23549581	720	722	O
chemotherapeutic	23549581	723	739	O
drug	23549581	740	744	O
and	23549581	745	748	O
comorbid	23549581	749	757	O
pain	23549581	758	762	O
risk	23549581	763	767	O
,	23549581	767	768	O
patients	23549581	769	777	O
were	23549581	778	782	O
randomized	23549581	783	793	O
to	23549581	794	796	O
receive	23549581	797	804	O
either	23549581	805	811	O
duloxetine	23549581	812	822	O
followed	23549581	823	831	O
by	23549581	832	834	O
placebo	23549581	835	842	O
or	23549581	843	845	O
placebo	23549581	846	853	O
followed	23549581	854	862	O
by	23549581	863	865	O
duloxetine	23549581	866	876	O
.	23549581	876	877	O

Eligibility	23549581	878	889	O
required	23549581	890	898	O
that	23549581	899	903	O
patients	23549581	904	912	O
have	23549581	913	917	O
grade	23549581	918	923	O
1	23549581	924	925	O
or	23549581	926	928	O
higher	23549581	929	935	O
sensory	23549581	936	943	O
neuropathy	23549581	944	954	O
according	23549581	955	964	O
to	23549581	965	967	O
the	23549581	968	971	O
NCI	23549581	972	975	O
Common	23549581	976	982	O
Terminology	23549581	983	994	O
Criteria	23549581	995	1003	O
for	23549581	1004	1007	O
Adverse	23549581	1008	1015	O
Events	23549581	1016	1022	O
and	23549581	1023	1026	O
at	23549581	1027	1029	O
least	23549581	1030	1035	O
4	23549581	1036	1037	O
on	23549581	1038	1040	O
a	23549581	1041	1042	O
scale	23549581	1043	1048	O
of	23549581	1049	1051	O
0	23549581	1052	1053	O
to	23549581	1054	1056	O
10	23549581	1057	1059	O
,	23549581	1059	1060	O
representing	23549581	1061	1073	O
average	23549581	1074	1081	O
chemotherapy-induced	23549581	1082	1102	O
pain	23549581	1103	1107	O
,	23549581	1107	1108	O
after	23549581	1109	1114	O
paclitaxel	23549581	1115	1125	O
,	23549581	1125	1126	O
other	23549581	1127	1132	O
taxane	23549581	1133	1139	O
,	23549581	1139	1140	O
or	23549581	1141	1143	O
oxaliplatin	23549581	1144	1155	O
treatment	23549581	1156	1165	O
.	23549581	1165	1166	O

INTERVENTIONS	23549581	1168	1181	O
:	23549581	1182	1183	O
The	23549581	1184	1187	O
initial	23549581	1188	1195	O
treatment	23549581	1196	1205	O
consisted	23549581	1206	1215	O
of	23549581	1216	1218	O
taking	23549581	1219	1225	O
1	23549581	1226	1227	O
capsule	23549581	1228	1235	O
daily	23549581	1236	1241	O
of	23549581	1242	1244	O
either	23549581	1245	1251	O
30	23549581	1252	1254	O
mg	23549581	1255	1257	O
of	23549581	1258	1260	O
duloxetine	23549581	1261	1271	O
or	23549581	1272	1274	O
placebo	23549581	1275	1282	O
for	23549581	1283	1286	O
the	23549581	1287	1290	O
first	23549581	1291	1296	O
week	23549581	1297	1301	O
and	23549581	1302	1305	O
2	23549581	1306	1307	O
capsules	23549581	1308	1316	O
of	23549581	1317	1319	O
either	23549581	1320	1326	O
30	23549581	1327	1329	O
mg	23549581	1330	1332	O
of	23549581	1333	1335	O
duloxetine	23549581	1336	1346	O
or	23549581	1347	1349	O
placebo	23549581	1350	1357	O
daily	23549581	1358	1363	O
for	23549581	1364	1367	O
4	23549581	1368	1369	O
additional	23549581	1370	1380	O
weeks	23549581	1381	1386	O
.	23549581	1386	1387	O

MAIN	23549581	1389	1393	O
OUTCOME	23549581	1394	1401	O
MEASURES	23549581	1402	1410	O
:	23549581	1411	1412	O
The	23549581	1413	1416	O
primary	23549581	1417	1424	O
hypothesis	23549581	1425	1435	O
was	23549581	1436	1439	O
that	23549581	1440	1444	O
duloxetine	23549581	1445	1455	O
would	23549581	1456	1461	O
be	23549581	1462	1464	O
more	23549581	1465	1469	O
effective	23549581	1470	1479	O
than	23549581	1480	1484	O
placebo	23549581	1485	1492	O
in	23549581	1493	1495	O
decreasing	23549581	1496	1506	O
chemotherapy-induced	23549581	1507	1527	O
peripheral	23549581	1528	1538	O
neuropathic	23549581	1539	1550	O
pain	23549581	1551	1555	O
.	23549581	1555	1556	O

Pain	23549581	1557	1561	O
severity	23549581	1562	1570	O
was	23549581	1571	1574	O
assessed	23549581	1575	1583	O
using	23549581	1584	1589	O
the	23549581	1590	1593	O
Brief	23549581	1594	1599	O
Pain	23549581	1600	1604	O
Inventory-Short	23549581	1605	1620	O
Form	23549581	1621	1625	O
"	23549581	1626	1627	O
average	23549581	1627	1634	O
pain	23549581	1635	1639	O
"	23549581	1639	1640	O
item	23549581	1641	1645	O
with	23549581	1646	1650	O
0	23549581	1651	1652	O
representing	23549581	1653	1665	O
no	23549581	1666	1668	O
pain	23549581	1669	1673	O
and	23549581	1674	1677	O
10	23549581	1678	1680	O
representing	23549581	1681	1693	O
as	23549581	1694	1696	O
bad	23549581	1697	1700	O
as	23549581	1701	1703	O
can	23549581	1704	1707	O
be	23549581	1708	1710	O
imagined	23549581	1711	1719	O
.	23549581	1719	1720	O

RESULTS	23549581	1722	1729	O
:	23549581	1730	1731	O
Individuals	23549581	1732	1743	O
receiving	23549581	1744	1753	O
duloxetine	23549581	1754	1764	O
as	23549581	1765	1767	O
their	23549581	1768	1773	O
initial	23549581	1774	1781	O
5-week	23549581	1782	1788	O
treatment	23549581	1789	1798	O
reported	23549581	1799	1807	O
a	23549581	1808	1809	O
mean	23549581	1810	1814	B-Outcome
decrease	23549581	1815	1823	I-Outcome
in	23549581	1824	1826	I-Outcome
average	23549581	1827	1834	I-Outcome
pain	23549581	1835	1839	I-Outcome
of	23549581	1840	1842	O
1.06	23549581	1843	1847	O
(	23549581	1848	1849	O
95	23549581	1849	1851	O
%	23549581	1851	1852	O
CI	23549581	1853	1855	O
,	23549581	1855	1856	O
0.72	23549581	1857	1861	O
-	23549581	1861	1862	O
1.40	23549581	1862	1866	O
)	23549581	1866	1867	O
vs	23549581	1868	1870	O
0.34	23549581	1871	1875	O
(	23549581	1876	1877	O
95	23549581	1877	1879	O
%	23549581	1879	1880	O
CI	23549581	1881	1883	O
,	23549581	1883	1884	O
0.01	23549581	1885	1889	O
-	23549581	1889	1890	O
0.66	23549581	1890	1894	O
)	23549581	1894	1895	O
among	23549581	1896	1901	O
those	23549581	1902	1907	O
who	23549581	1908	1911	O
received	23549581	1912	1920	O
placebo	23549581	1921	1928	O
(	23549581	1929	1930	O
P	23549581	1930	1931	O
=	23549581	1932	1933	O
.003	23549581	1934	1938	O
;	23549581	1938	1939	O
effect	23549581	1940	1946	O
size	23549581	1947	1951	O
,	23549581	1951	1952	O
0.513	23549581	1953	1958	O
)	23549581	1958	1959	O
.	23549581	1959	1960	O

The	23549581	1961	1964	O
observed	23549581	1965	1973	O
mean	23549581	1974	1978	O
difference	23549581	1979	1989	O
in	23549581	1990	1992	O
the	23549581	1993	1996	O
average	23549581	1997	2004	B-Outcome
pain	23549581	2005	2009	I-Outcome
score	23549581	2010	2015	I-Outcome
between	23549581	2016	2023	O
duloxetine	23549581	2024	2034	O
and	23549581	2035	2038	O
placebo	23549581	2039	2046	O
was	23549581	2047	2050	O
0.73	23549581	2051	2055	O
(	23549581	2056	2057	O
95	23549581	2057	2059	O
%	23549581	2059	2060	O
CI	23549581	2061	2063	O
,	23549581	2063	2064	O
0.26	23549581	2065	2069	O
-	23549581	2069	2070	O
1.20	23549581	2070	2074	O
)	23549581	2074	2075	O
.	23549581	2075	2076	O

Fifty-nine	23549581	2077	2087	O
percent	23549581	2088	2095	O
of	23549581	2096	2098	O
those	23549581	2099	2104	O
initially	23549581	2105	2114	O
receiving	23549581	2115	2124	O
duloxetine	23549581	2125	2135	O
vs	23549581	2136	2138	O
38	23549581	2139	2141	O
%	23549581	2141	2142	O
of	23549581	2143	2145	O
those	23549581	2146	2151	O
initially	23549581	2152	2161	O
receiving	23549581	2162	2171	O
placebo	23549581	2172	2179	O
reported	23549581	2180	2188	O
decreased	23549581	2189	2198	B-Outcome
pain	23549581	2199	2203	I-Outcome
of	23549581	2204	2206	O
any	23549581	2207	2210	O
amount	23549581	2211	2217	O
.	23549581	2217	2218	O

CONCLUSION	23549581	2220	2230	O
AND	23549581	2231	2234	O
RELEVANCE	23549581	2235	2244	O
:	23549581	2245	2246	O
Among	23549581	2247	2252	O
patients	23549581	2253	2261	O
with	23549581	2262	2266	O
painful	23549581	2267	2274	O
chemotherapy-induced	23549581	2275	2295	O
peripheral	23549581	2296	2306	O
neuropathy	23549581	2307	2317	O
,	23549581	2317	2318	O
the	23549581	2319	2322	O
use	23549581	2323	2326	O
of	23549581	2327	2329	O
duloxetine	23549581	2330	2340	O
compared	23549581	2341	2349	O
with	23549581	2350	2354	O
placebo	23549581	2355	2362	O
for	23549581	2363	2366	O
5	23549581	2367	2368	O
weeks	23549581	2369	2374	O
resulted	23549581	2375	2383	O
in	23549581	2384	2386	O
a	23549581	2387	2388	O
greater	23549581	2389	2396	O
reduction	23549581	2397	2406	B-Outcome
in	23549581	2407	2409	I-Outcome
pain	23549581	2410	2414	I-Outcome
.	23549581	2414	2415	O

TRIAL	23549581	2417	2422	O
REGISTRATION	23549581	2423	2435	O
:	23549581	2436	2437	O
clinicaltrials.gov	23549581	2438	2456	O
Identifier	23549581	2457	2467	O
:	23549581	2467	2468	O
NCT00489411	23549581	2469	2480	O
.	23549581	2480	2481	O


Methylphenidate	23690414	0	15	O
and/or	23690414	16	22	O
a	23690414	23	24	O
nursing	23690414	25	32	O
telephone	23690414	33	42	O
intervention	23690414	43	55	O
for	23690414	56	59	O
fatigue	23690414	60	67	O
in	23690414	68	70	O
patients	23690414	71	79	O
with	23690414	80	84	O
advanced	23690414	85	93	O
cancer	23690414	94	100	O
:	23690414	100	101	O
a	23690414	102	103	O
randomized	23690414	104	114	O
,	23690414	114	115	O
placebo-controlled	23690414	116	134	O
,	23690414	134	135	O
phase	23690414	136	141	O
II	23690414	142	144	O
trial	23690414	145	150	O
.	23690414	150	151	O

PURPOSE	23690414	153	160	O
:	23690414	161	162	O
Cancer-related-fatigue	23690414	163	185	O
(	23690414	186	187	O
CRF	23690414	187	190	O
)	23690414	190	191	O
is	23690414	192	194	O
common	23690414	195	201	O
in	23690414	202	204	O
advanced	23690414	205	213	O
cancer	23690414	214	220	O
.	23690414	220	221	O

The	23690414	222	225	O
primary	23690414	226	233	O
objective	23690414	234	243	O
of	23690414	244	246	O
the	23690414	247	250	O
study	23690414	251	256	O
was	23690414	257	260	O
to	23690414	261	263	O
compare	23690414	264	271	O
the	23690414	272	275	O
effects	23690414	276	283	O
of	23690414	284	286	O
methylphenidate	23690414	287	302	O
(	23690414	303	304	O
MP	23690414	304	306	O
)	23690414	306	307	O
with	23690414	308	312	O
those	23690414	313	318	O
of	23690414	319	321	O
placebo	23690414	322	329	O
(	23690414	330	331	O
PL	23690414	331	333	O
)	23690414	333	334	O
on	23690414	335	337	O
CRF	23690414	338	341	O
as	23690414	342	344	O
measured	23690414	345	353	O
using	23690414	354	359	O
the	23690414	360	363	O
Functional	23690414	364	374	O
Assessment	23690414	375	385	O
of	23690414	386	388	O
Chronic	23690414	389	396	O
Illness	23690414	397	404	O
Therapy-Fatigue	23690414	405	420	O
(	23690414	421	422	O
FACIT-F	23690414	422	429	O
)	23690414	429	430	O
fatigue	23690414	431	438	O
subscale	23690414	439	447	O
.	23690414	447	448	O

The	23690414	449	452	O
effect	23690414	453	459	O
of	23690414	460	462	O
a	23690414	463	464	O
combined	23690414	465	473	O
intervention	23690414	474	486	O
including	23690414	487	496	O
MP	23690414	497	499	O
plus	23690414	500	504	O
a	23690414	505	506	O
nursing	23690414	507	514	O
telephone	23690414	515	524	O
intervention	23690414	525	537	O
(	23690414	538	539	O
NTI	23690414	539	542	O
)	23690414	542	543	O
was	23690414	544	547	O
also	23690414	548	552	O
assessed	23690414	553	561	O
.	23690414	561	562	O

PATIENTS	23690414	564	572	O
AND	23690414	573	576	O
METHODS	23690414	577	584	O
:	23690414	585	586	O
Patients	23690414	587	595	O
with	23690414	596	600	O
advanced	23690414	601	609	O
cancer	23690414	610	616	O
with	23690414	617	621	O
a	23690414	622	623	O
fatigue	23690414	624	631	O
score	23690414	632	637	O
of	23690414	638	640	O
≥	23690414	641	642	O
4	23690414	643	644	O
out	23690414	645	648	O
of	23690414	649	651	O
10	23690414	652	654	O
on	23690414	655	657	O
the	23690414	658	661	O
Edmonton	23690414	662	670	O
Symptom	23690414	671	678	O
Assessment	23690414	679	689	O
Scale	23690414	690	695	O
(	23690414	696	697	O
ESAS	23690414	697	701	O
)	23690414	701	702	O
were	23690414	703	707	O
randomly	23690414	708	716	O
assigned	23690414	717	725	O
to	23690414	726	728	O
one	23690414	729	732	O
of	23690414	733	735	O
the	23690414	736	739	O
following	23690414	740	749	O
four	23690414	750	754	O
groups	23690414	755	761	O
:	23690414	761	762	O
MP+NTI	23690414	763	769	O
,	23690414	769	770	O
PL+NTI	23690414	771	777	O
,	23690414	777	778	O
MP	23690414	779	781	O
+	23690414	782	783	O
control	23690414	784	791	O
telephone	23690414	792	801	O
intervention	23690414	802	814	O
(	23690414	815	816	O
CTI	23690414	816	819	O
)	23690414	819	820	O
,	23690414	820	821	O
and	23690414	822	825	O
PL+CTI	23690414	826	832	O
.	23690414	832	833	O

Methylphenidate	23690414	834	849	O
dose	23690414	850	854	O
was	23690414	855	858	O
5	23690414	859	860	O
mg	23690414	861	863	O
every	23690414	864	869	O
2	23690414	870	871	O
hours	23690414	872	877	O
as	23690414	878	880	O
needed	23690414	881	887	O
up	23690414	888	890	O
to	23690414	891	893	O
20	23690414	894	896	O
mg	23690414	897	899	O
per	23690414	900	903	O
day	23690414	904	907	O
.	23690414	907	908	O

The	23690414	909	912	O
primary	23690414	913	920	O
end	23690414	921	924	O
point	23690414	925	930	O
was	23690414	931	934	O
the	23690414	935	938	O
median	23690414	939	945	O
difference	23690414	946	956	O
in	23690414	957	959	O
FACIT-F	23690414	960	967	O
fatigue	23690414	968	975	O
at	23690414	976	978	O
day	23690414	979	982	O
15	23690414	983	985	O
.	23690414	985	986	O

Secondary	23690414	987	996	O
outcomes	23690414	997	1005	O
included	23690414	1006	1014	O
anxiety	23690414	1015	1022	O
,	23690414	1022	1023	O
depression	23690414	1024	1034	O
,	23690414	1034	1035	O
and	23690414	1036	1039	O
sleep	23690414	1040	1045	O
.	23690414	1045	1046	O

RESULTS	23690414	1048	1055	O
:	23690414	1056	1057	O
One	23690414	1058	1061	O
hundred	23690414	1062	1069	O
forty-one	23690414	1070	1079	O
patients	23690414	1080	1088	O
were	23690414	1089	1093	O
evaluable	23690414	1094	1103	O
.	23690414	1103	1104	O

Median	23690414	1105	1111	B-Outcome
FACIT-F	23690414	1112	1119	I-Outcome
fatigue	23690414	1120	1127	I-Outcome
scores	23690414	1128	1134	I-Outcome
improved	23690414	1135	1143	O
from	23690414	1144	1148	O
baseline	23690414	1149	1157	O
to	23690414	1158	1160	O
day	23690414	1161	1164	O
15	23690414	1165	1167	O
in	23690414	1168	1170	O
all	23690414	1171	1174	O
groups	23690414	1175	1181	O
:	23690414	1181	1182	O
MP+NTI	23690414	1183	1189	O
(	23690414	1190	1191	O
median	23690414	1191	1197	O
score	23690414	1198	1203	O
,	23690414	1203	1204	O
4.5	23690414	1205	1208	O
;	23690414	1208	1209	O
P	23690414	1210	1211	O
=	23690414	1212	1213	O
.005	23690414	1214	1218	O
)	23690414	1218	1219	O
,	23690414	1219	1220	O
PL+NTI	23690414	1221	1227	O
(	23690414	1228	1229	O
median	23690414	1229	1235	O
score	23690414	1236	1241	O
,	23690414	1241	1242	O
8.0	23690414	1243	1246	O
;	23690414	1246	1247	O
P	23690414	1248	1249	O
<	23690414	1250	1251	O
.001	23690414	1252	1256	O
)	23690414	1256	1257	O
,	23690414	1257	1258	O
MP+CTI	23690414	1259	1265	O
(	23690414	1266	1267	O
median	23690414	1267	1273	O
score	23690414	1274	1279	O
,	23690414	1279	1280	O
7.0	23690414	1281	1284	O
;	23690414	1284	1285	O
P	23690414	1286	1287	O
=	23690414	1288	1289	O
.004	23690414	1290	1294	O
)	23690414	1294	1295	O
,	23690414	1295	1296	O
and	23690414	1297	1300	O
PL+CTI	23690414	1301	1307	O
(	23690414	1308	1309	O
median	23690414	1309	1315	O
score	23690414	1316	1321	O
,	23690414	1321	1322	O
5.0	23690414	1323	1326	O
;	23690414	1326	1327	O
P	23690414	1328	1329	O
=	23690414	1330	1331	O
.03	23690414	1332	1335	O
)	23690414	1335	1336	O
.	23690414	1336	1337	O

However	23690414	1338	1345	O
,	23690414	1345	1346	O
there	23690414	1347	1352	O
were	23690414	1353	1357	O
no	23690414	1358	1360	O
significant	23690414	1361	1372	O
differences	23690414	1373	1384	O
in	23690414	1385	1387	O
the	23690414	1388	1391	O
median	23690414	1392	1398	O
improvement	23690414	1399	1410	O
in	23690414	1411	1413	O
FACIT-F	23690414	1414	1421	B-Outcome
fatigue	23690414	1422	1429	I-Outcome
between	23690414	1430	1437	O
the	23690414	1438	1441	O
MP	23690414	1442	1444	O
and	23690414	1445	1448	O
PL	23690414	1449	1451	O
groups	23690414	1452	1458	O
(	23690414	1459	1460	O
5.5	23690414	1460	1463	O
v	23690414	1464	1465	O
6.0	23690414	1466	1469	O
,	23690414	1469	1470	O
respectively	23690414	1471	1483	O
;	23690414	1483	1484	O
P	23690414	1485	1486	O
=	23690414	1487	1488	O
.69	23690414	1489	1492	O
)	23690414	1492	1493	O
and	23690414	1494	1497	O
among	23690414	1498	1503	O
all	23690414	1504	1507	O
four	23690414	1508	1512	O
groups	23690414	1513	1519	O
(	23690414	1520	1521	O
P	23690414	1521	1522	O
=	23690414	1523	1524	O
.16	23690414	1525	1528	O
)	23690414	1528	1529	O
.	23690414	1529	1530	O

Fatigue	23690414	1531	1538	B-Outcome
(	23690414	1539	1540	O
P	23690414	1540	1541	O
<	23690414	1542	1543	O
.001	23690414	1544	1548	O
)	23690414	1548	1549	O
,	23690414	1549	1550	O
nausea	23690414	1551	1557	B-Outcome
(	23690414	1558	1559	O
P	23690414	1559	1560	O
=	23690414	1561	1562	O
.01	23690414	1563	1566	O
)	23690414	1566	1567	O
,	23690414	1567	1568	O
depression	23690414	1569	1579	B-Outcome
(	23690414	1580	1581	O
P	23690414	1581	1582	O
=	23690414	1583	1584	O
.02	23690414	1585	1588	O
)	23690414	1588	1589	O
,	23690414	1589	1590	O
anxiety	23690414	1591	1598	B-Outcome
(	23690414	1599	1600	O
P	23690414	1600	1601	O
=	23690414	1602	1603	O
.01	23690414	1604	1607	O
)	23690414	1607	1608	O
,	23690414	1608	1609	O
drowsiness	23690414	1610	1620	B-Outcome
(	23690414	1621	1622	O
P	23690414	1622	1623	O
<	23690414	1624	1625	O
.001	23690414	1626	1630	O
)	23690414	1630	1631	O
,	23690414	1631	1632	O
appetite	23690414	1633	1641	B-Outcome
(	23690414	1642	1643	O
P	23690414	1643	1644	O
=	23690414	1645	1646	O
.009	23690414	1647	1651	O
)	23690414	1651	1652	O
,	23690414	1652	1653	O
sleep	23690414	1654	1659	B-Outcome
(	23690414	1660	1661	O
P	23690414	1661	1662	O
<	23690414	1663	1664	O
.001	23690414	1665	1669	O
)	23690414	1669	1670	O
,	23690414	1670	1671	O
and	23690414	1672	1675	O
feeling	23690414	1676	1683	B-Outcome
of	23690414	1684	1686	I-Outcome
well-being	23690414	1687	1697	I-Outcome
(	23690414	1698	1699	O
P	23690414	1699	1700	O
<	23690414	1701	1702	O
.001	23690414	1703	1707	O
)	23690414	1707	1708	O
,	23690414	1708	1709	O
as	23690414	1710	1712	O
measured	23690414	1713	1721	O
by	23690414	1722	1724	O
the	23690414	1725	1728	O
ESAS	23690414	1729	1733	B-Outcome
,	23690414	1733	1734	O
significantly	23690414	1735	1748	O
improved	23690414	1749	1757	O
in	23690414	1758	1760	O
patients	23690414	1761	1769	O
who	23690414	1770	1773	O
received	23690414	1774	1782	O
NTI	23690414	1783	1786	O
.	23690414	1786	1787	O

Grade	23690414	1788	1793	B-Outcome
≥	23690414	1794	1795	I-Outcome
3	23690414	1796	1797	I-Outcome
adverse	23690414	1798	1805	I-Outcome
events	23690414	1806	1812	I-Outcome
did	23690414	1813	1816	O
not	23690414	1817	1820	O
differ	23690414	1821	1827	O
between	23690414	1828	1835	O
MP	23690414	1836	1838	O
and	23690414	1839	1842	O
PL	23690414	1843	1845	O
(	23690414	1846	1847	O
40	23690414	1847	1849	O
of	23690414	1850	1852	O
93	23690414	1853	1855	O
patients	23690414	1856	1864	O
v	23690414	1865	1866	O
29	23690414	1867	1869	O
of	23690414	1870	1872	O
97	23690414	1873	1875	O
patients	23690414	1876	1884	O
,	23690414	1884	1885	O
respectively	23690414	1886	1898	O
;	23690414	1898	1899	O
P	23690414	1900	1901	O
=	23690414	1902	1903	O
.06	23690414	1904	1907	O
)	23690414	1907	1908	O
.	23690414	1908	1909	O

CONCLUSION	23690414	1911	1921	O
:	23690414	1922	1923	O
MP	23690414	1924	1926	O
and	23690414	1927	1930	O
NTI	23690414	1931	1934	O
alone	23690414	1935	1940	O
or	23690414	1941	1943	O
combined	23690414	1944	1952	O
were	23690414	1953	1957	O
not	23690414	1958	1961	O
superior	23690414	1962	1970	O
to	23690414	1971	1973	O
placebo	23690414	1974	1981	O
in	23690414	1982	1984	O
improving	23690414	1985	1994	O
CRF	23690414	1995	1998	B-Outcome
.	23690414	1998	1999	O


Ultrasonography-guided	23760519	0	22	O
bilateral	23760519	23	32	O
rectus	23760519	33	39	O
sheath	23760519	40	46	O
block	23760519	47	52	O
vs	23760519	53	55	O
local	23760519	56	61	O
anesthetic	23760519	62	72	O
infiltration	23760519	73	85	O
after	23760519	86	91	O
pediatric	23760519	92	101	O
umbilical	23760519	102	111	O
hernia	23760519	112	118	O
repair	23760519	119	125	O
:	23760519	125	126	O
a	23760519	127	128	O
prospective	23760519	129	140	O
randomized	23760519	141	151	O
clinical	23760519	152	160	O
trial	23760519	161	166	O
.	23760519	166	167	O

IMPORTANCE	23760519	169	179	O
:	23760519	180	181	O
Regional	23760519	182	190	O
anesthetic	23760519	191	201	O
techniques	23760519	202	212	O
can	23760519	213	216	O
be	23760519	217	219	O
used	23760519	220	224	O
to	23760519	225	227	O
alleviate	23760519	228	237	O
postoperative	23760519	238	251	O
pain	23760519	252	256	O
in	23760519	257	259	O
children	23760519	260	268	O
undergoing	23760519	269	279	O
pediatric	23760519	280	289	O
surgical	23760519	290	298	O
procedures	23760519	299	309	O
.	23760519	309	310	O

Use	23760519	311	314	O
of	23760519	315	317	O
ultrasonographic	23760519	318	334	O
guidance	23760519	335	343	O
for	23760519	344	347	O
bilateral	23760519	348	357	O
rectus	23760519	358	364	O
sheath	23760519	365	371	O
block	23760519	372	377	O
(	23760519	378	379	O
BRSB	23760519	379	383	O
)	23760519	383	384	O
has	23760519	385	388	O
been	23760519	389	393	O
shown	23760519	394	399	O
to	23760519	400	402	O
improve	23760519	403	410	O
immediate	23760519	411	420	O
pain	23760519	421	425	O
scores	23760519	426	432	O
and	23760519	433	436	O
reduce	23760519	437	443	O
use	23760519	444	447	O
of	23760519	448	450	O
postoperative	23760519	451	464	O
analgesia	23760519	465	474	O
in	23760519	475	477	O
the	23760519	478	481	O
postanesthesia	23760519	482	496	O
care	23760519	497	501	O
unit	23760519	502	506	O
(	23760519	507	508	O
PACU	23760519	508	512	O
)	23760519	512	513	O
.	23760519	513	514	O

OBJECTIVE	23760519	516	525	O
:	23760519	526	527	O
To	23760519	528	530	O
compare	23760519	531	538	O
efficacy	23760519	539	547	O
of	23760519	548	550	O
ultrasonography-guided	23760519	551	573	O
BRSB	23760519	574	578	O
and	23760519	579	582	O
local	23760519	583	588	O
anesthetic	23760519	589	599	O
infiltration	23760519	600	612	O
(	23760519	613	614	O
LAI	23760519	614	617	O
)	23760519	617	618	O
in	23760519	619	621	O
providing	23760519	622	631	O
postoperative	23760519	632	645	O
analgesia	23760519	646	655	O
after	23760519	656	661	O
pediatric	23760519	662	671	O
umbilical	23760519	672	681	O
hernia	23760519	682	688	O
repair	23760519	689	695	O
.	23760519	695	696	O

DESIGN	23760519	698	704	O
:	23760519	705	706	O
Prospective	23760519	707	718	O
,	23760519	718	719	O
observer-blinded	23760519	720	736	O
,	23760519	736	737	O
randomized	23760519	738	748	O
clinical	23760519	749	757	O
trial	23760519	758	763	O
.	23760519	763	764	O

SETTING	23760519	766	773	O
:	23760519	774	775	O
Tertiary-referral	23760519	776	793	O
urban	23760519	794	799	O
children	23760519	800	808	O
's	23760519	808	810	O
hospital	23760519	811	819	O
.	23760519	819	820	O

PARTICIPANTS	23760519	822	834	O
:	23760519	835	836	O
Eligible	23760519	837	845	O
children	23760519	846	854	O
3	23760519	855	856	O
to	23760519	857	859	O
12	23760519	860	862	O
years	23760519	863	868	O
of	23760519	869	871	O
age	23760519	872	875	O
undergoing	23760519	876	886	O
elective	23760519	887	895	O
umbilical	23760519	896	905	O
hernia	23760519	906	912	O
repair	23760519	913	919	O
from	23760519	920	924	O
November	23760519	925	933	O
16	23760519	934	936	O
,	23760519	936	937	O
2009	23760519	938	942	O
,	23760519	942	943	O
through	23760519	944	951	O
May	23760519	952	955	O
31	23760519	956	958	O
,	23760519	958	959	O
2011	23760519	960	964	O
.	23760519	964	965	O

INTERVENTIONS	23760519	967	980	O
:	23760519	981	982	O
Ropivacaine	23760519	983	994	O
hydrochloride	23760519	995	1008	O
administered	23760519	1009	1021	O
at	23760519	1022	1024	O
the	23760519	1025	1028	O
conclusion	23760519	1029	1039	O
of	23760519	1040	1042	O
surgery	23760519	1043	1050	O
as	23760519	1051	1053	O
LAI	23760519	1054	1057	O
by	23760519	1058	1060	O
the	23760519	1061	1064	O
surgeon	23760519	1065	1072	O
(	23760519	1073	1074	O
n	23760519	1074	1075	O
=	23760519	1076	1077	O
25	23760519	1078	1080	O
)	23760519	1080	1081	O
or	23760519	1082	1084	O
as	23760519	1085	1087	O
ultrasonography-guided	23760519	1088	1110	O
BRSB	23760519	1111	1115	O
by	23760519	1116	1118	O
the	23760519	1119	1122	O
anesthesiologist	23760519	1123	1139	O
(	23760519	1140	1141	O
n	23760519	1141	1142	O
=	23760519	1143	1144	O
27	23760519	1145	1147	O
)	23760519	1147	1148	O
.	23760519	1148	1149	O

MAIN	23760519	1151	1155	O
OUTCOMES	23760519	1156	1164	O
AND	23760519	1165	1168	O
MEASURES	23760519	1169	1177	O
:	23760519	1178	1179	O
Scores	23760519	1180	1186	O
on	23760519	1187	1189	O
the	23760519	1190	1193	O
FACES	23760519	1194	1199	O
Pain	23760519	1200	1204	O
Rating	23760519	1205	1211	O
Scale	23760519	1212	1217	O
measured	23760519	1218	1226	O
at	23760519	1227	1229	O
10-minute	23760519	1230	1239	O
intervals	23760519	1240	1249	O
and	23760519	1250	1253	O
all	23760519	1254	1257	O
use	23760519	1258	1261	O
of	23760519	1262	1264	O
analgesic	23760519	1265	1274	O
medications	23760519	1275	1286	O
in	23760519	1287	1289	O
the	23760519	1290	1293	O
PACU	23760519	1294	1298	O
.	23760519	1298	1299	O

RESULTS	23760519	1301	1308	O
:	23760519	1309	1310	O
Median	23760519	1311	1317	B-Outcome
FACES	23760519	1318	1323	I-Outcome
scores	23760519	1324	1330	I-Outcome
in	23760519	1331	1333	O
the	23760519	1334	1337	O
PACU	23760519	1338	1342	O
were	23760519	1343	1347	O
lower	23760519	1348	1353	O
in	23760519	1354	1356	O
the	23760519	1357	1360	O
BRSB	23760519	1361	1365	O
group	23760519	1366	1371	O
compared	23760519	1372	1380	O
with	23760519	1381	1385	O
the	23760519	1386	1389	O
LAI	23760519	1390	1393	O
group	23760519	1394	1399	O
at	23760519	1400	1402	O
10	23760519	1403	1405	O
minutes	23760519	1406	1413	O
(	23760519	1414	1415	O
0	23760519	1415	1416	O
vs	23760519	1417	1419	O
1	23760519	1420	1421	O
;	23760519	1421	1422	O
P	23760519	1423	1424	O
=	23760519	1425	1426	O
.04	23760519	1427	1430	O
)	23760519	1430	1431	O
,	23760519	1431	1432	O
30	23760519	1433	1435	O
minutes	23760519	1436	1443	O
(	23760519	1444	1445	O
0	23760519	1445	1446	O
vs	23760519	1447	1449	O
1	23760519	1450	1451	O
;	23760519	1451	1452	O
P	23760519	1453	1454	O
=	23760519	1455	1456	O
.01	23760519	1457	1460	O
)	23760519	1460	1461	O
,	23760519	1461	1462	O
and	23760519	1463	1466	O
40	23760519	1467	1469	O
minutes	23760519	1470	1477	O
or	23760519	1478	1480	O
later	23760519	1481	1486	O
(	23760519	1487	1488	O
0	23760519	1488	1489	O
vs	23760519	1490	1492	O
1	23760519	1493	1494	O
;	23760519	1494	1495	O
P	23760519	1496	1497	O
=	23760519	1498	1499	O
.03	23760519	1500	1503	O
)	23760519	1503	1504	O
.	23760519	1504	1505	O

Fewer	23760519	1506	1511	O
doses	23760519	1512	1517	B-Outcome
of	23760519	1518	1520	I-Outcome
opioid	23760519	1521	1527	I-Outcome
and	23760519	1528	1531	O
nonopioid	23760519	1532	1541	B-Outcome
medications	23760519	1542	1553	I-Outcome
were	23760519	1554	1558	O
given	23760519	1559	1564	O
to	23760519	1565	1567	O
the	23760519	1568	1571	O
BRSB	23760519	1572	1576	O
group	23760519	1577	1582	O
compared	23760519	1583	1591	O
with	23760519	1592	1596	O
the	23760519	1597	1600	O
LAI	23760519	1601	1604	O
group	23760519	1605	1610	O
(	23760519	1611	1612	O
5	23760519	1612	1613	O
vs	23760519	1614	1616	O
11	23760519	1617	1619	O
doses	23760519	1620	1625	O
for	23760519	1626	1629	O
opioids	23760519	1630	1637	O
;	23760519	1637	1638	O
5	23760519	1639	1640	O
vs	23760519	1641	1643	O
10	23760519	1644	1646	O
for	23760519	1647	1650	O
nonopioids	23760519	1651	1661	O
)	23760519	1661	1662	O
.	23760519	1662	1663	O

CONCLUSIONS	23760519	1665	1676	O
AND	23760519	1677	1680	O
RELEVANCE	23760519	1681	1690	O
:	23760519	1691	1692	O
In	23760519	1693	1695	O
the	23760519	1696	1699	O
PACU	23760519	1700	1704	O
,	23760519	1704	1705	O
ultrasonography-guided	23760519	1706	1728	O
BRSB	23760519	1729	1733	O
after	23760519	1734	1739	O
umbilical	23760519	1740	1749	O
hernia	23760519	1750	1756	O
repair	23760519	1757	1763	O
in	23760519	1764	1766	O
children	23760519	1767	1775	O
is	23760519	1776	1778	O
associated	23760519	1779	1789	O
with	23760519	1790	1794	O
lower	23760519	1795	1800	O
median	23760519	1801	1807	B-Outcome
FACES	23760519	1808	1813	I-Outcome
scores	23760519	1814	1820	I-Outcome
and	23760519	1821	1824	O
decreased	23760519	1825	1834	O
use	23760519	1835	1838	B-Outcome
of	23760519	1839	1841	I-Outcome
opioid	23760519	1842	1848	I-Outcome
and	23760519	1849	1852	O
nonopioid	23760519	1853	1862	B-Outcome
medications	23760519	1863	1874	I-Outcome
compared	23760519	1875	1883	O
with	23760519	1884	1888	O
LAI	23760519	1889	1892	O
.	23760519	1892	1893	O

Future	23760519	1894	1900	O
studies	23760519	1901	1908	O
could	23760519	1909	1914	O
examine	23760519	1915	1922	O
the	23760519	1923	1926	O
use	23760519	1927	1930	O
of	23760519	1931	1933	O
longer-acting	23760519	1934	1947	O
anesthetic	23760519	1948	1958	O
agents	23760519	1959	1965	O
with	23760519	1966	1970	O
ultrasonography-guided	23760519	1971	1993	O
BRSB	23760519	1994	1998	O
.	23760519	1998	1999	O

TRIAL	23760519	2001	2006	O
REGISTRATION	23760519	2007	2019	O
:	23760519	2020	2021	O
clinicaltrials.gov	23760519	2022	2040	O
Identifier	23760519	2041	2051	O
:	23760519	2051	2052	O
NCT01015053	23760519	2053	2064	O
.	23760519	2064	2065	O


Randomized	23775967	0	10	O
controlled	23775967	11	21	O
trial	23775967	22	27	O
of	23775967	28	30	O
entecavir	23775967	31	40	O
prophylaxis	23775967	41	52	O
for	23775967	53	56	O
rituximab-associated	23775967	57	77	O
hepatitis	23775967	78	87	O
B	23775967	88	89	O
virus	23775967	90	95	O
reactivation	23775967	96	108	O
in	23775967	109	111	O
patients	23775967	112	120	O
with	23775967	121	125	O
lymphoma	23775967	126	134	O
and	23775967	135	138	O
resolved	23775967	139	147	O
hepatitis	23775967	148	157	O
B.	23775967	158	160	O
PURPOSE	23775967	161	168	O
:	23775967	169	170	O
The	23775967	171	174	O
role	23775967	175	179	O
of	23775967	180	182	O
antiviral	23775967	183	192	O
prophylaxis	23775967	193	204	O
in	23775967	205	207	O
preventing	23775967	208	218	O
hepatitis	23775967	219	228	O
B	23775967	229	230	O
virus	23775967	231	236	O
(	23775967	237	238	O
HBV	23775967	238	241	O
)	23775967	241	242	O
reactivation	23775967	243	255	O
before	23775967	256	262	O
rituximab-based	23775967	263	278	O
chemotherapy	23775967	279	291	O
in	23775967	292	294	O
patients	23775967	295	303	O
with	23775967	304	308	O
lymphoma	23775967	309	317	O
and	23775967	318	321	O
resolved	23775967	322	330	O
hepatitis	23775967	331	340	O
B	23775967	341	342	O
is	23775967	343	345	O
unclear	23775967	346	353	O
.	23775967	353	354	O

PATIENTS	23775967	356	364	O
AND	23775967	365	368	O
METHODS	23775967	369	376	O
:	23775967	377	378	O
Eighty	23775967	379	385	O
patients	23775967	386	394	O
with	23775967	395	399	O
CD20(+	23775967	400	406	O
)	23775967	406	407	O
lymphoma	23775967	408	416	O
and	23775967	417	420	O
resolved	23775967	421	429	O
hepatitis	23775967	430	439	O
B	23775967	440	441	O
were	23775967	442	446	O
randomly	23775967	447	455	O
assigned	23775967	456	464	O
to	23775967	465	467	O
receive	23775967	468	475	O
either	23775967	476	482	O
prophylactic	23775967	483	495	O
entecavir	23775967	496	505	O
(	23775967	506	507	O
ETV	23775967	507	510	O
)	23775967	510	511	O
before	23775967	512	518	O
chemotherapy	23775967	519	531	O
to	23775967	532	534	O
3	23775967	535	536	O
months	23775967	537	543	O
after	23775967	544	549	O
completing	23775967	550	560	O
chemotherapy	23775967	561	573	O
(	23775967	574	575	O
ETV	23775967	575	578	O
prophylactic	23775967	579	591	O
group	23775967	592	597	O
,	23775967	597	598	O
n	23775967	599	600	O
=	23775967	601	602	O
41	23775967	603	605	O
)	23775967	605	606	O
or	23775967	607	609	O
to	23775967	610	612	O
receive	23775967	613	620	O
therapeutic	23775967	621	632	O
ETV	23775967	633	636	O
at	23775967	637	639	O
the	23775967	640	643	O
time	23775967	644	648	O
of	23775967	649	651	O
HBV	23775967	652	655	O
reactivation	23775967	656	668	O
and	23775967	669	672	O
hepatitis	23775967	673	682	O
B	23775967	683	684	O
surface	23775967	685	692	O
antigen	23775967	693	700	O
(	23775967	701	702	O
HBsAg	23775967	702	707	O
)	23775967	707	708	O
reverse	23775967	709	716	O
seroconversion	23775967	717	731	O
since	23775967	732	737	O
chemotherapy	23775967	738	750	O
(	23775967	751	752	O
control	23775967	752	759	O
group	23775967	760	765	O
,	23775967	765	766	O
n	23775967	767	768	O
=	23775967	769	770	O
39	23775967	771	773	O
)	23775967	773	774	O
.	23775967	774	775	O

RESULTS	23775967	777	784	O
:	23775967	785	786	O
Fifty-eight	23775967	787	798	O
patients	23775967	799	807	O
(	23775967	808	809	O
72.5	23775967	809	813	O
%	23775967	813	814	O
)	23775967	814	815	O
were	23775967	816	820	O
positive	23775967	821	829	O
for	23775967	830	833	O
hepatitis	23775967	834	843	O
B	23775967	844	845	O
surface	23775967	846	853	O
antibody	23775967	854	862	O
,	23775967	862	863	O
and	23775967	864	867	O
HBV	23775967	868	871	O
DNA	23775967	872	875	O
was	23775967	876	879	O
undetectable	23775967	880	892	O
in	23775967	893	895	O
50	23775967	896	898	O
patients	23775967	899	907	O
(	23775967	908	909	O
62.5	23775967	909	913	O
%	23775967	913	914	O
)	23775967	914	915	O
.	23775967	915	916	O

During	23775967	917	923	O
a	23775967	924	925	O
mean	23775967	926	930	O
18-month	23775967	931	939	O
follow-up	23775967	940	949	O
period	23775967	950	956	O
,	23775967	956	957	O
one	23775967	958	961	O
patient	23775967	962	969	O
(	23775967	970	971	O
2.4	23775967	971	974	O
%	23775967	974	975	O
)	23775967	975	976	O
in	23775967	977	979	O
the	23775967	980	983	O
ETV	23775967	984	987	O
prophylactic	23775967	988	1000	O
group	23775967	1001	1006	O
and	23775967	1007	1010	O
seven	23775967	1011	1016	O
patients	23775967	1017	1025	O
(	23775967	1026	1027	O
17.9	23775967	1027	1031	O
%	23775967	1031	1032	O
)	23775967	1032	1033	O
in	23775967	1034	1036	O
the	23775967	1037	1040	O
control	23775967	1041	1048	O
group	23775967	1049	1054	O
developed	23775967	1055	1064	O
HBV	23775967	1065	1068	B-Outcome
reactivation	23775967	1069	1081	I-Outcome
(	23775967	1082	1083	O
P	23775967	1083	1084	O
=	23775967	1085	1086	O
.027	23775967	1087	1091	O
)	23775967	1091	1092	O
.	23775967	1092	1093	O

The	23775967	1094	1097	O
cumulative	23775967	1098	1108	B-Outcome
HBV	23775967	1109	1112	I-Outcome
reactivation	23775967	1113	1125	I-Outcome
rates	23775967	1126	1131	I-Outcome
at	23775967	1132	1134	O
months	23775967	1135	1141	O
6	23775967	1142	1143	O
,	23775967	1143	1144	O
12	23775967	1145	1147	O
,	23775967	1147	1148	O
and	23775967	1149	1152	O
18	23775967	1153	1155	O
after	23775967	1156	1161	O
chemotherapy	23775967	1162	1174	O
were	23775967	1175	1179	O
8	23775967	1180	1181	O
%	23775967	1181	1182	O
,	23775967	1182	1183	O
11.2	23775967	1184	1188	O
%	23775967	1188	1189	O
,	23775967	1189	1190	O
and	23775967	1191	1194	O
25.9	23775967	1195	1199	O
%	23775967	1199	1200	O
,	23775967	1200	1201	O
respectively	23775967	1202	1214	O
,	23775967	1214	1215	O
in	23775967	1216	1218	O
the	23775967	1219	1222	O
control	23775967	1223	1230	O
group	23775967	1231	1236	O
,	23775967	1236	1237	O
and	23775967	1238	1241	O
0	23775967	1242	1243	O
%	23775967	1243	1244	O
,	23775967	1244	1245	O
0	23775967	1246	1247	O
%	23775967	1247	1248	O
,	23775967	1248	1249	O
and	23775967	1250	1253	O
4.3	23775967	1254	1257	O
%	23775967	1257	1258	O
in	23775967	1259	1261	O
the	23775967	1262	1265	O
ETV	23775967	1266	1269	O
prophylactic	23775967	1270	1282	O
group	23775967	1283	1288	O
(	23775967	1289	1290	O
P	23775967	1290	1291	O
=	23775967	1292	1293	O
.019	23775967	1294	1298	O
)	23775967	1298	1299	O
.	23775967	1299	1300	O

Four	23775967	1301	1305	O
patients	23775967	1306	1314	O
(	23775967	1315	1316	O
50	23775967	1316	1318	O
%	23775967	1318	1319	O
)	23775967	1319	1320	O
in	23775967	1321	1323	O
the	23775967	1324	1327	O
control	23775967	1328	1335	O
group	23775967	1336	1341	O
had	23775967	1342	1345	O
HBsAg	23775967	1346	1351	B-Outcome
reverse	23775967	1352	1359	I-Outcome
seroconversion	23775967	1360	1374	I-Outcome
after	23775967	1375	1380	I-Outcome
HBV	23775967	1381	1384	I-Outcome
reactivation	23775967	1385	1397	I-Outcome
.	23775967	1397	1398	O

The	23775967	1399	1402	O
cumulative	23775967	1403	1413	B-Outcome
HBsAg	23775967	1414	1419	I-Outcome
reverse	23775967	1420	1427	I-Outcome
seroconversion	23775967	1428	1442	I-Outcome
rates	23775967	1443	1448	I-Outcome
at	23775967	1449	1451	O
months	23775967	1452	1458	O
6	23775967	1459	1460	O
,	23775967	1460	1461	O
12	23775967	1462	1464	O
,	23775967	1464	1465	O
and	23775967	1466	1469	O
18	23775967	1470	1472	O
since	23775967	1473	1478	O
chemotherapy	23775967	1479	1491	O
were	23775967	1492	1496	O
0	23775967	1497	1498	O
%	23775967	1498	1499	O
,	23775967	1499	1500	O
6.4	23775967	1501	1504	O
%	23775967	1504	1505	O
,	23775967	1505	1506	O
and	23775967	1507	1510	O
16.3	23775967	1511	1515	O
%	23775967	1515	1516	O
in	23775967	1517	1519	O
the	23775967	1520	1523	O
control	23775967	1524	1531	O
group	23775967	1532	1537	O
,	23775967	1537	1538	O
respectively	23775967	1539	1551	O
,	23775967	1551	1552	O
which	23775967	1553	1558	O
were	23775967	1559	1563	O
significantly	23775967	1564	1577	O
higher	23775967	1578	1584	O
than	23775967	1585	1589	O
those	23775967	1590	1595	O
in	23775967	1596	1598	O
the	23775967	1599	1602	O
ETV	23775967	1603	1606	O
prophylactic	23775967	1607	1619	O
group	23775967	1620	1625	O
(	23775967	1626	1627	O
P	23775967	1627	1628	O
=	23775967	1629	1630	O
.032	23775967	1631	1635	O
)	23775967	1635	1636	O
.	23775967	1636	1637	O

Patients	23775967	1638	1646	O
with	23775967	1647	1651	O
detectable	23775967	1652	1662	O
or	23775967	1663	1665	O
undetectable	23775967	1666	1678	O
viral	23775967	1679	1684	O
load	23775967	1685	1689	O
could	23775967	1690	1695	O
develop	23775967	1696	1703	O
HBV	23775967	1704	1707	B-Outcome
reactivation	23775967	1708	1720	I-Outcome
and	23775967	1721	1724	O
HBsAg	23775967	1725	1730	B-Outcome
reverse	23775967	1731	1738	I-Outcome
seroconversion	23775967	1739	1753	I-Outcome
.	23775967	1753	1754	O

CONCLUSION	23775967	1756	1766	O
:	23775967	1767	1768	O
Undetectable	23775967	1769	1781	O
HBV	23775967	1782	1785	O
viral	23775967	1786	1791	O
load	23775967	1792	1796	O
before	23775967	1797	1803	O
chemotherapy	23775967	1804	1816	O
did	23775967	1817	1820	O
not	23775967	1821	1824	O
confer	23775967	1825	1831	O
reactivation-free	23775967	1832	1849	O
status	23775967	1850	1856	O
.	23775967	1856	1857	O

Antiviral	23775967	1858	1867	O
prophylaxis	23775967	1868	1879	O
can	23775967	1880	1883	O
potentially	23775967	1884	1895	O
prevent	23775967	1896	1903	O
rituximab-associated	23775967	1904	1924	O
HBV	23775967	1925	1928	O
reactivation	23775967	1929	1941	O
in	23775967	1942	1944	O
patients	23775967	1945	1953	O
with	23775967	1954	1958	O
lymphoma	23775967	1959	1967	O
and	23775967	1968	1971	O
resolved	23775967	1972	1980	O
hepatitis	23775967	1981	1990	O
B.	23775967	1991	1993	O

Tetrahydrobiopterin	23782126	0	19	O
as	23782126	20	22	O
a	23782126	23	24	O
treatment	23782126	25	34	O
for	23782126	35	38	O
autism	23782126	39	45	O
spectrum	23782126	46	54	O
disorders	23782126	55	64	O
:	23782126	64	65	O
a	23782126	66	67	O
double-blind	23782126	68	80	O
,	23782126	80	81	O
placebo-controlled	23782126	82	100	O
trial	23782126	101	106	O
.	23782126	106	107	O

OBJECTIVE	23782126	109	118	O
:	23782126	119	120	O
The	23782126	121	124	O
purpose	23782126	125	132	O
of	23782126	133	135	O
this	23782126	136	140	O
study	23782126	141	146	O
was	23782126	147	150	O
to	23782126	151	153	O
determine	23782126	154	163	O
if	23782126	164	166	O
tetrahydrobiopterin	23782126	167	186	O
(	23782126	187	188	O
BH4	23782126	188	191	O
)	23782126	191	192	O
reduced	23782126	193	200	O
core	23782126	201	205	O
symptoms	23782126	206	214	O
of	23782126	215	217	O
autism	23782126	218	224	O
spectrum	23782126	225	233	O
disorder	23782126	234	242	O
(	23782126	243	244	O
ASD	23782126	244	247	O
)	23782126	247	248	O
.	23782126	248	249	O

METHOD	23782126	251	257	O
:	23782126	258	259	O
In	23782126	260	262	O
this	23782126	263	267	O
study	23782126	268	273	O
,	23782126	273	274	O
46	23782126	275	277	O
children	23782126	278	286	O
,	23782126	286	287	O
3	23782126	288	289	O
-	23782126	289	290	O
7	23782126	290	291	O
years	23782126	292	297	O
of	23782126	298	300	O
age	23782126	301	304	O
diagnosed	23782126	305	314	O
with	23782126	315	319	O
an	23782126	320	322	O
ASD	23782126	323	326	O
were	23782126	327	331	O
randomly	23782126	332	340	O
assigned	23782126	341	349	O
to	23782126	350	352	O
double-blind	23782126	353	365	O
treatment	23782126	366	375	O
with	23782126	376	380	O
20	23782126	381	383	O
mg/kg/day	23782126	384	393	O
BH4	23782126	394	397	O
or	23782126	398	400	O
placebo	23782126	401	408	O
for	23782126	409	412	O
16	23782126	413	415	O
weeks	23782126	416	421	O
.	23782126	421	422	O

The	23782126	423	426	O
primary	23782126	427	434	O
outcome	23782126	435	442	O
measure	23782126	443	450	O
was	23782126	451	454	O
the	23782126	455	458	O
Clinical	23782126	459	467	O
Global	23782126	468	474	O
Impressions	23782126	475	486	O
Improvement	23782126	487	498	O
and	23782126	499	502	O
Severity	23782126	503	511	O
Scales	23782126	512	518	O
(	23782126	519	520	O
CGI-I	23782126	520	525	O
and	23782126	526	529	O
CGI-S	23782126	530	535	O
)	23782126	535	536	O
;	23782126	536	537	O
secondary	23782126	538	547	O
outcomes	23782126	548	556	O
were	23782126	557	561	O
the	23782126	562	565	O
Preschool	23782126	566	575	O
Language	23782126	576	584	O
Scale-4	23782126	585	592	O
(	23782126	593	594	O
PLS-4	23782126	594	599	O
)	23782126	599	600	O
,	23782126	600	601	O
Social	23782126	602	608	O
Responsiveness	23782126	609	623	O
Scale	23782126	624	629	O
(	23782126	630	631	O
SRS	23782126	631	634	O
)	23782126	634	635	O
,	23782126	635	636	O
Aberrant	23782126	637	645	O
Behavior	23782126	646	654	O
Checklist	23782126	655	664	O
(	23782126	665	666	O
ABC	23782126	666	669	O
)	23782126	669	670	O
,	23782126	670	671	O
and	23782126	672	675	O
Vineland	23782126	676	684	O
Adaptive	23782126	685	693	O
Behavior	23782126	694	702	O
Scales	23782126	703	709	O
(	23782126	710	711	O
Vineland	23782126	711	719	O
)	23782126	719	720	O
.	23782126	720	721	O

RESULTS	23782126	723	730	O
:	23782126	731	732	O
Overall	23782126	733	740	O
,	23782126	740	741	O
no	23782126	742	744	O
differences	23782126	745	756	O
were	23782126	757	761	O
found	23782126	762	767	O
on	23782126	768	770	O
global	23782126	771	777	O
improvement	23782126	778	789	O
as	23782126	790	792	O
measured	23782126	793	801	O
with	23782126	802	806	O
the	23782126	807	810	O
CGI-I	23782126	811	816	B-Outcome
or	23782126	817	819	O
CGI-S.	23782126	820	826	B-Outcome
Secondary	23782126	827	836	O
measures	23782126	837	845	O
indicated	23782126	846	855	O
significant	23782126	856	867	O
improvements	23782126	868	880	O
for	23782126	881	884	O
BH4	23782126	885	888	O
relative	23782126	889	897	O
to	23782126	898	900	O
placebo	23782126	901	908	O
with	23782126	909	913	O
regard	23782126	914	920	O
to	23782126	921	923	O
social	23782126	924	930	B-Outcome
awareness	23782126	931	940	I-Outcome
,	23782126	940	941	O
autism	23782126	942	948	B-Outcome
mannerisms	23782126	949	959	I-Outcome
,	23782126	959	960	O
hyperactivity	23782126	961	974	B-Outcome
,	23782126	974	975	O
and	23782126	976	979	O
inappropriate	23782126	980	993	B-Outcome
speech	23782126	994	1000	I-Outcome
.	23782126	1000	1001	O

Side	23782126	1002	1006	B-Outcome
effects	23782126	1007	1014	I-Outcome
were	23782126	1015	1019	O
minimal	23782126	1020	1027	O
and	23782126	1028	1031	O
similar	23782126	1032	1039	O
between	23782126	1040	1047	O
both	23782126	1048	1052	O
active	23782126	1053	1059	O
medication	23782126	1060	1070	O
and	23782126	1071	1074	O
placebo	23782126	1075	1082	O
.	23782126	1082	1083	O

CONCLUSIONS	23782126	1085	1096	O
:	23782126	1097	1098	O
These	23782126	1099	1104	O
results	23782126	1105	1112	O
indicate	23782126	1113	1121	O
that	23782126	1122	1126	O
BH4	23782126	1127	1130	O
offers	23782126	1131	1137	O
promise	23782126	1138	1145	O
in	23782126	1146	1148	O
reducing	23782126	1149	1157	O
symptoms	23782126	1158	1166	O
of	23782126	1167	1169	O
ASD	23782126	1170	1173	O
.	23782126	1173	1174	O

Clinical	23782126	1175	1183	O
Trials.gov	23782126	1184	1194	O
Identifier	23782126	1195	1205	O
:	23782126	1205	1206	O
NCT00850070	23782126	1207	1218	O
.	23782126	1218	1219	O


Determinants	23902627	0	12	O
of	23902627	13	15	O
exclusive	23902627	16	25	O
breastfeeding	23902627	26	39	O
in	23902627	40	42	O
an	23902627	43	45	O
urban	23902627	46	51	O
population	23902627	52	62	O
of	23902627	63	65	O
primiparas	23902627	66	76	O
in	23902627	77	79	O
Lebanon	23902627	80	87	O
:	23902627	87	88	O
a	23902627	89	90	O
cross-sectional	23902627	91	106	O
study	23902627	107	112	O
.	23902627	112	113	O

BACKGROUND	23902627	115	125	O
:	23902627	126	127	O
The	23902627	128	131	O
proportion	23902627	132	142	O
of	23902627	143	145	O
mothers	23902627	146	153	O
who	23902627	154	157	O
exclusively	23902627	158	169	O
breastfeed	23902627	170	180	O
their	23902627	181	186	O
babies	23902627	187	193	O
up	23902627	194	196	O
to	23902627	197	199	O
6	23902627	200	201	O
months	23902627	202	208	O
remains	23902627	209	216	O
low	23902627	217	220	O
.	23902627	220	221	O

Determinants	23902627	222	234	O
of	23902627	235	237	O
breastfeeding	23902627	238	251	O
practices	23902627	252	261	O
have	23902627	262	266	O
been	23902627	267	271	O
largely	23902627	272	279	O
documented	23902627	280	290	O
in	23902627	291	293	O
high-income	23902627	294	305	O
countries	23902627	306	315	O
.	23902627	315	316	O

Little	23902627	317	323	O
evidence	23902627	324	332	O
exists	23902627	333	339	O
on	23902627	340	342	O
possible	23902627	343	351	O
predictors	23902627	352	362	O
of	23902627	363	365	O
breastfeeding	23902627	366	379	O
behaviors	23902627	380	389	O
in	23902627	390	392	O
the	23902627	393	396	O
Middle	23902627	397	403	O
East	23902627	404	408	O
.	23902627	408	409	O

Our	23902627	410	413	O
aim	23902627	414	417	O
was	23902627	418	421	O
to	23902627	422	424	O
assess	23902627	425	431	O
the	23902627	432	435	O
prevalence	23902627	436	446	O
of	23902627	447	449	O
breastfeeding	23902627	450	463	O
in	23902627	464	466	O
Beirut	23902627	467	473	O
and	23902627	474	477	O
determine	23902627	478	487	O
the	23902627	488	491	O
factors	23902627	492	499	O
that	23902627	500	504	O
impact	23902627	505	511	O
breastfeeding	23902627	512	525	O
behavior	23902627	526	534	O
in	23902627	535	537	O
this	23902627	538	542	O
population	23902627	543	553	O
.	23902627	553	554	O

METHODS	23902627	556	563	O
:	23902627	564	565	O
Data	23902627	566	570	O
for	23902627	571	574	O
this	23902627	575	579	O
longitudinal	23902627	580	592	O
study	23902627	593	598	O
is	23902627	599	601	O
nested	23902627	602	608	O
within	23902627	609	615	O
a	23902627	616	617	O
randomized	23902627	618	628	O
controlled	23902627	629	639	O
trial	23902627	640	645	O
(	23902627	646	647	O
RCT	23902627	647	650	O
)	23902627	650	651	O
assessing	23902627	652	661	O
the	23902627	662	665	O
impact	23902627	666	672	O
of	23902627	673	675	O
a	23902627	676	677	O
24-hour	23902627	678	685	O
hotline	23902627	686	693	O
and	23902627	694	697	O
postpartum	23902627	698	708	O
support	23902627	709	716	O
film	23902627	717	721	O
on	23902627	722	724	O
postpartum	23902627	725	735	O
stress	23902627	736	742	O
.	23902627	742	743	O

Healthy	23902627	744	751	O
first-time	23902627	752	762	O
mothers	23902627	763	770	O
delivering	23902627	771	781	O
in	23902627	782	784	O
the	23902627	785	788	O
capital	23902627	789	796	O
Beirut	23902627	797	803	O
between	23902627	804	811	O
March	23902627	812	817	O
and	23902627	818	821	O
July	23902627	822	826	O
2009	23902627	827	831	O
,	23902627	831	832	O
were	23902627	833	837	O
interviewed	23902627	838	849	O
at	23902627	850	852	O
1	23902627	853	854	O
-	23902627	854	855	O
3	23902627	855	856	O
days	23902627	857	861	O
and	23902627	862	865	O
8	23902627	866	867	O
-	23902627	867	868	O
12	23902627	868	870	O
weeks	23902627	871	876	O
post	23902627	877	881	O
delivery	23902627	882	890	O
.	23902627	890	891	O

A	23902627	892	893	O
multiple	23902627	894	902	O
logistic	23902627	903	911	O
regression	23902627	912	922	O
analysis	23902627	923	931	O
was	23902627	932	935	O
used	23902627	936	940	O
to	23902627	941	943	O
determine	23902627	944	953	O
the	23902627	954	957	O
factors	23902627	958	965	O
associated	23902627	966	976	O
with	23902627	977	981	O
exclusive	23902627	982	991	O
breastfeeding	23902627	992	1005	O
at	23902627	1006	1008	O
8	23902627	1009	1010	O
-	23902627	1010	1011	O
12	23902627	1011	1013	O
weeks	23902627	1014	1019	O
postpartum	23902627	1020	1030	O
.	23902627	1030	1031	O

RESULTS	23902627	1033	1040	O
:	23902627	1041	1042	O
The	23902627	1043	1046	O
overall	23902627	1047	1054	B-Outcome
breastfeeding	23902627	1055	1068	I-Outcome
rate	23902627	1069	1073	I-Outcome
at	23902627	1074	1076	I-Outcome
8	23902627	1077	1078	I-Outcome
-	23902627	1078	1079	I-Outcome
12	23902627	1079	1081	I-Outcome
weeks	23902627	1082	1087	I-Outcome
postpartum	23902627	1088	1098	I-Outcome
was	23902627	1099	1102	O
67	23902627	1103	1105	O
%	23902627	1105	1106	O
.	23902627	1106	1107	O

The	23902627	1108	1111	O
exclusive	23902627	1112	1121	B-Outcome
breastfeeding	23902627	1122	1135	I-Outcome
rate	23902627	1136	1140	I-Outcome
was	23902627	1141	1144	O
27.4	23902627	1145	1149	O
%	23902627	1149	1150	O
.	23902627	1150	1151	O

Factors	23902627	1152	1159	B-Outcome
associated	23902627	1160	1170	I-Outcome
with	23902627	1171	1175	I-Outcome
exclusive	23902627	1176	1185	I-Outcome
breastfeeding	23902627	1186	1199	I-Outcome
included	23902627	1200	1208	O
maternal	23902627	1209	1217	O
work	23902627	1218	1222	O
(	23902627	1223	1224	O
OR=3.92	23902627	1224	1231	O
;	23902627	1231	1232	O
p-value<0.001	23902627	1233	1246	O
)	23902627	1246	1247	O
,	23902627	1247	1248	O
planned	23902627	1249	1256	O
pregnancy	23902627	1257	1266	O
(	23902627	1267	1268	O
OR=2.42	23902627	1268	1275	O
,	23902627	1275	1276	O
p-value=0.010	23902627	1277	1290	O
)	23902627	1290	1291	O
,	23902627	1291	1292	O
intention	23902627	1293	1302	O
to	23902627	1303	1305	O
breastfeed	23902627	1306	1316	O
(	23902627	1317	1318	O
OR=3.28	23902627	1318	1325	O
;	23902627	1325	1326	O
p-value=0.043	23902627	1327	1340	O
)	23902627	1340	1341	O
,	23902627	1341	1342	O
source	23902627	1343	1349	O
of	23902627	1350	1352	O
maternal	23902627	1353	1361	O
emotional	23902627	1362	1371	O
support	23902627	1372	1379	O
(	23902627	1380	1381	O
OR=1.87	23902627	1381	1388	O
,	23902627	1388	1389	O
p-value=0.039	23902627	1390	1403	O
)	23902627	1403	1404	O
and	23902627	1405	1408	O
the	23902627	1409	1412	O
use	23902627	1413	1416	O
the	23902627	1417	1420	O
postpartum	23902627	1421	1431	O
support	23902627	1432	1439	O
video	23902627	1440	1445	O
,	23902627	1445	1446	O
the	23902627	1447	1450	O
hotline	23902627	1451	1458	O
service	23902627	1459	1466	O
or	23902627	1467	1469	O
both	23902627	1470	1474	O
(	23902627	1475	1476	O
OR=2.55	23902627	1476	1483	O
,	23902627	1483	1484	O
p-value=0.044	23902627	1485	1498	O
;	23902627	1498	1499	O
OR=3.87	23902627	1500	1507	O
,	23902627	1507	1508	O
p-value=0.004	23902627	1509	1522	O
and	23902627	1523	1526	O
OR=4.13	23902627	1527	1534	O
,	23902627	1534	1535	O
p-value=0.003	23902627	1536	1549	O
)	23902627	1549	1550	O
.	23902627	1550	1551	O

CONCLUSIONS	23902627	1553	1564	O
:	23902627	1565	1566	O
The	23902627	1567	1570	O
proportion	23902627	1571	1581	O
of	23902627	1582	1584	O
healthy	23902627	1585	1592	O
first-time	23902627	1593	1603	O
mothers	23902627	1604	1611	O
who	23902627	1612	1615	O
exclusively	23902627	1616	1627	B-Outcome
breastfeed	23902627	1628	1638	I-Outcome
in	23902627	1639	1641	O
Beirut	23902627	1642	1648	O
is	23902627	1649	1651	O
extremely	23902627	1652	1661	O
low	23902627	1662	1665	O
.	23902627	1665	1666	O

Factors	23902627	1667	1674	B-Outcome
associated	23902627	1675	1685	I-Outcome
with	23902627	1686	1690	I-Outcome
breastfeeding	23902627	1691	1704	I-Outcome
behavior	23902627	1705	1713	I-Outcome
are	23902627	1714	1717	O
diverse	23902627	1718	1725	O
.	23902627	1725	1726	O

Future	23902627	1727	1733	O
research	23902627	1734	1742	O
and	23902627	1743	1746	O
interventions	23902627	1747	1760	O
should	23902627	1761	1767	O
target	23902627	1768	1774	O
different	23902627	1775	1784	O
levels	23902627	1785	1791	O
of	23902627	1792	1794	O
the	23902627	1795	1798	O
maternal-child	23902627	1799	1813	O
pair	23902627	1814	1818	O
's	23902627	1818	1820	O
ecosystem	23902627	1821	1830	O
.	23902627	1830	1831	O

TRIAL	23902627	1833	1838	O
REGISTRATION	23902627	1839	1851	O
:	23902627	1852	1853	O
ClinicalTrials.gov	23902627	1854	1872	O
,	23902627	1872	1873	O
NCT00857051	23902627	1874	1885	O
.	23902627	1885	1886	O


Efficacy	23964752	0	8	O
and	23964752	9	12	O
safety	23964752	13	19	O
of	23964752	20	22	O
diclofenac	23964752	23	33	O
diethylamine	23964752	34	46	O
1.16	23964752	47	51	O
%	23964752	51	52	O
gel	23964752	53	56	O
in	23964752	57	59	O
acute	23964752	60	65	O
neck	23964752	66	70	O
pain	23964752	71	75	O
:	23964752	75	76	O
a	23964752	77	78	O
randomized	23964752	79	89	O
,	23964752	89	90	O
double-blind	23964752	91	103	O
,	23964752	103	104	O
placebo-controlled	23964752	105	123	O
study	23964752	124	129	O
.	23964752	129	130	O

BACKGROUND	23964752	132	142	O
:	23964752	143	144	O
Neck	23964752	145	149	O
pain	23964752	150	154	O
(	23964752	155	156	O
NP	23964752	156	158	O
)	23964752	158	159	O
is	23964752	160	162	O
a	23964752	163	164	O
common	23964752	165	171	O
musculoskeletal	23964752	172	187	O
disorder	23964752	188	196	O
in	23964752	197	199	O
primary	23964752	200	207	O
care	23964752	208	212	O
that	23964752	213	217	O
frequently	23964752	218	228	O
causes	23964752	229	235	O
discomfort	23964752	236	246	O
.	23964752	246	247	O

Non-steroidal	23964752	248	261	O
anti-inflammatory	23964752	262	279	O
drugs	23964752	280	285	O
(	23964752	286	287	O
NSAIDs	23964752	287	293	O
)	23964752	293	294	O
may	23964752	295	298	O
be	23964752	299	301	O
used	23964752	302	306	O
to	23964752	307	309	O
reduce	23964752	310	316	O
neck	23964752	317	321	O
pain	23964752	322	326	O
and	23964752	327	330	O
associated	23964752	331	341	O
inflammation	23964752	342	354	O
and	23964752	355	358	O
facilitate	23964752	359	369	O
earlier	23964752	370	377	O
recovery	23964752	378	386	O
.	23964752	386	387	O

Topical	23964752	388	395	O
diclofenac	23964752	396	406	O
diethylamine	23964752	407	419	O
(	23964752	420	421	O
DDEA	23964752	421	425	O
)	23964752	425	426	O
1.16	23964752	427	431	O
%	23964752	431	432	O
gel	23964752	433	436	O
is	23964752	437	439	O
clinically	23964752	440	450	O
proven	23964752	451	457	O
to	23964752	458	460	O
be	23964752	461	463	O
effective	23964752	464	473	O
and	23964752	474	477	O
well	23964752	478	482	O
tolerated	23964752	483	492	O
in	23964752	493	495	O
acute	23964752	496	501	O
and	23964752	502	505	O
chronic	23964752	506	513	O
musculoskeletal	23964752	514	529	O
conditions	23964752	530	540	O
,	23964752	540	541	O
but	23964752	542	545	O
until	23964752	546	551	O
now	23964752	552	555	O
no	23964752	556	558	O
clinical	23964752	559	567	O
data	23964752	568	572	O
existed	23964752	573	580	O
for	23964752	581	584	O
its	23964752	585	588	O
use	23964752	589	592	O
in	23964752	593	595	O
acute	23964752	596	601	O
NP	23964752	602	604	O
.	23964752	604	605	O

The	23964752	606	609	O
aim	23964752	610	613	O
of	23964752	614	616	O
this	23964752	617	621	O
study	23964752	622	627	O
was	23964752	628	631	O
to	23964752	632	634	O
assess	23964752	635	641	O
the	23964752	642	645	O
efficacy	23964752	646	654	O
and	23964752	655	658	O
safety	23964752	659	665	O
of	23964752	666	668	O
DDEA	23964752	669	673	O
1.16	23964752	674	678	O
%	23964752	678	679	O
gel	23964752	680	683	O
compared	23964752	684	692	O
with	23964752	693	697	O
placebo	23964752	698	705	O
gel	23964752	706	709	O
in	23964752	710	712	O
acute	23964752	713	718	O
NP	23964752	719	721	O
.	23964752	721	722	O

METHODS	23964752	724	731	O
:	23964752	732	733	O
In	23964752	734	736	O
a	23964752	737	738	O
randomized	23964752	739	749	O
,	23964752	749	750	O
double-blind	23964752	751	763	O
,	23964752	763	764	O
placebo-controlled	23964752	765	783	O
study	23964752	784	789	O
,	23964752	789	790	O
patients	23964752	791	799	O
with	23964752	800	804	O
acute	23964752	805	810	O
NP	23964752	811	813	O
(	23964752	814	815	O
n	23964752	815	816	O
=	23964752	817	818	O
72	23964752	819	821	O
)	23964752	821	822	O
were	23964752	823	827	O
treated	23964752	828	835	O
with	23964752	836	840	O
DDEA	23964752	841	845	O
1.16	23964752	846	850	O
%	23964752	850	851	O
gel	23964752	852	855	O
(	23964752	856	857	O
2	23964752	857	858	O
g	23964752	859	860	O
,	23964752	860	861	O
4x/day	23964752	862	868	O
,	23964752	868	869	O
for	23964752	870	873	O
5	23964752	874	875	O
days	23964752	876	880	O
)	23964752	880	881	O
or	23964752	882	884	O
placebo	23964752	885	892	O
.	23964752	892	893	O

Efficacy	23964752	894	902	O
assessments	23964752	903	914	O
included	23964752	915	923	O
pain-on-movement	23964752	924	940	O
(	23964752	941	942	O
POM	23964752	942	945	O
)	23964752	945	946	O
,	23964752	946	947	O
pain-at-rest	23964752	948	960	O
(	23964752	961	962	O
PAR	23964752	962	965	O
)	23964752	965	966	O
,	23964752	966	967	O
functional	23964752	968	978	O
neck	23964752	979	983	O
disability	23964752	984	994	O
index	23964752	995	1000	O
(	23964752	1001	1002	O
NDI	23964752	1002	1005	O
)	23964752	1005	1006	O
and	23964752	1007	1010	O
response	23964752	1011	1019	O
to	23964752	1020	1022	O
treatment	23964752	1023	1032	O
(	23964752	1033	1034	O
decrease	23964752	1034	1042	O
in	23964752	1043	1045	O
POM	23964752	1046	1049	O
by	23964752	1050	1052	O
50	23964752	1053	1055	O
%	23964752	1055	1056	O
after	23964752	1057	1062	O
48	23964752	1063	1065	O
h	23964752	1066	1067	O
)	23964752	1067	1068	O
.	23964752	1068	1069	O

Adverse	23964752	1070	1077	O
events	23964752	1078	1084	O
(	23964752	1085	1086	O
AEs	23964752	1086	1089	O
)	23964752	1089	1090	O
were	23964752	1091	1095	O
recorded	23964752	1096	1104	O
throughout	23964752	1105	1115	O
the	23964752	1116	1119	O
study	23964752	1120	1125	O
.	23964752	1125	1126	O

RESULTS	23964752	1128	1135	O
:	23964752	1136	1137	O
The	23964752	1138	1141	O
primary	23964752	1142	1149	O
outcome	23964752	1150	1157	O
,	23964752	1157	1158	O
POM	23964752	1159	1162	B-Outcome
at	23964752	1163	1165	I-Outcome
48	23964752	1166	1168	I-Outcome
h	23964752	1169	1170	I-Outcome
,	23964752	1170	1171	O
was	23964752	1172	1175	O
statistically	23964752	1176	1189	O
significantly	23964752	1190	1203	O
lower	23964752	1204	1209	O
with	23964752	1210	1214	O
DDEA	23964752	1215	1219	O
gel	23964752	1220	1223	O
(	23964752	1224	1225	O
19.5	23964752	1225	1229	O
mm	23964752	1230	1232	O
)	23964752	1232	1233	O
vs.	23964752	1234	1237	O
placebo	23964752	1238	1245	O
(	23964752	1246	1247	O
56.9	23964752	1247	1251	O
mm	23964752	1252	1254	O
)	23964752	1254	1255	O
(	23964752	1256	1257	O
p	23964752	1257	1258	O
<	23964752	1259	1260	O
0.0001	23964752	1261	1267	O
)	23964752	1267	1268	O
,	23964752	1268	1269	O
representing	23964752	1270	1282	O
a	23964752	1283	1284	O
clinically	23964752	1285	1295	O
relevant	23964752	1296	1304	O
decrease	23964752	1305	1313	O
from	23964752	1314	1318	O
baseline	23964752	1319	1327	O
(	23964752	1328	1329	O
75	23964752	1329	1331	O
%	23964752	1331	1332	O
vs.	23964752	1333	1336	O
23	23964752	1337	1339	O
%	23964752	1339	1340	O
,	23964752	1340	1341	O
respectively	23964752	1342	1354	O
)	23964752	1354	1355	O
.	23964752	1355	1356	O

All	23964752	1357	1360	O
POM	23964752	1361	1364	B-Outcome
scores	23964752	1365	1371	I-Outcome
were	23964752	1372	1376	O
significantly	23964752	1377	1390	O
lower	23964752	1391	1396	O
with	23964752	1397	1401	O
DDEA	23964752	1402	1406	O
gel	23964752	1407	1410	O
vs.	23964752	1411	1414	O
placebo	23964752	1415	1422	O
from	23964752	1423	1427	O
1	23964752	1428	1429	O
h	23964752	1430	1431	O
,	23964752	1431	1432	O
as	23964752	1433	1435	O
were	23964752	1436	1440	O
PAR	23964752	1441	1444	B-Outcome
and	23964752	1445	1448	O
NDI	23964752	1449	1452	B-Outcome
scores	23964752	1453	1459	I-Outcome
from	23964752	1460	1464	O
first	23964752	1465	1470	O
assessment	23964752	1471	1481	O
(	23964752	1482	1483	O
24	23964752	1483	1485	O
h	23964752	1486	1487	O
)	23964752	1487	1488	O
onwards	23964752	1489	1496	O
(	23964752	1497	1498	O
all	23964752	1498	1501	O
p	23964752	1502	1503	O
<	23964752	1504	1505	O
0.0001	23964752	1506	1512	O
)	23964752	1512	1513	O
.	23964752	1513	1514	O

Response	23964752	1515	1523	B-Outcome
to	23964752	1524	1526	I-Outcome
treatment	23964752	1527	1536	I-Outcome
was	23964752	1537	1540	O
significantly	23964752	1541	1554	O
higher	23964752	1555	1561	O
with	23964752	1562	1566	O
DDEA	23964752	1567	1571	O
gel	23964752	1572	1575	O
(	23964752	1576	1577	O
94.4	23964752	1577	1581	O
%	23964752	1581	1582	O
)	23964752	1582	1583	O
vs.	23964752	1584	1587	O
placebo	23964752	1588	1595	O
(	23964752	1596	1597	O
8.3	23964752	1597	1600	O
%	23964752	1600	1601	O
)	23964752	1601	1602	O
(	23964752	1603	1604	O
p	23964752	1604	1605	O
<	23964752	1606	1607	O
0.0001	23964752	1608	1614	O
)	23964752	1614	1615	O
.	23964752	1615	1616	O

There	23964752	1617	1622	O
were	23964752	1623	1627	O
no	23964752	1628	1630	O
AEs	23964752	1631	1634	B-Outcome
with	23964752	1635	1639	O
DDEA	23964752	1640	1644	O
gel	23964752	1645	1648	O
.	23964752	1648	1649	O

CONCLUSIONS	23964752	1651	1662	O
:	23964752	1663	1664	O
DDEA	23964752	1665	1669	O
1.16	23964752	1670	1674	O
%	23964752	1674	1675	O
gel	23964752	1676	1679	O
,	23964752	1679	1680	O
which	23964752	1681	1686	O
is	23964752	1687	1689	O
available	23964752	1690	1699	O
over-the-counter	23964752	1700	1716	O
,	23964752	1716	1717	O
was	23964752	1718	1721	O
effective	23964752	1722	1731	O
and	23964752	1732	1735	O
well	23964752	1736	1740	O
tolerated	23964752	1741	1750	B-Outcome
in	23964752	1751	1753	O
the	23964752	1754	1757	O
treatment	23964752	1758	1767	O
of	23964752	1768	1770	O
acute	23964752	1771	1776	O
neck	23964752	1777	1781	O
pain	23964752	1782	1786	O
.	23964752	1786	1787	O

The	23964752	1788	1791	O
tools	23964752	1792	1797	O
used	23964752	1798	1802	O
to	23964752	1803	1805	O
assess	23964752	1806	1812	O
efficacy	23964752	1813	1821	B-Outcome
suggest	23964752	1822	1829	O
that	23964752	1830	1834	O
it	23964752	1835	1837	O
quickly	23964752	1838	1845	O
reduced	23964752	1846	1853	O
neck	23964752	1854	1858	B-Outcome
pain	23964752	1859	1863	I-Outcome
and	23964752	1864	1867	O
improved	23964752	1868	1876	O
neck	23964752	1877	1881	B-Outcome
function	23964752	1882	1890	I-Outcome
.	23964752	1890	1891	O

However	23964752	1892	1899	O
,	23964752	1899	1900	O
questions	23964752	1901	1910	O
remain	23964752	1911	1917	O
regarding	23964752	1918	1927	O
the	23964752	1928	1931	O
comparability	23964752	1932	1945	O
and	23964752	1946	1949	O
validity	23964752	1950	1958	O
of	23964752	1959	1961	O
such	23964752	1962	1966	O
tools	23964752	1967	1972	O
.	23964752	1972	1973	O

Further	23964752	1974	1981	O
studies	23964752	1982	1989	O
will	23964752	1990	1994	O
help	23964752	1995	1999	O
ascertain	23964752	2000	2009	O
whether	23964752	2010	2017	O
DDEA	23964752	2018	2022	O
1.16	23964752	2023	2027	O
%	23964752	2027	2028	O
gel	23964752	2029	2032	O
offers	23964752	2033	2039	O
an	23964752	2040	2042	O
alternative	23964752	2043	2054	O
treatment	23964752	2055	2064	O
option	23964752	2065	2071	O
in	23964752	2072	2074	O
this	23964752	2075	2079	O
common	23964752	2080	2086	O
,	23964752	2086	2087	O
often	23964752	2088	2093	O
debilitating	23964752	2094	2106	O
condition	23964752	2107	2116	O
.	23964752	2116	2117	O

TRIAL	23964752	2119	2124	O
REGISTRATION	23964752	2125	2137	O
:	23964752	2138	2139	O
ClinicalTrials.gov	23964752	2140	2158	O
identifier	23964752	2159	2169	O
:	23964752	2169	2170	O
NCT01335724	23964752	2171	2182	O
.	23964752	2182	2183	O


A	24004700	0	1	O
randomized	24004700	2	12	O
controlled	24004700	13	23	O
trial	24004700	24	29	O
to	24004700	30	32	O
improve	24004700	33	40	O
colon	24004700	41	46	O
cancer	24004700	47	53	O
screening	24004700	54	63	O
in	24004700	64	66	O
rural	24004700	67	72	O
family	24004700	73	79	O
medicine	24004700	80	88	O
:	24004700	88	89	O
an	24004700	90	92	O
Iowa	24004700	93	97	O
Research	24004700	98	106	O
Network	24004700	107	114	O
(	24004700	115	116	O
IRENE	24004700	116	121	O
)	24004700	121	122	O
study	24004700	123	128	O
.	24004700	128	129	O

BACKGROUND	24004700	131	141	O
:	24004700	142	143	O
Many	24004700	144	148	O
adults	24004700	149	155	O
have	24004700	156	160	O
not	24004700	161	164	O
been	24004700	165	169	O
screened	24004700	170	178	O
for	24004700	179	182	O
colon	24004700	183	188	O
cancer	24004700	189	195	O
,	24004700	195	196	O
a	24004700	197	198	O
potentially	24004700	199	210	O
preventable	24004700	211	222	O
cause	24004700	223	228	O
of	24004700	229	231	O
death	24004700	232	237	O
.	24004700	237	238	O

METHODS	24004700	240	247	O
:	24004700	248	249	O
This	24004700	250	254	O
was	24004700	255	258	O
a	24004700	259	260	O
randomized	24004700	261	271	O
controlled	24004700	272	282	O
trial	24004700	283	288	O
conducted	24004700	289	298	O
between	24004700	299	306	O
December	24004700	307	315	O
2008	24004700	316	320	O
and	24004700	321	324	O
April	24004700	325	330	O
2011	24004700	331	335	O
to	24004700	336	338	O
improve	24004700	339	346	O
CRC	24004700	347	350	O
screening	24004700	351	360	O
in	24004700	361	363	O
16	24004700	364	366	O
rural	24004700	367	372	O
family	24004700	373	379	O
physician	24004700	380	389	O
offices	24004700	390	397	O
.	24004700	397	398	O

Subjects	24004700	399	407	O
due	24004700	408	411	O
for	24004700	412	415	O
CRC	24004700	416	419	O
screening	24004700	420	429	O
were	24004700	430	434	O
randomized	24004700	435	445	O
within	24004700	446	452	O
each	24004700	453	457	O
practice	24004700	458	466	O
to	24004700	467	469	O
1	24004700	470	471	O
of	24004700	472	474	O
4	24004700	475	476	O
groups	24004700	477	483	O
:	24004700	483	484	O
(	24004700	485	486	O
1	24004700	486	487	O
)	24004700	487	488	O
usual	24004700	489	494	O
care	24004700	495	499	O
;	24004700	499	500	O
(	24004700	501	502	O
2	24004700	502	503	O
)	24004700	503	504	O
physician	24004700	505	514	O
chart	24004700	515	520	O
reminder	24004700	521	529	O
;	24004700	529	530	O
(	24004700	531	532	O
3	24004700	532	533	O
)	24004700	533	534	O
physician	24004700	535	544	O
chart	24004700	545	550	O
reminder	24004700	551	559	O
,	24004700	559	560	O
mailed	24004700	561	567	O
education	24004700	568	577	O
,	24004700	577	578	O
CRC	24004700	579	582	O
reminder	24004700	583	591	O
magnet	24004700	592	598	O
,	24004700	598	599	O
and	24004700	600	603	O
fecal	24004700	604	609	O
immunochemical	24004700	610	624	O
test	24004700	625	629	O
(	24004700	630	631	O
FIT	24004700	631	634	O
)	24004700	634	635	O
(	24004700	636	637	O
mailed	24004700	637	643	O
education/FIT	24004700	644	657	O
)	24004700	657	658	O
;	24004700	658	659	O
or	24004700	660	662	O
(	24004700	663	664	O
4	24004700	664	665	O
)	24004700	665	666	O
all	24004700	667	670	O
the	24004700	671	674	O
preceding	24004700	675	684	O
plus	24004700	685	689	O
a	24004700	690	691	O
structured	24004700	692	702	O
telephone	24004700	703	712	O
call	24004700	713	717	O
to	24004700	718	720	O
the	24004700	721	724	O
patient	24004700	725	732	O
from	24004700	733	737	O
project	24004700	738	745	O
staff	24004700	746	751	O
to	24004700	752	754	O
provide	24004700	755	762	O
education	24004700	763	772	O
,	24004700	772	773	O
assess	24004700	774	780	O
interest	24004700	781	789	O
in	24004700	790	792	O
screening	24004700	793	802	O
,	24004700	802	803	O
explain	24004700	804	811	O
the	24004700	812	815	O
screening	24004700	816	825	O
tests	24004700	826	831	O
,	24004700	831	832	O
and	24004700	833	836	O
address	24004700	837	844	O
barriers	24004700	845	853	O
(	24004700	854	855	O
mailed	24004700	855	861	O
education/FIT	24004700	862	875	O
plus	24004700	876	880	O
phone	24004700	881	886	O
call	24004700	887	891	O
)	24004700	891	892	O
.	24004700	892	893	O

The	24004700	894	897	O
main	24004700	898	902	O
outcome	24004700	903	910	O
was	24004700	911	914	O
completion	24004700	915	925	O
of	24004700	926	928	O
any	24004700	929	932	O
CRC	24004700	933	936	O
screening	24004700	937	946	O
.	24004700	946	947	O

RESULTS	24004700	949	956	O
:	24004700	957	958	O
This	24004700	959	963	O
study	24004700	964	969	O
enrolled	24004700	970	978	O
743	24004700	979	982	O
patients	24004700	983	991	O
.	24004700	991	992	O

CRC	24004700	993	996	B-Outcome
screening	24004700	997	1006	I-Outcome
was	24004700	1007	1010	O
completed	24004700	1011	1020	O
by	24004700	1021	1023	O
17.8	24004700	1024	1028	O
%	24004700	1028	1029	O
in	24004700	1030	1032	O
the	24004700	1033	1036	O
usual	24004700	1037	1042	O
care	24004700	1043	1047	O
group	24004700	1048	1053	O
,	24004700	1053	1054	O
20.5	24004700	1055	1059	O
%	24004700	1059	1060	O
in	24004700	1061	1063	O
the	24004700	1064	1067	O
chart	24004700	1068	1073	O
reminder	24004700	1074	1082	O
group	24004700	1083	1088	O
,	24004700	1088	1089	O
56.5	24004700	1090	1094	O
%	24004700	1094	1095	O
in	24004700	1096	1098	O
the	24004700	1099	1102	O
mailed	24004700	1103	1109	O
education/FIT	24004700	1110	1123	O
group	24004700	1124	1129	O
,	24004700	1129	1130	O
and	24004700	1131	1134	O
57.2	24004700	1135	1139	O
%	24004700	1139	1140	O
in	24004700	1141	1143	O
the	24004700	1144	1147	O
mailed	24004700	1148	1154	O
education/FIT	24004700	1155	1168	O
plus	24004700	1169	1173	O
phone	24004700	1174	1179	O
call	24004700	1180	1184	O
group	24004700	1185	1190	O
.	24004700	1190	1191	O

We	24004700	1192	1194	O
found	24004700	1195	1200	O
no	24004700	1201	1203	O
effect	24004700	1204	1210	O
from	24004700	1211	1215	O
the	24004700	1216	1219	O
chart	24004700	1220	1225	O
reminder	24004700	1226	1234	O
compared	24004700	1235	1243	O
with	24004700	1244	1248	O
usual	24004700	1249	1254	O
care	24004700	1255	1259	O
(	24004700	1260	1261	O
odds	24004700	1261	1265	O
ratio	24004700	1266	1271	O
[	24004700	1272	1273	O
OR	24004700	1273	1275	O
]	24004700	1275	1276	O
,	24004700	1276	1277	O
1.2	24004700	1278	1281	O
;	24004700	1281	1282	O
95	24004700	1283	1285	O
%	24004700	1285	1286	O
confidence	24004700	1287	1297	O
interval	24004700	1298	1306	O
[	24004700	1307	1308	O
CI	24004700	1308	1310	O
]	24004700	1310	1311	O
,	24004700	1311	1312	O
0.7	24004700	1313	1316	O
-	24004700	1316	1317	O
2.0	24004700	1317	1320	O
)	24004700	1320	1321	O
;	24004700	1321	1322	O
and	24004700	1323	1326	O
a	24004700	1327	1328	O
beneficial	24004700	1329	1339	O
effect	24004700	1340	1346	O
from	24004700	1347	1351	O
the	24004700	1352	1355	O
mailed	24004700	1356	1362	O
education/FIT	24004700	1363	1376	O
(	24004700	1377	1378	O
OR	24004700	1378	1380	O
,	24004700	1380	1381	O
6.0	24004700	1382	1385	O
;	24004700	1385	1386	O
95	24004700	1387	1389	O
%	24004700	1389	1390	O
CI	24004700	1391	1393	O
,	24004700	1393	1394	O
3.7	24004700	1395	1398	O
-	24004700	1398	1399	O
9.6	24004700	1399	1402	O
)	24004700	1402	1403	O
and	24004700	1404	1407	O
the	24004700	1408	1411	O
mailed	24004700	1412	1418	O
education/FIT	24004700	1419	1432	O
plus	24004700	1433	1437	O
phone	24004700	1438	1443	O
call	24004700	1444	1448	O
(	24004700	1449	1450	O
OR	24004700	1450	1452	O
,	24004700	1452	1453	O
6.2	24004700	1454	1457	O
;	24004700	1457	1458	O
95	24004700	1459	1461	O
%	24004700	1461	1462	O
CI	24004700	1463	1465	O
,	24004700	1465	1466	O
3.8	24004700	1467	1470	O
-	24004700	1470	1471	O
9.9	24004700	1471	1474	O
)	24004700	1474	1475	O
.	24004700	1475	1476	O

Both	24004700	1477	1481	O
FIT	24004700	1482	1485	O
and	24004700	1486	1489	O
colonoscopy	24004700	1490	1501	B-Outcome
rates	24004700	1502	1507	I-Outcome
increased	24004700	1508	1517	O
significantly	24004700	1518	1531	O
in	24004700	1532	1534	O
both	24004700	1535	1539	O
mailed	24004700	1540	1546	O
education	24004700	1547	1556	O
groups	24004700	1557	1563	O
.	24004700	1563	1564	O

CONCLUSION	24004700	1566	1576	O
:	24004700	1577	1578	O
CRC	24004700	1579	1582	B-Outcome
screening	24004700	1583	1592	I-Outcome
rates	24004700	1593	1598	I-Outcome
increased	24004700	1599	1608	O
significantly	24004700	1609	1622	O
among	24004700	1623	1628	O
patients	24004700	1629	1637	O
who	24004700	1638	1641	O
were	24004700	1642	1646	O
overdue	24004700	1647	1654	O
for	24004700	1655	1658	O
screening	24004700	1659	1668	O
after	24004700	1669	1674	O
they	24004700	1675	1679	O
received	24004700	1680	1688	O
mailed	24004700	1689	1695	O
educational	24004700	1696	1707	O
materials	24004700	1708	1717	O
and	24004700	1718	1721	O
a	24004700	1722	1723	O
FIT	24004700	1724	1727	O
.	24004700	1727	1728	O

The	24004700	1729	1732	O
addition	24004700	1733	1741	O
of	24004700	1742	1744	O
a	24004700	1745	1746	O
phone	24004700	1747	1752	O
call	24004700	1753	1757	O
did	24004700	1758	1761	O
not	24004700	1762	1765	O
further	24004700	1766	1773	O
increase	24004700	1774	1782	O
screening	24004700	1783	1792	B-Outcome
rates	24004700	1793	1798	I-Outcome
.	24004700	1798	1799	O


Baseline	24061784	0	8	O
factors	24061784	9	16	O
predicting	24061784	17	27	O
placebo	24061784	28	35	O
response	24061784	36	44	O
to	24061784	45	47	O
treatment	24061784	48	57	O
in	24061784	58	60	O
children	24061784	61	69	O
and	24061784	70	73	O
adolescents	24061784	74	85	O
with	24061784	86	90	O
autism	24061784	91	97	O
spectrum	24061784	98	106	O
disorders	24061784	107	116	O
:	24061784	116	117	O
a	24061784	118	119	O
multisite	24061784	120	129	O
randomized	24061784	130	140	O
clinical	24061784	141	149	O
trial	24061784	150	155	O
.	24061784	155	156	O

IMPORTANCE	24061784	158	168	O
:	24061784	169	170	O
The	24061784	171	174	O
finding	24061784	175	182	O
of	24061784	183	185	O
factors	24061784	186	193	O
that	24061784	194	198	O
differentially	24061784	199	213	O
predict	24061784	214	221	O
the	24061784	222	225	O
likelihood	24061784	226	236	O
of	24061784	237	239	O
response	24061784	240	248	O
to	24061784	249	251	O
placebo	24061784	252	259	O
over	24061784	260	264	O
that	24061784	265	269	O
of	24061784	270	272	O
an	24061784	273	275	O
active	24061784	276	282	O
drug	24061784	283	287	O
could	24061784	288	293	O
have	24061784	294	298	O
a	24061784	299	300	O
significant	24061784	301	312	O
impact	24061784	313	319	O
on	24061784	320	322	O
study	24061784	323	328	O
design	24061784	329	335	O
in	24061784	336	338	O
this	24061784	339	343	O
population	24061784	344	354	O
.	24061784	354	355	O

OBJECTIVE	24061784	357	366	O
:	24061784	367	368	O
To	24061784	369	371	O
identify	24061784	372	380	O
possible	24061784	381	389	O
nonspecific	24061784	390	401	O
,	24061784	401	402	O
baseline	24061784	403	411	O
predictors	24061784	412	422	O
of	24061784	423	425	O
response	24061784	426	434	O
to	24061784	435	437	O
intervention	24061784	438	450	O
in	24061784	451	453	O
a	24061784	454	455	O
large	24061784	456	461	O
randomized	24061784	462	472	O
clinical	24061784	473	481	O
trial	24061784	482	487	O
of	24061784	488	490	O
children	24061784	491	499	O
and	24061784	500	503	O
adolescents	24061784	504	515	O
with	24061784	516	520	O
autism	24061784	521	527	O
spectrum	24061784	528	536	O
disorders	24061784	537	546	O
.	24061784	546	547	O

DESIGN	24061784	549	555	O
,	24061784	555	556	O
SETTING	24061784	557	564	O
,	24061784	564	565	O
AND	24061784	566	569	O
PARTICIPANTS	24061784	570	582	O
:	24061784	583	584	O
Randomized	24061784	585	595	O
clinical	24061784	596	604	O
trial	24061784	605	610	O
of	24061784	611	613	O
citalopram	24061784	614	624	O
hydrobromide	24061784	625	637	O
for	24061784	638	641	O
children	24061784	642	650	O
and	24061784	651	654	O
adolescents	24061784	655	666	O
with	24061784	667	671	O
autism	24061784	672	678	O
spectrum	24061784	679	687	O
disorders	24061784	688	697	O
and	24061784	698	701	O
prominent	24061784	702	711	O
repetitive	24061784	712	722	O
behavior	24061784	723	731	O
.	24061784	731	732	O

Baseline	24061784	733	741	O
data	24061784	742	746	O
at	24061784	747	749	O
study	24061784	750	755	O
entry	24061784	756	761	O
were	24061784	762	766	O
examined	24061784	767	775	O
with	24061784	776	780	O
respect	24061784	781	788	O
to	24061784	789	791	O
final	24061784	792	797	O
outcome	24061784	798	805	O
to	24061784	806	808	O
determine	24061784	809	818	O
if	24061784	819	821	O
response	24061784	822	830	O
predictors	24061784	831	841	O
could	24061784	842	847	O
be	24061784	848	850	O
identified	24061784	851	861	O
.	24061784	861	862	O

A	24061784	863	864	O
total	24061784	865	870	O
of	24061784	871	873	O
149	24061784	874	877	O
children	24061784	878	886	O
and	24061784	887	890	O
adolescents	24061784	891	902	O
5	24061784	903	904	O
to	24061784	905	907	O
17	24061784	908	910	O
years	24061784	911	916	O
of	24061784	917	919	O
age	24061784	920	923	O
(	24061784	924	925	O
mean	24061784	925	929	O
[	24061784	930	931	O
SD	24061784	931	933	O
]	24061784	933	934	O
age	24061784	935	938	O
,	24061784	938	939	O
9.4	24061784	940	943	O
[	24061784	944	945	O
3.1	24061784	945	948	O
]	24061784	948	949	O
years	24061784	950	955	O
)	24061784	955	956	O
from	24061784	957	961	O
6	24061784	962	963	O
academic	24061784	964	972	O
centers	24061784	973	980	O
were	24061784	981	985	O
randomly	24061784	986	994	O
assigned	24061784	995	1003	O
to	24061784	1004	1006	O
citalopram	24061784	1007	1017	O
(	24061784	1018	1019	O
n	24061784	1019	1020	O
=	24061784	1021	1022	O
73	24061784	1023	1025	O
)	24061784	1025	1026	O
or	24061784	1027	1029	O
placebo	24061784	1030	1037	O
(	24061784	1038	1039	O
n	24061784	1039	1040	O
=	24061784	1041	1042	O
76	24061784	1043	1045	O
)	24061784	1045	1046	O
.	24061784	1046	1047	O

Participants	24061784	1048	1060	O
had	24061784	1061	1064	O
autistic	24061784	1065	1073	O
disorder	24061784	1074	1082	O
,	24061784	1082	1083	O
Asperger	24061784	1084	1092	O
syndrome	24061784	1093	1101	O
,	24061784	1101	1102	O
or	24061784	1103	1105	O
pervasive	24061784	1106	1115	O
developmental	24061784	1116	1129	O
disorder	24061784	1130	1138	O
,	24061784	1138	1139	O
not	24061784	1140	1143	O
otherwise	24061784	1144	1153	O
specified	24061784	1154	1163	O
;	24061784	1163	1164	O
had	24061784	1165	1168	O
illness	24061784	1169	1176	O
severity	24061784	1177	1185	O
ratings	24061784	1186	1193	O
that	24061784	1194	1198	O
were	24061784	1199	1203	O
moderate	24061784	1204	1212	O
or	24061784	1213	1215	O
more	24061784	1216	1220	O
than	24061784	1221	1225	O
moderate	24061784	1226	1234	O
on	24061784	1235	1237	O
the	24061784	1238	1241	O
Clinical	24061784	1242	1250	O
Global	24061784	1251	1257	O
Impression-Severity	24061784	1258	1277	O
scale	24061784	1278	1283	O
;	24061784	1283	1284	O
and	24061784	1285	1288	O
scored	24061784	1289	1295	O
moderate	24061784	1296	1304	O
or	24061784	1305	1307	O
more	24061784	1308	1312	O
than	24061784	1313	1317	O
moderate	24061784	1318	1326	O
on	24061784	1327	1329	O
compulsive	24061784	1330	1340	O
behaviors	24061784	1341	1350	O
measured	24061784	1351	1359	O
with	24061784	1360	1364	O
the	24061784	1365	1368	O
modified	24061784	1369	1377	O
Children	24061784	1378	1386	O
's	24061784	1386	1388	O
Yale-Brown	24061784	1389	1399	O
Obsessive-Compulsive	24061784	1400	1420	O
Scale	24061784	1421	1426	O
.	24061784	1426	1427	O

INTERVENTIONS	24061784	1429	1442	O
:	24061784	1443	1444	O
Twelve	24061784	1445	1451	O
weeks	24061784	1452	1457	O
of	24061784	1458	1460	O
treatment	24061784	1461	1470	O
with	24061784	1471	1475	O
citalopram	24061784	1476	1486	O
(	24061784	1487	1488	O
10	24061784	1488	1490	O
mg/5	24061784	1491	1495	O
mL	24061784	1496	1498	O
)	24061784	1498	1499	O
or	24061784	1500	1502	O
placebo	24061784	1503	1510	O
.	24061784	1510	1511	O

The	24061784	1512	1515	O
mean	24061784	1516	1520	O
(	24061784	1521	1522	O
SD	24061784	1522	1524	O
)	24061784	1524	1525	O
maximum	24061784	1526	1533	O
dose	24061784	1534	1538	O
of	24061784	1539	1541	O
citalopram	24061784	1542	1552	O
was	24061784	1553	1556	O
16.5	24061784	1557	1561	O
(	24061784	1562	1563	O
6.5	24061784	1563	1566	O
)	24061784	1566	1567	O
mg	24061784	1568	1570	O
by	24061784	1571	1573	O
mouth	24061784	1574	1579	O
daily	24061784	1580	1585	O
(	24061784	1586	1587	O
maximum	24061784	1587	1594	O
dose	24061784	1595	1599	O
,	24061784	1599	1600	O
20	24061784	1601	1603	O
mg/d	24061784	1604	1608	O
)	24061784	1608	1609	O
.	24061784	1609	1610	O

MAIN	24061784	1612	1616	O
OUTCOMES	24061784	1617	1625	O
AND	24061784	1626	1629	O
MEASURES	24061784	1630	1638	O
:	24061784	1639	1640	O
A	24061784	1641	1642	O
positive	24061784	1643	1651	O
response	24061784	1652	1660	O
was	24061784	1661	1664	O
defined	24061784	1665	1672	O
as	24061784	1673	1675	O
having	24061784	1676	1682	O
a	24061784	1683	1684	O
score	24061784	1685	1690	O
of	24061784	1691	1693	O
at	24061784	1694	1696	O
least	24061784	1697	1702	O
much	24061784	1703	1707	O
improved	24061784	1708	1716	O
on	24061784	1717	1719	O
the	24061784	1720	1723	O
Clinical	24061784	1724	1732	O
Global	24061784	1733	1739	O
Impression-Improvement	24061784	1740	1762	O
scale	24061784	1763	1768	O
at	24061784	1769	1771	O
week	24061784	1772	1776	O
12	24061784	1777	1779	O
.	24061784	1779	1780	O

Baseline	24061784	1781	1789	O
measures	24061784	1790	1798	O
included	24061784	1799	1807	O
demographic	24061784	1808	1819	O
(	24061784	1820	1821	O
sex	24061784	1821	1824	O
,	24061784	1824	1825	O
age	24061784	1826	1829	O
,	24061784	1829	1830	O
weight	24061784	1831	1837	O
,	24061784	1837	1838	O
and	24061784	1839	1842	O
pubertal	24061784	1843	1851	O
status	24061784	1852	1858	O
)	24061784	1858	1859	O
,	24061784	1859	1860	O
clinical	24061784	1861	1869	O
,	24061784	1869	1870	O
and	24061784	1871	1874	O
family	24061784	1875	1881	O
measures	24061784	1882	1890	O
.	24061784	1890	1891	O

Clinical	24061784	1892	1900	O
variables	24061784	1901	1910	O
included	24061784	1911	1919	O
baseline	24061784	1920	1928	O
illness	24061784	1929	1936	O
severity	24061784	1937	1945	O
ratings	24061784	1946	1953	O
(	24061784	1954	1955	O
the	24061784	1955	1958	O
Aberrant	24061784	1959	1967	O
Behavior	24061784	1968	1976	O
Checklist	24061784	1977	1986	O
,	24061784	1986	1987	O
the	24061784	1988	1991	O
Child	24061784	1992	1997	O
and	24061784	1998	2001	O
Adolescent	24061784	2002	2012	O
Symptom	24061784	2013	2020	O
Inventory	24061784	2021	2030	O
,	24061784	2030	2031	O
the	24061784	2032	2035	O
Vineland	24061784	2036	2044	O
Adaptive	24061784	2045	2053	O
Behavior	24061784	2054	2062	O
Scales	24061784	2063	2069	O
,	24061784	2069	2070	O
the	24061784	2071	2074	O
Repetitive	24061784	2075	2085	O
Behavior	24061784	2086	2094	O
Scale-Revised	24061784	2095	2108	O
,	24061784	2108	2109	O
and	24061784	2110	2113	O
the	24061784	2114	2117	O
Children	24061784	2118	2126	O
's	24061784	2126	2128	O
Yale-Brown	24061784	2129	2139	O
Obsessive-Compulsive	24061784	2140	2160	O
Scale	24061784	2161	2166	O
)	24061784	2166	2167	O
.	24061784	2167	2168	O

Family	24061784	2169	2175	O
measures	24061784	2176	2184	O
included	24061784	2185	2193	O
the	24061784	2194	2197	O
Caregiver	24061784	2198	2207	O
Strain	24061784	2208	2214	O
Questionnaire	24061784	2215	2228	O
.	24061784	2228	2229	O

RESULTS	24061784	2231	2238	O
:	24061784	2239	2240	O
Several	24061784	2241	2248	O
baseline	24061784	2249	2257	O
predictors	24061784	2258	2268	O
of	24061784	2269	2271	O
response	24061784	2272	2280	O
were	24061784	2281	2285	O
identified	24061784	2286	2296	O
,	24061784	2296	2297	O
and	24061784	2298	2301	O
a	24061784	2302	2303	O
principal	24061784	2304	2313	O
component	24061784	2314	2323	O
analysis	24061784	2324	2332	O
yielded	24061784	2333	2340	O
3	24061784	2341	2342	O
composite	24061784	2343	2352	O
measures	24061784	2353	2361	O
(	24061784	2362	2363	O
disruptive	24061784	2363	2373	O
behavior	24061784	2374	2382	O
,	24061784	2382	2383	O
autism/mood	24061784	2384	2395	O
,	24061784	2395	2396	O
and	24061784	2397	2400	O
caregiver	24061784	2401	2410	O
strain	24061784	2411	2417	O
)	24061784	2417	2418	O
that	24061784	2419	2423	O
significantly	24061784	2424	2437	O
predicted	24061784	2438	2447	O
response	24061784	2448	2456	B-Outcome
at	24061784	2457	2459	I-Outcome
week	24061784	2460	2464	I-Outcome
12	24061784	2465	2467	I-Outcome
.	24061784	2467	2468	O

Specifically	24061784	2469	2481	O
,	24061784	2481	2482	O
participants	24061784	2483	2495	O
in	24061784	2496	2498	O
the	24061784	2499	2502	O
placebo	24061784	2503	2510	O
group	24061784	2511	2516	O
were	24061784	2517	2521	O
significantly	24061784	2522	2535	O
less	24061784	2536	2540	O
likely	24061784	2541	2547	O
than	24061784	2548	2552	O
participants	24061784	2553	2565	O
in	24061784	2566	2568	O
the	24061784	2569	2572	O
citalopram	24061784	2573	2583	O
group	24061784	2584	2589	O
to	24061784	2590	2592	O
respond	24061784	2593	2600	B-Outcome
at	24061784	2601	2603	I-Outcome
week	24061784	2604	2608	I-Outcome
12	24061784	2609	2611	I-Outcome
if	24061784	2612	2614	O
they	24061784	2615	2619	O
entered	24061784	2620	2627	O
the	24061784	2628	2631	O
study	24061784	2632	2637	O
more	24061784	2638	2642	O
symptomatic	24061784	2643	2654	O
on	24061784	2655	2657	O
each	24061784	2658	2662	O
of	24061784	2663	2665	O
the	24061784	2666	2669	O
3	24061784	2670	2671	O
composite	24061784	2672	2681	O
measures	24061784	2682	2690	O
,	24061784	2690	2691	O
and	24061784	2692	2695	O
they	24061784	2696	2700	O
were	24061784	2701	2705	O
at	24061784	2706	2708	O
least	24061784	2709	2714	O
2	24061784	2715	2716	O
times	24061784	2717	2722	O
less	24061784	2723	2727	O
likely	24061784	2728	2734	O
to	24061784	2735	2737	O
be	24061784	2738	2740	O
responders	24061784	2741	2751	O
.	24061784	2751	2752	O

CONCLUSIONS	24061784	2754	2765	O
AND	24061784	2766	2769	O
RELEVANCE	24061784	2770	2779	O
:	24061784	2780	2781	O
This	24061784	2782	2786	O
analysis	24061784	2787	2795	O
suggests	24061784	2796	2804	O
strategies	24061784	2805	2815	O
that	24061784	2816	2820	O
may	24061784	2821	2824	O
be	24061784	2825	2827	O
useful	24061784	2828	2834	O
in	24061784	2835	2837	O
anticipating	24061784	2838	2850	O
and	24061784	2851	2854	O
potentially	24061784	2855	2866	O
mitigating	24061784	2867	2877	O
the	24061784	2878	2881	O
nonspecific	24061784	2882	2893	O
response	24061784	2894	2902	O
in	24061784	2903	2905	O
randomized	24061784	2906	2916	O
clinical	24061784	2917	2925	O
trials	24061784	2926	2932	O
of	24061784	2933	2935	O
children	24061784	2936	2944	O
and	24061784	2945	2948	O
adolescents	24061784	2949	2960	O
with	24061784	2961	2965	O
autism	24061784	2966	2972	O
spectrum	24061784	2973	2981	O
disorders	24061784	2982	2991	O
.	24061784	2991	2992	O

TRIAL	24061784	2994	2999	O
REGISTRATION	24061784	3000	3012	O
:	24061784	3013	3014	O
clinicaltrials.gov	24061784	3015	3033	O
Identifier	24061784	3034	3044	O
:	24061784	3044	3045	O
NCT00086645	24061784	3046	3057	O
.	24061784	3057	3058	O


Possible	24083350	0	8	O
etiology	24083350	9	17	O
of	24083350	18	20	O
improvements	24083350	21	33	O
in	24083350	34	36	O
both	24083350	37	41	O
quality	24083350	42	49	O
of	24083350	50	52	O
life	24083350	53	57	O
and	24083350	58	61	O
overlapping	24083350	62	73	O
gastroesophageal	24083350	74	90	O
reflux	24083350	91	97	O
disease	24083350	98	105	O
by	24083350	106	108	O
proton	24083350	109	115	O
pump	24083350	116	120	O
inhibitor	24083350	121	130	O
treatment	24083350	131	140	O
in	24083350	141	143	O
a	24083350	144	145	O
prospective	24083350	146	157	O
randomized	24083350	158	168	O
controlled	24083350	169	179	O
trial	24083350	180	185	O
.	24083350	185	186	O

BACKGROUND	24083350	188	198	O
:	24083350	199	200	O
Symptoms	24083350	201	209	O
suggestive	24083350	210	220	O
of	24083350	221	223	O
functional	24083350	224	234	O
dyspepsia	24083350	235	244	O
(	24083350	245	246	O
FD	24083350	246	248	O
)	24083350	248	249	O
and	24083350	250	253	O
irritable	24083350	254	263	O
bowel	24083350	264	269	O
syndrome	24083350	270	278	O
(	24083350	279	280	O
IBS	24083350	280	283	O
)	24083350	283	284	O
frequently	24083350	285	295	O
overlap	24083350	296	303	O
with	24083350	304	308	O
those	24083350	309	314	O
of	24083350	315	317	O
gastroesophageal	24083350	318	334	O
reflux	24083350	335	341	O
disease	24083350	342	349	O
.	24083350	349	350	O

Despite	24083350	351	358	O
the	24083350	359	362	O
high	24083350	363	367	O
prevalence	24083350	368	378	O
of	24083350	379	381	O
symptomatic	24083350	382	393	O
overlap	24083350	394	401	O
,	24083350	401	402	O
the	24083350	403	406	O
underlying	24083350	407	417	O
etiology	24083350	418	426	O
remains	24083350	427	434	O
poorly	24083350	435	441	O
defined	24083350	442	449	O
.	24083350	449	450	O

We	24083350	451	453	O
assessed	24083350	454	462	O
the	24083350	463	466	O
correlation	24083350	467	478	O
of	24083350	479	481	O
symptomatic	24083350	482	493	O
relief	24083350	494	500	O
and	24083350	501	504	O
health-related	24083350	505	519	O
quality	24083350	520	527	O
of	24083350	528	530	O
life	24083350	531	535	O
(	24083350	536	537	O
HRQoL	24083350	537	542	O
)	24083350	542	543	O
with	24083350	544	548	O
healing	24083350	549	556	O
of	24083350	557	559	O
reflux	24083350	560	566	O
esophagitis	24083350	567	578	O
to	24083350	579	581	O
further	24083350	582	589	O
derive	24083350	590	596	O
insights	24083350	597	605	O
into	24083350	606	610	O
the	24083350	611	614	O
underlying	24083350	615	625	O
etiology	24083350	626	634	O
.	24083350	634	635	O

METHODS	24083350	637	644	O
:	24083350	645	646	O
626	24083350	647	650	O
patients	24083350	651	659	O
with	24083350	660	664	O
reflux	24083350	665	671	O
esophagitis	24083350	672	683	O
were	24083350	684	688	O
enrolled	24083350	689	697	O
into	24083350	698	702	O
one	24083350	703	706	O
of	24083350	707	709	O
two	24083350	710	713	O
treatment	24083350	714	723	O
groups	24083350	724	730	O
(	24083350	731	732	O
classical	24083350	732	741	O
healing	24083350	742	749	O
concept	24083350	750	757	O
or	24083350	758	760	O
the	24083350	761	764	O
complete	24083350	765	773	O
remission	24083350	774	783	O
concept	24083350	784	791	O
)	24083350	791	792	O
to	24083350	793	795	O
investigate	24083350	796	807	O
differences	24083350	808	819	O
in	24083350	820	822	O
treatment	24083350	823	832	O
intensity	24083350	833	842	O
.	24083350	842	843	O

Patients	24083350	844	852	O
were	24083350	853	857	O
treated	24083350	858	865	O
with	24083350	866	870	O
pantoprazole	24083350	871	883	O
until	24083350	884	889	O
esophageal	24083350	890	900	O
mucosal	24083350	901	908	O
healing	24083350	909	916	O
.	24083350	916	917	O

Remission	24083350	918	927	O
was	24083350	928	931	O
followed	24083350	932	940	O
for	24083350	941	944	O
up	24083350	945	947	O
to	24083350	948	950	O
6	24083350	951	952	O
months	24083350	953	959	O
without	24083350	960	967	O
treatment	24083350	968	977	O
.	24083350	977	978	O

Gastro-intestinal	24083350	979	996	O
symptoms	24083350	997	1005	O
and	24083350	1006	1009	O
HRQoL	24083350	1010	1015	O
were	24083350	1016	1020	O
analyzed	24083350	1021	1029	O
using	24083350	1030	1035	O
disease-specific	24083350	1036	1052	O
,	24083350	1052	1053	O
psychometrically	24083350	1054	1070	O
validated	24083350	1071	1080	O
patient-reported	24083350	1081	1097	O
outcome	24083350	1098	1105	O
instruments	24083350	1106	1117	O
(	24083350	1118	1119	O
ReQuest	24083350	1119	1126	O
™	24083350	1126	1127	O
,	24083350	1127	1128	O
GERDyzer	24083350	1129	1137	O
™	24083350	1137	1138	O
)	24083350	1138	1139	O
.	24083350	1139	1140	O

RESULTS	24083350	1142	1149	O
:	24083350	1150	1151	O
Symptomatic	24083350	1152	1163	B-Outcome
burden	24083350	1164	1170	I-Outcome
reflected	24083350	1171	1180	I-Outcome
by	24083350	1181	1183	I-Outcome
ReQuest	24083350	1184	1191	I-Outcome
™	24083350	1191	1192	I-Outcome
substantially	24083350	1193	1206	O
decreased	24083350	1207	1216	O
from	24083350	1217	1221	O
baseline	24083350	1222	1230	O
to	24083350	1231	1233	O
end	24083350	1234	1237	O
of	24083350	1238	1240	O
treatment	24083350	1241	1250	O
by	24083350	1251	1253	O
83	24083350	1254	1256	O
%	24083350	1256	1257	O
and	24083350	1258	1261	O
88	24083350	1262	1264	O
%	24083350	1264	1265	O
in	24083350	1266	1268	O
either	24083350	1269	1275	O
treatment	24083350	1276	1285	O
group	24083350	1286	1291	O
,	24083350	1291	1292	O
respectively	24083350	1293	1305	O
.	24083350	1305	1306	O

ReQuest	24083350	1307	1314	B-Outcome
™	24083350	1314	1315	I-Outcome
scores	24083350	1316	1322	I-Outcome
significantly	24083350	1323	1336	O
decreased	24083350	1337	1346	O
in	24083350	1347	1349	O
patients	24083350	1350	1358	O
with	24083350	1359	1363	O
or	24083350	1364	1366	O
without	24083350	1367	1374	O
heartburn	24083350	1375	1384	O
and	24083350	1385	1388	O
in	24083350	1389	1391	O
those	24083350	1392	1397	O
with	24083350	1398	1402	O
symptoms	24083350	1403	1411	O
suggestive	24083350	1412	1422	O
of	24083350	1423	1425	O
FD	24083350	1426	1428	O
and	24083350	1429	1432	O
IBS	24083350	1433	1436	O
,	24083350	1436	1437	O
indicating	24083350	1438	1448	O
response	24083350	1449	1457	O
of	24083350	1458	1460	O
all	24083350	1461	1464	O
symptom	24083350	1465	1472	O
categories	24083350	1473	1483	O
to	24083350	1484	1486	O
treatment	24083350	1487	1496	O
(	24083350	1497	1498	O
p	24083350	1498	1499	O
<	24083350	1500	1501	O
0.005	24083350	1502	1507	O
)	24083350	1507	1508	O
.	24083350	1508	1509	O

Therapy-associated	24083350	1510	1528	B-Outcome
relief	24083350	1529	1535	I-Outcome
of	24083350	1536	1538	I-Outcome
symptoms	24083350	1539	1547	I-Outcome
was	24083350	1548	1551	O
paralleled	24083350	1552	1562	O
by	24083350	1563	1565	O
substantial	24083350	1566	1577	O
gains	24083350	1578	1583	O
in	24083350	1584	1586	O
HRQoL	24083350	1587	1592	B-Outcome
,	24083350	1592	1593	O
which	24083350	1594	1599	O
continued	24083350	1600	1609	O
to	24083350	1610	1612	O
stabilize	24083350	1613	1622	O
post-treatment	24083350	1623	1637	O
.	24083350	1637	1638	O

CONCLUSIONS	24083350	1640	1651	O
:	24083350	1652	1653	O
Pantoprazole	24083350	1654	1666	O
is	24083350	1667	1669	O
effective	24083350	1670	1679	O
in	24083350	1680	1682	O
relieving	24083350	1683	1692	O
upper	24083350	1693	1698	B-Outcome
and	24083350	1699	1702	O
lower	24083350	1703	1708	B-Outcome
gastro-intestinal	24083350	1709	1726	I-Outcome
symptoms	24083350	1727	1735	I-Outcome
overlapping	24083350	1736	1747	O
with	24083350	1748	1752	O
erosive	24083350	1753	1760	B-Outcome
esophagitis	24083350	1761	1772	I-Outcome
,	24083350	1772	1773	O
and	24083350	1774	1777	O
provides	24083350	1778	1786	O
sustained	24083350	1787	1796	O
improvement	24083350	1797	1808	O
in	24083350	1809	1811	O
HRQoL	24083350	1812	1817	B-Outcome
post-treatment	24083350	1818	1832	O
.	24083350	1832	1833	O

Our	24083350	1834	1837	O
results	24083350	1838	1845	O
propose	24083350	1846	1853	O
a	24083350	1854	1855	O
link	24083350	1856	1860	O
between	24083350	1861	1868	O
both	24083350	1869	1873	O
healing	24083350	1874	1881	O
of	24083350	1882	1884	O
erosive	24083350	1885	1892	B-Outcome
esophagitis	24083350	1893	1904	I-Outcome
and	24083350	1905	1908	O
the	24083350	1909	1912	O
slower	24083350	1913	1919	O
remission	24083350	1920	1929	O
of	24083350	1930	1932	O
upper	24083350	1933	1938	B-Outcome
and	24083350	1939	1942	O
lower	24083350	1943	1948	B-Outcome
gastro-intestinal	24083350	1949	1966	I-Outcome
symptoms	24083350	1967	1975	I-Outcome
.	24083350	1975	1976	O

Since	24083350	1977	1982	O
the	24083350	1983	1986	O
improvement	24083350	1987	1998	O
observed	24083350	1999	2007	O
is	24083350	2008	2010	O
likely	24083350	2011	2017	O
to	24083350	2018	2020	O
be	24083350	2021	2023	O
multifactorial	24083350	2024	2038	O
,	24083350	2038	2039	O
the	24083350	2040	2043	O
possibility	24083350	2044	2055	O
for	24083350	2056	2059	O
an	24083350	2060	2062	O
immune-mediated	24083350	2063	2078	O
etiology	24083350	2079	2087	O
and	24083350	2088	2091	O
identification	24083350	2092	2106	O
of	24083350	2107	2109	O
putative	24083350	2110	2118	O
susceptibility	24083350	2119	2133	O
factors	24083350	2134	2141	O
by	24083350	2142	2144	O
genome-wide	24083350	2145	2156	O
association	24083350	2157	2168	O
study	24083350	2169	2174	O
may	24083350	2175	2178	O
provide	24083350	2179	2186	O
focus	24083350	2187	2192	O
for	24083350	2193	2196	O
future	24083350	2197	2203	O
research	24083350	2204	2212	O
.	24083350	2212	2213	O

TRIAL	24083350	2215	2220	O
REGISTRATION	24083350	2221	2233	O
:	24083350	2234	2235	O
ClinicalTrials.gov	24083350	2236	2254	O
identifier	24083350	2255	2265	O
:	24083350	2265	2266	O
NCT00325676	24083350	2267	2278	O
.	24083350	2278	2279	O


Aripiprazole	24138011	0	12	O
treatment	24138011	13	22	O
of	24138011	23	25	O
irritability	24138011	26	38	O
associated	24138011	39	49	O
with	24138011	50	54	O
autistic	24138011	55	63	O
disorder	24138011	64	72	O
and	24138011	73	76	O
the	24138011	77	80	O
relationship	24138011	81	93	O
between	24138011	94	101	O
prior	24138011	102	107	O
antipsychotic	24138011	108	121	O
exposure	24138011	122	130	O
,	24138011	130	131	O
adverse	24138011	132	139	O
events	24138011	140	146	O
,	24138011	146	147	O
and	24138011	148	151	O
weight	24138011	152	158	O
change	24138011	159	165	O
.	24138011	165	166	O

OBJECTIVE	24138011	168	177	O
:	24138011	178	179	O
The	24138011	180	183	O
purpose	24138011	184	191	O
of	24138011	192	194	O
this	24138011	195	199	O
study	24138011	200	205	O
was	24138011	206	209	O
to	24138011	210	212	O
evaluate	24138011	213	221	O
the	24138011	222	225	O
impact	24138011	226	232	O
of	24138011	233	235	O
prior	24138011	236	241	O
antipsychotic	24138011	242	255	O
exposure	24138011	256	264	O
(	24138011	265	266	O
PAE	24138011	266	269	O
)	24138011	269	270	O
on	24138011	271	273	O
safety	24138011	274	280	O
and	24138011	281	284	O
tolerability	24138011	285	297	O
outcomes	24138011	298	306	O
in	24138011	307	309	O
pediatric	24138011	310	319	O
subjects	24138011	320	328	O
receiving	24138011	329	338	O
aripiprazole	24138011	339	351	O
treatment	24138011	352	361	O
.	24138011	361	362	O

METHODS	24138011	364	371	O
:	24138011	372	373	O
This	24138011	374	378	O
study	24138011	379	384	O
was	24138011	385	388	O
a	24138011	389	390	O
post-hoc	24138011	391	399	O
analysis	24138011	400	408	O
of	24138011	409	411	O
pooled	24138011	412	418	O
data	24138011	419	423	O
from	24138011	424	428	O
two	24138011	429	432	O
8-week	24138011	433	439	O
,	24138011	439	440	O
double-blind	24138011	441	453	O
,	24138011	453	454	O
randomized	24138011	455	465	O
,	24138011	465	466	O
placebo-controlled	24138011	467	485	O
studies	24138011	486	493	O
evaluating	24138011	494	504	O
aripiprazole	24138011	505	517	O
for	24138011	518	521	O
the	24138011	522	525	O
treatment	24138011	526	535	O
of	24138011	536	538	O
irritability	24138011	539	551	O
in	24138011	552	554	O
pediatric	24138011	555	564	O
subjects	24138011	565	573	O
with	24138011	574	578	O
autistic	24138011	579	587	O
disorder	24138011	588	596	O
,	24138011	596	597	O
aged	24138011	598	602	O
6	24138011	603	604	O
-	24138011	604	605	O
17	24138011	605	607	O
years	24138011	608	613	O
.	24138011	613	614	O

Subjects	24138011	615	623	O
were	24138011	624	628	O
stratified	24138011	629	639	O
by	24138011	640	642	O
PAE	24138011	643	646	O
;	24138011	646	647	O
adverse	24138011	648	655	O
events	24138011	656	662	O
(	24138011	663	664	O
AEs	24138011	664	667	O
)	24138011	667	668	O
,	24138011	668	669	O
and	24138011	670	673	O
changes	24138011	674	681	O
in	24138011	682	684	O
weight	24138011	685	691	O
,	24138011	691	692	O
and	24138011	693	696	O
metabolic	24138011	697	706	O
measures	24138011	707	715	O
were	24138011	716	720	O
evaluated	24138011	721	730	O
.	24138011	730	731	O

For	24138011	732	735	O
subjects	24138011	736	744	O
receiving	24138011	745	754	O
aripiprazole	24138011	755	767	O
,	24138011	767	768	O
regardless	24138011	769	779	O
of	24138011	780	782	O
PAE	24138011	783	786	O
,	24138011	786	787	O
baseline	24138011	788	796	O
weight	24138011	797	803	O
,	24138011	803	804	O
age	24138011	805	808	O
,	24138011	808	809	O
gender	24138011	810	816	O
,	24138011	816	817	O
and	24138011	818	821	O
symptom	24138011	822	829	O
severity	24138011	830	838	O
were	24138011	839	843	O
evaluated	24138011	844	853	O
in	24138011	854	856	O
a	24138011	857	858	O
regression	24138011	859	869	O
model	24138011	870	875	O
predicting	24138011	876	886	O
body	24138011	887	891	O
weight	24138011	892	898	O
change	24138011	899	905	O
.	24138011	905	906	O

RESULTS	24138011	908	915	O
:	24138011	916	917	O
Of	24138011	918	920	O
316	24138011	921	924	O
randomized	24138011	925	935	O
subjects	24138011	936	944	O
,	24138011	944	945	O
259	24138011	946	949	O
(	24138011	950	951	O
82.0	24138011	951	955	O
%	24138011	955	956	O
)	24138011	956	957	O
were	24138011	958	962	O
antipsychotic	24138011	963	976	O
naïve	24138011	977	982	O
(	24138011	983	984	O
AN	24138011	984	986	O
)	24138011	986	987	O
and	24138011	988	991	O
57	24138011	992	994	O
(	24138011	995	996	O
18.0	24138011	996	1000	O
%	24138011	1000	1001	O
)	24138011	1001	1002	O
had	24138011	1003	1006	O
a	24138011	1007	1008	O
PAE	24138011	1009	1012	O
.	24138011	1012	1013	O

Aripiprazole-treated	24138011	1014	1034	O
AN	24138011	1035	1037	O
subjects	24138011	1038	1046	O
were	24138011	1047	1051	O
more	24138011	1052	1056	O
likely	24138011	1057	1063	O
than	24138011	1064	1068	O
PAE	24138011	1069	1072	O
subjects	24138011	1073	1081	O
to	24138011	1082	1084	O
report	24138011	1085	1091	O
somnolence	24138011	1092	1102	O
(	24138011	1103	1104	O
11.9	24138011	1104	1108	O
%	24138011	1108	1109	O
vs.	24138011	1110	1113	O
2.8	24138011	1114	1117	O
%	24138011	1117	1118	O
)	24138011	1118	1119	O
,	24138011	1119	1120	O
sedation	24138011	1121	1129	O
(	24138011	1130	1131	O
22.7	24138011	1131	1135	O
%	24138011	1135	1136	O
vs.	24138011	1137	1140	O
11.1	24138011	1141	1145	O
%	24138011	1145	1146	O
)	24138011	1146	1147	O
,	24138011	1147	1148	O
or	24138011	1149	1151	O
fatigue	24138011	1152	1159	O
(	24138011	1160	1161	O
17.0	24138011	1161	1165	O
%	24138011	1165	1166	O
vs.	24138011	1167	1170	O
13.9	24138011	1171	1175	O
%	24138011	1175	1176	O
)	24138011	1176	1177	O
.	24138011	1177	1178	O

Rates	24138011	1179	1184	O
of	24138011	1185	1187	O
extrapyramidal	24138011	1188	1202	O
disorder	24138011	1203	1211	O
and	24138011	1212	1215	O
drooling	24138011	1216	1224	O
,	24138011	1224	1225	O
but	24138011	1226	1229	O
not	24138011	1230	1233	O
akathisia	24138011	1234	1243	O
or	24138011	1244	1246	O
tremor	24138011	1247	1253	O
,	24138011	1253	1254	O
were	24138011	1255	1259	O
marginally	24138011	1260	1270	O
higher	24138011	1271	1277	O
in	24138011	1278	1280	O
AN	24138011	1281	1283	O
subjects	24138011	1284	1292	O
.	24138011	1292	1293	O

Overall	24138011	1294	1301	O
,	24138011	1301	1302	O
10.8	24138011	1303	1307	O
%	24138011	1307	1308	O
of	24138011	1309	1311	O
aripiprazole-treated	24138011	1312	1332	O
AN	24138011	1333	1335	O
subjects	24138011	1336	1344	O
had	24138011	1345	1348	O
at	24138011	1349	1351	O
least	24138011	1352	1357	O
one	24138011	1358	1361	O
AE	24138011	1362	1364	B-Outcome
leading	24138011	1365	1372	O
to	24138011	1373	1375	O
discontinuation	24138011	1376	1391	O
compared	24138011	1392	1400	O
with	24138011	1401	1405	O
8.3	24138011	1406	1409	O
%	24138011	1409	1410	O
of	24138011	1411	1413	O
aripiprazole-treated	24138011	1414	1434	O
PAE	24138011	1435	1438	O
subjects	24138011	1439	1447	O
.	24138011	1447	1448	O

AN	24138011	1449	1451	O
subjects	24138011	1452	1460	O
receiving	24138011	1461	1470	O
aripiprazole	24138011	1471	1483	O
had	24138011	1484	1487	O
a	24138011	1488	1489	O
larger	24138011	1490	1496	O
change	24138011	1497	1503	B-Outcome
in	24138011	1504	1506	I-Outcome
weight	24138011	1507	1513	I-Outcome
from	24138011	1514	1518	O
baseline	24138011	1519	1527	O
to	24138011	1528	1530	O
endpoint	24138011	1531	1539	O
compared	24138011	1540	1548	O
with	24138011	1549	1553	O
those	24138011	1554	1559	O
receiving	24138011	1560	1569	O
placebo	24138011	1570	1577	O
(	24138011	1578	1579	O
1.9	24138011	1579	1582	O
vs.	24138011	1583	1586	O
0.7	24138011	1587	1590	O
kg	24138011	1591	1593	O
;	24138011	1593	1594	O
treatment	24138011	1595	1604	O
difference	24138011	1605	1615	O
1.2	24138011	1616	1619	O
kg	24138011	1620	1622	O
,	24138011	1622	1623	O
95	24138011	1624	1626	O
%	24138011	1626	1627	O
CI	24138011	1628	1630	O
:	24138011	1630	1631	O
0.5	24138011	1632	1635	O
,	24138011	1635	1636	O
1.9	24138011	1637	1640	O
)	24138011	1640	1641	O
than	24138011	1642	1646	O
PAE	24138011	1647	1650	O
subjects	24138011	1651	1659	O
receiving	24138011	1660	1669	O
aripiprazole	24138011	1670	1682	O
compared	24138011	1683	1691	O
with	24138011	1692	1696	O
subjects	24138011	1697	1705	O
receiving	24138011	1706	1715	O
placebo	24138011	1716	1723	O
(	24138011	1724	1725	O
0.4	24138011	1725	1728	O
vs.	24138011	1729	1732	O
-0.4	24138011	1733	1737	O
kg	24138011	1738	1740	O
;	24138011	1740	1741	O
treatment	24138011	1742	1751	O
difference	24138011	1752	1762	O
0.9	24138011	1763	1766	O
kg	24138011	1767	1769	O
,	24138011	1769	1770	O
95	24138011	1771	1773	O
%	24138011	1773	1774	O
CI	24138011	1775	1777	O
:	24138011	1777	1778	O
-0.6	24138011	1779	1783	O
,	24138011	1783	1784	O
2.4	24138011	1785	1788	O
)	24138011	1788	1789	O
.	24138011	1789	1790	O

Regression	24138011	1791	1801	O
analysis	24138011	1802	1810	O
identified	24138011	1811	1821	O
that	24138011	1822	1826	O
younger	24138011	1827	1834	O
subjects	24138011	1835	1843	O
with	24138011	1844	1848	O
higher	24138011	1849	1855	O
baseline	24138011	1856	1864	O
weight	24138011	1865	1871	O
z-score	24138011	1872	1879	O
were	24138011	1880	1884	O
at	24138011	1885	1887	O
highest	24138011	1888	1895	O
risk	24138011	1896	1900	O
for	24138011	1901	1904	O
weight	24138011	1905	1911	B-Outcome
gain	24138011	1912	1916	O
.	24138011	1916	1917	O

There	24138011	1918	1923	O
were	24138011	1924	1928	O
no	24138011	1929	1931	O
significant	24138011	1932	1943	O
changes	24138011	1944	1951	O
in	24138011	1952	1954	O
metabolic	24138011	1955	1964	B-Outcome
measures	24138011	1965	1973	I-Outcome
compared	24138011	1974	1982	O
with	24138011	1983	1987	O
placebo	24138011	1988	1995	O
in	24138011	1996	1998	O
either	24138011	1999	2005	O
group	24138011	2006	2011	O
.	24138011	2011	2012	O

CONCLUSIONS	24138011	2014	2025	O
:	24138011	2026	2027	O
Weight	24138011	2028	2034	B-Outcome
gain	24138011	2035	2039	O
was	24138011	2040	2043	O
more	24138011	2044	2048	O
pronounced	24138011	2049	2059	O
in	24138011	2060	2062	O
AN	24138011	2063	2065	O
subjects	24138011	2066	2074	O
and	24138011	2075	2078	O
more	24138011	2079	2083	O
likely	24138011	2084	2090	O
to	24138011	2091	2093	O
occur	24138011	2094	2099	O
in	24138011	2100	2102	O
younger	24138011	2103	2110	O
subjects	24138011	2111	2119	O
with	24138011	2120	2124	O
a	24138011	2125	2126	O
higher	24138011	2127	2133	O
baseline	24138011	2134	2142	O
weight	24138011	2143	2149	O
z-score	24138011	2150	2157	O
.	24138011	2157	2158	O

AN	24138011	2159	2161	O
subjects	24138011	2162	2170	O
were	24138011	2171	2175	O
more	24138011	2176	2180	O
likely	24138011	2181	2187	O
to	24138011	2188	2190	O
experience	24138011	2191	2201	O
AEs	24138011	2202	2205	B-Outcome
related	24138011	2206	2213	O
to	24138011	2214	2216	O
somnolence	24138011	2217	2227	O
.	24138011	2227	2228	O

However	24138011	2229	2236	O
,	24138011	2236	2237	O
based	24138011	2238	2243	O
on	24138011	2244	2246	O
discontinuations	24138011	2247	2263	O
rates	24138011	2264	2269	O
from	24138011	2270	2274	O
AEs	24138011	2275	2278	B-Outcome
,	24138011	2278	2279	O
overall	24138011	2280	2287	O
tolerability	24138011	2288	2300	B-Outcome
was	24138011	2301	2304	O
good	24138011	2305	2309	O
for	24138011	2310	2313	O
both	24138011	2314	2318	O
AN	24138011	2319	2321	O
and	24138011	2322	2325	O
PAE	24138011	2326	2329	O
groups	24138011	2330	2336	O
.	24138011	2336	2337	O

CLINICAL	24138011	2339	2347	O
TRIAL	24138011	2348	2353	O
REGISTRATION	24138011	2354	2366	O
:	24138011	2367	2368	O
Study	24138011	2369	2374	O
of	24138011	2375	2377	O
aripiprazole	24138011	2378	2390	O
in	24138011	2391	2393	O
the	24138011	2394	2397	O
treatment	24138011	2398	2407	O
of	24138011	2408	2410	O
children	24138011	2411	2419	O
and	24138011	2420	2423	O
adolescents	24138011	2424	2435	O
with	24138011	2436	2440	O
autistic	24138011	2441	2449	O
disorder	24138011	2450	2458	O
.	24138011	2458	2459	O

Registry	24138011	2460	2468	O
:	24138011	2468	2469	O
www.clinicaltrials.gov	24138011	2470	2492	O
.	24138011	2493	2494	O

Identifiers	24138011	2495	2506	O
:	24138011	2506	2507	O
NCT00332241	24138011	2508	2519	O
and	24138011	2520	2523	O
NCT00337571	24138011	2524	2535	O
.	24138011	2535	2536	O


Improving	24217336	0	9	O
maternal	24217336	10	18	O
mental	24217336	19	25	O
health	24217336	26	32	O
after	24217336	33	38	O
a	24217336	39	40	O
child	24217336	41	46	O
's	24217336	46	48	O
diagnosis	24217336	49	58	O
of	24217336	59	61	O
autism	24217336	62	68	O
spectrum	24217336	69	77	O
disorder	24217336	78	86	O
:	24217336	86	87	O
results	24217336	88	95	O
from	24217336	96	100	O
a	24217336	101	102	O
randomized	24217336	103	113	O
clinical	24217336	114	122	O
trial	24217336	123	128	O
.	24217336	128	129	O

IMPORTANCE	24217336	131	141	O
:	24217336	142	143	O
The	24217336	144	147	O
prevalence	24217336	148	158	O
of	24217336	159	161	O
psychological	24217336	162	175	O
distress	24217336	176	184	O
among	24217336	185	190	O
mothers	24217336	191	198	O
of	24217336	199	201	O
children	24217336	202	210	O
with	24217336	211	215	O
autism	24217336	216	222	O
spectrum	24217336	223	231	O
disorder	24217336	232	240	O
(	24217336	241	242	O
ASD	24217336	242	245	O
)	24217336	245	246	O
suggests	24217336	247	255	O
a	24217336	256	257	O
need	24217336	258	262	O
for	24217336	263	266	O
interventions	24217336	267	280	O
that	24217336	281	285	O
address	24217336	286	293	O
parental	24217336	294	302	O
mental	24217336	303	309	O
health	24217336	310	316	O
during	24217336	317	323	O
the	24217336	324	327	O
critical	24217336	328	336	O
period	24217336	337	343	O
after	24217336	344	349	O
the	24217336	350	353	O
child	24217336	354	359	O
's	24217336	359	361	O
autism	24217336	362	368	O
diagnosis	24217336	369	378	O
when	24217336	379	383	O
parents	24217336	384	391	O
are	24217336	392	395	O
learning	24217336	396	404	O
to	24217336	405	407	O
navigate	24217336	408	416	O
the	24217336	417	420	O
complex	24217336	421	428	O
system	24217336	429	435	O
of	24217336	436	438	O
autism	24217336	439	445	O
services	24217336	446	454	O
.	24217336	454	455	O

OBJECTIVE	24217336	457	466	O
:	24217336	467	468	O
To	24217336	469	471	O
investigate	24217336	472	483	O
whether	24217336	484	491	O
a	24217336	492	493	O
brief	24217336	494	499	O
cognitive	24217336	500	509	O
behavioral	24217336	510	520	O
intervention	24217336	521	533	O
,	24217336	533	534	O
problem-solving	24217336	535	550	O
education	24217336	551	560	O
(	24217336	561	562	O
PSE	24217336	562	565	O
)	24217336	565	566	O
,	24217336	566	567	O
decreases	24217336	568	577	O
parenting	24217336	578	587	O
stress	24217336	588	594	O
and	24217336	595	598	O
maternal	24217336	599	607	O
depressive	24217336	608	618	O
symptoms	24217336	619	627	O
during	24217336	628	634	O
the	24217336	635	638	O
period	24217336	639	645	O
immediately	24217336	646	657	O
following	24217336	658	667	O
a	24217336	668	669	O
child	24217336	670	675	O
's	24217336	675	677	O
diagnosis	24217336	678	687	O
of	24217336	688	690	O
ASD	24217336	691	694	O
.	24217336	694	695	O

DESIGN	24217336	697	703	O
,	24217336	703	704	O
SETTING	24217336	705	712	O
,	24217336	712	713	O
AND	24217336	714	717	O
PARTICIPANTS	24217336	718	730	O
:	24217336	731	732	O
A	24217336	733	734	O
randomized	24217336	735	745	O
clinical	24217336	746	754	O
trial	24217336	755	760	O
compared	24217336	761	769	O
6	24217336	770	771	O
sessions	24217336	772	780	O
of	24217336	781	783	O
PSE	24217336	784	787	O
with	24217336	788	792	O
usual	24217336	793	798	O
care	24217336	799	803	O
.	24217336	803	804	O

Settings	24217336	805	813	O
included	24217336	814	822	O
an	24217336	823	825	O
autism	24217336	826	832	O
clinic	24217336	833	839	O
and	24217336	840	843	O
6	24217336	844	845	O
community-based	24217336	846	861	O
early	24217336	862	867	O
intervention	24217336	868	880	O
programs	24217336	881	889	O
that	24217336	890	894	O
primarily	24217336	895	904	O
serve	24217336	905	910	O
low-income	24217336	911	921	O
families	24217336	922	930	O
.	24217336	930	931	O

Participants	24217336	932	944	O
were	24217336	945	949	O
mothers	24217336	950	957	O
of	24217336	958	960	O
122	24217336	961	964	O
young	24217336	965	970	O
children	24217336	971	979	O
(	24217336	980	981	O
mean	24217336	981	985	O
age	24217336	986	989	O
,	24217336	989	990	O
34	24217336	991	993	O
months	24217336	994	1000	O
)	24217336	1000	1001	O
who	24217336	1002	1005	O
recently	24217336	1006	1014	O
received	24217336	1015	1023	O
a	24217336	1024	1025	O
diagnosis	24217336	1026	1035	O
of	24217336	1036	1038	O
ASD	24217336	1039	1042	O
.	24217336	1042	1043	O

Among	24217336	1044	1049	O
mothers	24217336	1050	1057	O
assessed	24217336	1058	1066	O
for	24217336	1067	1070	O
eligibility	24217336	1071	1082	O
,	24217336	1082	1083	O
17.0	24217336	1084	1088	O
%	24217336	1088	1089	O
declined	24217336	1090	1098	O
participation	24217336	1099	1112	O
.	24217336	1112	1113	O

We	24217336	1114	1116	O
report	24217336	1117	1123	O
outcomes	24217336	1124	1132	O
after	24217336	1133	1138	O
3	24217336	1139	1140	O
months	24217336	1141	1147	O
of	24217336	1148	1150	O
follow-up	24217336	1151	1160	O
(	24217336	1161	1162	O
immediate	24217336	1162	1171	O
postdiagnosis	24217336	1172	1185	O
period	24217336	1186	1192	O
)	24217336	1192	1193	O
.	24217336	1193	1194	O

INTERVENTIONS	24217336	1196	1209	O
:	24217336	1210	1211	O
Problem-solving	24217336	1212	1227	O
education	24217336	1228	1237	O
is	24217336	1238	1240	O
a	24217336	1241	1242	O
brief	24217336	1243	1248	O
,	24217336	1248	1249	O
cognitive	24217336	1250	1259	O
intervention	24217336	1260	1272	O
delivered	24217336	1273	1282	O
in	24217336	1283	1285	O
six	24217336	1286	1289	O
30-minute	24217336	1290	1299	O
individualized	24217336	1300	1314	O
sessions	24217336	1315	1323	O
by	24217336	1324	1326	O
existing	24217336	1327	1335	O
staff	24217336	1336	1341	O
(	24217336	1342	1343	O
early	24217336	1343	1348	O
intervention	24217336	1349	1361	O
programs	24217336	1362	1370	O
)	24217336	1370	1371	O
or	24217336	1372	1374	O
research	24217336	1375	1383	O
staff	24217336	1384	1389	O
without	24217336	1390	1397	O
formal	24217336	1398	1404	O
mental	24217336	1405	1411	O
health	24217336	1412	1418	O
training	24217336	1419	1427	O
(	24217336	1428	1429	O
autism	24217336	1429	1435	O
clinic	24217336	1436	1442	O
)	24217336	1442	1443	O
.	24217336	1443	1444	O

MAIN	24217336	1446	1450	O
OUTCOMES	24217336	1451	1459	O
AND	24217336	1460	1463	O
MEASURES	24217336	1464	1472	O
:	24217336	1473	1474	O
Primary	24217336	1475	1482	O
outcomes	24217336	1483	1491	O
were	24217336	1492	1496	O
parental	24217336	1497	1505	O
stress	24217336	1506	1512	O
and	24217336	1513	1516	O
maternal	24217336	1517	1525	O
depressive	24217336	1526	1536	O
symptoms	24217336	1537	1545	O
.	24217336	1545	1546	O

RESULTS	24217336	1548	1555	O
:	24217336	1556	1557	O
Fifty-nine	24217336	1558	1568	O
mothers	24217336	1569	1576	O
were	24217336	1577	1581	O
randomized	24217336	1582	1592	O
to	24217336	1593	1595	O
receive	24217336	1596	1603	O
PSE	24217336	1604	1607	O
and	24217336	1608	1611	O
63	24217336	1612	1614	O
to	24217336	1615	1617	O
receive	24217336	1618	1625	O
usual	24217336	1626	1631	O
care	24217336	1632	1636	O
.	24217336	1636	1637	O

The	24217336	1638	1641	O
follow-up	24217336	1642	1651	O
rate	24217336	1652	1656	O
was	24217336	1657	1660	O
91.0	24217336	1661	1665	O
%	24217336	1665	1666	O
.	24217336	1666	1667	O

Most	24217336	1668	1672	O
intervention	24217336	1673	1685	O
mothers	24217336	1686	1693	O
(	24217336	1694	1695	O
78.0	24217336	1695	1699	O
%	24217336	1699	1700	O
)	24217336	1700	1701	O
received	24217336	1702	1710	O
the	24217336	1711	1714	O
full	24217336	1715	1719	O
PSE	24217336	1720	1723	O
course	24217336	1724	1730	O
.	24217336	1730	1731	O

At	24217336	1732	1734	O
the	24217336	1735	1738	O
3-month	24217336	1739	1746	O
follow-up	24217336	1747	1756	O
assessment	24217336	1757	1767	O
,	24217336	1767	1768	O
PSE	24217336	1769	1772	O
mothers	24217336	1773	1780	O
were	24217336	1781	1785	O
significantly	24217336	1786	1799	O
less	24217336	1800	1804	O
likely	24217336	1805	1811	O
than	24217336	1812	1816	O
those	24217336	1817	1822	O
serving	24217336	1823	1830	O
as	24217336	1831	1833	O
controls	24217336	1834	1842	O
to	24217336	1843	1845	O
have	24217336	1846	1850	O
clinically	24217336	1851	1861	O
significant	24217336	1862	1873	O
parental	24217336	1874	1882	B-Outcome
stress	24217336	1883	1889	I-Outcome
(	24217336	1890	1891	O
3.8	24217336	1891	1894	O
%	24217336	1894	1895	O
vs	24217336	1896	1898	O
29.3	24217336	1899	1903	O
%	24217336	1903	1904	O
;	24217336	1904	1905	O
adjusted	24217336	1906	1914	O
relative	24217336	1915	1923	O
risk	24217336	1924	1928	O
[	24217336	1929	1930	O
aRR	24217336	1930	1933	O
]	24217336	1933	1934	O
,	24217336	1934	1935	O
0.17	24217336	1936	1940	O
;	24217336	1940	1941	O
95	24217336	1942	1944	O
%	24217336	1944	1945	O
CI	24217336	1946	1948	O
,	24217336	1948	1949	O
0.04	24217336	1950	1954	O
to	24217336	1955	1957	O
0.65	24217336	1958	1962	O
)	24217336	1962	1963	O
.	24217336	1963	1964	O

For	24217336	1965	1968	O
depressive	24217336	1969	1979	B-Outcome
symptoms	24217336	1980	1988	I-Outcome
,	24217336	1988	1989	O
the	24217336	1990	1993	O
risk	24217336	1994	1998	O
reduction	24217336	1999	2008	O
in	24217336	2009	2011	O
clinically	24217336	2012	2022	B-Outcome
significant	24217336	2023	2034	I-Outcome
symptoms	24217336	2035	2043	I-Outcome
did	24217336	2044	2047	O
not	24217336	2048	2051	O
reach	24217336	2052	2057	O
statistical	24217336	2058	2069	O
significance	24217336	2070	2082	O
(	24217336	2083	2084	O
5.7	24217336	2084	2087	O
%	24217336	2087	2088	O
vs	24217336	2089	2091	O
22.4	24217336	2092	2096	O
%	24217336	2096	2097	O
;	24217336	2097	2098	O
aRR	24217336	2099	2102	O
,	24217336	2102	2103	O
0.33	24217336	2104	2108	O
;	24217336	2108	2109	O
95	24217336	2110	2112	O
%	24217336	2112	2113	O
CI	24217336	2114	2116	O
,	24217336	2116	2117	O
0.10	24217336	2118	2122	O
to	24217336	2123	2125	O
1.08	24217336	2126	2130	O
)	24217336	2130	2131	O
;	24217336	2131	2132	O
however	24217336	2133	2140	O
,	24217336	2140	2141	O
the	24217336	2142	2145	O
reduction	24217336	2146	2155	O
in	24217336	2156	2158	O
mean	24217336	2159	2163	B-Outcome
depressive	24217336	2164	2174	I-Outcome
symptoms	24217336	2175	2183	I-Outcome
was	24217336	2184	2187	O
statistically	24217336	2188	2201	O
significant	24217336	2202	2213	O
(	24217336	2214	2215	O
Quick	24217336	2215	2220	B-Outcome
Inventory	24217336	2221	2230	I-Outcome
of	24217336	2231	2233	I-Outcome
Depressive	24217336	2234	2244	I-Outcome
Symptomatology	24217336	2245	2259	I-Outcome
score	24217336	2260	2265	I-Outcome
,	24217336	2265	2266	O
4.6	24217336	2267	2270	O
with	24217336	2271	2275	O
PSE	24217336	2276	2279	O
vs	24217336	2280	2282	O
6.9	24217336	2283	2286	O
with	24217336	2287	2291	O
usual	24217336	2292	2297	O
care	24217336	2298	2302	O
;	24217336	2302	2303	O
adjusted	24217336	2304	2312	O
mean	24217336	2313	2317	O
difference	24217336	2318	2328	O
,	24217336	2328	2329	O
-1.67	24217336	2330	2335	O
;	24217336	2335	2336	O
95	24217336	2337	2339	O
%	24217336	2339	2340	O
CI	24217336	2341	2343	O
,	24217336	2343	2344	O
-3.17	24217336	2345	2350	O
to	24217336	2351	2353	O
-0.18	24217336	2354	2359	O
)	24217336	2359	2360	O
.	24217336	2360	2361	O

CONCLUSIONS	24217336	2363	2374	O
AND	24217336	2375	2378	O
RELEVANCE	24217336	2379	2388	O
:	24217336	2389	2390	O
The	24217336	2391	2394	O
positive	24217336	2395	2403	O
effects	24217336	2404	2411	O
of	24217336	2412	2414	O
PSE	24217336	2415	2418	O
in	24217336	2419	2421	O
reducing	24217336	2422	2430	O
parenting	24217336	2431	2440	B-Outcome
stress	24217336	2441	2447	I-Outcome
and	24217336	2448	2451	O
depressive	24217336	2452	2462	B-Outcome
symptoms	24217336	2463	2471	I-Outcome
during	24217336	2472	2478	O
the	24217336	2479	2482	O
critical	24217336	2483	2491	O
postdiagnosis	24217336	2492	2505	O
period	24217336	2506	2512	O
,	24217336	2512	2513	O
when	24217336	2514	2518	O
parents	24217336	2519	2526	O
are	24217336	2527	2530	O
asked	24217336	2531	2536	O
to	24217336	2537	2539	O
navigate	24217336	2540	2548	O
a	24217336	2549	2550	O
complex	24217336	2551	2558	O
service	24217336	2559	2566	O
delivery	24217336	2567	2575	O
system	24217336	2576	2582	O
,	24217336	2582	2583	O
suggest	24217336	2584	2591	O
that	24217336	2592	2596	O
it	24217336	2597	2599	O
may	24217336	2600	2603	O
have	24217336	2604	2608	O
a	24217336	2609	2610	O
place	24217336	2611	2616	O
in	24217336	2617	2619	O
clinical	24217336	2620	2628	O
practice	24217336	2629	2637	O
.	24217336	2637	2638	O

Further	24217336	2639	2646	O
work	24217336	2647	2651	O
will	24217336	2652	2656	O
monitor	24217336	2657	2664	O
these	24217336	2665	2670	O
families	24217336	2671	2679	O
for	24217336	2680	2683	O
a	24217336	2684	2685	O
total	24217336	2686	2691	O
of	24217336	2692	2694	O
9	24217336	2695	2696	O
months	24217336	2697	2703	O
to	24217336	2704	2706	O
determine	24217336	2707	2716	O
the	24217336	2717	2720	O
trajectory	24217336	2721	2731	O
of	24217336	2732	2734	O
outcomes	24217336	2735	2743	O
.	24217336	2743	2744	O

TRIAL	24217336	2746	2751	O
REGISTRATION	24217336	2752	2764	O
:	24217336	2765	2766	O
clinicaltrials.gov	24217336	2767	2785	O
Identifier	24217336	2786	2796	O
:	24217336	2796	2797	O
NCT01021384	24217336	2798	2809	O
.	24217336	2809	2810	O


Randomized	24323035	0	10	O
,	24323035	10	11	O
placebo-controlled	24323035	12	30	O
,	24323035	30	31	O
phase	24323035	32	37	O
III	24323035	38	41	O
trial	24323035	42	47	O
of	24323035	48	50	O
sunitinib	24323035	51	60	O
plus	24323035	61	65	O
prednisone	24323035	66	76	O
versus	24323035	77	83	O
prednisone	24323035	84	94	O
alone	24323035	95	100	O
in	24323035	101	103	O
progressive	24323035	104	115	O
,	24323035	115	116	O
metastatic	24323035	117	127	O
,	24323035	127	128	O
castration-resistant	24323035	129	149	O
prostate	24323035	150	158	O
cancer	24323035	159	165	O
.	24323035	165	166	O

PURPOSE	24323035	168	175	O
:	24323035	176	177	O
We	24323035	178	180	O
evaluated	24323035	181	190	O
angiogenesis-targeted	24323035	191	212	O
sunitinib	24323035	213	222	O
therapy	24323035	223	230	O
in	24323035	231	233	O
a	24323035	234	235	O
randomized	24323035	236	246	O
,	24323035	246	247	O
double-blind	24323035	248	260	O
trial	24323035	261	266	O
of	24323035	267	269	O
metastatic	24323035	270	280	O
castration-resistant	24323035	281	301	O
prostate	24323035	302	310	O
cancer	24323035	311	317	O
(	24323035	318	319	O
mCRPC	24323035	319	324	O
)	24323035	324	325	O
.	24323035	325	326	O

PATIENTS	24323035	328	336	O
AND	24323035	337	340	O
METHODS	24323035	341	348	O
:	24323035	349	350	O
Men	24323035	351	354	O
with	24323035	355	359	O
progressive	24323035	360	371	O
mCRPC	24323035	372	377	O
after	24323035	378	383	O
docetaxel-based	24323035	384	399	O
chemotherapy	24323035	400	412	O
were	24323035	413	417	O
randomly	24323035	418	426	O
assigned	24323035	427	435	O
2:1	24323035	436	439	O
to	24323035	440	442	O
receive	24323035	443	450	O
sunitinib	24323035	451	460	O
37.5	24323035	461	465	O
mg/d	24323035	466	470	O
continuously	24323035	471	483	O
or	24323035	484	486	O
placebo	24323035	487	494	O
.	24323035	494	495	O

Patients	24323035	496	504	O
also	24323035	505	509	O
received	24323035	510	518	O
oral	24323035	519	523	O
prednisone	24323035	524	534	O
5	24323035	535	536	O
mg	24323035	537	539	O
twice	24323035	540	545	O
daily	24323035	546	551	O
.	24323035	551	552	O

The	24323035	553	556	O
primary	24323035	557	564	O
end	24323035	565	568	O
point	24323035	569	574	O
was	24323035	575	578	O
overall	24323035	579	586	O
survival	24323035	587	595	O
(	24323035	596	597	O
OS	24323035	597	599	O
)	24323035	599	600	O
;	24323035	600	601	O
secondary	24323035	602	611	O
end	24323035	612	615	O
points	24323035	616	622	O
included	24323035	623	631	O
progression-free	24323035	632	648	O
survival	24323035	649	657	O
(	24323035	658	659	O
PFS	24323035	659	662	O
)	24323035	662	663	O
.	24323035	663	664	O

Two	24323035	665	668	O
interim	24323035	669	676	O
analyses	24323035	677	685	O
were	24323035	686	690	O
planned	24323035	691	698	O
.	24323035	698	699	O

RESULTS	24323035	701	708	O
:	24323035	709	710	O
Overall	24323035	711	718	O
,	24323035	718	719	O
873	24323035	720	723	O
patients	24323035	724	732	O
were	24323035	733	737	O
randomly	24323035	738	746	O
assigned	24323035	747	755	O
to	24323035	756	758	O
receive	24323035	759	766	O
sunitinib	24323035	767	776	O
(	24323035	777	778	O
n	24323035	778	779	O
=	24323035	780	781	O
584	24323035	782	785	O
)	24323035	785	786	O
or	24323035	787	789	O
placebo	24323035	790	797	O
(	24323035	798	799	O
n	24323035	799	800	O
=	24323035	801	802	O
289	24323035	803	806	O
)	24323035	806	807	O
.	24323035	807	808	O

The	24323035	809	812	O
independent	24323035	813	824	O
data	24323035	825	829	O
monitoring	24323035	830	840	O
committee	24323035	841	850	O
stopped	24323035	851	858	O
the	24323035	859	862	O
study	24323035	863	868	O
for	24323035	869	872	O
futility	24323035	873	881	O
after	24323035	882	887	O
the	24323035	888	891	O
second	24323035	892	898	O
interim	24323035	899	906	O
analysis	24323035	907	915	O
.	24323035	915	916	O

After	24323035	917	922	O
a	24323035	923	924	O
median	24323035	925	931	O
overall	24323035	932	939	O
follow-up	24323035	940	949	O
of	24323035	950	952	O
8.7	24323035	953	956	O
months	24323035	957	963	O
,	24323035	963	964	O
median	24323035	965	971	B-Outcome
OS	24323035	972	974	I-Outcome
was	24323035	975	978	O
13.1	24323035	979	983	O
months	24323035	984	990	O
and	24323035	991	994	O
11.8	24323035	995	999	O
months	24323035	1000	1006	O
for	24323035	1007	1010	O
sunitinib	24323035	1011	1020	O
and	24323035	1021	1024	O
placebo	24323035	1025	1032	O
,	24323035	1032	1033	O
respectively	24323035	1034	1046	O
(	24323035	1047	1048	O
hazard	24323035	1048	1054	O
ratio	24323035	1055	1060	O
[	24323035	1061	1062	O
HR	24323035	1062	1064	O
]	24323035	1064	1065	O
,	24323035	1065	1066	O
0.914	24323035	1067	1072	O
;	24323035	1072	1073	O
95	24323035	1074	1076	O
%	24323035	1076	1077	O
CI	24323035	1078	1080	O
,	24323035	1080	1081	O
0.762	24323035	1082	1087	O
to	24323035	1088	1090	O
1.097	24323035	1091	1096	O
;	24323035	1096	1097	O
stratified	24323035	1098	1108	O
log-rank	24323035	1109	1117	O
test	24323035	1118	1122	O
,	24323035	1122	1123	O
P	24323035	1124	1125	O
=	24323035	1126	1127	O
.168	24323035	1128	1132	O
)	24323035	1132	1133	O
.	24323035	1133	1134	O

PFS	24323035	1135	1138	B-Outcome
was	24323035	1139	1142	O
significantly	24323035	1143	1156	O
improved	24323035	1157	1165	O
in	24323035	1166	1168	O
the	24323035	1169	1172	O
sunitinib	24323035	1173	1182	O
arm	24323035	1183	1186	O
(	24323035	1187	1188	O
median	24323035	1188	1194	O
5.6	24323035	1195	1198	O
v	24323035	1199	1200	O
4.1	24323035	1201	1204	O
months	24323035	1205	1211	O
;	24323035	1211	1212	O
HR	24323035	1213	1215	O
,	24323035	1215	1216	O
0.725	24323035	1217	1222	O
;	24323035	1222	1223	O
95	24323035	1224	1226	O
%	24323035	1226	1227	O
CI	24323035	1228	1230	O
,	24323035	1230	1231	O
0.591	24323035	1232	1237	O
to	24323035	1238	1240	O
0.890	24323035	1241	1246	O
;	24323035	1246	1247	O
stratified	24323035	1248	1258	O
log-rank	24323035	1259	1267	O
test	24323035	1268	1272	O
,	24323035	1272	1273	O
P	24323035	1274	1275	O
<	24323035	1276	1277	O
.001	24323035	1278	1282	O
)	24323035	1282	1283	O
.	24323035	1283	1284	O

Toxicity	24323035	1285	1293	B-Outcome
and	24323035	1294	1297	O
rates	24323035	1298	1303	O
of	24323035	1304	1306	O
discontinuations	24323035	1307	1323	O
because	24323035	1324	1331	O
of	24323035	1332	1334	O
adverse	24323035	1335	1342	B-Outcome
events	24323035	1343	1349	I-Outcome
(	24323035	1350	1351	O
AEs	24323035	1351	1354	B-Outcome
;	24323035	1354	1355	O
27	24323035	1356	1358	O
%	24323035	1358	1359	O
v	24323035	1360	1361	O
7	24323035	1362	1363	O
%	24323035	1363	1364	O
)	24323035	1364	1365	O
were	24323035	1366	1370	O
greater	24323035	1371	1378	O
with	24323035	1379	1383	O
sunitinib	24323035	1384	1393	O
than	24323035	1394	1398	O
placebo	24323035	1399	1406	O
.	24323035	1406	1407	O

The	24323035	1408	1411	O
most	24323035	1412	1416	O
common	24323035	1417	1423	O
treatment-related	24323035	1424	1441	B-Outcome
grade	24323035	1442	1447	I-Outcome
3/4	24323035	1448	1451	I-Outcome
AEs	24323035	1452	1455	I-Outcome
were	24323035	1456	1460	O
fatigue	24323035	1461	1468	O
(	24323035	1469	1470	O
9	24323035	1470	1471	O
%	24323035	1471	1472	O
v	24323035	1473	1474	O
1	24323035	1475	1476	O
%	24323035	1476	1477	O
)	24323035	1477	1478	O
,	24323035	1478	1479	O
asthenia	24323035	1480	1488	O
(	24323035	1489	1490	O
8	24323035	1490	1491	O
%	24323035	1491	1492	O
v	24323035	1493	1494	O
2	24323035	1495	1496	O
%	24323035	1496	1497	O
)	24323035	1497	1498	O
,	24323035	1498	1499	O
and	24323035	1500	1503	O
hand-foot	24323035	1504	1513	O
syndrome	24323035	1514	1522	O
(	24323035	1523	1524	O
7	24323035	1524	1525	O
%	24323035	1525	1526	O
v	24323035	1527	1528	O
0	24323035	1529	1530	O
%	24323035	1530	1531	O
)	24323035	1531	1532	O
.	24323035	1532	1533	O

Frequent	24323035	1534	1542	O
treatment-emergent	24323035	1543	1561	B-Outcome
grade	24323035	1562	1567	I-Outcome
3/4	24323035	1568	1571	I-Outcome
hematologic	24323035	1572	1583	I-Outcome
abnormalities	24323035	1584	1597	I-Outcome
were	24323035	1598	1602	O
lymphopenia	24323035	1603	1614	O
(	24323035	1615	1616	O
20	24323035	1616	1618	O
%	24323035	1618	1619	O
v	24323035	1620	1621	O
11	24323035	1622	1624	O
%	24323035	1624	1625	O
)	24323035	1625	1626	O
,	24323035	1626	1627	O
anemia	24323035	1628	1634	O
(	24323035	1635	1636	O
9	24323035	1636	1637	O
%	24323035	1637	1638	O
v	24323035	1639	1640	O
8	24323035	1641	1642	O
%	24323035	1642	1643	O
)	24323035	1643	1644	O
,	24323035	1644	1645	O
and	24323035	1646	1649	O
neutropenia	24323035	1650	1661	O
(	24323035	1662	1663	O
6	24323035	1663	1664	O
%	24323035	1664	1665	O
v	24323035	1666	1667	O
<	24323035	1668	1669	O
1	24323035	1670	1671	O
%	24323035	1671	1672	O
)	24323035	1672	1673	O
.	24323035	1673	1674	O

CONCLUSION	24323035	1676	1686	O
:	24323035	1687	1688	O
The	24323035	1689	1692	O
addition	24323035	1693	1701	O
of	24323035	1702	1704	O
sunitinib	24323035	1705	1714	O
to	24323035	1715	1717	O
prednisone	24323035	1718	1728	O
did	24323035	1729	1732	O
not	24323035	1733	1736	O
improve	24323035	1737	1744	O
OS	24323035	1745	1747	B-Outcome
compared	24323035	1748	1756	O
with	24323035	1757	1761	O
placebo	24323035	1762	1769	O
in	24323035	1770	1772	O
docetaxel-refractory	24323035	1773	1793	O
mCRPC	24323035	1794	1799	O
.	24323035	1799	1800	O

The	24323035	1801	1804	O
role	24323035	1805	1809	O
of	24323035	1810	1812	O
antiangiogenic	24323035	1813	1827	O
therapy	24323035	1828	1835	O
in	24323035	1836	1838	O
mCRPC	24323035	1839	1844	O
remains	24323035	1845	1852	O
investigational	24323035	1853	1868	O
.	24323035	1868	1869	O


Short-	24330473	0	6	O
and	24330473	7	10	O
long-term	24330473	11	20	O
effects	24330473	21	28	O
of	24330473	29	31	O
tactile	24330473	32	39	O
massage	24330473	40	47	O
on	24330473	48	50	O
salivary	24330473	51	59	O
cortisol	24330473	60	68	O
concentrations	24330473	69	83	O
in	24330473	84	86	O
Parkinson	24330473	87	96	O
's	24330473	96	98	O
disease	24330473	99	106	O
:	24330473	106	107	O
a	24330473	108	109	O
randomised	24330473	110	120	O
controlled	24330473	121	131	O
pilot	24330473	132	137	O
study	24330473	138	143	O
.	24330473	143	144	O

BACKGROUND	24330473	146	156	O
:	24330473	157	158	O
Parkinson	24330473	159	168	O
's	24330473	168	170	O
disease	24330473	171	178	O
(	24330473	179	180	O
PD	24330473	180	182	O
)	24330473	182	183	O
is	24330473	184	186	O
a	24330473	187	188	O
chronic	24330473	189	196	O
neurodegenerative	24330473	197	214	O
disorder	24330473	215	223	O
with	24330473	224	228	O
limited	24330473	229	236	O
knowledge	24330473	237	246	O
about	24330473	247	252	O
the	24330473	253	256	O
normal	24330473	257	263	O
function	24330473	264	272	O
and	24330473	273	276	O
effects	24330473	277	284	O
of	24330473	285	287	O
non-pharmacological	24330473	288	307	O
therapies	24330473	308	317	O
on	24330473	318	320	O
the	24330473	321	324	O
hypothalamic-pituitary-adrenal	24330473	325	355	O
(	24330473	356	357	O
HPA	24330473	357	360	O
)	24330473	360	361	O
axis	24330473	362	366	O
.	24330473	366	367	O

The	24330473	368	371	O
aim	24330473	372	375	O
of	24330473	376	378	O
the	24330473	379	382	O
study	24330473	383	388	O
was	24330473	389	392	O
to	24330473	393	395	O
analyse	24330473	396	403	O
the	24330473	404	407	O
basal	24330473	408	413	O
diurnal	24330473	414	421	O
and	24330473	422	425	O
total	24330473	426	431	O
secretion	24330473	432	441	O
of	24330473	442	444	O
salivary	24330473	445	453	O
cortisol	24330473	454	462	O
in	24330473	463	465	O
short-	24330473	466	472	O
and	24330473	473	476	O
long-term	24330473	477	486	O
aspects	24330473	487	494	O
of	24330473	495	497	O
tactile	24330473	498	505	O
massage	24330473	506	513	O
(	24330473	514	515	O
TM	24330473	515	517	O
)	24330473	517	518	O
.	24330473	518	519	O

DESIGN	24330473	521	527	O
:	24330473	528	529	O
Prospective	24330473	530	541	O
,	24330473	541	542	O
Controlled	24330473	543	553	O
and	24330473	554	557	O
Randomised	24330473	558	568	O
Multicentre	24330473	569	580	O
Trial	24330473	581	586	O
.	24330473	586	587	O

SETTING	24330473	589	596	O
AND	24330473	597	600	O
INTERVENTIONS	24330473	601	614	O
:	24330473	615	616	O
Forty-five	24330473	617	627	O
women	24330473	628	633	O
and	24330473	634	637	O
men	24330473	638	641	O
,	24330473	641	642	O
aged	24330473	643	647	O
50	24330473	648	650	O
-	24330473	650	651	O
79	24330473	651	653	O
years	24330473	654	659	O
,	24330473	659	660	O
were	24330473	661	665	O
recruited	24330473	666	675	O
.	24330473	675	676	O

Twenty-nine	24330473	677	688	O
of	24330473	689	691	O
them	24330473	692	696	O
were	24330473	697	701	O
blindly	24330473	702	709	O
randomised	24330473	710	720	O
to	24330473	721	723	O
tactile	24330473	724	731	O
massage	24330473	732	739	O
(	24330473	740	741	O
TM	24330473	741	743	O
)	24330473	743	744	O
and	24330473	745	748	O
16	24330473	749	751	O
of	24330473	752	754	O
them	24330473	755	759	O
to	24330473	760	762	O
the	24330473	763	766	O
control	24330473	767	774	O
group	24330473	775	780	O
,	24330473	780	781	O
rest	24330473	782	786	O
to	24330473	787	789	O
music	24330473	790	795	O
(	24330473	796	797	O
RTM	24330473	797	800	O
)	24330473	800	801	O
.	24330473	801	802	O

Ten	24330473	803	806	O
interventions	24330473	807	820	O
were	24330473	821	825	O
given	24330473	826	831	O
during	24330473	832	838	O
8	24330473	839	840	O
weeks	24330473	841	846	O
followed	24330473	847	855	O
by	24330473	856	858	O
a	24330473	859	860	O
26	24330473	861	863	O
weeks	24330473	864	869	O
of	24330473	870	872	O
follow	24330473	873	879	O
up	24330473	880	882	O
.	24330473	882	883	O

Salivary	24330473	884	892	O
cortisol	24330473	893	901	O
was	24330473	902	905	O
collected	24330473	906	915	O
at	24330473	916	918	O
8	24330473	919	920	O
am	24330473	921	923	O
,	24330473	923	924	O
1	24330473	925	926	O
pm	24330473	927	929	O
,	24330473	929	930	O
8	24330473	931	932	O
pm	24330473	933	935	O
,	24330473	935	936	O
and	24330473	937	940	O
8	24330473	941	942	O
am	24330473	943	945	O
the	24330473	946	949	O
next	24330473	950	954	O
day	24330473	955	958	O
,	24330473	958	959	O
on	24330473	960	962	O
five	24330473	963	967	O
occasions	24330473	968	977	O
.	24330473	977	978	O

With	24330473	979	983	O
the	24330473	984	987	O
first	24330473	988	993	O
and	24330473	994	997	O
eighth	24330473	998	1004	O
interventions	24330473	1005	1018	O
,	24330473	1018	1019	O
it	24330473	1020	1022	O
was	24330473	1023	1026	O
collected	24330473	1027	1036	O
immediately	24330473	1037	1048	O
before	24330473	1049	1055	O
and	24330473	1056	1059	O
after	24330473	1060	1065	O
intervention	24330473	1066	1078	O
.	24330473	1078	1079	O

MAIN	24330473	1081	1085	O
OUTCOME	24330473	1086	1093	O
MEASURES	24330473	1094	1102	O
:	24330473	1103	1104	O
The	24330473	1105	1108	O
primary	24330473	1109	1116	O
aim	24330473	1117	1120	O
was	24330473	1121	1124	O
to	24330473	1125	1127	O
assess	24330473	1128	1134	O
and	24330473	1135	1138	O
compare	24330473	1139	1146	O
cortisol	24330473	1147	1155	O
concentrations	24330473	1156	1170	O
before	24330473	1171	1177	O
and	24330473	1178	1181	O
immediately	24330473	1182	1193	O
after	24330473	1194	1199	O
intervention	24330473	1200	1212	O
and	24330473	1213	1216	O
also	24330473	1217	1221	O
during	24330473	1222	1228	O
the	24330473	1229	1232	O
follow-up	24330473	1233	1242	O
period	24330473	1243	1249	O
.	24330473	1249	1250	O

The	24330473	1251	1254	O
secondary	24330473	1255	1264	O
aim	24330473	1265	1268	O
was	24330473	1269	1272	O
to	24330473	1273	1275	O
assess	24330473	1276	1282	O
the	24330473	1283	1286	O
impact	24330473	1287	1293	O
of	24330473	1294	1296	O
age	24330473	1297	1300	O
,	24330473	1300	1301	O
gender	24330473	1302	1308	O
,	24330473	1308	1309	O
body	24330473	1310	1314	O
mass	24330473	1315	1319	O
index	24330473	1320	1325	O
(	24330473	1326	1327	O
BMI	24330473	1327	1330	O
)	24330473	1330	1331	O
,	24330473	1331	1332	O
duration	24330473	1333	1341	O
and	24330473	1342	1345	O
severity	24330473	1346	1354	O
of	24330473	1355	1357	O
PD	24330473	1358	1360	O
,	24330473	1360	1361	O
effects	24330473	1362	1369	O
of	24330473	1370	1372	O
interventional	24330473	1373	1387	O
time-point	24330473	1388	1398	O
of	24330473	1399	1401	O
the	24330473	1402	1405	O
day	24330473	1406	1409	O
,	24330473	1409	1410	O
and	24330473	1411	1414	O
levodopa	24330473	1415	1423	O
doses	24330473	1424	1429	O
on	24330473	1430	1432	O
cortisol	24330473	1433	1441	O
concentration	24330473	1442	1455	O
.	24330473	1455	1456	O

RESULTS	24330473	1458	1465	O
:	24330473	1466	1467	O
The	24330473	1468	1471	O
median	24330473	1472	1478	B-Outcome
cortisol	24330473	1479	1487	I-Outcome
concentrations	24330473	1488	1502	I-Outcome
for	24330473	1503	1506	O
all	24330473	1507	1510	O
participants	24330473	1511	1523	O
were	24330473	1524	1528	O
16.0	24330473	1529	1533	O
,	24330473	1533	1534	O
5.8	24330473	1535	1538	O
,	24330473	1538	1539	O
2.8	24330473	1540	1543	O
,	24330473	1543	1544	O
and	24330473	1545	1548	O
14.0	24330473	1549	1553	O
nmol/L	24330473	1554	1560	O
at	24330473	1561	1563	O
baseline	24330473	1564	1572	O
,	24330473	1572	1573	O
later	24330473	1574	1579	O
reproduced	24330473	1580	1590	O
four	24330473	1591	1595	O
times	24330473	1596	1601	O
without	24330473	1602	1609	O
significant	24330473	1610	1621	O
differences	24330473	1622	1633	O
.	24330473	1633	1634	O

Cortisol	24330473	1635	1643	B-Outcome
concentrations	24330473	1644	1658	I-Outcome
decreased	24330473	1659	1668	O
significantly	24330473	1669	1682	O
after	24330473	1683	1688	O
TM	24330473	1689	1691	O
intervention	24330473	1692	1704	O
but	24330473	1705	1708	O
no	24330473	1709	1711	O
change	24330473	1712	1718	O
in	24330473	1719	1721	O
diurnal	24330473	1722	1729	B-Outcome
salivary	24330473	1730	1738	I-Outcome
cortisol	24330473	1739	1747	I-Outcome
pattern	24330473	1748	1755	I-Outcome
was	24330473	1756	1759	O
found	24330473	1760	1765	O
.	24330473	1765	1766	O

The	24330473	1767	1770	O
findings	24330473	1771	1779	O
of	24330473	1780	1782	O
reduced	24330473	1783	1790	O
salivary	24330473	1791	1799	B-Outcome
cortisol	24330473	1800	1808	I-Outcome
concentrations	24330473	1809	1823	I-Outcome
immediately	24330473	1824	1835	O
after	24330473	1836	1841	O
the	24330473	1842	1845	O
interventions	24330473	1846	1859	O
are	24330473	1860	1863	O
in	24330473	1864	1866	O
agreement	24330473	1867	1876	O
with	24330473	1877	1881	O
previous	24330473	1882	1890	O
studies	24330473	1891	1898	O
.	24330473	1898	1899	O

However	24330473	1900	1907	O
,	24330473	1907	1908	O
there	24330473	1909	1914	O
was	24330473	1915	1918	O
no	24330473	1919	1921	O
significant	24330473	1922	1933	O
difference	24330473	1934	1944	O
between	24330473	1945	1952	O
the	24330473	1953	1956	O
TM	24330473	1957	1959	O
and	24330473	1960	1963	O
control	24330473	1964	1971	O
groups	24330473	1972	1978	O
.	24330473	1978	1979	O

There	24330473	1980	1985	O
were	24330473	1986	1990	O
no	24330473	1991	1993	O
significant	24330473	1994	2005	O
correlations	24330473	2006	2018	O
between	24330473	2019	2026	O
cortisol	24330473	2027	2035	B-Outcome
concentrations	24330473	2036	2050	I-Outcome
and	24330473	2051	2054	O
age	24330473	2055	2058	O
,	24330473	2058	2059	O
gender	24330473	2060	2066	O
,	24330473	2066	2067	O
BMI	24330473	2068	2071	O
,	24330473	2071	2072	O
time-point	24330473	2073	2083	O
for	24330473	2084	2087	O
intervention	24330473	2088	2100	O
,	24330473	2100	2101	O
time	24330473	2102	2106	O
interval	24330473	2107	2115	O
between	24330473	2116	2123	O
anti-parkinson	24330473	2124	2138	O
pharmacy	24330473	2139	2147	O
intake	24330473	2148	2154	O
and	24330473	2155	2158	O
sampling	24330473	2159	2167	O
,	24330473	2167	2168	O
levodopa	24330473	2169	2177	O
doses	24330473	2178	2183	O
,	24330473	2183	2184	O
duration	24330473	2185	2193	O
,	24330473	2193	2194	O
or	24330473	2195	2197	O
severity	24330473	2198	2206	O
of	24330473	2207	2209	O
PD	24330473	2210	2212	O
.	24330473	2212	2213	O

CONCLUSIONS	24330473	2215	2226	O
:	24330473	2227	2228	O
Diurnal	24330473	2229	2236	B-Outcome
salivary	24330473	2237	2245	I-Outcome
cortisol	24330473	2246	2254	I-Outcome
rhythm	24330473	2255	2261	I-Outcome
was	24330473	2262	2265	O
normal	24330473	2266	2272	O
.	24330473	2272	2273	O

Salivary	24330473	2274	2282	B-Outcome
cortisol	24330473	2283	2291	I-Outcome
concentrations	24330473	2292	2306	I-Outcome
were	24330473	2307	2311	O
significantly	24330473	2312	2325	O
reduced	24330473	2326	2333	O
after	24330473	2334	2339	O
the	24330473	2340	2343	O
TM	24330473	2344	2346	O
intervention	24330473	2347	2359	O
and	24330473	2360	2363	O
after	24330473	2364	2369	O
RTM	24330473	2370	2373	O
,	24330473	2373	2374	O
but	24330473	2375	2378	O
there	24330473	2379	2384	O
were	24330473	2385	2389	O
no	24330473	2390	2392	O
significant	24330473	2393	2404	O
differences	24330473	2405	2416	O
between	24330473	2417	2424	O
the	24330473	2425	2428	O
groups	24330473	2429	2435	O
and	24330473	2436	2439	O
no	24330473	2440	2442	O
sustained	24330473	2443	2452	O
long-term	24330473	2453	2462	O
effect	24330473	2463	2469	O
.	24330473	2469	2470	O

No	24330473	2471	2473	O
associations	24330473	2474	2486	O
were	24330473	2487	2491	O
seen	24330473	2492	2496	O
between	24330473	2497	2504	O
salivary	24330473	2505	2513	B-Outcome
cortisol	24330473	2514	2522	I-Outcome
concentration	24330473	2523	2536	I-Outcome
and	24330473	2537	2540	O
clinical	24330473	2541	2549	O
and/or	24330473	2550	2556	O
pharmacological	24330473	2557	2572	O
characteristics	24330473	2573	2588	O
.	24330473	2588	2589	O

TRIAL	24330473	2591	2596	O
REGISTRATION	24330473	2597	2609	O
:	24330473	2610	2611	O
ClinicalTrial.gov	24330473	2612	2629	O
,	24330473	2629	2630	O
NCT01734876	24330473	2631	2642	O
and	24330473	2643	2646	O
FoU	24330473	2647	2650	O
Sweden	24330473	2651	2657	O
108881	24330473	2658	2664	O
.	24330473	2664	2665	O


Vitamin	24335055	0	7	O
D	24335055	8	9	O
supplementation	24335055	10	25	O
increases	24335055	26	35	O
calcium	24335055	36	43	O
absorption	24335055	44	54	O
without	24335055	55	62	O
a	24335055	63	64	O
threshold	24335055	65	74	O
effect	24335055	75	81	O
.	24335055	81	82	O

BACKGROUND	24335055	84	94	O
:	24335055	95	96	O
The	24335055	97	100	O
maximal	24335055	101	108	O
calcium	24335055	109	116	O
absorption	24335055	117	127	O
in	24335055	128	130	O
response	24335055	131	139	O
to	24335055	140	142	O
vitamin	24335055	143	150	O
D	24335055	151	152	O
has	24335055	153	156	O
been	24335055	157	161	O
proposed	24335055	162	170	O
as	24335055	171	173	O
a	24335055	174	175	O
biomarker	24335055	176	185	O
for	24335055	186	189	O
vitamin	24335055	190	197	O
D	24335055	198	199	O
sufficiency	24335055	200	211	O
.	24335055	211	212	O

OBJECTIVE	24335055	214	223	O
:	24335055	224	225	O
The	24335055	226	229	O
objective	24335055	230	239	O
was	24335055	240	243	O
to	24335055	244	246	O
determine	24335055	247	256	O
whether	24335055	257	264	O
there	24335055	265	270	O
is	24335055	271	273	O
a	24335055	274	275	O
threshold	24335055	276	285	O
beyond	24335055	286	292	O
which	24335055	293	298	O
increasing	24335055	299	309	O
doses	24335055	310	315	O
of	24335055	316	318	O
vitamin	24335055	319	326	O
D	24335055	327	328	O
,	24335055	328	329	O
or	24335055	330	332	O
concentrations	24335055	333	347	O
of	24335055	348	350	O
serum	24335055	351	356	O
25-hydroxyvitamin	24335055	357	374	O
D	24335055	375	376	O
[	24335055	377	378	O
25(OH)D	24335055	378	385	O
]	24335055	385	386	O
,	24335055	386	387	O
no	24335055	388	390	O
longer	24335055	391	397	O
increase	24335055	398	406	O
calcium	24335055	407	414	O
absorption	24335055	415	425	O
.	24335055	425	426	O

DESIGN	24335055	428	434	O
:	24335055	435	436	O
This	24335055	437	441	O
was	24335055	442	445	O
a	24335055	446	447	O
placebo-controlled	24335055	448	466	O
,	24335055	466	467	O
dose-response	24335055	468	481	O
,	24335055	481	482	O
randomized	24335055	483	493	O
,	24335055	493	494	O
double-blind	24335055	495	507	O
study	24335055	508	513	O
of	24335055	514	516	O
the	24335055	517	520	O
effect	24335055	521	527	O
of	24335055	528	530	O
vitamin	24335055	531	538	O
D	24335055	539	540	O
on	24335055	541	543	O
calcium	24335055	544	551	O
absorption	24335055	552	562	O
in	24335055	563	565	O
healthy	24335055	566	573	O
postmenopausal	24335055	574	588	O
women	24335055	589	594	O
.	24335055	594	595	O

Seventy-six	24335055	596	607	O
healthy	24335055	608	615	O
postmenopausal	24335055	616	630	O
women	24335055	631	636	O
were	24335055	637	641	O
randomly	24335055	642	650	O
assigned	24335055	651	659	O
to	24335055	660	662	O
placebo	24335055	663	670	O
or	24335055	671	673	O
800	24335055	674	677	O
IU	24335055	678	680	O
(	24335055	681	682	O
20	24335055	682	684	O
μg	24335055	685	687	O
)	24335055	687	688	O
,	24335055	688	689	O
2000	24335055	690	694	O
IU	24335055	695	697	O
(	24335055	698	699	O
50	24335055	699	701	O
μg	24335055	702	704	O
)	24335055	704	705	O
,	24335055	705	706	O
or	24335055	707	709	O
4000	24335055	710	714	O
IU	24335055	715	717	O
(	24335055	718	719	O
100	24335055	719	722	O
μg	24335055	723	725	O
)	24335055	725	726	O
vitamin	24335055	727	734	O
D₃	24335055	735	737	O
for	24335055	738	741	O
8	24335055	742	743	O
wk	24335055	744	746	O
.	24335055	746	747	O

The	24335055	748	751	O
technique	24335055	752	761	O
of	24335055	762	764	O
dual	24335055	765	769	O
isotopes	24335055	770	778	O
of	24335055	779	781	O
stable	24335055	782	788	O
calcium	24335055	789	796	O
was	24335055	797	800	O
used	24335055	801	805	O
with	24335055	806	810	O
a	24335055	811	812	O
calcium	24335055	813	820	O
carrier	24335055	821	828	O
to	24335055	829	831	O
measure	24335055	832	839	O
calcium	24335055	840	847	O
absorption	24335055	848	858	O
at	24335055	859	861	O
baseline	24335055	862	870	O
and	24335055	871	874	O
after	24335055	875	880	O
8	24335055	881	882	O
wk	24335055	883	885	O
.	24335055	885	886	O

RESULTS	24335055	888	895	O
:	24335055	896	897	O
Seventy-one	24335055	898	909	O
women	24335055	910	915	O
with	24335055	916	920	O
a	24335055	921	922	O
mean	24335055	923	927	O
±	24335055	928	929	O
SD	24335055	930	932	O
age	24335055	933	936	O
of	24335055	937	939	O
58.8	24335055	940	944	O
±	24335055	945	946	O
4.9	24335055	947	950	O
y	24335055	951	952	O
completed	24335055	953	962	O
the	24335055	963	966	O
study	24335055	967	972	O
.	24335055	972	973	O

The	24335055	974	977	O
mean	24335055	978	982	O
calcium	24335055	983	990	O
intake	24335055	991	997	O
was	24335055	998	1001	O
1142	24335055	1002	1006	O
±	24335055	1007	1008	O
509	24335055	1009	1012	O
mg/d	24335055	1013	1017	O
and	24335055	1018	1021	O
serum	24335055	1022	1027	O
25(OH)D	24335055	1028	1035	O
was	24335055	1036	1039	O
63	24335055	1040	1042	O
±	24335055	1043	1044	O
14	24335055	1045	1047	O
nmol/L	24335055	1048	1054	O
at	24335055	1055	1057	O
baseline	24335055	1058	1066	O
.	24335055	1066	1067	O

A	24335055	1068	1069	O
statistically	24335055	1070	1083	O
significant	24335055	1084	1095	O
linear	24335055	1096	1102	O
trend	24335055	1103	1108	O
of	24335055	1109	1111	O
an	24335055	1112	1114	O
increase	24335055	1115	1123	B-Outcome
in	24335055	1124	1126	I-Outcome
calcium	24335055	1127	1134	I-Outcome
absorption	24335055	1135	1145	I-Outcome
adjusted	24335055	1146	1154	O
for	24335055	1155	1158	O
age	24335055	1159	1162	O
and	24335055	1163	1166	O
body	24335055	1167	1171	O
mass	24335055	1172	1176	O
index	24335055	1177	1182	O
with	24335055	1183	1187	O
increasing	24335055	1188	1198	O
vitamin	24335055	1199	1206	O
D₃	24335055	1207	1209	O
dose	24335055	1210	1214	O
or	24335055	1215	1217	O
serum	24335055	1218	1223	O
25(OH)D	24335055	1224	1231	O
concentration	24335055	1232	1245	O
was	24335055	1246	1249	O
observed	24335055	1250	1258	O
.	24335055	1258	1259	O

A	24335055	1260	1261	O
6.7	24335055	1262	1265	O
%	24335055	1265	1266	O
absolute	24335055	1267	1275	B-Outcome
increase	24335055	1276	1284	I-Outcome
in	24335055	1285	1287	I-Outcome
calcium	24335055	1288	1295	I-Outcome
absorption	24335055	1296	1306	I-Outcome
was	24335055	1307	1310	O
found	24335055	1311	1316	O
in	24335055	1317	1319	O
the	24335055	1320	1323	O
highest	24335055	1324	1331	O
vitamin	24335055	1332	1339	O
D₃	24335055	1340	1342	O
group	24335055	1343	1348	O
(	24335055	1349	1350	O
100	24335055	1350	1353	O
μg	24335055	1354	1356	O
)	24335055	1356	1357	O
.	24335055	1357	1358	O

No	24335055	1359	1361	O
evidence	24335055	1362	1370	O
of	24335055	1371	1373	O
nonlinearity	24335055	1374	1386	O
was	24335055	1387	1390	O
observed	24335055	1391	1399	O
in	24335055	1400	1402	O
the	24335055	1403	1406	O
dose-response	24335055	1407	1420	O
curve	24335055	1421	1426	O
.	24335055	1426	1427	O

CONCLUSIONS	24335055	1429	1440	O
:	24335055	1441	1442	O
No	24335055	1443	1445	O
evidence	24335055	1446	1454	O
of	24335055	1455	1457	O
a	24335055	1458	1459	O
threshold	24335055	1460	1469	B-Outcome
of	24335055	1470	1472	I-Outcome
calcium	24335055	1473	1480	I-Outcome
absorption	24335055	1481	1491	I-Outcome
was	24335055	1492	1495	O
found	24335055	1496	1501	O
with	24335055	1502	1506	O
a	24335055	1507	1508	O
serum	24335055	1509	1514	O
25(OH)D	24335055	1515	1522	O
range	24335055	1523	1528	O
from	24335055	1529	1533	O
40	24335055	1534	1536	O
to	24335055	1537	1539	O
130	24335055	1540	1543	O
nmol/L.	24335055	1544	1551	O
Calcium	24335055	1552	1559	B-Outcome
absorption	24335055	1560	1570	I-Outcome
in	24335055	1571	1573	O
this	24335055	1574	1578	O
range	24335055	1579	1584	O
is	24335055	1585	1587	O
not	24335055	1588	1591	O
a	24335055	1592	1593	O
useful	24335055	1594	1600	O
biomarker	24335055	1601	1610	O
to	24335055	1611	1613	O
determine	24335055	1614	1623	O
nutritional	24335055	1624	1635	O
recommendations	24335055	1636	1651	O
for	24335055	1652	1655	O
vitamin	24335055	1656	1663	O
D.	24335055	1664	1666	O

An	24350813	0	2	O
open-label	24350813	3	13	O
extension	24350813	14	23	O
study	24350813	24	29	O
of	24350813	30	32	O
the	24350813	33	36	O
safety	24350813	37	43	O
and	24350813	44	47	O
efficacy	24350813	48	56	O
of	24350813	57	59	O
risperidone	24350813	60	71	O
in	24350813	72	74	O
children	24350813	75	83	O
and	24350813	84	87	O
adolescents	24350813	88	99	O
with	24350813	100	104	O
autistic	24350813	105	113	O
disorder	24350813	114	122	O
.	24350813	122	123	O

OBJECTIVE	24350813	125	134	O
:	24350813	135	136	O
The	24350813	137	140	O
purpose	24350813	141	148	O
of	24350813	149	151	O
this	24350813	152	156	O
study	24350813	157	162	O
was	24350813	163	166	O
to	24350813	167	169	O
evaluate	24350813	170	178	O
the	24350813	179	182	O
long-term	24350813	183	192	O
safety	24350813	193	199	O
and	24350813	200	203	O
efficacy	24350813	204	212	O
of	24350813	213	215	O
risperidone	24350813	216	227	O
in	24350813	228	230	O
treating	24350813	231	239	O
irritability	24350813	240	252	O
and	24350813	253	256	O
related	24350813	257	264	O
behaviors	24350813	265	274	O
in	24350813	275	277	O
children	24350813	278	286	O
and	24350813	287	290	O
adolescents	24350813	291	302	O
with	24350813	303	307	O
autistic	24350813	308	316	O
disorders	24350813	317	326	O
.	24350813	326	327	O

METHODS	24350813	329	336	O
:	24350813	337	338	O
In	24350813	339	341	O
this	24350813	342	346	O
6	24350813	347	348	O
month	24350813	349	354	O
(	24350813	355	356	O
26	24350813	356	358	O
week	24350813	359	363	O
)	24350813	363	364	O
open-label	24350813	365	375	O
extension	24350813	376	385	O
(	24350813	386	387	O
OLE	24350813	387	390	O
)	24350813	390	391	O
study	24350813	392	397	O
,	24350813	397	398	O
patients	24350813	399	407	O
(	24350813	408	409	O
5	24350813	409	410	O
-	24350813	410	411	O
17	24350813	411	413	O
years	24350813	414	419	O
of	24350813	420	422	O
age	24350813	423	426	O
,	24350813	426	427	O
who	24350813	428	431	O
completed	24350813	432	441	O
the	24350813	442	445	O
previous	24350813	446	454	O
fixed-dose	24350813	455	465	O
,	24350813	465	466	O
6	24350813	467	468	O
week	24350813	469	473	O
,	24350813	473	474	O
double-blind	24350813	475	487	O
[	24350813	488	489	O
DB	24350813	489	491	O
]	24350813	491	492	O
phase	24350813	493	498	O
)	24350813	498	499	O
were	24350813	500	504	O
flexibly	24350813	505	513	O
dosed	24350813	514	519	O
with	24350813	520	524	O
risperidone	24350813	525	536	O
based	24350813	537	542	O
on	24350813	543	545	O
body	24350813	546	550	O
weight	24350813	551	557	O
.	24350813	557	558	O

The	24350813	559	562	O
maximum	24350813	563	570	O
allowed	24350813	571	578	O
dose	24350813	579	583	O
was	24350813	584	587	O
1.25	24350813	588	592	O
mg/day	24350813	593	599	O
for	24350813	600	603	O
those	24350813	604	609	O
weighing	24350813	610	618	O
20	24350813	619	621	O
to	24350813	622	624	O
<	24350813	625	626	O
45	24350813	626	628	O
kg	24350813	629	631	O
,	24350813	631	632	O
and	24350813	633	636	O
1.75	24350813	637	641	O
mg/day	24350813	642	648	O
for	24350813	649	652	O
those	24350813	653	658	O
weighing	24350813	659	667	O
≥	24350813	668	669	O
45	24350813	670	672	O
kg	24350813	673	675	O
.	24350813	675	676	O

The	24350813	677	680	O
study	24350813	681	686	O
primarily	24350813	687	696	O
assessed	24350813	697	705	O
risperidone	24350813	706	717	O
's	24350813	717	719	O
safety	24350813	720	726	O
;	24350813	726	727	O
efficacy	24350813	728	736	O
was	24350813	737	740	O
assessed	24350813	741	749	O
as	24350813	750	752	O
a	24350813	753	754	O
secondary	24350813	755	764	O
end-point	24350813	765	774	O
.	24350813	774	775	O

RESULTS	24350813	777	784	O
:	24350813	785	786	O
Fifty-six	24350813	787	796	O
(	24350813	797	798	O
71	24350813	798	800	O
%	24350813	800	801	O
)	24350813	801	802	O
out	24350813	803	806	O
of	24350813	807	809	O
79	24350813	810	812	O
enrolled	24350813	813	821	O
patients	24350813	822	830	O
completed	24350813	831	840	O
the	24350813	841	844	O
OLE	24350813	845	848	O
;	24350813	848	849	O
the	24350813	850	853	O
most	24350813	854	858	O
common	24350813	859	865	O
discontinuations	24350813	866	882	O
were	24350813	883	887	O
for	24350813	888	891	O
insufficient	24350813	892	904	O
response	24350813	905	913	O
(	24350813	914	915	O
7	24350813	915	916	O
[	24350813	917	918	O
9	24350813	918	919	O
%	24350813	919	920	O
]	24350813	920	921	O
)	24350813	921	922	O
or	24350813	923	925	O
adverse	24350813	926	933	B-Outcome
events	24350813	934	940	I-Outcome
(	24350813	941	942	O
AE	24350813	942	944	B-Outcome
)	24350813	944	945	O
(	24350813	946	947	O
5	24350813	947	948	O
[	24350813	949	950	O
6	24350813	950	951	O
%	24350813	951	952	O
]	24350813	952	953	O
)	24350813	953	954	O
.	24350813	954	955	O

The	24350813	956	959	O
most	24350813	960	964	O
common	24350813	965	971	O
(	24350813	972	973	O
≥	24350813	973	974	O
5	24350813	975	976	O
%	24350813	976	977	O
frequency	24350813	978	987	O
in	24350813	988	990	O
the	24350813	991	994	O
total	24350813	995	1000	O
group	24350813	1001	1006	O
)	24350813	1006	1007	O
AEs	24350813	1008	1011	B-Outcome
were	24350813	1012	1016	O
increased	24350813	1017	1026	O
appetite	24350813	1027	1035	O
(	24350813	1036	1037	O
11	24350813	1037	1039	O
%	24350813	1039	1040	O
[	24350813	1041	1042	O
n=9	24350813	1042	1045	O
]	24350813	1045	1046	O
)	24350813	1046	1047	O
;	24350813	1047	1048	O
increased	24350813	1049	1058	O
weight	24350813	1059	1065	O
and	24350813	1066	1069	O
vomiting	24350813	1070	1078	O
(	24350813	1079	1080	O
9	24350813	1080	1081	O
%	24350813	1081	1082	O
[	24350813	1083	1084	O
n=7	24350813	1084	1087	O
]	24350813	1087	1088	O
each	24350813	1089	1093	O
)	24350813	1093	1094	O
;	24350813	1094	1095	O
sedation	24350813	1096	1104	O
,	24350813	1104	1105	O
pyrexia	24350813	1106	1113	O
,	24350813	1113	1114	O
and	24350813	1115	1118	O
upper	24350813	1119	1124	O
respiratory	24350813	1125	1136	O
tract	24350813	1137	1142	O
infection	24350813	1143	1152	O
(	24350813	1153	1154	O
8	24350813	1154	1155	O
%	24350813	1155	1156	O
[	24350813	1157	1158	O
n=6	24350813	1158	1161	O
]	24350813	1161	1162	O
each	24350813	1163	1167	O
)	24350813	1167	1168	O
;	24350813	1168	1169	O
nasopharyngitis	24350813	1170	1185	O
(	24350813	1186	1187	O
6	24350813	1187	1188	O
%	24350813	1188	1189	O
[	24350813	1190	1191	O
n=5	24350813	1191	1194	O
]	24350813	1194	1195	O
)	24350813	1195	1196	O
;	24350813	1196	1197	O
and	24350813	1198	1201	O
somnolence	24350813	1202	1212	O
and	24350813	1213	1216	O
fatigue	24350813	1217	1224	O
(	24350813	1225	1226	O
5	24350813	1226	1227	O
%	24350813	1227	1228	O
[	24350813	1229	1230	O
n=4	24350813	1230	1233	O
]	24350813	1233	1234	O
each	24350813	1235	1239	O
)	24350813	1239	1240	O
.	24350813	1240	1241	O

Extrapyramidal	24350813	1242	1256	B-Outcome
AEs	24350813	1257	1260	I-Outcome
were	24350813	1261	1265	O
reported	24350813	1266	1274	O
in	24350813	1275	1277	O
6	24350813	1278	1279	O
(	24350813	1280	1281	O
8	24350813	1281	1282	O
%	24350813	1282	1283	O
)	24350813	1283	1284	O
patients	24350813	1285	1293	O
.	24350813	1293	1294	O

Increase	24350813	1295	1303	O
in	24350813	1304	1306	O
mean	24350813	1307	1311	B-Outcome
weight	24350813	1312	1318	I-Outcome
(	24350813	1319	1320	O
11	24350813	1320	1322	O
-	24350813	1322	1323	O
15	24350813	1323	1325	O
%	24350813	1325	1326	O
)	24350813	1326	1327	O
and	24350813	1328	1331	O
body	24350813	1332	1336	B-Outcome
mass	24350813	1337	1341	I-Outcome
index	24350813	1342	1347	I-Outcome
(	24350813	1348	1349	O
5	24350813	1349	1350	O
-	24350813	1350	1351	O
10	24350813	1351	1353	O
%	24350813	1353	1354	O
)	24350813	1354	1355	O
occurred	24350813	1356	1364	O
;	24350813	1364	1365	O
one	24350813	1366	1369	O
patient	24350813	1370	1377	O
discontinued	24350813	1378	1390	O
because	24350813	1391	1398	O
of	24350813	1399	1401	O
weight	24350813	1402	1408	O
increase	24350813	1409	1417	O
.	24350813	1417	1418	O

One	24350813	1419	1422	O
potentially	24350813	1423	1434	O
prolactin-related	24350813	1435	1452	B-Outcome
AE	24350813	1453	1455	I-Outcome
(	24350813	1456	1457	O
irregular	24350813	1457	1466	O
menstruation	24350813	1467	1479	O
)	24350813	1479	1480	O
was	24350813	1481	1484	O
reported	24350813	1485	1493	O
.	24350813	1493	1494	O

The	24350813	1495	1498	O
risperidone	24350813	1499	1510	O
high-dose	24350813	1511	1520	O
group	24350813	1521	1526	O
had	24350813	1527	1530	O
the	24350813	1531	1534	O
greatest	24350813	1535	1543	O
mean	24350813	1544	1548	O
improvement	24350813	1549	1560	O
in	24350813	1561	1563	O
sleep	24350813	1564	1569	B-Outcome
visual	24350813	1570	1576	I-Outcome
analog	24350813	1577	1583	I-Outcome
scale	24350813	1584	1589	I-Outcome
(	24350813	1590	1591	O
24.6	24350813	1591	1595	O
)	24350813	1595	1596	O
.	24350813	1596	1597	O

All	24350813	1598	1601	O
groups	24350813	1602	1608	O
showed	24350813	1609	1615	O
additional	24350813	1616	1626	O
improvement	24350813	1627	1638	O
in	24350813	1639	1641	O
efficacy	24350813	1642	1650	B-Outcome
scale	24350813	1651	1656	O
scores	24350813	1657	1663	O
during	24350813	1664	1670	O
the	24350813	1671	1674	O
OLE	24350813	1675	1678	O
.	24350813	1678	1679	O

CONCLUSIONS	24350813	1681	1692	O
:	24350813	1693	1694	O
During	24350813	1695	1701	O
this	24350813	1702	1706	O
OLE	24350813	1707	1710	O
,	24350813	1710	1711	O
safety	24350813	1712	1718	B-Outcome
findings	24350813	1719	1727	O
with	24350813	1728	1732	O
risperidone	24350813	1733	1744	O
treatment	24350813	1745	1754	O
(	24350813	1755	1756	O
maximum	24350813	1756	1763	O
weight-based	24350813	1764	1776	O
dose	24350813	1777	1781	O
of	24350813	1782	1784	O
1.25	24350813	1785	1789	O
mg/day	24350813	1790	1796	O
or	24350813	1797	1799	O
1.75	24350813	1800	1804	O
mg/day	24350813	1805	1811	O
)	24350813	1811	1812	O
were	24350813	1813	1817	O
consistent	24350813	1818	1828	O
with	24350813	1829	1833	O
those	24350813	1834	1839	O
observed	24350813	1840	1848	O
in	24350813	1849	1851	O
the	24350813	1852	1855	O
DB	24350813	1856	1858	O
phase	24350813	1859	1864	O
,	24350813	1864	1865	O
and	24350813	1866	1869	O
with	24350813	1870	1874	O
the	24350813	1875	1878	O
current	24350813	1879	1886	O
safety	24350813	1887	1893	O
information	24350813	1894	1905	O
for	24350813	1906	1909	O
risperidone	24350813	1910	1921	O
in	24350813	1922	1924	O
autistic	24350813	1925	1933	O
,	24350813	1933	1934	O
psychiatric	24350813	1935	1946	O
,	24350813	1946	1947	O
and	24350813	1948	1951	O
behavioral	24350813	1952	1962	O
disorders	24350813	1963	1972	O
.	24350813	1972	1973	O

Patients	24350813	1974	1982	O
experienced	24350813	1983	1994	O
some	24350813	1995	1999	O
additional	24350813	2000	2010	O
improvement	24350813	2011	2022	O
in	24350813	2023	2025	O
irritability	24350813	2026	2038	O
and	24350813	2039	2042	O
related	24350813	2043	2050	O
behaviors	24350813	2051	2060	O
.	24350813	2060	2061	O

CLINICAL	24350813	2063	2071	O
TRIALS	24350813	2072	2078	O
REGISTRY	24350813	2079	2087	O
:	24350813	2088	2089	O
This	24350813	2090	2094	O
phase-4	24350813	2095	2102	O
study	24350813	2103	2108	O
is	24350813	2109	2111	O
registered	24350813	2112	2122	O
at	24350813	2123	2125	O
ClinicalTrials.gov	24350813	2126	2144	O
(	24350813	2145	2146	O
NCT00576732	24350813	2146	2157	O
)	24350813	2157	2158	O
.	24350813	2158	2159	O


Weight	24384588	0	6	O
and	24384588	7	10	O
lean	24384588	11	15	O
body	24384588	16	20	O
mass	24384588	21	25	O
change	24384588	26	32	O
with	24384588	33	37	O
antiretroviral	24384588	38	52	O
initiation	24384588	53	63	O
and	24384588	64	67	O
impact	24384588	68	74	O
on	24384588	75	77	O
bone	24384588	78	82	O
mineral	24384588	83	90	O
density	24384588	91	98	O
.	24384588	98	99	O

OBJECTIVE	24384588	101	110	O
:	24384588	111	112	O
To	24384588	113	115	O
compare	24384588	116	123	O
the	24384588	124	127	O
effect	24384588	128	134	O
that	24384588	135	139	O
initiating	24384588	140	150	O
different	24384588	151	160	O
antiretroviral	24384588	161	175	O
therapy	24384588	176	183	O
(	24384588	184	185	O
ART	24384588	185	188	O
)	24384588	188	189	O
regimens	24384588	190	198	O
has	24384588	199	202	O
on	24384588	203	205	O
weight	24384588	206	212	O
,	24384588	212	213	O
BMI	24384588	214	217	O
,	24384588	217	218	O
and	24384588	219	222	O
lean	24384588	223	227	O
body	24384588	228	232	O
mass	24384588	233	237	O
(	24384588	238	239	O
LBM	24384588	239	242	O
)	24384588	242	243	O
and	24384588	244	247	O
explore	24384588	248	255	O
how	24384588	256	259	O
changes	24384588	260	267	O
in	24384588	268	270	O
body	24384588	271	275	O
composition	24384588	276	287	O
are	24384588	288	291	O
associated	24384588	292	302	O
with	24384588	303	307	O
bone	24384588	308	312	O
mineral	24384588	313	320	O
density	24384588	321	328	O
(	24384588	329	330	O
BMD	24384588	330	333	O
)	24384588	333	334	O
.	24384588	334	335	O

METHODS	24384588	337	344	O
:	24384588	345	346	O
A5224s	24384588	347	353	O
was	24384588	354	357	O
a	24384588	358	359	O
sub-study	24384588	360	369	O
of	24384588	370	372	O
A5202	24384588	373	378	O
,	24384588	378	379	O
a	24384588	380	381	O
prospective	24384588	382	393	O
trial	24384588	394	399	O
of	24384588	400	402	O
1857	24384588	403	407	O
ART-naive	24384588	408	417	O
participants	24384588	418	430	O
randomized	24384588	431	441	O
to	24384588	442	444	O
blinded	24384588	445	452	O
abacavir-lamivudine	24384588	453	472	O
(	24384588	473	474	O
ABC/3TC	24384588	474	481	O
)	24384588	481	482	O
or	24384588	483	485	O
tenofovir	24384588	486	495	O
DF-emtricitabine	24384588	496	512	O
(	24384588	513	514	O
TDF/FTC	24384588	514	521	O
)	24384588	521	522	O
with	24384588	523	527	O
open-label	24384588	528	538	O
efavirenz	24384588	539	548	O
(	24384588	549	550	O
EFV	24384588	550	553	O
)	24384588	553	554	O
or	24384588	555	557	O
atazanavir-ritonavir	24384588	558	578	O
(	24384588	579	580	O
ATV/r	24384588	580	585	O
)	24384588	585	586	O
.	24384588	586	587	O

All	24384588	588	591	O
participants	24384588	592	604	O
underwent	24384588	605	614	O
dual-energy	24384588	615	626	O
absorptiometry	24384588	627	641	O
(	24384588	642	643	O
DXA	24384588	643	646	O
)	24384588	646	647	O
and	24384588	648	651	O
abdominal	24384588	652	661	O
computed	24384588	662	670	O
tomography	24384588	671	681	O
for	24384588	682	685	O
body	24384588	686	690	O
composition	24384588	691	702	O
.	24384588	702	703	O

Analyses	24384588	704	712	O
used	24384588	713	717	O
two-sample	24384588	718	728	O
t-tests	24384588	729	736	O
and	24384588	737	740	O
linear	24384588	741	747	O
regression	24384588	748	758	O
.	24384588	758	759	O

RESULTS	24384588	761	768	O
:	24384588	769	770	O
A5224s	24384588	771	777	O
included	24384588	778	786	O
269	24384588	787	790	O
participants	24384588	791	803	O
:	24384588	803	804	O
85	24384588	805	807	O
%	24384588	807	808	O
men	24384588	809	812	O
,	24384588	812	813	O
47	24384588	814	816	O
%	24384588	816	817	O
white	24384588	818	823	O
non-Hispanic	24384588	824	836	O
,	24384588	836	837	O
median	24384588	838	844	O
age	24384588	845	848	O
38	24384588	849	851	O
years	24384588	852	857	O
,	24384588	857	858	O
HIV-1	24384588	859	864	O
RNA	24384588	865	868	O
4.6	24384588	869	872	O
log10	24384588	873	878	O
copies/ml	24384588	879	888	O
,	24384588	888	889	O
and	24384588	890	893	O
CD4	24384588	894	897	O
cell	24384588	898	902	O
count	24384588	903	908	O
233	24384588	909	912	O
cells/μl	24384588	913	921	O
.	24384588	921	922	O

Overall	24384588	923	930	O
,	24384588	930	931	O
significant	24384588	932	943	O
gains	24384588	944	949	O
occurred	24384588	950	958	O
in	24384588	959	961	O
weight	24384588	962	968	B-Outcome
,	24384588	968	969	O
BMI	24384588	970	973	B-Outcome
,	24384588	973	974	O
and	24384588	975	978	O
LBM	24384588	979	982	B-Outcome
at	24384588	983	985	O
96	24384588	986	988	O
weeks	24384588	989	994	O
post-randomization	24384588	995	1013	O
(	24384588	1014	1015	O
all	24384588	1015	1018	O
P<0.001	24384588	1019	1026	O
)	24384588	1026	1027	O
.	24384588	1027	1028	O

Assignment	24384588	1029	1039	O
to	24384588	1040	1042	O
ATV/r	24384588	1043	1048	O
(	24384588	1049	1050	O
vs.	24384588	1050	1053	O
EFV	24384588	1054	1057	O
)	24384588	1057	1058	O
resulted	24384588	1059	1067	O
in	24384588	1068	1070	O
significantly	24384588	1071	1084	O
greater	24384588	1085	1092	O
weight	24384588	1093	1099	B-Outcome
(	24384588	1100	1101	O
mean	24384588	1101	1105	O
difference	24384588	1106	1116	O
3.35	24384588	1117	1121	O
kg	24384588	1122	1124	O
)	24384588	1124	1125	O
and	24384588	1126	1129	O
BMI	24384588	1130	1133	B-Outcome
gain	24384588	1134	1138	O
(	24384588	1139	1140	O
0.88	24384588	1140	1144	O
kg/m	24384588	1145	1149	O
;	24384588	1149	1150	O
both	24384588	1151	1155	O
P=0.02	24384588	1156	1162	O
)	24384588	1162	1163	O
,	24384588	1163	1164	O
but	24384588	1165	1168	O
not	24384588	1169	1172	O
LBM	24384588	1173	1176	B-Outcome
(	24384588	1177	1178	O
0.67	24384588	1178	1182	O
kg	24384588	1183	1185	O
;	24384588	1185	1186	O
P=0.15	24384588	1187	1193	O
)	24384588	1193	1194	O
,	24384588	1194	1195	O
whereas	24384588	1196	1203	O
ABC/3TC	24384588	1204	1211	O
and	24384588	1212	1215	O
TDF/FTC	24384588	1216	1223	O
were	24384588	1224	1228	O
not	24384588	1229	1232	O
significantly	24384588	1233	1246	O
different	24384588	1247	1256	O
(	24384588	1257	1258	O
P≥0.10	24384588	1258	1264	O
)	24384588	1264	1265	O
.	24384588	1265	1266	O

In	24384588	1267	1269	O
multivariable	24384588	1270	1283	O
analysis	24384588	1284	1292	O
,	24384588	1292	1293	O
only	24384588	1294	1298	O
lower	24384588	1299	1304	O
baseline	24384588	1305	1313	O
CD4	24384588	1314	1317	O
cell	24384588	1318	1322	O
count	24384588	1323	1328	O
and	24384588	1329	1332	O
higher	24384588	1333	1339	O
HIV-1	24384588	1340	1345	O
RNA	24384588	1346	1349	O
were	24384588	1350	1354	O
associated	24384588	1355	1365	O
with	24384588	1366	1370	O
greater	24384588	1371	1378	O
increase	24384588	1379	1387	O
in	24384588	1388	1390	O
weight	24384588	1391	1397	B-Outcome
,	24384588	1397	1398	O
BMI	24384588	1399	1402	B-Outcome
,	24384588	1402	1403	O
or	24384588	1404	1406	O
LBM	24384588	1407	1410	B-Outcome
.	24384588	1410	1411	O

In	24384588	1412	1414	O
multivariable	24384588	1415	1428	O
analyses	24384588	1429	1437	O
,	24384588	1437	1438	O
increased	24384588	1439	1448	O
LBM	24384588	1449	1452	B-Outcome
was	24384588	1453	1456	O
associated	24384588	1457	1467	O
with	24384588	1468	1472	O
an	24384588	1473	1475	O
increased	24384588	1476	1485	O
hip	24384588	1486	1489	B-Outcome
BMD	24384588	1490	1493	I-Outcome
.	24384588	1493	1494	O

CONCLUSION	24384588	1496	1506	O
:	24384588	1507	1508	O
ABC/3TC	24384588	1509	1516	O
vs.	24384588	1517	1520	O
TDF/FTC	24384588	1521	1528	O
did	24384588	1529	1532	O
not	24384588	1533	1536	O
differ	24384588	1537	1543	O
in	24384588	1544	1546	O
change	24384588	1547	1553	O
in	24384588	1554	1556	O
weight	24384588	1557	1563	B-Outcome
,	24384588	1563	1564	O
BMI	24384588	1565	1568	B-Outcome
,	24384588	1568	1569	O
or	24384588	1570	1572	O
LBM	24384588	1573	1576	B-Outcome
;	24384588	1576	1577	O
ATV/r	24384588	1578	1583	O
vs.	24384588	1584	1587	O
EFV	24384588	1588	1591	O
resulted	24384588	1592	1600	O
in	24384588	1601	1603	O
greater	24384588	1604	1611	O
weight	24384588	1612	1618	B-Outcome
and	24384588	1619	1622	O
BMI	24384588	1623	1626	B-Outcome
gain	24384588	1627	1631	O
but	24384588	1632	1635	O
not	24384588	1636	1639	O
LBM	24384588	1640	1643	B-Outcome
.	24384588	1643	1644	O

A	24384588	1645	1646	O
positive	24384588	1647	1655	O
association	24384588	1656	1667	O
between	24384588	1668	1675	O
increased	24384588	1676	1685	O
LBM	24384588	1686	1689	B-Outcome
and	24384588	1690	1693	O
increased	24384588	1694	1703	O
hip	24384588	1704	1707	B-Outcome
BMD	24384588	1708	1711	I-Outcome
should	24384588	1712	1718	O
be	24384588	1719	1721	O
further	24384588	1722	1729	O
investigated	24384588	1730	1742	O
through	24384588	1743	1750	O
prospective	24384588	1751	1762	O
interventional	24384588	1763	1777	O
studies	24384588	1778	1785	O
to	24384588	1786	1788	O
verify	24384588	1789	1795	O
the	24384588	1796	1799	O
impact	24384588	1800	1806	O
of	24384588	1807	1809	O
increased	24384588	1810	1819	O
LBM	24384588	1820	1823	O
on	24384588	1824	1826	O
hip	24384588	1827	1830	O
BMD	24384588	1831	1834	O
.	24384588	1834	1835	O


Changes	24406481	0	7	O
in	24406481	8	10	O
body	24406481	11	15	O
weight	24406481	16	22	O
and	24406481	23	26	O
blood	24406481	27	32	O
pressure	24406481	33	41	O
:	24406481	41	42	O
paradoxical	24406481	43	54	O
outcome	24406481	55	62	O
events	24406481	63	69	O
in	24406481	70	72	O
overweight	24406481	73	83	O
and	24406481	84	87	O
obese	24406481	88	93	O
subjects	24406481	94	102	O
with	24406481	103	107	O
cardiovascular	24406481	108	122	O
disease	24406481	123	130	O
.	24406481	130	131	O

BACKGROUND/OBJECTIVES	24406481	133	154	O
:	24406481	155	156	O
The	24406481	157	160	O
Sibutramine	24406481	161	172	O
Cardiovascular	24406481	173	187	O
OUTcomes	24406481	188	196	O
(	24406481	197	198	O
SCOUT	24406481	198	203	O
)	24406481	203	204	O
trial	24406481	205	210	O
showed	24406481	211	217	O
a	24406481	218	219	O
significantly	24406481	220	233	O
increased	24406481	234	243	O
relative	24406481	244	252	O
risk	24406481	253	257	O
of	24406481	258	260	O
nonfatal	24406481	261	269	O
cardiovascular	24406481	270	284	O
events	24406481	285	291	O
,	24406481	291	292	O
but	24406481	293	296	O
not	24406481	297	300	O
mortality	24406481	301	310	O
,	24406481	310	311	O
in	24406481	312	314	O
overweight	24406481	315	325	O
and	24406481	326	329	O
obese	24406481	330	335	O
subjects	24406481	336	344	O
receiving	24406481	345	354	O
long-term	24406481	355	364	O
sibutramine	24406481	365	376	O
treatment	24406481	377	386	O
with	24406481	387	391	O
diet	24406481	392	396	O
and	24406481	397	400	O
exercise	24406481	401	409	O
.	24406481	409	410	O

We	24406481	411	413	O
examined	24406481	414	422	O
the	24406481	423	426	O
relationship	24406481	427	439	O
between	24406481	440	447	O
early	24406481	448	453	O
changes	24406481	454	461	O
(	24406481	462	463	O
both	24406481	463	467	O
increases	24406481	468	477	O
and	24406481	478	481	O
decreases	24406481	482	491	O
)	24406481	491	492	O
in	24406481	493	495	O
body	24406481	496	500	O
weight	24406481	501	507	O
and	24406481	508	511	O
blood	24406481	512	517	O
pressure	24406481	518	526	O
,	24406481	526	527	O
and	24406481	528	531	O
the	24406481	532	535	O
impact	24406481	536	542	O
of	24406481	543	545	O
these	24406481	546	551	O
changes	24406481	552	559	O
on	24406481	560	562	O
subsequent	24406481	563	573	O
cardiovascular	24406481	574	588	O
outcome	24406481	589	596	O
events	24406481	597	603	O
.	24406481	603	604	O

SUBJECTS/METHODS	24406481	606	622	O
:	24406481	623	624	O
A	24406481	625	626	O
total	24406481	627	632	O
of	24406481	633	635	O
9804	24406481	636	640	O
male	24406481	641	645	O
and	24406481	646	649	O
female	24406481	650	656	O
subjects	24406481	657	665	O
,	24406481	665	666	O
aged	24406481	667	671	O
55	24406481	672	674	O
years	24406481	675	680	O
or	24406481	681	683	O
older	24406481	684	689	O
,	24406481	689	690	O
with	24406481	691	695	O
a	24406481	696	697	O
body	24406481	698	702	O
mass	24406481	703	707	O
index	24406481	708	713	O
of	24406481	714	716	O
27	24406481	717	719	O
-	24406481	719	720	O
45	24406481	720	722	O
kg	24406481	723	725	O
m(-2	24406481	726	730	O
)	24406481	730	731	O
were	24406481	732	736	O
included	24406481	737	745	O
in	24406481	746	748	O
this	24406481	749	753	O
current	24406481	754	761	O
subanalysis	24406481	762	773	O
of	24406481	774	776	O
the	24406481	777	780	O
SCOUT	24406481	781	786	O
trial	24406481	787	792	O
.	24406481	792	793	O

Subjects	24406481	794	802	O
were	24406481	803	807	O
required	24406481	808	816	O
to	24406481	817	819	O
have	24406481	820	824	O
a	24406481	825	826	O
history	24406481	827	834	O
of	24406481	835	837	O
cardiovascular	24406481	838	852	O
disease	24406481	853	860	O
and/or	24406481	861	867	O
type	24406481	868	872	O
2	24406481	873	874	O
diabetes	24406481	875	883	O
mellitus	24406481	884	892	O
with	24406481	893	897	O
at	24406481	898	900	O
least	24406481	901	906	O
one	24406481	907	910	O
cardiovascular	24406481	911	925	O
risk	24406481	926	930	O
factor	24406481	931	937	O
(	24406481	938	939	O
hypertension	24406481	939	951	O
,	24406481	951	952	O
dyslipidemia	24406481	953	965	O
,	24406481	965	966	O
current	24406481	967	974	O
smoking	24406481	975	982	O
or	24406481	983	985	O
diabetic	24406481	986	994	O
nephropathy	24406481	995	1006	O
)	24406481	1006	1007	O
to	24406481	1008	1010	O
assess	24406481	1011	1017	O
cardiovascular	24406481	1018	1032	O
outcomes	24406481	1033	1041	O
.	24406481	1041	1042	O

Post	24406481	1043	1047	O
hoc	24406481	1048	1051	O
subgroup	24406481	1052	1060	O
analyses	24406481	1061	1069	O
of	24406481	1070	1072	O
weight	24406481	1073	1079	O
change	24406481	1080	1086	O
(	24406481	1087	1088	O
categories	24406481	1088	1098	O
)	24406481	1098	1099	O
and	24406481	1100	1103	O
blood	24406481	1104	1109	O
pressure	24406481	1110	1118	O
were	24406481	1119	1123	O
performed	24406481	1124	1133	O
overall	24406481	1134	1141	O
and	24406481	1142	1145	O
by	24406481	1146	1148	O
treatment	24406481	1149	1158	O
group	24406481	1159	1164	O
(	24406481	1165	1166	O
6-week	24406481	1166	1172	O
sibutramine	24406481	1173	1184	O
followed	24406481	1185	1193	O
by	24406481	1194	1196	O
randomized	24406481	1197	1207	O
placebo	24406481	1208	1215	O
or	24406481	1216	1218	O
continued	24406481	1219	1228	O
sibutramine	24406481	1229	1240	O
)	24406481	1240	1241	O
.	24406481	1241	1242	O

The	24406481	1243	1246	O
primary	24406481	1247	1254	O
outcome	24406481	1255	1262	O
event	24406481	1263	1268	O
(	24406481	1269	1270	O
POE	24406481	1270	1273	O
)	24406481	1273	1274	O
was	24406481	1275	1278	O
a	24406481	1279	1280	O
composite	24406481	1281	1290	O
of	24406481	1291	1293	O
nonfatal	24406481	1294	1302	O
myocardial	24406481	1303	1313	O
infarction	24406481	1314	1324	O
,	24406481	1324	1325	O
nonfatal	24406481	1326	1334	O
stroke	24406481	1335	1341	O
,	24406481	1341	1342	O
resuscitated	24406481	1343	1355	O
cardiac	24406481	1356	1363	O
arrest	24406481	1364	1370	O
or	24406481	1371	1373	O
cardiovascular	24406481	1374	1388	O
death	24406481	1389	1394	O
.	24406481	1394	1395	O

Time-to-event	24406481	1396	1409	O
analyses	24406481	1410	1418	O
of	24406481	1419	1421	O
the	24406481	1422	1425	O
POE	24406481	1426	1429	O
were	24406481	1430	1434	O
performed	24406481	1435	1444	O
using	24406481	1445	1450	O
Cox	24406481	1451	1454	O
regression	24406481	1455	1465	O
models	24406481	1466	1472	O
with	24406481	1473	1477	O
factors	24406481	1478	1485	O
for	24406481	1486	1489	O
treatment	24406481	1490	1499	O
,	24406481	1499	1500	O
subgroups	24406481	1501	1510	O
and	24406481	1511	1514	O
interactions	24406481	1515	1527	O
.	24406481	1527	1528	O

RESULTS	24406481	1530	1537	O
:	24406481	1538	1539	O
During	24406481	1540	1546	O
the	24406481	1547	1550	O
initial	24406481	1551	1558	O
6-week	24406481	1559	1565	O
sibutramine	24406481	1566	1577	O
treatment	24406481	1578	1587	O
period	24406481	1588	1594	O
,	24406481	1594	1595	O
systolic	24406481	1596	1604	B-Outcome
blood	24406481	1605	1610	I-Outcome
pressure	24406481	1611	1619	I-Outcome
decreased	24406481	1620	1629	O
progressively	24406481	1630	1643	O
with	24406481	1644	1648	O
increasing	24406481	1649	1659	O
weight	24406481	1660	1666	B-Outcome
loss	24406481	1667	1671	O
in	24406481	1672	1674	O
hypertensive	24406481	1675	1687	O
subjects	24406481	1688	1696	O
(	24406481	1697	1698	O
-8.1±10.5	24406481	1698	1707	O
mm	24406481	1708	1710	O
Hg	24406481	1711	1713	O
with	24406481	1714	1718	O
<	24406481	1719	1720	O
5	24406481	1720	1721	O
kg	24406481	1722	1724	O
weight	24406481	1725	1731	B-Outcome
loss	24406481	1732	1736	O
to	24406481	1737	1739	O
-10.8±11.0	24406481	1740	1750	O
mm	24406481	1751	1753	O
Hg	24406481	1754	1756	O
with	24406481	1757	1761	O
⩾5	24406481	1762	1764	O
kg	24406481	1765	1767	O
weight	24406481	1768	1774	B-Outcome
loss	24406481	1775	1779	O
)	24406481	1779	1780	O
.	24406481	1780	1781	O

The	24406481	1782	1785	O
highest	24406481	1786	1793	O
POE	24406481	1794	1797	O
incidence	24406481	1798	1807	O
occurred	24406481	1808	1816	O
mainly	24406481	1817	1823	O
in	24406481	1824	1826	O
groups	24406481	1827	1833	O
with	24406481	1834	1838	O
increases	24406481	1839	1848	O
in	24406481	1849	1851	O
both	24406481	1852	1856	O
weight	24406481	1857	1863	B-Outcome
and	24406481	1864	1867	O
blood	24406481	1868	1873	B-Outcome
pressure	24406481	1874	1882	I-Outcome
.	24406481	1882	1883	O

However	24406481	1884	1891	O
,	24406481	1891	1892	O
with	24406481	1893	1897	O
long-term	24406481	1898	1907	O
sibutramine	24406481	1908	1919	O
treatment	24406481	1920	1929	O
,	24406481	1929	1930	O
a	24406481	1931	1932	O
markedly	24406481	1933	1941	O
lower	24406481	1942	1947	O
blood	24406481	1948	1953	B-Outcome
pressure	24406481	1954	1962	I-Outcome
tended	24406481	1963	1969	O
to	24406481	1970	1972	O
increase	24406481	1973	1981	O
POEs	24406481	1982	1986	O
.	24406481	1986	1987	O

CONCLUSION	24406481	1989	1999	O
:	24406481	2000	2001	O
Modest	24406481	2002	2008	O
weight	24406481	2009	2015	B-Outcome
loss	24406481	2016	2020	O
and	24406481	2021	2024	O
modest	24406481	2025	2031	O
lower	24406481	2032	2037	O
blood	24406481	2038	2043	B-Outcome
pressure	24406481	2044	2052	I-Outcome
each	24406481	2053	2057	O
reduced	24406481	2058	2065	O
the	24406481	2066	2069	O
incidence	24406481	2070	2079	O
of	24406481	2080	2082	O
cardiovascular	24406481	2083	2097	B-Outcome
events	24406481	2098	2104	I-Outcome
,	24406481	2104	2105	O
as	24406481	2106	2108	O
expected	24406481	2109	2117	O
.	24406481	2117	2118	O

However	24406481	2119	2126	O
,	24406481	2126	2127	O
the	24406481	2128	2131	O
combination	24406481	2132	2143	O
of	24406481	2144	2146	O
early	24406481	2147	2152	O
marked	24406481	2153	2159	O
weight	24406481	2160	2166	B-Outcome
loss	24406481	2167	2171	O
and	24406481	2172	2175	O
rapid	24406481	2176	2181	O
blood	24406481	2182	2187	B-Outcome
pressure	24406481	2188	2196	I-Outcome
reduction	24406481	2197	2206	O
seems	24406481	2207	2212	O
to	24406481	2213	2215	O
be	24406481	2216	2218	O
harmful	24406481	2219	2226	O
in	24406481	2227	2229	O
this	24406481	2230	2234	O
obese	24406481	2235	2240	O
elderly	24406481	2241	2248	O
cardiovascular	24406481	2249	2263	O
diseased	24406481	2264	2272	O
population	24406481	2273	2283	O
.	24406481	2283	2284	O


A	24424141	0	1	O
comparison	24424141	2	12	O
of	24424141	13	15	O
the	24424141	16	19	O
effectiveness	24424141	20	33	O
of	24424141	34	36	O
treating	24424141	37	45	O
those	24424141	46	51	O
with	24424141	52	56	O
and	24424141	57	60	O
without	24424141	61	68	O
the	24424141	69	72	O
complications	24424141	73	86	O
of	24424141	87	89	O
superficial	24424141	90	101	O
venous	24424141	102	108	O
insufficiency	24424141	109	122	O
.	24424141	122	123	O

OBJECTIVE	24424141	125	134	O
:	24424141	135	136	O
To	24424141	137	139	O
test	24424141	140	144	O
the	24424141	145	148	O
hypothesis	24424141	149	159	O
that	24424141	160	164	O
patients	24424141	165	173	O
with	24424141	174	178	O
soft	24424141	179	183	O
tissue	24424141	184	190	O
changes	24424141	191	198	O
related	24424141	199	206	O
to	24424141	207	209	O
superficial	24424141	210	221	O
venous	24424141	222	228	O
insufficiency	24424141	229	242	O
(	24424141	243	244	O
SVI	24424141	244	247	O
)	24424141	247	248	O
have	24424141	249	253	O
greater	24424141	254	261	O
benefits	24424141	262	270	O
from	24424141	271	275	O
treatment	24424141	276	285	O
than	24424141	286	290	O
those	24424141	291	296	O
with	24424141	297	301	O
only	24424141	302	306	O
symptomatic	24424141	307	318	O
varicose	24424141	319	327	O
veins	24424141	328	333	O
.	24424141	333	334	O

BACKGROUND	24424141	336	346	O
:	24424141	347	348	O
A	24424141	349	350	O
commonly	24424141	351	359	O
held	24424141	360	364	O
view	24424141	365	369	O
is	24424141	370	372	O
that	24424141	373	377	O
SVI	24424141	378	381	O
is	24424141	382	384	O
only	24424141	385	389	O
a	24424141	390	391	O
minor	24424141	392	397	O
ailment	24424141	398	405	O
,	24424141	405	406	O
yet	24424141	407	410	O
randomized	24424141	411	421	O
clinical	24424141	422	430	O
trials	24424141	431	437	O
(	24424141	438	439	O
RCTs	24424141	439	443	O
)	24424141	443	444	O
show	24424141	445	449	O
that	24424141	450	454	O
treatment	24424141	455	464	O
improves	24424141	465	473	O
quality	24424141	474	481	O
of	24424141	482	484	O
life	24424141	485	489	O
(	24424141	490	491	O
QoL	24424141	491	494	O
)	24424141	494	495	O
and	24424141	496	499	O
is	24424141	500	502	O
cost-effective	24424141	503	517	O
.	24424141	517	518	O

In	24424141	519	521	O
an	24424141	522	524	O
effort	24424141	525	531	O
to	24424141	532	534	O
curb	24424141	535	539	O
the	24424141	540	543	O
treatment	24424141	544	553	O
costs	24424141	554	559	O
of	24424141	560	562	O
this	24424141	563	567	O
common	24424141	568	574	O
disorder	24424141	575	583	O
,	24424141	583	584	O
rationing	24424141	585	594	O
is	24424141	595	597	O
applied	24424141	598	605	O
in	24424141	606	608	O
many	24424141	609	613	O
health	24424141	614	620	O
care	24424141	621	625	O
systems	24424141	626	633	O
,	24424141	633	634	O
often	24424141	635	640	O
limiting	24424141	641	649	O
the	24424141	650	653	O
reimbursement	24424141	654	667	O
of	24424141	668	670	O
treatment	24424141	671	680	O
to	24424141	681	683	O
those	24424141	684	689	O
with	24424141	690	694	O
soft	24424141	695	699	O
tissue	24424141	700	706	O
changes	24424141	707	714	O
.	24424141	714	715	O

METHODS	24424141	717	724	O
:	24424141	725	726	O
This	24424141	727	731	O
cohort	24424141	732	738	O
study	24424141	739	744	O
draws	24424141	745	750	O
its	24424141	751	754	O
data	24424141	755	759	O
from	24424141	760	764	O
an	24424141	765	767	O
interventional	24424141	768	782	O
RCT	24424141	783	786	O
.	24424141	786	787	O

After	24424141	788	793	O
informed	24424141	794	802	O
consent	24424141	803	810	O
,	24424141	810	811	O
consecutive	24424141	812	823	O
patients	24424141	824	832	O
with	24424141	833	837	O
symptomatic	24424141	838	849	O
unilateral	24424141	850	860	O
SVI	24424141	861	864	O
were	24424141	865	869	O
randomized	24424141	870	880	O
to	24424141	881	883	O
receive	24424141	884	891	O
surgical	24424141	892	900	O
ligation	24424141	901	909	O
and	24424141	910	913	O
stripping	24424141	914	923	O
or	24424141	924	926	O
endovenous	24424141	927	937	O
laser	24424141	938	943	O
ablation	24424141	944	952	O
.	24424141	952	953	O

This	24424141	954	958	O
analysis	24424141	959	967	O
differentially	24424141	968	982	O
studies	24424141	983	990	O
the	24424141	991	994	O
outcomes	24424141	995	1003	O
of	24424141	1004	1006	O
patients	24424141	1007	1015	O
with	24424141	1016	1020	O
simple	24424141	1021	1027	O
varicose	24424141	1028	1036	O
veins	24424141	1037	1042	O
(	24424141	1043	1044	O
C2	24424141	1044	1046	O
:	24424141	1046	1047	O
n	24424141	1048	1049	O
=	24424141	1050	1051	O
191	24424141	1052	1055	O
)	24424141	1055	1056	O
and	24424141	1057	1060	O
soft	24424141	1061	1065	O
tissue	24424141	1066	1072	O
complications	24424141	1073	1086	O
(	24424141	1087	1088	O
C3	24424141	1088	1090	O
-	24424141	1090	1091	O
4	24424141	1091	1092	O
:	24424141	1092	1093	O
n	24424141	1094	1095	O
=	24424141	1096	1097	O
76	24424141	1098	1100	O
)	24424141	1100	1101	O
.	24424141	1101	1102	O

Effectiveness	24424141	1103	1116	O
outcomes	24424141	1117	1125	O
measured	24424141	1126	1134	O
up	24424141	1135	1137	O
to	24424141	1138	1140	O
1	24424141	1141	1142	O
year	24424141	1143	1147	O
included	24424141	1148	1156	O
the	24424141	1157	1160	O
following	24424141	1161	1170	O
:	24424141	1170	1171	O
Qol	24424141	1172	1175	O
[	24424141	1176	1177	O
short	24424141	1177	1182	O
form	24424141	1183	1187	O
36	24424141	1188	1190	O
(	24424141	1191	1192	O
SF36	24424141	1192	1196	O
)	24424141	1196	1197	O
,	24424141	1197	1198	O
EuroQol	24424141	1199	1206	O
,	24424141	1206	1207	O
and	24424141	1208	1211	O
the	24424141	1212	1215	O
Aberdeen	24424141	1216	1224	O
Varicose	24424141	1225	1233	O
Veins	24424141	1234	1239	O
Questionnaire	24424141	1240	1253	O
]	24424141	1253	1254	O
,	24424141	1254	1255	O
clinical	24424141	1256	1264	O
recurrence	24424141	1265	1275	O
,	24424141	1275	1276	O
and	24424141	1277	1280	O
the	24424141	1281	1284	O
need	24424141	1285	1289	O
for	24424141	1290	1293	O
secondary	24424141	1294	1303	O
procedures	24424141	1304	1314	O
.	24424141	1314	1315	O

Multivariable	24424141	1316	1329	O
regression	24424141	1330	1340	O
analysis	24424141	1341	1349	O
was	24424141	1350	1353	O
used	24424141	1354	1358	O
to	24424141	1359	1361	O
control	24424141	1362	1369	O
for	24424141	1370	1373	O
potential	24424141	1374	1383	O
confounding	24424141	1384	1395	O
factors	24424141	1396	1403	O
.	24424141	1403	1404	O

RESULTS	24424141	1406	1413	O
:	24424141	1414	1415	O
Both	24424141	1416	1420	O
groups	24424141	1421	1427	O
saw	24424141	1428	1431	O
significant	24424141	1432	1443	O
improvements	24424141	1444	1456	O
in	24424141	1457	1459	O
QoL.	24424141	1460	1464	B-Outcome
All	24424141	1465	1468	O
improvements	24424141	1469	1481	O
were	24424141	1482	1486	O
equal	24424141	1487	1492	O
between	24424141	1493	1500	O
groups	24424141	1501	1507	O
apart	24424141	1508	1513	O
from	24424141	1514	1518	O
the	24424141	1519	1522	O
SF36	24424141	1523	1527	B-Outcome
domain	24424141	1528	1534	I-Outcome
of	24424141	1535	1537	I-Outcome
Bodily	24424141	1538	1544	I-Outcome
Pain	24424141	1545	1549	I-Outcome
,	24424141	1549	1550	O
where	24424141	1551	1556	O
C2	24424141	1557	1559	O
saw	24424141	1560	1563	O
an	24424141	1564	1566	O
improvement	24424141	1567	1578	O
of	24424141	1579	1581	O
12.8	24424141	1582	1586	O
[	24424141	1587	1588	O
95	24424141	1588	1590	O
%	24424141	1590	1591	O
confidence	24424141	1592	1602	O
interval	24424141	1603	1611	O
(	24424141	1612	1613	O
CI	24424141	1613	1615	O
):	24424141	1615	1617	O
4.8	24424141	1618	1621	O
-	24424141	1621	1622	O
20.8	24424141	1622	1626	O
]	24424141	1626	1627	O
points	24424141	1628	1634	O
over	24424141	1635	1639	O
C3	24424141	1640	1642	O
-	24424141	1642	1643	O
4	24424141	1643	1644	O
participants	24424141	1645	1657	O
(	24424141	1658	1659	O
P	24424141	1659	1660	O
=	24424141	1661	1662	O
0.002	24424141	1663	1668	O
)	24424141	1668	1669	O
,	24424141	1669	1670	O
who	24424141	1671	1674	O
also	24424141	1675	1679	O
suffered	24424141	1680	1688	O
more	24424141	1689	1693	O
recurrence	24424141	1694	1704	O
[	24424141	1705	1706	O
odds	24424141	1706	1710	O
ratio	24424141	1711	1716	O
(	24424141	1717	1718	O
OR	24424141	1718	1720	O
)	24424141	1720	1721	O
=	24424141	1722	1723	O
2.7	24424141	1724	1727	O
,	24424141	1727	1728	O
95	24424141	1729	1731	O
%	24424141	1731	1732	O
CI	24424141	1733	1735	O
:	24424141	1735	1736	O
1.2	24424141	1737	1740	O
-	24424141	1740	1741	O
6.1	24424141	1741	1744	O
,	24424141	1744	1745	O
P	24424141	1746	1747	O
=	24424141	1748	1749	O
0.022	24424141	1750	1755	O
]	24424141	1755	1756	O
and	24424141	1757	1760	O
required	24424141	1761	1769	O
more	24424141	1770	1774	O
secondary	24424141	1775	1784	O
procedures	24424141	1785	1795	O
(	24424141	1796	1797	O
OR	24424141	1797	1799	O
=	24424141	1800	1801	O
4.4	24424141	1802	1805	O
,	24424141	1805	1806	O
95	24424141	1807	1809	O
%	24424141	1809	1810	O
CI	24424141	1811	1813	O
:	24424141	1813	1814	O
1.2	24424141	1815	1818	O
-	24424141	1818	1819	O
16.3	24424141	1819	1823	O
,	24424141	1823	1824	O
P	24424141	1825	1826	O
=	24424141	1827	1828	O
0.028	24424141	1829	1834	O
)	24424141	1834	1835	O
.	24424141	1835	1836	O

CONCLUSIONS	24424141	1838	1849	O
:	24424141	1850	1851	O
This	24424141	1852	1856	O
study	24424141	1857	1862	O
suggests	24424141	1863	1871	O
that	24424141	1872	1876	O
rationing	24424141	1877	1886	O
by	24424141	1887	1889	O
clinical	24424141	1890	1898	O
severity	24424141	1899	1907	O
contradicts	24424141	1908	1919	O
the	24424141	1920	1923	O
evidence	24424141	1924	1932	O
.	24424141	1932	1933	O

Delaying	24424141	1934	1942	O
treatment	24424141	1943	1952	O
until	24424141	1953	1958	O
the	24424141	1959	1962	O
development	24424141	1963	1974	O
of	24424141	1975	1977	O
skin	24424141	1978	1982	O
damage	24424141	1983	1989	O
leads	24424141	1990	1995	O
to	24424141	1996	1998	O
a	24424141	1999	2000	O
degree	24424141	2001	2007	O
of	24424141	2008	2010	O
irreversible	24424141	2011	2023	O
morbidity	24424141	2024	2033	O
and	24424141	2034	2037	O
greater	24424141	2038	2045	O
recurrence	24424141	2046	2056	O
.	24424141	2056	2057	O

TRIAL	24424141	2059	2064	O
REGISTRATION	24424141	2065	2077	O
:	24424141	2078	2079	O
NCT00759434	24424141	2080	2091	O
Clinicaltrials.gov	24424141	2092	2110	O
.	24424141	2110	2111	O


Assessment	24451146	0	10	O
of	24451146	11	13	O
osteopontin	24451146	14	25	O
in	24451146	26	28	O
early	24451146	29	34	O
breast	24451146	35	41	O
cancer	24451146	42	48	O
:	24451146	48	49	O
correlative	24451146	50	61	O
study	24451146	62	67	O
in	24451146	68	70	O
a	24451146	71	72	O
randomised	24451146	73	83	O
clinical	24451146	84	92	O
trial	24451146	93	98	O
.	24451146	98	99	O

BACKGROUND	24451146	101	111	O
:	24451146	112	113	O
Osteopontin	24451146	114	125	O
(	24451146	126	127	O
OPN	24451146	127	130	O
)	24451146	130	131	O
is	24451146	132	134	O
a	24451146	135	136	O
malignancy-associated	24451146	137	158	O
glycoprotein	24451146	159	171	O
that	24451146	172	176	O
contributes	24451146	177	188	O
functionally	24451146	189	201	O
to	24451146	202	204	O
tumor	24451146	205	210	O
aggressiveness	24451146	211	225	O
.	24451146	225	226	O

In	24451146	227	229	O
metastatic	24451146	230	240	O
breast	24451146	241	247	O
cancer	24451146	248	254	O
,	24451146	254	255	O
we	24451146	256	258	O
previously	24451146	259	269	O
demonstrated	24451146	270	282	O
that	24451146	283	287	O
elevated	24451146	288	296	O
OPN	24451146	297	300	O
in	24451146	301	303	O
primary	24451146	304	311	O
tumor	24451146	312	317	O
and	24451146	318	321	O
blood	24451146	322	327	O
was	24451146	328	331	O
associated	24451146	332	342	O
with	24451146	343	347	O
poor	24451146	348	352	O
prognosis	24451146	353	362	O
.	24451146	362	363	O

METHODS	24451146	365	372	O
:	24451146	373	374	O
We	24451146	375	377	O
measured	24451146	378	386	O
OPN	24451146	387	390	O
in	24451146	391	393	O
plasma	24451146	394	400	O
by	24451146	401	403	O
ELISA	24451146	404	409	O
,	24451146	409	410	O
and	24451146	411	414	O
in	24451146	415	417	O
tumors	24451146	418	424	O
by	24451146	425	427	O
immunohistochemistry	24451146	428	448	O
,	24451146	448	449	O
in	24451146	450	452	O
624	24451146	453	456	O
(	24451146	457	458	O
94	24451146	458	460	O
%	24451146	460	461	O
)	24451146	461	462	O
and	24451146	463	466	O
462	24451146	467	470	O
(	24451146	471	472	O
69	24451146	472	474	O
%	24451146	474	475	O
)	24451146	475	476	O
,	24451146	476	477	O
respectively	24451146	478	490	O
,	24451146	490	491	O
of	24451146	492	494	O
667	24451146	495	498	O
postmenopausal	24451146	499	513	O
women	24451146	514	519	O
with	24451146	520	524	O
hormone	24451146	525	532	O
responsive	24451146	533	543	O
early	24451146	544	549	O
breast	24451146	550	556	O
cancer	24451146	557	563	O
treated	24451146	564	571	O
by	24451146	572	574	O
surgery	24451146	575	582	O
followed	24451146	583	591	O
by	24451146	592	594	O
adjuvant	24451146	595	603	O
treatment	24451146	604	613	O
with	24451146	614	618	O
tamoxifen	24451146	619	628	O
+	24451146	629	630	O
/-	24451146	630	632	O
octreotide	24451146	633	643	O
in	24451146	644	646	O
a	24451146	647	648	O
randomized	24451146	649	659	O
trial	24451146	660	665	O
(	24451146	666	667	O
NCIC	24451146	667	671	O
CTG	24451146	672	675	O
MA.14	24451146	676	681	O
;	24451146	681	682	O
National	24451146	683	691	O
Cancer	24451146	692	698	O
Institute	24451146	699	708	O
of	24451146	709	711	O
Canada	24451146	712	718	O
Clinical	24451146	719	727	O
Trials	24451146	728	734	O
Group	24451146	735	740	O
Mammary.14	24451146	741	751	O
)	24451146	751	752	O
.	24451146	752	753	O

RESULTS	24451146	755	762	O
:	24451146	763	764	O
Plasma	24451146	765	771	B-Outcome
OPN	24451146	772	775	I-Outcome
was	24451146	776	779	O
measured	24451146	780	788	O
in	24451146	789	791	O
2,540	24451146	792	797	O
samples	24451146	798	805	O
;	24451146	805	806	O
688	24451146	807	810	O
at	24451146	811	813	O
baseline	24451146	814	822	O
and	24451146	823	826	O
1,852	24451146	827	832	O
collected	24451146	833	842	O
during	24451146	843	849	O
follow-up	24451146	850	859	O
.	24451146	859	860	O

Mean	24451146	861	865	B-Outcome
baseline	24451146	866	874	I-Outcome
plasma	24451146	875	881	I-Outcome
OPN	24451146	882	885	I-Outcome
was	24451146	886	889	O
46	24451146	890	892	O
ng/ml	24451146	893	898	O
(	24451146	899	900	O
range	24451146	900	905	O
22.6	24451146	906	910	O
to	24451146	911	913	O
290	24451146	914	917	O
)	24451146	917	918	O
which	24451146	919	924	O
did	24451146	925	928	O
not	24451146	929	932	O
differ	24451146	933	939	O
from	24451146	940	944	O
normal	24451146	945	951	O
levels	24451146	952	958	O
.	24451146	958	959	O

Mean	24451146	960	964	B-Outcome
percentage	24451146	965	975	I-Outcome
OPN	24451146	976	979	I-Outcome
tumor	24451146	980	985	I-Outcome
cell	24451146	986	990	I-Outcome
positivity	24451146	991	1001	I-Outcome
was	24451146	1002	1005	O
33.9	24451146	1006	1010	O
(	24451146	1011	1012	O
95	24451146	1012	1014	O
%	24451146	1014	1015	O
CI	24451146	1016	1018	O
:	24451146	1018	1019	O
30.2	24451146	1020	1024	O
to	24451146	1025	1027	O
37.9	24451146	1028	1032	O
)	24451146	1032	1033	O
.	24451146	1033	1034	O

There	24451146	1035	1040	O
was	24451146	1041	1044	O
no	24451146	1045	1047	O
correlation	24451146	1048	1059	O
between	24451146	1060	1067	O
plasma	24451146	1068	1074	B-Outcome
and	24451146	1075	1078	O
tumor	24451146	1079	1084	B-Outcome
OPN	24451146	1085	1088	I-Outcome
values	24451146	1089	1095	I-Outcome
.	24451146	1095	1096	O

In	24451146	1097	1099	O
multivariate	24451146	1100	1112	O
analysis	24451146	1113	1121	O
,	24451146	1121	1122	O
neither	24451146	1123	1130	O
was	24451146	1131	1134	O
associated	24451146	1135	1145	O
with	24451146	1146	1150	O
event-free	24451146	1151	1161	B-Outcome
survival	24451146	1162	1170	I-Outcome
(	24451146	1171	1172	O
EFS	24451146	1172	1175	B-Outcome
)	24451146	1175	1176	O
,	24451146	1176	1177	O
relapse-free	24451146	1178	1190	B-Outcome
survival	24451146	1191	1199	I-Outcome
(	24451146	1200	1201	O
RFS	24451146	1201	1204	B-Outcome
)	24451146	1204	1205	O
,	24451146	1205	1206	O
overall	24451146	1207	1214	B-Outcome
survival	24451146	1215	1223	I-Outcome
(	24451146	1224	1225	O
OS	24451146	1225	1227	B-Outcome
)	24451146	1227	1228	O
,	24451146	1228	1229	O
bone	24451146	1230	1234	B-Outcome
RFS	24451146	1235	1238	I-Outcome
or	24451146	1239	1241	O
non-bone	24451146	1242	1250	B-Outcome
RFS	24451146	1251	1254	I-Outcome
.	24451146	1254	1255	O

An	24451146	1256	1258	O
exploratory	24451146	1259	1270	O
analysis	24451146	1271	1279	O
in	24451146	1280	1282	O
patients	24451146	1283	1291	O
with	24451146	1292	1296	O
recurrence	24451146	1297	1307	O
showed	24451146	1308	1314	O
higher	24451146	1315	1321	O
mean	24451146	1322	1326	B-Outcome
OPN	24451146	1327	1330	I-Outcome
plasma	24451146	1331	1337	I-Outcome
levels	24451146	1338	1344	I-Outcome
60.7	24451146	1345	1349	O
ng/ml	24451146	1350	1355	O
(	24451146	1356	1357	O
23.9	24451146	1357	1361	O
to	24451146	1362	1364	O
543	24451146	1365	1368	O
)	24451146	1368	1369	O
in	24451146	1370	1372	O
the	24451146	1373	1376	O
recurrence	24451146	1377	1387	O
period	24451146	1388	1394	O
compared	24451146	1395	1403	O
with	24451146	1404	1408	O
baseline	24451146	1409	1417	O
levels	24451146	1418	1424	O
.	24451146	1424	1425	O

CONCLUSIONS	24451146	1427	1438	O
:	24451146	1439	1440	O
The	24451146	1441	1444	O
hypothesis	24451146	1445	1455	O
that	24451146	1456	1460	O
OPN	24451146	1461	1464	O
tumor	24451146	1465	1470	O
expression	24451146	1471	1481	O
would	24451146	1482	1487	O
have	24451146	1488	1492	O
independent	24451146	1493	1504	O
prognostic	24451146	1505	1515	O
value	24451146	1516	1521	O
in	24451146	1522	1524	O
early	24451146	1525	1530	O
breast	24451146	1531	1537	O
cancer	24451146	1538	1544	O
was	24451146	1545	1548	O
not	24451146	1549	1552	O
supported	24451146	1553	1562	O
by	24451146	1563	1565	O
multivariate	24451146	1566	1578	O
analysis	24451146	1579	1587	O
of	24451146	1588	1590	O
this	24451146	1591	1595	O
study	24451146	1596	1601	O
population	24451146	1602	1612	O
.	24451146	1612	1613	O

Plasma	24451146	1614	1620	B-Outcome
OPN	24451146	1621	1624	I-Outcome
levels	24451146	1625	1631	I-Outcome
in	24451146	1632	1634	O
women	24451146	1635	1640	O
with	24451146	1641	1645	O
hormone	24451146	1646	1653	O
responsive	24451146	1654	1664	O
early	24451146	1665	1670	O
breast	24451146	1671	1677	O
cancer	24451146	1678	1684	O
in	24451146	1685	1687	O
the	24451146	1688	1691	O
MA.14	24451146	1692	1697	O
trial	24451146	1698	1703	O
were	24451146	1704	1708	O
not	24451146	1709	1712	O
elevated	24451146	1713	1721	O
and	24451146	1722	1725	O
there	24451146	1726	1731	O
was	24451146	1732	1735	O
no	24451146	1736	1738	O
evidence	24451146	1739	1747	O
for	24451146	1748	1751	O
prognostic	24451146	1752	1762	O
value	24451146	1763	1768	O
of	24451146	1769	1771	O
plasma	24451146	1772	1778	B-Outcome
OPN	24451146	1779	1782	I-Outcome
in	24451146	1783	1785	O
this	24451146	1786	1790	O
defined	24451146	1791	1798	O
group	24451146	1799	1804	O
of	24451146	1805	1807	O
patients	24451146	1808	1816	O
.	24451146	1816	1817	O

However	24451146	1818	1825	O
,	24451146	1825	1826	O
our	24451146	1827	1830	O
finding	24451146	1831	1838	O
of	24451146	1839	1841	O
elevated	24451146	1842	1850	O
mean	24451146	1851	1855	B-Outcome
OPN	24451146	1856	1859	I-Outcome
plasma	24451146	1860	1866	I-Outcome
level	24451146	1867	1872	I-Outcome
around	24451146	1873	1879	O
the	24451146	1880	1883	O
time	24451146	1884	1888	O
of	24451146	1889	1891	O
recurrence	24451146	1892	1902	O
warrants	24451146	1903	1911	O
further	24451146	1912	1919	O
study	24451146	1920	1925	O
.	24451146	1925	1926	O

BACKGROUND	24451146	1928	1938	O
:	24451146	1939	1940	O
NCT00002864	24451146	1941	1952	O
,	24451146	1952	1953	O
http://clinicaltrials.gov/show/NCT00002864	24451146	1954	1996	O
.	24451146	1996	1997	O


Postoperative	24634631	0	13	O
sleep	24634631	14	19	O
disturbances	24634631	20	32	O
after	24634631	33	38	O
zolpidem	24634631	39	47	O
treatment	24634631	48	57	O
in	24634631	58	60	O
fast-track	24634631	61	71	O
hip	24634631	72	75	O
and	24634631	76	79	O
knee	24634631	80	84	O
replacement	24634631	85	96	O
.	24634631	96	97	O

STUDY	24634631	99	104	O
OBJECTIVES	24634631	105	115	O
:	24634631	116	117	O
Previous	24634631	118	126	O
studies	24634631	127	134	O
have	24634631	135	139	O
demonstrated	24634631	140	152	O
pronounced	24634631	153	163	O
reduction	24634631	164	173	O
of	24634631	174	176	O
REM	24634631	177	180	O
sleep	24634631	181	186	O
on	24634631	187	189	O
the	24634631	190	193	O
first	24634631	194	199	O
nights	24634631	200	206	O
following	24634631	207	216	O
major	24634631	217	222	O
surgery	24634631	223	230	O
which	24634631	231	236	O
may	24634631	237	240	O
influence	24634631	241	250	O
pain	24634631	251	255	O
,	24634631	255	256	O
analgesic	24634631	257	266	O
use	24634631	267	270	O
,	24634631	270	271	O
and	24634631	272	275	O
recovery	24634631	276	284	O
.	24634631	284	285	O

This	24634631	286	290	O
placebo-controlled	24634631	291	309	O
,	24634631	309	310	O
randomized	24634631	311	321	O
,	24634631	321	322	O
double-blind	24634631	323	335	O
study	24634631	336	341	O
set	24634631	342	345	O
out	24634631	346	349	O
to	24634631	350	352	O
evaluate	24634631	353	361	O
the	24634631	362	365	O
effect	24634631	366	372	O
of	24634631	373	375	O
zolpidem	24634631	376	384	O
on	24634631	385	387	O
sleep	24634631	388	393	O
architecture	24634631	394	406	O
in	24634631	407	409	O
an	24634631	410	412	O
elderly	24634631	413	420	O
population	24634631	421	431	O
undergoing	24634631	432	442	O
fast-track	24634631	443	453	O
total	24634631	454	459	O
hip	24634631	460	463	O
and	24634631	464	467	O
knee	24634631	468	472	O
arthroplasty	24634631	473	485	O
(	24634631	486	487	O
THA/TKA	24634631	487	494	O
)	24634631	494	495	O
with	24634631	496	500	O
length	24634631	501	507	O
of	24634631	508	510	O
stay	24634631	511	515	O
<	24634631	516	517	O
3	24634631	518	519	O
days	24634631	520	524	O
.	24634631	524	525	O

METHODS	24634631	527	534	O
:	24634631	535	536	O
Twenty	24634631	537	543	O
patients	24634631	544	552	O
(	24634631	553	554	O
≥	24634631	554	555	O
60	24634631	556	558	O
years	24634631	559	564	O
)	24634631	564	565	O
undergoing	24634631	566	576	O
THA	24634631	577	580	O
or	24634631	581	583	O
TKA	24634631	584	587	O
in	24634631	588	590	O
a	24634631	591	592	O
standardized	24634631	593	605	O
setup	24634631	606	611	O
with	24634631	612	616	O
spinal	24634631	617	623	O
anesthesia	24634631	624	634	O
and	24634631	635	638	O
multimodal	24634631	639	649	O
opioid-sparing	24634631	650	664	O
postoperative	24634631	665	678	O
analgesia	24634631	679	688	O
were	24634631	689	693	O
included	24634631	694	702	O
.	24634631	702	703	O

Polysomnography	24634631	704	719	O
measures	24634631	720	728	O
were	24634631	729	733	O
performed	24634631	734	743	O
for	24634631	744	747	O
2	24634631	748	749	O
nights	24634631	750	756	O
,	24634631	756	757	O
1	24634631	758	759	O
night	24634631	760	765	O
at	24634631	766	768	O
home	24634631	769	773	O
prior	24634631	774	779	O
to	24634631	780	782	O
surgery	24634631	783	790	O
and	24634631	791	794	O
on	24634631	795	797	O
the	24634631	798	801	O
first	24634631	802	807	O
night	24634631	808	813	O
after	24634631	814	819	O
surgery	24634631	820	827	O
,	24634631	827	828	O
when	24634631	829	833	O
the	24634631	834	837	O
patient	24634631	838	845	O
received	24634631	846	854	O
placebo	24634631	855	862	O
or	24634631	863	865	O
zolpidem	24634631	866	874	O
10	24634631	875	877	O
mg	24634631	878	880	O
.	24634631	880	881	O

Analgesic	24634631	882	891	O
use	24634631	892	895	O
,	24634631	895	896	O
pain	24634631	897	901	O
levels	24634631	902	908	O
,	24634631	908	909	O
and	24634631	910	913	O
subjective	24634631	914	924	O
measures	24634631	925	933	O
of	24634631	934	936	O
fatigue	24634631	937	944	O
and	24634631	945	948	O
sleep	24634631	949	954	O
quality	24634631	955	962	O
were	24634631	963	967	O
recorded	24634631	968	976	O
.	24634631	976	977	O

Analysis	24634631	978	986	O
of	24634631	987	989	O
sleep	24634631	990	995	O
data	24634631	996	1000	O
was	24634631	1001	1004	O
performed	24634631	1005	1014	O
according	24634631	1015	1024	O
to	24634631	1025	1027	O
the	24634631	1028	1031	O
American	24634631	1032	1040	O
Academy	24634631	1041	1048	O
of	24634631	1049	1051	O
Sleep	24634631	1052	1057	O
Medicine	24634631	1058	1066	O
manual	24634631	1067	1073	O
.	24634631	1073	1074	O

RESULTS	24634631	1076	1083	O
:	24634631	1084	1085	O
Objective	24634631	1086	1095	O
sleep	24634631	1096	1101	O
data	24634631	1102	1106	O
did	24634631	1107	1110	O
not	24634631	1111	1114	O
show	24634631	1115	1119	O
a	24634631	1120	1121	O
significant	24634631	1122	1133	O
difference	24634631	1134	1144	O
between	24634631	1145	1152	O
groups	24634631	1153	1159	O
in	24634631	1160	1162	O
any	24634631	1163	1166	O
of	24634631	1167	1169	O
the	24634631	1170	1173	O
sleep	24634631	1174	1179	B-Outcome
stages	24634631	1180	1186	I-Outcome
.	24634631	1186	1187	O

However	24634631	1188	1195	O
,	24634631	1195	1196	O
subjective	24634631	1197	1207	O
data	24634631	1208	1212	O
on	24634631	1213	1215	O
sleep	24634631	1216	1221	B-Outcome
quality	24634631	1222	1229	I-Outcome
and	24634631	1230	1233	O
fatigue	24634631	1234	1241	B-Outcome
showed	24634631	1242	1248	O
significantly	24634631	1249	1262	O
less	24634631	1263	1267	O
fatigue	24634631	1268	1275	B-Outcome
and	24634631	1276	1279	O
better	24634631	1280	1286	O
sleep	24634631	1287	1292	B-Outcome
quality	24634631	1293	1300	I-Outcome
in	24634631	1301	1303	O
the	24634631	1304	1307	O
zolpidem	24634631	1308	1316	O
group	24634631	1317	1322	O
(	24634631	1323	1324	O
p	24634631	1324	1325	O
<	24634631	1326	1327	O
0.05	24634631	1328	1332	O
)	24634631	1332	1333	O
,	24634631	1333	1334	O
and	24634631	1335	1338	O
reduced	24634631	1339	1346	O
objectively	24634631	1347	1358	O
recorded	24634631	1359	1367	O
number	24634631	1368	1374	B-Outcome
of	24634631	1375	1377	I-Outcome
arousals	24634631	1378	1386	I-Outcome
(	24634631	1387	1388	O
p	24634631	1388	1389	O
=	24634631	1390	1391	O
0.004	24634631	1392	1397	O
)	24634631	1397	1398	O
.	24634631	1398	1399	O

Levels	24634631	1400	1406	B-Outcome
of	24634631	1407	1409	I-Outcome
pain	24634631	1410	1414	I-Outcome
and	24634631	1415	1418	O
opioid	24634631	1419	1425	B-Outcome
use	24634631	1426	1429	I-Outcome
were	24634631	1430	1434	O
similar	24634631	1435	1442	O
in	24634631	1443	1445	O
the	24634631	1446	1449	O
2	24634631	1450	1451	O
groups	24634631	1452	1458	O
.	24634631	1458	1459	O

CONCLUSIONS	24634631	1461	1472	O
:	24634631	1473	1474	O
Our	24634631	1475	1478	O
objective	24634631	1479	1488	O
data	24634631	1489	1493	O
did	24634631	1494	1497	O
not	24634631	1498	1501	O
support	24634631	1502	1509	O
the	24634631	1510	1513	O
primary	24634631	1514	1521	O
hypothesis	24634631	1522	1532	O
that	24634631	1533	1537	O
one	24634631	1538	1541	O
night	24634631	1542	1547	O
's	24634631	1547	1549	O
treatment	24634631	1550	1559	O
with	24634631	1560	1564	O
zolpidem	24634631	1565	1573	O
would	24634631	1574	1579	O
significantly	24634631	1580	1593	O
improve	24634631	1594	1601	O
sleep	24634631	1602	1607	B-Outcome
architecture	24634631	1608	1620	I-Outcome
following	24634631	1621	1630	O
major	24634631	1631	1636	O
surgery	24634631	1637	1644	O
,	24634631	1644	1645	O
although	24634631	1646	1654	O
there	24634631	1655	1660	O
was	24634631	1661	1664	O
improved	24634631	1665	1673	O
feeling	24634631	1674	1681	O
of	24634631	1682	1684	O
sleep	24634631	1685	1690	B-Outcome
quality	24634631	1691	1698	I-Outcome
and	24634631	1699	1702	O
fatigue	24634631	1703	1710	B-Outcome
associated	24634631	1711	1721	O
with	24634631	1722	1726	O
fewer	24634631	1727	1732	O
postoperative	24634631	1733	1746	B-Outcome
arousals	24634631	1747	1755	I-Outcome
.	24634631	1755	1756	O

CITATION	24634631	1758	1766	O
:	24634631	1767	1768	O
Krenk	24634631	1769	1774	O
L	24634631	1775	1776	O
;	24634631	1776	1777	O
Jennum	24634631	1778	1784	O
P	24634631	1785	1786	O
;	24634631	1786	1787	O
Kehlet	24634631	1788	1794	O
H.	24634631	1795	1797	O
Postoperative	24634631	1798	1811	O
sleep	24634631	1812	1817	O
disturbances	24634631	1818	1830	O
after	24634631	1831	1836	O
zolpidem	24634631	1837	1845	O
treatment	24634631	1846	1855	O
in	24634631	1856	1858	O
fast-track	24634631	1859	1869	O
hip	24634631	1870	1873	O
and	24634631	1874	1877	O
knee	24634631	1878	1882	O
replacement	24634631	1883	1894	O
.	24634631	1894	1895	O


Omitting	24637998	0	8	O
radiotherapy	24637998	9	21	O
in	24637998	22	24	O
early	24637998	25	30	O
positron	24637998	31	39	O
emission	24637998	40	48	O
tomography-negative	24637998	49	68	O
stage	24637998	69	74	O
I/II	24637998	75	79	O
Hodgkin	24637998	80	87	O
lymphoma	24637998	88	96	O
is	24637998	97	99	O
associated	24637998	100	110	O
with	24637998	111	115	O
an	24637998	116	118	O
increased	24637998	119	128	O
risk	24637998	129	133	O
of	24637998	134	136	O
early	24637998	137	142	O
relapse	24637998	143	150	O
:	24637998	150	151	O
Clinical	24637998	152	160	O
results	24637998	161	168	O
of	24637998	169	171	O
the	24637998	172	175	O
preplanned	24637998	176	186	O
interim	24637998	187	194	O
analysis	24637998	195	203	O
of	24637998	204	206	O
the	24637998	207	210	O
randomized	24637998	211	221	O
EORTC/LYSA/FIL	24637998	222	236	O
H10	24637998	237	240	O
trial	24637998	241	246	O
.	24637998	246	247	O

PURPOSE	24637998	249	256	O
:	24637998	257	258	O
Combined-modality	24637998	259	276	O
treatment	24637998	277	286	O
is	24637998	287	289	O
standard	24637998	290	298	O
treatment	24637998	299	308	O
for	24637998	309	312	O
patients	24637998	313	321	O
with	24637998	322	326	O
clinical	24637998	327	335	O
stage	24637998	336	341	O
I/II	24637998	342	346	O
Hodgkin	24637998	347	354	O
lymphoma	24637998	355	363	O
(	24637998	364	365	O
HL	24637998	365	367	O
)	24637998	367	368	O
.	24637998	368	369	O

We	24637998	370	372	O
hypothesized	24637998	373	385	O
that	24637998	386	390	O
an	24637998	391	393	O
early	24637998	394	399	O
positron	24637998	400	408	O
emission	24637998	409	417	O
tomography	24637998	418	428	O
(	24637998	429	430	O
PET	24637998	430	433	O
)	24637998	433	434	O
scan	24637998	435	439	O
could	24637998	440	445	O
be	24637998	446	448	O
used	24637998	449	453	O
to	24637998	454	456	O
adapt	24637998	457	462	O
treatment	24637998	463	472	O
.	24637998	472	473	O

Therefore	24637998	474	483	O
,	24637998	483	484	O
we	24637998	485	487	O
started	24637998	488	495	O
the	24637998	496	499	O
randomized	24637998	500	510	O
EORTC/LYSA/FIL	24637998	511	525	O
Intergroup	24637998	526	536	O
H10	24637998	537	540	O
trial	24637998	541	546	O
evaluating	24637998	547	557	O
whether	24637998	558	565	O
involved-node	24637998	566	579	O
radiotherapy	24637998	580	592	O
(	24637998	593	594	O
IN-RT	24637998	594	599	O
)	24637998	599	600	O
could	24637998	601	606	O
be	24637998	607	609	O
omitted	24637998	610	617	O
without	24637998	618	625	O
compromising	24637998	626	638	O
progression-free	24637998	639	655	O
survival	24637998	656	664	O
in	24637998	665	667	O
patients	24637998	668	676	O
attaining	24637998	677	686	O
a	24637998	687	688	O
negative	24637998	689	697	O
early	24637998	698	703	O
PET	24637998	704	707	O
scan	24637998	708	712	O
after	24637998	713	718	O
two	24637998	719	722	O
cycles	24637998	723	729	O
of	24637998	730	732	O
ABVD	24637998	733	737	O
(	24637998	738	739	O
doxorubicin	24637998	739	750	O
,	24637998	750	751	O
bleomycin	24637998	752	761	O
,	24637998	761	762	O
vinblastine	24637998	763	774	O
,	24637998	774	775	O
and	24637998	776	779	O
dacarbazine	24637998	780	791	O
)	24637998	791	792	O
as	24637998	793	795	O
compared	24637998	796	804	O
with	24637998	805	809	O
standard	24637998	810	818	O
combined-modality	24637998	819	836	O
treatment	24637998	837	846	O
.	24637998	846	847	O

PATIENTS	24637998	849	857	O
AND	24637998	858	861	O
METHODS	24637998	862	869	O
:	24637998	870	871	O
Patients	24637998	872	880	O
age	24637998	881	884	O
15	24637998	885	887	O
to	24637998	888	890	O
70	24637998	891	893	O
years	24637998	894	899	O
with	24637998	900	904	O
untreated	24637998	905	914	O
clinical	24637998	915	923	O
stage	24637998	924	929	O
I/II	24637998	930	934	O
HL	24637998	935	937	O
were	24637998	938	942	O
eligible	24637998	943	951	O
.	24637998	951	952	O

Here	24637998	953	957	O
we	24637998	958	960	O
report	24637998	961	967	O
the	24637998	968	971	O
clinical	24637998	972	980	O
outcome	24637998	981	988	O
of	24637998	989	991	O
the	24637998	992	995	O
preplanned	24637998	996	1006	O
interim	24637998	1007	1014	O
futility	24637998	1015	1023	O
analysis	24637998	1024	1032	O
scheduled	24637998	1033	1042	O
to	24637998	1043	1045	O
occur	24637998	1046	1051	O
after	24637998	1052	1057	O
documentation	24637998	1058	1071	O
of	24637998	1072	1074	O
34	24637998	1075	1077	O
events	24637998	1078	1084	O
in	24637998	1085	1087	O
the	24637998	1088	1091	O
early	24637998	1092	1097	O
PET-negative	24637998	1098	1110	O
group	24637998	1111	1116	O
.	24637998	1116	1117	O

Because	24637998	1118	1125	O
testing	24637998	1126	1133	O
for	24637998	1134	1137	O
futility	24637998	1138	1146	O
in	24637998	1147	1149	O
this	24637998	1150	1154	O
noninferiority	24637998	1155	1169	O
trial	24637998	1170	1175	O
corresponds	24637998	1176	1187	O
to	24637998	1188	1190	O
testing	24637998	1191	1198	O
the	24637998	1199	1202	O
hypothesis	24637998	1203	1213	O
of	24637998	1214	1216	O
no	24637998	1217	1219	O
difference	24637998	1220	1230	O
,	24637998	1230	1231	O
a	24637998	1232	1233	O
one-sided	24637998	1234	1243	O
superiority	24637998	1244	1255	O
test	24637998	1256	1260	O
was	24637998	1261	1264	O
conducted	24637998	1265	1274	O
.	24637998	1274	1275	O

RESULTS	24637998	1277	1284	O
:	24637998	1285	1286	O
The	24637998	1287	1290	O
analysis	24637998	1291	1299	O
included	24637998	1300	1308	O
1,137	24637998	1309	1314	O
patients	24637998	1315	1323	O
.	24637998	1323	1324	O

In	24637998	1325	1327	O
the	24637998	1328	1331	O
favorable	24637998	1332	1341	O
subgroup	24637998	1342	1350	O
,	24637998	1350	1351	O
85.8	24637998	1352	1356	O
%	24637998	1356	1357	O
had	24637998	1358	1361	O
a	24637998	1362	1363	O
negative	24637998	1364	1372	B-Outcome
early	24637998	1373	1378	I-Outcome
PET	24637998	1379	1382	I-Outcome
scan	24637998	1383	1387	I-Outcome
(	24637998	1388	1389	O
standard	24637998	1389	1397	O
arm	24637998	1398	1401	O
,	24637998	1401	1402	O
one	24637998	1403	1406	O
event	24637998	1407	1412	O
v	24637998	1413	1414	O
experimental	24637998	1415	1427	O
arm	24637998	1428	1431	O
,	24637998	1431	1432	O
nine	24637998	1433	1437	O
events	24637998	1438	1444	O
)	24637998	1444	1445	O
.	24637998	1445	1446	O

In	24637998	1447	1449	O
the	24637998	1450	1453	O
unfavorable	24637998	1454	1465	O
subgroup	24637998	1466	1474	O
,	24637998	1474	1475	O
74.8	24637998	1476	1480	O
%	24637998	1480	1481	O
had	24637998	1482	1485	O
a	24637998	1486	1487	O
negative	24637998	1488	1496	B-Outcome
early	24637998	1497	1502	I-Outcome
PET	24637998	1503	1506	I-Outcome
scan	24637998	1507	1511	I-Outcome
(	24637998	1512	1513	O
standard	24637998	1513	1521	O
arm	24637998	1522	1525	O
,	24637998	1525	1526	O
seven	24637998	1527	1532	O
events	24637998	1533	1539	O
v	24637998	1540	1541	O
experimental	24637998	1542	1554	O
arm	24637998	1555	1558	O
,	24637998	1558	1559	O
16	24637998	1560	1562	O
events	24637998	1563	1569	O
)	24637998	1569	1570	O
.	24637998	1570	1571	O

The	24637998	1572	1575	O
independent	24637998	1576	1587	O
data	24637998	1588	1592	O
monitoring	24637998	1593	1603	O
committee	24637998	1604	1613	O
concluded	24637998	1614	1623	O
it	24637998	1624	1626	O
was	24637998	1627	1630	O
unlikely	24637998	1631	1639	O
that	24637998	1640	1644	O
we	24637998	1645	1647	O
would	24637998	1648	1653	O
show	24637998	1654	1658	O
noninferiority	24637998	1659	1673	O
in	24637998	1674	1676	O
the	24637998	1677	1680	O
final	24637998	1681	1686	O
results	24637998	1687	1694	O
for	24637998	1695	1698	O
the	24637998	1699	1702	O
experimental	24637998	1703	1715	O
arm	24637998	1716	1719	O
and	24637998	1720	1723	O
advised	24637998	1724	1731	O
stopping	24637998	1732	1740	O
random	24637998	1741	1747	O
assignment	24637998	1748	1758	O
for	24637998	1759	1762	O
early	24637998	1763	1768	O
PET-negative	24637998	1769	1781	O
patients	24637998	1782	1790	O
.	24637998	1790	1791	O

CONCLUSION	24637998	1793	1803	O
:	24637998	1804	1805	O
On	24637998	1806	1808	O
the	24637998	1809	1812	O
basis	24637998	1813	1818	O
of	24637998	1819	1821	O
this	24637998	1822	1826	O
analysis	24637998	1827	1835	O
,	24637998	1835	1836	O
combined-modality	24637998	1837	1854	O
treatment	24637998	1855	1864	O
resulted	24637998	1865	1873	O
in	24637998	1874	1876	O
fewer	24637998	1877	1882	O
early	24637998	1883	1888	B-Outcome
progressions	24637998	1889	1901	I-Outcome
in	24637998	1902	1904	I-Outcome
clinical	24637998	1905	1913	I-Outcome
stage	24637998	1914	1919	I-Outcome
I/II	24637998	1920	1924	I-Outcome
HL	24637998	1925	1927	I-Outcome
,	24637998	1927	1928	O
although	24637998	1929	1937	O
early	24637998	1938	1943	O
outcome	24637998	1944	1951	O
was	24637998	1952	1955	O
excellent	24637998	1956	1965	O
in	24637998	1966	1968	O
both	24637998	1969	1973	O
arms	24637998	1974	1978	O
.	24637998	1978	1979	O

The	24637998	1980	1983	O
final	24637998	1984	1989	O
analysis	24637998	1990	1998	O
will	24637998	1999	2003	O
reveal	24637998	2004	2010	O
whether	24637998	2011	2018	O
this	24637998	2019	2023	O
finding	24637998	2024	2031	O
is	24637998	2032	2034	O
maintained	24637998	2035	2045	O
over	24637998	2046	2050	O
time	24637998	2051	2055	O
.	24637998	2055	2056	O


Clonidine	24679061	0	9	O
in	24679061	10	12	O
patients	24679061	13	21	O
undergoing	24679061	22	32	O
noncardiac	24679061	33	43	O
surgery	24679061	44	51	O
.	24679061	51	52	O

BACKGROUND	24679061	54	64	O
:	24679061	65	66	O
Marked	24679061	67	73	O
activation	24679061	74	84	O
of	24679061	85	87	O
the	24679061	88	91	O
sympathetic	24679061	92	103	O
nervous	24679061	104	111	O
system	24679061	112	118	O
occurs	24679061	119	125	O
during	24679061	126	132	O
and	24679061	133	136	O
after	24679061	137	142	O
noncardiac	24679061	143	153	O
surgery	24679061	154	161	O
.	24679061	161	162	O

Low-dose	24679061	163	171	O
clonidine	24679061	172	181	O
,	24679061	181	182	O
which	24679061	183	188	O
blunts	24679061	189	195	O
central	24679061	196	203	O
sympathetic	24679061	204	215	O
outflow	24679061	216	223	O
,	24679061	223	224	O
may	24679061	225	228	O
prevent	24679061	229	236	O
perioperative	24679061	237	250	O
myocardial	24679061	251	261	O
infarction	24679061	262	272	O
and	24679061	273	276	O
death	24679061	277	282	O
without	24679061	283	290	O
inducing	24679061	291	299	O
hemodynamic	24679061	300	311	O
instability	24679061	312	323	O
.	24679061	323	324	O

METHODS	24679061	326	333	O
:	24679061	334	335	O
We	24679061	336	338	O
performed	24679061	339	348	O
a	24679061	349	350	O
blinded	24679061	351	358	O
,	24679061	358	359	O
randomized	24679061	360	370	O
trial	24679061	371	376	O
with	24679061	377	381	O
a	24679061	382	383	O
2-by-2	24679061	384	390	O
factorial	24679061	391	400	O
design	24679061	401	407	O
to	24679061	408	410	O
allow	24679061	411	416	O
separate	24679061	417	425	O
evaluation	24679061	426	436	O
of	24679061	437	439	O
low-dose	24679061	440	448	O
clonidine	24679061	449	458	O
versus	24679061	459	465	O
placebo	24679061	466	473	O
and	24679061	474	477	O
low-dose	24679061	478	486	O
aspirin	24679061	487	494	O
versus	24679061	495	501	O
placebo	24679061	502	509	O
in	24679061	510	512	O
patients	24679061	513	521	O
with	24679061	522	526	O
,	24679061	526	527	O
or	24679061	528	530	O
at	24679061	531	533	O
risk	24679061	534	538	O
for	24679061	539	542	O
,	24679061	542	543	O
atherosclerotic	24679061	544	559	O
disease	24679061	560	567	O
who	24679061	568	571	O
were	24679061	572	576	O
undergoing	24679061	577	587	O
noncardiac	24679061	588	598	O
surgery	24679061	599	606	O
.	24679061	606	607	O

A	24679061	608	609	O
total	24679061	610	615	O
of	24679061	616	618	O
10,010	24679061	619	625	O
patients	24679061	626	634	O
at	24679061	635	637	O
135	24679061	638	641	O
centers	24679061	642	649	O
in	24679061	650	652	O
23	24679061	653	655	O
countries	24679061	656	665	O
were	24679061	666	670	O
enrolled	24679061	671	679	O
.	24679061	679	680	O

For	24679061	681	684	O
the	24679061	685	688	O
comparison	24679061	689	699	O
of	24679061	700	702	O
clonidine	24679061	703	712	O
with	24679061	713	717	O
placebo	24679061	718	725	O
,	24679061	725	726	O
patients	24679061	727	735	O
were	24679061	736	740	O
randomly	24679061	741	749	O
assigned	24679061	750	758	O
to	24679061	759	761	O
receive	24679061	762	769	O
clonidine	24679061	770	779	O
(	24679061	780	781	O
0.2	24679061	781	784	O
mg	24679061	785	787	O
per	24679061	788	791	O
day	24679061	792	795	O
)	24679061	795	796	O
or	24679061	797	799	O
placebo	24679061	800	807	O
just	24679061	808	812	O
before	24679061	813	819	O
surgery	24679061	820	827	O
,	24679061	827	828	O
with	24679061	829	833	O
the	24679061	834	837	O
study	24679061	838	843	O
drug	24679061	844	848	O
continued	24679061	849	858	O
until	24679061	859	864	O
72	24679061	865	867	O
hours	24679061	868	873	O
after	24679061	874	879	O
surgery	24679061	880	887	O
.	24679061	887	888	O

The	24679061	889	892	O
primary	24679061	893	900	O
outcome	24679061	901	908	O
was	24679061	909	912	O
a	24679061	913	914	O
composite	24679061	915	924	O
of	24679061	925	927	O
death	24679061	928	933	O
or	24679061	934	936	O
nonfatal	24679061	937	945	O
myocardial	24679061	946	956	O
infarction	24679061	957	967	O
at	24679061	968	970	O
30	24679061	971	973	O
days	24679061	974	978	O
.	24679061	978	979	O

RESULTS	24679061	981	988	O
:	24679061	989	990	O
Clonidine	24679061	991	1000	O
,	24679061	1000	1001	O
as	24679061	1002	1004	O
compared	24679061	1005	1013	O
with	24679061	1014	1018	O
placebo	24679061	1019	1026	O
,	24679061	1026	1027	O
did	24679061	1028	1031	O
not	24679061	1032	1035	O
reduce	24679061	1036	1042	O
the	24679061	1043	1046	O
number	24679061	1047	1053	O
of	24679061	1054	1056	O
primary-outcome	24679061	1057	1072	O
events	24679061	1073	1079	O
(	24679061	1080	1081	O
367	24679061	1081	1084	O
and	24679061	1085	1088	O
339	24679061	1089	1092	O
,	24679061	1092	1093	O
respectively	24679061	1094	1106	O
;	24679061	1106	1107	O
hazard	24679061	1108	1114	O
ratio	24679061	1115	1120	O
with	24679061	1121	1125	O
clonidine	24679061	1126	1135	O
,	24679061	1135	1136	O
1.08	24679061	1137	1141	O
;	24679061	1141	1142	O
95	24679061	1143	1145	O
%	24679061	1145	1146	O
confidence	24679061	1147	1157	O
interval	24679061	1158	1166	O
[	24679061	1167	1168	O
CI	24679061	1168	1170	O
]	24679061	1170	1171	O
,	24679061	1171	1172	O
0.93	24679061	1173	1177	O
to	24679061	1178	1180	O
1.26	24679061	1181	1185	O
;	24679061	1185	1186	O
P=0.29	24679061	1187	1193	O
)	24679061	1193	1194	O
.	24679061	1194	1195	O

Myocardial	24679061	1196	1206	B-Outcome
infarction	24679061	1207	1217	I-Outcome
occurred	24679061	1218	1226	O
in	24679061	1227	1229	O
329	24679061	1230	1233	O
patients	24679061	1234	1242	O
(	24679061	1243	1244	O
6.6	24679061	1244	1247	O
%	24679061	1247	1248	O
)	24679061	1248	1249	O
assigned	24679061	1250	1258	O
to	24679061	1259	1261	O
clonidine	24679061	1262	1271	O
and	24679061	1272	1275	O
in	24679061	1276	1278	O
295	24679061	1279	1282	O
patients	24679061	1283	1291	O
(	24679061	1292	1293	O
5.9	24679061	1293	1296	O
%	24679061	1296	1297	O
)	24679061	1297	1298	O
assigned	24679061	1299	1307	O
to	24679061	1308	1310	O
placebo	24679061	1311	1318	O
(	24679061	1319	1320	O
hazard	24679061	1320	1326	O
ratio	24679061	1327	1332	O
,	24679061	1332	1333	O
1.11	24679061	1334	1338	O
;	24679061	1338	1339	O
95	24679061	1340	1342	O
%	24679061	1342	1343	O
CI	24679061	1344	1346	O
,	24679061	1346	1347	O
0.95	24679061	1348	1352	O
to	24679061	1353	1355	O
1.30	24679061	1356	1360	O
;	24679061	1360	1361	O
P=0.18	24679061	1362	1368	O
)	24679061	1368	1369	O
.	24679061	1369	1370	O

Significantly	24679061	1371	1384	O
more	24679061	1385	1389	O
patients	24679061	1390	1398	O
in	24679061	1399	1401	O
the	24679061	1402	1405	O
clonidine	24679061	1406	1415	O
group	24679061	1416	1421	O
than	24679061	1422	1426	O
in	24679061	1427	1429	O
the	24679061	1430	1433	O
placebo	24679061	1434	1441	O
group	24679061	1442	1447	O
had	24679061	1448	1451	O
clinically	24679061	1452	1462	B-Outcome
important	24679061	1463	1472	I-Outcome
hypotension	24679061	1473	1484	I-Outcome
(	24679061	1485	1486	O
2385	24679061	1486	1490	O
patients	24679061	1491	1499	O
[	24679061	1500	1501	O
47.6	24679061	1501	1505	O
%	24679061	1505	1506	O
]	24679061	1506	1507	O
vs.	24679061	1508	1511	O
1854	24679061	1512	1516	O
patients	24679061	1517	1525	O
[	24679061	1526	1527	O
37.1	24679061	1527	1531	O
%	24679061	1531	1532	O
]	24679061	1532	1533	O
;	24679061	1533	1534	O
hazard	24679061	1535	1541	O
ratio	24679061	1542	1547	O
1.32	24679061	1548	1552	O
;	24679061	1552	1553	O
95	24679061	1554	1556	O
%	24679061	1556	1557	O
CI	24679061	1558	1560	O
,	24679061	1560	1561	O
1.24	24679061	1562	1566	O
to	24679061	1567	1569	O
1.40	24679061	1570	1574	O
;	24679061	1574	1575	O
P<0.001	24679061	1576	1583	O
)	24679061	1583	1584	O
.	24679061	1584	1585	O

Clonidine	24679061	1586	1595	O
,	24679061	1595	1596	O
as	24679061	1597	1599	O
compared	24679061	1600	1608	O
with	24679061	1609	1613	O
placebo	24679061	1614	1621	O
,	24679061	1621	1622	O
was	24679061	1623	1626	O
associated	24679061	1627	1637	O
with	24679061	1638	1642	O
an	24679061	1643	1645	O
increased	24679061	1646	1655	O
rate	24679061	1656	1660	B-Outcome
of	24679061	1661	1663	I-Outcome
nonfatal	24679061	1664	1672	I-Outcome
cardiac	24679061	1673	1680	I-Outcome
arrest	24679061	1681	1687	I-Outcome
(	24679061	1688	1689	O
0.3	24679061	1689	1692	O
%	24679061	1692	1693	O
[	24679061	1694	1695	O
16	24679061	1695	1697	O
patients	24679061	1698	1706	O
]	24679061	1706	1707	O
vs.	24679061	1708	1711	O
0.1	24679061	1712	1715	O
%	24679061	1715	1716	O
[	24679061	1717	1718	O
5	24679061	1718	1719	O
patients	24679061	1720	1728	O
]	24679061	1728	1729	O
;	24679061	1729	1730	O
hazard	24679061	1731	1737	O
ratio	24679061	1738	1743	O
,	24679061	1743	1744	O
3.20	24679061	1745	1749	O
;	24679061	1749	1750	O
95	24679061	1751	1753	O
%	24679061	1753	1754	O
CI	24679061	1755	1757	O
,	24679061	1757	1758	O
1.17	24679061	1759	1763	O
to	24679061	1764	1766	O
8.73	24679061	1767	1771	O
;	24679061	1771	1772	O
P=0.02	24679061	1773	1779	O
)	24679061	1779	1780	O
.	24679061	1780	1781	O

CONCLUSIONS	24679061	1783	1794	O
:	24679061	1795	1796	O
Administration	24679061	1797	1811	O
of	24679061	1812	1814	O
low-dose	24679061	1815	1823	O
clonidine	24679061	1824	1833	O
in	24679061	1834	1836	O
patients	24679061	1837	1845	O
undergoing	24679061	1846	1856	O
noncardiac	24679061	1857	1867	O
surgery	24679061	1868	1875	O
did	24679061	1876	1879	O
not	24679061	1880	1883	O
reduce	24679061	1884	1890	O
the	24679061	1891	1894	O
rate	24679061	1895	1899	O
of	24679061	1900	1902	O
the	24679061	1903	1906	O
composite	24679061	1907	1916	O
outcome	24679061	1917	1924	O
of	24679061	1925	1927	O
death	24679061	1928	1933	B-Outcome
or	24679061	1934	1936	O
nonfatal	24679061	1937	1945	B-Outcome
myocardial	24679061	1946	1956	I-Outcome
infarction	24679061	1957	1967	I-Outcome
;	24679061	1967	1968	O
it	24679061	1969	1971	O
did	24679061	1972	1975	O
,	24679061	1975	1976	O
however	24679061	1977	1984	O
,	24679061	1984	1985	O
increase	24679061	1986	1994	O
the	24679061	1995	1998	O
risk	24679061	1999	2003	O
of	24679061	2004	2006	O
clinically	24679061	2007	2017	B-Outcome
important	24679061	2018	2027	I-Outcome
hypotension	24679061	2028	2039	I-Outcome
and	24679061	2040	2043	O
nonfatal	24679061	2044	2052	B-Outcome
cardiac	24679061	2053	2060	I-Outcome
arrest	24679061	2061	2067	I-Outcome
.	24679061	2067	2068	O

(	24679061	2069	2070	O
Funded	24679061	2070	2076	O
by	24679061	2077	2079	O
the	24679061	2080	2083	O
Canadian	24679061	2084	2092	O
Institutes	24679061	2093	2103	O
of	24679061	2104	2106	O
Health	24679061	2107	2113	O
Research	24679061	2114	2122	O
and	24679061	2123	2126	O
others	24679061	2127	2133	O
;	24679061	2133	2134	O
POISE-2	24679061	2135	2142	O
ClinicalTrials.gov	24679061	2143	2161	O
number	24679061	2162	2168	O
,	24679061	2168	2169	O
NCT01082874	24679061	2170	2181	O
.	24679061	2181	2182	O
)	24679061	2182	2183	O
.	24679061	2183	2184	O


Spironolactone	24716680	0	14	O
for	24716680	15	18	O
heart	24716680	19	24	O
failure	24716680	25	32	O
with	24716680	33	37	O
preserved	24716680	38	47	O
ejection	24716680	48	56	O
fraction	24716680	57	65	O
.	24716680	65	66	O

BACKGROUND	24716680	68	78	O
:	24716680	79	80	O
Mineralocorticoid-receptor	24716680	81	107	O
antagonists	24716680	108	119	O
improve	24716680	120	127	O
the	24716680	128	131	O
prognosis	24716680	132	141	O
for	24716680	142	145	O
patients	24716680	146	154	O
with	24716680	155	159	O
heart	24716680	160	165	O
failure	24716680	166	173	O
and	24716680	174	177	O
a	24716680	178	179	O
reduced	24716680	180	187	O
left	24716680	188	192	O
ventricular	24716680	193	204	O
ejection	24716680	205	213	O
fraction	24716680	214	222	O
.	24716680	222	223	O

We	24716680	224	226	O
evaluated	24716680	227	236	O
the	24716680	237	240	O
effects	24716680	241	248	O
of	24716680	249	251	O
spironolactone	24716680	252	266	O
in	24716680	267	269	O
patients	24716680	270	278	O
with	24716680	279	283	O
heart	24716680	284	289	O
failure	24716680	290	297	O
and	24716680	298	301	O
a	24716680	302	303	O
preserved	24716680	304	313	O
left	24716680	314	318	O
ventricular	24716680	319	330	O
ejection	24716680	331	339	O
fraction	24716680	340	348	O
.	24716680	348	349	O

METHODS	24716680	351	358	O
:	24716680	359	360	O
In	24716680	361	363	O
this	24716680	364	368	O
randomized	24716680	369	379	O
,	24716680	379	380	O
double-blind	24716680	381	393	O
trial	24716680	394	399	O
,	24716680	399	400	O
we	24716680	401	403	O
assigned	24716680	404	412	O
3445	24716680	413	417	O
patients	24716680	418	426	O
with	24716680	427	431	O
symptomatic	24716680	432	443	O
heart	24716680	444	449	O
failure	24716680	450	457	O
and	24716680	458	461	O
a	24716680	462	463	O
left	24716680	464	468	O
ventricular	24716680	469	480	O
ejection	24716680	481	489	O
fraction	24716680	490	498	O
of	24716680	499	501	O
45	24716680	502	504	O
%	24716680	504	505	O
or	24716680	506	508	O
more	24716680	509	513	O
to	24716680	514	516	O
receive	24716680	517	524	O
either	24716680	525	531	O
spironolactone	24716680	532	546	O
(	24716680	547	548	O
15	24716680	548	550	O
to	24716680	551	553	O
45	24716680	554	556	O
mg	24716680	557	559	O
daily	24716680	560	565	O
)	24716680	565	566	O
or	24716680	567	569	O
placebo	24716680	570	577	O
.	24716680	577	578	O

The	24716680	579	582	O
primary	24716680	583	590	O
outcome	24716680	591	598	O
was	24716680	599	602	O
a	24716680	603	604	O
composite	24716680	605	614	O
of	24716680	615	617	O
death	24716680	618	623	O
from	24716680	624	628	O
cardiovascular	24716680	629	643	O
causes	24716680	644	650	O
,	24716680	650	651	O
aborted	24716680	652	659	O
cardiac	24716680	660	667	O
arrest	24716680	668	674	O
,	24716680	674	675	O
or	24716680	676	678	O
hospitalization	24716680	679	694	O
for	24716680	695	698	O
the	24716680	699	702	O
management	24716680	703	713	O
of	24716680	714	716	O
heart	24716680	717	722	O
failure	24716680	723	730	O
.	24716680	730	731	O

RESULTS	24716680	733	740	O
:	24716680	741	742	O
With	24716680	743	747	O
a	24716680	748	749	O
mean	24716680	750	754	O
follow-up	24716680	755	764	O
of	24716680	765	767	O
3.3	24716680	768	771	O
years	24716680	772	777	O
,	24716680	777	778	O
the	24716680	779	782	O
primary	24716680	783	790	O
outcome	24716680	791	798	O
occurred	24716680	799	807	O
in	24716680	808	810	O
320	24716680	811	814	O
of	24716680	815	817	O
1722	24716680	818	822	O
patients	24716680	823	831	O
in	24716680	832	834	O
the	24716680	835	838	O
spironolactone	24716680	839	853	O
group	24716680	854	859	O
(	24716680	860	861	O
18.6	24716680	861	865	O
%	24716680	865	866	O
)	24716680	866	867	O
and	24716680	868	871	O
351	24716680	872	875	O
of	24716680	876	878	O
1723	24716680	879	883	O
patients	24716680	884	892	O
in	24716680	893	895	O
the	24716680	896	899	O
placebo	24716680	900	907	O
group	24716680	908	913	O
(	24716680	914	915	O
20.4	24716680	915	919	O
%	24716680	919	920	O
)	24716680	920	921	O
(	24716680	922	923	O
hazard	24716680	923	929	O
ratio	24716680	930	935	O
,	24716680	935	936	O
0.89	24716680	937	941	O
;	24716680	941	942	O
95	24716680	943	945	O
%	24716680	945	946	O
confidence	24716680	947	957	O
interval	24716680	958	966	O
[	24716680	967	968	O
CI	24716680	968	970	O
]	24716680	970	971	O
,	24716680	971	972	O
0.77	24716680	973	977	O
to	24716680	978	980	O
1.04	24716680	981	985	O
;	24716680	985	986	O
P=0.14	24716680	987	993	O
)	24716680	993	994	O
.	24716680	994	995	O

Of	24716680	996	998	O
the	24716680	999	1002	O
components	24716680	1003	1013	O
of	24716680	1014	1016	O
the	24716680	1017	1020	O
primary	24716680	1021	1028	O
outcome	24716680	1029	1036	O
,	24716680	1036	1037	O
only	24716680	1038	1042	O
hospitalization	24716680	1043	1058	B-Outcome
for	24716680	1059	1062	I-Outcome
heart	24716680	1063	1068	I-Outcome
failure	24716680	1069	1076	I-Outcome
had	24716680	1077	1080	O
a	24716680	1081	1082	O
significantly	24716680	1083	1096	O
lower	24716680	1097	1102	O
incidence	24716680	1103	1112	O
in	24716680	1113	1115	O
the	24716680	1116	1119	O
spironolactone	24716680	1120	1134	O
group	24716680	1135	1140	O
than	24716680	1141	1145	O
in	24716680	1146	1148	O
the	24716680	1149	1152	O
placebo	24716680	1153	1160	O
group	24716680	1161	1166	O
(	24716680	1167	1168	O
206	24716680	1168	1171	O
patients	24716680	1172	1180	O
[	24716680	1181	1182	O
12.0	24716680	1182	1186	O
%	24716680	1186	1187	O
]	24716680	1187	1188	O
vs.	24716680	1189	1192	O
245	24716680	1193	1196	O
patients	24716680	1197	1205	O
[	24716680	1206	1207	O
14.2	24716680	1207	1211	O
%	24716680	1211	1212	O
]	24716680	1212	1213	O
;	24716680	1213	1214	O
hazard	24716680	1215	1221	O
ratio	24716680	1222	1227	O
,	24716680	1227	1228	O
0.83	24716680	1229	1233	O
;	24716680	1233	1234	O
95	24716680	1235	1237	O
%	24716680	1237	1238	O
CI	24716680	1239	1241	O
,	24716680	1241	1242	O
0.69	24716680	1243	1247	O
to	24716680	1248	1250	O
0.99	24716680	1251	1255	O
,	24716680	1255	1256	O
P=0.04	24716680	1257	1263	O
)	24716680	1263	1264	O
.	24716680	1264	1265	O

Neither	24716680	1266	1273	O
total	24716680	1274	1279	B-Outcome
deaths	24716680	1280	1286	I-Outcome
nor	24716680	1287	1290	O
hospitalizations	24716680	1291	1307	B-Outcome
for	24716680	1308	1311	I-Outcome
any	24716680	1312	1315	I-Outcome
reason	24716680	1316	1322	I-Outcome
were	24716680	1323	1327	O
significantly	24716680	1328	1341	O
reduced	24716680	1342	1349	O
by	24716680	1350	1352	O
spironolactone	24716680	1353	1367	O
.	24716680	1367	1368	O

Treatment	24716680	1369	1378	O
with	24716680	1379	1383	O
spironolactone	24716680	1384	1398	O
was	24716680	1399	1402	O
associated	24716680	1403	1413	O
with	24716680	1414	1418	O
increased	24716680	1419	1428	O
serum	24716680	1429	1434	B-Outcome
creatinine	24716680	1435	1445	I-Outcome
levels	24716680	1446	1452	I-Outcome
and	24716680	1453	1456	O
a	24716680	1457	1458	O
doubling	24716680	1459	1467	O
of	24716680	1468	1470	O
the	24716680	1471	1474	O
rate	24716680	1475	1479	B-Outcome
of	24716680	1480	1482	I-Outcome
hyperkalemia	24716680	1483	1495	I-Outcome
(	24716680	1496	1497	O
18.7	24716680	1497	1501	O
%	24716680	1501	1502	O
,	24716680	1502	1503	O
vs.	24716680	1504	1507	O
9.1	24716680	1508	1511	O
%	24716680	1511	1512	O
in	24716680	1513	1515	O
the	24716680	1516	1519	O
placebo	24716680	1520	1527	O
group	24716680	1528	1533	O
)	24716680	1533	1534	O
but	24716680	1535	1538	O
reduced	24716680	1539	1546	O
hypokalemia	24716680	1547	1558	B-Outcome
.	24716680	1558	1559	O

With	24716680	1560	1564	O
frequent	24716680	1565	1573	O
monitoring	24716680	1574	1584	O
,	24716680	1584	1585	O
there	24716680	1586	1591	O
were	24716680	1592	1596	O
no	24716680	1597	1599	O
significant	24716680	1600	1611	O
differences	24716680	1612	1623	O
in	24716680	1624	1626	O
the	24716680	1627	1630	O
incidence	24716680	1631	1640	O
of	24716680	1641	1643	O
serious	24716680	1644	1651	B-Outcome
adverse	24716680	1652	1659	I-Outcome
events	24716680	1660	1666	I-Outcome
,	24716680	1666	1667	O
a	24716680	1668	1669	O
serum	24716680	1670	1675	B-Outcome
creatinine	24716680	1676	1686	I-Outcome
level	24716680	1687	1692	I-Outcome
of	24716680	1693	1695	O
3.0	24716680	1696	1699	O
mg	24716680	1700	1702	O
per	24716680	1703	1706	O
deciliter	24716680	1707	1716	O
(	24716680	1717	1718	O
265	24716680	1718	1721	O
μmol	24716680	1722	1726	O
per	24716680	1727	1730	O
liter	24716680	1731	1736	O
)	24716680	1736	1737	O
or	24716680	1738	1740	O
higher	24716680	1741	1747	O
,	24716680	1747	1748	O
or	24716680	1749	1751	O
dialysis	24716680	1752	1760	B-Outcome
.	24716680	1760	1761	O

CONCLUSIONS	24716680	1763	1774	O
:	24716680	1775	1776	O
In	24716680	1777	1779	O
patients	24716680	1780	1788	O
with	24716680	1789	1793	O
heart	24716680	1794	1799	O
failure	24716680	1800	1807	O
and	24716680	1808	1811	O
a	24716680	1812	1813	O
preserved	24716680	1814	1823	O
ejection	24716680	1824	1832	O
fraction	24716680	1833	1841	O
,	24716680	1841	1842	O
treatment	24716680	1843	1852	O
with	24716680	1853	1857	O
spironolactone	24716680	1858	1872	O
did	24716680	1873	1876	O
not	24716680	1877	1880	O
significantly	24716680	1881	1894	O
reduce	24716680	1895	1901	O
the	24716680	1902	1905	O
incidence	24716680	1906	1915	O
of	24716680	1916	1918	O
the	24716680	1919	1922	O
primary	24716680	1923	1930	O
composite	24716680	1931	1940	O
outcome	24716680	1941	1948	O
of	24716680	1949	1951	O
death	24716680	1952	1957	B-Outcome
from	24716680	1958	1962	I-Outcome
cardiovascular	24716680	1963	1977	I-Outcome
causes	24716680	1978	1984	I-Outcome
,	24716680	1984	1985	O
aborted	24716680	1986	1993	B-Outcome
cardiac	24716680	1994	2001	I-Outcome
arrest	24716680	2002	2008	I-Outcome
,	24716680	2008	2009	O
or	24716680	2010	2012	O
hospitalization	24716680	2013	2028	B-Outcome
for	24716680	2029	2032	I-Outcome
the	24716680	2033	2036	I-Outcome
management	24716680	2037	2047	I-Outcome
of	24716680	2048	2050	I-Outcome
heart	24716680	2051	2056	I-Outcome
failure	24716680	2057	2064	I-Outcome
.	24716680	2064	2065	O

(	24716680	2066	2067	O
Funded	24716680	2067	2073	O
by	24716680	2074	2076	O
the	24716680	2077	2080	O
National	24716680	2081	2089	O
Heart	24716680	2090	2095	O
,	24716680	2095	2096	O
Lung	24716680	2097	2101	O
,	24716680	2101	2102	O
and	24716680	2103	2106	O
Blood	24716680	2107	2112	O
Institute	24716680	2113	2122	O
;	24716680	2122	2123	O
TOPCAT	24716680	2124	2130	O
ClinicalTrials.gov	24716680	2131	2149	O
number	24716680	2150	2156	O
,	24716680	2156	2157	O
NCT00094302	24716680	2158	2169	O
.	24716680	2169	2170	O
)	24716680	2170	2171	O
.	24716680	2171	2172	O


Quantitative	24885187	0	12	O
measurements	24885187	13	25	O
of	24885187	26	28	O
HER2	24885187	29	33	O
and	24885187	34	37	O
phospho-HER2	24885187	38	50	O
expression	24885187	51	61	O
:	24885187	61	62	O
correlation	24885187	63	74	O
with	24885187	75	79	O
pathologic	24885187	80	90	O
response	24885187	91	99	O
to	24885187	100	102	O
neoadjuvant	24885187	103	114	O
chemotherapy	24885187	115	127	O
and	24885187	128	131	O
trastuzumab	24885187	132	143	O
.	24885187	143	144	O

BACKGROUND	24885187	146	156	O
:	24885187	157	158	O
Preoperative	24885187	159	171	O
therapy	24885187	172	179	O
with	24885187	180	184	O
chemotherapy	24885187	185	197	O
and	24885187	198	201	O
the	24885187	202	205	O
HER2-targeted	24885187	206	219	O
monoclonal	24885187	220	230	O
antibody	24885187	231	239	O
trastuzumab	24885187	240	251	O
is	24885187	252	254	O
valuable	24885187	255	263	O
for	24885187	264	267	O
patients	24885187	268	276	O
with	24885187	277	281	O
large	24885187	282	287	O
or	24885187	288	290	O
locally	24885187	291	298	O
advanced	24885187	299	307	O
HER2-positive	24885187	308	321	O
(	24885187	322	323	O
HER2	24885187	323	327	O
+	24885187	327	328	O
)	24885187	328	329	O
breast	24885187	330	336	O
cancers	24885187	337	344	O
but	24885187	345	348	O
traditional	24885187	349	360	O
methods	24885187	361	368	O
of	24885187	369	371	O
measuring	24885187	372	381	O
HER2	24885187	382	386	O
expression	24885187	387	397	O
do	24885187	398	400	O
not	24885187	401	404	O
accurately	24885187	405	415	O
stratify	24885187	416	424	O
patients	24885187	425	433	O
for	24885187	434	437	O
likelihood	24885187	438	448	O
of	24885187	449	451	O
response	24885187	452	460	O
.	24885187	460	461	O

Quantitative	24885187	462	474	O
immunofluorescent	24885187	475	492	O
approaches	24885187	493	503	O
have	24885187	504	508	O
the	24885187	509	512	O
potential	24885187	513	522	O
to	24885187	523	525	O
provide	24885187	526	533	O
a	24885187	534	535	O
mathematically	24885187	536	550	O
continuous	24885187	551	561	O
measure	24885187	562	569	O
of	24885187	570	572	O
HER2	24885187	573	577	O
.	24885187	577	578	O

Here	24885187	579	583	O
we	24885187	584	586	O
seek	24885187	587	591	O
to	24885187	592	594	O
determine	24885187	595	604	O
whether	24885187	605	612	O
quantitative	24885187	613	625	O
measurement	24885187	626	637	O
of	24885187	638	640	O
HER2	24885187	641	645	O
or	24885187	646	648	O
phospho-HER2	24885187	649	661	O
correlates	24885187	662	672	O
with	24885187	673	677	O
likelihood	24885187	678	688	O
of	24885187	689	691	O
response	24885187	692	700	O
to	24885187	701	703	O
trastuzumab-	24885187	704	716	O
containing	24885187	717	727	O
neoadjuvant	24885187	728	739	O
therapy	24885187	740	747	O
.	24885187	747	748	O

METHODS	24885187	750	757	O
:	24885187	758	759	O
We	24885187	760	762	O
evaluated	24885187	763	772	O
core	24885187	773	777	O
biopsy	24885187	778	784	O
samples	24885187	785	792	O
from	24885187	793	797	O
27	24885187	798	800	O
HER2	24885187	801	805	O
+	24885187	805	806	O
breast	24885187	807	813	O
cancer	24885187	814	820	O
patients	24885187	821	829	O
enrolled	24885187	830	838	O
in	24885187	839	841	O
a	24885187	842	843	O
preoperative	24885187	844	856	O
clinical	24885187	857	865	O
trial	24885187	866	871	O
using	24885187	872	877	O
trastuzumab	24885187	878	889	O
,	24885187	889	890	O
nab-paclitaxel	24885187	891	905	O
and	24885187	906	909	O
carboplatin	24885187	910	921	O
combination	24885187	922	933	O
therapy	24885187	934	941	O
(	24885187	942	943	O
BrUOG	24885187	943	948	O
BR-211B	24885187	949	956	O
(	24885187	957	958	O
NCT00617942	24885187	958	969	O
)	24885187	969	970	O
)	24885187	970	971	O
.	24885187	971	972	O

Tumor	24885187	973	978	O
core	24885187	979	983	O
biopsies	24885187	984	992	O
were	24885187	993	997	O
taken	24885187	998	1003	O
before	24885187	1004	1010	O
initiation	24885187	1011	1021	O
of	24885187	1022	1024	O
treatment	24885187	1025	1034	O
and	24885187	1035	1038	O
9	24885187	1039	1040	O
-	24885187	1040	1041	O
13	24885187	1041	1043	O
days	24885187	1044	1048	O
after	24885187	1049	1054	O
patients	24885187	1055	1063	O
received	24885187	1064	1072	O
"	24885187	1073	1074	O
run-in	24885187	1074	1080	O
"	24885187	1080	1081	O
doses	24885187	1082	1087	O
of	24885187	1088	1090	O
either	24885187	1091	1097	O
single	24885187	1098	1104	O
agent	24885187	1105	1110	O
trastuzumab	24885187	1111	1122	O
or	24885187	1123	1125	O
nab-paclitaxel	24885187	1126	1140	O
.	24885187	1140	1141	O

The	24885187	1142	1145	O
AQUA	24885187	1146	1150	O
method	24885187	1151	1157	O
of	24885187	1158	1160	O
quantitative	24885187	1161	1173	O
immunofluorescence	24885187	1174	1192	O
was	24885187	1193	1196	O
used	24885187	1197	1201	O
for	24885187	1202	1205	O
analysis	24885187	1206	1214	O
of	24885187	1215	1217	O
in	24885187	1218	1220	O
situ	24885187	1221	1225	O
protein	24885187	1226	1233	O
expression	24885187	1234	1244	O
.	24885187	1244	1245	O

Patients	24885187	1246	1254	O
then	24885187	1255	1259	O
received	24885187	1260	1268	O
18	24885187	1269	1271	O
weeks	24885187	1272	1277	O
of	24885187	1278	1280	O
treatment	24885187	1281	1290	O
,	24885187	1290	1291	O
followed	24885187	1292	1300	O
by	24885187	1301	1303	O
surgery	24885187	1304	1311	O
to	24885187	1312	1314	O
assess	24885187	1315	1321	O
pathologic	24885187	1322	1332	O
response	24885187	1333	1341	O
to	24885187	1342	1344	O
the	24885187	1345	1348	O
neoadjuvant	24885187	1349	1360	O
regimen	24885187	1361	1368	O
.	24885187	1368	1369	O

RESULTS	24885187	1371	1378	O
:	24885187	1379	1380	O
A	24885187	1381	1382	O
HER2	24885187	1383	1387	O
score	24885187	1388	1393	O
of	24885187	1394	1396	O
2111	24885187	1397	1401	O
by	24885187	1402	1404	O
AQUA	24885187	1405	1409	O
analysis	24885187	1410	1418	O
has	24885187	1419	1422	O
been	24885187	1423	1427	O
shown	24885187	1428	1433	O
to	24885187	1434	1436	O
be	24885187	1437	1439	O
equivalent	24885187	1440	1450	O
to	24885187	1451	1453	O
HER2	24885187	1454	1458	O
3	24885187	1459	1460	O
+	24885187	1460	1461	O
by	24885187	1462	1464	O
immunohistochemical	24885187	1465	1484	O
staining	24885187	1485	1493	O
in	24885187	1494	1496	O
previous	24885187	1497	1505	O
studies	24885187	1506	1513	O
.	24885187	1513	1514	O

Of	24885187	1515	1517	O
20	24885187	1518	1520	O
evaluable	24885187	1521	1530	O
patients	24885187	1531	1539	O
,	24885187	1539	1540	O
10	24885187	1541	1543	O
cases	24885187	1544	1549	O
who	24885187	1550	1553	O
achieved	24885187	1554	1562	O
a	24885187	1563	1564	O
pathologic	24885187	1565	1575	B-Outcome
complete	24885187	1576	1584	I-Outcome
response	24885187	1585	1593	I-Outcome
(	24885187	1594	1595	O
pathCR	24885187	1595	1601	B-Outcome
)	24885187	1601	1602	O
with	24885187	1603	1607	O
neoadjuvant	24885187	1608	1619	O
treatment	24885187	1620	1629	O
had	24885187	1630	1633	O
a	24885187	1634	1635	O
mean	24885187	1636	1640	B-Outcome
HER2	24885187	1641	1645	I-Outcome
level	24885187	1646	1651	I-Outcome
of	24885187	1652	1654	O
10251	24885187	1655	1660	O
compared	24885187	1661	1669	O
with	24885187	1670	1674	O
4766	24885187	1675	1679	O
in	24885187	1680	1682	O
the	24885187	1683	1686	O
patients	24885187	1687	1695	O
without	24885187	1696	1703	O
pathCR	24885187	1704	1710	O
(	24885187	1711	1712	O
p	24885187	1712	1713	O
=	24885187	1714	1715	O
0.0021	24885187	1716	1722	O
)	24885187	1722	1723	O
.	24885187	1723	1724	O

Measurement	24885187	1725	1736	O
of	24885187	1737	1739	O
phospho-HER2	24885187	1740	1752	B-Outcome
showed	24885187	1753	1759	O
no	24885187	1760	1762	O
difference	24885187	1763	1773	O
in	24885187	1774	1776	O
pathCR	24885187	1777	1783	B-Outcome
vs	24885187	1784	1786	O
non-pathCR	24885187	1787	1797	B-Outcome
groups	24885187	1798	1804	O
.	24885187	1804	1805	O

In	24885187	1806	1808	O
9	24885187	1809	1810	O
patients	24885187	1811	1819	O
who	24885187	1820	1823	O
had	24885187	1824	1827	O
HER2	24885187	1828	1832	O
levels	24885187	1833	1839	O
repeated	24885187	1840	1848	O
after	24885187	1849	1854	O
a	24885187	1855	1856	O
single	24885187	1857	1863	O
treatment	24885187	1864	1873	O
with	24885187	1874	1878	O
trastuzumab	24885187	1879	1890	O
there	24885187	1891	1896	O
was	24885187	1897	1900	O
no	24885187	1901	1903	O
evidence	24885187	1904	1912	O
of	24885187	1913	1915	O
a	24885187	1916	1917	O
reduction	24885187	1918	1927	O
in	24885187	1928	1930	O
the	24885187	1931	1934	O
HER2	24885187	1935	1939	B-Outcome
or	24885187	1940	1942	O
phospho-HER2	24885187	1943	1955	B-Outcome
levels	24885187	1956	1962	I-Outcome
following	24885187	1963	1972	O
that	24885187	1973	1977	O
exposure	24885187	1978	1986	O
.	24885187	1986	1987	O

CONCLUSIONS	24885187	1989	2000	O
:	24885187	2001	2002	O
High	24885187	2003	2007	O
levels	24885187	2008	2014	B-Outcome
of	24885187	2015	2017	I-Outcome
HER2	24885187	2018	2022	I-Outcome
are	24885187	2023	2026	O
associated	24885187	2027	2037	O
with	24885187	2038	2042	O
achievement	24885187	2043	2054	O
of	24885187	2055	2057	O
a	24885187	2058	2059	O
pathCR	24885187	2060	2066	B-Outcome
in	24885187	2067	2069	O
the	24885187	2070	2073	O
preoperative	24885187	2074	2086	O
setting	24885187	2087	2094	O
,	24885187	2094	2095	O
while	24885187	2096	2101	O
levels	24885187	2102	2108	B-Outcome
of	24885187	2109	2111	I-Outcome
Phospho-HER2	24885187	2112	2124	I-Outcome
were	24885187	2125	2129	O
not	24885187	2130	2133	O
predictive	24885187	2134	2144	O
of	24885187	2145	2147	O
response	24885187	2148	2156	O
.	24885187	2156	2157	O

This	24885187	2158	2162	O
data	24885187	2163	2167	O
suggests	24885187	2168	2176	O
that	24885187	2177	2181	O
accurate	24885187	2182	2190	O
measurement	24885187	2191	2202	O
of	24885187	2203	2205	O
HER2	24885187	2206	2210	B-Outcome
may	24885187	2211	2214	O
help	24885187	2215	2219	O
determine	24885187	2220	2229	O
the	24885187	2230	2233	O
likelihood	24885187	2234	2244	O
of	24885187	2245	2247	O
response	24885187	2248	2256	O
in	24885187	2257	2259	O
the	24885187	2260	2263	O
pre-surgical	24885187	2264	2276	O
setting	24885187	2277	2284	O
.	24885187	2284	2285	O

Further	24885187	2286	2293	O
validation	24885187	2294	2304	O
in	24885187	2305	2307	O
larger	24885187	2308	2314	O
cohorts	24885187	2315	2322	O
is	24885187	2323	2325	O
required	24885187	2326	2334	O
,	24885187	2334	2335	O
but	24885187	2336	2339	O
this	24885187	2340	2344	O
pilot	24885187	2345	2350	O
data	24885187	2351	2355	O
shows	24885187	2356	2361	O
the	24885187	2362	2365	O
feasibility	24885187	2366	2377	O
of	24885187	2378	2380	O
this	24885187	2381	2385	O
approach	24885187	2386	2394	O
.	24885187	2394	2395	O


36-month	24926950	0	8	O
treatment	24926950	9	18	O
experience	24926950	19	29	O
of	24926950	30	32	O
two	24926950	33	36	O
doses	24926950	37	42	O
of	24926950	43	45	O
leuprolide	24926950	46	56	O
acetate	24926950	57	64	O
3-month	24926950	65	72	O
depot	24926950	73	78	O
for	24926950	79	82	O
children	24926950	83	91	O
with	24926950	92	96	O
central	24926950	97	104	O
precocious	24926950	105	115	O
puberty	24926950	116	123	O
.	24926950	123	124	O

CONTEXT	24926950	126	133	O
:	24926950	134	135	O
We	24926950	136	138	O
have	24926950	139	143	O
recently	24926950	144	152	O
demonstrated	24926950	153	165	O
short-term	24926950	166	176	O
(	24926950	177	178	O
6-month	24926950	178	185	O
)	24926950	185	186	O
efficacy	24926950	187	195	O
and	24926950	196	199	O
safety	24926950	200	206	O
of	24926950	207	209	O
leuprolide	24926950	210	220	O
acetate	24926950	221	228	O
3-month	24926950	229	236	O
depot	24926950	237	242	O
11.25	24926950	243	248	O
and	24926950	249	252	O
30	24926950	253	255	O
mg	24926950	256	258	O
in	24926950	259	261	O
children	24926950	262	270	O
with	24926950	271	275	O
central	24926950	276	283	O
precocious	24926950	284	294	O
puberty	24926950	295	302	O
(	24926950	303	304	O
CPP	24926950	304	307	O
)	24926950	307	308	O
.	24926950	308	309	O

OBJECTIVE	24926950	311	320	O
:	24926950	321	322	O
To	24926950	323	325	O
assess	24926950	326	332	O
long-term	24926950	333	342	O
(	24926950	343	344	O
36-month	24926950	344	352	O
)	24926950	352	353	O
hypothalamic-pituitary-gonadal	24926950	354	384	O
axis	24926950	385	389	O
suppression	24926950	390	401	O
and	24926950	402	405	O
safety	24926950	406	412	O
of	24926950	413	415	O
leuprolide	24926950	416	426	O
acetate	24926950	427	434	O
3-month	24926950	435	442	O
depot	24926950	443	448	O
11.25	24926950	449	454	O
and	24926950	455	458	O
30	24926950	459	461	O
mg	24926950	462	464	O
in	24926950	465	467	O
children	24926950	468	476	O
with	24926950	477	481	O
CPP	24926950	482	485	O
.	24926950	485	486	O

DESIGN	24926950	488	494	O
:	24926950	495	496	O
Open-label	24926950	497	507	O
,	24926950	507	508	O
36-month	24926950	509	517	O
extension	24926950	518	527	O
.	24926950	527	528	O

SETTING	24926950	530	537	O
:	24926950	538	539	O
Twenty	24926950	540	546	O
pediatric	24926950	547	556	O
endocrine	24926950	557	566	O
centers	24926950	567	574	O
.	24926950	574	575	O

PATIENTS	24926950	577	585	O
:	24926950	586	587	O
Seventy-two	24926950	588	599	O
children	24926950	600	608	O
(	24926950	609	610	O
mean	24926950	610	614	O
age	24926950	615	618	O
,	24926950	618	619	O
8.5	24926950	620	623	O
±	24926950	624	625	O
1.6	24926950	626	629	O
y	24926950	630	631	O
;	24926950	631	632	O
65	24926950	633	635	O
females	24926950	636	643	O
)	24926950	643	644	O
with	24926950	645	649	O
CPP	24926950	650	653	O
completed	24926950	654	663	O
and	24926950	664	667	O
showed	24926950	668	674	O
maintenance	24926950	675	686	O
of	24926950	687	689	O
LH	24926950	690	692	O
suppression	24926950	693	704	O
after	24926950	705	710	O
a	24926950	711	712	O
6-month	24926950	713	720	O
lead-in	24926950	721	728	O
study	24926950	729	734	O
.	24926950	734	735	O

INTERVENTION	24926950	737	749	O
:	24926950	750	751	O
Leuprolide	24926950	752	762	O
acetate	24926950	763	770	O
depot	24926950	771	776	O
(	24926950	777	778	O
11.25	24926950	778	783	O
or	24926950	784	786	O
30	24926950	787	789	O
mg	24926950	790	792	O
)	24926950	792	793	O
administered	24926950	794	806	O
i	24926950	807	808	O
m	24926950	808	809	O
every	24926950	810	815	O
3	24926950	816	817	O
months	24926950	818	824	O
.	24926950	824	825	O

MAIN	24926950	827	831	O
OUTCOME	24926950	832	839	O
MEASURES	24926950	840	848	O
:	24926950	849	850	O
Peak-stimulated	24926950	851	866	O
LH	24926950	867	869	O
,	24926950	869	870	O
estradiol	24926950	871	880	O
,	24926950	880	881	O
T	24926950	882	883	O
,	24926950	883	884	O
growth	24926950	885	891	O
rate	24926950	892	896	O
,	24926950	896	897	O
pubertal	24926950	898	906	O
progression	24926950	907	918	O
,	24926950	918	919	O
and	24926950	920	923	O
adverse	24926950	924	931	O
events	24926950	932	938	O
(	24926950	939	940	O
AEs	24926950	940	943	O
)	24926950	943	944	O
.	24926950	944	945	O

RESULTS	24926950	947	954	O
:	24926950	955	956	O
Twenty-nine	24926950	957	968	O
of	24926950	969	971	O
34	24926950	972	974	O
subjects	24926950	975	983	O
in	24926950	984	986	O
the	24926950	987	990	O
11.25-mg	24926950	991	999	O
group	24926950	1000	1005	O
and	24926950	1006	1009	O
36	24926950	1010	1012	O
of	24926950	1013	1015	O
38	24926950	1016	1018	O
subjects	24926950	1019	1027	O
in	24926950	1028	1030	O
the	24926950	1031	1034	O
30-mg	24926950	1035	1040	O
group	24926950	1041	1046	O
had	24926950	1047	1050	O
LH	24926950	1051	1053	B-Outcome
values	24926950	1054	1060	I-Outcome
<	24926950	1061	1062	O
4	24926950	1063	1064	O
mIU/mL	24926950	1065	1071	O
after	24926950	1072	1077	O
day	24926950	1078	1081	O
1	24926950	1082	1083	O
at	24926950	1084	1086	O
all	24926950	1087	1090	O
time	24926950	1091	1095	O
points	24926950	1096	1102	O
.	24926950	1102	1103	O

All	24926950	1104	1107	O
seven	24926950	1108	1113	O
subjects	24926950	1114	1122	O
who	24926950	1123	1126	O
escaped	24926950	1127	1134	O
LH	24926950	1135	1137	B-Outcome
suppression	24926950	1138	1149	I-Outcome
at	24926950	1150	1152	O
any	24926950	1153	1156	O
time	24926950	1157	1161	O
still	24926950	1162	1167	O
maintained	24926950	1168	1178	O
sex	24926950	1179	1182	B-Outcome
steroid	24926950	1183	1190	I-Outcome
concentrations	24926950	1191	1205	I-Outcome
at	24926950	1206	1208	O
prepubertal	24926950	1209	1220	O
levels	24926950	1221	1227	O
and	24926950	1228	1231	O
showed	24926950	1232	1238	O
no	24926950	1239	1241	O
signs	24926950	1242	1247	O
of	24926950	1248	1250	O
pubertal	24926950	1251	1259	B-Outcome
progression	24926950	1260	1271	I-Outcome
.	24926950	1271	1272	O

AEs	24926950	1273	1276	B-Outcome
were	24926950	1277	1281	O
comparable	24926950	1282	1292	O
between	24926950	1293	1300	O
groups	24926950	1301	1307	O
,	24926950	1307	1308	O
with	24926950	1309	1313	O
injection	24926950	1314	1323	O
site	24926950	1324	1328	O
pain	24926950	1329	1333	O
being	24926950	1334	1339	O
the	24926950	1340	1343	O
most	24926950	1344	1348	O
common	24926950	1349	1355	O
(	24926950	1356	1357	O
26.4	24926950	1357	1361	O
%	24926950	1361	1362	O
overall	24926950	1363	1370	O
)	24926950	1370	1371	O
.	24926950	1371	1372	O

No	24926950	1373	1375	O
AE	24926950	1376	1378	B-Outcome
led	24926950	1379	1382	O
to	24926950	1383	1385	O
discontinuation	24926950	1386	1401	O
of	24926950	1402	1404	O
study	24926950	1405	1410	O
drug	24926950	1411	1415	O
.	24926950	1415	1416	O

The	24926950	1417	1420	O
safety	24926950	1421	1427	B-Outcome
profile	24926950	1428	1435	O
over	24926950	1436	1440	O
36	24926950	1441	1443	O
months	24926950	1444	1450	O
was	24926950	1451	1454	O
comparable	24926950	1455	1465	O
to	24926950	1466	1468	O
that	24926950	1469	1473	O
observed	24926950	1474	1482	O
during	24926950	1483	1489	O
the	24926950	1490	1493	O
6-month	24926950	1494	1501	O
pivotal	24926950	1502	1509	O
study	24926950	1510	1515	O
.	24926950	1515	1516	O

CONCLUSIONS	24926950	1518	1529	O
:	24926950	1530	1531	O
The	24926950	1532	1535	O
two	24926950	1536	1539	O
doses	24926950	1540	1545	O
of	24926950	1546	1548	O
leuprolide	24926950	1549	1559	O
acetate	24926950	1560	1567	O
3-month	24926950	1568	1575	O
depot	24926950	1576	1581	O
were	24926950	1582	1586	O
associated	24926950	1587	1597	O
with	24926950	1598	1602	O
an	24926950	1603	1605	O
acceptable	24926950	1606	1616	O
safety	24926950	1617	1623	B-Outcome
profile	24926950	1624	1631	O
and	24926950	1632	1635	O
provided	24926950	1636	1644	O
maintenance	24926950	1645	1656	O
of	24926950	1657	1659	O
LH	24926950	1660	1662	B-Outcome
suppression	24926950	1663	1674	I-Outcome
in	24926950	1675	1677	O
the	24926950	1678	1681	O
majority	24926950	1682	1690	O
of	24926950	1691	1693	O
children	24926950	1694	1702	O
with	24926950	1703	1707	O
CPP	24926950	1708	1711	O
during	24926950	1712	1718	O
the	24926950	1719	1722	O
36	24926950	1723	1725	O
months	24926950	1726	1732	O
of	24926950	1733	1735	O
the	24926950	1736	1739	O
study	24926950	1740	1745	O
or	24926950	1746	1748	O
until	24926950	1749	1754	O
readiness	24926950	1755	1764	O
for	24926950	1765	1768	O
puberty	24926950	1769	1776	O
.	24926950	1776	1777	O


Effect	24938562	0	6	O
of	24938562	7	9	O
selumetinib	24938562	10	21	O
vs	24938562	22	24	O
chemotherapy	24938562	25	37	O
on	24938562	38	40	O
progression-free	24938562	41	57	O
survival	24938562	58	66	O
in	24938562	67	69	O
uveal	24938562	70	75	O
melanoma	24938562	76	84	O
:	24938562	84	85	O
a	24938562	86	87	O
randomized	24938562	88	98	O
clinical	24938562	99	107	O
trial	24938562	108	113	O
.	24938562	113	114	O

IMPORTANCE	24938562	116	126	O
:	24938562	127	128	O
Uveal	24938562	129	134	O
melanoma	24938562	135	143	O
is	24938562	144	146	O
characterized	24938562	147	160	O
by	24938562	161	163	O
mutations	24938562	164	173	O
in	24938562	174	176	O
GNAQ	24938562	177	181	O
and	24938562	182	185	O
GNA11	24938562	186	191	O
,	24938562	191	192	O
resulting	24938562	193	202	O
in	24938562	203	205	O
mitogen-activated	24938562	206	223	O
protein	24938562	224	231	O
kinase	24938562	232	238	O
pathway	24938562	239	246	O
activation	24938562	247	257	O
.	24938562	257	258	O

OBJECTIVE	24938562	260	269	O
:	24938562	270	271	O
To	24938562	272	274	O
assess	24938562	275	281	O
the	24938562	282	285	O
efficacy	24938562	286	294	O
of	24938562	295	297	O
selumetinib	24938562	298	309	O
,	24938562	309	310	O
a	24938562	311	312	O
selective	24938562	313	322	O
,	24938562	322	323	O
non-adenosine	24938562	324	337	O
triphosphate	24938562	338	350	O
competitive	24938562	351	362	O
inhibitor	24938562	363	372	O
of	24938562	373	375	O
MEK1	24938562	376	380	O
and	24938562	381	384	O
MEK2	24938562	385	389	O
,	24938562	389	390	O
in	24938562	391	393	O
uveal	24938562	394	399	O
melanoma	24938562	400	408	O
.	24938562	408	409	O

DESIGN	24938562	411	417	O
,	24938562	417	418	O
SETTING	24938562	419	426	O
,	24938562	426	427	O
AND	24938562	428	431	O
PARTICIPANTS	24938562	432	444	O
:	24938562	445	446	O
Randomized	24938562	447	457	O
,	24938562	457	458	O
open-label	24938562	459	469	O
,	24938562	469	470	O
phase	24938562	471	476	O
2	24938562	477	478	O
clinical	24938562	479	487	O
trial	24938562	488	493	O
comparing	24938562	494	503	O
selumetinib	24938562	504	515	O
vs	24938562	516	518	O
chemotherapy	24938562	519	531	O
conducted	24938562	532	541	O
from	24938562	542	546	O
August	24938562	547	553	O
2010	24938562	554	558	O
through	24938562	559	566	O
December	24938562	567	575	O
2013	24938562	576	580	O
among	24938562	581	586	O
120	24938562	587	590	O
patients	24938562	591	599	O
with	24938562	600	604	O
metastatic	24938562	605	615	O
uveal	24938562	616	621	O
melanoma	24938562	622	630	O
at	24938562	631	633	O
15	24938562	634	636	O
academic	24938562	637	645	O
oncology	24938562	646	654	O
centers	24938562	655	662	O
in	24938562	663	665	O
the	24938562	666	669	O
United	24938562	670	676	O
States	24938562	677	683	O
and	24938562	684	687	O
Canada	24938562	688	694	O
.	24938562	694	695	O

INTERVENTIONS	24938562	697	710	O
:	24938562	711	712	O
One	24938562	713	716	O
hundred	24938562	717	724	O
one	24938562	725	728	O
patients	24938562	729	737	O
were	24938562	738	742	O
randomized	24938562	743	753	O
in	24938562	754	756	O
a	24938562	757	758	O
1:1	24938562	759	762	O
ratio	24938562	763	768	O
to	24938562	769	771	O
receive	24938562	772	779	O
selumetinib	24938562	780	791	O
,	24938562	791	792	O
75	24938562	793	795	O
mg	24938562	796	798	O
orally	24938562	799	805	O
twice	24938562	806	811	O
daily	24938562	812	817	O
on	24938562	818	820	O
a	24938562	821	822	O
continual	24938562	823	832	O
basis	24938562	833	838	O
(	24938562	839	840	O
n	24938562	840	841	O
=	24938562	842	843	O
50	24938562	844	846	O
)	24938562	846	847	O
,	24938562	847	848	O
or	24938562	849	851	O
chemotherapy	24938562	852	864	O
(	24938562	865	866	O
temozolomide	24938562	866	878	O
,	24938562	878	879	O
150	24938562	880	883	O
mg/m2	24938562	884	889	O
orally	24938562	890	896	O
daily	24938562	897	902	O
for	24938562	903	906	O
5	24938562	907	908	O
of	24938562	909	911	O
every	24938562	912	917	O
28	24938562	918	920	O
days	24938562	921	925	O
,	24938562	925	926	O
or	24938562	927	929	O
dacarbazine	24938562	930	941	O
,	24938562	941	942	O
1000	24938562	943	947	O
mg/m2	24938562	948	953	O
intravenously	24938562	954	967	O
every	24938562	968	973	O
21	24938562	974	976	O
days	24938562	977	981	O
[	24938562	982	983	O
investigator	24938562	983	995	O
choice	24938562	996	1002	O
]	24938562	1002	1003	O
;	24938562	1003	1004	O
n	24938562	1005	1006	O
=	24938562	1007	1008	O
51	24938562	1009	1011	O
)	24938562	1011	1012	O
until	24938562	1013	1018	O
disease	24938562	1019	1026	O
progression	24938562	1027	1038	O
,	24938562	1038	1039	O
death	24938562	1040	1045	O
,	24938562	1045	1046	O
intolerable	24938562	1047	1058	O
adverse	24938562	1059	1066	O
effects	24938562	1067	1074	O
,	24938562	1074	1075	O
or	24938562	1076	1078	O
withdrawal	24938562	1079	1089	O
of	24938562	1090	1092	O
consent	24938562	1093	1100	O
.	24938562	1100	1101	O

After	24938562	1102	1107	O
primary	24938562	1108	1115	O
outcome	24938562	1116	1123	O
analysis	24938562	1124	1132	O
,	24938562	1132	1133	O
19	24938562	1134	1136	O
patients	24938562	1137	1145	O
were	24938562	1146	1150	O
registered	24938562	1151	1161	O
and	24938562	1162	1165	O
18	24938562	1166	1168	O
treated	24938562	1169	1176	O
with	24938562	1177	1181	O
selumetinib	24938562	1182	1193	O
without	24938562	1194	1201	O
randomization	24938562	1202	1215	O
to	24938562	1216	1218	O
complete	24938562	1219	1227	O
the	24938562	1228	1231	O
planned	24938562	1232	1239	O
120-patient	24938562	1240	1251	O
enrollment	24938562	1252	1262	O
.	24938562	1262	1263	O

Patients	24938562	1264	1272	O
in	24938562	1273	1275	O
the	24938562	1276	1279	O
chemotherapy	24938562	1280	1292	O
group	24938562	1293	1298	O
could	24938562	1299	1304	O
receive	24938562	1305	1312	O
selumetinib	24938562	1313	1324	O
at	24938562	1325	1327	O
the	24938562	1328	1331	O
time	24938562	1332	1336	O
of	24938562	1337	1339	O
radiographic	24938562	1340	1352	O
progression	24938562	1353	1364	O
.	24938562	1364	1365	O

MAIN	24938562	1367	1371	O
OUTCOMES	24938562	1372	1380	O
AND	24938562	1381	1384	O
MEASURES	24938562	1385	1393	O
:	24938562	1394	1395	O
Progression-free	24938562	1396	1412	O
survival	24938562	1413	1421	O
,	24938562	1421	1422	O
the	24938562	1423	1426	O
primary	24938562	1427	1434	O
end	24938562	1435	1438	O
point	24938562	1439	1444	O
,	24938562	1444	1445	O
was	24938562	1446	1449	O
assessed	24938562	1450	1458	O
as	24938562	1459	1461	O
of	24938562	1462	1464	O
April	24938562	1465	1470	O
22	24938562	1471	1473	O
,	24938562	1473	1474	O
2013	24938562	1475	1479	O
.	24938562	1479	1480	O

Additional	24938562	1481	1491	O
end	24938562	1492	1495	O
points	24938562	1496	1502	O
,	24938562	1502	1503	O
including	24938562	1504	1513	O
overall	24938562	1514	1521	O
survival	24938562	1522	1530	O
,	24938562	1530	1531	O
response	24938562	1532	1540	O
rate	24938562	1541	1545	O
,	24938562	1545	1546	O
and	24938562	1547	1550	O
safety/toxicity	24938562	1551	1566	O
,	24938562	1566	1567	O
were	24938562	1568	1572	O
assessed	24938562	1573	1581	O
as	24938562	1582	1584	O
of	24938562	1585	1587	O
December	24938562	1588	1596	O
31	24938562	1597	1599	O
,	24938562	1599	1600	O
2013	24938562	1601	1605	O
.	24938562	1605	1606	O

RESULTS	24938562	1608	1615	O
:	24938562	1616	1617	O
Median	24938562	1618	1624	B-Outcome
progression-free	24938562	1625	1641	I-Outcome
survival	24938562	1642	1650	I-Outcome
among	24938562	1651	1656	O
patients	24938562	1657	1665	O
randomized	24938562	1666	1676	O
to	24938562	1677	1679	O
chemotherapy	24938562	1680	1692	O
was	24938562	1693	1696	O
7	24938562	1697	1698	O
weeks	24938562	1699	1704	O
(	24938562	1705	1706	O
95	24938562	1706	1708	O
%	24938562	1708	1709	O
CI	24938562	1710	1712	O
,	24938562	1712	1713	O
4.3	24938562	1714	1717	O
-	24938562	1717	1718	O
8.4	24938562	1718	1721	O
weeks	24938562	1722	1727	O
;	24938562	1727	1728	O
median	24938562	1729	1735	B-Outcome
treatment	24938562	1736	1745	I-Outcome
duration	24938562	1746	1754	I-Outcome
,	24938562	1754	1755	O
8	24938562	1756	1757	O
weeks	24938562	1758	1763	O
;	24938562	1763	1764	O
interquartile	24938562	1765	1778	O
range	24938562	1779	1784	O
[	24938562	1785	1786	O
IQR	24938562	1786	1789	O
]	24938562	1789	1790	O
,	24938562	1790	1791	O
4.3	24938562	1792	1795	O
-	24938562	1795	1796	O
16	24938562	1796	1798	O
weeks	24938562	1799	1804	O
)	24938562	1804	1805	O
and	24938562	1806	1809	O
among	24938562	1810	1815	O
those	24938562	1816	1821	O
randomized	24938562	1822	1832	O
to	24938562	1833	1835	O
selumetinib	24938562	1836	1847	O
was	24938562	1848	1851	O
15.9	24938562	1852	1856	O
weeks	24938562	1857	1862	O
(	24938562	1863	1864	O
95	24938562	1864	1866	O
%	24938562	1866	1867	O
CI	24938562	1868	1870	O
,	24938562	1870	1871	O
8.4	24938562	1872	1875	O
-	24938562	1875	1876	O
21.1	24938562	1876	1880	O
weeks	24938562	1881	1886	O
;	24938562	1886	1887	O
median	24938562	1888	1894	B-Outcome
treatment	24938562	1895	1904	I-Outcome
duration	24938562	1905	1913	I-Outcome
,	24938562	1913	1914	O
16.1	24938562	1915	1919	O
weeks	24938562	1920	1925	O
;	24938562	1925	1926	O
IQR	24938562	1927	1930	O
,	24938562	1930	1931	O
8.1	24938562	1932	1935	O
-	24938562	1935	1936	O
25.3	24938562	1936	1940	O
weeks	24938562	1941	1946	O
)	24938562	1946	1947	O
(	24938562	1948	1949	O
hazard	24938562	1949	1955	O
ratio	24938562	1956	1961	O
,	24938562	1961	1962	O
0.46	24938562	1963	1967	O
;	24938562	1967	1968	O
95	24938562	1969	1971	O
%	24938562	1971	1972	O
CI	24938562	1973	1975	O
,	24938562	1975	1976	O
0.30	24938562	1977	1981	O
-	24938562	1981	1982	O
0.71	24938562	1982	1986	O
;	24938562	1986	1987	O
P	24938562	1988	1989	O
<	24938562	1990	1991	O
.001	24938562	1992	1996	O
)	24938562	1996	1997	O
.	24938562	1997	1998	O

Median	24938562	1999	2005	B-Outcome
overall	24938562	2006	2013	I-Outcome
survival	24938562	2014	2022	I-Outcome
time	24938562	2023	2027	I-Outcome
was	24938562	2028	2031	O
9.1	24938562	2032	2035	O
months	24938562	2036	2042	O
(	24938562	2043	2044	O
95	24938562	2044	2046	O
%	24938562	2046	2047	O
CI	24938562	2048	2050	O
,	24938562	2050	2051	O
6.1	24938562	2052	2055	O
-	24938562	2055	2056	O
11.1	24938562	2056	2060	O
months	24938562	2061	2067	O
)	24938562	2067	2068	O
with	24938562	2069	2073	O
chemotherapy	24938562	2074	2086	O
and	24938562	2087	2090	O
11.8	24938562	2091	2095	O
months	24938562	2096	2102	O
(	24938562	2103	2104	O
95	24938562	2104	2106	O
%	24938562	2106	2107	O
CI	24938562	2108	2110	O
,	24938562	2110	2111	O
9.8	24938562	2112	2115	O
-	24938562	2115	2116	O
15.7	24938562	2116	2120	O
months	24938562	2121	2127	O
)	24938562	2127	2128	O
with	24938562	2129	2133	O
selumetinib	24938562	2134	2145	O
(	24938562	2146	2147	O
hazard	24938562	2147	2153	O
ratio	24938562	2154	2159	O
,	24938562	2159	2160	O
0.66	24938562	2161	2165	O
;	24938562	2165	2166	O
95	24938562	2167	2169	O
%	24938562	2169	2170	O
CI	24938562	2171	2173	O
,	24938562	2173	2174	O
0.41	24938562	2175	2179	O
-	24938562	2179	2180	O
1.06	24938562	2180	2184	O
;	24938562	2184	2185	O
P	24938562	2186	2187	O
=	24938562	2188	2189	O
.09	24938562	2190	2193	O
)	24938562	2193	2194	O
.	24938562	2194	2195	O

No	24938562	2196	2198	O
objective	24938562	2199	2208	B-Outcome
responses	24938562	2209	2218	I-Outcome
were	24938562	2219	2223	O
observed	24938562	2224	2232	O
with	24938562	2233	2237	O
chemotherapy	24938562	2238	2250	O
.	24938562	2250	2251	O

Forty-nine	24938562	2252	2262	O
percent	24938562	2263	2270	O
of	24938562	2271	2273	O
patients	24938562	2274	2282	O
treated	24938562	2283	2290	O
with	24938562	2291	2295	O
selumetinib	24938562	2296	2307	O
achieved	24938562	2308	2316	O
tumor	24938562	2317	2322	B-Outcome
regression	24938562	2323	2333	I-Outcome
,	24938562	2333	2334	O
with	24938562	2335	2339	O
14	24938562	2340	2342	O
%	24938562	2342	2343	O
achieving	24938562	2344	2353	O
an	24938562	2354	2356	O
objective	24938562	2357	2366	B-Outcome
radiographic	24938562	2367	2379	I-Outcome
response	24938562	2380	2388	I-Outcome
to	24938562	2389	2391	I-Outcome
therapy	24938562	2392	2399	I-Outcome
.	24938562	2399	2400	O

Treatment-related	24938562	2401	2418	B-Outcome
adverse	24938562	2419	2426	I-Outcome
events	24938562	2427	2433	I-Outcome
were	24938562	2434	2438	O
observed	24938562	2439	2447	O
in	24938562	2448	2450	O
97	24938562	2451	2453	O
%	24938562	2453	2454	O
of	24938562	2455	2457	O
patients	24938562	2458	2466	O
treated	24938562	2467	2474	O
with	24938562	2475	2479	O
selumetinib	24938562	2480	2491	O
,	24938562	2491	2492	O
with	24938562	2493	2497	O
37	24938562	2498	2500	O
%	24938562	2500	2501	O
requiring	24938562	2502	2511	O
at	24938562	2512	2514	O
least	24938562	2515	2520	O
1	24938562	2521	2522	O
dose	24938562	2523	2527	B-Outcome
reduction	24938562	2528	2537	I-Outcome
.	24938562	2537	2538	O

CONCLUSIONS	24938562	2540	2551	O
AND	24938562	2552	2555	O
RELEVANCE	24938562	2556	2565	O
:	24938562	2566	2567	O
In	24938562	2568	2570	O
this	24938562	2571	2575	O
hypothesis-generating	24938562	2576	2597	O
study	24938562	2598	2603	O
of	24938562	2604	2606	O
patients	24938562	2607	2615	O
with	24938562	2616	2620	O
advanced	24938562	2621	2629	O
uveal	24938562	2630	2635	O
melanoma	24938562	2636	2644	O
,	24938562	2644	2645	O
selumetinib	24938562	2646	2657	O
compared	24938562	2658	2666	O
with	24938562	2667	2671	O
chemotherapy	24938562	2672	2684	O
resulted	24938562	2685	2693	O
in	24938562	2694	2696	O
a	24938562	2697	2698	O
modestly	24938562	2699	2707	O
improved	24938562	2708	2716	O
progression-free	24938562	2717	2733	B-Outcome
survival	24938562	2734	2742	I-Outcome
and	24938562	2743	2746	O
response	24938562	2747	2755	B-Outcome
rate	24938562	2756	2760	I-Outcome
;	24938562	2760	2761	O
however	24938562	2762	2769	O
,	24938562	2769	2770	O
no	24938562	2771	2773	O
improvement	24938562	2774	2785	O
in	24938562	2786	2788	O
overall	24938562	2789	2796	B-Outcome
survival	24938562	2797	2805	I-Outcome
was	24938562	2806	2809	O
observed	24938562	2810	2818	O
.	24938562	2818	2819	O

Improvement	24938562	2820	2831	O
in	24938562	2832	2834	O
clinical	24938562	2835	2843	B-Outcome
outcomes	24938562	2844	2852	I-Outcome
was	24938562	2853	2856	O
accompanied	24938562	2857	2868	O
by	24938562	2869	2871	O
a	24938562	2872	2873	O
high	24938562	2874	2878	O
rate	24938562	2879	2883	O
of	24938562	2884	2886	O
adverse	24938562	2887	2894	B-Outcome
events	24938562	2895	2901	I-Outcome
.	24938562	2901	2902	O

TRIAL	24938562	2904	2909	O
REGISTRATION	24938562	2910	2922	O
:	24938562	2923	2924	O
clinicaltrials.gov	24938562	2925	2943	O
Identifier	24938562	2944	2954	O
:	24938562	2954	2955	O
NCT01143402	24938562	2956	2967	O
.	24938562	2967	2968	O


The	24986270	0	3	O
effects	24986270	4	11	O
of	24986270	12	14	O
two	24986270	15	18	O
Chinese	24986270	19	26	O
herbal	24986270	27	33	O
medicinal	24986270	34	43	O
formulae	24986270	44	52	O
vs.	24986270	53	56	O
placebo	24986270	57	64	O
controls	24986270	65	73	O
for	24986270	74	77	O
treatment	24986270	78	87	O
of	24986270	88	90	O
allergic	24986270	91	99	O
rhinitis	24986270	100	108	O
:	24986270	108	109	O
a	24986270	110	111	O
randomised	24986270	112	122	O
controlled	24986270	123	133	O
trial	24986270	134	139	O
.	24986270	139	140	O

BACKGROUND	24986270	142	152	O
:	24986270	153	154	O
Allergic	24986270	155	163	O
rhinitis	24986270	164	172	O
is	24986270	173	175	O
a	24986270	176	177	O
chronic	24986270	178	185	O
illness	24986270	186	193	O
,	24986270	193	194	O
affecting	24986270	195	204	O
10	24986270	205	207	O
to	24986270	208	210	O
40	24986270	211	213	O
%	24986270	213	214	O
of	24986270	215	217	O
the	24986270	218	221	O
worldwide	24986270	222	231	O
population	24986270	232	242	O
.	24986270	242	243	O

Chinese	24986270	244	251	O
herbal	24986270	252	258	O
medicines	24986270	259	268	O
,	24986270	268	269	O
the	24986270	270	273	O
treatment	24986270	274	283	O
of	24986270	284	286	O
allergic	24986270	287	295	O
rhinitis	24986270	296	304	O
,	24986270	304	305	O
adopted	24986270	306	313	O
thousands	24986270	314	323	O
of	24986270	324	326	O
years	24986270	327	332	O
in	24986270	333	335	O
ancient	24986270	336	343	O
China	24986270	344	349	O
,	24986270	349	350	O
has	24986270	351	354	O
recently	24986270	355	363	O
raised	24986270	364	370	O
much	24986270	371	375	O
attention	24986270	376	385	O
among	24986270	386	391	O
researchers	24986270	392	403	O
globally	24986270	404	412	O
.	24986270	412	413	O

This	24986270	414	418	O
study	24986270	419	424	O
evaluates	24986270	425	434	O
the	24986270	435	438	O
effects	24986270	439	446	O
of	24986270	447	449	O
two	24986270	450	453	O
Chinese	24986270	454	461	O
herbal	24986270	462	468	O
formulae	24986270	469	477	O
[	24986270	478	479	O
Cure-allergic-rhinitis	24986270	479	501	O
Syrup	24986270	502	507	O
(	24986270	508	509	O
CS	24986270	509	511	O
)	24986270	511	512	O
and	24986270	513	516	O
Yu-ping-feng	24986270	517	529	O
San	24986270	530	533	O
(	24986270	534	535	O
YS	24986270	535	537	O
)	24986270	537	538	O
]	24986270	538	539	O
in	24986270	540	542	O
treating	24986270	543	551	O
undergraduate	24986270	552	565	O
nursing	24986270	566	573	O
students	24986270	574	582	O
with	24986270	583	587	O
allergic	24986270	588	596	O
rhinitis	24986270	597	605	O
over	24986270	606	610	O
a	24986270	611	612	O
3-month	24986270	613	620	O
follow-up	24986270	621	630	O
,	24986270	630	631	O
when	24986270	632	636	O
compared	24986270	637	645	O
to	24986270	646	648	O
a	24986270	649	650	O
placebo	24986270	651	658	O
control	24986270	659	666	O
group	24986270	667	672	O
.	24986270	672	673	O

METHODS	24986270	675	682	O
:	24986270	683	684	O
A	24986270	685	686	O
double-blind	24986270	687	699	O
,	24986270	699	700	O
randomised	24986270	701	711	O
controlled	24986270	712	722	O
trial	24986270	723	728	O
with	24986270	729	733	O
repeated-measures	24986270	734	751	O
,	24986270	751	752	O
three-parallel-groups	24986270	753	774	O
design	24986270	775	781	O
was	24986270	782	785	O
conducted	24986270	786	795	O
in	24986270	796	798	O
a	24986270	799	800	O
random	24986270	801	807	O
sample	24986270	808	814	O
of	24986270	815	817	O
249	24986270	818	821	O
participants	24986270	822	834	O
recruited	24986270	835	844	O
from	24986270	845	849	O
one	24986270	850	853	O
university	24986270	854	864	O
in	24986270	865	867	O
Hong	24986270	868	872	O
Kong	24986270	873	877	O
.	24986270	877	878	O

After	24986270	879	884	O
baseline	24986270	885	893	O
measurements	24986270	894	906	O
,	24986270	906	907	O
participants	24986270	908	920	O
were	24986270	921	925	O
randomly	24986270	926	934	O
assigned	24986270	935	943	O
to	24986270	944	946	O
CS	24986270	947	949	O
,	24986270	949	950	O
YS	24986270	951	953	O
,	24986270	953	954	O
or	24986270	955	957	O
placebo	24986270	958	965	O
groups	24986270	966	972	O
(	24986270	973	974	O
n=83	24986270	974	978	O
per	24986270	979	982	O
group	24986270	983	988	O
)	24986270	988	989	O
.	24986270	989	990	O

The	24986270	991	994	O
main	24986270	995	999	O
outcomes	24986270	1000	1008	O
,	24986270	1008	1009	O
including	24986270	1010	1019	O
symptom	24986270	1020	1027	O
severity	24986270	1028	1036	O
,	24986270	1036	1037	O
quality	24986270	1038	1045	O
of	24986270	1046	1048	O
life	24986270	1049	1053	O
,	24986270	1053	1054	O
and	24986270	1055	1058	O
body	24986270	1059	1063	O
constitution	24986270	1064	1076	O
,	24986270	1076	1077	O
were	24986270	1078	1082	O
measured	24986270	1083	1091	O
with	24986270	1092	1096	O
self-administered	24986270	1097	1114	O
questionnaires	24986270	1115	1129	O
at	24986270	1130	1132	O
baseline	24986270	1133	1141	O
and	24986270	1142	1145	O
immediately	24986270	1146	1157	O
,	24986270	1157	1158	O
1	24986270	1159	1160	O
and	24986270	1161	1164	O
3	24986270	1165	1166	O
months	24986270	1167	1173	O
after	24986270	1174	1179	O
the	24986270	1180	1183	O
4-week	24986270	1184	1190	O
interventions	24986270	1191	1204	O
.	24986270	1204	1205	O

RESULTS	24986270	1207	1214	O
:	24986270	1215	1216	O
240	24986270	1217	1220	O
participants	24986270	1221	1233	O
completed	24986270	1234	1243	O
the	24986270	1244	1247	O
trial	24986270	1248	1253	O
,	24986270	1253	1254	O
with	24986270	1255	1259	O
9	24986270	1260	1261	O
(	24986270	1262	1263	O
3.6	24986270	1263	1266	O
%	24986270	1266	1267	O
)	24986270	1267	1268	O
drop-outs	24986270	1269	1278	O
.	24986270	1278	1279	O

The	24986270	1280	1283	O
results	24986270	1284	1291	O
of	24986270	1292	1294	O
Generalised	24986270	1295	1306	O
Estimating	24986270	1307	1317	O
Equations	24986270	1318	1327	O
test	24986270	1328	1332	O
followed	24986270	1333	1341	O
by	24986270	1342	1344	O
pairwise	24986270	1345	1353	O
contrasts	24986270	1354	1363	O
tests	24986270	1364	1369	O
indicated	24986270	1370	1379	O
that	24986270	1380	1384	O
the	24986270	1385	1388	O
participants	24986270	1389	1401	O
who	24986270	1402	1405	O
received	24986270	1406	1414	O
CS	24986270	1415	1417	O
showed	24986270	1418	1424	O
significantly	24986270	1425	1438	O
greater	24986270	1439	1446	O
reduction	24986270	1447	1456	O
of	24986270	1457	1459	O
symptoms	24986270	1460	1468	B-Outcome
(	24986270	1469	1470	O
mean	24986270	1470	1474	O
difference	24986270	1475	1485	O
of	24986270	1486	1488	O
CS	24986270	1489	1491	O
vs.	24986270	1492	1495	O
placebo=26.13	24986270	1496	1509	O
-	24986270	1509	1510	O
34.55	24986270	1510	1515	O
,	24986270	1515	1516	O
P<0.0005	24986270	1517	1525	O
)	24986270	1525	1526	O
and	24986270	1527	1530	O
improvements	24986270	1531	1543	O
in	24986270	1544	1546	O
quality	24986270	1547	1554	B-Outcome
of	24986270	1555	1557	I-Outcome
life	24986270	1558	1562	I-Outcome
(	24986270	1563	1564	O
mean	24986270	1564	1568	O
difference	24986270	1569	1579	O
of	24986270	1580	1582	O
CS	24986270	1583	1585	O
vs.	24986270	1586	1589	O
placebo=12.81	24986270	1590	1603	O
-	24986270	1603	1604	O
16.76	24986270	1604	1609	O
,	24986270	1609	1610	O
P<0.001	24986270	1611	1618	O
)	24986270	1618	1619	O
,	24986270	1619	1620	O
and	24986270	1621	1624	O
body	24986270	1625	1629	B-Outcome
constitution	24986270	1630	1642	I-Outcome
in	24986270	1643	1645	I-Outcome
'	24986270	1646	1647	I-Outcome
Qi-deficiency	24986270	1647	1660	I-Outcome
'	24986270	1660	1661	I-Outcome
,	24986270	1661	1662	O
'	24986270	1663	1664	B-Outcome
Yang-deficiency	24986270	1664	1679	I-Outcome
'	24986270	1679	1680	I-Outcome
,	24986270	1680	1681	O
and	24986270	1682	1685	O
'	24986270	1686	1687	B-Outcome
Inherited	24986270	1687	1696	I-Outcome
Special	24986270	1697	1704	I-Outcome
'	24986270	1704	1705	I-Outcome
(	24986270	1706	1707	O
mean	24986270	1707	1711	O
difference	24986270	1712	1722	O
of	24986270	1723	1725	O
CS	24986270	1726	1728	O
vs.	24986270	1729	1732	O
placebo=7.05	24986270	1733	1745	O
-	24986270	1745	1746	O
8.12	24986270	1746	1750	O
,	24986270	1750	1751	O
7.56	24986270	1752	1756	O
-	24986270	1756	1757	O
8.92	24986270	1757	1761	O
,	24986270	1761	1762	O
and	24986270	1763	1766	O
4.48	24986270	1767	1771	O
-	24986270	1771	1772	O
8.10	24986270	1772	1776	O
,	24986270	1776	1777	O
P=0.01-	24986270	1778	1785	O
<	24986270	1785	1786	O
0.0005	24986270	1787	1793	O
,	24986270	1793	1794	O
0.001	24986270	1795	1800	O
-	24986270	1800	1801	O
0.004	24986270	1801	1806	O
,	24986270	1806	1807	O
and	24986270	1808	1811	O
0.01-	24986270	1812	1817	O
<	24986270	1817	1818	O
0.0005	24986270	1819	1825	O
,	24986270	1825	1826	O
accordingly	24986270	1827	1838	O
,	24986270	1838	1839	O
at	24986270	1840	1842	O
three	24986270	1843	1848	O
post-tests	24986270	1849	1859	O
)	24986270	1859	1860	O
.	24986270	1860	1861	O

The	24986270	1862	1865	O
participants	24986270	1866	1878	O
who	24986270	1879	1882	O
received	24986270	1883	1891	O
YS	24986270	1892	1894	O
also	24986270	1895	1899	O
indicated	24986270	1900	1909	O
significant	24986270	1910	1921	O
greater	24986270	1922	1929	O
improvements	24986270	1930	1942	O
in	24986270	1943	1945	O
symptom	24986270	1946	1953	B-Outcome
severity	24986270	1954	1962	I-Outcome
,	24986270	1962	1963	O
quality	24986270	1964	1971	B-Outcome
of	24986270	1972	1974	I-Outcome
life	24986270	1975	1979	I-Outcome
,	24986270	1979	1980	O
and	24986270	1981	1984	O
a	24986270	1985	1986	O
few	24986270	1987	1990	O
patterns	24986270	1991	1999	O
of	24986270	2000	2002	O
body	24986270	2003	2007	B-Outcome
constitution	24986270	2008	2020	I-Outcome
when	24986270	2021	2025	O
compared	24986270	2026	2034	O
to	24986270	2035	2037	O
the	24986270	2038	2041	O
placebo	24986270	2042	2049	O
group	24986270	2050	2055	O
.	24986270	2055	2056	O

However	24986270	2057	2064	O
,	24986270	2064	2065	O
its	24986270	2066	2069	O
effects	24986270	2070	2077	O
were	24986270	2078	2082	O
lesser	24986270	2083	2089	O
in	24986270	2090	2092	O
strength	24986270	2093	2101	O
(	24986270	2102	2103	O
i.e.	24986270	2103	2107	O
,	24986270	2107	2108	O
smaller	24986270	2109	2116	O
effect	24986270	2117	2123	O
sizes	24986270	2124	2129	O
)	24986270	2129	2130	O
,	24986270	2130	2131	O
varieties	24986270	2132	2141	O
of	24986270	2142	2144	O
symptoms	24986270	2145	2153	B-Outcome
,	24986270	2153	2154	O
and	24986270	2155	2158	O
body	24986270	2159	2163	B-Outcome
constitution	24986270	2164	2176	I-Outcome
and	24986270	2177	2180	O
sustainability	24986270	2181	2195	O
over	24986270	2196	2200	O
the	24986270	2201	2204	O
3	24986270	2205	2206	O
months	24986270	2207	2213	O
.	24986270	2213	2214	O

CONCLUSIONS	24986270	2216	2227	O
:	24986270	2228	2229	O
The	24986270	2230	2233	O
herbal	24986270	2234	2240	O
formula	24986270	2241	2248	O
CS	24986270	2249	2251	O
was	24986270	2252	2255	O
found	24986270	2256	2261	O
effective	24986270	2262	2271	O
to	24986270	2272	2274	O
reduce	24986270	2275	2281	O
symptoms	24986270	2282	2290	B-Outcome
and	24986270	2291	2294	O
enhance	24986270	2295	2302	O
quality	24986270	2303	2310	B-Outcome
of	24986270	2311	2313	I-Outcome
life	24986270	2314	2318	I-Outcome
in	24986270	2319	2321	O
young	24986270	2322	2327	O
adults	24986270	2328	2334	O
(	24986270	2335	2336	O
nursing	24986270	2336	2343	O
students	24986270	2344	2352	O
)	24986270	2352	2353	O
with	24986270	2354	2358	O
allergic	24986270	2359	2367	O
rhinitis	24986270	2368	2376	O
in	24986270	2377	2379	O
'	24986270	2380	2381	B-Outcome
Yang-	24986270	2381	2386	I-Outcome
and/or	24986270	2387	2393	I-Outcome
Qi-deficiency	24986270	2394	2407	I-Outcome
'	24986270	2407	2408	I-Outcome
body	24986270	2409	2413	I-Outcome
constitution	24986270	2414	2426	I-Outcome
.	24986270	2426	2427	O

Further	24986270	2428	2435	O
controlled	24986270	2436	2446	O
trials	24986270	2447	2453	O
of	24986270	2454	2456	O
its	24986270	2457	2460	O
effects	24986270	2461	2468	O
in	24986270	2469	2471	O
Chinese	24986270	2472	2479	O
and/or	24986270	2480	2486	O
Asians	24986270	2487	2493	O
with	24986270	2494	2498	O
allergic	24986270	2499	2507	O
rhinitis	24986270	2508	2516	O
in	24986270	2517	2519	O
terms	24986270	2520	2525	O
of	24986270	2526	2528	O
socio-demographic	24986270	2529	2546	O
,	24986270	2546	2547	O
ethnic	24986270	2548	2554	O
and	24986270	2555	2558	O
illness	24986270	2559	2566	O
characteristics	24986270	2567	2582	O
and	24986270	2583	2586	O
a	24986270	2587	2588	O
longer-term	24986270	2589	2600	O
follow-up	24986270	2601	2610	O
are	24986270	2611	2614	O
recommended	24986270	2615	2626	O
.	24986270	2626	2627	O

TRIAL	24986270	2629	2634	O
REGISTRATION	24986270	2635	2647	O
:	24986270	2648	2649	O
The	24986270	2650	2653	O
trial	24986270	2654	2659	O
has	24986270	2660	2663	O
registered	24986270	2664	2674	O
at	24986270	2675	2677	O
ClinicalTrials.gov	24986270	2678	2696	O
with	24986270	2697	2701	O
an	24986270	2702	2704	O
ID	24986270	2705	2707	O
:	24986270	2707	2708	O
NCT02027194	24986270	2709	2720	O
(	24986270	2721	2722	O
3	24986270	2722	2723	O
January	24986270	2724	2731	O
2014	24986270	2732	2736	O
)	24986270	2736	2737	O
.	24986270	2737	2738	O


Quality	24998293	0	7	O
of	24998293	8	10	O
life	24998293	11	15	O
and	24998293	16	19	O
fatigue	24998293	20	27	O
of	24998293	28	30	O
patients	24998293	31	39	O
with	24998293	40	44	O
spinal	24998293	45	51	O
bone	24998293	52	56	O
metastases	24998293	57	67	O
under	24998293	68	73	O
combined	24998293	74	82	O
treatment	24998293	83	92	O
with	24998293	93	97	O
resistance	24998293	98	108	O
training	24998293	109	117	O
and	24998293	118	121	O
radiation	24998293	122	131	O
therapy-	24998293	132	140	O
a	24998293	141	142	O
randomized	24998293	143	153	O
pilot	24998293	154	159	O
trial	24998293	160	165	O
.	24998293	165	166	O

BACKGROUND	24998293	168	178	O
:	24998293	179	180	O
The	24998293	181	184	O
aim	24998293	185	188	O
of	24998293	189	191	O
this	24998293	192	196	O
trial	24998293	197	202	O
was	24998293	203	206	O
to	24998293	207	209	O
compare	24998293	210	217	O
the	24998293	218	221	O
effects	24998293	222	229	O
of	24998293	230	232	O
resistance	24998293	233	243	O
training	24998293	244	252	O
versus	24998293	253	259	O
passive	24998293	260	267	O
physical	24998293	268	276	O
therapy	24998293	277	284	O
on	24998293	285	287	O
quality	24998293	288	295	O
of	24998293	296	298	O
life	24998293	299	303	O
(	24998293	304	305	O
QoL	24998293	305	308	O
)	24998293	308	309	O
,	24998293	309	310	O
fatigue	24998293	311	318	O
,	24998293	318	319	O
and	24998293	320	323	O
emotional	24998293	324	333	O
distress	24998293	334	342	O
outcomes	24998293	343	351	O
during	24998293	352	358	O
radiation	24998293	359	368	O
therapy	24998293	369	376	O
in	24998293	377	379	O
patients	24998293	380	388	O
with	24998293	389	393	O
spinal	24998293	394	400	O
bone	24998293	401	405	O
metastases	24998293	406	416	O
under	24998293	417	422	O
radiotherapy	24998293	423	435	O
(	24998293	436	437	O
RT	24998293	437	439	O
)	24998293	439	440	O
.	24998293	440	441	O

METHODS	24998293	443	450	O
:	24998293	451	452	O
In	24998293	453	455	O
this	24998293	456	460	O
randomized	24998293	461	471	O
trial	24998293	472	477	O
,	24998293	477	478	O
60	24998293	479	481	O
patients	24998293	482	490	O
were	24998293	491	495	O
treated	24998293	496	503	O
from	24998293	504	508	O
September	24998293	509	518	O
2011	24998293	519	523	O
until	24998293	524	529	O
March	24998293	530	535	O
2013	24998293	536	540	O
into	24998293	541	545	O
one	24998293	546	549	O
of	24998293	550	552	O
the	24998293	553	556	O
two	24998293	557	560	O
groups	24998293	561	567	O
:	24998293	567	568	O
isometric	24998293	569	578	O
resistance	24998293	579	589	O
training	24998293	590	598	O
or	24998293	599	601	O
physical	24998293	602	610	O
therapy	24998293	611	618	O
with	24998293	619	623	O
thirty	24998293	624	630	O
patients	24998293	631	639	O
in	24998293	640	642	O
each	24998293	643	647	O
group	24998293	648	653	O
during	24998293	654	660	O
RT	24998293	661	663	O
.	24998293	663	664	O

EORTC	24998293	665	670	O
QLQ-BM22	24998293	671	679	O
,	24998293	679	680	O
EORTC	24998293	681	686	O
QLQ-FA13	24998293	687	695	O
,	24998293	695	696	O
and	24998293	697	700	O
FBK-R10	24998293	701	708	O
were	24998293	709	713	O
assessed	24998293	714	722	O
at	24998293	723	725	O
baseline	24998293	726	734	O
,	24998293	734	735	O
three	24998293	736	741	O
months	24998293	742	748	O
,	24998293	748	749	O
and	24998293	750	753	O
six	24998293	754	757	O
months	24998293	758	764	O
after	24998293	765	770	O
RT	24998293	771	773	O
.	24998293	773	774	O

RESULTS	24998293	776	783	O
:	24998293	784	785	O
Psychosocial	24998293	786	798	B-Outcome
aspects	24998293	799	806	I-Outcome
in	24998293	807	809	O
resistance	24998293	810	820	O
training	24998293	821	829	O
group	24998293	830	835	O
(	24998293	836	837	O
Arm	24998293	837	840	O
A	24998293	841	842	O
)	24998293	842	843	O
were	24998293	844	848	O
significantly	24998293	849	862	O
improved	24998293	863	871	O
after	24998293	872	877	O
three	24998293	878	883	O
(	24998293	884	885	O
p	24998293	885	886	O
=	24998293	887	888	O
0.001	24998293	889	894	O
)	24998293	894	895	O
and	24998293	896	899	O
six	24998293	900	903	O
months	24998293	904	910	O
(	24998293	911	912	O
p	24998293	912	913	O
=	24998293	914	915	O
0.010	24998293	916	921	O
)	24998293	921	922	O
.	24998293	922	923	O

Other	24998293	924	929	O
rated	24998293	930	935	O
items	24998293	936	941	O
of	24998293	942	944	O
the	24998293	945	948	O
QLQ-BM22	24998293	949	957	B-Outcome
painful	24998293	958	965	I-Outcome
site	24998293	966	970	I-Outcome
,	24998293	970	971	O
and	24998293	972	975	O
pain	24998293	976	980	B-Outcome
characteristics	24998293	981	996	I-Outcome
were	24998293	997	1001	O
without	24998293	1002	1009	O
significant	24998293	1010	1021	O
differences	24998293	1022	1033	O
.	24998293	1033	1034	O

Functional	24998293	1035	1045	B-Outcome
interference	24998293	1046	1058	I-Outcome
showed	24998293	1059	1065	O
a	24998293	1066	1067	O
positive	24998293	1068	1076	O
trend	24998293	1077	1082	O
after	24998293	1083	1088	O
six	24998293	1089	1092	O
months	24998293	1093	1099	O
(	24998293	1100	1101	O
p	24998293	1101	1102	O
=	24998293	1103	1104	O
0.081	24998293	1105	1110	O
)	24998293	1110	1111	O
.	24998293	1111	1112	O

After	24998293	1113	1118	O
six	24998293	1119	1122	O
months	24998293	1123	1129	O
,	24998293	1129	1130	O
physical	24998293	1131	1139	B-Outcome
fatigue	24998293	1140	1147	I-Outcome
(	24998293	1148	1149	O
p	24998293	1149	1150	O
=	24998293	1151	1152	O
0.013	24998293	1153	1158	O
)	24998293	1158	1159	O
,	24998293	1159	1160	O
and	24998293	1161	1164	O
interference	24998293	1165	1177	B-Outcome
with	24998293	1178	1182	I-Outcome
daily	24998293	1183	1188	I-Outcome
life	24998293	1189	1193	I-Outcome
(	24998293	1194	1195	O
p	24998293	1195	1196	O
=	24998293	1197	1198	O
0.006	24998293	1199	1204	O
)	24998293	1204	1205	O
according	24998293	1206	1215	O
to	24998293	1216	1218	O
the	24998293	1219	1222	O
QLQ-FA13	24998293	1223	1231	B-Outcome
assessment	24998293	1232	1242	I-Outcome
improved	24998293	1243	1251	O
in	24998293	1252	1254	O
Arm	24998293	1255	1258	O
A	24998293	1259	1260	O
significantly	24998293	1261	1274	O
.	24998293	1274	1275	O

Emotional	24998293	1276	1285	B-Outcome
distress	24998293	1286	1294	I-Outcome
was	24998293	1295	1298	O
in	24998293	1299	1301	O
Arm	24998293	1302	1305	O
A	24998293	1306	1307	O
lower	24998293	1308	1313	O
after	24998293	1314	1319	O
six	24998293	1320	1323	O
months	24998293	1324	1330	O
(	24998293	1331	1332	O
p	24998293	1332	1333	O
=	24998293	1334	1335	O
0.016	24998293	1336	1341	O
)	24998293	1341	1342	O
.	24998293	1342	1343	O

The	24998293	1344	1347	O
Cohen	24998293	1348	1353	O
's	24998293	1353	1355	O
effect	24998293	1356	1362	O
size	24998293	1363	1367	O
confirmed	24998293	1368	1377	O
the	24998293	1378	1381	O
clinically	24998293	1382	1392	O
significant	24998293	1393	1404	O
improvement	24998293	1405	1416	O
of	24998293	1417	1419	O
these	24998293	1420	1425	O
findings	24998293	1426	1434	O
.	24998293	1434	1435	O

CONCLUSIONS	24998293	1437	1448	O
:	24998293	1449	1450	O
In	24998293	1451	1453	O
this	24998293	1454	1458	O
group	24998293	1459	1464	O
of	24998293	1465	1467	O
patients	24998293	1468	1476	O
we	24998293	1477	1479	O
were	24998293	1480	1484	O
able	24998293	1485	1489	O
to	24998293	1490	1492	O
show	24998293	1493	1497	O
that	24998293	1498	1502	O
guided	24998293	1503	1509	O
isometric	24998293	1510	1519	O
resistance	24998293	1520	1530	O
training	24998293	1531	1539	O
of	24998293	1540	1542	O
the	24998293	1543	1546	O
paravertebral	24998293	1547	1560	O
muscles	24998293	1561	1568	O
can	24998293	1569	1572	O
improve	24998293	1573	1580	O
functional	24998293	1581	1591	B-Outcome
capacity	24998293	1592	1600	I-Outcome
,	24998293	1600	1601	O
reduce	24998293	1602	1608	O
fatigue	24998293	1609	1616	B-Outcome
and	24998293	1617	1620	O
thereby	24998293	1621	1628	O
enhance	24998293	1629	1636	O
QoL	24998293	1637	1640	B-Outcome
over	24998293	1641	1645	O
a	24998293	1646	1647	O
6-months	24998293	1648	1656	O
period	24998293	1657	1663	O
in	24998293	1664	1666	O
patients	24998293	1667	1675	O
with	24998293	1676	1680	O
stable	24998293	1681	1687	O
spinal	24998293	1688	1694	O
metastases	24998293	1695	1705	O
.	24998293	1705	1706	O

The	24998293	1707	1710	O
results	24998293	1711	1718	O
offer	24998293	1719	1724	O
a	24998293	1725	1726	O
rationale	24998293	1727	1736	O
for	24998293	1737	1740	O
future	24998293	1741	1747	O
large	24998293	1748	1753	O
controlled	24998293	1754	1764	O
investigations	24998293	1765	1779	O
to	24998293	1780	1782	O
confirm	24998293	1783	1790	O
these	24998293	1791	1796	O
findings	24998293	1797	1805	O
.	24998293	1805	1806	O

TRIAL	24998293	1808	1813	O
REGISTRATION	24998293	1814	1826	O
:	24998293	1827	1828	O
Clinical	24998293	1829	1837	O
trial	24998293	1838	1843	O
identifier	24998293	1844	1854	O
NCT01409720	24998293	1855	1866	O
.	24998293	1866	1867	O


Pharmacokinetics	25078976	0	16	O
of	25078976	17	19	O
pregabalin	25078976	20	30	O
controlled-release	25078976	31	49	O
in	25078976	50	52	O
healthy	25078976	53	60	O
volunteers	25078976	61	71	O
:	25078976	71	72	O
effect	25078976	73	79	O
of	25078976	80	82	O
food	25078976	83	87	O
in	25078976	88	90	O
five	25078976	91	95	O
single-dose	25078976	96	107	O
,	25078976	107	108	O
randomized	25078976	109	119	O
,	25078976	119	120	O
clinical	25078976	121	129	O
pharmacology	25078976	130	142	O
studies	25078976	143	150	O
.	25078976	150	151	O

BACKGROUND	25078976	153	163	O
:	25078976	164	165	O
The	25078976	166	169	O
pharmacokinetic	25078976	170	185	O
properties	25078976	186	196	O
of	25078976	197	199	O
the	25078976	200	203	O
immediate-release	25078976	204	221	O
(	25078976	222	223	O
IR	25078976	223	225	O
)	25078976	225	226	O
and	25078976	227	230	O
the	25078976	231	234	O
recently	25078976	235	243	O
developed	25078976	244	253	O
controlled-release	25078976	254	272	O
(	25078976	273	274	O
CR	25078976	274	276	O
)	25078976	276	277	O
formulation	25078976	278	289	O
of	25078976	290	292	O
pregabalin	25078976	293	303	O
are	25078976	304	307	O
dose	25078976	308	312	O
proportional	25078976	313	325	O
.	25078976	325	326	O

Pregabalin	25078976	327	337	O
IR	25078976	338	340	O
can	25078976	341	344	O
be	25078976	345	347	O
taken	25078976	348	353	O
with	25078976	354	358	O
or	25078976	359	361	O
without	25078976	362	369	O
food	25078976	370	374	O
.	25078976	374	375	O

OBJECTIVES	25078976	377	387	O
:	25078976	388	389	O
This	25078976	390	394	O
analysis	25078976	395	403	O
characterizes	25078976	404	417	O
the	25078976	418	421	O
effect	25078976	422	428	O
of	25078976	429	431	O
food	25078976	432	436	O
on	25078976	437	439	O
pregabalin	25078976	440	450	O
CR	25078976	451	453	O
.	25078976	453	454	O

The	25078976	455	458	O
objectives	25078976	459	469	O
of	25078976	470	472	O
this	25078976	473	477	O
analysis	25078976	478	486	O
were	25078976	487	491	O
:	25078976	491	492	O
(	25078976	493	494	O
1	25078976	494	495	O
)	25078976	495	496	O
to	25078976	497	499	O
evaluate	25078976	500	508	O
the	25078976	509	512	O
effect	25078976	513	519	O
of	25078976	520	522	O
administration	25078976	523	537	O
time	25078976	538	542	O
and	25078976	543	546	O
fat	25078976	547	550	O
or	25078976	551	553	O
caloric	25078976	554	561	O
content	25078976	562	569	O
of	25078976	570	572	O
an	25078976	573	575	O
accompanying	25078976	576	588	O
meal	25078976	589	593	O
on	25078976	594	596	O
the	25078976	597	600	O
pharmacokinetic	25078976	601	616	O
properties	25078976	617	627	O
of	25078976	628	630	O
a	25078976	631	632	O
single	25078976	633	639	O
dose	25078976	640	644	O
of	25078976	645	647	O
pregabalin	25078976	648	658	O
CR	25078976	659	661	O
(	25078976	662	663	O
330	25078976	663	666	O
mg	25078976	667	669	O
)	25078976	669	670	O
relative	25078976	671	679	O
to	25078976	680	682	O
a	25078976	683	684	O
single	25078976	685	691	O
dose	25078976	692	696	O
of	25078976	697	699	O
pregabalin	25078976	700	710	O
IR	25078976	711	713	O
(	25078976	714	715	O
300	25078976	715	718	O
mg	25078976	719	721	O
)	25078976	721	722	O
;	25078976	722	723	O
(	25078976	724	725	O
2	25078976	725	726	O
)	25078976	726	727	O
to	25078976	728	730	O
evaluate	25078976	731	739	O
the	25078976	740	743	O
pharmacokinetic	25078976	744	759	O
properties	25078976	760	770	O
of	25078976	771	773	O
a	25078976	774	775	O
single	25078976	776	782	O
dose	25078976	783	787	O
of	25078976	788	790	O
pregabalin	25078976	791	801	O
CR	25078976	802	804	O
administered	25078976	805	817	O
fasted	25078976	818	824	O
relative	25078976	825	833	O
to	25078976	834	836	O
a	25078976	837	838	O
single	25078976	839	845	O
dose	25078976	846	850	O
of	25078976	851	853	O
pregabalin	25078976	854	864	O
CR	25078976	865	867	O
administered	25078976	868	880	O
immediately	25078976	881	892	O
after	25078976	893	898	O
food	25078976	899	903	O
;	25078976	903	904	O
and	25078976	905	908	O
(	25078976	909	910	O
3	25078976	910	911	O
)	25078976	911	912	O
to	25078976	913	915	O
determine	25078976	916	925	O
the	25078976	926	929	O
safety	25078976	930	936	O
and	25078976	937	940	O
tolerability	25078976	941	953	O
of	25078976	954	956	O
single-dose	25078976	957	968	O
administration	25078976	969	983	O
of	25078976	984	986	O
pregabalin	25078976	987	997	O
CR	25078976	998	1000	O
and	25078976	1001	1004	O
IR	25078976	1005	1007	O
with	25078976	1008	1012	O
and	25078976	1013	1016	O
without	25078976	1017	1024	O
food	25078976	1025	1029	O
.	25078976	1029	1030	O

METHODS	25078976	1032	1039	O
:	25078976	1040	1041	O
The	25078976	1042	1045	O
effect	25078976	1046	1052	O
of	25078976	1053	1055	O
food	25078976	1056	1060	O
on	25078976	1061	1063	O
the	25078976	1064	1067	O
pharmacokinetic	25078976	1068	1083	O
properties	25078976	1084	1094	O
of	25078976	1095	1097	O
pregabalin	25078976	1098	1108	O
CR	25078976	1109	1111	O
was	25078976	1112	1115	O
determined	25078976	1116	1126	O
in	25078976	1127	1129	O
five	25078976	1130	1134	O
phase	25078976	1135	1140	O
I	25078976	1141	1142	O
,	25078976	1142	1143	O
open-label	25078976	1144	1154	O
,	25078976	1154	1155	O
single-dose	25078976	1156	1167	O
,	25078976	1167	1168	O
crossover	25078976	1169	1178	O
studies	25078976	1179	1186	O
(	25078976	1187	1188	O
24	25078976	1188	1190	O
-	25078976	1190	1191	O
28	25078976	1191	1193	O
participants/study	25078976	1194	1212	O
)	25078976	1212	1213	O
.	25078976	1213	1214	O

Caloric	25078976	1215	1222	O
and	25078976	1223	1226	O
fat	25078976	1227	1230	O
content	25078976	1231	1238	O
of	25078976	1239	1241	O
meals	25078976	1242	1247	O
were	25078976	1248	1252	O
varied	25078976	1253	1259	O
and	25078976	1260	1263	O
treatments	25078976	1264	1274	O
were	25078976	1275	1279	O
administered	25078976	1280	1292	O
in	25078976	1293	1295	O
the	25078976	1296	1299	O
morning	25078976	1300	1307	O
,	25078976	1307	1308	O
at	25078976	1309	1311	O
midday	25078976	1312	1318	O
,	25078976	1318	1319	O
or	25078976	1320	1322	O
in	25078976	1323	1325	O
the	25078976	1326	1329	O
evening	25078976	1330	1337	O
.	25078976	1337	1338	O

Blood	25078976	1339	1344	O
samples	25078976	1345	1352	O
were	25078976	1353	1357	O
collected	25078976	1358	1367	O
up	25078976	1368	1370	O
to	25078976	1371	1373	O
48	25078976	1374	1376	O
h	25078976	1377	1378	O
post-dose	25078976	1379	1388	O
.	25078976	1388	1389	O

Pharmacokinetic	25078976	1390	1405	O
parameters	25078976	1406	1416	O
were	25078976	1417	1421	O
estimated	25078976	1422	1431	O
from	25078976	1432	1436	O
plasma	25078976	1437	1443	O
concentration-time	25078976	1444	1462	O
data	25078976	1463	1467	O
using	25078976	1468	1473	O
standard	25078976	1474	1482	O
noncompartmental	25078976	1483	1499	O
methods	25078976	1500	1507	O
.	25078976	1507	1508	O

Adverse	25078976	1509	1516	O
events	25078976	1517	1523	O
were	25078976	1524	1528	O
monitored	25078976	1529	1538	O
throughout	25078976	1539	1549	O
all	25078976	1550	1553	O
studies	25078976	1554	1561	O
.	25078976	1561	1562	O

RESULTS	25078976	1564	1571	O
:	25078976	1572	1573	O
One	25078976	1574	1577	O
hundred	25078976	1578	1585	O
and	25078976	1586	1589	O
twenty-eight	25078976	1590	1602	O
healthy	25078976	1603	1610	O
participants	25078976	1611	1623	O
(	25078976	1624	1625	O
19	25078976	1625	1627	O
-	25078976	1627	1628	O
54	25078976	1628	1630	O
years	25078976	1631	1636	O
of	25078976	1637	1639	O
age	25078976	1640	1643	O
)	25078976	1643	1644	O
received	25078976	1645	1653	O
pregabalin	25078976	1654	1664	O
.	25078976	1664	1665	O

Peak	25078976	1666	1670	B-Outcome
plasma	25078976	1671	1677	I-Outcome
concentrations	25078976	1678	1692	I-Outcome
(	25078976	1693	1694	I-Outcome
C	25078976	1694	1695	I-Outcome
max	25078976	1696	1699	I-Outcome
)	25078976	1699	1700	I-Outcome
were	25078976	1701	1705	O
lower	25078976	1706	1711	O
for	25078976	1712	1715	O
CR	25078976	1716	1718	O
than	25078976	1719	1723	O
the	25078976	1724	1727	O
respective	25078976	1728	1738	O
pregabalin	25078976	1739	1749	O
IR	25078976	1750	1752	O
doses	25078976	1753	1758	O
,	25078976	1758	1759	O
and	25078976	1760	1763	O
time	25078976	1764	1768	B-Outcome
to	25078976	1769	1771	I-Outcome
C	25078976	1772	1773	I-Outcome
max	25078976	1774	1777	I-Outcome
occurred	25078976	1778	1786	O
later	25078976	1787	1792	O
.	25078976	1792	1793	O

When	25078976	1794	1798	O
pregabalin	25078976	1799	1809	O
CR	25078976	1810	1812	O
was	25078976	1813	1816	O
administered	25078976	1817	1829	O
with	25078976	1830	1834	O
food	25078976	1835	1839	O
at	25078976	1840	1842	O
midday	25078976	1843	1849	O
or	25078976	1850	1852	O
in	25078976	1853	1855	O
the	25078976	1856	1859	O
evening	25078976	1860	1867	O
,	25078976	1867	1868	O
total	25078976	1869	1874	B-Outcome
exposures	25078976	1875	1884	I-Outcome
[	25078976	1885	1886	I-Outcome
area	25078976	1886	1890	I-Outcome
under	25078976	1891	1896	I-Outcome
the	25078976	1897	1900	I-Outcome
plasma	25078976	1901	1907	I-Outcome
concentration-time	25078976	1908	1926	I-Outcome
curve	25078976	1927	1932	I-Outcome
from	25078976	1933	1937	I-Outcome
time	25078976	1938	1942	I-Outcome
zero	25078976	1943	1947	I-Outcome
extrapolated	25078976	1948	1960	I-Outcome
to	25078976	1961	1963	I-Outcome
infinite	25078976	1964	1972	I-Outcome
time	25078976	1973	1977	I-Outcome
(	25078976	1978	1979	O
AUC∞	25078976	1979	1983	B-Outcome
)	25078976	1983	1984	O
]	25078976	1984	1985	O
were	25078976	1986	1990	O
equivalent	25078976	1991	2001	O
for	25078976	2002	2005	O
pregabalin	25078976	2006	2016	O
CR	25078976	2017	2019	O
and	25078976	2020	2023	O
IR	25078976	2024	2026	O
formulations	25078976	2027	2039	O
regardless	25078976	2040	2050	O
of	25078976	2051	2053	O
fat	25078976	2054	2057	O
or	25078976	2058	2060	O
caloric	25078976	2061	2068	O
content	25078976	2069	2076	O
.	25078976	2076	2077	O

When	25078976	2078	2082	O
pregabalin	25078976	2083	2093	O
CR	25078976	2094	2096	O
was	25078976	2097	2100	O
administered	25078976	2101	2113	O
with	25078976	2114	2118	O
an	25078976	2119	2121	O
800	25078976	2122	2125	O
-	25078976	2125	2126	O
1,000	25078976	2126	2131	O
calorie	25078976	2132	2139	O
medium-fat	25078976	2140	2150	O
breakfast	25078976	2151	2160	O
,	25078976	2160	2161	O
AUC∞	25078976	2162	2166	B-Outcome
was	25078976	2167	2170	O
equivalent	25078976	2171	2181	O
for	25078976	2182	2185	O
pregabalin	25078976	2186	2196	O
CR	25078976	2197	2199	O
and	25078976	2200	2203	O
IR	25078976	2204	2206	O
.	25078976	2206	2207	O

Bioequivalence	25078976	2208	2222	B-Outcome
criteria	25078976	2223	2231	I-Outcome
for	25078976	2232	2235	O
comparison	25078976	2236	2246	O
of	25078976	2247	2249	O
pregabalin	25078976	2250	2260	O
CR	25078976	2261	2263	O
after	25078976	2264	2269	O
a	25078976	2270	2271	O
low-	25078976	2272	2276	O
or	25078976	2277	2279	O
medium-calorie	25078976	2280	2294	O
breakfast	25078976	2295	2304	O
relative	25078976	2305	2313	O
to	25078976	2314	2316	O
pregabalin	25078976	2317	2327	O
IR	25078976	2328	2330	O
were	25078976	2331	2335	O
not	25078976	2336	2339	O
met	25078976	2340	2343	O
;	25078976	2343	2344	O
however	25078976	2345	2352	O
,	25078976	2352	2353	O
bioavailability	25078976	2354	2369	B-Outcome
of	25078976	2370	2372	O
the	25078976	2373	2376	O
pregabalin	25078976	2377	2387	O
CR	25078976	2388	2390	O
vs.	25078976	2391	2394	O
IR	25078976	2395	2397	O
formulation	25078976	2398	2409	O
was	25078976	2410	2413	O
relatively	25078976	2414	2424	O
high	25078976	2425	2429	O
(	25078976	2430	2431	O
75	25078976	2431	2433	O
-	25078976	2433	2434	O
86	25078976	2434	2436	O
%	25078976	2437	2438	O
)	25078976	2438	2439	O
.	25078976	2439	2440	O

When	25078976	2441	2445	O
pregabalin	25078976	2446	2456	O
CR	25078976	2457	2459	O
was	25078976	2460	2463	O
administered	25078976	2464	2476	O
fasted	25078976	2477	2483	O
,	25078976	2483	2484	O
the	25078976	2485	2488	O
AUC∞	25078976	2489	2493	B-Outcome
was	25078976	2494	2497	O
70	25078976	2498	2500	O
-	25078976	2500	2501	O
78	25078976	2501	2503	O
%	25078976	2504	2505	O
of	25078976	2506	2508	O
the	25078976	2509	2512	O
AUC∞	25078976	2513	2517	B-Outcome
of	25078976	2518	2520	O
pregabalin	25078976	2521	2531	O
CR	25078976	2532	2534	O
administered	25078976	2535	2547	O
with	25078976	2548	2552	O
food	25078976	2553	2557	O
and	25078976	2558	2561	O
bioequivalence	25078976	2562	2576	O
criteria	25078976	2577	2585	O
were	25078976	2586	2590	O
not	25078976	2591	2594	O
met	25078976	2595	2598	O
.	25078976	2598	2599	O

Additionally	25078976	2600	2612	O
,	25078976	2612	2613	O
the	25078976	2614	2617	O
AUC∞	25078976	2618	2622	B-Outcome
of	25078976	2623	2625	O
the	25078976	2626	2629	O
pregabalin	25078976	2630	2640	O
CR	25078976	2641	2643	O
formulation	25078976	2644	2655	O
administered	25078976	2656	2668	O
fasted	25078976	2669	2675	O
was	25078976	2676	2679	O
62	25078976	2680	2682	O
-	25078976	2682	2683	O
69	25078976	2683	2685	O
%	25078976	2686	2687	O
of	25078976	2688	2690	O
that	25078976	2691	2695	O
of	25078976	2696	2698	O
pregabalin	25078976	2699	2709	O
IR	25078976	2710	2712	O
administered	25078976	2713	2725	O
fasted	25078976	2726	2732	O
and	25078976	2733	2736	O
bioequivalence	25078976	2737	2751	O
criteria	25078976	2752	2760	O
were	25078976	2761	2765	O
not	25078976	2766	2769	O
met	25078976	2770	2773	O
.	25078976	2773	2774	O

Single-dose	25078976	2775	2786	O
pregabalin	25078976	2787	2797	O
CR	25078976	2798	2800	O
and	25078976	2801	2804	O
IR	25078976	2805	2807	O
were	25078976	2808	2812	O
well	25078976	2813	2817	O
tolerated	25078976	2818	2827	B-Outcome
in	25078976	2828	2830	O
all	25078976	2831	2834	O
studies	25078976	2835	2842	O
,	25078976	2842	2843	O
with	25078976	2844	2848	O
no	25078976	2849	2851	O
serious	25078976	2852	2859	B-Outcome
or	25078976	2860	2862	O
severe	25078976	2863	2869	B-Outcome
adverse	25078976	2870	2877	I-Outcome
events	25078976	2878	2884	I-Outcome
reported	25078976	2885	2893	O
.	25078976	2893	2894	O

CONCLUSION	25078976	2896	2906	O
:	25078976	2907	2908	O
Time	25078976	2909	2913	O
of	25078976	2914	2916	O
day	25078976	2917	2920	O
of	25078976	2921	2923	O
administration	25078976	2924	2938	O
and	25078976	2939	2942	O
the	25078976	2943	2946	O
fat	25078976	2947	2950	O
and	25078976	2951	2954	O
caloric	25078976	2955	2962	O
content	25078976	2963	2970	O
of	25078976	2971	2973	O
the	25078976	2974	2977	O
accompanying	25078976	2978	2990	O
meal	25078976	2991	2995	O
had	25078976	2996	2999	O
minimal	25078976	3000	3007	O
overall	25078976	3008	3015	O
effect	25078976	3016	3022	O
on	25078976	3023	3025	O
the	25078976	3026	3029	O
pharmacokinetic	25078976	3030	3045	B-Outcome
properties	25078976	3046	3056	I-Outcome
and	25078976	3057	3060	O
bioavailability	25078976	3061	3076	B-Outcome
of	25078976	3077	3079	O
the	25078976	3080	3083	O
pregabalin	25078976	3084	3094	O
CR	25078976	3095	3097	O
formulation	25078976	3098	3109	O
.	25078976	3109	3110	O


Effects	25119339	0	7	O
of	25119339	8	10	O
iron	25119339	11	15	O
supplements	25119339	16	27	O
and	25119339	28	31	O
perinatal	25119339	32	41	O
factors	25119339	42	49	O
on	25119339	50	52	O
fetal	25119339	53	58	O
hemoglobin	25119339	59	69	O
disappearance	25119339	70	83	O
in	25119339	84	86	O
LBW	25119339	87	90	O
infants	25119339	91	98	O
.	25119339	98	99	O

BACKGROUND	25119339	101	111	O
:	25119339	112	113	O
The	25119339	114	117	O
homeostatic	25119339	118	129	O
mechanisms	25119339	130	140	O
of	25119339	141	143	O
iron	25119339	144	148	O
metabolism	25119339	149	159	O
and	25119339	160	163	O
erythropoiesis	25119339	164	178	O
in	25119339	179	181	O
infants	25119339	182	189	O
are	25119339	190	193	O
unclear	25119339	194	201	O
.	25119339	201	202	O

Infants	25119339	203	210	O
synthesize	25119339	211	221	O
both	25119339	222	226	O
fetal	25119339	227	232	O
hemoglobin	25119339	233	243	O
(	25119339	244	245	O
HbF	25119339	245	248	O
)	25119339	248	249	O
and	25119339	250	253	O
adult	25119339	254	259	O
hemoglobin	25119339	260	270	O
(	25119339	271	272	O
HbA	25119339	272	275	O
)	25119339	275	276	O
,	25119339	276	277	O
and	25119339	278	281	O
it	25119339	282	284	O
is	25119339	285	287	O
not	25119339	288	291	O
known	25119339	292	297	O
how	25119339	298	301	O
the	25119339	302	305	O
hemoglobin	25119339	306	316	O
switch	25119339	317	323	O
is	25119339	324	326	O
regulated	25119339	327	336	O
.	25119339	336	337	O

We	25119339	338	340	O
hypothesized	25119339	341	353	O
that	25119339	354	358	O
iron	25119339	359	363	O
supplements	25119339	364	375	O
to	25119339	376	378	O
infants	25119339	379	386	O
affect	25119339	387	393	O
the	25119339	394	397	O
disappearance	25119339	398	411	O
of	25119339	412	414	O
HbF.	25119339	415	419	O
METHODS	25119339	420	427	O
:	25119339	428	429	O
We	25119339	430	432	O
randomized	25119339	433	443	O
285	25119339	444	447	O
low-birth-weight	25119339	448	464	O
infants	25119339	465	472	O
(	25119339	473	474	O
2,000	25119339	474	479	O
-	25119339	479	480	O
2,500	25119339	480	485	O
g	25119339	486	487	O
)	25119339	487	488	O
into	25119339	489	493	O
three	25119339	494	499	O
intervention	25119339	500	512	O
groups	25119339	513	519	O
receiving	25119339	520	529	O
0	25119339	530	531	O
,	25119339	531	532	O
1	25119339	533	534	O
,	25119339	534	535	O
or	25119339	536	538	O
2	25119339	539	540	O
mg/kg/d	25119339	541	548	O
of	25119339	549	551	O
iron	25119339	552	556	O
supplements	25119339	557	568	O
from	25119339	569	573	O
6	25119339	574	575	O
wk	25119339	576	578	O
to	25119339	579	581	O
6	25119339	582	583	O
mo	25119339	584	586	O
of	25119339	587	589	O
age	25119339	590	593	O
.	25119339	593	594	O

In	25119339	595	597	O
the	25119339	598	601	O
present	25119339	602	609	O
secondary	25119339	610	619	O
analysis	25119339	620	628	O
,	25119339	628	629	O
we	25119339	630	632	O
analyzed	25119339	633	641	O
iron	25119339	642	646	O
status	25119339	647	653	O
,	25119339	653	654	O
total	25119339	655	660	O
hemoglobin	25119339	661	671	O
(	25119339	672	673	O
Hb	25119339	673	675	O
)	25119339	675	676	O
,	25119339	676	677	O
and	25119339	678	681	O
HbF	25119339	682	685	O
fraction	25119339	686	694	O
at	25119339	695	697	O
6	25119339	698	699	O
wk	25119339	700	702	O
,	25119339	702	703	O
12	25119339	704	706	O
wk	25119339	707	709	O
,	25119339	709	710	O
and	25119339	711	714	O
at	25119339	715	717	O
6	25119339	718	719	O
mo	25119339	720	722	O
and	25119339	723	726	O
calculated	25119339	727	737	O
absolute	25119339	738	746	O
levels	25119339	747	753	O
of	25119339	754	756	O
HbF.	25119339	757	761	O
RESULTS	25119339	762	769	O
:	25119339	770	771	O
We	25119339	772	774	O
observed	25119339	775	783	O
dose-dependent	25119339	784	798	O
increased	25119339	799	808	O
levels	25119339	809	815	B-Outcome
of	25119339	816	818	I-Outcome
Hb	25119339	819	821	I-Outcome
in	25119339	822	824	O
iron-supplemented	25119339	825	842	O
groups	25119339	843	849	O
at	25119339	850	852	O
6	25119339	853	854	O
mo	25119339	855	857	O
of	25119339	858	860	O
age	25119339	861	864	O
.	25119339	864	865	O

However	25119339	866	873	O
,	25119339	873	874	O
for	25119339	875	878	O
absolute	25119339	879	887	B-Outcome
HbF	25119339	888	891	I-Outcome
concentration	25119339	892	905	I-Outcome
,	25119339	905	906	O
there	25119339	907	912	O
was	25119339	913	916	O
no	25119339	917	919	O
similar	25119339	920	927	O
effect	25119339	928	934	O
of	25119339	935	937	O
intervention	25119339	938	950	O
.	25119339	950	951	O

Mean	25119339	952	956	B-Outcome
(	25119339	957	958	I-Outcome
SD	25119339	958	960	I-Outcome
)	25119339	960	961	I-Outcome
HbF	25119339	962	965	I-Outcome
was	25119339	966	969	O
81.2	25119339	970	974	O
(	25119339	975	976	O
16.8	25119339	976	980	O
)	25119339	980	981	O
,	25119339	981	982	O
37.0	25119339	983	987	O
(	25119339	988	989	O
13.8	25119339	989	993	O
)	25119339	993	994	O
,	25119339	994	995	O
and	25119339	996	999	O
8.1	25119339	1000	1003	O
(	25119339	1004	1005	O
5.6	25119339	1005	1008	O
)	25119339	1008	1009	O
g/l	25119339	1010	1013	O
at	25119339	1014	1016	O
6	25119339	1017	1018	O
wk	25119339	1019	1021	O
,	25119339	1021	1022	O
12	25119339	1023	1025	O
wk	25119339	1026	1028	O
,	25119339	1028	1029	O
and	25119339	1030	1033	O
6	25119339	1034	1035	O
mo	25119339	1036	1038	O
,	25119339	1038	1039	O
respectively	25119339	1040	1052	O
,	25119339	1052	1053	O
similar	25119339	1054	1061	O
in	25119339	1062	1064	O
all	25119339	1065	1068	O
groups	25119339	1069	1075	O
.	25119339	1075	1076	O

In	25119339	1077	1079	O
linear	25119339	1080	1086	O
regression	25119339	1087	1097	O
analyses	25119339	1098	1106	O
,	25119339	1106	1107	O
postconceptional	25119339	1108	1124	O
age	25119339	1125	1128	O
turned	25119339	1129	1135	O
out	25119339	1136	1139	O
as	25119339	1140	1142	O
the	25119339	1143	1146	O
major	25119339	1147	1152	O
predictor	25119339	1153	1162	O
of	25119339	1163	1165	O
HbF	25119339	1166	1169	B-Outcome
,	25119339	1169	1170	O
independent	25119339	1171	1182	O
of	25119339	1183	1185	O
gestational	25119339	1186	1197	O
age	25119339	1198	1201	O
at	25119339	1202	1204	O
birth	25119339	1205	1210	O
.	25119339	1210	1211	O

CONCLUSION	25119339	1213	1223	O
:	25119339	1224	1225	O
Our	25119339	1226	1229	O
hypothesis	25119339	1230	1240	O
was	25119339	1241	1244	O
rejected	25119339	1245	1253	O
.	25119339	1253	1254	O

Instead	25119339	1255	1262	O
,	25119339	1262	1263	O
we	25119339	1264	1266	O
confirmed	25119339	1267	1276	O
a	25119339	1277	1278	O
close	25119339	1279	1284	O
correlation	25119339	1285	1296	O
to	25119339	1297	1299	O
postconceptional	25119339	1300	1316	O
age	25119339	1317	1320	O
,	25119339	1320	1321	O
supporting	25119339	1322	1332	O
a	25119339	1333	1334	O
genetically	25119339	1335	1346	O
programmed	25119339	1347	1357	O
switch	25119339	1358	1364	O
,	25119339	1364	1365	O
insensitive	25119339	1366	1377	O
to	25119339	1378	1380	O
most	25119339	1381	1385	O
environmental	25119339	1386	1399	O
factors	25119339	1400	1407	O
including	25119339	1408	1417	O
birth	25119339	1418	1423	O
.	25119339	1423	1424	O


Safety	25122429	0	6	O
and	25122429	7	10	O
effectiveness	25122429	11	24	O
of	25122429	25	27	O
bevacizumab-containing	25122429	28	50	O
treatment	25122429	51	60	O
for	25122429	61	64	O
non-small-cell	25122429	65	79	O
lung	25122429	80	84	O
cancer	25122429	85	91	O
:	25122429	91	92	O
final	25122429	93	98	O
results	25122429	99	106	O
of	25122429	107	109	O
the	25122429	110	113	O
ARIES	25122429	114	119	O
observational	25122429	120	133	O
cohort	25122429	134	140	O
study	25122429	141	146	O
.	25122429	146	147	O

INTRODUCTION	25122429	149	161	O
:	25122429	162	163	O
Bevacizumab	25122429	164	175	O
,	25122429	175	176	O
a	25122429	177	178	O
recombinant	25122429	179	190	O
humanized	25122429	191	200	O
monoclonal	25122429	201	211	O
antibody	25122429	212	220	O
against	25122429	221	228	O
vascular	25122429	229	237	O
endothelial	25122429	238	249	O
growth	25122429	250	256	O
factor	25122429	257	263	O
,	25122429	263	264	O
was	25122429	265	268	O
approved	25122429	269	277	O
by	25122429	278	280	O
the	25122429	281	284	O
US	25122429	285	287	O
Food	25122429	288	292	O
and	25122429	293	296	O
Drug	25122429	297	301	O
Administration	25122429	302	316	O
for	25122429	317	320	O
the	25122429	321	324	O
treatment	25122429	325	334	O
of	25122429	335	337	O
advanced	25122429	338	346	O
non-small-cell	25122429	347	361	O
lung	25122429	362	366	O
cancer	25122429	367	373	O
(	25122429	374	375	O
NSCLC	25122429	375	380	O
)	25122429	380	381	O
in	25122429	382	384	O
combination	25122429	385	396	O
with	25122429	397	401	O
carboplatin	25122429	402	413	O
and	25122429	414	417	O
paclitaxel	25122429	418	428	O
.	25122429	428	429	O

ARIES	25122429	430	435	O
(	25122429	436	437	O
Avastin	25122429	437	444	O
Regimens	25122429	445	453	O
:	25122429	453	454	O
Investigation	25122429	455	468	O
of	25122429	469	471	O
Effectiveness	25122429	472	485	O
and	25122429	486	489	O
Safety	25122429	490	496	O
)	25122429	496	497	O
,	25122429	497	498	O
a	25122429	499	500	O
prospective	25122429	501	512	O
observational	25122429	513	526	O
cohort	25122429	527	533	O
study	25122429	534	539	O
,	25122429	539	540	O
evaluated	25122429	541	550	O
outcomes	25122429	551	559	O
in	25122429	560	562	O
a	25122429	563	564	O
large	25122429	565	570	O
,	25122429	570	571	O
community-based	25122429	572	587	O
population	25122429	588	598	O
of	25122429	599	601	O
patients	25122429	602	610	O
with	25122429	611	615	O
first-line	25122429	616	626	O
NSCLC	25122429	627	632	O
.	25122429	632	633	O

METHODS	25122429	635	642	O
:	25122429	643	644	O
From	25122429	645	649	O
2006	25122429	650	654	O
to	25122429	655	657	O
2009	25122429	658	662	O
,	25122429	662	663	O
ARIES	25122429	664	669	O
enrolled	25122429	670	678	O
patients	25122429	679	687	O
with	25122429	688	692	O
locally	25122429	693	700	O
advanced	25122429	701	709	O
or	25122429	710	712	O
metastatic	25122429	713	723	O
NSCLC	25122429	724	729	O
who	25122429	730	733	O
were	25122429	734	738	O
eligible	25122429	739	747	O
for	25122429	748	751	O
bevacizumab	25122429	752	763	O
,	25122429	763	764	O
excluding	25122429	765	774	O
those	25122429	775	780	O
with	25122429	781	785	O
predominantly	25122429	786	799	O
squamous	25122429	800	808	O
histology	25122429	809	818	O
.	25122429	818	819	O

Patients	25122429	820	828	O
were	25122429	829	833	O
required	25122429	834	842	O
to	25122429	843	845	O
provide	25122429	846	853	O
informed	25122429	854	862	O
consent	25122429	863	870	O
and	25122429	871	874	O
to	25122429	875	877	O
have	25122429	878	882	O
initiated	25122429	883	892	O
bevacizumab	25122429	893	904	O
with	25122429	905	909	O
chemotherapy	25122429	910	922	O
within	25122429	923	929	O
4	25122429	930	931	O
months	25122429	932	938	O
before	25122429	939	945	O
enrollment	25122429	946	956	O
.	25122429	956	957	O

There	25122429	958	963	O
were	25122429	964	968	O
no	25122429	969	971	O
protocol-defined	25122429	972	988	O
treatments	25122429	989	999	O
or	25122429	1000	1002	O
assessments	25122429	1003	1014	O
.	25122429	1014	1015	O

The	25122429	1016	1019	O
dosing	25122429	1020	1026	O
of	25122429	1027	1029	O
bevacizumab	25122429	1030	1041	O
and	25122429	1042	1045	O
chemotherapy	25122429	1046	1058	O
,	25122429	1058	1059	O
and	25122429	1060	1063	O
the	25122429	1064	1067	O
choice	25122429	1068	1074	O
of	25122429	1075	1077	O
chemotherapy	25122429	1078	1090	O
regimen	25122429	1091	1098	O
,	25122429	1098	1099	O
was	25122429	1100	1103	O
at	25122429	1104	1106	O
the	25122429	1107	1110	O
discretion	25122429	1111	1121	O
of	25122429	1122	1124	O
the	25122429	1125	1128	O
treating	25122429	1129	1137	O
physician	25122429	1138	1147	O
.	25122429	1147	1148	O

RESULTS	25122429	1150	1157	O
:	25122429	1158	1159	O
ARIES	25122429	1160	1165	O
enrolled	25122429	1166	1174	O
1967	25122429	1175	1179	O
patients	25122429	1180	1188	O
with	25122429	1189	1193	O
first-line	25122429	1194	1204	O
NSCLC	25122429	1205	1210	O
.	25122429	1210	1211	O

At	25122429	1212	1214	O
study	25122429	1215	1220	O
closure	25122429	1221	1228	O
,	25122429	1228	1229	O
median	25122429	1230	1236	O
follow-up	25122429	1237	1246	O
was	25122429	1247	1250	O
12.5	25122429	1251	1255	O
months	25122429	1256	1262	O
(	25122429	1263	1264	O
range	25122429	1264	1269	O
,	25122429	1269	1270	O
0.2	25122429	1271	1274	O
-	25122429	1274	1275	O
65.5	25122429	1275	1279	O
)	25122429	1279	1280	O
.	25122429	1280	1281	O

Median	25122429	1282	1288	O
age	25122429	1289	1292	O
was	25122429	1293	1296	O
65	25122429	1297	1299	O
years	25122429	1300	1305	O
(	25122429	1306	1307	O
range	25122429	1307	1312	O
,	25122429	1312	1313	O
31	25122429	1314	1316	O
-	25122429	1316	1317	O
93	25122429	1317	1319	O
)	25122429	1319	1320	O
,	25122429	1320	1321	O
and	25122429	1322	1325	O
252	25122429	1326	1329	O
patients	25122429	1330	1338	O
(	25122429	1339	1340	O
12.8	25122429	1340	1344	O
%	25122429	1344	1345	O
)	25122429	1345	1346	O
identified	25122429	1347	1357	O
as	25122429	1358	1360	O
never	25122429	1361	1366	O
smokers	25122429	1367	1374	O
.	25122429	1374	1375	O

Median	25122429	1376	1382	B-Outcome
progression-free	25122429	1383	1399	I-Outcome
survival	25122429	1400	1408	I-Outcome
was	25122429	1409	1412	O
6.6	25122429	1413	1416	O
months	25122429	1417	1423	O
(	25122429	1424	1425	O
95	25122429	1425	1427	O
%	25122429	1427	1428	O
confidence	25122429	1429	1439	O
interval	25122429	1440	1448	O
,	25122429	1448	1449	O
6.3	25122429	1450	1453	O
-	25122429	1453	1454	O
6.9	25122429	1454	1457	O
)	25122429	1457	1458	O
,	25122429	1458	1459	O
and	25122429	1460	1463	O
median	25122429	1464	1470	B-Outcome
overall	25122429	1471	1478	I-Outcome
survival	25122429	1479	1487	I-Outcome
was	25122429	1488	1491	O
13.0	25122429	1492	1496	O
months	25122429	1497	1503	O
(	25122429	1504	1505	O
95	25122429	1505	1507	O
%	25122429	1507	1508	O
confidence	25122429	1509	1519	O
interval	25122429	1520	1528	O
,	25122429	1528	1529	O
12.2	25122429	1530	1534	O
-	25122429	1534	1535	O
13.8	25122429	1535	1539	O
)	25122429	1539	1540	O
with	25122429	1541	1545	O
first-line	25122429	1546	1556	O
bevacizumab	25122429	1557	1568	O
plus	25122429	1569	1573	O
chemotherapy	25122429	1574	1586	O
.	25122429	1586	1587	O

Incidences	25122429	1588	1598	O
of	25122429	1599	1601	O
bevacizumab-associated	25122429	1602	1624	B-Outcome
adverse	25122429	1625	1632	I-Outcome
events	25122429	1633	1639	I-Outcome
(	25122429	1640	1641	O
19.7	25122429	1641	1645	O
%	25122429	1645	1646	O
overall	25122429	1647	1654	O
)	25122429	1654	1655	O
were	25122429	1656	1660	O
consistent	25122429	1661	1671	O
with	25122429	1672	1676	O
those	25122429	1677	1682	O
in	25122429	1683	1685	O
randomized	25122429	1686	1696	O
controlled	25122429	1697	1707	O
trials	25122429	1708	1714	O
of	25122429	1715	1717	O
bevacizumab	25122429	1718	1729	O
in	25122429	1730	1732	O
NSCLC	25122429	1733	1738	O
.	25122429	1738	1739	O

CONCLUSION	25122429	1741	1751	O
:	25122429	1752	1753	O
Results	25122429	1754	1761	O
from	25122429	1762	1766	O
ARIES	25122429	1767	1772	O
demonstrate	25122429	1773	1784	O
similar	25122429	1785	1792	O
outcomes	25122429	1793	1801	O
to	25122429	1802	1804	O
randomized	25122429	1805	1815	O
controlled	25122429	1816	1826	O
trials	25122429	1827	1833	O
of	25122429	1834	1836	O
bevacizumab	25122429	1837	1848	O
when	25122429	1849	1853	O
added	25122429	1854	1859	O
to	25122429	1860	1862	O
standard	25122429	1863	1871	O
chemotherapy	25122429	1872	1884	O
in	25122429	1885	1887	O
a	25122429	1888	1889	O
real-world	25122429	1890	1900	O
patient	25122429	1901	1908	O
population	25122429	1909	1919	O
with	25122429	1920	1924	O
advanced	25122429	1925	1933	O
NSCLC	25122429	1934	1939	O
.	25122429	1939	1940	O


PLAY	25264862	0	4	O
Project	25264862	5	12	O
Home	25264862	13	17	O
Consultation	25264862	18	30	O
intervention	25264862	31	43	O
program	25264862	44	51	O
for	25264862	52	55	O
young	25264862	56	61	O
children	25264862	62	70	O
with	25264862	71	75	O
autism	25264862	76	82	O
spectrum	25264862	83	91	O
disorders	25264862	92	101	O
:	25264862	101	102	O
a	25264862	103	104	O
randomized	25264862	105	115	O
controlled	25264862	116	126	O
trial	25264862	127	132	O
.	25264862	132	133	O

OBJECTIVE	25264862	135	144	O
:	25264862	145	146	O
To	25264862	147	149	O
evaluate	25264862	150	158	O
the	25264862	159	162	O
effectiveness	25264862	163	176	O
of	25264862	177	179	O
the	25264862	180	183	O
Play	25264862	184	188	O
and	25264862	189	192	O
Language	25264862	193	201	O
for	25264862	202	205	O
Autistic	25264862	206	214	O
Youngsters	25264862	215	225	O
(	25264862	226	227	O
PLAY	25264862	227	231	O
)	25264862	231	232	O
Project	25264862	233	240	O
Home	25264862	241	245	O
Consultation	25264862	246	258	O
model	25264862	259	264	O
,	25264862	264	265	O
in	25264862	266	268	O
combination	25264862	269	280	O
with	25264862	281	285	O
usual	25264862	286	291	O
community	25264862	292	301	O
services	25264862	302	310	O
(	25264862	311	312	O
CS	25264862	312	314	O
)	25264862	314	315	O
,	25264862	315	316	O
to	25264862	317	319	O
improve	25264862	320	327	O
parent-child	25264862	328	340	O
interaction	25264862	341	352	O
,	25264862	352	353	O
child	25264862	354	359	O
development	25264862	360	371	O
,	25264862	371	372	O
and	25264862	373	376	O
autism	25264862	377	383	O
symptomatology	25264862	384	398	O
in	25264862	399	401	O
young	25264862	402	407	O
children	25264862	408	416	O
with	25264862	417	421	O
autism	25264862	422	428	O
spectrum	25264862	429	437	O
disorders	25264862	438	447	O
(	25264862	448	449	O
ASDs	25264862	449	453	O
)	25264862	453	454	O
compared	25264862	455	463	O
with	25264862	464	468	O
CS	25264862	469	471	O
only	25264862	472	476	O
.	25264862	476	477	O

METHODS	25264862	479	486	O
:	25264862	487	488	O
Children	25264862	489	497	O
(	25264862	498	499	O
N	25264862	499	500	O
=	25264862	501	502	O
128	25264862	503	506	O
)	25264862	506	507	O
with	25264862	508	512	O
autism	25264862	513	519	O
or	25264862	520	522	O
PDD-NOS	25264862	523	530	O
(	25264862	531	532	O
DSM-4	25264862	532	537	O
criteria	25264862	538	546	O
)	25264862	546	547	O
aged	25264862	548	552	O
2	25264862	553	554	O
years	25264862	555	560	O
8	25264862	561	562	O
months	25264862	563	569	O
to	25264862	570	572	O
5	25264862	573	574	O
years	25264862	575	580	O
11	25264862	581	583	O
months	25264862	584	590	O
and	25264862	591	594	O
recruited	25264862	595	604	O
from	25264862	605	609	O
5	25264862	610	611	O
disability	25264862	612	622	O
agencies	25264862	623	631	O
in	25264862	632	634	O
4	25264862	635	636	O
US	25264862	637	639	O
states	25264862	640	646	O
were	25264862	647	651	O
randomized	25264862	652	662	O
in	25264862	663	665	O
two	25264862	666	669	O
1-year	25264862	670	676	O
cohorts	25264862	677	684	O
.	25264862	684	685	O

Using	25264862	686	691	O
videotape	25264862	692	701	O
and	25264862	702	705	O
written	25264862	706	713	O
feedback	25264862	714	722	O
within	25264862	723	729	O
a	25264862	730	731	O
developmental	25264862	732	745	O
framework	25264862	746	755	O
,	25264862	755	756	O
PLAY	25264862	757	761	O
consultants	25264862	762	773	O
coached	25264862	774	781	O
caregivers	25264862	782	792	O
monthly	25264862	793	800	O
for	25264862	801	804	O
12	25264862	805	807	O
months	25264862	808	814	O
to	25264862	815	817	O
improve	25264862	818	825	O
caregiver-child	25264862	826	841	O
interaction	25264862	842	853	O
.	25264862	853	854	O

CS	25264862	855	857	O
included	25264862	858	866	O
speech/language	25264862	867	882	O
and	25264862	883	886	O
occupational	25264862	887	899	O
therapy	25264862	900	907	O
and	25264862	908	911	O
public	25264862	912	918	O
education	25264862	919	928	O
services	25264862	929	937	O
.	25264862	937	938	O

Primary	25264862	939	946	O
outcomes	25264862	947	955	O
included	25264862	956	964	O
change	25264862	965	971	O
in	25264862	972	974	O
parent-child	25264862	975	987	O
interactions	25264862	988	1000	O
,	25264862	1000	1001	O
language	25264862	1002	1010	O
and	25264862	1011	1014	O
development	25264862	1015	1026	O
,	25264862	1026	1027	O
and	25264862	1028	1031	O
autism-related	25264862	1032	1046	O
diagnostic	25264862	1047	1057	O
category/symptoms	25264862	1058	1075	O
.	25264862	1075	1076	O

Secondary	25264862	1077	1086	O
outcomes	25264862	1087	1095	O
included	25264862	1096	1104	O
parent	25264862	1105	1111	O
stress	25264862	1112	1118	O
and	25264862	1119	1122	O
depression	25264862	1123	1133	O
and	25264862	1134	1137	O
home	25264862	1138	1142	O
consultant	25264862	1143	1153	O
fidelity	25264862	1154	1162	O
.	25264862	1162	1163	O

Data	25264862	1164	1168	O
were	25264862	1169	1173	O
collected	25264862	1174	1183	O
pre-	25264862	1184	1188	O
and	25264862	1189	1192	O
post-intervention	25264862	1193	1210	O
.	25264862	1210	1211	O

RESULTS	25264862	1213	1220	O
:	25264862	1221	1222	O
Using	25264862	1223	1228	O
intent-to-treat	25264862	1229	1244	O
analysis	25264862	1245	1253	O
(	25264862	1254	1255	O
ITT	25264862	1255	1258	O
)	25264862	1258	1259	O
,	25264862	1259	1260	O
large	25264862	1261	1266	O
treatment	25264862	1267	1276	O
effects	25264862	1277	1284	O
were	25264862	1285	1289	O
evident	25264862	1290	1297	O
for	25264862	1298	1301	O
parent	25264862	1302	1308	B-Outcome
and	25264862	1309	1312	I-Outcome
child	25264862	1313	1318	I-Outcome
interactional	25264862	1319	1332	I-Outcome
behaviors	25264862	1333	1342	I-Outcome
on	25264862	1343	1345	I-Outcome
the	25264862	1346	1349	I-Outcome
Maternal	25264862	1350	1358	I-Outcome
and	25264862	1359	1362	I-Outcome
Child	25264862	1363	1368	I-Outcome
Behavior	25264862	1369	1377	I-Outcome
Rating	25264862	1378	1384	I-Outcome
Scales	25264862	1385	1391	I-Outcome
.	25264862	1391	1392	O

Child	25264862	1393	1398	B-Outcome
language	25264862	1399	1407	I-Outcome
and	25264862	1408	1411	O
developmental	25264862	1412	1425	B-Outcome
quotient	25264862	1426	1434	I-Outcome
did	25264862	1435	1438	O
not	25264862	1439	1442	O
differ	25264862	1443	1449	O
over	25264862	1450	1454	O
time	25264862	1455	1459	O
by	25264862	1460	1462	O
group	25264862	1463	1468	O
,	25264862	1468	1469	O
although	25264862	1470	1478	O
functional	25264862	1479	1489	B-Outcome
development	25264862	1490	1501	I-Outcome
improved	25264862	1502	1510	O
significantly	25264862	1511	1524	O
.	25264862	1524	1525	O

PLAY	25264862	1526	1530	O
children	25264862	1531	1539	O
improved	25264862	1540	1548	O
in	25264862	1549	1551	O
diagnostic	25264862	1552	1562	O
categories	25264862	1563	1573	O
on	25264862	1574	1576	O
the	25264862	1577	1580	O
Autism	25264862	1581	1587	B-Outcome
Diagnostic	25264862	1588	1598	I-Outcome
Observation	25264862	1599	1610	I-Outcome
Schedule	25264862	1611	1619	I-Outcome
(	25264862	1620	1621	O
ADOS	25264862	1621	1625	B-Outcome
)	25264862	1625	1626	O
.	25264862	1626	1627	O

PLAY	25264862	1628	1632	O
caregivers	25264862	1633	1643	B-Outcome
'	25264862	1643	1644	I-Outcome
stress	25264862	1645	1651	I-Outcome
did	25264862	1652	1655	O
not	25264862	1656	1659	O
increase	25264862	1660	1668	O
,	25264862	1668	1669	O
and	25264862	1670	1673	O
depressive	25264862	1674	1684	B-Outcome
symptomatology	25264862	1685	1699	I-Outcome
decreased	25264862	1700	1709	O
.	25264862	1709	1710	O

Home	25264862	1711	1715	O
consultants	25264862	1716	1727	O
administered	25264862	1728	1740	O
the	25264862	1741	1744	O
intervention	25264862	1745	1757	O
with	25264862	1758	1762	O
fidelity	25264862	1763	1771	O
.	25264862	1771	1772	O

CONCLUSIONS	25264862	1774	1785	O
:	25264862	1786	1787	O
PLAY	25264862	1788	1792	O
intervention	25264862	1793	1805	O
demonstrated	25264862	1806	1818	O
substantial	25264862	1819	1830	O
changes	25264862	1831	1838	O
in	25264862	1839	1841	O
parent-child	25264862	1842	1854	B-Outcome
interaction	25264862	1855	1866	I-Outcome
without	25264862	1867	1874	O
increasing	25264862	1875	1885	O
parents	25264862	1886	1893	B-Outcome
'	25264862	1893	1894	I-Outcome
stress/depression	25264862	1895	1912	I-Outcome
.	25264862	1912	1913	O

ADOS	25264862	1914	1918	O
findings	25264862	1919	1927	O
must	25264862	1928	1932	O
be	25264862	1933	1935	O
interpreted	25264862	1936	1947	O
cautiously	25264862	1948	1958	O
because	25264862	1959	1966	O
results	25264862	1967	1974	O
do	25264862	1975	1977	O
not	25264862	1978	1981	O
align	25264862	1982	1987	O
with	25264862	1988	1992	O
clinical	25264862	1993	2001	O
experience	25264862	2002	2012	O
.	25264862	2012	2013	O

PLAY	25264862	2014	2018	O
offers	25264862	2019	2025	O
communities	25264862	2026	2037	O
a	25264862	2038	2039	O
relatively	25264862	2040	2050	O
inexpensive	25264862	2051	2062	O
effective	25264862	2063	2072	O
intervention	25264862	2073	2085	O
for	25264862	2086	2089	O
children	25264862	2090	2098	O
with	25264862	2099	2103	O
ASD	25264862	2104	2107	O
and	25264862	2108	2111	O
their	25264862	2112	2117	O
parents	25264862	2118	2125	O
.	25264862	2125	2126	O


Safety	25344395	0	6	O
and	25344395	7	10	O
possible	25344395	11	19	O
effects	25344395	20	27	O
of	25344395	28	30	O
low-intensity	25344395	31	44	O
resistance	25344395	45	55	O
training	25344395	56	64	O
associated	25344395	65	75	O
with	25344395	76	80	O
partial	25344395	81	88	O
blood	25344395	89	94	O
flow	25344395	95	99	O
restriction	25344395	100	111	O
in	25344395	112	114	O
polymyositis	25344395	115	127	O
and	25344395	128	131	O
dermatomyositis	25344395	132	147	O
.	25344395	147	148	O

INTRODUCTION	25344395	150	162	O
:	25344395	163	164	O
Our	25344395	165	168	O
aim	25344395	169	172	O
was	25344395	173	176	O
to	25344395	177	179	O
evaluate	25344395	180	188	O
the	25344395	189	192	O
safety	25344395	193	199	O
and	25344395	200	203	O
efficacy	25344395	204	212	O
of	25344395	213	215	O
a	25344395	216	217	O
low-intensity	25344395	218	231	O
resistance	25344395	232	242	O
training	25344395	243	251	O
program	25344395	252	259	O
combined	25344395	260	268	O
with	25344395	269	273	O
partial	25344395	274	281	O
blow	25344395	282	286	O
flow	25344395	287	291	O
restriction	25344395	292	303	O
(	25344395	304	305	O
BFR	25344395	305	308	O
training	25344395	309	317	O
)	25344395	317	318	O
in	25344395	319	321	O
a	25344395	322	323	O
cohort	25344395	324	330	O
of	25344395	331	333	O
patients	25344395	334	342	O
with	25344395	343	347	O
polymyositis	25344395	348	360	O
(	25344395	361	362	O
PM	25344395	362	364	O
)	25344395	364	365	O
and	25344395	366	369	O
dermatomyositis	25344395	370	385	O
(	25344395	386	387	O
DM	25344395	387	389	O
)	25344395	389	390	O
.	25344395	390	391	O

METHODS	25344395	393	400	O
:	25344395	401	402	O
In	25344395	403	405	O
total	25344395	406	411	O
,	25344395	411	412	O
13	25344395	413	415	O
patients	25344395	416	424	O
with	25344395	425	429	O
PM	25344395	430	432	O
and	25344395	433	436	O
DM	25344395	437	439	O
completed	25344395	440	449	O
a	25344395	450	451	O
12-week	25344395	452	459	O
twice	25344395	460	465	O
a	25344395	466	467	O
week	25344395	468	472	O
low-intensity	25344395	473	486	O
(	25344395	487	488	O
that	25344395	488	492	O
is	25344395	493	495	O
,	25344395	495	496	O
30	25344395	497	499	O
%	25344395	499	500	O
one-repetition-maximum	25344395	501	523	O
(	25344395	524	525	O
1RM	25344395	525	528	O
)	25344395	528	529	O
)	25344395	529	530	O
resistance	25344395	531	541	O
exercise	25344395	542	550	O
training	25344395	551	559	O
program	25344395	560	567	O
combined	25344395	568	576	O
with	25344395	577	581	O
partial	25344395	582	589	O
blood	25344395	590	595	O
flow	25344395	596	600	O
restriction	25344395	601	612	O
(	25344395	613	614	O
BFR	25344395	614	617	O
)	25344395	617	618	O
.	25344395	618	619	O

Assessments	25344395	620	631	O
of	25344395	632	634	O
muscle	25344395	635	641	O
strength	25344395	642	650	O
,	25344395	650	651	O
physical	25344395	652	660	O
function	25344395	661	669	O
,	25344395	669	670	O
quadriceps	25344395	671	681	O
cross	25344395	682	687	O
sectional	25344395	688	697	O
(	25344395	698	699	O
CSA	25344395	699	702	O
)	25344395	702	703	O
area	25344395	704	708	O
,	25344395	708	709	O
health-related	25344395	710	724	O
quality	25344395	725	732	O
of	25344395	733	735	O
life	25344395	736	740	O
,	25344395	740	741	O
and	25344395	742	745	O
clinical	25344395	746	754	O
and	25344395	755	758	O
laboratory	25344395	759	769	O
parameters	25344395	770	780	O
were	25344395	781	785	O
assessed	25344395	786	794	O
at	25344395	795	797	O
baseline	25344395	798	806	O
and	25344395	807	810	O
after	25344395	811	816	O
the	25344395	817	820	O
intervention	25344395	821	833	O
.	25344395	833	834	O

RESULTS	25344395	836	843	O
:	25344395	844	845	O
The	25344395	846	849	O
BFR	25344395	850	853	O
training	25344395	854	862	O
program	25344395	863	870	O
was	25344395	871	874	O
effective	25344395	875	884	O
in	25344395	885	887	O
increasing	25344395	888	898	O
the	25344395	899	902	O
maximal	25344395	903	910	B-Outcome
dynamic	25344395	911	918	I-Outcome
strength	25344395	919	927	I-Outcome
in	25344395	928	930	O
both	25344395	931	935	O
the	25344395	936	939	O
leg-press	25344395	940	949	O
(	25344395	950	951	O
19.6	25344395	951	955	O
%	25344395	955	956	O
,	25344395	956	957	O
P	25344395	958	959	O
<	25344395	960	961	O
0.001	25344395	961	966	O
)	25344395	966	967	O
and	25344395	968	971	O
knee-extension	25344395	972	986	O
exercises	25344395	987	996	O
(	25344395	997	998	O
25.2	25344395	998	1002	O
%	25344395	1002	1003	O
P	25344395	1004	1005	O
<	25344395	1006	1007	O
0.001	25344395	1007	1012	O
)	25344395	1012	1013	O
,	25344395	1013	1014	O
as	25344395	1015	1017	O
well	25344395	1018	1022	O
as	25344395	1023	1025	O
in	25344395	1026	1028	O
the	25344395	1029	1032	O
timed-stands	25344395	1033	1045	O
(	25344395	1046	1047	O
15.1	25344395	1047	1051	O
%	25344395	1051	1052	O
,	25344395	1052	1053	O
P	25344395	1054	1055	O
<	25344395	1056	1057	O
0.001	25344395	1057	1062	O
)	25344395	1062	1063	O
and	25344395	1064	1067	O
timed-up-and-go	25344395	1068	1083	O
test	25344395	1084	1088	O
(	25344395	1089	1090	O
-4.5	25344395	1090	1094	O
%	25344395	1094	1095	O
,	25344395	1095	1096	O
P	25344395	1097	1098	O
=	25344395	1099	1100	O
0.002	25344395	1100	1105	O
)	25344395	1105	1106	O
.	25344395	1106	1107	O

Quadriceps	25344395	1108	1118	B-Outcome
CSA	25344395	1119	1122	I-Outcome
was	25344395	1123	1126	O
also	25344395	1127	1131	O
significantly	25344395	1132	1145	O
increased	25344395	1146	1155	O
after	25344395	1156	1161	O
the	25344395	1162	1165	O
intervention	25344395	1166	1178	O
(	25344395	1179	1180	O
4.57	25344395	1180	1184	O
%	25344395	1184	1185	O
,	25344395	1185	1186	O
P	25344395	1187	1188	O
=	25344395	1189	1190	O
0.01	25344395	1190	1194	O
)	25344395	1194	1195	O
.	25344395	1195	1196	O

Similarly	25344395	1197	1206	O
,	25344395	1206	1207	O
all	25344395	1208	1211	O
of	25344395	1212	1214	O
the	25344395	1215	1218	O
components	25344395	1219	1229	O
of	25344395	1230	1232	O
the	25344395	1233	1236	O
Short	25344395	1237	1242	B-Outcome
Form-36	25344395	1243	1250	I-Outcome
Health	25344395	1251	1257	I-Outcome
Survey	25344395	1258	1264	I-Outcome
,	25344395	1264	1265	O
the	25344395	1266	1269	O
Health	25344395	1270	1276	B-Outcome
Assessment	25344395	1277	1287	I-Outcome
Questionnaire	25344395	1288	1301	I-Outcome
scores	25344395	1302	1308	I-Outcome
,	25344395	1308	1309	O
and	25344395	1310	1313	O
the	25344395	1314	1317	O
patient-	25344395	1318	1326	B-Outcome
and	25344395	1327	1330	O
physician	25344395	1331	1340	B-Outcome
reported	25344395	1341	1349	I-Outcome
Visual	25344395	1350	1356	I-Outcome
Analogue	25344395	1357	1365	I-Outcome
Scale	25344395	1366	1371	I-Outcome
were	25344395	1372	1376	O
significantly	25344395	1377	1390	O
improved	25344395	1391	1399	O
after	25344395	1400	1405	O
training	25344395	1406	1414	O
(	25344395	1415	1416	O
P	25344395	1416	1417	O
<	25344395	1418	1419	O
0.05	25344395	1419	1423	O
)	25344395	1423	1424	O
.	25344395	1424	1425	O

Importantly	25344395	1426	1437	O
,	25344395	1437	1438	O
no	25344395	1439	1441	O
clinical	25344395	1442	1450	O
evidence	25344395	1451	1459	O
or	25344395	1460	1462	O
any	25344395	1463	1466	O
other	25344395	1467	1472	O
self-reported	25344395	1473	1486	O
adverse	25344395	1487	1494	B-Outcome
event	25344395	1495	1500	I-Outcome
were	25344395	1501	1505	O
found	25344395	1506	1511	O
.	25344395	1511	1512	O

Laboratory	25344395	1513	1523	O
parameters	25344395	1524	1534	O
(	25344395	1535	1536	O
creatine	25344395	1536	1544	B-Outcome
kinase	25344395	1545	1551	I-Outcome
and	25344395	1552	1555	O
aldolase	25344395	1556	1564	B-Outcome
)	25344395	1564	1565	O
were	25344395	1566	1570	O
also	25344395	1571	1575	O
unchanged	25344395	1576	1585	O
(	25344395	1586	1587	O
P	25344395	1587	1588	O
>	25344395	1589	1590	O
0.05	25344395	1590	1594	O
)	25344395	1594	1595	O
after	25344395	1596	1601	O
the	25344395	1602	1605	O
intervention	25344395	1606	1618	O
.	25344395	1618	1619	O

CONCLUSIONS	25344395	1621	1632	O
:	25344395	1633	1634	O
We	25344395	1635	1637	O
demonstrated	25344395	1638	1650	O
that	25344395	1651	1655	O
a	25344395	1656	1657	O
12-week	25344395	1658	1665	O
supervised	25344395	1666	1676	O
low-intensity	25344395	1677	1690	O
resistance	25344395	1691	1701	O
training	25344395	1702	1710	O
program	25344395	1711	1718	O
associated	25344395	1719	1729	O
with	25344395	1730	1734	O
partial	25344395	1735	1742	O
blood	25344395	1743	1748	O
flow	25344395	1749	1753	O
restriction	25344395	1754	1765	O
may	25344395	1766	1769	O
be	25344395	1770	1772	O
safe	25344395	1773	1777	B-Outcome
and	25344395	1778	1781	O
effective	25344395	1782	1791	O
in	25344395	1792	1794	O
improving	25344395	1795	1804	O
muscle	25344395	1805	1811	B-Outcome
strength	25344395	1812	1820	I-Outcome
and	25344395	1821	1824	O
function	25344395	1825	1833	B-Outcome
as	25344395	1834	1836	O
well	25344395	1837	1841	O
as	25344395	1842	1844	O
muscle	25344395	1845	1851	B-Outcome
mass	25344395	1852	1856	I-Outcome
and	25344395	1857	1860	O
health-related	25344395	1861	1875	B-Outcome
quality	25344395	1876	1883	I-Outcome
of	25344395	1884	1886	I-Outcome
life	25344395	1887	1891	I-Outcome
in	25344395	1892	1894	O
patients	25344395	1895	1903	O
with	25344395	1904	1908	O
PM	25344395	1909	1911	O
and	25344395	1912	1915	O
DM	25344395	1916	1918	O
.	25344395	1918	1919	O

TRIAL	25344395	1921	1926	O
REGISTRATION	25344395	1927	1939	O
:	25344395	1940	1941	O
Clinicaltrials.gov	25344395	1942	1960	O
NCT01501019	25344395	1961	1972	O
.	25344395	1972	1973	O

Registered	25344395	1974	1984	O
November	25344395	1985	1993	O
29	25344395	1994	1996	O
,	25344395	1996	1997	O
2011	25344395	1998	2002	O
.	25344395	2002	2003	O


Atomoxetine	25369243	0	11	O
in	25369243	12	14	O
autism	25369243	15	21	O
spectrum	25369243	22	30	O
disorder	25369243	31	39	O
:	25369243	39	40	O
no	25369243	41	43	O
effects	25369243	44	51	O
on	25369243	52	54	O
social	25369243	55	61	O
functioning	25369243	62	73	O
;	25369243	73	74	O
some	25369243	75	79	O
beneficial	25369243	80	90	O
effects	25369243	91	98	O
on	25369243	99	101	O
stereotyped	25369243	102	113	O
behaviors	25369243	114	123	O
,	25369243	123	124	O
inappropriate	25369243	125	138	O
speech	25369243	139	145	O
,	25369243	145	146	O
and	25369243	147	150	O
fear	25369243	151	155	O
of	25369243	156	158	O
change	25369243	159	165	O
.	25369243	165	166	O

UNLABELLED	25369243	168	178	O
:	25369243	179	180	O
Abstract	25369243	181	189	O
Objective	25369243	190	199	O
:	25369243	199	200	O
The	25369243	201	204	O
objective	25369243	205	214	O
of	25369243	215	217	O
this	25369243	218	222	O
study	25369243	223	228	O
was	25369243	229	232	O
to	25369243	233	235	O
investigate	25369243	236	247	O
the	25369243	248	251	O
short-term	25369243	252	262	O
treatment	25369243	263	272	O
effects	25369243	273	280	O
of	25369243	281	283	O
atomoxetine	25369243	284	295	O
on	25369243	296	298	O
autism	25369243	299	305	O
spectrum	25369243	306	314	O
disorder	25369243	315	323	O
(	25369243	324	325	O
ASD	25369243	325	328	O
)	25369243	328	329	O
symptoms	25369243	330	338	O
in	25369243	339	341	O
children	25369243	342	350	O
and	25369243	351	354	O
adolescents	25369243	355	366	O
with	25369243	367	371	O
both	25369243	372	376	O
ASD	25369243	377	380	O
and	25369243	381	384	O
attention-deficit/hyperactivity	25369243	385	416	O
disorder	25369243	417	425	O
(	25369243	426	427	O
ADHD	25369243	427	431	O
)	25369243	431	432	O
.	25369243	432	433	O

METHODS	25369243	435	442	O
:	25369243	443	444	O
A	25369243	445	446	O
total	25369243	447	452	O
of	25369243	453	455	O
97	25369243	456	458	O
patients	25369243	459	467	O
6	25369243	468	469	O
-	25369243	469	470	O
17	25369243	470	472	O
years	25369243	473	478	O
of	25369243	479	481	O
age	25369243	482	485	O
,	25369243	485	486	O
with	25369243	487	491	O
ASD	25369243	492	495	O
and	25369243	496	499	O
ADHD	25369243	500	504	O
,	25369243	504	505	O
were	25369243	506	510	O
treated	25369243	511	518	O
with	25369243	519	523	O
1.2	25369243	524	527	O
mg/kg/day	25369243	528	537	O
of	25369243	538	540	O
atomoxetine	25369243	541	552	O
during	25369243	553	559	O
an	25369243	560	562	O
8	25369243	563	564	O
week	25369243	565	569	O
double-blind	25369243	570	582	O
placebo-controlled	25369243	583	601	O
period	25369243	602	608	O
.	25369243	608	609	O

Here	25369243	610	614	O
,	25369243	614	615	O
we	25369243	616	618	O
investigated	25369243	619	631	O
effects	25369243	632	639	O
on	25369243	640	642	O
two	25369243	643	646	O
parent-based	25369243	647	659	O
secondary	25369243	660	669	O
outcome	25369243	670	677	O
measures	25369243	678	686	O
,	25369243	686	687	O
the	25369243	688	691	O
Aberrant	25369243	692	700	O
Behavior	25369243	701	709	O
Checklist	25369243	710	719	O
(	25369243	720	721	O
ABC	25369243	721	724	O
)	25369243	724	725	O
and	25369243	726	729	O
the	25369243	730	733	O
Children	25369243	734	742	O
's	25369243	742	744	O
Social	25369243	745	751	O
Behavior	25369243	752	760	O
Questionnaire	25369243	761	774	O
(	25369243	775	776	O
CSBQ	25369243	776	780	O
)	25369243	780	781	O
.	25369243	781	782	O

RESULTS	25369243	784	791	O
:	25369243	792	793	O
After	25369243	794	799	O
8	25369243	800	801	O
weeks	25369243	802	807	O
of	25369243	808	810	O
double-blind	25369243	811	823	O
treatment	25369243	824	833	O
,	25369243	833	834	O
atomoxetine	25369243	835	846	O
administration	25369243	847	861	O
was	25369243	862	865	O
associated	25369243	866	876	O
with	25369243	877	881	O
significant	25369243	882	893	O
treatment	25369243	894	903	O
effects	25369243	904	911	O
on	25369243	912	914	O
the	25369243	915	918	O
ABC	25369243	919	922	B-Outcome
subscales	25369243	923	932	I-Outcome
Hyperactivity	25369243	933	946	B-Outcome
,	25369243	946	947	O
Inappropriate	25369243	948	961	B-Outcome
Speech	25369243	962	968	I-Outcome
,	25369243	968	969	O
and	25369243	970	973	O
Stereotypic	25369243	974	985	B-Outcome
Behavior	25369243	986	994	I-Outcome
,	25369243	994	995	O
and	25369243	996	999	O
on	25369243	1000	1002	O
the	25369243	1003	1006	O
CSBQ	25369243	1007	1011	B-Outcome
subscale	25369243	1012	1020	I-Outcome
Fear	25369243	1021	1025	I-Outcome
for	25369243	1026	1029	I-Outcome
Changes	25369243	1030	1037	I-Outcome
.	25369243	1037	1038	O

CONCLUSIONS	25369243	1040	1051	O
:	25369243	1052	1053	O
Our	25369243	1054	1057	O
study	25369243	1058	1063	O
results	25369243	1064	1071	O
indicate	25369243	1072	1080	O
no	25369243	1081	1083	O
beneficial	25369243	1084	1094	O
effects	25369243	1095	1102	O
of	25369243	1103	1105	O
atomoxetine	25369243	1106	1117	O
on	25369243	1118	1120	O
social	25369243	1121	1127	B-Outcome
functioning	25369243	1128	1139	I-Outcome
.	25369243	1139	1140	O

However	25369243	1141	1148	O
,	25369243	1148	1149	O
atomoxetine	25369243	1150	1161	O
may	25369243	1162	1165	O
ameliorate	25369243	1166	1176	O
restricted	25369243	1177	1187	O
and	25369243	1188	1191	O
stereotyped	25369243	1192	1203	O
behaviors	25369243	1204	1213	O
and	25369243	1214	1217	O
communication	25369243	1218	1231	O
.	25369243	1231	1232	O

This	25369243	1233	1237	O
study	25369243	1238	1243	O
has	25369243	1244	1247	O
been	25369243	1248	1252	O
registered	25369243	1253	1263	O
in	25369243	1264	1266	O
ClinicalTrials.gov	25369243	1267	1285	O
(	25369243	1286	1287	O
www.clinicaltrials.gov	25369243	1288	1310	O
)	25369243	1311	1312	O
under	25369243	1313	1318	O
registration	25369243	1319	1331	O
number	25369243	1332	1338	O
NCT00380692	25369243	1339	1350	O
.	25369243	1350	1351	O


Anthropometric	25407464	0	14	O
indices	25407464	15	22	O
of	25407464	23	25	O
Gambian	25407464	26	33	O
children	25407464	34	42	O
after	25407464	43	48	O
one	25407464	49	52	O
or	25407464	53	55	O
three	25407464	56	61	O
annual	25407464	62	68	O
rounds	25407464	69	75	O
of	25407464	76	78	O
mass	25407464	79	83	O
drug	25407464	84	88	O
administration	25407464	89	103	O
with	25407464	104	108	O
azithromycin	25407464	109	121	O
for	25407464	122	125	O
trachoma	25407464	126	134	O
control	25407464	135	142	O
.	25407464	142	143	O

BACKGROUND	25407464	145	155	O
:	25407464	156	157	O
Mass	25407464	158	162	O
drug	25407464	163	167	O
administration	25407464	168	182	O
(	25407464	183	184	O
MDA	25407464	184	187	O
)	25407464	187	188	O
with	25407464	189	193	O
azithromycin	25407464	194	206	O
,	25407464	206	207	O
carried	25407464	208	215	O
out	25407464	216	219	O
for	25407464	220	223	O
the	25407464	224	227	O
control	25407464	228	235	O
of	25407464	236	238	O
blinding	25407464	239	247	O
trachoma	25407464	248	256	O
,	25407464	256	257	O
has	25407464	258	261	O
been	25407464	262	266	O
linked	25407464	267	273	O
to	25407464	274	276	O
reduced	25407464	277	284	O
mortality	25407464	285	294	O
in	25407464	295	297	O
children	25407464	298	306	O
.	25407464	306	307	O

While	25407464	308	313	O
the	25407464	314	317	O
mechanism	25407464	318	327	O
behind	25407464	328	334	O
this	25407464	335	339	O
reduction	25407464	340	349	O
is	25407464	350	352	O
unclear	25407464	353	360	O
,	25407464	360	361	O
it	25407464	362	364	O
may	25407464	365	368	O
be	25407464	369	371	O
due	25407464	372	375	O
,	25407464	375	376	O
in	25407464	377	379	O
part	25407464	380	384	O
,	25407464	384	385	O
to	25407464	386	388	O
improved	25407464	389	397	O
nutritional	25407464	398	409	O
status	25407464	410	416	O
via	25407464	417	420	O
a	25407464	421	422	O
potential	25407464	423	432	O
reduction	25407464	433	442	O
in	25407464	443	445	O
the	25407464	446	449	O
community	25407464	450	459	O
burden	25407464	460	466	O
of	25407464	467	469	O
infectious	25407464	470	480	O
disease	25407464	481	488	O
.	25407464	488	489	O

To	25407464	490	492	O
determine	25407464	493	502	O
whether	25407464	503	510	O
MDA	25407464	511	514	O
with	25407464	515	519	O
azithromycin	25407464	520	532	O
improves	25407464	533	541	O
anthropometric	25407464	542	556	O
indices	25407464	557	564	O
at	25407464	565	567	O
the	25407464	568	571	O
community	25407464	572	581	O
level	25407464	582	587	O
,	25407464	587	588	O
we	25407464	589	591	O
measured	25407464	592	600	O
the	25407464	601	604	O
heights	25407464	605	612	O
and	25407464	613	616	O
weights	25407464	617	624	O
of	25407464	625	627	O
children	25407464	628	636	O
aged	25407464	637	641	O
1	25407464	642	643	O
to	25407464	644	646	O
4	25407464	647	648	O
years	25407464	649	654	O
in	25407464	655	657	O
communities	25407464	658	669	O
where	25407464	670	675	O
one	25407464	676	679	O
(	25407464	680	681	O
single	25407464	681	687	O
MDA	25407464	688	691	O
arm	25407464	692	695	O
)	25407464	695	696	O
or	25407464	697	699	O
three	25407464	700	705	O
annual	25407464	706	712	O
rounds	25407464	713	719	O
(	25407464	720	721	O
annual	25407464	721	727	O
MDA	25407464	728	731	O
arm	25407464	732	735	O
)	25407464	735	736	O
of	25407464	737	739	O
azithromycin	25407464	740	752	O
had	25407464	753	756	O
been	25407464	757	761	O
distributed	25407464	762	773	O
.	25407464	773	774	O

METHODS	25407464	776	783	O
:	25407464	784	785	O
Data	25407464	786	790	O
collection	25407464	791	801	O
took	25407464	802	806	O
place	25407464	807	812	O
three	25407464	813	818	O
years	25407464	819	824	O
after	25407464	825	830	O
treatment	25407464	831	840	O
in	25407464	841	843	O
the	25407464	844	847	O
single	25407464	848	854	O
MDA	25407464	855	858	O
arm	25407464	859	862	O
and	25407464	863	866	O
one	25407464	867	870	O
year	25407464	871	875	O
after	25407464	876	881	O
the	25407464	882	885	O
final	25407464	886	891	O
round	25407464	892	897	O
of	25407464	898	900	O
treatment	25407464	901	910	O
in	25407464	911	913	O
the	25407464	914	917	O
annual	25407464	918	924	O
MDA	25407464	925	928	O
arm	25407464	929	932	O
.	25407464	932	933	O

Mean	25407464	934	938	O
height-for-age	25407464	939	953	O
,	25407464	953	954	O
weight-for-age	25407464	955	969	O
and	25407464	970	973	O
weight-for-height	25407464	974	991	O
z	25407464	992	993	O
scores	25407464	994	1000	O
were	25407464	1001	1005	O
compared	25407464	1006	1014	O
between	25407464	1015	1022	O
treatment	25407464	1023	1032	O
arms	25407464	1033	1037	O
.	25407464	1037	1038	O

RESULTS	25407464	1040	1047	O
:	25407464	1048	1049	O
No	25407464	1050	1052	O
significant	25407464	1053	1064	O
differences	25407464	1065	1076	O
in	25407464	1077	1079	O
mean	25407464	1080	1084	B-Outcome
height-for-age	25407464	1085	1099	I-Outcome
,	25407464	1099	1100	O
weight-for-age	25407464	1101	1115	B-Outcome
or	25407464	1116	1118	O
weight-for-height	25407464	1119	1136	B-Outcome
z	25407464	1137	1138	I-Outcome
scores	25407464	1139	1145	I-Outcome
were	25407464	1146	1150	O
found	25407464	1151	1156	O
between	25407464	1157	1164	O
the	25407464	1165	1168	O
annual	25407464	1169	1175	O
MDA	25407464	1176	1179	O
and	25407464	1180	1183	O
single	25407464	1184	1190	O
MDA	25407464	1191	1194	O
arms	25407464	1195	1199	O
,	25407464	1199	1200	O
nor	25407464	1201	1204	O
was	25407464	1205	1208	O
there	25407464	1209	1214	O
a	25407464	1215	1216	O
significant	25407464	1217	1228	O
reduction	25407464	1229	1238	O
in	25407464	1239	1241	O
prevalence	25407464	1242	1252	B-Outcome
of	25407464	1253	1255	I-Outcome
stunting	25407464	1256	1264	I-Outcome
,	25407464	1264	1265	O
wasting	25407464	1266	1273	B-Outcome
or	25407464	1274	1276	O
underweight	25407464	1277	1288	B-Outcome
between	25407464	1289	1296	O
arms	25407464	1297	1301	O
.	25407464	1301	1302	O

CONCLUSIONS	25407464	1304	1315	O
:	25407464	1316	1317	O
Our	25407464	1318	1321	O
data	25407464	1322	1326	O
do	25407464	1327	1329	O
not	25407464	1330	1333	O
provide	25407464	1334	1341	O
evidence	25407464	1342	1350	O
that	25407464	1351	1355	O
community	25407464	1356	1365	O
MDA	25407464	1366	1369	O
with	25407464	1370	1374	O
azithromycin	25407464	1375	1387	O
improved	25407464	1388	1396	O
anthropometric	25407464	1397	1411	B-Outcome
outcomes	25407464	1412	1420	I-Outcome
of	25407464	1421	1423	O
children	25407464	1424	1432	O
in	25407464	1433	1435	O
The	25407464	1436	1439	O
Gambia	25407464	1440	1446	O
.	25407464	1446	1447	O

This	25407464	1448	1452	O
may	25407464	1453	1456	O
suggest	25407464	1457	1464	O
reductions	25407464	1465	1475	O
in	25407464	1476	1478	O
mortality	25407464	1479	1488	O
associated	25407464	1489	1499	O
with	25407464	1500	1504	O
azithromycin	25407464	1505	1517	O
MDA	25407464	1518	1521	O
are	25407464	1522	1525	O
due	25407464	1526	1529	O
to	25407464	1530	1532	O
a	25407464	1533	1534	O
mechanism	25407464	1535	1544	O
other	25407464	1545	1550	O
than	25407464	1551	1555	O
improved	25407464	1556	1564	O
nutritional	25407464	1565	1576	O
status	25407464	1577	1583	O
.	25407464	1583	1584	O


A	25675062	0	1	O
randomized	25675062	2	12	O
,	25675062	12	13	O
double-blind	25675062	14	26	O
controlled	25675062	27	37	O
trial	25675062	38	43	O
of	25675062	44	46	O
lumbar	25675062	47	53	O
interlaminar	25675062	54	66	O
epidural	25675062	67	75	O
injections	25675062	76	86	O
in	25675062	87	89	O
central	25675062	90	97	O
spinal	25675062	98	104	O
stenosis	25675062	105	113	O
:	25675062	113	114	O
2-year	25675062	115	121	O
follow-up	25675062	122	131	O
.	25675062	131	132	O

BACKGROUND	25675062	134	144	O
:	25675062	145	146	O
While	25675062	147	152	O
low	25675062	153	156	O
back	25675062	157	161	O
pain	25675062	162	166	O
is	25675062	167	169	O
the	25675062	170	173	O
number	25675062	174	180	O
one	25675062	181	184	O
cause	25675062	185	190	O
of	25675062	191	193	O
disability	25675062	194	204	O
in	25675062	205	207	O
the	25675062	208	211	O
United	25675062	212	218	O
States	25675062	219	225	O
,	25675062	225	226	O
lumbar	25675062	227	233	O
spinal	25675062	234	240	O
stenosis	25675062	241	249	O
along	25675062	250	255	O
with	25675062	256	260	O
intervertebral	25675062	261	275	O
disc	25675062	276	280	O
herniation	25675062	281	291	O
and	25675062	292	295	O
degenerative	25675062	296	308	O
spondylolisthesis	25675062	309	326	O
is	25675062	327	329	O
one	25675062	330	333	O
of	25675062	334	336	O
the	25675062	337	340	O
3	25675062	341	342	O
most	25675062	343	347	O
common	25675062	348	354	O
diagnosis	25675062	355	364	O
of	25675062	365	367	O
low	25675062	368	371	O
back	25675062	372	376	O
and	25675062	377	380	O
leg	25675062	381	384	O
pain	25675062	385	389	O
for	25675062	390	393	O
which	25675062	394	399	O
surgery	25675062	400	407	O
is	25675062	408	410	O
performed	25675062	411	420	O
.	25675062	420	421	O

Numerous	25675062	422	430	O
modalities	25675062	431	441	O
of	25675062	442	444	O
treatments	25675062	445	455	O
including	25675062	456	465	O
drug	25675062	466	470	O
therapy	25675062	471	478	O
and	25675062	479	482	O
complex	25675062	483	490	O
surgical	25675062	491	499	O
fusions	25675062	500	507	O
have	25675062	508	512	O
been	25675062	513	517	O
recommended	25675062	518	529	O
for	25675062	530	533	O
treatment	25675062	534	543	O
of	25675062	544	546	O
central	25675062	547	554	O
spinal	25675062	555	561	O
stenosis	25675062	562	570	O
.	25675062	570	571	O

Epidural	25675062	572	580	O
injections	25675062	581	591	O
are	25675062	592	595	O
one	25675062	596	599	O
of	25675062	600	602	O
the	25675062	603	606	O
commonly	25675062	607	615	O
performed	25675062	616	625	O
nonsurgical	25675062	626	637	O
interventions	25675062	638	651	O
in	25675062	652	654	O
managing	25675062	655	663	O
central	25675062	664	671	O
spinal	25675062	672	678	O
stenosis	25675062	679	687	O
;	25675062	687	688	O
however	25675062	689	696	O
,	25675062	696	697	O
there	25675062	698	703	O
has	25675062	704	707	O
been	25675062	708	712	O
paucity	25675062	713	720	O
of	25675062	721	723	O
literature	25675062	724	734	O
in	25675062	735	737	O
reference	25675062	738	747	O
to	25675062	748	750	O
efficacy	25675062	751	759	O
of	25675062	760	762	O
epidural	25675062	763	771	O
injections	25675062	772	782	O
in	25675062	783	785	O
managing	25675062	786	794	O
central	25675062	795	802	O
spinal	25675062	803	809	O
stenosis	25675062	810	818	O
with	25675062	819	823	O
lumbar	25675062	824	830	O
interlaminar	25675062	831	843	O
epidural	25675062	844	852	O
injections	25675062	853	863	O
.	25675062	863	864	O

STUDY	25675062	866	871	O
DESIGN	25675062	872	878	O
:	25675062	879	880	O
A	25675062	881	882	O
randomized	25675062	883	893	O
,	25675062	893	894	O
double-blind	25675062	895	907	O
,	25675062	907	908	O
active	25675062	909	915	O
controlled	25675062	916	926	O
trial	25675062	927	932	O
.	25675062	932	933	O

SETTING	25675062	935	942	O
:	25675062	943	944	O
Private	25675062	945	952	O
interventional	25675062	953	967	O
pain	25675062	968	972	O
management	25675062	973	983	O
practice	25675062	984	992	O
and	25675062	993	996	O
specialty	25675062	997	1006	O
referral	25675062	1007	1015	O
center	25675062	1016	1022	O
in	25675062	1023	1025	O
the	25675062	1026	1029	O
United	25675062	1030	1036	O
States	25675062	1037	1043	O
.	25675062	1043	1044	O

OBJECTIVE	25675062	1046	1055	O
:	25675062	1056	1057	O
To	25675062	1058	1060	O
assess	25675062	1061	1067	O
the	25675062	1068	1071	O
effectiveness	25675062	1072	1085	O
of	25675062	1086	1088	O
lumbar	25675062	1089	1095	O
interlaminar	25675062	1096	1108	O
epidural	25675062	1109	1117	O
injections	25675062	1118	1128	O
with	25675062	1129	1133	O
or	25675062	1134	1136	O
without	25675062	1137	1144	O
steroids	25675062	1145	1153	O
in	25675062	1154	1156	O
providing	25675062	1157	1166	O
effective	25675062	1167	1176	O
and	25675062	1177	1180	O
long-lasting	25675062	1181	1193	O
pain	25675062	1194	1198	O
relief	25675062	1199	1205	O
with	25675062	1206	1210	O
improvement	25675062	1211	1222	O
in	25675062	1223	1225	O
functional	25675062	1226	1236	O
status	25675062	1237	1243	O
for	25675062	1244	1247	O
the	25675062	1248	1251	O
management	25675062	1252	1262	O
of	25675062	1263	1265	O
chronic	25675062	1266	1273	O
low	25675062	1274	1277	O
back	25675062	1278	1282	O
and	25675062	1283	1286	O
lower	25675062	1287	1292	O
extremity	25675062	1293	1302	O
pain	25675062	1303	1307	O
related	25675062	1308	1315	O
to	25675062	1316	1318	O
lumbar	25675062	1319	1325	O
central	25675062	1326	1333	O
spinal	25675062	1334	1340	O
stenosis	25675062	1341	1349	O
.	25675062	1349	1350	O

METHODS	25675062	1352	1359	O
:	25675062	1360	1361	O
A	25675062	1362	1363	O
randomized	25675062	1364	1374	O
,	25675062	1374	1375	O
double-blind	25675062	1376	1388	O
,	25675062	1388	1389	O
active-control	25675062	1390	1404	O
trial	25675062	1405	1410	O
was	25675062	1411	1414	O
designed	25675062	1415	1423	O
with	25675062	1424	1428	O
the	25675062	1429	1432	O
inclusion	25675062	1433	1442	O
of	25675062	1443	1445	O
120	25675062	1446	1449	O
patients	25675062	1450	1458	O
assigned	25675062	1459	1467	O
to	25675062	1468	1470	O
2	25675062	1471	1472	O
groups	25675062	1473	1479	O
.	25675062	1479	1480	O

Group	25675062	1481	1486	O
I	25675062	1487	1488	O
patients	25675062	1489	1497	O
received	25675062	1498	1506	O
lumbar	25675062	1507	1513	O
interlaminar	25675062	1514	1526	O
epidural	25675062	1527	1535	O
injections	25675062	1536	1546	O
of	25675062	1547	1549	O
local	25675062	1550	1555	O
anesthetic	25675062	1556	1566	O
(	25675062	1567	1568	O
lidocaine	25675062	1568	1577	O
0.5	25675062	1578	1581	O
%	25675062	1581	1582	O
)	25675062	1582	1583	O
6	25675062	1584	1585	O
mL	25675062	1586	1588	O
,	25675062	1588	1589	O
whereas	25675062	1590	1597	O
Group	25675062	1598	1603	O
II	25675062	1604	1606	O
received	25675062	1607	1615	O
lumbar	25675062	1616	1622	O
interlaminar	25675062	1623	1635	O
epidural	25675062	1636	1644	O
injections	25675062	1645	1655	O
with	25675062	1656	1660	O
local	25675062	1661	1666	O
anesthetic	25675062	1667	1677	O
(	25675062	1678	1679	O
lidocaine	25675062	1679	1688	O
0.5	25675062	1689	1692	O
%	25675062	1692	1693	O
)	25675062	1693	1694	O
5	25675062	1695	1696	O
mL	25675062	1697	1699	O
mixed	25675062	1700	1705	O
with	25675062	1706	1710	O
1	25675062	1711	1712	O
mL	25675062	1713	1715	O
of	25675062	1716	1718	O
steroids	25675062	1719	1727	O
and	25675062	1728	1731	O
6	25675062	1732	1733	O
mg	25675062	1734	1736	O
of	25675062	1737	1739	O
betamethasone	25675062	1740	1753	O
.	25675062	1753	1754	O

OUTCOMES	25675062	1756	1764	O
ASSESSMENT	25675062	1765	1775	O
:	25675062	1776	1777	O
Outcomes	25675062	1778	1786	O
were	25675062	1787	1791	O
assessed	25675062	1792	1800	O
utilizing	25675062	1801	1810	O
the	25675062	1811	1814	O
numeric	25675062	1815	1822	O
pain	25675062	1823	1827	O
rating	25675062	1828	1834	O
scale	25675062	1835	1840	O
(	25675062	1841	1842	O
NRS	25675062	1842	1845	O
)	25675062	1845	1846	O
and	25675062	1847	1850	O
Oswestry	25675062	1851	1859	O
Disability	25675062	1860	1870	O
Index	25675062	1871	1876	O
(	25675062	1877	1878	O
ODI	25675062	1878	1881	O
)	25675062	1881	1882	O
at	25675062	1883	1885	O
3	25675062	1886	1887	O
,	25675062	1887	1888	O
6	25675062	1889	1890	O
,	25675062	1890	1891	O
12	25675062	1892	1894	O
,	25675062	1894	1895	O
18	25675062	1896	1898	O
,	25675062	1898	1899	O
and	25675062	1900	1903	O
24	25675062	1904	1906	O
months	25675062	1907	1913	O
post	25675062	1914	1918	O
treatment	25675062	1919	1928	O
.	25675062	1928	1929	O

The	25675062	1930	1933	O
primary	25675062	1934	1941	O
outcome	25675062	1942	1949	O
measure	25675062	1950	1957	O
was	25675062	1958	1961	O
significant	25675062	1962	1973	O
improvement	25675062	1974	1985	O
,	25675062	1985	1986	O
defined	25675062	1987	1994	O
as	25675062	1995	1997	O
50	25675062	1998	2000	O
%	25675062	2000	2001	O
improvement	25675062	2002	2013	O
in	25675062	2014	2016	O
pain	25675062	2017	2021	O
and	25675062	2022	2025	O
disability	25675062	2026	2036	O
scores	25675062	2037	2043	O
.	25675062	2043	2044	O

RESULTS	25675062	2046	2053	O
:	25675062	2054	2055	O
Significant	25675062	2056	2067	B-Outcome
relief	25675062	2068	2074	I-Outcome
and	25675062	2075	2078	O
functional	25675062	2079	2089	B-Outcome
status	25675062	2090	2096	I-Outcome
improvement	25675062	2097	2108	I-Outcome
was	25675062	2109	2112	O
seen	25675062	2113	2117	O
in	25675062	2118	2120	O
72	25675062	2121	2123	O
%	25675062	2123	2124	O
and	25675062	2125	2128	O
73	25675062	2129	2131	O
%	25675062	2131	2132	O
of	25675062	2133	2135	O
patients	25675062	2136	2144	O
in	25675062	2145	2147	O
Groups	25675062	2148	2154	O
I	25675062	2155	2156	O
and	25675062	2157	2160	O
II	25675062	2161	2163	O
at	25675062	2164	2166	O
the	25675062	2167	2170	O
end	25675062	2171	2174	O
of	25675062	2175	2177	O
2	25675062	2178	2179	O
years	25675062	2180	2185	O
considering	25675062	2186	2197	O
all	25675062	2198	2201	O
participants	25675062	2202	2214	O
;	25675062	2214	2215	O
however	25675062	2216	2223	O
,	25675062	2223	2224	O
this	25675062	2225	2229	O
was	25675062	2230	2233	O
84	25675062	2234	2236	O
%	25675062	2236	2237	O
and	25675062	2238	2241	O
85	25675062	2242	2244	O
%	25675062	2244	2245	O
in	25675062	2246	2248	O
the	25675062	2249	2252	O
successful	25675062	2253	2263	O
group	25675062	2264	2269	O
.	25675062	2269	2270	O

Overall	25675062	2271	2278	O
significant	25675062	2279	2290	O
improvement	25675062	2291	2302	O
was	25675062	2303	2306	O
achieved	25675062	2307	2315	O
for	25675062	2316	2319	O
65.7	25675062	2320	2324	O
±	25675062	2325	2326	O
37.3	25675062	2327	2331	O
weeks	25675062	2332	2337	O
in	25675062	2338	2340	O
Group	25675062	2341	2346	O
1	25675062	2347	2348	O
and	25675062	2349	2352	O
68.9	25675062	2353	2357	O
±	25675062	2358	2359	O
37.7	25675062	2360	2364	O
weeks	25675062	2365	2370	O
in	25675062	2371	2373	O
Group	25675062	2374	2379	O
II	25675062	2380	2382	O
at	25675062	2383	2385	O
the	25675062	2386	2389	O
end	25675062	2390	2393	O
of	25675062	2394	2396	O
2	25675062	2397	2398	O
years	25675062	2399	2404	O
when	25675062	2405	2409	O
all	25675062	2410	2413	O
participants	25675062	2414	2426	O
were	25675062	2427	2431	O
considered	25675062	2432	2442	O
;	25675062	2442	2443	O
whereas	25675062	2444	2451	O
,	25675062	2451	2452	O
this	25675062	2453	2457	O
was	25675062	2458	2461	O
77	25675062	2462	2464	O
±	25675062	2465	2466	O
27.8	25675062	2467	2471	O
weeks	25675062	2472	2477	O
and	25675062	2478	2481	O
77.9	25675062	2482	2486	O
±	25675062	2487	2488	O
30.2	25675062	2489	2493	O
weeks	25675062	2494	2499	O
when	25675062	2500	2504	O
they	25675062	2505	2509	O
were	25675062	2510	2514	O
separated	25675062	2515	2524	O
into	25675062	2525	2529	O
successful	25675062	2530	2540	O
categories	25675062	2541	2551	O
.	25675062	2551	2552	O

The	25675062	2553	2556	O
average	25675062	2557	2564	O
number	25675062	2565	2571	O
of	25675062	2572	2574	O
procedures	25675062	2575	2585	O
per	25675062	2586	2589	O
patient	25675062	2590	2597	O
was	25675062	2598	2601	O
5	25675062	2602	2603	O
to	25675062	2604	2606	O
6	25675062	2607	2608	O
in	25675062	2609	2611	O
both	25675062	2612	2616	O
groups	25675062	2617	2623	O
.	25675062	2623	2624	O

LIMITATIONS	25675062	2626	2637	O
:	25675062	2638	2639	O
Limitations	25675062	2640	2651	O
of	25675062	2652	2654	O
this	25675062	2655	2659	O
trial	25675062	2660	2665	O
include	25675062	2666	2673	O
lack	25675062	2674	2678	O
of	25675062	2679	2681	O
placebo	25675062	2682	2689	O
control	25675062	2690	2697	O
group	25675062	2698	2703	O
and	25675062	2704	2707	O
treatment	25675062	2708	2717	O
of	25675062	2718	2720	O
patients	25675062	2721	2729	O
with	25675062	2730	2734	O
multiple	25675062	2735	2743	O
procedures	25675062	2744	2754	O
over	25675062	2755	2759	O
a	25675062	2760	2761	O
period	25675062	2762	2768	O
of	25675062	2769	2771	O
2	25675062	2772	2773	O
years	25675062	2774	2779	O
.	25675062	2779	2780	O

CONCLUSION	25675062	2782	2792	O
:	25675062	2793	2794	O
Lumbar	25675062	2795	2801	O
interlaminar	25675062	2802	2814	O
epidural	25675062	2815	2823	O
injections	25675062	2824	2834	O
of	25675062	2835	2837	O
local	25675062	2838	2843	O
anesthetic	25675062	2844	2854	O
with	25675062	2855	2859	O
or	25675062	2860	2862	O
without	25675062	2863	2870	O
steroids	25675062	2871	2879	O
provide	25675062	2880	2887	O
relief	25675062	2888	2894	B-Outcome
in	25675062	2895	2897	O
a	25675062	2898	2899	O
significant	25675062	2900	2911	O
proportion	25675062	2912	2922	O
of	25675062	2923	2925	O
patients	25675062	2926	2934	O
with	25675062	2935	2939	O
lumbar	25675062	2940	2946	O
central	25675062	2947	2954	O
spinal	25675062	2955	2961	O
stenosis	25675062	2962	2970	O
.	25675062	2970	2971	O

CLINICAL	25675062	2973	2981	O
TRIAL	25675062	2982	2987	O
:	25675062	2988	2989	O
NCT00681447	25675062	2990	3001	O
.	25675062	3001	3002	O


Safety	25798575	0	6	O
and	25798575	7	10	O
benefit	25798575	11	18	O
of	25798575	19	21	O
discontinuing	25798575	22	35	O
statin	25798575	36	42	O
therapy	25798575	43	50	O
in	25798575	51	53	O
the	25798575	54	57	O
setting	25798575	58	65	O
of	25798575	66	68	O
advanced	25798575	69	77	O
,	25798575	77	78	O
life-limiting	25798575	79	92	O
illness	25798575	93	100	O
:	25798575	100	101	O
a	25798575	102	103	O
randomized	25798575	104	114	O
clinical	25798575	115	123	O
trial	25798575	124	129	O
.	25798575	129	130	O

IMPORTANCE	25798575	132	142	O
:	25798575	143	144	O
For	25798575	145	148	O
patients	25798575	149	157	O
with	25798575	158	162	O
limited	25798575	163	170	O
prognosis	25798575	171	180	O
,	25798575	180	181	O
some	25798575	182	186	O
medication	25798575	187	197	O
risks	25798575	198	203	O
may	25798575	204	207	O
outweigh	25798575	208	216	O
the	25798575	217	220	O
benefits	25798575	221	229	O
,	25798575	229	230	O
particularly	25798575	231	243	O
when	25798575	244	248	O
benefits	25798575	249	257	O
take	25798575	258	262	O
years	25798575	263	268	O
to	25798575	269	271	O
accrue	25798575	272	278	O
;	25798575	278	279	O
statins	25798575	280	287	O
are	25798575	288	291	O
one	25798575	292	295	O
example	25798575	296	303	O
.	25798575	303	304	O

Data	25798575	305	309	O
are	25798575	310	313	O
lacking	25798575	314	321	O
regarding	25798575	322	331	O
the	25798575	332	335	O
risks	25798575	336	341	O
and	25798575	342	345	O
benefits	25798575	346	354	O
of	25798575	355	357	O
discontinuing	25798575	358	371	O
statin	25798575	372	378	O
therapy	25798575	379	386	O
for	25798575	387	390	O
patients	25798575	391	399	O
with	25798575	400	404	O
limited	25798575	405	412	O
life	25798575	413	417	O
expectancy	25798575	418	428	O
.	25798575	428	429	O

OBJECTIVE	25798575	431	440	O
:	25798575	441	442	O
To	25798575	443	445	O
evaluate	25798575	446	454	O
the	25798575	455	458	O
safety	25798575	459	465	O
,	25798575	465	466	O
clinical	25798575	467	475	O
,	25798575	475	476	O
and	25798575	477	480	O
cost	25798575	481	485	O
impact	25798575	486	492	O
of	25798575	493	495	O
discontinuing	25798575	496	509	O
statin	25798575	510	516	O
medications	25798575	517	528	O
for	25798575	529	532	O
patients	25798575	533	541	O
in	25798575	542	544	O
the	25798575	545	548	O
palliative	25798575	549	559	O
care	25798575	560	564	O
setting	25798575	565	572	O
.	25798575	572	573	O

DESIGN	25798575	575	581	O
,	25798575	581	582	O
SETTING	25798575	583	590	O
,	25798575	590	591	O
AND	25798575	592	595	O
PARTICIPANTS	25798575	596	608	O
:	25798575	609	610	O
This	25798575	611	615	O
was	25798575	616	619	O
a	25798575	620	621	O
multicenter	25798575	622	633	O
,	25798575	633	634	O
parallel-group	25798575	635	649	O
,	25798575	649	650	O
unblinded	25798575	651	660	O
,	25798575	660	661	O
pragmatic	25798575	662	671	O
clinical	25798575	672	680	O
trial	25798575	681	686	O
.	25798575	686	687	O

Eligibility	25798575	688	699	O
included	25798575	700	708	O
adults	25798575	709	715	O
with	25798575	716	720	O
an	25798575	721	723	O
estimated	25798575	724	733	O
life	25798575	734	738	O
expectancy	25798575	739	749	O
of	25798575	750	752	O
between	25798575	753	760	O
1	25798575	761	762	O
month	25798575	763	768	O
and	25798575	769	772	O
1	25798575	773	774	O
year	25798575	775	779	O
,	25798575	779	780	O
statin	25798575	781	787	O
therapy	25798575	788	795	O
for	25798575	796	799	O
3	25798575	800	801	O
months	25798575	802	808	O
or	25798575	809	811	O
more	25798575	812	816	O
for	25798575	817	820	O
primary	25798575	821	828	O
or	25798575	829	831	O
secondary	25798575	832	841	O
prevention	25798575	842	852	O
of	25798575	853	855	O
cardiovascular	25798575	856	870	O
disease	25798575	871	878	O
,	25798575	878	879	O
recent	25798575	880	886	O
deterioration	25798575	887	900	O
in	25798575	901	903	O
functional	25798575	904	914	O
status	25798575	915	921	O
,	25798575	921	922	O
and	25798575	923	926	O
no	25798575	927	929	O
recent	25798575	930	936	O
active	25798575	937	943	O
cardiovascular	25798575	944	958	O
disease	25798575	959	966	O
.	25798575	966	967	O

Participants	25798575	968	980	O
were	25798575	981	985	O
randomized	25798575	986	996	O
to	25798575	997	999	O
either	25798575	1000	1006	O
discontinue	25798575	1007	1018	O
or	25798575	1019	1021	O
continue	25798575	1022	1030	O
statin	25798575	1031	1037	O
therapy	25798575	1038	1045	O
and	25798575	1046	1049	O
were	25798575	1050	1054	O
monitored	25798575	1055	1064	O
monthly	25798575	1065	1072	O
for	25798575	1073	1076	O
up	25798575	1077	1079	O
to	25798575	1080	1082	O
1	25798575	1083	1084	O
year	25798575	1085	1089	O
.	25798575	1089	1090	O

The	25798575	1091	1094	O
study	25798575	1095	1100	O
was	25798575	1101	1104	O
conducted	25798575	1105	1114	O
from	25798575	1115	1119	O
June	25798575	1120	1124	O
3	25798575	1125	1126	O
,	25798575	1126	1127	O
2011	25798575	1128	1132	O
,	25798575	1132	1133	O
to	25798575	1134	1136	O
May	25798575	1137	1140	O
2	25798575	1141	1142	O
,	25798575	1142	1143	O
2013	25798575	1144	1148	O
.	25798575	1148	1149	O

All	25798575	1150	1153	O
analyses	25798575	1154	1162	O
were	25798575	1163	1167	O
performed	25798575	1168	1177	O
using	25798575	1178	1183	O
an	25798575	1184	1186	O
intent-to-treat	25798575	1187	1202	O
approach	25798575	1203	1211	O
.	25798575	1211	1212	O

INTERVENTIONS	25798575	1214	1227	O
:	25798575	1228	1229	O
Statin	25798575	1230	1236	O
therapy	25798575	1237	1244	O
was	25798575	1245	1248	O
withdrawn	25798575	1249	1258	O
from	25798575	1259	1263	O
eligible	25798575	1264	1272	O
patients	25798575	1273	1281	O
who	25798575	1282	1285	O
were	25798575	1286	1290	O
randomized	25798575	1291	1301	O
to	25798575	1302	1304	O
the	25798575	1305	1308	O
discontinuation	25798575	1309	1324	O
group	25798575	1325	1330	O
.	25798575	1330	1331	O

Patients	25798575	1332	1340	O
in	25798575	1341	1343	O
the	25798575	1344	1347	O
continuation	25798575	1348	1360	O
group	25798575	1361	1366	O
continued	25798575	1367	1376	O
to	25798575	1377	1379	O
receive	25798575	1380	1387	O
statins	25798575	1388	1395	O
.	25798575	1395	1396	O

MAIN	25798575	1398	1402	O
OUTCOMES	25798575	1403	1411	O
AND	25798575	1412	1415	O
MEASURES	25798575	1416	1424	O
:	25798575	1425	1426	O
Outcomes	25798575	1427	1435	O
included	25798575	1436	1444	O
death	25798575	1445	1450	O
within	25798575	1451	1457	O
60	25798575	1458	1460	O
days	25798575	1461	1465	O
(	25798575	1466	1467	O
primary	25798575	1467	1474	O
outcome	25798575	1475	1482	O
)	25798575	1482	1483	O
,	25798575	1483	1484	O
survival	25798575	1485	1493	O
,	25798575	1493	1494	O
cardiovascular	25798575	1495	1509	O
events	25798575	1510	1516	O
,	25798575	1516	1517	O
performance	25798575	1518	1529	O
status	25798575	1530	1536	O
,	25798575	1536	1537	O
quality	25798575	1538	1545	O
of	25798575	1546	1548	O
life	25798575	1549	1553	O
(	25798575	1554	1555	O
QOL	25798575	1555	1558	O
)	25798575	1558	1559	O
,	25798575	1559	1560	O
symptoms	25798575	1561	1569	O
,	25798575	1569	1570	O
number	25798575	1571	1577	O
of	25798575	1578	1580	O
nonstatin	25798575	1581	1590	O
medications	25798575	1591	1602	O
,	25798575	1602	1603	O
and	25798575	1604	1607	O
cost	25798575	1608	1612	O
savings	25798575	1613	1620	O
.	25798575	1620	1621	O

RESULTS	25798575	1623	1630	O
:	25798575	1631	1632	O
A	25798575	1633	1634	O
total	25798575	1635	1640	O
of	25798575	1641	1643	O
381	25798575	1644	1647	O
patients	25798575	1648	1656	O
were	25798575	1657	1661	O
enrolled	25798575	1662	1670	O
;	25798575	1670	1671	O
189	25798575	1672	1675	O
of	25798575	1676	1678	O
these	25798575	1679	1684	O
were	25798575	1685	1689	O
randomized	25798575	1690	1700	O
to	25798575	1701	1703	O
discontinue	25798575	1704	1715	O
statins	25798575	1716	1723	O
,	25798575	1723	1724	O
and	25798575	1725	1728	O
192	25798575	1729	1732	O
were	25798575	1733	1737	O
randomized	25798575	1738	1748	O
to	25798575	1749	1751	O
continue	25798575	1752	1760	O
therapy	25798575	1761	1768	O
.	25798575	1768	1769	O

Mean	25798575	1770	1774	O
(	25798575	1775	1776	O
SD	25798575	1776	1778	O
)	25798575	1778	1779	O
age	25798575	1780	1783	O
was	25798575	1784	1787	O
74.1	25798575	1788	1792	O
(	25798575	1793	1794	O
11.6	25798575	1794	1798	O
)	25798575	1798	1799	O
years	25798575	1800	1805	O
,	25798575	1805	1806	O
22.0	25798575	1807	1811	O
%	25798575	1811	1812	O
of	25798575	1813	1815	O
the	25798575	1816	1819	O
participants	25798575	1820	1832	O
were	25798575	1833	1837	O
cognitively	25798575	1838	1849	O
impaired	25798575	1850	1858	O
,	25798575	1858	1859	O
and	25798575	1860	1863	O
48.8	25798575	1864	1868	O
%	25798575	1868	1869	O
had	25798575	1870	1873	O
cancer	25798575	1874	1880	O
.	25798575	1880	1881	O

The	25798575	1882	1885	O
proportion	25798575	1886	1896	O
of	25798575	1897	1899	O
participants	25798575	1900	1912	O
in	25798575	1913	1915	O
the	25798575	1916	1919	O
discontinuation	25798575	1920	1935	O
vs	25798575	1936	1938	O
continuation	25798575	1939	1951	O
groups	25798575	1952	1958	O
who	25798575	1959	1962	O
died	25798575	1963	1967	B-Outcome
within	25798575	1968	1974	I-Outcome
60	25798575	1975	1977	I-Outcome
days	25798575	1978	1982	I-Outcome
was	25798575	1983	1986	O
not	25798575	1987	1990	O
significantly	25798575	1991	2004	O
different	25798575	2005	2014	O
(	25798575	2015	2016	O
23.8	25798575	2016	2020	O
%	25798575	2020	2021	O
vs	25798575	2022	2024	O
20.3	25798575	2025	2029	O
%	25798575	2029	2030	O
;	25798575	2030	2031	O
90	25798575	2032	2034	O
%	25798575	2034	2035	O
CI	25798575	2036	2038	O
,	25798575	2038	2039	O
-3.5	25798575	2040	2044	O
%	25798575	2044	2045	O
to	25798575	2046	2048	O
10.5	25798575	2049	2053	O
%	25798575	2053	2054	O
;	25798575	2054	2055	O
P=.36	25798575	2056	2061	O
)	25798575	2061	2062	O
and	25798575	2063	2066	O
did	25798575	2067	2070	O
not	25798575	2071	2074	O
meet	25798575	2075	2079	O
the	25798575	2080	2083	O
noninferiority	25798575	2084	2098	O
end	25798575	2099	2102	O
point	25798575	2103	2108	O
.	25798575	2108	2109	O

Total	25798575	2110	2115	B-Outcome
QOL	25798575	2116	2119	I-Outcome
was	25798575	2120	2123	O
better	25798575	2124	2130	O
for	25798575	2131	2134	O
the	25798575	2135	2138	O
group	25798575	2139	2144	O
discontinuing	25798575	2145	2158	O
statin	25798575	2159	2165	O
therapy	25798575	2166	2173	O
(	25798575	2174	2175	O
mean	25798575	2175	2179	O
McGill	25798575	2180	2186	O
QOL	25798575	2187	2190	O
score	25798575	2191	2196	O
,	25798575	2196	2197	O
7.11	25798575	2198	2202	O
vs	25798575	2203	2205	O
6.85	25798575	2206	2210	O
;	25798575	2210	2211	O
P=.04	25798575	2212	2217	O
)	25798575	2217	2218	O
.	25798575	2218	2219	O

Few	25798575	2220	2223	O
participants	25798575	2224	2236	O
experienced	25798575	2237	2248	O
cardiovascular	25798575	2249	2263	B-Outcome
events	25798575	2264	2270	I-Outcome
(	25798575	2271	2272	O
13	25798575	2272	2274	O
in	25798575	2275	2277	O
the	25798575	2278	2281	O
discontinuation	25798575	2282	2297	O
group	25798575	2298	2303	O
vs	25798575	2304	2306	O
11	25798575	2307	2309	O
in	25798575	2310	2312	O
the	25798575	2313	2316	O
continuation	25798575	2317	2329	O
group	25798575	2330	2335	O
)	25798575	2335	2336	O
.	25798575	2336	2337	O

Mean	25798575	2338	2342	B-Outcome
cost	25798575	2343	2347	I-Outcome
savings	25798575	2348	2355	I-Outcome
were	25798575	2356	2360	O
$	25798575	2361	2362	O
3.37	25798575	2362	2366	O
per	25798575	2367	2370	O
day	25798575	2371	2374	O
and	25798575	2375	2378	O
$	25798575	2379	2380	O
716	25798575	2380	2383	O
per	25798575	2384	2387	O
patient	25798575	2388	2395	O
.	25798575	2395	2396	O

CONCLUSIONS	25798575	2398	2409	O
AND	25798575	2410	2413	O
RELEVANCE	25798575	2414	2423	O
:	25798575	2424	2425	O
This	25798575	2426	2430	O
pragmatic	25798575	2431	2440	O
trial	25798575	2441	2446	O
suggests	25798575	2447	2455	O
that	25798575	2456	2460	O
stopping	25798575	2461	2469	O
statin	25798575	2470	2476	O
medication	25798575	2477	2487	O
therapy	25798575	2488	2495	O
is	25798575	2496	2498	O
safe	25798575	2499	2503	B-Outcome
and	25798575	2504	2507	O
may	25798575	2508	2511	O
be	25798575	2512	2514	O
associated	25798575	2515	2525	O
with	25798575	2526	2530	O
benefits	25798575	2531	2539	O
including	25798575	2540	2549	O
improved	25798575	2550	2558	O
QOL	25798575	2559	2562	B-Outcome
,	25798575	2562	2563	O
use	25798575	2564	2567	O
of	25798575	2568	2570	O
fewer	25798575	2571	2576	O
nonstatin	25798575	2577	2586	B-Outcome
medications	25798575	2587	2598	I-Outcome
,	25798575	2598	2599	O
and	25798575	2600	2603	O
a	25798575	2604	2605	O
corresponding	25798575	2606	2619	O
reduction	25798575	2620	2629	O
in	25798575	2630	2632	O
medication	25798575	2633	2643	B-Outcome
costs	25798575	2644	2649	I-Outcome
.	25798575	2649	2650	O

Thoughtful	25798575	2651	2661	O
patient-provider	25798575	2662	2678	O
discussions	25798575	2679	2690	O
regarding	25798575	2691	2700	O
the	25798575	2701	2704	O
uncertain	25798575	2705	2714	O
benefit	25798575	2715	2722	O
and	25798575	2723	2726	O
potential	25798575	2727	2736	O
decrement	25798575	2737	2746	O
in	25798575	2747	2749	O
QOL	25798575	2750	2753	O
associated	25798575	2754	2764	O
with	25798575	2765	2769	O
statin	25798575	2770	2776	O
continuation	25798575	2777	2789	O
in	25798575	2790	2792	O
this	25798575	2793	2797	O
setting	25798575	2798	2805	O
are	25798575	2806	2809	O
warranted	25798575	2810	2819	O
.	25798575	2819	2820	O

TRIAL	25798575	2822	2827	O
REGISTRATION	25798575	2828	2840	O
:	25798575	2841	2842	O
clinicaltrials.gov	25798575	2843	2861	O
Identifier	25798575	2862	2872	O
:	25798575	2872	2873	O
NCT01415934	25798575	2874	2885	O
.	25798575	2885	2886	O


Effect	25898050	0	6	O
of	25898050	7	9	O
parent	25898050	10	16	O
training	25898050	17	25	O
vs	25898050	26	28	O
parent	25898050	29	35	O
education	25898050	36	45	O
on	25898050	46	48	O
behavioral	25898050	49	59	O
problems	25898050	60	68	O
in	25898050	69	71	O
children	25898050	72	80	O
with	25898050	81	85	O
autism	25898050	86	92	O
spectrum	25898050	93	101	O
disorder	25898050	102	110	O
:	25898050	110	111	O
a	25898050	112	113	O
randomized	25898050	114	124	O
clinical	25898050	125	133	O
trial	25898050	134	139	O
.	25898050	139	140	O

IMPORTANCE	25898050	142	152	O
:	25898050	153	154	O
Disruptive	25898050	155	165	O
behavior	25898050	166	174	O
is	25898050	175	177	O
common	25898050	178	184	O
in	25898050	185	187	O
children	25898050	188	196	O
with	25898050	197	201	O
autism	25898050	202	208	O
spectrum	25898050	209	217	O
disorder	25898050	218	226	O
.	25898050	226	227	O

Behavioral	25898050	228	238	O
interventions	25898050	239	252	O
are	25898050	253	256	O
used	25898050	257	261	O
to	25898050	262	264	O
treat	25898050	265	270	O
disruptive	25898050	271	281	O
behavior	25898050	282	290	O
but	25898050	291	294	O
have	25898050	295	299	O
not	25898050	300	303	O
been	25898050	304	308	O
evaluated	25898050	309	318	O
in	25898050	319	321	O
large-scale	25898050	322	333	O
randomized	25898050	334	344	O
trials	25898050	345	351	O
.	25898050	351	352	O

OBJECTIVE	25898050	354	363	O
:	25898050	364	365	O
To	25898050	366	368	O
evaluate	25898050	369	377	O
the	25898050	378	381	O
efficacy	25898050	382	390	O
of	25898050	391	393	O
parent	25898050	394	400	O
training	25898050	401	409	O
for	25898050	410	413	O
children	25898050	414	422	O
with	25898050	423	427	O
autism	25898050	428	434	O
spectrum	25898050	435	443	O
disorder	25898050	444	452	O
and	25898050	453	456	O
disruptive	25898050	457	467	O
behavior	25898050	468	476	O
.	25898050	476	477	O

DESIGN	25898050	479	485	O
,	25898050	485	486	O
SETTING	25898050	487	494	O
,	25898050	494	495	O
AND	25898050	496	499	O
PARTICIPANTS	25898050	500	512	O
:	25898050	513	514	O
This	25898050	515	519	O
24-week	25898050	520	527	O
randomized	25898050	528	538	O
trial	25898050	539	544	O
compared	25898050	545	553	O
parent	25898050	554	560	O
training	25898050	561	569	O
(	25898050	570	571	O
n	25898050	571	572	O
=	25898050	573	574	O
89	25898050	575	577	O
)	25898050	577	578	O
to	25898050	579	581	O
parent	25898050	582	588	O
education	25898050	589	598	O
(	25898050	599	600	O
n	25898050	600	601	O
=	25898050	602	603	O
91	25898050	604	606	O
)	25898050	606	607	O
at	25898050	608	610	O
6	25898050	611	612	O
centers	25898050	613	620	O
(	25898050	621	622	O
Emory	25898050	622	627	O
University	25898050	628	638	O
,	25898050	638	639	O
Indiana	25898050	640	647	O
University	25898050	648	658	O
,	25898050	658	659	O
Ohio	25898050	660	664	O
State	25898050	665	670	O
University	25898050	671	681	O
,	25898050	681	682	O
University	25898050	683	693	O
of	25898050	694	696	O
Pittsburgh	25898050	697	707	O
,	25898050	707	708	O
University	25898050	709	719	O
of	25898050	720	722	O
Rochester	25898050	723	732	O
,	25898050	732	733	O
Yale	25898050	734	738	O
University	25898050	739	749	O
)	25898050	749	750	O
.	25898050	750	751	O

We	25898050	752	754	O
screened	25898050	755	763	O
267	25898050	764	767	O
children	25898050	768	776	O
;	25898050	776	777	O
180	25898050	778	781	O
children	25898050	782	790	O
(	25898050	791	792	O
aged	25898050	792	796	O
3	25898050	797	798	O
-	25898050	798	799	O
7	25898050	799	800	O
years	25898050	801	806	O
)	25898050	806	807	O
with	25898050	808	812	O
autism	25898050	813	819	O
spectrum	25898050	820	828	O
disorder	25898050	829	837	O
and	25898050	838	841	O
disruptive	25898050	842	852	O
behaviors	25898050	853	862	O
were	25898050	863	867	O
randomly	25898050	868	876	O
assigned	25898050	877	885	O
(	25898050	886	887	O
86	25898050	887	889	O
%	25898050	889	890	O
white	25898050	891	896	O
,	25898050	896	897	O
88	25898050	898	900	O
%	25898050	900	901	O
male	25898050	902	906	O
)	25898050	906	907	O
between	25898050	908	915	O
September	25898050	916	925	O
2010	25898050	926	930	O
and	25898050	931	934	O
February	25898050	935	943	O
2014	25898050	944	948	O
.	25898050	948	949	O

INTERVENTIONS	25898050	951	964	O
:	25898050	965	966	O
Parent	25898050	967	973	O
training	25898050	974	982	O
(	25898050	983	984	O
11	25898050	984	986	O
core	25898050	987	991	O
,	25898050	991	992	O
2	25898050	993	994	O
optional	25898050	995	1003	O
sessions	25898050	1004	1012	O
;	25898050	1012	1013	O
2	25898050	1014	1015	O
telephone	25898050	1016	1025	O
boosters	25898050	1026	1034	O
;	25898050	1034	1035	O
2	25898050	1036	1037	O
home	25898050	1038	1042	O
visits	25898050	1043	1049	O
)	25898050	1049	1050	O
provided	25898050	1051	1059	O
specific	25898050	1060	1068	O
strategies	25898050	1069	1079	O
to	25898050	1080	1082	O
manage	25898050	1083	1089	O
disruptive	25898050	1090	1100	O
behavior	25898050	1101	1109	O
.	25898050	1109	1110	O

Parent	25898050	1111	1117	O
education	25898050	1118	1127	O
(	25898050	1128	1129	O
12	25898050	1129	1131	O
core	25898050	1132	1136	O
sessions	25898050	1137	1145	O
,	25898050	1145	1146	O
1	25898050	1147	1148	O
home	25898050	1149	1153	O
visit	25898050	1154	1159	O
)	25898050	1159	1160	O
provided	25898050	1161	1169	O
information	25898050	1170	1181	O
about	25898050	1182	1187	O
autism	25898050	1188	1194	O
but	25898050	1195	1198	O
no	25898050	1199	1201	O
behavior	25898050	1202	1210	O
management	25898050	1211	1221	O
strategies	25898050	1222	1232	O
.	25898050	1232	1233	O

MAIN	25898050	1235	1239	O
OUTCOMES	25898050	1240	1248	O
AND	25898050	1249	1252	O
MEASURES	25898050	1253	1261	O
:	25898050	1262	1263	O
Parents	25898050	1264	1271	O
rated	25898050	1272	1277	O
disruptive	25898050	1278	1288	O
behavior	25898050	1289	1297	O
and	25898050	1298	1301	O
noncompliance	25898050	1302	1315	O
on	25898050	1316	1318	O
co-primary	25898050	1319	1329	O
outcomes	25898050	1330	1338	O
:	25898050	1338	1339	O
the	25898050	1340	1343	O
Aberrant	25898050	1344	1352	O
Behavior	25898050	1353	1361	O
Checklist-Irritability	25898050	1362	1384	O
subscale	25898050	1385	1393	O
(	25898050	1394	1395	O
range	25898050	1395	1400	O
,	25898050	1400	1401	O
0	25898050	1402	1403	O
-	25898050	1403	1404	O
45	25898050	1404	1406	O
)	25898050	1406	1407	O
and	25898050	1408	1411	O
the	25898050	1412	1415	O
Home	25898050	1416	1420	O
Situations	25898050	1421	1431	O
Questionnaire-Autism	25898050	1432	1452	O
Spectrum	25898050	1453	1461	O
Disorder	25898050	1462	1470	O
(	25898050	1471	1472	O
range	25898050	1472	1477	O
,	25898050	1477	1478	O
0	25898050	1479	1480	O
-	25898050	1480	1481	O
9	25898050	1481	1482	O
)	25898050	1482	1483	O
.	25898050	1483	1484	O

On	25898050	1485	1487	O
both	25898050	1488	1492	O
measures	25898050	1493	1501	O
,	25898050	1501	1502	O
higher	25898050	1503	1509	O
scores	25898050	1510	1516	O
indicate	25898050	1517	1525	O
greater	25898050	1526	1533	O
severity	25898050	1534	1542	O
and	25898050	1543	1546	O
a	25898050	1547	1548	O
25	25898050	1549	1551	O
%	25898050	1551	1552	O
reduction	25898050	1553	1562	O
indicates	25898050	1563	1572	O
clinical	25898050	1573	1581	O
improvement	25898050	1582	1593	O
.	25898050	1593	1594	O

A	25898050	1595	1596	O
clinician	25898050	1597	1606	O
blind	25898050	1607	1612	O
to	25898050	1613	1615	O
treatment	25898050	1616	1625	O
assignment	25898050	1626	1636	O
rated	25898050	1637	1642	O
the	25898050	1643	1646	O
Improvement	25898050	1647	1658	O
scale	25898050	1659	1664	O
of	25898050	1665	1667	O
the	25898050	1668	1671	O
Clinical	25898050	1672	1680	O
Global	25898050	1681	1687	O
Impression	25898050	1688	1698	O
(	25898050	1699	1700	O
range	25898050	1700	1705	O
,	25898050	1705	1706	O
1	25898050	1707	1708	O
-	25898050	1708	1709	O
7	25898050	1709	1710	O
)	25898050	1710	1711	O
,	25898050	1711	1712	O
a	25898050	1713	1714	O
secondary	25898050	1715	1724	O
outcome	25898050	1725	1732	O
,	25898050	1732	1733	O
with	25898050	1734	1738	O
a	25898050	1739	1740	O
positive	25898050	1741	1749	O
response	25898050	1750	1758	O
less	25898050	1759	1763	O
than	25898050	1764	1768	O
3	25898050	1769	1770	O
.	25898050	1770	1771	O

RESULTS	25898050	1773	1780	O
:	25898050	1781	1782	O
At	25898050	1783	1785	O
week	25898050	1786	1790	O
24	25898050	1791	1793	O
,	25898050	1793	1794	O
the	25898050	1795	1798	O
Aberrant	25898050	1799	1807	B-Outcome
Behavior	25898050	1808	1816	I-Outcome
Checklist-Irritability	25898050	1817	1839	I-Outcome
subscale	25898050	1840	1848	I-Outcome
declined	25898050	1849	1857	O
47.7	25898050	1858	1862	O
%	25898050	1862	1863	O
in	25898050	1864	1866	O
parent	25898050	1867	1873	O
training	25898050	1874	1882	O
(	25898050	1883	1884	O
from	25898050	1884	1888	O
23.7	25898050	1889	1893	O
to	25898050	1894	1896	O
12.4	25898050	1897	1901	O
)	25898050	1901	1902	O
compared	25898050	1903	1911	O
with	25898050	1912	1916	O
31.8	25898050	1917	1921	O
%	25898050	1921	1922	O
for	25898050	1923	1926	O
parent	25898050	1927	1933	O
education	25898050	1934	1943	O
(	25898050	1944	1945	O
23.9	25898050	1945	1949	O
to	25898050	1950	1952	O
16.3	25898050	1953	1957	O
)	25898050	1957	1958	O
(	25898050	1959	1960	O
treatment	25898050	1960	1969	O
effect	25898050	1970	1976	O
,	25898050	1976	1977	O
-3.9	25898050	1978	1982	O
;	25898050	1982	1983	O
95	25898050	1984	1986	O
%	25898050	1986	1987	O
CI	25898050	1988	1990	O
,	25898050	1990	1991	O
-6.2	25898050	1992	1996	O
to	25898050	1997	1999	O
-1.7	25898050	2000	2004	O
;	25898050	2004	2005	O
P	25898050	2006	2007	O
<	25898050	2008	2009	O
.001	25898050	2010	2014	O
,	25898050	2014	2015	O
standardized	25898050	2016	2028	O
effect	25898050	2029	2035	O
size	25898050	2036	2040	O
=	25898050	2041	2042	O
0.62	25898050	2043	2047	O
)	25898050	2047	2048	O
.	25898050	2048	2049	O

The	25898050	2050	2053	O
Home	25898050	2054	2058	B-Outcome
Situations	25898050	2059	2069	I-Outcome
Questionnaire-Autism	25898050	2070	2090	I-Outcome
Spectrum	25898050	2091	2099	I-Outcome
Disorder	25898050	2100	2108	I-Outcome
declined	25898050	2109	2117	O
55	25898050	2118	2120	O
%	25898050	2120	2121	O
(	25898050	2122	2123	O
from	25898050	2123	2127	O
4.0	25898050	2128	2131	O
to	25898050	2132	2134	O
1.8	25898050	2135	2138	O
)	25898050	2138	2139	O
compared	25898050	2140	2148	O
with	25898050	2149	2153	O
34.2	25898050	2154	2158	O
%	25898050	2158	2159	O
in	25898050	2160	2162	O
parent	25898050	2163	2169	O
education	25898050	2170	2179	O
(	25898050	2180	2181	O
3.8	25898050	2181	2184	O
to	25898050	2185	2187	O
2.5	25898050	2188	2191	O
)	25898050	2191	2192	O
(	25898050	2193	2194	O
treatment	25898050	2194	2203	O
effect	25898050	2204	2210	O
,	25898050	2210	2211	O
-0.7	25898050	2212	2216	O
;	25898050	2216	2217	O
95	25898050	2218	2220	O
%	25898050	2220	2221	O
CI	25898050	2222	2224	O
,	25898050	2224	2225	O
-1.1	25898050	2226	2230	O
to	25898050	2231	2233	O
-0.3	25898050	2234	2238	O
;	25898050	2238	2239	O
P	25898050	2240	2241	O
<	25898050	2242	2243	O
.001	25898050	2244	2248	O
,	25898050	2248	2249	O
standardized	25898050	2250	2262	O
effect	25898050	2263	2269	O
size	25898050	2270	2274	O
=	25898050	2275	2276	O
0.45	25898050	2277	2281	O
)	25898050	2281	2282	O
.	25898050	2282	2283	O

Neither	25898050	2284	2291	O
measure	25898050	2292	2299	O
met	25898050	2300	2303	O
the	25898050	2304	2307	O
prespecified	25898050	2308	2320	O
minimal	25898050	2321	2328	O
clinically	25898050	2329	2339	O
important	25898050	2340	2349	O
difference	25898050	2350	2360	O
.	25898050	2360	2361	O

The	25898050	2362	2365	O
proportions	25898050	2366	2377	B-Outcome
with	25898050	2378	2382	I-Outcome
a	25898050	2383	2384	I-Outcome
positive	25898050	2385	2393	I-Outcome
response	25898050	2394	2402	I-Outcome
on	25898050	2403	2405	I-Outcome
the	25898050	2406	2409	I-Outcome
Clinical	25898050	2410	2418	I-Outcome
Global	25898050	2419	2425	I-Outcome
Impression-Improvement	25898050	2426	2448	I-Outcome
scale	25898050	2449	2454	I-Outcome
were	25898050	2455	2459	O
68.5	25898050	2460	2464	O
%	25898050	2464	2465	O
for	25898050	2466	2469	O
parent	25898050	2470	2476	O
training	25898050	2477	2485	O
vs	25898050	2486	2488	O
39.6	25898050	2489	2493	O
%	25898050	2493	2494	O
for	25898050	2495	2498	O
parent	25898050	2499	2505	O
education	25898050	2506	2515	O
(	25898050	2516	2517	O
P	25898050	2517	2518	O
<	25898050	2519	2520	O
.001	25898050	2521	2525	O
)	25898050	2525	2526	O
.	25898050	2526	2527	O

CONCLUSIONS	25898050	2529	2540	O
AND	25898050	2541	2544	O
RELEVANCE	25898050	2545	2554	O
:	25898050	2555	2556	O
For	25898050	2557	2560	O
children	25898050	2561	2569	O
with	25898050	2570	2574	O
autism	25898050	2575	2581	O
spectrum	25898050	2582	2590	O
disorder	25898050	2591	2599	O
,	25898050	2599	2600	O
a	25898050	2601	2602	O
24-week	25898050	2603	2610	O
parent	25898050	2611	2617	O
training	25898050	2618	2626	O
program	25898050	2627	2634	O
was	25898050	2635	2638	O
superior	25898050	2639	2647	O
to	25898050	2648	2650	O
parent	25898050	2651	2657	O
education	25898050	2658	2667	O
for	25898050	2668	2671	O
reducing	25898050	2672	2680	O
disruptive	25898050	2681	2691	B-Outcome
behavior	25898050	2692	2700	I-Outcome
on	25898050	2701	2703	I-Outcome
parent-reported	25898050	2704	2719	I-Outcome
outcomes	25898050	2720	2728	I-Outcome
,	25898050	2728	2729	O
although	25898050	2730	2738	O
the	25898050	2739	2742	O
clinical	25898050	2743	2751	O
significance	25898050	2752	2764	O
of	25898050	2765	2767	O
the	25898050	2768	2771	O
improvement	25898050	2772	2783	O
is	25898050	2784	2786	O
unclear	25898050	2787	2794	O
.	25898050	2794	2795	O

The	25898050	2796	2799	O
rate	25898050	2800	2804	B-Outcome
of	25898050	2805	2807	I-Outcome
positive	25898050	2808	2816	I-Outcome
response	25898050	2817	2825	I-Outcome
judged	25898050	2826	2832	O
by	25898050	2833	2835	O
a	25898050	2836	2837	O
blinded	25898050	2838	2845	O
clinician	25898050	2846	2855	O
was	25898050	2856	2859	O
greater	25898050	2860	2867	O
for	25898050	2868	2871	O
parent	25898050	2872	2878	O
training	25898050	2879	2887	O
vs	25898050	2888	2890	O
parent	25898050	2891	2897	O
education	25898050	2898	2907	O
.	25898050	2907	2908	O

TRIAL	25898050	2910	2915	O
REGISTRATION	25898050	2916	2928	O
:	25898050	2929	2930	O
clinicaltrials.gov	25898050	2931	2949	O
Identifier	25898050	2950	2960	O
:	25898050	2960	2961	O
NCT01233414	25898050	2962	2973	O
.	25898050	2973	2974	O


Peritonsillar	25912590	0	13	O
infiltration	25912590	14	26	O
with	25912590	27	31	O
levobupivacaine	25912590	32	47	O
for	25912590	48	51	O
posttonsillectomy	25912590	52	69	O
pain	25912590	70	74	O
relief	25912590	75	81	O
:	25912590	81	82	O
does	25912590	83	87	O
concentration	25912590	88	101	O
have	25912590	102	106	O
any	25912590	107	110	O
effect	25912590	111	117	O
?	25912590	117	118	O

A	25912590	119	120	O
double-blind	25912590	121	133	O
randomized	25912590	134	144	O
controlled	25912590	145	155	O
clinical	25912590	156	164	O
study	25912590	165	170	O
.	25912590	170	171	O

OBJECTIVE	25912590	173	182	O
:	25912590	183	184	O
Post-tonsillectomy	25912590	185	203	O
pain	25912590	204	208	O
is	25912590	209	211	O
believed	25912590	212	220	O
to	25912590	221	223	O
be	25912590	224	226	O
mediated	25912590	227	235	O
by	25912590	236	238	O
noxious	25912590	239	246	O
stimulation	25912590	247	258	O
of	25912590	259	261	O
C-fiber	25912590	262	269	O
afferents	25912590	270	279	O
located	25912590	280	287	O
in	25912590	288	290	O
the	25912590	291	294	O
peritonsillary	25912590	295	309	O
space	25912590	310	315	O
,	25912590	315	316	O
and	25912590	317	320	O
local	25912590	321	326	O
anesthetic	25912590	327	337	O
infiltration	25912590	338	350	O
to	25912590	351	353	O
this	25912590	354	358	O
area	25912590	359	363	O
may	25912590	364	367	O
decrease	25912590	368	376	O
pain	25912590	377	381	O
by	25912590	382	384	O
blocking	25912590	385	393	O
the	25912590	394	397	O
sensory	25912590	398	405	O
pathways	25912590	406	414	O
and	25912590	415	418	O
thus	25912590	419	423	O
preventing	25912590	424	434	O
the	25912590	435	438	O
nociceptive	25912590	439	450	O
impulses	25912590	451	459	O
.	25912590	459	460	O

We	25912590	461	463	O
aimed	25912590	464	469	O
to	25912590	470	472	O
compare	25912590	473	480	O
the	25912590	481	484	O
effects	25912590	485	492	O
of	25912590	493	495	O
different	25912590	496	505	O
concentrations	25912590	506	520	O
of	25912590	521	523	O
preincisional	25912590	524	537	O
peritonsillar	25912590	538	551	O
levobupivacaine	25912590	552	567	O
(	25912590	568	569	O
0.25	25912590	569	573	O
%	25912590	573	574	O
and	25912590	575	578	O
0.5	25912590	579	582	O
%	25912590	582	583	O
)	25912590	583	584	O
infiltration	25912590	585	597	O
on	25912590	598	600	O
postoperative	25912590	601	614	O
pain	25912590	615	619	O
and	25912590	620	623	O
bleeding	25912590	624	632	O
in	25912590	633	635	O
a	25912590	636	637	O
placebo-controlled	25912590	638	656	O
design	25912590	657	663	O
.	25912590	663	664	O

PATIENTS	25912590	666	674	O
AND	25912590	675	678	O
METHODS	25912590	679	686	O
:	25912590	687	688	O
After	25912590	689	694	O
obtaining	25912590	695	704	O
Institutional	25912590	705	718	O
Ethics	25912590	719	725	O
Committee	25912590	726	735	O
approval	25912590	736	744	O
,	25912590	744	745	O
72	25912590	746	748	O
ASA	25912590	749	752	O
I-II	25912590	753	757	O
patients	25912590	758	766	O
between	25912590	767	774	O
3	25912590	775	776	O
and	25912590	777	780	O
12	25912590	781	783	O
years	25912590	784	789	O
of	25912590	790	792	O
age	25912590	793	796	O
,	25912590	796	797	O
scheduled	25912590	798	807	O
to	25912590	808	810	O
undergo	25912590	811	818	O
tonsillectomy	25912590	819	832	O
were	25912590	833	837	O
enrolled	25912590	838	846	O
and	25912590	847	850	O
randomly	25912590	851	859	O
assigned	25912590	860	868	O
to	25912590	869	871	O
one	25912590	872	875	O
of	25912590	876	878	O
the	25912590	879	882	O
three	25912590	883	888	O
groups	25912590	889	895	O
using	25912590	896	901	O
the	25912590	902	905	O
sealed	25912590	906	912	O
envelope	25912590	913	921	O
technique	25912590	922	931	O
,	25912590	931	932	O
as	25912590	933	935	O
Group	25912590	936	941	O
I	25912590	942	943	O
(	25912590	944	945	O
Control	25912590	945	952	O
group	25912590	953	958	O
)	25912590	958	959	O
,	25912590	959	960	O
Group	25912590	961	966	O
II	25912590	967	969	O
,	25912590	969	970	O
and	25912590	971	974	O
Group	25912590	975	980	O
III	25912590	981	984	O
receiving	25912590	985	994	O
preincisional	25912590	995	1008	O
bilateral	25912590	1009	1018	O
peritonsillar	25912590	1019	1032	O
infiltration	25912590	1033	1045	O
with	25912590	1046	1050	O
saline	25912590	1051	1057	O
,	25912590	1057	1058	O
0.25	25912590	1059	1063	O
%	25912590	1063	1064	O
levobupivacaine	25912590	1065	1080	O
and	25912590	1081	1084	O
0.5	25912590	1085	1088	O
%	25912590	1088	1089	O
levobupivacaine	25912590	1090	1105	O
,	25912590	1105	1106	O
respectively	25912590	1107	1119	O
(	25912590	1120	1121	O
3	25912590	1121	1122	O
mL	25912590	1123	1125	O
to	25912590	1126	1128	O
each	25912590	1129	1133	O
tonsil	25912590	1134	1140	O
)	25912590	1140	1141	O
.	25912590	1141	1142	O

Pain	25912590	1143	1147	O
,	25912590	1147	1148	O
fever	25912590	1149	1154	O
,	25912590	1154	1155	O
dysphagia	25912590	1156	1165	O
;	25912590	1165	1166	O
nausea-vomiting	25912590	1167	1182	O
and	25912590	1183	1186	O
hemorrhage	25912590	1187	1197	O
were	25912590	1198	1202	O
evaluated	25912590	1203	1212	O
at	25912590	1213	1215	O
postoperative	25912590	1216	1229	O
0	25912590	1230	1231	O
,	25912590	1231	1232	O
30	25912590	1233	1235	O
,	25912590	1235	1236	O
and	25912590	1237	1240	O
60	25912590	1241	1243	O
minutes	25912590	1244	1251	O
and	25912590	1252	1255	O
2	25912590	1256	1257	O
,	25912590	1257	1258	O
6	25912590	1259	1260	O
,	25912590	1260	1261	O
12	25912590	1262	1264	O
,	25912590	1264	1265	O
and	25912590	1266	1269	O
24	25912590	1270	1272	O
hours	25912590	1273	1278	O
.	25912590	1278	1279	O

Oral	25912590	1280	1284	O
paracetamol	25912590	1285	1296	O
was	25912590	1297	1300	O
administered	25912590	1301	1313	O
at	25912590	1314	1316	O
a	25912590	1317	1318	O
dose	25912590	1319	1323	O
of	25912590	1324	1326	O
15	25912590	1327	1329	O
mg/kg	25912590	1330	1335	O
when	25912590	1336	1340	O
FLACC	25912590	1341	1346	O
score	25912590	1347	1352	O
was	25912590	1353	1356	O
>	25912590	1357	1358	O
4	25912590	1359	1360	O
.	25912590	1360	1361	O

The	25912590	1362	1365	O
number	25912590	1366	1372	O
of	25912590	1373	1375	O
paracetamol	25912590	1376	1387	O
administrations	25912590	1388	1403	O
within	25912590	1404	1410	O
the	25912590	1411	1414	O
first	25912590	1415	1420	O
24	25912590	1421	1423	O
hours	25912590	1424	1429	O
were	25912590	1430	1434	O
recorded	25912590	1435	1443	O
.	25912590	1443	1444	O

RESULTS	25912590	1446	1453	O
:	25912590	1454	1455	O
The	25912590	1456	1459	O
patients	25912590	1460	1468	O
in	25912590	1469	1471	O
Groups	25912590	1472	1478	O
I	25912590	1479	1480	O
,	25912590	1480	1481	O
II	25912590	1482	1484	O
and	25912590	1485	1488	O
III	25912590	1489	1492	O
defined	25912590	1493	1500	O
pain	25912590	1501	1505	B-Outcome
(	25912590	1506	1507	O
FLACC	25912590	1507	1512	O
>	25912590	1513	1514	O
4	25912590	1515	1516	O
)	25912590	1516	1517	O
at	25912590	1518	1520	O
a	25912590	1521	1522	O
rate	25912590	1523	1527	O
of	25912590	1528	1530	O
87	25912590	1531	1533	O
%	25912590	1533	1534	O
,	25912590	1534	1535	O
60.9	25912590	1536	1540	O
%	25912590	1540	1541	O
,	25912590	1541	1542	O
and	25912590	1543	1546	O
54.2	25912590	1547	1551	O
%	25912590	1551	1552	O
within	25912590	1553	1559	O
the	25912590	1560	1563	O
postoperative	25912590	1564	1577	O
first	25912590	1578	1583	O
24	25912590	1584	1586	O
hours	25912590	1587	1592	O
,	25912590	1592	1593	O
respectively	25912590	1594	1606	O
.	25912590	1606	1607	O

The	25912590	1608	1611	O
total	25912590	1612	1617	B-Outcome
number	25912590	1618	1624	I-Outcome
of	25912590	1625	1627	I-Outcome
additional	25912590	1628	1638	I-Outcome
analgesic	25912590	1639	1648	I-Outcome
requirements	25912590	1649	1661	I-Outcome
was	25912590	1662	1665	O
significantly	25912590	1666	1679	O
low	25912590	1680	1683	O
in	25912590	1684	1686	O
Group	25912590	1687	1692	O
II	25912590	1693	1695	O
and	25912590	1696	1699	O
III	25912590	1700	1703	O
when	25912590	1704	1708	O
compared	25912590	1709	1717	O
with	25912590	1718	1722	O
Group	25912590	1723	1728	O
I.	25912590	1729	1731	O
There	25912590	1732	1737	O
was	25912590	1738	1741	O
no	25912590	1742	1744	O
difference	25912590	1745	1755	O
between	25912590	1756	1763	O
groups	25912590	1764	1770	O
in	25912590	1771	1773	O
terms	25912590	1774	1779	O
of	25912590	1780	1782	O
fever	25912590	1783	1788	B-Outcome
,	25912590	1788	1789	O
dysphagia	25912590	1790	1799	B-Outcome
,	25912590	1799	1800	O
nausea-vomiting	25912590	1801	1816	B-Outcome
,	25912590	1816	1817	O
hemorrhage	25912590	1818	1828	B-Outcome
.	25912590	1828	1829	O

CONCLUSIONS	25912590	1831	1842	O
:	25912590	1843	1844	O
Both	25912590	1845	1849	O
concentrations	25912590	1850	1864	O
(	25912590	1865	1866	O
0.50	25912590	1866	1870	O
%	25912590	1870	1871	O
and	25912590	1872	1875	O
0.25	25912590	1876	1880	O
%	25912590	1880	1881	O
)	25912590	1881	1882	O
of	25912590	1883	1885	O
levobupivacaine	25912590	1886	1901	O
were	25912590	1902	1906	O
found	25912590	1907	1912	O
to	25912590	1913	1915	O
be	25912590	1916	1918	O
equally	25912590	1919	1926	O
safe	25912590	1927	1931	B-Outcome
and	25912590	1932	1935	O
effective	25912590	1936	1945	O
during	25912590	1946	1952	O
preincisional	25912590	1953	1966	O
peritonsillar	25912590	1967	1980	O
infiltration	25912590	1981	1993	O
in	25912590	1994	1996	O
children	25912590	1997	2005	O
.	25912590	2005	2006	O

NCT	25912590	2007	2010	O
number	25912590	2011	2017	O
:	25912590	2017	2018	O
02322346	25912590	2019	2027	O
.	25912590	2027	2028	O


Erlotinib	26046796	0	9	O
is	26046796	10	12	O
effective	26046796	13	22	O
in	26046796	23	25	O
pancreatic	26046796	26	36	O
cancer	26046796	37	43	O
with	26046796	44	48	O
epidermal	26046796	49	58	O
growth	26046796	59	65	O
factor	26046796	66	72	O
receptor	26046796	73	81	O
mutations	26046796	82	91	O
:	26046796	91	92	O
a	26046796	93	94	O
randomized	26046796	95	105	O
,	26046796	105	106	O
open-label	26046796	107	117	O
,	26046796	117	118	O
prospective	26046796	119	130	O
trial	26046796	131	136	O
.	26046796	136	137	O

OBJECTIVE	26046796	139	148	O
:	26046796	149	150	O
To	26046796	151	153	O
analyze	26046796	154	161	O
the	26046796	162	165	O
efficacy	26046796	166	174	O
of	26046796	175	177	O
gemcitabine	26046796	178	189	O
with	26046796	190	194	O
or	26046796	195	197	O
without	26046796	198	205	O
erlotinib	26046796	206	215	O
for	26046796	216	219	O
pancreatic	26046796	220	230	O
cancer	26046796	231	237	O
,	26046796	237	238	O
and	26046796	239	242	O
to	26046796	243	245	O
determine	26046796	246	255	O
the	26046796	256	259	O
predictive	26046796	260	270	O
role	26046796	271	275	O
of	26046796	276	278	O
epidermal	26046796	279	288	O
growth	26046796	289	295	O
factor	26046796	296	302	O
receptor	26046796	303	311	O
(	26046796	312	313	O
EGFR	26046796	313	317	O
)	26046796	317	318	O
and	26046796	319	322	O
KRAS	26046796	323	327	O
mutations	26046796	328	337	O
in	26046796	338	340	O
these	26046796	341	346	O
patients	26046796	347	355	O
.	26046796	355	356	O

METHODS	26046796	358	365	O
:	26046796	366	367	O
This	26046796	368	372	O
was	26046796	373	376	O
a	26046796	377	378	O
single-center	26046796	379	392	O
,	26046796	392	393	O
randomized	26046796	394	404	O
,	26046796	404	405	O
open-label	26046796	406	416	O
,	26046796	416	417	O
prospective	26046796	418	429	O
trial	26046796	430	435	O
.	26046796	435	436	O

Eighty-eight	26046796	437	449	O
chemotherapy-naïve	26046796	450	468	O
metastatic	26046796	469	479	O
pancreatic	26046796	480	490	O
cancer	26046796	491	497	O
patients	26046796	498	506	O
were	26046796	507	511	O
randomized	26046796	512	522	O
for	26046796	523	526	O
treatment	26046796	527	536	O
with	26046796	537	541	O
gemcitabine	26046796	542	553	O
or	26046796	554	556	O
gemcitabine	26046796	557	568	O
plus	26046796	569	573	O
erlotinib	26046796	574	583	O
.	26046796	583	584	O

EGFR	26046796	585	589	O
and	26046796	590	593	O
KRAS	26046796	594	598	O
mutations	26046796	599	608	O
were	26046796	609	613	O
analyzed	26046796	614	622	O
,	26046796	622	623	O
respectively	26046796	624	636	O
.	26046796	636	637	O

The	26046796	638	641	O
primary	26046796	642	649	O
endpoint	26046796	650	658	O
was	26046796	659	662	O
the	26046796	663	666	O
disease	26046796	667	674	O
control	26046796	675	682	O
rate	26046796	683	687	O
.	26046796	687	688	O

RESULTS	26046796	690	697	O
:	26046796	698	699	O
Disease	26046796	700	707	B-Outcome
control	26046796	708	715	I-Outcome
rate	26046796	716	720	I-Outcome
(	26046796	721	722	O
64	26046796	722	724	O
%	26046796	724	725	O
vs.	26046796	726	729	O
25	26046796	730	732	O
%	26046796	732	733	O
;	26046796	733	734	O
P	26046796	735	736	O
<	26046796	737	738	O
0.001	26046796	739	744	O
)	26046796	744	745	O
,	26046796	745	746	O
progression-free	26046796	747	763	B-Outcome
survival	26046796	764	772	I-Outcome
(	26046796	773	774	O
median	26046796	774	780	O
3.8	26046796	781	784	O
vs.	26046796	785	788	O
2.4	26046796	789	792	O
months	26046796	793	799	O
;	26046796	799	800	O
P	26046796	801	802	O
<	26046796	803	804	O
0.001	26046796	805	810	O
)	26046796	810	811	O
,	26046796	811	812	O
and	26046796	813	816	O
overall	26046796	817	824	B-Outcome
survival	26046796	825	833	I-Outcome
(	26046796	834	835	O
median	26046796	835	841	O
7.2	26046796	842	845	O
vs.	26046796	846	849	O
4.4	26046796	850	853	O
months	26046796	854	860	O
;	26046796	860	861	O
P	26046796	862	863	O
<	26046796	864	865	O
0.001	26046796	866	871	O
)	26046796	871	872	O
were	26046796	873	877	O
better	26046796	878	884	O
in	26046796	885	887	O
the	26046796	888	891	O
gemcitabine	26046796	892	903	O
plus	26046796	904	908	O
erlotinib	26046796	909	918	O
group	26046796	919	924	O
than	26046796	925	929	O
in	26046796	930	932	O
the	26046796	933	936	O
gemcitabine	26046796	937	948	O
alone	26046796	949	954	O
group	26046796	955	960	O
.	26046796	960	961	O

In	26046796	962	964	O
the	26046796	965	968	O
gemcitabine	26046796	969	980	O
plus	26046796	981	985	O
erlotinib	26046796	986	995	O
group	26046796	996	1001	O
,	26046796	1001	1002	O
disease	26046796	1003	1010	B-Outcome
control	26046796	1011	1018	I-Outcome
(	26046796	1019	1020	O
85	26046796	1020	1022	O
%	26046796	1022	1023	O
vs.	26046796	1024	1027	O
33	26046796	1028	1030	O
%	26046796	1030	1031	O
;	26046796	1031	1032	O
P	26046796	1033	1034	O
=	26046796	1035	1036	O
0.001	26046796	1037	1042	O
)	26046796	1042	1043	O
,	26046796	1043	1044	O
progression-free	26046796	1045	1061	B-Outcome
survival	26046796	1062	1070	I-Outcome
(	26046796	1071	1072	O
median	26046796	1072	1078	O
5.9	26046796	1079	1082	O
vs.	26046796	1083	1086	O
2.4	26046796	1087	1090	O
months	26046796	1091	1097	O
;	26046796	1097	1098	O
P	26046796	1099	1100	O
=	26046796	1101	1102	O
0.004	26046796	1103	1108	O
)	26046796	1108	1109	O
,	26046796	1109	1110	O
and	26046796	1111	1114	O
overall	26046796	1115	1122	B-Outcome
survival	26046796	1123	1131	I-Outcome
(	26046796	1132	1133	O
median	26046796	1133	1139	O
8.7	26046796	1140	1143	O
vs.	26046796	1144	1147	O
6.0	26046796	1148	1151	O
months	26046796	1152	1158	O
;	26046796	1158	1159	O
P	26046796	1160	1161	O
=	26046796	1162	1163	O
0.044	26046796	1164	1169	O
)	26046796	1169	1170	O
were	26046796	1171	1175	O
better	26046796	1176	1182	O
in	26046796	1183	1185	O
patients	26046796	1186	1194	O
with	26046796	1195	1199	O
EGFR	26046796	1200	1204	O
mutations	26046796	1205	1214	O
than	26046796	1215	1219	O
in	26046796	1220	1222	O
those	26046796	1223	1228	O
without	26046796	1229	1236	O
EGFR	26046796	1237	1241	O
mutations	26046796	1242	1251	O
.	26046796	1251	1252	O

KRAS	26046796	1253	1257	O
mutation	26046796	1258	1266	O
was	26046796	1267	1270	O
not	26046796	1271	1274	O
associated	26046796	1275	1285	O
with	26046796	1286	1290	O
treatment	26046796	1291	1300	B-Outcome
response	26046796	1301	1309	I-Outcome
or	26046796	1310	1312	O
survival	26046796	1313	1321	B-Outcome
.	26046796	1321	1322	O

CONCLUSIONS	26046796	1324	1335	O
:	26046796	1336	1337	O
Gemcitabine	26046796	1338	1349	O
plus	26046796	1350	1354	O
erlotinib	26046796	1355	1364	O
is	26046796	1365	1367	O
more	26046796	1368	1372	O
effective	26046796	1373	1382	O
than	26046796	1383	1387	O
gemcitabine	26046796	1388	1399	O
alone	26046796	1400	1405	O
for	26046796	1406	1409	O
treating	26046796	1410	1418	O
metastatic	26046796	1419	1429	O
pancreatic	26046796	1430	1440	O
cancer	26046796	1441	1447	O
patients	26046796	1448	1456	O
,	26046796	1456	1457	O
especially	26046796	1458	1468	O
those	26046796	1469	1474	O
with	26046796	1475	1479	O
EGFR	26046796	1480	1484	O
mutations	26046796	1485	1494	O
.	26046796	1494	1495	O

ClinicalTrials.gov	26046796	1496	1514	O
number	26046796	1515	1521	O
,	26046796	1521	1522	O
NCT01608841	26046796	1523	1534	O
.	26046796	1534	1535	O


Improvement	26068086	0	11	O
in	26068086	12	14	O
Patient-Reported	26068086	15	31	O
Visual	26068086	32	38	O
Function	26068086	39	47	O
After	26068086	48	53	O
Ocriplasmin	26068086	54	65	O
for	26068086	66	69	O
Vitreomacular	26068086	70	83	O
Adhesion	26068086	84	92	O
:	26068086	92	93	O
Results	26068086	94	101	O
of	26068086	102	104	O
the	26068086	105	108	O
Microplasmin	26068086	109	121	O
for	26068086	122	125	O
Intravitreous	26068086	126	139	O
Injection-Traction	26068086	140	158	O
Release	26068086	159	166	O
Without	26068086	167	174	O
Surgical	26068086	175	183	O
Treatment	26068086	184	193	O
(	26068086	194	195	O
MIVI-TRUST	26068086	195	205	O
)	26068086	205	206	O
Trials	26068086	207	213	O
.	26068086	213	214	O

IMPORTANCE	26068086	216	226	O
:	26068086	227	228	O
The	26068086	229	232	O
impact	26068086	233	239	O
of	26068086	240	242	O
vitreomacular	26068086	243	256	O
adhesion	26068086	257	265	O
(	26068086	266	267	O
VMA	26068086	267	270	O
)	26068086	270	271	O
resolution	26068086	272	282	O
on	26068086	283	285	O
patient-reported	26068086	286	302	O
visual	26068086	303	309	O
function	26068086	310	318	O
in	26068086	319	321	O
symptomatic	26068086	322	333	O
VMA/vitreomacular	26068086	334	351	O
traction	26068086	352	360	O
(	26068086	361	362	O
VMT	26068086	362	365	O
)	26068086	365	366	O
has	26068086	367	370	O
not	26068086	371	374	O
yet	26068086	375	378	O
been	26068086	379	383	O
documented	26068086	384	394	O
,	26068086	394	395	O
to	26068086	396	398	O
our	26068086	399	402	O
knowledge	26068086	403	412	O
.	26068086	412	413	O

OBJECTIVE	26068086	415	424	O
:	26068086	425	426	O
To	26068086	427	429	O
determine	26068086	430	439	O
the	26068086	440	443	O
impact	26068086	444	450	O
of	26068086	451	453	O
intravitreal	26068086	454	466	O
ocriplasmin	26068086	467	478	O
on	26068086	479	481	O
patient-reported	26068086	482	498	O
visual	26068086	499	505	O
function	26068086	506	514	O
using	26068086	515	520	O
the	26068086	521	524	O
25-item	26068086	525	532	O
National	26068086	533	541	O
Eye	26068086	542	545	O
Institute	26068086	546	555	O
Visual	26068086	556	562	O
Function	26068086	563	571	O
Questionnaire	26068086	572	585	O
(	26068086	586	587	O
NEI	26068086	587	590	O
VFQ-25	26068086	591	597	O
)	26068086	597	598	O
during	26068086	599	605	O
a	26068086	606	607	O
6-month	26068086	608	615	O
follow-up	26068086	616	625	O
in	26068086	626	628	O
patients	26068086	629	637	O
with	26068086	638	642	O
symptomatic	26068086	643	654	O
VMA	26068086	655	658	O
.	26068086	658	659	O

DESIGN	26068086	661	667	O
,	26068086	667	668	O
SETTING	26068086	669	676	O
,	26068086	676	677	O
AND	26068086	678	681	O
PARTICIPANTS	26068086	682	694	O
:	26068086	695	696	O
Two	26068086	697	700	O
multicenter	26068086	701	712	O
,	26068086	712	713	O
randomized	26068086	714	724	O
,	26068086	724	725	O
masked	26068086	726	732	O
,	26068086	732	733	O
phase	26068086	734	739	O
3	26068086	740	741	O
clinical	26068086	742	750	O
trials	26068086	751	757	O
(	26068086	758	759	O
studies	26068086	759	766	O
TG-MV-006	26068086	767	776	O
[	26068086	777	778	O
between	26068086	778	785	O
December	26068086	786	794	O
2008	26068086	795	799	O
and	26068086	800	803	O
April	26068086	804	809	O
2010	26068086	810	814	O
]	26068086	814	815	O
and	26068086	816	819	O
TG-MV-007	26068086	820	829	O
[	26068086	830	831	O
between	26068086	831	838	O
December	26068086	839	847	O
2008	26068086	848	852	O
and	26068086	853	856	O
July	26068086	857	861	O
2010	26068086	862	866	O
]	26068086	866	867	O
)	26068086	867	868	O
at	26068086	869	871	O
clinic-based	26068086	872	884	O
centers	26068086	885	892	O
in	26068086	893	895	O
the	26068086	896	899	O
United	26068086	900	906	O
States	26068086	907	913	O
and	26068086	914	917	O
Europe	26068086	918	924	O
.	26068086	924	925	O

A	26068086	926	927	O
total	26068086	928	933	O
of	26068086	934	936	O
652	26068086	937	940	O
patients	26068086	941	949	O
with	26068086	950	954	O
symptomatic	26068086	955	966	O
VMA/VMT	26068086	967	974	O
,	26068086	974	975	O
including	26068086	976	985	O
when	26068086	986	990	O
associated	26068086	991	1001	O
with	26068086	1002	1006	O
a	26068086	1007	1008	O
macular	26068086	1009	1016	O
hole	26068086	1017	1021	O
400	26068086	1022	1025	O
μm	26068086	1026	1028	O
or	26068086	1029	1031	O
smaller	26068086	1032	1039	O
,	26068086	1039	1040	O
were	26068086	1041	1045	O
studied	26068086	1046	1053	O
.	26068086	1053	1054	O

Analysis	26068086	1055	1063	O
was	26068086	1064	1067	O
by	26068086	1068	1070	O
intent-to-treat	26068086	1071	1086	O
population	26068086	1087	1097	O
and	26068086	1098	1101	O
performed	26068086	1102	1111	O
in	26068086	1112	1114	O
May	26068086	1115	1118	O
2013	26068086	1119	1123	O
.	26068086	1123	1124	O

INTERVENTIONS	26068086	1126	1139	O
:	26068086	1140	1141	O
Patients	26068086	1142	1150	O
with	26068086	1151	1155	O
symptomatic	26068086	1156	1167	O
VMA/VMT	26068086	1168	1175	O
were	26068086	1176	1180	O
randomly	26068086	1181	1189	O
assigned	26068086	1190	1198	O
(	26068086	1199	1200	O
2:1	26068086	1200	1203	O
or	26068086	1204	1206	O
3:1	26068086	1207	1210	O
in	26068086	1211	1213	O
study	26068086	1214	1219	O
TG-MV-006	26068086	1220	1229	O
and	26068086	1230	1233	O
study	26068086	1234	1239	O
TG-MV-007	26068086	1240	1249	O
,	26068086	1249	1250	O
respectively	26068086	1251	1263	O
)	26068086	1263	1264	O
to	26068086	1265	1267	O
receive	26068086	1268	1275	O
a	26068086	1276	1277	O
single	26068086	1278	1284	O
intravitreal	26068086	1285	1297	O
injection	26068086	1298	1307	O
of	26068086	1308	1310	O
ocriplasmin	26068086	1311	1322	O
,	26068086	1322	1323	O
125	26068086	1324	1327	O
μg	26068086	1328	1330	O
,	26068086	1330	1331	O
or	26068086	1332	1334	O
placebo-injected	26068086	1335	1351	O
vehicle	26068086	1352	1359	O
(	26068086	1360	1361	O
placebo	26068086	1361	1368	O
)	26068086	1368	1369	O
.	26068086	1369	1370	O

The	26068086	1371	1374	O
NEI	26068086	1375	1378	O
VFQ-25	26068086	1379	1385	O
was	26068086	1386	1389	O
administered	26068086	1390	1402	O
at	26068086	1403	1405	O
baseline	26068086	1406	1414	O
and	26068086	1415	1418	O
6	26068086	1419	1420	O
months	26068086	1421	1427	O
following	26068086	1428	1437	O
ocriplasmin	26068086	1438	1449	O
injection	26068086	1450	1459	O
.	26068086	1459	1460	O

MAIN	26068086	1462	1466	O
OUTCOMES	26068086	1467	1475	O
AND	26068086	1476	1479	O
MEASURES	26068086	1480	1488	O
:	26068086	1489	1490	O
Mean	26068086	1491	1495	O
changes	26068086	1496	1503	O
between	26068086	1504	1511	O
baseline	26068086	1512	1520	O
and	26068086	1521	1524	O
6-month	26068086	1525	1532	O
follow-up	26068086	1533	1542	O
NEI	26068086	1543	1546	O
VFQ-25	26068086	1547	1553	O
composite	26068086	1554	1563	O
and	26068086	1564	1567	O
subscale	26068086	1568	1576	O
scores	26068086	1577	1583	O
and	26068086	1584	1587	O
the	26068086	1588	1591	O
proportion	26068086	1592	1602	O
of	26068086	1603	1605	O
patients	26068086	1606	1614	O
with	26068086	1615	1619	O
a	26068086	1620	1621	O
clinically	26068086	1622	1632	O
meaningful	26068086	1633	1643	O
change	26068086	1644	1650	O
(	26068086	1651	1652	O
≥5	26068086	1652	1654	O
points	26068086	1655	1661	O
)	26068086	1661	1662	O
in	26068086	1663	1665	O
scores	26068086	1666	1672	O
.	26068086	1672	1673	O

RESULTS	26068086	1675	1682	O
:	26068086	1683	1684	O
Across	26068086	1685	1691	O
the	26068086	1692	1695	O
2	26068086	1696	1697	O
studies	26068086	1698	1705	O
,	26068086	1705	1706	O
464	26068086	1707	1710	O
patients	26068086	1711	1719	O
received	26068086	1720	1728	O
ocriplasmin	26068086	1729	1740	O
and	26068086	1741	1744	O
188	26068086	1745	1748	O
received	26068086	1749	1757	O
placebo	26068086	1758	1765	O
.	26068086	1765	1766	O

At	26068086	1767	1769	O
6	26068086	1770	1771	O
months	26068086	1772	1778	O
,	26068086	1778	1779	O
the	26068086	1780	1783	O
ocriplasmin	26068086	1784	1795	O
group	26068086	1796	1801	O
reported	26068086	1802	1810	O
greater	26068086	1811	1818	O
mean	26068086	1819	1823	B-Outcome
improvements	26068086	1824	1836	I-Outcome
from	26068086	1837	1841	I-Outcome
baseline	26068086	1842	1850	I-Outcome
in	26068086	1851	1853	I-Outcome
the	26068086	1854	1857	I-Outcome
NEI	26068086	1858	1861	I-Outcome
VFQ-25	26068086	1862	1868	I-Outcome
composite	26068086	1869	1878	I-Outcome
score	26068086	1879	1884	I-Outcome
than	26068086	1885	1889	O
the	26068086	1890	1893	O
placebo	26068086	1894	1901	O
group	26068086	1902	1907	O
(	26068086	1908	1909	O
mean	26068086	1909	1913	O
change	26068086	1914	1920	O
,	26068086	1920	1921	O
3.4	26068086	1922	1925	O
vs	26068086	1926	1928	O
0.7	26068086	1929	1932	O
,	26068086	1932	1933	O
respectively	26068086	1934	1946	O
;	26068086	1946	1947	O
P	26068086	1948	1949	O
=	26068086	1950	1951	O
.005	26068086	1952	1956	O
)	26068086	1956	1957	O
.	26068086	1957	1958	O

Improvements	26068086	1959	1971	O
were	26068086	1972	1976	O
also	26068086	1977	1981	O
noted	26068086	1982	1987	O
in	26068086	1988	1990	O
subscale	26068086	1991	1999	O
scores	26068086	2000	2006	O
,	26068086	2006	2007	O
with	26068086	2008	2012	O
the	26068086	2013	2016	O
following	26068086	2017	2026	O
respective	26068086	2027	2037	O
mean	26068086	2038	2042	O
changes	26068086	2043	2050	O
for	26068086	2051	2054	O
the	26068086	2055	2058	O
ocriplasmin	26068086	2059	2070	O
vs	26068086	2071	2073	O
placebo	26068086	2074	2081	O
groups	26068086	2082	2088	O
:	26068086	2088	2089	O
vision-related	26068086	2090	2104	B-Outcome
dependency	26068086	2105	2115	I-Outcome
,	26068086	2115	2116	O
1.7	26068086	2117	2120	O
vs	26068086	2121	2123	O
-2.1	26068086	2124	2128	O
(	26068086	2129	2130	O
P	26068086	2130	2131	O
=	26068086	2132	2133	O
.009	26068086	2134	2138	O
)	26068086	2138	2139	O
;	26068086	2139	2140	O
driving	26068086	2141	2148	B-Outcome
difficulty	26068086	2149	2159	I-Outcome
,	26068086	2159	2160	O
2.7	26068086	2161	2164	O
vs	26068086	2165	2167	O
-1.5	26068086	2168	2172	O
(	26068086	2173	2174	O
P	26068086	2174	2175	O
=	26068086	2176	2177	O
.03	26068086	2178	2181	O
)	26068086	2181	2182	O
;	26068086	2182	2183	O
distance	26068086	2184	2192	B-Outcome
vision	26068086	2193	2199	I-Outcome
activities	26068086	2200	2210	I-Outcome
,	26068086	2210	2211	O
4.1	26068086	2212	2215	O
vs	26068086	2216	2218	O
0.8	26068086	2219	2222	O
(	26068086	2223	2224	O
P	26068086	2224	2225	O
=	26068086	2226	2227	O
.03	26068086	2228	2231	O
)	26068086	2231	2232	O
;	26068086	2232	2233	O
and	26068086	2234	2237	O
general	26068086	2238	2245	B-Outcome
vision	26068086	2246	2252	I-Outcome
,	26068086	2252	2253	O
6.1	26068086	2254	2257	O
vs	26068086	2258	2260	O
2.1	26068086	2261	2264	O
(	26068086	2265	2266	O
P	26068086	2266	2267	O
=	26068086	2268	2269	O
.003	26068086	2270	2274	O
)	26068086	2274	2275	O
.	26068086	2275	2276	O

A	26068086	2277	2278	O
higher	26068086	2279	2285	O
proportion	26068086	2286	2296	O
of	26068086	2297	2299	O
the	26068086	2300	2303	O
ocriplasmin	26068086	2304	2315	O
group	26068086	2316	2321	O
had	26068086	2322	2325	O
a	26068086	2326	2327	O
clinically	26068086	2328	2338	B-Outcome
meaningful	26068086	2339	2349	I-Outcome
(	26068086	2350	2351	I-Outcome
≥5-point	26068086	2351	2359	I-Outcome
)	26068086	2359	2360	I-Outcome
improvement	26068086	2361	2372	I-Outcome
in	26068086	2373	2375	I-Outcome
NEI	26068086	2376	2379	I-Outcome
VFQ-25	26068086	2380	2386	I-Outcome
composite	26068086	2387	2396	I-Outcome
score	26068086	2397	2402	I-Outcome
from	26068086	2403	2407	I-Outcome
baseline	26068086	2408	2416	I-Outcome
than	26068086	2417	2421	O
the	26068086	2422	2425	O
placebo	26068086	2426	2433	O
group	26068086	2434	2439	O
(	26068086	2440	2441	O
36.0	26068086	2441	2445	O
%	26068086	2445	2446	O
vs	26068086	2447	2449	O
27.2	26068086	2450	2454	O
%	26068086	2454	2455	O
,	26068086	2455	2456	O
respectively	26068086	2457	2469	O
;	26068086	2469	2470	O
P	26068086	2471	2472	O
=	26068086	2473	2474	O
.03	26068086	2475	2478	O
)	26068086	2478	2479	O
.	26068086	2479	2480	O

Fewer	26068086	2481	2486	O
ocriplasmin-treated	26068086	2487	2506	O
patients	26068086	2507	2515	O
had	26068086	2516	2519	O
a	26068086	2520	2521	O
clinically	26068086	2522	2532	O
meaningful	26068086	2533	2543	O
worsening	26068086	2544	2553	O
in	26068086	2554	2556	O
their	26068086	2557	2562	O
visual	26068086	2563	2569	B-Outcome
function	26068086	2570	2578	I-Outcome
than	26068086	2579	2583	O
the	26068086	2584	2587	O
placebo	26068086	2588	2595	O
group	26068086	2596	2601	O
(	26068086	2602	2603	O
15.0	26068086	2603	2607	O
%	26068086	2607	2608	O
vs	26068086	2609	2611	O
24.3	26068086	2612	2616	O
%	26068086	2616	2617	O
,	26068086	2617	2618	O
respectively	26068086	2619	2631	O
;	26068086	2631	2632	O
P	26068086	2633	2634	O
=	26068086	2635	2636	O
.005	26068086	2637	2641	O
)	26068086	2641	2642	O
.	26068086	2642	2643	O

Changes	26068086	2644	2651	B-Outcome
in	26068086	2652	2654	I-Outcome
NEI	26068086	2655	2658	I-Outcome
VFQ-25	26068086	2659	2665	I-Outcome
composite	26068086	2666	2675	I-Outcome
score	26068086	2676	2681	I-Outcome
and	26068086	2682	2685	O
various	26068086	2686	2693	O
subscale	26068086	2694	2702	B-Outcome
scores	26068086	2703	2709	I-Outcome
were	26068086	2710	2714	O
observed	26068086	2715	2723	O
in	26068086	2724	2726	O
ocriplasmin-treated	26068086	2727	2746	O
patients	26068086	2747	2755	O
who	26068086	2756	2759	O
achieved	26068086	2760	2768	O
VMA	26068086	2769	2772	O
resolution	26068086	2773	2783	O
at	26068086	2784	2786	O
day	26068086	2787	2790	O
28	26068086	2791	2793	O
.	26068086	2793	2794	O

CONCLUSIONS	26068086	2796	2807	O
AND	26068086	2808	2811	O
RELEVANCE	26068086	2812	2821	O
:	26068086	2822	2823	O
Ocriplasmin	26068086	2824	2835	O
produces	26068086	2836	2844	O
clinically	26068086	2845	2855	O
meaningful	26068086	2856	2866	O
improvement	26068086	2867	2878	O
in	26068086	2879	2881	O
patient-reported	26068086	2882	2898	B-Outcome
visual	26068086	2899	2905	I-Outcome
function	26068086	2906	2914	I-Outcome
in	26068086	2915	2917	O
symptomatic	26068086	2918	2929	O
VMA/VMT	26068086	2930	2937	O
.	26068086	2937	2938	O

TRIAL	26068086	2940	2945	O
REGISTRATION	26068086	2946	2958	O
:	26068086	2959	2960	O
clinicaltrials.gov	26068086	2961	2979	O
Identifiers	26068086	2980	2991	O
:	26068086	2991	2992	O
NCT00781859	26068086	2993	3004	O
and	26068086	3005	3008	O
NCT00798317	26068086	3009	3020	O
.	26068086	3020	3021	O


Efficacy	26082615	0	8	O
of	26082615	9	11	O
fimasartan/hydrochlorothiazide	26082615	12	42	O
combination	26082615	43	54	O
in	26082615	55	57	O
hypertensive	26082615	58	70	O
patients	26082615	71	79	O
inadequately	26082615	80	92	O
controlled	26082615	93	103	O
by	26082615	104	106	O
fimasartan	26082615	107	117	O
monotherapy	26082615	118	129	O
.	26082615	129	130	O

BACKGROUND	26082615	132	142	O
:	26082615	143	144	O
The	26082615	145	148	O
study	26082615	149	154	O
reported	26082615	155	163	O
here	26082615	164	168	O
compared	26082615	169	177	O
the	26082615	178	181	O
blood	26082615	182	187	O
pressure	26082615	188	196	O
(BP)-lowering	26082615	197	210	O
efficacy	26082615	211	219	O
of	26082615	220	222	O
fimasartan	26082615	223	233	O
alone	26082615	234	239	O
with	26082615	240	244	O
that	26082615	245	249	O
of	26082615	250	252	O
fimasartan/hydrochlorothiazide	26082615	253	283	O
(	26082615	284	285	O
HCTZ	26082615	285	289	O
)	26082615	289	290	O
combination	26082615	291	302	O
in	26082615	303	305	O
patients	26082615	306	314	O
whose	26082615	315	320	O
BP	26082615	321	323	O
goal	26082615	324	328	O
was	26082615	329	332	O
not	26082615	333	336	O
achieved	26082615	337	345	O
after	26082615	346	351	O
4	26082615	352	353	O
weeks	26082615	354	359	O
of	26082615	360	362	O
treatment	26082615	363	372	O
with	26082615	373	377	O
once-daily	26082615	378	388	O
fimasartan	26082615	389	399	O
60	26082615	400	402	O
mg	26082615	403	405	O
.	26082615	405	406	O

METHODS	26082615	408	415	O
:	26082615	416	417	O
Patients	26082615	418	426	O
with	26082615	427	431	O
sitting	26082615	432	439	O
diastolic	26082615	440	449	O
blood	26082615	450	455	O
pressure	26082615	456	464	O
(	26082615	465	466	O
siDBP	26082615	466	471	O
)	26082615	471	472	O
≥90	26082615	473	476	O
mmHg	26082615	477	481	O
with	26082615	482	486	O
4	26082615	487	488	O
weeks	26082615	489	494	O
of	26082615	495	497	O
once-daily	26082615	498	508	O
fimasartan	26082615	509	519	O
60	26082615	520	522	O
mg	26082615	523	525	O
were	26082615	526	530	O
randomly	26082615	531	539	O
assigned	26082615	540	548	O
to	26082615	549	551	O
receive	26082615	552	559	O
either	26082615	560	566	O
once-daily	26082615	567	577	O
fimasartan	26082615	578	588	O
60	26082615	589	591	O
mg/HCTZ	26082615	592	599	O
12.5	26082615	600	604	O
mg	26082615	605	607	O
or	26082615	608	610	O
fimasartan	26082615	611	621	O
60	26082615	622	624	O
mg	26082615	625	627	O
for	26082615	628	631	O
4	26082615	632	633	O
weeks	26082615	634	639	O
.	26082615	639	640	O

After	26082615	641	646	O
4	26082615	647	648	O
weeks	26082615	649	654	O
,	26082615	654	655	O
the	26082615	656	659	O
dose	26082615	660	664	O
was	26082615	665	668	O
increased	26082615	669	678	O
from	26082615	679	683	O
fimasartan	26082615	684	694	O
60	26082615	695	697	O
mg/HCTZ	26082615	698	705	O
12.5	26082615	706	710	O
mg	26082615	711	713	O
to	26082615	714	716	O
fimasartan	26082615	717	727	O
120	26082615	728	731	O
mg/HCTZ	26082615	732	739	O
12.5	26082615	740	744	O
mg	26082615	745	747	O
or	26082615	748	750	O
from	26082615	751	755	O
fimasartan	26082615	756	766	O
60	26082615	767	769	O
mg	26082615	770	772	O
to	26082615	773	775	O
fimasartan	26082615	776	786	O
120	26082615	787	790	O
mg	26082615	791	793	O
if	26082615	794	796	O
siDBP	26082615	797	802	O
was	26082615	803	806	O
≥90	26082615	807	810	O
mmHg	26082615	811	815	O
.	26082615	815	816	O

RESULTS	26082615	818	825	O
:	26082615	826	827	O
Of	26082615	828	830	O
the	26082615	831	834	O
263	26082615	835	838	O
randomized	26082615	839	849	O
patients	26082615	850	858	O
,	26082615	858	859	O
256	26082615	860	863	O
patients	26082615	864	872	O
who	26082615	873	876	O
had	26082615	877	880	O
available	26082615	881	890	O
efficacy	26082615	891	899	B-Outcome
data	26082615	900	904	O
were	26082615	905	909	O
analyzed	26082615	910	918	O
.	26082615	918	919	O

The	26082615	920	923	O
fimasartan/HCTZ	26082615	924	939	O
treatment	26082615	940	949	O
group	26082615	950	955	O
showed	26082615	956	962	O
a	26082615	963	964	O
greater	26082615	965	972	O
reduction	26082615	973	982	O
of	26082615	983	985	O
siDBP	26082615	986	991	B-Outcome
compared	26082615	992	1000	O
to	26082615	1001	1003	O
the	26082615	1004	1007	O
fimasartan	26082615	1008	1018	O
treatment	26082615	1019	1028	O
group	26082615	1029	1034	O
at	26082615	1035	1037	O
Week	26082615	1038	1042	O
4	26082615	1043	1044	O
(	26082615	1045	1046	O
6.88±8.10	26082615	1046	1055	O
mmHg	26082615	1056	1060	O
vs	26082615	1061	1063	O
3.38±7.33	26082615	1064	1073	O
,	26082615	1073	1074	O
P=0.0008	26082615	1075	1083	O
)	26082615	1083	1084	O
,	26082615	1084	1085	O
and	26082615	1086	1089	O
the	26082615	1090	1093	O
effect	26082615	1094	1100	O
persisted	26082615	1101	1110	O
at	26082615	1111	1113	O
Week	26082615	1114	1118	O
8	26082615	1119	1120	O
(	26082615	1121	1122	O
8.67±9.39	26082615	1122	1131	O
mmHg	26082615	1132	1136	O
vs	26082615	1137	1139	O
5.02±8.27	26082615	1140	1149	O
mmHg	26082615	1150	1154	O
,	26082615	1154	1155	O
P=0.0023	26082615	1156	1164	O
)	26082615	1164	1165	O
.	26082615	1165	1166	O

Reduction	26082615	1167	1176	O
of	26082615	1177	1179	O
sitting	26082615	1180	1187	B-Outcome
systolic	26082615	1188	1196	I-Outcome
BP	26082615	1197	1199	I-Outcome
in	26082615	1200	1202	O
the	26082615	1203	1206	O
fimasartan/HCTZ	26082615	1207	1222	O
treatment	26082615	1223	1232	O
group	26082615	1233	1238	O
was	26082615	1239	1242	O
also	26082615	1243	1247	O
greater	26082615	1248	1255	O
than	26082615	1256	1260	O
that	26082615	1261	1265	O
in	26082615	1266	1268	O
the	26082615	1269	1272	O
fimasartan	26082615	1273	1283	O
treatment	26082615	1284	1293	O
group	26082615	1294	1299	O
(	26082615	1300	1301	O
at	26082615	1301	1303	O
Week	26082615	1304	1308	O
4	26082615	1309	1310	O
,	26082615	1310	1311	O
10.50±13.76	26082615	1312	1323	O
mmHg	26082615	1324	1328	O
vs	26082615	1329	1331	O
5.75±12.18	26082615	1332	1342	O
mmHg	26082615	1343	1347	O
,	26082615	1347	1348	O
P=0.0069	26082615	1349	1357	O
and	26082615	1358	1361	O
,	26082615	1361	1362	O
at	26082615	1363	1365	O
Week	26082615	1366	1370	O
8	26082615	1371	1372	O
,	26082615	1372	1373	O
13.45±15.15	26082615	1374	1385	O
mmHg	26082615	1386	1390	O
vs	26082615	1391	1393	O
6.84±13.57	26082615	1394	1404	O
mmHg	26082615	1405	1409	O
,	26082615	1409	1410	O
P=0.0007	26082615	1411	1419	O
)	26082615	1419	1420	O
.	26082615	1420	1421	O

The	26082615	1422	1425	O
proportion	26082615	1426	1436	O
of	26082615	1437	1439	O
patients	26082615	1440	1448	O
who	26082615	1449	1452	O
achieved	26082615	1453	1461	O
a	26082615	1462	1463	O
reduction	26082615	1464	1473	O
of	26082615	1474	1476	O
siDBP	26082615	1477	1482	B-Outcome
≥10	26082615	1483	1486	O
mmHg	26082615	1487	1491	O
from	26082615	1492	1496	O
baseline	26082615	1497	1505	O
and/or	26082615	1506	1512	O
a	26082615	1513	1514	O
mean	26082615	1515	1519	B-Outcome
siDBP	26082615	1520	1525	I-Outcome
<	26082615	1526	1527	O
90	26082615	1527	1529	O
mmHg	26082615	1530	1534	O
after	26082615	1535	1540	O
4	26082615	1541	1542	O
weeks	26082615	1543	1548	O
of	26082615	1549	1551	O
treatment	26082615	1552	1561	O
was	26082615	1562	1565	O
higher	26082615	1566	1572	O
in	26082615	1573	1575	O
the	26082615	1576	1579	O
fimasartan/HCTZ	26082615	1580	1595	O
treatment	26082615	1596	1605	O
group	26082615	1606	1611	O
than	26082615	1612	1616	O
in	26082615	1617	1619	O
the	26082615	1620	1623	O
fimasartan	26082615	1624	1634	O
treatment	26082615	1635	1644	O
group	26082615	1645	1650	O
(	26082615	1651	1652	O
53.6	26082615	1652	1656	O
%	26082615	1656	1657	O
vs	26082615	1658	1660	O
39.8	26082615	1661	1665	O
%	26082615	1665	1666	O
,	26082615	1666	1667	O
P=0.0359	26082615	1668	1676	O
)	26082615	1676	1677	O
.	26082615	1677	1678	O

The	26082615	1679	1682	O
overall	26082615	1683	1690	O
incidence	26082615	1691	1700	O
of	26082615	1701	1703	O
adverse	26082615	1704	1711	B-Outcome
drug	26082615	1712	1716	I-Outcome
reaction	26082615	1717	1725	I-Outcome
was	26082615	1726	1729	O
11.79	26082615	1730	1735	O
%	26082615	1735	1736	O
with	26082615	1737	1741	O
no	26082615	1742	1744	O
significant	26082615	1745	1756	O
difference	26082615	1757	1767	O
between	26082615	1768	1775	O
the	26082615	1776	1779	O
treatment	26082615	1780	1789	O
groups	26082615	1790	1796	O
.	26082615	1796	1797	O

CONCLUSION	26082615	1799	1809	O
:	26082615	1810	1811	O
The	26082615	1812	1815	O
combination	26082615	1816	1827	O
treatment	26082615	1828	1837	O
of	26082615	1838	1840	O
fimasartan	26082615	1841	1851	O
and	26082615	1852	1855	O
HCTZ	26082615	1856	1860	O
achieved	26082615	1861	1869	O
better	26082615	1870	1876	O
BP	26082615	1877	1879	B-Outcome
control	26082615	1880	1887	I-Outcome
than	26082615	1888	1892	O
fimasartan	26082615	1893	1903	O
monotherapy	26082615	1904	1915	O
,	26082615	1915	1916	O
and	26082615	1917	1920	O
had	26082615	1921	1924	O
comparable	26082615	1925	1935	O
safety	26082615	1936	1942	B-Outcome
and	26082615	1943	1946	O
tolerance	26082615	1947	1956	B-Outcome
to	26082615	1957	1959	O
fimasartan	26082615	1960	1970	O
monotherapy	26082615	1971	1982	O
.	26082615	1982	1983	O


Quadratus	26225500	0	9	O
lumborum	26225500	10	18	O
block	26225500	19	24	O
for	26225500	25	28	O
postoperative	26225500	29	42	O
pain	26225500	43	47	O
after	26225500	48	53	O
caesarean	26225500	54	63	O
section	26225500	64	71	O
:	26225500	71	72	O
A	26225500	73	74	O
randomised	26225500	75	85	O
controlled	26225500	86	96	O
trial	26225500	97	102	O
.	26225500	102	103	O

BACKGROUND	26225500	105	115	O
:	26225500	116	117	O
Effective	26225500	118	127	O
postoperative	26225500	128	141	O
analgesia	26225500	142	151	O
after	26225500	152	157	O
caesarean	26225500	158	167	O
section	26225500	168	175	O
is	26225500	176	178	O
important	26225500	179	188	O
because	26225500	189	196	O
it	26225500	197	199	O
enables	26225500	200	207	O
early	26225500	208	213	O
ambulation	26225500	214	224	O
and	26225500	225	228	O
facilitates	26225500	229	240	O
breast-feeding	26225500	241	255	O
.	26225500	255	256	O

Several	26225500	257	264	O
case	26225500	265	269	O
reports	26225500	270	277	O
have	26225500	278	282	O
shown	26225500	283	288	O
that	26225500	289	293	O
local	26225500	294	299	O
anaesthetic	26225500	300	311	O
injection	26225500	312	321	O
around	26225500	322	328	O
the	26225500	329	332	O
quadratus	26225500	333	342	O
lumborum	26225500	343	351	O
muscle	26225500	352	358	O
is	26225500	359	361	O
effective	26225500	362	371	O
in	26225500	372	374	O
providing	26225500	375	384	O
pain	26225500	385	389	O
relief	26225500	390	396	O
after	26225500	397	402	O
various	26225500	403	410	O
abdominal	26225500	411	420	O
operations	26225500	421	431	O
and	26225500	432	435	O
in	26225500	436	438	O
patients	26225500	439	447	O
with	26225500	448	452	O
chronic	26225500	453	460	O
pain	26225500	461	465	O
.	26225500	465	466	O

The	26225500	467	470	O
quadratus	26225500	471	480	O
lumborum	26225500	481	489	O
block	26225500	490	495	O
(	26225500	496	497	O
QLB	26225500	497	500	O
)	26225500	500	501	O
is	26225500	502	504	O
performed	26225500	505	514	O
in	26225500	515	517	O
close	26225500	518	523	O
proximity	26225500	524	533	O
to	26225500	534	536	O
the	26225500	537	540	O
surface	26225500	541	548	O
and	26225500	549	552	O
uses	26225500	553	557	O
a	26225500	558	559	O
fascial	26225500	560	567	O
compartment	26225500	568	579	O
path	26225500	580	584	O
to	26225500	585	587	O
extend	26225500	588	594	O
the	26225500	595	598	O
distribution	26225500	599	611	O
of	26225500	612	614	O
local	26225500	615	620	O
anaesthesia	26225500	621	632	O
into	26225500	633	637	O
the	26225500	638	641	O
posterior	26225500	642	651	O
abdominal	26225500	652	661	O
wall	26225500	662	666	O
and	26225500	667	670	O
paravertebral	26225500	671	684	O
space	26225500	685	690	O
.	26225500	690	691	O

This	26225500	692	696	O
central	26225500	697	704	O
effect	26225500	705	711	O
can	26225500	712	715	O
be	26225500	716	718	O
of	26225500	719	721	O
vital	26225500	722	727	O
importance	26225500	728	738	O
when	26225500	739	743	O
managing	26225500	744	752	O
the	26225500	753	756	O
visceral	26225500	757	765	O
pain	26225500	766	770	O
after	26225500	771	776	O
caesarean	26225500	777	786	O
section	26225500	787	794	O
.	26225500	794	795	O

OBJECTIVE	26225500	797	806	O
:	26225500	807	808	O
We	26225500	809	811	O
hypothesised	26225500	812	824	O
that	26225500	825	829	O
the	26225500	830	833	O
QLB	26225500	834	837	O
after	26225500	838	843	O
caesarean	26225500	844	853	O
section	26225500	854	861	O
can	26225500	862	865	O
provide	26225500	866	873	O
adequate	26225500	874	882	O
pain	26225500	883	887	O
relief	26225500	888	894	O
as	26225500	895	897	O
part	26225500	898	902	O
of	26225500	903	905	O
a	26225500	906	907	O
multimodal	26225500	908	918	O
approach	26225500	919	927	O
.	26225500	927	928	O

DESIGN	26225500	930	936	O
:	26225500	937	938	O
Double-blind	26225500	939	951	O
,	26225500	951	952	O
randomised	26225500	953	963	O
and	26225500	964	967	O
controlled	26225500	968	978	O
clinical	26225500	979	987	O
trial	26225500	988	993	O
.	26225500	993	994	O

SETTING	26225500	996	1003	O
:	26225500	1004	1005	O
A	26225500	1006	1007	O
single	26225500	1008	1014	O
centre	26225500	1015	1021	O
between	26225500	1022	1029	O
June	26225500	1030	1034	O
2014	26225500	1035	1039	O
and	26225500	1040	1043	O
December	26225500	1044	1052	O
2014	26225500	1053	1057	O
.	26225500	1057	1058	O

PATIENTS	26225500	1060	1068	O
:	26225500	1069	1070	O
Fifty	26225500	1071	1076	O
patients	26225500	1077	1085	O
who	26225500	1086	1089	O
were	26225500	1090	1094	O
American	26225500	1095	1103	O
Society	26225500	1104	1111	O
of	26225500	1112	1114	O
Anesthesiologists	26225500	1115	1132	O
physical	26225500	1133	1141	O
status	26225500	1142	1148	O
1	26225500	1149	1150	O
or	26225500	1151	1153	O
2	26225500	1154	1155	O
,	26225500	1155	1156	O
with	26225500	1157	1161	O
normal	26225500	1162	1168	O
singleton	26225500	1169	1178	O
pregnancies	26225500	1179	1190	O
with	26225500	1191	1195	O
a	26225500	1196	1197	O
gestation	26225500	1198	1207	O
of	26225500	1208	1210	O
at	26225500	1211	1213	O
least	26225500	1214	1219	O
37	26225500	1220	1222	O
weeks	26225500	1223	1228	O
,	26225500	1228	1229	O
and	26225500	1230	1233	O
scheduled	26225500	1234	1243	O
for	26225500	1244	1247	O
elective	26225500	1248	1256	O
caesarean	26225500	1257	1266	O
section	26225500	1267	1274	O
under	26225500	1275	1280	O
spinal	26225500	1281	1287	O
anaesthesia	26225500	1288	1299	O
,	26225500	1299	1300	O
were	26225500	1301	1305	O
enrolled	26225500	1306	1314	O
into	26225500	1315	1319	O
the	26225500	1320	1323	O
study	26225500	1324	1329	O
.	26225500	1329	1330	O

They	26225500	1331	1335	O
were	26225500	1336	1340	O
randomly	26225500	1341	1349	O
assigned	26225500	1350	1358	O
to	26225500	1359	1361	O
receive	26225500	1362	1369	O
a	26225500	1370	1371	O
QLB	26225500	1372	1375	O
(	26225500	1376	1377	O
n	26225500	1377	1378	O
=	26225500	1379	1380	O
25	26225500	1381	1383	O
)	26225500	1383	1384	O
with	26225500	1385	1389	O
0.125	26225500	1390	1395	O
%	26225500	1395	1396	O
bupivacaine	26225500	1397	1408	O
0.2	26225500	1409	1412	O
ml	26225500	1413	1415	O
kg⁻¹	26225500	1416	1420	O
(	26225500	1421	1422	O
Group	26225500	1422	1427	O
1	26225500	1428	1429	O
)	26225500	1429	1430	O
or	26225500	1431	1433	O
a	26225500	1434	1435	O
QLB	26225500	1436	1439	O
(	26225500	1440	1441	O
n	26225500	1441	1442	O
=	26225500	1443	1444	O
25	26225500	1445	1447	O
)	26225500	1447	1448	O
with	26225500	1449	1453	O
0.9	26225500	1454	1457	O
%	26225500	1457	1458	O
Normal	26225500	1459	1465	O
saline	26225500	1466	1472	O
0.2	26225500	1473	1476	O
ml	26225500	1477	1479	O
kg⁻¹	26225500	1480	1484	O
(	26225500	1485	1486	O
Group	26225500	1486	1491	O
2	26225500	1492	1493	O
)	26225500	1493	1494	O
.	26225500	1494	1495	O

MAIN	26225500	1497	1501	O
OUTCOME	26225500	1502	1509	O
MEASURES	26225500	1510	1518	O
:	26225500	1519	1520	O
The	26225500	1521	1524	O
primary	26225500	1525	1532	O
outcome	26225500	1533	1540	O
measure	26225500	1541	1548	O
for	26225500	1549	1552	O
the	26225500	1553	1556	O
study	26225500	1557	1562	O
was	26225500	1563	1566	O
the	26225500	1567	1570	O
morphine	26225500	1571	1579	O
demands	26225500	1580	1587	O
and	26225500	1588	1591	O
doses	26225500	1592	1597	O
delivered	26225500	1598	1607	O
by	26225500	1608	1610	O
a	26225500	1611	1612	O
patient-controlled	26225500	1613	1631	O
analgesia	26225500	1632	1641	O
system	26225500	1642	1648	O
at	26225500	1649	1651	O
predetermined	26225500	1652	1665	O
intervals	26225500	1666	1675	O
(	26225500	1676	1677	O
1	26225500	1677	1678	O
,	26225500	1678	1679	O
2	26225500	1680	1681	O
,	26225500	1681	1682	O
4	26225500	1683	1684	O
,	26225500	1684	1685	O
6	26225500	1686	1687	O
,	26225500	1687	1688	O
12	26225500	1689	1691	O
,	26225500	1691	1692	O
24	26225500	1693	1695	O
and	26225500	1696	1699	O
48	26225500	1700	1702	O
h	26225500	1703	1704	O
)	26225500	1704	1705	O
after	26225500	1706	1711	O
surgery	26225500	1712	1719	O
.	26225500	1719	1720	O

The	26225500	1721	1724	O
secondary	26225500	1725	1734	O
endpoints	26225500	1735	1744	O
were	26225500	1745	1749	O
visual	26225500	1750	1756	O
analogue	26225500	1757	1765	O
scale	26225500	1766	1771	O
(	26225500	1772	1773	O
VAS	26225500	1773	1776	O
)	26225500	1776	1777	O
for	26225500	1778	1781	O
pain	26225500	1782	1786	O
at	26225500	1787	1789	O
rest	26225500	1790	1794	O
and	26225500	1795	1798	O
on	26225500	1799	1801	O
movement	26225500	1802	1810	O
(	26225500	1811	1812	O
dynamic	26225500	1812	1819	O
)	26225500	1819	1820	O
,	26225500	1820	1821	O
heart	26225500	1822	1827	O
rate	26225500	1828	1832	O
,	26225500	1832	1833	O
blood	26225500	1834	1839	O
pressure	26225500	1840	1848	O
,	26225500	1848	1849	O
pruritus	26225500	1850	1858	O
,	26225500	1858	1859	O
itching	26225500	1860	1867	O
,	26225500	1867	1868	O
nausea	26225500	1869	1875	O
,	26225500	1875	1876	O
vomiting	26225500	1877	1885	O
and	26225500	1886	1889	O
sedation	26225500	1890	1898	O
.	26225500	1898	1899	O

RESULTS	26225500	1901	1908	O
:	26225500	1909	1910	O
The	26225500	1911	1914	O
patients	26225500	1915	1923	O
who	26225500	1924	1927	O
received	26225500	1928	1936	O
local	26225500	1937	1942	O
anaesthetic	26225500	1943	1954	O
used	26225500	1955	1959	O
significantly	26225500	1960	1973	O
less	26225500	1974	1978	O
morphine	26225500	1979	1987	B-Outcome
than	26225500	1988	1992	O
the	26225500	1993	1996	O
control	26225500	1997	2004	O
group	26225500	2005	2010	O
(	26225500	2011	2012	O
P	26225500	2012	2013	O
<	26225500	2014	2015	O
0.001	26225500	2016	2021	O
)	26225500	2021	2022	O
at	26225500	2023	2025	O
6	26225500	2026	2027	O
and	26225500	2028	2031	O
12	26225500	2032	2034	O
h	26225500	2035	2036	O
,	26225500	2036	2037	O
but	26225500	2038	2041	O
not	26225500	2042	2045	O
at	26225500	2046	2048	O
24	26225500	2049	2051	O
and	26225500	2052	2055	O
48	26225500	2056	2058	O
hours	26225500	2059	2064	O
after	26225500	2065	2070	O
caesarean	26225500	2071	2080	O
section	26225500	2081	2088	O
.	26225500	2088	2089	O

The	26225500	2090	2093	O
local	26225500	2094	2099	O
anaesthetic	26225500	2100	2111	O
group	26225500	2112	2117	O
had	26225500	2118	2121	O
significantly	26225500	2122	2135	O
less	26225500	2136	2140	O
morphine	26225500	2141	2149	B-Outcome
demand	26225500	2150	2156	I-Outcome
than	26225500	2157	2161	O
the	26225500	2162	2165	O
control	26225500	2166	2173	O
group	26225500	2174	2179	O
(	26225500	2180	2181	O
P	26225500	2181	2182	O
<	26225500	2183	2184	O
0.001	26225500	2185	2190	O
)	26225500	2190	2191	O
6	26225500	2192	2193	O
,	26225500	2193	2194	O
12	26225500	2195	2197	O
,	26225500	2197	2198	O
24	26225500	2199	2201	O
and	26225500	2202	2205	O
48	26225500	2206	2208	O
h	26225500	2209	2210	O
after	26225500	2211	2216	O
caesarean	26225500	2217	2226	O
section	26225500	2227	2234	O
.	26225500	2234	2235	O

The	26225500	2236	2239	O
VAS	26225500	2240	2243	B-Outcome
was	26225500	2244	2247	O
significantly	26225500	2248	2261	O
lower	26225500	2262	2267	O
in	26225500	2268	2270	O
the	26225500	2271	2274	O
local	26225500	2275	2280	O
anaesthetic	26225500	2281	2292	O
group	26225500	2293	2298	O
than	26225500	2299	2303	O
the	26225500	2304	2307	O
control	26225500	2308	2315	O
group	26225500	2316	2321	O
,	26225500	2321	2322	O
including	26225500	2323	2332	O
VAS	26225500	2333	2336	B-Outcome
for	26225500	2337	2340	I-Outcome
pain	26225500	2341	2345	I-Outcome
at	26225500	2346	2348	I-Outcome
rest	26225500	2349	2353	I-Outcome
at	26225500	2354	2356	O
all	26225500	2357	2360	O
times	26225500	2361	2366	O
except	26225500	2367	2373	O
24	26225500	2374	2376	O
h	26225500	2377	2378	O
after	26225500	2379	2384	O
caesarean	26225500	2385	2394	O
section	26225500	2395	2402	O
,	26225500	2402	2403	O
and	26225500	2404	2407	O
VAS	26225500	2408	2411	B-Outcome
for	26225500	2412	2415	I-Outcome
pain	26225500	2416	2420	I-Outcome
on	26225500	2421	2423	I-Outcome
movement	26225500	2424	2432	I-Outcome
(	26225500	2433	2434	I-Outcome
dynamic	26225500	2434	2441	I-Outcome
)	26225500	2441	2442	I-Outcome
at	26225500	2443	2445	O
all	26225500	2446	2449	O
times	26225500	2450	2455	O
.	26225500	2455	2456	O

CONCLUSION	26225500	2458	2468	O
:	26225500	2469	2470	O
The	26225500	2471	2474	O
QLB	26225500	2475	2478	O
after	26225500	2479	2484	O
caesarean	26225500	2485	2494	O
section	26225500	2495	2502	O
was	26225500	2503	2506	O
effective	26225500	2507	2516	O
and	26225500	2517	2520	O
provided	26225500	2521	2529	O
satisfactory	26225500	2530	2542	O
analgesia	26225500	2543	2552	B-Outcome
in	26225500	2553	2555	O
combination	26225500	2556	2567	O
with	26225500	2568	2572	O
a	26225500	2573	2574	O
typical	26225500	2575	2582	O
postoperative	26225500	2583	2596	O
analgesic	26225500	2597	2606	O
regimen	26225500	2607	2614	O
.	26225500	2614	2615	O

TRIAL	26225500	2617	2622	O
REGISTRATION	26225500	2623	2635	O
:	26225500	2636	2637	O
ClinicalTrials.gov	26225500	2638	2656	O
identifier	26225500	2657	2667	O
:	26225500	2667	2668	O
NCT02328378	26225500	2669	2680	O
.	26225500	2680	2681	O


High	26317618	0	4	O
Platelet	26317618	5	13	O
Reactivity	26317618	14	24	O
in	26317618	25	27	O
Patients	26317618	28	36	O
with	26317618	37	41	O
Acute	26317618	42	47	O
Coronary	26317618	48	56	O
Syndromes	26317618	57	66	O
Undergoing	26317618	67	77	O
Percutaneous	26317618	78	90	O
Coronary	26317618	91	99	O
Intervention	26317618	100	112	O
:	26317618	112	113	O
Randomised	26317618	114	124	O
Controlled	26317618	125	135	O
Trial	26317618	136	141	O
Comparing	26317618	142	151	O
Prasugrel	26317618	152	161	O
and	26317618	162	165	O
Clopidogrel	26317618	166	177	O
.	26317618	177	178	O

BACKGROUND	26317618	180	190	O
:	26317618	191	192	O
Prasugrel	26317618	193	202	O
is	26317618	203	205	O
more	26317618	206	210	O
effective	26317618	211	220	O
than	26317618	221	225	O
clopidogrel	26317618	226	237	O
in	26317618	238	240	O
reducing	26317618	241	249	O
platelet	26317618	250	258	O
aggregation	26317618	259	270	O
in	26317618	271	273	O
acute	26317618	274	279	O
coronary	26317618	280	288	O
syndromes	26317618	289	298	O
.	26317618	298	299	O

Data	26317618	300	304	O
available	26317618	305	314	O
on	26317618	315	317	O
prasugrel	26317618	318	327	O
reloading	26317618	328	337	O
in	26317618	338	340	O
clopidogrel	26317618	341	352	O
treated	26317618	353	360	O
patients	26317618	361	369	O
with	26317618	370	374	O
high	26317618	375	379	O
residual	26317618	380	388	O
platelet	26317618	389	397	O
reactivity	26317618	398	408	O
(	26317618	409	410	O
HRPR	26317618	410	414	O
)	26317618	414	415	O
i.e.	26317618	416	420	O
poor	26317618	421	425	O
responders	26317618	426	436	O
,	26317618	436	437	O
is	26317618	438	440	O
limited	26317618	441	448	O
.	26317618	448	449	O

OBJECTIVES	26317618	451	461	O
:	26317618	462	463	O
To	26317618	464	466	O
determine	26317618	467	476	O
the	26317618	477	480	O
effects	26317618	481	488	O
of	26317618	489	491	O
prasugrel	26317618	492	501	O
loading	26317618	502	509	O
on	26317618	510	512	O
platelet	26317618	513	521	O
function	26317618	522	530	O
in	26317618	531	533	O
patients	26317618	534	542	O
on	26317618	543	545	O
clopidogrel	26317618	546	557	O
and	26317618	558	561	O
high	26317618	562	566	O
platelet	26317618	567	575	O
reactivity	26317618	576	586	O
undergoing	26317618	587	597	O
percutaneous	26317618	598	610	O
coronary	26317618	611	619	O
intervention	26317618	620	632	O
for	26317618	633	636	O
acute	26317618	637	642	O
coronary	26317618	643	651	O
syndrome	26317618	652	660	O
(	26317618	661	662	O
ACS	26317618	662	665	O
)	26317618	665	666	O
.	26317618	666	667	O

PATIENTS	26317618	669	677	O
:	26317618	678	679	O
Patients	26317618	680	688	O
with	26317618	689	693	O
ACS	26317618	694	697	O
on	26317618	698	700	O
clopidogrel	26317618	701	712	O
who	26317618	713	716	O
were	26317618	717	721	O
scheduled	26317618	722	731	O
for	26317618	732	735	O
PCI	26317618	736	739	O
found	26317618	740	745	O
to	26317618	746	748	O
have	26317618	749	753	O
a	26317618	754	755	O
platelet	26317618	756	764	O
reactivity	26317618	765	775	O
≥40	26317618	776	779	O
AUC	26317618	780	783	O
with	26317618	784	788	O
the	26317618	789	792	O
Multiplate	26317618	793	803	O
Analyzer	26317618	804	812	O
,	26317618	812	813	O
i.e.	26317618	814	818	O
"	26317618	819	820	O
poor	26317618	820	824	O
responders	26317618	825	835	O
"	26317618	835	836	O
were	26317618	837	841	O
randomised	26317618	842	852	O
to	26317618	853	855	O
prasugrel	26317618	856	865	O
(	26317618	866	867	O
60	26317618	867	869	O
mg	26317618	870	872	O
loading	26317618	873	880	O
and	26317618	881	884	O
10	26317618	885	887	O
mg	26317618	888	890	O
maintenance	26317618	891	902	O
dose	26317618	903	907	O
)	26317618	907	908	O
or	26317618	909	911	O
clopidogrel	26317618	912	923	O
(	26317618	924	925	O
600	26317618	925	928	O
mg	26317618	929	931	O
reloading	26317618	932	941	O
and	26317618	942	945	O
150	26317618	946	949	O
mg	26317618	950	952	O
maintenance	26317618	953	964	O
dose	26317618	965	969	O
)	26317618	969	970	O
.	26317618	970	971	O

The	26317618	972	975	O
primary	26317618	976	983	O
outcome	26317618	984	991	O
measure	26317618	992	999	O
was	26317618	1000	1003	O
proportion	26317618	1004	1014	O
of	26317618	1015	1017	O
patients	26317618	1018	1026	O
with	26317618	1027	1031	O
platelet	26317618	1032	1040	O
reactivity	26317618	1041	1051	O
<	26317618	1052	1053	O
40	26317618	1053	1055	O
AUC	26317618	1056	1059	O
4	26317618	1060	1061	O
hours	26317618	1062	1067	O
after	26317618	1068	1073	O
loading	26317618	1074	1081	O
with	26317618	1082	1086	O
study	26317618	1087	1092	O
medication	26317618	1093	1103	O
,	26317618	1103	1104	O
and	26317618	1105	1108	O
also	26317618	1109	1113	O
at	26317618	1114	1116	O
one	26317618	1117	1120	O
hour	26317618	1121	1125	O
(	26317618	1126	1127	O
secondary	26317618	1127	1136	O
outcome	26317618	1137	1144	O
)	26317618	1144	1145	O
.	26317618	1145	1146	O

44	26317618	1147	1149	O
patients	26317618	1150	1158	O
were	26317618	1159	1163	O
enrolled	26317618	1164	1172	O
and	26317618	1173	1176	O
the	26317618	1177	1180	O
study	26317618	1181	1186	O
was	26317618	1187	1190	O
terminated	26317618	1191	1201	O
early	26317618	1202	1207	O
as	26317618	1208	1210	O
clopidogrel	26317618	1211	1222	O
use	26317618	1223	1226	O
decreased	26317618	1227	1236	O
sharply	26317618	1237	1244	O
due	26317618	1245	1248	O
to	26317618	1249	1251	O
introduction	26317618	1252	1264	O
of	26317618	1265	1267	O
newer	26317618	1268	1273	O
P2Y12	26317618	1274	1279	O
inhibitors	26317618	1280	1290	O
.	26317618	1290	1291	O

RESULTS	26317618	1293	1300	O
:	26317618	1301	1302	O
At	26317618	1303	1305	O
4	26317618	1306	1307	O
hours	26317618	1308	1313	O
after	26317618	1314	1319	O
study	26317618	1320	1325	O
medication	26317618	1326	1336	O
100	26317618	1337	1340	O
%	26317618	1340	1341	O
of	26317618	1342	1344	O
patients	26317618	1345	1353	O
treated	26317618	1354	1361	O
with	26317618	1362	1366	O
prasugrel	26317618	1367	1376	O
compared	26317618	1377	1385	O
to	26317618	1386	1388	O
91	26317618	1389	1391	O
%	26317618	1391	1392	O
of	26317618	1393	1395	O
those	26317618	1396	1401	O
treated	26317618	1402	1409	O
with	26317618	1410	1414	O
clopidogrel	26317618	1415	1426	O
had	26317618	1427	1430	O
platelet	26317618	1431	1439	B-Outcome
reactivity	26317618	1440	1450	I-Outcome
<	26317618	1451	1452	I-Outcome
40	26317618	1452	1454	I-Outcome
AUC	26317618	1455	1458	I-Outcome
(	26317618	1459	1460	O
p	26317618	1460	1461	O
=	26317618	1462	1463	O
0.49	26317618	1464	1468	O
)	26317618	1468	1469	O
,	26317618	1469	1470	O
while	26317618	1471	1476	O
at	26317618	1477	1479	O
1	26317618	1480	1481	O
hour	26317618	1482	1486	O
the	26317618	1487	1490	O
proportions	26317618	1491	1502	O
were	26317618	1503	1507	O
95	26317618	1508	1510	O
%	26317618	1510	1511	O
and	26317618	1512	1515	O
64	26317618	1516	1518	O
%	26317618	1518	1519	O
respectively	26317618	1520	1532	O
(	26317618	1533	1534	O
p	26317618	1534	1535	O
=	26317618	1536	1537	O
0.02	26317618	1538	1542	O
)	26317618	1542	1543	O
.	26317618	1543	1544	O

Mean	26317618	1545	1549	B-Outcome
platelet	26317618	1550	1558	I-Outcome
reactivity	26317618	1559	1569	I-Outcome
at	26317618	1570	1572	I-Outcome
4	26317618	1573	1574	I-Outcome
and	26317618	1575	1578	O
1	26317618	1579	1580	B-Outcome
hours	26317618	1581	1586	I-Outcome
after	26317618	1587	1592	O
study	26317618	1593	1598	O
medication	26317618	1599	1609	O
in	26317618	1610	1612	O
prasugrel	26317618	1613	1622	O
and	26317618	1623	1626	O
clopidogrel	26317618	1627	1638	O
groups	26317618	1639	1645	O
respectively	26317618	1646	1658	O
were	26317618	1659	1663	O
12	26317618	1664	1666	O
versus	26317618	1667	1673	O
22	26317618	1674	1676	O
(	26317618	1677	1678	O
p	26317618	1678	1679	O
=	26317618	1680	1681	O
0.005	26317618	1682	1687	O
)	26317618	1687	1688	O
and	26317618	1689	1692	O
19	26317618	1693	1695	O
versus	26317618	1696	1702	O
34	26317618	1703	1705	O
(	26317618	1706	1707	O
p	26317618	1707	1708	O
=	26317618	1709	1710	O
0.01	26317618	1711	1715	O
)	26317618	1715	1716	O
respectively	26317618	1717	1729	O
.	26317618	1729	1730	O

CONCLUSIONS	26317618	1732	1743	O
:	26317618	1744	1745	O
Routine	26317618	1746	1753	O
platelet	26317618	1754	1762	O
function	26317618	1763	1771	O
testing	26317618	1772	1779	O
identifies	26317618	1780	1790	O
patients	26317618	1791	1799	O
with	26317618	1800	1804	O
high	26317618	1805	1809	O
residual	26317618	1810	1818	B-Outcome
platelet	26317618	1819	1827	I-Outcome
reactivity	26317618	1828	1838	I-Outcome
(	26317618	1839	1840	O
"	26317618	1840	1841	O
poor	26317618	1841	1845	O
responders	26317618	1846	1856	O
"	26317618	1856	1857	O
)	26317618	1857	1858	O
on	26317618	1859	1861	O
clopidogrel	26317618	1862	1873	O
.	26317618	1873	1874	O

A	26317618	1875	1876	O
strategy	26317618	1877	1885	O
of	26317618	1886	1888	O
prasugrel	26317618	1889	1898	O
rather	26317618	1899	1905	O
than	26317618	1906	1910	O
clopidogrel	26317618	1911	1922	O
reloading	26317618	1923	1932	O
results	26317618	1933	1940	O
in	26317618	1941	1943	O
earlier	26317618	1944	1951	O
and	26317618	1952	1955	O
more	26317618	1956	1960	O
sustained	26317618	1961	1970	O
suppression	26317618	1971	1982	O
of	26317618	1983	1985	O
platelet	26317618	1986	1994	B-Outcome
reactivity	26317618	1995	2005	I-Outcome
.	26317618	2005	2006	O

Future	26317618	2007	2013	O
trials	26317618	2014	2020	O
need	26317618	2021	2025	O
to	26317618	2026	2028	O
identify	26317618	2029	2037	O
if	26317618	2038	2040	O
this	26317618	2041	2045	O
translates	26317618	2046	2056	O
into	26317618	2057	2061	O
clinical	26317618	2062	2070	O
benefit	26317618	2071	2078	O
.	26317618	2078	2079	O

TRIAL	26317618	2081	2086	O
REGISTRATION	26317618	2087	2099	O
:	26317618	2100	2101	O
ClinicalTrials.gov	26317618	2102	2120	O
NCT01339026	26317618	2121	2132	O
.	26317618	2132	2133	O


Elective	26551184	0	8	O
Induction	26551184	9	18	O
of	26551184	19	21	O
Labor	26551184	22	27	O
Compared	26551184	28	36	O
With	26551184	37	41	O
Expectant	26551184	42	51	O
Management	26551184	52	62	O
of	26551184	63	65	O
Nulliparous	26551184	66	77	O
Women	26551184	78	83	O
at	26551184	84	86	O
39	26551184	87	89	O
Weeks	26551184	90	95	O
of	26551184	96	98	O
Gestation	26551184	99	108	O
:	26551184	108	109	O
A	26551184	110	111	O
Randomized	26551184	112	122	O
Controlled	26551184	123	133	O
Trial	26551184	134	139	O
.	26551184	139	140	O

OBJECTIVE	26551184	141	150	O
:	26551184	151	152	O
To	26551184	153	155	O
evaluate	26551184	156	164	O
whether	26551184	165	172	O
the	26551184	173	176	O
elective	26551184	177	185	O
induction	26551184	186	195	O
of	26551184	196	198	O
labor	26551184	199	204	O
in	26551184	205	207	O
nulliparous	26551184	208	219	O
women	26551184	220	225	O
with	26551184	226	230	O
an	26551184	231	233	O
unfavorable	26551184	234	245	O
cervix	26551184	246	252	O
affects	26551184	253	260	O
the	26551184	261	264	O
cesarean	26551184	265	273	O
delivery	26551184	274	282	O
rate	26551184	283	287	O
.	26551184	287	288	O

METHODS	26551184	290	297	O
:	26551184	298	299	O
We	26551184	300	302	O
conducted	26551184	303	312	O
a	26551184	313	314	O
randomized	26551184	315	325	O
controlled	26551184	326	336	O
trial	26551184	337	342	O
at	26551184	343	345	O
a	26551184	346	347	O
tertiary	26551184	348	356	O
care	26551184	357	361	O
medical	26551184	362	369	O
center	26551184	370	376	O
.	26551184	376	377	O

Nulliparous	26551184	378	389	O
woman	26551184	390	395	O
between	26551184	396	403	O
38	26551184	404	406	O
0/7	26551184	407	410	O
and	26551184	411	414	O
38	26551184	415	417	O
6/7	26551184	418	421	O
weeks	26551184	422	427	O
of	26551184	428	430	O
gestation	26551184	431	440	O
who	26551184	441	444	O
were	26551184	445	449	O
least	26551184	450	455	O
18	26551184	456	458	O
years	26551184	459	464	O
of	26551184	465	467	O
age	26551184	468	471	O
with	26551184	472	476	O
a	26551184	477	478	O
singleton	26551184	479	488	O
gestation	26551184	489	498	O
and	26551184	499	502	O
a	26551184	503	504	O
Bishop	26551184	505	511	O
score	26551184	512	517	O
of	26551184	518	520	O
5	26551184	521	522	O
or	26551184	523	525	O
less	26551184	526	530	O
were	26551184	531	535	O
randomized	26551184	536	546	O
to	26551184	547	549	O
elective	26551184	550	558	O
induction	26551184	559	568	O
of	26551184	569	571	O
labor	26551184	572	577	O
or	26551184	578	580	O
expectant	26551184	581	590	O
management	26551184	591	601	O
.	26551184	601	602	O

The	26551184	603	606	O
induction	26551184	607	616	O
of	26551184	617	619	O
labor	26551184	620	625	O
group	26551184	626	631	O
was	26551184	632	635	O
induced	26551184	636	643	O
within	26551184	644	650	O
1	26551184	651	652	O
week	26551184	653	657	O
of	26551184	658	660	O
enrollment	26551184	661	671	O
but	26551184	672	675	O
not	26551184	676	679	O
before	26551184	680	686	O
39	26551184	687	689	O
0/7	26551184	690	693	O
weeks	26551184	694	699	O
of	26551184	700	702	O
gestation	26551184	703	712	O
.	26551184	712	713	O

The	26551184	714	717	O
control	26551184	718	725	O
group	26551184	726	731	O
continued	26551184	732	741	O
routine	26551184	742	749	O
prenatal	26551184	750	758	O
care	26551184	759	763	O
with	26551184	764	768	O
admission	26551184	769	778	O
for	26551184	779	782	O
labor	26551184	783	788	O
or	26551184	789	791	O
obstetric	26551184	792	801	O
indication	26551184	802	812	O
.	26551184	812	813	O

The	26551184	814	817	O
primary	26551184	818	825	O
outcome	26551184	826	833	O
was	26551184	834	837	O
cesarean	26551184	838	846	O
delivery	26551184	847	855	O
.	26551184	855	856	O

Assuming	26551184	857	865	O
a	26551184	866	867	O
20	26551184	868	870	O
%	26551184	870	871	O
rate	26551184	872	876	O
in	26551184	877	879	O
women	26551184	880	885	O
in	26551184	886	888	O
a	26551184	889	890	O
control	26551184	891	898	O
group	26551184	899	904	O
,	26551184	904	905	O
80	26551184	906	908	O
%	26551184	908	909	O
power	26551184	910	915	O
,	26551184	915	916	O
and	26551184	917	920	O
a	26551184	921	922	O
goal	26551184	923	927	O
to	26551184	928	930	O
detect	26551184	931	937	O
a	26551184	938	939	O
twofold	26551184	940	947	O
increase	26551184	948	956	O
to	26551184	957	959	O
40	26551184	960	962	O
%	26551184	962	963	O
in	26551184	964	966	O
the	26551184	967	970	O
induction	26551184	971	980	O
of	26551184	981	983	O
labor	26551184	984	989	O
group	26551184	990	995	O
,	26551184	995	996	O
162	26551184	997	1000	O
patients	26551184	1001	1009	O
were	26551184	1010	1014	O
needed	26551184	1015	1021	O
.	26551184	1021	1022	O

RESULTS	26551184	1024	1031	O
:	26551184	1032	1033	O
From	26551184	1034	1038	O
March	26551184	1039	1044	O
2010	26551184	1045	1049	O
to	26551184	1050	1052	O
February	26551184	1053	1061	O
2014	26551184	1062	1066	O
,	26551184	1066	1067	O
82	26551184	1068	1070	O
patients	26551184	1071	1079	O
were	26551184	1080	1084	O
randomly	26551184	1085	1093	O
allocated	26551184	1094	1103	O
to	26551184	1104	1106	O
induction	26551184	1107	1116	O
of	26551184	1117	1119	O
labor	26551184	1120	1125	O
and	26551184	1126	1129	O
80	26551184	1130	1132	O
to	26551184	1133	1135	O
expectant	26551184	1136	1145	O
management	26551184	1146	1156	O
.	26551184	1156	1157	O

Baseline	26551184	1158	1166	O
characteristics	26551184	1167	1182	O
were	26551184	1183	1187	O
similar	26551184	1188	1195	O
between	26551184	1196	1203	O
groups	26551184	1204	1210	O
.	26551184	1210	1211	O

The	26551184	1212	1215	O
cesarean	26551184	1216	1224	B-Outcome
delivery	26551184	1225	1233	I-Outcome
rate	26551184	1234	1238	I-Outcome
in	26551184	1239	1241	O
the	26551184	1242	1245	O
induction	26551184	1246	1255	O
of	26551184	1256	1258	O
labor	26551184	1259	1264	O
group	26551184	1265	1270	O
was	26551184	1271	1274	O
30.5	26551184	1275	1279	O
%	26551184	1279	1280	O
(	26551184	1281	1282	O
25/82	26551184	1282	1287	O
)	26551184	1287	1288	O
compared	26551184	1289	1297	O
with	26551184	1298	1302	O
17.7	26551184	1303	1307	O
%	26551184	1307	1308	O
(	26551184	1309	1310	O
14/79	26551184	1310	1315	O
)	26551184	1315	1316	O
in	26551184	1317	1319	O
the	26551184	1320	1323	O
expectant	26551184	1324	1333	O
management	26551184	1334	1344	O
group	26551184	1345	1350	O
(	26551184	1351	1352	O
relative	26551184	1352	1360	O
risk	26551184	1361	1365	O
1.72	26551184	1366	1370	O
,	26551184	1370	1371	O
95	26551184	1372	1374	O
%	26551184	1374	1375	O
confidence	26551184	1376	1386	O
interval	26551184	1387	1395	O
0.96	26551184	1396	1400	O
-	26551184	1400	1401	O
3.06	26551184	1401	1405	O
)	26551184	1405	1406	O
.	26551184	1406	1407	O

CONCLUSION	26551184	1409	1419	O
:	26551184	1420	1421	O
In	26551184	1422	1424	O
nulliparous	26551184	1425	1436	O
women	26551184	1437	1442	O
with	26551184	1443	1447	O
a	26551184	1448	1449	O
Bishop	26551184	1450	1456	O
score	26551184	1457	1462	O
of	26551184	1463	1465	O
5	26551184	1466	1467	O
or	26551184	1468	1470	O
less	26551184	1471	1475	O
,	26551184	1475	1476	O
elective	26551184	1477	1485	O
induction	26551184	1486	1495	O
after	26551184	1496	1501	O
39	26551184	1502	1504	O
0/7	26551184	1505	1508	O
weeks	26551184	1509	1514	O
of	26551184	1515	1517	O
gestation	26551184	1518	1527	O
compared	26551184	1528	1536	O
with	26551184	1537	1541	O
expectant	26551184	1542	1551	O
management	26551184	1552	1562	O
of	26551184	1563	1565	O
pregnancy	26551184	1566	1575	O
did	26551184	1576	1579	O
not	26551184	1580	1583	O
double	26551184	1584	1590	O
the	26551184	1591	1594	O
rate	26551184	1595	1599	B-Outcome
of	26551184	1600	1602	I-Outcome
cesarean	26551184	1603	1611	I-Outcome
delivery	26551184	1612	1620	I-Outcome
.	26551184	1620	1621	O

CLINICAL	26551184	1623	1631	O
TRIAL	26551184	1632	1637	O
REGISTRACTION	26551184	1638	1651	O
:	26551184	1652	1653	O
ClinicalTrials.gov	26551184	1654	1672	O
,	26551184	1672	1673	O
www.clinicaltrials.gov	26551184	1674	1696	O
,	26551184	1696	1697	O
NCT01076062	26551184	1698	1709	O
.	26551184	1709	1710	O

LEVEL	26551184	1712	1717	O
OF	26551184	1718	1720	O
EVIDENCE	26551184	1721	1729	O
:	26551184	1730	1731	O
I.	26551184	1732	1734	O

